Scientific Panel on Dietetic Products, Nutrition and Allergies UnitParma, 25 February 2010 Consolidated list of Article 13 health claims List of references received by EFSA Part 2 IDs 1001 – 2000 (This document contains the list of references for claims which have passed the EFSA screening. In addition, it includes the list of references for claims which were adopted by NDA Panel in 2009 after having received clarifications from the Commission in November 2009.) BACKGROUND In accordance with Article 13 of Regulation (EC) No 1924/20061 Member States had provided the European Commission with lists of claims accompanied by the conditions applying to them and by references to the relevant scientific justification by 31 January 2008. EFSA has received from the European Commission nine Access databases with a consolidated list of 4,185 main health claim entries with around 10,000 similar health claims. The similar health claims were accompanied by the conditions of use and scientific references. The nine Access databases were sent in three batches - in July 2008, in November 2008 and in December 2008. Subsequently, EFSA combined the databases into one master database and re-allocated upon request of the Commission and Member States similar health claims which had been accidentally placed under a wrong main health claim entry (misplaced claims). During this process some Member States also identified a number of similar health claims which still needed to be submitted to EFSA (―missing claims‖). These similar claims were also added to the database. The references to the scientific justifications provided by Member States were either included in the database or were provided in separate files. In addition, full-text copies of references were provided directly to EFSA from stakeholders. The deadline for submission of these references was end of 2008. EFSA wishes to acknowledge the full-text copies of relevant literature provided by stakeholders until that date. In some instances, references provided to EFSA were referring to papers which were submitted for publication. In case the publication had in the meanwhile taken place EFSA has included the correct citation in the list of references and this may result in some references carrying a 2009 publication date. EFSA has screened all health claims on the list using six criteria established by the NDA Panel to identify claims for which EFSA considers sufficient information has been provided for evaluation and those for which for which more information or clarification is needed before evaluation can be carried 1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. European Food Safety Authority - Largo N. Palli 5/A, I - 43121 Parma Tel: (+39) 0521 036 425 • Fax: (+39) 0521 036 525 •
[email protected] • www.efsa.europa.eu 1 out. The claims which had been sent back to the Commission and the Member States for further clarification in January 2009 were received back with additional information in November 2009. Further information can be found on the EFSA website under the following link: http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_article13.htm. LIST OF REFERENCES The present document compiles the lists of references for claims with ID numbers between 1001 and 2000 and which passed the EFSA screening. In addition, it includes the list of references for ID numbers between 1001 and 2000 which were adopted by NDA Panel in 2009 after having received clarifications from the Commission in November 2009. The list takes into account references provided through different sources and those coming from misplaced or missing claims. The main health claim entries are sorted in ascending order of the ID number. This document will be updated according to the progress of adoption of opinions related to Art 13 health claims. In the update of 25 February 2010, the following ID numbers have 2936, 2937, 2938, 2939, 2940, 2941, 2943, 2944, 2960, 2961, 2965, 2980, 2983, 2986, 2989, 2990, 2992, 2993, 2994, 2995, 2998, 3000, 3022, 3023, 3024, 3028, 3029, 3030, 3031, 3032, 3039, 3047, 3048, 4227. been added (in red font): 159, 2968, 2969, 2974, 2975, 2978, 3001, 3007, 3008, 3010, 3021, 3055, 3057, 3058, 3059, 3060, 2 TABLE OF CONTENTS Table of contents ........................................................................................................................................................ 3 ID 1001: ―Lactobacillus reuteri THT 030803‖ and ―Natural defences/ immune system‖ ....................................... 20 ID 1002: ―Lactobacillus rhamnosus THT 030901‖ and ―Digestive health/ Intestinal flora‖................................... 20 ID 1003: ―Lactobacillus rhamnosus THT 030901‖ and ―Natural defences/ immune system‖ ................................ 20 ID 1004: ―Lactobacillus rhamnosus THT 030902‖ and ―Digestive health/ Intestinal flora‖................................... 21 ID 1005: ―Lactobacillus rhamnosus THT 030902‖ and ―Natural defences/ immune system‖ ................................ 21 ID 1006: ―Lactobacillus salivarius THT 031001‖ and ―Digestive health/ Intestinal flora‖ .................................... 21 ID 1007: ―Lactobacillus salivarius THT 031001‖ and ―Natural defences/ immune system‖ .................................. 22 ID 1008: ―Lactococcus lactis THT 090101‖ and ―Digestive health/ Intestinal flora‖ ............................................. 22 ID 1009: ―Lactococcus lactis THT 090101‖ and ―Natural defences/ immune system‖ .......................................... 23 ID 1010: ―Saccharomyces boulardii ATY-SB-101‖ and ―Gastro-intestinal function / Intestinal microflora‖ ........ 23 ID 1011: ―Saccharomyces boulardii ATY-SB-101‖ and ―Natural defences / Immune system‖ ............................. 23 ID 1012: ―Streptococcus thermophilus THT 070101‖ and ―Digestive health/ Intestinal flora‖ .............................. 24 ID 1013: ―Streptococcus thermophilus THT 070101‖ and ―Natural defences/ immune system‖ ........................... 24 ID 1014: ―Streptococcus thermophilus THT 070102‖ and ―Digestive health/ Intestinal flora‖ .............................. 25 ID 1015: ―Streptococcus thermophilus THT 070102‖ and ―Natural defences/ immune system‖ ........................... 25 ID 1030: ―Lactobacillus crispatus P 17631‖ and ―Benessere del tratto intestinale‖ ................................................ 25 ID 1055: ―Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus rhamnosus and Bifidobacterium lactis lactic acid bacteria‖ and ―Gut health‖ ........................................................................................................ 26 ID 1056: ―Lactobacilus acidophilus, Lactobacillus paracasei, Lactobacillus rhamnosus and Bifidobacterium lactis lactic acid bacteria‖ and ―Immunity‖ ......................................................................................................... 26 ID 1057: ―Lactobacillus reuteri lactic acid bacteria‖ and ―Mouth, teeth‖ ............................................................... 26 ID 1060: ―Lactococcus lactis L1A NCIMB 40157 (Verum® Hälsofil)‖ and ―Digestive system‖ .......................... 27 ID 1062: ―Lactococcus lactis L1A NCIMB 40157‖ and ―Intestinal flora Digestive health‖ .................................. 27 ID 1063: ―Lactobacillus plantarum LB931 DSM 11918‖ and ―Intestinal flora Digestive health Urogenital health‖ .................................................................................................................................................................. 28 ID 1064: ―Lactobacillus rhamnosus LB21 NCIMB 40564‖ and ―Intestinal flora Digestive health Oral flora‖...... 28 ID 1065: ―Lactobacillus plantarum LB7c DSM 17853‖ and ―Intestinal flora Digestive health‖ ............................ 29 ID 1066: ―Lactobacillus plantarum LB3e DSM 17852‖ and ―Intestinal flora Digestive health‖ ............................ 29 ID 1067: ―Streptococcus sanguis NCIMB 40104‖ and ―Oral health Throat health‖ ............................................... 29 ID 1068: ―Streptococcus sanguis NCIMB 40873‖ and ―Oral health Throat health‖ ............................................... 30 ID 1069: ―Streptococcus oralis NCIMB 40875‖ and ―Oral health Throat health‖ .................................................. 31 ID 1070: ―Streptococcus oralis NCIMB 40876‖ and ―Oral health Throat health‖ .................................................. 32 ID 1071: ―Lactobacillus plantarum HEAL 9 (DSM 15312 = 39D)‖ and ―Strengthens the immune system. Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina‖ .................. 33 ID 1072: ―Lactobacillus plantarum HEAL 19 (DSM 15313 = 52A)‖ and ―Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina‖ and ―Reduces the insulin response after a meal. Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina.‖ ....... 33 ID 1073: ―Lactobacillus plantarum HEAL 99 (DSM 15316 = 61A)‖ and ―Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina‖ ....................................................................... 33 3 ID 1074: ―Lactobacillus paracasei 8700:2 (DSM 13434, 240HI)‖ and ―Strengthens the immune system Establishment of lactobacilli and beneficial changes in the microflora‖ ............................................................. 33 ID 1075: ―Lactobacillus parcasei 02A (DSM 13432)‖ and ―Establishment of lactobacilli and beneficial changes in the microflora‖ ................................................................................................................................... 34 ID 1076: ―Lactobacillus rhamnosus 271 (DSM 6594)‖ and ―Gut Health‖ .............................................................. 34 ID 1077: ―Lactobacillus plantarum 299 (DSM 6595, 67B)‖ and ―Immune systems‖ ............................................. 34 ID 1078: ―Lactobacillus plantarum 299 (DSM 6595, 67B)‖ and ―Increase the amount of Lactobacilli in the intestine. Decrease the amount of Enterobacteriaceae. Inhibit pathogenic bacteria‖ .......................................... 35 ID 1079: ―Lactobacillus crispatus VPC111 (DSM 16741)‖ and ―Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina‖ ........................................................................................ 36 ID 1080: ―Lactobacillus crispatus VPC177 (DSM 16743)‖ and ―Gut health, Vaginal health/flora‖ ...................... 36 ID 1081: ―Lactobacillus plantarum 299v (DSM 9843)‖ and ―Immune systems‖ .................................................... 36 ID 1083: ―Lactobacillus plantarum 299v (DSM 9843)‖ and ―Antioxidant properties‖ ........................................... 37 ID 1084: ―Lactobacillus plantarum 299v (DSM 9843)‖ and ―Gut health‖ .............................................................. 37 ID 1085: ―A combination of three probiotic ingredients; Lactobacillus casei F19, Bifidobacterium lactis Bb12, Lactobacillus acidophilus La5‖ and ―Gut function/health‖ ...................................................................... 38 ID 1086: ―Dairy products containing the combination of three probiotic ingredients; Lactobacillus casei F19, Bifidobacterium lactis Bb12, Lactobacillus acidophilus La5‖ and ―Gut Health. Immune systems‖ .................. 38 ID 1087: ―Lactobacillus reuteri DSM 17938‖ and ―Gut microflora‖ ...................................................................... 38 ID 1088: ―Lactobacillus reuteri DSM 17938 Lactobacillus reuteri ATCC PTA 5289‖ and ―Immune defence‖ .... 40 ID 1089: ―Lactobacillus reuteri DSM 17938 Lactobacillus reuteri ATCC PTA 5289‖ and ―Healthy oral flora‖ .................................................................................................................................................................... 41 ID 1090: ―A combination of the probiotics: Lactobacillus casei F19, Lactobacillus plantarum 2592, Leuconostoc mesenteroides 77:1, Pediococcus pentosaceus 16:1‖ and ―Natural defence/immune system‖ ...... 41 ID 1091: ―Bacillus subtilis HU58‖ and ―Intestinal / digestive health‖ .................................................................... 42 ID 1092: ―Bacillus subtilis HU58‖ and ―Immune function‖.................................................................................... 42 ID 1093: ―Bifidobacterium infantis UCC35624‖ and ―Promotion of healthy digestion‖ ........................................ 42 ID 1094: ―Bifidobacterium infantis UCC35624‖ and ―Immune Response‖............................................................ 43 ID 1095: ―Lactobacillus paracaseii CUL08 NCIMB 30154 Lactobacillus salivarius CUL 61 Bifidobacterium adolescentis (bifidum) CUL20 NCIMB 30153 Bifidobacterium lactis CUL34 NCIMB 30172‖ and ―Gut Flora/ Immune System‖ ....................................................................................................................................... 44 ID 1096: ―Probiotics (Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) & Antioxidants (Vitamin C, Green Tea Extract, Grape Seed Extract, Pine Bark Extract) as contained in the probiotic formula Immunox‖ and ―Maintains healthy digestive function and supports immunity‖ ............................................................................................................................................. 45 ID 1097: ―Lactobacilus acidophilus CUL60 Lactobacillus casei LC11 Bifidobacterium lactis CUL34‖ and ―Gut Flora‖ .......................................................................................................................................................... 45 ID 1098: ―Lactobacillus LA-5‖ and ―Verdauungsapparat‖ ..................................................................................... 45 ID 1099: ―Coffee‖ and ―Protection of body tissues, lipids, cells and DNA from oxidative damage‖ ..................... 50 ID 1100: ―Coffee‖ and ―Glucose homeostasis‖ ....................................................................................................... 55 ID 1103: ―Camelia sinensis (Common Name: Tea)‖ and ―Protection of body tissues and cells from oxidative damage‖ ............................................................................................................................................................... 57 ID 1104: ―Camelia sinensis (Common Name: Tea)‖ and ―Physical and mental stimulation (hydration and caffeine)‖ ............................................................................................................................................................. 63 4 ID 1105: ―Camelia sinensis (Common Name: Tea)‖ and ―Oral health‖.................................................................. 64 ID 1107: ―Camelia sinensis (Common Name: Tea)‖ and ―Weight management/metabolism of lipids‖ ................ 65 ID 1108: ―Camelia sinensis(Common Name: Tea)‖ and ―Glucose metabolism‖ .................................................... 67 ID 1109: ―Camelia sinensis (Common Name: Tea)‖ and ―Bone health‖ ................................................................ 67 ID 1110: ―Camelia sinensis (Common Name: Tea)‖ and ―Skin health‖ ................................................................. 67 ID 1111: ―Catechins – Green tea (camellia sinensis)‖ and ―Dental health‖ ............................................................ 67 ID 1112: ―Catechins – Green tea (camellia sinensis)‖ and ―Weight management‖ ................................................ 68 ID 1113: ―Catechins – Green tea (camellia sinensis)‖ and ―Cholesterol‖ ............................................................... 69 ID 1114: ―Catechins – Green tea (camellia sinensis)‖ and ―Heart health‖ .............................................................. 70 ID 1115: ―Catechins – Green tea (camellia sinensis)‖ and ―Glucose metabolism‖ ................................................. 71 ID 1116: ―Catechins – Green tea (camellia sinensis)‖ and ―Gut flora‖ ................................................................... 73 ID 1117: ―Catechins – Green tea (camellia sinensis)‖ and ―Cognitive function‖.................................................... 73 ID 1119: ―Catechins – Green tea (camellia sinensis)‖ and ―Skin care‖................................................................... 77 ID 1120: ―Catechins – Green tea (camellia sinensis)‖ and ―Women health‖ .......................................................... 77 ID 1121: ―Catechins – Green tea (camellia sinensis)‖ and ―Men health / prostate health‖ ..................................... 78 ID 1123: ―Camellia sinensis Tea (Green, Oolong and Black Tea)‖ and ―Resting metabolic rate and thermogenesis‖ .................................................................................................................................................... 78 ID 1124: ―Green Tea‖ and ―Fat metabolism‖ .......................................................................................................... 78 ID 1126: ―Whole grain foods‖ and ―Weight management‖ ..................................................................................... 79 ID 1130: ―Nuts - peanuts and tree nuts (almonds, hazelnuts, pecans, pistachios and walnuts), excluding brazil, macadamia and cashew nuts‖ and ―Weight management via satieaty (by proteins and fibre)‖ ............... 83 ID 1131: ―Almonds‖ and ―Maintains healthy blood total and LDL cholesterol and heart health‖.......................... 84 ID 1135: ―Soya (Glycine max [L.] Merr.)‖ and ―Cholesterol management / heart health‖ ..................................... 86 ID 1137: ―Water soluble tomato concentrate (WSTC)‖ and ―Suppression of blood platelet activity, circulatory and heart health‖ ................................................................................................................................ 88 ID 1142: ―Milk‖ and ―Dental health‖ ...................................................................................................................... 88 ID 1149: ―Sugar-free chewing gum‖ and ―Dental health/ Oral health, Gum and tooth protection/ strength‖ ......... 89 ID 1150: ―Sugar-free chewing gum‖ and ―Plaque acid neutralisation‖ ................................................................... 92 ID 1151: ―Sugar-free chewing gum‖ and ―Localised tooth mineralisation (non-systemic)‖................................... 93 ID 1152: ―Sugar-free chewing gum containing polyols‖ and ―Beneficial for weight management‖ ...................... 96 ID 1153: ―Sugar-free chewing gum with Carbamide‖ and ―Improved plaque acid neutralisation‖ ........................ 96 ID 1154: ―Sugar-free chewing gum with Fluoride‖ and ―Increases resistance of enamel to acid attacks and rate of remineralisation‖ ...................................................................................................................................... 97 ID 1159: ―Honey (as defined by The Honey Regulations 2003 (as amended))‖ and ―Antioxidant properties Plus Antimicrobial properties‖ ............................................................................................................................ 98 ID 1161: ―Honey, including the antioxidants in honey‖ and ―Respiratory Health through presence of antioxidant phytochemicals.‖ .................................................................................................................................... 99 ID 1162: ―Pomegranate‖ and ―Cardiovascular health‖ .......................................................................................... 100 ID 1164: ―Prunes (dried plums)‖ and ―Normal bowel function/normal gastrointestinal function/normal colonic function‖ ............................................................................................................................................... 102 5 ID 1165: ―Prunes (dried plums)‖ and ―Can aid satiety/ increase sense of satiety due to NSP content and low Glycaemic index‖ .............................................................................................................................................. 102 ID 1166: ―Prune Juice‖ and ―Normal bowel function/normal gastrointestinal function/normal colonic function‖ ............................................................................................................................................................ 103 ID 1169: ―Energy drinks containing 0.032% caffeine, 0.4% taurine and 0.24% glucuronolactone‖ and ―Mood and performance‖............................................................................................................................................... 103 ID 1175: ―Mjölkprotein-koncentrat med högt innehåll av fosfolipider (effektiv komponent fosfatidylserin); Milk protein concentrate with a high content of phospholipids. (Effective component: Phosphatidyl serine); LacprodanÒPL-20‖ and ―Minskning av stress Förbättrad minnesfunktion Stress reduction Enhanced memory function‖ ............................................................................................................................. 113 ID 1179: ―Rye bread‖ and ―Carbohydrate metabolism and insulin sensitivity‖ .................................................... 114 ID 1181: ―Xylitol-sweetened chewing gum‖ and ―Mouth, teeth‖ ......................................................................... 115 ID 1182: ―Xylitol in candy and bakery industry products and in dairy products‖ and ―Mouth, teeth‖ ................. 119 ID 1184: ―Berries (lingonberry, cloudberry, blueberry, currants, raspberry and strawberry)‖ and ―Cardiovascular system‖ ................................................................................................................................... 119 ID 1185: ―Natural berries/sodium‖ and ―Cardiovascular system‖......................................................................... 120 ID 1186: ―Berries and fruit juices/flavonoids + ascorbic acid‖ and ―Antioxidativity‖.......................................... 120 ID 1187: ―Coffee drink/caffeine‖ and ―Mental state and performance‖ ................................................................ 120 ID 1189: ―Nutritional preparation, powdery‖ and ―Weight control‖ ..................................................................... 121 ID 1197: ―Grape juice‖ and ―Maintenance of cardiovascular system‖ .................................................................. 121 ID 1200: ―Black Currant juice‖ and ―Oxidative stress control‖ ............................................................................ 122 ID 1201: ―Pomegranate juice‖ and ―Oxidative stress control‖ .............................................................................. 122 ID 1202: ―Tomato juice‖ and ―Cardiovascular System‖ ....................................................................................... 123 ID 1205: ―Phyto-complex based on extracts of mushroom (Shiitake thalle Lentinula edodes), plants (Acerola fruit Malpighia punicifolia, Papaya fruit Carica papaya, Grapefruit fruit Citrus paradisi, Lemon oil Citrus limon), vitamin C, concentrated fruits juices and‖ and ―Immune health‖ ......................................................... 123 ID 1206: ―Food supplement of plants (meadosweet, birch, green tea, green coffee, yerba mate), concentrated fruits juices and pectin.‖ and ―Slimming - Silhouette‖ ...................................................................................... 128 ID 1208: ―Water‖ and ―Regulation of normal body temperature‖ ......................................................................... 128 ID 1209: ―Water‖ and ―Hydration, eg. body function, physical and cognitive performance‖............................... 129 ID 1211: ―Fruits (fresh, frozen, canned, bottled, dried, juiced)‖ and ―Protection of body tissues and cells from oxidative damage‖ .................................................................................................................................... 129 ID 1214: ―Fruits (fresh, frozen, canned, bottled, dried, juiced)‖ and ―Modulation of glycemic response‖........... 132 ID 1216: ―Vegetables (fresh, frozen, canned, bottled, dried, juiced)‖ and ―Protection of body tissues and cells from oxidative damage‖ .................................................................................................................................... 132 ID 1219: ―Vegetables (fresh, frozen, canned, bottled, dried, juiced)‖ and ―Modulation of glycemic response‖ .. 135 ID 1222: ―Camellia sinensis (Common Name: Tea)‖ and ―Mental and cognitive health‖ .................................... 135 ID 1228: ―Royal jelly‖ and ―Glands function‖ ...................................................................................................... 137 ID 1229: ―Royal jelly‖ and ―Antioxidant properties‖ ............................................................................................ 138 ID 1240: ―Sugar-free chewing gum‖ and ―Dry Mouth (Reduces/ Improves Dry Mouth)‖ ................................... 138 ID 1241: ―Plain Biscuits (such as "LU petit déjeuner")‖ and ―The appearance, in the blood circulation, of exogenous glucose from biscuits consumed for breakfast is moderate and stable throughout the morning.‖... 139 ID 1242: ―Propolis‖ and ―improvement of ventilatory functions /Respiratory health‖ ......................................... 140 6 ID 1243: ―Propolis‖ and ―Antioxidant properties‖ ................................................................................................ 140 ID 1246: ―Propolis‖ and ―throat comfort‖ ............................................................................................................. 141 ID 1256: ―Acerola‖ and ―Antioxidant activity‖ ..................................................................................................... 141 ID 1257: ―Banana‖ and ―Antioxidant activity‖ ..................................................................................................... 142 ID 1258: ―Guava‖ and ―Antioxidative activity‖ .................................................................................................... 143 ID 1260: ―Kaki‖ and ―Antioxidant activity‖ .......................................................................................................... 147 ID 1261: ―Kaki‖ and ―Eye health‖ ......................................................................................................................... 148 ID 1262: ―Pitanga‖ and ―Antioxidant activity‖ ..................................................................................................... 151 ID 1264: ―Purple Grape Juice‖ and ―Antioxidant activity‖ ................................................................................... 151 ID 1272: ―Caffeinated carbohydrate containing energy drinks‖ and ―Cognitive performance and mood‖ ........... 152 ID 1276: ―Camellia sinensis Tea (Green, Oolong and Black Tea)‖ and ―Antioxidant‖ ........................................ 161 ID 1280: ―Catechins – Green tea (camellia sinensis)‖ and ―Eye health‖ ............................................................... 161 ID 1284: ―Peanuts, Peanut butter, Peanut oil‖ and ―Helps achieve normal cholesterol levels by reducing blood total and LDL cholesterol and thereby promoting heart health‖ ............................................................. 162 ID 1285: ―Prunes (Dried plums)‖ and ―Contains antioxidants‖ ............................................................................ 164 ID 1286: ―Soy‖ and ―Vascular effects including protection from oxidative damage‖ .......................................... 165 ID 1289: ―Beef and beef products‖ and ―Antioxidant to prevent oxidative stress, Proper thyroid function,M aintenance of cellular redox status‖ ................................................................................................................... 167 ID 1290: ―Chicken and chicken products‖ and ―Antioxidant to prevent oxidative stress, Proper thyroid function. Maintenance of cellular redox status‖ ................................................................................................ 167 ID 1291: ―Egg and egg products‖ and ―Antioxidant to prevent oxidative stress, Proper thyroid function, Maintenance of cellular redox status‖ ............................................................................................................... 167 ID 1292: ―Milk and dairy products‖ and ―Antioxidant to prevent oxidative stress. Proper thyroid function. Maintenance of cellular redox status‖ ............................................................................................................... 167 ID 1293: ―Pork and related products‖ and ―Antioxidant to prevent oxidative stress. Proper thyroid function. Maintenance of cellular redox status‖ ............................................................................................................... 167 ID 1295: ―Bilberry fruits (Vaccinium myrtillus fruit)‖ and ―Eye Health‖............................................................. 168 ID 1297: ―Bilberry fruits (Vaccinium myrtillus fruit)‖ and ―Capillary wessels and vein health‖ ......................... 168 ID 1299: ―Oatbran and oatbran products‖ and ―Blood cholesterol level‖ ............................................................. 169 ID 1300: ―Carbohydrate sources with low glycaemic index (GI <55), e.g. legumes, vegetables, whole grain cereals‖ and ―Blood sugar level, -lipid level and body mass‖ ........................................................................... 171 ID 1308: ―Soy lecithin‖ and ―Control of cholesterol‖ ........................................................................................... 173 ID 1311: ―Epigallo-catechin-3-gallate (EGCG) / Green tea extract, rich in EGCG‖ and ―Protection of body tissues and cells from oxidative damage‖ .......................................................................................................... 173 ID 1312: ―Brassicaceae (Cruciferae) (Common Name: Botanical family that include broccoli, couliflower, cabbage, Bruxelles sprouts etc.)‖ and ―Antioxidant activity‖ ........................................................................... 173 ID 1315: ―Chios Mastiha Natural resin. Protected Designation of Origin product. (PDO) (EC)123/1997 (L022/24.1.97)‖ and ―Mastiha Chiou has an antioxidant action. Target Group: Whole population / no restrictions‖ ........................................................................................................................................................ 174 ID 1319: ―Pomegranate Juice - phenolic compounds (anthocyanins, tannines, ellagic acid)‖ and ―Antioxidant activity. Target group: humans of all ages. Excluded group: due to inadequate data, pregnant women, nursing women, patients over antidepressant medicines (Mirtazapine), antipsychotic medicines (Risperidone, Ketiapine), statines medicines (Simvastatine, atorvastatine), antihypertensive medicines should take doctor‘s advice (relative contra-indication)‖ .................................................................................. 175 7 ID 1320: ―Pomegranate Juice - phenolic compounds (anthocyanins, tannines, ellagic acid)‖ and ―Fights factors which cause atherosclerosis Target group: humans of high risk of vessel atheromatoses. Excluded group: due to inadequate data, pregnant women, nursing women, patients over antidepressant medicines (Mirtazapine), antipsychotic medicines (Risperidone, Ketiapine), statines medicines (Simvastatine, atorvastatine), antihypertensive medicines should take doctor‘s advice (relative contra-indication).‖ ............. 175 ID 1321: ―Honey‖ and ―Antioxidant properties‖ ................................................................................................... 176 ID 1330: ―Vitalinea fermented dairy products (low fat/reduced or no-added sugars) enriched with protein, enriched with guar gum‖ and ―appetite‖............................................................................................................ 176 ID 1331: ―Water‖ and ―Hydration‖........................................................................................................................ 183 ID 1332: ―Olive Oil‖ and ―Improves blood lipid profile‖ ..................................................................................... 183 ID 1333: ―Olive Oil‖ and ―reduces oxidative stress.‖ ............................................................................................ 186 ID 1334: ―Standardized grape seed extract [dry extract from grape seeds of vitis viniferaL. (Vitaceae), solvent of extraction acetone/water 8.5-13.0% proanthocyanidins]‖ and ―antioxidant protection system‖ ...... 186 ID 1338: ―Juice Plus+® (juice concentrate from fruits and vegetables mixtures)‖ and ―Protection of body tissues and cells from oxidative damage‖ .......................................................................................................... 187 ID 1340: ―Water-based product (Water purified by reverse osmosis to monomolecular level, complex of salts)‖ and ―Improves renal function‖ ............................................................................................................... 187 ID 1341: ―Water-based product (Water purified by reverse osmosis to monomolecular level, complex of salts)‖ and ―Improves hepatic functions‖ .......................................................................................................... 187 ID 1342: ―Water-based product (Water purified by reverse osmosis to monomolecular level, complex of salts)‖ and ―Improves mechanical activity of gall- bladder‖ ............................................................................. 187 ID 1349: ―Name of Food product: Toasted Sunflower Mix.Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Contains antioxidants & promotes healthy skin. Do benefits relate to a disease risk factor: No. Target group: All of the general population including children and adults‖ ............... 188 ID 1351: ―Name of Food product: Club Energise Energy / Energise Energy. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Energy for longer Provide sustained energy rather than a quick burst followed by a slump. Do benefits relate to a disease risk factor: No. Target group: All adults aged 18 years and over‖ ..................................................................................................................................... 188 ID 1354: ―Name of Food product: Club Energise Sport (Orange, Blackcurrant, Lemon) / Energise Sport (Orange, Blackcurrant, lemon). Description of food in terms of food legislation categories: Food intended to meet the expenditure of intense muscular effort, especially for sports people. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Aids recovery by reducing muscle damage during exercise. Do benefits relate to a disease risk factor: No. Target group: All adults aged 18 years and over‖ .................................................................................................................................................................. 188 ID 1358: ―Name of Food product: Club Energise Sport / Energise Sport (Orange, Blackcurrant, Lemon). Description of food in terms of food legislation categories: Food intended to meet the expenditure of intense muscular effort, especially for sports people. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Ensures better concentration. Do benefits relate to a disease risk factor: No. Target group: All adults aged 18 years and over‖ ............................................................................................. 189 ID 1360: ―Name of Food product: Dairygold Omega-3 Spread. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Dairygold Omega-3 spread contain omeag- 3 fatty acids (EPA & DHA) which may have a beneficial role to play in the functioning of the brain and can help maintain a healthy heart. Do benefits relate to a disease risk factor: No. Target group: All of the general population including children and adults‖ ......................................................................................................... 189 ID 1367: ―Name of Food product: Olive Biophenols. Description of food in terms of food legislation categories: Food supplement. Was food on Irish market before 1st July 2007: No‖ and ―Health benefits of food: A potent source of antioxidant biophenols for strengthening and balancing of the immune system 8 from free radicals. Do benefits relate to a disease risk factor: No. Target group: All of the general population including children and adults‖ ......................................................................................................... 189 ID 1371: ―Name of Food product: Cheese. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Ingestion of cheese containing probiotic culture Lb. paracasei NFBC 338 positively influences the healthy balance of the gut microflora. Do benefits relate to a disease risk factor: No. Target group: All of the general population including children and adults‖ ................................................................. 190 ID 1372: ―Name of Food product: chocolate. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Cocoa in chocolate may be a major dietary source of antioxidants. Cocoa flavanols show antioxidative effects and help protect the cells against oxidative stress & help protect from radicals. Do benefits relate to a disease risk factor: No. Target group: All adults aged 18 years and over‖ ......................... 191 ID 1373: ―Name of Food product: Liquid Milk. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: contains Vitamin A which contributes to good eyesight/normal vision. Do benefits relate to a disease risk factor: No. Target group: All of the general population including children and adults‖ ......................................................................................................................................................... 191 ID 1376: ―Name of Food product: fermented dairy products. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Healthy Digestion. Do benefits relate to a disease risk factor: No. Target group: All adults aged 18 years and over‖ ............................................................................................. 191 ID 1377: ―Apple cider vinegar‖ and ―Digestive health and bowel function‖ ........................................................ 195 ID 1380: ―Apple cider vinegar‖ and ―Weight management‖ ................................................................................. 196 ID 1382: ―Brewer`s Yeast‖ and ―Cardiovascular health‖ ...................................................................................... 196 ID 1386: ―Wheat germ oil‖ and ―Cardiovascular system‖ .................................................................................... 196 ID 1389: ―Wheat germ oil‖ and ―Metabolism‖...................................................................................................... 196 ID 1390: ―Wheat germ oil‖ and ―Skin health‖....................................................................................................... 196 ID 1396: ―Name of Food product: Club Energise Sport Recovery 20 / Energise Sport recovery 20 mixed berry). Description of food in terms of food legislation categories: Food intended to meet the expenditure of intense muscular effort, especially for sports people. Was food on Irish market before 1st July 2007: Yes‖ and ―Health benefits of food: Recover Faster for Better Sports Performance. High protein drink. Carbohydrate and Protein recovery drink. Do benefits relate to a disease risk factor: No. Target group: Adults aged 18 years and over with some exceptions. If exceptions describe: Not suitable for children under 16 years of age or pregnant women. Reasons for excluding these groups: Targeted for specific group - sports people. Should be used in conjunction with an appropriate physical training or exercise program. Should be consumed with a nutritious diet.‖ ...................................................................................... 197 ID 1410: ―Very low calorie diet (VLCD) Programme‖ and ―1) Safe and effective weight loss 2) long term weight maintenance‖ ......................................................................................................................................... 197 ID 1411: ―Very low calorie diet (VLCD) Programme‖ and ―Reduced hunger‖.................................................... 200 ID 1412: ―Very low calorie diet (VLCD) Programme‖ and ―Burning fat for energy, preserving lean tissue‖ ..... 201 ID 1414: ―Very low calorie diet (VLCD) Programme‖ and ―Low glycaemic index‖ ........................................... 203 ID 1417: ―Meal replacement for weight control (as defined in Directive 96/8/EC energy restricted diets for weight reduction)‖ and ―Safe, effective & healthy weight loss. Greater weight loss than with conventional calorie counting‖ ................................................................................................................................................ 203 ID 1418: ―Meal replacement for weight control (as defined in Directive 96/8/EC energy restricted diets for weight reduction)‖ and ―Maintenance of weight loss‖ ...................................................................................... 205 ID 1419: ―Calcium‖ and ―Cardiovascular system‖ ................................................................................................ 205 9 ID 1421: ―Very low calorie diet (VLCD) Programme‖ and ―VLCD/low carbohydrate diets helps to the maintenance of normal blood lipid profile‖ ....................................................................................................... 206 ID 1426: ―Fruit-rich diet‖ and ―Weight management via fibre‖ ............................................................................ 206 ID 1427: ―Fruit-rich diet‖ and ―Modulation of glycemic response‖ ...................................................................... 206 ID 1429: ―Vegetable-rich diet‖ and ―Weight management via fibre‖ ................................................................... 207 ID 1430: ―Vegetable-rich diet‖ and ―Modulation of glycemic response‖ ............................................................. 207 ID 1434: ―Alpha-lipoic-acid‖ and ―Antioxidant properties‖ ................................................................................. 207 ID 1435: ―Alpha-lipoic-acid‖ and ―Metabolism of carbohydrates‖....................................................................... 209 ID 1437: ―Amylopectin‖ and ―Carbohydrate metabolism‖ ................................................................................... 210 ID 1438: ―Amylopectin and L-carnitine‖ and ―Carbohydrate and lipid metabolism‖ ........................................... 210 ID 1439: ―Antioxidant from processed fruits and vegetables and juices‖ and ―Antioxidant properties‖ .............. 210 ID 1442: ―Arabinogalactan (extract from larch tree)‖ and ―Intestinal health‖ ...................................................... 212 ID 1444: ―Aspartame sucrose substitute‖ and ―Weight control, including weight loss‖ ....................................... 214 ID 1445: ―Anthocyanins‖ and ―Antioxidant‖ ........................................................................................................ 214 ID 1448: ―Astaxanthin from Haematococcus pluvialis‖ and ―Beneficial for eye health‖ ..................................... 215 ID 1449: ―Astaxanthin from Haematococcus pluvialis‖ and ―Supports a healthy oxidative balance‖ .................. 216 ID 1450: ―Astaxanthin from Haematococcus pluvialis‖ and ―Supports a healthy cardiovascular system.‖ ......... 216 ID 1452: ―Beta-alanine‖ and ―Physical performance‖ ........................................................................................... 216 ID 1453: ―Beta-alanine‖ and ―Beta-alanine improves exercise performance‖ ...................................................... 217 ID 1454: ―Beta-alanine‖ and ―Beta-alanine improves cycling performance‖ ....................................................... 217 ID 1455: ―Beta-alanine‖ and ―Beta-alanine reduces muscle fatigue‖.................................................................... 217 ID 1456: ―Beta-alanine‖ and ―Beta-alanine improves muscle work capacity‖...................................................... 218 ID 1457: ―Beta-alanine‖ and ―Beta-alanine increases muscle carnosine stores‖ ................................................... 218 ID 1458: ―Beta-alanine‖ and ―Beta-alanine increases carnosine stores in fast twitch muscle fibres‖ ................... 219 ID 1460: ―Beta-Carotene‖ and ―Antioxidant properties/Protection of DNA‖ ....................................................... 219 ID 1461: ―Beta-Carotene‖ and ―Skin aging/Skin health‖ ...................................................................................... 222 ID 1463: ―Beta-Carotene‖ and ―Immune health in relation to UV-radiation‖ ....................................................... 224 ID 1464: ―Beta carotene in combination with vitamin E and vitamin C‖ and ―Eye health and vision‖ ................ 225 ID 1465: ―Beta-glucans‖ and ―Blood lipid profile‖ ............................................................................................... 230 ID 1466: ―Beta sitosterol‖ and ―Cholesterol‖ ........................................................................................................ 234 ID 1468: ―Betalains‖ and ―Antioxidant properties‖............................................................................................... 237 ID 1475: ―Bovine colostrum‖ and ―Supports an increase in lean body mass when combined with resistance exercise‖ ............................................................................................................................................................ 238 ID 1481: ―Broccoli Sprout Powder‖ and ―Antioxidant properties‖ ....................................................................... 239 ID 1483: ―C12-peption‖ and ―Vascular health‖..................................................................................................... 239 ID 1484: ―Caffeine‖ and ―Fat metabolism/Energy expenditure‖........................................................................... 241 ID 1485: ―Caffeine (from tea/coffee/chocolate or added in pure form)‖ and ―Cognitive and mental performance‖ ..................................................................................................................................................... 243 ID 1486: ―Caffeine (from tea/coffee/chocolate or added in pure form)‖ and ―Physical Performance (short term and endurance activities)‖ ......................................................................................................................... 249 10 ID 1487: ―Caffeine‖ and ―Supports resting metabolic rate and thermogenesis‖ ................................................... 252 ID 1488: ―Caffeine‖ and ―Supports exercise performance (reduction in perceived exertion, improve time to exhaustion and exercise capacity)‖ .................................................................................................................... 253 ID 1489: ―Caffeine‖ and ―Endurance during short term high intensity exercise‖ ................................................. 256 ID 1491: ―Caffeine (with or without carbohydrate)‖ and ―Enhances mental alertness during intense muscular activity.‖ ............................................................................................................................................................ 257 ID 1492: ―Carnitine‖ and ―Fat metabolism‖ .......................................................................................................... 258 ID 1493: ―Carnitine‖ and ―Muscle metabolism / Recovery after exercise‖........................................................... 260 ID 1494: ―Carnitine‖ and ―Heart health‖ ............................................................................................................... 262 ID 1495: ―Carnitine‖ and ―Pregnancy‖ .................................................................................................................. 264 ID 1496: ―Carotenoids from fruits and vegetables juices‖ and ―Antioxidant properties‖ ..................................... 265 ID 1497: ―Casein protein hydrolysate‖ and ―Physical performance‖ .................................................................... 268 ID 1499: ―Chitosan‖ and ―Weight Management‖ .................................................................................................. 269 ID 1501: ―Acerola‖ and ―Antioxidant activity‖ ..................................................................................................... 270 ID 1504: ―Chondroitin‖ and ―Joint Health‖ ........................................................................................................... 271 ID 1505: ―Chondroitin Sulphate‖ and ―Joint Health and Mobility‖ ...................................................................... 274 ID 1506: ―Cocoa flavanols‖ and ―Antioxidative properties‖ ................................................................................. 276 ID 1507: ―Cocoa flavanols‖ and ―Vascular health‖ ............................................................................................... 278 ID 1509: ―Coenzyme Q10 (Ubiquinone)‖ and ―Heart health‖ .............................................................................. 283 ID 1510: ―Coenzyme Q10 (Ubiquinone)‖ and ―Antioxidant properties, Normal antioxidant activity‖ ................ 285 ID 1513: ―Collagen hydrolysate‖ and ―Joint health‖ ............................................................................................. 288 ID 1514: ―Combination of millet extract + L-cystine + vitamin B5 (calcium panthothenate)‖ and ―Support of hair growth‖ ....................................................................................................................................................... 291 ID 1516: ―Conjugated linoleic acid (CLA)‖ and ―Weight management‖ .............................................................. 291 ID 1517: ―Conjugated linoleic acid (CLA)‖ and ―Insulin sensitivity‖ .................................................................. 293 ID 1518: ―Conjugated linoleic acid (CLA)‖ and ―Body Weight management‖ .................................................... 293 ID 1520: ―Creatine‖ and ―Energy metabolism‖ ..................................................................................................... 295 ID 1521: ―Creatine‖ and ―Muscular effort‖ ........................................................................................................... 298 ID 1522: ―Creatine‖ and ―Muscular effort / Recovery‖ ......................................................................................... 298 ID 1523: ―Creatine‖ and ―Bodily Constitution‖ .................................................................................................... 299 ID 1524: ―Creatine‖ and ―Cognitive performance‖ ............................................................................................... 300 ID 1525: ―Creatine‖ and ―Increasing Strength‖ ..................................................................................................... 300 ID 1526: ―Creatine‖ and ―Increasing Mass‖ .......................................................................................................... 304 ID 1527: ―Creatine‖ and ―Increasing Workout Capacity‖ ..................................................................................... 304 ID 1528: ―Creatine‖ and ―Brain / Memory / Older people / Parents‖ .................................................................... 304 ID 1529: ―Cystein rich protein hydrolysates‖ and ―Glutathione metabolism‖ ...................................................... 305 ID 1531: ―EAS Creatine (EAS Phosphagen)‖ and ―Increasing Strength‖ ............................................................. 306 ID 1532: ―EAS Creatine (EAS Phosphagen)‖ and ―Increasing Mass‖ .................................................................. 306 ID 1533: ―EAS Creatine (EAS Phosphagen)‖ and ―Increasing Lifting Volume and Performance‖ ..................... 307 ID 1534: ―EAS Creatine (EAS Phosphagen)‖ and ―Increasing Power‖ ................................................................ 308 11 .............ID 1535: ―EAS Creatine (EAS Phosphagen) and ―Increasing Work Capacity‖ ................................................ 309 ID 1542: ―EAS Phosphagen HP‖ and ―Increasing Lifting Volume and Performance‖ ............................ rich in EGCG‖ and ―Blood glucose levels‖ ..... 309 ID 1541: ―EAS Phosphagen HP‖ and ―Increasing Mass‖.................................. 327 ID 1570: ―Glutamine‖ and ―Mental health‖............................................................. 313 ID 1547: ―Ester-C‖ and ―Antioxidant properties/Immune health‖ ........................................................................................hydroxy B............. 321 ID 1560: ―Glucomannan (Konjac)‖ and ―Cholesterol level‖ .................................................... 320 ID 1559: ―Glucomannan (Konjac)‖ and ―Reduction of glycemic response‖ ............................................................................................................................................................................................ 308 ID 1537: ―EAS Phosphagen Elite‖ and ―Increasing Work Capacity‖ .. 309 ID 1538: ―EAS Phosphagen Elite‖ and ―Enhancing Training Volume & Intensity‖ ................................................................................................................ 309 ID 1544: ―Epigallo-catechin-3-gallate (EGCG) / Green tea extract.. rich in EGCG‖ and ―Cardio-vascular health‖ ............................................................................................... 336 12 ...............................................................................................................methylbutyrate monohydrate)‖ and ―Increasing strength‖ ............................................................................................ 331 ID 1575: ―5-HTP‖ and ―Mood enhancement‖ .... 319 ID 1557: ―Glucomannan (Konjac)‖ and ―Bowel / colonic function‖ .................................................. 326 ID 1564: ―Glucosamine (Glucosamine HCl or Glucosamine sulphate) and Chondroitin sulphate‖ and ―Joint health‖ .......... 322 ID 1561: ―Glucosamine‖ and ―Joint health‖ ............................................................................................................................................................................................................................................................................. 330 ID 1572: ―Hyaluronic Acid‖ and ―Joint Health‖ ..................................................................... 312 ID 1546: ―Epigallo-catechin-3-gallate (EGCG) / Green tea extract................................................................................................ 316 ID 1553: ―Formulated palm and oat oil emulsion‖ and ―Weight management‖............................................ 333 ID 1579: ―HMB (B-hydroxy B-methylbutyrate monohydrate)‖ and ―Increasing Mass‖ .......................................... 309 ID 1540: ―EAS Phosphagen HP‖ and ―Increasing Strength‖ ............................................................................ allowing sports people to improve performance‖ .......................................................................................... 329 ID 1571: ―Green Lipped Mussel Extract.......... 332 ID 1578: ―HMB (B........................... 309 ID 1543: ―EAS Phosphagen HP‖ and ―Enhancing Anaerobic Working Capacity‖...........methylbutyrate monohydrate)‖ and ―Increasing exercise lactate threshold and VO2 peak‖ ...................................................................................................... 310 ID 1545: ―Epigallo-catechin-3-gallate (EGCG) / Green tea extract..... especially knees‖ .......................................................................................................................................................... 320 ID 1558: ―Glucomannan (Konjac)‖ and ―Prebiotic action / Bifidogenic action‖ ................................................................................................................... 331 ID 1577: ―HMB (B-hydroxy B-methylbutyrate monohydrate)‖ and ―Minimize muscle protein breakdown‖ ........................................................................... 322 ID 1562: ―Glucosamine‖ and ―Joint health........................................................................... 335 ID 1580: ―HMB (B-hydroxy B................ rich in EGCG‖ and ―Weight management‖ ......................................................................................................................... 319 ID 1556: ―Glucomanan‖ and ―Weight management‖ ............................................. 315 ID 1552: ―Evening primrose oil and fish oil‖ and ―Bone health‖ ..................................... 318 ID 1555: ―Glisodin‖ and ―Prevents lactic acid build up.......................................... 327 ID 1565: ―Glucosamine hydrochloride‖ and ―Joint Health‖ ................................................................A freeze dried powder extract of New Zealand Green Lipped Mussel Perna canaliculus‖ and ―Joint health‖ .. 308 ID 1536: ―EAS Phosphagen Elite and ―Increasing Strength‖ ..... 326 ID 1563: ―Glucosamine (Glucosamine HCl or Glucosamine sulphate)‖ and ―Joint health‖ ............................................... 309 ID 1539: ―EAS Phosphagen Elite‖ and ―Increasing Exercise Thresholds‖ ................................................................ 316 ID 1554: ―Gamma Linolenic acid (GLA) from Evening primrose Oil‖ and ―Skin health‖ .. .......... 347 ID 1605: ―Lutein‖ and ―Skin health‖ ................. haemoglobin and energy production‖ ............................................................................................................................................. 379 ID 1630: ―Phosphatidyl choline / lecithin‖ and ―Cholesterol / Heart health‖ ....... Stigmastanol......... 366 ID 1614: ―Medium Chain Triglycerides (MCT)‖ and ―Weight management‖ ............................................................................. Campesterol................................................................................................................... 376 ID 1619: ―Mycoprotein‖ and ―Cholesterol maintenance‖ ........................................................................................................................................................................................ 345 ID 1603: ―Lutein (Marigold Extract)‖ and ―Required for Macular Pigmentation in the eyes which helps maintenance of healthy eye functions‖ ........................................... 371 ID 1615: ―Methionine‖ and ―Lipid metabolism‖ ........................................................................................................................................................................ 375 ID 1616: ―Methylsulfonylmethane (MSM)‖ and ―Joint support‖ ............................................... 343 ID 1595: ―Lactic acid bacteria/ Entero coccus faecium‖ and ―Intestinal health‖ .................... 338 ID 1586: ―HMB and HMB/KIC combinations‖ and ―normal muscle repair‖ .............theanine‖ and ―Cognitive function‖ .................................................. 386 ID 1634: ―Phytosterols (mixture of Beta-sitosterol........................................................................................................................................................................... 378 ID 1621: ―Natural Palm Oil Carotenes‖ and ―Antioxidant properties/protection of DNA‖ .................... Brassicasterol............................................................................................................. 338 ID 1588: ―Inositol (Common Names: Inositol.......................................................................................................... 375 ID 1617: ―Methylsulfonylmethane (MSM) in combination with glucosamine HCl‖ and ―Joint support synergistic effect‖ ............... 339 ID 1589: ―Iron-Micronised microencapsulated ferric pyrophosphate‖ and ―Blood..................................... 361 ID 1609: ―Lycopene‖ and ―Prostate health‖ ..... 341 ID 1594: ―Lacprodan CGMP-10 (active ingredient: Sialic acid)‖ and ―Plays a role in development of the brain‖ ..................... 344 ID 1597: ―Lecithin‖ and ―For fat metabolism‖ ................................................................................... Campestanol)‖ and ―Cholesterol metabolism‖ ......................... 345 ID 1600: ―L................... 338 ID 1587: ―HMB and HMB/KIC combinations‖ and ―changes in muscle strength during training‖ .................. myo-inositol)‖ and ―Cognitive and mental performance‖ ....................................................................................................... 345 ID 1604: ―Lutein‖ and ―Eye health‖ ............................................................................................... 341 ID 1591: ―Isomalt‖ and ―Dental health – General‖ ................................................................ 378 ID 1627: ―Omega-3 fatty acids (Hi-EPA) with Glucosamine‖ and ―Joint health‖ ............................................................. 345 ID 1602: ―L-glutamine‖ and ―Intestinal Health‖ ......................... 359 ID 1608: ―Lycopene‖ and ―Antioxidant properties‖ ........................................................................ID 1582: ―HMB‖ and ―lean body mass‖ ................ 376 ID 1618: ―Moderated sodium carbohydrate-electrolyte drinks‖ and ―Hydration‖ ............. 378 ID 1629: ―Phenylalanine‖ and ―Mental health‖ ........ Stigmasterol............................................................ 382 ID 1632: ―Phosphatidyl serine‖ and ―Mental health / Cognitive function‖ ............ 377 ID 1620: ―Mycoprotein‖ and ―Reduction in calorie content due to increased satiety‖ .............................................................................................................................................................................................................................. 363 ID 1611: ―Lycopenes from tomato juices‖ and ―Antioxidant properties‖ ..... 380 ID 1631: ―Phosphatidyl choline / lecithin‖ and ―Cognitive function‖ .......... 338 ID 1585: ―HMB and HMB/KIC combinations‖ and ―muscle recovery after training‖ ..................................................................................................................................................................................................... 340 ID 1590: ―Isomalt‖ and ―Low glycemic properties‖............................... 337 ID 1584: ―HMB and HMB/KIC combinations‖ and ―exercise induced muscle breakdown‖ ..................... 391 ID 1636: ―Polyphenols from processed fruits and vegetables and juices‖ and ―Antioxidant properties‖ ................ Ergostanol...................................................................................................................................................................... 392 13 .......... .............................................................................................................................................................................................................................................................. 460 ID 1679: ―VitaGrape® Grape Seed Extract 95% OPC‖ and ―Excellent source of oligoremic proanthocyanidins that have been associated with the reduction of oxidative stress................................... 477 ID 1711: ―Amino acids‖ and ―Stimulate protein synthesis‖ .................................................................................. 468 ID 1683: ―Whey Protein Milk Mineral Complex‖ and ―Weight management‖ ......... 468 ID 1682: ―Wheat dextrin‖ and ―Heart Health‖ ............................................................................... 476 ID 1697: ―Lattasi (beta-galattosidasi)‖ and ―Digestion‖........ 418 ID 1645: ―Propolis‖ and ―Maintain oral healththrough the presence of high levels of antioxidant bioflavonoids‖............................................................................ 467 ID 1681: ―Wheat dextrin‖ and ―Bowel health/SCFA production‖ ........................................... 425 ID 1647: ―Quercetin‖ and ―Antioxidant properties‖ ................................................................................................................................................................................................................................................................................. rich in EGCG‖ and ―Protection of body tissues and cells from oxidative damage‖ ................ 403 ID 1639: ―Polyphenols from olive (olive fruit........................................................................................................................................... olive and cacao in particular)‖ and ―Antioxidant properties‖ ............ 470 ID 1684: ―Zeaxanthin‖ and ―Eye health and vision‖ .................................................... 452 ID 1656: ―Standardised Potato Extract‖ and 2Satiety/Weight management/Promotion of CCK release and soy foods‖ .........................................................................................................................‖...................................... olive mild waste waters or olive oil)‖ and ―Lipid metabolism‖ .............................................................. skin and hair‖ .... 477 14 ...........................ID 1637: ―Polyphenols (general and from grape.................. 405 ID 1640: ―Polyphenols from red wine‖ and ―Antioxidant properties‖ .. 430 ID 1650: ―Rye Grass Pollen‖ and ―Maintenance of normal urinary function‖ .......................................................................................................... oleuropein complex polyphenol belonging to ai secoiridoids‖ and ―Antioxidant activity......................... 431 ID 1652: ―Silica / Silicious earth‖ and ―Essential part of the connective tissues................. 433 ID 1654: ―Soy Isoflavones‖ and ―Menopause‖ ..................................... 454 ID 1657: ―Stearic acid‖ and ―Lipid metabolism‖ ............................................................. 395 ID 1638: ―Polyphenols from olive (olive fruit.................... 433 ID 1655: ―Soy Isoflavones‖ and ―Bone health and soy foods‖........... 406 ID 1641: ―Polyphenols derived from red wine‖ and ―Lipid metabolism‖ ................................... 476 ID 1706: ―squalene idrocarburo‖ and ―Antioxidant activity....................................................................... olive mild waste waters or olive oil)‖ and ―Antioxidant properties‖................................... 412 ID 1643: ―Polyphenols from tea‖ and ―Antioxidant properties / Heart health‖ .............. they protect body cells and LDL from oxidative damages‖ ........................................................................ 476 ID 1708: ―Epigallo-catechin-3-gallate (EGCG) / Green tea extract.......................................................................................................................... 456 ID 1658: ―Taurine‖ and ―Antioxidant properties‖ .... 471 ID 1690: ―Alfa-galattosidasi‖ and ―Digestion‖........................... 427 ID 1648: ―Red yeast rice (Monascus Purpureus / Ang-Khak)‖ and ―Cholesterol‖.............. protection of body tessue and skin from oxidant agents (UV rays)‖ ............................................................................................ 414 ID 1644: ―Propolis‖ and ―Immune Support Propolis helps to protect cells from free radical damage and helps maintain a healthy immune system through action of high levels of antioxidant bioflavonoids..................... 424 ID 1646: ―Protein hydrolysate‖ and ―Insulin secretion and blood sugar levels‖ ..................................................................................... 476 ID 1696: ―hydroxytyrosol simple phenol.................... 464 ID 1680: ―Wheat dextrin‖ and ―Bowel health/digestive health/bowel movement‖ ..................‖ ............ 460 ID 1671: ―Tryptophan‖ and ―Mental and nerve function‖ ............................................................................................................................ 456 ID 1660: ―Taurine‖ and ―Ergogenic role in sports and exercise‖ ............................................................ 432 ID 1653: ―Sodium bicarbonate‖ and ―Supports an optimal pH environment in the stomach‖ .................... ......................‖ .....5-13..................................................................................................................... Healthy women and men...................................... sodium salt‖ and ―Respiratory health‖ ............................................................................ 477 ID 1714: ―Ascorbic acid‖ and ―Respiratory health‖ ....................................... 481 ID 1731: ―Hyaluronic acid / Sodium Hyaluronate‖ and ―Joint Health‖ ............................consisting primarily of 1-Octacosanol............. 485 ID 1765: ―Standardized grape seed extract [dry extract from grape seeds of vitis viniferaL......................... 481 ID 1730: ―Glycerol‖ and ―Respiratory health‖ ................................................................................................................. 480 ID 1724: ―Copper enriched Saccharomyces cerevisiae ATY-SC-108‖ and ―Skin and hair pigment‖ ........ ch-OSA is a stabilized and concentrated source of orthosilicic acid)‖ and ―Helps support hair quality by helping to maintain healthy connective tissue in the dermis............................. 477 ID 1715: ―Ascorbic acid........................................................ Healty women and men.................... 1-Tetracosanol and 1-Hexacosanol ............................................. 480 ID 1727: ―Copper enriched Saccharomyces cerevisiae ATY-SC-108‖ and ―Transport and metabolism of iron‖ . (Vitaceae)............................................ 480 ID 1721: ―Co-Enzyme Q 10‖ and ―For maintenance and promotion of heart health‖ ............................... 477 ID 1716: ―Bonito protein peptide‖ and ―Natural Blood Pressure Support‖ ............................................................................................................... 486 ID 1771: ―Gamma-linolenic acid‖ and ―Vascular health‖ ..........................0% proanthocyanidins]‖ and ―Antioxidant protection system‖ .............. 485 ID 1768: ―Gamma-amino butyric acid (GABA)‖ and ―Mental health‖.......... 480 ID 1722: ―Copper enriched Saccharomyces cerevisiae ATY-SC-108‖ and ―Connective tissues‖ ...... 484 ID 1762: ―D.............................. 480 ID 1726: ―Copper enriched Saccharomyces cerevisiae ATY-SC-108‖ and ―Protection of body tissues and cells from oxidative damage‖ ................. 479 ID 1720: ―Co-Enzyme Q 10‖ and ―For physiological energy‖ ............Tagatose (ingredient not found in the spanish food laws)‖ and ―Postprandial blood glucose‖ ..................................................................... 482 ID 1756: ―Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109‖ and ―Bone formation‖ .................... 484 ID 1764: ―Hesperidin (a component of citrus peel extract and precursor of hesperitin) (ingredient not found in the spanish food laws)‖ and ―Bone health‖ ................................. 478 ID 1719: ―choline-stabilized orthosilicic acid (ch-OSA) (The mineral silicon is present in water as orthosilicic acid............................................ 1-Triacontanol........................................................................................ 486 ID 1772: ―Gamma-linolenic acid‖ and ―Immune health‖ ..................................................................................‖ ................ 481 ID 1748: ―Policosanol [from sugarcane wax (Saccarum officinarum)]‖ and ―Support for Healthy Blood Lipid Levels‖ .......................................................................... 478 ID 1717: ―Chlorophyllin [Sodium copper chlorophyllin] and ―Relief for Gastric Discomfort‖ ...................‖ And ―Cholesterol‖ ......................... solvent of extraction acetone/water 8... 484 ID 1763: ―Hesperidin (a component of citrus peel extract and precursor of hesperitin) (ingredient not found in the spanish food laws)‖ and ―Cardiovascular health‖ .................................................................. 483 ID 1759: ―Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109‖ and ―DNA synthesis / cell division‖..................................................................................................ID 1712: ―Arginine‖ and ―For muscle integrity and haematopoiesis (red blood cells building)‖ .................. 482 ID 1757: ―Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109‖ and ―Immune System‖ ...............................................................................................from sugar cane (Saccharum officinarum)..................... 486 15 ................... ch-OSA is a stabilized and concentrated source of orthosilicic acid)‖ and ―Maintenance and promotion of healthy connective tissue in bone by stimulating bone collagen synthesis..................................................................................................................................................................... 481 ID 1747: ―Policosanol / Blend of aliphatic alcohols ............ 478 ID 1718: ―choline-stabilized orthosilicic acid (ch-OSA) (The mineral silicon is present in water as orthosilicic acid.............. 483 ID 1758: ―Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109‖ and ―Protection of body tissues and cells from oxidative damage‖ ................................................................................................. 481 ID 1751: ―Selenomethionine enriched Saccharomyces cerevisiae ATY-SC-107‖ and ―Protection of body tissues and cells from oxidative damage‖ .......................................................... ... 492 ID 1804: ―Flavonoids in cranberry juice‖ and ―Antioxidativity‖ ......................... 494 ID 1810: ―Floral pollen + fermented pollen + royal jelly‖ and ―Bone‖ .............. 501 ID 1834: ―Phospolipids‖ and ―Immunity‖ ................................................................................................................. 493 ID 1808: ―Flaxseed husk extract/lignans‖ and ―Antioxidativity‖ .................................................................................................................................................................. 501 ID 1839: ―Pollen pistil extract + SOD‖ and ―Mental state and performance............................... 505 ID 1853: ―Shark cartilage‖ and ―Joints‖ ............... 495 ID 1813: ―Green-lipped mussel (Perna canaliculus)‖ and ―Musculoskeletal system‖ ........................ 486 ID 1779: ―Lutein‖ and ―Antioxidant activity‖ ........................... 489 ID 1800: ―Epigallocatechin gallate (ECGC) + caffeine‖ and ―Weight control‖ ........................................................... 488 ID 1796: ―Carotenoids (alpha................................................... phenolic acids.............................................................................................................................. IPP + valine-proline-proline.................................................................................................................................................................................................... 486 ID 1783: ―Rutin‖ and ―Vascular health‖ ...................... 498 ID 1832: ―Peptides (isoleucine-proline-proline................................... 487 ID 1789: ―Anthocyanidines + proanthocyanidines‖ and ―Carbohydrate metabolism and insulin sensitivity‖ ............................. 491 ID 1802: ―Fenugreek + alpha-lipoic acid + chrome‖ and ―Blood lipid levels‖ ....................................................................................................................................... antioxidativity‖............... 496 ID 1822: ―L-carnitine‖ and ―Sexual organs..................................................... helveticus lactic acid bacteria)‖ and ―Cardiovascular system‖ ................ID 1774: ―Gamma-linolenic acid‖ and ―Bone health‖ ............ 492 ID 1805: ―Flavonoids from green tea................................................................................................................... 503 ID 1850: ―Sea buckthorn oil and flavonoids extracted from sea buckthorn berries‖ and ―Antioxidativity‖ ..... apple and onion‖ and ―Weight control‖ ...................... anthocyanins....................................................... 500 ID 1833: ―Phenol compounds of cranberry and lingonberry (catechins........................ 496 ID 1823: ―L-carnitine + green tea extract‖ and ―Weight control‖ ........................ flavonoids....... 505 ID 1852: ―Shark cartilage‖ and ―Joints....................................................................................... 495 ID 1818: ―Lactase enzyme‖ and ―Digestion‖ .. 487 ID 1785: ―Superoxide dismutase‖ and ―Antioxidant activity‖ ....................................................................... 501 ID 1835: ―Phospolipids‖ and ―Mental state and performance‖ ................................................ 490 ID 1801: ―Fenugreek + alpha-lipoic acid + chrome‖ and ―Carbohydrate metabolism and insulin sensitivity‖ ............... 487 ID 1794: ―Boswellia + shark cartilage extract‖ and ―Joints‖ ................................................................................... lycopene)‖ and ―Skin‖.............................................. 489 ID 1799: ―Citrus bioflavonoids‖ and ―Joints‖ ... supportive tissue‖ ........................................................................................................................................... 505 16 ................. beta and gamma carotene............................................................ hormone activity‖ ............................................................................ apple and onion‖ and ―Antioxidativity‖ ................... 491 ID 1803: ―Fermented whey‖ and ―Gut health‖ .................................................................................................................... 502 ID 1840: ―Pollen pistil extract + SOD‖ and ―Physical performance and condition‖ ... 497 ID 1831: ―Peptides (milk products fermented with L.............................................................................. lignans) + ascorbic acid‖ and ―Antioxidativity‖ .................... 497 ID 1824: ―L-carnosine‖ and ―Physical performance and condition‖ .... VPP)‖ and ―Cardiovascular system‖ ....................................... 489 ID 1797: ―Chlorella algae (Chorella pyrenoidosa)‖ and ―Antioxidativity‖ ... 502 ID 1841: ―Proanthocyanidins in cranberry juice‖ and ―Urinary tract‖ .......................................................................... 495 ID 1816: ―Herbal yeast plasmolycate (saccharomyces cerevisiae)‖ and ―Mental state and performance‖ .................................................................... 487 ID 1784: ―Rutin‖ and ―Antioxidant properties‖......................................... 492 ID 1806: ―Flavonoids from green tea.................................................................................................. 497 ID 1828: ―L-5 hydroxytyptophan‖ and ―Mental state and performance‖ ......................................................... .... skin and nails‖ .......... lactating women and children and those with brittle bones or calcium deficiency..........‖ .................... children and those with brittle bones or calcium deficiencies........................ 513 17 ........... Sodium alginate may decrease the absorption of calcium if taken concomitantly therefore it should be avoided by pregnant.............. Also those with calcium deficiency or brittle bones................................................. 512 ID 1902: ―Sunfiber(enzymatically partially depolymerised guar gum)‖ and ―Intestinal health and regularity........ Was food on Irish market before 1st July 2007: No‖ and ―Health benefits of food: Alginate can reduce the activity of digestive enzymes and reduce glucose absorption................................................................................................‖ . Description of food in terms of food legislation categories: food not covered by specific food legislation... Reasons for excluding these groups: Sodium alginate may decrease the absorption of calcium if taken concomitantly therefore it should be avoided by pregnant...... 507 ID 1867: ―Spirulina‖ and ―Antioxidative‖ ..... 508 ID 1874: ―Methylsulpony/methane (MSM)‖ and ―To help strengthen hair......... Was food on Irish market before 1st July 2007: No‖ and ―Health benefits of food: Triphala has a strong antioxidant effect............. 507 ID 1868: ―Sodium alginate and ascophyllum nodosum‖ and ―Alginate can reduce the activity of digestive enzymes and reduce glucose absorption............................................... If exceptions describe: Pregnant............................. Do benefits relate to a disease risk factor: Yes...... lactating women............... 509 ID 1879: ―Name of Food product: gelatin & cystine..... 508 ID 1872: ―Ipriflavone‖ and ―Ipriflavone supresses bone resorption‖ .......... lactating women and children............... Do benefits relate to a disease risk factor: No Target group: Adults aged 18 years and over with some exceptions.. 510 ID 1884: ―Name of Food product: Product-specific claim: sodium alginate... In healthy people:‖....................................... Piperine increases the bioavailability of the un-trapped HCA and enhances satiety...................... skin and nails..... Do benefits relate to a disease risk factor: No Target group: All adults aged 18 years and over‖ ...................... 509 ID 1881: ―Name of Food product: Product-specific claim: Sodium alginate and ascophyllum nodosum.................. 509 ID 1880: ―Name of Food product: Triphala.. 507 ID 1869: ―Glucosamine sulfate‖ and ―Glucosamine sulfate possesses antiinflammatory activity‖ ...... lactating women and children............ Reasons for excluding these groups: HCA can influence the body‘s own production of cholesterol and therefore it may influence indirectly the production of sterols........................ Pregnancy is a time of extreme sensitivity to steroid hormones so HCA should be avoided and also during lactation.................... 506 ID 1865: ―Theanine + oat shoot extract‖ and ―Mental state and performance‖...................... Description of food in terms of food legislation categories: Food supplement Was food on Irish market before 1st July 2007: No‖ and ―Health benefits of food: healthy hair............. Description of food in terms of food legislation categories: food not covered by specific food legislation.................................................. Do benefits relate to a disease risk factor: No Target group: Adults aged 18 years and over with some exceptions If exceptions describe: Pregnant........... 509 ID 1878: ―Olive Biophenols‖ and ―A potent source of olive biophenols that have anti-UV damage properties‖........... Polyphenols found in ascophyllum nodosum inhibit enzyme activity and reduce the glycaemic load of meals‖ ............. Triphala is not suitable during pregnancy as its "downward flowing" energy is believed to favour miscarriage‖ ........................ID 1857: ―Sodium bicarbonate + wine acid + anhydrous citric acid + sodium carbonate‖ and ―Gut health‖ ........ Reasons for excluding these groups: These groups of people should avoid taking Triphala just as they should avoid taking any unnecessary supplements due to being vulnerable populations................. 508 ID 1875: ―Olivenol livin' BEGIN‖ and ―A potent source of antioxidant‖ ............. 511 ID 1899: ―Lycopenes from tomato pulp and sauces‖ and ―Antioxidant Properties‖ ........................................ Target group: Adults aged 18 years and over with some exceptions.. lactating women and children...... If exceptions describe: Pregnant................ It may also trap a portion of HCA.................... Description of food in terms of food legislation categories: Food supplement.................................................................................................................. Polyphenols found in ascophyllulm nodosum inhibit enzyme activity and reduce the glycemic load of meals......................................... HCA and piperine............................................. Was food on Irish market before 1st July 2007: No‖ and ―Health benefits of food: Alginate forms a gel in the stomach and promotes an immediate feeling of satiety........................................................ People with brittle bones or calcium deficiency.... 509 ID 1877: ―Olive Biophenols‖ and ―A potent source of olive biophenols with strong anti-bacterial properties‖ ......................................................................................................................................................... 506 ID 1858: ―Spirulina alga‖ and ―Weight control‖ ........................................................... .................................................................... In people receiving total or supplemental enteral nutrition‖ .................................................................................................................................................................................................................ubiquinone‖ and ―Blood pressure‖ ........ 515 ID 1914: ―Lutein/........................................................... 535 ID 1961: ―Lecithine de soja: soy lecithin‖ and ―Rate cholesterol stabilization‖ ..................................................................................... Reduces the amount of oxidative stress or cell destruction caused by free radicals................................................... 514 ID 1911: ―Coenzyme Q10.... 515 ID 1916: ―L-Methionine‖ and ―Epidermic tissue‖........................................................................................................(Ubiquinone)‖ and ―Physical activity‖ ...................................................................................................................................................................... 527 ID 1937: ―CLA (conjugated linoleic acid)‖ and ―Antioxidant capability‖ ........... 528 ID 1946: ―Adenosine triphosphate (ATP)‖ and ―Muscular and nervous system‖ ............................................................................................................ hair................................. joints. 529 ID 1951: ―Policosanols‖ and ―Cholesterol‖ ............................................... 525 ID 1931: ―Lutein‖ and ―Macular pigment Blue light filter in eyes Antioxidant activity‖ ..................................... 523 ID 1927: ―Lacprodan PL-20.............. 526 ID 1934: ―Sulphoraphane Glucosinolate‖ and ―Enhancing anti-oxidant activity............ 513 ID 1904: ―Sunfiber(enzymatically partially depolymerised guar gum)‖ and ―Intestinal health and regularity.............................................................. 515 ID 1913: ―Coenzyme Q10............................................................. 515 ID 1918: ―Astaxanthin from Haematococcus pluvialis‖ and ―Beneficial for connective tissue and joints‖ ................................................................................. Milk protein concentrate with a high content of phospholipids............................................................................................................ 530 ID 1953: ―Melatonin‖ and ―Sleep-wake cycle regulation‖ .. 528 ID 1942: ―Lycopenes from tomato juice‖ and ―Oxidative stress control‖ ..... 514 ID 1905: ―D-Tagatose‖ and ―Intestinal health‖ .............................................. 514 ID 1907: ―Naringin (a component of citrus peel extract and precursor of naringenin)‖ and ―Bone health‖ ................................................. 515 ID 1915: ―L-Lysine‖ and ―Bones‖ ............................................................................................................................... (Effective component: Phosphatidyl serine)‖ and ―Stress reduction.................................................................................. In people with irritable bowel syndrom:‖ ................... 535 18 .................................... 523 ID 1929: ―L-Tyrosine‖ and ―Essential for muscle function and for optimal muscle contraction‖ ...... 533 ID 1957: ―Resveratrol‖ and ―Antioxydant properties‖ ............................. Silicon is an essential element for normal structure of connective tissues such as skin.........ID 1903: ―Sunfiber(enzymatically partially depolymerised guar gum)‖ and ―Intestinal health and regularity................................................................................................................... 528 ID 1945: ―Monométhylsilanetriol: other substance with nutritionnal or physiological effects‖ and ―Bioavailable Silicon form....................... 516 ID 1923: ―Creatine‖ and ―Increasing Power‖ .................. 516 ID 1922: ―Creatine‖ and ―Increasing Performance‖ ............. bone and blood vessels‖................................................................. 532 ID 1956: ―Pollen‖ and ―Menopause‖ ....................... 531 ID 1954: ―Policosanols‖ and ―Cholesterol‖ .......................... 527 ID 1941: ―Antioxidants from pomegranate juice‖ and ―Oxidative stress control‖ ............................................................................Zeaxanthin‖ and ―Antioxidant‖ ....................... 533 ID 1959: ―Taurine‖ and ―Antioxidant/ detoxifying properties‖.................................................. 527 ID 1940: ―Anthocyans from elderberry juice‖ and ―Antioxidant capability‖ .... 529 ID 1950: ―Collagen‖ and ―Skin health‖ ...............................................................................................................................................................................................................‖ .......... 520 ID 1924: ―EAS Creatine (EAS Phosphagen)‖ and ―Increasing time to exhaustion‖ ...... 525 ID 1932: ―Sodium Hyaluronate‖ and ―Related to joint health‖ ................. 535 ID 1962: ―Chlorogenic acids from Coffee‖ and ―Glucose homeostasis‖ ..................................... Enhanced memory function‖ ...................................................... 516 ID 1921: ―Chlorophyll in sprouted seed‖ and ―Naturally occuring antioxidants directly neutralise free radicals‖ ......................................................................................................... ....................... 542 ID 1987: ―Allium cepa (Common Name: Onion)‖ and ―Glucose metabolism‖ .................................................................................................. 539 ID 1973: ―SAMe (S-adenosylmethionine)‖ and ―Joint health...ID 1964: ―Single and oligomeric flavan-3-ols‖ and ―Vascular Activity‖ .................. 540 ID 1976: ―Acacia gum (gum arabic)‖ and ―Acacia gum and cholesterol‖ .................... 536 ID 1965: ―Single and oligomeric flavan-3-ols‖ and ―Dermal Activity‖ ............. mobility and joint comfort‖ ........................... 552 ID 1999: ―Aspalathus linearis (Common Name: Rooibos/Red bush)‖ and ―Antioxidant properties‖.......................................... 544 ID 1992: ―Alium sativum (Common Name: Garlic)‖ and ―Heart Health/ Blood lipids‖ ........................................................... 538 ID 1969: ―Polyphenols from French maritime pine bark‖ and ―antioxidant properties‖ ............ 554 19 ............................................................ 538 ID 1970: ―Superoxide dismutase (SOD)‖ and ―Antioxidant properties‖ ............ 543 ID 1991: ―Allium sativum (aged garlic) (Common Name: Aged garlic)‖ and ―Heart Health‖ ........................................ 537 ID 1966: ―Single and oligomeric flavan-3-ols‖ and ―Antioxidant Activity‖ ......................... 541 ID 1978: ―Astaxanthin from Haematococcus pluvialis‖ and ―Beneficial for connective tissue and joints‖ ............... 541 ID 1983: ―Lecithin‖ and ―Memory and concentration‖ ....................................................................... 550 ID 1998: ―Aronia melanocarpa (Common Name: Chokeberry)‖ and ―Vein health/Vascular health‖..... 543 ID 1989: ―Allium sativum (aged garlic) (Common Name: Aged garlic)‖ and ―Antioxidant activity‖ ........................ 548 ID 1997: ―Aronia melanocarpa (Common Name: Chokeberry)‖ and ―Antioxidant properties/source of anthocyanins and polyphenols with antioxidant activity‖ ..................................... 540 ID 1977: ―Acacia gum (gum arabic)‖ and ―Blood glucose control‖......................................................................... 542 ID 1986: ―Allium cepa (Common Name: Onion)‖ and ―Lipid metabolism‖........... 543 ID 1988: ―Allium cepa (Common Name: Onion)‖ and ―Antioxidative properties‖ ................................................................................................................................................................................................................................................................................................................................. 538 ID 1971: ―Glutathion‖ and ―Antioxydant‖ ..... Satokari R. Carbajal N. Hallak R. 2005. 799-802. Kirschner BS. 4949-4956. open-label study. Vilpponen-Salmela T. Ahokas JT. ID 1003: “Lactobacillus rhamnosus THT 030901” and “Natural defences/ immune system” 1 2 Gupta P. Matsuguchi T. 2 3 4 5 6 7 8 2 3 4 20 . 9. International Dairy Journal. 361-364. Darmawan S. Vaisman N. 2004. 351-354. Kirjavainen PV. Yokokura T. 24. 45-51. Applied and Environmental Microbiology. Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci. 453-457. Environ Health. Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp. 1999. 36. Korpela R. Salminen SJ. 6. 25. Saxelin M. double-blind placebo-controlled study. Wheeler KB. Weizman Z. 65. Letters in Applied Microbiology. Stan V. Guandalini S. ID 1002: “Lactobacillus rhamnosus THT 030901” and “Digestive health/ Intestinal flora” 1 Alander M. Gronlund MM. Wolf BW. 11761181. Niv E. Jakobsen M. 1999. Mattila-Sandholm T. 1999. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Appl Environ Microbiol. Matsumoto A. 219-223. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Tubelius P. 2005. Zachrisson A. 65. 31. Nagaoka M. 41. Recovery of Lactobacillus rhamnosus GG from human colonic biopsies. Yoshikai Y. Asli G. Persistence of colonization of human colonic mucosa by a probiotic strain. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Rosenfeldt Nielsen V. International Journal of Food Microbiology. El Nezami HS. Ishida K. Clin Diagn Lab Immunol. Ladefoged K. 1997. 1998. Hamada T. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. 10. placebo-controlled. Michaelsen KF. Takemoto T. Food Chem Toxicol. Adhesion of probiotic micro-organisms to intestinal mucus. randomized study. Engel P. Vilpponen Salmela T. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract.ID 1001: “Lactobacillus reuteri THT 030803” and “Natural defences/ immune system” 1 Jacobsen CN. 1085-1094. Andrew H. Tuomola EM and Salminen SJ. Lactobacillus rhamnosus GG. J Pediatr Gastroenterol Nutr. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. Connolly E. Paerregaard A. shermanii JS on mouse lymphocyte proliferation. Mattila Sandholm T. Isolauri E. Alander M. Ozaki Y. Appl Environ Microbiol. 115. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised. Tvede M. 4. Hara K. 2005. after oral consumption. Ishikawa K. Moller PL. Korpela R. 70. Fukushima H. Kirjavainen PV. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary. Salminen SJ. von Wright A. 2000. Makihira S. Takagi A. Wright PF. 24. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. 5-9. Alsheikh A. Garleb KA. Clin Diagn Lab Immunol. Ouwehand AC. Int J Food Microbiol. 259-266. Nishimura H. Hayford AE. 1998. 2003. Clin Nutr. Matsuzaki T. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind. Pediatrics. 95. Nikawa H. 1999. 623-630. Valeur N. Naftali T. Saxelin M. Ataya DG. Aimi R. 2004. Sandstrom B. 925-931. von Wright A. Kuitunen M. Viljanen M. Pessi T. 31. Adhesion of probiotic micro-organisms to intestinal mucus. 45-51. Isolauri E. von Wright A. Cell Microbiol. Schultz M. shermanii JS on mouse lymphocyte proliferation. 2004. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. 2000. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. Zimmermann K. Savilahti E. Sutas Y. Kiely B. J Dairy Res. Saxelin M. Salminen SJ. 9. Alander M. J Allergy Clin Immunol. Falk W. 351-354. Clin Diagn Lab Immunol. Shanahan F. Vilpponen-Salmela T. 1997. 73. Korpela R. Vaarala O. open-label study. 386S-392S. El Nezami HS. Pohjavuori E. Scholmerich J. Ahokas JT. J Allergy Clin Immunol. 114. 165-173. Feeney M. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. 70. Kirjavainen PV. Tiittanen M. Murphy L. Viljanen M. Isolauri E. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. 277-285. Flynn S. Savilahti E. ID 1006: “Lactobacillus salivarius THT 031001” and “Digestive health/ Intestinal flora” 3 4 5 6 1 Dunne C. 799-802. International Dairy Journal. Collins JK. Letters in Applied Microbiology. Fitzgerald G. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Vaarala O. 2003. Am J Clin Nutr. Grossmann J. Vilpponen-Salmela T. 1804-1808. Hurme M. Falk W. Clin Exp Allergy. Guandalini S. Kirschner BS. 2000. von Wright A. Korpela R. 30. 1999. 623-630. 21 . Lehn N. 2003. 277-285. J Dairy Res. J Pediatr Gastroenterol Nutr. Cell Microbiol. Grossmann J. Recovery of Lactobacillus rhamnosus GG from human colonic biopsies. 131-136. 2004. 6. 1999. Lehn N. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary. Wright PF. Korpela R. Ouwehand AC. after oral consumption. O'Sullivan GC. Pessi T. 41. 453-457. O'Halloran S. Korpela R. Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp.3 Pena JA and Versalovic J. Persistence of colonization of human colonic mucosa by a probiotic strain. Linde HJ. Clin Exp Allergy. ID 1004: “Lactobacillus rhamnosus THT 030902” and “Digestive health/ Intestinal flora” 4 5 6 1 Alander M. ID 1005: “Lactobacillus rhamnosus THT 030902” and “Natural defences/ immune system” 2 3 4 1 2 Gupta P. Pohjavuori E. 131-136. Saxelin M. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Pena JA and Versalovic J. Zimmermann K. 5. 1999. Tiittanen M. 1804-1808. O'Mahony L. 30. Isolauri E. 2003. Daly C. Applied and Environmental Microbiology. 2001. Kuitunen M. Mattila-Sandholm T. Morrissey D. Gronlund MM. 5. 70. Hurme M. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. 2000. Tuomola EM and Salminen SJ. Lactobacillus rhamnosus GG. 165-173. Salminen SJ. Satokari R. 1998. Thornton G. 114. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. Schultz M. 24. Sutas Y. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. Scholmerich J. 65. Kirjavainen PV. Mattila-Sandholm T. 361-364. Andrew H. International Journal of Food Microbiology. Linde HJ. 2003. Murphy L. Collins JK. 696-701. Kiely B. Collins JK. Kiely B. a predominant intestinal Lactobacillus species of the horse isolated from faeces of healthy horses. 2002. Clin Diagn Lab Immunol. Feeney M. Fitzgibbon J. 52. Ryan P. Marteau P. ID 1008: “Lactococcus lactis THT 090101” and “Digestive health/ Intestinal flora” 2 3 4 5 6 7 8 1 2 3 4 Drouault S. and immune modulation capacities of lactic acid bacteria. Watanabe K. 171. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826. Lactobacillus casei strain Shirota. McCarthy J. 53. 694-700. Desreumaux P. Shimazaki T. Fitzgibbon J. Shanahan F. 4881-4886. 10. O'Callaghan L. Fitzgibbon JJ. Fitzgibbon J. 1998. Alimentary Pharmacology & Therapeutics. O'Mahony L. Tagami Y. 2001. safety. Fitzgerald G. Mike A. O'Sullivan GC. and lysis of Lactococcus lactis in the digestive tract. placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Kiely B. Aliment Pharmacol Ther. Shanahan F. Gut. Survival. Double blind. 15. Lee G. 52. 48. Tanaka R. 975-980.. O'Callaghan L. Tuomola EM and Salminen SJ. 73. Vesa T. inflammation and tumour development in IL-10 knockout mice. Pochart P. McCarthy J. 2000. Daly C. 2003. 1999. O'Mahony L. Kavanagh E. Yuyama T. Shanahan F. Probiotic impact on microbial flora. safety. Lee G. 14. Dunn NW. 2003. Gut. Fitzsimons N. Collins JK. Int J Food Microbiol.2 McCarthy J. and immune modulation capacities of lactic acid bacteria. FEMS Microbiol Lett. Sibartie S. 386S-392S. 51-57. 290. Murphy L. Kado Y. 10. 2006. Use of mouse models to evaluate the persistence. 22 . O'Mahony L. 45-51. Sheil B. 1999. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Yuki N. Collins JK. Renault P. Shanahan F. Differentiation of Lactococcus lactis subspecies lactis and subspecies cremoris strains by their adaptive response to stresses. Yuki N. Lactobacillus fermentum KLD. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. inflammation and tumour development in IL-10 knockout mice. Kiely B. Corthier G. Morotomi M. Shilling D. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Collins JK. and Lactococcus lactis MG 1363 in the human gastrointestinal tract. O'Sullivan G. Aliment Pharmacol Ther. Ren J. Shanahan F. Flynn S. Vaughan EE. 2003. 1219-1225. Kirwan WO. Shanahan F. Thornton G. Am J Physiol Gastrointest Liver Physiol. Applied and Environmental Microbiology. Scully P. Survival of a probiotic. Kiely B. Am J Clin Nutr. Ehrlich SD. 15. Bennett MW. 2001. McCarthy J. placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. O'Sullivan GC. 52. nov. Probiotic impact on microbial flora. in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. Pavan S. International Journal of Food Microbiology. O'Halloran S. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. O'Sullivan G. 696-701. O'Halloran S. Morrissey D. Morotomi M. Fitzgibbon J. Desreumaux P. Redmond HP. Vaughan EE. 823-828. Feeney M. ID 1007: “Lactobacillus salivarius THT 031001” and “Natural defences/ immune system” 3 4 1 Dunne C. 211-214. 57-65. 65. Clin Diagn Lab Immunol. Kim WS. Collins JK. 2001. O'Halloran S. 1999. Double blind. 41. 2004. Collins JK. Kiely B. 2003. Lactobacillus equi sp. Use of mouse models to evaluate the persistence. Int J Syst Evol Microbiol. Mercenier A. Shanahan F. Gut. physiology. O'Callaghan L. Sheil B. O'Mahony L. Murphy L. Fitzsimons N. O'Mahony L. 975-980. Watanabe K. Mercenier A. O'Sullivan GC. O'Mahony L. Ohwaki M. G839-845. 1219-1225. Kushiro A. Pavan S. Feeney M. Sheil B. O'Mahony L. 1999. 29-39. Dunn NW. Rampal P. Rampal P. Roux I. Effect of Saccharomyces boulardii on cAMP. FEMS Microbiol Lett. Rossi B. Czerucka D and Rampal P. Roux I. 65-72. and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Ann Ped. International Journal of Food Microbiology. 57-65. 1982. Mograbi B. [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice]. Jespersen L. 65. 44. 32. 2000. 1994. 2000. 42. Czerucka D. 6. Tasteyre A. Adherence of Escherichia coli serogroup 0 157 and the Salmonella Typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. 5998-6004.ID 1009: “Lactococcus lactis THT 090101” and “Natural defences/ immune system” 1 2 3 4 Drouault S. 65-72. Kim WS. Elmer GW. 491-501.5'-Cyclic-Monophosphate Induction in Intestinal-Cells. Czerucka D and Rampal P. Tuomola EM and Salminen SJ. Appl Environ Microbiol. 1994. and lysis of Lactococcus lactis in the digestive tract. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. 2359-2368. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826. Czerucka D. ID 1010: “Saccharomyces boulardii ATY-SB-101” and “Gastro-intestinal function / Intestinal microflora” 1 2 3 Czerucka D. 2005. 171. 4881-4886. Dig Dis Sci. 1998. Karjalainen T. Survival. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3'. Infect Immun. Digestive Diseases and Sciences. Gastroenterology. 1999. 68. Skovgaard K. Czerucka D. physiology. Ren J.5'-cyclic monophosphate induction in intestinal cells. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Ann Microbiol (Paris). Rossi B. 1999. Ducluzeau R and Bensaada M. Differentiation of Lactococcus lactis subspecies lactis and subspecies cremoris strains by their adaptive response to stresses.and Ca2+ -dependent Clsecretion in T84 cells. 5998-6004. Marteau P. 58. 2000. Mograbi B. Pochart P. boulardii and food-borne Saccharomyces cerevisiae strains. 45-51. 133. Comparative Effect of a Single or Continuous Administration of Saccharomyces Boulardii on the Establishment of Various Strains of Candida in the Digestive-Tract of Gnotobiotic Mice. 1999. 68. 2002. 261-264. 1994. Corthier G. Gastroenterology. Gedek BR.and Ca2+-dependent Clsecretion in T84 cells. Dahan S. Ducluzeau R and Bensaada M. Saccharomyces-Boulardii Inhibits Secretagogue-Mediated Adenosine 3'. Renault P. 1982. Vesa T. 41. ID 1011: “Saccharomyces boulardii ATY-SB-101” and “Natural defences / Immune system” 1 2 3 4 Cetina-Sauri G and Sierra Basto G. Microbial Pathogenesis. 2001. 1999. Ehrlich SD. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coliinfected T84 cells. Lactobacillus fermentum KLD. 106. 491-501. Barc MC. Mycoses. Aliment Pharmacol Ther. Collignon A. 14. Annales De Microbiologie. American Journal of Health-System Pharmacy. Probiotics: "Living drugs". B133. Dahan S. Infection and Immunity. 11011109. 4 5 6 7 8 5 23 . Int J Food Microbiol. Rampal P. Kuhle AVDA. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Effect of Saccharomyces boulardii on cAMP. 101. 823-828. 2359-2368. 44. 397-400. 106. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coliinfected T84 cells. 219-225. Rampal P. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. Bourlioux P. 96. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. 2001. Jespersen L. 13. Alvarez S. Minekus M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. 66. 2001. 45. 2003. Acta Paediatr. Villarruel G. Barc MC. Huis in't Veld JH. 1987. American Journal of Health-System Pharmacy. Survie des ferments du yaourt dans le tube digestif du lapin. 1997. Cintioni J. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. Oliver G. 2005. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Int J Food Microbiol. Le Lait. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. 5 6 24 . 1-12. placebo-controlled study. Warny M. 1997. Goldin BR. Giollo P. A pilot trial of Saccharomyces boulardii in ulcerative colitis.6 7 8 9 10 Elmer GW. Lopez F. 2762-2765. Matteuzzi D. Eur J Gastroenterol Hepatol. Gionchetti P. Aliment Pharmacol Ther. Testoni PA. 1031-1037. 70. 80. 2002. Skovgaard K. 2002. Marteau P. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. Lait. Vandenplas Y. Enhancement of immune response in mice fed with Streptococcus thermophilus and Lactobacillus acidophilus. Bourlioux P. Rizzello F. Role of food in the stimulation of cytokine production. Guslandi M. 538-541. Gorbach SL. Survie des ferments du yaourt dans le tube digestif du lapin. Pesce de Ruiz Holgado AA. 247-253. 2000. 58. Am J Clin Nutr. 80. Zucconi E. Sorghi M. Mycoses. 1031-1037. Matteuzzi D. Dig Dis Sci. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. 1999. 101. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. Pothoulakis C. 1462-1464. Romero G. Kelly CP. J Dairy Sci. 1-12. 70. Rubio DM. Nader de Macias ME. Havenaar R. ID 1013: “Streptococcus thermophilus THT 070101” and “Natural defences/ immune system” 1 2 3 4 Conway PL. 1103-1108. 2002. Microb Pathog. 697-698. 11011109. 1999. LaMont JT. Testoni PA. Saccharomyces boulardii in acute childhood diarrhoea: a randomized. Johansson R. Solis-Pereyra B. Perdigon G. Aliment Pharmacol Ther. Gionchetti P. Lemonnier D. Marteau P. Gedek BR. Venturi A. 69. 1997. 32. Goldin BR. 82. 82. 1999. 70. Venturi A. 1987. 521S-525. 261-264. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Minekus M. 919-926. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Aboudola S. 1103-1108. Johansson R. Karjalainen T. Huis in't Veld JH. van der Aa Kuhle A. Gorbach SL. J Dairy Sci. Qamar A. Campieri M. Tasteyre A. Dilmi-Bouras A and Sadoun D. Infect Immun. Aattouri N. J Dairy Sci. Campieri M. 13. 247-253. ID 1012: “Streptococcus thermophilus THT 070101” and “Digestive health/ Intestinal flora” 11 12 13 1 2 3 4 Conway PL. 15. Rizzello F. Mezzi G. boulardii and food-borne Saccharomyces cerevisiae strains. 219-225. 29-39. J Dairy Sci. J Dairy Sci. Havenaar R. Gurevech R. Dilmi-Bouras A and Sadoun D. Brigidi P. 1987. Collignon A. Probiotics:" living drugs". Guslandi M. 42. 2007. Zucconi E. Michetti P. Brigidi P. Matteuzzi D. Aliment Pharmacol Ther. 1999. 70. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. 1031-1037. Aliment Pharmacol Ther. Bonetti A. 1103-1108. 1987. Martinotti MG. Marteau P. J Dairy Sci. Le Lait. 66. 1998. 1999. Nader de Macias ME. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. 1-12.Laboratorium voor Microbiologie Universiteit Gent). 1987. 1987. Am J Clin Nutr. Huis in't Veld JH.etc. Perdigon G. Lattobacilli ad uso …. 919-926. Method for the selection of adhesive lactobacilli strains having therapeutical properties and strains obtained by said method. Havenaar R. EP0949330A3. Identification of 3 bacterial isolates reported 29/01/97. 2003. ID 1030: “Lactobacillus crispatus P 17631” and “Benessere del tratto intestinale” 1 2 BCCM-LMG (Belgian co-ordinated collections of micro-organisms . 13. J Dairy Sci. Zucconi E. Johansson R. Rizzello F. Rizzello F. Minekus M. Gorbach SL. 1997. 247-253. Venturi A. Huis in't Veld JH. Johansson R. Alvarez S. Dondi G and It P. Zucconi E. Brigidi P. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures. 2002. Role of food in the stimulation of cytokine production. United States Patent 6. Lait. Havenaar R. Brigidi P. J Dairy Sci. Minekus M. Gionchetti P. Campieri M. Morelli et al. Proceedings of the 5° Congresso Federazione Italiana Scienze della Vita (FISV). 1997. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. 82. Goldin BR. Morelli L. 80.366 B1. 1997. 70. 1031-1037. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. 521S-525. Venturi A. 247-253. Enhancement of immune response in mice fed with Streptococcus thermophilus and Lactobacillus acidophilus. Dilmi-Bouras A and Sadoun D. 1997. Gorbach SL. 168. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Università Cattolica del Sacro Cuore di Piacenza. 80. Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures. European Patent Office. Survie des ferments du yaourt dans le tube digestif du lapin. 13. 1997. Dondi G and Morelli L. Goldin BR. Università degli Studi del Piemonte Orientale. ID 1015: “Streptococcus thermophilus THT 070102” and “Natural defences/ immune system” 1 2 3 4 Conway PL. Lemonnier D. Oliver G. 82. 70. Dondi G and Morelli L. European Patent Office. 2002. European Patent EP 1046713A2. Marteau P. 1-12. Campieri M. 25 5 6 3 4 5 6 7 8 . J Dairy Sci. J Dairy Sci. Matteuzzi D. 1999. 1103-1108. Aattouri N. Survie des ferments du yaourt dans le tube digestif du lapin. Pesce de Ruiz Holgado AA. 2002. Caratterizzazione delle proprietà probiotiche di alcuni ceppi del genere Lactobacillus spp. Solis-Pereyra B. Dilmi-Bouras A and Sadoun D.ID 1014: “Streptococcus thermophilus THT 070102” and “Digestive health/ Intestinal flora” 1 2 3 4 Conway PL. Caratterizzazione ceppo…etc. Microbiological analysis of 6 strains of lactobacillus for a patent deposit. Pietronave S. Gionchetti P.342. 60. Arvilommi H. bulgaricus and Lactobacillus acidophilus. 74. 5-9. 51. American Journal of Clinical Nutrition. Department of Food Technology. J Food Prot. Green-Johnson JM. 1999. Weizman Z. 1994. Int J Food Microbiol. Arvola T. Vuopio-Varkila J. Prakticky Lekar. Mikkonen M and von Wright A. 115. 66. J Dairy Sci. 1999. Cesko-Slovenska Pediatrie. Isolauri E. Finland. 1994. Buckley ND. Link-Amster H. teeth” 1 2 Björkman P. 78. Hara H. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. 30. The survival of and cytokine induction by lactic acid bacteria after passage through a gastrointestinal model. Kocian J. Colonization of the human gastrointestinal tract by the lactic acid bacteria Lactobacillus reuteri. Abi-Hanna A. ID 1056: “Lactobacilus acidophilus. Sutas Y. Arvola T. Further possibilities in the treatment of lactose intolerance-lactobacilli. 221-224. Miettinen M. 42. Kawata Y. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Journal of Pediatric Gastroenterology and Nutrition. Microbial Ecology in Health and Disease. Mitsuoka T. Alsheikh A. Schiffrin EJ. Yolken RH. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut. Green-Johnson JM. von Wright A. Rautava S. Acidified milk formula supplemented with bifidobacterium lactis: Impact on infant diarrhea in residential care settings. Lactobacillus rhamnosus and Bifidobacterium lactis lactic acid bacteria” and “Gut health” 1 Chouraqui JP. Pediatrics. Pediatr Res. Mattila-Sandholm T. Terada A. Isolauri E. 2004. 1995. Donnet-Hughes A. 615-619. 466-472. 2006. 2001. 10. Moore N. Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents. ID 1057: “Lactobacillus reuteri lactic acid bacteria” and “Mouth. Fichot MC. Van Egroo LD. Lactobacillus paracasei. Kuopion yliopisto. Alander M. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. 2005. Bradley S. 40. Lactobacilli in the treatment of dyspepsia due to dysmicrobia of various causes. Tlaskal P. 73-83. 2003. Rochat F. 1604-1610. 38. Aeschlimann JM. 288-292. Clin Exp Allergy. Asli G. Interactions of lactic acid bacteria with human intestinal epithelial cells: effects on cytokine production. 79. Lactobacillus acidophilus in the treatment of children with gastrointestinal tract illness. 1995. 491-497. 141-147. 79-83. Munroe J. Marteau P. Fukushima Y. 2002. Probiotics in the management of atopic eczema. Lactobacillus rhamnosus and Bifidobacterium lactis lactic acid bacteria” and “Immunity” 1 Easo JG. Vnitr Lek. Huis in‘t Veld J. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. 51-55. 2000. The effect of food matrix on the intestinal viability and adhesion of probiotics bacteria. 212-214. 2002. Salminen S. 2004. Measham JD. Kocian J. 2 3 4 5 6 7 2 3 4 5 6 7 26 . 261267. Kirjavainen PV.ID 1055: “Lactobacillus acidophilus. Saavedra JM. Isolauri E. 1998. Food and Agricultural Immunology. Lactobacillus paracasei. Moilanen E. 14. 39-44. University of Helsinki. Wallace TD. Salminen SJ. Immunostimulatory Actions of Lactobacilli: Mitogenic Induction of Antibody Production and Spleen Cell Proliferation by Lactobacillus delbrueckii subsp. 1995. 2004. Eklund M. Grahn E. 219-223. Grahn E. Håkansson G. Uppsala (Sweden). Hara K. Turk M. Sandberg AS. Grahn E. Salminen S. 18-19 Oct 1995. randomised. Human studies on probiotics: aspects of scientific documentation. Makihira S. 3. 2-4. Holm SE. 1. Sellgren K. Sellgren K. Eklund M. 2001. 1995. Am J Clin Nutr. Support Care Cancer. Scand J Nutr. 2001. Deb S. Int J Food Microbiol. Support Care Cancer. 1234-1238. Grahn E. Bosaeus I. Proceedings of Livsmedel 95. Sellgren K. 8-12. ID 1060: “Lactococcus lactis L1A NCIMB 40157 (Verum® Hälsofil)” and “Digestive system” 1 Andersson H. Tidehag P. Holm S. 1994. 2006. Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci. Lilja H. Hallmans G. Ellegard L. Lancet Infect Dis. 1995. 38. Franzen L. 49. Arevarn M. Franzen L. 95. Holm SE. Grahn Håkansson E. Holm SE. Holm S. Karlsson AK. Interference of a Lactococcus lactis strain on the human gut flora and its capacity to pass the stomach and intestine. Dietistaktuellt. Malik P. Human studies on probiotics: aspects of scientific documentation. Hallmans G. Salminen S. Scandinavian Journal of Nutrition/Näringsforskning. Grahn Håkansson E. Lactococcus lactis (L1A) reduces antibiotic associated diarrhoea. 6. Hiremath G. Hallmans G. Nordin A. Grahn Håkansson E. Nishimura H. Lactococcus lactis (L1A) reduces antibiotic associated diarrhoea. Tidehag P. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked. 2 3 4 5 6 7 8 27 . Sandstrom K. Effects of active addition of bacterial cultures in fermented milk to patients with chronic bowel discomfort following irradiation. Matsumoto A. Eur J Clin Nutr. 1995. Scand J Nutr. Sandberg AS. 2-4. Effects of active addition of bacterial cultures in fermented milk to patients with chronic bowel discomfort following irradiation. Scandinavian Journal of Nutrition/Näringsforskning. ID 1062: “Lactococcus lactis L1A NCIMB 40157” and “Intestinal flora Digestive health” 2 3 4 5 6 7 8 9 1 Andersson H. Eur J Clin Nutr. 81-83. 62. 1995. Documentation of effect of Verum Halsofil (specialist report). Uppsala (Sweden). Sandstrom K. Documentation of effect of Verum Halsofil (specialist report). 1995. Takemoto T. 49. Holm S. 13-14. 274-281. Henriksson R. Dhingra U. Grahn Håkansson E. Grahn E. Hamada T. Nordin A. 45. Sandberg AS. Ozaki Y. Effects of low-fat milk and fermented low-fat milk on cholesterol absorption and excretion in ileostomy subjects. Arevarn M. 1. Effects of a synbiotic milk product on faecal microflora and bowel habits in healthy volunteers. Henriksson R. Black RE. 1995. 8-12. Ellegard L. A fermented milk product which improves bowel habits in geriatric patients. Larsson C. 1994.3 Nikawa H. 81-83. Tidehag P. 3. Grahn E. A fermented milk product which improves bowel habits in geriatric patients. 13-14. Darmawan S. Sazawal S. 274-281. 1995. Interference of a Lactococcus lactis strain on the human gut flora and its capacity to pass the stomach and intestine. placebo-controlled trials. 45. Proceedings of Livsmedel 95. Wing K. Holm SE. 1995. Fukushima H. Dietistaktuellt. Aimi R. Lilja H. 374-382. Sellgren K. Bosaeus I. 18-19 Oct 1995. Effect of milk and fermented milk on iron absorption in ileostomy subjects. 38. 2007. Grahn E. 2007. Ishida K. Effects of low-fat milk and fermented low-fat milk on cholesterol absorption and excretion in ileostomy subjects. Rajkumar C. Am J Clin Nutr. 75-82. 2006. Hallberg L. 17. Ivarsson M. 2003. Black RE. Wold AE. D'Souza AL. 2007. 308-314. Institutionen för kvinnors och barns hälsa vid Karolinska Institutet. Acta Obstetricia et Gynecologica Scandinavica. Lactobacillusmediated interference of mutans streptococci in caries-free vs. Turk M. Forsgren-Brusk UB. 80. Intraspecific genotypic characterization of Lactobacillus rhamnosus strains intended for probiotic use and isolates of human origin. ID 1064: “Lactobacillus rhamnosus LB21 NCIMB 40564” and “Intestinal flora Digestive health Oral flora” 1 2 3 4 Andersson J and Larsson M. double-blind. 8. 35. Microbial Ecology in Health and Disease. 2007. Håkansson EG. Jacobsson C. Roos K. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. Effect of milk and fermented milk on iron absorption in ileostomy subjects. Malik P. 5376-5383. 2006. Lefebvre K. Forsgren-Brusk U. Umeå University. Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH. placebo-controlled trial in 64 healthy women. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Deb S. 726735. 94. randomised. Beuerman D. Osazuwa E. Elmér C. Degree project in Engineering Biology 30 ECTS credits. Muthu N. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked. Ahonkhai I. 374-382. Rogers TR. 6. Holm S. Charbonneau D. 1996. British Medical Journal. Selection and characterization of a Lactobacillus plantarum strain promising as a urogenital probiotic. Oral use of Lactobacillus rhamnosus GR-1 and L. Grahn E. 85. FEMS Immunol Med Microbiol. 92. 2009. Grahn Hakansson E. Grahn-Håkansson EE. Hiremath G. Vankerckhoven V. 1234-1238. Kochanowski B. The ability of probiotic lactic acid bacteria to influence human T lymphocytes cytokine responses. Effekten av probiotika som profylax mot kolangit hos Kasaiopererade barn med gallvägsatresi. Rönnqvist D. 2 3 4 5 5 6 7 28 . Sandberg AS. Reid G. placebo-controlled trials. caries-active subjects. The ability of probiotic lactic acid bacteria to influence human T lymphocytes cytokine responses. Ngwu M. Bruce AW.9 Sazawal S. Want S. 335. Goossens H. Reid G. Holm SE. Institutionen för kostvetenskap vid Umeå Universitet. 2007. Hakansson EG. Vancanneyt M. Bulpitt CJ. Tidehag P. 2005. Nowrouzian F. Huys G. Emilson CG. Holm S. Adlerberth I. 2006. D-uppsats. Degree project in Engineering Biology 30 ECTS credits. 2007. Lancet Infect Dis. Hallmans G. Simark-Mattsson C. Hickson M. Rönnqvist PDJ. Bakteriella och kliniska effekter av tillförda lactobaciller vid antibiotikaintag. Umeå University. Wing K. Roos K. Appl Environ Microbiol. 2006. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized. 1995. 131-134. Swings J. Ström H. 115. Skovbjerg S. 10 ID 1063: “Lactobacillus plantarum LB931 DSM 11918” and “Intestinal flora Digestive health Urogenital health” 1 Anukam K. Erb J. 2007. Microbes Infect. Osemene G. Bruce AW. Poehner R. placebo controlled trial. Eur J Oral Sci. fermentum RC-14 significantly alters vaginal flora: randomized. Dhingra U. Elmér C. 1450-1454. Archives of Disease in Childhood. 62. 72. Want S. 335. Degree project in Engineering Biology 30 ECTS credits. Holm SE. Grahn E. Muthu N. 92-98. Grahn-Hakansson E. 1999. Rajkumar C. 2007. Holm S. Scand J Infect Dis. 1992. Roos K. Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. BMJ. Scand J Infect Dis. 335. 47. Grahn-Hakansson E. 459-462. 28. Roos K. 1989. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Degree project in Engineering Biology 30 ECTS credits. 1993b. Grahn Hakansson E. Muthu N. Roos K. 1999. 72-79. Grahn-Hakansson E. 1996. Nowrouzian F. 2 3 4 5 6 7 8 9 10 11 12 29 . 31-35. 47. Wold AE. Interfering alpha-streptococci as a protection against recurrent streptococcal pharyngotonsillitis. Holm SE. 25. 2007. 25. 1983. 8. 322. Treatment of recurrent streptococcal tonsillitis by recolonization with alpha-streptococci. 119. Olofsson C. Roos K. 210-212. Alpha-streptococci-inhibiting beta-streptococci group A in treatment of recurrent streptococcal tonsillitis. Lagergren L. Grahn E. Lagergren L. Lind L. 80. Holm SE. Roos K. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. 2007. 2007. The ability of probiotic lactic acid bacteria to influence human T lymphocytes cytokine responses.ID 1065: “Lactobacillus plantarum LB7c DSM 17853” and “Intestinal flora Digestive health” 1 2 Elmér C. 944-948. In vitro inhibition of S. Interfering alpha-streptococci as a protection against recurrent streptococcal tonsillitis in children. Int J Pediatr Otorhinolaryngol. Lind L. ID 1066: “Lactobacillus plantarum LB3e DSM 17852” and “Intestinal flora Digestive health” 1 2 Elmér C. 318-319. Holm SE. Umeå University. Int J Pediatr Otorhinolaryngol. 1992. Roos K. 142-145. Umeå University. catharralis by alpha-hemolytic streptococci from healthy children. 141-148. 1999. D'Souza AL. 17. ID 1067: “Streptococcus sanguis NCIMB 40104” and “Oral health Throat health” 1 Falck G. Alpha-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study. 2001. Recolonization with selected alphastreptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis--a randomized placebocontrolled multicentre study. Grahn-Hakansson E. Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area. Rajkumar C. Ivarsson M. 168-171. Adv Otorhinolaryngol. BMJ. 80. 49-56. Holm SE. pneumoniae. Tano K. Arch Dis Child. Johansson H. Holm SE. Grahn E. Grahn E. 1993a. Roos K. Grahn E and Holm SE. 94. The ability of probiotic lactic acid bacteria to influence human T lymphocytes cytokine responses. Perianal streptococcal dermatitis. D'Souza AL. Rogers TR. Hickson M. Rogers TR. BMJ. Holm SE. Roos K. Want S. Lilja H. Acta Otolaryngol. 46-48. Scand J Prim Health Care. Hickson M. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. influenzae and M. Roos K. Holm S. Adlerberth I. Hakansson EG. Roos K. 2009. Lind L. 256. Skovbjerg S. Holm SE. Lind L. 47. nontypable H. Tolerance and efficacy of interfering alpha-streptococci in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study. Lind L. Eur J Clin Microbiol Infect Dis. Adv Otorhinolaryngol. Grahn E. The possible protective role of alpha-streptococci against spread and recurrence of group A streptococcal throat infection. Bulpitt CJ. Zentralbl Bakteriol Mikrobiol Hyg [A]. Holm SE. Bulpitt CJ. 8. Holm SE. Nowrouzian F. Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area. Eur J Clin Microbiol Infect Dis. children with SOM and children with rAOM. Olofsson C. 47. 1999. 322. 56. 1992. Roos K. Perianal streptococcal dermatitis. Grahn E. Holm S. 25. 1996. Holm SE. Hakansson EG. 459-462. Tolerance and efficacy of interfering alpha-streptococci in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study. Int J Pediatr Otorhinolaryngol. Holm SE. pneumoniae. 1992. Holm SE. Hellstrom S. nontypable H. children with SOM and children with rAOM. Lind L. Grahn-Hakansson E. Tano K. 141-148. Inhibition of OM pathogens by alphahemolytic streptococci from healthy children. Int J Pediatr Otorhinolaryngol. Grahn-Hakansson E. 256. Lagergren L. Roos K. 1999. 2002a. 31-35. Is hydrogen peroxide responsible for the inhibitory activity of alpha-haemolytic streptococci sampled from the nasopharynx? Acta Otolaryngol. Adv Otorhinolaryngol. Adlerberth I. Treatment of recurrent streptococcal tonsillitis by recolonization with alpha-streptococci. 944-948. 123. 49-56. Acta Otolaryngol. 210-212. Hellstrom S. Holm SE. Tano K. 119. 92-98. Holm SE. Holm SE. 318-319. 47. 72-79. Grahn E. Interfering alpha-streptococci as a protection against recurrent streptococcal pharyngotonsillitis. influenzae and M. Lind L. Holm SE. Scand J Infect Dis. Grahn E. Holm SE. Holm SE. Hellstrom S. Tano K. Roos K. Grahn E. Scand J Infect Dis. Grahn Hakansson E. Grahn E. 1723. Arch Dis Child. Lind L. ID 1068: “Streptococcus sanguis NCIMB 40873” and “Oral health Throat health” 14 15 16 1 Falck G. Lind L. Holm SE. Grahn-Hakansson E. Bacterial interference between pathogens in otitis media and alpha-haemolytic Streptococci analysed in an in vitro model. Roos K. Int J Pediatr Otorhinolaryngol. Grahn Hakansson E. 94. 185-190. Ronnqvist D. BMJ. Scand J Prim Health Care. Wallbrandt P. 2009. Recolonization with selected alphastreptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis--a randomized placebocontrolled multicentre study. Interfering alpha-streptococci as a protection against recurrent streptococcal tonsillitis in children.13 Tano K. Tano K. 2001. 28. 17. Int J Pediatr Otorhinolaryngol. Johansson H. Alpha-streptococci-inhibiting beta-streptococci group A in treatment of recurrent streptococcal tonsillitis. Zentralbl Bakteriol Mikrobiol Hyg [A]. 1999. Holm S. 1993a. Lagergren L. 25. Adv Otorhinolaryngol. Holm SE. 62. Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. Grahn Hakansson E. Grahn E and Holm SE. 46-48. Hellstrom S. Grahn-Hakansson E. Lilja H. 142-145. Roos K. 185-190. 168-171. Grahn-Hakansson E. 2002b. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Skovbjerg S. 1993b. 2000. 47. 1989. Holm SE. The possible protective role of alpha-streptococci against spread and recurrence of group A streptococcal throat infection. A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. Hakansson EG. Roos K. 2000. Acta Otolaryngol. Roos K. Roos K. 78-85. Holm SE. Lind L. Alpha-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study. In vitro inhibition of S. 56. Int J Pediatr Otorhinolaryngol. catharralis by alpha-hemolytic streptococci from healthy children. Ivarsson M. Roos K. 1983. 2 3 4 5 6 7 8 9 10 11 12 13 30 . 122. 724-729. Wold AE. Roos K. Tano K. Inhibition of OM pathogens by alphahemolytic streptococci from healthy children. 2003. Grahn-Hakansson E. Hellstrom S. 256. Lagergren L. Hakansson EG. Grahn E. Olofsson C. Wallbrandt P. Grahn-Hakansson E. Lilja H. Scand J Infect Dis. 17. Scand J Prim Health Care. 318-319. 31-35. Perianal streptococcal dermatitis. Grahn E. 8. Bacterial interference between pathogens in otitis media and alpha-haemolytic Streptococci analysed in an in vitro model. Is hydrogen peroxide responsible for the inhibitory activity of alpha-haemolytic streptococci sampled from the nasopharynx? Acta Otolaryngol.14 Tano K. BMJ. 2002a. Skovbjerg S. Lind L. Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area. 47. 119. Lagergren L. 1996. 123. Grahn E. Lind L. 185-190. 78-85. In vitro inhibition of S. 1992. Alpha-streptococci-inhibiting beta-streptococci group A in treatment of recurrent streptococcal tonsillitis. Roos K. Int J Pediatr Otorhinolaryngol. Tano K. Holm SE. Int J Pediatr Otorhinolaryngol. 944-948. Grahn Hakansson E. Roos K. 1999. influenzae and M. Int J Pediatr Otorhinolaryngol. 142-145. 62. Hakansson EG. Interfering alpha-streptococci as a protection against recurrent streptococcal pharyngotonsillitis. Interfering alpha-streptococci as a protection against recurrent streptococcal tonsillitis in children. Grahn E. Holm SE. Tano K. Adlerberth I. 322. 210-212. Holm SE. Holm S. Scand J Infect Dis. Grahn E. Adv Otorhinolaryngol. 1993a. 92-98. Recolonization with selected alphastreptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis--a randomized placebocontrolled multicentre study. Hellstrom S. Grahn E and Holm SE. 56. Holm SE. Acta Otolaryngol. 122. Holm SE. The possible protective role of alpha-streptococci against spread and recurrence of group A streptococcal throat infection. Inhibition of OM pathogens by alphahemolytic streptococci from healthy children. 1723. 1992. Roos K. Roos K. 1999. Holm SE. Lind L. A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. nontypable H. 47. 1989. Johansson H. Grahn-Hakansson E. 1983. Tolerance and efficacy of interfering alpha-streptococci in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study. 141-148. 49-56. 2002b. 62. Roos K. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Roos K. 78-85. Hellstrom S. Roos K. Alpha-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study. Holm SE. Tano K. Holm SE. Grahn Hakansson E. 72-79. Int J Pediatr Otorhinolaryngol. 46-48. Holm SE. 2000. Acta Otolaryngol. Int J Pediatr Otorhinolaryngol. 122. catharralis by alpha-hemolytic streptococci from healthy children. Holm S. Holm SE. Treatment of recurrent streptococcal tonsillitis by recolonization with alpha-streptococci. Hellstrom S. Holm SE. Eur J Clin Microbiol Infect Dis. children with SOM and children with rAOM. Holm SE. 25. 459-462. Hakansson EG. 724-729. Roos K. Zentralbl Bakteriol Mikrobiol Hyg [A]. Ronnqvist D. Wold AE. 94. Ivarsson M. Holm SE. 2002a. Hellstrom S. Adv Otorhinolaryngol. Tano K. Holm SE. 25. Lind L. ID 1069: “Streptococcus oralis NCIMB 40875” and “Oral health Throat health” 15 16 1 Falck G. Nowrouzian F. Grahn Hakansson E. 2001. Roos K. Grahn-Hakansson E. Hellstrom S. Tano K. Grahn-Hakansson E. Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. Hellstrom S. Roos K. 31 2 3 4 5 6 7 8 9 10 11 12 13 14 15 . Grahn Hakansson E. 2002b. 1993b. Arch Dis Child. Holm SE. Acta Otolaryngol. 2009. 1999. pneumoniae. Grahn-Hakansson E. 168-171. 47. Bacterial interference between pathogens in otitis media and alpha-haemolytic Streptococci analysed in an in vitro model. Tano K. 28. Lind L. 2003. 1723. A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. 1996. children with SOM and children with rAOM. Lind L. Holm SE. influenzae and M. Grahn E. Adv Otorhinolaryngol. Holm SE. 94. The possible protective role of alpha-streptococci against spread and recurrence of group A streptococcal throat infection. Grahn Hakansson E. Grahn E. 47. Zentralbl Bakteriol Mikrobiol Hyg [A]. Grahn E and Holm SE. 1992. 1989. Lind L. Holm SE. Alpha-streptococci-inhibiting beta-streptococci group A in treatment of recurrent streptococcal tonsillitis. 123. Tano K. Int J Pediatr Otorhinolaryngol. 72-79. Is hydrogen peroxide responsible for the inhibitory activity of alpha-haemolytic streptococci sampled from the nasopharynx? Acta Otolaryngol. 25. Holm SE. Inhibition of OM pathogens by alphahemolytic streptococci from healthy children. Scand J Prim Health Care. Wold AE. Roos K. Holm SE. Grahn Hakansson E. 1999. Hellstrom S. Olofsson C. Int J Pediatr Otorhinolaryngol. 1723. 123. 724-729. 92-98. Grahn E. 8. Acta Otolaryngol. Tano K. Roos K. 47. 185-190. 28. Skovbjerg S. Wallbrandt P. Lagergren L. 2009. 119. 724-729. 2000. 1993a. 1999. 122. 168-171. Roos K. Holm SE. 56. Ronnqvist D. 1983. Grahn Hakansson E. Holm SE. 49-56. Roos K. 2002b. Tano K. 142-145. 1992. Grahn Hakansson E. Holm SE. Arch Dis Child. Johansson H. Holm S. Lind L. Lilja H. Grahn E. 2002a. 2001. Holm SE. Hellstrom S. Int J Pediatr Otorhinolaryngol. Grahn-Hakansson E. 62. 31-35. Int J Pediatr Otorhinolaryngol. Holm SE. Grahn-Hakansson E. nontypable H. Roos K. Lagergren L. pneumoniae. 2003. Lind L. Scand J Infect Dis. 322. 256. 210-212. 1999. Bacterial interference between pathogens in otitis media and alpha-haemolytic Streptococci analysed in an in vitro model. Tano K. Grahn E. Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area. Grahn-Hakansson E. Holm SE. Roos K. Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial. 1993b. Interfering alpha-streptococci as a protection against recurrent streptococcal pharyngotonsillitis. Tano K. Treatment of recurrent streptococcal tonsillitis by recolonization with alpha-streptococci. 459-462. Is hydrogen peroxide responsible for the inhibitory activity of alpha-haemolytic streptococci sampled from the nasopharynx? Acta Otolaryngol. Holm SE. 2003. catharralis by alpha-hemolytic streptococci from healthy children. 47. Roos K. 46-48. In vitro inhibition of S. Holm SE. Tolerance and efficacy of interfering alpha-streptococci in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study. Roos K. Recolonization with selected alphastreptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis--a randomized placebocontrolled multicentre study. 141-148. Adv Otorhinolaryngol. Roos K. Hellstrom S. Roos K. Wallbrandt P. Grahn-Hakansson E. Hakansson EG. 78-85. A nasal spray with alpha-haemolytic streptococci as long term prophylaxis against recurrent otitis media. Perianal streptococcal dermatitis. Grahn-Hakansson E. 944-948. Holm SE. Adlerberth I. Hellstrom S. Holm S. Nowrouzian F. Interfering alpha-streptococci as a protection against recurrent streptococcal tonsillitis in children. Ivarsson M. 318-319. Hellstrom S. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Alpha-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo-controlled study. Ronnqvist D. BMJ. Acta Otolaryngol. Lind L. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 32 . Eur J Clin Microbiol Infect Dis. Scand J Infect Dis. Hakansson EG. ID 1070: “Streptococcus oralis NCIMB 40876” and “Oral health Throat health” 1 Falck G. 17. 25.16 Tano K. Osman N. Nilsson M. Internal report. Lavasani S. Mekanismer för insulinsparande effekter av probiotisk produkt med blåbär (Mechanism for insulin saving effects of a probiotic product with blueberries). Lavasani S. Clin Microbiol Infect.” 1 2 3 Falagas ME. 657-664. Athanasiou S. Ahrne S. University of Lund. 17. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero. Clin Microbiol Infect. Probiotic for common cold prevention Hutt P. 15-20. Molin G. Probiotics for the treatment of women with bacterial vaginosis. Betsi GI. Shchepetova J. Oral administration of Lactobacillus and Bifidobacterium strains of intestinal and vaginal origin to healthy human females: Re-isolation from faeces and vagina. Endotoxin. Oral administration of Lactobacillus and Bifidobacterium strains of intestinal and vaginal origin to healthy human females: Re-isolation from faeces and vagina. Novel immunotherapies and immunoregulation in a chronic inflammatory disease of the central nervous system. 2007. Doctoral thesis. 2005. 657-664. Vásquez A. Adawi D. ID 1074: “Lactobacillus paracasei 8700:2 (DSM 13434. Berggren et al. 2007. 240HI)” and “Strengthens the immune system Establishment of lactobacilli and beneficial changes in the microflora” 1 2 3 4 Antonsson M. Doctoral thesis. Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina. 2005. Lactobacillus in semi-hard cheese and their use as adjunct cultures. Vásquez A.and D-galactosamine-induced liver injury improved by the administration of Lactobacillus. 2006. Falagas ME. Jeppsson B. 15-20. Ahrné S. 2006. 2001. 1324-1332. ID 1072: “Lactobacillus plantarum HEAL 19 (DSM 15313 = 52A)” and “Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina” and “Reduces the insulin response after a meal. 13. 17. Microbial Ecology in Health and Disease. 2006. Microbial Ecology in Health and Disease. Jeppsson B. 849-856. Doctoral thesis. Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina” 1 2 3 4 5 Berggren A. Dig Liver Dis. Granfeldt Y. 2006. Molin G. Probiotics for the treatment of women with bacterial vaginosis. 2005. Clin Microbiol Infect. 33 . 39. 15-20. Probiotic for common cold prevention. Betsi GI. 2005. Vásquez A. 4 ID 1073: “Lactobacillus plantarum HEAL 99 (DSM 15316 = 61A)” and “Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina” 1 2 Falagas ME. Kullisaar T. Molin G. Probiotics for the treatment of women with bacterial vaginosis. 657-664. Ahrné S. 2007. University of Lund. 100. Microbial Ecology in Health and Disease.and uropathogens. Berggren A et al. Molin G. Björck I. 13. Probiotic for vaginal health. Oral administration of Lactobacillus and Bifidobacterium strains of intestinal and vaginal origin to healthy human females: Re-isolation from faeces and vagina. 2007. Betsi GI. Mikelsaar M. Ahrné S. Jeppsson B. Jeppsson B. Bifidobacterium and blueberry. 17. 13.. Athanasiou S. Athanasiou S. J Appl Microbiol. Loivukene K. University of Lund.ID 1071: “Lactobacillus plantarum HEAL 9 (DSM 15312 = 39D)” and “Strengthens the immune system. 2007. 2007. Novel immunotherapies and immunoregulation in a chronic inflammatory disease of the central nervous system. Johansson ML. 1999. Nobaek S. ID 1077: “Lactobacillus plantarum 299 (DSM 6595. 2244-2251. 49. Rask C. Nobaek S. 1999. Molin G. 1997. Europabio 2005: European Conference on Probiotics and their Applications. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. Jeppsson B. Molin G. Nobaek S. Hepatology. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Modulation of the Colonic Bacterial Flora Affects Differently Bacterial Translocation and Liver Injury in an Acute Liver Injury Model. 1997. Ahrne S. Johansson ML. Intestinal passage of Lactobacillus rhamnosus DSM 6594 after oral administration in fermented milk. Michaelsen KF. Ahrne S. Syst Appl Microbiol. Hanson LA. Adawi D. Vasquez A. Sandstrom B. Kasravi FB. Pettersson B. Tvede M. Molin G. Jeppsson B. 642-647. Molin G. Molin G. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Comparison of the effects of different strains of Lactobacillus in reducing bacterial translocation on methotrexate-induced enterocolitis in rats. 28. Molin G. Adlerberth I. 59. Krakow. Doctoral thesis. 4949-4956. Appl Environ Microbiol. Digestive Surgery. Moller PL. 320-327. Wold AE. Jeppsson B. Mao Y. Berggren A. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Adawi D. Molin G. Björck I. Antonsson M. 2001. 430-441. Jeppsson B. Ahrné S. Ahrne S. ID 1075: “Lactobacillus parcasei 02A (DSM 13432)” and “Establishment of lactobacilli and beneficial changes in the microflora” 6 7 8 1 2 Antonsson M. Microbial Ecology in Health and Disease. (Unpublished). Appl Environ Microbiol. 25. Differential effect on the innate and acquired cellular immune system by intake of different lactobacilli in human volunteers. 1993. 67B)” and “Immune systems” 2 3 4 5 6 1 Adawi D. Wold AE. Probiotic strains of Lactobacillus and Bifidobacterium affect the translocation and intestinal load of Enterobacteriaceae differently after Dgalactose-induced liver injury in rats. Hayford AE. 276-282. Netherlands Milk and Dairy Journal. Jeppsson B. ID 1076: “Lactobacillus rhamnosus 271 (DSM 6594)” and “Gut Health” 1 Adawi D. 17. Jeppsson B. 1996. 15-20. 116. Molin G. 2005. Jacobsen CN. Ahrne S. 284-291. Nyman M. 40-46. A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. 1999. Hanson LA. Rosenfeldt Nielsen V. 201-206. Jeppsson B. Jakobsen M. DNA-based classification and sequence heterogeneities in the 16S rRNA genes of Lactobacillus casei/paracasei and related species.5 Osman N. 11. Adlerberth I. Molin G. Clin Exp Immunol. 1995. Wold A. 2005. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Appl Environ Microbiol. 49. 62. Berggren A. 47-54. Bengmark S. Lactobacillus in semi-hard cheese and their use as adjunct cultures. 2005. Molin G. Ahrne S. 2004. Microbial Ecology in Health and Disease. Dig Dis Sci. Johansson ML. Osman N. Adawi D. University of Lund. 2 34 . 65. Hessle C. 14. Administration of Lactobacillus rhamnosus DSM 6594 in fermented milk to patients with irritable bowel syndrome (IBS). Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Paerregaard A. Ahrne S. Hayford AE. Bengtsson P. Ahrne S. 19. Hansen S. 19-23. Mao Y. Appl Environ Microbiol. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Neuhaus P. Seehofer D. Internal report. 1997. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Boucsein K. Poster Presentation at the 26th ESPEN Congress. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. 166-173. Michaelsen KF. 284-291. Bengmark S. Mack DR. Neuhaus P. Jeppsson B. 284-291. 65. Jeppsson B. Nobaek S. Jakobsen M. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. Bengmark S. 2002a. Li CK. 15-20. Appl Environ Microbiol. 1103-1107. Adawi D. 67B)” and “Increase the amount of Lactobacilli in the intestine. Jeppsson B. 2006. Inhibit pathogenic bacteria” 1 Adawi D. Comparison of the effects of different strains of Lactobacillus in reducing bacterial translocation on methotrexate-induced enterocolitis in rats. Bengmark S. Molin G. 2 3 4 5 35 . Appl Environ Microbiol. Jeppsson B. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. Bengmark S. Bengmark S. Sandstrom B. Digestive Surgery. 2004. Moller PL. Hoper M. 1999. Lett Appl Microbiol. Issekutz A. 123-127. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Nutrition. Rayes N. Moller PL. Gamal ME. Pathmakanthan S. 2002. Nobaek S. 59. Modulation of the colonic bacterial flora affects differently bacterial translocation and liver injury in an acute liver injury model. 1993. The probiotic bacterium Lactobacillus plantarum species 299 reduces intestinal permeability in experimental biliary obstruction. Establishing the presence of Lactobacillus plantarum 299 in faeces following ingestion of the bacteria in two different dry formulations. Hansen S. Bengmark S. Hayford AE. Lactobacillus plantarum 299 and intestinal mucines (MUC2 and MUC3). 14. Adawi D. Jacobsen CN. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. 1999. Internal report. Johansson ML. 14. Berggren A. 2005. Appl Environ Microbiol. Digestive Surgery. Tvede M. Diamond T.3 Alenfall J. Muller AR. Transplantation. Nobaek S. Molin G. 609-615. Serke S. Olah A. 89. 42. 11. Rosenfeldt Nielsen V. 1993. Comparison of the effects of different strains of Lactobacillus in reducing bacterial translocation on methotrexate-induced enterocolitis in rats. Belagyi T. 59. Michaelsen KF. 4949-4956. Molin G. 2004. Seehofer D. White JS. Sandstrom B. Ahrné S. 1997. J Gastroenterol Hepatol. Parks RW. Serke S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Jakobsen M. 4949-4956. 2002b. Jeppsson B. Mao Y. Early enteral supply of fiber and Lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Lisbon. Decrease the amount of Enterobacteriaceae. Rayes N. Br J Surg. Paerregaard A. Hawkey CJ. 4 5 6 7 8 9 10 11 12 ID 1078: “Lactobacillus plantarum 299 (DSM 6595. Early enteral supply of Lactobacillus plantarum 299 reduce the incidence of infections in severely ill patients: A meta-analysis of three randomized controlled trials. Paerregaard A. Molin G. 18. Bengmark S. 1999. 2005. 74. Microbial Ecology in Health and Disease. Rosenfeldt Nielsen V. 65. Johansson ML. 15-20. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. Cowie J. Ahrne S. 47-54. Molin G. Clements WD. Muller AR. Åstrom M. Nobaek S. Jacobsen CN. Tvede M. 13. Larsson A. Woodcock NP. Internal Report. 1999. Malmö. Microbial Ecology in Health and Disease. 116. Molin G. Hinds G. 2000. 211-219. 2002. Baldeon ME. ID 1080: “Lactobacillus crispatus VPC177 (DSM 16743)” and “Gut health. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Vásquez A. 15-20. 15-20. Clin Microbiol Infect. Oral administration of Lactobacillus and Bifidobacterium strains of intestinal and vaginal origin to healthy human females: Re-isolation from faeces and vagina. 2005. R285-293. McCracken VJ. Probiotics for the treatment of women with bacterial vaginosis. 13. Herias MV. 2005. Molin G. McNaught CE. Gaskins HR. Immunomodulatory effects of Lactobacillus plantarum colonizing the intestine of gnotobiotic rats. Bränning C. Oral administration of Lactobacillus and Bifidobacterium strains of intestinal and vaginal origin to healthy human females: Re-isolation from faeces and vagina. Probiotics for the treatment of women with bacterial vaginosis. Athanasiou S. 17. Poster presented at the International Food and Health Innovation Conference. Johann-Liang R. Yu JL. Sweden. Probiotic for vaginal health. Effect of a symbiotic treatment in DSS induced colitis in rats. 2005. 24. Differential effect on the innate and acquired cellular immune system by intake of different lactobacilli in human volunteers. Molin G. 2006. Wold AE. Nyman M. Falagas ME. Ahrné S.ID 1079: “Lactobacillus crispatus VPC111 (DSM 16741)” and “Establishment of lactobacilli and beneficial changes in the microflora of the intestine and vagina” 1 2 3 Berggren A. 9.. Dunn AM. Mackie RI. A prospective randomised trial of probiotics in critically ill patients. Probiotic for vaginal health. Ahrné S. Chun T. Internal report. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. S2225. Jeppsson B. 2006. 2005. Metakis L. Adlerberth I. Athanasiou S. MacFie J. Clin Microbiol Infect. Clinical Nutrition. Håkansson Å. Falagas ME. Lactobacillus plantarum DSM 9843. Hessle C. Håkansson Å and et al. Krakow. 657-664. Sweden. Molin G. Microbial Ecology in Health and Disease. 2005. Jeppsson B. 17. TNF-alpha sensitizes HT-29 colonic epithelial cells to intestinal lactobacilli. 261-270. Molin G. pectin and oatbase on methotrexateinduced enterocolitis in rats. 116. 3 4 5 2 3 4 5 6 7 8 36 . Wold AE. 2007. Am J Gastroenterol. Hanson LA. Marshall F. Exp Biol Med (Maywood). Intestinal immune response to oral administration of Lactobacillus reuteri R 2 LC. Jeppsson B. Crit Care. Califano C. Europabio 2005: European Conference on Probiotics and their Applications. 2005. Anderson ADG. Ahrné S. Poster presented at the International Food and Health Innovation Conference. Microbial Ecology in Health and Disease. Vásquez A. Hanson LA. Malmö. Betsi GI. Hessle C. 9. Probiotics and immune response. 2005. Clin Exp Immunol. Rask C. 227. 283-290. Vaginal health/flora” 1 2 Berggren A. 1999. 95. 657-664. Telemo E. Midtvedt T. Grassey C. Ahrne S. Jeppsson B. Berggren A. Wold A. ID 1081: “Lactobacillus plantarum 299v (DSM 9843)” and “Immune systems” 1 Cunningham-Rundles S. Mao Y. Molin G. Cervia J. Ljungh Å. Jeppsson B. Betsi GI. 1996. Combined effect of prebiotics and probiotics to optimise the gut health. 2007. Ahrne S. Johansson ML. Bengmark S. Clin Exp Immunol. Klarin B. 276-282. 665-670. with and without gastric acid inhibition. Jeppsson B. 37. Goossens D. 9. Ahrne S. Goossens D. (unpublished). Aliment Pharmacol Ther. Ahrne S. 2000. Johansson Hagslatt ML. Birkenfeld B. Ahrne S. Sallerfors B. Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. 2094-2101. Lindberg AM. Nobaek S. Holm F. Larsson A. 281-289. Molin G. Johansson ML. Johansson ML. 365-367. 2002. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. International Journal of Food Microbiology. Crit Care. and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink with fermented oats. Berggren A. Jeppsson B. selenium status and faecal microbial flora. Kordecki H. 54. 13. Russel M. 1993. 2003. Am J Gastroenterol. 35. Jeppsson B. ID 1084: “Lactobacillus plantarum 299v (DSM 9843)” and “Gut health” 1 2 Berggren A. Influence of a drink containing different antioxidants and Lactobacillus plantarum 299v on plasma total antioxidant capacity. 495-505. Johansson Hagslatt ML. Molin G. Mihaescu A. Dig Dis Sci. Survival of the probiotic. 2007. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Jeppsson B. Drevelius M. 2005. Rose hip and Lactobacillus plantarum DSM 9843 reduce ischemia/reperfusion injury in the mouse colon. Odenholt I. Dig Liver Dis. selenium status and faecal microbial flora. 95. Van Den Bogaard A. Onning G. Berggren A. van den Bogaard A. Survival of Lactobacillus plantarum DSM 9843 (299v). Dig Dis Sci. Int J Food Sci Nutr. 52. 15-20. Molin G. 2938. Hagslatt ML. 2003. 1231-1238. 59. Stobberingh E. Thijs A. L. Johansson ML. double-blind. Onning G. 2006. 44-50. Nobaek S. Molin G. Niedzielin K. Johansson ML. Bengmark S. 1143-1147. Scand J Infect Dis. Berggren A. Wullt M. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Odenholt I. 18. Influence of a drink containing different antioxidants and Lactobacillus plantarum 299v on plasma total antioxidant capacity. randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Food products with Lactobacillus plantarum 299v developed for children. 2082-2086. 2001. Internal report. Klarin B. Ahrne S. Stockbrügger R. Int J Food Sci Nutr. Stobberingh E. 1998. 281-289. 42. 2003. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind. Stene C. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. The World of Food Ingredients. Johansson ML. A controlled.ID 1083: “Lactobacillus plantarum 299v (DSM 9843)” and “Antioxidant properties” 1 Hakansson A. 51. 2003. 2005. 54. Jeppsson B. 2 3 4 5 6 7 8 9 10 11 12 13 37 . Thorlacius H. Jeppsson B. Molin G. Drevelius M. Stockbrügger R. Wullt M. Jeppsson B. Jonkers D. Lööf L. placebo-controlled trial. Nobaek S. Nyman M. Appl Environ Microbiol. Jonkers D. Gut health and diet: The benefits of probiotic and prebiotics on human health. Johansson Hagslatt ML. Jeppsson B. Russel M. Berggren A. Eur J Gastroenterol Hepatol. 2003. plantarum 299v and its effects on the faecal bacterial flora. Lindberg AM. Molin G. Björck I. High doses of Lactobacillus Plantarum DSM 9873 to patients receiving autologous stemcell transplantation: a pilot study. R285-293. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Probiotics for treating infectious diarrhoea. Barkholt L. Edlund C. Jansson JK. 2002. 501-506. Mättö J. Fonden R. 16. Ouwehand AC. Vaughan EE. Martinez E. 2253-2257. Lidbeck A. Lactobacillus acidophilus La5” and “Gut Health. 2003. 2007. 329-336. J Antimicrob Chemother.ID 1085: “A combination of three probiotic ingredients. 1997. 22-26. Orrhage K. Bifidobacterium lactis Bb12. Salminen S. Lactobacillus acidophilus. Gregorio G. ID 1087: “Lactobacillus reuteri DSM 17938” and “Gut microflora” 1 2 3 4 Allen SJ. Lind A. paracasei F19: survival. 52. Viitanen M. Strid H. Nord CE. 308-311. De Vos WM. Edlund C. Oral supplementation with lactic acid-producing bacteria during intake of clindamycin. Sullivan Å. 1988. 2007. Sullivan Å. Gastroenterology. 2001 Salmonella challenge animal model: Lactobacillus reuteri SD2112 (human isolate) protective effect against Salmonella infection in mice. Microbial Ecology in Health and Disease. 124-132. Am J Pathol. Sjostedt S. 2004. Nord CE. BioGaia study report NC001/R&D. Nord CE. 7. Microbial Ecology in Health and Disease. Appl Environ Microbiol. Palmgren AC. 132. Nord CE. Abrahamsson H. Kager L. Lactobacillus acidophilus La5” and “Gut function/health” 1 Crittenden R. Simrén M. 1991. Jernberg C. Björkman P. Effect of yoghurt containing three probiotic bacteria on patients with IBS (Report ongoing). Saarela M. 3. Lactobacillus casei F19. University of Helsinki. Okoko B. 1994. 2002. Nord CE. 2001. 23. Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. 1999. Cochrane Database Syst Rev. Colonization of the human gastrointestinal tract by the lactic acid bacteria Lactobacillus reuteri. ecology and safety in the human intestinal tract-a survey of feeding studies within the PROBDEMO project. Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. 2005. S1269. Nord CE. 17-25. Lactobacillus acidophilus. 2002. ID 1086: “Dairy products containing the combination of three probiotic ingredients. Effect of Lactobacillus paracasei on intestinal colonisation of Lactobacilli. Orrhage K. Masters thesis. Samulelsson L. 247-254. 7. Anaerobe. Influence of Lactobacillus F19 on intestinal microflora in children and elderly persons and impact on Helicobacter pylori infections. Sullivan A. Lidbeck A. Nord CE. 52. Posserud I. 308-311. Von Wright A. Suppl 2. 2003. Lidbeck A. 17-21. 71. Bennet R. Lactobacillus casei F19. Bifidobacterium lactis Bb12. Scand J Infect Dis. Söndergaard B and Bytzer P. Clin Microbiol Infect. 160. Brismar B. Sullivan A. Infection. Microbial Ecology in Health and Disease. Orrhage K. Gustafsson JA. Bifidobacteria andClostridium difficile in elderly persons. Palmgren AC. 3. Lactobacillus paracasei subsp. 67-70. 38 2 3 4 5 6 3 4 5 6 . Effect of supplements with Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Einarsson K. Pelto L. 3. Balish E and Warner T. Carbajal N. Barkholt L. Sullivan A. Nord CE. Impact of Lactobacillus acidophilus on the normal intestinal microflora after administration of two antimicrobial agents. Effect of yoghurt containing three probiotic bacteria on patients with IBS. Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. Dans LF. CD003048. Immune systems” 1 2 Black F. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. J Antimicrob Chemother. 2002. BioGaia study report EC024/AH. Presence of Lactobacillus ssp. Hide D. 247-285. Ierardi E. Salminen SJ. CSAS. 13. Appl Environ Microbiol. Antimicrobial activity of Lactobacillus reuteri against Escherichia coli O157:H7. Helicobacter. 159-162. Indrio F. Casas IA and Dobrogosz WJ. 2002. Eom T-H. Magista AM. Thesis.144. Korean J Pediatr. 2000. 4. Kim S. 140 . 2005. Imase K. 2007. Cavallo L. 48. 2007. Jung W. 81:326. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Suppl 81 / J Dairy Sci 85. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Park J. Francavilla R. 2000. 2002. Helicobacter. 127134. Lactobacillus reuteri ATCC 55730: a clinically proven probiotic. Roos S. Hur J. Noh K. Lim J. Salmon DM. 2004. Jang PS. reuteri DSM 17938. 6032-6040. De Canio A. 2008. Takahashi S. 15-28. Miniello VL. 21-25. The effect of probiotic drinks containing homofermentative or hetrofermentative strains of lactobacilli on the growth of Candida albicans and Escherichia coli in mixed culture. Specific Bifidobacterium strains isolated from elderly subjects inhibit growth of Staphylococcus aureus.. Il. Suomalainen T. Effect of probiotics on constipation. 2004. Enhancement of human health with Lactobacillus reuteri – A probiotic. Kim J-T. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 39 . The study of reinforcement effects of host cellular immunity by Lactobacillus reuteri. 2003. 74. Castellaneta SP. Dobrogosz WJ. Ibrahim S. 2002. Connolly E. Jonsson H. Salminen S. 117. Roos S. 6. Removal of antibiotic resistance plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain L. Kwon N. J Anim Sci. A pilot study. 3. Growth inhibition of Salmonella typhimurium and Clostridium difficile by Lactobacillus reuteri strains. Microbial Ecology in Health and Disease. Ouwehand AC. Lahtinen SJ. Int J Food Microbiol. Bae W. Anti Helicobacter pylori activity among lactic acid bacteria isolated from gastric biopsies and strains of Lactobacillus reuteri. 15-22. Bucci N. Ejehorn M. Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study. Nutrafoods. 80. Inhibition of Helicobacter pylori Infection in Humans by Lactobacillus reuteri ATCC 44730 and Effect on Eradication Therapy. Long-term administration of Lactobacillus reuteri (ATCC55730) has no influence on gastric mucosal inflammation and colonization of Helicobacter pylori in humans. BioGaia study report NC005/R&D. fecal azoreductase activity and fecal mucin content in the elderly. Maurogiovanni G. 2006. immunobiotic and immuno-probiotic. July. Lagstrom H. Connolly E. USA. Kang H. Kim D-U. Rosander A. Kim Y-H. Lionetti E. Ann Nutr Metab. 1. Oh E-Y. Suppl. ASAS. Francavilla R and et al. 2006. 81. Joint Meeting of ADSA. University of Uppsala. Glintborg V. Int J Probiotics Prebiotics. Jalonen L. 2008. 2005. Ouwehand AC. Quebec City. Kansenshogaku Zasshi. Microbial Ecology in Health and Disease. Tokunaga K. Annual Meeting of the IFT (Institute for Food Technologists). Elsom GK. 473. Sugano H. (Unpublished). Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. 2003. Ishida H. 125-128.5 6 Carbajal N. Chicago. Lee B-C. 387-393. Johnson C. Kim J. 19. Lee H-S. Colonization Property of Lactobacillus reuteri and it`s Antagonistic Activity in Mice Infected With Salmonella enterica serovar Typhimurium DT104. Park Y. Yoo B. Tanaka A. in the human stomach and their effects on Helicobacter pylori. 2007. Nutrafoods. Kim K. Shin S. 46. 12.. 219-223. Dicksved J. 986-990 Food and Agriculture Organization of the United Nations (FAO) and World Health Organization (WHO). 74. Connolly E. van Kooyk Y. 1260-1267. 275-284. 37 (Suppl 1). Brandtzaeg P. Proc Natl Acad Sci USA. 3. 2005. Appl Environ Microbiol. immunobiotic and immuno-probiotic. Casas I. Kang H and et al. 65. Yazdanbakhsh M. 102. Roberts L. Selective probiotic bacteria induce IL-10producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. Helicobacter pylori eradication with lactobacillus reuteri. van Capel TM. Bourdet-Sicard R. Effects of probiotic bacteria on humoral immunity to Candida albicans in immunodeficient bg/bg-nu/nu and bg/bg-nu/+ mice. Pena JA. 2000. The effect of oral supplementation of Lactobacillus reuteri. L. 2880-2885. 8. 2005. Lee BC. Lin YP. van Eden W. Infect Immun. 2004. BioGaia study report EC024/AH. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. 41-50. de Jong EC. 20 (Suppl. Ferry GD. Ataya DG. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain. Kim YH. Smits HH. Journal of Pediatric Gastroenterology and Nutrition. Valeur N. Nutrafoods. Jang PS. Connolly E. 36. Kalina WV. Engel P. Lee HS. 48. Kim JT. Kim DU. Weinstock JV. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. Balish E. Wagner RD. Schipper K. Björkstén B. Pilone G. Wolf BW. Ladefoged K. Enhancement of human health with Lactobacillus reuteri – A probiotic. Garleb KA. Bavari S. 1995. Engering A. 1068-1083. 2005. Ruthel G. 2005. Sinkiewicz G. 4. Oh EY. 2005. Wierenga EA. 1998. Warfield KL. Pierson C. Rosander A.. 1997. Demmin GL. Caroli M. Tubelius P. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Versalovic J. Revista Iberoamericana de Micología. Inhibition of pathogens by the probiotic Lactobacillus reuteri. on the immunologic composition of breast milk. Versalovic J. Stan V. Warner T.24 Saggioro A. 70. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. 25. Bortoluzzi F. Hilty M. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Wheeler KB. van der Kleij D. Garleb KA. Mohamadzadeh M. 2004. Abrahamsson T. Korean J Pediatr. Thibodeaux CH. Klaenhammer TR. 3). 2005. Rook GA. 986-990. Mechanisms of disease: the hygiene hypothesis revisited. 6032-6040. 14. Digestive and Liver Disease. 55-59. Casas IA. Olson S. 4165-4172. Microbial Ecology in Health and Disease. A double blind placebo-controled study. McGuirk P. 88. Jakobsson T. 2008. Fredrikson M. Wolf BW. Gill HS. double-blind placebo-controlled study. 4 5 6 7 8 9 40 . Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects. Zaat BA. 17. Thorball J. 15-28. Eom TH. reuteri DSM 17938. Ataya DG. Food Chem Toxicol. 624. Guarner F. 2005. 40. Farmer J. The study of reinforcement effects of host cellular immunity by Lactobacillus reuteri. Environ Health. Zachrisson A. Appl Environ Microbiol. Dohnalek M. 4. Inflamm Bowel Dis. ID 1088: “Lactobacillus reuteri DSM 17938 Lactobacillus reuteri ATCC PTA 5289” and “Immune defence” 25 26 27 28 29 30 31 1 2 3 Dobrogosz WJ. 1085-1094. 11761181. 115. J Allergy Clin Immunol. 2006. Kapsenberg ML. Dohnalek M. Nat Clin Pract Gastroenterol Hepatol. 2001. Pasini M. Balish E. Carbajal N. 2008. Hilty M. Clinical Nutrition. Wagner RD. Girardi L. Vazquez-Torres A. Roos S. Stan V. 2005. Sweden.10 11 Tubelius P. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli. Fantini MC. 2007. L. Aimi R. Hamada T. Grossi E. 125-130. 4. Twetman S. 13. Caspani G. 425-429. Darmawan S. 5. Hepatology. Monteleone G. Christensen HR. 2008. Sinkiewicz G. 2008. 18. Engel P. Carlsson B. Rosander A. Caglar E. International Journal of Paediatric Dentistry. Lactobacillus plantarum 2592. 2008. Makihira S. Jonas S. Caruso R. 95. Ha DK. Takemoto T. 11. Supply of pre. Epithelial cells prime the immune response to an array of gutderived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta. 365-375. Ishida K. Leuconostoc mesenteroides 77:1. Zachrisson A. 35. Caprioli F. Appl Environ Microbiol. Kuscu OO. 2004. Riordan SM. Appl Environ Microbiol. Fina D. Seehofer D. 123. 1730-1737. Rayes N. 2004. double-blind trial. Matsumoto A. Kurtovic J. Acta Odontol Scand. double-blind placebo-controlled study. Poster at the 8th Biennial Congress of the Anaerobe Society of the Americas. 55-60. 2004. Carbajal N. Frokiaer H. 25-28 July 2006. Ergeneli S. Cildir SK.and probiotics reduces bacterial infection rates after liver transplantation--a randomized. Sandalli N. 3 4 5 6 7 8 3 41 . Caglar E. Kuscu OO. Sandalli N. In vitro growth inhibition of periodontitis-associated bacteria by Lactobacillus reuteri. Am J Transplant. Clinical Oral Investigations. 314-318. Connolly E. Paone FM. 2006. Dept. 1441-1449. Nilsson A. Int J Food Microbiol. Hedberg M. Caglar E. Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci. Kavaloglu SC. Ozaki Y. Nishimura H. reuteri DSM 17938. Environ Health. Stolfi C. 2007. Clin Vaccine Immunol. Umeå University. Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria. Paulsson A. Holgerson PL. Langrehr JM. Fukushima H. Oral Microbiology. Twetman S. ID 1090: “A combination of the probiotics: Lactobacillus casei F19. Krasse P. Infect Immunity 75. 12 13 ID 1089: “Lactobacillus reuteri DSM 17938 Lactobacillus reuteri ATCC PTA 5289” and “Healthy oral flora” 1 2 Asikainen S. Duan ZP. Connolly E. Neuhaus P. Ladefoged K. Dahl C. Karched M. Asikainen SEA. 74. In-vitro growth inhibition of periodontitis-associated species by Lactobacillus reuteri. 2006. Peluso I. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Bengmark S. Lactobacillus paracsei ssp paracasei B21060 supressess human T-cell proliferation. Zeuthen LH. 25. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain. 197-208. USA. (unpublished). 219-223. Schiller RA. Kuvvetli SS. Di Iorio L. Fink LN. 39. Pallone F. Hara K. Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. 70. Swed Dent J. Valeur N. Zeuthen LH. 6032-6040. 2006. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. ID. Pediococcus pentosaceus 16:1” and “Natural defence/immune system” 1 2 Liu Q. 2005. Immunology. Cildir SK. Boise. Frokiaer H. Roos S. 2006. Nikawa H. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised. Sandalli N. 11761181. 64. Bengmark S. Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. Theruvath T. 30. Fitzsimons N. O‘Sullivan GC. Fitzgerald G. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Chen K. O'Halloran S. Double blind. 128. 6. Cutting SM. Nutrition Research. Gastroenterology. Bidlack WR. Demonstration of functionality in animal models of disease and in human clinical trials. Hamilton JA. 37. McCallum H. Quigley EM. Cerovic O. Abnormal colonic fermentation in irritable bowel syndrome. Kurtovic J. Naidu AS. Skinner N. Cutting SM. medicine and technology. Fecal flora effects following oral supplementation with Bifidobacteria infantis 35624 in healthy and IBS subjects. Gut. King TS. O‘Mahony L. September 2005. 352. 31. Inflamm Bowel Dis. 188. or peptide in early enteral nutrition: a randomized study in trauma patients. Role of Bifidobacteria in nutrition. Sheil B. Poehner R. 128. Kiely B. J Bacteriol. Vaughan EE. Vovk I. 531-536. Kompan L. Kiely B. Crit Rev Food Sci Nutr. ID 1092: “Bacillus subtilis HU58” and “Immune function” 1 Tam NK. Elia M. 2005. Hoa TT. 1154-1164. 3 4 5 6 7 8 9 10 11 42 . Jang C. O‘Mahony L. Luo F. Williams R. glutamine. O'Mahony L. Mombelli B and Gismondo MR. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Spindler-Vesel A. Hunter JO. Int J Antimicrob Agents. 1187-1189. Shanahan F. Nagree A. 279-292. 1999. J Bacteriol. 119-126. Kelly P. Thornton G. Uyen NQ. Fawcett DH. Feeney M. Quigley E. Henriques AO. 2005. The use of probiotics in medical practice. Collins JK. Flynn S. 1990. Bengmark S. Hong HA. Charbonneau DL. The intestinal life cycle of Bacillus subtilis and close relatives. ID 1091: “Bacillus subtilis HU58” and “Intestinal / digestive health” 5 1 Tam NK. Dunne C. Charbonnneau D. 39. Duc le H. 2003. Synbiotics. 975-980. Hong HA. 2007. Serra CR. Luo F. Collins JK. Canada. Hurley G. Chen K. 2006. Kiely B. 52. McCarthy J. 136-145. Bengmark S. prebiotics. 2692-2700. Visvanathan K. Serra CR. Henriques AO. Hepatology. 2005. Probiotics: from myth to reality. McCarthy J. O'Mahony L. Carryl O. 263-267. placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Altringer L. Montreal. Dunne C. Gastroenterology. Morrissey D. Trowbridge MM. Daly C. Hendrix S. Clemens RA. Poehner RD. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Kidd KJ. JPEN J Parenter Enteral Nutr. 1999. Mitsuoka T. Altringer LA. Probiotic spectra of lactic acid bacteria (LAB). O'Sullivan GC. 2003. Shanahan F. Chen KS. 7. 2692-2700. McIver CJ. O'Sullivan GC. 541-551. Modulation of cytokine profiles in healthy and IBS subjects following supplementation with the unique probiotic strain Bifidobacterium infantis 35624. 76. Trowbridge M. 2001. Collins JK. 1999. Hoa TT. Bifidobacteria and their role in human health. ID 1093: “Bifidobacterium infantis UCC35624” and “Promotion of healthy digestion” 1 2 Arunachalam KD.4 Riordan SM. Carryl OR. Meller ST. The intestinal life cycle of Bacillus subtilis and close relatives. Darcy T. Shanahan F. O'Callaghan L. Fitzgibbon J. World Congress of Gastroenterology. Lancet. Duc le H. 13-126. Luo F. 188. 2006. 1559-1597. Antonie Van Leeuwenhoek. 2000. Journal of Industrial Microbiology and Biotechnology. 16. 19. Murphy L. Uyen NQ. Shanahan F. 1998. O'Mahony L. Salminen SJ. O'Halloran S. McCarthy J. 273-280. Gastroenterology. Thornton G. 16. Gastroenterol Clin North Am. Hendrix S. Shanahan F. Kiely B. 2004. promote T regulatory cells and attenuation of inflammatory responses to murine Salmonella infection. The role of probiotic cultures in the control of gastrointestinal health. 34. J Nutr. Am J Gastroenterol. 19. 279-292. P&G Health Sciences Institute. Scully P. 26. Drugs Exp Clin Res. What immunologists should know about bacterial communities of the human bowel. Rolfe RD. Shanahan F. Clin Exp Immunol. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. O'Callaghan L. Orrhage K and Nord CE. Dunne C. 2005. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. O'Callaghan L. Macsharry J. Demonstration of functionality in animal models of disease and in human clinical trials. Altringer L. 95-111. 132. Matuchansky C. Bifidobacterium infantis 35624. Reid G. O'Riordan A. Kirwan WO. Trowbridge M. Best Practice & Research Clinical Gastroenterology. Sibartie S. 2000. 2007. Picard C. Collins JK. Shanahan F. Symonds E. Irritable bowel syndrome. Collins JK. Murphy L. Commensal microbiota. Charbonnneau D. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. O'Mahony L. Isolauri E. 396S402S. ID 1094: “Bifidobacterium infantis UCC35624” and “Immune Response” 13 14 15 16 17 18 19 20 21 22 23 24 25 26 1 2 Arunachalam KD. Kiely B. Whorwell PJ. Nutrition Research. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Shilling D. Verdu EF and Collins SM. Scully P. O'Sullivan GC. Kavanagh E. Semin Immunol. Lyons A. 2006. Role of bifidobacteria in nutrition. 290. Poehner R. Quigley EM. Morgan J. Sebulsky MT. Review article: bifidobacteria as probiotic agents -. Bond Y. A714 (Abstract W1575). 1294-1298. Best Pract Res Clin Gastroenterol. Chen K. McCormick JK. 2002. A401 (Abstract M1695). 2005. Clin Microbiol Rev. 2007. Robinson T. 19. Neant F. Probiotic Prevention of Digestive Enzyme Damage in a Mouse Model of Salmonella. O'Mahony C. 1581-1590. Quigley EM. O'Mahony L. 43 3 . Quigley EM. 533-545. Quigley EM and Flourie B. 2007. Carryl O. Fioramonti J. including probiotics. Fitzgerald G. 22. Luo F.physiological effects and clinical benefits. 135. 132. Gastroenterology. 839-845. O'Mahony D. 101. Shanahan F. Charbonneau D. American Journal of PhysiologyGastrointestinal and Liver Physiology. 1559-1597. 2007. The use of probiotics in functional bowel disease. The host-microbe interface within the gut. 2006. Redmond HP. MacSharry J. 315-321. Feeney M. 658-672. Daly C. 18. O'Mahony L. Morrissey D. 2005.12 O'Mahony L. Shanahan F. Modulation of cytokine profiles in healthy and IBS subjects following supplementation with the unique probiotic strain. 19. Collins JK. J Nutr. 2003. 1999. O'Sullivan D. Sheil B. Francois A. 1999. Probiotics: from myth to reality. 130. Quigley EM. 94-105. medicine and technology. Probiotics that modify disease risk. 915931. O‘Mahony L. 166-172. Altringer L. Morel J. Tannock GW. Aliment Pharmacol Ther. Kiely B. O'Mahony C. O'Mahony D. 2000. Flynn S. 76. 2006. Waters A. 144. Bifidobacteria and lactobacilli in human health. 16. 495-512. O'Mahony L. Neurogastroenterol Motil. Antonie Van Leeuwenhoek. Shanahan F. Shanahan F. Jass J. Gueimonde M. Potential uses of probiotics in clinical practice. Kiely B. 39. Gastroenterology. 1294-1298. Reid G. 44 . Double blind. 2005. Pot B. Semin Immunol. Shanahan F. Jass J. Quigley EMM. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Collins JK. 533-546. Kavanagh E. placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. 975-980. 72. Appl Environ Microbiol. 290. 94-105. Gueimonde M. Poiret S. 144. 495-512. Shanahan F. Robinson T. Bifidobacteria and their role in human health. 2006. Scully P. 2005. 2002. 34. Kelly P. Verdu EF and Collins SM. ISRCTN Register No 26287422 ongoing randomised controlled trial (expected end date 31/12/2011). 128. The host-microbe interface within the gut. Collins JK. Mattila-Sandholm T. Curr Opin Biotechnol. 135. 531-536. 1990. 16. Quigley EMM and Flourie B. MacSharry J. Shanahan F. Irritable bowel syndrome. 19. Clinical and Experimental Immunology. The use of probiotics in functional bowel disease. Probiotics that modify disease risk. 273. O'Callaghan L. 52. Fitzsimons N. Collins JK. Saxelin M. Matuchansky C. Kirwan WO.physiological effects and clinical benefits. 13-126. 2007. Kiely B. ID 1095: “Lactobacillus paracaseii CUL08 NCIMB 30154 Lactobacillus salivarius CUL 61 Bifidobacterium adolescentis (bifidum) CUL20 NCIMB 30153 Bifidobacterium lactis CUL34 NCIMB 30172” and “Gut Flora/ Immune System” 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 Daniel C. Sebulsky MT. O'Callaghan L. 18. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Mombelli B and Gismondo MR. O‘Mahony L. Int J Antimicrob Agents. 315-321. 5799-5805. Fioramonti J. 658-672. Collins JK. 16. 2005. 1999. O'Callaghan L. Naidu AS. Mitsuoka T. Neurogastroenterology and Motility. Shilling D. Aliment Pharmacol Ther. Salminen SJ. 915931. Potential uses of probiotics in clinical practice. Neant F. 22. Gastroenterology Clinics of North America. 2005. 2006. Isolauri E. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Chen K. 541-551. O‘Sullivan GC. Morgan J. 6. 2007. 2006. O'Mahony L. 19. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Luo F. O'Sullivan GC. 16. J Nutr. Sheil B. Waters A. Dennin V. The use of probiotics in medical practice. American Journal of PhysiologyGastrointestinal and Liver Physiology. Clemens RA. Probiotic spectra of lactic acid bacteria (LAB). 2003. What immunologists should know about bacterial communities of the human bowel. 2005. Crit Rev Food Sci Nutr. O'Riordan A. O'Mahony L. McCarthy J. Redmond HP. Tynkkynen S. Review article: bifidobacteria as probiotic agents -. Francois A. Fitzgibbon J. 839-845. Probiotics of in the prevention of atopy in infants and children. Journal of Industrial Microbiology and Biotechnology. Morgan G. Sibartie S. Vaughan EE. Best Pract Res Clin Gastroenterol. Shanahan F. McCormick JK. 2003. Hurley G. de Vos WM. Leyer G. Probiotic and other functional microbes: from markets to mechanisms. Tannock GW. Clin Microbiol Rev. Sheil B. 16. Goudercourt D. Picard C. Best Practice & Research Clinical Gastroenterology.4 McCarthy J. Bidlack WR. McCarthy J. 166-172. 2000. 2005. 263-267. O'Mahony L. 204-211. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. 2004. Gut. 3 Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, Kimpen JL, Rijkers GT, 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. Clin Exp Immunol, 149, 344-352. Plummer SF, Garaiova I, Sarvotham T, Cottrell SL, Le Scouiller S, Weaver MA, Tang J, Dee P, Hunter J, 2005. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents, 26, 69-74. 4 ID 1096: “Probiotics (Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) & Antioxidants (Vitamin C, Green Tea Extract, Grape Seed Extract, Pine Bark Extract) as contained in the probiotic formula Immunox” and “Maintains healthy digestive function and supports immunity” 1 Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, Pannemans D, Shortt C, Tuijtelaars S, Watzl B, 2004. PASSCLAIM--gut health and immunity. Eur J Nutr, 43 Suppl 2, II118-II173. Drisko JA, Giles CK, Bischoff BJ, 2003. Probiotics in health maintenance and disease prevention. Altern Med Rev, 8, 143-155. Famularo G, De Simone C, Pandey V, Sahu AR, Minisola G, 2005. Probiotic lactobacilli: an innovative tool to correct the malabsorption syndrome of vegetarians? Med Hypotheses, 65, 1132-1135. Fasano A and Shea-Donohue T, 2005. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol, 2, 416-422. Forchielli ML and Walker WA, 2005. The role of gut-associated lymphoid tissues and mucosal defence. Br J Nutr, 93 Suppl 1, S41-48. Hebuterne X, 2003. Gut changes attributed to ageing: effects on intestinal microflora. Curr Opin Clin Nutr Metab Care, 6, 49-54. Hill MJ, 1997. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev, 6 Suppl 1, S43-45. Hughes DA, 1999. Effects of dietary antioxidants on the immune function of middle-aged adults. Proc Nutr Soc, 58, 79-84. Tlaskalová-Hogenová H, Tucková L, Lodinová-Zádniková R, Stepánková R, Cukrowska B, Funda DP, Striz I, Kozáková H, Trebichavsky I, Sokol D, 2002. Mucosal immunity: its role in defense and allergy. International Archives of Allergy and Immunology, 128, 77-89. 2 3 4 5 6 7 8 9 ID 1097: “Lactobacilus acidophilus CUL60 Lactobacillus casei LC11 Bifidobacterium lactis CUL34” and “Gut Flora” 1 Madden JA, Plummer SF, Tang J, Garaiova I, Plummer NT, Herbison M, Hunter JO, Shimada T, Cheng L, Shirakawa T, 2005. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol, 5, 1091-1097. ID 1098: “Lactobacillus LA-5” and “Verdauungsapparat” 1 2 3 Abschlussbericht der Arbeitsgruppe ―Probiotische Mikroorganismenkulturen in Lebensmitteln‖ am BgVV. 1999. Abi-Hanna A, Moore N, Yolken R, Saavedra J, 1998. Long term consumption of infant formulas with live probiotic bacteria: safety and tolerance. Journal of Pediatric Gastroenterology & Nutrition, 27, 484. Alander M, Mättö J, Kneifel W, Johansson M, Kögler B, Crittenden R, Mattila-Sandholm T, Saarela M, 2001. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. International Dairy Journal, 11, 817-825. 45 4 Alm L, Ryd-Kjellen E, Setterberg G, Blomquist L, 1993. Effect of new fermented milk product ‗Cultura‘ on constipation in geriatric patients. In: The lactic acid bacteria. Proceedings of the first Lactic Acid Bacteria Computer Conference. Foo EL, Griffin HG, Mollby R, Heden CG (eds.). Horizon Scientific Press, Norfolk, Va. Anderson AD, McNaught CE, MacFie J, Tring I, Barker P, Mitchell CJ, 2003. Randomized clinical trial of multimodal optimization and standard perioperative surgical care. Br J Surg, 90, 1497-1504. Anderson AD, McNaught CE, Jain PK, MacFie J, 2004. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut, 53, 241-245. Berufsgenossenschaft der chemischen Industrie, 1997. Eingruppierung biologischer Agenzien: Bakterien. Sichere Biotechnologie, Merkblatt B006, 2/97, ZH 1/346. Biffi A, Coradini D, Larsen R, Riva L, Di Fronzo G, 1997. Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line. Nutr Cancer, 28, 93-99. Black F, Anderson PL, Orskov J, Orskov F, Gaarslev K, Laulund S, 1989. Prophylactic efficacy of lactobacilli on traveler‗s diarrhea. Travel Medicine, 333-335. Black F, Einarsson K, Lidbeck A, Orrhage K, Nord CE, 1991. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis, 23, 247-254. Black FT, Andersen PL, Laulund S, 1995. Report from a double-blind plazebo-controlled trial with HIP against traveler‗s diarrhea with a new dosage regimen. Internal report. Black FT, 1996. Placebo-controlled double-blind trial of 4 lactobacilli strains (HIP) used as prophylactic agent against travellers diarrhea (2 trials). Report by G. Nirnberger, Bioconsult, GmbH, Austria. Cardona ME, deVanay VV, Midtvedt T, Norin KE, 2000. Probiotics in gnotobiotic mice. Conversion of cholesterol to coprostanol invitro and invivo and bile acid deconjugation in vitro. Microb. Ecol. Health Dis, 12, 219-224. Chumchalova J, Jytte JJ, Plockova M, 1995. Characterization of acidocin CH 5, a saccharolytic sensitive bacteriocin of Lactobacillus acidophilus CH 5. Advances in Food Sciences, 17, 145-150. Chumchalova J, Josephsen J, Plockova M, 1998. The antimicrobial activity of acidocin CH5 in MRS broth and milk with added NaCl, NaNO3 and lysozyme. Int J Food Microbiol, 43, 33-38. de Vrese M and Möller, 2003. 38. de Vrese M, Kristen H, Laue C, 2005. Einfluß eines probiotischen Milchproduktes auf Helicobacterlnfektionen und die Nebenwirkungen einer Eradikation. Ellegaard J, Peterslund N, Black FT, 1992. Infection prophylaxis in neutropenic patients by oral administration of Lactobacilli. The Seventh International Symposium on lnfections in the lmmunocompromised host, Boulde, June 21-24, 1992. Femia AP, Luceri C, Dolara P, Giannini A, Biggeri A, Salvadori M, Clune Y, Collins KJ, Paglierani M, Caderni G, 2002. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethaneinduced colon carcinogenesis in rats. Carcinogenesis, 23, 1953-1960. Fukushima Y, Li ST, Hara H, Terada A, Mitsuoka T, 1997. Effect of follow-up formula containing bifidobacteria (NAN BF) on fecal flora and fecal metabolites in healthy children. Bioscience Microflora, 16, 65-72. Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T, 1998. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol, 42, 39-44. Fukushima Y, Kawata Y, Mizumachi K, Kurisaki J, Mitsuoka T, 1999. Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Int J Food Microbiol, 46, 193-197. Gatt M, Anderson AD, Reddy BS, Hayward-Sampson P, Tring IC, MacFie J, 2005. Randomized clinical trial of multimodal optimization of surgical care in patients undergoing major colonic resection. Br J Surg, 92, 1354-1362. 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 46 24 Gilliland SE and Walker DK, 1990. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci, 73, 905911. Ha CL, Lee JH, Zhou HR, Ustunol Z, Pestka JJ, 1999. Effects of yogurt ingestion on mucosal and systemic cytokine gene expression in the mouse. J Food Prot, 62, 181-188. Haschke F, Wang W, Ping G, Varavithya W, Podhipak A, Rochat F, Link-Amster H, Pfeifer A, DialloGinstl E, Steenhout P, 1998. Clinical trials prove the safety and efficacy of the probiotic strain Bifidobacterium BB 12 in the follow-up formula and growing-up milks. Monatsschrift für Kinderheilkunde, 146. Hatcher GE and Lambrecht RS, 1993. Augmentation of macrophage phagocytic activity by cell-free extracts of selected lactic acid-producing bacteria. J Dairy Sci, 76, 2485-2492. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT, 1992. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med, 116, 353-357. Hoier E and Hier E, 1992. Säure und Gallentoleranz von Lactobacillus acidophilus und Bifidobakterien. Lebensmittelindustrie und Milchwirtschaft, 26, 769-772. Hove H, Nordgaard-Andersen I, Mortensen PB, 1994. Effect of lactic acid bacteria on the intestinal production of lactate and short-chain fatty acids, and the absorption of lactose. Am J Clin Nutr, 59, 74-79. Hynonen U, Virkola R, Westerlund B, Sillanpaa J, Vartio T, Korhonen T, (Unpublished). Tissue-binding properties of Bifidobacterium Ion gum and Bifidobacferium animalis. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S, 2000. Probiotics in the management of atopic eczema. Clin Exp Allergy, 30, 1604-1610. Jain PK, McNaught CE, Anderson AD, MacFie J, Mitchell CJ, 2004. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin Nutr, 23, 467-475. Jiang T-A and Savaiano DA, 1993. Impact of Lactobacilli supplements on colonic fermentation of lactose in vitro. University of Minnesota. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, Isolauri E, 2001. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol, 8, 293-296. Kankaanpää P, Sutas Y, Salminen S, Isolauri E, 1998. Results on clinical demonstration of probiotics in children. In: Functional food research in Europe 3rd workshop FAIR CT96-1028, VTT symposium 187. Mattila-Sandholm T and Kauppila T (eds.). Edita, Espoo, Finland, 38–39. Kim HY, Bae HS, Baek YJ, 1991. In vivo antitumor effects of lactic acid bacteria on sarcoma 180 and mouse Lewis lung carcinoma. J Korean Cancer Assoc, 23, 188-196. Kirjavainen PV, Ouwehand AC, Isolauri E, Salminen SJ, 1998. The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Microbiol Lett, 167, 185-189. Klaver FA and van der Meer R, 1993. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol, 59, 11201124. Kneifel W, 2000. In vitro growth behaviour of probiotic bacteria in culture media with carbohydrates of prebiotic importance. Microbial Ecology in Health and Disease, 12, 27-34. Laake KO, Bjørneklett A, Bakka A, Midtvedt T, Norin KE, Eide TJ, Jacobsen MB, Lingaas E, Axelsen AK, Løtveit T, 1999. Influence of fermented milk on clinical state, fecal bacterial counts and biochemical characteristics in patients with ileal-pouch-anal-anastomosis. Microbial Ecology in Health and Disease, 11, 211-217. Laake KO, Line PD, Aabakken L, Lotveit T, Bakka A, Eide J, Roseth A, Grzyb K, Bjorneklett A, Vatn MH, 2003. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol, 38, 409-414. 47 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Laake KO, Line PD, Grzyb K, Aamodt G, Aabakken L, Roset A, Hvinden AB, Bakka A, Eide J, Bjorneklett A, Vatn MH, 2004. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol, 39, 1228-1235. Laake KO, Bjorneklett A, Aamodt G, Aabakken L, Jacobsen M, Bakka A, Vatn MH, 2005. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol, 40, 43-51. Langhendries JP, Detry J, Van Hees J, Lamboray JM, Darimont J, Mozin MJ, Secretin MC, Senterre J, 1995. Effect of a fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants. J Pediatr Gastroenterol Nutr, 21, 177-181. Lewis SJ and Freedman AR, 1998. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Alimentary pharmacology & therapeutics, 12, 807. Lidbeck A and Nord CE, 1991. Lactobacilli in relation to human ecology and antimicrobial therapy. Int J Tissue React, 13, 115-122. Lidbeck A, Orrhage K, Nord CE, 1995. Effect of oral supplementation with Lactic acid bacteria during intake of an antimicrobial agent. Poster at the International Dairy Lactic Acid Bacteria Conference, New Zealand. Lin MY, Savaiano D, Harlander S, 1991. Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans. Journal of Dairy Science, 74, 87-95. Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschlimann JM, 1994. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol, 10, 55-63. Mann GV, 1974. Studies of a surfactant and cholesteremia in the Maasai. Am J Clin Nutr, 27, 464-469. Mattila-Sandholm T, Mättö J, Saarela M, 1999. Lactic acid bacteria with health claims-interference and interactions with gastrointestinal flora. Int Dairy J, 9, 25–35. Miettinen M, Vuopio-Varkila J, Varkila K, 1996. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun, 64, 5403-5405. Miettinen M, Alander M, von Wright A, Vuopio-Varkila J, Marteau P, Huis in‘t Veld J, Mattila-Sandholm T, 1999. The survival of and cytokine induction by lactic acid bacteria after passage through a gastrointestinal model. Microbial Ecology in Health and Disease, 10, 141-147. Noh DO and Gilliland SE, 1993. Influence of bile on cellular integrity and beta-galactosidase activity of Lactobacillus acidophilus. J Dairy Sci, 76, 1253-1259. Nopchinda S, Varavithya W, Phuapradit P, Sangchai R, Suthutvoravut U, Chantraruksa V, Haschke F, 2002. Effect of bifidobacterium Bb12 with or without Streptococcus thermophilus supplemented formula on nutritional status. J Med Assoc Thai, 85 Suppl 4, S1225-1231. Nord CE, Lidbeck A, Orrhage K, Sjostedt S, 1997. Oral supplementation with lactic acid-producing bacteria during intake of clindamycin. Clin Microbiol Infect, 3, 124-132. Obradovic D, Curic M, Ivanovic M, Trbojevic B, Djordjevic M, 1996. Probiotic function of the fermented milk yogurt Plus. 5th Symposium on Lactic Acid Bacteria: Genetics, Metabolism, and Applications, The Netherlands. Ouwehand AC, Kirjavainen PV, Shortt C, Salminen S, 1999. Probiotics: mechanisms and established effects. International Dairy Journal, 9, 43-52. Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, Salminen SJ, 2000. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol, 30, 10-13. Ouwehand AC, Tolkko S, Kulmala J, Salminen S, Salminen E, 2000. Adhesion of inactivated probiotic strains to intestinal mucus. Lett Appl Microbiol, 31, 82-86. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 48 62 Perdigon G, Nader de Macias ME, Alvarez S, Oliver G, Pesce de Ruiz Holgado AA, 1987. Enhancement of immune response in mice fed with Streptococcus thermophilus and Lactobacillus acidophilus. J Dairy Sci, 70, 919-926. Peterslund NA, Norgaard JM, Nielsen JE, Black F, (Unpublished). lnfection prophylaxis in neutropenic patients by oral administration of lactobacilli. Plockova M, Chumchalova J, Pluharova B, 1996. The pH tolerance, bile resistance and production of antimicrobial compounds by lactobacilli. Potravinářské vědy (Czech Journal of Food Sciences), 14, 165165. Plockova M, Tomanovà J, Chumchalovà J, 1997. Inhibition of mould growth and spore production by Lactobacillus acidophilus CH5 metabolites. Bulletin Potravinarskeho Vyskumu (Slovakian Bulletin of Food Research). Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH, 1994. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet, 344, 1046-1049. Saavedra J, Abi-Hanna A, Moore N, Yolken R, 1998. Effect of long term consumption of infant formulas with Bifidobacteria (B) and S. thermophilus (ST) on stool patterns and diaper rash in infants. Journal of Pediatric Gastroenterology & Nutrition, 27, 483. Sagen OB, 1998. Treatment of functional disturbance in the intestines by administration of lactic acid bacteria. Internal Report, Chr. Hansen. Salminen S, Laine M, Von Wright A, Vuopio-Varkila J, Korhonen T, Mattila-Sandholm T, 1996. Development of selection criteria for probiotic strains to assess their potential in functional foods: a Nordic and European approach. Biosci Microflora, 15, 61-67. Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, Fonden R, Saxelin M, Collins K, Mogensen G, Birkeland SE, Mattila-Sandholm T, 1998. Demonstration of safety of probiotics -- a review. Int J Food Microbiol, 44, 93-106. Satokari R, 2001. Molecular identification and characterization of bifidobacteria and lactobacilli in the human gastrointestinal tract. VTT Publications 454. VTT Biotechnology, Espoo. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A, 1995. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci, 78, 491-497. Schiffrin EJ, Brassart D, Servin AL, Rochat F, Donnet-Hughes A, 1997. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. 66, 515-520. Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD, 2002. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther, 16, 1669-1675. Shioya M, Nakaoka K, Igarashi R, 2000. Effect of fermented milk containing Bifidobacterium lactis FK 120 on the fecal flora and fecal properties in healthy female volunteers. J Nutritional Food, 3, 19-32. Shioya M, Nakaoka K, Iizuka N, Sato M, Benno Y, 2000. Effect of fermented milk containing Bifidobacterium lactis FK 120 on the fecal flora, with special reference to Bifidobacterium species, and the fecal properties in elderly volunteers. J Nutritional Food, 3, 33-44. Silva AM, Bambirra EA, Oliveira AL, Souza PP, Gomes DA, Vieira EC, Nicoli JR, 1999. Protective effect of bifidus milk on the experimental infection with Salmonella enteritidis subsp. typhimurium in conventional and gnotobiotic mice. J Appl Microbiol, 86, 331-336. Tasic N, Trbojevic B, Zarkovic M, 1994. Effect of fermented milk on cholesterol and triglyceride level in noninsulin dependent diabetics. Tejada-Simon MV, Lee JH, Ustunol Z, Pestka JJ, 1999. Ingestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin A responses to cholera toxin in mice. J Dairy Sci, 82, 649-660. 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 49 80 Trbojevic B, Jankovic, Stojanovic M, Ciric J, Zarkovic M, Tasic N, Nesovic M, 1994. Effect of concentrated probiotic culture on plasma lipoprotein level in noninsulin dependent diabetics. Poster at the Yugoslav Congress of Diabetes. Vanderhoof JA and Young RJ, 1998. Use of probiotics in childhood gastrointestinal disorders. Journal of Pediatric Gastroenterology and Nutrition, 27, 323. Ventura M, Reniero R, Zink R, 2001. Specific identification and targeted characterization of Bifidobacterium lactis from different environmental isolates by a combined multiplex-PCR approach. Appl Environ Microbiol, 67, 2760-2765. Virta P, Otterström K, Niemi L, Wieser-Aho M-T, Lähteenmäki A-L, Leppänen T, 1993. The effect of a preparation containing freeze-dried lactic acid bacteria on laktose intolerance. External report. Wagner RD, Pierson C, Warner T, Dohnalek M, Farmer J, Roberts L, Hilty M, Balish E, 1997. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun, 65, 4165-4172. Wagner RD, Warner T, Pierson C, Roberts L, Farmer J, Dohnalek M, Hilty M, Balish E, 1998. Biotherapeutic effects of Bifidobacterium spp. on orogastric and systemic candidiasis in immunodeficient mice. Rev Iberoam Micol, 15, 265-270. Wagner RD, Warner T, Roberts L, Farmer J, Dohnalek M, Hilty M, Balish E, 1998. Variable biotherapeutic effects of Lactobacillus acidophilus isolates on orogastric and systemic candidiasis in immunodeficient mice. Rev Iberoam Micol, 15, 271-276. Wildt S, Munck LK, Vinter-Jensen L, Hanse BF, Nordgaard-Lassen I, Christensen S, Avnstroem S, Rasmussen SN, Rumessen JJ, 2006. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis. Inflamm Bowel Dis, 12, 395-401. ID 1099: “Coffee” and “Protection of body tissues, lipids, cells and DNA from oxidative damage” 81 82 83 84 85 86 87 1 Aggett PJ, Antoine JM, Asp NG, Bellisle F, Contor L, Cummings JH, Howlett J, Muller DJ, Persin C, Pijls LT, Rechkemmer G, Tuijtelaars S, Verhagen H, 2005. PASSCLAIM: consensus on criteria. Eur J Nutr, 44 Suppl 1, i5-30. Andersen LF, Jacobs DR, Jr., Carlsen MH, Blomhoff R, 2006. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's Health Study. Am J Clin Nutr, 83, 1039-1046. Baker JA, Beehler GP, Sawant AC, Jayaprakash V, McCann SE, Moysich KB, 2006. Consumption of coffee, but not black tea, is associated with decreased risk of premenopausal breast cancer. J Nutr, 136, 166-171. Bandyopadhyay G, Biswas T, Roy KC, Mandal S, Mandal C, Pal BC, Bhattacharya S, Rakshit S, Bhattacharya DK, Chaudhuri U, Konar A, Bandyopadhyay S, 2004. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood, 104, 2514-2522. Baptista MZ, Altundag K, Altundag O, 2006. Coffee and breast cancer risk. Int J Cancer, 118, 1852. Bhathena SJ and Velasquez MT, 2002. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr, 76, 1191-1201. Bichler J, Cavin C, Simic T, Chakraborty A, Ferk F, Hoelzl C, Schulte-Hermann R, Kundi M, Haidinger G, Angelis K, Knasmuller S, 2007. Coffee consumption protects human lymphocytes against oxidative and 3amino-1-methyl-5H-pyrido[4,3-b]indole acetate (Trp-P-2) induced DNA-damage: results of an experimental study with human volunteers. Food Chem Toxicol, 45, 1428-1436. Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, Rizzoli R, 1997. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest, 99, 1287-1294. 2 3 4 5 6 7 8 50 9 10 Burke SJ, Gibney MJ, O'Dwyer NA, McCarthy SN, 2005. The influence of cereal and dairy consumption on the Irish diet: implications for developing food-based dietary guidelines. Public Health Nutr, 8, 227-237. Ceriello A and Motz E, 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol, 24, 816-823. Clifford MN, 1985. Chlorogenic acids. In: Coffee. Clarke RJ and Macrae R (eds.). Elsevier, London, 153202. Clifford MN, 1999. Chlorogenic acids and other cinnamates–nature, occurrence and dietaryburden. Journal of the Science of Food and Agriculture, 79, 362-372. Clifford MN, 2000. Chlorogenic acids and other cinnamates–nature, occurrence and dietaryburden adsorption and metabolism. Journal of the Science of Food and Agriculture 80,1033-1043. Corrao G, Zambon A, Bagnardi V, D'Amicis A, Klatsky A, 2001. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol, 11, 458-465. Crozier A and Stewart A, 2004. Chlorogenic Acids in Coffee – Absorption and Excretion by Human Volunteers. Proceedings of the 20th International Scientific Colloquium on Coffee, Bangalore. Daglia M, Papetti A, Gregotti C, Berte F, Gazzani G, 2000. In vitro antioxidant and ex vivo protective activities of green and roasted coffee. J Agric Food Chem, 48, 1449-1454. Daglia M, Papetti A, Grisoli P, Aceti C, Spini V, Dacarro C, Gazzani G, 2007. Isolation, identification, and quantification of roasted coffee antibacterial compounds. J Agric Food Chem, 55, 10208-10213. Department of Health and Children Ireland -Health Promotion Unit, 2005. Food Pyramid. Dietary guidelines for Ireland. Esposito F, Morisco F, Verde V, Ritieni A, Alezio A, Caporaso N, Fogliano V, 2003. Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. Aliment Pharmacol Ther, 17, 595-601. Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M, 2005. Inhibition of activator protein-1, NFkappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem, 280, 27888-27895. Gallus S, Tavani A, Negri E, La Vecchia C, 2002. Does coffee protect against liver cirrhosis? Ann Epidemiol, 12, 202-205. Gao X, Wilde PE, Lichtenstein AH, Tucker KL, 2006. Meeting adequate intake for dietary calcium without dairy foods in adolescents aged 9 to 18 years (National Health and Nutrition Examination Survey 20012002). J Am Diet Assoc, 106, 1759-1765. Garsetti M, Pellegrini N, Baggio C, Brighenti F, 2000. Antioxidant activity in human faeces. Br J Nutr, 84, 705-710. Giovannelli L, Saieva C, Masala G, Testa G, Salvini S, Pitozzi V, Riboli E, Dolara P, Palli D, 2002. Nutritional and lifestyle determinants of DNA oxidative damage: a study in a Mediterranean population. Carcinogenesis, 23, 1483-1489. Gómez-Ruiz J, Leake DS, Ames JM, 2007. In vitro antioxidant activity of coffee compounds and their metabolites. J Agric Food Chem, 55, 6962-6969. Goya L, Delgado-Andrade C, Rufian-Henares JA, Bravo L, Morales FJ, 2007. Effect of coffee melanoidin on human hepatoma HepG2 cells. Protection against oxidative stress induced by tert-butylhydroperoxide. Mol Nutr Food Res, 51, 536-545. Greer FR and Krebs NF, 2006. Optimizing bone health and calcium intakes of infants, children, and adolescents. 117, 578-585. Grubben MJ, Van Den Braak CC, Broekhuizen R, De Jong R, Van Rijt L, De Ruijter E, Peters WH, Katan MB, Nagengast FM, 2000. The effect of unfiltered coffee on potential biomarkers for colonic cancer risk in healthy volunteers: a randomized trial. Aliment Pharmacol Ther, 14, 1181-1190. 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 51 29 Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Jr., Kempf J, Zinman B, Haffner SM, 2004. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 53, 2623-2632. Heaney RP, 2000. Calcium, dairy products and osteoporosis. J Am Coll Nutr, 19, 83S-99S. Honjo S, Kono S, Coleman MP, Shinchi K, Sakurai Y, Todoroki I, Umeda T, Wakabayashi K, Imanishi K, Nishikawa H, Ogawa S, Katsurada M, Nakagawa K, Yoshizawa N, 1999. Coffee drinking and serum gamma-glutamyltransferase: an extended study of Self-Defense Officials of Japan. Ann Epidemiol, 9, 325331. Honjo S, Kono S, Coleman MP, Shinchi K, Sakurai Y, Todoroki I, Umeda T, Wakabayashi K, Imanishi K, Nishikawa H, Ogawa S, Katsurada M, Nakagawa K, Yoshizawa N, 2001. Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol, 54, 823-829. Hoolihan L, 2004. Beyond Calcium: The Protective Attributes of Dairy Products and Their Constituents. Nutr Today, 39, 69-77. Inoue M, Yoshimi I, Sobue T, Tsugane S, 2005. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst, 97, 293-300. Kalkwarf HJ, Khoury JC, Lanphear BP, 2003. Milk intake during childhood and adolescence, adult bone density, and osteoporotic fractures in US women. Am J Clin Nutr, 77, 257-265. Kim HG, Kim JY, Hwang YP, Lee KJ, Lee KY, Kim DH, Jeong HG, 2006. The coffee diterpene kahweol inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules in human endothelial cells. Toxicol Appl Pharmacol, 217, 332-341. Klatsky AL and Armstrong MA, 1992. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol, 136, 1248-1257. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, Tamakoshi A, 2005. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer, 93, 607-610. Lee DH, Silventoinen K, Jacobs DR, Jr., Jousilahti P, Tuomileto J, 2004. gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab, 89, 5410-5414. Lee KJ and Jeong HG, 2007. Protective effects of kahweol and cafestol against hydrogen peroxide-induced oxidative stress and DNA damage. Toxicol Lett, 173, 80-87. Lodovici M, Caldini S, Luceri C, Bambi F, Boddi V, Dolara P, 2005. Active and passive smoking and lifestyle determinants of 8-oxo-7,8-dihydro-2'-deoxyguanosine levels in human leukocyte DNA. Cancer Epidemiol Biomarkers Prev, 14, 2975-2977. Lopez-Garcia E, van Dam RM, Qi L, Hu FB, 2006. Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am J Clin Nutr, 84, 888-893. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L, 2004. Polyphenols: food sources and bioavailability. Am J Clin Nutr, 79, 727-747. Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr, 81, 230S-242S. Mattila P, Hellstrom J, Torronen R, 2006. Phenolic acids in berries, fruits, and beverages. J Agric Food Chem, 54, 7193-7199. Mensink RP, Aro A, Den Hond E, German JB, Griffin BA, ten Meer HU, Mutanen M, Pannemans D, Stahl W, 2003. PASSCLAIM - Diet-related cardiovascular disease. Eur J Nutr, 42 Suppl 1, I6-27. Michels KB, Willett WC, Fuchs CS, Giovannucci E, 2005. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst, 97, 282-292. Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC, 2005. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr, 93, 393-402. 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 52 49 Milder IE, Feskens EJ, Arts IC, Bueno de Mesquita HB, Hollman PC, Kromhout D, 2005. Intake of the plant lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr, 135, 1202-1207. Moller P and Loft S, 2004. Interventions with antioxidants and nutrients in relation to oxidative DNA damage and repair. Mutat Res, 551, 79-89. Mursu J, Voutilainen S, Nurmi T, Alfthan G, Virtanen JK, Rissanen TH, Happonen P, Nyyssonen K, Kaikkonen J, Salonen R, Salonen JT, 2005. The effects of coffee consumption on lipid peroxidation and plasma total homocysteine concentrations: a clinical trial. Free Radic Biol Med, 38, 527-534. Nakanishi N, Nakamura K, Nakajima K, Suzuki K, Tatara K, 2000. Coffee consumption and decreased serum gamma-glutamyltransferase: a study of middle-aged Japanese men. Eur J Epidemiol, 16, 419-423. Nakanishi N, Nakamura K, Suzuki K, Tatara K, 2000. Effects of coffee consumption against the development of liver dysfunction: a 4-year follow-up study of middle-aged Japanese male office workers. Ind Health, 38, 99-102. Nardini M, D'Aquino M, Tomassi G, Gentili V, Di Felice M, Scaccini C, 1995. Inhibition of human lowdensity lipoprotein oxidation by caffeic acid and other hydroxycinnamic acid derivatives. Free Radic Biol Med, 19, 541-552. Nardini M, Natella F, Gentili V, Di Felice M, Scaccini C, 1997. Effect of caffeic acid dietary supplementation on the antioxidant defense system in rat: an in vivo study. Arch Biochem Biophys, 342, 157-160. Nardini M, Pisu P, Gentili V, Natella F, Di Felice M, Piccolella E, Scaccini C, 1998. Effect of caffeic acid on tert-butyl hydroperoxide-induced oxidative stress in U937. Free Radic Biol Med, 25, 1098-1105. Nardini M, Cirillo E, Natella F, Scaccini C, 2002. Absorption of phenolic acids in humans after coffee consumption. J Agric Food Chem, 50, 5735-5741. Natella F, Nardini M, Giannetti I, Dattilo C, Scaccini C, 2002. Coffee drinking influences plasma antioxidant capacity in humans. J Agric Food Chem, 50, 6211-6216. Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes W, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA, 2006. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer, 118, 103-107. Olthof MR, Hollman PC, Katan MB, 2001. Chlorogenic acid and caffeic acid are absorbed in humans. J Nutr, 131, 66-71. Olthof MR, Hollman PC, Buijsman MN, van Amelsvoort JM, Katan MB, 2003. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J Nutr, 133, 18061814. Ovaskainen ML, Torronen R, Koponen JM, Sinkko H, Hellstrom J, Reinivuo H, Mattila P, 2008. Dietary intake and major food sources of polyphenols in Finnish adults. J Nutr, 138, 562-566. Pellegrini N, Serafini M, Colombi B, Del Rio D, Salvatore S, Bianchi M, Brighenti F, 2003. Total antioxidant capacity of plant foods, beverages and oils consumed in Italy assessed by three different in vitro assays. J Nutr, 133, 2812-2819. Pulido R, Hernandez-Garcia M, Saura-Calixto F, 2003. Contribution of beverages to the intake of lipophilic and hydrophilic antioxidants in the Spanish diet. Eur J Clin Nutr, 57, 1275-1282. Rafter J, Govers M, Martel P, Pannemans D, Pool-Zobel B, Rechkemmer G, Rowland I, Tuijtelaars S, van Loo J, 2004. PASSCLAIM--diet-related cancer. Eur J Nutr, 43 Suppl 2, II47-II84. Richelle M, Tavazzi I, Offord E, 2001. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J Agric Food Chem, 49, 34383442. Ruhl CE and Everhart JE, 2005. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology, 128, 24-32. 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 53 68 69 70 Ruhl CE and Everhart JE, 2005. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology, 129, 1928-1936. Scalbert A and Williamson G, 2000. Dietary intake and bioavailability of polyphenols. J Nutr, 130, 2073S2085S. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, Shibuya D, Tsuji I, 2005. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer, 116, 150-154. Sivak A, 2000. Coffee Consumption and Cancer. In: Caffeinated Beverages. Health Benefits, Physiological Effects, and Chemistry. ACS Symposium Series, No. 754. Parliment TH, Ho C-T, Schieberle P (eds.). Oxford University Press, New York, 64-70. Somoza V, Lindenmeier M, Wenzel E, Frank O, Erbersdobler HF, Hofmann T, 2003. Activity-guided identification of a chemopreventive compound in coffee beverage using in vitro and in vivo techniques. J Agric Food Chem, 51, 6861-6869. Steinkellner H, Hoelzl C, Uhl M, Cavin C, Haidinger G, Gsur A, Schmid R, Kundi M, Bichler J, Knasmuller S, 2005. Coffee consumption induces GSTP in plasma and protects lymphocytes against (+/-)anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide induced DNA-damage: results of controlled human intervention trials. Mutat Res, 591, 264-275. Svilaas A, Sakhi AK, Andersen LF, Svilaas T, Strom EC, Jacobs DR, Jr., Ose L, Blomhoff R, 2004. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr, 134, 562-567. Tanaka K, Tokunaga S, Kono S, Tokudome S, Akamatsu T, Moriyama T, Zakouji H, 1998. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol, 27, 438-443. Tavani A and La Vecchia C, 2004. Coffee, decaffeinated coffee, tea and cancer of the colon and rectum: a review of epidemiological studies, 1990-2003. Cancer Causes Control, 15, 743-757. Terry P, Bergkvist L, Holmberg L, Wolk A, 2001. Coffee consumption and risk of colorectal cancer in a population based prospective cohort of Swedish women. Gut, 49, 87-90. Thomas B and Bishop J, 2007. Manual of Dietetic Practice. Blackwell Publishers, Oxford. Tsuchiya T, Suzuki O, Igarashi K, 1996. Protective effects of chlorogenic acid on paraquat-induced oxidative stress in rats. Biosci Biotechnol Biochem, 60, 765-768. Urgert R, Meyboom S, Kuilman M, Rexwinkel H, Vissers MN, Klerk M, Katan MB, 1996. Comparison of effect of cafetiere and filtered coffee on serum concentrations of liver aminotransferases and lipids: six month randomised controlled trial. BMJ, 313, 1362-1366. US Department of Health and Human Services, 2004. Bone Health and Osteoporosis: A Report of the Surgeon General. van Dam RM, 2006. Coffee and type 2 diabetes: from beans to beta-cells. Nutr Metab Cardiovasc Dis, 16, 69-77. van Zeeland AA, de Groot AJ, Hall J, Donato F, 1999. 8-Hydroxydeoxyguanosine in DNA from leukocytes of healthy adults: relationship with cigarette smoking, environmental tobacco smoke, alcohol and coffee consumption. Mutat Res, 439, 249-257. Williamson G and Manach C, 2005. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr, 81, 243S-255S. Yukawa GS, Mune M, Otani H, Tone Y, Liang XM, Iwahashi H, Sakamoto W, 2004. Effects of coffee consumption on oxidative susceptibility of low-density lipoproteins and serum lipid levels in humans. Biochemistry (Mosc), 69, 70-74. 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 54 ID 1100: “Coffee” and “Glucose homeostasis” 1 2 Adeney KL, Williams MA, Schiff MA, Qiu C, Sorensen TK, 2007. Coffee consumption and the risk of gestational diabetes mellitus. Acta Obstet Gynecol Scand, 86, 161-166. Agardh EE, Carlsson S, Ahlbom A, Efendic S, Grill V, Hammar N, Hilding A, Ostenson CG, 2004. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J Intern Med, 255, 645-652. Arion WJ, Canfield WK, Ramos FC, Schindler PW, Burger HJ, Hemmerle H, Schubert G, Below P, Herling AW, 1997. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6phosphatase. Arch Biochem Biophys, 339, 315-322. Arnlov J, Vessby B, Riserus U, 2004. Coffee consumption and insulin sensitivity. JAMA, 291, 1199-1201. Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L, Pineo A, Busardo A, Paolisso G, 2003. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med, 24, 39-52. Barbagallo M and Dominguez LJ, 2007. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys, 458, 40-47. Battram DS, Arthur R, Weekes A, Graham TE, 2006. The glucose intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men. J Nutr, 136, 1276-1280. Bidel S, Hu G, Qiao Q, Jousilahti P, Antikainen R, Tuomilehto J, 2006. Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes. Diabetologia, 49, 2618-2626. Bidel S, Hu G, Sundvall J, Kaprio J, Tuomilehto J, 2006. Effects of coffee consumption on glucose tolerance, serum glucose and insulin levels--a cross-sectional analysis. Horm Metab Res, 38, 38-43. Clifford MN, 1999. Chlorogenic acids and other cinnamates – nature, occurrence and dietaryburden. Journal of the Science of Food and Agriculture, 79, 362-372. Clifford MN, 2000. Chlorogenic acids and other cinnamates - nature, occurrence, dietary burden, absorption and metabolism. Journal of the Science of Food and Agriculture, 80, 1033-1043. Greenberg JA, Axen KV, Schnoll R, Boozer CN, 2005. Coffee, tea and diabetes: the role of weight loss and caffeine. Int J Obes (Lond), 29, 1121-1129. Greenberg JA, Boozer CN, Geliebter A, 2006. Coffee, diabetes, and weight control. Am J Clin Nutr, 84, 682-693. Gruber A, Nasser K, Smith R, Sharma JC, Thomson GA, 2006. Diabetes prevention: is there more to it than lifestyle changes? Int J Clin Pract, 60, 590-594. Hino A, Adachi H, Enomoto M, Furuki K, Shigetoh Y, Ohtsuka M, Kumagae S, Hirai Y, Jalaldin A, Satoh A, Imaizumi T, 2007. Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. Diabetes Res Clin Pract, 76, 383389. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC, 2001. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med, 345, 790-797. Hu FB, van Dam RM, Liu S, 2001. Diet and risk of Type II diabetes: the role of types of fat and carbohydrate. Diabetologia, 44, 805-817. Hu G, Jousilahti P, Peltonen M, Bidel S, Tuomilehto J, 2006. Joint association of coffee consumption and other factors to the risk of type 2 diabetes: a prospective study in Finland. Int J Obes (Lond), 30, 17421749. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A, 2006. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Annals of Internal Medicine, 144, 554. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 55 2003. 91. Makri K. Med Hypotheses. Deacon CF. 2385-2390. 2006. 62. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. 2004. Hücking K. 364. Lionis C. 2007. Barrett-Connor E. Stehouwer CD. 2006. 2990-2992. Coffee and sweetened beverage consumption and the risk of type 2 diabetes mellitus: the atherosclerosis risk in communities study. Jousilahti P. 2002. Moderate Coffee Consumption is Associated With Lower Prevalence of Diabetes Mellitus Among Elderly Non-Tea Drinkers from the Mediterranean Islands (MEDIS Study). 554. Am J Epidemiol. 5618-5623. Coffee consumption and human health--beneficial or detrimental?-Mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus. Meier J. van Dam RM. 47. 2004. 2004. Tuomilehto J. Ebert R. 1075-1084. Diabetes Care. 301-307. Schmidt MI. JAMA. 2001. Heine RJ. and type 2 diabetes: the Hoorn Study. Nijpels G. 2006. 291. Holst JJ. Bidel S. 48. Folsom AR. Morgan LM. Bountziouka V. Am J Clin Nutr. Tuomilehto-Wolf E. BMJ. 2000. Virtala E. Shimizu M. van Dam RM and Hu FB.20 Johnston KL. Keijzers GB. Clifford MN. Diabetes Care. Bouter LM. Diabetes. caffeine. Nauck MA. 16. 300. Vlachou I. Wingard DL. 1311-1316. Effects of coffee consumption on fasting blood glucose and insulin concentrations: randomized controlled trials in healthy volunteers. Willett WC. 728-733. Creutzfeldt W. McCarty MF. De Galan BE. 69-77. Holst J. 2005. 2005. Smith TC. 2497-2504. Does coffee consumption reduce the risk of type 2 diabetes in individuals with impaired glucose? Diabetes Care. Manson JE. Kritz-Silverstein D. 1993. 642-643. 848-853. Tuomilehto J. Rev Diabet Stud. 2007. Coffee consumption and risk of type 2 diabetes mellitus: an 11year prospective study of 28 812 postmenopausal women. Revue medicale de Liège. 2006. Pasman WJ. Brancati FL. Coffee consumption and incidence of impaired fasting glucose. Verhoef P. 1213-1219. Heiss G. Miyamoto Y. Metallinos G. women. Arch Intern Med. Paynter NP. Caffeine can decrease insulin sensitivity in humans. 49. 4. Smits P. Pereira MA. 50. Parker ED. Hu G. Folsom AR. La consommation regulière de cafe reduirait le risque de diabete de type 2. 105-112. Legrand D and Scheen AJ. Long-Term. impaired glucose tolerance. 29. Suzuki K. van Dam RM. Lindstrom J. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Micheli M. J Agric Food Chem. Tack CJ. Panagiotakos DB. 97-104. 27. and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U. Coffee consumption as trigger for insulin dependent diabetes mellitus in childhood. 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 56 . 294. Diabetologia. Kao WH. Hara Y. Polychronopoulos E. 274-284. 1990. Coffee. Dekker JM. Smith B. 2005. van Dam RM. Economou M. 2152-2159. Kobayashi Y. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. J Clin Invest. 78. 166. Coffee and type 2 diabetes: from beans to beta-cells. Nauck MA. Nutr Metab Cardiovasc Dis. Arai S. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. Zeimbekis A.S. Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. Heimesaat MM. Satsu H. Yeh HC. 398-403. Schmiegel WH. Voutilainen S. Hu FB. 2006. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA. Mol Nutr Food Res. van Dam RM. Orskov C. 164. 29. Ranheim T and Halvorsen B. 64. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Tsakountakis N. 25. LaPorte R. Diabetes Care. Suzuki M. Chhabra SK and Yang CS. Chantre P and Lairon D. 1390-1396. 1998. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Springer Verlag. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. 1738-1744. 15-27. D‘Arcy B. 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 57 . Benzie IF and Strain JJ. Szeto YT. Hackenthal E. 23. 7-20. Caffin N. Consumption of green tea causes rapid increase in plasma antioxidant power in humans. Epidemiologic Reviews. Yao L. Green tea and cancer in humans: A review of the literature. 3268S-3274S. Wiseman SA. Molecular Nutrition & Food Research. 2004.naturaldatabase. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Antioxidant capacity of human plasma and serum as affected by a single dose of a beverage rich in antioxidants-use of three different assay systems. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. Developing an Index of Quality for Australian Tea. 74-78. Hankinson SE. 475. Sofic E. Wu AHB. 2003. Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Birch MR. Hung SH. http://www. 5340-5347. 9. 79-99. 2001. 693-704. Ames BN. Keller K. 50. Strain JJ. Marx S. Tea and cancer prevention: Studies in animals and humans. 1095-1104. Publication No. Journal of Agricultural and Food Chemistry. 1996. Chen CH. Astill C. Kler A. Automated-Assay of Oxygen Radical Absorbency Capacity with the COBAS FARA II. Free Radical Research. 2002. Agriculture & Environment. Prior RL. Ebel S.39 Wu T. Ho ML. 2001. Nutrition and Cancer. Bushman JL. Clinical Chemistry. Prior RL. Chang JK. UQ-88A. Journal of Agricultural and Food Chemistry. 16. Reichling J.A review. Methods Enzymol. 2039-2045. 44. 299. 2006. 151-159. Artacho R. 37. Phytomedicine. 1997. Cabrera C. Diabetes Care. 1999. a marker of insulin secretion. 1999. 41. Beneficial effects of green tea . Chung FL. 106-109. Willett WC. 04/033. Tomlinson B. Gimenez R. Verdon CP. 28. Giovannucci E. Dacombe C. 144-151. Blaschek W. 3426-3431. 2006. 31. Caffeinated coffee. 133. Cao GH.S. Rintoul G. and caffeine in relation to plasma C-peptide levels. The chemistry of tea flavonoids. Journal of the American College of Nutrition. 25. Bohm V. 2006. women. Schulz V. Chemoprevention of lung cancer by tea. Bouwens LCM. Journal of Nutrition. 3-8. Schwartz J.com. Polyphenols from green tea and pomegranate for prevention of prostate cancer. 1995. decaffeinated coffee. 2005. 2005. Clark J and You M. Geiss KR. Journal of Food. 2004. 40. Antioxidant capacity of tea and common vegetables. Yang YM. Rural Industries Research and Development Corporation. Balentine DA. 2006. Netzel M. Cao G. 34. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 49. Critical Reviews in Food Science and Nutrition. Nutrition and Cancer. in U. 83-87. Humphrey PG. 2001. Wang H. Wang GJ. Weiss M. Tea and prostate cancer. 2. Heidelberg. Adhami VM and Mukhtar H. Project No. Benzie IFF. Martin PT. Osteoporosis International. Herzog CR. ID 1103: “Camelia sinensis (Common Name: Tea)” and “Protection of body tissues and cells from oxidative damage” 1 2 3 4 Natural Medicines Comprehensive Database Monograph on Green Tea. Hager Rom Hagers Handbuch der Drogen und Arzneistoffe. Holzgrabe U. Journal of Cancer Research and Clinical Oncology. Journal of Chromatography. Rocha-Pereira P. Cooper R. Gupta S. 755-809. International Journal for Vitamin and Nutrition Research. Comparative antimutagenic and anticlastogenic effects of green tea and black tea: a review. Cancer Letters. Current Drug Metabolism. Journal of Alternative and Complementary Medicine. 639-652. Rebelo I. Journal of Nutritional Biochemistry. Frei B and Higdon JV. Wissenschaftlicher Informationsdienst Tee.html. 11. 133. www. Jacobs DR. American Journal of Clinical Nutrition. 2006. Chow HHS. 112-119. Engelhardt UH. Santos-Silva A. 16. Hagen. 9. Determination of minerals extracted from several commercial teas (Camellia sinensis) to hot water (Infusion). 45. Clinical Nutrition. Saha B. Journal of Alternative and Complementary Medicine. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 58 . Fujiki H. Medicinal benefits of green tea: Part I. 84. Short. 95-135. Atalay E. Ernährungs-Umschau. 2003. Ozcan MM. 7. 2004. 11. 1992. 89-143. Chromatography of Tea Constituents. 5. Harris RB. 2003. 2003. Halvorsen BL. Tea chemistry. Green tea: cancer preventive beverage and/or drug. 624. Finger A. Circulation. 2005. Fujiki H. 521-528. Brown S. Wiseman S. Thomson Reuters. 589-597. Felter H and Lloyd J. 2006.and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Riso P. Vita JA. Green tea: Health benefits as cancer preventive for humans. Gesamtpolyphenolgehalt und antioxidative Kapazität handelsüblicher Getränke. Gokce N. Holte K. 790-796. 123-127. The effect of green tea in oxidative stress. Polyphenole in Tee. Frei B. Fujiki H. 2001. 415-480. 1898. 1997. Montvale. Mutation Research-Reviews in Mutation Research. Cooper R. Metabolism of green tea catechins: An overview. Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. 151-156. Journal of Medicinal Food. 2003. 2005. Imai K. Two stages of cancer prevention with green tea. Antioxidant actions of polyphenols in humans. 2002. 2002. Bohn SK. 73. Henn T and Stehle P.henriettesherbal. Testolin G. Morre DM. Effect of increased tea consumption on oxidative DNA damage among smokers: A randomized controlled study. PDR for herbal medicines. Rocha S. Blomhoff R. Review of anticancer properties. Nakachi K. Bordoni A. Content of redox-active compounds (ie. 25. Medicinal benefits of green tea: Part II. Carlsen MH. Journal of Nutrition. 2006. Castro E. Tea catechins and polyphenols: Health effects. 43. 16. 119-132. Gezgin S. Jaenicke C. Keaney JF. 308-313. Morre J. Brendler T. metabolism. 1998. Camellia sinensis. 37-65. Feng WY. Critical Reviews in Food Science and Nutrition. 2005. 9-13. 1999. Dragsted LO. Morre DM. Critical Reviews in Plant Sciences. Higdon JV and Frei B. Suganuma M. Erba D. Kuhr S. 125. 2006. 293-315. 1992. Holbrook M. Review of noncancer health benefits. 144-149. and antioxidant functions.20 21 22 23 24 Coimbra S. 104. Giri AK. Chemical Record. Foti P. King‘s American dispensatory. 512. Agarwal S. 188. Morre DJ. 2005. Engelhardt UH. Hakim IA. 3275s-3284s. Journal of Nutrition. 133. 1998. Gruenwald J. Phillips KM. Harbowy ME and Balentine DA. Biagi PL. Talbot W. Swerdloff PL. antioxidants) in foods consumed in the United States. Duffy SJ.com/eclectic/kings/index. 3303S-3309S. Jankun J. Lee IP. 65. Oya K. Leung LK. A single dose of tea with or without milk increases plasma antioxidant activity in humans. 2000. 500. A pulse radiolysis study. International Journal of Cancer. 2511-2519. 1997. Gao YT. Wiseman SA. isotheaflavin-3 '-O-gallate and neotheaflavin-3-O-gallate: Three polyphenolic pigments from black tea. Jovanovic SV. Katiyar SK. Croft KD. Luo M. OBrien RC. 68-75. 2001. 86. 1997. Simic MG. Nature. 1307-1313. Mandel S and Youdim MBH. 70. Matsumoto H. 1997. 1998. Swiercz R. Journal of Food Lipids. 2003. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. 18. Puddey IB. Pharmacological effects of green tea on the gastrointestinal system. Wahlqvist ML. Kim YH. 54. Steenken S. Theaflavate B. Antioxidant potential of theaflavins. 234-242. Yamane T. Lapczynski S. Mori TA. Journal of Cellular Biochemistry. McLaughlin JK. Hara Y. 71. Selman SH. Roh JK. drugs. Iwashima A. Consumption of black tea elicits an increase in plasma antioxidant potential in humans. Davies AP. Roberts C. Chen RY. Hsing AW. 2248-2251.2-Dimethylhydrazine-Induced Oxidative DNA-Damage by Green Tea Extract in Rat. Journal of Agricultural and Food Chemistry. Journal of Nutrition. 3. Steenken S. Antioxidative activity of green tea polyphenols in edible oils. Lewis JR. Journal of the American Chemical Society. 48. European Journal of Clinical Nutrition. Chow WH. 2848-2852. Encyclopedia of common natural ingredients used in food. 561-561. Chen ZY. Shim JS. 1-9. 177-185. Cai Y. Kang MH. American Journal of Clinical Nutrition. 387. Skrzypczak-Jankun E. Bergamo BM. Phytochemistry. Ji BT. Dai Q. Blot WJ. Which ring in flavonoids is responsible for antioxidant activity? Perkin Transactions 2. Catechin polyphenols: Neurodegeneration and neuroprotection in neurodegenerative diseases. Simic MG. 2004.43 Hodgson JM. 1997. Lakenbrink C. 2004. 49. Katiyar SK. Burke V. 309-315. International Journal of Food Sciences and Nutrition. Su YL. Beilin LJ. New York. 2497-2504. Inhibition of LDL oxidation by green tea extract. Kitao Y. Curr Drug Targets Immune Endocr Metabol Disord. and cosmetics. 131. Hara Y. 87-92. Katiyar SK and Elmets CA. 1997. 360-361. Leenen R. Tijburg LBM. 4. Why drinking green tea could prevent cancer. Nishimura H. Takahashi T. 27. 2000. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Lancet. 11031107. Japanese Journal of Cancer Research. 2001. Reduction potentials of flavonoid and model phenoxyl radicals. Kikuoka N. Maiwald B. Kannar K. 1106-1111. 1996. European Journal of Pharmacology. Leung A and Foster S. Langley-Evans SC. Zhang ZH. 37. Green tea polyphenols: DNA photodamage and photoimmunology. 119. Nakatani H. Pennington M. Roodenburg AJC. 2000. 1980. Davis AL. Flavonoids and other polyphenols in consumer brews of tea and other caffeinated beverages. Elmets CA. 349. Koo MWL and Cho CH. Wilkins JPG. Acute effects of ingestion of black and green tea on lipoprotein oxidation. Free Radical Biology and Medicine. Inhibition of 1. 1997. Huang Y. Vyalil PK. 304-317. 1995. International Journal of Oncology. John Wiley & Sons. 5337-5343. Fraumeni JF. Green tea polyphenolic antioxidants and skin photoprotection. 109-114. 2000. 255258. J Photochem Photobiol B. Caccetta RA. Koketsu M and Satoh YI. 2001. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 59 . Engelhardt UH. Jovanovic SV. Inagake M. Green tea consumption and the risk of pancreatic and colorectal cancers. Chemopreventive effect of green tea (Camellia sinensis) against cigarette smoke-induced mutations (SCE) in humans. 51. 849-853. The antioxidant properties of theaflavins and their gallate esters . Sugano M. Hasegawa M. Morel I. Steele L. Kim M. Ferreira D. Kondo K. 2001. The polyphenolic content of fruit and vegetables and their antioxidant activities. Itakura H.63 64 65 Maxwell S and Thorpe G. Biochemical Pharmacology. Castelluccio C. 1849-1855. 15-22. 2000. Pastore RL and Fratellone P. 2006. Picard ND. Jung M. Juneja LR. Nakagawa T. Cogrel P. Tago M. 2005. 229-229. 392. 50. 531-539. 327-365. Yokozawa T. Antioxidant nutrients: current dietary recommendations and research update. 153-164. Journal of Agricultural and Food Chemistry. 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 60 . Miller N. Antioxidant activity of various teas against free radicals and LDL oxidation. 407-412. Shu S. 13-19. A Novel Method for Measuring Antioxidant Capacity and Its Application to Monitoring the Antioxidant Status in Premature Neonates. The green tea polyphenol (-)epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Salter L. Poole C. Terasawa K.gov/health/greentea/. 30. Riceevans C. 45. 1996. Takeo T. 84. Quercetin and Diosmetin on Iron-Loaded Rat Hepatocyte Cultures. Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. Shibata T. 785-799. Brissot P. Miyazawa T. 40. Paganga G. Biofactors. http://nccam. Lipids. 40. 1. Arab L. Nagle DG. 21. Rice-Evans CA. 1996. British Medical Journal. Okubo T. Absorption. 13.Radical scavengers or metal chelators? FEBS Letters. The Biochemistry of Green Tea Polyphenols and Their Potential Application in Human Skin Cancer. Protective activity of green tea against free radical. 2005. Tea flavonoids have little short term impact on serum antioxidant activity. Miller NJ. 1993. 40-44. Davies MJ. Cillard J. Shankel D. 529-534. 3967-3973. Curnow A. 1996. 17. 24182422. Aoi N. Gould D. 1999. Antioxidative effect of Green Tea Catechins and their Clinical Efficacy in Hemodialysis Patients. Miller NJ. Composition of Volatile Flavor Compounds and Plain Black Tea Chemical-Quality Parameters of Clonal Leaf. 31-42. Medicinal Research Reviews. Journal of Agricultural and Food Chemistry. What does a serving constitute? Free Radical Research. Antioxidant and Iron-Chelating Activities of the Flavonoids Catechin. Osada K. Tea catechins inhibit cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. Morley N. 2004. 128. Cillard P. Hoshina S. 2006.and glucose-mediated protein damage. Dou JH. Tea catechin supplementation increases antioxidant capacity and prevents phospholipid hydroperoxidation in plasma of humans. Tijburg L. Gopinathan V. National Institute of Health National Center for Complementary and Alternative Medicine. Pasdeloup N. Campbell S. Peters U. J Am Pharm Assoc. Unno T. 47. 67. 1995. Nakagawa K. Altern Med Rev. Takahashi M. Iwamoto T. Potential health benefits of green tea (camellia sinensis): A narrative review.nih. Journal of the Science of Food and Agriculture. Juneja L. 154. 1993. Milner A. 2. RiceEvans C. Zhou YD. 313. 69. 2000. 2001. Does tea affect cardiovascular disease? A meta-analysis. 1999. Nakamura M. Nakamura S. Lescoat G. Herbs at a Glance: Green Tea. Clinical Science. Mitscher LA. 495-503. Ninomiya M. Okubo T. Comparative Biochemistry and Physiology C-Toxicology & Pharmacology. 1997. Yokozawa T. Yamanaka K. Clifford T. 2002. Chemoprotection: A review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Impact of Shoot Maturity on Chlorophyll Content. Miyazawa T. American Journal of Epidemiology. Sergent O. Phytochemistry. Juneja LR. Obanda M and Owuor PO. Explore. Pillai SP. metabolism and antioxidative effects of tea catechin in humans. 55-59. Ohmori R. Photodermatology Photoimmunology & Photomedicine. McDermott JH. 153-162. Molecular Nutrition & Food Research. Yokozawa T. 307-314. 2004. Okubo T. 46. Catechin metabolites after intake of green tea infusions. 2004. 1996. 274-280. Laranjinha JAN. 527-529. Van De Put F. 4. 2001. 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 61 . Prior RL and Cao GH. 2000. Henning SM. 54. Free Radical Research. Schmidt M. Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans. Chu D. Suganuma M. Serafini M. 928. Imai K. Sueoka E. 152-159. 8. Camellia sinensis (L. Chemopreventive Effect of Green Tea (Camellia-Sinensis) among Cigarette Smokers. Saffari Y and Sadrzadeh SMH. Kim YH. 1999. Simonetti P. Min WK. 895-903. 217-233. Proceedings of the Society for Experimental Biology and Medicine. Bombardelli E. Sung H. 2005. Kang MH. 2. Juneja LR. 2002-3. Schmitz H. Schrenk D. 1995. 11. Stangl K. Sueoka N. Seeram NP. 255-261. Paganga G. Proceedings of the Society for Experimental Biology and Medicine. Mills EJ. Simonetti P. 218-228. Lorenz M. 36. Guyatt GH.) O. Cancer Epidemiology Biomarkers & Prevention. Morazzoni P. 220. Bombardelli E. Dacombe C. 43. Rao TP. Proteggente AR. Kuntze. 235-250. 111-118. Antioxidant properties of phenolic compounds. Journal of Agricultural and Food Chemistry. Life Sciences. 1599-1603. Chun S. Biofactors. Heber D. 17. 74. Roberts C. Schmidlin CB. Shim JS. Gardana C. Rice-Evans C. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: a systematic review and meta-analysis. Rice-Evans CA. Van Buren L. Ferro Luzzi A. Roh JK. 1513-1518. Rao TP. 2005. 50. Park H. Niu YT. Rice-Evans CA. Preventive effects of green tea polyphenols against oxidative stress of renal disease. Lee IP. European Journal of Clinical Nutrition. Relationship between rate and extent of catechin absorption and plasma antioxidant status. Pietta PG. 2. Zeitschrift für Phytotherapie. 28-32. International Journal of Tea Science. 1995. Verma S. The role of tea and tea flavonoids in cardiovascular health. Matsuyama S. 1997. Serafini M. 4. Wagner E. 262-266. Fujiki H. Yang SE. Maiani G. Miller J. Integrative Cancer Therapies. Nah J. Kreuter MH. In vivo antioxidant effect of green tea. Pannala AS. Annals of the New York Academy of Sciences. Stangl V. Okabe S. European Journal of Clinical Nutrition. Scheuller HS. Wu P. 2000. Biochemistry and Molecular Biology International. 144. Wiseman S. Der Teestrauch. Seely D. Trends in Plant Science. Journal of Nutritional Biochemistry. Lee R. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. International Journal of Tea Science. Antioxidant capacity and polyphenolic components of teas: Implications for altering in vivo antioxidant status. Baumgart A. The antioxidant activity of regularly consumed fruit and vegetables reflects their phenolic and vitamin C composition. 2006. Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Yokosawa T. Juneja LR. Paganga G. 2002. 387391. Brusamolino A. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. 50. 220. Almeida LM. Gardana C. 585-590. 54. Nakachi K. A new function of green tea: prevention of lifestyle-related diseases. 1998. Food and Chemical Toxicology. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. Morazzoni P. Guedon D.83 Pietta P. Ghiselli A. 1998. 1999. Brusamolino A. Scholz E and Bertram B. 2006. In vivo antioxidant effect of green and black tea in man. Netsch MI. Green Tea Polyphenols Against Renal Disorders. 11. 45. Wang H. Del Rio D. Yang CS. Critical Reviews in Food Science and Nutrition. 44. and liver function without altering markers of oxidative stress. 2004. Plasma concentrations of individual tea catechins after a single oral dose in humans. Yokozawa T. Mulder TPJ. Medpharm GmbH Scientific Publishers. 2009-2012. Koketsu M. Inhibitory Effect of Tannin in Green Tea on the Proliferation of Mesangial Cells. 705-718. Especially Tea Flavonols. Herbal Drugs and Phytopharmaceuticals. American Journal of Clinical Nutrition. 50. 1997. Van Amelsvoort JMM. 37. 2800-2802. 2001. Sakanaka S. Wang HF. http://www. Yang GY. Jang JH. 74.htm. 1993. Medpharm Scientific Publishers. Possible mechanisms of the cancer-preventive activities of green tea. 50. Spectrophotometric assay for total peroxyl radical-trapping antioxidant potential in human serum. Cao GH. Tijburg LBM. Journal of Lipid Research. Xue KX. Germany. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. 2008. 701-705. Iwano M. Oura H. 702-705. 25-54. Xu Z. Food selection based on total antioxidant capacity can modify antioxidant intake. Bianchi M. Hattori M. Balentine DA. Are Powerful Antioxidants Using an in-Vitro Oxidation Model for Heart-Disease. Chung JY. Frei B. Tijburg LBM. University of Maryland Medical Centre. Wu PQ. 1992. Dohi K. Consumption of green or black tea does not increase resistance of low-density lipoprotein to oxidation in humans. Stuttgart. Ju JY. 1997. Tea flavonoids: their functions. Wissenschaftliche Verlagsgesellschaft. Lambert JD. Zavaroni I. Zhou P. Maliakal P.102 Ullmann U. 2000. Wang YQ. 596-600. Stuttgart. Plant Flavonoids. Stuttgart. 66. Antioxidants in tea. 56. 38. 31.edu/altmed/articles/green-tea000255. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Helliwell K. Molecular Nutrition & Food Research. Sakanaka S. Unten L.umm. Green tea. 269-278. Ardigò D. Hof KHV. Kim M. 2001. Inhibition of carcinogenesis by tea. systemic inflammation. van het Hof KH. 2006. Dabbagh YA. Weststrate JA. Wichtl M. Wiersma A. Provan CJ. 1290-1297. Yang CS. Trends in Food Science & Technology. Lien N. 1997. 160-169. Yang CS. Haller J. International Journal of Cancer. Tea and tea polyphenols in cancer prevention. Total antioxidant capacity of fruits. Xenobiotica. Wiseman SA. Effect of Tannins in Green Tea on the Urinary Methylguanidine Excretion in Rats Indicating a Possible Radical Scavenging Action. Pellegrini N. Bioscience Biotechnology and Biochemistry. Piatti P. 823-833. Antidiscoloring activity of green tea polyphenols on beta-carotene. Journal of Agricultural and Food Chemistry. 2006. Weber P. Wang S. 42. Prior RL. Journal of Agricultural and Food Chemistry. 152-160. Hou Z. Kim M. Wiseman SA. 1992. Valkonen M and Kuusi T. 896-899. Oura H. Nephron. 1125-1132. Decourt JD. Lee MJ. 65. 87. 2000. Valtueña S. 1996. Tea. Meng XF. Girault J. Micronucleus Formation in Peripheral-Blood Lymphocytes from Smokers and the Influence of Alcohol-Drinking and Tea-Drinking Habits. utilisation and analysis. Journal of Nutrition. 130. de Boer HSM. 1997. 472S-478S. Chhabra SK. Wichtl M. Mathot JNJJ. hormone-related cancers and endogenous hormone levels. Spitzer V. Kim M. Brighenti F. Zhang RF. Lu G. 43. 50. Journal of Agricultural and Food Chemistry. 2002. Ma GJ. 1997. Am J Clin Nutr. Yokozawa T. Wu AH and Yu MC. Teedrogen und Phytopharmaka. Sang SM. International Journal for Vitamin and Nutrition Research. Scazzina F. 2004. 891-901. Molecular Nutrition & Food Research. 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 62 . Vinson JA. Annual Review of Pharmacology and Toxicology. 170-175. Wichtl M. 1995. Chen WS. Franzini L. Serry MM. Biol Psychol. Utsunomiya K. Yokogoshi H. Kakuda T. 21342136. Biosci Biotechnol Biochem. 60. sleep onset and sleep quality. Chem Pharm Bull (Tokyo). Sakanaka S. Nielsen SE. 1158-1166. Bundesinstitut für Risikobewertung (BfR). Depressor Effect of Tannin in Green Tea on Rats with Renal-Hypertension. Sakanaka S. Effectiveness of green tea tannin on rats with chronic renal failure. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. 1995. and [3H]MDL 105. Bioscience Biotechnology and Biochemistry. 1998. Bioscience Biotechnology and Biochemistry. Hall W. coffee and water on alertness. Parkin C. 3-18. Gardner EJ. Kim M. Li XL. Lemasters JJ. Young JF. Kitaoka S. 2006. A naturalistic investigation of the effects of day-long consumption of tea. J Tradit Med. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. 1999. 1996. Yanase H. Chu DC. Kimura R and Murata T. Kimura R and Murata T. 1257-1261. Photoprotective effects of green tea polyphenols. 139. Getränke mit isoliertem L-Theanin. Nozawa A. 189-192. Biosci Biotechnol Biochem. Central depressant effect of theanine. Suzuki Y. Hindmarch I. Nakagawa H. Nilsson L. Transmural potential changes associated with the in vitro absorption of theanine in the guinea pig intestine. L-Theanine reduces psychological and physiological stress responses. Mason RP. Daneshvar B. Thurman RG. Katiyar SK. Effects of a Component of Green Tea on the Proliferation of Vascular Smooth-Muscle Cells. 2002. Sandstrom B. 199-204. 1994. 10. Trends in Food Science & Technology. Bioscience Biotechnology and Biochemistry. Effects of green tea tannin in dialysis patients. Sugimoto A. Okamura N. G957-G964. Hindmarch I. [3H]kainate. Nozawa A. Mayer B. Oura H. Juneja LR. I. Dragsted LO. Ohira H. 230-238. Ishida K. Biosci Biotechnol Biochem. Quinlan P. 74. Elmets CA. 287-293. 2000. Oura H. Kim M. Prevention of hepatic ischemia-reperfusion injury by green tea extract. Ozeki M. Eur J Clin Nutr. 2007. Sakanaka S. Lane J. Chem Pharm Bull (Tokyo). Haraldsdottir J. Yokogoshi H. Kakuda T. Okai O.519 to glutamate receptors. Oura H. Black tea-helpful or harmful? A review of the evidence. Niino H. 1971. Ishigaki S. Loft S. 125 126 127 128 129 ID 1104: “Camelia sinensis (Common Name: Tea)” and “Physical and mental stimulation (hydration and caffeine)” 1 2 3 4 5 Borzelleca JF. Hermetter A. 2007. 58. 2003. Hayashi H. Shibata T. Nozawa A. 2007. A 13-week dietary toxicity and toxicokinetic study with l-theanine in rats. 63 6 7 8 9 10 11 12 13 . American Journal of PhysiologyGastrointestinal and Liver Physiology. 2002. 1000-1005. 66. 2002. Kataoka K. Unno T. Skibsted LH. 124-134. 2000. Zhong Z. Kimura K. Kall MA. Neurosci Lett. 343-355. Hasegawa M. Huynh-Ba T. 34. 23. Connor HD. Unno T. Oura H. British Journal of Nutrition. 149. Psychopharmacology (Berl). Leeds AR. 59. Moore KL. 1768-1771. Yokozawa T. The effects of black tea and other beverages on aspects of cognition and psychomotor performance. Psychopharmacology (Berl). Ruxton CH. 289. He LQ. Inhibition by theanine of binding of [3H]AMPA. Stanley N. 87. 2683-2686. Conzelmann LO. Chung HY. Yusuf N. Rigney U. 39-45. Photodermatology Photoimmunology & Photomedicine. Rycroft J. Protective effect of gammaglutamylethylamide (theanine) on ischemic delayed neuronal death in gerbils. 64. 48-56. Kakuda T. 1986. 60.123 124 Yokozawa T. Food Chem Toxicol. Green tea extract only affects markers of oxidative status postprandially: lasting antioxidant effect of flavonoid-free diet. 855-858. Quinlan PT. Yokozawa T. Effect of theanine on norepinephrine and serotonin levels in rat brain. Peters D. L-theanine . Irby C. 61. 203-216. Nagato Y. Juneja LR. 1996. 283. 13. Kaneko M. 19. Kim M. 3053-3057. 2000. 1996. 44. Froh M.a unique amino acid of green tea and its relaxation effect in humans. Yokozawa T. Okubo T. Juneja LR. A new proposed guidance system for beverage consumption in the United States. rglutamylethylamide. 153-157. Moore KL. 6. Nagasawa K. Chapman C. 59. Lu K. 770-778. Pharmacol Biochem Behav. Willett WC. 88-92. Psychopharmacology (Berl). r-glutamylethylamide. Hum Psychopharmacol. Journal of the Agricultural Chemical Society of Japan. Rao TP. Nathan PJ. Metabolism of theanine. O'Brien DC. 1997. Maughan RJ and Griffin J. 1999. Inhibitory effect of tannic acid on the lactate metabolism in human saliva. Armstrong LE. Caballero B. Aspinall L. 219-226. Gray MA. gammaglutamylethylamide. Cremer HD and Buttner W. Factors that Affect the Body's Nervous System: Relaxation Effects of Tea L-Theanine. 30. Terashima T. 2000. 2003. 141. 134. Chen YE. Boca Raton. 569-577. Aspen J. Biochem Biophys Res Commun. Scott D. Effects of theanine. J Herb Pharmacother. 64 . Yokogoshi H. 19. Fluoride content in caffeinated. Time for tea: mood. Brown B. Neurochemical research. 8. 2006. Wu KG. The effect of drinking tea at high altitude on hydration status and mood. 19-28. The acute physiological and mood effects of tea and coffee: the role of caffeine level. 116-122. 667673. Effects of L-theanine on the release of alpha-brain waves in human volunteers. Unno T. Mochizuki M. Psychopharmacology (Berl). Frei B. Eur J Appl Physiol. 66. Nagato Y. Chan JT and Koh SH.14 Kobayashi K. 1987. Effects of hot tea. Shimohama S. Nutr Neurosci. Oliver C. water and beverage type. Phan KL. 21-30. Fujimoto S. coffee and water ingestion on physiological responses and mood: the role of caffeine. Liley DT. 1970. 1996. Nathan PJ. Yasuda E. Am J Clin Nutr. Aoki H. Monogr Ser World Health Organ. Yamamoto T. Bartholomeusz CF. 47. Possible involvement of group I mGluRs in neuroprotective effect of theanine. 377-393. Suzuki Y. Observation of caries incidence among a tea-drinking population. Oliver C. Quinlan P. Juneja LR.). Ozeki M. Yamada T. J Dental Health. 83. Lane J. Hayakawa T. 2004. Terashima T. 2008. ID 1105: “Camelia sinensis (Common Name: Tea)” and “Oral health” 15 16 17 18 19 20 21 22 23 24 25 26 27 28 1 2 3 4 Cao J. Heatherley SV. 1998. 529-542. 91. 31. 411. 195. Yokogoshi H. Rycroft JA. Dentistry. 1999. 1998. 16. Smith JE. Kobayashi M. 1980. 2006. 493-498. Absorption of fluorides. Rycroft JA. Caries Res. Juneja LR. 2005. on brain monoamines and striatal dopamine release in conscious rats. 2004. Caffeine ingestion and fluid balance: a review. Gray M. Mine Y and Shahidi F (eds. 164173. Tsuge H. Aspen J. Popkin BM. 72. Okubo T. 457-465. Kakuda T. In: Nutraceutical proteins and peptides in health and disease. 315-321. 320. Rogers PJ. 86-89. in rats. 23. Psychopharmacology (Berl). Effect of theanine. coffee and tea. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. 75-91. 67. Lu K. blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Harrison BJ. 2004. 1593-1596. Iizuka S. on neurotransmitter release and its relationship with glutamic acid neurotransmission. Bray GM. Mood and drinking: a naturalistic diary study of alcohol. Kim M. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Lane J. CRC Press. 2005. decaffeinated and herbal teas. Sugimoto S. Quinlan PT. Nagai K. J Agric Food Chem. Aoi N. Steptoe A and Wardle J. Pleydell-Pearce CW. Journal of Human Nutrition & Dietetics. Oxford. [Effectiveness of green tea catechines for the correction of the alimentary obesity in the experiment]. Manual of Dietetic Practice. Caries Res. Hardwick JL. 163-178. The bio-availability of fluoride from black tea. 2006. Developing an Index of Quality for Australian Tea. Gimenez R. Caffin N. Kuroki T. and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome--a randomized placebo-controlled trial. 1991. Kashket S. Crit Rev Food Sci Nutr. Paolino VJ. 2004. 65 4 5 6 7 . Gallotannins inhibit growth. 233-238. Sanikidze T. Tamacas JC. Ng EH. 63-68. Chanadiri T. 190. Effects of Chinese green tea on weight. 1998. 42. Nutrition. 9. 2005. Nihon Univ J Oral Sci. Georgian Med News. Smith AJ. 29. Xu LX. Inhibition of dextran synthesis by tannic acid. 733-741. 1995. Hattab FN. A functional food product for the management of weight. Publication No. Smith AJ. 61-63. Dental Health. Wei SH. Mellberg JR. 60-65. Thomas B and Bishop J. Otake S. 17. Koo MW. Dore J. Eur J Clin Nutr. Caries Res. Chkhikvishvili I. Concentration of fluoride and selected other elements in teas. Project No. Br Dent J. Yamamoto T. Tooth surface pH during drinking of black tea. 25. 56. Makimura M. Inhibition of cariogenic factor of mutans streptococci by tannic acid. Br J Nutr. 2005. Dietary intake and bioavailability of fluoride. 1984. 7999. 04/033. 237-240. Tachibana Y. Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men. Sato T. Blackwell Publishers. Inhibitory Effects of Green Tea Polyphenols on Glucan Synthesis and Cellular Adherence of Cariogenic Streptococci. 2007. 389. Simpson A. 1975. Ramsey AC. 13. 35. 59. 432-436. Nishihara Y. 51-55. 5. Fluoride intakes and caries increments in relation to tea consumption by British children. Inhibition of salivary amylase by black and green teas and their effects on the intraoral hydrolysis of starch. Analysis of data obtained from 5 years tea drinking program for the caries prevention by means of the linear caries extent/risk relation. 54. Onisi M. 1989. Simpson A. Rao GS. Datunashvili I. 15-21. Berube-Parent S. 2005. 1985. J Am Coll Nutr. 138-139. 101-105. Kim M. J Dent. Rural Industries Research and Development Corporation. 1988. Beneficial effects of green tea--a review. Annu Rev Nutr. 10. Bioactive food stimulants of sympathetic activity: effect on 24-h energy expenditure and fat oxidation. Sakanaka S. Esaishvili M. 1991. ID 1107: “Camelia sinensis (Common Name: Tea)” and “Weight management/metabolism of lipids” 12 13 14 15 16 17 18 19 1 2 3 Bell SJ and Goodrick GK. water-insoluble glucan synthesis. D‘Arcy B. Yeung WS. Shaw L. 67. Hirasawa M. Tang OS. 23. 2001. J Soc Gynecol Investig. 438-443. Yao L. Tremblay A. Ho PC. Wu-Yuan CD. Chan CC. Anticaries effects of polyphenolic compounds from Japanese green tea. Rintoul G. Oho T. The effect of suppression of the tannin fluoride preparation upon the development of dental plaque. 94. Yu H. 1990. 115-136. J Dent. and aggregation of mutans streptococci. J Dent Res. 115-126. 1980. Shaw L. Caries Res. 312. Pelletier C. 2006. Sparagna CA.5 6 7 8 9 10 11 Itoh T. 2925-2929. Artacho R. 25. 374376. Belza A and Jessen AB. 1989. Journal of Dental Research. UQ-88A. 2002. Agricultural and Biological Chemistry. 2001. 4. Cabrera C. Zhang J and Kashket S. Effects of several tea components on acid resistance of human tooth enamel. 32. J Jpn Endodont. 11. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. 2007. Seale J. Hase T. caffeine and sympathetic activity. St-Onge MP. 2004. capsaicin. 521-528. 70. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Br J Nutr. Oolong tea increases metabolic rate and fat oxidation in men. Chantre P. Ferruzzi MG. Meguro S. Nagao T. New York. J Nutr. Rumpler W. 7-15. Cooper R. Girardier L. Int J Obes Relat Metab Disord. John Wiley & Sons. Seydoux J. Nijs I. Obesity (Silver Spring). teas. Komatsu T. Yamamoto S. 1473-1483. Jiang Y. J Altern Complement Med. Obesity (Silver Spring). 2005. Medicinal benefits of green tea: Part I. Westerterp-Plantenga MS. Kunii D. 134. Duret C. Vandermander J. Crespy V and Williamson G. Tokimitsu I. 87. 2848-2852. Ishikura Y. 252-258. 81. Okamura M. Komine Y. Moulin J. 2002. 9. Shimotoyodome A. dairy. Tappy L. Wiley E. 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 66 . Kovacs EM. 2007. Judd J. Hase T. 141. Dulloo AG. Meguro S. Effects of combination of regular exercise and tea catechins intake on energy expenditure in humans. Clevidence B. 185-191. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Tokimitsu I. Westerterp-Plantenga MS. Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. 24. Review of noncancer health benefits. 9. Vogels N. Chantre P. Oolong tea increases energy metabolism in Japanese females. Dulloo AG.8 9 10 11 12 Chantre P and Lairon D. Physiol Behav. Anti-obesity effects of tea catechins in humans. 233-236. 2005. Takahashi H. Diepvens K. Am J Clin Nutr. Hiipakka RA. Kao YH. Ota N. 2006. 599-605. and cosmetics. Mol Nutr Food Res. 15. Sawaki T. Girardier L. 2000. 50. Mol Nutr Food Res. ephedrine. Nagao T. Shimasaki H. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Westerterp-Plantenga MS. Westerterp KR. and green tea. 2006. Metabolic effects of green tea and of phases of weight loss. Hosoda K. Green tea and thermogenesis: interactions between catechin-polyphenols. Haramizu S. Endocrinology. Vandermander J. Fathi M. obesity. 3431S-3440S. Hosoda K. Effects of green tea on weight maintenance after body-weight loss. 131. Lin JK and Lin-Shiau SY. and nuts: potential functional foods for weight control? Am J Clin Nutr. Liao S. Kovacs EM. 349-355. 431-437. Kao YH. 1999. 2000. Shixian Q. Morre DM. and diabetes. Phytomedicine. Tea. Soga S. J Med Food. 2005. Journal of Health Science. Kakuda Y. Rudelle S. 15. Tanaka Y. R77-85. Tokimitsu I. 451-458. 2006. Komatsu T. 2006. Murase T. Mace K. Yamamoto S. 51. Chang HH. Encyclopedia of common natural ingredients used in food. 2001. Cristiani I. A review of the health effects of green tea catechins in in vivo animal models. Am J Physiol Regul Integr Comp Physiol. 980-987. 2001. J Nutr. Nakamori M. Lejeune MP. 50. Shi J. J Oleo Sci. 91. Morre DJ. 1040-1045. 1980. 50. Sakai T. 2003. VanCrey B. Dietary fats. Ishikura Y. Leung A and Foster S. Am J Clin Nutr. 2005. Lee MJ. Takeda Y. Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-O-methyltransferase. Toyama K. 50. Tokimitsu I. Acheson KJ. Inaba M. Komine Y. Soga S. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. J Med Invest. Rohrer D. Effect of a thermogenic beverage on 24-hour energy metabolism in humans. 122-129. Komatsu K. Diepvens K. Obesity and thermogenesis related to the consumption of caffeine. 81. 170175. 3-8. Mensi N. 292. Hase T. 2004. Matsui Y. Itakura H. 2007. Chen CL. 188-210. drugs. 211-217. 2006. Dent. Chang CS. Irby C. Gardner EJ. 2001. Khaw KT. J Nutr Biochem. 11. 48-56. Wang X. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Shimbo M. 176-187. Elmets CA. Ho ML. 2005. 15-22. Wolfram S. Wolfram S. Wu CH. Biotechnol Appl Biochem. Lejeune MP. Katiyar SK. 22. ID 1108: “Camelia sinensis(Common Name: Tea)” and “Glucose metabolism” 35 1 2 3 Anderson RA and Polansky MM. 41. Aoki N. Stuttgart. 1003-1007. 654-659 67 . 2007. Black tea--helpful or harmful? A review of the evidence. 341-347. 1-7. Novel inhibitors of fatty-acid synthase from green tea (Camellia sinensis Xihu Longjing) with high activity and a new reacting site. 2002. International Journal of Food Science & Technology. A review of recent studies in China on the possible beneficial health effects of tea. May HM. 50. J Nutr. Thielecke F. J. Photodermatol Photoimmunol Photomed. 50. Medpharm Scientific Publishers. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. Photoprotective effects of green tea polyphenols. ID 1109: “Camelia sinensis (Common Name: Tea)” and “Bone health” 1 2 3 4 Chen CH. Osteoporos Int. 2512-2518. 335-342. 2005. Ruxton CH. The green tea polyphenol (-)epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Salter L. Clifford T. 2039-2045. Epigallocatechin gallate supplementation alleviates diabetes in rodents. 2189-2203. Weber P. 23.29 30 31 32 33 34 Takashi T. Relationship among habitual tea consumption. Nihon Univ. Gould D. 1088-1095. Chang TC. Preller M. and body fat distribution. percent body fat. 18. Westerterp-Plantenga MS. Xiao W. 61. 43. 333-340. 21. Teixeira SR. Wang RH. El-Sohemy A. Tea enhances insulin activity. 71. J Agric Food Chem. Haruo N. 7182-7186. Hung SH. ID 1111: “Catechins – Green tea (camellia sinensis)” and “Dental health” 2 1 Preventive effects of tea polyphenols (Sunphenon TM) on plaque formation in men. Progress in Medicine. Wang Y. Campbell S. Zhu Y-X. Riegger C. Chang JK. 2006. Wu X. Eur J Clin Nutr. Wichtl M. Am J Clin Nutr. 3-18. Wang Y. Curnow A. Tu Y-Y. Obes Res. Tian W. 2006. ID 1110: “Camelia sinensis (Common Name: Tea)” and “Skin health” 1 Morley N. 7. Huang H. Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells. 2007. Vali B. Okubo T. Chang CJ. Lu FH. 51. Tea drinking and bone mineral density in older women. Iso H. 1195-1204.. Fukino Y. 136. Raederstorff D. Rao LG. 2003. 2006. 2002. 2005. Leeds AR. Photodermatol Photoimmunol Photomed. Mol Nutr Food Res. Herbal Drugs and Phytopharmaceuticals. J Nutr Sci Vitaminol (Tokyo). Obes Res. 2000. Reduction of Body Fat in Humans by Long-term Ingestion of Catechins. 2007. Hegarty VM. Yusuf N. 13. 16. Wang GJ. Anti-obesity effects of green tea: from bedside to bench. 2005. Kovacs EM. Zhang R. Hiroshige I. Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. Hirasawa M.mhlw. The inhibitory effects of Polyphenol Compounds from Camellia sinenis on Collagenase Activity. Inhibitory Effects of Green Tea Polyphenols on Glucan Synthesis and Cellular Adherence of Cariogenic Streptococci. 2 68 . ID 1112: “Catechins – Green tea (camellia sinensis)” and “Weight management” 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 Ashida H.2 FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use). Kim M. Ito M. [Experimental study on polyphenol anti-plaque effect in human]. Inhibitory effects of green tea polyphenols on growth and cellular adherence of an oral bacterium. 745-749. Otake S. Kanazawa K. Furuyashiki T. Rohrer D. Aizawa M. Labour. J Endod. Boca Raton. Kim M. Parajas I and Tobias E. Krahwinkel T and Willershausen B. and Welfare. Dulloo AG. Report of the Philipine Dental Association. 53. Matsumoto T. Inhibitory effects of Fluoride and Tea Catechins on Dental Caries in Rats. Fathi M. 35. 37. Hirasawa M. 1998. Sakanaka S. 438-443. Japan: Food with Health Claims. Horiba N. Improvement of periodontal status by green tea catechin using a local delivery system: a clinical pilot study. Hashimoto T. 1999. 70. Bessho H. 508-515. Sakanaka S. Zhonghua Kou Qiang Yi Xue Za Zhi. Kim M. The effect of sugar-free green tea chew candies on the degree of inflammation of the gingiva. Kim M. Yamamoto T. Antiobesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Nishihara Y. Chantre P. J Oral Sci.jp/english/topics/foodsafety/fhc/index. a Cariogenic Bacterium. 341-349. 463-467. Caries Res. 17. J Oral Sci. 1991. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Satoh S. 2006. Agricultural and Biological Chemistry. Caries Res. 1992. Liu T and Chi Y. Nakamura H. Sakanaka S and Okada Y. 1996. Inhibition of acid production in dental plaque bacteria by green tea catechins. 21. Yamamoto T. Sakanaka S. Am J Clin Nutr. Kuroki T. J Oral Sci. A pilot study of Japanese green tea as a medicament: antibacterial and bactericidal effects. 1997. 22. 2002. 1040-1045. Ikematsu T. J Agric Food Chem. Ministry of Health. 122-124. Effect of Sunphenon on Periodontal Disease. Sato T.html. 1995. Preventive effect of green tea polyphenols against dental caries in conventional rats. 383-384. 52. Juneja LR. Takada K. Yamamoto T. Maekawa Y. Makimura M. Agricultural and Biological Chemistry. Chu DC. Food for Special Dietary Uses. and Nutrition Labeling http://www. Biosci Biotechnol Biochem. 2004. Sakanaka S.go. 265-270. 2000. Nagayasu H. Taniguchi M. 592-594. Porphyromonas gingivalis. 1989. Mensi N. Otake S. Biosci Biotechnol Biochem. 40. Yamamoto T. 2307-2311. 433-438. 1991. Takada K. Kim M. 60. CRC Press. 56. Chemistry and Applications of Green Tea. 1991. 21-28. Yamamoto T. 2000. Effect of Green Tea Catechins by Local Delivery System in Periodontitis. 5. Duret C. Anticaries effects of polyphenolic compounds from Japanese green tea. Otake S. 1688-1692. Shimura N. J Periodontal Res. 2004. 1990. Hirasawa M. 24. 2925-2929. Aizawa M. Sakakibara H. Makimura M. 2002. Vandermander J. Girardier L. Biofactors. Eur J Med Res. Inhibitory effects of green tea polyphenols on the production of a virulence factor of the periodontal-disease-causing anaerobic bacterium Porphyromonas gingivalis. 54. 17. 25. Antibacterial Substances in Japanese Green Tea Extract against Streptococcus mutans. Yamada H. 135-140. Cheng X. 2004. http://healthlibrary.epnet. Green tea and thermogenesis: interactions between catechin-polyphenols. 2000. 1996. Biosci Biotechnol Biochem. catechins.3 Dulloo AG. Ogawa S. 16. Chantre P. Anti-obesity effects of green tea: from bedside to bench. EBSCO CAM Review Board. Pultz S. Zheng G. 2006. 128-133. Thone-Reineke C. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. 1999. 1040-1045. 2005. Lairon D. Girardier L. J Nutr. in mice. J Epidemiol. Nozawa A. 29. Soga S. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Gruenwald J. 24. Dulloo AG. 693-696. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. 3 4 5 6 7 8 9 10 69 . Kono S. Zheng G. J Nutr Biochem. Fong WP.aspx?token=e0498803-7f62-4563-8d475fe33da65dd4&chunkiid=21771. Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet. Komine Y. Bordoni A. Vandermander J. 615623. Oguni I. Unno T. Hofman A. Imai K and Nakachi K. Yun JH. 211-217. Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. 11. 1884-1892. Sayama K. In Vivo. Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. 81. J Nutr Biochem. Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. Ho WK. 176-187. Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. Wolfram S. 55-62. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. 6. Haramizu S. 50. In Vivo. Riso P.com/GetContent. Int J Obes Relat Metab Disord. Thielecke F. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Inaba M. Arch Intern Med. Montvale. Mol Nutr Food Res. Nagao T. 252-258. Kim W. Murohara T. 122-129. Chen ZY. 18. Chantre P. 50. Tanaka Y. Int J Obes (Lond). 159. Kang JC. 37. Foti P. Huang Y. 129. Sayama K. 1999. Mol Nutr Food Res. Honjo S. Pafumi Y. food utilization and lipid metabolism in mice. Pols HA. Armand M. 69. Juneja LR. 2005. 1052-1057. Wolfram S. Fathi M. Suzuki Y. Witteman JC. Kondo T. Tokimitsu I. Lin S. 1995. Meguro S. Girardier L. Erba D. Effects of green tea on growth. Chae HJ. Exercise and green tea extract stimulate fat oxidation and prevent obesity in mice. ID 1113: “Catechins – Green tea (camellia sinensis)” and “Cholesterol” 4 5 6 7 8 9 10 11 1 2 Chan PT. 2000. 2170-2174. Lee MC. 2004. Vandermander J. Lin JK and Lin-Shiau SY. 70. Okubo T. Klaus S. Murase T. Jaenicke C. Sagesaka Y. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Hase T. Am J Clin Nutr. 310. Med Sci Sports Exerc. Shinchi K. Duret C. Oguni I. Cho SH. Kakuda T. Green Tea. Cheung YL. Kobayashi M. Am J Clin Nutr. 2005. caffeine and sympathetic activity. 14. 481-484. Wang Y. Heat-epimerized tea catechins have the same cholesterol-lowering activity as green tea catechins in cholesterol-fed rats. 2005. 144-149. 2006. Circ J. Biagi PL. 2455-2458. Geleijnse JM. 45-51. 2000. Anti-obesity effects of three major components of green tea. 2006. Mensi N. Katsurada M. Jeong MH. Rosier C. BMJ. Thomson Reuters. Juhel C. 1094-1101. Launer LJ. 1999. Wakabayashi K. Ahn YK. Brendler T. Todoroki I. Shimotoyodome A. Rohrer D. Vandermander J. Nishikawa H. PDR for herbal medicines. 2005. Imanishi K. Ikeda I. Tokimitsu I. 70. Testolin G. Sakurai Y. Seydoux J. caffeine and theanine. Egawa K. 50. 35. 835840. 1448-1453. 2006. 1986. Tsubono Y. Tago M. Yun YP. 229-237. 1052-1057. Chen H. Kondo K. Kang WS. J Nutr Biochem. Br J Nutr. Natural Medicines: Comprehensive Database. cancer. Lin JK and Lin-Shiau SY. 2005. 13. Tea consumption and mortality after acute myocardial infarction. Therapeutic Research Faculty. 2476-2481. Moriyama T. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. Yamori Y. 70 2 3 4 5 6 7 8 . Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. Nishino Y.com/. Chung KH. Comp Biochem Physiol C Toxicol Pharmacol. Ahn YK. Cheng X. 2001. 38. Negishi H. Tea catechins inhibit cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. 157-165. Tsuji I. Kuriyama S. 543-547. Med Sci Monit. Son JE. Kikuchi N. Kakuda T. 326-332. Mol Nutr Food Res. Inhibitory effects of purified green tea epicatechins on contraction and proliferation of arterial smooth muscle cells. Nozawa A.11 12 13 Lee W. Elste V. Chun S. J Nutr Sci Vitaminol (Tokyo). 84-87. BR40-45. 2000. ID 1114: “Catechins – Green tea (camellia sinensis)” and “Heart health” 14 15 16 17 18 19 20 21 22 1 Chen ZY.naturaldatabase. Yang TT and Koo MW. Complement Ther Med. Chae HJ. White IR. Zhao J. Murohara T.com/. Natural Medicines Comprehensive Database. Lu GP. Kono S. J Nutr. Frost C. 128. Fraser ML. Sugano M. 505-512. 2007. Weber P. 1255-1265. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Lau CW. Preventive effects of green tea catechins on spontaneous stroke in rats. Kim W. 2006. 66. 163. Njelekela M. Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. Jeong MH. Life Sci. Pharmacol Res. 211-217. Ikeda M. Zakouji H. Sherwood JB. JAMA. Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. Ann Epidemiol. Circulation. 296. Thromb Res. Nara Y. 32. 2005. 2007. 1997. Tanaka K. Xu JW. Nakamura S. 2006. Mok GS. Jin XJ. Li YH. Tokudome S. Saito K. Ho WK. Lim IH. Cai NS. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Tokunaga S. Raederstorff DG. 613-622. Hoshina S. Suzuki C. Unno T. Hara Y. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Suzuki Y. 96. Akamatsu T. Yoo HS. Wu ZG. Zhu JQ. Cho SH. Lee YW. Yao XQ. 93. Nakamura M. Kondo T. Law WI. Effect of EGCG on lipid absorption and plasma lipid levels in rats. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. 1999. Acta Pharmacol Sin. Green tea and stroke prevention: emerging evidence. 15. Fukuyo M. Yang TT and Koo MW. Clin Biochem. Maclure M. http://www. Muramatsu K. Effect of tea catechins on postprandial plasma lipid responses in human subjects. Umegaki K. 153-164. Yuk DY. 2003. Mukamal KJ. Muller JE. 70. 12. Park H. Nakaya N. 14. Tabuchi M. 134. 46-53. Therapeutic Research Faculty. Lee YK. Circ J. 2002. Shimazu T. Lee MC. Osada K. Park JB. Green tea consumption and mortality due to cardiovascular disease. Wouters BC. and all causes in Japan: the Ohsaki study. Huang Y. 21. 105. Lee DH. Schlachter MF. 2003.naturaldatabase. Takahashi M. Lee AH. Maron DJ. Yun JH. Hypocholesterolemic effects of Chinese tea. Arch Intern Med. 2004. Min WK. 38-42. 2000. 2002. Ikeda K. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Tomita T. Kang JC. Mittleman MA. 411-423. Sagesaka YM. http://www. Ohmori K. J Chromatogr A. Lu FH. 2001. 43. 2003. Higdon JV and Frei B. 1998. 2005. 543-547. Takano T. Suzuki Y. Inaoka S. 2005. Liao ML. Kondo K. Folsom AR. Chen YH. Br J Nutr. 38. 134. Sagesaka YM. Ikeda A. 137-142. 68. Shimizu H. 50. Am J Physiol Cell Physiol. Tea catechins and polyphenols: health effects. 1534-1540. 56. Eur J Clin Nutr. Chung JH. C1094-1108. Maruyama K. dietary sources. Leem K. Okabe S. 953-960. Bravo L. Wu MH. Iwamoto Y. Circ J. Epidemiology. Hase T. Chung WJ. Anti-obesity effects of tea catechins in humans. elimination of tea polyphenols in rats. Dietary catechins in relation to coronary heart disease death among postmenopausal women. Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways. Nakatsuka H.. Crit Rev Food Sci Nutr. Ichinowatari Y. Kato K. Shin DH. Hosoda K. Hisamichi S. Sato Y. 693-699. Iha M. 71 . Stangl K. Gross M. Chang CJ. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. 337-343. 1998. Ohba T. 2008. Okubo T. Tokimitsu I. Wang MF. Chen L. and antioxidant functions. 164. Wu CH. Drug Metab Dispos. Hong MS. 665-670. Suda S. Iso H. 89-143. Suga K. Arch Intern Med. Chen HC. J Nutr. Method for determining the content of catechins in tea infusions by high-performance liquid chromatography. 2004. Lee MJ. Mutat Res. Lorenz M. Antihyperglycemic effect of oolong tea in type 2 diabetes. Journal of Oleo Science.induced diabetic rats. Yang CS. Sueoka E. Lee MJ. 157. The protective effect of habitual tea consumption on hypertension. Jacobs DR Jr. Wu JS. Ida Y. Mol Nutr Food Res. Komine Y. 402. 2005. Yamamoto S. Absorption. 2006. 1045-1050. Katsuragi Y. Inami S. J Nutr Biochem. Diabetes Care. Tada Y. 307-310. Kakuda T. Suganuma M. 2006. Int Urol Nephrol. Crespy V and Williamson G. 1714-1718. Chen CL. Imai K. Cancer inhibition by green tea. The role of tea and tea flavonoids in cardiovascular health. Iso H. Takeda Y. 2001. 12. A review of the health effects of green tea catechins in in vivo animal models. Yang YC. Takahashi H. J Nutr Sci Vitaminol (Tokyo). 805. Kozu T. Yoon SH. 2006. Aoki N. 404-421. Effect of tea catechins on postprandial plasma lipid responses in human subjects. Okubo T. 28262832. Komori A. 668-675. Watanabe T. Sueoka N. 1997. Nakachi K. Liu HC. Li H. 26. Ikeda M. 1989. ID 1115: “Catechins – Green tea (camellia sinensis)” and “Glucose metabolism” 10 11 12 13 14 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Arts IC. 218-228. Harnack LJ. Fujisaku S. Seimiya K. 78. 288. Bae JH. 51. Wu BT. Karibe S. 3431S-3440S. Nutr Rev. metabolism. 93. Epigallocatechin gallate reduces hypoxia-induced apoptosis in human hepatoma cells. Chuang CK. A review of latest research findings on the health promotion properties of tea. Effects of green tea intake on the development of coronary artery disease. 2004. and nutritional significance. Tago M. Matsui Y. Mizuno K. 1998. Clevidence B.9 Park HJ. metabolism. 62. 599-605. 12. Dufresne CJ and Farnworth ER. Fujiki H. Egawa K. 335-342. distribution. Bronner WE and Beecher GR. Meguro S. Renoprotective effects of tea catechin in streptozotocin. Shimbo M. Polyphenols: chemistry. Fukino Y. Hwang JS. 2001. Tohoku J Exp Med. Hase M. 2004. Hung PF. Nozawa A. Babazono T. Possible contribution of green tea drinking habits to the prevention of stroke. Sano J. Fukino Y. 25. Sakai S. Kinae N. 317-333. Life Sci. 2003. Kao YH. Shimasaki H. Stangl V. Unno T. Aoki N. 50. insulin resistance and pulse wave velocity in type 2 diabetes patients. Antidiabetic activity of lipophilic (-)-epigallocatechin-3-gallate derivative under its role of alpha-glucosidase inhibition. Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. Yang CS. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Tanaka K. 231-246. Ideishi M. Liu Y. 2006. Wakai K. Min DS. Absorption and distribution of tea catechin. 554562. 61. 2003. Lee J. 4. Nakagawa K and Miyazawa T. Smith TJ. Balentine DA. Sheng S. Fukui M. Rizvi SI and Zaid MA. Lambert G. J Nutr Sci Vitaminol (Tokyo). Simonetti P. 46. 2007. 2001. and diabetes. 481-486. 15. Intracellular reduced glutathione content in normal and type 2 diabetic erythrocytes: effect of insulin and (-)epicatechin. Kono S. J Physiol Pharmacol. Effects of green tea consumption on inflammation. Kim NH. Hahn SJ. Biochem Mol Biol Int. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Washio M. Gobbo S. Seo JA. Chen L. 10214-10221. Bombardelli E. 144. J Biol Chem. Shirai K. 70-75. Li C. 73. obesity. Kim SG. Tea. Biomed Pharmacother. 10. 2007. Mol Nutr Food Res. Najafi H. Qin W. mice. Clin Exp Pharmacol Physiol. Meng X. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Lee MJ. Ryu OH. Kim TG. Pietta P. Lee MJ. Matschinsky FM. 1995. Sim SS. 43. Nii T. Kim HY. Relationship between rate and extent of catechin absorption and plasma antioxidant status. 693-696. Mohr S. Mishra N. Ryu GR. and rats. Cancer Epidemiol Biomarkers Prev. 2000. Zaid MA. Takeshita A. Choi DS. 71. Protective effects of epicatechin against the toxic effects of streptozotocin on rat pancreatic islets: in vivo and in vitro. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans. Kuntze Zeitschrift für Phytotherapie. 1997. Jo YH. Chang HH. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. 483-488. 2006. 32. XXXVIII. Ann Intern Med. Ji G. Meng X.Camellia sinensis (L. Scholz E. 4. Li H. 1998. Arai H.) O. Mohri M. Kodama H. Food Chemistry. Yang CS. Pancreas. Maliakal P. Doliba NM. Chen L. Kao YH. Zhu N. Prabhu S. Moon HS. Gardana C. Kwagh J. 1042-1050. 26. Schlesier K. Ann Epidemiol. 2005. Chung JS. Liu J. 401-408. Arakawa K. 895-903. Bitsch R. Cho CS. 292-299. Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. 2001. Proposed mechanisms of (-)-epigallocatechin-3gallate for anti-obesity. 1995. Morazzoni P. Der Teestrauch . Doi Y. Unterschiede im protektiven Potential von Grün-und Schwarztee aus gleichen Teeblättern. and Bertram B. BMJ. Koyanagi S. in the rat. Gießen. 10251032. Date C. 167. Wang ZY. Bondoc FY. Chem Res Toxicol. 2006. Zhang X. Chem Biol Interact. 22. 2001. Tokunaga S. Lee MJ. Anis R. 85-98. Lee MJ. Baik SH. Takada K. Choi KM. 356-358. Lu H. Cancer Epidemiol Biomarkers Prev. Simulated intestinal digestion of green and black teas. Choi YJ. 2002. 281. Rizvi SI. 50.15 16 Imai K and Nakachi K. Yoon SH. 52. Chen CL. Wissenschaftlicher Kongreß der Deutschen Gesellschaft für Ernährung. Kawano T. Kim MS. Allen A. Lee KW. (-)-epigallocatechin-3gallate. 679-684. Yoshimasu K. Stanley CA. Analysis of plasma and urinary tea polyphenols in human subjects. 2002. Record IR and Lane JM. Nakagaki O. Diabetes Res Clin Pract. Tamakoshi A. Sun Y. Li T. 1995. Rhie DJ. Lee HG. 2006. Kim MJ. Brusamolino A. 393-399. Yang CS. 310. Ho CT. Collins HW. Hiyamuta K. Sang S. 188-210. Sasazuki S. 91-96. Böhm V. 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 72 . 11. Iso H. Lee MJ. Dacombe C. Weber P. Bocker KB. Decourt JP. 2006. Plasma concentrations of individual tea catechins after a single oral dose in humans. Dietary differences with green tea intake among middle-aged Japanese men and women. Furne JK. 220. Yamaguchi K. 88-101. Van Amelsvoort JM. Low CS. Mulder TP. 2001. Decourt JD. Kim M.34 35 36 Teeverband. 13. 112. Microbial Ecology in Health and Disease. de Munck JC. 56. An extract of black. Serit M. 24092412. 2001. Agricultural and Biological Chemistry. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. 2006. Diabetologia. Ahn YJ. Sasaoka T. Yamaji T. Akabane M. Biofactors. 84. Riegger C. Yamamoto T. 50. 47. Prev Med. Yamamoto T. Okubo T. Yang CS and Landau JM. green. 704-710. Mineshita M. Mechanisms of inhibition of carcinogenesis by tea. 2004. 5340-5347. Shimizu E. Sakanaka S. 26. 1990. Effect of Green Tea Extract on Growth of Intestinal Bacteria. Chung JY. Press Release. Int J Vitam Nutr Res. Takahashi T. Wiersma A. Ogawa S. biotechnology. Res Microbiol. 551-555. 2001. J Nutr. 1992. Girault J. Haller J. 2004. 55. Tsuneki H. Kawamura T. Kimura I. 1991. Xenobiotica. 2004. Wang Y. Teixeira SR. Preller M. Fujisawa T. Kawamura T. Klassiker als Trendgetränk: Teekonsum auf hohem Niveau stabil Deutsche Teewirtschaft mit Geschäftsjahr zufrieden. Mathot JN. 335-338. Raederstorff D. Kim MJ. Meng X. Pineau B. 4. Wu JB. Weber P. 176-187. 3. 2003. and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. Thielecke F. Tijburg LB. Yang GY. Event-related desynchronization during anticipatory attention for an upcoming stimulus: a comparative EEG/MEG study. 1997. Iitoi Y. 49. 2145-2151. Li C. 1425-1426. Van Hof KH. 73-79. 2512-2518. J Int Med Res. Iwase Y. Mitsuoka T. 18. Humphrey PG. Epigallocatechin gallate supplementation alleviates diabetes in rodents. Ishihara N. and biochemistry. Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. 588-591. 393-403. 136. Wolfram S. Girault N. Levitt MD. A single ascending dose study of epigallocatechin gallate in healthy volunteers. Spekreijse H. Richard-Caudron AS. 269-278. Yang CS. Mizoue T. Tsubono Y. Clin Neurophysiol. Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. 31. Oura A. Liao J. Proc Soc Exp Biol Med. 2006. Lee MJ. Haller J. Weber P. ID 1117: “Catechins – Green tea (camellia sinensis)” and “Cognitive function” 1 2 Astill C. Tabata S. Kim M. 130. 891-901. 213-217. Kim S. 73 . Chung JY. Mitsuoka T. Ullmann U. Anti-obesity effects of green tea: from bedside to bench. Wang Y. Tea Polyphenols: Selective Growth Inhibitors of Clostridium spp. 876-884. 157. Ullmann U. Lee YK. Am J Clin Nutr. Effects of tea consumption on nutrition and health. 74. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. In vivo effects of tea polyphenol intake on human intestinal microflora and metabolism. Kono S. Jenner AM. J Nutr. Lee HC. Ho CT. 31. 2000. Girault J. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. Tsugane S. Zhong L. Yang CS. Brunia CH. Wolfram S. ID 1116: “Catechins – Green tea (camellia sinensis)” and “Gut flora” 37 38 39 40 41 42 43 44 45 46 1 2 3 4 Ahn YJ. Mol Nutr Food Res. Birch MR. 2000. Mitsuoka T. Bastiaansen MC. Martin PT. Coffee consumption and glucose tolerance status in middle-aged Japanese men. BMC Pharmacol. 1999. 2006. Ishizuka M. Spitzer V. Bioscience. Terasawa M. 2003. J Agric Food Chem. Yang GY. Hashimoto M. Biochim Biophys Acta. Mahoney J. Anticipatory attention: an event-related desynchronization approach. Katakura M. Psychophysiology. Tsai CJ. 3929-3933. Lehnfeld R. Brice CF and Smith AP. Hum Psychopharmacol. 59. Arch. Murray MM. Zvartau EE. J Nutr Sci Vitaminol (Tokyo). 1043-1047. Effects of caffeine on mood and performance: a study of realistic consumption. Neuroreport. 164. 188-192. Theanine. Lehnfeld R. 45. Legleiter J. 1992. J Pharm Pharmacol. Gardner EJ. 2007. Theogallin and L-theanine as active ingredients in decaffeinated green tea extract: II. J Pharm Pharmacol. Hosoda K. 25-38. Keplinger-Dimpfel IK. Psychopharmacology (Berl). 83-133. 59. Gomez-Ramirez M. Muchowski PJ. Parieto-occipital approximately 10 Hz activity reflects anticipatory state of visual attention mechanisms. 2743-2751. Nutr Neurosci. Wang MF. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Chan YC. 217-231. 2006. Schroeder CE. Favorable effects of tea on reducing the cognitive deficits and brain morphological changes in senescence-accelerated mice. 2007. 2002. J Nutr. 2005. 47-53. Hara Y. Duennwald M. 2007. Kler A. 1984. 5. Casimir J. Sutherland D. Kler A. 1970. 9. Long-term administration of green tea catechins improves spatial cognition learning ability in rats. Theogallin and L-theanine as active ingredients in decaffeinated green tea extract: I. 20. Markovic P. 6. 39. 1397-1403. Attention-dependent suppression of distracter visual input can be cross-modally cued as indexed by anticipatory parietooccipital alpha-band oscillations. 2001. 2001. Pharmacol Rev. Int J Neurosci. Christopher G. 51. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. 1997. Foxe JJ. 3-18. Über das Elektroenzephalogramm des Menschen. Brain Res Cogn Brain Res. Engemann S. Engelhardt UH. Foxe JJ. The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Jadot J. 2006. Taylor A. Electrocortical activity and related phenomena associated with meditation practice: a literature review. Yamamoto S. Nehlig A. 169-180. Renard M. Nervenk. 462-468. Rycroft JA. 52. Tanabe Y. Dimpfel W. Int J Psychophysiol. Finger A. Battig K. Berger H. Lehnfeld R. Eur J Clin Nutr. 353-363. 91-107. Source density analysis of the human EEG after ingestion of a drink containing decaffeinated extract of green tea enriched with Ltheanine and theogallin. 442-452. Haque AM. Cartwright RA. 15. Holmen J. Dimpfel W. Black tea--helpful or harmful? A review of the evidence. Clin Neuropharmacol. Fredholm BB. Kriesl E. 1929. Ekborg-Ott KH. Simpson GV. Journal of the Science of Food and Agriculture. 1954. Kriesl E. Kriesl E. Kler A. 1131-1136. 87. Marsh JL. [Separation and characterization of N-ethyl-gamma-glutamine from Xerocomus badius. 293-315. 2006. 10. Characterization in the freely moving rat by means of quantitative field potential analysis. Hum Mol Genet. Roark M. 527-570. Delmonte MM. Ruxton CH. 1999. 1960. Varietal differences in the total and enantiomeric composition of theanine in tea. 2007. 74 10 11 12 13 14 15 16 17 18 19 20 21 22 23 . 266-273. Smith A. Javitt DC. Brown BB. 24. 12. 2007. Wood DJ. Wanker EE. J Agric Food Chem. 624. 30. 136. Roberts EAH. Psychit. Leeds AR. 597-599. 43. an amino-acid n-ethyl amide present in tea. Armstrong DW. Chromatography of tea constituents. Ahlfors SP. Thompson LM. 61. Lindquist S. Higgins BA. Wacker JL. Foxe JJ. 1998. Shido O. Owen GN. Kuhr S.3 4 5 6 7 8 9 Bastiaansen MC and Brunia CH. Shpaner M.]. Dimpfel W. electrophysiological characterization in the rat hippocampus in-vitro. J Chromatogr. Fu KM. Effects of caffeine in non-withdrawn volunteers. 145-152. Ehrnhoefer DE. Recognition of aspects of consciousness through association with EEG alpha activity represented by a light signal. Higgins BA. Am J Clin Nutr. The effects of black tea and other beverages on aspects of cognition and psychomotor performance. Quinlan PT. Visual spatial attention tracking using high-density SSVEP data for independent brain-computer communication. Doppelmayr M. 153-157. 2000. Swaine D. Rycroft J. 1957. 1977. 1969. Kimura H. Toriumi Y. 31. Effects of L-theanine on the release of α-brain waves in human volunteers. Tokumura H. 1998. Effect of changes in muscle tension and brain alpha wave activity induced by functional beverage on golf performance. Yokogoshi H. Kimura R and Murata T. Aoi N. coffee and water on alertness. 1986. Hindmarch I. Awata S. A naturalistic investigation of the effects of day-long consumption of tea. Lorist MM and Snel J. Oda S. 102. 2001. Nagato Y. 2006. Clin Sci (Lond). Effect of palatinose administration on alpha 1 brain waves in human volunteers. Crispin DJ. Spektrum Akademischer Verlag. Chu DC. 253-259. Renal and cardiovascular effects of caffeine: a doseresponse study. Okubo T. Ebihara S. Chem. 2001. Kashimura J. Central depressant effect of theanine.S. Matsui T. Kim M. 401-413. Sea-Air-Land. 1998. 2002. Russegger H. Kimura R and Murata T. Kimura K. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. and stress on cognitive performance and mood during U. Sugimoto S. Navy SEAL training. Juneja LR. Passmore AP. Nutrition and Health for the 21st Century. Drogenkunde. Nippon Nōgei Kagakukaishi. Tharion WJ. sleep loss. Soc. Ealter de Gruyter & Co. Nonvolatile components of black tea and their contribution to the character of the beverage. Foxe JJ. Kamei T. Psychopharmacology (Berl). Kondowe GB. Chem Pharm Bull (Tokyo). Konishi S and Takahashi E. Effect of theanine on norepinephrine and serotonin levels in rat brain. IEEE Trans Neural Syst Rehabil Eng. Psychopharmacology (Berl). 171-175. Lee Y. Are we dependent upon coffee and caffeine? A review on human and animal data. Nagato Y. Parkin C. Lalor EC. Neurosci Biobehav Rev. Tsuji I. Yamamoto T. 2003. Caffeine effects on perceptual and motor processes. 169-173. Trends in Food Science & Technology. Eur J Appl Physiol Occup Physiol. Nehlig A. Journal of Agricultural and Food Chemistry. 3053-3057. 1971. 199-204. Moriya K. I. Psychopharmacology (Berl). 355-361. Moore KL. Ebashi T. 717-722. 19. Pachinger T. Klimesch W. Lane J. 141-145. Food Sci Technol Res. 17. 72. Electroencephalogr Clin Neurophysiol. Shukitt-Hale B. Effects of caffeine. Lexikon der Arzneipflanzen und Drogen. 7. Machi Y. 9. Stress and Health. 1966. Reilly RB. Stanley N. Hozawa A. Nakagawa K. 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 75 . Tulley R. 203-216. 83. 2003. Hoppe HA. 250-261. 1997. 1257-1261. Chem Pharm Bull (Tokyo). 1998. 34. Juneja LR. Hindmarch I. Nagashima Z. 164. Ohmori K. Agr. 1999. Kelly SP. Nagai Y. 13. Berlin. Induced alpha band power changes in the human EEG and attention. Kuriyama S. Plant Cell Physiol. Rigney U. Millin DJ. 139. 73-76. Shimazu T. 10. Toriumi Y. 1999. Relaxation effects in humans of underwater exercise of moderate intensity. 1999. Schwaiger J. Arai H. 357-360. Heidelberg. 23. Free amino acids in tea IV: quantitative changes in the manufacture of black and green tea. Yum KS. L-theanine . Proceedings of the International Symposium on Food. 80. sleep onset and sleep quality.24 25 26 Hiller K and Melzig MF. 230-238. 149. Nakagawa M.a unique amino acid of green tea and its relaxation effect in humans. 72. Japan. 749-756. Kim KS. Matsumoto T. Speckman KL. Sato H. Quinlan P. Neurosci Lett. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. 172-178. Nagatomi R. 244. Existence and synthesis of L-glutamic acid g-methylamide in tea plants. Correlation between alpha rhythms and natural killer cell activity during yogic respiratory exercise. 1987. Lieberman HR. 563-576. 17. 2005. Johnston GD. Kobayashi K. Sakato J. 88078814. Rycroft JA. The effect of drinking tea at high altitude on hydration status and mood. 8. J Neurosci. coffee and tea. Aspinall L. Suzuki Y. Gibson EL. 615618. Song CH. 2002. Studies on the chemical constituents of tea. Bioscience. 637-645. Mood and drinking: a naturalistic diary study of alcohol. Rycroft JA. Kikunaga N. Scholz E and Bertram B. Hardy J. Psychophysiology. Wissenschaftliche Verlagsgesellschaft. Erusalimsky JD. and Biochemistry. Brown B. Travis F. 47. Chapman C. 1997. 2003. Zeng J. 2005. Quinlan PT. Food Chem Toxicol. 427-439. Eur J Appl Physiol. Smith A. The effects of caffeine on visual selective attention to color: an ERP study. Oku N. Kizuki M. in rats. Lorist MM. Wirkstoffe. Tan J. Takabayashi F. Effects of caffeine on human behavior. Chung KI. Steptoe A and Wardle J. 8. Unno T.) O. Journal of Psychophysiology. Stoyva J and Kamiya J. 473-482. 1593-1596. brain and urine of rats administered with theanine. 1999. 25. The Effects of L-theanine Containing Functional Beverage on Mental Relaxation and Fatigue Perception. 37. Mori T. 71-80. 40. Effects of Theanine on the Release of Brain Alpha Wave in Adults Males. Pharmacol Biochem Behav. Tsuge H. Yokogoshi H. 2002. Kim KS. Sun N. Shytle D. Snel J. The acute physiological and mood effects of tea and coffee: the role of caffeine level. Town T. Aspen J. Agr. 23. Rycroft JA. Shimbo M. Song CH. The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. 89-95. Hou H. Yoshida H. Soc. Olson T. Psychol Rev. 190. 2007. 2005. 1950. 81-89. 1300-1306. 1968. 1995. Camellia sinensis (L. Morgan D. 141. Rezai-Zadeh K. Electrophysiological studies of dreaming as the prototype of a new strategy in the study of consciousness. 63. 2000. 13. Jeanniton D. 91. Snel J. Terashima T. Lane J. coffee and water ingestion on physiological responses and mood: the role of caffeine. 14. Gallagher J. Seino K. A new amide–theanine. Green tea consumption in everyday life and mental health. gammaglutamylethylamide. Sturges W. Ehrhart J. Takido J. 2000. The influence of different doses of caffeine on visual task performance. 36. 192-205. Nakamura K. Smith A. Unno K. Sang WS. 23. Scott D. Daily consumption of green tea catechin delays memory regression in aged mice. Kishido T. J Agric Food Chem. Egenes T. 1999. Stuttgart. 1999. Arzneidrogen. 66. Townsend K.46 Quinlan P. Public Health Nutr. Inose T. Human Psychopharmacology: Clinical and Experimental. water and beverage type. Moore KL. Ruijter J. Physiological patterns during practice of the Transcendental Meditation technique compared with patterns while reading Sanskrit and a modern language. 164173. Zeitschrift für Phytotherapie. Wardle J. J Korean Acad Fam Med. 76 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 . Anwendungen. Psychopharmacology (Berl). Kuntze. 315-321. 231-246. 1999. Time-dependent changes of amino acids in the serum. Hayakawa T. Takano T. 493-498. 109. Korean Journal of Nutrition. Fukutomi R. Japan. 75. Kakuda T. Oh JS. Steptoe A. 37-48. Chung KI. 2007. Int J Neurosci. Lane J. 2004. O'Brien DC. Psychopharmacology (Berl). Kim KS. Williams ED. 1243-1255. 262-267. 2004. Psychopharmacology (Berl). Hamer M. 1999. 918-923. 19-28. Aspen J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. Schönfelder I and Schönfelder P. Hoshino M. Choba D. 2001. Vuononvirta R. Effects of a low dose of caffeine given in different drinks on mood and performance. Metabolism of theanine. Chem. 4. 134. Biogerontology. liver. Der Teestrauch. Ruijter J. De Ruiter MB. Effects of hot tea. Jing Shi H. Das neue Handbuch der Heilpflanzen: Botanik. Gupta HK. Biotechnology. 63. 1989. Arch Intern Med. Worden MS. 1992. 62. Agarwal R. Simpson GV. J Nutr Biochem. Mochizuki M. Riedisser A. Tea intake. Biosci Biotechnol Biochem. Katiyar SK. Meeran SM. Wu AH. Tseng CC. black tea and breast cancer risk: a meta-analysis of epidemiological studies. angiogenesis and DNA repair. J Nutr. 1978. 7141-7147. 10. 27. 1998. Van Den Berg D. Effect of theanine. 4. Orally administered green tea polyphenols prevent ultraviolet radiation-induced skin cancer in mice through activation of cytotoxic T cells and inhibition of angiogenesis in tumors. ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. Tea. Modulation of the parieto-occipital alpha rhythm during object detection. r-glutamylethylamide. 2871-2877. McBride WH. Tea consumption and ovarian cancer risk in a population-based cohort. 2005. Carcinogenesis. 17. Yuan JM. Yu MC. Yu MC. Green tea. 411-415. Protection against polycyclic aromatic hydrocarboninduced skin tumor initiation in mice by green tea polyphenols. 1310-1315. Wang ZY. 7526-7529. J Neurosci. Neurochem Res. Elmets CA. 2003. Wissenschaftliche Verlagsgesellschaft. Katiyar SK. Hari R. Fiebich B. Mantena SK. Wickremasinghe RL. Sun CL. Revonsuo A. Prev Med. 428-435. 287-296. Yu MC. Sun CL. Khan WA. Henke M. Mukhtar H. Ahmad N. Wu AH. 351-360. Terashima T. 2006. Anticipatory biasing of visuospatial attention indexed by retinotopically specific alpha-band electroencephalography increases over occipital cortex. Psychophysiology. 1389-1394. ID 1119: “Catechins – Green tea (camellia sinensis)” and “Skin care” 72 73 1 Katiyar SK. 18. Green tea and skin cancer: photoimmunology. 816-817. Mukhtar H. Stuttgart. 229-286. on brain monoamines and striatal dopamine release in conscious rats. Yokogoshi H. The effects of tea extracts on proinflammatory signaling. Kobayashi M. 2003. Yuan JM. 1997. 106. 574-579. Saitoh K. Agarwal R. Int J Cancer. 14.67 68 69 70 71 Vanni S. 2006. Wang N. 2002. Cancer Res. Carcinogenesis. Carcinogenesis. 2683-2686. J Neurosci. Tea components: antimutagenic and anticarcinogenic effects. 667-673. ID 1120: “Catechins – Green tea (camellia sinensis)” and “Women health” 2 3 4 5 6 7 1 2 3 4 5 Larsson SC and Wolk A. 513-521. 23. Katiyar SK. Mochizuki M. Carcinogenesis. Foxe JJ. Mukhtar H. Int J Cancer. 24. Inhibition of both stage I and stage II skin tumor promotion in SENCAR mice by a polyphenolic fraction isolated from green tea: inhibition depends on the duration of polyphenol treatment. Yu MC. Advanced Food Research. Anti-proliferative and proapoptotic effects of (-)epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. 11. 1998. 2641-2643. Pike MC. 2005. 1993. 2005. Yokogoshi H. Nihal M. Mukhtar H. 21. Tseng CC. Koh WP. 114. 2000. 20. COMT genotype. Green tea and risk of breast cancer in Asian Americans. Walsh DH. Pajonk F. Wang ZY. Lee HP. and breast cancer in Asian-American women. Koh WP. Wood GS. Bickers DR. 135. Green tea intake. 2007. Elmets CA. 26. 1974. Hankin J. Teedrogen und Phytopharmaka. 165. 2005. 28. Interactive effects of alpha feedback and instructional set on subjective state. Theanine-induced reduction of brain serotonin concentration in rats. RC63. 77 . Katiyar S. Wichtl M. BMC Med. Sawaki T. Murase T. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. 131. 130-135. Nutr Cancer. Huang JP. Int J Obes Relat Metab Disord. Fathi M. Vandermander J. Adhami VM. 1611-1619. 13. Green tea and thermogenesis: interactions between catechin-polyphenols. Chantre P. Hase T. 1234-1240. Int J Cancer. Vandermander J. ID 1124: “Green Tea” and “Fat metabolism” 3 4 5 6 1 Cabrera C. 1999. Brausi M. Seeram NP. Tea beverage in chemoprevention of prostate cancer: a mini-review. Castagnetti G. Clin Cancer Res. Lee NH. Lee AH. 1040-1045. Dulloo AG.6 7 Zhang M. Conde F. ID 1121: “Catechins – Green tea (camellia sinensis)” and “Men health / prostate health” 1 Adhami VM. Int J Cancer. ID 1123: “Camellia sinensis Tea (Green. Syed DN. Am J Clin Nutr. 26. Pak-Shan L. 2006. Nagasawa A. Tokimitsu I. Harris DM. Okuda H. Gimenez R. Go VL. 25. Xie X. Siddiqui IA. Zaman N. Komatsu T. 2002. 1074-1078. Zhang M. Girardier L. 1839-1843. J Nutr. 2007. Int J Obes Relat Metab Disord. 66. Wiley E. Artacho R. Malik A. 252-258. Judd J. Dulloo AG. Hosoda K. 2007. Duret C. 47. Cancer Res. Hong J. Mukhtar H. 1459-1464. 13-23. Csathy G. Sarfaraz S. Seydoux J. Lee AH. Siddiqui IA. Rohrer D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. 3-8. Aronson W. Henning SM. Xie LP. 465-469. Lee RP. Carcinogenesis. Binns CW. 2002. Phytomedicine. 2001. Protective effect of green tea against prostate cancer: a casecontrol study in southeast China. Binns CW. Chantre P. caffeine and sympathetic activity. Takaku T. Int J Cancer. Hussain T. Moro A. Rizzi F. Beneficial effects of tea catechins on dietinduced obesity: stimulation of lipid catabolism in the liver. Clevidence B. J Nutr. 2004. Suzuki J. Ziaee HG. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Green tea and the prevention of breast cancer: a casecontrol study in Southeast China. Barnard RJ. 9. Wang H. 136. Adhami VM. Han LK. Saleem M. Niu Y. Pasha FS. 2848-2852. 2003. 660-669. Saleem M. Girardier L. 2006. 112. 7999. Rumpler W. 2000. Kimura Y. Mensi N. Mukhtar H. Jian L. Anti-obesity action of oolong tea. 70. Bettuzzi S. Holman CD. 2005. Peracchia G. J Am Coll Nutr. Gupta S. Yamamoto S. 98-105. Li J. Oolong tea increases metabolic rate and fat oxidation in men. 2006. Corti A. Ishikura Y. Int J Obes Relat Metab Disord. 23. 28. Beneficial effects of green tea--a review. 24. Mukhtar H. 108. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. 1999. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Oolong and Black Tea)” and “Resting metabolic rate and thermogenesis” 2 3 4 5 6 1 2 Chantre P and Lairon D. Heber D. Afaq F. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. 113. Lu J. Xie X. 78 . Green tea consumption enhances survival of epithelial ovarian cancer. Seale J. 2004. Bazzano LA. 2004. Hosoda K. 19. Phytochemistry. Holzmeister LA. Chiasson JL. Chiasson JL. Whole-grain intake and the prevalence of hypertriglyceridemic waist phenotype in Tehranian adults. dairy. 1952-1960. Komatsu T.2 Dulloo AG. Oddy WH. Bubes V. Health survey for England. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. 2005. St-Onge MP. Edmond LM. Dietary carbohydrates and health: do we still need the fibre concept? Clinical Nutrition Supplements. 7-15. 2006. Newnham JP. 135-142. Good CK. Wheeler M. 8. and nuts: potential functional foods for weight control? Am J Clin Nutr. 25. 1. Jiang Y. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. 636-640. Subchapter B Food for Human Consumption Part 101 Food labeling. Brunzell JD. Wiley E. 55-63. MayerDavis E. Dulloo AG. Shi J. 2005. 2. Rohrer D. Magee EA. Int J Obes (Lond). Shixian Q. 148-198. 2005. teas. A place for dietary fibre in the management of the metabolic syndrome. 2005. Ishikura Y. Wheeler M. Am J Clin Nutr. 70. Whole grains protect against atherosclerotic cardiovascular disease. Sawaki T. Bantle JP. Feng WY. Nagle DG. Kakuda Y. Moshfegh AJ. VanCrey B. 15-23. Kendall GE. Pastore RL and Fratellone P. 2003. J Nutr. 24. 2003. 1999. Beebe CA. Cummings JH. 2004. ID 1126: “Whole grain foods” and “Weight management” 3 4 5 6 7 8 9 1 Title 21. Cleveland LE. DoH (Deparment of Health). 2006. 2001. Diabetes Care. 331S-338S. 62. 7. Purnell JQ. Int J Obes Relat Metab Disord. Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-O-methyltransferase. Green tea and thermogenesis: interactions between catechin-polyphenols. Clevidence B. Dietary intake of whole and refined grain breakfast cereals and weight gain in men. 451-458. Mirmiran P. 2003. Fathi M. 29. caffeine and sympathetic activity. Brunzell JD. Chantre P. Landau LI. Am J Clin Nutr. Bantle JP. 131. Hoogwerf B. Zhou YD. Dietary fats. Garg A. Albertson AM. Vandermander J. 2005. Vandermander J. Blake KV. DoH (Deparment of Health). Curr Opin Clin Nutr Metab Care. Predictors of body mass index and associations with cardiovascular risk factors in Australian children: a prospective cohort study. 2006. Duret C. Doherty D. 67. Garg A. 81. Stanley FJ. Metabolism of green tea catechins: an overview. 2000. Liu S. DoH (Department of Health). Yamamoto S. Explore (NY). 2004. Anderson JW. 5-17. Oolong tea increases metabolic rate and fat oxidation in men. Seale J. 9. 13. Girardier L. Beebe CA. Dietary intake of whole grains. Rumpler W. MayerDavis E. 1849-1855. Burke V. Purnell JQ. Esmaillzadeh A. Girardier L. Seydoux J. Franz MJ. 81. Song Y. 252-258. Proc Nutr Soc. J Med Food. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Mooradian AD. 2000. Beilin LJ. Azizi F. Simmer K. 531-539. Food and Drugs. Mooradian AD. 2848-2852. Ferreira D. Delzenne NM and Cani PD. Potential health benefits of green tea (Camellia sinensis): a narrative review. Manson JE. Holzmeister LA. Chantre P. Judd J. 2006. Code of Federal Regulations (Revised 2008). Chapter I Food and Drug Administration Departement of Health and Human Services. Mensi N. Obes Res. Evidence-based nutrition principles and 2 3 4 5 6 7 8 9 10 11 12 13 79 . J Am Coll Nutr. Hoogwerf B. Health survey for England. 755-809. Goldman JD. Franz MJ. Curr Drug Metab. Summary of Intelligence on Obesity. 2002. 1040-1045. Jacobs DR. Hu FB. Saltzman E.000 women. 20652071. Am J Clin Nutr. 129-139. 2001. 1998b. 2008.recommendations for the treatment and prevention of diabetes and related complications. Koh-Banerjee P. Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Kim OY. Lee SY. Am J Clin Nutr. Jacobs DR. 14 Fung TT. 85-96. S51-61. Pereira MA. 6167. Richardson DP.. HHS (Department of Health and Human Services) and USDA (Department of Agriculture). Hu FB. Willett WC. 76. 2005. Dietary Guidelines for Americans. Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. Meyer HE. Giovannucci E. Willett WC. 554-563. Proc Nutr Soc. Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Sampson L. Holt SH. Kris-Etherton PM. 675-690. 2003. Willett WC. Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60. Whole grain consumption and weight gain: a review of the epidemiological evidence. Koh-Banerjee P. Am J Clin Nutr.. 2005. and germ and the risk of coronary heart disease in men. Br J Cancer. Folsom AR. Farmakalidis E. 535-540. 80. Liu S. 1237-1245. Koh-Banerjee P and Rimm EB. Bergkvist L. Jang Y. 21. Spiegelman D. 70. Whole-grain intake as a marker of healthy body weight and adiposity. Kushi LH. Rimm E. Kunselman AR. Petocz P. Diabetes Care. Reduced mortality among whole grain bread eaters in men and women in the Norwegian County Study. 1999. 62.vtt. Franz M. Wolk A. Katcher HI. Larsson SC. Coulson J. 1995. Legro RS. bran. Am J Clin Nutr. 26 Suppl 1. Manson JE. 2001. Liu S. 1492-1499.. Tofler GH. Solvoll K. 92. Rimm E. Jr. Harland JI and Garton LE. Miller JC. Liu S. 25-29. potential mechanisms and opportunities for future research. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. 2008. Arterioscler Thromb Vasc Biol. Kuznesof S. 2004. Whole-grain intake and cancer: an expanded review and meta-analysis. Jacobs DR. 87. 412-419. 70A. Jr. 2001. 73. Dietary fiber and weight regulation. and plasma homocysteine concentrations in patients with coronary artery disease: randomized controlled clinical trial. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. Stampfer MJ. 1803-1807.. Jr. 68. Health and Functionality. Intakes of whole grains. Kushi LH. Rifai N. 137-143. Eur J Clin Nutr. Jacobs DR. 2001. 49. and cereal fiber consumption in relation to 8-y weight gain among men. Hu FB. Colditz GA. Eur J Clin Nutr. Public Health Nutr. Hennekens CH. 79-90. Gillies PJ. A satiety index of common foods. Gronbaek M. bran. Stampfer MJ. Demers LM. Spiegelman D. Am J Clin Nutr. Sampson L. Nutr Rev. Seal CJ. lipid peroxidation. Fung TT. Rye: Nutrition. Am J Clin Nutr. 5697/2006 PN). 63. Jensen MK. 2004. Consumption of whole grain and legume powder reduces insulin demand. 59. Hepples ML. Am J Clin Nutr. Increased wholegrain food consumption and indicators of adiposity: preliminary results from the CHEW-IT study. Giovannucci E. 2002. Park HY. Willett W. Proceedings of the Nutrition Society. Bagshaw DM. Rimm EB. Hu FB. Marquart L. 80. 30. Nordic Rye Research Group. Jones AR. 11. Jr. Lebensmitteluntersuchungsanstalt der Stadt Wien. 248-257. Untersuchungsbericht der Lebensmitteluntersuchungsanstalt der Stadt Wien (Bericht Nr. Franz M. 2004.fi. Nutr Cancer. Meyer KA. Roberts SB. 1998a. Changes in whole-grain. http://rye. Howarth NC. Slavin J. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 80 . Rimm EB. Lee JH. 55. St Paul. Murtaugh MA. Hennekens CH. Seaquist ER. 1998. Epidemiological support for the protection of whole grains against diabetes. Blanco I. 62. Jr. vitamin B-6. Manson JE. Dietary fiber and body-weight regulation. In: Whole-Grain Foods in Health and Disease. McKeown NM. 75. Zukley L. 2003. Pereira MA. 34. Eagan Press. 2007. Montonen J. 1409-1415. Jarvinen R. Kartashov AI. Liu S. diabetes and subclinical CVD: The MESA Study. Hilner JE. Hu FB. Steffen LM. Knekt P. 1380-1388. Steffen LM. Jacobs DR. 103. Mellen PB. Szklo M. 622-629. 283-290. Majzoub JA. 2000. McKeown NM. 337-347. 18. Am J Public Health. Van Horn L. 2003. Murtaugh M and et al. Whole grain intake and cardiovascular disease: a metaanalysis. Rosner B. Am J Clin Nutr. Meigs JB. 2003. Gross MD. A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women. Whole grain intake and its cross-sectional association with obesity. 969-980. 2004. Fiutem JJ. J Am Diet Assoc. FASEB J. 143-149. Wilson PW. 18. Nutr Metab Cardiovasc Dis. Pereira MA and Ludwig DS. Mayer-Davis E. Yount BW. Meigs JB. 62. Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. CVD Prevention. Mälkki Y and Virtanen E. Willett WC. Slavin JL. insulin resistance. Jacobs DR. Jacques PF. Dairy consumption.33 Liu S. Jr. 390-398. identification and management of obesity and overweight in adults and children. insulin resistance. Lowndes J. Richardson DP. 397-405. Tracy R. 2002. Consumption of whole-grain cereals during weight loss: effects on dietary quality. Pins JJ. 1998. 77. and the insulin resistance syndrome in young adults: the CARDIA Study. 2081-2089. and obesity. 98. Commercially available whole grain foods reduce body weight compared to equal servings of refined grain foods. Pereira MA. Jacobs DR. Jr. Whole-grain and fiber intake and the incidence of type 2 diabetes. 161-169. E26. Liu S. 27. Am J Clin Nutr. Dube TJ. Pediatrics. magnesium. A148. 2006.. Observations and mechanisms. 2002. Willett WC. 106. Dallal GE. Saltzman E. Herrington DM.. Reunanen A. Nguyen VT. Jr. NICE Obesity: Guidance on the prevention. 2003. dietary fiber. Br J Nutr. 76. 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 81 . Slattery ML. 2002. 1999. Roberts SB. and obesity. Aromaa A. Walsh TF. NICE clinical guideline 43. obesity. The association of whole grain intake and fasting insulin in a biracial cohort of young adults: The CARDIA study. 2006. Wholegrain health claims in Europe. Manson JE. Jacob B. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Proc Nutr Soc. 2002. Jacques PF. High glycemic index foods. 2001. 2004. 848-855. 538-546. Pediatr Clin North Am. Melanson KJ. Ludwig DS. JAMA. Fulcher RG (eds. Marquart L. Shea S. Colditz G. and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Kori S. Raatz SK. Ludwig DS. Lutsey PL. 2008. NHS (National Institute for Health and Clinical Excellence).).. Proc Nutr Soc. Van Horn L.. Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study. Jacobs DR. 920-927. Al-Zahrani A. Martini M. Jacobs DR. Diabetes Care. Pereira MA. Gastrointestinal Effects of Oat Bran and Oat Gum: A Review. 48. Slavin JL. 1. Carbohydrate nutrition. 287. Kushi LH. Am J Clin Nutr. Hu FB. Angelopoulos TJ. Stampfer MJ. Wilson PW. Giovannucci E. 90.. Lebensmittel-Wissenschaft und-Technologie. Marquart L. Am J Clin Nutr. Whole Grain Consumption and Body Weight Regulation. Colditz GA. Ruth KJ. Slattery ML. Pereira MA. 78. Liu S. 2001. overeating. quiz 1389-1390. inflammation. Rippe JM. Corrales A. Das SK. Corrales A. 78. 124-131. van der Kamp JW. J Nutr. Eur J Clin Nutr. Whole-grain intake of British young people aged 4-18 years. 2006. Jacques PF. Dietary fibre: Bioactive carbohydrates for food and feed. 825-831. 24-34. 50-57.52 Ruston D. Steinberger J. Hallfrisch J. Schaafsma G. 2004. Folsom AR. Pereira MA. 2003. 2006. 32-42. Wageningen Academic Publishers. 20. S91-101. 97. Seal CJ. 2006. Proc Nutr Soc. A typically high insulin responses to some foods relate to sugars and satiety. blood pressure and physical activity. 1992. Moran A. Journal of Human Nutrition and Dietetics. Jebb SA. Murtaugh MA. Steffen LM. 129-134. 2007. 94. Greenberg AS. Saltzman E. Comparative whole-grain intake of British adults in 1986-7 and 2000-1.. Glycaemic index of foods. 243-250. London. Turnbaugh PJ. Hong CP. Jones AR. Bazzano R. 1027-1031. dietary fibre intake and body mass index in the Netherlands cohort study. refined-grain. Thane CW. Gregory J. Am J Clin Nutr.. An obesity-associated gut microbiome with increased capacity for energy harvest. Mardis ER. Das SK.int/dietphysicalactivity/publications/facts/obesity/en/. Porrini M. Associations of plant food. 32. Henderson L. http://www.who. Hoare J. Thane CW. quiz 1363-1164. Roberts SB. Lichtenstein AH. 55. 65. Chronic disease information sheets: obesity and overweight. Goldbohm RA. Moriguti JC. Van Horn L. 63. Am J Clin Nutr. Wageningen. Helsinki. J Am Coll Nutr. 1993. Crovetti R. 46 Suppl 2. 1169-1177. Associations of wholegrain. Bates C. 62. Whole-grain consumption. Seal CJ. High-calorie fibre-rich breakfast: its effect on satiety. Asp NG. Int J Food Sci Nutr. Trout DL. Br J Nutr. Her Majesty's Stationery Office. Seal CJ. Stephen AM. Mahowald MA. An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. 6. 2001. Birch M. 1465-1470. 383-390. Dietary fibre and satiety. Carithers T. 158. Whole grain intake is associated with lower body mass and greater insulin sensitivity among adolescents. Slavin J and Green H. Ley RE. 2005. Am J Epidemiol. Nutrition Bulletin. Jacobs DR. Prentice A. Roberts SB. Edita Prima Oy. Volume 4: nutritional status (anthropometry and blood analytes). Eur J Clin Nutr. 131. and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. 82. and meat intakes with 15-y incidence of elevated blood pressure in young black and white adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Caramella R. Shahar E.. WHO (World Health Organization). McKeown NM. Zhang XL. Steffen LM. 577-588. Nature. 2000. Steffen LM. Yu X. Sahyoun NR. Behall KM. Jacobs DR Jr. 2005. van den Brandt PA. 2003. Jr. Am J Clin Nutr. Gross MD. Truswell AS. Slattery ML. 245-252. Sinaiko AR. Jones AR. Fuss P. Stephen AM. Whole-grain intake is inversely associated with the metabolic syndrome and mortality in older adults. Greenberg AS. 2007. Dallal GE. Slavin JL. Mechanisms for the impact of whole grain foods on cancer risk. 2009. Jebb SA. 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 82 . Suomalaiset ravitsemussuositukset . dairy product. Edita publishing Oy. 2001. 83. Stevens J. Why whole grains are protective: biological mechanisms.ravinto ja liikunta tasapainoon. 444. Jones JM. Farron M. Proc Nutr Soc. Gordon JI. van den Bosch LM. Magrini V. Turconi G. Jacobs DR Jr. 2003. 987-992. Whole grains and CVD risk. 300S-307S. Br J Nutr. Juan W. The National Diet & Nutrition Survey: adults aged 19 to 64 years. 2005. Valtion ravitsemusneuvottelukunta. J Am Coll Nutr. Kroenke CH. Schaefer EJ. Swan G. van de Vijver LP. 19. 2004. Slavin J. 2004. 31-38. Effects of a cereal rich in soluble fiber on body composition and dietary compliance during consumption of a hypocaloric diet. Saltzman E. Eissenstat B. de Souza R. No 894. Mauger DT. 2000. low-energy diet for weight loss in overweight adults. 83. 353-358. 2003. excluding brazil. 18. WHO Technical Series. Gomez-Gracia E. 2000. Nutrition and weight control for longevity 2007 (Johns Hopiins White Papers). Johns Hopkins Medicine Baltimore. S79-86. Hsieh G. Martinez JA. Kris-Etherton PM. low-energy diet compared with a low fat. Higgs J. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. 660-668. 329. Kemp T. Am J Clin Nutr. 2284-2299. Griel AE. 1129-1137. Holmes C. Robinson K. 25. In: Expert Report: Diet. Kris-Etherton PM. 582-591. S8-11. 2003. 2007. 2006. 35. Appel LJ. Vidgen E. Marchie A. Obesity: Preventing and managing the global epidemic. 2004. Mullis R. WHO/FAO (World Health Organization and Food and Agriculture Organization). Vol. 204-212. Nut consumption and body weight. BMJ. Brown-Wilder L. Leiter LA. pistachios and walnuts). Bonneux L. Nutrition & Food Science. The Polymeal: a more natural. Krauss RM. Steyerberg EW. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Emam A. Improved diet quality with peanut consumption. Kotchen TA. Obesity (Silver Spring). Eur J Clin Nutr. Effects of chronic peanut consumption on energy balance and hedonics. 1447-1450. 26. 2000. Daniels SR. Alonso A. Curr Opin Lipidol. 2007. macadamia and cashew nuts” and “Weight management via satieaty (by proteins and fibre)” 1 2 Alper CM and Mattes RD. Coates AM and Howe PR. Rajaram S and Sabate J. Nut consumption and weight gain in a Mediterranean cohort: The SUN study. 647S-650S. Mitch WE. Eckel RH. 23. Nuts. 2007. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 83 . Jenkins DJ. Report of a Joint WHO/FAO Expert Consultation. 2003. hazelnuts. Cheskin LJ. Maddox DH. Circulation. Effects of food attributes on hunger and food intake. Franco OH. Geneva. Bes-Rastrollo M. Lichtenstein AH. Fishell VK. Kris-Etherton P. Am J Clin Nutr. Suttie J.73 74 WHO (World Health Organization). Kirkmeyer SV and Mattes RD. 79.. Garcia-Lorda P. Megias Rangil I. Peanut evidence. Juturu V. Lapsley KG. Int J Obes Relat Metab Disord. 2001. 15. Bazzarre TL. 25-30. body weight and insulin resistance. Edible nuts and metabolic health. Pearson TA. and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. 96 Suppl 2. Pelkman CL. CAP (Committee of Advertising Practice). Am J Clin Nutr. 102. Mackenbach JP.peanuts and tree nuts (almonds. 2002. 1503-1511. Antinoro L. Br J Nutr. Nguyen T. Deckelbaum RJ. nutrition and prevention of chronic diseases. Tribble DL. The potential role of peanuts in the prevention of obesity. Nut consumption. Sacks F. Trautwein EA. WHO Technical Report Series 916. Sabate J. J Am Coll Nutr. Kendall CW. Singer W. Erdman JW. St Jeor S. safer. Martinez-Gonzalez MA. Recommendations for Preventing Excess Weight Gain and Obesity. Josse RG. Howard B. Margolis S. pecans. McManus K. 2004. Wylie-Rosett J. Salas-Salvado J. Faulkner DA. Int J Obes Relat Metab Disord. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Wong JM. Peeters A. 2001. Int J Obes Relat Metab Disord. body weight and insulin resistance. 107116. ID 1130: “Nuts . 2006. 2005. 57 Suppl 1. Goldberg IJ. Connelly PW. 2004. de Laet C. Jr. 1167-1175. A randomized controlled trial of a moderate-fat. 24. Sabate J. 78. Marchie A. JAMA. J Am Diet Assoc. 1327-1332. Griel AE. Jenab M. 372-377. St-Onge MP. Juturu V. Florentin L. Lovejoy J. Peto R. Curr Opin Lipidol. Noakes M. 1917-1927. FASEB J. Rosner BA. Etherton TD. Nutr Metab Cardiovasc Dis. Cole SE. Rajaram S. Haight JS. Parker TL. BMJ. 2005. 2005. 131. 660-668. Qian W. Wien MA. Frost C. Rimm EB. 2001. Hennekens CH. Almonds and almond oil have similar effects on plasma lipids and LDL oxidation in healthy men and women. Hargrove RL. Cordero-Macintyre Z. and pulmonary nitric oxide: a randomized. Gardner CD and Kraemer HC. Almonds in the diet simultaneously improve plasma alpha-tocopherol concentrations and reduce plasma lipids. crossover trial. 290. BMJ. Kushi LH. 502-510. Whelan MF. Folsom AR. 2002. Pearson TA. Hu FB. 22. Kris-Etherton PM. Tanzman J. 16. J Nutr. Eissenstat B. 965-969. Schneeman BO. Comparison of monounsaturated fatty acids and carbohydrates for reducing raised levels of plasma cholesterol in man.17 18 19 Sabate J. 314. 2004. ID 1131: “Almonds” and “Maintains healthy blood total and LDL cholesterol and heart health” 1 Abbey M. Vanden Heuvel JP. Am J Clin Nutr. Vidgen E. 1998. Ellsworth JL. Low fat and high monounsaturated fat diets decrease human low density lipoprotein oxidative susceptibility in vitro. Haddad E. Sabate JM. Edible nuts and metabolic health. Peanut consumption improves indices of cardiovascular disease risk in healthy adults. 1757S-1762S. Lapsley KG. Vidgen E. dairy. Fulgoni VL. Furlong T. Spiller GA. Faulkner DA. Almonds lower blood cholesterol and LDL-cholesterol but not HDL-cholesterol in human subjects: results of a metaanalysis. Int J Obes Relat Metab Disord. Circulation. Lapsley KG. Trautwein EA. 2008. 703-707. 2007. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 84 . Collins R. J Am Coll Nutr. 81. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. J Nutr. J Am Coll Nutr. 138. homocysteine. 133-141. Taylor S. Grundy SM. 317. Alper CM and Mattes RD. Marchie A. lipoprotein(a). Sabate J. 15. Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women: the Iowa Women's Health Study. teas. Almonds vs complex carbohydrates in a weight reduction program. Speizer FE. Wong JM. 995-999. 18. oxidized low-density lipoproteins. 25-30. 449-454. Clarke R. Jenkins D. Jambazian PR. 23. Arterioscler Thromb Vasc Biol. 1758-1763. Josse RG. 105. Sabate J. Davis PA. Coates AM and Howe PR. Colditz GA. 112-117. Dose response of almonds on coronary heart disease risk factors: blood lipids. Partial replacement of saturated fatty acids with almonds or walnuts lowers total plasma cholesterol and low-density-lipoprotein cholesterol. Nix D. Haddad E. Dietary fats. Belling GB. Jenkins DJ. de Souza R. and nuts: potential functional foods for weight control? Am J Clin Nutr. Davis PA. 1341-1345. Abbey M. 7-15. Monounsaturated versus polyunsaturated dietary fat and serum lipids. 1997. Tree nut and peanut consumption in relation to chronic and metabolic diseases including allergy. 11. Harrison EH. Willett WC. controlled. Connelly PW. A meta-analysis. 94. 2005. 859-864. A981-A981. 106. Ikle DN. 2002. Kendall CW. Spiller G. Davis P. Siapco G. 1995. 27. 2003. Appleby P. 2003. Jenkins DJ. Emam A. Does regular walnut consumption lead to weight gain? Br J Nutr. Faulkner D. 59. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. J Nutr. Improved diet quality with peanut consumption. Most M. Hyson DA. Manson JE. 132. Parker TL. Kris-Etherton PM. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. 47. 1994. Leiter LA. Kandeel FR. 1365-1372. Connelly PW. 1988. Stampfer MJ. Am J Clin Nutr. 2001. 2003. 2002. Kendall CW. Torabian S. Nestel PJ. Hsieh G. Trautwein EA. Hu FB. 2001. Hargrove RL. hazelnuts and the macadamia nut. Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure. Galvin K. de Souza R. AHA science advisory: monounsaturated fatty acids and risk of cardiovascular disease. Carrasco W. 70. Ratcliffe HE. Etherton TD. 2005. 138. Effect of dietary fatty acids on serum lipids and lipoproteins. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Kris-Etherton PM. Suttie J. J Nutr. Willett WC. Nguyen TH. A randomized controlled trial of a moderate-fat. 171-178. Daniels SR. Am J Clin Nutr. 1746S-1751S. Trautwein EA. Wylie-Rosett J. Kris-Etherton PM. Oosthuizen W. Foster GD. 1741S-1745S. J Nutr. J Nutr. Emam A. Jenner JL. Mattes RD. 2280-2284. Vidgen E. Eur J Clin Nutr. Effects of canola. Nut and peanut butter consumption and risk of type 2 diabetes in women. Kris-Etherton P. Fishell V. Zhao G. 31. Manson JE. 194-202. Arterioscler Thromb. Marchie A. Ingwersen L. 76. Jr. and olive oils on fasting and postprandial plasma lipoproteins in humans as part of a National Cholesterol Education Program Step 2 diet. 12.. 2008. Am J Clin Nutr. 55. Kris-Etherton PM. Alvarez-Sala LA. O'Brien NM. 1503-1511. 62. Robinson K. 2008. King JC. J Lipid Res. 2002. Lichtenstein AH. Blumberg J. Lichtenstein AH. 2004. Emam A. Mullis R. 13. Am J Clin Nutr. 2006. 504S511S. and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. tocopherol. 138. Kotchen TA. Ausman LM. 1736S-1740S. 77-83. 2002. Goldberg IJ. Marchie A. J Nutr. 25. 1999. peanuts. O'Sullivan SM. Yu-Poth S. Ordovas JM. 781-788. Vidgen E. Kris-Etherton PM. A systematic review of the effects of nuts on blood lipid profiles in humans. Ordovas JM. Maguire LS. 70. Etherton TD. Leiter LA. Most MM. Int J Obes Relat Metab Disord. 2008. Lapsley KG. Wan Y. Arterioscler Thromb. Tucker KL. Comparison of effects of dietary saturated. 2000. Stroke. Gualtieri LJ. Faulkner DA. Kemp T. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Jiang R. Nuts and their bioactive constituents: effects on serum lipids and other factors that affect disease risk. Schaefer EJ. Effect of dietary monounsaturated fatty acids on plasma lipoproteins and apolipoproteins in women. Sacks F. Kris-Etherton PM. JAMA. Josse RG. Int J Food Sci Nutr. Holmes C. 1000-1006. 85 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 . 288. 2751-2766. Goldin BR. 2082-2089. 1999. Leiter LA. Tribble DL. 83. Stampfer MJ. Mattson FH and Grundy SM. Tree nuts and peanuts as components of a healthy diet. Sabate J. Jerling JC. 1533-1542. 138. Howard B. St Jeor S. Impact of peanuts and tree nuts on body weight and healthy weight loss in adults. Bazzarre TL. Hu FB. McManus K. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. A metaanalysis of 27 trials. Wong JM. Mata P. monounsaturated. 1009-1015. Lapsley KG. low-energy diet compared with a low fat. Faulkner DA. Wong JM. Ros E. Garrido JA. 129. Rood JC. de Oya M. Connelly PW. Am J Clin Nutr. Mukuddem-Petersen J. Eckel RH. Jenab M. Jenkins DJ. Antinoro L. Krauss RM. 2554-2560. Effect of diets enriched in almonds on insulin action and serum lipids in adults with normal glucose tolerance or type 2 diabetes. Lovejoy JC. 911-919. 582-591. 135. J Nutr. Deckelbaum RJ. Fatty acid profile. 26. 1992. 1992. Blazquez E. 1993. Greenway FL. Pearson TA. Nguyen T. Singer W. Lefevre M. Mensink RP and Katan MB. 56. Singer W. Moriarty K. Josse RG. Appel LJ. Erdman JW. de Souza R. O'Connor TP. Mitch WE. Kemp T. Am J Clin Nutr. 1985. 2008. low-energy diet for weight loss in overweight adults. Alonso R. Kendall CW. Highmonounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Sabate J.17 Jenkins DJ. 1999. Liu S. Kendall CW. squalene and phytosterol content of walnuts. Rubio MJ. corn. almonds. 2003. 50-57.)” and “Cholesterol management / heart health” 36 37 38 39 40 41 42 43 44 45 46 1 2 3 Food Labeling: Health Claims: Soy Protein and Coronary Heart Disease. or roasted almond butter on serum lipoproteins in humans. 24. Yaqoob P. Surya P. Gadbury G. Soy compared to casein meal replacement shakes with energy-restricted diets for obese women: randomized controlled trial. Pearson TA. Patterson K. 11. Fuller J. Effect of nut rich in monounsaturated fatty acid on serum lipids in hyperlipidemia. Yan SF. Tredger JA. Gustafsson IB. Gates JE. 56. Sabate JM. J Am Coll Nutr. Calder PC. Rudd C. 1994. Meijer G. 2004.35 Nydahl MC. Tamizifar B. 1997. Curtis C. Rajaram S. 8. Hoie LH. 12. 126-130. Bosello O. 2004. Roche H. Haddad E. 79. Bruce B. Pelkman CL. J Am Coll Nutr. 2003. Weigel RM. Lian XJ. 57. 1992. Lipid-lowering diets enriched with monounsaturated or polyunsaturated fatty acids but low in saturated fatty acids have similar effects on serum lipid concentrations in hyperlipidemic patients. Williams CM. Tamizifar B. 81. Knauft DA. 2003. 204-212. 195-200. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Wright J. Wang JB. 514-522. Farquhar JW. Stevenson M. Allison DB. J of China Public Health. Jenkins DA. 2007. Kandeel FR. Becker DM. 2002. 32. Rismankarzadeh M. 280288. 59. 115-122. Miller B. Jr. Fishell VK. Tanzman JS. Persky VW. Allen JK. Nuts and plasma lipids: an almond-based diet lowers LDL-C while preserving HDL-C. Katan MB. 1999. Gibney MJ. Rafieeyan M. Potter SM. Cragen LN. Serum lipid response to the graduated enrichment of a Step I diet with almonds: a randomized feeding trial. Number 206). Miller A. Am J Clin Nutr. Br J Nutr. Arch Iranian Med. 1992.] Merr. 1998. 45-51. Lindenstruth KA. Jauhiainen M. Weight loss and lipid changes with low-energy diets: comparator study of milk-based versus soy-based liquid meal replacement interventions. Mauger DT. Effect of a diet high in monounsaturated fat from almonds on plasma cholesterol and lipoproteins. Fontaine KR. Sabate J. Spiller GA. Heymsfield SB. O'Byrne DJ. Valsta LM. 210-216. 2005. 14. Dewell A. Baum JA. Olivera K. 687-695. 21. Ikle DN. Kraker JL. Tabor A. 1365-1372. Cholesterol reduction using manufactured foods high in monounsaturated fatty acids: a randomized crossover study. Klein BP. Anderson JW. Liu Y. 1999. Am J Clin Nutr. 439-446. J Am Coll Nutr. Aro A. Almonds vs complex carbohydrates in a weight reduction program. 1998. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. Effects of a monounsaturated rapeseed oil and a polyunsaturated sunflower oil diet on lipoprotein levels in humans. Brookes CA. Bakhit RM. Murugesan R. Heshka S. Shireman RB. Final Rule. Francis-Knapper JA. 22. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. 61-75. Anderson JW and Hoie LH. Vosoughi A-A. Blair R. Arterioscler Thromb. Mutanen M. Adv Ther. Cragen LN. 2003. Xiao Y. 931-932. Spiller GA. 77. Ramos E. Lipids. 1379-1384.. ID 1135: “Soya (Glycine max [L. 17. Jambazian P. Menopause. 285-290. Cole SE. Aminzade A. Shay NF. Spiller GA. Eur J Clin Nutr. Wien MA. Am J Clin Nutr. Effects of plant-based diets high in raw or roasted almonds. Schwartz LG. Webb D. 27. Reynolds J. Int J Obes Relat Metab Disord. Zampelas A. Kwiterovich PO. Jenkins DJ. Luan J. 1999 (Volume 64. Teng H. 2005. 18. Gates JE. Federal Register: October 26. A low dose almond based diet decreases LDL-C while preserving HDL-C. Metabolism. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Low fat-monounsaturated rich diets containing high-oleic peanuts improve serum lipoprotein profiles. Superko R. Erdman JW. Freels S. Maddox DH. J Am Coll Nutr. Bosello O. 106-114. Anderson JW. Tang Y. Long-term intake of soy protein improves blood lipid profiles and 4 5 6 7 86 . Kris-Etherton PM. Berra K. Vessby B. Morse SJ. 2007. 275-285. Lipids. Yamori Y. Kreijkamp-Kaspers S. 2002. Davis S. Kanda T. Kok L. Dadd T. 78. Campbell CG. Maesta N. Lahti T. placebo-controlled trial. Villablanca AC. Effects of dietary intake of soy protein and isoflavones on cardiovascular disease risk factors in high risk. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Phytoestrogene in der Prävention. Sagara M. 2005. 159. Rohr U and Mitglieder des Konsensustreffens. postmenopausal women. Huff MW. Thorland WG. and lipids in healthy men. Dufner D. Soya Protein Association. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Biochem J. Effects of soy protein and resistance exercise on body composition and blood lipids in postmenopausal women. Chiriboga D. 2004. decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Fernandes CE. Hallund J. Grobbee DE. Ferrari M. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity--a controlled crossover trial. Smerud KT. Kotsopoulos D. Cooke JP.. Ztg. M NJ. McGrath BP. Teede HJ. Aleman A. Edwards JY. 41. Am J Clin Nutr. Murray MJ. Koebnick C. Kendall CW. Armitage L. Korpelainen V. Lissin LW. Jenkins DJ. Metabolism. Soy-isoflavoneenriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production. Soy in hypercholesterolaemia: a double-blind. Am J Clin Nutr. Nicolosi R. 2002. 2007. Vasc Med. Birt N. Agarwal S. 123-130. 82. 2000. Diamandis EP. 2003. quiz 1365-1266. J Am Coll Nutr. Ockene IS. 56. Hasler CM. 86. Wilcox LJ. Jackson CJ. Rosenberg-Zand RS. 2000. 537-543. 531-539. 8 Borradaile NM. Weigel R.increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic. Rao AV. Nilsson M. Faulkner D. Am J Clin Nutr. 71. Brown BD. 26-30. Vuksan V. 49. Arch Intern Med. Talbot D. Williams CM. Liang YL. J Am Coll Nutr. Terry JG. Birt C. 366. Effect of soy protein containing isoflavones on blood lipids in moderately hypercholesterolemic adults: a randomized controlled trial. Crouse JR. 45. Guthrie NL. Puska P. 2001. Burini RC. 257-265. Am J Clin Nutr. bone mineral density. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 87 . JAMA. de Haan EH. 1999. Vafeiadou K. Burke GL. Dalais FS. 1077-1084. Does the inclusion of 25g soya protein per day as part of a diet low in saturated fat help to reduce blood cholesterol? Steinberg FM. Teramoto T. Eur J Clin Nutr. Nahas-Neto J. 2006. Hall WL. inflammation. Hannum S. Branca F. Potter SM. 545-551. Soya phytoestrogens. Maturitas. Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women. Parker T. 2004. 2005. 23. Lakshmi S. 3rd. 350-358. Skovlund E. Dahlman-Wright K. Jr. 85-91. 352-357. Garsetti M. Gustafsson JA. Reimann M. 2004. Olendzki BC. and plasma lipids in postmenopausal women: a randomized controlled trial. Pharm. Vitolins M. genistein and daidzein. Oka R. Vidgen E. Ma Y. middle-aged men in Scotland. 2002. 68. van der Schouw YT. Minihane AM. 2070-2076. Nahas EA. Effects of soy or milk protein during a high-fat feeding challenge on oxidative stress. Ellis J. 3053-3060. Morgan T. 2004. Isoflavones improve vascular reactivity in postmenopausal women with hypercholesterolemia. A Health Claim Submission by the Soya Protein Association to the JHCI For a Generic Soya Protein Health Claim In The UK. 65-74. 24. Effect of soy protein containing isoflavones on cognitive function. Merriam PA. 9. Orsatti FL. 1260-1268. J Clin Endocrinol Metab. Erdman JW. Bugel S. de Dreu LE. Traiman P. 56. Hoie LH. Lampe JW. Kumar K. 292. Teixeira SR. 134. 2006. 165. Grenby TH. ID 1142: “Milk” and “Dental health” 6 7 8 1 2 3 4 5 6 7 8 Aimutis WR. 1991. Lazarus SA. Shapira L. 84. Shu XO. 90. 2004. Whelan S. Crosbie L. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. Smith M. 2004. Oto A. Enamel softening with Coca-Cola and rehardening with milk or saliva. Horgan G. Willcox JK. 294-300. Goultschin J. Shapira L. Mistry M. J Contemp Dent Pract. 501-506. Al-Zahrani MS. Yamada K. 24. Yildirir A. Dakuar A. Arch Intern Med. Li H. Jenkins GN and Ferguson DB. 1991. 1031-1038. Yamashita T. 88 . Bioactive properties of milk proteins with particular focus on anticariogenesis. circulatory and heart health” 25 26 1 2 3 4 5 Dutta-Roy AK. Lewinstein I. J Nutr. 472-477. 989S-995S. Oral Health. 805-806. Assessment of the effect of selected snack foods on the remineralization/demineralization of enamel and dentin. Kirk M. Hirata Y. ID 1137: “Water soluble tomato concentrate (WSTC)” and “Suppression of blood platelet activity. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women.24 Urban D. 2001. Report of the British Nutrition Foundation Task Force. 2000. Crosbie L. Lazarus SA and Garg ML. Broom JI. Diet and Other Factors. 292. Li Q. 218-227. Oiwa K. Ijiri Y. 1. Ben-Mosheh S. 2005. Zhang X. Webb DJ. Br Dent J. 289-294. Ionat-Bendat D. Yang G. 570-579. J Periodontol. O'Kennedy N. Tooth enamel softening with a cola type drink and rehardening with hard cheese or stimulated saliva in situ. Webb DJ. Myers R. Tomatoes and cardiovascular health. J Oral Rehabil. Tokgozoglu SL. 711-716. 2007. Haznedaroglu I. Murakami M. Catignani GL. Soy protein diet significantly improves endothelial function and lipid parameters. Koksal G. Am J Dent. 4. Gordon MJ. 1890-1895. Tomatoes have natural anti-thrombotic effects. Gao YT. Jensen ME. Barnes S. 12 Suppl. 120-122. Gedalia I. 1999. 1966. Kes S. Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. 77. Rahamim E. Lazarus SA and Garg ML. Amsterdam. Oduncu T. Donly K. Effects of tomato extract on human platelet aggregation in vitro. 249-256. 18. 2003. The effects of tomato extract (TE) and omega-3 fatty acids on platelet cAMP levels and inositol triphosphate (IP(3)) release. 29. Arens U and British Nutrition Foundation. 55. Am J Clin Nutr. Increased intake of dairy products is related to lower periodontitis prevalence. Int J Food Sci Nutr. Akinci D. J Urol. 1-18. Weiss H. 1-17. Gedalia I. 120. Luther V. 12. Crosbie L. Crit Rev Food Sci Nutr. S20. Milk and dental caries. British Journal of Nutrition. Irwin W. Platelets. J Dent. 165. Andrews AT. Sade E. 2006. Lazarus S. JAMA. Williams RJ. van Lieshout M. 2001. Bowen K. Tomato juice and platelet aggregation in type 2 diabetes. Duttaroy AK. Dental caries-protective agents in milk and milk products: investigations in vitro. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. 2001. Elsevier Science. Markiewicz MA. 2004. Broom JI. Kirazli S. 2003. 2006. 561-569. Yamamoto J. Wefel JS. Naemura A. Am J Clin Nutr. Zheng W. Grizzle WE. 2001. Garg ML. 83-92. 84. Asia Pac J Clin Nutr. O'Kennedy N. Clin Cardiol. Hashimoto M. 43. Tomato extract inhibits human platelet aggregation in vitro without increasing basal cAMP levels. Duttaroy AK. Taka T. Richter R. Nieuw Amerongen AV. Swed Dent J. Merritt J. 2006. Bots CP. Ada Position and Statement: Role of Sugar-Free Foods and Medications in Maintaining Good Oral Health. New York. 76. 40. Relative buffering capacity of goat milk. 34. Backman B. 2002. Nayak R. 41. 361-366. 60. Diet intake and caries prevalence in four-year-old children living in a low-prevalence country. J Clin Dent. Barton J. 3326-3333. Bjornstrom M. Oxford University Press. 129. 34-38. Cheese consumption and the development and progression of dental caries. Volkswirtschaftlicher Verlag. 1998. cow milk.Oral Health Policies. WHO/FAO (World Health Organization and Food and Agriculture Organization). 881S-892S. Brand HS. Burt BA. Expert Report: Diet. 124-129. München. 2007. 578584. Vos PF. 1998. Mau MS. 74. Lutchman D. 1623-1626. WHO Technical Report Series 916. Fluoridation Facts. Mandel ID. Lambrou D. Anusavice KJ.9 10 Kashket S and DePaola DP. 46. Xu T. Axell T. The use of sorbitol. J Am Dent Assoc. Fejerskov O. Nutrition and dental health. Rughoobeer A. Rugg-Gunn AJ and Hackett AF. 78. Park YW. Report of a Joint WHO/FAO Expert Consultation. 2005. J Dent Hyg. 1993. The effect of chewing sugar-free gum after meals on clinical caries incidence. 2006. 1982. Caries Res. J Am Dent Assoc. Community Dent Oral Epidemiol. J Clin Dent. Valentijn RM. 2002. Touger-Decker R and van Loveren C. Ohlund I. and monitoring of dental caries. and xylitol chewing gum: underutilized preventive therapies? Gen Dent. Korevaar JC. 2003. 137. 190-196. 97-103. fluoride varnish. Lind T. Larsen MJ. 11 12 89 . 14. Nephrol Dial Transplant. Curtis J. 2005. Abelson DC. Policy on the Use of Xylitol in Caries Prevention. Bezemer PD. Qi F. Bruun C. Stookey GK. 2006. Evidence-based prevention. management. J Dairy Sci. Hernell O. ADA (American Dental Association). Barber LR and Wilkins EM. The effect of chewing sorbitol-sweetened gum on salivary flow and cemental plaque pH in subjects with low salivary flow. Shi W. Boneta AE. Shangase N. Katz BP. Fluoride in mixed human saliva after different topical fluoride treatments and possible relation to caries inhibition. Chewing gum and a saliva substitute alleviate thirst and xerostomia in patients on haemodialysis. 96. ADA (American Dental Association). A multi-centre study. Beiswanger BB. Nutr Rev. Bijlsma JA. 11 12 13 14 15 16 17 ID 1149: “Sugar-free chewing gum” and “Dental health/ Oral health. Birkhed D. 153-161. Johansson I. 30. Milk helps build strong teeth and promotes oral health. Gum and tooth protection/ strength” 1 2 3 4 5 6 7 8 9 10 AAPD (American Academy of Pediatric Dentistry). Reference Manual 2006-2007 . Clinical evaluation of the anti-plaque effect of a commercial chewing gum. goat's and soy milk and non-prescription antacids in the treatment of non-ulcer dyspepsia. 1982.and xylitol-sweetened chewing gum in caries control. Milch und Milchprodukte in der Ernährung des Menschen. 16. S Afr Med J. 10. 1990. J Calif Dent Assoc. Santarpia P. Chlorhexidine. 20. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. 26-33. Sugars and dental caries. 2001. 2003. 31-32. Valentijn-Benz M. Naidoo R. 2005. Thylstrup A. soy-based infant formulas and commercial nonprescription antacid drugs. Holgerson PL. 1991. 2. Pillay S. Am J Clin Nutr. Van Amerongen BM. 3-5. 2006. nutrition and prevention of chronic diseases. Renner E. Evaluation of the buffering capacity of powdered cow's. 270-275. 1-5. Proskin HM. Veerman EC. 57-61. ter Wee PM. 1990. Barnes VM. Chewing gum and saliva in oral health. Mok YC. Higham SM. Responses of interproximal plaque pH to snack foods and effect of chewing sorbitolcontaining gum. 106-109. chewing gum and dental caries--a review. (Revised 2008) FDI (World Dental Federation). 2004. Griffin SO. Adv Dent Res. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 90 . London. August 23. Pang KM. Subchapter B Food for Human Consumption Part 101 Food labeling. Caries Res. 1997. The science and practice of caries prevention. Edgar WM. 28. Corpron RE. Gordon J. 1992. 2007. 441-446.80. J Dent Res. 131. Clinical implications of saliva: report of a consensus meeting. 887-899. Stecksen-Blicks C. Effect of fluoride-containing chewing gum on remineralization of carious lesions and on fluoride uptake in man. Three clinical trials comparing xylitol. J Clin Dent.80). 1997. Lin YT. Jensen ME and Wefel JS. 1996. J Clin Dent. Palliat Med. 3. Code of Federal Regulations. 2000. 86. 2000. 1994. Recommendations for Using Fluoride to Prevent and Control Dental Caries in the United States. Dental plaque formation and salivary mutans streptococci in schoolchildren after use of xylitol-containing chewing gum. Hattab FN. FDI Statement: Fluoride and Dental Caries. 410-415. Federal Register 61 (154) 43433-43445. Beltran ED. 10. Balbo F. 1996. Landry PA. Crit Rev Oral Biol Med. 75-78. 8. 159-162. Jensen ME. 2001. Proposed study protocol for "Davies AN. Holgerson PL.13 14 15 CDC (Center for Disease Control and Prevention). Food and Drugs. 2000. 14. 11. De Los Santos R. Systemic versus topical fluoride. 1. Chewing gum--facts and fiction: a review of gum-chewing and oral health. Twetman S. O'Mullane DM. Strachan DS. 1986. 2000. 204-208. 96-98. 167. 2007. Effectiveness of fluoride in preventing caries in adults. 1994. 258-262. Saliva stimulation and caries prevention. 14. J Am Dent Assoc. Edgar WM. Br Dent J. Title 21. Effect of gum chewing on the pH of dental plaque. Br Dent J. Int J Paediatr Dent. 5. Subpart E. 1989. Edgar WM. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. 113. J Am Dent Assoc. 6-19. Featherstone JD. Reardon R. Clin Prev Dent. Huntley V. 1990. Maiwald HJ. Flowerdew G. British Dental Association Publication. FDA (Food and Drug Administration). Edgar WM. Palliative Medicine. 262-266. Human plaque pH responses to meals and the effects of chewing gum. J Clin Dent. Saliva and Oral Health.and sorbitolcontaining chewing gums for their effect on supragingival plaque accumulation. Imfeld T. Davies AN.Specific Requirements for Health Claims (21CFR101. J Clin Dent. Manning RH. 239-245. Effects of chewing sorbitol gum on human salivary and interproximal plaque pH. Frohlich S. 197-203. 2004. Br Dent J. Health claims: dietary sugar alcohols and dental caries. 29-32. Cronin M. Itthagarun A and Wei SH. 38. Jensen ME. In situ remineralization of root surface lesions using a fluoride chewing gum or fluoride-releasing device. 405-419. 1988. Green RM. Davies AN. 197-203". Regnier E. 79-85. 1998. Griffin PM. Health claims: dietary noncariogenic carbohydrate sweeteners and dental caries. Saliva and dental health. and 21CFR §101. 184. 1999. 8. 1989. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. 1994. Chapter I Food and Drug Administration Departement of Health and Human Services. Caries Res. Sjostrom I. Dawes C. 17. Sugar substitutes. Hellwig E and Lennon AM. 6-11. 169. [Effect of sugared and sugarfree chewing gum on plaque pH]. Am J Dent. 1992. 14. 2006. Chewing gum as aid in treatment of hyposalivation. 1982. 1989. J Dent Res. A clinical and biochemical study.org/dental/xerostomia. Ten Cate JM. 40. 319-336. 304-309. 33-40. Quintessence Int. Effect on plaque of a xylitol-containing chewing-gum. Salivary stimulation by chewing gum and its role in the remineralization of caries-like lesions in human enamel in situ. 28-31. Isotupa KP. 522-529. More FG. Lin YT and Corpron RE.or sugar-free gum. 30. and their modification by chewing sugared. 1988. 3.nidcr. 71-74. In vivo study of fluoride chewing gum for the remineralization of human root lesions. Lynch RJ. Polyol chewing gums and caries rates in primary dentition: a 24-month cohort study. 241-244. 70. 68. Manning RH. Pape HR. 1990. 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 91 . Isotupa KP. Axell T.36 Kandelman D and Gagnon G. 69.oralcancerfoundation. 1995. Mandel ID. Acta Odontol Scand. 1975. 185-191. Edgar WM. Walia R. Abelson DC. 3. Agalamanyi EA. Jr. 33. The effect of fluoride at plaque fluid concentrations on enamel deand remineralisation at low pH. Mouton C. Caries Res. Sorbitol gum in xerostomics: the effects on dental plaque pH and salivary flow rates. Int Dent J. 273-279. Isokangas PJ. Isotupa KP. 1904-1913. J Dent Res. 1991. 174-185. Hujoel PP. Oral Cancer Foundation. 1992. Bennett CA. Isokangas PJ. Int Dent J. 174. NIDCR (National Institute of Dental and Craniofacial Research). Lynch RJ. 54. 1989. Edgar WM. Pape HR. In situ remineralization of subsurface enamel lesion after the use of a fluoride chewing gum. NY State Dent J. Manning RH and Edgar WM. Allen P. Park KK. Navada R. Manning RH and Edgar WM. Toth Z. Makinen PL. 1771-1775. Makinen KK. 1991. 71-75. Banoczy J. Gerodontology. 47. Olsson H. 1992. Bennett CA. 1064-1068. Caries Res. Lamb WJ. 1993. Makinen PL. 68. 27. Dry Mouth. 26. Remineralization of artificial caries-like lesions in human enamel in situ by chewing sorbitol gum. Schemehorn BR. Lopez LR. Acta Odontol Scand. 57. 1993. Lee IK and Schachtele CF. Zahn Mund Kieferheilkd Zentralbl. 49. 598-604. Kashket S. Yaskell T. Makinen KK. J Clin Dent. J Dent Res. A 24-month clinical study of the incidence and progression of dental caries in relation to consumption of chewing gum containing xylitol in school preventive programs. Xylitol chewing gums and caries rates: a 40-month cohort study. Markovic N. http://www. Dent Clin North Am. Corpron RE. 111-116. Mony U. Stabilisation of rampant caries: polyol gums and arrest of dentine caries in two long-term cohort studies in young subjects. 45.gov/OralHealth/Topics/DryMouth/.nih. The effect of a chewing gum on salivary secretion. Scheinin A. Caries Res. Bennett CA. Lee GT. Allen P. pH changes in plaque after eating snacks and meals. 455-459. 7. 2004. Changgeng Yi Xue Za Zhi. 104-109. Prevention of sucrose-induced demineralization of tooth enamel by chewing sorbitol gum. http://www. oral mucosal friction. Effect of sorbitol gum chewing on plaque pH response after ingesting snacks containing predominantly sucrose or starch. Low-levels of fluoride in plaque and saliva and their effects on the demineralisation and remineralisation of enamel. Effects of chewing gums sweetened with sorbitol or a sorbitol/xylitol mixture on the remineralisation of human enamel lesions in situ.. Makinen KK. Kowalski CJ. Odusola F. J Dent Res. Vegh A. role of fluoride toothpastes. 2003. Makinen PL. Bolton JW. Hujoel PP. Maiwald HJ. 74. Br Dent J. Jr. 1990a. Leach SA. Mobley CC. Xerostomia information for dentists. 460-462. Stookey GK. Makinen KK. and the feeling of dry mouth in xerostomic patients. Tietze W. 23. 93-107. 1991. Nutrition and dental caries. Strachan DS. 408-417. 1995. Effect of gum chewing following food ingestion on the pH of interproximal dental plaque. Spak CJ. Caries Res. 1996..htm. Beltran ED. 1990b. Preventive dentistry for the general dental practitioner. Mandel ID. 40-43. 286-293. Katz BP. Salivary stimulation by chewing gum and lozenges in rheumatic patients with xerostomia. Caries Res. 17. Microradiographic data. Xylitol: a review of its action on mutans streptococci and dental plaque--its clinical significance. and swallowing rates from chewing a flavored or unflavored chewing gum. Sugar alcohols: what is the evidence for caries-preventive and caries-therapeutic effects? Caries Res. 2003. Influence of fluoride in solution on tooth demineralization.59 60 61 62 63 Park KK. Jr. 101. and dry mouth patients. antiplaque and antigingivitis effects of xylitol and sorbitol sweetened chewing gum. Lingstrom P. 3. Makinen PL. 1992. 38. 1988. 62. 101. 45. Saliva and Oral Health. Makinen KK. 1725-1729. ten Cate JM and Duijsters PP. 141-147. Damen JJ. Chemical data. Banoczy J. 1. 1990. August. 513-519. 45. Persson LG. Stookey GK. 1997. Int Dent J. xylitol. Hernandez D. Am J Clin Nutr. 378-384. Dentistry Monthly. 15. Touger-Decker R and van Loveren C. xylitol-sorbitol. 1983b. 92 . ASDC J Dent Child. Remineralizing potential. Birkhed D. 64-69. 77-92. Eur J Oral Sci. Thornhill M. Aust Dent J. Trahan L. Steinberg LM. Walsh LJ. Bolton JW. 87-91. I. Clin Prev Dent. 170-177. 193-199. 1993. Proskin HM. adults. Edgar WM. Buijs MJ. II. O'Mullane DM. 78. Caries Res. Schemehorn BR. Hakkinen L. and xylitol/sorbitol chewing gums on dental plaque. Schemehorn BR. 197-202. Tammiala-Salonen T. Risheim H and Arneberg P. 1983a. 881S-892S. British Dental Association Publication. 36. ten Cate JM and Duijsters PP. 169. 231-235. Sugars and dental caries. 1981. 23. Trahan L. Pediatr Dent. Caries Res. 180-186. Schemehorn BR. Scand J Dent Res. Odusola F. 1993. Sjogren K. 1989. 2001. pCa. Caries Res. Birkhed D. and placebo chewing gums on the plaque of habitual xylitol consumers. ID 1150: “Sugar-free chewing gum” and “Plaque acid neutralisation” 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 1 2 Edgar WM. London. Stookey GK. Saliva and dental health. Sjogren K. 274278. 80. 96-98. 1995. Care of Dry Mouth. Soderling E. Vratsanos SM and Mandel ID. 1998. 76-82. Yankell SL and Emling RC. Sanders PG. Dawes C. Chen CY. Loesche W. Clinical implications of saliva: report of a consensus meeting. 1993. Noren JG. Inhibition of dentin demineralization by fluoride in vitro. J Clin Dent. 17. Park KK. Stookey GK. 46-49. ten Cate JM. Am J Dent. 14. 2002. Salivary fluoride clearance after a single intake of fluoride tablets and chewing gums in children.. Scand J Dent Res. Butchko HH. Lundberg AB. 1995. 32. Soderling E. 1998. Fluoride and urea chewing gums in an intra-oral experimental caries model. 2000. Clinical effects on plaque pH. 105. The effect of sucrose and hexitol--containing chewing gums on plaque acidogenesis in vivo. Caries Res. Effects of xylitol. 31-34. J Dent Res. 2004. Park KK. The impact of chewing sugarless gum on the acidogenicity of fast-food meals. Szoke J. Effect of chewing gums on plaque pH after a sucrose challenge. Ruben J. Effect of time and duration of sorbitol gum chewing on plaque acidogenicity. Br Dent J. Van Loveren C. Effect of after-meal sucrose-free gum-chewing on clinical caries. Pape HR. 51-53. 6. Influence of fluoride in solution on tooth demineralization. Pharmacol Ther Dent. 2004. Effect of sorbitol. 3-5. 93 . 113. Br Dent J. 1996. Imfeld T. 1988.or sugar-free gum. pH changes in plaque after eating snacks and meals. 87-91. Ada Position and Statement: Role of Sugar-Free Foods and Medications in Maintaining Good Oral Health. 1992. 1982. 2003. and their modification by chewing sugared. Health claims: dietary noncariogenic carbohydrate sweeteners and dental caries (Revised 2008). 262-266. Am J Dent. J Clin Dent. Clinical effects on plaque pH. 3. Toth Z. J Clin Dent. Xu T. 2005. 174. Sugars and dental caries. 185-191. Jensen ME. 1993. Park KK. ADA (American Dental Association). 167. 1990. Santarpia P. 1988. Curtis J. Reference Manual 2006-2007 .80).80. Quintessence Int. Effect of gum chewing on the pH of dental plaque. 1986. 455-459. Health claims: dietary sugar alcohols and dental caries. Effect of gum chewing following food ingestion on the pH of interproximal dental plaque. J Clin Dent. 1990a. Bolton JW. Katz BP.Specific Requirements for Health Claims (21CFR101. J Am Dent Assoc. The effect of sucrose and hexitol--containing chewing gums on plaque acidogenesis in vivo. 1993. Food and Drugs. 231-235. Schemehorn BR. Barton J. Flowerdew G. 2. Banoczy J. Schemehorn BR. Jensen ME. 78. 2006. Human plaque pH responses to meals and the effects of chewing gum. ASDC J Dent Child. Policy on the Use of Xylitol in Caries Prevention. Subpart E. 241-244. Stookey GK. Zahn Mund Kieferheilkd Zentralbl. and swallowing rates from chewing a flavored or unflavored chewing gum. Vegh A. Park KK. 75-78. Hernandez D. 10. Pediatr Dent. Effects of chewing sorbitol gum on human salivary and interproximal plaque pH. Abelson DC. Richter R. 23. Vratsanos SM and Mandel ID. Barnes VM. 2001. pCa. Responses of interproximal plaque pH to snack foods and effect of chewing sorbitolcontaining gum. Effect of chewing gums on plaque pH after a sucrose challenge. 1989. 1999. Federal Register 61 (154) 43433-43445. Sanders PG. Code of Federal Regulations. Am J Dent. Yankell SL and Emling RC. Maiwald HJ. 1992. Pharmacol Ther Dent. Lee IK and Schachtele CF. 15. Butchko HH. 51-53. The impact of chewing sugarless gum on the acidogenicity of fast-food meals. [Effect of sugared and sugarfree chewing gum on plaque pH]. 31-32. 1-5. 62. Tietze W. Schemehorn BR. 1995. Bolton JW. Am J Clin Nutr. Park KK. 6. 70. Title 21. Stookey GK. Subchapter B Food for Human Consumption Part 101 Food labeling. Jensen ME and Wefel JS. Schemehorn BR. 881S-892S. Mandel ID. 1990b. J Clin Dent. Effect of time and duration of sorbitol gum chewing on plaque acidogenicity. 1. 204-208. and 21CFR §101. 1981.Oral Health Policies. Touger-Decker R and van Loveren C. 598-604. Manning RH and Edgar WM. 16. 1996. Park KK. The effect of chewing sorbitol-sweetened gum on salivary flow and cemental plaque pH in subjects with low salivary flow. Crit Rev Oral Biol Med. Stookey GK. Stookey GK. ID 1151: “Sugar-free chewing gum” and “Localised tooth mineralisation (non-systemic)” 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 AAPD (American Academy of Pediatric Dentistry). Frohlich S. Clinical evaluation of the anti-plaque effect of a commercial chewing gum. 180-186.3 4 FDA (Food and Drug Administration). 30. 1. Chewing gum--facts and fiction: a review of gum-chewing and oral health. 197-202. 3. 405-419. August 23. Maiwald HJ. Chapter I Food and Drug Administration Departement of Health and Human Services. 6-19. J Clin Dent. Effect of sorbitol gum chewing on plaque pH response after ingesting snacks containing predominantly sucrose or starch. 3. Br Dent J. Edgar WM. Crit Rev Oral Biol Med. Human plaque pH responses to meals and the effects of chewing gum. 79-85. J Am Dent Assoc. 1989. 20. 1988. Br Dent J. Kandelman D and Gagnon G. Van Amerongen BM. 405-419. 68. 578584. Saliva stimulation and caries prevention. 239-245. Health claims: dietary sugar alcohols and dental caries (Revised 2008) Featherstone JD. Saliva and Oral Health. 1064-1068. Brand HS. Imfeld T. J Am Dent Assoc. Effect of gum chewing on the pH of dental plaque. 1990. Three clinical trials comparing xylitol. Gordon J. 1986. J Dent Res. 8. Burt BA. 167. Adv Dent Res. Dawes C. Stecksen-Blicks C. Title 21. 68. 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 94 . Edgar WM. 1990. Jensen ME and Wefel JS. Yaskell T. Nephrol Dial Transplant. chewing gum and dental caries--a review. Jensen ME. Axell T. Maiwald HJ. 1989. Food and Drugs. J Am Dent Assoc. 1990. Bijlsma JA. Edgar WM. J Clin Dent. Subchapter B Food for Human Consumption Part 101 Food labeling. 129. 184. Code of Federal Regulations. Higham SM. Reardon R. Jensen ME. Br Dent J. British Dental Association Publication. Swed Dent J. 2006. Twetman S. The effect of chewing sugar-free gum after meals on clinical caries incidence. Dental plaque formation and salivary mutans streptococci in schoolchildren after use of xylitol-containing chewing gum. J Clin Dent. 1994. Palliat Med. 69. 262-266. Lee GT. Flowerdew G. Boneta AE. Manning RH. 2000. 1771-1775. Vos PF. Clinical implications of saliva: report of a consensus meeting. 17. Davies AN. Prevention of sucrose-induced demineralization of tooth enamel by chewing sorbitol gum. Effects of chewing sorbitol gum on human salivary and interproximal plaque pH.80). O'Mullane DM. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. 137. Valentijn-Benz M. Frohlich S. 6-19. Lopez LR. 14. The use of sorbitol. 2005. Nieuw Amerongen AV. 106-109.Specific Requirements for Health Claims (21CFR101. Leach SA. 75-78. Veerman EC. A multi-centre study. Sugar substitutes. 159-162. 2007. 2000. 169. 1997. J Dent Res. Proskin HM. Chapter I Food and Drug Administration Departement of Health and Human Services. 204-208. 1998. 10. 29-32. 1994. 1992. 131. 14. J Dent Res. Subpart E. J Clin Dent. A 24-month clinical study of the incidence and progression of dental caries in relation to consumption of chewing gum containing xylitol in school preventive programs. Sjostrom I. 1989. 197-203. Mau MS. Kashket S. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. London. Br Dent J.and sorbitolcontaining chewing gums for their effect on supragingival plaque accumulation. 1998. Edgar WM. Birkhed D. 96-98. Cronin M. The science and practice of caries prevention. 3. Chewing gum--facts and fiction: a review of gum-chewing and oral health. Valentijn RM. Saliva and dental health. Bjornstrom M. Itthagarun A and Wei SH. Korevaar JC. ter Wee PM. Bezemer PD. Holgerson PL. 887-899. Remineralization of artificial caries-like lesions in human enamel in situ by chewing sorbitol gum. Int J Paediatr Dent. Chewing gum and a saliva substitute alleviate thirst and xerostomia in patients on haemodialysis. 460-462. 2004.and xylitol-sweetened chewing gum in caries control. 1623-1626. 113. Chewing gum and saliva in oral health. 190-196. Responses of interproximal plaque pH to snack foods and effect of chewing sorbitolcontaining gum. 5. 1999. 153-161. Katz BP. Balbo F.5 6 7 Beiswanger BB. J Clin Dent. Bots CP. Stookey GK. 1. J Am Dent Assoc. 8. Edgar WM. 1997. Toth Z. Szoke J. 185-191. 1995b. J Clin Dent. Manning RH and Edgar WM.gov/OralHealth/Topics/DryMouth/. Allen P. Pape HR. Agalamanyi EA. 1993. 378-384. Proskin HM. Mandel ID.nih. Hujoel PP. Effect of after-meal sucrose-free gum-chewing on clinical caries. Chen CY. 33. Makinen KK. 455-459. Stabilisation of rampant caries: polyol gums and arrest of dentine caries in two long-term cohort studies in young subjects. 71-75. Park KK. 197-202. and their modification by chewing sugared. Polyol chewing gums and caries rates in primary dentition: a 24-month cohort study. 74. http://www. Tietze W. and placebo chewing gums on the plaque of habitual xylitol consumers. 71-74. Effect on plaque of a xylitol-containing chewing-gum. Park KK. 1992. A clinical and biochemical study. 1993. The effect of a chewing gum on salivary secretion. Schemehorn BR. oral mucosal friction. ASDC J Dent Child. 1996. Oral Cancer Foundation. 1989. 23. Mouton C.or sugar-free gum. Jr.. 30. Stookey GK. 104-109. 49. 3. xylitol-sorbitol. Abelson DC. Makinen KK. Scheinin A. Makinen PL. Am J Dent. 14. Park KK. pH changes in plaque after eating snacks and meals. Xylitol chewing gums and caries rates: a 40-month cohort study. Spak CJ. Effect of chewing gums on plaque pH after a sucrose challenge. Dry Mouth. Makinen PL. 1904-1913. Acta Odontol Scand. Am J Dent. Makinen PL. Remineralizing potential. Quintessence Int. 1993. 241-244. Isokangas PJ. and xylitol/sorbitol chewing gums on dental plaque. 1975. Trahan L.htm. 105. antiplaque and antigingivitis effects of xylitol and sorbitol sweetened chewing gum. Soderling E. Tammiala-Salonen T. Effects of xylitol. NY State Dent J. Zahn Mund Kieferheilkd Zentralbl. 62. 57. Acta Odontol Scand. Katz BP. 101.. 1725-1729. 31-34. Stookey GK. 1988. 273-279.org/dental/xerostomia. Salivary stimulation by chewing gum and its role in the remineralization of caries-like lesions in human enamel in situ. Hujoel PP. 598-604. 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 95 . 1990b. Caries Res. Park KK. Mandel ID. 1982. Loesche W. 70.oralcancerfoundation.27 28 29 30 Lee IK and Schachtele CF. Stookey GK. Risheim H and Arneberg P. Olsson H. Axell T. Markovic N. Banoczy J. Eur J Oral Sci. Manning RH. Effect of sorbitol. Effect of gum chewing following food ingestion on the pH of interproximal dental plaque. 1990a. 28-31. Hernandez D. Xerostomia information for dentists. J Dent Res. Isotupa KP. and the feeling of dry mouth in xerostomic patients. 40-43. Effect of sorbitol gum chewing on plaque pH response after ingesting snacks containing predominantly sucrose or starch. Isotupa KP. Soderling E. 1992. Gerodontology. Jr. 408-417. 7. Chewing gum as aid in treatment of hyposalivation. 1991. Sorbitol gum in xerostomics: the effects on dental plaque pH and salivary flow rates. Vegh A.nidcr. Odusola F. Pape HR. Salivary stimulation by chewing gum and lozenges in rheumatic patients with xerostomia. Bennett CA. Clin Prev Dent. Effects of chewing gums sweetened with sorbitol or a sorbitol/xylitol mixture on the remineralisation of human enamel lesions in situ. Maiwald HJ. 23. Caries Res. Allen P. 1992. 231-235. Scand J Dent Res. Butchko HH. J Dent Res. 1995a. 33-40. 170-177. The impact of chewing sugarless gum on the acidogenicity of fast-food meals. Stookey GK. 1995. 1991. Makinen KK. 3. Bolton JW. http://www. Br Dent J. 93-107. 15. 3. [Effect of sugared and sugarfree chewing gum on plaque pH]. Hakkinen L. Odusola F. Bennett CA. Caries Res. NIDCR (National Institute of Dental and Craniofacial Research). Banoczy J. Makinen KK. Sanders PG. Schemehorn BR. 45. 26. Makinen KK. Int Dent J. Schemehorn BR. Effect of time and duration of sorbitol gum chewing on plaque acidogenicity. Bolton JW. Edgar WM. 80. Pape HR. Steinberg LM. Bennett CA. Pediatr Dent. 2001. 180-186. Jr. Manning RH and Edgar WM. 1992. 174. Isotupa KP.. Isokangas PJ. Schemehorn BR. Makinen PL. xylitol. Vratsanos SM and Mandel ID. Levine J. 1995. Petersen PE and Razanamihaja N. Caries Res. Clinical effects on plaque pH. 1998. Baelum V. 286-293. 10. 341. ID 1152: “Sugar-free chewing gum containing polyols” and “Beneficial for weight management” 1 2 3 4 5 Calorie Control Council. 2003. Dentistry Monthly. A mathematical model of the influence of salivary urea on the pH of fasted dental plaque and on the changes occurring during a cariogenic challenge. The effect of sucrose and hexitol--containing chewing gums on plaque acidogenesis in vivo. Ruxton CH. The effect of chewing gums on acidogenicity of plaque after a sucrose challenge. 1999. 226-230. 1998. Caries preventive effect of sugar-substituted chewing gum. Crit Rev Oral Biol Med. Nyvad B. or urea/arginine to sorbitol gum. 2100. Determinants of dropout in a community intervention trial on the caries-preventive effect of chewing gums. J Dent Res. Tandon S. Hetherington MM and Boyland E. Birkhed D. Effect of three months' frequent use of sugar-free chewing gum with and without urea on calculus formation. Shirwaikar A. 1998. An investigation of the role of oro-sensory stimulation in sugar satiety? Int J Obes Relat Metab Disord. ID 1153: “Sugar-free chewing gum with Carbamide” and “Improved plaque acid neutralisation” 1 Dawes C and Dibdin GH. 45. Trahan L. 38. Van Loveren C. Pharmacol Ther Dent.50 51 52 53 54 55 Thornhill M. pH-rise effect of adding urea. 881S-892S. 1988. Community Dent Oral Epidemiol. Dibdin GH and Dawes C. Denmark. 48. Birkhed D. 2007. Gopinath VK.Reduced Calorie Foods in Reducing the Risk of Obesity. 21-27. 1981. Am J Clin Nutr. Sugars and dental caries. N Engl J Med. 2 3 4 5 6 7 8 9 10 96 . and swallowing rates from chewing a flavored or unflavored chewing gum. 22. Caries Res. 2004. 1999. 51-53. Pavlidis I. 77. 1993. Lingstrom P. arginine. Int Dent J. Machiulskiene V. 46-49. 2004. Machiulskiene V. J Clin Pediatr Dent. J Public Health Dent. Touger-Decker R and van Loveren C. 2002. French SJ. 32. Xylitol: a review of its action on mutans streptococci and dental plaque--its clinical significance. Int Dent J. 1995. 62. Nyvad B. Fure S. 1630-1637. Read NW. Short-term effects of chewing gum on snack intake and appetite. Response letter of 24 June 2004 to Citizen Petition ―Reduced Calorie Foods in Reducing the Risk of Obesity‖. Salivary concentrations of urea released from a chewing gum containing urea and how these affect the urea content of gel-stabilized plaques and their pH after exposure to sucrose. 344-353. Yankell SL and Emling RC. Caries Res. Care of Dry Mouth. 6. 397-401. 78. Baukol P. 1. Nyvad B. 49. Appetite. 29. Lingstrom P. 2002. 77-81. Chewing gum--facts and fiction: a review of gum-chewing and oral health. 1993. Carbamide-containing polyol chewing gum and prevention of dental caries in schoolchildren in Madagascar. 1999. 29. 1997. 278-288. Lavin JH. Sugar alcohols: what is the evidence for caries-preventive and caries-therapeutic effects? Caries Res. August. 2003. Abstract fot the 2nd NOF/CED Joint Meeting August 25-28. Citizen Petition . 70-74. FDA (Food and Drug Administration). 2001. 26. Kolding. Imfeld T. Baelum V. J Clin Dent. Imfeld T. 384-388. Effect of urea in sugar-free chewing gums on pH recovery in human dental plaque evaluated with three different methods. The energy expended in chewing gum. 405-419. 77-92. pCa. 87-91. 172-180. 2001. 35. 40. Evidence-based prevention. 101. 522-529. Persson LG. Fluoride in mixed human saliva after different topical fluoride treatments and possible relation to caries inhibition. Community Dent Oral Epidemiol. and monitoring of dental caries. 2004. Lundberg AB. Birkhed D. 2004. Caries Res. 2004. Caries Res. Rathbone M (ed. The use of sorbitol.11 12 13 Rassing MR. Specialized Oral Mucosal Drug Delivery Systems: Chewing Gum. In situ remineralization of root surface lesions using a fluoride chewing gum or fluoride-releasing device. Smith PW. 1998. More FG. Huntley V. 137. 1993. Chlorhexidine. role of fluoride toothpastes. 40. 38. Walia R. 10. 1996. 28. The effect of chewing urea-containing gum on plaque acidogenic and alkaligenic parameters. Barber LR and Wilkins EM. 54. Birkhed D. 38. Lingstrom P. Green RM. Caries Res. 64-69. Kowalski CJ. Bruun C. Verran J. 47. 111-116. 27. Int Dent J. The effect of fluoride at plaque fluid concentrations on enamel deand remineralisation at low pH. and xylitol chewing gum: underutilized preventive therapies? Gen Dent. Caries Res. Ruben J. Changgeng Yi Xue Za Zhi. Clin Prev Dent. Strachan DS. Anusavice KJ. Mony U. and dry mouth patients. Sjogren K. 2006. 304-309. Fluoride and urea chewing gums in an intra-oral experimental caries model. Larsen MJ. 2003. 34-38. Nutrition and dental caries. Smith CA. 258-262. Birkhed D. ADA (American Dental Association). De Los Santos R. Griffin SO. 270-275. Beltran ED. Fluoride and urea chewing gums in an intra-oral experimental caries model. 2006.) 319-353. 2002. 36. Lynch RJ. J Dent Res. 11. FDI Statement: Fluoride and Dental Caries. 441-446. Higham SM. 2002. 2001. adults. CDC (Center for Disease Control and Prevention). Navada R. In: Oral Mucosal Drug Delivery. Griffin PM. Strachan DS.and xylitol-sweetened chewing gum in caries control. 319-336. 190-196. 410-415. In situ remineralization of subsurface enamel lesion after the use of a fluoride chewing gum. 76. 124-129. Mok YC. Burt BA. J Am Dent Assoc. Low-levels of fluoride in plaque and saliva and their effects on the demineralisation and remineralisation of enamel. 36. 2007. Scand J Dent Res. management. J Dent Hyg. Regnier E. In vivo study of fluoride chewing gum for the remineralization of human root lesions. Mobley CC. 14. Lin YT. Caries Res. Ten Cate JM. Beltran ED. FDI (World Dental Federation). 124-129. 274278. Lingstrom P. Dent Clin North Am. Landry PA. 1982. 174-185. Systemic versus topical fluoride. Sjogren K. 86. Effect of fluoride-containing chewing gum on remineralization of carious lesions and on fluoride uptake in man. 2002. 46. 2000. Salivary fluoride clearance after a single intake of fluoride tablets and chewing gums in children. Hellwig E and Lennon AM. ID 1154: “Sugar-free chewing gum with Fluoride” and “Increases resistance of enamel to acid attacks and rate of remineralisation” 1 2 3 4 5 Arreté du Ministère de l'économie des finances et de l'industrie du 2 mai 2002 relatif à l'emploi de fluorure de sodium dans les gommes à macher. 64-69. Fluoridation Facts. 1994. Lundberg AB. Lin YT and Corpron RE. 97 6 7 8 9 10 11 12 13 14 15 16 17 18 19 . Thylstrup A. fluoride varnish. 6-11. Recommendations for Using Fluoride to Prevent and Control Dental Caries in the United States. Pang KM. Caries Res. Lambrou D. Ruben J. Lynch RJ. Fejerskov O. Hattab FN. 1993. Corpron RE. Lamb WJ. Corpron RE. Caries Res. 1989. Noren JG. 1991. Effectiveness of fluoride in preventing caries in adults. 2005. Sjogren K. 1228-1237. 2002. 210-222. 2004. 2005. 2003. Al Mahrooqi Z. Molan P. 1980. 1991. 76-82. Caries Res. Med Sci Monit. A survey of the antibacterial activity of some New Zealand honeys. Facino RM. Cooper R and Molan P. II. 17. 32. 1983b. 283-285. Orioli M. 50. Buijs MJ. 193-199. 9-12. 9 10 11 12 13 14 15 16 17 98 . Bang LM. Bulman MW. 224. 1983a. 55. J Altern Complement Med. Trop Gastroenterol. 23. 52. The effect of dilution on the rate of hydrogen peroxide production in honey and its implications for wound healing. Badawy OF. 2006. 141-147. 1991. 881S-892S. Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey. 2004. 8. Gheldof N. JAMA. Honey as a surgical dressing. Beretta G. 78. Caries Res. Al-Waili FS. 73. 1998. Al-Waili NS. 9. Al Naqdy A. Al-Jabri AA. 43. Inhibition of dentin demineralization by fluoride in vitro. Nzeako B. The antimicrobial potential of honey from United Arab Emirates on some microbial isolates. Chowdhury MN. 1-4. Armon PJ. Damen JJ. 50. Rev Sci Tech. Al-Waili NS. Tharwat EE. 1955. Walsh LJ. J R Soc Med. 2003. ten Cate JM. 91. 2007. Ali AT. Engeseth NJ. Aust Dent J. In vitro antibacterial activity of Omani and African honey. ID 1159: “Honey (as defined by The Honey Regulations 2003 (as amended))” and “Antioxidant properties Plus Antimicrobial properties” 1 2 3 4 5 6 7 8 al Somal N. Planta Med. Buntting C. 7. 60. J Wound Care. Preventive dentistry for the general dental practitioner. Kamal AM. 10. The use of honey in the treatment of infected wounds. Molan PC. J Pharm Pharmacol. Allen KL. Ali A. Influence of fluoride in solution on tooth demineralization. 1999. Wang XH. Chemical data. Am J Clin Nutr. 3050-3055. 188-189. Molan PC. Saloom KY. 17. Inhibitory effect of natural honey on Helicobacter pylori. 161-164. J Med Food. Antioxidant capacity of honeys from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of in vitro lipoprotein oxidation in human serum samples. The use of honey as an antiseptic in managing Pseudomonas infection. 92. Identification and quantification of antioxidant components of honeys from various floral sources. Effect of hydrogen peroxide on antibacterial activities of Canadian honeys. 1994. Can J Microbiol. Gheldof N and Engeseth NJ. Molan PC. 1011-1022. Brudzynski K. 87. Harding KG. 139-143. Microradiographic data. Influence of fluoride in solution on tooth demineralization. ten Cate JM and Duijsters PP. Sugars and dental caries. I. 2000. Coley KE. Hancock BM. Tropical doctor. Reid GM. 1973. 2003. Shafii SS. Honey for decubitus ulcers. Antioxidant and radical scavenging activity of honey in endothelial cell cultures (EA. 1999. Antibacterial activity of bee honey and its therapeutic usefulness against Escherichia coli O157:H7 and Salmonella typhimurium infection. 11. 267-273.hy926). Cooper RA. Bromfield R. 905. J Agric Food Chem. BR433-438. al Humayyd MS. 2002. Caries Res. Middlesex Hosp J. 12. 817-822.20 21 22 23 24 ten Cate JM and Duijsters PP. Akmal M. 5870-5877. Touger-Decker R and van Loveren C. J Agric Food Chem. 513-519. Br J Biomed Sci. J R Soc Med. Nsanze H. 1182-1189. Investigating the antimicrobial activity of natural honey and its effects on the pathogenic bacterial infections of surgical wounds and conjunctiva. 45. Antibacterial activity of honey against strains of Staphylococcus aureus from infected wounds. 29. 2006. 2001. 2002. Osmotic effect of honey on growth and viability of Helicobacter pylori. Arch Med Res. Int J Food Microbiol. 231-237. 69. Namias N. 58. Al-Habori M. Burton N. 22-24. 51. 51. Al-Mamary M. 2002. 51. Al-Meeri A. 97. Schrader HR. 439-441. Wilkinson JM. J Med Food. 86-87. Mullai V and Menon T. Engeseth N. Atlanta. Bactericidal activity of different honeys against pathogenic bacteria. Guo J. Graham DY. 384-385. J R Soc Med. 1999. 464-467. J Med Microbiol. 217-225. Temnov V. Proceedings of the Annual Meeting of the Institute of Food Technologists. 100-103. 1985. Reddy SG. Engeseth NJ. 1989. J Altern Complement Med. Bactericidal activity of different types of honey against clinical and environmental isolates of Pseudomonas aeruginosa. Ruottinen L. Honey in the treatment of infantile gastroenteritis. Cardetti M. Lusby PE. US honeys varying in glucose and fructose content elicit similar glycemic indexes. 2003. Wang XH. J Agric Food Chem. 2005. Henriques A. Wang XH. Engeseth NJ. 2004. 4. Growth inhibition of foodborne pathogens and food spoilage organisms by select raw honeys. 1500-1505. 219-226. Teraguchi S. J Agric Food Chem. Nutrition Research. 1866-1867. Helsinki. Coombes A. Bactericidal properties of honey and utilisation of honey and other beekeeping products for healing of wounds. 1732-1735. Antimicrobial activity of extracts of local cough mixtures on upper respiratory tract bacterial pathogens. Mundo MA. Honey--a remedy rediscovered. 6923-6928. 22. 2003. Niemira BA. McKibben J.” 1 2 Adeleye IA and Opiah L. 2002. Subrahmanyam M. Honey as a protective agent against lipid oxidation in muscle foods. 25. 1260-1262. 1-8. Bee World. Free radical production and quenching in honeys with wound healing potential. J Am Diet Assoc. 462-464. 2002. 188-190. Honey with high levels of antioxidants can provide protection to healthy human subjects. Haffejee IE and Moosa A. Susceptibility of Helicobacter pylori and its urease activity to the peroxidase-hydrogen peroxide-thiocyanate antimicrobial system. West Indian Med J. Wilkinson JM and Cavanagh HM. 82. including the antioxidants in honey” and “Respiratory Health through presence of antioxidant phytochemicals. Taormina PJ. Andrae L. Beuchat LR. Suomen Mehiläishoitajain. 290. J Agric Food Chem. 1944. 44. J Antimicrob Chemother. Pawar SG. Surg Infect (Larchmt). Hayasawa H. 2005. Keen CL. Hemmady A. 8. 2005. Cooper R. Lusby PE. 52. 14. Padilla-Zakour OI. 1041-1047. Schramm DD. 2007. Buckwheat honey increases serum antioxidant capacity in humans. 32 33 34 35 36 37 ID 1161: “Honey. Mehiläishoitoa käytännössä osa II. 295-300. 1998. Osato MS. Yamauchi K. Shin K. Antioxidant activities and total phenolics of different types of honey. Ischayek JI and Kern M. Honey in the management of infections. Antibacterial activity of 13 honeys against Escherichia coli and Pseudomonas aeruginosa. Annals of Burns and Fire Disasters. Holt RR. Inhibitory activity of honey against foodborne pathogens as influenced by the presence of hydrogen peroxide and level of antioxidant power. Worobo RW. Antibacterial activity of honey on bacteria isolated from wounds. 2001. 106. Jackson S. 2003. Antimutagenic effect of various honeys and sugars against Trpp-1. 99 . 2006. Imoto I. Br Med J (Clin Res Ed). Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs. Wilkinson JM. 773-777. 2003. Karim M. Int J Food Microbiol. Zumla A and Lulat A. 50.18 19 20 21 22 23 24 25 26 27 28 29 30 31 Gheldof N. Dig Dis Sci. Coombes AL. 36. 13. Pomegranate juice flavonoids inhibit low-density 100 4 5 6 . J Ethnopharmacol. Cough suppressants. London. 773-777. 40. 2006. placebo controlled preliminary study. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning.02. 2004. Hayek T. In: The Holy Bible. Millogo J. 158. 2004. Therapeutic uses of honey and honeybee larvae in central Burkina Faso. mucolytics and nasal decongestants. Purified Honey. International Journal of Pediatric Otorhinolaryngology. Antioxidant capacity of honeys from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of in vitro lipoprotein oxidation in human serum samples. Ahmed S. 2002a. 50. Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs. extract inhibits IL1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappaB in human chondrocytes in vitro. Aviram M. 29. Dornfeld L. Lusby PE. Tezer M. Pack AR. Punica granatum L. Hofman A. 2005. 95. 2008. 1062-1076. Aviram M and Dornfeld L. Dornfeld L. 2006. 2005. Wilkinson JM. 1082. 6. randomized. Coleman R. J Antimicrob Chemother. Can postoperative pains following tonsillectomy be relieved by honey? A prospective. 63-67. 1030. Volkova N. 2002b. Jackson S. 2002. Coombes A. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. The effects of manuka honey on plaque and gingivitis: a pilot study. Aggarwal BB and Shishodia S. WHO/FCH/CAH/01. Udoh EE. 2001. Titiz A. Sweetman SC (ed. 2096-2102. Kaplan M. Lamien CE. Cahier Conseil II. expectorants. J Agric Food Chem. Cooper R. Am J Clin Nutr.3 4 English HK. 2. Sweetman SC. Volkova N. Ivanauskas L. Honey for acute cough in children [Intervention Protocol] Cochrane Database of Systematic Reviews. atherogenic modifications to LDL. WHO (World Health Organization). Kaplan M. Meda A. Meremikwu MM. Nacoulma OG. Medicina (Kaunas). Pinostrobin from honey and Thai ginger (Boesenbergia pandurata): a potent flavonoid inducer of mammalian phase 2 chemoprotective and antioxidant enzymes. Ollier C. [Bee products for treatment of diseases of mouth and upper respiratory tract]. In: Martindale: The Complete Drug Reference. 2000. Cheruvu VK. 195-198. Hafeez BB. Genc S. In: Martindale: The Complete Drug Reference.) Pharmaceutical Press. 50. 2002. 1929-1934. 135. Ozlugedik S. 2002. Gaitini D. Ann NY Acad Sci. 1366. Oduwole O. 58.) Pharmaceutical Press. Romito M. Oyo-Ita A. Cough and cold remedies for the treatment of acute respiratory infections in young children. 2002. 434-441. Fahey JW and Stephenson KK. Attias J. Gheldof N and Engeseth NJ. Caregiver booklet: Symptom management and end-of-life care 3rd draft. 3050-3055. J Agric Food Chem. Atherosclerosis. Phytothérapie et pathologies hivernales. Molan PC. Rosenblat M. 2600 1-13. Free radical production and quenching in honeys with wound healing potential. J Int Acad Periodontol. 7472-7476. 71. Aviram M. ID 1162: “Pomegranate” and “Cardiovascular health” 5 6 7 8 9 10 11 12 13 14 15 16 1 2 3 Old Testament. Unal A. 2004. Gendrolis A. Haqqi TM. Brusokas V. Le Moniteur des Pharmacies et des Laboratoires. Presser D. London. and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. J Nutr. WHO (World Health Organization). 2005. 768-770. 70. Sweetman SC (ed. Presser D. Nitecki S. Rosenblat M. Burton N. Henriques A. 295-300. 2004. Pomegranate juice consumption reduces oxidative stress. Fuhrman B. Lukosius A. Sweetman SC. Hayek T. Fuhrman B. Wang N. Coleman R. Elhan AH. 2001. 103-107. 570-576. 24. Iwakiri T. 1472. Arimori K. Kodama H. Holtzman DM. Rios J. Hingorani L. Siroky MB.) polyphenols after ingestion of a standardized extract in healthy human volunteers. Drug Metabolism and Disposition. Schulman RN. Gaieni I. Absorption. Therapeutic Research Faculty. J Agric Food Chem. 810-814. Seeram NP. 2004. 423433. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness. 1153-1154. 23. Hess-Pierce B. 2006. 96. Seeram NP. Int J Vitam Nutr Res. 187. Gil MI. metabolism. Alavi-Majd H. Expert Report: Diet. Fujita K. Weidner G. Holcroft DM. 2006. Daubenmier JJ. Drugs Exp Clin Res. 2004. 32. 2006. Shah A. Sumner MD. Clin Chim Acta. J Agric Food Chem. 2003. 2006.lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. http://www. Okumura M. Ornish D. Chew MH. Fuhrman B. 40. Schulman R. J Nutr Biochem. Ogikubo T. Parsadanian M. Azadzoi KM. Atherosclerosis. 174. WHO/FAO (World Health Organization and Food and Agriculture Organization). Yamasaki K. 76. 2006. Esmaillzadeh A. Azadbakht L. Aviram M. Seeram N. Hayek T. Schulman RN. Holtzman DM. 2004.) juice. Boca Raton. 2000. Report of a Joint WHO/FAO Expert Consultation. Potential Drug-Food Interactions with Pomegranate Juice. 506-515. 858-864. Kader AA. 49-62. WHO Technical Report Series 916. 63-68. Finn MB. Fagan AM. 28. Why a pomegranate? BMJ. 581-583. blood pressure and LDL oxidation. Marlin R. Liker H. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Langley P. 2005. Presser D. 57. CRC Press. Aviram M.naturaldatabase. 147-151. 386-393. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. Rosenblat M. 16. Neurobiol Dis. 2005. Am J Cardiol. Jilma-Stohlawetz P. nutrition and prevention of chronic diseases. 363-371. Schulman RN. 54. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Dornfeld L. 2006. Heber D.com. Nitecki S. 321. The Annals of Pharmacotherapy. 2005. Rosenblat M. Maternal dietary supplementation with pomegranate juice is neuroprotective in an animal model of neonatal hypoxic-ischemic brain injury. Raisin CJ. Elliott-Eller M. and antioxidant effects of pomegranate (Punica granatum l. Gaitini D. Pomegranates: Ancient Roots to Modern Medicine. Hartman RE. Summers KM. Volkova N. Tomas-Barberan FA. Schwetye KE. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. 48. Mertens-Talcott SU. 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 101 . 348. Hayek T. J Urol. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. Derendorf H. Volkova N. Natural Medicines Comprehensive Database. 8956-8961. Loren DJ. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. 7 Aviram M. 2005. Hidaka M. Lee R. Tahbaz F. Pediatr Res. Clin Nutr. 2000. 4581-4589. Hoffman A. Aviram M. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. Heber D. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Attias J. In: Précis de Matière Médicale Tome 2 Pharmacognosie spéciale. 52. 2535-2544. Prune. Consumption of prunes as a source of dietary fiber in men with mild hypercholesterolemia. 1991. 76. J Appl Res. 424-426. République Française. NHS (National Health Services). Biggs WS and Dery WH. Apports nutritionnels conseillés pour la population française. Carbohydrates in Human Nutrition: Report of a Joint FAO/WHO Expert Consultation Rome. http://www. Cohen T. 251-286. Marthinsen D. Paris.5aday. Sweetman SC. 85 Suppl 1. Fruit portion guide. 1998. Salminen S. Livesey G. 1981. Carbohydrates in Human Nutrition: Report of a Joint FAO/WHO Expert Consultation Rome. 2001. Trop M. Lucas E. International table of glycemic index and glycemic load values: 2002. http://www. Fahey GC. 1986. J Nutr. Paris. 1998. Arjmandi B. FAO Food and Nutrition Paper 66. Behall KM. 27. Evaluation and treatment of constipation in infants and children. Davis PA. 2002. 2002. Chemical composition and potential health effects of prunes: a functional food? Crit Rev Food Sci Nutr. 2006. Stacewicz-Sapuntzakis M. American Journal of Clinical Nutrition.uk/WhatCounts/PortionSizesFruit. Carbohydrate composition of selected plum/prune preparations. Farnsworth NR. FAO Food and Nutrition Paper 66. 1849-1852. Colonic function and fermentation in men consuming high fiber diets. Médicaments à base de plantes. 469-477.uk/WhatCounts/PortionSizesFruit. Piirainen L. Daily consumption of dried plum by postmenopausal women does not cause undesirable changes in bowel function. Holt SHA. FAO (Food and Agriculture Organization of the United Nations). Isr J Med Sci. 22. Foster-Powell K. Smith B. Odes HS. 2007. Hussain EA. Arquitt A. Pilot study of the efficacy of spent grain dietary fiber in the treatment of constipation. Effect of fiber from fruits and vegetables on metabolic responses of human subjects: fiber intakes.nhs. In: Martindale: The Complete Drug Reference. 34. NHS (National Health Services). Korpela R. 53. 1259-1265. fecal excretions. Am Fam Physician. J Agric Food Chem. Paris R and Myose H. 2004. Am J Clin Nutr. Kelsay JL. Fruit portion guide. 1998. 5. Br J Nutr. 14-18 April 1997. 14-18 April 1997. Schneeman BO. Trolinger A. Namir S. S7-16. Tolerance of low-digestible carbohydrates: a general view. Bauer LL.5aday. Gallaher DD. Bäckström K. Soung D. Damayanti-Wood BI. 6 7 8 9 10 11 12 13 14 15 16 ID 1165: “Prunes (dried plums)” and “Can aid satiety/ increase sense of satiety due to NSP content and low Glycaemic index” 1 FAO (Food and Agriculture Organization of the United Nations). Prune juice has a mild laxative effect in adults with certain gastrointestinal symptoms. Brand-Miller JC. Rosacées alimentaires. Les Cahiers de l‘agence n°3. 2004. 73. Kuhnlein H. Gross J. 4. Madar Z. Bowen PE. Prather ES. 41. Ministère de l'Emploi et de la Solidarité. 853-859. Khalil D. 1245. Jr. 511-513. 2001. Daggy B.aspx.ID 1164: “Prunes (dried plums)” and “Normal bowel function/normal gastrointestinal function/normal colonic function” 1 2 3 4 5 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Am J Clin Nutr. 12-15. Peuhkuri K.. Paris. 113. 1983. Goering HK.aspx. Mucano V. Waggoner CR. and apparent digestibilities. 1981. Pharmaceutical Press. 2001. Cahiers de L'Agence. Masson. Hammond L. Editions Tec&Doc. 102 2 3 . 37-43. Dikeman CL. London. Nutrition Research. Fleming SE. Tinker LF.nhs. 21. Allen RH. 2001. Cox H.4 Stacewicz-Sapuntzakis M. 6.032% caffeine. Jequier E. Hussain EA.uk/WhatCounts/PortionSizesFruit. 10..24% glucuronolactone” and “Mood and performance” 5 6 7 8 9 10 1 2 3 Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling for foodstuffs OJ L 276. Consumption of prunes as a source of dietary fiber in men with mild hypercholesterolemia. 2001. Am Fam Physician. Daggy B. 268. S7-16. Nutrition Research. p.aspx. Waggoner CR. 53. 1995. Effects of caffeine ingestion on NE kinetics. Fahey GC.4% taurine and 0. 0. Anantharaman K. Lindenbaum J. Hawley JA. 41.1990. 4 5 6 7 103 . 2004. Fraser SF. http://www. 989-997. Transactions of the American Clinical and Climatological Association. 37. The effects of red bull energy drink on human performance and mood. 85 Suppl 1. Bauer LL. 251-286.nhs. Am J Clin Nutr. Zahorska-Markiewicz B. Berlin. Anderson ME. Calles-Escandon J. and energy expenditure in younger and older men. 1990. Stabler SP. 1995. fat oxidation. Carbohydrate composition of selected plum/prune preparations. Davis PA. J Agric Food Chem. 139-150. 1980. Pittet P. Arjmandi B. Gardner AW. 1259-1265. Acheson KJ. Bruce CR. 2000. 33. 14-18 April 1997. Lucas E. Carbohydrates in Human Nutrition: Report of a Joint FAO/WHO Expert Consultation Rome. Soung D. Chemical composition and potential health effects of prunes: A functional food? Critical Reviews in Food Science and Nutrition. 40–44. 2001. 73. 2001. Korpela R. ID 1166: “Prune Juice” and “Normal bowel function/normal gastrointestinal function/normal colonic function” 1 2 3 4 Biggs WS and Dery WH. 1991. Evaluation and treatment of constipation in infants and children.10. Salminen S. Daily consumption of dried plum by postmenopausal women does not cause undesirable changes in bowel function J Appl Res. 52. Stepto NK. Farnsworth NR. E1192-1198. Arquitt A. République Française. Farnsworth NR. 2006. Int J Sport Nutr Exerc Metab. Tolerance of low-digestible carbohydrates: a general view. 511-513. Hussain EA. Stacewicz-Sapuntzakis M. 1998. Dikeman CL. Amino Acids. High prevalence of cobalamin deficiency in the elderly. Paris. Smith B. Bäckström K. Ministère de l'Emploi et de la Solidarité. 464-475. FAO (Food and Agriculture Organization of the United Nations). Prune juice has a mild laxative effect in adults with certain gastrointestinal symptoms. Schneeman BO. Improved 2000meter rowing performance in competitive oarswomen after caffeine ingestion. Mucano V. 251-286. 4. NHS (National Health Services). Bowen PE. Damayanti-Wood BI. Am J Physiol. Peuhkuri K. 2004. 1998. Hammond L. Hagers Handbuch der Pharmazeutischen Praxis. Springer. 853-859. Br J Nutr. Klein R. Wescott R. Benowitz NL. 2007. Cahier de l'Agence.5aday. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Médicaments à base de plantes: Cahiers de l'Agence no 3. Am J Clin Nutr. Khalil D. 37-43. Livesey G. ID 1169: “Energy drinks containing 0. Bowen PE. Hopkins WG. Piirainen L. Chemical composition and potential health effects of prunes: a functional food? Crit Rev Food Sci Nutr. Alford C. FAO Food and Nutrition Paper 66. 469-477. Damayanti-Wood BI. Trolinger A. Gallaher DD. Poehlman ET. 107. Fruit portion guide. Arciero PJ. Tinker LF. 27. 41. Jr. Apotheker und Ernährungswissenschaftler.) CRC press. Benton D. Toubro S. 164. Fordy J. Tran H. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. 188-192. 191-201. 32. The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. Loew D. Metabolism. 35. Cannon S. Med Sci Sports Exerc. Ruhleder M. Berglund B and Hemmingsson P. Am J Clin Nutr. Fraser SF. Neuropsychobiology. Bridge CA and Jones MA. Bell DG and McLellan TM. Stuttgart. Lübeck. Haller J. Psychopharmacology (Berl). Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Handbook of Nutrition and Food.and caffeine-containing drink on performance and haemodynamics in acyclic trained athletes. metabolic. 1995. 1990. Grigereit A. Feldman EB. Prentice A. Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over. placebocontrolled study of its thermogenic. Effects of caffeine on mood and performance: a study of realistic consumption. Gustav Fischer Verlag. 2001. Burgerstein L. Rucker RB. Int J Sports Med. Madsen J. New York. Breum L. Bougopoulos CL. 2006. Psychopharmacology (Berl). Boca Raton. Graham HN. The impact of long-term vitamin supplementation on cognitive functioning. Thieme Verlag. Schurgast H. JAMA. 2002.). Finch S. 3. Stepto NK. Bruce CR. 2002. (Unpublished). Hein P. Heil S. W. Pentieva KD. J Sports Sci. Exercise endurance 1. J. Baik HW and Russell RM. Munchen. Chemistry and Consumption of the Beverage. Beck WS. 98-105. Enhancement of 2000-m rowing performance after caffeine ingestion. 234-236. 24. 51. Loew D. 117. Haug Fachbuchverlag. 433-439. Anderson ME. Annu Rev Nutr. J Appl Physiol. Apotheker und Ernährungswissenschaftler. Vitamin supplementation for 1 year improves mood. 357-377. Klein R. Omenn GS. Brice CF and Smith AP. 1998. Golly I. Suttie JW. 2000. Goethe University. 2002. In: Caffeine. Beresford SA. 20. 1227-1234. Schümann K. 19. Balentine DA. Stuttgart. 1982. 101-107. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 104 . Ulm Bates CJ. Golly I. Caffeine: a double-blind. 1999. 1995. Nindl BC. Cobalamin (Vitamin B12). Karl F. 274. Machlin LJ (eds. Bernhard M. Vitamin-Lexikon für Ärzte. 2002. Urban & Fischer. CRC Press. Harbowy ME. Fordy J. 1995. In: Handbook of vitamins. 463-512 Bell DG and McLellan TM. Astrup A. Probable benefits of increasing folic acid intakes. and 6 h after caffeine ingestion in caffeine users and nonusers. Br J Nutr. 1348-1354. Berdanier CD. Marcel Dekker. and cardiovascular effects in healthy volunteers. Burgersteins Handbuch Nährstoffe. 298-305. 1997. Motulsky AG. Tea: the Plant and its Manufacture. Bässler KH. Boca Raton. Department of Sports Medicine. Baum M and Weiss M. 1999. Influence of age on the thermic response to caffeine in women. Institute of Sports Sciences. Jena. 2001. Burgerstein UP. Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. Dwyer JT. Hopkins WG. Benton D. 2002. 1958-1963. Spiller GA (ed. Hawley JA. 75-82. Stuttgart. Benowitz NL. McCormick DB. Effect of repeated caffeine ingestion on repeated exhaustive exercise endurance. Boushey CJ.8 9 Arciero PJ. Zimmermann M. Effects of a taurine. Vitamin B12 deficiency in the elderly. Pietrzik K. 93. Vitamin-Lexikon für Ärzte. 1049-1057. 759-767. 2002. 3. Med Sci Sports Exerc. 2003. Pietrzik K. The effect of caffeine ingestion on 8 km run performance in a field setting. Bässler KH. Mansoor MA. 49. Banzer W. 81. Vitamine. Frankfurt am Main. Biesalski HK. 2000. Köhrle J. Haller J. 32. Amino Acids. 15. Eur J Appl Physiol Occup Physiol. 2005. Desbrow B. Ahmaidi S. 1423. 1999. 220-225. Evans WJ. J Appl Physiol. Smith P. 1978. Vandermander J. 64. Geissler CA. Shangari N. Goodpaster BH. Mitochondrial function and toxicity: role of B vitamins on the one-carbon transfer pathways. Bruce CR. 150. Dalsky GP. Macrides TA. Encyclopedia of Human Nutrition. 1998. Olson JA. Willemsen G. Girardier L. Hawley JA. Fink WJ. Referenzwerte für die Nährstoffzufuhr.). Fathi M. Effect of caffeine ingestion on perception of effort and subsequent work production. Prentice A. 155-158. Effects of varied dosages of caffeine on endurance exercise to fatigue. and zinc on psychological well-being in healthy young male volunteers: a doubleblind placebo-controlled trial. 105 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 . 637-643. 113-132. In: Biochemistry of Exercise Conference Proceedings. Chem Biol Interact. 990-999. Chem Biol Interact. Boca Raton. Moss J. Suter M.30 B-Vitamin Treatment Trialists' Collaboration. Psychopharmacology (Berl). Effect of a divided caffeine dose on endurance cycling performance. Knuttgen H. Audran M.Schweizerische Vereinigung für Ernährung). Mehta R. Anderson ME. Herb RA. Human Kinetics Europe. 1040-1045. Bruce WR. 2006. Caffeine and exercise performance. Braz J Med Biol Res. 871-877. 1996. Chantre P. Dulloo AG. Martin DT. Costill DL. 44-50. The effects of an oral multivitamin combination with calcium. Montgomery PG. Vogel JA. Effects of caffeine ingestion on metabolism and exercise performance. Benefits of caffeine ingestion on sprint performance in trained and untrained swimmers. 2004. Caballero B. 31. Mehta R. 69-78. Costill DL. 14-23. Poortmans J (eds. 2003. Baltimore. Hughes M. Levine L. Med Sci Sports. 626-646. Miller DS. In: Sports Nutrition. McElvaney NG. In: Modern Nutrition in Health and Disease Shils ME. Doherty M. Wolinsky I (ed. Roberts A. 1557-1562. O'Brien PJ. Cox GR. Moquin A.). 1999. Conway KJ. Depeint F. Rohrer D. 377-380. Fink WJ. 401-411 Cole KJ. Burke LM. Depeint F. Elsevier. O'Brien PJ. 93. 163. Williams & Wilkins. Ross AC (eds. Duret C. 94-112. 15. 151. 2000. 1983. Shangari N. Davison R. Effects of caffeine ingestion on exercise testing: a meta-analysis. Int J Sport Nutr Exerc Metab. 1989. Cadarette BS. Prefaut C. 581-585. 2004. Doherty M and Smith PM. Scand J Med Sci Sports. 1992. Oxford. 49-83. 2005. Mensi N. Effects of caffeine ingestion on rating of perceived exertion during and after exercise: a meta-analysis. Am J Clin Nutr. J Sports Sci. 2002. magnesium. Cervantes-Laurean D. 14.) CRC Press. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. 2006. Int J Sport Nutr. Horton T. 49. Bruce WR. Berube CL. Carroll D. Niacin. Starling RD. Caffeine lowers perceptual response and increases power output during high-intensity cycling. Effects of caffeine on time to exhaustion in exercise performed below and above the anaerobic threshold. Frankfurt am Main. Effect of different protocols of caffeine intake on metabolism and endurance performance. and plasma paraxanthine. 94. Driskell JA. 22.Österreichische Gesellschaft für Ernährung Schweizerische Gesellschaft für Ernährungsforschung . Powers SK. Leeds. 163. D-A-CH (Deutsche Gesellschaft für Ernährung . Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Stannard SR. postexercise urinary caffeine concentration. 2006. Umschau Braus Verlag. 10. 1993. Dulloo AG. Dodd SL. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. J Appl Physiol. 282-287. Collomp K. Allen L. Trappe SW. Sports Med. Vitamins. Shike M. Collins A. Am J Clin Nutr. Chatard JC. 70. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. An update. 2000. 6. Orr R. Doherty M and Smith PM. The American Heart Journal. Posner BM. 1999. Denadai BS and Denadai ML. Ring C. Can J Appl Physiol. Eugen Ulmer Verlag. 2004. 865-871. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. 1. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine. Lieberman HR. The effects of a low dose of caffeine on cognitive performance. related genetic polymorphisms. French C. 2002. Nehlig A. Geiss KR. Nieto FJ. Kok F. catecholamine. Tipper SP. McGovern PG. Schümann K (eds. Rock PB. Vitamin B12. 1999. Biesalski H-K. Ernährung des Menschen. 433-442. Young PM. Cymerman A. Acute caffeine intake before and after fatiguing exercise improves target shooting engagement time. Borgkvist A. Int J Sports Med. Fine BJ. 63 64 65 66 67 68 69 70 71 72 73 106 . Caffeine and exercise: metabolism and performance. 425-432. Vitamin B6. Biesalski H-K. Holmen J.. van Soeren MH. 83-133. 45-56. Performance and metabolic responses to a high caffeine dose during prolonged exercise. Caffeine ingestion prior to incremental cycling to exhaustion in recreational cyclists. Gregory J. Struder HK. Keefe AA. Ferrauti A. Jester I. 1995. In: Vitamine. Finnish Food Safety Authority. McNaughton LR.). 233-238. http://www. Marlowe B. Frank J. Wiley-Blackwell. Fisone G. Flinn S. 86–90. 539-545. Essig D. Costill DL. 2002. 51. Aviat Space Environ Med. 5. Aviat Space Environ Med. Usiello A. Effects of caffeine or diphenhydramine on visual vigilance. 98. 140. Davies P. 71. Falke W. Schümann K (eds. Effect of caffeine on submaximal exercise performance at altitude. 111-138. 1998. 2292-2298. 1994. Edmunds R. 1998. Hess DL. Vorster H. Psychopharmacology. Amino Acids. Gibney MJ.). Köhrle J. 258-266. Köhrle J. Metabolic. A rapid effect of caffeinated beverages on two choice reaction time tasks. 188-193. Durlach PJ. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Malinow MR. EVM (Expert Group on Vitamins and Minerals). Revision. J Appl Physiol. Rush JW. London. Battig K. Van Handel PJ. 19. Graham TE and Spriet LL. and exercise performance responses to various doses of caffeine.51 52 53 54 55 56 57 58 59 60 61 62 Durlach PJ. Psychopharmacology (Berl). 31. Fulco CS. Weber K. Thieme Verlag. Kobrick JL. Davies P. 2004. 2002. Caffeine ingestion during exercise to exhaustion in elite distance runners. Eckfeldt JH. 75. Pharmacol Rev. 1991. Introduction to Human Nutrition (The Nutrition Society Textbook). J Appl Physiol. Tsai MY. Graham TE. Graham TE and Spriet LL. Cell Mol Life Sci. Circulation. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Trad LA. Tharion WJ. Safe Upper Levels for Vitamins and Minerals. Chichester. 1980. 204-210. Nutr Neurosci. Caffeine as a psychomotor stimulant: mechanism of action. 1994. Elmadfa I and Leitzmann C. Effects of caffeine ingestion on utilisation of muscle glycogen and lipid during leg ergometer cycling. J Sports Med Phys Fitness. International Journal of Sports Medicine. McNaughton L. 1994. 61. Tikuisis P. Davis CE. In: Vitamine. Stuttgart. Gillingham RL. 65. Stuttgart. Folsom AR. Food Standards Agency. 857-872. Hamm M. 867-874. Waag KL. 78. 1991. 1994. Forte VA. Rose MS. Metabolic and ergogenic effects of carbohydrate and caffeine beverages in tennis. Fredholm BB. 2002. Zvartau EE. 1998. 37.evira. 7. 11. 2003. Review of Niacin – Revised Version EVM (Expert Group on Vitamins and Minerals). J Sports Med Phys Fitness. 1990. Frank J. Tristram S. Stuttgart. 116-119. and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Thieme Verlag. Riley RH. Howard L.fi/portal/fi/. 2002. Tristram S. Jr. 1997. The effect of a taurine-containing drink on performance in 10 endurance-athletes. 114. Am J Clin Nutr. Turner AP. coffee and water on alertness. sleep onset and sleep quality. Int J Vitam Nutr Res. 1992. 2001. Evans SM. Graham TE. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. Heishman SJ. Horne JA and Reyner LA. Sathasivam P. Kovacs E. 894-898. Psychopharmacology (Berl). Amino Acids. Kennedy DO. 1999. 1995. Haller J. Cawthorne MA. Graham TE. Graham TE. Homocysteine Lowering Trialists' Collaboration. J Appl Physiol. 252. 1990. Lieberman HR. Stuttgart. 339-350. Caffeine and exercise performance. 1996. Am J Clin Nutr. Hadjicharalambous M. 203-216. Interaction of vitamins with mental performance. Peterson JC. 2005. Rycroft J. Rigney U. Caffeine improves cognitive performance after strenuous physical exercise. J Psychopharmacol. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. 72. 82. Kilduff LP. Hibbert E. 813-825. Lane J. Orthomolekulare Medizin. Wesnes KA. 160-168. Hogervorst E. 21. 13. 2002. Physiol Rev. Physiological actions of taurine. Am J Hypertens. 20. 2000. Westenhofer J. Hewlett P and Smith A. multi-dose evaluation of the acute behavioural effects of guarana in humans. Beneficial effects of an "energy drink" given to sleepy drivers. 2005. 2001. 2000. 20. Low-dose caffeine discrimination in humans. Tsofliou F. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. 9. Gröber U. 316. 316. Georgiades E. Wissenschaftliche Verlagsgesellschaft. 883-889. 1-11. Huxtable RJ. Caffeine and exercise: metabolism. 875-887. In: Nutritional Neuroscience. Kennedy DO. IoM (Institute of Medicine). Scholey AB. 83-89. Scholey AB. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. 85. Milne AL. 970-978. 1998. 2291-2294. 1999. 105-110. Griffiths RR. 2000. 107 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 . Friars D. Pudel V. Kanarek RB. British Medical Journal. Wolf B. Quinlan P. Sannerud CA. Prasad C (eds. Greer F. 2006. J Pharmacol Exp Ther. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Haskell CF. 149. endurance and performance. metabolism and exercise performance following a high-fat meal. 179. Hindmarch I. Wesnes KA. 1998. 101-163. Boca Raton. Hollands MA. 69. Spence JD. Preston KL.74 75 76 77 78 79 80 Graham TE and Spriet LL. 894-898. placebo-controlled. 354-361. 1837-1844. 6570. Homocysteine Lowering Trialists Collaboration. BMJ. Metabolic and exercise endurance effects of coffee and caffeine ingestion. Homocysteine Lowering Trialists' Collaboration.). Influence of caffeine on perception of effort. Woodson PP. 806-812. 43-55. Brouns F. Dietary references for vitamins and minerals. 31. Haskell CF. Riedel WJ. Stanley N. Sports Science Exchange (Gatorade Sports Science Institute). 785807. J Appl Physiol. Kubler W. Bibl Nutr Dieta. 1981. 2005. 22. Jolles J. Pitsiladis YP. Haller J. A naturalistic investigation of the effects of day-long consumption of tea. Hackam DG. Psychopharmacology. CRC Press. Sports Med. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. J Sports Sci. 24. Heseker H. Vitamins and brain function. Hum Psychopharmacol. Comparison of caffeine and theophylline ingestion: exercise metabolism and endurance. 34. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. The vitamin status and its adequacy in the elderly: an international overview. 2007. 2007. 89. 1998. A double-blind. Arch JR. Int J Sports Med. 250-261. J Clin Endocrinol Metab. headache. Prev Med. folate. Shulman GI. 1979. cold and exercise on multiple choice reaction time. sleep loss. Kruk B. James JE. vitamin B12. 1998. J Appl Physiol. biotin and choline. 5. Kendler BS. New York.). niacin. and stress on cognitive performance and mood during U. Sea-Air-Land. Jackman M. Psychopharmacology (Berl). Machlin LJ (eds. Machlin LJ (eds. Vitamin B6. 331-333. Krzeminski K. Johnson D. Shike M. pantothenic acid. Stegen J. Laurent D. 2006. 38. Vogel SM. Psychopharmacology (Berl). Diet-induced mood changes in normal populations. Influence of caffeine. Chmura J. Tharion WJ. 2170-2175. 92. Caffeine for the sustainment of mental task performance: formulations for military operations. In: Handbook of vitamins. Lieberman HR. Friars D. 1998.97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 IoM (Institute of Medicine). 32-41. 17. Med Sci Sports. In: Handbook of vitamins. 2000. Lane JD and Phillips-Bute BG. 245-254. 1987. Acute and chronic effects of caffeine on performance. Ivy JL. 2004. National Academy Press. Psychopharmacology. 164. Krssak M. J Psychiatr Res. Goforth HW. J Appl Physiol. and sleep. 79-100. and endurance responses to caffeine during intense exercise. Lower RW. Marcel Dekker. 1995. Leathwood PD and Pollet P. 18. Pekkarinen H. Kamimori GH. Influence of caffeine and carbohydrate feedings on endurance performance. Appetite. Thorne D. Dietary reference intakes for thiamin. Wendling P. Leklem JE. Coviella ILG. 1658-1663. In: Modern Nutrition in Health and Disease. New York. Kirkland JB and Rawling JM. Caffeine as an ergogenic aid. Brouns F. Rucker RB.). Effects of caffeine on muscle glycogen utilization and the neuroendocrine axis during exercise. 215-219. Vitamin B6. 2002.). Appetite. 1046-1050.S. 45-52. 709-715. 112 113 114 115 116 117 118 119 108 . Costill DL. Lieberman HR. Shils M. Final Technical Report A List of Well Established Nutrient Function Statements. Comparison of changes in energy expenditure and body temperatures after caffeine consumption. Koot P and Deurenberg P. Caffeine deprivation affects vigilance performance and mood. 197-201. 147-154. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology (Berl). 81. Leklem JE. 2nd. 6-11. IoM (Institute of Medicine). Schneider KE. 1998. Lieberman HR. 2003. Multiple caffeine doses maintain vigilance during early morning operations. Suttie JW. Kovacs EM. 65. mood. 110. Wurtman RJ. 157. Tulley R. Rucker RB. McCormick DB. Effects of caffeine. Navy SEAL training. Belenky G. Franklin C. JHCI (Joint Health Claims Initiative). 42. Kennedy DO and Scholey AB. The effects of low doses of caffeine on human performance and mood. Olson J. 2001. 85. 40. Metabolic catecholamine. Keisler BD and Armsey TD. 135-142. Taurine: an overview of its role in preventive medicine. 1998. 2001. 171-175. 2005. Washington DC. 1993. A glucose-caffeine'energy drink'ameliorates subjective and performance deficits during prolonged cognitive demand. 76. Jarvis MJ. Williams & Wilkins. 39. 85. Speckman KL. Marcel Dekker. 2003. Physiol Behav. Ross A (eds. Baltimore. Aviat Space Environ Med. Fink WJ. 11. Nazar K. Kaciuba-Uscilko H. 1996. National Academies Press. Graham TE. riboflavin. Ziemba AW. 1982. Prusaczyk WK. Ann Nutr Metab. brain function and cognitive performance. 2001. Roberts C. Curr Sports Med Rep. Effect of caffeinated drinks on substrate metabolism. 1989. 308-312. and performance. Emde GG. 2001. McCormick DB. Neuropsychobiology. Petersen KF. Shukitt-Hale B. Suttie JW. 1999. vitamin B6. Nutrition. caffeine excretion. Niacin. 2005. 647-654. Bostom AG. Malek MH. 460-466. Savage DG. Studies on vitamin B12 status in the elderly--prophylactic and therapeutic consequences. 17. 207-213. Rucker RB. The influence of caffeine ingestion on incremental treadmill running. 2005. Am J Clin Nutr. 1994. Weir DG. Int J Vitam Nutr Res. Kamimori GH. Healton EB. 72. Scott JM. Podell ER. 99. 109-112. MacIntosh BR and Wright BM. and vitamin B-6 requirements. Allen RH. Circulation. Schroedter A. Garrett TJ. Lukaski HC. 2004. Brunton L. Housh DJ.). 226. Lindenbaum J. 5. Metzner C. 1999. J Strength Cond Res. 2000. 20. Beck TW. Caffeine and related methylxanthines: possible naturally occurring pesticides. Chang HH. 228-233. 20. 181. diet. 598S-606S. Washington DC. Nutrition Research. 1984. 27-38. 188-192. 2004. 73. Effects of eight weeks of caffeine supplementation and endurance training on aerobic fitness and body composition. Loew D. Buxton I. Kamimori GH. McGraw-Hill Professional. Lee BJ. Low-dose folic acid supplementation reduces homocysteine concentration in hyperhomocysteinemic coronary artery disease patients. Caffeine. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. 76. Voss DM. 1555-1572. Strain JJ. 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 109 . Brust JC. Bowman BA and Russell RM (eds. Caffeine and sports activity: a review. 2003. Washington DC. 2001. 168-177. Krauss RM. 2001. 1988. biochemical. Brain Res Brain Res Rev. 751-755. McCormick DB. 24. Homocyst(e)ine. Caffeine maintains vigilance and improves run times during night operations for Special Forces. Malinow MR. 2518–2522. ILSI Press. 182. Br J Sports Med. 253-260. Caffeine ingestion and performance of a 1. Amino Acids. Vitamin B6. Blumenthal D (eds. riboflavin. Arginin und Taurin . Stabler SP. Lorist MM and Tops M. 1995. Bowman BA and Russel RM (eds. Debry G. Science. 20. 26. 15. Bell DG. Huang YC. 2001. 82-94. Manore MM.). Tsai AJ. discussion 180. Lazo J. Brain and Cognition. 2006. Parker K. Ernährungsumschau. McNulty H. Marcell PD. 2006. 53. McKinley MC. 1999.). Coburn JW. McLellan TM. and cognition. Johnson GO. Miller JW. Caffeine and the central nervous system: mechanisms of action. Nathanson JA. 69. and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee. Nutrition. 75. McPartlin J. Pentieva K. Effect of physical activity on thiamine. 2001. Nehlig A and Debry G. Lovett R. In: Present Knowledge in Nutrition. fatigue. American Heart Association. Water-soluble vitamins. 1995. Caffeine improves physical performance during 24 h of active wakefulness. Marcus R and Coulston AM. 139-170. Int J Sports Med. 666-672. 1996. Lowdose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. 20. Rogers LM. Vitamin and mineral status: effects on physical performance. 178-182. Johnson D. Wanitschke R. 1986. ILSI Press. McNaughton LR. 632-644. 215-223. Cole KG.präventive Nahrungsfaktoren bei kardiovaskulären Erkrankungen. 1992. Aviat Space Environ Med. Housh TJ. 759-764. Nutrition. In: Goodman and Gilman‘s: The Pharmacological Basis of Therapeutics. Taurine modulates kallikrein activity and glucose metabolism in insulin resistant rats. 22. 2002. 11. Nehlig A. McLellan TM.120 Lin PT. Nandhini AT and Anuradha CV. Panthotenic Acid In: Present knowledge in Nutrition. Ward M. Aviat Space Environ Med. Schmidt RJ. Daval JL. metabolic and psychostimulant effects.500-metre swim Can J Appl Physiol. Cheng CH. Bell DG. 184-187. Coffee: The demon drink? New Scientist. Am J Clin Nutr. 2. 2002. Baltimore. 46-53. NNR (Nordic Nutrition Recommendations). 213-219. Miller DP. Rumpler W. Nissen SE. Curr Sports Med Rep. Colditz GA. Kamimori G. Rogers NL and Dinges DF. Nutr Neurosci. Caffeine reversal of sleep deprivation effects on alertness and mood. Roth T. 263. 1995. van Lente F. Ross AC (eds. Plesofsky NS. 2000. Savon SR. Hennekens C. Palma-Reis R. 317-337 Plesofsky-Vig N. 351. Schieberle P (eds. Hyperhomocysteinemia and low pyridoxal phosphate. Mayer EL. Lancet.). 1993. Robinson K. Pickett JP. Alerting effects of caffeine after normal and restricted sleep. 1998. Neuropsychopharmacology. Wiley E. Penetar D. Seale J. Med Sci Sports Exerc.) Houghton Mifflin. Am Chem Society. Park S and Johnson MA. peripheral vascular disease. Galinski C. McCormick DB. Moore KL. Ueland P.142 Nehlig A. Hu H. MA. 64. Rao A. Kottke-Marchant K. Sawaki T. Zwyghuizen-Doorenbos A. Hosoda K. Washington DC. Vollebregt L. Clin Sports Med. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Hopkins WG. Plath D. 359-364. Manson JE. 2005. Refsum H. Clevidence B. In: Caffeineated beverages: Health benefits. Boers G. Pasman WJ. Oolong tea increases metabolic rate and fat oxidation in men. In: Handbook of vitamins. Pantothenic Acid. van Baak MA. Int J Sports Med. Yamamoto S. 19-28. 1999. Aspen J. 373-378. Caffeine and exercise. physiological effects. Caffein. 225-230. Robinson K. Caffeine effects on the brain and behaviour: A metabolic approach. Selhub J. Rycroft JA. Williams & Wilkins. Rucker RB. J Nutr. Kutner M. Daly L. 1998. Judd J. Brattstrom L. Efficacy of a functional energy drink' in counteracting driver sleepiness. 1998. Shike M. Rimm EB.). Thomas M. 2825-2830. Marcel Dekker. 2001. Editors of The American Heritage Dictionaries (ed. 331-335. and coronary artery disease. Shils ME. 97. Jacobsen DW. Ishikura Y. 423-432 Quinlan PT. Suttie JW. Olson JA. 2000. Little effect of caffeine ingestion on repeated sprints in teamsport athletes. 75. 2848-2852. Rogers PJ and Dernoncourt C. Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. Stampfer MJ. In: Modern Nutrition in Health and Disease. 359-365. Meleady R. Physiology & Behavior. Witteman J. Ho C-T. 822-825. Machlin LJ (eds. 2006. Rubba P. Hu FB. 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 110 . Jeukendrup AE. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. Lane J. New York. Circulation. Caffeine: implications for alertness in athletes. 59. Roehrs T. 24. Paton CD. In: The American Heritage Dictionary of the English Language. Green R. 112. Common and independent reversible risk factors for coronary artery disease. 141-153. Low circulating folate and vitamin B6 concentrations: risk factors for stroke. e113. Reyner LA and Horne JA. McCann U. 2000. Boston. 92. Nordic Council of Ministers. Arheart K. 1039-1045. 2001. Rosenthal L. Peterson JC and Spence JD. Willett WC. Graham I. Sing H. 1995. de Haan A. 8. Topol EJ. Psychopharmacology (Berl). Nobre A. 2005. Gupta A. What is an adequate dose of oral vitamin B12 in older people with poor vitamin B12 status? Nutr Rev. The effects of combined caffeine and glucose drinks on attention in the human brain. 279. Pharmacol Biochem Behav. Pantothenic acid. and chemistry. 2004. JAMA. Circulation. European COMAC Group. Belenky G. O'Brien DC. 33. 4. The effect of different dosages of caffeine on endurance performance time. The acute physiological and mood effects of tea and coffee: the role of caffeine level. Integrating nutrition and physical activity. Pharmacol Biochem Behav. Paluska SA. 1991. Parliment TH. 103-108. 2003.). Sampson L. 2001. Thorne D. 1998. 131. Copenhagen. Komatsu T. 16. 66. 437-443. 2002. vitamin B12. and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. Med Clin North Am. 2001. 2003. Smit HJ and Rogers PJ. Ross C. Thomas M. The association of caffeinated beverages with blood pressure in adolescents. Grady ML. SCF (Scientific Committee of Food) 2000.163 164 165 166 167 168 169 170 171 172 173 Ryu S. Santalla A. Jpn J Physiol. 167-173. 38. Effects of low doses of caffeine on cognitive performance. Harshfield GA. Joung SS. SCF (Scientific Committee on Food). Cousins R. 973-979. 2004. 1990. 19. Ishiko T. 261-265. Hackett LP. Schnyder G. homocysteine. Effect of homocysteine-lowering therapy with folic acid. Int J Sports Med. Cha YS. especially for sportsmen. Rogers PJ. Bagley LC. Maeda J. Neuropsychobiology. Turi ZG. Rogers PJ. 139-146. 635-642. Miller J. glucose and carbonation. Sasaki H. 84. 91. 2000. Med Sci Sports Exerc. 288. Brockman P. Seidl R. 761-764. 27. 2002. Nicham R. San Diego. 614S-620S. Opinion on the Tolerable Upper Intake Levels of Nicotinic Acid and Nicotinamide (Niacin) Schneiker KT. 2006. Hess OM. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. Baltimore. 1265-1269. 217-223. 1993. Encyclopedia of Human Nutrition. 158. 2002. 578-585. Ludwig DA. Smith AP. Scholey AB and Kennedy DO. 2004. Lim K. Selhub J. B vitamins. SCF (Scientific Committee on Food). Wilson ME. 152. Hughes SC. 176. 47. Choi SK. Pin R. Hauser E. Smit HJ. Cognitive and physiological effects of an ―energy drink‖: an evaluation of the whole drink and of glucose. 2006. Savory M. Homocysteine. Hughes SAC. 2000. J Nutr Sci Vitaminol (Tokyo). 2000. JAMA. 127-139. Flammer Y. 215-237. Am J Clin Nutr. Sadler MJ. 111 174 175 176 177 178 179 180 181 182 183 184 185 . Suh H. Amino Acids. Lucia A. Flammer Y. 51. 1999. 2001. Rusted JM. Physiology & Behavior. Effects of sucrose or caffeine ingestion on running performance and biochemical responses to endurance running. B vitamins. Takaoka I. Role of familiarity on effects of caffeine-and glucose-containing soft drinks. Effects of caffeine on prolonged intermittent-sprint ability in team-sport athletes. Smit HJ and Rogers PJ. 71. Mood and cognitive performance effects of "energy" drink constituents: caffeine. 287-297. 23. and coronary artery disease. Perez M. 8. Hess OM. 8. Seshadri N and Robinson K. Philadephia. Caballero B. 203-207. Academic Press. Flynn R. Maben A. Smith AP. Meier B. 320-330. Nutritional Neuroscience 7. Ishiko T. Caballero B. Int J Sports Med. Savoca MR. Shike M. Investigation of the effects of coffee on alertness and performance during the day and night. Leathwood P. Effects of ‗energy‘drinks on mood and mental performance: critical methodology. Shils M. 2000. Modern Nutrition in Health and Disease. Roffi M. Pin R. 2006. Lee S. Food quality and preference. Schnyder G. mood and thirst in low and higher caffeine consumers. Sasaki H. Eaton-Williams P. Opinion on the Tolerable Upper Intake Levels of Vitamin B12. Cotton JR. Lippincott Williams & Wilkins. 13. Eberli FR. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Arch Pediatr Adolesc Med. Psychopharmacology. 160-163. Bishop D. 87. 2001. Effects of caffeine given before and after lunch on sustained attention. Am J Cardiol. Usui S. Rosenberg IH. Cotton JR. Psychopharmacology. 473-477. and neurocognitive function in the elderly. Neuropsychobiology. x. 317-326. Evans CD. 2004. Roffi M. Finnegan YE. Effect of sucrose and caffeine ingestion on performance of prolonged strenuous running. 1987. Strain JJ. Composition and specification of food intended to meet the expenditure of intense muscular effort. Caffeine ingestion attenuates the VO(2) slow component during intense exercise. Dawson B. A taurine and caffeine-containing drink stimulates cognitive performance and well-being. caffeine and herbal flavouring fractions. Peyrl A. 1987. Smit HJ. Vitamin B(12) and folate in relation to the development of Alzheimer's disease.. Nassar BA. 85. Int J Sport Nutr. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Sweeney E. 1995. 1243-1255. Wiles JD. 813-819. Vitamin B12 In: Present knowledge in Nutrition. Hopkins WG. Ross AC (eds. Kapoor SC. vitamin status and risk of vascular disease. Wang HX. Baltimore. Boers GH. Graham IM. Cairns SP. Wemple RD. Ernährungsumschau. Washington DC. 2001. effects of gender and menopausal status. Wahlin A. 1998-2005. Weir DG and Scott JM. J Am Coll Cardiol. Effects of caffeine on human behavior. Tagliabue A. 2002. Spiller GA. 5. Coleman D. 1195-1204. Neurology. 2005. 2000. Genest JJ. Westerterp-Plantenga MS. 1999. Effects of caffeine on cognition and mood without caffeine abstinence. Zijdewind I. Caffeine ingestion and muscle metabolism during prolonged exercise in humans. 758765. Hultman E. Daly LE. Dyck DJ. 230-240 Stehle P. 1994. Cena H. CRC press. Immunonutrition Nährstoffe mit immunmodulierender Wirkung. Effects of caffeine ingestion on exercise-induced changes during highintensity. Int J Obes Relat Metab Disord. J Appl Physiol. Stuart GR. Shike M. 37-44. Robinson K. Basun H. Aengevaeren WR. Winblad B. 1165-1171. 24. 2005. 40. 47. 18. Lebensmittel-Lexikon. 2001. Lamb DR. Mullington JM. Boers GH. Am J Physiol. 2001. Cederblad G. 1188-1194. Eur Heart J. Tegerdine M. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. and catecholamine responses after withdrawal. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. 2001. 1998. J Am Coll Cardiol. Shils ME.). 158. Sleep. Cook C. MacLean DA. Willems FF. Szuba MP. 195 196 197 198 199 200 201 202 203 204 205 206 207 112 . 216-222. Spriet LL. Blom HJ. 1998. intermittent exercise. 2006. 1999. Coffee induced thermogenesis and skin temperature. Kovacs EM. Vitamin B12 ―cobalamin‖. Title LM.186 187 188 189 190 191 192 193 194 Smith A. Turconi G. Giddens K. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. 1995. McKeever KH. Trice I and Haymes EM. Meleady R. 447-458. Psychopharmacology (Berl). Caffeine. Warburton DM. 13. 18. Psychopharmacology (Berl). J Sports Sci. E891-898. 2000. Homocysteine. Fratiglioni L. Psychopharmacology (Berl). 1234-1244. Bowman BA and Russel RM (eds. In: Modern Nutrition in Health and Disease. Lejeune MP. 40-46. Bersellini E. Tunger L. Täufel A. 180. 537-541. 539-547. Swaine IL. Warburton DM. Verhoef P. Med Sci Sports Exerc. Zobel M. Int J Sports Med. Obes Res. Montomoli C. speed and power during a laboratory-based 1 km cycling time-trial. Van Dongen HP. Food Chem Toxicol. Terracina D. 37.). memory and information processing in healthy volunteers without caffeine abstinence. Multiple effects of caffeine on simulated high-intensity team-sport performance. Hamburg. An evaluation of a caffeinated taurine drink on mood. Cummings PM. Price NJ. 1997. Jr. 56. 36. Ternes W. Boca Raton. Dinges DF. van Duinen H. ILSI Press. Verheugt FW. 1493-1501. exercise endurance. Stabler SP. 40. 2005. Graham TE. Williams & Wilkins. 2005. 66-70. Fastbom J. European COMAC Group. Olson JA. The effects of caffeine ingestion on performance time. Van Soeren MH and Graham TE. The effect of caffeine on cognitive task performance and motor fatigue. 262. 1992. Lanzola E. 24. Lorist MM. 322-328. 119. Effect of caffeine on metabolism. Behr's Verlag. 2002. 20. 766-772. Baggen M. Nabb S. Farina C. 51-56. Ochiai N. Maggioni M. 130-134. Mistlberger G. Gerke S. Benton D. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Crepaldi G. 99-103. Study finished in May 2006. Miyazaki T. Fiori MG. Kathmann N. Sanderson JE. Buss C. Clin Trials J. Cenacchi T. 119-126. Hippius H. Chan LL. LacprodanÒPL-20” and “Minskning av stress Förbättrad minnesfunktion Stress reduction Enhanced memory function” 1 2 3 4 5 Allegro L. Effects of taurine administration in rat skeletal muscles on exercise. 169-178. Funfgeld EW. Metreweli C. 209 210 211 ID 1175: “Mjölkprotein-koncentrat med högt innehåll av fosfolipider (effektiv komponent fosfatidylserin). Amaducci L. Thomas GN. 1989. 1987. 24. 2002. Amino Acids. Gunther W. 2004. Chook P. Yatabe Y. Izumi I. 24. Cheung AS. 215-226. 1998. Neuropsychobiology. Intervention study (N=46). 24. Yamagami T. 97. 123-133. 415-419. The effects of phosphatidylserine in patients with mild cognitive decline. Phosphatidylserine in elderly patients. Prog Clin Biol Res. Sacerdote P. J Orthop Sci. Wells C. Satzger W. 1987. 6 7 8 9 10 11 12 13 14 113 . 2003. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. placebo-controlled multicenter study on efficacy of phosphatidylserine administration. An open study. 24. 1987. Engert V. Favaretto V. Hellhammer J. Massari DC. Am J Med. Brambilla F. Miyakawa S. 535-539. Oral phosphatidylserine in elderly patients with cognitive deterioration. 203207. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Data in preparation . 12. Nutr Health. Kagamimori S. Matsuzaki Y. Qiao M. Munch U. Liu Z. 5. 1235-1246. 1993. 1995. (Effective component: Phosphatidyl serine). Nedwidek P. 309-313. 2. Bertoldin T.208 Woo KS. Brambilla F and Maggioni M. Bove D. 1992. Sacerdote P. 2006. 2001. Zhang M. Blood levels of cytokines in elderly patients with major depressive disorder. Aging (Milano). Effects of phosphatidylserine in Alzheimer's disease. Cenacchi T. 7. Clinical Trials Journal. 112. 109-114. Donohoe RT. Panerai AR. 317. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients--effects of phosphatidylserine therapy. Fries E. Petrie W. 18-21. 1992. Ziliotto G. Sokejima S. 149-155. Panerai AE. Stress. Acta Psychiatr Scand. placebo in patients with early dementia of the Alzheimer type. Milk protein concentrate with a high content of phospholipids. Hellmann J. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Engel RR. Eur Neuropsychopharmacol. 1988. Nutr Neurosci. Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men. Brambilla F. Clinical Trials Journal. 34. T-lymphocyte proliferative response to mitogen stimulation in elderly depressed patients. Maggioni M. J Affect Disord. Qi B. 28. Celermajer DS.confidential. 36. Rutenberg D. An open trial. 8. Hellhammer D. Tuch A. 104-108. 61-66. The danger of B12 deficiency in the elderly. Sillance B. Doubleblind cross-over study of phosphatidylserine vs. Crook T. Cognitive decline in the elderly: a doubleblind. Caffarra P and Santamaria V. 1996. Cenacchi T. 1998. Wynn M and Wynn A. Psychopharmacol Bull. 26. Granata Q and Di Michele J. Richstein B. 4. Lolin YI. Psychopharmacol Bull. Fung WH. 2004. Natale M. Gualtieri S. ID 1179: “Rye bread” and “Carbohydrate metabolism and insulin sensitivity” 16 17 18 19 20 21 1 2 Brand JC. Am J Clin Nutr. Piironen V. Korhola M. Kekalainen J. 175-186. Uusitupa M. Mykkanen HM. 254-262. 265270. Josse RG. Poutanen KS. Int J Food Microbiol. Katina K. Kemali D. Aittamaa M. High-fiber rye bread and insulin secretion and sensitivity in healthy postmenopausal women. Katina K. 37. 1992. Pennisi G. 1990. Am J Clin Nutr.15 Maggioni M. 2004. Niskanen LK. Piironen V. Cognitive decline in ageing brain. 24. Crossman S. Poutanen K. 137-142. Vahteristo L. Niskanen LK. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Liukkonen KH. Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENUT Study. Oppenheim Y. 24. Clin Trials J. Salmeri G. 516-520. 1986. Structural differences between rye and wheat breads but not total fiber content may explain the lower postprandial insulin response to rye bread. Mykkanen HM. Am J Clin Nutr. Clin Trials J. 104-112. Holst JJ. Juntunen KS. 2005. Wong GS. 24. Heinonen SM. Diabetes Nutr Metab. Trends in Food Science & Technology. 2003. Ransmayr G. Poutanen K. 77. Landberg R. Cereal Chemistry. Kampf-Sherf O. Katina K. Clin Trials J. 46. Postprandial glucose. Kolehmainen M. Schreiber S. "Brain-specific" nutrients: a memory cure? Nutrition. 62-72. Katina K. Jenkins AL. and incretin responses to grain products in healthy subjects. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. 81. Beinat L. Kaukovirta-Norja A. 2002. Piironen V. Kelly D. 106. Autio K. 1987. Salopuro T. Effects of yeasts and bacteria on the levels of folates in rye sourdoughs. Potential of sourdough for healthier cereal products. 78. 3 4 5 6 7 8 9 10 11 114 . 2007. Isr J Psychiatry Relat Sci. Juntunen KS. Therapeutic approach with phosphatidylserine. 19. Juvonen R. Niskanen L. 957-964. Poutanen KS. Low glycemic response to traditionally processed wheat and rye products: bulgur and pumpernickel bread. Kariluoto S. An open trial of plantsource derived phosphatydilserine for treatment of age-related cognitive decline. 302-307. Eur J Clin Pharmacol. 385-391. Liukkonen KH. Double-blind placebo-controlled trial of phosphatidylserine in elderly subjects with arteriosclerotic encephalopathy. Merlo P. Villardita C. Salovaara H. Monteleone P. 137-143. The glycaemic and insulin indices of realistic meals and rye breads tested in healthy subjects. Flander L. Foster KA. 3. Acta Psychiatr Scand. Giudici S. McDaniel MA. Picotti GB. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Grioli S. Lampi AM. Agostinis C. Poutanen KS. Poutanen KS. 2007. Kariluoto S. Aman P. Food Microbiol. Truswell AS. 2007. 348-355. Pulkkinen L. 134-139. Laaksonen DE. 2003. Vahteristo L. 1987. Jenkins DJ. Liukkonen KH. 84-93. Am J Clin Nutr. Laaksonen DE. Effect of baking method and fermentation on folate content of rye and wheat breads. Cenacchi T. 24. Salovaara H. Bran fermentation as a means to enhance technological properties and bioactivity of rye. Nobile P. Niskanen LK. 85. Poutanen K. Journal of Cereal Science. Am J Clin Nutr. Mancuso A. 2000. 957-975. Lerer B. Mykkanen HM. Einstein GO. 1987. Fermentation-induced changes in the nutritional value of native or germinated rye. 115-124. Maier SF. Maj M. 16. 1417-1427. Mauri M. 43. Kallio P. 75. Nicoletti F. Laitila A. Liukkonen KH. 2006. Kalmusky J. Mykkanen HM. Brambilla F. Gorfine M. Liukkonen KH. Arendt E. Kariluoto S. insulin. 2003. Holst JJ. Pihlava JM. Sivenius K. 42. Laaksonen DE. 81. 1990. 385-388. Autio K. Adlercreutz H. Panerai A. Giordano C. Savolainen KE. Thompson LU. Sinforiani E. Wolever TM. Bondiolotti GP. Juntunen KS. Liukkonen KH. J Am Dent Assoc. Niskanen L. 2005. 10.vtt. The effect of chewing sorbitol-sweetened gum on salivary flow and cemental plaque pH in subjects with low salivary flow. Lampi AM. http://rye. 27.Oral Health Policies. Axell T. Barnes VM. Lundin EA. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. Hallmans G. 58. Chapter I Food and Drug Administration Departement of Health and Human Services. J Clin Dent. Effect of chewing xylitol chewing gum on salivary flow rate and the acidogenic potential of dental plaque. Am J Clin Nutr. 1-5. Code of Federal Regulations. Zhang JX. 39-43. Eur J Clin Nutr. Juntunen KS. 116-127.). Chewing gum and a saliva 115 2 3 4 5 6 7 8 9 10 11 12 . 2001. Liukkonen KH. Katina K. Barton J. Veerman EC. 1990. 1218-1227. Likkonen K. 262267. 53. 2005. Xu T. Birkhed D. 129. Poutanen K. Subchapter B Food for Human Consumption Part 101 Food labeling Subpart e 101. Policy on the Use of Xylitol in Caries Prevention. Nurmi T. Rye bread decreases postprandial insulin response but does not alter glucose response in healthy Finnish subjects. 1169-1170. Vos PF. 2006. Ada Position and Statement: Role of Sugar-Free Foods and Medications in Maintaining Good Oral Health. Proskin HM. Hietaniemi V. ADA (American Dental Association). 85. Aman P. 136-137. Wilhelmsson A. Nieuw Amerongen AV. Proc Nutr Soc. Bartels CL. 55-59. Mandel ID. Salsberg SL and Ludwig DS. Toppinen LK. 1623-1626. ID 1181: “Xylitol-sweetened chewing gum” and “Mouth. Uusitupa M. Brand HS. Process-induced changes on bioactive compounds in whole grain rye. Mykkanen HM. Ylönen K. AAPD (American Academy of Pediatric Denstistry). 1998. Kariluoto S. Bjornstrom M. Adlercreutz H. Proskin HM. Reference Manual . Autio K. Liukkonen KH. Hallmans G. Abelson DC. Poutanen K (eds. A multi-centre study. Aguirre-Zero O. 1999. Groop LSM.VTT International Symposium. 2004. 3-5. Acta Odontol Scand. 117-122. Food and Drugs. Myllymaki O. Xylitol candies in caries prevention: results of a field study in Estonian children. 14. The intake of rye is directly related to insulin sensitivity among nondiabetic relatives of subjects with type 2 diabetes . Caries Res. Zero DT. Gutmann K. Lairon D. Leinonen K. Richter R. 2003. Eur J Clin Nutr. Clinical evaluation of the anti-plaque effect of a commercial chewing gum. http://www.12 Laaksonen DE. Health and Functionality. VTT (Technical Research Centre of Finland). Piironen V. Helping patients with dry mouth.80 Dietary Noncariogenic Carbohydrate Sweeteners and Dental Caries. Katz BP. 2005. Pihlava JM.fi. Bots CP. J Clin Dent. Diabete Metab. In: Whole Grain and Human Health . teeth” 13 14 15 16 17 18 19 1 Title 21. Putting your genes on a diet: the molecular effects of carbohydrate. Santarpia P. Aro A. Swed Dent J. 30. 31-32. Lithner F. 2001. Dietary carbohydrate modification enhances insulin secretion in persons with the metabolic syndrome. Birkhed D. Boneta AE. 218-224. The effect of chewing sugar-free gum after meals on clinical caries incidence. Espoo. Valentijn RM. 16. Nygren C. Rye: Nutrition. 1994. Effects of meal frequency and high-fibre rye-bread diet on glucose and lipid metabolism and ileal excretion of energy and sterols in ileostomy subjects. Mykkanen H. Poutanen KS. Beiswanger BB. Am J Clin Nutr. 2000. 1990. 1410-1419. 1993. 2007. 82. 1984. Kuokka A. Tidehag P. Van Amerongen BM. Isokangas P. Stookey GK. 62. Liukkonen K. Valentijn-Benz M. 153-161.htm.oralcancerfoundation. Korevaar JC. 2. Adlercreutz H. Bezemer PD. ter Wee PM. 28.org/dental/xerostomia. Bijlsma JA. Nordic Rye Research Group. Effects of high-bran bread on blood glucose control in insulindependent diabetic patients. Heinonen SM. Poutanen K. Cariologic aspects of xylitol and its use in chewing gum: a review. 52. Curtis J. Peltoketo A.the Botania dietary group. Community Dent Oral Epidemiol. Alanen P. Mau MS. and xylitol-sweetened chewing gum in caries control. 3. Isokangas PJ. 239-245. Three clinical trials comparing xylitol. Twetman S. Pienihakkinen K. Occurrence of dental decay in children after maternal consumption of xylitol chewing gum. 1994. Makinen PL. Soderling E. Caries Res. 17. Mannisto H. Edgar WM. 1991. chewing gum and dental caries--a review. 18851889. Isokangas P. J Am Dent Assoc. Saliva and dental health. Dawes C. J Am Dent Assoc. J Am Dent Assoc. Cronin M. Featherstone JD. Dental plaque formation and salivary mutans streptococci in schoolchildren after use of xylitol-containing chewing gum. 1999. J Dent Res. Long-term effect of xylitol chewing gum on dental caries. Chen CY. 107. Isokangas P.and sorbitolcontaining chewing gums for their effect on supragingival plaque accumulation. Jensen ME. 1993. Community Dent Oral Epidemiol. Saliva and Oral Health. Clinical implications of saliva: report of a consensus meeting. J Clin Dent. 262-266. J Clin Dent. 13 14 15 16 17 18 19 20 21 22 Burt BA. Makinen KK. Isotupa KP. 117. Saliva stimulation and caries prevention. Frohlich S. Maiwald HJ. 1994. 20. 405-419. Responses of interproximal plaque pH to snack foods and effect of chewing sorbitolcontaining gum. 113. Tiekso J. J Clin Dent. Manning RH. J Am Dent Assoc. 887-899. The optimum time to initiate habitual xylitol gum-chewing for obtaining long-term caries prevention. Allen P. Nephrol Dial Transplant. 8. Edgar WM. 8. 190-196. 444-448. 83 Suppl 1. Isokangas P. Br Dent J. 29-32. Proc Finn Dent Soc. Hujoel PP. 75-78. Makinen KK. Tiekso J. 23 24 25 26 27 28 29 30 31 32 33 116 . A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. 169. 197-203. Isotupa KP. 159-162. 27. 79-85. Chewing gum and saliva in oral health. Int J Paediatr Dent. 1997. 1990. Gunn S. Soderling E. J Dent Res. 2004. 797-803. 1988. Dental caries and mutans streptococci in the proximal areas of molars affected by the habitual use of xylitol chewing gum. Br Dent J. Holgerson PL. Alanen P. Imfeld T. Higham SM. A longitudinal study on Finnish school children. 1987. Bennett CA. Alanen P. Itthagarun A and Wei SH. 1986. 79. 1992. Balbo F. Makinen KK. Sjostrom I. 200-203. Reardon R. 495-498. Makinen KK. 25. Gordon J. 578584. Stecksen-Blicks C. 2007. 78. Caries Res. Chewing gum--facts and fiction: a review of gum-chewing and oral health. 1989. The use of sorbitol. Lopatin D. 2000. Isokangas P. Makinen KK. British Dental Association Publication. Isokangas P. a follow-up from 0 to 5 years of age. 1999. 1-117. Effect of polyol gums on dental plaque in orthodontic patients. Adv Dent Res. Crit Rev Oral Biol Med. Alanen P. Flowerdew G. 96-98. The science and practice of caries prevention. 14. Sugar substitutes. Isokangas P. 5. Edgar WM. Effect of gum chewing on the pH of dental plaque. Am J Orthod Dentofacial Orthop. Alanen P. Tenovuo J. 497-504. Xylitol chewing gum in caries prevention. 131. 184. 1995. Palliat Med. 137. 17. 2006. Davies AN. 10. 106-109. Long-term effect of xylitol chewing gum in the prevention of dental caries: a follow-up 5 years after termination of a prevention program.substitute alleviate thirst and xerostomia in patients on haemodialysis. Tiekso J. 1998. London. 2000. 315-320. O'Mullane DM. Makinen KK. 2000. Xylitol chewing gum in caries prevention: a field study in children. Edgar WM. 41. Baseline prevalence and 32-month caries increment. Jr. J Am Coll Health. Bennett CA. Jr. 46. Petaja J. 23. Jensen ME and Wefel JS. Makinen KK. 61. 167. Int Dent J. Makinen KK. Effect of gum chewing following food ingestion on the pH of interproximal dental plaque. Makinen PL. Caries Res. J Clin Dent. Peldyak J. Sugar. Isotupa K. 69. 1990. Makinen KK. Leach SA. Toth Z. 1988. Vegh A. Finland. Stabilisation of rampant caries: polyol gums and arrest of dentine caries in two long-term cohort studies in young subjects. Acta Odontol Scand. I. Quintessence Int. Soederling E. 2002. 68. Kivilompolo T. Makinen KK. Xylitol chewing gums and caries rates: a 40-month cohort study. [Effect of sugared and sugarfree chewing gum on plaque pH]. 187-193. 1987. Kandelman D and Gagnon G. Br Dent J. sorbitol of sucrose. Properties of whole saliva and dental plaque in relation to 40-month consumption of chewing gums containing xylitol. Pape HR. 1989. Use of xylitol chewing gum in daycare centers: a follow-up study in Savonlinna. Human plaque pH responses to meals and the effects of chewing gum. Isotupa KP. 22. Zahn Mund Kieferheilkd Zentralbl. 1992. Bennett CA. Polyol chewing gums and caries rates in primary dentition: a 24-month cohort study. 172-180. Prevention of sucrose-induced demineralization of tooth enamel by chewing sorbitol gum. J Dent Res. Effects of chewing sorbitol gum on human salivary and interproximal plaque pH. Murtomaa S. Makinen PL. Bar A. 194. Pape HR. Caries Res. Kandelman D.. 93-107. Maiwald HJ. 2003. 408-417. Clinical results after 12 months from a study of the incidence and progression of dental caries in relation to consumption of chewing-gum containing xylitol in school preventive programs. Allen P. Bennett CA. Allen P. Makinen PL. 1995. Lee GT. J Dent Res. Makinen KK.. 1989. Remineralization of artificial caries-like lesions in human enamel in situ by chewing sorbitol gum. 74. 1904-1913. Bennett CA. J Dent Res. 1. Toivanen J. Bennett CA. Caries Res. 68. 455-459. 22-34. 1996. Isokangas PJ. 30. Isokangas P. Hujoel PP. 2003. 107-112. Isokangas PJ. Isotupa KP. 1988. Isotupa KP. 1771-1775. Chen CY. Allen P. Makinen PL. Int Dent J. 32. Collaborative WHO xylitol field study in French Polynesia. 1989. 1982.. 6-19. Edgar WM. A dietary procedure for preventing dental caries in young adults. 1407-1411. S121-128. 55-62. Makinen PL. 22. 598-604. Caries Res. 1064-1068. Conclusion and review of the Michigan Xylitol Programme (1986-1995) for the prevention of dental caries. 180-188. Pape HR. Isotupa KP. 77 Suppl 1. J Dent Res. Makinen KK. Soderling E. Maguire A and Rugg-Gunn AJ. 1998. Yaskell T. Makinen KK. Isokangas PJ. Bennett C. 1996. 70. Alanen P. Kovari H. Kashket S. 45. Kandelman D. Hujoel PP. 1997. Makinen PL. Hujoel P. 1993. mutans levels in plaque and saliva of patients with mental retardation. Tietze W. 1996. The effect of polyol-combinant saliva stimulants on S. Isotupa KP. Makinen KK. Hujoel PP. Kandelman D and Gagnon G. Lopez LR. 460-462. Jr. 66. 367-370. A descriptive report of the effects of a 16-month xylitol chewing-gum programme subsequent to a 40-month sucrose gum programme. Lee IK and Schachtele CF. 30. Isokangas PJ. Pienihakkinen K. Br J Nutr. 1995. Isotupa KP.34 35 36 Jensen ME.. 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 117 . 204-208. Pape HR. Pape HR. Hefti A. 429-436. J Dent Res. Banoczy J. A 24-month clinical study of the incidence and progression of dental caries in relation to consumption of chewing gum containing xylitol in school preventive programs. Makinen PL. Xylitol and caries prevention--is it a magic bullet? Br Dent J. alternative sweeteners and meal frequency in relation to caries prevention: new perspectives. Jr. Spec Care Dentist. 1992. Manning RH and Edgar WM. 1993. 2001. Scheinin A and Mäkinen KK. 1991. 14. 35. Sanders PG. 33-40. 1989. antiplaque and antigingivitis effects of xylitol and sorbitol sweetened chewing gum. 80. Isokangas P. Odusola F. Bolton JW. 65-76. Effect of sorbitol gum chewing on plaque pH response after ingesting snacks containing predominantly sucrose or starch. Salivary stimulation by chewing gum and lozenges in rheumatic patients with xerostomia. Schemehorn BR. Effect of after-meal sucrose-free gum-chewing on clinical caries. Tanzer JM. 3. Tenovuo J. NIDCR (National Institute of Dental and Craniofacial Research). Jr. xylitol. Szoke J. 25. Banoczy J. Chen CY. Effect of time and duration of sorbitol gum chewing on plaque acidogenicity.htm. 1975. Salivary stimulation by chewing gum and its role in the remineralization of caries-like lesions in human enamel in situ. 173177. Effect on plaque of a xylitol-containing chewing-gum. Mouton C. and their modification by chewing sugared.or sugar-free gum. 104-109. 40-43. 197-202. Isokangas P. NY State Dent J. pH changes in plaque after eating snacks and meals. Makinen KK. Caries Res. Effects of chewing gums sweetened with sorbitol or a sorbitol/xylitol mixture on the remineralisation of human enamel lesions in situ. 101. Stookey GK. Mandel ID. 2001. 1993. 241-244. 3. 1995. 87. Xylitol chewing gum and dental caries. 882-887. Schemehorn BR. Pape HR. Tammiala-Salonen T. 1990. Turku sugar studies I-XXI. Markovic N. 45. 28-31. Soderling E. 153-157. Caries Res. Perspectives on xylitol-induced oral effects. Agalamanyi EA. Mustakallio S. ASDC J Dent Child. Odusola F. Katz BP. 1991. 33. 1975. Soderling E.. http://www. Proc Finn Dent Soc. Tenovuo J.gov/OralHealth/Topics/DryMouth/default. Mandel ID. Park KK. Influence of maternal xylitol consumption on acquisition of mutans streptococci by infants. Caries Res. Effect of chewing gums on plaque pH after a sucrose challenge. Acta Odont Scand.fi/hammaslaeaekaeriliitto/tavoitteet/kannanotot/2007/1782007recommendations-of-the-finnish-dental-assiciation/. Effects of xylitol. Schemehorn BR. Trahan L. Park KK. Hernandez D. 1-349 Soderling E. Schemehorn BR. 15. Pienihakkinen K. Sorbitol gum in xerostomics: the effects on dental plaque pH and salivary flow rates. Loesche W. Eur J Oral Sci. 3. 2007. Edgar WM. 62. 2000. 170-177. Risheim H and Arneberg P. Chewing gum as aid in treatment of hyposalivation. Soderling E and Scheinin A. Stookey GK. and placebo chewing gums on the plaque of habitual xylitol consumers. Makinen KK. 1997. 185-191. 1988. Effect of sorbitol. Pienihakkinen K. Stookey GK. Tenovuo J. 71-75. 23. 31-34. Park KK.nih. Hakkinen L. Soderling E. 79.nidcr. Long-term xylitol consumption and mutans streptococci in plaque and saliva. 26.54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 Manning RH and Edgar WM. Am J Dent. Soderling E. 1993. J Dent Res. Scheinin A. Makinen KK. Isokangas P. 1992. Remineralizing potential. Abelson DC. Br Dent J. 7. Caries Res. Manning RH. Steinberg LM. Makinen PL. The impact of chewing sugarless gum on the acidogenicity of fast-food meals. Int Dent J. 1990. 180-186. 231-235. 1991. Scand J Dent Res. Alanen P. A clinical and biochemical study. Dry Mouth (Xerostomia). Clin Prev Dent. Butchko HH. Bolton JW. Park KK. Am J Dent. Acta Odontol Scand. http://www. 105. 1992. Influence of maternal xylitol consumption on mother-child transmission of mutans streptococci: 6-year follow-up. 71-74. 1725-1729. J Clin Dent. 57. Pediatr Dent. 378-384. Suomen Hammaslääkäriliitto. J Dent Res. 1995. Stookey GK. and xylitol/sorbitol chewing gums on dental plaque. 73 74 75 76 118 . xylitol-sorbitol.hammaslaakariliitto. Proskin HM. 217-229. Gerodontology. 33 (suppl 70). 174. 2000. 1981. Toxicological evaluation of certain food additives and contaminants. 881S-892S. 1995. 45. Makinen KK. 77-92. Journal of Food Composition and Analysis. Hujoel PP. Pape HR. 119 . blueberry. No 35-38. Bennett CA. ID 1184: “Berries (lingonberry. Frostell G. teeth” 78 79 80 81 82 83 84 85 1 Title 21. Proc Finn Dent Soc. chlorhexidine and fluoride. pCa. Effect of maternal use of chewing gums containing xylitol. Birkhed D. 1996. Kontiokari T. Sugar alcohols: what is the evidence for caries-preventive and caries-therapeutic effects? Caries Res. 1904-1913. 1983. 1995. 218-224. 74. Gutmann K.. 06/10/1990 P. Thorild I. Vratsanos SM and Mandel ID. Oral Health Prev Dent. currants. Care of the Dry Mouth. Sugars and dental caries. Uhari M. Isokangas PJ. Tapiainen T. J Dent Res. Chapter I Food and Drug Administration Departement of Health and Human Services. Makinen PL. 2000. sorbitol or a mixture of xylitol and sorbitol on plaque formation. Toxicological evaluation of certain food additives and contaminants. pH changes and acid production in human dental plaque. Koskela M. JECFA (Joint FAO/WHO Expert Committee on Food Additives). Van Loveren C. Makinen PL. Code of Federal Regulations. Antiadhesive effects of xylitol on otopathogenic bacteria. Yankell SL and Emling RC. 6. Kolling D. 1998. 1983. raspberry and strawberry)” and “Cardiovascular system” 2 3 4 5 6 7 8 9 1 Hägg M. Effect of chewing gums containing xylitol. 78. 369-378. J Antimicrob Chemother. 2003. Vaccine. Topitsoglou V.80 Dietary Noncariogenic Carbohydrate Sweeteners and Dental Caries. 1998. S144-147. 70-74. Twetman S. 53-57. chlorhexidine or fluoride on mutans streptococci colonization in the mothers' infant children. Uhari M. 1995. Xylitol candies in caries prevention: results of a field study in Estonian children. Subchapter B Food for Human Consumption Part 101 Food labeling Subpart e 101. Kumpulainen J. The effect of high oral dosage of xylitol and sucrose on the biochemical properties of whole saliva in human volunteers after long-term regular consumption of xylitol. 2003. 0040 . Xylitol chewing gums and caries rates: a 40-month cohort study. cloudberry. Eur Arch Paediatr Dent. Vitamin C content in fruits and berries consumed in Finland. 1989. Twetman S. 7. 46-49. Lindau B. The effect of sucrose and hexitol--containing chewing gums on plaque acidogenesis in vivo. Kontiokari T. 262-270. WHO Food Additives Series. Caries Res. WHO Technical Report Series 696. Community Dent Oral Epidemiol. sorbitol. Alanen P. 38. Dentistry Monthly. Food and Drugs. Isokangas P. 1981.77 Thorild I. JECFA (Joint FAO/WHO Expert Committee on Food Additives).0044. 12-20. Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling for foodstuffs. Lindau B. Touger-Decker R and van Loveren C. Ylikoski S. Xylitol in preventing acute otitis media. Xylitol: a review of its action on mutans streptococci and dental plaque--its clinical significance. Larsson LA. Isotupa KP. 8. 77. Am J Clin Nutr. Trahan L. Jr. 241245. 17. Int Dent J. 41. and swallowing rates. Thornhill MH. 19 Suppl 1. 1. 563-565. Clinical study to evaluate the effects of three marketed sugarless chewing gum products on plaque pH. 28. Makinen KK. 2004. 1. Pharmacol Ther Dent. 286-293. Caries in 4-year-old children after maternal chewing of gums containing combinations of xylitol. 87-91. 2006. Official Journal L 276. J Clin Dent. ID 1182: “Xylitol in candy and bakery industry products and in dairy products” and “Mouth. Sodium and blood pressure. Flavonols and phenolic acids in berries and berry products. Lieberman HR. 856-861. Metabolism-Clinical and Experimental. ID 1185: “Natural berries/sodium” and “Cardiovascular system” 7 1 2 De Wardener HE and MacGregor GA. 93. Couillard C. Electroencephalogr Clin Neurophysiol. Kahkonen MP. Liu S. Academic Press. 560-568. Ascherio A. Flavonoid intake and risk of chronic diseases. Dorea JG and da Costa TH. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. Doctoral thesis. Lorist MM and Snel J. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Flavonoid intake and coronary mortality in Finland: a cohort study. 2005. University of Kuopio. 2001. Luben R. 2002. Pereira MA. Rissanen H. Bertelsen B. 97-104. Heitmann BL. 2001. Pietinen P. Lamarche B. 49. 1571-1573. Ruel G. Changes in plasma antioxidant capacity and oxidized low-density lipoprotein levels in men after short-term cranberry juice consumption. Kylli P. The use of caffeine versus prophylactic naps in sustained performance. 102. Hopia AI. 1995. Effects of caffeine. 478-481. 157. University of Helsinki. 401-413. Gomez S. ID 1187: “Coffee drink/caffeine” and “Mental state and performance” 4 5 1 2 3 4 5 Bonnet MH. Goldbourt U. 2002. Fraser GE. Smith A and Jones D (eds. Wareham N. Welch A. Reunanen A. 2005. Curr Opin Cardiol. Arch Intern Med. 164. Heliovaara M. Hakulinen T. Riihinen K.2 3 4 5 6 Häkkinen S. Sleep. Heinonen M. 2005. Bingham S. Augustsson K. Willett WC. Kumpulainen J. Flaten MA. 360-367. 2005. 54. Mikalsen A. 120 . Rissanen H. University of Kuopio. Cranberries inhibit LDL oxidation and induce LDL receptor expression in hepatocytes. 1892-1901. caffeine-associated stimuli. Jarvinen R. Phenolic compounds is berries. ID 1186: “Berries and fruit juices/flavonoids + ascorbic acid” and “Antioxidativity” 1 2 3 Chu YF and Liu RH. Caffeine effects on perceptual and motor processes. Day N. Berry phenolics and their antioxidant activity. O'Brien E. Pomerleau S. 322. J Agric Food Chem. Heliovaara M. 76. American Journal of Clinical Nutrition. In: Handbook of Human Performance: The Physical Environment. Caffeine. and caffeinerelated information on physiological and psychological arousal. Psychopharmacology (Berl). O'Reilly E. 76. Doctoral thesis. Jarvinen R. 560-568. Aromaa A. Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). 373-380. 4076-4082. Hallmans G. 1992. Aromaa A. 18. Reunanen A. Couture P. Knekt P. Virtamo J. Uhari M. Koskela M. 77. 2002. 370-376. Wirth O. Sundqvist K. Jarvinen R. 17. New York. Pokka T. 80. Arand DL. Spiegelman D. Nuutinen M. Is coffee a functional food? Br J Nutr. 773-782. 2004. Hakulinen T. 2000. Knekt P. Maatela J. Life Sciences. Khaw KT. Kumpulainen J. Am J Clin Nutr. 1997. 312. Stevens J. 2005. Reunanen A. 2001. 2004. 1397-1403. Am J Clin Nutr. Kontiokari T. Marjojen fenolisten yhdisteiden vaikutus proteiinien ja lipidien hapettumiseen.). Knekt P. Flavonoid intake and risk of chronic diseases. 1996. BMJ. British Medical Journal. Knekt P. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. powdery” and “Weight control” 7 8 9 10 11 12 13 1 Metz JA. Lane J. water and beverage type. 1999. 76. 2001. 164173. Vanderlinde R. Is oxidative stress the pathogenic mechanism underlying insulin resistance. Meyboom S. Brockman P. ID 1197: “Grape juice” and “Maintenance of cardiovascular system” 2 1 2 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). diabetes. Etherton T. Brouwer IA. 160. Warburton DM. Robelin M and Rogers PJ. Hautvast JGAJ. Neuropsychobiology. Ceriello A and Motz E. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Aspinall L. 45. Neuropsychobiology. 24. Hof KHV. Steptoe A and Wardle J. and cardiovascular disease? The common soil hypothesis revisited. Clifford MN. 26. Chester L. 816-823. 121 4 5 6 7 . Bonatto D. Health Psychol. 2000.nature. 141. Duran M. 1989. Food and Chemical Toxicology. Journal of the Science of Food and Agriculture. ID 1189: “Nutritional preparation. Effects of hot tea. 2000. Henriques JAP. 2007. Lane J. Salvador M. Mood and psychomotor performance effects of the first. 1191-1201. Thomas M. Zhao G. Moore KL. Paris. 217-223. Quinlan PT. cup-of-coffee equivalent doses of caffeine consumed after overnight caffeine abstinence. Thomas CMG. Aspen J. 9. 66. Jonnalagadda S. 2002. Mood and drinking: a naturalistic diary study of alcohol. Pharmacol Biochem Behav. 79. 362-372. 129. Resnick LM. 8.nature. 1995. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. coffee and water ingestion on physiological responses and mood: the role of caffeine. O'Keeffe MK. The acute physiological and mood effects of tea and coffee: the role of caffeine level. dietary burden. 2150-2158. 1992. Oparil S. Arteriosclerosis Thrombosis and Vascular Biology. 1999. coffee and tea. Hatton DC. 80. Dani C. 27. Clark S. 2004. Chlorogenic acids and other cinnamates . Smith AP. Haynes RB. 1033-1043. occurrence and dietary burden. Beneficial role of dietary phytoestrogens in obesity and diabetes. Baum A. American Journal of Clinical Nutrition. absorption and metabolism. Eskes TKAB. Naglak M. Psychopharmacology. Ratliff-Crain J. 1999. Phenolic content and antioxidant activities of white and purple juices manufactured with organically. 632-646. Reusser ME. but not of subsequent. Am J Clin Nutr. Snyder GW. Behav Pharmacol. 1993.6 Quinlan P. van Dusseldorp M. 611-618. 119. Flynn R. Stern JS. Maben AL. 19-28. Effects of caffeine on cognition and mood without caffeine abstinence. Yu-Poth S. 198-204. Psychopharmacology. and task performance in deprived and nondeprived coffee drinkers. 134. 315-321. 66-70. Morris CD. 69. Bhathena SJ and Velasquez MT. Chlorogenic acids and other cinnamates . Maben A. Oliboni LS. Psychopharmacology (Berl). Cardiovascular reactivity. 1997. 1998. McCarron DA. 1135-1139. Apports nutritionnels conseillés pour la population française. Effects of breakfast and caffeine on performance and mood in the late morning and after lunch. Clifford MN. 2000. Kris-Etherton PM. Kris-Etherton P. Steegers-Theunissen RPM. Pi-Sunyer FX. Kendrick AM. 1999. 427-447. Smith AP. O'Brien DC. Editions Tec&Doc. Arch Intern Med.or conventionallyproduced grapes. Journal of Nutrition. Investigation of the effects of coffee on alertness and performance during the day and night. occurrence. West CE. McMahon M. 2574-2580. Rycroft JA. mood. Journal of the Science of Food and Agriculture. Ruxton CHS. O'Byrne DJ. Rev Fr Endocrinol Clin. anti-oxydants et athérosclérose. Evaluation of phenolic compounds in commercial fruit juices and fruit drinks. Polyphenols from green tea and pomegranate for prevention of prostate cancer. 3148-3157. Rosenblat M. Morand C. 67. 40. Folsom AR. Colemann R. 119-141. Rosenberg IH. Wilson PWF. Pomegranate juice consumption reduces oxidative stress. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Deak LR. Williamson G. Presser D. Jialal I. I. Lecerf J. Scalbert A. Chung MH. Sagee O. 57. ID 1201: “Pomegranate juice” and “Oxidative stress control” 1 2 Adhami VM and Mukhtar H. Bostick RM. Marks SC. 76. Reed JD. 2005. 1367-1374. Tucker KL. American Journal of Clinical Nutrition. Gardner EJ. Dietary intake and bioavailability of polyphenols. Devaraj S. Harats D. 2073S-2085S. 249-272. atherogenic modifications to LDL. Wu Y. Kim HS. Norman Y. Perlman JA. Ko SH. 130. Functional claims of Article 13: Polyphenols in juices. Folts JD. 126. Folts JD. Walker D. 334. 2792-2798. 1997. Ernährung im Fokus. Berry EM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. Keevil JG. American Journal of Clinical Nutrition. 1996. Journal of Agricultural and Food Chemistry. Comparison of the antioxidant effects of Concord grape juice flavonoids and alpha-tocopherol on markers of oxidative stress in healthy adults. N Engl J Med. Nahir M. International Journal of Food Sciences and Nutrition. Iafrati MD. Jimenez L. 41-46. 1996. Circulation. 8. Review of 97 bioavailability studies. 3025-3031. Bioavailability and bioefficacy of polyphenols in humans. Prineas RJ. but not orange juice or grapefruit juice. 2001. 1999. 325-330. 2006. Chevion S. 130. ID 1200: “Black Currant juice” and “Oxidative stress control” 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 Netzel M. Frei B. Journal of Nutrition. Li LQ. Comparison of the antioxidant activities of nine different fruits in human plasma. Scalbert A and Williamson G. 103. 2002. Ivanov V. Bartolome B. 2000. Food Chemistry. Polyphenols: food sources and bioavailability. Schwarzer Johannisbeersaft als Quelle bioaktiver Substanzen. Nutrition. Choi SW. 2003. 1998. Gomez-Cordoves C. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. 300-304. Lecerf J. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. Parker C. Freedman JE. Mullen W. Bitsch I. 727-747. Lecerf J. 53-56. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. 230S-242S. 93. 79. and 122 . Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. 2004. Antioxidant properties of commercial grape juices and vinegars. Bitsch R. Kushi LH. Mink PJ. Journal of Medicinal Food. Osman HE. 2000. Scalbert A. Straß G. Journal of Nutrition. Fuhrman B. inhibits human platelet aggregation. American Journal of Clinical Nutrition. Dornfeld L. American Journal of Clinical Nutrition. Free Radical Research. Manach C. Dietrich H. Crozier A. Selhub J. 81. 2007. Aviram M. Kaplan M. Journal of Nutrition. Grape juice. Ye SK.8 9 Davalos A. 2005. 1156-1162. 2000. Pasteur Institute-Lille. Morand C. 2005. Grundy SM. Hayek T. 2006. 10. Cho BL. 2006. 1095-1104. 38. Pasteur Institute-Lille. Remesy C. Manach C. 240-245. Remesy C. Frank T. Volkova N. 55. 4 5 6 7 8 9 ID 1205: “Phyto-complex based on extracts of mushroom (Shiitake thalle Lentinula edodes). Effects of flavonoids on the Oxidation of Low-Density Lipoprotein and Atherosclerosis. 6. 857-866. Alvarez-Gonzalez I. Corey P. Anderson R. Research Communications in Molecular Pathology and Pharmacology. Leppert JT. 71. 19-45. Bagchi M. Décembre. 2004. Madrigal-Bujaidar E. Stohs SJ. In: Diet and human immune function. 133-148. Carr RE. 2004. Totowa. Heber D. Schorah CJ. Adv Nutr Res. Bendich A (eds. 12. Tomato juice and platelet aggregation in type 2 diabetes. 17. 3 Bagchi D. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo.wisc. Theron A. Pantuck AJ. 203-211. Ignarro L. Anderson TW. Beaton GH. 123 5 6 7 8 . The effects of increasing weekly doses of ascorbate on certain cellular and humoral immune functions in normal volunteers. JAMA. Hemilä H. Prévention et Santé.platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Melnick SJ. Lansky EP. Garg ML. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Oxygen free radical scavenging abilities of vitamins C and E. 179-189. Hong J. 1997. 4018-4026. Antigenotoxic and antioxidant effect of grapefruit juice in mice treated with daunorubicin. 2004. plants (Acerola fruit Malpighia punicifolia.naturaldatabase. 71-76. Zomorodian N. 112. 121-128. American Journal of Clinical Nutrition. Aronson W. Anderson R. Lemon oil Citrus limon). Nutranews. Humana Press. Garg A. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. 823-826. Van Rensburg AJ. In: Flavonoids in Health and Disease. Mukhtar H. Can Med Assoc J. Suchard M. Bates CJ. Grapefruit fruit Citrus paradisi. Bando H. Science. 1997. University of Wisconsin School of Medicine and Public Health. 78. Krohn RL. 1062-1076. Nutrition Discussion Forum: Vitamin C intake and susceptibility to the common cold . Bowen K. 33. Zhang YJ. Aviram M.asp. Clinical Cancer Research. Martino-Roaro L. Ramachandran C. Liker H. Winter illness and vitamin C: the effect of relatively low doses. Papaya fruit Carica papaya. 2003. Imai A. vitamin C. Oosthuizen R. New York. Natural Medicines Comprehensive Database. Anderson R. 2003. Seeram NP. http://www. http://www. 1984. and A grape seed proanthocyanidin extract in vitro. 19-22. Therapeutic Research Faculty. 2007. Spero L. Aviram M and Fuhrman B. Pomegranate derived products for cancer chemoprevention. concentrated fruits juices and” and “Immune health” 1 2 3 4 Des nutriments pour renforcer le système immunitaire et faire échec aux infections de l‘hiver. Toi M. 136. 2004. Barnard RJ. Henning SM. Seminars in Cancer Biology. Fife RS. 6.Invited commentary . 2006. Li ZP. 95. Vitamin C. 2006. NJ. Belldegrun A. Study Shows Pomegranate Juice May Help Fight Lung Cancer. ID 1202: “Tomato juice” and “Cardiovascular System” 1 Lazarus SA. Hughes D. The immunostimulatory. Espinosa-Aguirre JJ.Reply.).cancer.com. Angiogenesis. 152. Darlington L. 2481-2485. Afaq F. Seeram N.edu/uwccc/article_mukhtar_pomegranate. Oikawa T. Nutrition.). 377-385. 292. Tran MX. Maritz R. Heber D. 1980. Syed DN. 805-806. British Journal of Nutrition. Toxicol Lett. 1975. Am J Clin Nutr. Journal of Nutrition. Rice-Evans C and Packer L (eds. Elashoff R. antiinflammatory and anti-allergic properties of ascorbate. Wang HJ. Marcel Dekker. 811-821. Nutrition. 1086-1107. Antioxidant Status and Function: Relationships to Aging and Exercise. Field CJ. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Brenner G. Pajdo R. Chandra RK. 1975. Lueken B. Dwenger A. 2002. Baldi S.) Masson. 205-211. 1219-1222. J Leukoc Biol. Schley PD. Caria E. In: Antioxidant Status. Vitamin C for preventing and treating the common cold. Nutrients and their role in host resistance to infection. Elia C. 22. Treacy B. Sun J. nutritionnels et thérapeutiques. 45. 311-314. London. Kwiecien S. 194. Grapefruit-seed extract attenuates ethanol-and stress-induced gastric lesions via activation of prostaglandin. Konturek SJ. J Physiol Pharmacol. Bucca C. Campbell JD. 2004. Vella AT. 1997. Med Klin. 16-32. Carr AC and Frei B. Del Rio JA. Nutrition and the immune system from birth to old age. Cell Immunol. 2565-2569. Tang JX. Zheng SB. 2005. Shen DM. Ann Allergy. Johnson IR. Paris. Blumberg J and Halpner A. Rolla G. World J Gastroenterol. Kusnierz-Cabala B. Treacy B. Dembinski A. 71. Dembinski M. Am J Clin Nutr. 1987. 1989.) CRC Press. Ascorbic acid is a potent inhibitor of various forms of T cell apoptosis. 69. Pawlik WW. Farina JC. Du WD. Food Standards Agency. Nebiolo F. 2003. D'Souza R. Cole M. Naskalski JW.Aspects métaboliques. 65. Bucca C. ERNA (European Responsible Nutrition Alliance). 55. Warzecha Z. Eur J Clin Chem Clin Biochem. 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 124 . 2004. Cochrane Database Syst Rev. 1992. Hemila H. Zayachivska O. Marin FR. Brzozowski T. Papas AM (ed. Hahn EG. Cheng AQ. 1991. Ortuño A. Bunditrutavorn B. Song XH. 187-191. Extract of grapefruit-seed reduces acute pancreatitis induced by ischemia/reperfusion in rats: possible implication of tissue antioxidants. Modigh A. Chalker EB. génétiques. Diet. Journal of Agricultural and Food Chemistry. 55. Cochrane Database Syst Rev. Chalker EB. Douglas RM. Lehmann U. Ceranowicz P. Prendergast JM. Boca Raton. Nutrition Research. 56 Suppl 3. 11. Munich A (ed. 5-11. 1990. Rolla G. oxygen-derived radicals. 2000. Arossa W. Influence of multinutrient supplement on immune responses and infection-related illness in 50–65 year old individuals. [Enteral absoprtion of ascorbic acid in man after application of a micro-encapsulated retard preparation (author's transl)]. Uses and Properties of Citrus Flavonoids. Konturek PC. Konturek SJ. 1999. Huang CJ. 9. CD000980. Douglas RM. Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. Schweitzer G. 1999. 2003. Courtand M and Sagaut P. Delafuente JC. Drozdowicz D. World J Gastroenterol. London. and Health. Castillo J. S73-76. CD000980. Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. 2002. In: Les Vitamines . Int J Immunopharmacol. Eur J Clin Nutr. 70. Yuan ZR. Effect of ascorbic acid on neutrophil functions and hypoxanthine/xanthine oxidase-generated. Effect of ascorbic acid on increased bronchial responsiveness during upper airway infection. Immunologic modulation by vitamin C in the elderly. 1-5. 64506458. Funck M. 214-219. 1986. Acide ascorbique (Vitamine C). 30. Oliva A. Chandra RK. 2004. 1999. Pawlik WW. Vitamin C Fact sheet EVM (Expert Group on Vitamins and Minerals). 2002.9 10 11 12 Benavente-Garcia O. HMSO. 326-346. 4505-4515. Effect of vitamin C on histamine bronchial responsiveness of patients with allergic rhinitis. COMA (Committee on Medical Aspects of Food Policy). Safe Upper Levels for Vitamins and Minerals. Yu XF. nitric oxide and sensory nerve pathways. 8. Respiration. Vitamin C for preventing and treating the common cold. Delgado-Licon E. 337-343. 221-224. Gorinstein S. 2005. Galli F. 2004. J Nutr Health Aging. Drzewiecki J. Gorinstein S. 2002. Vitamin C intake and susceptibility to the common cold. Caspi A. Life Sci.). Traber MG. 1997. Tapia MS. 52. 3. Gralak M.30 31 32 33 Fraker PJ and Lill-Elghanian DA. Vitamin C and common cold incidence: a review of studies with subjects under heavy physical stress. Williams. Gorinstein S. Katrich E. Guilland JC and Lequeu B. 2004. In: Les Vitamines: du nutriment au médicament. 3-16. 19. J Agric Food Chem. Heuser G and Vojdani A. 1995. 2004c. respiratory infections and the immune system. 1973. 379-383. author reply 258. J Nutr Biochem. 52. Changes in leucocyte ascorbic acid during the common cold. Libman I. Leontowicz M. Vitamin C: An Introduction. 291-312.An exploration of tradition. Vitamine C et grippe. Br J Nutr. Vitamin C. Trakhtenberg S. 56-63. 1999. Frei B (eds. Hemila H. 2004b. Trends Immunol. Trakhtenberg S. Gill H (eds. Tashma Z. Pawelzik E. 2003. In: Medicinal Mushrooms . 75. Leontowicz H.) Botanica Press. Fresh israeli jaffa sweetie juice consumption improves lipid metabolism and increases antioxidant capacity in hypercholesterolemic patients suffering from coronary artery disease: studies in vitro and in humans and positive changes in albumin and fibrinogen fractions. Hume R and Weyers E. 77. Hughes D. Katrich E. Vitamin C. Leontowicz H. 5215-5222. J Agric Food Chem. Bucchini A. 54. healing & culture. 1-6. 24. Trakhtenberg S. Trakhtenberg S. 16. 1992. Leontowicz M. Field C. Red Star Ruby (Sunrise) and blond qualities of Jaffa grapefruits and their influence on plasma lipid levels and plasma antioxidant activity in rats fed with cholesterol-containing and cholesterol-free diets. 37. Hemila H and Douglas RM. 17. Calder P. Katrich E. Hemila H. Int J Sports Med. New York. Lavoisier. 59-72. Immunopharmacol Immunotoxicol.). Leontowicz H. Scand J Infect Dis. Haruenkit R. Katrich E. Fraternale D. Fitoterapia. IL. Gorinstein S. 1992. 1997c. Hobbs C. Scott Med J. Hemila H. Leontowicz M. Lerner HT. Fresh Israeli Jaffa blond (Shamouti) orange and Israeli Jaffa red Star Ruby (Sunrise) grapefruit juices affect plasma lipid metabolism and antioxidant capacity in rats fed added cholesterol. Giamperi L. Trakhtenberg S. 67. In: Nutrition and immune function. 1997a. Lerner HT. Packer L. Libman I. Br J Nutr. 125-136. AOCS Press. Jung ST. J Agric Food Chem. 67. 8. In: The Antioxidant Vitamins C and E. Int J Tuberc Lung Dis. Hobbs C (ed. CABI Publishing in association with The Nutrition Society. 756-761. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans. 77. Huang D. 1994. Comparison of the contents of the main antioxidant compounds and the antioxidant activity of white grapefruit and his new hybrid. 4853-4859. Krzeminski R. Vitamin C supplementation and the common cold--was Linus Pauling right or wrong? Int J Vitam Nutr Res. Jastrzebski Z. Hemila H. The many roles of apoptosis in immunity as modified by aging and nutritional status. 18871892. Does vitamin C alleviate the symptoms of the common cold?--a review of current evidence. Vitamin C and acute respiratory infections. 2384-2397. Kraemer K. Paris. Haruenkit R. Antioxidant activity of Citrus paradisi seeds glyceric extract. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase-C. Lentinula edodes Shiitake. 1996. 125 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 . 26. Ricci D. 3-7. 171-191. 579-580. 257. Hemila H. 329-335. Vitamin C and the common cold. 2006. Park YS. Hemila H. Katrich E. 18. Martin-Belloso O. 2002. Antioxidant vitamins and immune function. Caspi A. Feng S. 2004a. Zachwieja Z. Martin-Belloso O. Higdon JV and Frei B. vitamin E and immune response. 2005. Champaign. LWT-Food Science and Technology. Gorinstein S. 38. Choi YK. Kim EH. Am J Clin Nutr. 29. Heart Disease and More. J Nutr Biochem. 2002. Welch RW. 2002. Shike M. Levine M. Cantilena LR. Graumlich JF. Lenton KJ. Kennes B. Dietary antioxidants in preventing atherogenesis. 187. Chemistry. 76. 2003. 681-688. Essential nutrients and immunologic functions. Asou K. Vitamin E.). Schmidt H. Sane AT. Fraga CG. Park YB. Lazarev A. Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits. 2006. Kim JR. Hernandez T. 1996. 1-17. Biochemistry and Applications. 499-501. Venkatesha VA. Vitamin C augments lymphocyte glutathione in subjects with ascorbate deficiency. 219-263. Biochemistry and Applications. Jang MK. 2003. Le Marchand L. and Carotenoids. 337-343. Hankin JH. 857-917. Viricel M. Flavonoid intake and risk of chronic diseases. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Heliovaara M. Ames BN. Williams & Wilkins. 166-170. Jung UJ. JHCI (Joint Health Claims Initiative).). Lee MK. Jeong TS. 63. Zhang JZ. Therriault H. 1997. Vitamin C. Zdunczyk Z. Diabetes. protects against radiationinduced chromosome damage in mouse bone marrow. 1302S-1309S. Dedoussis GV. Atherosclerosis. Kelley DS. Andersen Ø and Markham K (eds. Conry-Cantilena C. Dietary Reference Intakes for Vitamin C. New Canaan.). 1999. Selenium. CRC Press. Shouji A. Gonnet J. 2006. Jay M. Wilkens LR. Effect of vitamin C supplements on cellmediated immunity in old people. Andersen Ø and Markham K (eds. Kang MA. Ct. Rissanen H. Wróblewska M. Brohee D. 181-190. Naringin. Oh GT. King J. Neve P. Swendseid ME. In: Medicinal Benefits of Mushrooms: Healing for More Than 20 Centuries--Their Effects on Cancer. Baltimore. Proc Natl Acad Sci USA. Han JI. Payette H. Final Technical Report A List of Well Established Nutrient Function Statements. Shiitake: the forest mushroom. 1983. 560-568. 1996. Aromaa A. Kim YH. Antiatherogenic effect of citrus flavonoids. Ishikawa M. Jagetia GC. 35. 317. 92. Immunocompetence and oxidant defense during ascorbate depletion of healthy men. Nam KT. 2002. Clin Chim Acta. Biochem Biophys Res Commun. 284. Lee WH and Friedrich JA. Peters JH. Dumont I. 2006. Olson J. Keats Publishing Inc. Lee CH. Oszmianski J. Am J Clin Nutr. 3704-3709. In: Modern Nutrition in Health and Disease. Juskiewicz J. Effects of naringin on hydrogen peroxide-induced cytotoxicity and apoptosis in P388 cells. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Am J Clin Nutr. 994S996S. J Natl Cancer Inst. 18. Intake of flavonoids and lung cancer. 189-195. 201-205. 467-483. Flavonoids in Food. 2. Choi MS. Kanno S. 54. 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 126 . 2006. CRC Press. 1991. Jarvinen R. Choi MS. Jeong TS. Boca Raton. The response of rats to feeding with diets containing grapefruit flavonoid extract. 1991. J Pharmacol Sci. Kelley DS and Bendich A. Pianalto FS. Kaliora AC. associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Hubert C. Cantin AM. Dhariwal KR. Jacob RA. Johnston CS.51 52 IoM (Institute of Medicine). 154-160. Kolonel LN. Reddy TK. naringin and naringenin. Food Research International. 1134-1145. Henning SM. Hyun BH. In: Flavonoides. Boca Raton. 2000. 77. Park JB. Jeon SM. Hakulinen T. a citrus flavonone. Kyle J and Duthie G. 92. Bok SH. 305-310. Wagner JR. Int J Biochem Cell Biol. Bok SH. 93. Kumpulainen J. National Academies Press. Wang Y. Murphy SP. Ross A (eds. Shils M. 29-32. Complement component C1q unaltered by ascorbate supplementation in healthy men and women. 2003. Reunanen A. Park YB. C-Glycosylflavonoids. Gerontology. 2001. Knekt P. Chemistry. Washko PW. Am J Clin Nutr. Washington DC. In: Flavonoides. Mutagenesis. 2000. 2003. Jacob RA. Nakamura T. Brown DJ. Peters EM. 75-90. J Infect Dis. Grohmann K. Vitamin C and the immune response in health and disease. Ng ML and Yap AT. Modulation of interleukin production by ascorbic acid. 20. Hongkong. 27. J Infect Dis. Nevines EI. In: Handbook of Vitamins. 1991. Modern Nutrition in Health and Disease. Contact Dermatitis. Shiitake. 401-436. Bhagwat SA. 60. Cunningham-Rundles S (ed. Dwyer JT. Olson J. Evaluation of the efficacy of ascorbic acid in prophylaxis of induced rhinovirus 44 infection in man. Hornick RB. 1998. Proteggente A.72 73 74 75 76 77 78 79 Levy R. van Leeuwen PA. Schlaeffer F. New York. 23. 500-505. 1993. Rice-Evans C and Packer L (eds. In: Nutrient modulation of the immune response. Schwartz AR. Williams & Wilkins. 1502-1505. Shankar AH. Phenolic compounds and their role in oxidative processes in fruits. New York. 65-70. Shriker O. Panush RS. Siegel BV and Morton JI. Effect of vitamin C on common cold: randomized controlled trial. van Hoorn DE. 418-425.) Marcel Dekker. 1992. Nieman DC. 1983. Shiitake (Lentinus edodes) dermatitis. Gleckman RA. Wright J. Gebhardt SE. Modulation of certain immunologic responses by vitamin C. Guthrie N. Eur J Clin Nutr. Robards K. Flavonoids: a review of probable mechanisms of action and potential applications. 135-153. van Norren K. Porath A. 9-17. Henson DA. Sasaki S. lemons. Potentiation of in vitro and in vivo lymphocyte responses. New York. Beecher GR. Sasazuki S. 173. Nutritional modulation of malaria morbidity and mortality. 2001. 8. 1982. 45-57. III. Noakes TD. 310-311. Tsugane S. Schwager J and Schulze J. Influence of vitamin C supplementation on cytokine changes following an ultramarathon. Flavanones in grapefruit. Biological properties of citrus flavonoids pertaining to cancer and inflammation. 53. Hayashi M. Glover W. Am J Clin Nutr. Am J Clin Nutr. 2004. Prenzler PD. Riesenberg K. 1999. Lininger SW. Swatsitang P. 1992. Vet Immunol Immunopathol. J Infect Dis. Delafuente JC. Wiseman S. 1998. Int J Vitam Nutr Res. The Journal of Alternative & Complementary Medicine. 195-232. Manthey JA. In: Nutrition and immunology. Vitamin C and phagocytes. 10291035. Siegel BV. New York. 1973. Johnson J. Thompson MM. 1996. 2001. Int J Vitam Nutr Res Suppl.) Plenum Press. 8. Goetzsche JM. Okubo S. Shils M. J Interferon Cytokine Res. 182 Suppl 1. 2000. Boelens PG. 80 81 82 83 84 85 86 87 88 89 90 91 92 93 127 . 2006. 170-174. Roseville. In: The natural pharmacy.) Marcel Dekker. Moser U and Bendich A. Holden JM. 179-183. Opinion on the Tolerable Upper Intake Level of Vitamin C. Muggli R. Austin S. California. Peters EM. 2006. 66. Peterson JJ. Katz P. 2002. S37-53. Marcel Dekker. Grobbelaar B. Togo Y. Put F. 57. Curr Med Chem. 35-47. Shike M. Nijveldt RJ. Machlin LJ (ed. Ross A. Klurfeld DM (ed. 64. Vitamin C and immunity: natural killer (NK) cell factor. 1993. Basel. 128. In: Flavonoids in Health and Disease. Food Chemistry. 1999. van Nood E. Tominaga S. 2000. 74. Journal of food composition and analysis. 2003. 74-80. 581-589. Vitamin C for the treatment of recurrent furunculosis in patients with imparied neutrophil functions. 19. 167-196. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes). Rice-Evans C. Tucker G.). Baltimore. Vitamin C supplementation reduces the incidence of postrace symptoms of upper-respiratory-tract infection in ultramarathon runners. The relationship Between the Phenolic Composition and the Antioxidant Activity of Fruits and Vegetables. Prima Publishing. Tsubono Y. SCF (Scientific Committee on Food). Haytowitz DB. Vitamin C. and limes: A compilation and review of the data from the analytical literature. Liang X. Pike LM. Thompson D. 466-481. Grapefruit: the last decade acquisitions. Sandone N. 17. 2005. Vinson JA.94 Tauler P. Agusti A. 53. Tirillini B. Boston. Kodama D. Dancel J. Whitney EN and Rolfes SR. Adv Exp Med Biol. 2006. 2001. Ascorbic acid in human neutrophils. Eastwood M. Kobayashi M. Turner ND. 2002. 128 . 2009-2014. Uptake of ascorbic acid by human neutrophils. 2003. Wilcox LJ. Biofortis. ILSI Press. 2005. Oxford. 71 Suppl 1. Cardioprotective effects of dietary polyphenols. S29-37. Zern TL and Fernandez ML. Walzem RL. Protection against D-galactosamine-induced acute liver injury by oral administration of extracts from Lentinus edodes mycelia. concentrated fruits juices and pectin. Vitamin C. Yagi K. Maggini S. J Med Food. Wilson CW and Loh HS. Fourth edition. Watanabe A. Principles of human nutrition. 2002. UK. Wadsworth Publishing. 11. J Agric Food Chem. Hornig DH. 54. Wolf G. 57. 29. 337-338. 2004. Rotrosen D. Lancet. Nutrition Now. Am J Clin Nutr. Prolonged vitamin C supplementation and recovery from demanding exercise. Biol Pharm Bull. Belmont. 19. 1257-1265. Wang L. 135. 2001. Int J Sport Nutr Exerc Metab. Lupton JR. Aguilo A. 37. Free Radic Res. Vinson JA and Jang J. ID 1206: “Food supplement of plants (meadosweet. Huff MW. Gimeno I. Contemporary nutrition. Isoda K. Patil BS. Hayashi S. 2006. 2003. Williams C. Jackson MJ. Pons A. McGraw-Hill International. Tamesada M. CA. Yu J. Understanding Nutrition. Grandjean A and Campbell S. 2004. 50. 2006. Webb R. 638-641. Wintergerst ES. Give a boost to your immune system. yerba mate). Common cold and vitamin C. Vanamala J. Patil BS. Pike LM. Levine M. Carcinogenesis. Antioxidant activity of citrus limonoids. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Kawase M. J Nutr. Chapkin RS. Wiley-Blackwell. 17-19. Washko P. Van Straten M and Josling P.” and “Slimming . Murphy ME. Wardlaw GM and Smith AM. Water is an essential nutrient. 2006. Nicholas CW. 2004. placebo-controlled survey. 1991. 2005. Hontz BA. 4. Adv Ther. ID 1208: “Water” and “Regulation of normal body temperature” 1 2 3 4 5 Brown JE. 2005. Diabetes Forecast. 151-159. flavonoids. In Vitro and In Vivo Lipoprotein Antioxidant Effect of a Citrus Extract and Ascorbic Acid on Normal and Hypercholesterolemic Human Subjects. 51. 85-94. 2291-2294. Leonardi T. Differential response of lymphocytes and neutrophils to high intensity physical activity and to vitamin C diet supplementation.Silhouette” 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 1 2 Biofortis. Borradaile NM. 2000. 27. 1. a citrus flavonoid. 187-192. 113-122. and coumarins. Ann Nutr Metab. 1221S1227S. Cardiovascular Drug Reviews. Suppression of colon carcinogenesis by bioactive compounds in grapefruit. Preventing the common cold with a vitamin C supplement: a doubleblind. 505. Noguera A. Etude minceur – Etude d‘efficacité «Actimincyl Bio». 2005. 931-938. Etude minceur – Etude d‘efficacité «Cellimine». Nutr Rev. green coffee. 1993. Antiatherogenic properties of naringenin. Taddeo SS. green tea. Proch J. 1973. Fitoterapia. Tur JA. Washington DC. McGregor SJ. birch. Powell JR. Kondoh M. Hydration: Fluids for life. Polyphenol antioxidants in citrus juices: in vitro and in vivo studies relevant to heart disease. Miller EG. 1651-1654. 1999. McArdle F. 160-178. Fourth edition. Moore TJ. S14-21.aprifel. Appel LJ. Anlasik T. Nutr Rev. Karanja N. Rohm K. The importance of good hydration for work and exercise performance. A clinical trial of the effects of dietary patterns on blood pressure. Wiley-Blackwell. Mann J and Truswell AS.) Springer. Nutr Rev. CA. Aviram M. ID 1211: “Fruits (fresh. Duran M. dietary sources. Kok F. 1999. Wang CY. Ritz P and Berrut G. Eskes TKAB. McGraw-Hill International. Principles of human nutrition. 2003. Sacks FM. Gonzalez-Aguilar GA. Griffiths HR. Berlin. Vorster H. Boston. Wadsworth Publishing. Vollmer WM. 94. 63. Stahl W. 37. 1997. 2005. metabolism. Hof KHV. von Eckardstein A (ed. Belmont. 687-695. Oxford University Press. Wiley-Blackwell. New England Journal of Medicine. Lin PH. Contemporary nutrition. Journal of Nutrition. Svetkey LP. Bohm V. Garrow JS. Windhauser MM. 2005. body function. Understanding Nutrition. Thomas CMG. Improving the nutritional quality of microwave-vacuum dried strawberries: A preliminary study. Meyboom S. 56. 3 4 5 6 7 8 9 10 11 129 . Hydration: Fluids for life. Gibney MJ.ID 1209: “Water” and “Hydration. Essentials of Human Nutrition. www. Brouwer IA. 2003. Polidori MC. Plants: Diet and Health – The Report of the British Nutrition Foundation Task Force. 2000. Kuhnert S. 63. Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. 1998. Sies H. British Journal of Nutrition. and nutritional significance. Apports nutritionnels conseillés pour la population française. Ralph A. 317-333. Hautvast JGAJ. Bray GA. eg. 2002. bottled. Wang SY. Paris. 67-75. Vogt TM. Washington DC. 336. Canada. 2004. Chichester. UK. Ayala-Zavala JF. Nutrition Now. Cutler JA. 5 to 10 a day for better health.com. West CE. frozen. Effect of storage temperatures on antioxidant capacity and aroma compounds in strawberry fruit. BNF (British Nutrition Foundation). Introduction to Human Nutrition (The Nutrition Society Textbook). Rosenblat M. Mecocci P. The importance of good hydration for day-to-day health. Editions Tec&Doc. Shirreffs SM. Human Nutrition and Dietetics. 2006. Oxford. In: Atherosclerosis: Diet and Drugs.5to10aday. 2006. Water is an essential nutrient. Polyphenols: Chemistry. 2001. Kaplan M. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. 129. Steegers-Theunissen RPM. 2004. Grandjean A and Campbell S. dried. canned. Churchill Livingstone. Eastwood M. 12. 2005. 1135-1139. Edinburgh. Whitney EN and Rolfes SR. physical and cognitive performance” 1 2 3 4 5 6 7 8 9 10 Brown JE. 1117-1124. Nutrition Reviews. James WPT. Obarzanek E. Scholze G. Wardlaw GM and Smith AM. Fuhrman B. 639-642. S6-13. juiced)” and “Protection of body tissues and cells from oxidative damage” 1 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 2004. 263-300. van Dusseldorp M. 2002. www. 2005. ILSI Press. 2005. Bravo L. Food Science and Technology International. Lebensmittel-Wissenschaft UndTechnologie-Food Science and Technology.com. Aprifel (Agence fruits et legumes frais). New York. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. London. 1-4. Liu RH. 2006. Filesi C. 4959-4964. 334. Journal of Agricultural and Food Chemistry. 143-147. 23-28. Fruit and vegetable juices and Alzheimer's disease: The Kame Project. Caspi A. http://www. 2004. 1996. Effect of high intakes of fruit and vegetables on redox status in type 2 onset diabetes: A pilot study. Prentice A (eds. Annals of Nutrition and Metabolism.). Wu YG. Effects of production and processing factors on major fruit and vegetable antioxidants. Uhley V. Bibliographical study on the nutritional benefits of processed fruit and vegetables. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. 313-320. Norman Y. 2004. Journal of Agricultural and Food Chemistry. Elsevier. 490-497. Oxford. American Journal of Medicine. Journal of Agricultural and Food Chemistry. 10. Processed sweet corn has higher antioxidant activity. Dietary flavonoids and cardiovascular disease. Dai Q. New England Journal of Medicine. 54. Kalt W. Bolton C. Chevion S. Feng SB. Leontowicz H. Reactive Oxygen Species: From Radiation to Molecular Biology. R11-R19. Chaovanalikit A and Wrolstad RE. Freese R.unaproa. 1999.12 13 14 15 Cassidy A. Markers of oxidative DNA damage in human interventions with fruit and berries. 2005. Goddyn K. 2006. Nahir M. Heilbrun LK. Wu XZ. Tashma Z. Larson EB. Smith D. 1999. Prineas RJ. Journal of Food Science. Oxidant-induced apoptosis of glomerular cells: Intracellular signaling and its intervention by bioflavonoid. 42. D'Archivio M. Nutritevi dei colori della vita. Phytochemicals Classification and Occurrence In: Encyclopedia of Human Nutrition. Borenstein AR. Santangelo C. 56. Anthierens K. Flavonoids in food and natural antioxidants in wine. 899. 326-334. 751-759. Dewanto V. Folsom AR. Van Camp J. 1998. Bostick RM. 2004. Jovanovic SV and Simic MG. 74. vegetables. Cantagallo A. 240-245. conditiva) and green beans (Phaseolus vulgaris L. Hartog M. Wu Y. Masella R. 50. 2006. Kidney International. Depper JB. Stansbie D. Trakhtenberg S. Lerner HT. Nutrition Metabolism and Cardiovascular Diseases. 524-528. 1887-1892. 54. Djuric Z. Katrich E. Total anthocyanins and total phenolics of fresh and processed cherries and their antioxidant properties. 119. 1998. 2659-2670. 2006. Lababidi S. OEITFL study.). Journal of Food Science. Verbeken D. Martino S. Kushi LH. Jiratanan T and Liu RH. 2006. 1223-1229. 8. Italia. Dragoni F. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: Studies in vitro and in humans. Antioxidant activity of processed table beets (Beta vulgaris var. Jackson JC. 98. 1997. Kemp HJ. Giammarioli S. 2002. Giovannini C. Day AP. and fruits. International Journal for Vitamin and Nutrition Research. 67. 353-357. 1156-1162. 41. American Journal of Clinical Nutrition. 2005. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. Ann Ist Super Sanita.com/icoloridellavita. Libman I. Scazzocchio B. Sanzini E. C67-C72. Current Opinion in Lipidology. Huang DJ. Lairon D and Amiot MJ. 70. Oxidative DNA damage levels in blood from women at high risk for breast cancer are associated with dietary intakes of meats. Leontowicz M. Filesi C. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 130 . Mink PJ. Journal of the American Dietetic Association. Allen L. Nutrition and Cancer-an International Journal. Antioxidants in nutrition. Katan MB and Hollman PCH. Kitamura M and Ishikawa Y. 336-347. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. Berry EM. 2000. 69. Dewettinck K. Gorinstein S. Sagee O. [Polyphenols and endogenous antioxidant defences: effects on glutathione and glutathione related enzymes]. Caballero B. 1998. 52. Harats D. Vitale B. 615-623. Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. Les polyphénols en agroalimentaire. Riso P. Erlinger TP. Revue française d'endocrinologie clinique. 1050-1055.nz/. Kirkham PA. Porrini M. 1997. 72. Culebras JM. Functional claims of article 13: Carotenoids in juices. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Journal of Agricultural and Food Chemistry. 246. 2002.co. New Zealand. Tunon MJ. Folts JD. 2005. 2005. 2000. 95-100. 41. Volkovova K. 78. Ibanez R. Walker D. Prior RL. Noroozi M. Raguzzini A. nutrition et métabolisme. Lin PH. 2006. Scalbert A. 17. anti-oxydants et athérosclérose. Nutr Hosp. 1998. Rounova O. Sacks FM. Lombardia C. 230S-242S. http://www.5aday. 38. Hahn SE. Martinez-Florez S. Lajdova A. 2006. Lecerf J. 419-426. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Importance of diet in protection against oxidative damage. Lecerf J. Oriani G. Collins A. Food habits are associated with lipid peroxidation in an elderly population. Gonzalez S. Neuroendocrinology Letters. Charleston J. PaceAsciak CR. Huerta JM.32 Lasheras C. Bioavailability and bioefficacy of polyphenols in humans. Nutrition. 51. 183. Stein JH. 5 al dia. Diamandis EP. 1480-1487. Maiani G.com/. Lecerf J. 103. Review of 97 bioavailability studies. 88. Ninfali P and Bacchiocca M. 119-141. European Journal of Nutrition. Paris. 271-278. 1439-1452. Serafini M. 27. 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 131 . Wsolova L. Salucci M. 2003. Staruch L. 2003. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: Results from a randomized controlled feeding study. Angerson WJ. American Journal of Clinical Nutrition. 57. 163-182. 2006. 2003. Sanders TAB. http://www. I. Flavonoids protect against oxidative damage to LDL in vitro: Use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radical Research. 570S-578S. Dusinska M. 100. Lean MEJ. 67. Atherosclerosis. 81. Biswas SK. Fruits and vegetables in the prevention of cellular oxidative damage. Functional claims of Article 13: Polyphenols in juices. 1210-1218. British Journal of Nutrition. Effect of acute ingestion of fresh and stored-lettuce (Lactuca sativa) on plasma total antioxidant capacity and antioxidant levels in human subjects. 1999. 33. Circulation. 5+ A Day fruits and vegetables. 249-272. Appel LJ. [Flavonoids: properties and antioxidizing action]. Remesy C. Azzini E. American Journal of Clinical Nutrition. American Journal of Clinical Nutrition. Morand C. 175-182. International Journal of Food Sciences and Nutrition. Polyphenols and antioxidant capacity of vegetables under fresh and frozen conditions. Bugianesi R. Biochemical Pharmacology. 2006. Manach C. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Sarni-Manchado P and Cheynier V 2006. Ruxton CHS. O'Reilly JD. 2222-2226. 1999. 2002. Gardner EJ. 2002. Journal of the American Dietetic Association. 1996. 2006. Clinica Chimica Acta. Lecerf J. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. Williamson G. Svetkey LP. Rahman I. Patterson AM. 112-115. Staruchova M. Spain. Fernandez S. Tec & Doc. Keevil JG.5aldia. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. Gonzalez-Gallego J. Wiseman H. Goldberg DM. Wiebe DA. Miller ER. Aeschlimann S. Regulation of inflammation and redox signaling by dietary polyphenols. Miseanova C. 6126-6132. 2004. Wang SY. Urquiaga I and Leighton F. González-Aguilar GA. Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. Anlasik T. 55-64. 2004. 2003. Fuhrman B. Journal of Agricultural and Food Chemistry. 37. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. Review of 93 intervention studies. 126. Griffiths HR. Heimendinger J. Bray GA.fruitsandveggiesmatter. 2000. Kaplan M. 943-948. Sacks FM. Improving the nutritional quality of microwave-vacuum dried strawberries: A preliminary study. 94. Aprifel (Agence fruits et legumes frais). Handb Exp Pharmacol. Polidori MC. N Engl J Med. Bioavailability and bioefficacy of polyphenols in humans. Obarzanek E. 2001. Scholze G. 1999. Williams RJ. Selhub J. BNF (British Nutrition Foundation). 31. 2005. Gillette C. WHO Technical Report Series 916. Rice-Evans C. ID 1216: “Vegetables (fresh. Wang CY. Williamson G and Manach C. 838-849. Heimendinger J. 687-695. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. In vivo investigation of changes in biomarkers of oxidative stress induced by plant food rich diets. bottled. UK.com. Effect of storage temperatures on antioxidant capacity and aroma compounds in strawberry fruit. Rosenberg IH. Paris. USA. canned. Wilson PWF. bottled. Kuhnert S. Gillette C. 639-642. 81. 3025-3031. Stahl W. Aviram M. Biological Research. Expert Report: Diet. Wolfe P.eatincolour. 1996. Sedlacek SM. frozen. Plants: Diet and Health – The Report of the British Nutrition Foundation Task Force. Bohm V. Vascular and anti-oxidant actions of flavonols and flavones. 2004. 4 5 6 7 8 132 . Rohm H. Woodman OL and Chan EC. 1117-1124. dried. Vogt TM. Haegele A. 2261-2266. 20. frozen. Sedlacek SM. Karanja N. Mecocci P. 263-300. juiced)” and “Protection of body tissues and cells from oxidative damage” 1 2 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Food and Chemical Toxicology. 243S-255S. 2005. Eat a variety of fruits & vegetables every day. 2005. www. Cutler JA. Flavonoids: Antioxidants or signalling molecules? Free Radical Biology and Medicine. Vollmer WM. 2003. Wolfe P. Plant polyphenol antioxidants and oxidative stress. 33. nutrition and prevention of chronic diseases. 55 56 57 58 59 60 61 62 63 ID 1214: “Fruits (fresh. 1997. Clinical and Experimental Pharmacology and Physiology.54 Thompson HJ. Tucker KL. 2006. Br J Nutr. Apports nutritionnels conseillés pour la population française. Appel LJ. Thompson HJ. 67. 1999. 36. 336. Report of a Joint WHO/FAO Expert Consultation. Weisburger JH. II. Conroy C. A clinical trial of the effects of dietary patterns on blood pressure. Editions Tec&Doc. dried. Journal of Nutrition. Windhauser MM. DASH Collaborative Research Group. 786-790. O'Neill C. American Journal of Clinical Nutrition. 37. LWT-Food Science and Technology. juiced)” and “Modulation of glycemic response” 1 WHO/FAO (World Health Organization and Food and Agriculture Organization). Svetkey LP. Ayala-Zavala JF. 2005. Food Science and Technology International. Haegele A. Carcinogenesis. www. Mechanisms of action of antioxidants as exemplified in vegetables.aprifel. Spencer JPE. O'Neill C.gov.com. Moore TJ. Effect of increased vegetable and fruit consumption on markers of oxidative cellular damage. 53. www. canned. tomatoes and tea. Eat in colour. Rosenblat M. 12. Sies H. Lin PH. 70. Dewanto V. 2007. Leontowicz M. Wu X. Nutr Cancer. Effects of production and processing factors on major fruit and vegetable antioxidants. Journal of Food Science. 2004. Wu Y. vegetables. J Agric Food Chem. 2004. 129. Hautvast JG. 50.). Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. 490-497. Stansbie D. 899. J Agric Food Chem. 98. Effect of high intakes of fruit and vegetables on redox status in type 2 onset diabetes: a pilot study. Bostick RM. DGE (Deutsche Gesellschaft für Ernährung). Prentice A (eds. 2005. Am J Clin Nutr. Martino S. N Engl J Med. 751-759. Jovanovic SV and Simic MG. 2002. 2005. Nutr Rev. Am J Med. Allen L. Nahir M. Norman Y. Journal of Food Science. 1998. Total anthocyanins and total phenolics of fresh and processed cherries and their antioxidant properties. 52. Eskes TK. Polyphenols: chemistry. Ann NY Acad Sci. J Agric Food Chem. Sagee O. 133 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 . 74. Goddyn K. 11-19. Dragoni F. Jackson JC. Kidney Int. Obst und Gemüse in der Prävention chronischer Krankheiten. Santangelo C. Kitamura M and Ishikawa Y. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. Caspi A. conditiva) and green beans (Phaseolus vulgaris L. 42. Duran M. Van Camp J. Antioxidant activity of processed table beets (Beta vulgaris var. 54. 1135-1139. Folsom AR. Giammarioli S. Elsevier. Markers of oxidative DNA damage in human interventions with fruit and berries. Lerner HT. Huang D. Oxidant-induced apoptosis of glomerular cells: intracellular signaling and its intervention by bioflavinoid. Dai Q. Vitale B. Verbeken D. Katan MB and Hollman PCH. [Polyphenols and endogenous antioxidant defences: effects on glutathione and glutathione related enzymes]. D'Archivio M. Caballero B. Meyboom S. Liu RH. 1-4. Kushi LH. Borenstein AR. 119. Jiratanan T and Liu RH. 1156-1162. 2006. 1998. 1999. Feng S. 4959-4964. 41. J Am Diet Assoc.). 2004. Ann Nutr Metab. 240-245. Steegers-Theunissen RP. Oxidative DNA damage levels in blood from women at high risk for breast cancer are associated with dietary intakes of meats. OEITFL study. Thomas CM. 2006. Wu Y. 2000. 2006. and nutritional significance. Sanzini E. Katrich E. 56. 1223-1229. dietary sources. 2006. Libman I. 2659-2670. 2006. Cassidy A. Chevion S. Anthierens K. Dietary flavonoids and cardiovascular disease. Mink PJ. Hartog M. Giovannini C. 69. Int J Vitam Nutr Res. Prineas RJ. Bolton C. Trakhtenberg S. Phytochemicals Classification and Occurrence In: Encyclopedia of Human Nutrition. 334. Chaovanalikit A and Wrolstad RE. 18871892. metabolism. van Dusseldorp M. 1996. Filesi C. 524-528. Bibliographical study on the nutritional benefits of processed fruit and vegetables. Cantagallo A. 1999. Lababidi S. Processed sweet corn has higher antioxidant activity. and fruits. 317-333. Smith D. Freese R. Uhley V. 54. Oxford. Brouwer IA. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. Scazzocchio B. Gorinstein S. Tashma Z. West CE. 336-347. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans. Antioxidants in nutrition. Larson EB.9 10 Bravo L. 67. Nutrition Metabolism and Cardiovascular Diseases. 8. 313-320. van het Hof KH. Kemp HJ. Heilbrun LK. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Day AP. Harats D. J Nutr. 1998. 56. Depper JB. 353-357. Leontowicz H. 1998. Filesi C. Berry EM. 326-334. 143-147. Ann Ist Super Sanita. Kalt W. Djuric Z. 1997. Masella R. Dewettinck K. 39 40 41 42 43 44 45 46 47 48 49 50 51 134 . Bugianesi R. 1996. Kirkham PA. 72. Aeschlimann S. Int J Food Sci Nutr. Sanders TA. Lasheras C. Folts JD. Manach C. Patterson AM. Wiebe DA. 112-115. Pasteur Institute-Lille. 2003. Keevil JG. Huerta JM. 163-182. Wolfe P. Heimendinger J. Goldberg DM. 2261-2266. 2002. 2000. Salucci M. Culebras JM. Les polyphénols en agroalimentaire. Miller ER. Lecerf J. 17.30 31 32 33 34 35 36 37 38 Lairon D and Amiot MJ. Volkova K. Morand C. Sarni-Manchado P and Cheynier V 2006. Angerson WJ. 100. Bioavailability and bioefficacy of polyphenols in humans. Functional claims of article 13: Carotenoids in juices. 183. 20. 419-426. Dusinska M. 57. Polyphenols and antioxidant capacity of vegetables under fresh and frozen conditions. 1999. Appel LJ. Nutr Hosp. Ruxton CH. Wsolova L. Pasteur Institute-Lille. Charleston J. 95-100. 2005. 570S-578S. Porrini M. 1999. Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. Lecerf J. 33. Thompson HJ. Svetkey LP. 78. Azzini E. O'Neill C. 271-278. Nutrition. 230S-242S. Gonzalez-Gallego J. Fernandez S. Haegele A. Effect of increased vegetable and fruit consumption on markers of oxidative cellular damage. 23-28. 119-141. Staruchova M. Hahn SE. 1999. Eur J Nutr. J Am Diet Assoc. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: results from a randomized controlled feeding study. Tunon MJ. Martinez-Florez S. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Flavonoids in food and natural antioxidants in wine. Regulation of inflammation and redox signaling by dietary polyphenols. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. 615-623. Prior RL. Importance of diet in protection against oxidative damage. 2002. Pace-Asciak CR. Rahman I. J Agric Food Chem. 51. Curr Opin Lipidol. Gonzalez S. 67. Wiseman H. 2006. 27 Suppl 2. Br J Nutr. Lecerf J. Erlinger TP. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. I. 103. 2006. 175-182. Collins A. Pasteur Institute-Lille. Williamson G. Oriani G. 2005. Functional claims of Article 13: Polyphenols in juices. Clin Chim Acta. Staruch L. Lean ME. [Flavonoids: properties and antioxidizing action]. 246. 2006. Scalbert A. Am J Clin Nutr. Effect of acute ingestion of fresh and stored lettuce (Lactuca sativa) on plasma total antioxidant capacity and antioxidant levels in human subjects. 10. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. 1999. 1210-1218. 88. Ibanez R. Biochem Pharmacol. Lecerf J. 2002. Gardner EJ. Serafini M. 2003. 1050-1055. Am J Clin Nutr. 38. Biswas SK. Conry C. Gillette C. 2006. Flavonoids protect against oxidative damage to LDL in vitro: use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radic Res. Fruits and vegetables in the prevention of cellular oxidative damage. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. Maiani G. Food habits are associated with lipid peroxidation in an elderly population. Raguzzini A. Misl'anova C. 41. Lombardia C. Review of 97 bioavailability studies. Ninfali P and Bacchiocca M. Paris. Neuro Endocrinol Lett. 2003. O'Reilly JD. 1439-1452. Tec & Doc. Am J Clin Nutr. Walker D. 1480-1487. Sedlacek SM. anti-oxydants et athérosclérose. 249-272. Circulation. Remesy C. 1998. Atherosclerosis. Lajdova A. Lin PH. Riso P. Sacks FM. 2006. Carcinogenesis. Rounova O. 81. 1997. Rev Fr Endocrinol Clin. Diamandis EP. Stein JH. 2222-2226. Noroozi M. Smith A. 293-315. bottled. Archiv fur Psychiatrie und Nervenkrankheiten. 1997. Urquiaga I and Leighton F. 2001. www. 1929. 3025-3031. Tucker KL.52 Thompson HJ. 943-948. 87. Review of 93 intervention studies. Heimendinger J. 624. Sutherland D. 527-570. ID 1219: “Vegetables (fresh. 217-231. Effects of caffeine on mood and performance: a study of realistic consumption. Brunia CH. Christopher G. 33. 31. Bastiaansen MC and Brunia CH. Sedlacek SM. Williamson G and Manach C. Selhub J. 112. Williams RJ. Vascular and anti-oxidant actions of flavonols and flavones. 2 3 4 5 6 7 8 9 10 11 135 . Ekborg-Ott KH. 2000. Int J Neurosci. 6. UK. 47-53. J Agric Food Chem. 2003. 45. 1954. In vivo investigation of changes in biomarkers of oxidative stress induced by plant food rich diets. Roberts EAH. ID 1222: “Camellia sinensis (Common Name: Tea)” and “Mental and cognitive health” 1 Bastiaansen MC. Rosenberg IH. Anticipatory attention: an event-related desynchronization approach. Cartwright RA. 2004. Gillette C. Journal of the Science of Food and Agriculture. 838-849. 353-363. 55-64. 91-107. Effects of caffeine in non-withdrawn volunteers. WHO Technical Report Series 916. 2001. Wolfe P. Renard M. Jadot J. Über das Electroencephalogram des Menschen. dried. 1999. de Munck JC. Expert Report: Diet. 2005. 6126-6132. Psychopharmacology (Berl). Burger H. nutrition and prevention of chronic diseases. 5. Am J Clin Nutr. [Separation and characterization of N-ethyl-gamma-glutamine from Xerocomus badius. juiced)” and “Modulation of glycemic response” 53 54 55 56 57 58 59 1 WHO/FAO (World Health Organization and Food and Agriculture Organization). 126. canned. 442-452. Armstrong DW. Bocker KB. Plant polyphenol antioxidants and oxidative stress. Delmonte MM. Weisburger JH. 243S-255S. Taylor A.eatincolour. Clin Exp Pharmacol Physiol. 188-192. Haegele A. II. tomatoes and tea. Biol Res. 2005. 1992. Mechanisms of action of antioxidants as exemplified in vegetables. Woodman OL and Chan E. 393-403. Casimir J. 2002. 1984. 1970. J Chromatogr. 37. Spekreijse H. 24. Event-related desynchronization during anticipatory attention for an upcoming stimulus: a comparative EEG/MEG study.]. Wood DJ. Hum Psychopharmacol. 39. 1960. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. 462-468. an amino-acid n-ethyl amide present in tea. 36. Varietal differences in the total and enantiomeric composition of theanine in tea. Engelhardt UH. Clin Neurophysiol. 164. 53. Kuhr S. 20. Wilson PW. 786-790. Brown BB. Food Chem Toxicol. Chromatography of tea constituents.com. Bioavailability and bioefficacy of polyphenols in humans. Recognition of aspects of consciousness through association with EEG alpha activity represented by a light signal. Brice CF and Smith AP. frozen. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med. 1996. Finger A. Psychophysiology. 2004. Rice-Evans C. 43. Int J Psychophysiol. Biochim Biophys Acta. Eat in colour. J Agric Food Chem. Report of a Joint WHO/FAO Expert Consultation. 2005. Theanine. Electrocortical activity and related phenomena associated with meditation practice: a literature review. 81. Spencer JP. J Nutr. O'Neill C. Kobayashi K. Ebashi T. Fu KM. Plant Cell Physiol. Kimura R and Murata T. Higgins BA. 136. Nakagawa M. Central depressant effect of theanine. Yonago J. 1998. Ahlfors SP. J Nutr. Kamei T. Yokogoshi H. Okubo T. Kim KS. Nehlig A. 1998. Simpson GV. Nagai Y. Lee Y. Hashimoto M. Machi Y. 3929-3933. Emmanuele L. Lieberman HR. Holmen J. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. Gomez-Ramirez M. Parieto-occipital approximately 10 Hz activity reflects anticipatory state of visual attention mechanisms. Kimura H. 17. Effect of Palatinose Administration on a1 Brain Waves in Human Volunteers. 153-157. Tulley R. Speckman KL. Pachinger T. 1998. Nutrition and Health for the 21st Century. Nonvolatile components of black tea and their contribution to the character of the beverage. Lorist MM and Snel J. Fredholm BB. Nagashima Z. 141-145. Owen GN. Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein. Sugimoto S. 1999. Locher R. 1999. 434. 13. Brain Res Cogn Brain Res. 3053-3057. Eur J Pharmacol. Swaine D. Yum KS. 2001. sleep loss. Nagato Y. 145-152.a unique amino acid of green tea and its relaxation effect in humans. Effect of changes in muscle tension and brain alpha wave activity induced by functional beverage on golf activity. Murray MM. Konishi S and Takahashi E. 2002. 717-722. Katakura M. Crispin DJ. Reilly RB. Klimesch W. Shukitt-Hale B. Free amino acids in tea IV: quantitative changes in the manufacture of black and green tea. 401-413. Journal of Agricultural and Food Chemistry. 2006. Effects of L-theanine on the release of α-brain waves in human volunteers. 2001. 1999. L-theanine . 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 136 . Chem Pharm Bull (Tokyo). 1969. IEEE Trans Neural Syst Rehabil Eng. 30. Schwaiger J. Battig K. 2007. Psychopharmacology (Berl). Lalor EC. and stress on cognitive performance and mood during U. Javitt DC. Doppelmayr M. 12. Attention-dependent suppression of distracter visual input can be cross-modally cued as indexed by anticipatory parietooccipital alpha-band oscillations. Foxe JJ. 51. Vetter W. Kim M. 164. Existence and synthesis of L-glutamic acid g-methylamide in tea plants. Nehlig A. Nippon Nōgei Kagakukaishi. 1-7. Aoi N. Toriumi Y. 563-576. 72. Kashimura J. 7. 357-360. Juneja LR. 1966. Zvartau EE. Pharmacol Rev. Caffeine effects on perceptual and motor processes. 1043-1047. Agr Chem Soc Japan. Clinical Neuropharmacology. 2003. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Chu DC. 172-178. Stress and Health. Electroencephalogr Clin Neurophysiol. 9. Navy SEAL training. Long-term administration of green tea catechins improves spatial cognition learning ability in rats.12 13 14 Foxe JJ. Neurosci Lett. Effect of theanine on norepinephrine and serotonin levels in rat brain. The Deployment of Intersensory Selective Attention: A High-density Electrical Mapping Study of the Effects of Theanine. Are we dependent upon coffee and caffeine? A review on human and animal data. 19. Effects of caffeine. 199-204. Sato H. 83-133. I. 2001. 1957. Shido O. Rycroft JA. 23. 17. Correlation between alpha rhythms and natural killer cell activity during yogic respiratory exercise. Tokumura H. Food Science and Technology Research. 9. Shpaner M. Foxe JJ. Proceedings of the International Symposium on Food. 171-175. Induced alpha band power changes in the human EEG and attention. Trends in Food Science & Technology. Neurosci Biobehav Rev. Kelly SP. Schroeder CE. Kimura K. 244. 1971. 10. 102. 1257-1261. 169-173. 250-261. Toriumi Y. 34. Mahoney J. Hara Y. Juneja LR. 73-76. Niketan JY. Sea-Air-Land. 1986. Kimura R and Murata T. 2005. Tanabe Y. Foxe JJ. Nagato Y. Yamamoto T. 2002. Chem Pharm Bull (Tokyo).S. 25. 31. Tharion WJ. 1997. Suter PM. Visual spatial attention tracking using high-density SSVEP data for independent brain-computer communication. Higgins BA. Millin DJ. Russegger H. Neuroreport. Haque AM. Barton M. Chung KI. Saitoh K. Snel J. Kobayashi M. Royal Jelly monograph. 2000. J Neurosci. 24. Hari R. 1997. 428-435. Electrophysiological studies of dreaming as the prototype of a new strategy in the study of consciousness. Song CH. Song CH. Olson T. 473-482. 7141-7147. Theanine-induced reduction of brain serotonin concentration in rats. Yokogoshi H. Englewood. The effects of caffeine on visual selective attention to color: an ERP study. Passmore AP. Time-dependent changes of amino acids in the serum. Smith AP. 2001. Terashima T. 749-756. Effect of theanine. Physiological patterns during practice of the Transcendental Meditation technique compared with patterns while reading Sanskrit and a modern language. Takido J. Psychophysiology. 1593-1596. 20. Mochizuki M. Gupta HK. Unno T. Modulation of the parieto-occipital alpha rhythm during object detection. Kondowe GB. 637-645. Hayakawa T. Kim KS. 137 . Wickremasinghe RL. The influence of different doses of caffeine on visual task performance. 1999. 1243-1255. Savory M. Biosci Biotechnol Biochem. 2000. Kakuda T. Micromedex Inc. 1968. Korean Journal of Nutrition. Yokogoshi H. Psychophysiology. 80. Moriya K. Food Chem Toxicol. Mochizuki M. gammaglutamylethylamide. 2003. J Agric Food Chem. J Korean Acad Fam Med. ID 1228: “Royal jelly” and “Glands function” 46 47 48 49 50 51 52 1 No authors listed. 75. brain and urine of rats administered with theanine. 23. Eaton-Williams P. 71-80. Johnston GD. Rusted JM. Walsh DH. A new amide–theanine. 72. r-glutamylethylamide. 1974. 1999. 262-267. 2001. Egenes T. liver. Kim KS. Eur J Appl Physiol Occup Physiol. Neurochem Res. 63. Leathwood P. Gallagher J. In: Micromedex Healthcare Series. Effects of Theanine on the Release of Brain Alpha Wave in Adults Males. 47. Biosci Biotechnol Biochem. Relaxation effects in humans of underwater exercise of moderate intensity. Yokogoshi H. Travis F. Effects of caffeine on human behavior. Sakato J. J Neurosci. Ruijter J. 1990. 36. 667-673. Nakagawa K. in rats. Sang WS. Worden MS. Psychol Rev. Agr Chem Soc Japan. 23. 13. 1950. Ruijter J. 1999. Neuropsychobiology. 1978. 1998. Hum Psychopharmacol Clin Exp.33 34 35 36 37 38 39 40 41 42 43 44 45 Oda S. Suzuki Y. 160-163. 1999. 14. Effects of a low dose of caffeine given in different drinks on mood and performance. Lorist MM. De Ruiter MB. Tea. Advanced Food Research. Effects of caffeine given before and after lunch on sustained attention. 37-48. Snel J. 62. 192-205. Int J Neurosci. Terashima T. Simpson GV. 918-923. Metabolism of theanine. Wang N. 1999. 40. 17. 253-259. Tsuge H. The Effects of L-theanine Containing Functional Beverage on Mental Relaxation and Fatigue Perception. 229-286. Studies on the chemical constituents of tea. Chung KI. 1987. Interactive effects of alpha feedback and instructional set on subjective state. 2002. Sturgess W. 1998. Stoyva J and Kamiya J. 23. 427-439. 11. Journal of Psychophysiology. RC63. Matsumoto T. Oh JS. 37. 109. Smith A. Renal and cardiovascular effects of caffeine: a doseresponse study. Smith A. 615-618. 23. Anticipatory biasing of visuospatial attention indexed by retinotopically specific alpha-band electroencephalography increases over occipital cortex. 816-817. 2002. Clin Sci (Lond). Revonsuo A. Vanni S. on brain monoamines and striatal dopamine release in conscious rats. Foxe JJ. ID 1229: “Royal jelly” and “Antioxidant properties” 3 4 5 1 2 3 4 5 6 Fontana R. Vittek J. Reardon R. Palma MS. Nephrol Dial Transplant. Шатохина РК. Xu T. 31-32. 30. AAPD (American Academy of Pediatric Denstistry). 127-131. Mandel ID. Bee pollen as a health food. Bartels CL. 1984. Paniushkin VV. Valentijn-Benz M.124.Oral Health Policies. http://www. Chapter I Food and Drug Administration Departement of Health and Human Services. New York. 1994.80 Dietary Noncariogenic Carbohydrate Sweeteners and Dental Caries. Bots CP. Bezemer PD. Valentijn RM. 1996. 919-928. 18. Санкт-Петербург. 51. Suzuki N. 363-367. 1990. 2005. Orsolic N. and cosmetics. Eksp Klin Farmakol. Burt BA. 65. J Clin Dent. Korevaar JC. 2 3 4 5 6 7 8 9 10 138 . Barton J. de Souza BM.org/dental/xerostomia. 153-161. Comp Immunol Microbiol Infect Dis. Experientia. drugs. J Med Food. 137. Helping patients with dry mouth. Antioxidant properties of enzymatic hydrolysates from royal jelly. Barnes VM. J Pharmacol Sci. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. 2006. 14. Balbo F. 2004. Tadic Z.htm. Helping patients with Dry Mouth. [Comparative study of anabolizing activity of apilac and methandrostenolone on a model of isolated overload of the rat skeletal muscle]. The effect of chewing sorbitol-sweetened gum on salivary flow and cemental plaque pH in subjects with low salivary flow. ter Wee PM.2 Gadzhieva DM. 9. Inoue R. Birkhed D. Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (Apis mellifera).and sorbitolcontaining chewing gums for their effect on supragingival plaque accumulation. 1995. Policy on the Use of Xylitol in Caries Prevention. Curtis J. Food and Agriculture Organization of the United Nations. Bijlsma JA. 106-109. Value-added products from beekeeping. 927-935. Seifulla RD. Njari B.oralcancerfoundation. 1990. 190-196. John Wiley & Sons. Valpotic I. Krell R. Van Amerongen BM. 2. Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. 2007. Santarpia P. 16. 578584.and xylitol-sweetened chewing gum in caries control. Cronin M. 25. Brand HS. Peptides. FAO Agricultural Services Bulletin No. J Am Dent Assoc. Pharmacological basis of traditional medicines and health supplements as curatives. ID 1240: “Sugar-free chewing gum” and “Dry Mouth (Reduces/ Improves Dry Mouth)” 1 Title 21. 20. Rome. 1-5. Chewing gum and a saliva substitute alleviate thirst and xerostomia in patients on haemodialysis. Mendes MA. 1996. Code of Federal Regulations. Axell T. FDA Consumer. Three clinical trials comparing xylitol. Larkin T. Leung A and Foster S. Лекарственное растительное сырье животного происхождения. 1996. Abelson DC. Reference Manual . Konno K. Basic I. 5. 2006. Nagai T. 2006. A multi-centre study. Gordon J. 103. 1994. 56-57. 2002. 21-22. Food and Drugs. Cesar LM. The use of sorbitol. Swed Dent J. Veerman EC. Nagashima T. J Clin Dent. Subchapter B Food for Human Consumption Part 101 Food labeling Subpart e 101. Текст лекций. Nieuw Amerongen AV. 2005. Vos PF. 31-38. Clinical evaluation of the anti-plaque effect of a commercial chewing gum. Encyclopedia of common natural ingredients used in food. Sver L. 3-5. Bartels and Foundation OC. Miyata T. A royal jelly as a new potential immunomodulator in rats and mice. 19. Richter R. Malaspina O. J Clin Dent. Bjornstrom M. Ordzhonikidze ZG. 1997. Dawes C. Portugal H. 2007. 159-162.htm. Glycemic and insulinemic meal responses modulate postprandial hepatic and intestinal lipoprotein accumulation in obese. London. 2000. 378-384. Chen CY. Chewing gum and saliva in oral health. Perdreau S. Trahan L. Kraft Biscuits Europe R& D. A clinical and biochemical study. 2007. NIDCR (National Institute of Dental and Craniofacial Research). and the feeling of dry mouth in xerostomic patients. 101. Agnetti V. 77-92. Soderling E. 28-31. Effect of sorbitol. British Dental Association Publication. Chewing gum as aid in treatment of hyposalivation. 14 15 16 17 18 19 20 21 22 23 24 25 26 ID 1241: “Plain Biscuits (such as "LU petit déjeuner")” and “The appearance. Risheim H and Arneberg P. Lorec AM. xylitol-sorbitol. Synopsis of individual human intervention study. Xylitol: a review of its action on mutans streptococci and dental plaque--its clinical significance. Chewing gum-facts and fiction: a review of gum-chewing and oral health. Clin Prev Dent. 57. Markovic N. 71-75. Loesche W. 197-203. Makinen KK. 1975. 80. 1998. 2006. 170-177. (Unpublished). 31-34. Charbonnier M. Dry Mouth (Xerostomia). 1988. 4 5 139 . 79-85. Clinical study report. 10. Atkinson F. Scientific Dossier to substantiate the generic health claim for the biscuit food category: ―Biscuits supply carbohydrates. Dentistry Monthly. 1991. Harbis A. 2008. 33-40. Int Dent J. Vincent-Baudry S.” 1 2 3 Brand-Miller J. Crit Rev Oral Biol Med. Dental plaque formation and salivary mutans streptococci in schoolchildren after use of xylitol-containing chewing gum. Eur J Oral Sci. J Clin Dent. Lang V. Odusola F. 1992. Spak CJ. 273-279.gov/OralHealth/Topics/DryMouth/default. Makinen PL. and placebo chewing gums on the plaque of habitual xylitol consumers. 46-49. 7. Huyghebaert A. Palliat Med. Trahan L. Raccah D. 14. Mandel ID. The glycemic index of cereal products in a realistic breakfast modulates satiety. NY State Dent J. in the blood circulation. Ghent University. regularly and continuously absorbed and released throughout the morning‖. Acta Odontol Scand. Effect on plaque of a xylitol-containing chewing-gum. Mandel ID. Salivary stimulation by chewing gum and lozenges in rheumatic patients with xerostomia.11 12 13 Davies AN. 8. 40-43. Int J Paediatr Dent. Edgar WM. 1991. Caries Res. 49. 105.nih. 33. Itthagarun A and Wei SH. Pape HR. Abelson DC. 896-902. 1989. American Journal of Clinical Nutrition. Fuzellier G. Gerodontology. O'Mullane DM. 1997. Saliva and Oral Health. Vinoy S. Senft M. Soderling E. 45. Remineralizing potential. Axell T. Bernard MC. oral mucosal friction. Determination of the postprandial responses to two cereal foods eaten alone or as part of a mixed meal. Odusola F. 23. and xylitol/sorbitol chewing gums on dental plaque. 2004. The effect of a chewing gum on salivary secretion. insulin-resistant subjects. Olsson H. Scheinin A. antiplaque and antigingivitis effects of xylitol and sorbitol sweetened chewing gum. Scand J Dent Res. Holgerson PL. 17. Acta Odontol Scand. Vinoy S. of exogenous glucose from biscuits consumed for breakfast is moderate and stable throughout the morning. Thornhill MH. xylitol. Mouton C. http://www. Imfeld T. Chapelot D. Stecksen-Blicks C. Hakkinen L. Effects of xylitol. Makinen KK. 14. Louis-Sylvestre J.. Sjostrom I. Steinberg LM.nidcr. 1993. Tammiala-Salonen T. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Jr. Defoort C. Sorbitol gum in xerostomics: the effects on dental plaque pH and salivary flow rates. 2004. Holt S. 1999. Review report. Twetman S. 1995. Care of the Dry Mouth. Donazzolo Y. Lairon D. 405-419. antiinflammatory and antipyretic studies on propolis bee products. Natural propolis extract NIVCRISOL in the treatment of acute and chronic rhinopharyngitis in children. Melliou E and Chinou I. Petrescu A. 158. Review Report. 229-238. 217-221. Shah SA. 77-82. 73 Suppl 1. 1993. placebo-controlled. multicenter study. Degirmenci U. 29-32. Fuzellier G. de Castro SL and Higashi KO. 35. Effect of different formulations of propolis on mice infected with Trypanosoma cruzi. Belu O. Bactericidal effect of propolis in vitro against agents causing upper respiratory tract infections. Metabolic fate of 4 cereal products consumed as part of a breakfast by healthy female subjects. Dobrowolski JW. Sharma K. Khayyal MT. Recent trends and important developments in propolis research. Sharma K. 35. 140 . Rom J Virol. Antibacterial. Ercil M. 561-571. Naqvi SA. J Ethnopharmacol. antiamoebic. J Ethnopharmacol. Naqvi SA. 115-133. Martins CH. Fitoterapia. 2006. antiinflammatory and antipyretic studies on propolis bee products. Gremiao MP. Gausseres N. Vinholis AH. el-Shafei S. Crisan I. 17. Casemiro LA. Jucu V. 90-95. Unlu S. 46. Varsano I. 1991. Lara EH. Popovici F. 32. Uziel Y. Cinel L. 77-82. Shah SA. Rabasa-Lhoret R. Focht J. ID 1242: “Propolis” and “improvement of ventilatory functions /Respiratory health” 1 2 3 Bankova V. Clincal Study Report. 2002. Tezuka Y. propolis. 2001. Recent progress in pharmacological research of propolis. 1991. Nielsen JV. J Ethnopharmacol. S1-6. antifungal.6 7 8 Laville M. Clinical study report. Preparation and antimicrobial activity of gelatin microparticles containing propolis against oral pathogens. van den Berg-Segers A. 1995. de Castro SL and Higashi KO. Kadota S. Dobrowolski JW. Effects of caffeic acid phenethyl ester on lipopolysaccharide-induced lung injury in rats. Arzneimittelforschung. Kadota S. Antibacterial. Braesco V. antifungal. Phytother Res. Tezuka Y. Sarrell EM. and vitamin C in preventing respiratory tract infections in children: a randomized. ID 1243: “Propolis” and “Antioxidant properties” 4 5 6 7 8 9 10 11 12 1 2 3 Banskota AH. antiamoebic. Jannot C. Drug Dev Ind Pharm. Phytother Res. Dandiya PC. Tamer L. 2004. 70. Chemical analysis and antimicrobial activity of Greek propolis. Mutiu A. Normand S. Castaldo S and Capasso F. 19. el-Khatib AS. Planta Med. Recent progress in pharmacological research of propolis. Vohora SB. Arch Pediatr Adolesc Med. Cohen HA. 1995. 46. Rabasa-Lhoret R. an old remedy used in modern medicine. 921-923. Paquot N. Kanik A. 2001. el-Ghazaly MA. 55-58. Hansen SH. 46. 55-58. Vohora SB. 15. Koksel O. 2007. J Ethnopharmacol. Dascalu C. Evid Based Complement Alternat Med. Peronnet F. Panzeri H. Dandiya PC. Bruschi ML. 15. Effectiveness of an herbal preparation containing echinacea. Riezler R. 561-571. double-blind. 2003. A clinical pharmacological study of the potential beneficial effects of a propolis food product as an adjuvant in asthmatic patients. 2005. 93-102. 1995. 515-519. Kahan E. Hatem AM. Khattab MM. Pulm Pharmacol Ther. 2007. de Vries PJ. Effect of different formulations of propolis on mice infected with Trypanosoma cruzi. Fundam Clin Pharmacol. Measurement of metabolic outcome of carbohydrates of 2 types of cereal products. 2004. Propolis. Zaharia CN. Banskota AH. 43. Centre Hospitalier Universitaire de Liège. 2006. 2005. Ozdulger A. 2. 1187-1193. 1135-1139.) fruit. Paulino N. Clarke RJ and Macrae R (ed. Scremin A. 845-852. 4 5 6 7 8 141 . J Agric Food Chem. Biosci Biotechnol Biochem. and cardiovascular disease? The common soil hypothesis revisited. Duran M. occurrence. 54. Abreu SR. Bulgarian propolis induces analgesic and anti-inflammatory effects in mice and inhibits in vitro contraction of airway smooth muscle. Hagiwara T. ID 1256: “Acerola” and “Antioxidant activity” 4 5 1 2 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Paulino N. 899-906.) Elsevier Applied Science Publications. de Castro SL. Martins R. Mornar A. 2007. Chlorogenic acids and other cinnamates–nature. J Ethnopharmacol. Paulino N. Saric A. Apports nutritionnels conseillés pour la population française. In: Coffee. Van Dusseldorp M. dietary burden. 362-372. Marotti T. 2002. Balog T. Radic S. Scremin A. Hautvast T. Vol 1. 80. Is oxidative stress the pathogenic mechanism underlying insulin resistance. Journal of the Science of Food and Agriculture. Water extract of propolis and its main constituents. Marcucci MC. 72. 2003. Van Het Hof KH. 1033-1043. Bucan K. Chemistry. 79. 80. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. The Journal of Nutrition. Shimazawa M. Fombeur J and Samana. Sverko V. diabetes. Medic-Saric M. 2005. Scremin A. Anti-hyperalgesic effect of an ethanolic extract of propolis in mice and rats. London. 2000. 76. 8018-8026. Calixto JB. Kusic B. Calixto JB. Hanamura T. Katalinic V. Thomas CMG. Paulino N. Brouwer IA. 1191-1201. 2007.4 Jasprica I. Mayer L. Oxidant/antioxidant properties of Croatian native propolis. ID 1246: “Propolis” and “throat comfort” 5 6 7 1 2 3 de Campos RO. 1999. 110. Calixto JB. Ueda R. In vivo study of propolis supplementation effects on antioxidative status and red blood cells. 1998. 55. Rusak G. da Silva CH. J Pharmacol Sci. Eskes T. Longhi DT. 2004. Teixeira C. Bankova V. Hara H. J Pharm Pharmacol. 548-554. J Pharm Pharmacol. Dirsch VM. Structural and functional characterization of polyphenols isolated from acerola (Malpighia emarginata DC. Etude Pilote propolis versus placebo. Sverko V. Debeljak Z. Clifford M. Editions Tec&Doc. Rapport clinique. Japan. Sobocanec S. 816-823. exert neuroprotective effects via antioxidant actions. Chlorogenic acids and other cinnamates-nature. Clifford MN. Kawagishi H. 1991. Nakayama T. Smolcic-Bubalo A. occurrence and dietaryburden. West CE. Balog T. Beneficial role of dietary phytoestrogens in obesity and diabetes. 2006. Antioxidant prenylated flavonoids from propolis collected in Okinawa. Am J Clin Nutr. 280-286. 370-377. Planta Med. 1985. Bhathena SJ and Velasquez MT. 7722-7725. Paris. Arterioscler Thromb Vasc Biol. Steegers-Theunissen RPM. Raichaski LB. Nakajima Y. J Agric Food Chem. Clifford MN. Meyboom S. 93. Evaluation of the analgesic and anti-inflammatory effects of a Brazilian green propolis. de Castro SL. 2001. Kumazawa S. 307-313. Vollmar AM. 24. 1999. 2007. Fujimoto T. 54. Ceriello A and Motz E. 50. Mechanisms involved in the relaxant action of the ethanolic extract of propolis in the guinea-pig trachea in-vitro. Journal of the Science of Food and Agriculture. Hamasaka T. Mishima S. Scremin A. Dantas AP. Chlorogenic acids. 2006. Fukumoto S. Marcucci MC. 69. Scremin FM. Likic S. Sobocanec S. Life Sci. caffeoylquinic acid derivatives. 2002. Romic Z. 129. absorption and metabolism. Scalbert A. productive characteristics and economic importance]. J Agric Food Chem. Tobe T. 2004. Wu Y. 3025-3031. Morand C. 32373241. 2073S2085S. Meyboom S. Satoh K. Scalbert A. Gardner EJ. Tucker KL. 53. 4 5 142 . Beneficial role of dietary phytoestrogens in obesity and diabetes. Arterioscler Thromb Vasc Biol. 1996. a fruit of Malpighia emarginata DC. J Nutr. 71. West CE. 2007. 2001. 57. Walker D. Jimenez L. and commercial frozen fruit pulps. Editions Tec&Doc. Kushi LH. 2002. Dietary intake and bioavailability of polyphenols. 1985. Bostick RM. 816-823. Manach C. 2000.) fruit. Scalbert A and Williamson G. J Agric Food Chem. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. Remesy C. Williamson G. Lecerf J. Lajolo FM. Hodis HN. 2006. Nahir M. 2004. 249-272. [The acerola fruit: composition. Am J Clin Nutr. Genovese MI. Morand C. Functional claims of article 13: Polyphenols in juices. Eskes TK. Chlorogenic acids. Brouwer IA. 76. Ceriello A and Motz E. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. 308-314. diabetes. Kawaguchi M. 2005. Berry EM. 727-747. 49. 119-141. Bioavailability and bioefficacy of polyphenols in humans. Rev Fr Endocrinol Clin. 2006. Villano D. J Nutr.2''-glycosidic linkage from green mature acerola (Malpighia emarginata DC. 230S-242S. Am J Clin Nutr. Nagamine K. 38. Steegers-Theunissen RP. Vol 1. Fernandez-Pachon MS. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. Antioxidant activity of dietary fruits. 81. J Nutr. 1998. 129. Mink PJ. Bhathena SJ and Velasquez MT. 1999. 67. Troncoso AM. 1191-1201. 130. Chemistry. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. Shirataki Y. Wakabayashi H. Lecerf J. 240-245. Polyphenols: food sources and bioavailability. 1996. Wilson PW. 2001. ID 1257: “Banana” and “Antioxidant activity” 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Mezadri T. 79. Sakagami H. Paris. Kawase M. Hassimotto NM. Am J Clin Nutr. 1997. Clifford M. 126. 56. Arch Latinoam Nutr. Fukushima H. Chevion S. Remesy C. 1130-1135. Folsom AR. Manach C. anti-oxydants et athéroclérose. In: Coffee. London. 334. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. 24. Clarke RJ and Macrae R (ed. Hwang J. Hashimoto K. Is oxidative stress the pathogenic mechanism underlying insulin resistance. vegetables. Thomas CM. Pasteur Institute-Lille. Soy and alfalfa phytoestrogen extracts become potent low-density lipoprotein antioxidants in the presence of acerola cherry extract. Ruxton CH. Review of 97 bioavailability studies. Isolation and characterization of a novel flavonoid possessing a 4. 2006. Motohashi N. Prineas RJ. Duran M. 1156-1162. Sevanian A. Biosci Biotechnol Biochem. Tanabe H. 2003. 1999. 2005. Hautvast JG. van het Hof KH. Apports nutritionnels conseillés pour la population française. Norman Y. Inhibition of LPS-stimulated NO production in mouse macrophage-like cells by Barbados cherry. Nutrition. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. Sagee O. Am J Clin Nutr. Garcia-Parrilla MC.9 Harats D. Kurihara T. Selhub J. 2928-2935. van Dusseldorp M. 23. and cardiovascular disease? The common soil hypothesis revisited. Pasteur Institute-Lille. Anticancer Res. 101-109. Yamada T. N Engl J Med. Int J Food Sci Nutr. I. Rosenberg IH. Lecerf J.) Elsevier Applied Science Publications. 1135-1139. Lecerf J. 79. 2000. occurrence. 51. Svetkey LP. Obarzanek E. Berry EM. Wu X. Rodriguez-Malaver AJ. Am J Clin Nutr. Polyphenols: food sources and bioavailability. Williamson G. occurrence and dietaryburden ¹. Windhauser MM. 336. Kanazawa K and Sakakibara H. 1998. 1996. Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. 64. Am J Clin Nutr. 727-747. 126. 2004. a strong antioxidant. Bray GA.6 7 8 Clifford MN. Am J Clin Nutr. Int J Food Sci Nutr. Morand C. 2000. Murcia MA. Sies H. 2003. Moore TJ. 1999. dietary burden. Polidori MC. Appel LJ. in Cavendish banana. Manach C. 3025-3031. High content of dopamine. Cutler JA. Vollmer WM. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. Dietary intake and bioavailability of polyphenols. Chu YF. Apports nutritionnels conseillés pour la population française. 230S-242S. Bostick RM. Padilla N. 48. Scalbert A. Walker D. 249-272. Herraiz T and Galisteo J. Norman Y. Pasteur Institute-Lille. 130. 362-372. 2006. Jimenez AM. Editions Tec&Doc. Griffiths HR. Anlasik T. 1033-1043. Mecocci P. Pasteur Institute-Lille. absorption and metabolism. A clinical trial of the effects of dietary patterns on blood pressure. 1117-1124. Lin PH. N Engl J Med. Manach C. 336. Review of 97 bioavailability studies. Nahir M. 2002. 67. Journal of the Science of Food and Agriculture. 94. 7449-7454. J Nutr. 3 4 143 . Wu Y. Medina-Ramirez G. J Med Food. Remesy C. Davila J. A clinical trial of the effects of dietary patterns on blood pressure. Antioxidant capacity of crude extracts from clones of banana and plane species. Chlorogenic acids and other cinnamates-nature. DASH Collaborative Research Group. Selhub J. 1996. 1997. 2005. 2006. 2001. British Journal of Nutrition. Remesy C. Prineas RJ. 844-848. 119-141. 1997. 2006. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. Functional claims of article 13: Polyphenols in juices. 9. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. Sun J. antioxydants et athéroclérose. 240-245. Antioxidant and antiproliferative activities of common fruits. Martinez-Tome M. Morand C. 517-523. Nutrition. 81. Appel LJ. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. 2000. Perez-Perez EM. Jimenez L. N Engl J Med. 334. Windhauser MM. J Agric Food Chem. Vollmer WM. 1999. Scalbert A and Williamson G. Bioavailability and bioefficacy of polyphenols in humans. 2005. Rosenberg IH. 2073S2085S. Mink PJ. Sacks FM. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. Folsom AR. 2001. Vogt TM. 2037-2046. Chevion S. Obarzanek E. Liu RH. 80. 7156-7161. I. Tetrahydro-beta-carboline alkaloids occur in fruits and fruit juices. J Agric Food Chem. J Agric Food Chem. J Nutr. 639-642. Lin PH. Clifford MN. Ruxton CH. Sacks FM. 1156-1162. Rev Fr Endocrinol Clin. ID 1258: “Guava” and “Antioxidative activity” 9 10 11 12 13 14 15 16 17 18 19 20 21 22 1 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Cutler JA. Kushi LH. 1117-1124. Chlorogenic acids and other cinnamates–nature. Journal of the Science of Food and Agriculture. Svetkey LP. Karanja N. Wilson PW. Paris. Scalbert A. Moore TJ. Karanja N. 57. Evaluation of the antioxidant properties of Mediterranean and tropical fruits compared with common food additives. Lecerf J. 50. 38. J Food Prot. Stahl W. 79. Gardner EJ. Vogt TM. N Engl J Med. Harats D. Lecerf J. Activity as antioxidants and radical scavengers. 1997. Bray GA. Sagee O. Tucker KL. West CE. 98. occurrence and dietary burden. 143-147. 362-372. 317-333. 2002. and fruits. Polyphenols: Chemistry. Jackson JC. Thomas CMG. van Dusseldorp M. Day AP. 144 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 .com. 2004. 1999.5 6 7 Aprifel (Agence fruits et legumes frais). Kaplan M. 2006. Thomas CM. 2004. 263-300. Larson EB. 2004. Handbook of experimental pharmacology. Total anthocyanins and total phenolics of fresh and processed cherries and their antioxidant properties. 816-823. Fuhrman B. San Diego. Meyboom S. Dai Q. Filesi C. 79. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Kuhnert S. 1998. 1999. 54. Van Camp J. Cassidy A. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. Djuric Z. metabolism. diabetes. Fruit and vegetable juices and Alzheimer's disease: The Kame Project. Gonzalez-Aguilar GA. Clifford MN. Wang CY. van het Hof KH. 1999. Eskes TK. 170. 313-320. 524-528. Lababidi S. American Journal of Medicine. Journal of the Science of Food and Agriculture. Wu XZ. 80. Academic Press. Bhathena SJ and Velasquez MT. Phytochemicals-classification and occurrence. 2006. 687-695. 67-75. Anthierens K. Journal of the American Dietetic Association. Giammarioli S. 41.nature. www. Duran M. International Journal for Vitamin and Nutrition Research. 1997.aprifel. Uhley V. 12. Rosenblat M. 2006. Ayala-Zavala JF. Scholze G. 1135-1139. Heilbrun LK. 1998. J Nutr. Stansbie D. Processed sweet corn has higher antioxidant activity. Freese R. Ceriello A and Motz E. 1135-1139. 24. 129. Chlorogenic acids and other cinnamates . 1033-1043. Clifford MN. occurrence. Bohm V. Journal of Nutrition. Strain JJ. OEITFL study. Canada. and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis Thrombosis and Vascular Biology. 50. 4959-4964. Brouwer IA. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. Sadler MJ. vegetables. Verbeken D. 37. and nutritional significance. For better health. van Dusseldorp M. Hof KHV. Beneficial role of dietary phytoestrogens in obesity and diabetes. Depper JB. 2006. 2000.com. Chlorogenic acids and other cinnamates . Rohm K.5to10aday. 119. Journal of Agricultural and Food Chemistry. Eskes TKAB. Dewanto V.). 69. Goddyn K. Effect of high intakes of fruit and vegetables on redox status in type 2 onset diabetes: A pilot study. Annals of Nutrition and Metabolism. Nutrition Reviews. Bolton C. Lebensmittel Wissenschaft und Technologie (Food Science and Technology). Martino S. Chaovanalikit A and Wrolstad RE. Improving the nutritional quality of microwave-vacuum dried strawberries: A preliminary study. 74. Hartog M. Wang SY. Oxidative DNA damage levels in blood from women at high risk for breast cancer are associated with dietary intakes of meats. 2004. Cantagallo A. Bibliographical study on the nutritional benefits of processed fruit and vegetables. absorption and metabolism. Borenstein AR. Dragoni F.nature. Hautvast JG. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. Caballero B (eds. Dewettinck K. C67-C72. Kemp HJ. Smith D. 2005. Steegers-Theunissen RP. American Journal of Clinical Nutrition. Is oxidative stress the pathogenic mechanism underlying insulin resistance. Effect of storage temperatures on antioxidant capacity and aroma compounds in strawberry fruit. Duran M. 353-357. www. Sanzini E. Steegers-Theunissen RPM. Wu YG. Vitale B. Brouwer IA. 76. Markers of oxidative DNA damage in human interventions with fruit and berries. Liu RH. Bravo L. 5 to 10 a day. 2005. West CE. In: Encyclopedia of Human Nutrition. Food Science and Technology International. 56. 129. dietary sources. Aviram M. Journal of Food Science. Meyboom S. Hautvast JGAJ. Nutrition and Cancer. Journal of the Science of Food and Agriculture. 751-759. 2002. dietary burden. 1191-1201. Atherosclerosis. 79. Antioxidants in nutrition. 38. Leontowicz M. Lin PH. 1-4. 2001. 2003. 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 145 . 8. Leontowicz H. Journal of Agricultural and Food Chemistry. Journal of Agricultural and Food Chemistry. Feng SB. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. In: Plants: Diet and Health. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. American Journal of Clinical Nutrition. Antioxidant activity of processed table beets (Beta vulgaris var. Lecerf J. 3106-3112. Kushi LH. Remesy C. Chevion S. Bioavailability and bioefficacy of polyphenols in humans. Ninfali P and Bacchiocca M. 2005. 727-747. kaempferol. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. Manach C. 2004. Wu Y. Potential mechanism of action of bioactive substances found in foods. Katan MB and Hollman PCH. R11-R19. Prineas RJ. Charleston J. Food habits are associated with lipid peroxidation in an elderly population. Sacks FM. Folsom AR. Berry EM. Lerner HT.5aday.unaproa. Polyphenols: food sources and bioavailability. Jovanovic SV and Simic MG. 1480-1487. Sagee O. 51. 1887-1892. Harats D. 54. Pulido R. Kitamura M and Ishikawa Y. Caspi A. 49. 2001. A dietary pattern that lowers oxidative stress increases antibodies to oxidized LDL: Results from a randomized controlled feeding study. Nutrition Metabolism and Cardiovascular Diseases. 175-182. anti-oxydants et athéroclérose. Williamson G. Rev Fr Endocrinol Clin. Appel LJ. 1998. Saura-Calixto F. Nutrition. Nutritevi dei colori della vita. Norman Y. 81. 2222-2226. Nahir M. Ibanez R. 5+ A Day fruits and vegetables. Trakhtenberg S. Kidney International. Italia. Remesy C. Lecerf J. 1223-1229. 2003. 240-245. N Engl J Med. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: Studies in vitro and in humans. 5489-5493. Current Opinion in Lipidology. 326-334.) 65-75. Journal of the American Dietetic Association. 1999. 2003. 899. Polyphenols and antioxidant capacity of vegetables under fresh and frozen conditions. Journal of Agricultural and Food Chemistry. 52.) as a new source of antioxidant dietary fiber.26 Gorinstein S. Bostick RM. Patterson AM. Erlinger TP.nz/. Journal of Agricultural and Food Chemistry. Gonzalez S. Pasteur Institute-Lille. 70. conditiva) and green beans (Phaseolus vulgaris L. American Journal of Clinical Nutrition. Manach C. 1156-1162. Lecerf J. 1999. 2004. Scalbert A. 2006.com/icoloridellavita. Lasheras C. Huerta JM. Jackson M. Miean KH and Mohamed S. Flavonoids in food and natural antioxidants in wine. Fernandez S.co. Rincon M. 2000. 103. http://www. 1999. Review of 97 bioavailability studies. 67. Functional claims of article 13: Polyphenols in juices. Jimenez-Escrig A. Pasteur Institute-Lille. Tashma Z. http://www. Jiratanan T and Liu RH. 119-141. 23-28. Lombardia C. American Journal of Clinical Nutrition. I. 1996. Kalt W. Mink PJ. 56. luteolin. Morand C. 2005. 334. Guava fruit (Psidium guajava L. 10. 1998. Reactive Oxygen Species: From Radiation to Molecular Biology. Miller ER. Jimenez L. 2006. Oxidant-induced apoptosis of glomerular cells: Intracellular signaling and its intervention by bioflavonoid. New Zealand. and apigenin) content of edible tropical plants. Morand C. Lairon D and Amiot MJ. 1997. 2005. Journal of Agricultural and Food Chemistry. 230s-242s. Huang DJ. Dietary flavonoids and cardiovascular disease. Effects of production and processing factors on major fruit and vegetable antioxidants. Libman I. Scalbert A. Goldberg G and BNF (British Nutrition Foundation) (eds. 183. Flavonoid (myricetin.). quercetin. 49. Katrich E. Svetkey LP. Journal of Food Science. 2659-2670. 3025-3031. 5 al dia. 163-182. Eat a variety of fruits & vegetables every day. http://www. 112-115. Walker D. Rosenberg IH. Journal of Nutrition. 33. 943-948.fruitsandveggiesmatter. 41. Lajdova A. Serafini M. Salucci M. Hahn SE. 2000. www. 1996. tomatoes and tea.gov Weisburger JH. 2002. Wilson PW. 2002. Sanders TAB. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. 1996. British Journal of Nutrition. Sedlacek SM.com Urquiaga I and Leighton F. 2261-2266. J Nutr. Byrne DH. 1998. Tucker KL. O'Reilly JD. Wiseman H. Stein JH. Plant polyphenol antioxidants and oxidative stress. 20. USA. 2003. 100. 2005. 1996. Selhub J. Sedlacek SM. Rounova O. 2073s-2085s. Rosenberg IH. Gillette C. Mechanisms of action of antioxidants as exemplified in vegetables. Journal of Nutrition. 254. Importance of diet in protection against oxidative damage. UK. Wiebe DA. Journal of Agricultural and Food Chemistry. 1999. Biswas SK. Maiani G. www. Thaipong K. Thompson HJ. Gardner EJ.eatincolour. 53. 27. 33.5aldia. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. Clinica Chimica Acta. Wolfe P. Staruch L. Regulation of inflammation and redox signaling by dietary polyphenols. Spinach and tomato consumption increases lymphocyte DNA resistance to oxidative stress but this is not related to cell carotenoid concentrations. Tech & Doc. Southeast Asian Journal of Tropical Medicine and Public Health. Conroy C. Wilson PWF. 1210-1218. Carcinogenesis. American Journal of Clinical Nutrition. 3025-3031. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Raguzzini A. Wsolova L. European Journal of Nutrition. 2006. Staruchova M. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 146 .com/. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. 95-100. Effect of acute ingestion of fresh and stored-lettuce (Lactuca sativa) on plasma total antioxidant capacity and antioxidant levels in human subjects. Heimendinger J. O'Neill C. Miseanova C. Hydrophilic and lipophilic antioxidant activities of guava fruits. 249-272. 36. 2000. Eat in colour. Keevil JG. 2005. 78. Biochemical Pharmacology. Am J Clin Nutr. Haegele A. Biological Research. Angerson WJ. Effect of increased vegetable and fruit consumption on markers of oxidative cellular damage. 6126-6132. Flavonoids protect against oxidative damage to LDL in vitro: Use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radical Research. Sarni-Manchado P and Cheynier V 2006. Ruxton CHS. Volkovova K. O'Neill C. 1439-1452. 419-426. Wolfe P. Gillette C. Dusinska M. 67. 55-64. Haegele A. 88. 126. Folts JD. 570S-578S. Lean MEJ. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. 130. Bugianesi R. 246. Oriani G. In vivo investigation of changes in biomarkers of oxidative stress induced by plant food rich diets. Collins A. Azzini E. Cisneros-Zevallos L. Tucker KL.48 49 Noroozi M. Circulation. Prior RL. Diamandis EP. Neuroendocrinology Letters. Paris. Selhub J. Food and Chemical Toxicology. 126. 2006. Porrini M. 2006. Spain. Scalbert A and Williamson G. PaceAsciak CR. Riso P. 1999. 57. Fruits and vegetables in the prevention of cellular oxidative damage. 1999. Boonprakob U. Rahman I. 1050-1055. 2000. Lavoisier. 615-623. 37. Kirkham PA. Thompson HJ. Heimendinger J. 72. Dietary intake and bioavailability of polyphenols. International Journal of Food Sciences and Nutrition. Les polyphenols en IAA. Goldberg DM. Aeschlimann S. Duran M. Nutrition. 230S-242S. Bioavailability and bioefficacy of polyphenols in humans. Beneficial role of dietary phytoestrogens in obesity and diabetes. absorption and metabolism. Wu Y. Clarke RJ and Macrae R (ed. Manach C. Bioavailability and bioefficacy of polyphenols in humans. 31. Vol 1. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. 129. 838-849. Ceriello A and Motz E. London. American Journal of Clinical Nutrition. Am J Clin Nutr. Gardner EJ. J Nutr. Pasteur Institute-Lille. Rice-Evans C. Am J Clin Nutr. 67. Clifford MN. 2391-2396. Scalbert A and Williamson G. Spencer JPE. 1191-1201.70 71 72 Williams RJ. Steegers-Theunissen RP. Am J Clin Nutr. Williamson G and Manach C. Kushi LH. Dietary intake and bioavailability of polyphenols. Remesy C. 2005. Yamasaki Y. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. 119-141. Harats D. Flavonoids: Antioxidants or signalling molecules? Free Radical Biology and Medicine. 816-823. 81. Scalbert A. Pasteur Institute-Lille. Brouwer IA. Lecerf JM. Is oxidative stress the pathogenic mechanism underlying insulin resistance. 52. 1999. van het Hof KH. Clifford MN. 80. Clinical and Experimental Pharmacology and Physiology. 1135-1139. Int J Food Sci Nutr. Bhathena SJ and Velasquez MT. Chevion S. Int J Food Sci Nutr. 362-372. Shiwaku K. Williamson G. Journal of the Science of Food and Agriculture. 1985. 2006. Bostick RM. 1033-1043. Berry EM. 130. Remesy C. DPPH radical scavenging assay. 2004. 1996. Functional claims of article 13: Polyphenols in juices. 2005. 2006. ID 1260: “Kaki” and “Antioxidant activity” 1 2 3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 1-6. Chlorogenic acids. 1999. Hautvast JG. 1999. Manach C. Clifford M. Norman Y. Tabata H. Jimenez L. 36. van Dusseldorp M. 2004. Katsube T. 1997. Apports nutritionnels conseillés pour la population française.) Elsevier Applied Science Publications. occurrence. 79. antioxydants et athéroclérose. Chlorogenic acids and other cinnamates-nature. Phenolic and antioxidant diversity among persimmon (Diospyrus kaki L. Lecerf J. Ohta Y. 2001. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. dietary burden. Eskes TK. 243s-255s. 2004. Review of 93 intervention studies. 2004. Orhan E. Anuurad E. 76. Prineas RJ. Scalbert A. Polyphenols: food sources and bioavailability. J Agric Food Chem. 2000. Ozdemir O. Chlorogenic acids and other cinnamates–nature. 727-747. 240-245. 2000. Woodman OL and Chan EC. occurrence and dietaryburden. Paris. and cardiovascular disease? The common soil hypothesis revisited. Nahir M. Walker D. Yamane Y. 249-272. J Nutr. Review of 97 bioavailability studies. Screening for antioxidant activity in edible plant products: comparison of low-density lipoprotein oxidation assay. Arterioscler Thromb Vasc Biol. Folsom AR. Journal of the Science of Food and Agriculture. 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 147 . Morand C. Sagee O. 57. N Engl J Med. I. 2004. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. 1156-1162. and Folin-Ciocalteu assay. Thomas CM. Editions Tec&Doc. Ruxton CH. 334. 79. 81. 2002. Rev Fr Endocrinol Clin. 2073S2085S. In: Coffee. 38. 2007. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. Morand C. Vascular and anti-oxidant actions of flavonols and flavones. II. 24. Sengul M. 1998. 786-790. Akbulut M. Am J Clin Nutr. Lecerf J.) genotypes in Turkey. Mink PJ. Ercisli S. Chemistry. West CE. diabetes. Meyboom S. 3 4 5 6 7 Lutein and zeaxanthin. Goldbohm RA. van de Kraats J. Basel. 1999. ID 1261: “Kaki” and “Eye health” 1 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 2002. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. Birkhäuser. 239-245. Am J Clin Nutr. Landrum JT. assessed with two objective techniques. serum and diet of human subjects. 2001. Toxicol Lett. Invest Ophthalmol Vis Sci. BMC Ophthalmol. McClane RW. 1531-1535. Astley SB and Lindsay DG. 42. Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. 41. Wilson PW. J Nutr. 150. Ophthalmic Physiol Opt. Gellermann W. Exp Eye Res. Maguire MG. Vision Res. 1997. 23. Landrum JT. Marks DA. Pfander H. Tibor SE. Invest Ophthalmol Vis Sci. Goldbohm RA. 2004. 57-83. Nutrition and the eye: basic and clinical research. Melia M. Ermakov IV. Public statement Saisine Nr2003SA-0205. Lutein and zeaxanthin in the eyes. Exp Eye Res. Gomez CM. Influence of lutein supplementation on macular pigment. Landrum JT. Steinberg JD. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Murray IJ. 6. Klopping-Ketelaars IA. Gardner LM. 2006. 126. van Poppel G. 1740. Bahrami H. 1873-1881. Dixon Z. 2000. Berendschot TT. Klopping WA. Bone RA. Mol Aspects Med. 39. 128-135. Macular pigment in donor eyes with and without AMD: a case-control study. Aleman TS. 116-121. van Norren D. Henson D. Bone RA. de Vries AJ. Basel. Macular pigment and age related macular degeneration. 2005. 2005. Bartlett H and Eperjesi F. Kilburn MD. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. Dagnelie G. Duncan JL. Koh HH. 1998. 23. Jacobson SG. Liaaen-Jensen S. Gellermann W. European Research on the Functional Effects of Dietary Antioxidants (EUROFEDA). Tijburg LB. Conclusions. 2002. Broekmans WM. 8 9 10 11 12 13 14 15 16 17 18 19 20 148 . Altern Med Rev. Carotenoids. 76. 2003-2011. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Zhao DY. Llerena CM. Mayne ST. Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. 1780-1787.19 Tucker KL. Raman detection of macular carotenoid pigments in intact human retina. 2001. 10. Alves-Rodrigues A and Shao A. Friedes LM. 71. Tarsis SL. 2004. Boulton M. Bernstein PS. Bhosale P and Bernstein PS. Bone RA. 2002. Wang W. Guerra LH. Katz NB. Augustin AJ. 3025-3031. Br J Ophthalmol. Invest Ophthalmol Vis Sci. 595-603. 2005. Yoshida MD. Ruiz CA. Wintch SW. Menendez E. Twaroska EE. 1996. Preliminary identification of the human macular pigment. 211-218. 25. Bone RA. van Norel J. Kardinaal AF. McClane RW. J Nutr. Karger. Gomez CM. Rosenberg IH. Vidal I. 64. Ophthalmology. 992-998. Britton G. de Castro E. 2000. Berendschot TT. 2003. Landrum JT. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. Invest Ophthalmol Vis Sci. Cideciyan AV. 383-399. Monograph. 133. 287-291. Biochim Biophys Acta. Bieber ML. 42. 23. 867-877. Macular pigment density in relation to serum and adipose tissue concentrations of lutein and serum concentrations of zeaxanthin. 235-240. Selhub J. Landrum JT. 109. Bernstein PS. 1998. The science behind lutein. 2003. 3322-3326. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. 83. 1985. Bone RA. Chen Y. Beatty S. Pratt LM. Hall NF. Carriere I. Hankinson SE. Martinez C. 2000. 36. J Chromatogr B Biomed Sci Appl. Hankinson SE. 1999. 1983. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. 47. 147-164. Hammond BR. Jose Tormo M. Ophthalmology. Jr. Tyssandier V. Cooper DA. Arnaud R. Ham WT. Zorge IS. vitamin E and specific carotenoids in Spain. Chasan-Taber L. De Castro E. Short-term supplementation with lutein affects biomarkers of lutein status similarly in young and elderly subjects. Fadda A. Relation between dietary intake. McDonald TM. Ophthalmology. Danis RB. Flood V. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Mitchell P. 71. 91.. Merendino E. 101103. Firshein R (ed. 1998. Exp Eye Res. Anal Chem. Falsini B. Smith W. Bieber ML. Amiano P. 73. 720. 90. 509-516. 2002. 51-60. Glaser T. A prospective study of carotenoid intake and risk of cataract extraction in US men. Kohler K. Stone EM. 1996. Seddon JM. Hammond BR. Dachtler M.. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. Rock E. Stampfer MJ. Nutritional and clinical relevance of lutein in human health. 10051011. Jacobson SG. Barricarte A. Piccardi M. Martyn CN. 25. Speizer FE. 149 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 . 38. Yeum KJ. Berenguer A.) Riverhead Books. Valentini P. 2329-2335. Dorronsoro M. Cideciyan AV. Albert K. Kohler K. Olmedilla B. Marks DA. Rosner B. Dietary modification of human macular pigment density. Wooten BR. Jr. Gonzalez CA. Jr. 2002. serum concentrations. Investigative Ophthalmology and Visual Science. In: The nutraceutical revolution: 20 cutting-edge nutrients to help you design your own perfect whole-life program. Webb K.. Br J Nutr. Am J Clin Nutr. 70. Chasan-Taber L. Schalch W. Jr. 2001. Barberger-Gateau P. Johnson EJ. 1795-1801. 573-582. 38. 70. Dachtler M. Edwards RB.21 Brown L. Lutein and zeaxanthin status and risk of age-related macular degeneration. Wang JJ. discussion 61. Bennett J. and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Ocular hazards of light sources: review of current knowledge.. 487-502. J Occup Med. Vision Res. Cardinault N. 2003. Gale CR. 2461-2465. 74. 371-381. Burke JD. Snodderly DM. Krinsky NI. Hammond BR. 211-216. MacDonald IM. Combined HPLC-MS and HPLC-NMR on-line coupling for the separation and determination of lutein and zeaxanthin stereoisomers in spinach and in retina. 109. Spiegelman D. Ardanaz E. Manzi F. Russell RM. Quiros JR. Rimm EB. Curran Celentano J. 1997. Steinberg JD. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. 535S-539S. Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Colditz GA. Dolores Chirlaque M. Willett WC. 1999. 3003-3009. 2003. Phillips DIW. 667-674. 74. Gardner LM. Emmons JM. New York. Albert K. Giovannucci EL. Curran-Celentano J. Invest Ophthalmol Vis Sci. 2006. 2004. Optometry.. 132. Aleman TS. Jose Sanchez M. Iarossi G. 2001. Snodderly DM. Dietary sources of vitamin C. Delcourt C. Willett WC. Garcia-Closas R. 110. Seddon JM. Delage M. 796-802. Invest Ophthalmol Vis Sci. Br J Nutr. Lutein: sight for sore eyes. Macular pigment and lutein supplementation in choroideremia. 2002. 517-524. Exp Gerontol. Firshein R. 2003. Grolier P. Ciulla TA. Am J Clin Nutr. Agudo A. In vivo assessment of retinal carotenoids: macular pigment detection techniques and their impact on monitoring pigment status. Duncan JL. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. J Nutr. 44. Dagnelie G. 1998. Blanco I. 2003. Reversed-phase high-performance liquid chromatographic identification of lutein and zeaxanthin stereoisomers in bovine retina using a C30 bonded phase. Jr. Granado F. 2272-2278. Hammond BR. Borel P. Navarro C. Maguire MG. Gorrand JM. Am J Clin Nutr. Snodderly DM. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Bone RA. Feather J. Khachik F. Palta M. Vaquero M. New York. Barker FM. Krinsky NI. Nolan D. 1981. 2001. zeaxanthin. 2005. 98. Beatty S. 2000. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Landrum JT and Bone RA. In: Functional Foods for Disease Prevention I. Moore LL. 71. The macular pigment: a possible role in protection from agerelated macular degeneration. Exp Eye Res. Zhao Z. 1. Stahl W. [Macular pigment and age-related macular degeneration]. Preservation of visual sensitivity of older subjects: association with macular pigment density. Hammond BR. Arch Biochem Biophys. 1518-1523. Marcel Dekker. 1997. 23. Ophthalmologe.. 537-556. Klein R. 397-406. Olmedilla B. 296-310. Rapp LM. 28-40. van Kuijk FJ. 2000. 2006. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Choi JH. Jr. 21-24.40 41 42 43 Hammond BR. Carotenoids in Health and Disease. Schalch W. Granado F. Klein BE. 2004. Brady WE.. 1998. 84. 160-164. Edgar DF. Nadeau D. Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Castaneda C. Exp Eye Res. Hammond BR. Invest Ophthalmol Vis Sci. Sies H. 2003. Invest Ophthalmol Vis Sci. 391. CFF thresholds: relation to macular pigment optical density. Shibamoto T. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Kilburn MD. Murray IJ. Ophthalmic Physiol Opt. 38. Terao J. Jr. Arch Ophthalmol. Kilburn MD. 39. 1997. Sprague KE. 362-371. 41-46. J Am Optom Assoc. Junghans A. Garland DL. Macular yellow pigment. Yeum KJ. 315-319. Pruett RC. Historic perspectives. 19. Wooten BR. Landrum JT. Krinsky NI. Lutein. Blanco I. New York. Landrum JT. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch Biochem Biophys. Carotenoids in the retina and lens: possible acute and chronic effects on human visual performance. Oxford. Khachik F. and the macular pigment. supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Osawa T (eds. 2002. Annu Rev Nutr. Exp Eye Res. 2001. Metabolism of dietary carotenoids and their potential role in prevention of cancer and age-related macular degeneration. Invest Ophthalmol Vis Sci. 385. 24-36. 61-74. Stacewicz-Sapuntzakis M. Nutrition. Russell RM. Arch Biochem Biophys. Sies H. 70. 41. Beatty S. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 150 . Wang XD. Jr. Johnson EJ. placebo-controlled pilot study. Cohen LA. 1802-1811. Nolan JM. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. Hammond BR. 57-62. Bird AC. but not alpha-tocopherol. Carden D. Bowen P. 1997. Am J Clin Nutr. Stack J. Delori FC. Curran-Celentano J. 1998. Mayne ST.). 65. Richer S. Wooten BR. The color code: a revolutionary eating plan for optimum health. The first 200 years. Kopcke W. Koh HH. Adv Pharmacol. Landrum JT. Bernstein PS. 171-201. Retina. Pauleikhoff D. 511-519. Barbur JL. 2001. Underwood A. 1995. 2004. Lutein. O OD. Bone RA. 2003. 26. Joseph JA. Kvansakul J. and Wooten BR. 1999. Loane E. 1200-1209. 113. Nussbaum JJ. 385. Hyperion. 2001. Qin J. Mares-Perlman JA. 25. Snodderly DM. Maple SS. Oxford Press. Rodriguez-Carmona M. 79. ARMD--pilot (case series) environmental intervention data. 21-27. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. 38. Ophthalmic Physiol Opt. 1555-1562. Bone RA. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Joa H. 2007. Lang GK. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin . Double-masked. Hoyng CB. 75. 660-673. Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. Van Den Hoogen GW. Burton TC. 59-64. Taylor A. 427. 31. Semba RD and Dagnelie G. 61. 80. randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. Sies H. 151 . Measurement of carotenoids. Seddon JM. 21. 99. 62. I. and tocopherols in human lenses. Carotenoids in the retina--a review of their possible role in preventing or limiting damage caused by light and oxygen. Nutr Rev. 25. Ajani UA. and discrimination from other yellow pigments in primate retinas. 2756-2761. Dietary lutein and zeaxanthin: possible effects on visual function. Thamm E. Driomina ES. van Kuijk FJ. vitamins A. Shaban H and Richter C. Stahl W. Spraul CW. 2001. Snodderly DM. Dietary carotenoids. Bird AC. Stringham JM and Hammond BR. Tsipursky M. 128-135. Cohn W. Rudy D. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Free Radic Biol Med.the LUXEA (LUtein Xanthophyll Eye Accumulation) study. 225-240. Auran JD. [Objective determination of optical density of xanthophyll after supplementation of lutein]. Verbeek AL. 2002.62 Richer S. Fitzke FF. Tang G. Snodderly DM. Kopcke W. 2002. 36. Arch Ophthalmol. Jr. 2002. 1998. 537-545. 1999. 368-371. Brown PK. A2E and blue light in the retina: the paradigm of age-related macular degeneration. FEBS Lett. 1992. Lipofuscin-formation in retinal pigment epithelial cells is reduced by antioxidants. Blair N. Frankowski J. Farber MD. ID 1264: “Purple Grape Juice” and “Antioxidant activity” No references provided. EXS. Schweitzer D. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. and advanced agerelated macular degeneration. 383. Hammer M. Gragoudas ES. 2006. Mares JA. Nyland J. JAMA. 2007. Macular pigment: influences on visual acuity and visibility. localization. Am J Clin Nutr. 270-275. Barker FM. 217-225. The macular pigment. Danis RP. Junghans A.. 272. 2004. 1038-1045. Pei K. Miller DT. Pulido J. Wooten BR and Hammond BR. Taylor A. 2005. Snellen EL. 1413-1420. Beuermann B. 1994. Cruysberg JR. Briviba K. Robson AG. Nutritional and environmental influences on the eye. 1995. Eye Disease Case-Control Study Group. Invest Ophthalmol Vis Sci. 1984. Arch Biochem Biophys. Lang GE. 62. Russell RM. Absorbance spectra. Sperduto RD. 465-472. Invest Ophthalmol Vis Sci. Statkute L. Whitehead AJ. Prog Retin Eye Res. Are lutein and zeaxanthin conditionally essential nutrients for eye health? Med Hypotheses. de Boer B. Boca Raton. Schalch W. Yannuzzi LA. C. 1448S-1461S. Macular pigment: a review of current knowledge. Hiller R. 216-230. ID 1262: “Pitanga” and “Antioxidant activity” 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 No references provided. 305-308. Mellerio J. 1995. Yeum KJ. Stiles W. CRC Press. Delori FC. and E. Acta Ophthalmol Scand. retinoids. 280-298. 2002. 124. 2003. Haller J. 458. Ophthalmologe. Sundelin SP and Nilsson SE. Biol Chem. Schalch W. placebo-controlled. Remsch H. Willett W. 63. 357-377. Rucker RB. Frankfurt am Main. Hein P. Gardner AW. 1980. 1995. 101-107. Effects of a taurine. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Toubro S. 151. Lübeck. Am Heart J. 21. Bässler KH. Oxford. Caffeine. Golly I. Apotheker und Ernährungswissenschaftler. Allen RH. In: Encyclopedia of Human Nutrition. placebocontrolled study of its thermogenic. 316. 107. 19. J. Golly I. Prentice A (eds. 2001. 1999. Amino Acids. Hawley JA. Benowitz NL. Amino Acids. Lindenbaum J. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 152 . Munchen. Jena. Pietrzik K. Acheson KJ. Bougopoulos CL. Arciero PJ. Stabler SP. 1998. Loew D. Calles-Escandon J. Br J Nutr. (Unpublished). 20. Breum L. Urban & Fischer. High prevalence of cobalamin deficiency in the elderly. Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over. fat oxidation.1990. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. 759-767. Nindl BC. Harbowy ME. 81. Baik HW and Russell RM. Arnaud MJ. 282-287.). 894-898. Am J Clin Nutr. 464-475. E1192-1198. B-Vitamin Treatment Trialists' Collaboration. Loew D. Madsen J. Balentine DA. Benowitz NL. Annu Rev Nutr. Spiller GA (ed. Allen L. Ulm Bates CJ. 1997. 2002. In: Handbook of vitamins. Ruhleder M. Department of Sports Medicine. Vitamin-Lexikon für Ärzte. Grigereit A. Bässler KH. Baum M and Weiss M. New York. Heil S. Boca Raton. 1999. 75-82. Astrup A. Metabolism. Anderson ME. Bernhard M. In: Caffeine. 989-997. 2000.ID 1272: “Caffeinated carbohydrate containing energy drinks” and “Cognitive performance and mood” 1 2 Council Directive 90/496/EEC of 24 September 1990 on nutrition labelling for foodstuffs OJ L 276. Fraser SF. The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. Suttie JW. Pittet P. Boca Raton. Arciero PJ. 463-512 Berdanier CD. 268. Mansoor MA. Marcel Dekker. Tea: the Plant and its Manufacture. 2000. Apotheker und Ernährungswissenschaftler. Handbook of Nutrition and Food. Graham HN. Am J Physiol. Zahorska-Markiewicz B. Caballero B. Tran H. Effects of caffeine ingestion on NE kinetics. 2006. Beck WS. Vitamin-Lexikon für Ärzte. Klein R. Pietrzik K. BMJ. 2001. 1995. 2002. Poehlman ET. Feldman EB. Transactions of the American Clinical and Climatological Association. Goethe University. Jequier E. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. 139-150. The effects of red bull energy drink on human performance and mood. Prentice A. Stuttgart.10.) CRC press. Homocysteine Lowering Trialists' Collaboration. 2001. Chemistry and Consumption of the Beverage. Caffeine: a double-blind. Cox H. CRC Press. Stepto NK. metabolic. Machlin LJ (eds. Int J Sport Nutr Exerc Metab. Cobalamin (Vitamin B12). 49.). Institute of Sports Sciences. Finch S. Gustav Fischer Verlag. Influence of age on the thermic response to caffeine in women. Bruce CR. 1990. McCormick DB.and caffeine-containing drink on performance and haemodynamics in acyclic trained athletes. Am J Clin Nutr. 51. p. Pentieva KD. Hopkins WG. 37. Banzer W. 10. 33. 40–44. and cardiovascular effects in healthy volunteers. Alford C. 1998. 2005. 6. W. Vitamin B12 deficiency in the elderly. 191-201. Cannon S. Improved 2000meter rowing performance in competitive oarswomen after caffeine ingestion. Elsevier Ltd. and energy expenditure in younger and older men. Wescott R. Anantharaman K. Dwyer JT. Levine L. Karl F. 1958-1963. Olson JA. and plasma paraxanthine. Fink WJ. and zinc on psychological well-being in healthy young male volunteers: a doubleblind placebo-controlled trial. Benefits of caffeine ingestion on sprint performance in trained and untrained swimmers. Berube CL. Roberts A. J Sports Sci. Effect of repeated caffeine ingestion on repeated exhaustive exercise endurance. 94. 1996. Starling RD. 1983. Leeds. Motulsky AG. Dalsky GP. Benton D. Burgerstein UP. Collomp K. 990-999. Zimmermann M. Carroll D. Effects of varied dosages of caffeine on endurance exercise to fatigue. Fordy J. 1557-1562. 164. Beresford SA. Haug Fachbuchverlag. Moquin A. Willemsen G. 32. Burgersteins Handbuch Nährstoffe. The effects of an oral multivitamin combination with calcium. Referenzwerte für die Nährstoffzufuhr. Psychopharmacology (Berl). Cadarette BS. Cervantes-Laurean D. Effects of caffeine on mood and performance: a study of realistic consumption.). Costill DL. Philadelphia. Probable benefits of increasing folic acid intakes. 2000. Stuttgart. 871-877. Suter M. postexercise urinary caffeine concentration. Vogel JA. Macrides TA.Schweizerische Vereinigung für Ernährung). and 6 h after caffeine ingestion in caffeine users and nonusers. JAMA. Bridge CA and Jones MA. Effect of a divided caffeine dose on endurance cycling performance. Med Sci Sports Exerc. Haller J. Chatard JC.21 22 23 24 25 26 27 Bell DG and McLellan TM. 2002. 1995b. Stepto NK. Posner BM. Poortmans J (eds. 2003. Boushey CJ. Knuttgen H. Med Sci Sports Exerc. Montgomery PG. Vitamine.Österreichische Gesellschaft für Ernährung Schweizerische Gesellschaft für Ernährungsforschung . 2002. Ahmaidi S. In: Modern Nutrition in Health and Disease Shils ME. 2000. 234-236. Conway KJ. 1992.). 93. Neuropsychobiology. Hawley JA. McElvaney NG. 2003. Hopkins WG. Stuttgart. magnesium. Burke LM. Vitamin supplementation for 1 year improves mood. Biesalski HK. Anderson ME. 1995. Thieme. Exercise endurance 1. Goodpaster BH. J Appl Physiol. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. 1227-1234. Schurgast H. 1978. Human Kinetics Europe. Effect of different protocols of caffeine intake on metabolism and endurance performance. Moss J. 1995a. Trappe SW. Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. 155-158. 2000. 64. Effects of caffeine ingestion on metabolism and exercise performance. 6. Fraser SF. 274. J Appl Physiol. Fink WJ. Eur J Appl Physiol Occup Physiol. Hawley JA. 98-105. 2002. Orr R. Int J Sport Nutr. Haller J. Baltimore. Schümann K. Prefaut C. 32. 1982. Effect of caffeine ingestion on perception of effort and subsequent work production. The impact of long-term vitamin supplementation on cognitive functioning. 28 29 30 31 32 33 34 35 36 37 38 39 40 153 . Martin DT. Shike M. 2002. Bell DG and McLellan TM. Frankfurt am Main. Köhrle J. Cox GR. 14-23. 2006. Niacin. Klein R. In: Biochemistry of Exercise Conference Proceedings. Desbrow B. Audran M. Lippincott Williams & Wilkins. Burgerstein L. Bruce CR. Brice CF and Smith AP. The effect of caffeine ingestion on 8 km run performance in a field setting. 35. Benton D. 298-305. 10. 1348-1354. Anderson ME. Int J Sports Med. Omenn GS. Stannard SR. Ring C. Psychopharmacology (Berl). 2002. 377-380. D-A-CH (Deutsche Gesellschaft für Ernährung . J Appl Physiol. Med Sci Sports. Costill DL. Evans WJ. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Berglund B and Hemmingsson P. 150. 117. 93. 188-192. 220-225. Enhancement of 2000-m rowing performance after caffeine ingestion. 401411 Cole KJ. 3. 433-439. Umschau Braus Verlag. 3. 1999. Psychopharmacology (Berl). Bruce CR. 1049-1057. Ross C (eds. 24. Fordy J. 2004. Fisone G. Ernährung des Menschen. Driskell JA. Effects of caffeine ingestion on utilisation of muscle glycogen and lipid during leg ergometer cycling. 2002. 114. Davies P. Costill DL. Tsai MY. Effects of caffeine on time to exhaustion in exercise performed below and above the anaerobic threshold. Biesalski H-K. Vitamin B12. Doherty M and Smith PM. 1997. O'Brien PJ. Schümann K (eds. 98. Collins A. Stuttgart. Tristram S. EVIRA (Finnish Food Safety Authority). Scand J Med Sci Sports. Rohrer D. 140. Girardier L. Nieto FJ. Tipper SP. Thieme. 116-119. Duret C. and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Horton T. 433-442. Schümann K (eds. Boca Raton. 31. Fathi M. An update. Am J Clin Nutr. Wolinsky I (ed. Herb RA. 113-132. 637-643. Van Handel PJ. 233-238. Köhrle J. 1999. Vandermander J. Davison R. Edmunds R. 2005. International Journal of Sports Medicine. Biesalski H-K. Food Standards Agency. 69-78. 44-50. Ferrauti A. 1989. 258-266.41 42 43 44 45 46 47 48 Denadai BS and Denadai ML.). 2004. 2002. Am J Clin Nutr. Effects of caffeine ingestion on exercise testing: a meta-analysis. 1998. Durlach PJ. Stuttgart.) CRC press. 163. Nutr Neurosci. In: Sports Nutrition. Howard L. Braz J Med Biol Res. 1990.fi/portal/en/. Caffeine ingestion prior to incremental cycling to exhaustion in recreational cyclists.). Shangari N. Elmadfa I and Leitzmann C. A rapid effect of caffeinated beverages on two choice reaction time tasks. Bruce WR. Chem Biol Interact. 5. 857-872. Psychopharmacology (Berl). Review of Niacin – Revised Version EVM (Expert Group on Vitamins and Minerals). The effects of a low dose of caffeine on cognitive performance. Vitamin B6. 2004. 49. Effects of caffeine ingestion on rating of perceived exertion during and after exercise: a meta-analysis. 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 154 . Doherty M. Folsom AR. Circulation. 14. 22. 1998. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Geissler CA. Int J Sport Nutr Exerc Metab. Safe Upper Levels for Vitamins and Minerals. 1999. Depeint F. McGovern PG. Kobrick JL. 61. Metabolic and ergogenic effects of carbohydrate and caffeine beverages in tennis. 11. In: Vitamine. Dulloo AG. Davis CE. 86–90. J Sports Med Phys Fitness. Effects of caffeine or diphenhydramine on visual vigilance. Riley RH. Struder HK. Cell Mol Life Sci. Vitamins. Gregory J. Miller DS. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. 37. 204-210. McNaughton LR. 188-193. Caffeine lowers perceptual response and increases power output during high-intensity cycling. Malinow MR. J Sports Sci. Psychopharmacology (Berl). Smith P. 1993. Weber K. 1994. Eckfeldt JH. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Tharion WJ. Marlowe B. Eugen Ulmer Verlag. Chantre P. Caffeine and exercise performance. In: Vitamine. Powers SK. Dulloo AG.evira. EVM (Expert Group on Vitamins and Minerals). 15. 15. Caffeine as a psychomotor stimulant: mechanism of action. http://www. Flinn S. 1998. Frank J. Durlach PJ. 70. 2002. 626-646. Lieberman HR. Dodd SL. 2006. Sports Med. 1040-1045. Essig D. 2002. 581-585. Thieme. Mitochondrial function and toxicity: role of B vitamins on the one-carbon transfer pathways. Stuttgart. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. 1980. Doherty M and Smith PM. related genetic polymorphisms. Usiello A. 2003. Mensi N. 1998. 1423. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine. Hughes M. 49-83. Hess DL. Köhrle J. Int J Sports Med. Frank J. Borgkvist A. Mehta R. Fine BJ. London. 1. Heishman SJ. 51. 83-133. 2000. 2001. 105-110. 865-871. Zvartau EE. Vitamins and brain function. 2000. Vorster H. Tsofliou F. van Soeren MH. Graham TE. 1999. Cymerman A. Greer F. 875-887. J Appl Physiol. Introduction to Human Nutrition (The Nutrition Society Textbook) WileyBlackwell. Hackam DG. 21. multi-dose evaluation of the acute behavioural effects of guarana in humans. 1994. Performance and metabolic responses to a high caffeine dose during prolonged exercise. 2002. Revision. Int J Vitam Nutr Res. 2005. Wissenschaftliche Verlagsgesellschaft. metabolism and exercise performance following a high-fat meal. Acute caffeine intake before and after fatiguing exercise improves target shooting engagement time. Stuttgart. Battig K. 160-168. Effect of caffeine on submaximal exercise performance at altitude. Peterson JC. 1990. 1994. 2292-2298. Friars D. 111-138. Jester I. Graham TE and Spriet LL. Gibney M. Aviat Space Environ Med. Preston KL. Sports Med. 69. Haskell CF. Tikuisis P. 425-432. J Sports Sci. 2004. Kanarek RB. 75. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Georgiades E. Metabolic and exercise endurance effects of coffee and caffeine ingestion. 2007. 45-56. 19. J Appl Physiol. 78. catecholamine. Kennedy DO. 1837-1844. 7. 1996. Sathasivam P. Keefe AA. Prasad C (eds. 2006. J Pharmacol Exp Ther. Gillingham RL. 31. Caffeine and exercise performance. Rush JW. 89. Young PM. and exercise performance responses to various doses of caffeine. 85. Jr. 43-55. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pudel V. 1998. Graham TE and Spriet LL. Scholey AB. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. 883-889. 1994. 31. 179. Geiss KR. Graham TE. Boca Raton. Griffiths RR. Turner AP. 24. Rock PB. placebo-controlled. 970-978. Spence JD. 252. 1991.). The vitamin status and its adequacy in the elderly: an international overview. 785807. 13. J Psychopharmacol. Milne AL. Pharmacol Rev. Westenhofer J. 1-11. Caffeine and exercise: metabolism and performance. Holmen J. Pitsiladis YP. Graham TE. Am J Hypertens. Chichester. Fulco CS. Influence of caffeine on perception of effort. Heseker H. 1995. Kennedy DO. Can J Appl Physiol. J Appl Physiol. Tristram S. Falke W. Amino Acids. Haskell CF. Waag KL. Metabolic.64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 Fredholm BB. Aviat Space Environ Med. J Sports Med Phys Fitness. CRC Press. Bibl Nutr Dieta. 71. French C. Lieberman HR. 2002. Sannerud CA. Haller J. 2005. Graham TE. 1999. In: Nutritional Neuroscience. Rose MS. 65. Nehlig A. 1991. endurance and performance. Hibbert E. Wesnes KA. Trad LA. Caffeine and exercise: metabolism. Scholey AB. Comparison of caffeine and theophylline ingestion: exercise metabolism and endurance. Kubler W. 813-825. Psychopharmacology (Berl). Hadjicharalambous M. Wesnes KA. 80 81 82 83 84 85 155 . A double-blind. Forte VA. 9. Sports Science Exchange (Gatorade Sports Science Institute). Gröber U. The effect of a taurine-containing drink on performance in 10 endurance-athletes. Low-dose caffeine discrimination in humans. Kok F. J Appl Physiol. 1995. Hamm M. Haller J. Kilduff LP. Orthomolekulare Medizin. Caffeine ingestion during exercise to exhaustion in elite distance runners. Evans SM. 6570.. Interaction of vitamins with mental performance. 867-874. McNaughton L. Graham TE and Spriet LL. Davies P. Woodson PP. 539-545. Wolf B. 1998. 709-715. National Academy Press. coffee and water on alertness. Washington DC. Brouns F. 1981. Kaciuba-Uscilko H. Beneficial effects of an "energy drink" given to sleepy drivers. mood. Kovacs EM. Influence of caffeine. Horne JA and Reyner LA. IoM (Institute of Medicine). 157. Hogervorst E. Friars D. vitamin B6. Fink WJ. 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 156 . Am J Clin Nutr. 110. Caffeine for the sustainment of mental task performance: formulations for military operations. Acute and chronic effects of caffeine on performance. Prev Med. Belenky G. Ann Nutr Metab. Int J Sports Med. 2001. Cawthorne MA. folate. Lower RW. IoM (Institute of Medicine). 1993. Pekkarinen H. Brouns F. Homocysteine Lowering Trialists' Collaboration. 1995. Kennedy DO and Scholey AB. 316. Multiple caffeine doses maintain vigilance during early morning operations. Kovacs E. Jackman M. Kirkland JB and Rawling JM. New York. 1989. Comparison of changes in energy expenditure and body temperatures after caffeine consumption. 2001. riboflavin. Niacin. 38. Krzeminski K. and performance.86 87 Hewlett P and Smith A. Metabolic catecholamine. 203-216. 101-163. 39. Curr Sports Med Rep. Dietary reference intakes for thiamin. Arch JR. 2001. IoM (Institute of Medicine). Neuropsychobiology. 1999. 2nd. biotin and choline. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. Jarvis MJ. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. 2004. 2005. McCormick DB. Kamimori GH. Amino Acids. Appetite. 2000. 1658-1663. 18. 2003. 1992. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. 1979. 1998. 806-812. 2291-2294. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. sleep onset and sleep quality. National Academies Press. 354-361. Kendler BS. Psychopharmacology. 34. Final Technical Report A List of Well Established Nutrient Function Statements. headache. Machlin LJ (eds. A glucose-caffeine'energy drink'ameliorates subjective and performance deficits during prolonged cognitive demand. Quinlan P. niacin. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology (Berl). Am J Clin Nutr. 2001. 197-201. Lane J. Aviat Space Environ Med. 135-142. Caffeine improves cognitive performance after strenuous physical exercise. James JE. Effect of caffeinated drinks on substrate metabolism. Hollands MA. Caffeine as an ergogenic aid. 79-100. Nazar K. Johnson D. Homocysteine Lowering Trialists' Collaboration. cold and exercise on multiple choice reaction time. 2006. Thorne D. 82. 11. J Appl Physiol. 83-89. Costill DL. Med Sci Sports. Marcel Dekker. 339-350. A naturalistic investigation of the effects of day-long consumption of tea. 2005. 72. Wendling P. Rycroft J. caffeine excretion. Kruk B. 20. Stanley N. 76. Suttie JW. 6-11. vitamin B12. 81. BMJ. 894-898.). Chmura J. In: Handbook of vitamins. Keisler BD and Armsey TD. Washington DC. Rigney U. 1996. and sleep. 2007. 32-41. Huxtable RJ. 42. Hindmarch I. Ivy JL. 20. Physiological actions of taurine. 5. Dietary references for vitamins and minerals. Rucker RB. Hum Psychopharmacol. 1998. pantothenic acid. 45-52. 149. 85. Koot P and Deurenberg P. Psychopharmacology (Berl). Physiol Rev. JHCI (Joint Health Claims Initiative). Graham TE. Jolles J. 331-333. J Appl Physiol. 1998. 22. Influence of caffeine and carbohydrate feedings on endurance performance. Riedel WJ. Stegen J. and endurance responses to caffeine during intense exercise. 1046-1050. 215-219. Ziemba AW. Taurine: an overview of its role in preventive medicine. 1988. 2170-2175. diet. 69. Manore MM. Speckman KL. 1999. Vitamin B6. Philadelphia. 2003. Blumenthal D (eds. 11. 1555-1572.S. Effects of caffeine. Washington DC. Lowdose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. 2001. 1999. 2006. Allen RH. McCormick DB. 168-177. 171-175. Tsai AJ. Studies on vitamin B12 status in the elderly--prophylactic and therapeutic consequences. Vitamin B6. Baltimore. 20. Schneider KE. Stabler SP. 178-182. Caffeine. 1982. Franklin C. Leathwood PD and Pollet P. 2001. Petersen KF. Nutrition. 73. J Strength Cond Res. Lieberman HR. Int J Vitam Nutr Res.500-metre swim Can J Appl Physiol. and vitamin B-6 requirements. Malinow MR. Housh DJ. 24. Caffeine deprivation affects vigilance performance and mood. Coffee: The demon drink? New Scientist. Malek MH. Huang YC. 1996. 20. discussion 180. 1999. Lippincott Williams & Wilkins. Physiol Behav. Psychopharmacology (Berl). Lovett R. and stress on cognitive performance and mood during U. Shukitt-Hale B. Brunton L. 1987. Beck TW. Nutrition. New York.). 17. 65. Effect of physical activity on thiamine. Shils ME. 1995. 2000. Lorist MM and Tops M. Low-dose folic acid supplementation reduces homocysteine concentration in hyperhomocysteinemic coronary artery disease patients. Vitamin B6. Machlin LJ (eds. brain function and cognitive performance. Lee BJ. 250-261. 53. Caffeine ingestion and performance of a 1. Appetite. fatigue. Ross C (eds. Lindenbaum J. In: Goodman and Gilman‘s: The Pharmacological Basis of Therapeutics. Healton EB. 1998. Roberts C. 181. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. 72. Schmidt RJ. McPartlin J. American Heart Association. Am J Clin Nutr. 147-154. 2003. 82-94. Diet-induced mood changes in normal populations. ILSI Press. 2005. Cheng CH. 2001. Leklem JE. 20. 598S-606S. Homocyst(e)ine. Shike M. Housh TJ. Strain JJ. 2000. 2004. Circulation. In: Modern Nutrition in Health and Disease. In: Handbook of vitamins. Schroedter A. Water-soluble vitamins. Marcell PD. The effects of low doses of caffeine on human performance and mood. Brain and Cognition. 92. Parker K. Savage DG. Johnson GO. 2006. Sea-Air-Land. Lin PT. McKinley MC. Lieberman HR. Coviella ILG. 2002. Pentieva K. 460-466. Buxton I. Weir DG. Lieberman HR. Nutrition Research. 182. Olson JA. Scott JM. Prusaczyk WK. McCormick DB. Vogel SM. Shulman GI. In: Present Knowledge in Nutrition. 759-764. Wanitschke R. Suttie JW. Brust JC. Effects of caffeine on muscle glycogen utilization and the neuroendocrine axis during exercise. Tulley R. Effects of eight weeks of caffeine supplementation and endurance training on aerobic fitness and body composition. 164. Coburn JW. and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee. Wurtman RJ. Emde GG. Loew D. sleep loss. 2518–2522. 1995. Garrett TJ. Tharion WJ.110 111 Lane JD and Phillips-Bute BG. Marcus R and Coulston AM. Chang HH. and cognition. Vitamin and mineral status: effects on physical performance. J Psychiatr Res. Goforth HW. Lazo J. 308-312. Psychopharmacology. 40. Marcel Dekker. Laurent D. 99. 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 157 . Am J Clin Nutr. McNulty H. 85. 632-644.). Bostom AG. J Clin Endocrinol Metab. 751-755.). 245-254. 207-213. Podell ER. Lukaski HC. Navy SEAL training. Leklem JE. 228-233. Bowman BA and Russel RM (eds. Krauss RM. Rucker RB. McGraw-Hill Professional. riboflavin. Krssak M. Nutrition.). Ward M. 26. MacIntosh BR and Wright BM. ). Paluska SA. 22. Ross C (eds. Nehlig A. McLellan TM. Arginin und Taurin . 822-825. 2001. 46-53. and chemistry. 112. Amino Acids. 213-219. The effect of different dosages of caffeine on endurance performance time. What is an adequate dose of oral vitamin B12 in older people with poor vitamin B12 status? Nutr Rev. Philadelphia. Nehlig A. Rogers LM. Am Chem Society. Caffeine and the central nervous system: mechanisms of action. Rycroft JA. biochemical. 1993. 184-187. 263. 1992. Curr Sports Med Rep. Moore KL. 2001. Debry G. Aviat Space Environ Med. 75. Caffeine and exercise. 647-654. Olson JA. 359-365. Nobre A. Kamimori G. Shike M. Hopkins WG. The effects of combined caffeine and glucose drinks on attention in the human brain. 139-170. In: Handbook of vitamins. McNaughton LR.präventive Nahrungsfaktoren bei kardiovaskulären Erkrankungen Ernährungsumschau. 109-112. 76. Med Sci Sports Exerc. Nehlig A and Debry G. Ho C-T. 2000. Bowman BA and Russel RM (eds. Pantothenic acid. Brain Res Brain Res Rev. 2000. Physiology & Behavior. Paton CD. 66. Thomas M. Pasman WJ. 215-223. Little effect of caffeine ingestion on repeated sprints in teamsport athletes. Nordic Council of Ministers. Marcel Dekker. 2005. 666-672. Rao A. McCormick DB. 317-337 Plesofsky-Vig N. Psychopharmacology (Berl). Caffeine maintains vigilance and improves run times during night operations for Special Forces. 351. Washington DC. Boston. Pharmacol Biochem Behav. Integrating nutrition and physical activity. 1995. 75. Plesofsky NS. 2001. 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 158 . Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. 225-230. physiological effects. 19-28. In: Caffeineated beverages: Health benefits. Park S and Johnson MA. 2002.). van Baak MA. Metzner C. 1994. de Haan A. 17. Penetar D. Aviat Space Environ Med. Taurine modulates kallikrein activity and glucose metabolism in insulin resistant rats. Nandhini AT and Anuradha CV. Editors of The American Heritage Dictionaries (ed. Bell DG. 2004. In: Modern Nutrition in Health and Disease. 331-335. Kamimori GH.131 132 McLellan TM. Sing H. Aspen J. Suttie JW. Belenky G. 2002. McCann U. 27-38. 16. 20. Kamimori GH. Efficacy of a functional energy drink' in counteracting driver sleepiness. Int J Sports Med. Galinski C. 2006.). Lancet. ILSI Press. Lippincott Williams & Wilkins. 64. Pickett JP. Pantothenic Acid. O'Brien DC. 1984. Caffeine improves physical performance during 24 h of active wakefulness. 423-432 Quinlan PT. Rucker RB. Machlin LJ (eds. Vollebregt L. 1999. Caffein. 2005.). Science. 2. 253-260. 1998. Hu H. Voss DM. Peterson JC and Spence JD. Caffeine and related methylxanthines: possible naturally occurring pesticides. Lane J. 2000. Int J Sports Med. Shils ME. 2001. Baltimore. In: The American Heritage Dictionary of the English Language. Jeukendrup AE. Caffeine reversal of sleep deprivation effects on alertness and mood. The acute physiological and mood effects of tea and coffee: the role of caffeine level. 141-153. Washington DC. 188-192. 226. Nutr Neurosci. 2003.) Houghton Mifflin. Johnson D. Rucker RB. 15. Panthotenic Acid In: Present knowledge in Nutrition. 373-378. Caffeine effects on the brain and behaviour: A metabolic approach. MA. Bell DG. NNR (Nordic Nutrition Recommendations). Schieberle P (eds. 33. Nathanson JA. Thorne D. New York. 1986. 8. Parliment TH. Cole KG. Br J Sports Med. Reyner LA and Horne JA. The influence of caffeine ingestion on incremental treadmill running. 2004. Miller JW. metabolic and psychostimulant effects. Copenhagen. Daval JL. Caffeine and sports activity: a review. Savoca MR. Robinson K. Gupta A. 320-330. Zwyghuizen-Doorenbos A. 973-979. SCF (Scientific Committee on Food). 2005. Rosenthal L. Sasaki H. Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. 8. Palma-Reis R. Caballero B. Turi ZG. Am J Cardiol. Hess OM. Roth T. Int J Sports Med. Schnyder G. Mayer EL. Jacobsen DW. Savon SR. 2004. 2006. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. Rogers NL and Dinges DF. Nissen SE. Hosoda K. vitamin B12. 139-146. Eberli FR. Miller DP. A taurine and caffeine-containing drink stimulates cognitive performance and well-being. 1998. Ishiko T. Opinion on the Tolerable Upper Intake Levels of Nicotinic Acid and Nicotinamide (Niacin) Schneiker KT. Flammer Y. 2001. 91. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. J Nutr. 2004. Flammer Y. Hennekens C. 635-642. Harshfield GA. 2848-2852.154 Rimm EB. Daly L. Sawaki T. e113. JAMA. Plath D. Clevidence B. Sasaki H. Caffeine ingestion attenuates the VO(2) slow component during intense exercise. Ryu S. 2825-2830. Pin R. 51. 437-443. peripheral vascular disease. Cognitive and physiological effects of an ―energy drink‖: an evaluation of the whole drink and of glucose. San Diego. Rogers PJ and Dernoncourt C. Evans CD. Ludwig DA. Jpn J Physiol. 2001. Hyperhomocysteinemia and low pyridoxal phosphate. 158. Suh H. Scholey AB and Kennedy DO. Refsum H. Roffi M. Graham I. Academic Press. Judd J. SCF (Scientific Committee on Food). 473-477. Circulation. 2003. Meier B. Sadler MJ. Ishikura Y. and coronary artery disease. 8. Seale J. Nicham R. Oolong tea increases metabolic rate and fat oxidation in men. 761-764. Psychopharmacology. Kutner M. 2002. Effects of caffeine on prolonged intermittent-sprint ability in team-sport athletes. 1991. Common and independent reversible risk factors for coronary artery disease. Pin R. Int J Sports Med. 1998. Schnyder G. Hackett LP. Takaoka I. J Nutr Sci Vitaminol (Tokyo). Pharmacol Biochem Behav. Usui S. Rumpler W. European COMAC Group. and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. Dawson B. 24. 1987a. 176. 103-108. Witteman J. Lim K. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. Amino Acids. Brattstrom L. Effect of sucrose and caffeine ingestion on performance of prolonged strenuous running. The association of caffeinated beverages with blood pressure in adolescents. 159 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 . Neuropsychopharmacology. Colditz GA. especially for sportsmen. 203-207. 1265-1269. Seidl R. 1999. van Lente F. caffeine and herbal flavouring fractions. 1998. Lee S. Ueland P. Sampson L. 578-585. Effect of homocysteine-lowering therapy with folic acid. Selhub J. SCF (Scientific Committee of Food) 2000. Strain JJ. 279. 4. Effects of sucrose or caffeine ingestion on running performance and biochemical responses to endurance running. Boers G. Hauser E. 1039-1045. Peyrl A. Caffeine: implications for alertness in athletes. Hu FB. 38. Perez M. 92. 2000. Topol EJ. Kottke-Marchant K. Willett WC. Santalla A. 261-265. Stampfer MJ. 2001. Clin Sports Med. Manson JE. Arheart K. Alerting effects of caffeine after normal and restricted sleep. Hess OM. Ishiko T. 131. 97. Low circulating folate and vitamin B6 concentrations: risk factors for stroke. Arch Pediatr Adolesc Med. Rubba P. Med Sci Sports Exerc. Meleady R. Choi SK. 1987b. 288. Yamamoto S. Komatsu T. Roehrs T. Bishop D. Maeda J. 47. Circulation. Green R. Lucia A. Robinson K. Encyclopedia of Human Nutrition. Opinion on the Tolerable Upper Intake Levels of Vitamin B12. JAMA. 2002. Wilson ME. Cha YS. Wiley E. Joung SS. 59. 1995. Roffi M. 19. 2001. 359-364. Terracina D. 1998. 1992. 84. CRC press. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Cairns SP. Effects of caffeine given before and after lunch on sustained attention. Am J Clin Nutr. Miller J. Modern Nutrition in Health and Disease. Rogers PJ. 537-541. Psychopharmacology. Leathwood P. Immunonutrition Nährstoffe mit immunmodulierender Wirkung. Savory M. Cook C. Caffeine. 47. Shike M. 539-547. Hughes SAC. Med Sci Sports Exerc. Cummings PM. Boers GH. and coronary artery disease. 2002. Dyck DJ. 1993. Smith AP. Tagliabue A. Washington DC. 193 194 195 196 197 198 160 . Cena H. 215-237. Dinges DF. Homocysteine. Genest JJ. Hughes SC. Homocysteine. Behr's Verlag. Bowman BA and Russel RM (eds. 71. 1493-1501. Effects of low doses of caffeine on cognitive performance. Ternes W. glucose and carbonation. Montomoli C. Meleady R. Smit HJ and Rogers PJ. 2000. Mood and cognitive performance effects of "energy" drink constituents: caffeine. Cederblad G. Effects of ‗energy‘drinks on mood and mental performance: critical methodology. 87. Philadephia. Role of familiarity on effects of caffeine-and glucose-containing soft drinks. 20. 85. van Duinen H. 262. Physiology & Behavior. Täufel A. B vitamins. Smit HJ. 2000. Giddens K. E891-898. Nutritional Neuroscience 7. 317-326. Hagers Handbuch der pharmazeutischen Praxis. 2004.175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 Selhub J. Ernährungsumschau. homocysteine. 2005. Rusted JM. 160-163. 2005. Smit HJ and Rogers PJ. Thomas M. Hultman E. Turconi G. Baltimore. Title LM. 13. 1234-1244. Grady ML. 152. 127-139. Lorist MM. 1998. Flynn R. Effects of caffeine ingestion on exercise-induced changes during highintensity. Smith A. Neuropsychobiology. 18. 180. Cotton JR. Trice I and Haymes EM. Daly LE. 287-297. Nassar BA. Lippincott Williams & Wilkins. Finnegan YE. 2006. Spiller GA. Caballero B. Springer Verlag. Lanzola E. 1990. 2000. Int J Sport Nutr. Zijdewind I. 2005. Stuart GR. Bagley LC. Smit HJ. Hopkins WG. Hamburg. Boca Raton. Jr. 2002. Stabler SP. and catecholamine responses after withdrawal. Sleep. 1995. 2001. 230-240 Stehle P. Mullington JM. The effect of caffeine on cognitive task performance and motor fatigue. European COMAC Group. effects of gender and menopausal status. 614S-620S. intermittent exercise. Robinson K.. 2001. Psychopharmacology (Berl). Seshadri N and Robinson K. 1994. 758765. Maben A. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. 167-173.). vitamin status and risk of vascular disease. Rogers PJ. Ross C. 217-223. Tunger L. 813-819. 1990. Verhoef P. Effect of caffeine on metabolism. Price NJ. 27. Int J Obes Relat Metab Disord. Graham TE. Vitamin B12 In: Present knowledge in Nutrition. Van Dongen HP. Investigation of the effects of coffee on alertness and performance during the day and night. 1999. 40. 37-44. 1998-2005. 216-222. Eur Heart J. Multiple effects of caffeine on simulated high-intensity team-sport performance. 5. ILSI Press. Szuba MP. exercise endurance. Food quality and preference. Spriet LL. Van Soeren MH and Graham TE. Graham IM. MacLean DA. Shils ME. Effects of caffeine on human behavior. 23. 36. Am J Physiol. Cousins R. 2000. Food Chem Toxicol. Coffee induced thermogenesis and skin temperature. Neuropsychobiology. Kapoor SC. Brockman P. Cotton JR. Caffeine ingestion and muscle metabolism during prolonged exercise in humans. 1243-1255. mood and thirst in low and higher caffeine consumers. 2000. B vitamins. 2006. 37. Lebensmittel-Lexikon. 24. Eaton-Williams P. J Am Coll Cardiol. and neurocognitive function in the elderly. Smith AP. Berlin. J Appl Physiol. Med Clin North Am. Rosenberg IH. Phytochemistry. Beck KF. Sanderson JE. 2006. McKeever KH. 197. Medicinal benefits of green tea: part II. Morre DM. Warburton DM. attenuates damaging influences to the retina caused by ischemia/reperfusion. 1195-1204. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Eberhardt W. Olson JA. 1849-1855. Vitamin B12 ―cobalamin‖. 11. Thomas GN. Rafferty NS. Basun H. Weir DG and Scott JM. Medicinal benefits of green tea: Part I. 40-53. 1159. Matsuzaki Y. Lewis N. Morre DJ. 40-46. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Nagle DG. Zigman S. Verheugt FW. 13. Willems FF. 1998. Aengevaeren WR. 535-539. 8. 2005a. 18. Blom HJ. Shike M. review of anticancer properties. Wiles JD. 1188-1194. 521-528. 1999. J Am Coll Cardiol. Boers GH. Westerterp-Plantenga MS. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Kovacs EM. 1995. Baltimore. Mol Pharmacol. Oolong and Black Tea)” and “Antioxidant” 206 207 208 209 1 2 3 Cooper R. 2004. 40. 2005. Wemple RD. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. 447-458. 161 . an active ingredient from green tea. Qi B. Metreweli C. Qiao M. Tegerdine M. Nutr Health. 176-187. Coleman D. Lippincott Williams & Wilkins. 2001. Wahlin A. Lolin YI. Zhang M. Chook P. Sokejima S. The effects of caffeine ingestion on performance time. Effects of taurine administration in rat skeletal muscles on exercise. 203207. Brain Res. 2002. Rafferty KA. Rusciano D. Effects of green tea polyphenols on lens photooxidative stress. The danger of B12 deficiency in the elderly. Swaine IL. 1999. Chan LL. 2004. Ochiai N. Yatabe Y. 215-226. Izumi I. Effects of caffeine on cognition and mood without caffeine abstinence. Zhang B. Epigallocatechin gallate. 639-652. Cooper R. Morre DJ. Fratiglioni L. Miyakawa S. Safa R. 12. Yamagami T. 11. 2002. Philadelphia. Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men. Cheung AS. J Sports Sci. 56. Psychopharmacology (Berl).). Morre DM. Ferreira D. Ross C (eds. Zhang B and Osborne NN. J Altern Complement Med. Lejeune MP. In: Modern Nutrition in Health and Disease. 1124. 65. J Orthop Sci. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. Review of noncancer health benefits. Neurology. Kagamimori S. speed and power during a laboratory-based 1 km cycling time-trial.199 200 201 202 203 204 205 Wang HX. 1165-1171. 766-772. Osborne NN. Liu Z. Amino Acids. Fastbom J. 15-17. 26. Lamb DR. Woo KS. 112. Wynn M and Wynn A. 66-70. ID 1280: “Catechins – Green tea (camellia sinensis)” and “Eye health” 1 2 3 4 Kaszkin M. Zhou YD. Fung WH. Oxidative-induced retinal degeneration is attenuated by epigallocatechin gallate. Brain Res. Winblad B. Shils ME. 24. Miyazaki T. Am J Med. 67. 2006. Pfeilschifter J. Obes Res. Biol Bull. 2005b. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. ID 1276: “Camellia sinensis Tea (Green. 2007. J Altern Complement Med. Int J Sports Med. 119. Unravelling green tea's mechanisms of action: more than meets the eye. Celermajer DS. 1997. 2003. 2006. 415-419. 285-286. Beneficial role of peanuts in the diet – an update and rethink! Peanuts and their role in CHD. controlled. 1995. 32. BMJ. Lapsley KG. Davis PA. Ellsworth JL.218. Colditz GA. 22. 16. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 162 . Gurr MI. Belling GB. Tanzman J. Hennekens CH. 112-117. 995-999. J Am Coll Nutr. homocysteine. Mauger DT. Almonds and almond oil have similar effects on plasma lipids and LDL oxidation in healthy men and women. Hsieh G. 132. Am J Clin Nutr.ID 1284: “Peanuts. 59. J Nutr. Almonds in the diet simultaneously improve plasma alpha-tocopherol concentrations and reduce plasma lipids. Kushi LH. Lovejoy J. Jenab M. Noakes M. Kendall CW. Harrison EH. J Am Coll Nutr. Taylor S. Amezcua-Gastelum JL. 1994. oxidized low-density lipoproteins. Borlak N. 2002. Chavez-Carbajal F. 214 . 2004. Connelly PW. Gardner CD and Kraemer HC. Haddad E. Eissenstat B. Vanden Heuvel JP. 23. Monounsaturated versus polyunsaturated dietary fat and serum lipids. 1998. Higgs J. Abbey M. 15. 2001. Hyson DA. Kris-Etherton PM. 23. 2005. Appleby P. Parker TL. Hu FB. Kris-Etherton PM. Stampfer MJ. 2002. Alvizouri-Munoz M. 138. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. 2002. Peanut oil” and “Helps achieve normal cholesterol levels by reducing blood total and LDL cholesterol and thereby promoting heart health” 1 Abbey M. Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women: the Iowa Women's Health Study. Furlong T. Ganatra S. Tree nut and peanut consumption in relation to chronic and metabolic diseases including allergy. Haight JS. Florentin L. lipoprotein(a). Nix D. crossover trial. Clarke R. J Nutr. 105. Coates AM and Howe PR. Jenkins DJ. J Am Diet Assoc. Schneeman BO. Fulgoni VL. Sabate J. Collins R. 25-30. Circulation. Rimm EB. BMJ. 2007. Curr Opin Lipidol. 703-707. FASEB J. J Nutr. Spiller GA. Vidgen E. Folsom AR. Sabate J. 2001. 449-454. Meta-Analysis: Effects of a moderate fat (MF) versus lower-fat (LF) diets on serum lipid profile. Herrera-Abarca JE. Peto R. Whelan MF. Edible nuts and metabolic health. 18. 2002. Speizer FE. Jenkins D. Arch Med Res. A981-A981. 1341-1345. 1992. 965-969. 1758-1763. 21. Rajaram S. Frost C. and pulmonary nitric oxide: a randomized. Nestel PJ. Grundy SM. 47. 106. 63-86. Carranza-Madrigal J. Peanut consumption improves indices of cardiovascular disease risk in healthy adults. 372-377. Alper CM and Mattes RD. Spiller G. Nutr Res Rev. 1988. Most M. 1327-1332. Dietary fat and plasma lipids. 2003. Faulkner D. 133-141. Peanut butter. Effects of avocado as a source of monounsaturated fatty acids on plasma lipid levels. 2. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. Willett WC. 2007. Etherton TD. Kris-Etherton PM. Almonds lower blood cholesterol and LDL-cholesterol but not HDL-cholesterol in human subjects: results of a metaanalysis. 163-167. Nutrition and Food Science. Comparison of monounsaturated fatty acids and carbohydrates for reducing raised levels of plasma cholesterol in man. 317. Qian W. Improved diet quality with peanut consumption. Nutr Metab Cardiovasc Dis. Rosner BA. 1757S-1762S. A meta-analysis. Pelkman CL. 660-668. Am J Clin Nutr. Juturu V. 1989. Davis P. Pearson TA. Griel AE. 1997. 2008. Cao YM. 131. Dose response of almonds on coronary heart disease risk factors: blood lipids. Manson JE. 11. Hargrove RL. Marchie A. Partial replacement of saturated fatty acids with almonds or walnuts lowers total plasma cholesterol and low-density-lipoprotein cholesterol. A698-A698. Davis PA. FASEB J. 1917-1927. Jambazian PR. 314. Low fat and high monounsaturated fat diets decrease human low density lipoprotein oxidative susceptibility in vitro. Arterioscler Thromb Vasc Biol. AHA science advisory: monounsaturated fatty acids and risk of cardiovascular disease. Howard B. 1741S-1745S. Foster GD. and olive oils on fasting and postprandial plasma lipoproteins in humans as part of a National Cholesterol Education Program Step 2 diet. Liu S. 171-178. Mitch WE. Eur J Clin Nutr. Pearson TA. St Jeor S. 1533-1542. 77-83. Mullis R. Wan Y. 781-788. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. Alonso R. Jenkins DJ. 2003. Lefevre M. 1999. Kris-Etherton PM. Parker TL. 502-510. 13. Am J Clin Nutr. Josse RG.. 1000-1006. Kris-Etherton PM. 1985. J Nutr. de Souza R. Effect of diets enriched in almonds on insulin action and serum lipids in adults with normal glucose tolerance or type 2 diabetes. Am J Clin Nutr. Emam A. 76. Vidgen E. de Oya M. Kris-Etherton P. O'Sullivan SM. Connelly PW. Hu FB. Int J Obes Relat Metab Disord. Robinson K. Appel LJ. Goldin BR. JAMA. Leiter LA. Sabate J. Etherton TD. 26. Blumberg J. Ingwersen L. Int J Food Sci Nutr. Deckelbaum RJ. 138. Rood JC. 504S-511S. 2008. Sabate J. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Kendall CW. 2001. Josse RG. Galvin K. 194-202. J Nutr. 56. Lichtenstein AH. King JC. 1992. Krauss RM. Jenner JL. tocopherol. Wong JM. low-energy diet for weight loss in overweight adults. Circulation.20 Jenkins DJ. squalene and phytosterol content of walnuts. Trautwein EA. Zhao G. Schaefer EJ. Lapsley KG. 2004. Mattes RD. Wylie-Rosett J. 288. 1503-1511. Leiter LA. hazelnuts and the macadamia nut. corn. Faulkner DA. Kotchen TA. 2006. Stampfer MJ. Am J Clin Nutr. Ratcliffe HE. Yu-Poth S. Vidgen E. J Lipid Res. Gualtieri LJ. Vidgen E. 62. Most MM. de Souza R. 1993. JAMA. Faulkner DA. Kris-Etherton PM. Effects of canola. Kendall CW. Marchie A. O'Connor TP. Ausman LM. Holmes C. 290. 138. O'Brien NM. 83. and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. Nguyen T. Comparison of effects of dietary saturated. 582-591. de Souza R. J Nutr. Faulkner DA. Marchie A. monounsaturated. Lapsley KG. Tree nuts and peanuts as components of a healthy diet. Kemp T. Blazquez E. 25. Fishell V. Impact of peanuts and tree nuts on body weight and healthy weight loss in adults. Rubio MJ. Alvarez-Sala LA. Jenkins DJ. Jiang R. 2280-2284. 2554-2560. Tucker KL. Bazzarre TL. Nut and peanut butter consumption and risk of type 2 diabetes in women. 138. Sacks F. Am J Clin Nutr. Tribble DL. Ordovas JM. Connelly PW. 2002. 2284-2299. peanuts. Highmonounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. 70. Josse RG. 55. Kris-Etherton PM. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. 2008. Emam A. Ros E. Erdman JW. Lichtenstein AH. Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure. 2008. Eckel RH. almonds. Singer W. Ordovas JM. 1009-1015. Goldberg IJ. Leiter LA. Lapsley KG. Emam A. Garrido JA. Fatty acid profile. McManus K. 1736S-1740S. Nguyen TH. 1999a. Manson JE. Am J Clin Nutr. Moriarty K. Greenway FL. Hargrove RL. Arterioscler Thromb. Kemp T. Singer W. Wong JM. Nuts and their bioactive constituents: effects on serum lipids and other factors that affect disease risk. 2000. 2008. Antinoro L. 1746S-1751S. Trautwein EA. 1999b. Kris-Etherton PM. Kendall CW. 2002. Trautwein EA. Willett WC. Jenab M. 102. low-energy diet compared with a low fat. Mattson FH and Grundy SM. Suttie J. Lovejoy JC. Hu FB. Marchie A. A randomized controlled trial of a moderate-fat. 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 163 . Effect of dietary monounsaturated fatty acids on plasma lipoproteins and apolipoproteins in women. J Nutr. 129. Wong JM. Daniels SR. Etherton TD. Carrasco W. Maguire LS. Mata P. Jr. 70. 47804784. 2003. 1992. 95-135. 59. 195-200. 911-919. Spiller GA. Prior RL. 1998. A systematic review of the effects of nuts on blood lipid profiles in humans. 46. LC/MS/MS characterization of phenolic constituents in dried plums. Miller A. 2005. Maddox DH. 11. Morse SJ. Tanzman JS. Calder PC. Cragen LN. Jerling JC. Meyer AS. Halvorsen BL. Oosthuizen W. Farquhar JW. 1379-1384. Jenkins DA. 1365-1372. Berra K. Valsta LM. 439-446. A metaanalysis of 27 trials. Webb D. Effects of plant-based diets high in raw or roasted almonds. Knauft DA. Rajaram S. 285-290. Nuts and plasma lipids: an almond-based diet lowers LDL-C while preserving HDL-C. Mukuddem-Petersen J. Miller B. O'Byrne DJ. 1999. Am J Clin Nutr. Wright J. 2003. Phillips KM. Gustafsson IB. 1989. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. 32. 1998. Serum lipid response to the graduated enrichment of a Step I diet with almonds: a randomized feeding trial. 126-130. Jr. 50. Yu S. Bohn SK. Waterhouse AL. 49. Pelkman CL. Roche H. antioxidant capacity. Jambazian P. Lipid-lowering diets enriched with monounsaturated or polyunsaturated fatty acids but low in saturated fatty acids have similar effects on serum lipid concentrations in hyperlipidemic patients. 115-122. Nydahl MC. Sabate JM.37 Mensink RP and Katan MB. 1747-1750. Effect of a diet high in monounsaturated fat from almonds on plasma cholesterol and lipoproteins. Fenu PM. 2001. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Effects of a monounsaturated rapeseed oil and a polyunsaturated sunflower oil diet on lipoprotein levels in humans. 3 4 5 164 . Arterioscler Thromb. Meijer G. 1247-1252. Mensink RP and Katan MB. Tredger JA. Pearson TA. Bosello O. J Nutr. Am J Clin Nutr. Rudd C. J Am Coll Nutr. Cragen LN. LC/ES-MS detection of hydroxycinnamates in human plasma and urine. Am J Clin Nutr. 2006. Carlsen MH. 2082-2089. Bosello O. 3579-3585. Jauhiainen M. 22. Kandeel FR. 12. Waterhouse AL. Cole SE. Stevenson M. Reynolds J. 77. 1992. ID 1285: “Prunes (Dried plums)” and “Contains antioxidants” 38 39 40 41 42 43 44 45 46 47 48 49 1 2 Cremin P. Fishell VK. Almonds vs complex carbohydrates in a weight reduction program. J Am Coll Nutr. Piga A. Zampelas A. Cholesterol reduction using manufactured foods high in monounsaturated fatty acids: a randomized crossover study. Phenolic composition and antioxidant activity of prunes and prune juice (Prunus domestica). 50-57. Katan MB. N Engl J Med. 17. Del Caro A. Agabbio M. Brookes CA. Bruce B. Am J Clin Nutr. 12. Gates JE. Blomhoff R. Francis-Knapper JA. 84. J Agric Food Chem. 1997. Donovan JL. Yaqoob P. Aro A. Jacobs DR. Effect of dietary fatty acids on serum lipids and lipoproteins. 2003. 436-441. Spiller GA. or roasted almond butter on serum lipoproteins in humans. Br J Nutr.. 27. 79. Kasim-Karakas S. J Agric Food Chem. 135. Dewell A. Content of redox-active compounds (ie. J Am Coll Nutr. Effect of drying conditions and storage period on polyphenolic content. Vessby B. Gates JE. 2004. J Agric Food Chem. Low fat-monounsaturated rich diets containing high-oleic peanuts improve serum lipoprotein profiles. Haddad E. Pinna I. Olivera K. Williams CM. 687-695. Int J Obes Relat Metab Disord. 2004. Jenkins DJ. Ikle DN. 2002. Gibney MJ. 204-212. Kris-Etherton PM. Lipids. 321. 1994. Mutanen M. Fang N. J Agric Food Chem. and ascorbic acid of prunes. Mauger DT. antioxidants) in foods consumed in the United States. 1992. Holte K. Spiller GA. 52. Arterioscler Thromb. Wien MA. 81. Sabate J. Superko R. Shireman RB. 2007. Ferretti G. 2007. 735-741. 2002. Curatola G. Holden JM. Fonseca FA. Hwang J. Soy consumption. 2005. Nutr Cancer. D'Alessandro C. Mitani T. Mitani T.Examples of portion sizes of everday fruit. 2007. 2006. Beecher GR. Effect of genistein against copper-induced lipid peroxidation of human high density lipoproteins (HDL). Wiinberg N. 85. Tholstrup T. Kasinski N. 2004. Nakatani N. Talbot D. Huang CW. J Agric Food Chem. Piekarska A. Ann Intern Med. Arnoldi A. Br J Pharmacol. Hu FB. 2004. Prior RL. DiSilvestro RA. Wang TA. Devor ST. Atherosclerosis. 29-33. 95. Bricarello LP. Effect of soybean protein on blood pressure: a randomized. controlled trial. 51. Locati D. UK.uk/WhatCounts/PortionSizesFruit. Kikuzaki H. antioxidative capacity and urinary estrogen metabolites in postmenopausal women on hormone therapy. 50. Mattern C. Del Caro A. 967-973. 1-9. Nestel PJ. Barsotti G. Mehrabi Y. Ikami T. 98. Kimiagar M. Mehrabi Y. Soy protein intake by active young adult men raises plasma antioxidant capacity without altering plasma testosterone. 2003. 2007. Nutrition. Wu X. Lipophilic and hydrophilic antioxidant capacities of common foods in the United States. Antioxidant activity of prune (Prunus domestica L. Sevanian A. 79-89. Azadbakht L. 2003. Chin-Dusting JP. Kimiagar M. Br J Nutr. Ihara SS. 2006. Padyab M. J Agric Food Chem. Hsu IP. Fisher LJ. Ferrari M. Hallund J. Corda G. He J. Bugel S. Gebhardt SE. J Agric Food Chem. Wu X. Suzuki T. 2000. Wood N. Free Radic Biol Med. Wu WH. ID 1286: “Soy” and “Vascular effects including protection from oxidative damage” 8 9 10 11 1 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 229-234. Williams CM. Yang Y and Gallaher DD. Faludi A. Ghiadoni L. 143. Comparison between the effects of soy milk and non-fat cow milk on lipid profile and lipid peroxidation in patients with primary hypercholesterolemia. 117-125. Bertolami MC.nhs. Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Shioaki K. Morandi S. 3708-3712. Haytowitz DB. 3675-3681. Soy protein diet improves endothelial dysfunction in renal transplant patients. Cupisti A. Nephrol Dial Transplant. 2001. Salvetti A. Willett WC. 2005. Reimann M. Willett WC. 5 a day: Everyday fruit . Hodis HN. 92-95. and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. markers of inflammation. Kardasz I. Gu D. Esmaillzadeh A. Nutrition Research. From plums to prunes: influence of drying parameters on polyphenols and antioxidant activity. Tufik S. 20. 52. Piga A. 26. Menanno F. Kayano S. Lewis TV. 22. Nakatani N. Int J Gynaecol Obstet.Recommandations. Husband A. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. 3 4 5 6 7 8 9 10 11 12 165 . 200-204. Ursini F. 51. 30. 29. 172. Am J Clin Nutr. Yamada NF. 1120-1126. 133. J Agric Food Chem. Pinto LA. The vascular activity of some isoflavone metabolites: implications for a cardioprotective role. Sécurité et bénéfices des phytoestrogènes apportés par l'alimentation . Chen J. Taddei S. 1480-1485. Hall WL. Azadbakht L. 2004. Bacchetti T. Esmaillzadeh A.). Jou HJ. Hu FB. 55-61. Synergistic inhibition of LDL oxidation by phytoestrogens and ascorbic acid.) constituents and a new synergist. Effect of dried plums on colon cancer risk factors in rats. The effects of soygerm extracts on blood lipoproteins. Saba A. http://www.5aday. Panichi V. Morelli E. Diabetes Care. Kikuzaki H. Fukutsuka N.aspxn. Quantitative evaluation of antioxidant components in prunes (Prunus domestica L. 53.6 7 Kayano S. 2005. Relvas WG. Duan X. Whelton PK. Izar MC. 4026-4037. 595-605. The joint effect of oxidative stress and antioxidants on the risk of an aneurysmal rupture subarachnoid hemorrhage: a case-control study in Japan. Sagara M. 339-347. 19. Washburn S. Parker TL. Yamashita T. M NJ. 85-91. blood pressure. Murray MJ. Yamori Y. 2006. Knock GA. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. middle-aged men in Scotland. Lapsley KG. Okamoto K and Horisawa R. Dietary antioxidant intake and risk of an aneurysmal rupture subarachnoid hemorrhage in Japan. Wong JM. Sugden D. Novaes N. homocysteine. Marchie A. Proc Natl Acad Sci USA. Cia P. 631S-638S. 132. 76. Wilcox JN and Blumenthal BF. 2001. Anthony M. and blood pressure in hyperlipidemic men and women. 2006. Eur J Cardiovasc Prev Rehabil. Vina J. 1998. 2003. Kumar K. Ann Epidemiol. Teede HJ. FASEB J. Taylor P.13 Jenkins DJ. Birt N. 2003. Mahn K. Ward JP. Jackson CJ. 17551757. Parker T. J Nutr. 2005.. Morabito N. 1. 61. Vidgen E. Eur J Clin Nutr. J Am Coll Nutr. Komesaroff P. Atherosclerosis. Silva RA. Escanero JF. D'Anna R. Adlercreutz H. 192.and low-isoflavone soyfoods on blood lipids. 502-510. 359-363. 17. Owen A. Am J Clin Nutr. 184-189. 284-287. Squadrito G. Garay RP. West SG. Menopause. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. Effect of soy protein supplementation on serum lipoproteins. Trautwein EA. Jr. Dart A. Squadrito F. An isoflavone metabolite reduces arterial stiffness and blood pressure in overweight men and postmenopausal women. Crisafulli A. Pereira IR. Borras C. Corrado F. 2007b. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Cia P. 78. Campo GM. Rivas M. Connelly PW. 23. Kendall CW. Fujii A. Arterioscler Thromb Vasc Biol. 2002. oxidized LDL. de Souza R. JAMA. 125. 3392-3398. Leiter LA. 2002. Faludi AA. Liang YL. 2002. 1997. Faulkner D. 290. Guthrie NL. Burke GL. 13. 1995. Abdalla DS. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Effects of soy germ isoflavones and hormone therapy on nitric oxide derivatives. Soy products and risk of an aneurysmal rupture subarachnoid hemorrhage in Japan. Saleh MH. Altavilla D. Atherosclerosis. 163. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 166 . endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Vihma V. Nestel PJ. Abbey M. Caputi AP. Emam A. Josse RG. Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women. J Clin Endocrinol Metab. 17-30. Cunnane SC. 942-950. Ruggeri P. Aaronson PI. Birt C. Connelly PW. Okamoto K and Horisawa R. Morgan T. Poston L. Ojala S. Steinberg FM. J Nutr. Mann GE. 365-372. 2007a. 2007. Pomeroy S. 2004. Davis S. Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. Leiter LA. 2003. 3053-3060. Current Topics Nutraceutical Res. Teramoto T. Josse RG. Kendall CW. Calapai G. Zhang L. Bertolami MC. Dalais FS. Sasahara T. 6. Wahala K. 1900-1902. Vidgen E. McGrath BP. Alda JO. Villablanca AC. 95. 13. and menopausal symptoms in perimenopausal women. Nakamura Y. 86. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations. 1999. Blood pressure and vascular effects of soy: how strong is the evidence. Campos MF. Nestel P. 7-13. Effects of dietary intake of soy protein and isoflavones on cardiovascular disease risk factors in high risk. and vascular reactivity in hypercholesterolemic postmenopausal women. 1140-1142. Sharpe RM. Faulkner DA. Aldrighi JM. Armitage L. low-density lipoprotein oxidation. Jenkins DJ. 17. 123-130. Menopause. Khan IY. Kanda T. Effects of high. Kotsopoulos D. Okamoto K and Horisawa R. Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. 3106-3110. Tikkanen MJ. Am J Clin Nutr. Pescatore AJ. Enhancing the selenium content of bovine milk through alteration of the form and concentration of selenium in the diet of the dairy cow. 111. 2172-2179. 395-400. Li HL. Arterial compliance. Richert B. Grešáková Ľ. 1998. Metabolism. Maintenance of cellular redox status” 1 Mahan DC and Parrett NA. 24. Shu XO. Sade E. Tokgozoglu SL. Poult Sci. Effects of dietary levels of selenium-enriched yeast and sodium selenite as selenium sources fed to growing-finishing pigs on performance. 74. Soy protein diet significantly improves endothelial function and lipid parameters. 2005. Gao YT. Haznedaroglu I. Maintenance of cellular redox status” 1 Paton ND. Smith CA. 1308-1314. Nestel PJ. Am J Clin Nutr. Rollin F. Proper thyroid function. 1548-1554. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Pavlata L. Proper thyroid function. 72. 72. Chicken selenium status when fed a diet supplemented with Se yeast. Leng Ľ. Proper thyroid function. Pachovà A. 2001. Adlercreutz H. Maintenance of cellular redox status” 1 Kuricová S. and loin quality. ID 1293: “Pork and related products” and “Antioxidant to prevent oxidative stress. Oto A. Zheng W. ID 1289: “Beef and beef products” and “Antioxidant to prevent oxidative stress. Li Q. Boldižárová K. serum glutathione peroxidase activity. Zhang X. 1999. Mahan DC. J Anim Sci. Akinci D. Collier G. Kirazli S. Jin F. 339-346. Proper thyroid function. Illek J. ID 1290: “Chicken and chicken products” and “Antioxidant to prevent oxidative stress. Ford MJ. Evaluating the efficacy of selenium-enriched yeast and sodium selenite on tissue selenium retention and serum glutathione peroxidase activity in grower and finisher swine. ID 1291: “Egg and egg products” and “Antioxidant to prevent oxidative stress. 811-817. 2000. Oduncu T.31 Wiseman H. carcass characteristics. Koksal G. ID 1292: “Milk and dairy products” and “Antioxidant to prevent oxidative stress. 2002.A comparison. Kes S. 77. Blood and tissue selenium concentrations in calves treated with inorganic or organic selenium compounds . 84.M aintenance of cellular redox status” 32 33 34 1 2 Guyot H. Bobček R. Rowland IR. Clin Cardiol. Yamashita T. Proper thyroid function. Spring P. 2 167 . 19-26. Cottrill B. 70. Bowey EA. 1996. 2967-2974. Cline TR. Yildirir A. and plasma lipids in women are improved with weight reduction equally with a meat-based diet and a plant-based diet. The effect of dietary selenium source and level on the uptake of selenium by developing chick embryos. Levkut M. Comparative responses to sodium selenite and organic selenium supplements in Belgian Blue cows and calves. Pomeroy SE. Acta Vet Brno. Journal of the Science of Food and Agriculture. Acta Vet Brno. 2003. 1012-1017. Mallet AI. Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Livestock science. 81. Maintenance of cellular redox status” 1 Givens DI. Sasahara T. O'Reilly JD. 81. 2001. plasma leptin. Yang G. 47. J Anim Sci. Sanders TA. Cantor AH. 2004. Allison R. blood pressure. Am J Clin Nutr. 259-263. 711-716. tissue selenium. Andieu S. Blake JS. 2007. 1996. Jayle GE. Rombi M and Robert D (eds. 1965. Pharmaceutical Press. Mills S and Bone K (eds. Prévention et Santé. Churchill Livingstone. Dagilyte A. 198.). Barnes J. Mills S and Bone K. Gruenwald J. Siravo D. Rozier J. Jaenicke C. 1173. Bruneton J. Hazebroucq G. Altern Med Rev. Aubry M. Phytochimie. Faure P. Chiellini S. L‘officine. 500-504. Natural therapies for ocular disorders.). 6. De la Baume C. Diabetic and hypertensive retinopathy therapy with Vaccinium myrtillus anthocyanosides (Tegens): Double-blind placebo controlled clinical trial. 31. 73-77. 970-975. Edinburgh. Ann Ocul (Paris). 183-187. Churchill Livingstone. 11 12 13 14 15 16 17 18 19 168 . Guidi G. Plantes médicinales.). 1984. 1965. Edinburgh. Faure P. Ann Ottalmol Clin Ocul. Bastide P. Pharmacol Res. Tronche P. Hazebroucq G. Thomson Reuters. Edinburgh. Vaccinium myrtillus (bilberry). Chevaleraud J. Bull Soc Ophtalmol Fr. Anderson LA. In: Pharmacognosie. Phillipson JD (eds. Perossini M. [Study concerning the action of anthocyanoside extracts of Vaccinium Myrtillus on night vision]. Potential interactions between pharmaceuticals and natural health products in Canada. Perdriel G. 1049-1053. 2004. Bilberry. Zitkevicius V. Apropos of various experimental facts]. Myrtille. 320-323. Effect of Vaccinium myrtillus anthocyanosides on ischaemia reperfusion injury in hamster cheek pouch microcirculation. In: Dorvault. 115. London. 38. Churchill Livingstone. 109-116. 1999. Nutrition. PDR for herbal medicines. Braccini G. Brendler T. Pizzorno JE and Murray MT. Anderson LA. Maccolini E. Barnes J. Pihouee P. 2000.ID 1295: “Bilberry fruits (Vaccinium myrtillus fruit)” and “Eye Health” 1 2 3 4 5 6 7 8 9 10 Prévenir le déclin lié au vieillissement. Airelle. 68. Gavini H. Lukosius A. 40. [Importance of biologically active components and plants in the prevention of complications of diabetes mellitus]. Bull Soc Ophtalmol Fr. 2001. 113. 2001.). London. Myrtille. Thomson Reuters. 2007. Ann Ottalmol Clin Ocul. 801-807. 106. Malandrino S. 361-363. 1995. Rieu C. 368-372. Bravetti GO. 2001. Textbook of Natural Medicines. 141-166. Phillipson JD. Head KA. 2002. Medicina (Kaunas). Montvale. Girre L. Bellanger A. 209. Rouher F. Bruneton J (ed. part two: cataracts and glaucoma. Singh SR and Levine MAH. Gruenwald J. J Clin Pharmacol. In: 120 plantes médicinales – Composition. 1-7. 1989. 556-562. Preventive medical treatment of senile cataract with Vitamin E and Vaccinum myrtillus anthocyanosides: Clinical evaluation. 65. Boniface R and Robert AM. Science. Lavoisier. In: Principles and practice of Phytotherapy. 297-302. 1968. Rieu C. Monograph. Mode d‘action et Intérêt thérapeutique. Bilberrry fruit. Paris. 1987. 2005. A guide for healthcare professionals. In: Herbal Medicines. Mercier A. Klinische Monatsblatter fur Augenheilkunde. London. Vigot. Le concours médical. 2007. PDR for herbal medicines. Jaenicke C. Brendler T. Bellanger A.) Tec & Doc. 2002. Pizzorno JE and Murray MT. Fraboni E. Pihouee P. Husson M-C. Delaveau P. [Note concerning the action of anthocyanin glycosides on the human electroretinogram]. Textbook of natural medicine. Colantuoni A. London. Monaco. 47. 4129-4130. [Rhodopsin and anthocyanosides. Paris. Husson M-C. Airelle myrtille. 1999. Terrier N (eds. Altern Med Rev. Terrier N. Alpen. 249-258. ID 1297: “Bilberry fruits (Vaccinium myrtillus fruit)” and “Capillary wessels and vein health” 1 2 3 Bertuglia S. Chicago. 2004. [Influence of anthocyanosides on human connective tissue metabolism]. Girre L. 1995. Nutranews. Savickiene N. Montvale. 6. Rombi M and Robert D. 2003. 47. Marlett JA. 2007. Ballaststoffe. Allen L. Eur J Clin Nutr. 2005. J Nutr. James WPT. In: Ernährungsmedizin und Diätetik. Yang CH. Nahrungsfasern. Wiggins HS. Effects on rat serum and liver cholesterol and triglycerides and on fecal characteristics. Gröber U (ed. Dressman JB. Atherosclerosis. Safety assessment of hydroxypropyl methylcellulose as a food ingredient. 1991. Kritchevsky D. Pearson JR. I. 1993. 538-541. Reppas C. retinol and tocopherol concentrations in mildly hypercholesterolemic subjects fed high molecular weight hydroxypropylmethylcellulose (HPMC) to lower serum cholesterol. 1468-1473. Arch Intern Med. Relationships between viscosity of hydroxypropyl methylcellulose and plasma cholesterol in hamsters. lipoprotein profile and gut hormones in NIDDM patients. 2005. Dietray fiber. Bonet MV. Increased intestinal contents viscosity reduces cholesterol absorption efficiency in hamsters fed hydroxypropyl methylcellulose. New York. Parr DD. 1996. 1463-1469. 153. 1993.). Campbell AJ. Elmadfa I and Leitzmann C. Cereal Chem. In vitro effects of a flavonoid-rich extract on LDL oxidation. Kasper H. Hosig KB. Gröber U. Curr Opin Clin Nutr Metab Care. Plasma Beta-Carotene. Physiology. 23-26. (Unpublished). Ballaststoffe (Pflanzenfasern. Chemistry. Hassel CA. Stuttgart. 8. Cereal Chemistry. Caballero B. Dressman J. 83-91. 45. Gallaher DD. 1996. Cossack ZT and Musaiger AO. 80. Hill MJ. Kasper H (ed. Jonhson MD. Prentice A (eds. 392-398. Physiological responses of men and women to barley and oat extracts (Nu-TrimX). 73. 126. Carter CM. Plenum Press. High-molecular-weight hydroxypropylmethylcellulose. 35-44. 1989. Israelsson B. Oxford. Comparison of large bowel function and calcium balance during soft wheat bran and oat bran consumption. 1990. Elsevier. engl. In: Orthomolekulare Medizin. Bonet B. 1990. Jarvenpaa KM. 2341-2351. Human Nutrition and Dietetics. Hallfrisch J and Behall KM. dietary fiber).) Wissenschaftliche Verlagsgesellschaft. 636-640. 67. Tobey SW. 37. Asp NG. 82-100. Cummings JH. 76-79. 146-149. Swidan SZ. Bonfield C. 8 9 10 11 12 13 14 15 16 17 18 19 20 169 . 1996. Rock CL. In: Encyclopedia of Human Nutrition. Busby WJ. Ernährung des Menschen. 2002. Dunn-Kucharski VA.) Urban and Fischer. Shinnick FL. Eugen Ulmer UTB. London. and gastrointestinal symptoms. Berardi RR. blood pressure. 2004. J Epidemiol Community Health. Food Chem Toxicol. Am J Clin Nutr. Jarnblad G. Carr TP. 1993. Serum Cholesterol Reduced with FIBREX®. Horwath CC. Elsevier Health Sciences. 105-110. A cholesterol-lowering agent. Anderson JW. I. Cereal Chem. Hagander B. Faserstoffe. Ralph A. Jenkins DJ. Ekman R. Dietary fibre enrichment. Effect on lipid metabolism of beet fibre in desert nomads with low habitual fibre intake. Schersten B. 1345-1353. Sowle CA. Klopfenstein CF. Changes in fecal composition and colonic function due to cereal fiber. Castro M. methane. Swidan SZ. 29. Fraile MV. Barnett JL. 1976. Johnson IT. Barbas C. Scandinavian Journal of Nutrition/Naringsforskning. 2004. and Health Effects. Nilsson-Ehle P. Herrera E.Breath hydrogen. 1993. Garrow JS. J Nutr. Reppas C. Gallaher DD. Adair CH. Dietary Fiber. Persson K. Munchen. Hassel CA. Lee KJ. 1732-1738. 123. A place for dietary fibre in the management of the metabolic syndrome. 43. Eur J Clin Nutr. 21. Story JA. Stuttgart. 45. Delzenne NM and Cani PD. Nutritional properties of coarse and fine sugar-beet fibre and hard red wheat bran.4 Viana M. ID 1299: “Oatbran and oatbran products” and “Blood cholesterol level” 1 2 3 4 5 6 7 Burdock GA. 2000. a sugar-beet fibre preparation. 123. Factors associated with constipation in a community based sample of people aged 70 years and over. Sandberg AS. Caballero B. 32nd series. 1245-1251. Ross C (eds. Berlin. 1996. Torri S. 102. Am J Cardiol. Ability of two comestible formulations of hydroxypropylmethylcellulose to lower serum cholesterol concentrations. Ingram KA. Malik KC. Reports of the Scientific Committee for Food. Yap M. Bergkvist L. Shao Q. Royle PJ. Ross C. J Am Coll Nutr. 2009. 2005. European Commission. 1985. Lenkins DJA.A component of Food . Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60. Leya J. Yokoyama WH and Shao Q. Gastroenterology. Berger S. 716-720. Effect of dietary fiber on colonic bacterial enzymes and bile acids in relation to colon cancer. Goldman M. Swidan SZ. 1803-1807. Lippincott Williams & Wilkins. 63. 1705-1710. Shike M. Journal of Human Nutrition and Dietetics 229-243. Barnett JL. Br J Nutr. 239-245. 565-568. 967-974. CA. 34. Daggy BP. Lebensm Wiss Technol. Turconi G. Foster PR. Lia A. 71-77. Hu W. Maki KC. Reppas C. 1475-1482. Bosaeus I. Eur J Clin Nutr. Luxembourg. Lazo GR. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Springer-Verlag. Reppas C. 944951. 130. 1994. 1996. Bioaktive Substanzen in Lebensmitteln. 757-766. O'Mullane J. Am J Clin Nutr. Yokoyama WH. 70. Wolk A. 1995. An open study of oat bran meal biscuits ('Lejfibre') in the treatment of constipation in the elderly. Modern Nutrition in Health and Disease. 1992. European Journal of Pharmaceutical Sciences. 1198-1203. Bazzano R.). Schweizer TF and Edwards CA. 84. DeMeo M. Sundberg B. Clifton PM. Albrecht HH. Engle A. Effect of high-amylose starch and oat bran on metabolic variables and bowel function in subjects with hypertriglyceridemia. Maki KC.21 22 23 Langkilde AM. Watzl B and Leitzmann C. Am J Clin Nutr. In: Modern Nutrition in Health and Disease Shils ME. Le Leu R. Nissom PM. Tobey SW. Reddy BS. Gastrointestinal effects of oat bran and oat gum: a review. Dietary Fibre . Philadelphia. Shils ME. The effects of high-fibre cereal-based breakfast meals on daily dietary intakes and bowel function. Aman P. Highmolecular-weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men. 2001. Swidan SZ. 9. Baltimore. Nutritional function in health and disease. Giovannucci E. Cousins R. Noakes M. Lippincott Williams & Wilkins. SCF (Scientific Committee for Food). Baltimore. Daggy BP. Valle-Jones JC. McIntosh G. 1999. Nestel PJ. Hippokrates. 229th ACS National Meeting San Diego. Mälkki Y and Virtanen E. 16-18. 1999. Andersson H. Dressman JB. Hallmans G. Philadephia. Albrecht HH. Zarling EJ. 64. Soluble fibers prevent insulin resistance in hamsters fed high saturated fat diets. McIntosh GH. Dressman JB. O'Mullane J. 51. Simi B. Lanzola E. 679-698. 13. Tobey SW. 2006. Sugar-beet fibre increases cholesterol and reduces bile acid excretion from the small bowel. Wolever TMS. J Nutr. Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Caramella R. Wlaschin K. Larsson SC. Hydroxypropylmethylcellulose (HPMC) may prevent insulin resistance in hamsters fed high saturated fat diet through regulation of metabolic genes. 92. Edison T. Tallman AM. Stuttgart. Shike M. 337-346. Br J Cancer. Davidson MH. Fiber and other dietary factors affecting nutrient absorption and metabolism. Olson JA. 2006. Cereal Food World. 1993.000 women. Hydroxypropylmethylcellulose significantly lowers blood cholesterol in mildly hypercholesterolemic human subjects. Greenwood DE. Davidson MH. 2000. 77. 4. Am J Clin Nutr. Whole-grain rye and wheat foods and markers of bowel health in overweight middle-aged men. Curr Med Res Opin. Jenkins AL. 62. 1999. Noakes M. Andersson H. 1994. 2003. 1995. Turowski M. 170 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 . 2005. Effect of dietary oat and soy fiber on bowel function and clinical tolerance in a tube feeding dependent population. Erbersdobler HF and Meyer AH (eds. 2007. Nyrop JE. Oxford. Br J Nutr. Lee JS. 76. Foster-Powell K. 18. Veronese A. Adamson J. Diabetes Care. 2002. 2000. Randles KM. Nutr J. Gibbs AL. low-glycemic index diet decreases total fat mass and improves plasma lipid profile in moderately overweight nondiabetic men.). Pohle RJ. 25. 2003. Fiveweek. 26. Diabetes Care. Berg A. Holt SH. Hamburg. and food intake in healthy humans. Pacher N. Thomas M. Meta-analysis of low-glycemic index diets in the management of diabetes . Franceschi S. 50. 145-171. In: Encyclopedia of Human Nutrition. Prentice A (eds. 2005. Br J Nutr. Bornet FRJ. Schaffer V. La Vecchia C. Mark Edwards C. Nutr Rev. Diabetes Care. 83 Suppl 1. Colagiuri S. Eur J Clin Nutr. Nutr Res Rev. glucose. Frost GS. Petocz P. Petocz P.). The beneficial effect of a diet with low glycaemic index on 24 h glucose profiles in healthy young people as assessed by continuous glucose monitoring. A high-glycemic meal pattern elicited increased subjective appetite sensations in overweight and obese women. Glycaemic response to foods: Impact on satiety and long-term weight regulation. Brynes AE. Galgani J. Brand-Miller JC. Theis S. Lee JL. 56. A low glycemic diet significantly improves the 24-h blood glucose profile in people with type 2 diabetes. 2005. Glycemic load and chronic disease. Ostman E. Dornhorst A. 61. 5-56. Glycemic Index. Kendall CW. 207218. Dusel G. Acute effect of meal glycemic index and glycemic load on blood glucose and insulin responses in humans. Influence glycemic index/load on glycemic response. Jardy-Gennetier AE. 2005. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 171 . 2003b. Glycemic index in chronic disease: a review. non-esterified fatty acids and triacylglycerols in middle-aged men. 93. Schauber J. Am J Clin Nutr. 26. Luhrs H. -lipid level and body mass” 1 2 Alfenas RCG and Mattes RD. Diaz E. 3363-3364. Br J Nutr. Augustin LS. Frayn KN. Slama G. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. 2006. 535-553. 2002. Aguirre C. Morgan LM. A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin. Kendall CW. S49-55. 548-549. e. 2728-2732. Brighton RE. Glycaemic index methodology. Anderson JW. Menzel T. 23. Ahmad ZI. 133. Dornhorst A. Nowak JK. Stowell J. whole grain cereals” and “Blood sugar level. Diabetes Care. legumes. Brand-Miller JC. Hamm M. Leeds AR. Colagiuri S. Lang V. Brand-Miller JC. Slama G.g. 2005. as assessed using the continuous glucose MiniMed monitor. Bouche C. Br J Nutr. appetite. Bjorck I. 2005. J Am Coll Nutr. Appetite. Ghatei MA. Luo J. 2004. Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers. J Nutr. Elsevier. Low glycaemic-index foods. Brynes AE. 94. Lang V. Frost GS. Frost G and Dornhurst A. Brouns F. Bloom SR. 28. 2003a. Rizkalla SW. 179-182. International table of glycemic index and glycemic load values: 2002. Melcher R.Response. 2003a. Kozianowski G. 2002. 215-222. 22. Swan V. Vidal H. Gostner A. Scheppach W. Allen L. Brand-Miller JC. 49. 1049-1071. Physiological validation of the concept of glycemic load in lean young adults. In: Praxishandbuch Functional Fod. Bjorck I. Kohlenhydrate und ihre glykamische Wirkung. 2003b. Jenkins DJ. Frost GS. Kudlich T. 2005. Jacquet N. Arumugam V. Theis S. vegetables. Jenkins DJ. Dornhorst A. 5. Leddy JJ. Caballero B. S149-155. Liljeberg H. Behr's Verlag. Fouquet C. 89. Wolever TM. 2123-2129. Appetite. 575-581. 822-828. Pelkman CL. Brynes AE. 5-17. Dorbath D. 2008.ID 1300: “Carbohydrate sources with low glycaemic index (GI <55). 60. Am J Clin Nutr. and cardiovascular disease. The impact of the addition of toppings/fillings on the glycaemic response to commonly consumed carbohydrate foods. Annals of Nutrition and Metabolism. Lipids. 163-191.a systematic review and meta-analysis: the database. Hessdorfer S. Am J Clin Nutr. 69. Augustin LS. Al-Zahrani A. 2003. Howlett J and Ashwell M. Livesey G. Nieuwenhuizen A. Theis S. Liljeberg HGM. 763-769. 454-461. Thompson RL. Pannemans D. Axelsen M. Livesey G.20 21 22 Henry CJK. Dusel G. Effect of the glycemic index and content of indigestible carbohydrates of cereal-based breakfast meals on glucose tolerance at lunch in healthy subjects. 922-930. Caterson I. P385. 1466-1475. 38. New York. Atkinson F. 115-122. 54. 51. 2006. 647-655. and macronutrient intakes. Lightowler HJ. Marchie A. Allolio B. Glycaemic response and health meta-analyses. Glycemic index and heart disease. Liljeberg H and Bjorck I. JAMA. J Am Coll Nutr. 2003. 2008. 212S-216S. Majzoub JA. Glycemic index: overview of implications in health and disease. 223s236s. Brighenti F. Intake of refined carbohydrates and whole grain foods in relation to risk of type 2 diabetes mellitus and coronary heart disease. Bender G. Dorbath D. 44. Taylor R. 1998. High glycemic index foods. Ludwig DS. Henry CJK. 24-28. Frayn K. Nutr Res Rev. Lightowler HJ. 166. 16. Backhaus K. Kendall FL. 2005. 287. 2002. Eur J Clin Nutr. Wirkung des Zuckeraustauschstoffes Isomalt auf Stoffwechsel. Am J Clin Nutr. Hamidi M. study characteristics. 76. and obesity. 2002. Vorster HH. 64. Riccardi G. Proc Nutr Soc. 2008. 266S-273S. PASSCLAIM 1—Body weight regulation. Tuijtelaars S. Proc Nutr Soc. Volk A. 76. 2004. Eur J Clin Nutr. Essentials of human nutrition. Renton H. Glycemic response and health . Eur J Clin Nutr. Expressing the glycaemic potency of foods. 445-455. Kendall CW. The glycemic index . 2007. Curr Atheroscler Rep. 286S-289S. Livesey G. Foods Food Ingred J Jpn. Arch Intern Med. Blanco I. 2002. 1999. Leeds AR. Dallal GE. McMillan-Price J. Steinbeck K. Strik CM. Hulshof T. Hails S. 21. 2005. Holub I. Jenkins DJ. Am J Clin Nutr. 2002. 64. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Ludwig DDS.und Risikoparameter bei Patienten mit Diabetes mellitus Typ 2. Delzenne N. Howlett J. 2004. Samman S. Glycemic response and health: summary of a workshop. 1999. Livesey G. Oxford University Press. Pediatrics. overeating. Livesey G. Willinger B. 2006. Akerberg AKE. Am J Clin Nutr.Physiological mechanisms relating to obesity. 51-52. Ludwig DS. 2006. 2005. 298-306. Glycaemic control with unavailable carbohydrates including polyols. with emphasis on low glycaemic properties. 92. 117-121. Mann J and Truswell AS. 103. Bjorck IME. Venter CS. O'Neill K. e26. Dietary glycemic load and atherothrombotic risk. Vessby B. Liu S. Brand-Miller J. 2000. 172 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 . Zeitschrift für Gastroenterologie. Liu S and Willett WC. Br J Nutr. Theis S. Kozianowski G. Gostner A. diabetes. Petocz P. Jenkins AL. Monro J. Dietary glycemic index and the regulation of body weight. Br J Nutr. 94. 105-113. 87. Low-glycaemic diets and health: implications for obesity. 2002. 43. Meta-analysis of the health effects of using the glycaemic index in meal-planning. 87. Franceschi S. Glycaemic index and glycaemic load values of commercially available products in the UK. Opperman AM. 367-381. Scheppach W. insulin sensitivity and diabetes risk. Oosthuizen W. 2006. Aggett P. Storey M. Roberts SB. 2414-2423. Health potential of polyols as sugar replacers. 211. Effects of a low-glycaemic index spaghetti meal on glucose tolerance and lipaemia at a subsequent meal in healthy subjects. 4. 48. 76. J Nutr. 1996. Report of a joint expert consultation: FAO Food and Nutrition Paper . Low glycaemic index or low glycaemic load diets for overweight and obesity.66. 57. Ziegler RG. 2000. Caballero B. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose. Dietary carbohydrates and insulin action in humans. and risk of type 2 diabetes. 2002. J Natl Cancer Inst. Baltimore. Source and amount of carbohydrate affect postprandial glucose and insulin in normal subjects. 92. Foods that fight cancer: Cruciferous vegetables http://www. Position of the American Dietetic Association:Functional Foods. Wolever TMS and Bolognesi C. Cousins R. Rao VA. Br J Nutr. triacylglycerol. 61-68. 126. 814-826. Vorster HH. 708-723. Speizer FE. S4048. J Natl Cancer Inst. Nutr Rev. Philadephia. WHO/FAO (World Health Organization and Food and Agriculture Organization). 2007. 173 . Journal of the American Dietetic Association. 19. Willett WC. Elliott EJ. Holt S. rich in EGCG” and “Protection of body tissues and cells from oxidative damage” No references provided. Am J Clin Nutr. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. Zimmet P. WHO Technical Report Series 916. Am J Clin Nutr. insulin. Unwin N. 104. cabbage. ID 1312: “Brassicaceae (Cruciferae) (Common Name: Botanical family that include broccoli. 2003. Thomas DE. 274s-280s. Wolever TMS.ADA Reports. glycemic load. 1812-1823. Modern Nutrition in Health and Disease. 2002. American Institute for Cancer Research. Björck I. 2000. Jenkins DJ. Kristal AR. 2798-2806. Wolever TMS and Mehling C. Determination of the glycaemic index of foods: interlaboratory study. 2004. Michaud DS. 2003. Ross C. Perry TL. Fruit and vegetable intakes and prostate cancer risk. Eur J Clin Nutr. Baur L. Diabetic Medicine. 1998. Cohen JH. ID 1311: “Epigallo-catechin-3-gallate (EGCG) / Green tea extract. 2006. 475-482. 2003. Cochrane Database Syst Rev. WHO/FAO (World Health Organization and Food and Agriculture Organization). 61. Shaw J. Bruxelles sprouts etc. Expert Report: Diet. 1041-1047. nutrition and prevention of chronic diseases. Colditz GA.aicr.org/site/PageServer?pagename=dc_foods_cruciferous. Wolever TMS. Alberti KGMM. Brighenti F. S97-S102. 83. Shike M. Carbohydrates in human nutrition. Willett W. Brand-Miller J.)” and “Antioxidant activity” 1 2 3 4 ADA (American Dietetic Association). Glycemic index. Wolever TM. Stanford JL. 612-621. Am J Clin Nutr. Wolever TM. Mann JI. Giovannucci EL. Lippincott Williams & Wilkins. Liu SM. couliflower. Granfeldt Y. Ramdath DD. CD005105.43 44 45 46 47 48 49 50 51 52 53 Shils ME. Carbohydrate and the regulation of blood glucose and metabolism. ID 1308: “Soy lecithin” and “Control of cholesterol” 54 No references provided. Feskanich D. Ocana AM. 2003. Collier GR. 1988. 92. Second-meal effect: low-glycemic-index foods eaten at dinner improve subsequent breakfast glycemic response. 77. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Manson J. and free fatty acid concentrations in subjects with impaired glucose tolerance. 2000. 1999. Biological activity of some naturally occurring resins. Andrikopoulos NK. Clinton SK. http://www. Song H. Liu Y. Target Group: Whole population / no restrictions” 10 11 12 13 14 15 1 Commission Regulation (EC) No 123/97 of 23 January 1997 supplementing the Annex to Commission Regulation (EC) No 1107/96 on the registration of geographical indications and designations of origin under the procedure laid down in Article 17 of Regulation (EEC) No 2081/92 OJ L 22. Glucosinolates: bioavailability and importance to health. Zhang Y. 5-12. Keum YS. 19–20 Abdel-Rahman AHY and Youssef AM. Food Chemistry. Assimopoulou AN. Papageorgiou VP. Drug News Perspect. (PDO) (EC)123/1997 (L022/24. Evaluation of hepatoprotective effect of Pistacia lentiscus.1997. Assimopoulou AN.1. A prospective study of cruciferous vegetables and prostate cancer. 100. 3027S-3033S. Giovannucci EL. National Cancer Institute. Mylona A. Antiatherogenic effect of Pistacia lentiscus via GSH restoration and downregulation of CD36 mRNA expression.html. 2 3 4 5 6 7 8 9 174 . Andrikopoulos NK. 24. Micronutrient Information Center: Cruciferous vegetables. 159-168. 472. 135-138. 131. Epidemiology and mechanisms. Biological activity of saliva against in vitro LDL oxidaton after chewing commercial chewing gums. Verhagen H. 2631. 198-204. Spiegelman D. Kaliora AC. Phytother Res. 43-49. J Ethnopharmacol. 2001. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Mutat Res. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Chaviaras N. 2002. 1975. 12. Murillo G and Mehta RG. 41. 2005. Rimm EB. 18. 111. Kaliora AC. http://lpi. Oregon State University Linus Pauling Institute. 83.oregonstate. Goldbohm RA. 445-451. Psarras S. Integr Cancer Ther. Papageorgiou VP. gums and pigments against in vitro LDL oxidation. Rimm EB. Kong AN. 2004. Protected Designation of Origin product. Brassica vegetables and cancer prevention. Dedoussis GV. 92. Azaizeh H. 72. Willett WC. 2004. 555. Antioxidant activity of natural resins and bioactive triterpenes in oil substrates. Chios mastic gum modulates serum biochemical parameters in a human population. Adv Exp Med Biol. 2003. Chiou A.5 6 7 8 9 Giovannucci E. 293-303. 2003. Cancer Epidemiol Biomarkers Prev. Zlatanos SN. 3.gov/. Assimopoulou AN. 52. Ital J Food Sci. J Ethnopharmacol. Papapeorgiou VP. Papadopoulos NG.cancer. J Natl Cancer Inst. Jeong WS. The effects of aqueous extracts prepared from the leaves of Pistacia lentiscus in experimental liver disease. 2007.97)” and “Mastiha Chiou has an antioxidant action. Janakat S and Al-Merie H. 2005. p. Stampfer MJ. 2001. 2002. 17-28. Talalay P and Fahey JW. 423. 2002. J Ethnopharmacol. Tsaknis J. 721-727. ID 1315: “Chios Mastiha Natural resin. Keck AS and Finley JW. 91. Journal of the American Oil Chemists' Society. Mastich as an antioxidant. 501-507.1. Cogan U. Verhoeven DT. Nutr Cancer. 1403-1409. 279-288. 1999. Kaliora AC. Phillyrea latifolia and Nicotiana glauca. Atherosclerosis. Int J Vitam Nutr Res. Andrikopoulos NK. Protopapa E. 173-190. 2004. Willett WC.edu/infocenter/foods/cruciferous/index. 605613. Triantafyllou A. Michaud DS. van Poppel G. J Nutr. Johnson IT. 2005. Chemopreventive functions of isothiocyanates. Ljubuncic P. Bomzon A. 17. Cruciferous vegetables and cancer prevention. Sergentanis TN. 174. 3. 2 3 4 5 6 2 3 4 5 6 7 175 . Summers KM. atorvastatine). atorvastatine). 305-308. Derendorf H. Fujita K. Target group: humans of all ages. Potential drug-food interactions with pomegranate juice. atherogenic modifications to LDL. Heber D. Henning SM. Vaya J. 570-576. Hingorani L. 2004.phenolic compounds (anthocyanins. Volkova N. statines medicines (Simvastatine. Excluded group: due to inadequate data. antipsychotic medicines (Risperidone. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. cellular cholesterol accumulation and development of atherosclerosis. Arimori K. Ketiapine). Excluded group: due to inadequate data. Summers KM. 23. 360367. 71. Kodama H. 32. 2001. and antioxidant effects of pomegranate (Punica granatum l. Rosenblat M. Hidaka M. Absorption. 16. 2000. 363-371. Ketiapine). apoptotic and antioxidant activities of punicalagin. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. 187. Tomas-Barberan FA. 48. Aviram M. Okumura M. Potential drug-food interactions with pomegranate juice. Nair MG. 1062-1076. Dornfeld L. Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. 2004. Kaplan M. ellagic acid)” and “Fights factors which cause atherosclerosis Target group: humans of high risk of vessel atheromatoses. Fuhrman B. Aviram M. patients over antidepressant medicines (Mirtazapine). 2006. Hidaka M. 40. Volkova N. Pomegranate juice consumption reduces oxidative stress. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Am J Clin Nutr. La Du BN. 468-474. nursing women. 16. 2000.) polyphenols after ingestion of a standardized extract in healthy human volunteers. 581-583. 581-583. 7. Ogikubo T. tannines. 40. Mertens-Talcott SU. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Gaieni I. 4581-4589. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. Iwakiri T. 2006. 2006. J Agric Food Chem. 2004. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation. Ann Pharmacother. Rios J. Okumura M. Fuhrman B. Draganov D. Aviram M. Kader AA. 54. 2082-2089. In vitro antiproliferative.phenolic compounds (anthocyanins. pregnant women. Iwakiri T. Adams LS. ID 1320: “Pomegranate Juice . Rosenblat M. Drug Metabolism and Disposition. 131. Esmaillzadeh A. J Agric Food Chem. tannines. Niu Y. Kaplan M.ID 1319: “Pomegranate Juice . Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. Hess-Pierce B. 2005. 1472-1473. Coleman R. Zhang Y. statines medicines (Simvastatine. Arterioscler Thromb Vasc Biol. pregnant women. Raz A. 1472-1473. 2003. Ogikubo T. Dornfeld L. 8956-8961. Drug Metab Dispos. J Nutr. Rosenblat M. Yamasaki K. and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. J Med Food. Presser D. ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. Hayek T. 2006. Kodama H. antihypertensive medicines should take doctor’s advice (relative contra-indication). 2005. Ann Pharmacother. 32. Arimori K. nursing women. Holcroft DM. metabolism. Bisgaier CL. Yamasaki K. antihypertensive medicines should take doctor’s advice (relative contra-indication)” 1 Gil MI. ellagic acid)” and “Antioxidant activity. patients over antidepressant medicines (Mirtazapine).” 1 Aviram M. antipsychotic medicines (Risperidone. Jilma-Stohlawetz P. Seeram NP. Alavi-Majd H. Watson CE. J Nutr Biochem. Azadbakht L. Tahbaz F. Atherosclerosis. J Nutr Biochem. Coleman R. Hayek T. Fujita K. Hayek T. Aviram M. 510-516. motivation to eat and food preferences. Hendriks HF. Read NW. 93. 94. Does guar gum improve post-prandial hyperglycaemia in humans by reducing small intestinal contact area? Br J Nutr. Anderson GH. 897-902. 2005. Johnson IT. 1992. Correlation between echographic gastric emptying and appetite: influence of psyllium. Rodriguez-Malaver AJ. 2002. 14. The mechanism of action of guar gum in improving glucose tolerance in man. 329336. 1182-1189. 2003. Proc Nutr Soc. Bellisle F. Petit A. Verhagen H. 407-418. Persin C. 14930-14935. Asp NG. Vrist E.hy926). Antioxidant and radical scavenging activity of honey in endothelial cell cultures (EA. Blackburn NA. 2007. Howlett J. Facino RM. Blackburn NA. Rechkemmer G. J Nutr. Bjorvell H. Perez E. Teixeira-Pinto A. 845-851. Effects of a high-protein meal (meat) and a high-carbohydrate meal (vegetarian) on satiety measured by automated computerized monitoring of subsequent food intake. Am J Clin Nutr. Vit P. Dietary fibre added to very low calorie diet reduces hunger and alleviates constipation. Eur J Nutr. Rossner S. Borzoei S. Caulin C. Blundell JE. 1988. Holgate AM. Regulation of nutrient supply: the brain and appetite control. 2006. Astrup A. Woodend DM. A comparison of effects of fish and beef protein on satiety in normal weight men. Slow and fast dietary proteins differently modulate postprandial protein accretion. enriched with guar gum” and “appetite” 1 2 Adam TC and Westerterp-Plantenga MS. Schramm DD. Maubois JL. Vinoy S. 1997. Cummings JH. London. Eur J Clin Nutr. Barkeling B. 2005. Blom WA. 2006. In: Food acceptability. Boirie Y. Lluch A. 66. Planta Med. Schrader HR. 73. 52. 134. 105-112. 1990. Rogers PJ. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr. 743-751. Schaafsma G.) Elsevier. Tuijtelaars S. Barkeling B. Antioxidant capacity of Venezuelan honey in wistar rat homogenates. Holt RR. Hill AJ. 9. Quaade F. 197-204.ID 1321: “Honey” and “Antioxidant properties” 1 2 3 Beretta G. Hanning I. 1984a. Effect of a highprotein breakfast on the postprandial ghrelin response. Anderson GH and Moore SE. Pijls LT. 76. Stafleu A. Inverse association between the effect of carbohydrates on blood glucose and subsequent short-term food intake in young men. 14. 1990. Kok FJ. de Graaf C. Int J Obes. Gut. Am J Clin Nutr. Dangin M. 81. 367-375. Holgate AM. i5-30. J Agric Food Chem. 1732-1735. Muller DJ. Chassany O. Hunger and the satiety cascade–their importance for food acceptance in the late 20th century. Gachon P. Karim M. 1023-1030. Ghrelin response to carbohydrate-enriched breakfast is related to insulin. 2004. 2005. Scarpello JH. 1042-1043. Thomson DMH (ed. Keen CL. Blundell JE and Halford JC. Rossner S. Beaufrere B. Blom WA. Proc Natl Acad Sci USA. Jarjis H. 1994. Redfern JS. Segrestaa JM. 3 4 5 6 7 8 9 10 11 12 13 14 15 176 . 51. Hendriks HF. 233– 250. 1984b. 60. Orioli M. 33. Schaafsma G. 211-220. 44 Suppl 1. J Med Food. Triki R. 53. Cardetti M. 2006. 83. Aggett PJ. Int J Obes. ID 1330: “Vitalinea fermented dairy products (low fat/reduced or no-added sugars) enriched with protein. Bergmann JF. Holst JJ. Honey with high levels of antioxidants can provide protection to healthy human subjects. Neovius M. Dietary proteins in the regulation of food intake and body weight in humans. Am J Clin Nutr. Read NW. Catherine NL. Wolever TM. PASSCLAIM: consensus on criteria. Clin Sci (Lond). Vasson MP. 974S-979S. Antoine JM. Stafleu A. Contor L. Appetite sensations and satiety quotient: predictors of energy intake and weight loss. Chaudhri O. Prentice AM. Gastroenterology. 2004. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. 906-914. De l‘intérêt du contrôle de l‘appétit. Aubert R. Callahan HS. 2000. 2000. Smeets PA. 91. Clifton PM. Almeras N. Marmonier C. 34. Graf S. Blom WA. 12. Saad MJ. 1997. 89. 3-21. 2006. 913-919. 1532-1535. Dietary fibers affect viscosity of solutions and simulated human gastric and small intestinal digesta. Submission of a health claim "Reduces appetite feelings". Murphy MR.and food-related cues. 72. 2003. 2007. Dikeman CL. 117. Physiol Behav. Gastrointestinal hormones regulating appetite. Menstrual cycle and appetite control: implications for weight regulation. Drewe J. J Clin Endocrinol Metab. 1997. Mauriege P. Buffenstein R. Brenelli SL. Tremblay A. 1319-1324. Br J Nutr. 136. and cholecystokinin after different carbohydrate and protein preloads in overweight men. Hendriks HF. 1430-1436. Blundell JE. 30. Imbeault P. Campos SD. 1142-1151. Appetite sensations as a marker of overall intake. An endocrine and metabolic definition of the intermeal interval in humans: evidence for a role of leptin on the prandial pattern through fatty acid disposal. Beglinger C. 24. Hum Reprod. Gastrointestinal regulation of food intake. Am J Physiol Endocrinol Metab. Biomarkers of satiation and satiety. 361. Clifton PM. Cummings DE and Overduin J. Cummings DE. Bloom S. J Nutr. 159-166. 2007. Stafleu A. J Clin Invest. Lawton C. Therrien F. Ghrelin-leptin tango in body-weight regulation. 1987. Tremblay A. 79. Chabert M. 287. (Unpublished). Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time. 13-23. Appetite. King N. Burley VJ. Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. 1997. Am J Clin Nutr. Blundell J. 91. Weigle DS. 11 Suppl 1. Submission of a health claim "Reduces appetite feelings". Small C. Leeds AR. Gastroenterology. Nutritopics. 2004. 1437-1440. Energy intake. Hetherington M. 1187-1209. Richard D. Danone Research. satiety and food intake in a subsequent meal. Fahey GC. Poppitt SD. 129. 1477-1483. 1995. 48. Doucet E. Socio-cultural determinants of meal size and frequency. The effect of high and low-fibre breakfasts on hunger. McDevitt RM. J Clin Endocrinol Metab. Food intake and the menstrual cycle: a retrospective analysis. Cummings DE and Foster KE. Bowen J. Chapelot D. Degen L. 273-280. with implications for appetite research. Noakes M. Doucet E. Frayo RS. Matthys CC. 77 Suppl 1. de Graaf C. Blundell J. 2005. Int J Obes Relat Metab Disord. 946-961. Oesch S. 93. Jr. St-Pierre S. 2004. 2006a. Drapeau V. 87-93. Trenerry C. 421-431. Cummings DE. Am J Clin Nutr.. Viscosity of gums in vitro and their ability to reduce postprandial hyperglycemia in normal subjects. Effect of peptide YY3-36 on food intake in humans. 124. Philos Trans R Soc Lond B Biol Sci. 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 177 . 58.16 Bowen J. de Castro JM. (Unpublished). Int J Obes. 2913-2919. 1067-1077. Louis-Sylvestre J. Noakes M. 2007. Aubert R. Appetite regulatory hormone responses to various dietary proteins differ by body mass index status despite similar reductions in ad libitum energy intake. Annex I Literature search strategy. Dye L and Blundell JE. discussion S54-35. Ketterer S. Danone Research. S39-54. ghrelin. Casanova M. Pepe MS. Tremblay A. Richard D. 2006b. 2005. Breen PA. Danone Research. Marmonier C. Braz J Med Biol Res. Chapelot D. 2006. E297-304. J Clin Endocrinol Metab. Br J Nutr. Drapeau V. Restrained and unrestrained eating. J Pers. Int J Obes Relat Metab Disord. Appetite. Fujise T. Food consistency modulates eating volume and speed through brain histamine in rat. 1988. 1994. 66-72. Flint A. 373-385. Oohara A. Long SJ. Colombani PC. Flint A. satiety and weight loss: a critical review. 53-61. 1981. A satiety quotient: a formulation to assess the satiating effect of food. 2003. Gut. 141-157. Harper A. Bernier JJ. 228-234. Englyst HN. Guinard JX and Brun P. Millward DJ. J Am Coll Nutr. 32. Yoshimatsu H. Appetite. Effect of guar gum on hunger and satiety after meals of differing fat content: relationship with gastric emptying. Appetite. 87-91. 906-909. 1975. 18. Astrup A. Davison P. 59. 291-304. Gibson EL and Booth DA. 42. serum insulin and satiety in normal subjects. Sakata T. Emotional influences on food choice: sensory. 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 178 . J Abnorm Psychol. 217. Evaluating structural equation models with unobservable variables and measurement error. Br J Nutr. Blundell JE.). Effect of pectin on jejunal glucose absorption and unstirred layer thickness in normal man. Br J Nutr. 46. Basic Clin Pharmacol Toxicol. 267-276. Fischer K. Br J Nutr. Metabolic and cognitive coefficients in the development of hunger sensations after pure macronutrient ingestion in the morning. 42. Nakata M. Reproducibility. In: Encyclopedia of Analytical Chemistry. 2004. Vidon N. Morgan LM. Am J Clin Nutr. Considine RV. 1975. Flourie B. Studies on blood glucose. Herman CP and Mack D.38 Edwards CA. Wiley. Hudson GJ. Sugden K. Ellis PR. gastrointestinal hormone secretion and appetite. placebo-controlled trial during controlled weight loss. Kang M. Florent CH. 579-583. 2004. power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Heini AF. New York. Food-conditioned odour rejection in the late stages of the meal. Edwards CA. Increased satiety after intake of a chocolate milk drink compared with a carbonated beverage. Kurokawa M. Joanes D. physiological and psychological pathways. 1998. 2007. Kirk KA. 24. 97. 936-941. Blackburn NA. Brain Res Bull. 49-61. Am J Clin Nutr. Proc Soc Exp Biol Med. Do viscous polysaccharides slow absorption by inhibiting diffusion or convection? Eur J Clin Nutr. Green SM. Anxiety. mediating learnt control of meal volume by aftereffects of food consumption. 1997. Sensory-specific satiety: comparison of taste and texture effects. 43. 89. Casein and whey exert different effects on plasma amino acid profiles. 84. Fujise T. restraint. Read NW. 31. Schneider H. Gibson EL. Johnson IT. Bolster NR. Erlanson-Albertsson C. 39-50. 46. 1993. 25. 2000. Appetite. How palatable food disrupts appetite regulation. Satiation and masticatory function modulated by brain histamine in rats. 89. 22. Starch analysis in food. Craigen L. 239-248. Int J Obes Relat Metab Disord. Yoshimatsu H. Weinsier RL. 61-73. Leeds AR. Nakata M. but no difference in subsequent ad libitum lunch intake. Kurokawa M. 555-559. Fukagawa K. 1981. Meyers RA and Chichester A (eds. Physiol Behav. 307-312. Herman CP and Polivy J. 38-48. 1984. 1998. Raben A. Sakata T. Englyst KN. Halton TL and Hu FB. Journal of Marketing Research. Hall WL. Effect of hydrolyzed guar fiber on fasting and postprandial satiety and satiety hormones: a double-blind. 295-303. Apling EC. Delargy HJ. Viscosity of food gums determined in vitro related to their hypoglycemic actions. Johnson IT. 23. Astrup A. and eating behavior. Tomlin J. 2000. Guar bread: acceptability and efficacy combined. Lara-Castro C. 34. 2000. 2005. James A. 1998. Blundell JE. 97. 7277. 2006. Read NW. The effects of high protein diets on thermogenesis. 1987. 647-660. 29. French SJ and Read NW. 4246-4262. Wenk C. Fornell C and Larcker DF. Lairon D. low-fat diet versus a high-carbohydrate. Short-term effects of chewing gum on snack intake and appetite. Bellisle F. The effects of a high-carbohydrate. 307-315. 48. 167-175. High-protein. Julis RA and Mattes RD. Goossens I. Huda MS. Rayment P. 84. Booth DA. 5768. casein. Oppert JM. Latner JD and Schwartz M. Lang V. 55-61. Influence of sweetened chewing gum on appetite. 361-375. high-protein or balanced lunch upon later food intake and hunger ratings. 2293-2300. 1070-1079. Bornet FR. J Am Coll Nutr. Hercberg S. Appetite. Guy-Grand B. Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. No unique role for nausea attributed to eating a food in the recalled acquisition of sensory aversion for that food. Johnston CS. Galetescu L. Slama G. 5-25. Kovacs EM. 82. Konturek PC. 2007. 2002. 134. J Physiol Pharmacol. 119-128. 753. low-fat diets are effective for weight loss and favorably alter biomarkers in healthy adults. Armstrong AM. 36. Neurohormonal control of food intake: basic mechanisms and clinical implications. 586-591. 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 179 . Swan PD. Appetite. Platts RG. and wheat gluten. Knibb RC. Am J Clin Nutr. Brouns F. 56 Suppl 6. Pinkney JH. Smith DM. Hetherington MM. Cues to overeat: psychological factors influencing overconsumption. Benamouzig R. Jequier E. 1185-1194. Rondeau P. 225-234. 2001. Macdonald A. Booth IW. Traynor C. 2004. Peters HP. meal patterning and energy intake. Int J Obes Relat Metab Disord.60 61 62 63 64 Hetherington M. 7. Am J Clin Nutr. Tjonn SL. Konturek JW. low-fat diet in healthy. 163182. Salah S. 67. 12. 1989. Czesnikiewicz-Guzik M. 1993. Spiller RC. Appetite. 25. Postprandial thermogenesis is increased 100% on a high-protein. Blundell JE. 2007. Lluch A. Hoad CL. Fouillet H. Pathways to obesity. Westerterp-Plantenga MS. 2006. 51. Rogers PJ. Appetite. Hetherington MM and Boyland E. Burley VJ. 2002. J Nutr. 26 Suppl 2. 8996. Dare S. Short-term appetite-reducing effects of a low-fat dairy product enriched in protein and fibre and consumed as a midmorning snack. The time course of sensory-specific satiety. 1995. Wilding JP. Luengo C. 19. Airinei G. Proc Nutr Soc. Dietary fiber intake and risk factors for cardiovascular disease in French adults. Bertrais S. hunger and subsequent intake. Satiating effect of proteins in healthy subjects: a comparison of egg albumin. 397-401. Bos C. Int J Obes Relat Metab Disord. 2008. 2007. Compared with casein or total milk protein. Mela DJ. 113-123. Geurten P. 33. Appetite. 134. 21. 25-39. 1999. Brzozowski T. Marciani L. Swan PD. S12-17. Effects of flavor and macronutrient composition of food servings on liking. Konturek SJ. Johnson J and Vickers Z. 25. Leonil J. gelatin. de Celis Alonso B. 2001. 66. Sito E. Appetite. Planells R. Johnston CS. 1197-1204. Gowland PA. Clero E. 21. 48. Int J Obes Relat Metab Disord. young women. pea protein. Rolls BJ. Am J Clin Nutr. Tome D. Day CS. Fauquant J. 1998. 2006. Craplet C. Lavin JH and Read NW. 2005. 2005. J Nutr. Salas-Salvadó J. The effect of addition of modified guar gum to a low-energy semisolid meal on appetite and body weight loss. digestion of milk soluble proteins is too rapid to sustain the anabolic postprandial amino acid requirement. Appetite. Saris WH. In vivo imaging of intragastric gelation and its effect on satiety in humans. L‘Heureux-Bouron D. Hill AJ. Lacroix M. Gut peptides and the regulation of appetite. Obes Rev. Appetite. 1995. 2004. Gaudichon C. Boutron-Ruault MC. The effect on hunger and satiety of slowing the absorption of glucose: relationship with gastric emptying and postprandial blood glucose and insulin responses. soy protein. Arnault N. 74. 2008. L'Heureux-Bouron D. Determinants of food choice: relationships with obesity and weight control. McBurney MI. 2005. Marcelino AS. Am J Clin Nutr. 725731. Spiller RC. Effects of a combination fiber system on appetite and energy intake in overweight humans. Westerterp-Plantenga MS. Marciani L. Enrichment of yoghurt with protein and fiber reduces appetite. Williams DL. French SJ. Int J Obes Relat Metab Disord. 2001. 11 Suppl 1. Gausserès N. Reiman EM. 76. Al-Sahab S. Eating Frequency and Health. Spiller RC. Blundell JE. Rhodes CJ. 2000. Gowland PA. JPEN J Parenter Enteral Nutr. 2006. 2000. Marmonier C. Leptin: a review of its peripheral actions and interactions. Guar gum does not impair the absorption and utilization of dietary nitrogen but affects early endogenous urea kinetics in humans. 280. Fillery-Travis AJ. Marmonier C. Leptin action in the forebrain regulates the hindbrain response to satiety signals. Lejeune MP. 17. Effects of macronutrient content and energy density of snacks consumed in a satiety state on the onset of the next meal. 9-14. J Am Diet Assoc. Krakoff J. 249S-255S. Schneider H. 26. Marlett JA. 161-168. Sieffermann JM. Kovacs EM. Surrey. Moore RJ. Position of the American Dietetic Association: health implications of dietary fiber. 2002. Am J Clin Nutr. Boelsma E. Gyr K. 2007. Mikkelsen PB. and emptying assessed by MRI. Mattes RD. Baskin DG. Pegg GG. 487-493. Mela DJ. 231-235. Wright J. Astrup A. Koster EP. Marmonier C. Appetite. Subjective appetite-reducing effects of a low-fat dairy product enriched in protein and fibre. 93. Appetite. Am J Physiol Gastrointest Liver Physiol. Gastric response to increased meal viscosity assessed by echo-planar magnetic resonance imaging in humans. Pannacciulli N. Garry J. 703-710. and carbohydrate. Meier R. Niswender KD. Appetite. G1227-1233. Br J Nutr. 705-711. 2002. Mariotti F. 34. 72. Garsetti M. 9 Suppl 4. Beglinger C. Am J Clin Nutr. Leeds AR. 130. Morton GJ. Del Parigi A. Am J Clin Nutr. Read NW. 90. 26. Lluch A. 50. Appetite. John Libby Eurotext Limited. Manoj P. Vinoy S. Slavin JL. 2004. 2001. Young P. Adam AS. Appetite. 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 180 . Obes Res. Louis-Sylvestre J. 1993. 2001. Mahe S. Chen K. Emotions and eating in everyday life. Louis-Sylvestre J. Effect of fat-reduced diets on 24-h energy expenditure: comparisons between animal protein. Benamouzig R. Chapelot D. Le DS. Lang V. Rowedder A. 35. Lluch A. Bush D. Moore RJ. 281-289. 102. Lluch A. Hill RA. 2001. Fillery-Travis AJ. Internal and external determinants of eating initiation in humans. Effect of meal viscosity and nutrients on satiety. Schwartz MW. 122-127. 2002. Gowland PA. 1135-1141. Salbe AD. Esher. 1407-1433. Manoj P. 309. Pueyo ME. Fantino M. 562. Blevins JE. J Nutr.80 81 Lavin JH. Int J Obes. Dietary fibre: mechanisms of action. 2002. 65-71. vegetable protein. Physiol Behav. Toubro S. Margetic S. Gazzola C. J Clin Invest. Marciani L. 2005. Chapelot D. 2000. 2000. 2007. 49. 993-1000. 84. Ruxton CH. Snacks consumed in a nonhungry state have poor satiating efficiency: influence of snack composition on substrate utilization and hunger. Hendriks HFJ. Additional protein intake limits weight regain after weight loss in humans. 384-388. 1987. Macht M and Simons G. Tome D. 36. Young P. 3-7. intragastric dilution. Couronne T. Effect of a liquid diet with and without soluble fiber supplementation on intestinal transit and cholecystokinin release in volunteers. L‘Heureux-Bouron D. 115. 518-528. Gelling RW. An investigation of the role of oro-sensory stimulation in sugar satiety? Int J Obes Relat Metab Disord. Less activation of the left dorsolateral prefrontal cortex in response to a meal: a feature of obesity. Holst JJ. Eating habits and appetite control: a psychobiological perspective. Physiol Behav. 77. Med Hypotheses. Appetite. 820-826. Economica. 1998a. Vansant G. El Akremi A. olfactory. Modai I. Asp NG. fat. Blundell JE. Furda I. 11. Testolin G. Rolls BJ. carbohydrate. Central insulin enhances sensitivity to cholecystokinin. 2005. 1995. 5967. Energy expenditure and net substrate utilization in men ingesting usual and high amounts of nonstarch polysaccharide. fat. 1998b. Poppitt SD. 755-760. 2003. Am J Clin Nutr. 2006. 56. The specificity of satiety: the influence of foods of different macronutrient content on the development of satiety. Udipi SA. 1-10. Testolin G. Weizman A. van Ree J. Pai S. 548-555. Figlewicz DP. Effect of one week of fibre supplementation on hunger and satiety ratings and energy intake. Short-term effects of macronutrient preloads on appetite and energy intake in lean women. Appetite. Am J Clin Nutr. Silva S. McGlone F. Proc Nutr Soc. 893-897. 360-367. Evaluation of satiety sensations and food intake after different preloads. protein. 58. Rogers PJ. 1988. 1997a. Rolls ET. Am J Clin Nutr. Physiol Behav. Nickols-Richardson SM. Weight. Westerterp-Plantenga MS. Physiol Behav. Hetherington M. Elia M. Flint A. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. Livesey G. Physiol Behav. Coleman MD. 85. Rolls BJ. 44. 409-417. Rolls ET. Muls E. 263-271. J Clin Invest. Paris. 105. wheat-based and rice-pulse combination preparations. 62. 145-153. 1995. 2000. Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Raben A. Bowtell R. Crovetti R. Rolls ET. 21. Waugh BA. Woods SC. Saris WH. How sensory properties of foods affect human feeding behavior. Francis S. J Am Diet Assoc. Ghugre PS. Nutr Rev. 2005. Rolls BJ. Neuroreport. Westerterp-Plantenga MS. Poppitt SD. Beglinger C. Saris WH. Appetite. 87. 2005. Read N. and food texture processing in the brain. Volpe JJ. 45-56. Pasman WJ. 25. Prosky L. 81. Riedy CA. Metabolic bioenergy homeostatic disruption: a cause of anorexia nervosa. 91-100. Bell EA. and the control of food intake. 17-30. 68. Cunningham K.101 102 Naisberg Y. 2002. 29. 1999. Journal of AOAC International. Satiety from rice-based. Pasman WJ. 1988. Meals with similar energy densities but rich in protein. Durrieu F. 72. Riso P. and timing of preloads affect food intake. 43. Ahne G. 58. 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 181 . French S. Rowe EA. The role of the gut in regulating food intake in man. 442-448. Polonsky KS. Degen L. 2000. or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake. 29. 1997. Determination of insoluble and soluble dietary fiber in foods and food products: collaborative study. Crovetti R. 2001. Schweizer TF. 1433-1437. Sensoryspecific satiety-related olfactory activation of the human orbitofrontal cortex. Perceived hunger is lower and weight loss is greater in overweight premenopausal women consuming a low-carbohydrate/high-protein vs highcarbohydrate/low-fat diet. Kobal G. 1994. Burley VJ. Buffenstein R. 1992. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Increasing the volume of a food by incorporating air affects satiety in men. 361-368. 52. Int J Obes Relat Metab Disord. 1997b. Campoy E. 563-570. Santangelo A. Porrini M. Astrup A. Taste. O'Doherty J. McCormack D. 75. Ruegg C. Renner B. Oesch S. Given BD. 279-285. Physiol Behav. Agerholm-Larsen L. 64. Wauters MA. 77-87. Méthodes d'équations structurelles: recherche et applications en gestion. Physiol Behav. De Vries JW. 454-461. 1982. Porrini M. Chavez M. 903-910. Hosig KW. Van Cauter E. Roussel P. Fischer B. Physiol Behav. Butterworth PJ. Vinni S. Long-term treatment of hypercholesterolaemia with a new palatable formulation of guar gum. 20. high-fat. 406-414. 101-108. 2004. van Wyk MC. Delargy H. The effect of guar gum and fiber-enriched wheat bran on gastric emptying of a semisolid meal in healthy subjects. Reasons for initiation and cessation of eating in obese men and women and the affective consequences of eating in everyday situations. 32-42. 45-48. 211-222. Hertzenberg L. van Dijk G and Thiele TE. 2006. Nature. Jackson EC. Voutilainen E. 409-417. Jr. Schwartz MW. Ruys J. Breakfasts high in protein. 1996. 84. 1571. 821-838. 233s-239s. 50. 2003. Eur J Clin Nutr. 47. Horowitz M. 330-334. Protein. Blundell JE. Stevens JE. Seeley RJ. Harbron CG. Hetherington M. Sakata T. 32. The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings. 2006. The effect of guar galactomannan and water availability during hydrothermal processing on the hydrolysis of starch catalysed by pancreatic alphaamylase. J Psychosom Res. Uhe AM. amino acids and the control of food intake. Homan K. 90-109. Ann Nutr Metab. Ellis PR. 2004. Porte D. 122. Comprehensive reviews in food science and food safety. personality traits and body mass in women. Berstad A. Tome D. Johnstone AM. Baskin DG. 208. 2000. Stubbs RJ. Obes Res. Slaughter SL. van Strien T. 467-472. 48. Variations in postprandial ghrelin status following ingestion of high-carbohydrate. Jones KL.. Atherosclerosis. and high-protein meals in males. Central nervous system control of food intake. Nutrition Bulletin. Stroebele N and de Castro JM. Wilson T. Simons LA. 1221-1229. Neuropeptides. J Nutr. Influence of physiological and subjective arousal on food intake in humans. Reid C. Obeid O. 1998. Eating behavior. 50. Johnstone AM. 405-415. 1. Dietary fibre and satiety. S27-30. Guar attenuates fall in postprandial blood pressure and slows gastric emptying of oral glucose in type 2 diabetes. 661-671. Scand J Gastroenterol. The three-factor eating questionnaire to measure dietary restraint. 30. Nondigestible oligo-and polysaccharides (dietary fiber): their physiology and role in human health and food. 404. Addict Behav. 92 Suppl 1. 29. Defares PB. Balasubramaniam S. 2000. Biochim Biophys Acta. Slavin J and Green H. 22. Appetite. Appetite. Br J Nutr. Tuomisto MT. 1995. 20. A very-low-calorie conventional Japanese diet: its implications for prevention of obesity.123 Russo A. 2002. A comparison of the effects of beef. Collier GR. 1982. Stratton R. 1992. 1999. Listening to music while eating is related to increases in people's food intake and meal duration. 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 182 . Dig Dis Sci. Effect of ambience on food intake and food choice. Stroebele N and de Castro JM. 2002. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. 333-343. Rowley E. Effect of guar gum on body weight and serum lipids in hypercholesterolemic females. 55-63. Stubbs RJ. 2007. 10. 2006. Br J Nutr. Nutrition. chicken and fish protein on satiety and amino acid profiles in lean male subjects. Knuiman-Hijl WJ. 33. Tonkin A. Acta Med Scand. Huttunen J. 45. Elia M. Rydning A. 1985. Tannous dit El Khoury D. 71-83. Gayst S. Hwalla N. Tungland BC and Meyer D. disinhibition and hunger. 996-1004. fat or carbohydrate: effect on within-day appetite and energy balance. Hughes DA. Roosen RG. O'Dea K. Stroebele N and De Castro JM. 285-289. King N. Berstad T. Wells F. 1985. Azar ST. Nutrition. Lappalainen R. Frijters JE. 3 Suppl 2. Tuomisto T. 1985. Woods SC. 260-269. Stunkard AJ and Messick S. Tuomilehto J. 1980. Rolland V. 2006. The measurement of gastric transit time in obese subjects using 24Na and the effects of energy content and guar gum on gastric emptying and satiety. Wilson SA. Breen PA. ID 1331: “Water” and “Hydration” 146 147 148 149 150 151 152 153 154 155 156 1 2 3 4 5 6 7 Brown JE. Kovacs EM. ID 1332: “Olive Oil” and “Improves blood lipid profile” 1 Aguilera CM. Understanding Nutrition. 522. 41-48. 8. Caballero B. 1996. Oler A. The importance of good hydration for day-to-day health. 2005. West/Wadsworth Belmont. Burden VR. van Ooijen M. Mc Graw-Hill International Edition Whitney EN and Rolfes SR. High protein intake sustains weight maintenance after body weight loss in humans. Westerterp-Plantenga MS. Obesity and overweight. Shirreffs SM. 82. 63. Fraser R. CA. Nutr Rev. 1997. Keogh J. ad libitum caloric intake. Frei B. Chapman I. Foster P. 2007. Seyler MF. 15. Purnell JQ. A Monograph by the North American Branch of the International Life Sciences Institute. Stanley S. Br J Nutr. Gastroenterology. Nutrition now. Gil A. Callahan HS. 443-450. Ramirez-Tortosa MC. 2004. Wilmshurst P and Crawley JC. 495-502. 1543-1547. 2116-2130. Westerterp-Plantenga MS. Asia Pac J Clin Nutr. WHO (World Health Organization). Clin Nutr. Global strategy on diet. Am J Clin Nutr. Armstrong LE. 53. 2003. 2006. 2005. 132. Cocchiaro C. Nijs I. Noakes M. High protein high fibre snack bars reduce food intake and improve short term glucose and insulin profiles compared with high fat snack bars. Vozzo R. Ritz P and Berrut G. Clifton P. 1980. 59. 1999. Wadsworth/Thomson Learning. 101-107. 2004. Satiety related to 24 h dietinduced thermogenesis during high protein/carbohydrate vs high fat diets measured in a respiration chamber. J Endocrinol. 2004. Eur J Clin Nutr. McGowan B. 44. Mudge J. Wynne K. Insel PM. 52. 2005. 2004. and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations. Wardlaw GM. Westerterp KR. Physiol Behav. Wren AM and Bloom SR. Mesa MD. Ober WC. A highprotein diet induces sustained reductions in appetite. The importance of good hydration for work and exercise performance. Garrison C. 184. Fact sheet 311.144 145 Vandewater K and Vickers Z. Eating-associated VMN-dopamine levels of rats: comparison of oral and intragastric feeding. physical activity and health. Int J Obes Relat Metab Disord. Energy and protein requirements: Report of a Joint FAO/WHO/UNU expert consultation. 291-318. S6-13. 63. 1973. Ros E. carbohydrate and fat on subsequent spontaneous food intake in healthy individuals. 40. 2005. Matthys CC. Belmont. Nestares MT. 83. Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease. Neuroreport. Weigle DS. A new proposed guidance system for beverage consumption in the United States. 183 . Lejeune MP. Wittert G. 2005. WHO/FAO (World Health Organization and Food and Agriculture Organization). Williams G. Bray GM. 673-681. 2006. S14-21. 2006. 57-64. Gut hormones and appetite control. 2005. WHO (World Health Organisation). 23. No. 579-583. Appetite. Meeuws KE. Popkin BM. FAO Nutrition meetings Report Series. Hydration: Fluids for Life. Grandjean AC and Campbell SM. Meguid MM. No. Higher-protein foods produce greater sensory-specific satiety. Contemporary nutrition: issues and insights. Yang ZJ. Am J Clin Nutr. Similar effects of foods high in protein. 529-542. 28. Bloom S. Tan WC. Nutr Rev. 1-6. Appetite control. and WHO Technical Report Series. Willett WC. Lopez-Sabater MC. Lopez-Miranda J. de TR. Assmann G. Caruso D. Pittaway JK. Weimann A. Ordovas JM. The role of fatty acid saturation on plasma lipids. Paz E. 114-120. de La Torre-Boronat MC. Kratz M. Postprandial and short-term effects of dietary virgin olive oil on oxidant/antioxidant status. Jimenez-Pereperez J. Effect of ingestion of virgin olive oil on human low-density lipoprotein composition. soybean oil. Metabolism. Marrugat J. and milk chocolate on the plasma lipids of young men. 56. 48. Galli G. Ball MJ. Fito M. Deulofeu R. 2002. dairy butter. Zamburlini A. Kiesewetter H. Lipids. 2000. Ann Intern Med. Covas MI. Marrugat J. 22. Nascetti S. 1043-1051. 1666-1671. olive oil. Fobker M. Perez-Heras A. 2002. 2005. 2001. Salas-Salvado J. Bonanome A. 2004. Tan L. Gaddi A. Kassner A. 111-120. Lopez-Sabater Mdel C. Ursini F. Choudhury N. Marin C. Covas MI. McDonnell ET. 259-265. Evidence of postprandial absorption of olive oil phenols in humans. 245251. Nutrition. Mursu J. Gimeno E. Castro P. Abuja PM. Fiol M. Kris-Etherton PM. Nicolosi RJ. Gruendel S. Sarkkinen ES. PI49-54. Fedeli E. Toia A. Cortes B. Derouiche A. Marin C. de la Torre R. Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. Kaikkonen J. Ann Nutr Metab. Balance of unsaturated fatty acids is important to a cholesterol-lowering diet: comparison of mid-oleic sunflower oil and olive oil on cardiovascular disease risk factors. normolipemic men. Gaddi A. Effects of olive oil and tomato lycopene combination on serum lycopene. de la Torre R. lipid profile. Comparison of palmolein and olive oil: effects on plasma lipids and vitamin E in young adults. Covas M. Lecerf JM. 145. 37. Adlouni A. Binkoski AE. 2002. Mountain ML. Mitchell DC. Gilabert R. Zidekova E. Eur J Clin Nutr. 1115-1119. Martinez-Gonzalez MA. El Messal M. 2006. Kaikkonen J. Zunft HJ. Kris-Etherton PM. Gomez-Gracia E. Kannenberg F. 49. Eur J Clin Nutr. Effects of whole food diets high in cocoa butter. Aros F. 1993. 2002. Wilson TA. Perez-Jimenez F. Cofan M. Idrissi-Oudghiri A. Casals E. Lamuela-Raventos RM. Fito M. Perez-Jimenez F. Marrugat J. 1995. Fito M. Nutritional intervention study with argan oil in man: effects on lipids and apolipoproteins. Fuentes F. Lopez-Sabater MC. Ros E. 1-11. Ruiz-Gutierrez V. J Am Coll Cardiol. 61. Virtanen J. 2006. Truswell AS. Machowetz A. Fito M. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Lahoz C. Low-fat and high-monounsaturated fatty acid diets decrease plasma cholesterol ester transfer protein concentrations in young. Castellote AI. Group ES. Zunft HJ. Selmi H. Am J Clin Nutr. 105. Corella D. 333-341. Lopez-Miranda J. Ordovas JM. Ann Intern Med. 184 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 . Kiesewetter H. Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function.2 3 Ahuja KD. Berra B. Jansen S. Nagyova A. Tapola NS. Salonen JT. Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. Ros E. 72-81. Gimeno E. Ann Intern Med. Uusitupa MI. Bamou Y. Sanchez F. Vinyoles E. 1080-1086. Miro E. 196-201. 145. Pagnan A. Nyyssonen K. Haban P. Lapetra J. 1253-1260. Mursu J. Klvanova J. Nutr Metab Cardiovasc Dis. Nunez I. 51. and apolipoproteins: I. Sanchez E. Cherki M. Lopez-Segura F. and lipid oxidation. Aro A. Farre M. 36-41. Derr J. Conde M. Drissi A. Paz-Rojas E. healthy. Karvonen HM. 2005. Gomez P. 56. Fuentes F. Xamin A. Mustad VA. 2006. 10. Cullen P. Poulsen HE. Estruch R. Effect of alpha-linolenic acid-rich Camelina sativa oil on serum fatty acid composition and serum lipids in hypercholesterolemic subjects. Salabsky D. Russell ME. Nascetti S. 2000. 121-129. Farre M. JimenezPereperez J. Med Sci Monit. Nyyssonen K. Metabolism. 10. Wahrburg U. Paez J. Dietary supplementation with olive oil leads to improved lipoprotein spectrum and lower n-6 PUFAs in elderly subjects. J Am Diet Assoc. Saez G. Pearson TA. Salminen I. Covas MI. Poulsen HE. Am J Clin Nutr. lipoproteins. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. 72. Salonen JT. Baumler H. 134. 2006. 42. Baumler H. Moschandreas J. 23. 77-83. Fatty acid saturation of the diet and plasma lipid concentrations. 185 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 . Ruano J. 129. 104. Farre M. 2002. Lipids. 56. Perez-Heras A. 1992. Vissers MN. 19 Marrugat J. 14. Lopez-Miranda J. Montero E. lipoprotein particle concentrations. Lozano A. Baumstark MW. Rubio MJ. Nielsen NS. 87. Gomez MC. Mercade I. 1113-1121. Haban P. 2004. Ramirez-Tortosa MC. Tan D. Rodriguez-Villar C. Comparison of a high-carbohydrate and a high-monounsaturated fat. Miro-Casas E. 142-149. Am J Clin Nutr. Perez-Martinez P. Lancet. Phenolic content of virgin olive oil improves ischemic reactive hyperemia in hypercholesterolemic patients. J Nutr. Lopez-Jurado M. Wiseman S. 218-221. J Am Coll Cardiol. Marckmann P. 2000. 24. Perona JS. 2000. J Am Coll Nutr. Effect of olive oils on biomarkers of oxidative DNA stress in Northern and Southern Europeans. 2005. 2002. Sandstrom B. Am J Clin Nutr. Alonso R. de Oya M. 75. 140-147. J Am Coll Nutr. Nestares T. 2007. 2003. 10241029. Fuentes F. Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in freeliving men with peripheral vascular disease. Similar effects of rapeseed oil (canola oil) and olive oil in a lipid-lowering diet for patients with hyperlipoproteinemia. Br J Nutr. Roche HM and Gibney MJ. Vessby B. van Putte KP. The impact of postprandial lipemia in accelerating atherothrombosis. Pedersen A. Marckmann P. Garrido JA. Bellido C. 21. Nagyova A. Masella R. Di Benedetto R. Mata P. Canizares J. 1. 36. 11. Merinero MC. Dietary exchange of an olive oil and sunflower oil blend for extra virgin olive oil decreases the estimate cardiovascular risk and LDL and apolipoprotein AII concentrations in postmenopausal women. Different effects of diets rich in olive oil. Ong AS. Castro GR. Coni E. Satgunasingam N. Mensink RP and Katan MB. Fito M. Ng TK. Mataix J. Covas MI. Bratisl Lek Listy. Fruchart JC. Ros E. Casals E. J Lipid Res. Fraone N. Blazquez E. Gerique JA. 43. Effects of dietary extra virgin olive oil on serum lipid resistance to oxidation and fatty acid composition in elderly lipidemic patients. Ordovas JM. 21. Gimeno E. J Am Coll Nutr. Dietary palmitic and oleic acids exert similar effects on serum cholesterol and lipoprotein profiles in normocholesterolemic men and women. Eur J Clin Nutr. Gomez P. Ruiz-Gutierrez V. de la Torre R. olive oil-rich diet on the susceptibility of LDL to oxidative modification in subjects with Type 2 diabetes mellitus. Gil A. Sanchez-Muniz FJ. 1987. 2001. FASEB J. Jimenez Y. Effects of dietary virgin olive oil phenols on low density lipoprotein oxidation in hyperlipidemic patients. Effect of dietary monounsaturated fatty acids on plasma lipoproteins and apolipoproteins in women. Extra virgin olive oil phenols and markers of oxidation in Greek smokers: a randomized cross-over study. 46. Hoy CE. An olive oil-rich diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles than rapeseed oil and sunflower oil diets. 7. 1195-1202. 489-499. Kadrabova J. Giovannini C. rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein concentrations and on lipoprotein oxidation susceptibility. Jegathesan M. 361-369. Ros E. 41. DeWitt GF. Virgin olive oil reduces blood pressure in hypertensive elderly subjects. Gustafsson IB. Klvanova J. 2002. Mir A. 1901-1911. Porres A. Ohrvall M. 317-324. Koebnick C. and cholesterol efflux capacity. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. Lopez-Sabater MC. 2004. 2004. Kafatos A. 383-390. Nydahl M. 2177-2183. Bucci A. Alvarez-Sala LA. Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Hayes KC. Volpe R. 2005. 1992. Sandstrom B. Perez Jimenez F. Diabet Med. Catala A. 45-52. Montoya MT. Rodenas S. Clin Nutr. 56.Covas MI. 643-651. Rodriguez-Gil S. Vari R. Sanchez-Dominguez JM. 1864-1868. Moreno JA. Serrano S. J Cardiovasc Risk. 1999. 122-125. Urbano G. 484-491. Eur J Nutr. Mata P. Pedersen A. Gylling H. Schroder H. 1995. Marrugat J. is dose. Sirtori C. 47. 133. Plasmati E. Caruso D. Fitoterapia (Milano). Pruess HG. 291-317. Jones PJ. Mulinacci N. Vissers MN. Marrugat J. Drugs Exp Clin Res. Wiseman SA. Manfredi B. Grande S. Gall C. Weinbrenner T. Bombardelli E and Morazzoni P. 1999. Katan MB. Albaladejo MF.0% proanthocyanidins]” and “antioxidant protection system” 2 3 4 5 6 7 1 Bagchi D. 2001b. Procyanidins from Vitis vinifera seeds display cardioprotection in an experimental model of ischemia-reperfusion damage. Olive phenol hydroxytyrosol prevents passive smoking-induced oxidative stress. Rijken P. 2314-2321. DuMont. Zarini S. Weinbrenner T. Antioxidant and other biological activities of olive mill waste waters. Conte D. 3. Zamburlini A. de la Torre R. Vitis vinifera L. Free Radic Res. 148. 134. ID 1334: “Standardized grape seed extract [dry extract from grape seeds of vitis viniferaL. 301-305. Mauger JF. 2001. Viappiani S. 334-341. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. solvent of extraction acetone/water 8. 207216. ID 1333: “Olive Oil” and “reduces oxidative stress. Kuszynski CA. Barrett M. 34. Visioli F. Galli C.5-13. Ursini F. Caruso D. 111-120. 2003. 55. Bagchi M. Galli C. 121-127. Rijken P. Galli C. a wine product. Blache D. J Nutr. Consumption of a functional oil rich in phytosterols and medium-chain triglyceride oil improves plasma lipid profiles in men. Visioli F. Bown D and Koziol C. Covas MI. Visioli F. 2000. van Putte KP. 2003. Haworth Herbal Press. Saez GT. Eur J Clin Nutr. Galli G. Fito M. Free Radic Res. Coolen S. Fito M. Colombo C. Effect of phenol-rich extra virgin olive oil on markers of oxidation in healthy volunteers. Caruso D. 2003. Galli G. 65-75. Toia A. Saez GT. 10. Roodenburg AJ. 51. Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. 2 3 4 5 6 186 . (Vitaceae). 66. Poli A. Bosisio R. Das DK. 2002. Lebensmittelchemie.dependently absorbed and increases the antioxidant capacity of rat plasma. Vissers MN. 2004. Romani A. Mantegazza P. Lesgards JF. Abanades S. Hernandez A. Abanades S. Berra B. Circulation. Plasmati E. 187-197. Villa M. Tormos C. Toxicology. Antioxidant properties of plant extracts and transresveratrol. Coolen S. DuMont's große Kräuterenzyklopädie. Pagnan A. 22. 2001. Galli C. J Nutr. 1995. Tormos C. Covas MI. 1815-1820.” 38 39 40 1 Bonanome A. Albaladejo MF. Joshi SS. 2169-2171. Leenen R. Visioli F. Berti F. Rossoni G. 102. 44. Antioxidant and other biological activities of phenols from olives and olive oil. Effect of consumption of phenols from olives and extra virgin olive oil on LDL oxidizability in healthy humans. Qualified health claim for monounsaturated fat from olive oil and reduced risk of coronary heart disease (CHD). Sala A. 2004. FDA (Food and Drug Administration). Zock PL. de la Torre R. 29. The Handbook of Clinically Tested Herbal Remedies. Zock PL. Stohs SJ. 35. 1997. 2000. revealed in vitro et es vivo a biological test. Hydroxytyrosol. as a component of olive mill waste water. 2000. Mulinacci N. J Nutr. Lamarche B. 619-629. Fedeli E. Rustan I. Schroder H. Med Res Rev. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. Xamin A. J Agric Food Chem. 2004. Köln. Meyboom S. Galli G. Katan MB.36 37 St-Onge MP. Eur J Nutr. Romani A. Visioli F. Schroder H. Evidence of postprandial absorption of olive oil phenols in humans. 134. 2001a. 3397-3401. 2314-2321. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Vincieri FF. Patelli R. Nutr Metab Cardiovasc Dis. 2005. Ray SD. Gomez-Cordoves C. Heilpflanzen . Böhmer H and Resch KL. Reshetnikov A.ATPase at various doses on practically healthy persons. 1998. 19. K. 2006. Nieves C. 136. Pļaviņš M. encapsulated fruit and vegetable juice concentrate. O'Neill KL. Sulfat-Heilwässer . K. 108. 3 187 . Goldfarb AH. Rīga. J Nutr. ID 1340: “Water-based product (Water purified by reverse osmosis to monomolecular level. Nantz MP. Orhan DD. Pļaviņš M. Riga. Yesilada E.bladder” 1 2 Monographie Sulfathaltige Heilwässer. Stuttgart. Oxidative stress response to aerobic exercise: comparison of antioxidant supplements. Aslan M. Jr. K. McKenzie MJ. Bartolome B. 54. Smiltēns I.ATPase in mesanglioproliferative glomerulonephritis. Rīga. K. Medicinal plants of the world.Wirkungen eines traditionellen Heilmittels. 2006.ATPase at various doses on practically healthy persons. Commercial dietary ingredients from Vitis vinifera L. Lapkovska A. complex of salts)” and “Improves hepatic functions” 1 2 Ponomarenko J. K. Watson RR. J Ethnopharmacol. Percival SS. Wise JA. 1098-1105. ID 1341: “Water-based product (Water purified by reverse osmosis to monomolecular level. Reshetnikov A. Gurinoviča T. In-vivo assessment of antidiabetic and antioxidant activities of grapevine leaves (Vitis vinifera) in diabetic rats. KATPase in studying kidney function.ATF-āzes aktivitātes paaugstināšanai izmantošana pielonefrīta un nefrolitiāzes gadījumos. van Wyk BE and Wink M. Gurinoviča T. J Agric Food Chem. Riga. Nutrition Research. 3239-3245. Supplementation with fruit and vegetable extracts may decrease DNA damage in the peripheral lymphocytes of an elderly population.Herbal Remedies. Timber Press. Smith MJ. 1. Immunity and antioxidant capacity in humans is enhanced by consumption of a dried. 2006. 1990. 9 10 ID 1338: “Juice Plus+® (juice concentrate from fruits and vegetables mixtures)” and “Protection of body tissues and cells from oxidative damage” 1 2 Bloomer RJ.7 8 Brendler T. Clinical trials of "Marin" composition for increase in the activity of Na. 1994c. complex of salts)” and “Improves mechanical activity of gall. Riga. 2004. Smiltēns I. leaves and grape skins: antioxidant and chemical characterization. ID 1342: “Water-based product (Water purified by reverse osmosis to monomolecular level.ATF-āzes aktivitātes paaugstināšanai izmantošana pielonefrīta un nefrolitiāzes gadījumos.. Clinical trials of "Marin" composition for increase in the activity of Na. 1996. CD-ROM. 1996. 1994a. complex of salts)” and “Improves renal function” 1 2 3 4 Ponomarenko J. Inserra PF. Clinical trials of "Marin" composition for increase in the activity of Na. 319-327. Ergun F. Preparāta ―Marina‖ Na. 1994b. Hofmane S. 38. Clinical trials of "Marina" composition for increase in the activity of Na. Grünwald J. Orhan N. 2003. Journal für Pharmakologie und Therapie. Jänicke C. Riga. Rowe CA. Hernandez-Ledesma B. Reshetnikov A and Ponomarenko J. Med Sci Sports Exerc. Medpharm Scientific Publishers. Hofmane S. Monagas M. 1999. Reshetnikov A and Ponomarenko J. 1994. 26062610. Bundesanzeiger 115. 1507-1518. Lapkovska A. Preparāta ―Marina‖ Na. 2006. 280-286. Description of food in terms of food legislation categories: Food intended to meet the expenditure of intense muscular effort. Carbohydrate Research Foundation. 1995. Galaškina A. Handbuch der Heilwasser . Description of food in terms of food legislation categories: food not covered by specific food legislation. 815S819S. Riga.).uk/home. Konzak K. Blackcurrant. 1993. Faculty of Sports and Exercise Medicine RCPI and RCSI. Pure Crystalline Fructose. Minerals.nutrition. O'Brien Nabors L and Gelardi RC (eds. Marcel Dekker. Lemon) / Energise Sport (Orange. K. Target group: All adults aged 18 years and over” 1 2 3 4 5 Craig BW. Proceedings of the 5th seminar on Inulin. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Energy for longer Provide sustained energy rather than a quick burst followed by a slump. Klinische Effekte einer Trinkkur mit einem Sulfat-haltigen Mineralwasser. 1994. 6 ID 1349: “Name of Food product: Toasted Sunflower Mix. Blackcurrant. Alekse R. 5. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Aids recovery by reducing muscle damage during exercise. Reshetnikov A and Ponomarenko J.asp?siteId=43§ionId=605&subSubSectionId=324&subSectionId=32 0&parentSection=299&which=2#1173. Target group: All adults aged 18 years and over” 1 Hennessy L.org.ATPase at various doses on practically healthy persons. Gurinoviča T. http://www. Understanding Nutrition: Scientific data krebs cycle (p. McCarthy C.Trinkkuren. O'Brien Nabors L and Gelardi RC (eds. Dublin. The influence of fructose feeding on physical performance. Osberger T and Bujake JE. Marcel Dekker. 1985b.Description of food in terms of food legislation categories: food not covered by specific food legislation. Do benefits relate to a disease risk factor: No.3 4 5 Breng R. New York. High Fructose syrups. Clinical trials of "Marina" composition for increase in the activity of Na. 58. Gutenbrunner C and Hildebrandt G. 1995. Target group: All of the general population including children and adults” 1 BNF (British Nutrition Foundation). Osberger T and Bujake JE. Physiological effects of fructose and inulin. Ärztliche Forschung. Heffernan W. New York. lemon). especially for sports people. 1993. Kneepkens CMF. 277-293. ID 1354: “Name of Food product: Club Energise Sport (Orange. 2005. Theorie und Praxis Sonntag-Verlag Stuttgart. In: Alternative Sweetners. 1994. Riga. 203-204). Do benefits relate to a disease risk factor: No. 188 . Wadsworth Publishing Company. 245-275. K. Whitney EN and Rolfes SR.). Am J Clin Nutr. In: Alternative Sweetners. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Contains antioxidants & promotes healthy skin. Do benefits relate to a disease risk factor: No. Ponomarenko J. Franke T. 1999.ATF-āzes aktivitātes paaugstināšanai "Marina" lietošana "Slydge" ārstēšanai un žultspūšļa mehanoaktivitātes paaugstināšanai. 1985a. ID 1351: “Name of Food product: Club Energise Energy / Energise Energy. The influence of a carbohydrate drink on physical performance. 2nd annual scientific meeting. Preparāta Na. Innis SM. Hughes D. Lemon). Whalley LJ. 1650-1657. Baghurst K. Description of food in terms of food legislation categories: food not covered by specific food legislation. Med Sci Sports Exerc. 16 Suppl 1. Nutr Rev. Diplomate ABT. Target group: All of the general population including children and adults” 1 2 3 4 Bourre JM. 5 6 7 8 9 ID 1367: “Name of Food product: Olive Biophenols. Starr JM. Zhang W. 137. Murphy EA. Conklin SM. depression. Bryan J. Med Sci Sports Exerc. 35 Suppl 1. 2005. Wahle KW. controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Peck L. Dietary (n-3) fatty acids and brain development. Sinclair AJ. 209-212. 295-306. Was food on Irish market before 1st July 2007: No” and “Health benefits of food: A potent source of antioxidant biophenols for strengthening and balancing of the immune system from free radicals. 71. Placental transfer of long-chain polyunsaturated fatty acids (LC-PUFA). Carbohydrate feedings during team sport exercise preserve physical and CNS function. Koletzko B. 1360-1366. 2007. J Nutr Health Aging. J Nutr. Carmichael MD. Calvaresi E. Burgess JR. 62. 35. 2 189 . Larque E. Hariri AR. Am J Clin Nutr. Welsh RS. 37. The Oxford-Durham study: a randomized. ID 1360: “Name of Food product: Dairygold Omega-3 Spread. behaviour. Do benefits relate to a disease risk factor: No. J Perinat Med. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Blackcurrant. dementia and aging. 589-594. Neurosci Lett.ID 1358: “Name of Food product: Club Energise Sport / Energise Sport (Orange. 421. Muldoon MF. Description of food in terms of food legislation categories: Food supplement. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Dairygold Omega-3 spread contain omeag. Yao JK. stress. 2005. Brunswick Laboratories. Blackmon JA. Do benefits relate to a disease risk factor: No. Burdock GA. Weisinger RS. 327S-330S. 2007. 2003. Do benefits relate to a disease risk factor: No. Cognitive aging. 31-38. 2007. CNS fatigue and prolonged exercise: Effect of glucose supplementation. Determination of GRAS status of hydrolyzed aqueous olive pulp extract (HIDROX) used as an antioxidant or antimicrobial agent. Fox HC. childhood intelligence. Stevens L. 2007. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Ensures better concentration. Fellow ACT. S5-11. Winnick JJ. 115. Christian MS. 9. and the use of food supplements: possible involvement of n-3 fatty acids. Mathai M. Demmelmair H. Brown SM. 2000. 2004. Pediatrics. 2004. Osendarp S. Comparison of ORAC Values. Nutrients for cognitive development in school-aged children. especially for sports people. Richardson AJ and Montgomery P. Deary IJ. 80. Manuck SB. Target group: All of the general population including children and adults” 1 Borzelleca JF. Am J Clin Nutr. Description of food in terms of food legislation categories: Food intended to meet the expenditure of intense muscular effort. Gianaros PJ. Omega 3 fatty acids and the brain: review of studies in depression. 391-397. Fellow ATS. 855-859. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. 2005. Target group: All adults aged 18 years and over” 1 2 Nybo L.3 fatty acids (EPA & DHA) which may have a beneficial role to play in the functioning of the brain and can help maintain a healthy heart. Davis JM. GRAS Report. Begg D. Asia Pac J Clin Nutr. 306 315. van Klinken JW. Dietary omega-3 Fatty acids and psychiatry: mood. 2004. Fitzgerald G. Stanton C. Saxelin M. ID 1371: “Name of Food product: Cheese. Desmond C. Cummings JH. S1-114. Sharper VA. Mattila-Sandholm T. Department of Medicine. Curr Opin Biotechnol. Collins JK. Food technology (Chicago). O'Halloran S. Savino F.3 4 Christian MS. parallel group. 2004. Ross RP. Oggero R. 2003. 2003. Gibson GR. 93. France. Hoberman AM. 64. 2001. Pautasso S. Double blind. Stanton C. Ishibashi N and Shimamura S. Intestinal microflora in breastfed colicky and non-colicky infants. Evaluation of cheddar cheese as a food carrier for delivery of a probiotic strain to the gastrointestinal tract. 11. Congress of the European Society of Parenteral and Enteral Nutrition. Cannes. Numano F. Dunne C. Do benefits relate to a disease risk factor: No. randomised. International Dairy Journal. Ross RP. Silvestro L. Fitzgerald GF. Pannemans D. 2005. placebo controlled trial to assess the use of cheese as an effective system for oral delivery of Lactobacillus paracasei UCC 43338 to the gastrointestinal tract of healthy adults. PASSCLAIM--gut health and immunity. Tullio V. Murphy L. Covell D. 1998. Gardiner G. 126-136. 2000. Azpiroz F. Bitler CM. Kelly J. 749-756. Clin Nutr. Flynn S. 20-23 September 2003. Fitzgerald GF. 27. Palumeri E. 1379-1387. O'Sullivan E. de Vos WM. 1996. 2004. Calder PC. 2004. 487-490. Collins JK. O'Sullivan GC. Shanahan F. Shortt C. Present and Future. Environmental adaptation of probiotic lactobacilli towards improvement of performance during spray drying. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 190 . Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. Guarner F. Target group: All of the general population including children and adults” 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 2001. 2192-2199. Sullivan GO. 2005. Gardiner G. 204-211. 1993. 2002. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Ingestion of cheese containing probiotic culture Lb. Kelly J. Collins JK. Brandtzaeg P. Fu L. Am J Clin Nutr. International Dairy Journal. Auty MA. Lynch PB. Bourdet-Sicard R. Antoine JM. Morrissey D. Evaluation of skin conditions in humans following OLIVENOL™ consumption. Fitzgerald G. (Unpublished). Eur J Nutr. Abstracts of the 25th Congress of the European Society of Parenteral and Enteral Nutrition. International Dairy Journal. Collins KJ. Stanton C. Crea R. Gut Flora and Health: Past. 1999. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Diener RM. Effets des probiotiques et prébiotiques sur la flore et l'immunité de l'homme adulte (Effects of probiotic and prebiotics on flora and immunity in adults). Leeds AR and Rowland IR. No authors listed. salivarius strains during heat treatment and spray drying. Gardiner GE. University College. 2605-2612. Cresi F. 16. The toxicity profile of hydrolyzed aqueous olive pulp extract. Ireland. Collins K. Collins JK. ICSS International Congress and Symposium Series 219. O‘Sullivan E. O'Mahony L. Daly C. Bouchier P. Ross PR. Bifidobacteria: research and development in Japan. Fitzgerald G. 12. A spray-dried culture for probiotic Cheddar cheese manufacture. paracasei NFBC 338 positively influences the healthy balance of the gut microflora. 801808. Isolauri E. 82. 309-330. Ross RP. II118-II173. 1998. Tynkkynen S. 43 Suppl 2. 8. Fitzgerald G. Kiely B. Acta Paediatr. Watzl B. J Dairy Sci. Roana J. 47. 66. 73. Tuijtelaars S. Ross PR. Thornton G. Stanton C. Probiotic and other functional microbes: from markets to mechanisms. Appl Environ Microbiol. 22 Suppl 1. Stanton C. Appl Environ Microbiol. Seng JE. Tokyo Vascular Disease Institute. Collins JK. Thornton G. Selection of probiotic strains for human applications. Drug Chem Toxicol. 386S-392S. Cork. 825-829. Feeney M. Development of a probiotic cheddar cheese containing human-derived Lactobacillus paracasei strains. 12. Gardiner GE. Description of food in terms of food legislation categories: food not covered by specific food legislation. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: contains Vitamin A which contributes to good eyesight/normal vision. Ottaviani JI. Do benefits relate to a disease risk factor: No. Scand J Gastroenterol. Lotito SB. Do benefits relate to a disease risk factor: No. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Cocoa in chocolate may be a major dietary source of antioxidants. Probiotic cheese. 2 ID 1373: “Name of Food product: Liquid Milk. Do benefits relate to a disease risk factor: No. Pfister E. 37. Molybdenum. Gardiner G. N Engl J Med. International Dairy Journal. Intolerance of small amounts of lactose by individuals with low lactase levels. 812-813. Massa C.16 17 Stanton C. Incidence and clinical significance of lactose malabsorption in adult coeliac disease. 2002. 65. Wiswedel I. Vanadium. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Healthy Digestion. Bayless TM. Encyclopedia of Human Nutrition. 191 . Lactose and milk intolerance: clinical implications. 5. Clin Dev Immunol. 12. Gilburd B. CRC Press. Boca Raton. Handbook of Nutrition and Food. Report of a Joint FAO/WHO Working Group. Chromium. 2002. Target group: All adults aged 18 years and over” 1 2 3 4 Amital H. Ross RP. Kropf S. Gruening M. 4 5 ID 1376: “Name of Food product: fermented dairy products. 8. Evaluation on health and nutritional properties of probiotics in food including powder milk with live Lactic acid bacteria. Bedine MS. Cocoa flavanols show antioxidative effects and help protect the cells against oxidative stress & help protect from radicals. Sies H. 1975. 292. 23. 1998. 1988. Description of food in terms of food legislation categories: food not covered by specific food legislation. Iodine. Report of a Joint FAO/WHO Expert Consultation. Rothfeld B. Target group: All of the general population including children and adults” 1 2 3 Berdanier CD. Manganese. 18 ID 1372: “Name of Food product: chocolate. WHO/FAO (World Health Organization and Food and Agriculture Organization). 2002. Lynch PB. Wise L. Review on Vitamin A .Revised version. Lazarus S. Hirsch D. 491-496. Collins JK. IoM (Institute of Medicine). Carrasquedo F. Bode S and Gudmand-Hoyer E. Silicon. Nickel. Intelligent nutrition: health-promoting mechanisms of probiotics. Iron. Description of food in terms of food legislation categories: food not covered by specific food legislation. Flavanol-rich cocoa drink lowers plasma F(2)-isoprostane concentrations in humans. 2005. Copper. Bedine MS and Bayless TM. Keen CL. 2004. Feldman EB. Vitamin K. 11-17. Sadler MJ. Paige D. 1999. Arsenic. 1973. National Academies Press. 2002. 411-421. 1156-1159. Schewe T. Dietary Reference Intakes for Vitamin A. Strain JJ. Gastroenterology. Regular consumption of a flavanol-rich chocolate can improve oxidant stress in young soccer players. San Diego. Target group: All adults aged 18 years and over” 1 Fraga CG. EVM (Expert Group on Vitamins and Minerals). 2001. Caballero B. Academic Press. Fitzgerald G. Actis-Goretta L. WHO/FAO (World Health Organization and Food and Agriculture Organization). 2003. Drafting guidelines for the evaluation of probiotics in food. 484-488. Schmitz HH. Opinion on the Tolerable Upper Intake Level of Vitamin D. Washington DC. Dwyer JT. 2000. Description of food in terms of food legislation categories: food not covered by specific food legislation. Shoenfeld Y. 735-743. Taylor and Francis Book. Isr Med Assoc J. Free Radic Biol Med. and Zinc. Boron. SCF (Scientific Committee on Food). Probiotics as modulators of the gut flora. 126. Noack J. 2002. Fernandes C and Shahani K. 88 Suppl 1. 1976. 4. 1989-1993. 148-151. Woodward G. 2004. Scand J Gastroenterol. 41. Gastroenterology. 1438S-1441S. Hertzler SR. J Nutr. A185. Jussila J. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. Cummings JH. Blessing LL. 23. 96. 1970. Brunser O. Symptom response to lactose-reduced milk in lactose-intolerant adults. Gudmand-Hoyer E and Simony K. Anderson AD. Kleessen B. 353-356. Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans. Fones HL. 365-378. Probiotics. Savaiano DA. Brady LJ. 1977. Donahoo JB. Wang X. Hourigan AG. J Pediatr Gastroenterol Nutr. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. S39-49. Launiala K. J Nutr. Chen RM. 1995. 5. The effect of symbiotics on colon carcinogenesis and tumor growth. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. Espinoza J. McNaught CE. cecal microflora. 1994. Brand JC and Holt S. 129. Br J Nutr. Gibson GR and Roberfroid MB. Lee SC. and aberrant crypts in the rat colon. 975-982. Effect of inulin on colonic bifidobacteria of elderly man.5 Bouhnik Y. Fichot MC. 50-64. Huynh BC. 29. 1999. 1999. S1478-S1482. Chichester CO. 1996. Individual sensitivity to lactose in lactose malabsorption. Probiotics in man and animals. Andrieux C. Journal of Applied Nutrition. Collection FAO: Alimentation et nutrition n° 28. Busta FF. Isokoski M. Huang AH. Briet F. Beatty ER. 38. Flourie B. 467-475. FAO (Food and Agriculture Organization). 125. Probiotics--scope and promise in inflammatory bowel disease. 1991. Influence of synbiotic containing Lactobacillus acidophilus La5. 633-638. FASEB J. Latham MC. Am J Clin Nutr. 132. Stallings WH. Fooks LJ and Gibson GR. 288-292. 1979. MacFie J. 269-273. 8. 472-477. Jones DV. J Appl Bacteriol. 82. 49-56. Long-term acceptance of low-lactose milk. Le lait et les produits laitiers dans la nutrition humaine. 22. J Nutr. 1999. 2002. 1995. Chouraqui JP. 2308-2314. Streptococcus thermophilus. 177-181. 1362-1371. 1989. 243246. 108. Gallaher DD and Khil J. Van Egroo LD. 129. 50. Am J Dig Dis. 32. Wu HM. Isr Med Assoc J. Prevalence of lactose malabsorption in a Finnish rural population. Cheng AH. Gibson GR. 1996. Acidified milk formula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. Relative effectiveness of milks with reduced amounts of lactose in alleviating milk intolerance. Mitchell CJ. J Nutr. Chermesh I and Eliakim R. Clin Nutr. How much lactose is low lactose? J Am Diet Assoc. Jain PK. Rand G. Zunft HJ. Increase of intestinal Bifidobacterium and suppression of coliform bacteria with short-term yogurt ingestion. 1996. Buddington KK. Am J Clin Nutr. Lactose intolerance and its modulation with Lactobacilli and other microbial supplements. 66. Gibson GR. 2004. Gallaher DD. 1401-1412. Eur J Clin Nutr. Monckeberg F. 54. Bisetti N. 1995. Bifidobacterium lactis Bb 12. J Dairy Sci. 2002. Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers. Kosikowski FV. 1989. Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Rambaud JC. Am J Clin Nutr. Wu JJ. Buddington RK. Fuller R. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 192 . Lami F. 2005. Pettoello-Mantovani M. Am J Gastroenterol. 1978. 18. 1991b. Hylander Moller E. Veld JH. Indolfi P. Benno Y. Probiotics in clinical conditions. Microbial Ecology in Health and Disease. Marteau P. Lactose intolerance. 129. Matsumoto M and Benno Y. Review: probiotic effects of selected acid bacteria. Kaestel P. Bjorneklett A. A role in development of osteoporosis? Raven Press. Destrebecq L. Di Tullio MT. 20. 77 . 1999. Bakka A. Blaut M. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. and osteopenia. Keldsbo IL. Rasmussen SN. 338. 60. 181-186.27 28 Kleessen B. Möller C and De Vrese M. Tolerance to lactose among lactase-deficient American Indians. Acta Endoscopica. 1995. Probiotics as functional foods. Mattila-Sandholm T. 2002. Lactose malabsorption and tolerance of lactose-hydrolyzed milk. Ohishi H. Eskesen DC. Pironi L. diMartino L. Tani H. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Calcium absorption and acceptance of low-lactose milk among children with primary lactase deficiency. 12. 2001. 1982. Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers. Alander M. A double-blind controlled crossover study.Problèmes nutritionels er thérapeutiques. Laake KO. 10. J Nutr. 2000. Casale F. New York. 189195. 31. Benno Y. Lactose malabsorption in adult patients with Crohn's disease. Nielsen OH. Impact of LKM512 yogurt on improvement of intestinal environment of the elderly. Matsumoto M. 1284-1293. Miettinen M. Sykura B. 2004. J Pediatr Gastroenterol Nutr. Effect of Bifidobacterium lactis LKM 512 yogurt on fecal microflora in middle to old aged persons. 1988. 1156-1157. Dubrovsky L. Callegari C. J Pediatr Gastroenterol Nutr. Zunft HJ. Matsumoto M.147. 212-215. 211-222. Destrebecq L. Rao AV. Am J Clin Nutr. 40. Gastroenterology. 861-864. Matsumoto M. 147-153. Corvino C. Mutat Res. Nagant de Deuxchaisnes C. Scand J Gastroenterol. 65. 2003. Nielsen S. 22. calcium intake. 1991a. von Wright A. 1999. 74. and bowel habit in elderly constipated persons. Consumption of Bifidobacterium lactis LKM512 yogurt reduces gut mutagenicity by increasing gut polyamine contents in healthy adult subjects. Faille I. Aabakken L. 44-46. Brockmann E. 43-51. Nutr Clin Pract. 2000. Microbial Ecology in Health and Disease. 83. 17. 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 193 . Krasilnikoff PA. 44. Norby Rasmussen S. 30. 2006. 497-506. FEMS Immunol Med Microbiol. Milchwissenschaft 59. Hofmann AF. Curr Microbiol. Lancet. Ohishi H. 1442S-1445S. Clin Rev Allergy Immunol. 1997. Giuliano M. Barbara L. 1267-1271. Devogelaer JP. Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects. Jensen HJ. Vuopio-Varkila J. 255-273. 2002. Scand J Gastroenterol. Newcomer AD. Eur J Clin Nutr. Christensen HR. 1397-1402. Vatn MH. Aamodt G. Bennedsen M. Faille I. Lin DC. Marteau PR. Larsen CN. Miglioli M. Effects of inulin and lactose on fecal microflora. 597-601. 2004.80. Cornia GL. Mainguet P. Jacobsen BL. Mainguet P. Jacobsen M. The survival of and cytokine induction by lactic acid bacteria after passage through a gastrointestinal model. Devogelaer J. 1984. 3. Rask Pedersen E. Mainguet P. Michaelsen KF. Jensen BH. Lifelong low calcium consumption in patients suffering from lactase deficiency. microbial activity. Thomas PJ. Schiotz PO. Deuxchaisnes Nd. 219-223. 141 . 568. Ono H. McGill DB. Adhesive property of Bifidobacterium lactis LKM512 and predominant bacteria of intestinal microflora to human intestinal mucin. Guandalini S. L'intolérance au lactose de l'adulte . Prebiotics and probiotics: are they functional foods? Am J Clin Nutr. Yang YJ. Effect of fermented milk containing bifidobacterium lactis FK120 on fecal flora and fecal properties in healthy female volunteers. fermented foods and lactose intolerance. 129. de Vos W. Wu HW. Roberfroid M. S50-55. J Nutr. 11-19. Am J Dig Dis. J Nutr. 137-146. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. 1998. Manifestation and occurrence of selective adult-type lactose malabsorption in Finnish teenagers. 79. 48. Savaiano DA and Levitt MD. Review article: the treatment of lactose intolerance. Concepts in functional foods: the case of inulin and oligofructose. Rowland IR. 1371-1374. Dietary fiber. inulin. Am J Clin Nutr. Lizuka N. Igarashi R. Am J Clin Nutr. Coutts JT. Shioya M. J Nutr. Roberfroid MB. Rumney CJ. 54-60. Eur J Clin Nutr. Lin MD. Nutr Rev. Gibson GR. 1993. The biochemistry of oligofructose. Moore N. Am J Clin Nutr. 718. Possible mechanisms by which pro. discussion 1688S-1690S. Rao CV. Lo CY. 56 57 58 59 60 61 62 63 64 65 66 67 194 . 2004. Aliment Pharmacol Ther. The bifidogenic nature of chicory inulin and its hydrolysis products. Cheng HC. 1999. Savaiano DA. 129. 15. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Fermentation. Jr. 589-597. Thayer WR. Delzenne N. 103-148. 56 Suppl 4. 1995a. 2000. Aliment Pharmacol Ther. 281-285. Am J Clin Nutr.47 48 49 50 51 52 53 54 55 Reasoner J. 70. J Nutr. Journal of Nutritional Food. Kao AW. Pretreatment with Lactobacillus. 397-406. Scrimshaw NS and Murray EB.. J Nutr. Impact of supplement with Lactobacillus. 2006. Suarez FL. a nondigestible fiber: an approach to calculate its caloric value. 1424S1427S. Carcinogenesis. Van Loo JA. 1669-1675. inulin and oligofructose: similarities and differences. Chapter 2 Prevalence of lactose maldigestion. 16.and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. 1987. 1999. 1086-1098. 153-156. Sheu BS. 2004. Fiber. 2000. Rand AG. 1988. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Yolken RH. Roller M. and oligofructose: a review comparing their physiological effects. Roberfroid M. Gibson GR. 1997. 864-869. 83. 33. 19. 2006. Hamid R. 18. Lievense LC. 558-562. 1682S1687S. 71. Reddy BS. 1998. Sahi T and Launiala K. 34. Levitt MD. Salminen S.and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. 2002. A follow-up study. 129. microbiota and future probiotics? Asia Pac J Clin Nutr. Watzl B. 1999. Yang HB. Clinical studies with low-lactose milk. Solomons NW. Wang ST.and prebiotics influence colon carcinogenesis and tumor growth. Milk intolerance and microbe-containing dairy foods. 699-704. Wu JJ. Reddy BS. Saavedra JM. Carcinogenesis. Crit Rev Food Sci Nutr. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. 1993. Chen JH. Wu JJ. 2002. 9. 128. Schneeman BO. Benno Y. 134. Intestinal colonisation. Roberfroid MB. Nakaoka K. 23. Abe T. Roberfroid MB. J Dairy Sci. Abi-Hanna A. 1981. 1398S-1401S. Maculan TP. 51. 1478S-1482S. 1978. Lin YS. Rechkemmer G. Sheu BS. Benno Y. 3. 261-267. 2002. Barkholt L. Mohamed SM. 2005. Tolerance to the daily ingestion of two cups of milk by individuals claiming lactose intolerance. Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar. Leeman M. Bennett M. 7. 59. Nord CE. Eur J Clin Nutr. Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes mellitus: a pilot study. Mohamed KA. 165S-175S. Bjorck IM. Woodruff LH. Franck A. Garrison MM. 80. Jan CM. Mohamed el OA. 93. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. 121-132. set-up. Functional food properties of nondigestible oligosaccharides: a consensus report from the ENDO project (DGXII AIRII-CT94-1095). Bjorck I. Delzenne N. 132. Effects of ingesting Lactobacillus. 1141-1144. Ostman E. The effect of cider vinegar on some nutritional and physiological parameters in mice. Su YC. 105. 1998. Liu CS. Foote JC. Liljeberg Elmstahl HG. van Vliet T. Br J Nutr. Quigley M. Curr Opin Clin Nutr Metab Care. Kok N. Marteau P. J Egypt Public Health Assoc.68 69 70 Suarez FL. Almer LO. Lactose intolerance. Bjorgell O. 1996. 1995b. 2006. Rao DR. 2004. Sullivan A. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. 9. Hopkins M. 1266-1271. 2001. Wang TN. 16. 2005. 17-36. 2007. BMC Gastroenterol. Levitt MD. 2804-2808. Wang WM. Korpela RA. 737-741. Esophageal injury by apple cider vinegar tablets and subsequent evaluation of products. The SYNCAN project: goals. Vesa TH. 2005. 109. Hlebowicz J. Ostman EM. J Nutr.and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Levitt MD. Darwiche G. 717-721. 74. Feudtner C. Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects. 46. 59. Am J Clin Nutr. 2002. 2005. 96-100. Am J Clin Nutr. 1-4. Prebiotic oligofructose-enriched chicory inulin combination with probiotics in the prevention of colon cancer in experimental models and human volunteers. Eur J Clin Nutr. Lactobacillus acidophilus. Christakis DA. Eur J Clin Nutr. 368-371. 1502-1506. van den Heuvel E. Arbisi P. Br J Nutr. Bosscher D. Am J Clin Nutr. ID 1377: “Apple cider vinegar” and “Digestive health and bowel function” 71 72 73 74 75 76 77 78 79 1 2 3 4 5 6 7 Hill LL. Van Niel CW. Verghese M. Savaiano D. 195 . Clune Y. Franck A. 19. 6-8. Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. 65. Persson L. Barreto-Alcoba M. Li SN. Liljeberg H and Bjorck I. Collins JK. J Am Coll Nutr. J Am Diet Assoc. Korpela R. Lai CH. Vesa TH. N Engl J Med. 1997. Van Loo J. Wang KY. S91-98. 2001. 678-684. Roberfroid M. 197-201. Englyst H. Chawan CB. Shackelford L. 308-311. 2005. Macfarlane G. 983-988. Dietary inulin suppresses azoxymethane-induced preneoplastic aberrant crypt foci in mature Fisher 344 rats. Am J Clin Nutr. Suarez FL. J Antimicrob Chemother. 76. Tolerance to small amounts of lactose in lactose maldigesters. Bjorck I. first results and settings of the human intervention study. 2003. van Loo J. 2000. 333. Sahi T. Savaiano DA. Clune Y. Pediatrics. Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. 64. 81. Probiotics as functional food in the treatment of diarrhea. Newton D. Granfeldt Y. Vinegar dressing and cold storage of potatoes lowers postprandial glycaemic and insulinaemic responses in healthy subjects. 1999. Agro FOOD industry hi-tech. 52. Cummings J. Yan F and Polk DB. 52. Van Loo J. Perng DS. Wu DC. Ostman E. 1141-1144.) Gacl. Beneficial effect of brewers' yeast extract on daily activity in a murine model of chronic fatigue syndrome. Leeman M. 2005. Senft M. 59. In: The Gale Encyclopedia of Alternative Medicine. 3. Loffredo L. Strong FM. Elvehjem CA. Hlebowicz J. Eur J Clin Nutr. Lafont H. Carnevale R. 105. European Pharmacopoeia. Lairon D. Sumino H. Esophageal injury by apple cider vinegar tablets and subsequent evaluation of products. 122. and Vascular Biology. 1992. Yamaguchi N. Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. 7. 1993. Yu F. Vinegar dressing and cold storage of potatoes lowers postprandial glycaemic and insulinaemic responses in healthy subjects. Violi F. Liljeberg H and Bjorck I. 196 4 2 3 4 5 . 52. Evid Based Complement Alternat Med. Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. 34-50. Olsson L. Martindale: The extra pharmacopoeia. Long-term wheat germ intake beneficially affects plasma lipids and lipoproteins in hypercholesterolemic human subjects. Woodruff LH. Del Ben M. London. Eur J Clin Nutr. Almer LO. J Nutr. Am J Clin Nutr. Bjorck I. 2005. 2005. 368-371. Long-term wheat germ intake beneficially affects plasma lipids and lipoproteins in hypercholesterolemic human subjects. 317-326. ID 1389: “Wheat germ oil” and “Metabolism” 1 Cara L. Borel P. 983-988. ID 1382: “Brewer`s Yeast” and “Cardiovascular health” 1 2 3 Gormley JJ. 2000. Moriya J. Barreto-Alcoba M. Liljeberg Elmstahl HG. Lenti L. 1997. J Nutr. Angelico F. Portugal H. Ostman E. 1266-1271. Arteriosclerosis. Morimoto S. 74. Zhu SJ. Lairon D. Pauli AM. Portugal H. 317-326. 2577. 167. Darwiche G. 2001. Drug information for the health care professional. 109-115. 2006. 24. Better Nutrition. Ferro D. 1942. Pauli AM. Senft M. USP (United States Pharmacopeial Convention). ID 1390: “Wheat germ oil” and “Skin health” 1 Cara L. Reynolds JEF. Pharmaceutical Press. Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects. Persson L. pantothenic acid and pyridoxine in wheat and wheat products. Wurges J. Nicotinic acid. Brewer`s yeast and lecithin – two underrated health promoters. Takahashi T. Microbiol Mol Biol Rev. Bjorck IM. Foote JC.ID 1380: “Apple cider vinegar” and “Weight management” 1 2 3 4 5 6 Hill LL. BMC Gastroenterol. Rockville. Brewer's yeast. Lafont H. Longe JL (ed. Borel P. 1992. Armand M. Thrombosis. 01/2008:1480. 122. 1991. Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar. Council of Europe. Nielsen J. Metabolic engineering of Saccharomyces cerevisiae. 2001. Armand M. Ostergaard S. Bjorck I. Teply LJ. J Am Diet Assoc. Kanda T. Ostman EM. Ostman E. J Nutr. 2006. 96-100. 2007. ID 1386: “Wheat germ oil” and “Cardiovascular system” 1 Alessandri C. Granfeldt Y. 26. 1998. Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes mellitus: a pilot study. United States Pharmacopeial Convention Inc. Bjorgell O. 59. Maryland. Pignatelli P. 01/2008:1379. Eur J Clin Nutr. 64. Perrone A. 46. especially for sportsmen. Tipton KD. Parsons EC.. Drug information for the health care professional. ID 1410: “Very low calorie diet (VLCD) Programme” and “1) Safe and effective weight loss 2) long term weight maintenance” 1 2 3 4 Adam-Perrot A. Ivy JL. 2002. Postexercise protein intake enhances whole-body and leg protein accretion in humans. 49-58. 2004. 167. European Pharmacopoeia. London. 1991. Muscle glycogen synthesis after exercise: effect of time of carbohydrate ingestion. 1992. Rasmussen BB. Am J Physiol Endocrinol Metab. United States Pharmacopeial Convention Inc. Owens-Stovall SK. Do benefits relate to a disease risk factor: No. 6-15. Coyle EF. 13371344. Timing of postexercise protein intake is important for muscle hypertrophy with resistance training in elderly humans. Rockville. 1942. Int J Sport Nutr Exerc Metab. 2001. 2001. Carlson MG. USP (United States Pharmacopeial Convention). 01/2008:1379. Carbohydrate and Protein recovery drink. Wolfe RR. 3 4 5 6 7 8 197 . Should be used in conjunction with an appropriate physical training or exercise program. Am J Gastroenterol. 2001. Levenhagen DK. Mizuno M. Goforth HW. 34. 1854-1859. especially for sports people. Effect of an amino acid. Konz EC. and carbohydrate mixture on net muscle protein balance after resistance exercise. Anderson JW. Carr C. Anderson JW. Miller SL. 14. Should be consumed with a nutritious diet. 7. 2001. Reynolds JEF. Wolf SE. 828-837. Target group: Adults aged 18 years and over with some exceptions. Am J Clin Nutr. 255-271. Ivy JL. Esmarck B. Timing of amino acid-carbohydrate ingestion alters anabolic response of muscle to resistance exercise.2 3 4 5 Council of Europe. Low-carbohydrate diets: nutritional and physiological aspects. J Physiol. Ivy JL. 01/2008:1480. Katz AL. Reasons for excluding these groups: Targeted for specific group sports people. 64. 93. ID 1396: “Name of Food product: Club Energise Sport Recovery 20 / Energise Sport recovery 20 mixed berry). 2006. Brinkman-Kaplan V. Journal of Applied Physiology. Price TB. Benefits and risks of an intensive very-lowcalorie diet program for severe obesity. Frederich RC. 579-584. 1993. 281. E197-206. pantothenic acid and pyridoxine in wheat and wheat products. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. 24. Andersen JL. Carbohydrate-protein complex increases the rate of muscle glycogen storage after exercise. J Appl Physiol. Luan J. Richter EA. Olsen S. Description of food in terms of food legislation categories: Food intended to meet the expenditure of intense muscular effort. Jr. 87. Yaspelkis BB. J Appl Physiol. Med Sci Sports Exerc. Sherman WM. 535. Aarsland A. Long-term weight-loss maintenance: a metaanalysis of US studies. 21. Nicotinic acid. Petrini BE. Kjaer M. Obes Rev. 1992. Pharmaceutical Press. 2004. Anderson JW. Adv Ther. 72. Maron DJ. 74. SCF (Scientific Committee on Food). Borel MJ. Brouns F. Maryland. Hamilton CC. If exceptions describe: Not suitable for children under 16 years of age or pregnant women. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. High protein drink. Elvehjem CA. 1988. Martindale: The extra pharmacopoeia. Was food on Irish market before 1st July 2007: Yes” and “Health benefits of food: Recover Faster for Better Sports Performance. Wolfe RR. McCauley TR. 61-75. Clifton P. protein. 2002. Flakoll PJ. Wood CL. Teply LJ. Zawadzki KM. 1480-1485. Cutler CL. J Nutr.” 1 2 Borsheim E. Hoie LH. Early postexercise muscle glycogen recovery is enhanced with a carbohydrate-protein supplement. 301311. Strong FM. Damon BM. 897-899. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Purdy L. 91. 1993. and insulin resistance in obese patients with type 2 diabetes. 1994. Ayyad C and Andersen T. The effect of low carbohydrate on energy metabolism. Effect of a very-low-calorie diet on body composition and resting metabolic rate in obese men and women. 102-106. 2000. 2005. O'Brien PE. 2004. Long-term follow-up of patients attending a combination very-low calorie diet and behaviour therapy weight loss programme. Homko C. sleeping on side. 14. 1. Journal of Human Nutrition & Dietetics. 854-858. 219. Clin Endocrinol Metab. Obesity reviews. Letizia KA. Combined use of behavior modification and very lowcalorie diet in weight loss and weight maintenance. Holden JH. Int J Obes (Lond). 325-328. Efficacy of very low-energy diets and meal replacements in the treatment of obesity. 142. Stettner DC. 403-411. Zuk L. 1283-1293. Sleep disturbance and obesity: changes following surgically induced weight loss. 17. 17-19. 12. Arch Intern Med. Int J Obes. Krissman P. Rapid weight loss and lean tissue: evidence for comparable body composition and metabolic rate in differing rates of weight loss. 430-434. Kopelman PG. Walld R. 17-20. Arch Intern Med. Kreitzman SN. 1989. 2002. Wadden TA. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 198 . Foster GD. 13 Suppl 2. 107. Dixon JB. Gilden Tsai A and Wadden TA. Obesity reviews. Doherty JU. 364. Schachter LM. Kern PA. Stein TP. 144. Brodie D. Kryger MH. 2005. J Clin Sleep Med. 307. Coxon A. Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? Lancet. Harper A. Kreitzman S. 29 Suppl 2. Safety and effectiveness of weight reduction using a very-low-calorie formulated food. 16. Reports on tasks for scientific cooperation. Hoie LH. Braver HM. Int J Obes Relat Metab Disord. 605-613. The Re-Shape Study: to evaluate the effectiveness of a commercial weight loss programme compared to usual care as delivered in a primary care environment. 1. Treatment for snoring. Ertel NH. 2001. Clements M. S26-30. Astrup A. Int J Obes Relat Metab Disord. 1998.3. 747750. and nasal spray. The evolution of very-low-calorie diets: an update and metaanalysis. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. 1991. J Am Diet Assoc. Thom E. 1995. Long-term evaluation of cardiac function in obese patients treated with a very-low-calorie diet: a controlled clinical study of patients without underlying cardiac disease. Int J Obes. Howard A. Lucas CP. 11. Mozzoli M. Astrup A and Rossner S. 2005. Task 7. Gorman J. 2004-2005. Ardito EA. Chest. Wolfe G. Increasing obesity trends in patients with sleep-disordered breathing referred to a sleep disorders center. 1991. Perri MG. 1984. Meinert Larsen T. 613-634. Boden G. Clinical complications of obesity. Nichols D. Jebb SA and Goldberg GR. 364-366. 113-119. 1283-1288. Reduction of body mass and change in body composition on a very low calorie diet. 1984. 69-80. Am J Med Sci. An eight-year experience with a very-low-calorie formula diet for control of major obesity. Banno K. Ann Intern Med.5 Appleton and Summerbell. DG SANCO (Directorate General Health and Consumer Protection). Block AJ. Schneider G. Erlanson-Albertsson C and Mei J. Pedersen M. Kirschner MA. Budell W. 2000. blood glucose levels. Am J Clin Nutr. Bruusgaard D. 1992. Effect of a low-carbohydrate diet on appetite. Day SC. Darga LL. 1988. Sargrad K. 161. 53. 1. Olson SM. Trozzolino L. 179-181. Obesity (Silver Spring). University of Teesside. School of Health & Social Care. Collection of data on products intended for use in very-low-calorie-diets. Combined weight loss. 2006. Burgess NS. 13. Arch Iran Med. J Intern Med. 1989. Int J Obes. 299-306. 1. Management of simple snoring. Obes Rev. Howard A. Two year maintenance of weight loss after a VLCD and behavioural therapy for obesity: correlation to the scores of questionnaires measuring eating behaviour. Value of VLCD supplementation with medium chain triglycerides. Are ketone bodies an appetite suppressant? Journal of Parental and Enteral Nutrition. comparative. 182-187. 2007. London. Int J Obes. Ikeda Y. 1989. 1983. Int J Obes. 34 35 36 37 38 39 40 41 42 43 44 45 46 47 199 . 10. Arch Intern Med. Saunders N. 1993. 30. Veale D. 13 Suppl 2. 13. Weinkove C. Smith Gordon. Mustajoki P. Morgan W. Int J Obes. 13th Clinical Congress Abstracts. 1393-1400. hunger. The effects of VLCD on body composition. 595-602. controlled long-term trial. Eberstein JA. 5. 215-226. Effect of 3-hydroxybutyrate in obese subjects on very-low-energy diets and during therapeutic starvation. London. Rich A. Use of very low-calorie diet in preoperative weight loss: efficacy and safety. Saris WH. 20.). 19. Ryde S. Birks J.. The long term effectiveness of combined therapy by behavior modification and very low calorie diet: 2 years follow-up. Independence of body composition from mode. 40 Suppl 1. 295S-301S. Int J Obes Relat Metab Disord. Quaade F and Astrup A. 2007. 15. 73-77. McClernon FJ. 15 (Suppl). Pekkarinen T. 190-192. A prospective. 1991. Jr. Al-Zeibak S.26 27 28 29 30 31 32 33 Kreitzman S and Coxon A. 1997. 1992. Chambers P. Rodgers M. Madani M. Pepin JL. 2001. 7S. Levy P. 13 Suppl 2. Smith Gordon. Stability of fat/lean loss demonstrated to relatively low body fat levels by personal fat ratio. Shapiro H. 2003. 1993. 9 Suppl 4. 15-17. 22. Very low energy diets in the treatment of obesity. 1996. rate or direction of weight change in women as a result of dieting or regaining weight. Johnston I. upper airway resistance syndrome. 1581-1585. Mayer P. 238. Kreitzman SL. 217S-223S. 1990. 25. 157. 13 Suppl 2. Dutton J. Atkins RC. Miura J. 107-111. Rossner S. Takala I. 1989. Westman EC. Weight maintenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. Am J Clin Nutr. 2. Int J Obes. Arai K. Int J Obes Relat Metab Disord. Kreitzman SN. 1995. Acta Diabetol. Int J Obes Relat Metab Disord.). Wuyam B. Factors influencing body composition during very-low-calorie diets. Coxon A. 125-129. 2001. Zahouani A. In: The Swansea Trial. Lancet. Hespel JP. Obes Res. Thomas D. Kreitzman S. 1998. 904. Obesity (Silver Spring). 1988. 14. Snoring and obstructive sleep apnea. Controlled carbohydrate refeeding after VLCD improves weight maintenance on low fat diet. Kreitzman S. Mustajoki P and Pekkarinen T.and long-term evolution of body composition in 1389 obese outpatients following a very low calorie diet (Pro'gram18 VLCD). Ohno M. Comparison of behavior therapy with and without very-low-energy diet in the treatment of morbid obesity. Intermittent vs continuous VLCD therapy in obesity treatment. Ryttig KR and Rossner S. and moderate sleep apnea syndrome. A 5-year outcome. randomized. Yancy WS. Pekkarinen T and Mustajoki P. 2001. Krotkiewski M. Kreitzman SN. 1996. Kreitzman S and Howard A (eds. Kreitzman S and Howard A (eds. Three year hospital experience with control of major obesity by VLCD in medically compromised individuals. and other self-reported symptoms. S149150. Tsukahara S. In: The Swansea Trial. Ali P. 332-337. Boulier A. Sleep. Pawan GL and Semple SJ. Pekkarinen T and Mustajoki P. S101-110. 56. Evans C. Initial very low calorie diet (VLCD) improves ultimate weight loss. 1997. Very-low-calorie diets and sustained weight loss. Sivyer A. The effects of a lowcarbohydrate ketogenic diet and a low-fat diet on mood. 6172. Obes Res. Short. 107. Effect of a very-low-calorie diet on body composition and resting metabolic rate in obese men and women. 1995. O'Brien PE. Kirschner MA. blood glucose levels. Block AJ. 2001. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. Thom E. 2000. 1992. 605-613. Frederich RC. Astrup A and Rossner S. Wood CL. 11. 1992. 1. Boden G. Journal of Human Nutrition & Dietetics. Erlanson-Albertsson C and Mei J. Collection of data on products intended for use in very-low-calorie-diets. Harper A. Rapid weight loss and lean tissue: evidence for comparable body composition and metabolic rate in differing rates of weight loss. Increasing obesity trends in patients with sleep-disordered breathing referred to a sleep disorders center. 430-434. Wolfe G. 2006. Anderson JW. Reduction of body mass and change in body composition on a very low calorie diet. Kern PA. 2001. Meinert Larsen T. Long-term follow-up of patients attending a combination very-low calorie diet and behaviour therapy weight loss programme. 16. 10 11 12 13 14 15 16 17 18 19 20 21 200 . Ertel NH. Am J Clin Nutr. 2005. Brouns F. Bruusgaard D. 102-106. Coxon A. 403-411. Burgess NS. 17-20. Trozzolino L. 7. Hamilton CC. Perri MG. Int J Obes Relat Metab Disord. Reports on tasks for scientific cooperation. 364. 142. 17. Gorman J. The evolution of very-low-calorie diets: an update and metaanalysis. 2000. 1283-1293. Obesity reviews. Anderson JW. Jebb SA and Goldberg GR. 17-19. Chest. 61-75. Efficacy of very low-energy diets and meal replacements in the treatment of obesity. 579-584. J Am Diet Assoc. Purdy L. Int J Obes. Banno K. sleeping on side. 1. Schachter LM. 2005. Obes Rev. 2002. Ayyad C and Andersen T. 307. 897-899. Walld R. Astrup A. 2004. and nasal spray. DG SANCO (Directorate General Health and Consumer Protection). 87. Kreitzman S. Konz EC. Obesity (Silver Spring). Arch Intern Med. Benefits and risks of an intensive very-lowcalorie diet program for severe obesity. S26-30. 1989. Int J Obes. 21. 1994. 6-15. An eight-year experience with a very-low-calorie formula diet for control of major obesity. Obesity reviews. J Clin Sleep Med. Stein TP. 1993. 13 Suppl 2. 219. Combined weight loss. Luan J. 69-80.3. Hoie LH. Ardito EA. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. 2005. 49-58. Task 7. 1. Braver HM. 325-328. Lucas CP. Gilden Tsai A and Wadden TA. Adv Ther. 91. Am J Gastroenterol. Sargrad K. 1998. Darga LL. Schneider G. 364-366. Int J Obes Relat Metab Disord. Holden JH. Homko C.ID 1411: “Very low calorie diet (VLCD) Programme” and “Reduced hunger” 1 2 3 4 5 6 7 8 9 Adam-Perrot A. Am J Med Sci. 1283-1288. Brinkman-Kaplan V. 179-181. 12. Olson SM. Effect of a low-carbohydrate diet on appetite. 113-119. Sleep disturbance and obesity: changes following surgically induced weight loss. The effect of low carbohydrate on energy metabolism. 2004. Stettner DC. Kryger MH. Clifton P. Combined use of behavior modification and very lowcalorie diet in weight loss and weight maintenance. Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? Lancet. and insulin resistance in obese patients with type 2 diabetes. Mozzoli M. 2006. 74. Long-term weight-loss maintenance: a metaanalysis of US studies. Dixon JB. Brodie D. Int J Obes (Lond). 14. Treatment for snoring. Anderson JW. 161. 1988. Ann Intern Med. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. 1991. Low-carbohydrate diets: nutritional and physiological aspects. Hoie LH. 29 Suppl 2. Howard A. . A prospective. Kreitzman SN. Rich A. Obes Rev. 15 (Suppl). 299-306. Kreitzman SN. 15. 613-634. controlled long-term trial. 2001. 6172. Obes Rev. 1988. Eberstein JA. Intermittent vs continuous VLCD therapy in obesity treatment.and long-term evolution of body composition in 1389 obese outpatients following a very low calorie diet (Program18 VLCD). Short. Arch Iran Med. Pekkarinen T. upper airway resistance syndrome. 182-187. Rossner S. Jr. 107-111. Low-carbohydrate diets: nutritional and physiological aspects. Are ketone bodies an appetite suppressant? Journal of Parental and Enteral Nutrition. Madani M. 25. 1581-1585. 87. Controlled carbohydrate refeeding after VLCD improves weight maintenance on low fat diet. The effects of a lowcarbohydrate ketogenic diet and a low-fat diet on mood. Clinical complications of obesity. Hamilton CC. 73-77. 13. 1995. 201 . Sleep. Quaade F and Astrup A. 1998. Obes Res. Kreitzman S and Coxon A. Int J Obes Relat Metab Disord. 215-226. Anderson JW. 1. Hespel JP. Comparison of behavior therapy with and without very-low-energy diet in the treatment of morbid obesity. 2003. Wuyam B. Mustajoki P. 15-17. 1996. 1991. 7. 1990. Veale D. Mustajoki P and Pekkarinen T. Very-low-calorie diets and sustained weight loss. Ohno M. 13 Suppl 2. and other self-reported symptoms. Boulier A. 13th Clinical Congress Abstracts. 56. Independence of body composition from mode. 30. 7S. 30 31 32 33 34 35 36 37 38 39 40 ID 1412: “Very low calorie diet (VLCD) Programme” and “Burning fat for energy. Pekkarinen T and Mustajoki P. A 5-year outcome. Obesity (Silver Spring). Management of simple snoring. 9 Suppl 4. 22. 2001. Levy P. Int J Obes. 1996. Int J Obes. and moderate sleep apnea syndrome. rate or direction of weight change in women as a result of dieting or regaining weight. S101-110. Am J Clin Nutr. 20. Two year maintenance of weight loss after a VLCD and behavioural therapy for obesity: correlation to the scores of questionnaires measuring eating behaviour. S149150. Acta Diabetol. preserving lean tissue” 1 2 Adam-Perrot A. Weight maintenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. Int J Obes. The long term effectiveness of combined therapy by behavior modification and very low calorie diet: 2 years follow-up. Westman EC. 295S-301S. comparative. Mayer P. 1992. 2007. Pepin JL. Factors influencing body composition during very-low-calorie diets. Chambers P. 2001. Johnston I. 1992. 2006. Brinkman-Kaplan V. Yancy WS. 1983. 157. Arch Intern Med. Int J Obes Relat Metab Disord. Int J Obes. 1393-1400. Value of VLCD supplementation with medium chain triglycerides. Tsukahara S. Zahouani A. 238. 6-15. Howard A. Brouns F. Kreitzman SL. 49-58. Int J Obes Relat Metab Disord. Benefits and risks of an intensive very-lowcalorie diet program for severe obesity. Krotkiewski M. 2. 1989. McClernon FJ. 332-337. 2007. 904.22 23 24 25 26 27 28 29 Kopelman PG. Ikeda Y. 1997. Clifton P. Saris WH. Very low energy diets in the treatment of obesity. 13 Suppl 2. Am J Gastroenterol. Ryttig KR and Rossner S. Arai K. randomized. 10. Lancet. Clin Endocrinol Metab. hunger. Snoring and obstructive sleep apnea. Atkins RC. Pawan GL and Semple SJ. 13. Takala I. Miura J. 190-192. Initial very low calorie diet (VLCD) improves ultimate weight loss. 1984. 40 Suppl 1. 19. J Intern Med. 1989. 14. 217S-223S. Effect of 3-hydroxybutyrate in obese subjects on very-low-energy diets and during therapeutic starvation. Ertel NH. 1991. Chest. Lucas CP. and insulin resistance in obese patients with type 2 diabetes. 13 Suppl 2. Wolfe G. 14. Int J Obes. 579-584. 1283-1293. 16. Burgess NS. 2006. Int J Obes. Hoie LH. and nasal spray. Schneider G. 403-411. Gorman J. Banno K. Walld R. 2004. Obesity (Silver Spring). DG SANCO (Directorate General Health and Consumer Protection). Long-term follow-up of patients attending a combination very-low calorie diet and behaviour therapy weight loss programme. 1990. Obesity reviews. 897-899. Howard A. Efficacy of very low-energy diets and meal replacements in the treatment of obesity. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. Am J Med Sci. 74. 1995. Howard A. Ardito EA. Boden G. Combined use of behavior modification and very lowcalorie diet in weight loss and weight maintenance. Journal of Human Nutrition & Dietetics. 364. Schachter LM. Kern PA. 325-328. 1993. Adv Ther. 2005. 113-119. 2004. Int J Obes Relat Metab Disord. Effect of a very-low-calorie diet on body composition and resting metabolic rate in obese men and women. Erlanson-Albertsson C and Mei J. Clin Endocrinol Metab.3. J Am Diet Assoc. Purdy L. Konz EC. blood glucose levels. Task 7. 30. Stein TP. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 202 . 29 Suppl 2. 13. 2001. Ann Intern Med. Kreitzman SN. 1988. 12. Effect of a low-carbohydrate diet on appetite. 179-181. Kreitzman S. Int J Obes Relat Metab Disord. Thom E. Coxon A. Astrup A and Rossner S. 1998. Braver HM. 2005. Collection of data on products intended for use in very-low-calorie-diets. Mozzoli M. Int J Obes (Lond). 1984. Dixon JB. Jebb SA and Goldberg GR. Treatment for snoring. 107. 904. O'Brien PE. 1989. Kirschner MA. 1992. 1991. Arch Intern Med. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. rate or direction of weight change in women as a result of dieting or regaining weight. 69-80. 61-75. Darga LL. Stettner DC. sleeping on side. Controlled carbohydrate refeeding after VLCD improves weight maintenance on low fat diet. 605-613. Long-term weight-loss maintenance: a metaanalysis of US studies. Am J Clin Nutr. 15 (Suppl). Kreitzman S and Coxon A. Frederich RC. J Clin Sleep Med. Harper A. The evolution of very-low-calorie diets: an update and metaanalysis. Holden JH. Rapid weight loss and lean tissue: evidence for comparable body composition and metabolic rate in differing rates of weight loss. Trozzolino L.3 4 5 6 7 8 9 Anderson JW. 2001. 21. 219. Meinert Larsen T. 91. 14. Brodie D. Combined weight loss. Int J Obes. Increasing obesity trends in patients with sleep-disordered breathing referred to a sleep disorders center. Kryger MH. Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? Lancet. 2002. Clinical complications of obesity. 2000. Luan J. 102-106. Reduction of body mass and change in body composition on a very low calorie diet. Bruusgaard D. 11. Perri MG. Gilden Tsai A and Wadden TA. An eight-year experience with a very-low-calorie formula diet for control of major obesity. 2005. 142. 17-20. Astrup A. Reports on tasks for scientific cooperation. 1283-1288. 1. S26-30. Block AJ. Hoie LH. Ayyad C and Andersen T. 1. 1. 161. Kopelman PG. 613-634. Anderson JW. 307. Independence of body composition from mode. 2000. The effect of low carbohydrate on energy metabolism. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. 364-366. Sleep disturbance and obesity: changes following surgically induced weight loss. Int J Obes. 1994. 17. 430-434. 17-19. Homko C. Obesity reviews. Olson SM. Sargrad K. Wood CL. Kreitzman SL. 2001. McClernon FJ. 1996. Obesity (Silver Spring). Ryttig KR and Rossner S. 6172. Mayer P. 107-111. Int J Obes Relat Metab Disord. Arch Intern Med. Tsukahara S.25 26 27 28 29 Kreitzman SN. 2007. effective & healthy weight loss. 20. 13th Clinical Congress Abstracts. Zahouani A. Very low energy diets in the treatment of obesity. Glycaemic index and glycaemic load values of cereal products and weight-management meals available in the UK. 73-77. Atkins RC. Are ketone bodies an appetite suppressant? Journal of Parental and Enteral Nutrition. ID 1414: “Very low calorie diet (VLCD) Programme” and “Low glycaemic index” 30 31 32 33 34 35 36 37 38 39 40 1 Henry CJ. Greater weight loss than with conventional calorie counting” 1 Allison DB. Int J Obes Relat Metab Disord. 7S. upper airway resistance syndrome.. 13 Suppl 2. 40 Suppl 1. hunger. Schwartz LG. Wynne JM. 15-17. 217S-223S. randomized. 1988. 299-306. The effects of a lowcarbohydrate ketogenic diet and a low-fat diet on mood. 1989. Kraker JL. Snoring and obstructive sleep apnea. 238. 57. Lancet. Eur J Clin Nutr. Rich A. Initial very low calorie diet (VLCD) improves ultimate weight loss. Heshka S. Arai K. Value of VLCD supplementation with medium chain triglycerides. 25. 2003. Effect of 3-hydroxybutyrate in obese subjects on very-low-energy diets and during therapeutic starvation. Levy P. 2007. Boulier A. Acta Diabetol. 1995. comparative. 182-187. controlled long-term trial. Int J Obes. Miura J. Ikeda Y. 2. 98. 13 Suppl 2. 15. S149150. 1393-1400. 2003. Pepin JL. Comparison of behavior therapy with and without very-low-energy diet in the treatment of morbid obesity. 215-226. Heymsfield SB. 1997. Westman EC. Rossner S. Saris WH. 1989. Krotkiewski M. Eberstein JA. 56. 9 Suppl 4. 332-337. 19. 2001. Int J Obes Relat Metab Disord. and moderate sleep apnea syndrome. Pawan GL and Semple SJ. 1. 2007. S101-110. Fontaine KR. Chambers P. Br J Nutr. 1992. 1998. Lightowler HJ. A 5-year outcome. Hespel JP. 2001. 190-192. Ohno M. Obes Res. Sleep.and long-term evolution of body composition in 1389 obese outpatients following a very low calorie diet (Pro'gram18 VLCD). Wuyam B. Pekkarinen T. Jr. 147-153. Am J Clin Nutr. ID 1417: “Meal replacement for weight control (as defined in Directive 96/8/EC energy restricted diets for weight reduction)” and “Safe. Int J Obes. Dodwell LM. 1996. Murugesan R. 22. 157. A prospective. Mustajoki P. 1983. Arch Iran Med. Two year maintenance of weight loss after a VLCD and behavioural therapy for obesity: correlation to the scores of questionnaires measuring eating behaviour. Intermittent vs continuous VLCD therapy in obesity treatment. Management of simple snoring. Veale D. Madani M. Very-low-calorie diets and sustained weight loss. Pekkarinen T and Mustajoki P. Mustajoki P and Pekkarinen T. 203 . 13. 295S-301S. Takala I. Weight maintenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. Yancy WS. Obes Rev. Quaade F and Astrup A. 1581-1585. 10. Gadbury G. J Intern Med. The long term effectiveness of combined therapy by behavior modification and very low calorie diet: 2 years follow-up. 514-522. and other self-reported symptoms. Factors influencing body composition during very-low-calorie diets. Short. Johnston I. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Anderson JW. Hoie LH. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. 321S-325S. Raatz SK. Value of structured meals for weight management: risk factors and long-term weight maintenance. 2505-2511. J Am Diet Assoc.domuk. Ashley JM. 344-348. Foster GD. Flechtner-Mors M. Adult Weight Management (AWM) Meal Replacements. Clinical evaluation of a minimal intervention meal replacement regimen for weight reduction. Espeland MA. 8. Elashoff R. Dhindsa P. Adler G. 2001. 134. Medscape Diabetes & Endocrinology. Flechtner-Mors M. Eur J Clin Nutr. Carr L. Heymsfield SB. Adv Ther. Haffner SM. 2004. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Redmon JB. Heber D. 2001. Schrage JP. 2002.org. Swanson JE. 9 Suppl 4. 25 (S1). Obes Res.com/support/support_approach4. 264-270. 9 Suppl 4. Kwong CA. 2004. Johnson KC. 2001. 610628. Thomas W. Ditschuneit HH. 537-549. 13. Cost effectiveness of meal replacement products in weight control. Skootsky S. 61-75. 2004. 1999. Bovee V. Rothacker DQ. Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects. 2003. http://www. 101.com/template. Int J Obes Relat Metab Disord. Anderson JW. http://www.uk/. Dietitians in Obesity Management. 399-402. Obes Res. Ashley JM. Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year. http://www. Int J Obes. Reck KP. Elashoff RM. Hubbard VS.org/. Ditschuneit HH. 2004. National Obesity Forum. Keogh JB. 21. Johnson TD. Gilbertson MC. Ellis PK. Rothacker DQ. 56. McCall NL. 16. 2000. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 204 . Johnson TD. Heo M. Knowler WC. 2003. Kahn SE. 284S-289S. Combination Approaches to Weight Management. Clifton PM.adaevidencelibrary.nationalobesityforum. Control Clin Trials. 1994. Heber D. Meal replacements. Donnelly R. Luan J. Liquid meal replacement vs traditional food: a potential model for women who cannot maintain eating habit change. J Nutr. Staniszewski BA. Perumean-Chaney SE. Ditschuneit HH. St Jeor ST. Diabetes Care. 1599-1604. West P. 198-204. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. 18941899. Fan Q. 143. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. 345-347. Foster PR. Am J Clin Nutr. Bantle JP. Noakes M. Wang HJ. Nutrition. Adler G. van Mierlo CA.html. Arch Intern Med. Implementation of a primary care physician network obesity management program. Frier HI. Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. Pimstone K. Yanovski SZ.cfm?template=guide_summary&key=625&auth=1. Scott AR. Ditschuneit HH and Flechtner-Mors M. Five-year self-management of weight using meal replacements: Comparison with matched controls in rural Wisconsin. 24. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Saltsman P. http://www. Weight control in the physician's office. Bowerman S. Diabet Med.2 3 4 5 6 American Dietetic Association. Ryan DH. 161. 2001. Obes Res. Suchard MA. O'Reilly J. 26. Frier HI.bdaweightwise. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. 2000. 27. British Dietetic Association. 20. 69. Flechtner-Mors M. 2003. 319-324. Garvey D. J Am Coll Nutr. Bellman M. van der Knaap HC. Wang HJ. 608-614. 2003. 399-402. Norman RL. 1994. 52. Weight control in the physician's office. Liquid meal replacements and glycemic control in obese type 2 diabetes patients. Four worksite weight loss programs with high-stress occupations using a meal replacement product. 264-270. Thames G. 8. Flechtner-Mors M. 11. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Winick C. Perumean-Chaney SE. Occup Med (Lond). Rothacker DQ. Saltsman P. 24 25 ID 1418: “Meal replacement for weight control (as defined in Directive 96/8/EC energy restricted diets for weight reduction)” and “Maintenance of weight loss” 1 2 3 4 5 6 7 8 Anderson JW. 2006. 26. 21. Five-year self-management of weight using meal replacements: Comparison with matched controls in rural Wisconsin. DeShields S. Adv Ther. Rothacker DQ. Fox KR. BMJ. Blackburn GL and Rothacker D. Swanson JE. Johnson TD. 2003. Bellman M. 1309-1314. 52. ID 1419: “Calcium” and “Cardiovascular system” 1 Allender PS. J Am Coll Nutr. 25-30. Ashley JM. Follmann D. Liquid meal replacement vs traditional food: a potential model for women who cannot maintain eating habit change. Yip I. 2000. Taylor MA. 341S-347S. Heymsfield SB. 13. Elashoff R. Bantle JP. Obes Res. Nutrition. Flechtner-Mors M. Logan CM. Cutler JA. 27. 2001. Ashley JM. Hoie LH. Redmon JB. 1999. Bellman M. Four worksite weight loss programs with high-stress occupations using a meal replacement product. 9 Suppl 4. Morgan LM. Ditschuneit HH. Rothacker DQ. Wang HJ. 2004. Go VL. 198-204. 2001. 2000. Reck KP. 61-75. 161. Long-term weight control with meal replacements. Obes Res. Fan Q. Rothacker DQ. 825-831. Kwong CA. 537-549. deLooy A. Schrage JP. Frier HI. 69. Arch Intern Med. Baic S. Elliott P. Frier HI. 2003. Thomas W. Heber D. 1996. Yip I. Murray S. Raatz SK. Bovee V. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. van der Knaap HC. Cappuccio FP. 1599-1604. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Clinical evaluation of a minimal intervention meal replacement regimen for weight reduction. 2003. McCall NL. Johnson TD. Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects. 101. Int J Obes Relat Metab Disord. 2505-2511. Livingstone MB. Heo M. Millward DJ. Ann Intern Med. Norman RL. Suchard MA. 2002. van Mierlo CA. Elashoff R. 2001. Heber D. Gilbertson MC. Obes Res. 25-30. Luan J. 124. Winick C. 332. 608-614. 16. 9 10 11 12 13 14 205 . 56. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ditschuneit HH. Obes Res. Pryer J. Eur J Clin Nutr. Thames G. Randomised controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC "diet trials". J Am Diet Assoc. Staniszewski BA.23 Truby H. 341S-347S. Ellis PK. 344-348. 9 Suppl 4. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. St Jeor ST. 2002. 2000. Ditschuneit HH. Adler G. 345-347. Hill JO. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. 16. DeShields S. Wang HJ. A103. Occup Med (Lond). Heber D. Diabetes Care. Saltsman P. Elashoff RM. Macdonald IA. Nutrition. Go VL. 385. Am J Clin Nutr. Adler G. 2002. Flechtner-Mors M. 2001. Ten-year self-management of weight using a meal replacement diet plan: comparison with matched controls. Murray S. Wang HJ. Liquid meal replacements and glycemic control in obese type 2 diabetes patients. 398S-405S. Streppel MT. McCarron DA. Expert Report: Diet. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. nutrition and prevention of chronic diseases. Cook DJ. Gleason JA. 118. 206 . Guyatt GH. Zeegers MP. Effect of a low-carbohydrate. Nordmann A. Dallongeville J. Ornish. van Mierlo LA. 2002. WHO Technical Report Series 916. Report of a Joint WHO/FAO Expert Consultation. Bongard V. Ferrieres J. 12. 1999. Cook RJ. WHO Technical Report Series 916. 293. Finding consensus in the dietary calcium-blood pressure debate. 661-666. Yancy WS. Schaefer EJ. Selker HP. 98. 212-216.2 Bucher HC. 2006. Cook DJ. 1998. 23. Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association Nutrition Committee. Blood pressure and nutrient intake in the United States. ID 1427: “Fruit-rich diet” and “Modulation of glycemic response” 1 WHO/FAO (World Health Organization and Food and Agriculture Organization). Henry HJ. Yancy WS. Briel M. 24. Griffith LE. Stanton JL. Grobbee DE. Amouyel P. 2003. Olsen MK. Hatala R. 1984. ID 1421: “Very low calorie diet (VLCD) Programme” and “VLCD/low carbohydrate diets helps to the maintenance of normal blood lipid profile” 3 4 5 6 7 8 9 10 1 Dansinger ML. 1999. Cook RJ. McCarron DA and Reusser ME. ID 1426: “Fruit-rich diet” and “Weight management via fibre” 2 3 4 1 WHO/FAO (World Health Organization and Food and Agriculture Organization). Int J Cardiol. Guyatt GH. 22. JAMA. Bucher HC. J Hum Hypertens. 166. Kohonneen verenpaineen hoito (Hypertension: Current Care Guidelines). 10161022.. Science. Takala I. 1996. Kotchen TA and McCarron DA. 20. 1994. Circulation. Ruidavets JB. 1392-1398. Working Group appointed by the Finnish Hypertension Society. A review. and Zone diets for weight loss and heart disease risk reduction: a randomized trial. ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. A meta-analysis of randomized controlled trials. Effects of dietary calcium supplementation on blood pressure. Geleijnse JM. Independent contribution of dairy products and calcium intake to blood pressure variations at a population level. Hatton DC and McCarron DA. 224. Dudley T. Guyton JR. Keller U. Weight loss with very-low-calorie diet and cardiovascular risk factors in moderately obese women: one-year follow-up study including ambulatory blood pressure monitoring. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. 275.. Comparison of the Atkins. Bucher HC. Am J Hypertens. 513-530. 285-293. Int J Obes Relat Metab Disord. 1998. 18. Dietary calcium and blood pressure in experimental models of hypertension. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. 2003. Arveiler D. Jr. 671-681. 84-92. 571-580. Simon C. Hunt DL. Nordmann AJ. Brehm BJ. 110-126. 2006. Duodecim. 613-617. J Am Coll Nutr. Expert Report: Diet. 2006. 110. Arends LR. Ducimetiere P. Bingham A. Kok FJ. Mustajoki P. Lang JD. Morris CD. Jr. 2006. JAMA. Westman EC. Pekkarinen T. 43-53. nutrition and prevention of chronic diseases. Arch Intern Med. J Hypertens. 2005. Griffith JL. Weight Watchers. Hypertension. 535-543. Kowluru RA and Odenbach S. Jialal I. 4161-4166. Free Radic Biol Med. Kowluru RA and Odenbach S. 11141121. 45. 2003. Nawroth P. 42. Haenen GR. 40. Swanson C. 6 7 8 9 10 11 12 13 14 15 16 17 207 . Henriksen EJ. Mayne ST. Expert Report: Diet. Bugert P. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Dietrich N. 1089-1096. Kagan VE. 2005. 7. 1581-1587. 1553-1567. 27. Antioxidant effects of sulfur-containing amino acids. Schopohl B. 2005. Biewenga GP. 2003. alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. 315-331. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. 199. 243-251. Brownlee M. 1999. Busse E. Sivas A. 933S-940S. Nourooz-Zadeh J. 133 Suppl 3. Urich H. Arzneimittelforschung. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Wissenschaftliche Verlagsgesellschaft. 2005. ID 1434: “Alpha-lipoic-acid” and “Antioxidant properties” 1 2 3 4 5 Atmaca G. Zimmer G. 53. 829-831. Invest Ophthalmol Vis Sci. ID 1430: “Vegetable-rich diet” and “Modulation of glycemic response” 1 WHO/FAO (World Health Organization and Food and Agriculture Organization). Kowluru RA. Akcay T. Gröber U. 1637-1649. Klevesath M. 57. Kayali R. 2004. Kornhuber B. 1999. nutrition and prevention of chronic diseases. Bilska A and Wlodek L. 29. Nawroth PP. 3-12. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Effect of alpha-lipoic acid supplementation on oxidative protein damage in the streptozotocin-diabetic rat. Khan S. Marangon K. Stuttgart. Postepy Hig Med Dosw (Online). Bierhaus A. Bloch-Damti A and Bashan N. Malinska D and Winiarska K. Yonsei Med J. 2000. 26. WHO Technical Report Series 916. Cakatay U. Powell R. The pharmacology of the antioxidant lipoic acid. WHO Technical Report Series 916. 1992.ID 1429: “Vegetable-rich diet” and “Weight management via fibre” 1 WHO/FAO (World Health Organization and Food and Agriculture Organization). Shvedova A. Telci A. Wolff SP. Free Radic Biol Med. Res Exp Med (Berl). Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. 2002. 49. 1495-1500. Tirosh O. Antioxid Redox Signal. Serbinova E. Hammes HP. Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. 2006. Free Radic Biol Med. Tritschler H. Lipoic acid . Bast A. Gen Pharmacol. 3233-3238. Biochem Pharmacol. 776-788. Reduction of peroxyl. Hofmann M. Halliwell B. Diabetologia. Vom Hagen F. Ziegler R. [Lipoic acid: characteristics and therapeutic application]. 2005. 44. nutrition and prevention of chronic diseases. Expert Report: Diet. 1992. Orthomolekulare Medizin. Packer L. ascorbyl and chromanoxyl radicals. 570-577. 2004.the drug of the future? Pharmacol Rep. Borcea V. Antioxid Redox Signal. J Nutr. 2006. 7. Packer L. 2004. 59. Lin J. Feng Y. 1997. 2003. 45. Devaraj S. Wahl P. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes. Dihydrolipoic acid-a universal antioxidant both in the membrane and in the aqueous phase. Voloboueva LA. Witt EH. 22. Park KG. 8. Stevens MJ. Lebensmittel-Lexikon. Preiss R. 653S-669S. and oxidative stress in experimental diabetic neuropathy. Hamburg. Shenvi SV. Kennedy A. 2002. Free Radic Biol Med. Alpha-Lipoic Acid in Diabetic Neuropathy. Chachich M. energy metabolism. Kraemer K. Kim MJ. Altern Med Rev. 4302-4310. S57-62. Lee SJ. Lee IK. J Clin Pharmacol. Täufel A. Fathallah L. 173179. Invest Ophthalmol Vis Sci. 45. Widlansky M. Baynes JW. and the increase in heart mitochondrial superoxide production. Frank RN. Obrosova IG. Elimadi A. 22. 44. Greene DA. Lipoic acid prevents hypertension. Suh JH. Cao X. Packer L. 17. 49. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Patrick L. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Roy S and Packer L. 1102-1110. J Nutr. Patrick L. 2003. Curr Med Chem. Hasche H. 2003. 2004. Lobisch M. blood flow. Obrosova IG. Biofactors. Eur J Pharmacol. 2004. 186-195. Achenbach H. 16. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Packer L. Haddad PS. Tritschler HJ. Redox regulation of cell functions by alpha-lipoate: biochemical and molecular aspects. 313-328. 133. The role of antioxidants in arsenic and cadmium toxicity. Smith AR. 398. 19. Stitt A. 11. 2003. 7. Stevens MJ. Diabetologia. 2005. Toxic metals and antioxidants: Part II. ALADIN III Study Group. 2000. 1999. de Champlain J. 8. Effects of DL-alpha-lipoic acid on peripheral nerve conduction. 2000. 2000. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 208 . Preiss C. Teichert J. 1006-1015. Greene DA. Wu L. Tunger L. Obrosova IG. 17-21. Fathallah L. Minchenko AG. 2003. 3327-3330. Ames BN. 2826-2832. Nutrition. Am J Clin Nutr. Fathallah L. 1296-1301. Diabetes Care. Nourooz-Zadeh J. 2001. Am J Hypertens. Diabetes Res Clin Pract. 106-128. Malessa R. 2005. Behr's Verlag. Miller SS. Obrosova I. Ziegler D. Hagen TM. Ruhnau KJ. 51. 888-895. Packer L. Januszewski AS. 1997. Suh JH. 1135-1146. Hermann R. hyperglycemia. Zobel M. Ternes W. 139-146. Duffy N. alpha-Lipoic acid as a biological antioxidant. Thiol homeostasis and supplements in physical exercise. 2002. 66 Suppl 1. (R)-alpha-lipoic acid protects retinal pigment epithelial cells from oxidative damage. Stockert CM. Tritschler HJ. Van Huysen C. Boyle C. 456-471. Free Radic Biol Med. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. Altern Med Rev. Liu J. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 34. Thorpe SR. Sen CK and Packer L. 46. Schutte K. 1995. Song DK. Rimbach G.18 Midaoui AE. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Liu E. Wollin SD and Jones PJ. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Free Radic Biol Med. Canning P. Alderson NL. Kerum G. 1998. 2005. Alpha-lipoic acid and cardiovascular disease. 2001. 72. Prevention and treatment of macroangiopathy: focusing on oxidative stress. Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Gardiner TA. Frizzell N. Wessel K. Hanefeld M. Kim HS. Marinescu V. Molecular aspects of lipoic acid in the prevention of diabetes complications. Ruus P. Tuemmers T. 359-378. 227-250. Diabetes. Ruus P. Augustin HJ. Widlansky M. Malessa R. Lee KU. Free Radic Biol Med. Maerker E. 55. 2006. 2. Diabetes Care. Lobisch M. 2006. Hasche H. Shenvi SV. 2004. 535-543. Yi X and Maeda N. 1135-1146. 1553-1567. Clancy DE. Kim HS. 872-874. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled. Schiemann AL. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. 251-258. 2006. 7. Pharmazie. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Reljanovic M. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Bolte B. Lee WJ. Ruhnau KJ. randomized. Lipoic acid . Simon I. 2006. Cobelli C. [Lipoic acid: characteristics and therapeutic application]. Dietze GJ. Smith AR. Molecular aspects of lipoic acid in the prevention of diabetes complications. Tritschler HJ. Suh JH. Zhang Y. Ziegler D. 570-577. 5. 2005. 59. Anuradha CV. Postepy Hig Med Dosw (Online). Moller W. 17. Gyulkhandanyan AV. Malinska D and Winiarska K. alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. 1999. Negrisanu G. 2005. Schuette K. 11. Augustin HJ. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Anitha Nandhini AT. Diabetes. Nutrition. Koh EH. 1998. Targonsky ED. Vicini P. 171-179. Tankova T. Henriksen EJ. Free Radic Biol Med. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). 42. 2005. 309-314. Tritschler HJ. 40. 1995. Lobisch M. 772-775. Lefter D. Kim MS. 31. Bilska A and Wlodek L. Rosu M. 45. Antioxid Redox Signal. 27. Hoflich A. Henriksen EJ. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid.the drug of the future? Pharmacol Rep. 3-12. Koshkin V. Konrad T. Tritschler HJ. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. 1999. Kraemer K. Rett K. 308-310. 297-306. Koh JM. open-label study). 197-202. alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. 2238-2244. 457-464. Jung WI. Rom J Intern Med. 2004. Youn JY. alpha-Lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Thirunavukkarasu V. Renn W. Song KH. 57. 326. 280-287. Biochem Biophys Res Commun. Diabetes Technol Ther. alpha-Lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet. Free Radic Res. 2005. Hermann R. Curr Med Chem. 3. Kamenova P. Hagen TM. 2001. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. Lipoic acid improves glucose utilisation and prevents protein glycation and AGE formation. Sewell A. Rimbach G. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month 7 8 9 10 11 12 13 14 15 16 17 18 19 20 209 . Jacob S. Evans JL and Goldfine ID. Dakovska L. Dabelea D. 2000. Chan CB. Dai F. Usadel KH. Bohles HJ. 1999. Jacob S. Koev D. Arzneimittelforschung. 2005. Bloch-Damti A and Bashan N. Diabetologia. Dietze GJ. Youn JH. Hormones (Athens). Assadkhani A. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial.ID 1435: “Alpha-lipoic-acid” and “Metabolism of carbohydrates” 1 2 3 4 5 6 alpha-Lipoic acid. Rett K. 401-413. Mehnert H. Wheeler MB. 1999. Rom J Intern Med. Tritschler HJ. 1999. Kerum G. Park HS. Schutte K. 37. Reichel G. 888-895. Altern Med Rev. Alpha Lipoic Acid in Diabetic Neuropathy. Kusterer K. 60. Hanefeld M. Packer L. Park JY. 22. Karaman GT. 2007. Soderlund K. Stephens FB. Constantin-Teodosiu D. 434-441. ID 1438: “Amylopectin and L-carnitine” and “Carbohydrate and lipid metabolism” 1 2 Leiper JB. Muscle glycogen resynthesis rate in humans after supplementation of drinks containing carbohydrates with low and high molecular masses. 2006. 149-154. ID 1437: “Amylopectin” and “Carbohydrate metabolism” 1 2 Leiper JB. 102. Armstrong G. ALADIN III Study Group. 2006. 35. Post-exercise ingestion of a unique. J Clin Endocrinol Metab. Soderlund K. Alpha-Lipoic Acid in Diabetic Neuropathy. 91. Greenhaff PL. Aggarwal BB and Shishodia S. Stephens FB. Greenhaff PL. Eur J Appl Physiol. 1397-1421. Greenhaff PL. 1296-1301. 2000. 2000. 26. 3 3 4 5 6 7 8 2 3 4 210 . Improved gastric emptying rate in humans of a unique glucose polymer with gel-forming properties. Simpson EJ. 2004. Laithwaite D. 20. 2000. Soderlund K. 431-444. 1065-1070. 81. 2006a. 2008. Carbohydrate ingestion augments Lcarnitine retention in humans. J Sports Sci. Aulin KP. Heber D. high molecular weight glucose polymer solution improves performance during a subsequent bout of cycling exercise. Constantin-Teodosiu D. Sand D. Roig M. 2007. Stephens FB. Pomegranate juice. Eur J Appl Physiol. Constantin-Teodosiu D. Simpson EJ. 1143-1149. 26. 1143-1149. 149-154. 71. AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Greenhaff PL. Improved gastric emptying rate in humans of a unique glucose polymer with gel-forming properties. total pomegranate ellagitannins. Muscle glycogen resynthesis rate in humans after supplementation of drinks containing carbohydrates with low and high molecular masses. 22. 292. 2001. Biochem Pharmacol. 35. Simpson EJ. Laithwaite D. 2008. Evans CE. ID 1439: “Antioxidant from processed fruits and vegetables and juices” and “Antioxidant properties” 1 Adams LS. Greenhaff PL. 1030. Roig M. J Sports Sci. 377-379. E637-641. Insulin stimulates L-carnitine accumulation in human skeletal muscle. Am J Physiol Endocrinol Metab. Scand J Gastroenterol. 2000. Stephens FB. high molecular weight glucose polymer solution improves performance during a subsequent bout of cycling exercise. Aggarwal BB. An acute increase in skeletal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. Greenhaff PL. Scand J Gastroenterol. Seeram NP. Soderlund K. Takada Y. Piehl Aulin K. Greenhaff PL. Piehl Aulin K. J Agric Food Chem. A threshold exists for the stimulatory effect of insulin on plasma L-carnitine clearance in humans. 2006b. Stephens FB. Aulin KP. Apports nutritionnels conseillés pour la population française. Armstrong G.multicenter randomized controlled trial (ALADIN III Study). J Physiol. 81. 346-351. 5013-5018. Editions Tec&Doc. Ann NY Acad Sci. Aggarwal BB and Shishodia S. Constantin-Teodosiu D. 980-985. J Appl Physiol. Constantin-Teodosiu D. 346-351. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. 581. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. Molecular targets of dietary agents for prevention and therapy of cancer. and punicalagin suppress inflammatory cell signaling in colon cancer cells. FASEB J. Stephens FB. Hultman E. Diabetes Care. Laithwaite D. 2007. Hultman E. Stephens FB. Paris. Post-exercise ingestion of a unique. 54. 2004. 2001. 2004. Hackenthal E. 402-404. Jiratanan T and Liu RH. Bioavailability and antioxidant effects of orange juice components in humans. Kelawala NS and Ananthanarayan L. Hautvast JG. 2002. Halvorsen BL. Int J Food Sci Nutr. Thieme. J Agric Food Chem.. Holte K. 2002. Processed sweet corn has higher antioxidant activity. J Nutr. Cheruvu VK. 2001. Blaschek W. Kader AA. 2005.). Frank T. Betalains--a new class of dietary cationized antioxidants. 227. Wu X.Wissenschaft und Technologie (Food Science and Technology). Keller K. Overview of mechanisms of action of lycopene. 511-516. 1999. Wang CY. 129. 5178-5185. Aro A. conditiva) and green beans (Phaseolus vulgaris L. Holcroft DM. 50. Ben-Arzi S. Carle R. Moskaug O. Harel S. Kikuzaki H. Ayala-Zavala JF. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. Antioxidant activity of processed table beets (Beta vulgaris var. 132. 2004. Punica granatum L. Eisenbrand G. 2005. Chevion S. Antioxidant activity of selected foodstuffs. Am J Clin Nutr. Chaovanalikit A and Wrolstad RE. Holzgrabe U. Custer LJ. Henning SM. Heber D and Lu QY. FCT67-FCT72. 53. 16. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 211 . Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. González-Aguilar GA. Effects of production and processing factors on major fruit and vegetable antioxidants. Hess-Pierce B. 5170-5178. Total anthocyanins and total phenolics of fresh and processed cherries and their antioxidant properties. Ebel S. RÖMPP Lexikon Lebensmittelchemie. Antioxidant properties of ferulic acid and its related compounds. A systematic screening of total antioxidants in dietary plants. Steegers-Theunissen RP. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: presumptive evidence for an interaction between vitamins C and E in vivo. The beneficial effects of tomatoes. 1998.5 Ahmed S. 52. Norman Y. 2000. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. Hirose K. 2004. Sagee O. Harats D. 2005. Lebensmittel . Stintzing FC. Meyer AH. 69. Blomhoff R. J Agric Food Chem. Franke AA. Hvattum E. 2659-2670. J Nutr. Haqqi TM. Taniguchi H. Stuttgart. 2002. 290-297. Remberg SF. 135. Kalt W. Myhrstad MC. J Nutr. Cooney RV. 4581-4589. 2161-2168. Eskes TK. Wold AB. Springer Verlag. 1135-1139. Haffner K. Andersen LF. Blum A. Berry EM. 49. Meririnne E. Heidelberg. 2006. 687-695. HagerROM 2003. 70. 55. Brouwer IA. 2005. van Dusseldorp M. J Agric Food Chem. Wang SY. Duran M. Alfthan G. 2005. Journal of Food Science. 235241. 67. Gil MI. Akiyama K. Reichling J. Strass G. Bitsch I. 50. Hisamoto M. van het Hof KH. Kanner J. Jr. Journal of Food Science. Granit R. J Agric Food Chem. 4959-4964. extract inhibits IL1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappaB in human chondrocytes in vitro. J Agric Food Chem. 920-923. 48. Jacobs DR. Urinary pharmacokinetics of betalains following consumption of red beet juice in healthy humans. Effect of storage temperatures on antioxidant capacity and aroma compounds in strawberry fruit. J Agric Food Chem. 131. 461-471. Liu RH. Thomas CM. J Nutr. Dewanto V. 37. Hafeez BB. Eur J Intern Med. Tomas-Barberan FA. Bitsch R. Erlund I. 2002. 52. 2096-2102. Hagers Handbuch der Drogen und Arzneistoffe. 240-245. Wang N. Nahir M. 2003. Meyboom S. Exp Biol Med (Maywood). Netzel M. Barikmo I. Quaas D. R11-R19. Schreier P. Baugerod H. Pharmacol Res. West CE. Monir M. Wirsansky I. In vitro antiproliferative. J Nat Prod. Deutscher Apotheker Verlag. 1999. 119-141. 16. Ernährungs-Umschau 48. 2005. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. Phenolsäuren. 1996. Heber D. 310-312. Zhang Y. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. antioxidants et athéroschlérose. Prineas RJ. Zobel M. Eur J Clin Nutr. 38. 360367. Pasteur Institute-Lille. 941-947. Frank T. ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice.-Ges. Henning SM. Flavonoide. Wollowski I. Quaas D. Morand C. Bitsch I. Rev Franc Endocrinol Clin. Straß G. 2001. Ternes W. 2003. Verl. Brusamolino A. Porrini M. 57. Watzl B and Leitzmann C. 1051-1058. 1999. Food Research International. 52. Carle R. Behr's Verlag. 57. Gil-Izquierdo A. J Nutr. Effects of blood orange juice intake on antioxidant bioavailability and on different markers related to oxidative stress. 53. 2222-2226. apoptotic and antioxidant activities of punicalagin. 1999. Schmandke H. Stuttgart. Fitoterapia. Functional claims of article 13: Polyphenols in juices. 1997. 2005. Folsom AR. Rechkemmer G. 2005. Bitsch R. Pool-Zobel BL. Lecerf JM. Pasteur Institute-Lille. Walker D. Ninfali P and Bacchiocca M. Ricci D. Täufel A. Ernährungs-Umschau 48. Fitoterapia. 2006. Rosenberg IH. Bucchini A. Lecerf JM. 1996. 2000. 3025-3031. Bostick RM. 76. Niu Y. Netzel M. J Agric Food Chem. Pedreno MA and Escribano J. Avis relatif à l‘évaluation des justificatifs concernant l'emploi d'arabinogalactane extrait de bois mélèze dans des compléments 212 . 1997. 56-58. Gardner EJ. 413-416. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. 2005. 1847-1850. 2005. Hamburg. 2006. Ruxton CH. 2005. Journal of Biological Education. Carcinogenesis. Bioaktive Substanzen in Lebensmitteln. Antioxidant activity of Punica granatum fruits. Adams LS. 2003. N Engl J Med. Wu Y. Biogene Arzneistoffe. J Nutr Biochem. Tucker KL. Flavonoids as antioxidants. 18. 1156-1162. Nair MG. Renal excretion of antioxidative constituents from red beet in humans. Ernährungs-Umschau. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Wichtl M and Czygan FC. J Agric Food Chem. Sudheesh S and Vijayalakshmi NR. Manach C. Wiss. Bouteloup-Demange C. Betalaine in Beten und Feigenkaktusfrüchten. Lebensmittel-Lexikon. Galvano G. Polyphenols and antioxidant capacity of vegetables under fresh and frozen conditions. Muller H. 498-502. Visioli F. 63. 235-242. 49-51. Wilson PW. 1996. Selhub J. 2000. Watzl B and Rechkemmer G. 2005. Riso P. Lecerf JM. Studying the oxidation and the antiradical activity of betalain from beetroot. Nutrition. Rimpler H. Stintzing FC. 249-272. Gardana C. Stuttgart. 1035-1042. Remesy C.25 26 27 28 29 Kushi LH. 51. Galvano F. Mink PJ. Can pure fruit and vegetable juices protect against cancer and cardiovascular disease too? A review of the evidence. Int J Food Sci Nutr. Grande S. 334. Watzl B. 181-186. Flavonoids from Punica granatum—potential antiperoxidative agents. ID 1442: “Arabinogalactan (extract from larch tree)” and “Intestinal health” 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 1 AFFSA (Agence Française de Sécurité Sanitaire des Aliments). Giamperi L. Pietta PG. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. Teedrogen und Phytopharmaka. Fraternale D. Tunger L. 2006. 126. 35. Bub A. 2001. 38. 77. Seeram NP. Cummings JH. 2002. Larch arabinogalactan. 33-37. 7. The importance of adequate fluid and fibre intake during pregnancy. FDA (Food and Drug Administration). 626-632. 221-229. The effect of lactulose. Mohlenkamp MJ. Oxford. 1961. Placebo-Controlled Pilot Study. Nazareth MR. Macfarlane S. 73. In: Advanced Dietary Fibre Technology. Wrong OM. Bhatia VN. Digestibility of selected carbohydrates by anaerobic bacteria. 415S-420S. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. 1999. Kennedy CE. 2001b. Meier R and Gassull MA. J Agric Food Chem. Waters RF. 14 15 16 17 18 19 20 21 22 213 . Minnesota. 24. 2002. 20. 1984. 14. 1. Blackwell Science Ltd. Slavin JL. Jeraci J and Van Soest P. Biological impacts of Arabinogalactans in humans: Ethnopharmacology and modern pharmacognosy. In: Handbook of dietary fiber in human nutrition. FDA GRAS Notification. Van Tassell RL. 2007. FCC Monograph. Causey J. 63. Kim LS. 21. 1993. Wager JD. Applied and Environmental Microbiology. 1996. 3. 1997. EAFUS: A Food Additive Database. Review article: prebiotics in the gastrointestinal tract. Am J Clin Nutr. Clinical Nutrition Supplements. McNeil NI. Nondigestible oligo-and polysaccharides (dietary fiber): their physiology and role in human health and food. 2002. FDA (Food and Drug Administration). 48. 1987. pectin. Boca Raton. Polysaccharide breakdown by mixed populations of human faecal bacteria. Prebiotic digestion and fermentation. 163-171. Mazur AW. Aliment Pharmacol Ther. Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects. 279-285. 1993.10. Robinson RR. arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system.) CRC Press. 96-103. Adv Dent Res. 73-80. Causey-O‘Brien JL. Journal of Pharmaceutical Sciences. Macfarlane GT. D'Adamo PJ. Double-Blind. 59-68. 2006. 50. Hay S. Wilkins TD. 41. 6. Journal of Naturopathic Medicin. McBain AJ. Effects of Low-Dose Larch Arabinogalactan From Larix Occidentalis: A Randomized. Affsa-Saisine no 2005-SA0098. 1990. FEMS Microbiology Ecology.alimentaires et l'apposition d'une allégation de type «fibre prébiotique». Macfarlane S. 2 3 4 5 6 7 8 9 10 11 12 13 Bayliss CE and Houston AP. Alternative Medicine Review. 560-563. Spiller GA (ed. Complementary Health Practice Review. Burkholder PM. 73-92. 2001. Hiler G. Nutritional benefits of larch arabinogalactan. 40-43. Englyst HN. Slavin JL. Consequences of biofilm and sessile growth in the large intestine. Macfarlane GT. Br J Nutr. 4. Federal Communications Commission. 371-376. Kelly GS. 443-451. Tungland BC and Meyer D. 2004. Derbyshire E. Studies on larch arabogalactan I. Consensus recommendations on the effects and benefits of fibre in clinical practice. Feirtag J. Englyst HN. 17-26. 2001a. Nursing standard. Cummings JH. PhD. Macfarlane GT. University of Minnesota. Interaction between human gut bacteria and fibrous substrates. 95.05. 1925-1930. Characterization of plant polysaccharide-and mucin-fermenting anaerobic bacteria from human feces. Macfarlane GT. Vince AJ. Comprehensive Reviews in Food Science and Food Safety. Robinson R. 11. McCleary BV and Prosky L (eds.). 701-714. Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. Tordoff MG and Alleva AM. Greenberg I. 52. Foltin RW. 1638-1644. 8. 1998. Van Wymelbeke V. including weight loss” 1 Blackburn GL. 29. Mela DJ. Fischman MW. 13-24. Am J Clin Nutr. Hesser MF. 128. The effect of sucrose. Blackburn GL. Mattes R. Am J Clin Nutr. 1998. hunger and food choice of female. Ashwell M.and aspartame-sweetened drinks on energy intake. McNelis AL. Whatley J. 58. Gibson S. Eur J Clin Nutr. 293-300. Adjustment in energy intake following the covert removal of sugar from the diet. moderately restrained eaters. 1037-1044. The effects of blind substitution of aspartame-sweetened for sugarsweetened soft drinks on appetite and mood. Kowalchuk MB. Caloric regulation in normal-weight men maintained on a palatable diet of conventional foods. Kanders BS. 10. J Nutr. Physiol Behav. 409-418. Lavin JH. 154-161. Prior RL. Vasilaras TH. Van Itallie TB. Serum antioxidant capacity is increased by consumption of strawberries. 73-84. Kelly TH. Nutrition Bulletin. Int J Obes Relat Metab Disord. Raben A.and long-term control of body weight. Lavin PT. Beridot-Therond ME. Appetite. 1997. 1992. 1997. 214 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 . Influence of repeated consumption of beverages containing sucrose or intense sweeteners on food intake. 2002. Extended use of foods modified in fat and sugar content: nutritional implications in a free-living female population. Effects of aspartame and sucrose on hunger and energy intake in humans. Gatenby SJ. Foltin RW. de La Gueronniere V. Am J Clin Nutr. 76. 13 (Suppl 1). 2383-2390. 115-128. Aaron JI. British Food Journal. 1988. Compensation for caloric dilution in humans given unrestricted access to food in a residential laboratory. van Itallie TB. 515. 254-259. 1990. Caloric. An evaluation of the effect of aspartame on weight loss. Am J Clin Nutr. 1990. 111. Kanders BS. 1989. 55. 721-729. 65. Foltin RW. Caloric compensation for lunches varying in fat and carbohydrate content by humans in a residential laboratory. 30. Rachlinski JJ. Porikos KP. Fischman MW. Reid M and Hammersley R. Read NW. 969-980. Am J Clin Nutr. Jack VA. Rolls BJ. 1867-1873. Lavin PT. 1982. 2004. 1977. Appetite. spinach. Moller AC. Keller SD. French SJ. Emurian CS. 2006. 1995. compensation by humans for required-eating occasions with meals and snack varying in fat and carbohydrate. 1990. red wine or vitamin C in elderly women.ID 1444: “Aspartame sucrose substitute” and “Weight control. Kowalchuk MB. Fantino M. but not macronutrient. Lischner N. Russell RM. Rolls BJ. Naismith DJ and Rhodes C. Physiol Behav. Evans E. 47. Blackburn GL. 1988. 21. 1997. 11 Suppl 1. 963-969. Effect of drinking soda sweetened with aspartame or high-fructose corn syrup on food intake and body weight. 37-42. Fischman MW. 65. Porikos KP. Moran TH. Int J Obes Relat Metab Disord. 331-342. Journal of Human Nutrition and Dietetics. Effect of withdrawal of artificial sweeteners on energy intake of stabilized post-obese women. Kelly TH. Moran TH. 100. Kanders BS. ID 1445: “Anthocyanins” and “Antioxidant” 1 Cao G. De la Hunty A. 1990. Effect of covert nutritive dilution on the spontaneous food intake of obese individuals: a pilot study. Am J Clin Nutr. 167-175. Astrup A. Do aspartame (APM) -sweetened foods and beverages in the long-term aid in long-term control of body weight? Am J Clin Nutr 51. 51. Booth G. 31. A review of the effectiveness of aspartame in helping with weight control. Am J Clin Nutr. Lavin JH. The effect of aspartame as part of a multidisciplinary weight-control program on short. Eur J Clin Nutr. 137. Folts JD.S. Cragg GM. 2002. Nutr Metab Cardiovasc Dis. 431-436. Uonomi T. Gebhardt SE. 2002. 1999. Blackman M. Jacob RA. Kay CD. 2005. 2000. Wiebe DA. Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. No. Carotenoids as singlet oxygen quenchers in marine organisms Fisheries Science. Am J Clin Nutr. Hayasaka Y. Joseph JA. New York. Kay CD and Holub BJ. Encyclopedia of Dietary Supplements. Haytowitz DB. Duthie GG. Jenkinson AM. Holub BJ. 7731-7737. Jialal I. Free Radic Biol Med. Prior RL. Grundy SM. 29. 19 170 . Partial resistance of low density lipoprotein to oxidation in vivo after increased intake of berries. Azumane A. Yamada T. 1244-1252. J Am Coll Nutr. Ahotupa M. Beecher GR. Mazza G. Twenty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives WHO Technical Report Series. 134-137. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. Sports performance benefits from taking natural astaxanthin characterized by visual acuity and muscle fatigue improvements in humans Journal of Clinical Therapeutics & Medicines. Circulation. Prior RL.88. The effect of wild blueberry (Vaccinium angustifolium) consumption on postprandial serum antioxidant status in human subjects. Evaluation of certain food additives and contaminants. Journal of Clinical Therapeutics and Medicines. Estimated dietary flavonoid intake and major food sources of U. Kader AA. Nagaki Y. Yoshigi H. 100. Wu X. Hayasaka S. J Nutr. 405-408. 2007. Concentrations of anthocyanins in common foods in the United States and estimation of normal consumption. Sotoudeh G. Song WO. Yamaguchi M. Levine MA. 2000. Wu X. Coates PM. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. 62. Effects of blueberry and cranberry juice consumption on the plasma antioxidant capacity of healthy female volunteers. Hakala P. Cottrell T. 683. Kyle J. Maki J. O'Byrne DJ. 1367-1374. J Agric Food Chem.2 3 4 5 6 7 Chun OK. Sawaki K. Br J Nutr. 21. Sanada M.173. Miki W. 78. Goto M. 2006. 2000. Takahashi N and Kajita M. Marniemi J. 2002. 76. 50. 51-60. 2002. 2007. Keevil JG. Aeschlimann S. 1050-1055. 570S-578S. White JD. Am J Clin Nutr. Shimidzu N. 170-181. Cook RA. 2005. Marcel Dekker. Aoki K. critical flicker fusion. Koikawa N. 54. 26. Youdim KA. 18 73 . Plasma antioxidant capacity changes following a meal as a measure of the ability of a food to alter in vivo antioxidant status. 2002. 389-398. 4069-4075. 10. McPhail DB. Kaneko K. 1996. Effects of astaxanthin on accommodative aecovery. 2007. Moss J. adults. Devaraj S. Gardner PT. 2003. 331-337. WHO/FAO (World Health Organization and Food and Agriculture Organization). Fruits and vegetables in the prevention of cellular oxidative damage. 1982. Prior RL. 88. Gu L. 3 4 5 215 . Holden JM. Effects of Astaxanthin on accommodation. Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. ID 1448: “Astaxanthin from Haematococcus pluvialis” and “Beneficial for eye health” 8 9 10 11 12 13 14 1 2 Notification pursuant to Article 5 of Regulation (EC) 258/97 of the European Parliament and of the Council for food supplements with astaxanthinrich oleoresin extracted from Haematococcus Pluvialis. Pedersen CB. Chung SJ. J Agric Food Chem. Journal of Traditional Medicines. Martin A. 54. Stein JH. and pattern visual evoked potential in visual display terminal workers. Margolis FL. Trends in Biotechnology. The effects of astaxanthin supplements on lipid peroxidation and antioxidant status in postmenopausal women. Effect on muscle fibre morphology and carnosine content after 12 days training of Korean speed skaters. Yamaguchi M. 210-216. 3-11. 63. 143. 1999. Kaikkonen J. Voutilainen S. 1998. Salonen JT. 18. 141-146. Olaizola M. 909-919. Voutilainen S. Greenhaff PL. ID 1450: “Astaxanthin from Haematococcus pluvialis” and “Supports a healthy cardiovascular system. Influence of oral beta-alanine and L-histidine supplementation on the carnosine content of the gluteus medius. Biochem J. Willan PL. Kim HJ. 21. 2007. 1991. 2002. Karppi J. Sawaki K. Olsson AG. 2004. Karppi J. 41-46. 31. 64. Lorenz RT. Kucera-Orallo CM. Dunnett M and Harris RC. 225. 62. Harris RC. Nyyssonen K. Eur J Appl Physiol Occup Physiol. 2003. Guerin M. Azumane A. Characterization of human tissue carnosinase. Koikawa N. Astaxanthin. Effects of astaxanthin supplementation on lipid peroxidation. Journal of Clinical Therapeutics & Medicines. 1-19. Int J Vitam Nutr Res. Peppers SC. Harris DB. 653-660. 77. Kaikkonen J. Wise JA. Sports performance benefits from taking natural astaxanthin characterized by visual acuity and muscle fatigue improvements in humans. 2007. 30. 7. Haematococcus astaxanthin: applications for human health and nutrition. Kim YK and Chyun J-H. 1085-1100. Pure and Applied Chemistry. Med Sci Sports Exerc. 543-548. 2000. 1994. 77. Aoki K. Grillo M. 16. J Neurochem. Miki W. J Exp Biol. Carnosine and taurine contents in individual fibres of human vastus lateralis muscle. George RP. Kaneko K. 7 8 216 . 2005. 37 (Suppl 5). Cameron JN. ID 1452: “Beta-alanine” and “Physical performance” 1 2 3 4 5 6 Bakardjiev A and Bauer K. Nature‘s Super Carotenoid. Sale C. Dunnett M. S192. Jakeman PM. Journal of Sports Sciences. 3-11. 7. Effects of astaxanthin supplementation on lipid peroxidation. 2007. 1992. Kim CJ. Dunnett M. 1989. 2004. Rissanen TH. Eur J Biochem. Equine Vet J Suppl. Int J Vitam Nutr Res. Carnosine and anserine concentrations in the quadriceps femoris muscle of healthy humans. 47-50. Horinishi H. 1985. Short Communication: Intracellular buffering by dipeptides at high and low temperature in the blue crab callinectes sapidus. 41-46. Mannion AF. Transport of beta-alanine and biosynthesis of carnosine by skeletal muscle cells in primary culture. Harris RC. Yoshigi H. BioAstin TM Technical Bulletin. Salonen JT. The effects of astaxanthin supplements on lipid peroxidation and antioxidant status in postmenopausal women. Nyyssonen K. 1978. Biological functions and activities of animal carotenoids.” 1 2 3 Notification pursuant to Article 5 of Regulation (EC) 258/97 of the European Parliament and of the Council for food supplements with astaxanthinrich oleoresin extracted from Haematococcus Pluvialis. Purification and characterization of carnosine synthetase from mouse olfactory bulbs.ID 1449: “Astaxanthin from Haematococcus pluvialis” and “Supports a healthy oxidative balance” 1 2 3 4 5 6 7 Notification pursuant to Article 5 of Regulation (EC) 258/97 of the European Parliament and of the Council for food supplements with astaxanthinrich oleoresin extracted from Haematococcus Pluvialis. Nutritional Sciences. Harris RC. Lenney JF. 617-623. Nutritional Sciences. 639-643. Olsson AG. Rissanen TH. Kim YK and Chyun J-H. 499-504. 2007. 228. Huntley ME. 217 . Saito K. balenine and carnosine in skeletal muscle. Combined training and ß-alanine supplementation muscle carnosine synthesis. 225-233. Harris RC. O'Kroy J. Stout JR. S348. 37. 199-205. Mukai N. S364. Harris RC. 725-729. Cramer JT. 2007. Takamatsu K. Sale C. Torok DJ. Harris RC. Hama T. 2007. Torok DJ. High level of skeletal muscle carnosine contributes to the latter half of exercise performance during 30-s maximal cycle ergometer sprinting. Stout JR. Wise JA. Kim C. 2002. Mielke M. Med Sci Sports Exerc. Tsunemori F. Kim HJ. Lee YW. Kim CK. Kim H. Zoeller RF. 39. 20. 39. Sale C. 2007. Influence of betaalanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Cramer JT. 32. Bulletin of the Japanese Society of Scientific Fisheries. Torok D. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Harris BD. 52. O'Kroy J. Amino Acids. 381-386. Suyama M. Amino Acids. Determination of carnosine. Zoeller RF. 32. 1988. Cramer JT. Harris RC. Boobis LH. 2006. Wise JA. 331-340. Hoffman JR. The Journal of Strength and Conditioning Research. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Jpn J Physiol. Med Sci Sports Exerc. Tallon MJ. S364. 1977. 2005. ID 1455: “Beta-alanine” and “Beta-alanine reduces muscle fatigue” 2 3 4 1 Hill CA. 2006. Kim HJ. 69-78. Boobis LH. Kim CK. CE. 23. 32. An evaluation of a method to differentiate the species of origin of meats on the basis of the contents of anserine. 45.9 Plowman JE and A. Harris DB. 36. Suzuki Y. Cramer JT. 2007. Combined training and ß-alanine supplementation muscle carnosine synthesis. Tamaki N. Influence of betaalanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Harris RC. Boobis LH. Kim H. Harris BD. Hoffman JR. Effects of beta-alanine supplementation on the onset of neuromuscular fatigue and ventilatory threshold in women. and balenine in the muscle of animal. Wise JA. Kim HJ. The effect of beta-alanine and creatine monohydrate supplementation on muscle composition and exercise performance. 381-386. Stout JR. Harris DB. Fallowfield JL. Costa P. Effect of histidine-free and -excess diets on anserine and carnosine contents in rat gastrocnemius muscle. 32. Costa P. Harris RC. Wakabayashi M. ID 1453: “Beta-alanine” and “Beta-alanine improves exercise performance” 10 11 12 13 1 Hill CA. 2007. ventilatory threshold and exercise capacity in cyclists. Amino Acids. Sale C. Zoeller RF. O'Kroy J. Amino Acids. Wise JA. Maruyama M. Boobis L. Wise JA. Journal of the Science of Food and Agriculture. 2007. Zoeller RF. O'Kroy J. J Strength Cond Res. Harris RC. 19. Torok D. 928-931. J Nutr Sci Vitaminol (Tokyo). 1970. Stout JR. anserine. Wise JA. Ito O. ID 1454: “Beta-alanine” and “Beta-alanine improves cycling performance” 2 3 4 1 Hill CA. Sale C. Harris RC. Mielke M. Sale C. Takahashi H. The carnosine content of vastus lateralis is elevated in resistance-trained bodybuilders. Lee YW. Suzuki T. Med Sci Sports Exerc. The Journal of Strength and Conditioning Research. Kim C. 225-233. 1048-1053. Effects of beta-alanine supplementation on the onset of neuromuscular fatigue and ventilatory threshold in women. 2005. 928-931. 20. ventilatory threshold and exercise capacity in cyclists. Boobis LH. Wise JA. ID 1457: “Beta-alanine” and “Beta-alanine increases muscle carnosine stores” 2 3 4 5 1 Harris RC. Torok DJ. Harris RC. Wise JA. Bui TT. Edge J. Stout JR. Kim H. Wise JA. Amino Acids. Wise JA. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Lam TQ. Torok DJ. Snow DH. Harris RC. Costa P. 21. Sale C. 2005. Cramer JT. Effects of beta-alanine supplementation on the onset of neuromuscular fatigue and ventilatory threshold in women. Zoeller RF. 2006. S348. O'Kroy J. Kim H. 381-386. Dang VH. 21. Sale C. 2007. Influence of betaalanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Dunnett M. 37. 279-289. The effect of beta-alanine and creatine monohydrate supplementation on muscle composition and exercise performance. Cramer JT. Zoeller RF. Harris RC. Harris RC. Hill CA. Coakley J. Dunnett M. Mielke M. Jones G. Hill CA. Harris RC. Harris DB.2 Hill CA. Wise JA. 225-233. Comp Biochem Physiol A Comp Physiol. Kim CK. Harris RC. A943. Harris BD. Kendrick IP. The Journal of Strength and Conditioning Research. The absorption of orally supplied beta-alanine and its effect on muscle carnosine synthesis in human vastus lateralis. Hoffman JR. Amino Acids. Harris RC. Boobis L. ventilatory threshold and exercise capacity in cyclists. 2007. Zoeller RF. 32. 20. Stout JR. Torok D. 2007. Zoeller RF. O'Kroy J. Tallon MJ. Harris RC. Hill CA. Boobis L. 928-931. Hultman E. ventilatory threshold and exercise capacity in cyclists. Stout JR. 39. 16. Combined training and ß-alanine supplementation muscle carnosine synthesis. Harris RC. Kim CK. 32. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Kim H. The effect of beta-alanine and creatine monohydrate supplementation on muscle composition and exercise performance. Lee YW. The carnosine content of V lateralis in vegetarians and omnivores. 2007b. Kim HJ. A944. 249-251. Torok D. Harris BD. Kim HJ. O'Kroy J. Boobis L. Wise JA. Kendrick IP. FASEB J. 39. greyhound dog and man. Sale C. Hill CA. 2007. Marlin DJ. Amino Acids. Amino Acids. Sale C. The Journal of Strength and Conditioning Research. Carnosine and taurine contents in individual fibres of human vastus lateralis muscle. 2006. 32. 2006. 928-931. 381-386. Mielke M. O'Kroy J. Cramer JT. 1998. Sale C. Influence of betaalanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Med Sci Sports Exerc. 30. Med Sci Sports Exerc. Costa P. 2 3 4 5 6 218 . 20. Cramer JT. Harris RC. Kim HJ. Kim HJ. Lee YW. 2007. 2007. Kim HJ. Muscle buffering capacity and dipeptide content in the thoroughbred horse. Kim C. 37. Journal of Sports Sciences. Harris RC. Dang VH. The effect of whole body physical training on the carnosine content of V lateralis. Kim C. Boobis L. 2005. Boobis LH. Hoffman JR. Wise JA. Kim H. 639-643. Greenhaff PL. Harris DB. Med Sci Sports Exerc. Kim C. 32. S364. Kim C. Fallowfield JL. Combined training and ß-alanine supplementation muscle carnosine synthesis. Wise JA. 225-233. Harris RC. Sale C. Dunnett M. 1990. S348. 2007a. Wise JA. S364. ID 1456: “Beta-alanine” and “Beta-alanine improves muscle work capacity” 3 4 5 1 Hill CA. FASEB J. Amino Acids. Med Sci Sports Exerc. 97. Effects of beta-alanine supplementation on the onset of neuromuscular fatigue and ventilatory threshold in women. Sale C. Stout JR. 2001. Ovalle WK. Southon S. 853-864. 1985. Del Vecchio AJ. 272-278. 2002. Thieme. 52. Roza L. 32. Influence of betaalanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. 170-176. Harris BD. 39. 58. Kim HJ. Sale C. Harris RC. S165-177. 2002. The immune system: a target for functional foods? Br J Nutr. Köhrle J. Ernährungsmedizin. Management of acute and cutaneous porphyrias. Gustav Fischer. Systemic photoprotection with alpha-tocopherol (vitamin E) and beta-carotene. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. 88 Suppl 2. 199-205. Golly I. Pölert W. Harris RC. Sale C. Kim CK. Wise JA. Boobis LH. Puchstein C. 2004. Harris RC. 2002. S364. Kasper H. Fürst P. UV light. Combined training and β-alanine supplementation muscle carnosine synthesis. Increased cellular carotenoid levels reduce the persistence of DNA single-strand breaks after oxidative challenge. Calder PC and Kew S. 2007. 202-213. Harris BD. Thieme Stuttgart. Dietary carotenoids contribute to normal human skin color and UV photosensitivity. 725-729. Nutritional skin care: health effects of micronutrients and fatty acids. Sale C. 14-17. Stuttgart. Kim HJ. Jena. Clin Exp Dermatol. Stahl W. The carnosine content of vastus lateralis is elevated in resistance-trained bodybuilders. 78. Kim CK. Suzuki Y. Buffering capacity of deproteinized human vastus lateralis muscle. Med Sci Sports Exerc. Biesalski HK. 2002. 2002. ID 1458: “Beta-alanine” and “Beta-alanine increases carnosine stores in fast twitch muscle fibres” 8 9 10 11 1 Hill CA. Influence of betaalanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. 134. Kluthe R. Pietrzik K. Ito O. Boelsma E. 73. Badminton MN and Elder GH. Tallon MJ. Nutr Cancer. 225-233. 32. 43. Heinrich U. 225S-230S. Bässler KH. J Strength Cond Res. Schümann K. Alaluf S. Bendich A. Kim C. J Nutr. Archer DB. Harris RC. Amino Acids.7 Hill CA. 399-403. Takamatsu K. Journal of the American Oil Chemists' Society. ventilatory threshold and exercise capacity in cyclists. ID 1460: “Beta-Carotene” and “Antioxidant properties/Protection of DNA” 1 2 3 4 5 6 7 8 9 10 11 12 13 Liste der in der Schweiz zulässigen Anpreisungen für Vitamine und Mineralstoffe. Int J Clin Pract. Amino Acids. Biesalski HK and Obermueller-Jevic UC. Wise JA. From 1989 to 2001: what have we learned about the "biological actions of betacarotene"? J Nutr. Elliott RM. 2005. Vitamin-Lexikon für Ärzte. 389. Stuttgart. beta-carotene and human skin--beneficial and potentially harmful effects. Boobis LH. Astley SB. McKenzie DC. Kim H. Anstey AV. Tronnier H. 27. 2001. Nutritional and potential disease prevention properties of carotenoids. Loew D. High level of skeletal muscle carnosine contributes to the latter half of exercise performance during 30-s maximal cycle ergometer sprinting. Parkhouse WS. Jpn J Physiol. Vitamine. Mukai N. 219 . Flider F. Harris DB. 56. Lee YW. 2001. 2007. Hochachka PW. Wiseman S. Biesalski H-K. Hendriks HF. Fallowfield JL. 2002. 19. Stählin HB. Am J Clin Nutr. Apotheker und Ernährungswissenschaftler. Boobis LH. 225-233. 2007. 2002. Basu HN. Wise JA. 2002. 2004. J Appl Physiol. Orthoeter FT. 132. Arch Biochem Biophys. 1-6. Wise JA. 665-675. Takahashi H. Divergent optimum levels of lycopene. Eugen Ulmer Verlag. Bernhardt J. Heinrich F. Bhawan J. Umschau Braus Verlag. 503-506. Darr D and Fridovich I. 182-189. Stahl W. S44-50. Int J Sports Med. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 220 . Carotenoid actions and their relation to health and disease. Michel L. Sterry W. 1991. J Invest Dermatol. Effect of supplemented and topically applied antioxidant substances on human tissue. Stuttgart. 2000. Wissenschaftliche Verlagsgesellschaft. L-ascorbic acid and beta-carotene in cutaneous photoprotection. Nutrition and immunity: lessons from the past and new insights into the future. Prävention. Ströhle A. Ribaya-Mercado JD. Hahn A. S45-52. Mol Aspects Med. 726-733. Chandra RK. Sies H. Stuttgart. Steere E. 84. 2005. 2001. Hopfenmüller W. 2006. 284-288. Photodermatol Photoimmunol Photomed. Dennis B. 26. Kosa K. 2008. Potentials and limitations of the natural antioxidants RRR-alpha-tocopherol. Heinrich U. 102. 2006. 200-205. 459-516.14 Cesarini JP. 1995. Russel RM. Committee on Military Nutrition Research. 19. Chun SC. Free radicals in cutaneous biology. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH. Maurette JM. Tronnier H. Biesalski HK. Skin Pharmacol Appl Skin Physiol. Lademann J. 1998. 6171. 2005. Hahn A. 307-315. Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. Stuttgart. J Nutr. Chen LC. Ambach A. Stuttgart. Heiss G. Exp Dermatol. Provitamin A carotenoid intake and carotid artery plaques: the Atherosclerosis Risk in Communities Study. Vitamin A in epithelial differentiation and skin carcinogenesis. Gollnick H. Therapie. beta-carotene and lutein protecting against UVB irradiation in human fibroblastst.Schweizerische Vereinigung für Ernährung). Celli G. Ernährung des Menschen. Stahl W. Schmid C. Gleeson M and Bishop NC. Am J Clin Nutr. Ernährung–Physiologische Grundlagen. 15. Eichler O. Darvin M. Protection from sunburn with beta-Carotene--a meta-analysis. Elite athlete immunology: importance of nutrition. Jones C. 25. 104-111.Österreichische Gesellschaft für Ernährung Schweizerische Gesellschaft für Ernährungsforschung . Photochem Photobiol. Deutsche Apotheker Zeitung. Sundermeier K. Free Radic Biol Med. Bejot M. 68. Effect of beta-carotene supplementation on the human sunburn reaction. Kritchevsky SB. Gilchrest BA. 1990 McCollum Award lecture. Systemic beta carotene plus topical UV-sunscreen are an optimal protection against harmful effects of natural UV-sunlight: results of the Berlin-Eilath study. Grundmann JU. 1996. 133. Wolters M. Daniel H and Benterbusch R. Nutr Rev. Ernährung und Immunsystem. 238-247. Li R. Tell GS. Hemmes C. Fuchs J. Shimakawa T. 1999. Am J Clin Nutr. 131. 52. Biesalski HK. 848-873. 2002. Krinsky NI and Johnson EJ. 1998. 1988. 21 Suppl 1. De Luca LM. 2000. Wissenschaftliche Verlagsgesellschaft mbH. Kohlmeier L. Referenzwerte für die Nährstoffzufuhr. 6. Photochem Photobiol. 1087-1101. Garmyn M. Zastrow L. carotenoids. 98-101. Sies H. 2002. European Journal of Dermatology. Adhoute H. Nahrungsergänzungsmittel Fakten und Daten der zur Nahrungsergänzung meistverwendeten Stoffe. 1991. 671-675. 1994. Pfitzner I. Wiebusch M. Ross S. Activity Report 1994-1999. Greul AK. D-A-CH (Deutsche Gesellschaft für Ernährung . 4. selenium and proanthocyanidins. Gollnick H. Skin Pharmacol Physiol. 75. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. Kopcke W and Krutmann J. Gartner C. 1994. 2003. 53. Frankfurt am Main. 2003. Eichler O. 19. Elmadfa I and Leitzmann C. Darwiche N. Hahn A. J Am Coll Nutr. 18. Carotenoids. 2002. Biochim Biophys Acta. Ross C (eds. Increased dermal carotenoid levels assessed by noninvasive reflection spectrophotometry correlate with serum levels in women ingesting Betatene. Skin Pharmacol Appl Skin Physiol. Hippokrates. Baltimore. Jack CI. 59. 1997. Carotenoid intake in the German National Food Consumption Survey. McArdle F. Krinsky NI. Heinrich U. 2001. Jiang S. 15. Sies H. Medeiros MH. Am J Clin Nutr. 54-60. 101-107. Parrish J. Friedmann PS. 2004. Philadephia. 2006. Sies H. 291-296. Bioactivity and protective effects of natural carotenoids. Boca Raton. Lippincott Williams & Wilkins. 2005. Hahn A. Levy Y. Boca Raton. Dietary antioxidants and beneficial effect on oxidatively damaged DNA. Vitamin A. Stahl W and Sies H. 41. Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans. Rhodes LE. Brehme U. Löffler G and Petrides PE. Pathak MA. 1998. A clinical trial of the effects of oral beta-carotene on the responses of human skin to solar radiation. Parslew RA. Kass EH. Ann Nutr Metab. Heinrich U. Stahl W. 2000. Silva AA. Biochemie und Pathobiochemie. 903-907. Effects of oral vitamin E and beta-carotene supplementation on ultraviolet radiation-induced oxidative stress in human skin. Tronnier H. 39. 170-174. 1270-1275. Stahl W and Sies H. Pelz R. Heimann JC. Braz J Med Biol Res. Moller P and Loft S. Paiva SA and Russell RM. Baltimore. Mathews-Roth MM. Palozza P. Springer. Mason P. J Nutr. 80. 388-415.). Stahl W and Sies H. Shike M. Aviram M. Leitzmann C. Annu Rev Nutr. Nutr Rev. Fitzpatrick TB. Kanter Y. Spallholz JE. Heseker H. Shils ME. 257-265. In: Carotenoids in Health and Disease. 128. Carotenoids and protection against solar UV radiation. 1972. Di Mascio P. Matos HR. Dietary supplementation of a natural isomer mixture of beta-carotene inhibits oxidation of LDL derived from patients with diabetes mellitus. Lycopene and beta-carotene protect in vivo iron-induced oxidative stress damage in rat prostate. 1993. Boylan LM. Zaltsberg H. Lippincott Williams & Wilkins. Mayne ST. Proc Soc Exp Biol Med. Close GL. 349-353. 2004. Jungmann H. Marques SA. Driskell JA. 2000. 1998. Stahl W. Carotenoids in systemic protection against sunburn. Philadephia. Ross C (eds. 2000. Stahl W and Sies H. 2004. CRC Press. Free Radic Biol Med. Ross AC. Am J Clin Nutr. Gomes OF. Jackson MJ. 1998. J Invest Dermatol. Carotenoids and intercellular communication via gap junctions. 10-19. Sies H (eds. 364-367. Shike M. Int J Vitam Nutr Res. Sies H and Stahl W. Schmidt-Faber B. 691. 37. 2006. Müller C. 491-502. In: Modern Nutrition in Health and Disease. 221 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 . London. 1999. Laube H. 1998. Z Ernahrungswiss. Heidelberg. 1999. CRC press. 1999. 426-433. 795-798.). 71. Physical quenching of singlet oxygen and cis-trans isomerization of carotenoids. Nutrition: Chemistry and Biology. In: Modern Nutrition in Health and Disease. Stuttgart. 56. von Laar J. 24. Nutritional protection against skin damage from sunlight. Dietary Supplements. Clemens W. Olson JA. Pharmaceutical Press. Carotenoid supplementation reduces erythema in human skin after simulated solar radiation exposure. Ben-Amotz A. Sies H and Stahl W. Olson JA. Watson RR. Olson JA.). Jungmann H. 203-210. Michel P. Ann NY Acad Sci. 223. Tronnier H. 1999. Beta-carotene and other carotenoids as antioxidants. 351-375.36 37 38 Lee J. 319-327. 67. 1740. Toda K. Prooxidant actions of carotenoids in biologic systems. Schietzel M. 44. Shils ME. Ernährung in Prävention und Therapie. 2001. 173-200. 525-539. Levine N. J Photochem Photobiol B. Bejot M. Pool-Zobel BI. Green A. ID 1461: “Beta-Carotene” and “Skin aging/Skin health” 62 63 64 65 66 67 68 1 2 3 Alaluf S. Boelsma E. 558-561. 1997. 383-389. 2000. Free Radic Res. 39. 182-189. 1999. Biesalski H-K. J Nutr. Heinrich U. Michel L. Chew BP and Park JS. 399-403. Honigsmann H. Hendriks HF. Bub A. Yeum KJ. Nutritional skin care: health effects of micronutrients and fatty acids. Participation of singlet oxygen in ultraviolet-a-induced lipid peroxidation in mouse skin and its inhibition by dietary beta-carotene: an ex vivo study. Nagao A. Am J Clin Nutr. 41. 215-224. 19. 853-864. 1996. Carotenoids and cardiovascular health. 368-377. psoralen phototoxicity. Mursu J. 1854-1863. Johnson EJ. Hopfenmuller W. Rissanen TH. 1997. Zhao X. Ernährungs-Umschau. 80-85. The use of endogenous antioxidants to improve photoprotection. Köhrle J. Hippokrates. 1999. Biesalski HK. 55-57. and immune function. Photodermatol Photoimmunol Photomed. Watzl B and Leitzmann C. Vitamine. Stuttgart. Aldini G. the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. Terao J. Yamauchi R. 2004. Br J Nutr. 2002. Williams DL. Miyoshi M. Tronnier H. Bässler KH. 1-10. Pietrzik K. J Nutr. 82. 134. 83. 2000. Watzl B. 1988. 2002. 1994. Annu Rev Nutr. Topical beta-carotene is converted to retinyl esters in human skin ex vivo and mouse skin in vivo. 4 5 6 7 8 9 10 222 . Hayashi H. Woolf H. 24. Gollnick HP. Rechkemmer G. Eur J Nutr. Urban & Fischer Battistutta D. Loew D. 41. Inakuma T. Stephensen CB. 2006. Hansch GM. Roza L. 37. Stuttgart. Carotenoid action on the immune response. Watzl B. 257S-261S. Adhoute H. Vitamin A. Vitamin-Lexikon für Ärzte. 83. Burgerstein's Handbook of Nutrition: Micronutrients in the Prevention and Therapy of Disease. Voutilainen S. Musaeus N. Krinsky NI. 2001. 21. 2001. 2001. Schmid C. Brandstetter BR. Bioaktive Substanzen in Lebensmitteln. San Francisco. Stahl W. Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. Torbergsen AC and Collins AR. Free Radic Biol Med. 2004. Sorg O. Wakamatsu S. infection. Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. Zimmermann M. 2006. Tran C. Modulation of human T-lymphocyte functions by the consumption of carotenoid-rich vegetables. Antille C. 13. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Maurette JM. Thieme. Wolf C. Kraemer K. and ultraviolet-induced DNA damage? J Invest Dermatol. 132. 90. Am J Clin Nutr. Ernaehrung und Immunsystem. 13th International Congress on Photobiology. Exp Dermatol. Rasmussen H. Am J Clin Nutr. Saurat JH. Effects of controlled exposure of sunlight on plasma and skin levels of beta-carotene.59 60 61 Steenvoorden DP and van Henegouwen GM. Russell RM. Cesarini JP. Effectiveness of daily sunscreen application and b-carotene intake for prevention of photaging: A community-based randomised trial (Abstract 58). 163-169. Steiner A. 2003. Nurmi T. Thieme Stuttgart. Do oral carotenoids protect human skin against ultraviolet erythema. 1265-1271. Recovery of human lymphocytes from oxidative DNA damage. Schümann K. 73. 2004. Golly I. Bando N. Apotheker und Ernährungswissenschaftler. 167-192. Dietary carotenoids contribute to normal human skin color and UV photosensitivity. Hemmes C. Wiseman S. Sundermeier K. Kurten V. Biesalski HK. 2008. Herraiz LA. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH. Bhawan J. Kass EH. 617-624. carotenoids. Effect of beta-carotene supplementation on photosuppression of delayed-type hypersensitivity in normal young men. J Nutr. Hopfenmüller W. European Journal of Dermatology. Jack CI. 1993. Ann NY Acad Sci. Sies H. Hahn A. 655-659. 1999. Close GL. Grundmann JU. Levine N. 84. 170-174. Swanson JE. Proc Nutr Soc. 307-315. 284-288. Skin Pharmacol Physiol. 1270-1275. Heinrich U. Britton G. Greul AK. Jackson MJ. 224-231. Hahn A. 2003. 2005. Referenzwerte für die Nährstoffzufuhr. Bendich A. Prävention. Nutrition. 19. Basel. Parslew RA. Gilchrest BA. Lee J. 2006. 200-205. Effects of carotenoids on human immune function. 713-718. Schmid C. Therapie. 127-138. Photochem Photobiol. Hsieh WC. Jiang S. Umschau Braus Verlag. Wiebusch M. Wild S.11 D-A-CH (Deutsche Gesellschaft für Ernährung . selenium and proanthocyanidins. Chun SC. Ernährung–Physiologische Grundlagen. Effect of beta-carotene supplementation on the human sunburn reaction. Carotenoid supplementation reduces erythema in human skin after simulated solar radiation exposure. Friedmann PS. 691. Enhancement of the UVA induction of haem oxygenase-1 expression by beta-carotene in human skin fibroblasts. J Invest Dermatol. 80. 2004. 4. 56. 2009. 349-353. Roe DA. Proc Soc Exp Biol Med. 2001. Goralczyk R. Gartner C. 17. Toda K. Ströhle A. J Am Coll Nutr. Frank J. 58. Betacarotene supplementation protects from photoaging-associated mitochondrial DNA mutation. Kopcke W and Krutmann J. 223. Gollnick H. Boston. Stuttgart. Goralczyk R and Wertz K. Wolters M. Effect of UV exposure and beta-carotene supplementation on delayed-type hypersensitivity response in healthy older men. Heinrich U. Gollnick H. Wissenschaftliche Verlagsgesellschaft. Stahl W. Ribaya-Mercado JD. 2. Hughes DA.Schweizerische Vereinigung für Ernährung). Francz PI. Pfitzner I. Birkhäuser Verlag. Parrish J. Heinrich U. Photochem Photobiol Sci. Parker RS.Österreichische Gesellschaft für Ernährung Schweizerische Gesellschaft für Ernährungsforschung . 142-215. Tronnier H. Ambach A. Skin Pharmacol Appl Skin Physiol. 1998. Garmyn M. Mathews-Roth MM. Am J Clin Nutr. Russel RM. 1972. Photoprotection of UV-irradiated human skin: an antioxidative combination of vitamins E and C. 2006. Hughes DA. 1996. Stuttgart. 59. Exp Dermatol. Fitzpatrick TB. Eichler O. Antioxidant supplements improve parameters related to skin structure in humans. Biesalski HK. Eicker J. Pfander H (eds. 223 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 . 2. Bendich A. Clemens W. Krutmann J. 15. Hemmes C. 2002. Pathak MA. Bejot M. Rhodes LE. Berneburg M. 6. Am J Clin Nutr. Heinrich F. 98-101. Tronnier H. Flaccus A. Protection from sunburn with beta-Carotene--a meta-analysis. Stahl W. 684-690. 460. Systemic beta carotene plus topical UV-sunscreen are an optimal protection against harmful effects of natural UV-sunlight: results of the Berlin-Eilath study. Biesalski HK. Effects of oral vitamin E and beta-carotene supplementation on ultraviolet radiation-induced oxidative stress in human skin. 17. 133. Mathews-Roth MM. Fuller CJ. 1996. Kosmetische Medizin. Frankfurt am Main.). Riss G. 2000. 1999. Skin photoprotection by carotenoids. 2000. Parker RS. In: Carotenoids Volume 5 Nutrition and Health. Maurette JM. Liaaen-Jensen S. 104-111. 2003. Obermuller-Jevic UC. Carotenoids in erythropoietic protoporphyria and other photosensitivity diseases. A clinical trial of the effects of oral beta-carotene on the responses of human skin to solar radiation. McArdle F. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. 1992. Watson RR. 1995. 212-216. 823-827. Dietary carotenoids and human immune function. Faulkner H. Bernhardt J. FEBS Lett. Roe DA. 1023-1033. 1293-1303. 55-57. Goralczyk R. Heinrich U. Lesourd B. Microfluorometry using fluorescein diacetate reflects the integrity of the plasma membrane in UVA-irradiated cultured skin fibroblasts. Someya K. 124. betaCarotene interferes with ultraviolet light A-induced gene expression by multiple pathways. 215-224. Calder PC. 40. 225S-230S. Hunziker W. and ultraviolet-induced DNA damage? J Invest Dermatol. 1998. beta-Carotene uptake and effects on intracellular levels of retinol in vitro. Ultraviolet light induced injury: immunological and inflammatory effects. J Dermatol Sci.). Tyrrell RM. Steiner A. Riss G. 42. Effect of beta-carotene supplementation on photosuppression of delayed-type hypersensitivity in normal young men. Free Radic Biol Med. Wyss A. Seifert N. Skoog ML. 1988.32 33 O'Connor I and O'Brien N. Immunol Cell Biol. 32. Nutr Cancer. Hemmes C. 1992. Ross C (eds. Antoine JM. Heinrich U. Olson JA. Kitano H. Goralczyk R. Philadephia. 389. 525-539. Scaletta C. 94. 2000. Avanti O. Offord EA. Tronnier H. Faulkner H. 90. Goralczyk R. 71. Beta-carotene inhibits UVA-induced matrix metalloprotease 1 and 10 expression in keratinocytes by a singlet oxygen-dependent mechanism. 2003. 1999. 134. 226-230. Effects of controlled exposure of sunlight on plasma and skin levels of beta-carotene. Pure and Applied Chemistry. 456-464. Miyazawa T. 56. vitamin E. 37. 684-690. 79. 1996. Hunziker W. 37-42. Biesalski HK. Seifert N. Arch Biochem Biophys. Seifert N. Stahl W. Free Radic Res. Free Radic Biol Med. Riss G. 1539-1550. Shike M. Wertz K. Free Radic Biol Med. 1998. Am J Clin Nutr. Trekli MC. 2001. Photoprotective potential of lycopene. Skogh M. Am J Clin Nutr. Parker RS. Wertz K. Do oral carotenoids protect human skin against ultraviolet erythema. Sies H. Samartin S. Clydesdale GJ. 428-434. 2002. vitamin C and carnosic acid in UVA-irradiated human skin fibroblasts. UV light. Tronnier H. Beta-carotene suppresses UVA-induced HO-1 gene expression in cultured FEK4. Murakoshi M. J Nutr Sci Vitaminol (Tokyo). Wolf C. Goralczyk R. 53-58. 30. Sanderson IR. Applegate LA. 2005. Wyss A. 303314. Shils ME. psoralen phototoxicity. Fuller CJ. The effect of natural carotenoid (palm fruit carotene) intake on skin lipid peroxidation in hairless mice. 2001. Photodermatol Photoimmunol Photomed. 2005. Wamer WG. Honigsmann H. Jungmann H. 1997. Van Loo J. Biesalski HK and Obermueller-Jevic UC. Hunziker PB. In: Modern Nutrition in Health and Disease. Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans. Olson JA. 24. Markers to measure immunomodulation in human nutrition intervention studies. Bendich A. Bendich A. 13. Evidence for antioxidant nutrientsinduced pigmentation in skin: results of a clinical trial. 1994. Watzl B. Modulation of UVA light-induced oxidative stress by beta-carotene. ID 1463: “Beta-Carotene” and “Immune health in relation to UV-radiation” 34 35 36 37 38 39 40 41 42 43 44 1 Albers R. Carotenoids. 78. 34. Runge F. 2004. Baltimore. Lambert LA. 1-6. Jungmann H. 2004. Schmid C. Gautier JC. Muller HK. Hunziker PB. Hopfenmuller W. J Invest Dermatol. Roe DA. Steiner G. Kornhauser A. Ollinger K. Postaire E. Riss G. 795-798. Gleeson M. Wei RR. Vas Dias FW. 452-481. Bourdet-Sicard R. Hunziker PB. Kramer K. 2006. beta-carotene. Dandie GW. Riss G. beta-carotene and human skin--beneficial and potentially harmful effects. 1997. From 1989 to 2001: what have we learned about the "biological actions of betacarotene"? J Nutr. Lippincott Williams & Wilkins. Wertz K. Biochem Mol Biol Int. 547-568. Beta-carotene interference with UVA-induced gene expression by multiple pathways. Br J Nutr. Gollnick HP. 654-670. Lankin C. lutein and astaxanthin in cultured fibroblasts. Totsuka Y. 16. Neeb M. Bejot M. 2 3 4 5 6 224 . Bub A. 64. Hopfenmüller W. Leka LS. The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans. Hennekens CH. NHPD) Food and Drug Regulations Section B. Mayne S. β-carotene supplementation enhances lymphocyte proliferation with mitogens in human peripheral blood lymphocytes. 1988. 47. Darban H. Meydani M. Carotenoids in systemic protection against sun-burn. Moseneder J. Ultraviolet light-induced reductions in plasma carotenoid levels. Hemmes C. Nutr Res 16. Roe DA. Wise J. Herraiz LA. Ann Nutr Metab. Hicks MJ. Zhang Z. 1991. London. White WS. Immune function in elderly smokers and nonsmokers improves during supplementation with fruit and vegetable extracts. Santos MS. J Am Coll Nutr. 200-205. Doi T. de la Consommation et de la Répression des fraudes) du 7 octobre 1997. 1996. Dietary Supplements. Mason P. 101-107. 2004. Sundermeier K. Sumida S. 2. Wood SM. Lee J. the Natural Health Products Directorate. 1998. 68. Santos MS. 1052-1058. Schmid C. Cutis. European Journal of Dermatology 6. Solkoff D. Beckham C. Sampliner RE. Briviba K. Bioactivity and protective effects of natural carotenoids. Fotouhi N. 255-261. Stahl W and Sies H. 1996. Watzl B. 85-92. Sies H (eds. 1996. Beta-caroteneinduced enhancement of natural killer cell activity in elderly men: an investigation of the role of cytokines. Integr Med. Am J Clin Nutr. Rechkemmer G. Granstein RD and Matsui MS. A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy. Kim CI. nonsmoking men. Okamura K. Effect of UV exposure and beta-carotene supplementation on delayed-type hypersensitivity response in healthy older men. 1999. Kishino Y.). 3-10.01. 2003. 1998. Inserra PF. Systemic beta carotene plus topical UV-sunscreen are an optimal protection against harmful effects of natural UVsunlight: results of the Berlin-Eilath study. 617-624. Leka L. Meydani SN. Biochim Biophys Acta. 4-9. Integrative Medicine. Barth SW. 1556-1560. 67. Garewal HS. Cancer. 2005. 2004. Meydani SN. Hsieh WC. 47. Pharmaceutical Press. Bendich A. 2.603. 491-502. Watson RR. ID 1464: “Beta carotene in combination with vitamin E and vitamin C” and “Eye health and vision” 8 9 10 11 12 13 14 15 16 17 18 19 20 21 1 Avis de la commission interministérielle d‘étude des produits destinés à une alimentation particulière (CEDAP) en date du 18 décembre 1996 sur les recommandations relatives au caractère non trompeur des seuils des allégations nutritionnelles fonctionnelles. Jiang S. Yosioka A. Natural killer cell activity in elderly men is enhanced by beta-carotene supplementation. 74. Parker RS. 2 3 225 . UV radiation-induced immunosuppression and skin cancer. Permitted Health Claims (Health Products and Food Branch of Health Canada. Roe DA. Chun S. Okishima N. Supplementation of a low-carotenoid diet with tomato or carrot juice modulates immune functions in healthy men. beta-Carotene and selenium supplementation enhances immune response in aged humans. Am J Clin Nutr. 2001. Hennekens CH. Am J Clin Nutr. Kalkwarf HJ. 17. 164-170. Krinsky N. Xu M. 2005. Stahl W and Sies H. Prabhala RH. 772-777. Moriguchi S. Bub A.7 Gollnick HP. Watzl B. Marcel Dekker. K BH. Gaziano JM. 879-883. BOCCRF (Bulletin Officiel de la Concurrence. Swanson JE. Am J Clin Nutr. In: Carotenoids in Health and Disease. Hesslink R. Ordonnance du Conseil Fédéral Suisse du 23 novembre 2005 sur les denrées alimentaires et les objets usuels (ODAIOUs). 82. 2000. Watson RR. 1740. Kulling SE. Watson RR. Gaziano JM. 211-218. Wu D. New York. Bustos P. Beharka AA. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. Mayne ST. A randomized. Melia M. Maguire MG. 6. Influence of lutein supplementation on macular pigment. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. Gaziano JM. van Poppel G. Gardner LM. Boulton M. Broekmans WM. European Research on the Functional Effects of Dietary Antioxidants (EUROFEDA). Macular pigment in donor eyes with and without AMD: a case-control study. assessed with two objective techniques. Br J Ophthalmol. Mol Aspects Med. 383-399. Murray IJ. van de Kraats J. Bone RA. Steinberg JD. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 226 . quiz 796-777. Köhrle J. 20. 316-321. Arch Ophthalmol. 1988. 1994. 867-877. Marks DA. 42. Exp Eye Res. 119. 569573. and the effect of a dietary supplement. Thieme Stuttgart. 8. 224. 2001. Macular pigment density in relation to serum and adipose tissue concentrations of lutein and serum concentrations of zeaxanthin. 41. Tibor SE. 2005. A randomized. 116-121. Control Clin Trials. de Vries AJ. Schmidt-Erfurth U. Berendschot TT. Beatty S. Koh HH. Biesalski H-K. Hennekens CH. Ann Epidemiol. in prevention of cancer. and review of results of completed trials. Bartlett H and Eperjesi F. Henson D. 937-945. [Cause and prevention of oxidative damage to the eye. Bates CJ and Cowen TD. Burton GW and Ingold KU. 2002. Antioxidant status and neovascular age-related macular degeneration. 23. van Norren D. Klopping-Ketelaars IA. Duncan JL. Augustin AJ. Christen WG. Tijburg LB. beta carotene. Conclusions. Age-Related Eye Disease Study Research Group. 330. 2001. Bieber ML. 10. Dagnelie G. Landrum JT. 1439-1452. 2002. placebo-controlled. 3322-3326. Schümann K. Current knowledge]. Int J Vitam Nutr Res. 2006. 2002. 1984. 2001. 2000. Am J Clin Nutr. Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1417-1436. Gomez CM. 1999. Science. Aleman TS. 1999. 23. Jacobson SG. 1873-1881. de Castro E. 42. Ophthalmologe. Biochim Biophys Acta. 104-109. 287-291. 111. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Design of Physicians' Health Study II--a randomized trial of beta-carotene. 1740. 235-240. Kardinaal AF. 2003. Eye Disease Case-Control Study Group. 76. 573-600. Bates CJ. and zinc for age-related macular degeneration and vision loss: AREDS report no. van Norel J. 1996. EDCC Study Group. 98. beta-Carotene: an unusual type of lipid antioxidant. Arch Ophthalmol. 2001. Quantitation of vitamin E and a carotenoid pigment in cataractous human lenses. 46. Berendschot TT. Invest Ophthalmol Vis Sci. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. Macdonald A. 1993. 125-134. Bhosale P and Bernstein PS. 66. Macular pigment and age related macular degeneration. Twaroska EE. vitamins E and C. Age-Related Eye Disease Study Research Group. Chen SJ. Design implications. Invest Ophthalmol Vis Sci. 2001. Ophthalmic Physiol Opt. Goldbohm RA. Cideciyan AV. clinical trial of high-dose supplementation with vitamins C and E. Arch Ophthalmol. cardiovascular disease. 119. 9. Bahrami H. Winkgen A. 83. and multivitamins. and eye disease. 23. 776-796. placebo-controlled. Klopping WA. Astley SB and Lindsay DG. Holden R. BMC Ophthalmol. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. Vitamine. clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. Dick HB. 595-603. Invest Ophthalmol Vis Sci. 10291035. 2000. Goldbohm RA.4 5 Age-Related Eye Disease Study Research Group. AREDS report no. Effects of age and dietary vitamin C on the contents of ascorbic acid and acid-soluble thiol in lens and aqueous humour of guinea-pigs. 1. Snodderly DM. Goukassian D. Hammond BR. 401-412. Dietary modification of human macular pigment density. Wilkins JH. Tung W. 1009-1019. Referenzwerte für die Nährstoffzufuhr. Long-term nutrient intake and early age-related nuclear lens opacities. Dratz EA. Bejot M. Curran-Celentano J. Jr. 2001. Manson JE. Johnson EJ. Hurst MA. Aravind S.go. Russett MD. Duraisami Thulasiraj R. Russell RM. 2003.. Martyn CN. Snodderly DM. Bron A. Handelman GJ. Brown NP. Br J Ophthalmol. Jr. Relation between dietary intake. Khu PM. A randomized trial of beta carotene and age-related cataract in US physicians. 25. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Gritz DC. Hennekens CH. Cooper DA. Age-related cataract in a randomized trial of beta-carotene in women. Umschau Braus Verlag. Srinivasan M. Thien U. Stahl W. Jr. Chylack LT. Whitcher JP. Japan: Food with Health Claims. Chylack LT. J Invest Dermatol. Methods Enzymol. Optom Vis Sci. Tung W. 2002. Am J Clin Nutr.. Tronnier H. Dietary lutein/zeaxanthin decreases ultraviolet B-induced epidermal hyperproliferation and acute inflammation in hairless mice. Arch Ophthalmol. Glynn R. 74. Validation of methods for the assessment of cataract progression in the Roche European-American Anticataract Trial (REACT).mhlw. Jr. Arch Ophthalmol. 39. Singer DM. 2001. 499-504. 90. Jr. Measurement of carotenoids in human and monkey retinas. 796-802. 1998. Friend J. Sperduto R. 1992. Skin Pharmacol Physiol. Wooten BR. Jacques PF and Chylack LT. Jacques PF. Hurst M. and Nutrition Labeling http://www. Ciulla TA. 74. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. 397-406. Am J Clin Nutr. 2000. Frankfurt am Main. Lutein and zeaxanthin status and risk of age-related macular degeneration. The Antioxidants in Prevention of Cataracts Study: effects of antioxidant supplements on cataract progression in South India. 2004. 1991. serum concentrations. Glynn RJ. 1997. 2001. Schalch W. 2003.. Hammond BR. Food for Special Dietary Uses. CFF thresholds: relation to macular pigment optical density. 1795-1801. Invest Ophthalmol Vis Sci. Invest Ophthalmol Vis Sci. Snodderly DM. 2461-2465. 352S-355S. 399-405. 847851. Ophthalmic Epidemiol. Phillips DI. 372378. Jr. Hankinson SE. Wooten BR. Preservation of visual sensitivity of older subjects: association with macular pigment density. S518. Chylack LT. 121. Wolfe JK.. John RK. Heinrich U. Lietman TM. Kim U. 224-231. 220-230. Jr. Ophthalmic Epidemiol. Krinsky NI. and Wooten BR. Ophthalmic Physiol Opt.jp/english/topics/foodsafety/fhc/index.. Hammond BR. Jr. Hall NF. 2003. Snodderly DM. D-A-CH (Deutsche Gesellschaft für Ernährung . 227 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 . 119. 49-80. Prajna NV. Kopcke W. Schalch W. Edwards RB.Österreichische Gesellschaft für Ernährung Schweizerische Gesellschaft für Ernährungsforschung . lutein and zeaxanthin. 59-75. 19. Antioxidant supplements improve parameters related to skin structure in humans. Beta-carotene and age-related cataract in a randomized trial of US physicians. Rogers G. 2006. Taylor A. Smith SD. 1997. Gonzalez S. Ophthalmic Epidemiol. Hammond BR. 1995. Density of the human crystalline lens is related to the macular pigment carotenoids. Gale CR.. Labour.. 213. 2005. FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use). and Welfare. 11. Chew E. Priyadharshini B. Christen W. 315-319. Sperduto RD. 2.24 25 Christen WG. Maurette JM. and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Jr.html. Wolfe JK. Adler AJ. Willett WC. 9. Kopcke W. 38. Invest Ophthalmol Vis Sci. Friend J. Buring J. 53. Gaziano JM. Danis RB. Christen WG. Pratt LM. 2006. Invest Ophthalmol Vis Sci. 44. Astner S. 42. An W. 121. Hammond BR. Pathak MA. Brown NP.Schweizerische Vereinigung für Ernährung). Ministry of Health.. Yeum KJ. Padhye N. Buring JE. Newsome DA. Yeum KJ. Russell RM. Bone RA. 71. Klein R. Kwan M. 1998. Joa H. Johnson EJ. Adv Pharmacol. Mares-Perlman JA. Barbur JL. 518S-524S. Carden D. Mayne ST. Lim BP. Knekt P. Landrum JT. Hankinson SE. Exp Eye Res. Landrum JT and Bone RA. Bowen P. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes.. 517-526. lutein and astaxanthin in cultured fibroblasts. 38. 132. Oral zinc in macular degeneration. Tung W. Sies H. 108-114. Rodriguez-Carmona M. Millen AE. 2001. Rogers G. Vaquero M. Modulation of UVA light-induced oxidative stress by beta-carotene. Bone RA. 2001. Kvansakul J. Long-term nutrient intake and 5-year change in nuclear lens opacities. Kopcke W. but not alpha-tocopherol. 57-62. Koh HH. Hunt TK. 1988. 2003. 26. Granado F. Hammond BR. Arch Ophthalmol. Ficek TL. Stahl W. Moore LL. 537-556. 192-198. Olmedilla B. 2003. Stacewicz-Sapuntzakis M. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. 19. Heliovaara M. Barker FM. Exp Eye Res. 12 1339S. 1993. 1518-1523. 106. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. zeaxanthin. Blanco I. Brady WE.43 Jacques PF. Final Technical Report A List of Well Established Nutrient Function Statements. Blanco I. Castaneda C. 1555-1562. supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind. Cajigal C. Landrum JT. Palta M. 1972. 1979. Schalch W. 11. Ophthalmic Physiol Opt. Sprague KE. J Dermatol Sci. Aromaa A. Arch Biochem Biophys. 2000. Lutein in patients with cataracts and agerelated macular degeneration: a long-term supplementation study. Carotenoid scavenging of radicals. 79. Edgar DF. Snodderly DM. Pure and Appl Chem. placebo-controlled pilot study. Granado F. Qin J. 1992. Taylor A. Arch Ophthalmol. BMJ. Nutrition. Carotenoids in Health and Disease. 2005. Kilburn MD. and anterior lens of the open eye. aqueous humor. and the macular pigment. 362-371. The macular pigment: a possible role in protection from agerelated macular degeneration. New York. Biochim Biophys Acta. 226-230. Krinsky NI. 2006. Kilburn MD. Aaran RK. O'Connor I and O'Brien N. Diet and risk of malignant melanoma in a case-control study. Z Lebensm Unters Forsch. 123. Serum antioxidant vitamins and risk of cataract. Wang XD. Rissanen A. Jr. Millen AE. Swartz M. Suzuki T. 391. 1995. 1997. Terao J. Lutein. Vaquero M. Olmedilla B. Arch Ophthalmol. Mares-Perlman JA. Antioxidant activity of xanthophylls on peroxyl radical-mediated phospholipid peroxidation. 65. 2001. 28-40. 2003. Carotenoid protection against oxidation. 196. 2004. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Miller E. 423-429. 904-909. Hankinson SE. Junghans A. JHCI (Joint Health Claims Initiative). Feather J. 649-660. 21-27. Effect of carotenoid structure and oxygen partial pressure on antioxidative activity. Murray IJ. Am J Clin Nutr. Klein BE. 21-24. Nagao A. Overview. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. Arch Biochem Biophys. Chylack LT. Tanaka K. 385. 1392-1394. Elston RC. Willett WC. 113. Ludovico J. Nolan D. J Sci Food Agric 81. Cancer Epidemiol Biomarkers Prev. 160-164. 178-184. Jorgensen K and Skibsted LH. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 228 . Moeller S. Niinikoski J. Marcel Dekker. 51. Leone NC. Takama K. Beatty S. Lutein. Sies H. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Invest Ophthalmol. 2002. 16. J Nutr. 305. In vivo measurements of oxygen tension in the cornea. 1992. 1997. Krinsky NI. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. 2004. 1126. C. J Opt Soc Am. Simon JA and Hudes ES. Robson AG. 857864. 104. Invest Ophthalmol Vis Sci. Jr. Yannuzzi LA. 270-275. 38. The Linxian cataract studies. Rosner M. 2002. Shibamoto T. Der Ophthalmologe(Berlin. 1989. Ajani UA. 16. Miller DT. Lang GK. Blair N. 231-234. 62. Farber MD. Cruysberg JR. 2005. Curr Eye Res. Reed RL. Hoyng CB. Mellerio J. Hiller R. AREDS und. Perrone G. 1999. Neovascular age-related macular degeneration and its relationship to antioxidant intake. 2005. 1995. vitamins A. 71 72 73 74 75 Seddon JM. Schweitzer D. and E. 753-755. 1-58. 1994. Zollman PE. Antioxidant protection against corneal damage by free radicals during phacoemulsification. Bird AC. Chemopreventive compounds in the diet. Macular pigment and chromatic aberration. 14131420. Rubowitz A. Brubaker RF. Topaz M. 61. 1993. N Engl J Med. 1448S-1461S. 2005. Dietary carotenoids. Schalch W and Chylack LT. 128-135. Sternberg P. Sperduto RD. Burton TC. Hammer M. Willett W. Reading VM and Weale RA. Handelman G. Kopcke W. Steering Committee of the Physicians' Health Study Research Group. Blot WJ. Acta Ophthalmol Scand. Bing L. 1993. Zhao JL. Arch Biochem Biophys. Blumberg J. Cheng QF. Verbeek AL. van Kuijk FJ. Everett DF. Schalch W. 1994. 1997. Li JY. Nowell T. Macular carotenoids: lutein and zeaxanthin. 2007. 34. Dawsey S. Taylor PR. 2002. Schmidt AJ. 2049-2054. Print). 2003. 100. Are lutein and zeaxanthin conditionally essential nutrients for eye health? Med Hypotheses. Schmidt-Erfurth U. Dev Ophthalmol. Eye Disease Case-Control Study Group. Milton RC.the LUXEA (LUtein Xanthophyll Eye Accumulation) study. Invest Ophthalmol Vis Sci. 80. 129-135. The role of lipid peroxidation caused by ultraviolet light in skin diseases. 44. Final report on the aspirin component of the ongoing Physicians' Health Study. Sperduto RD. Activity loss of glutathione synthesis enzymes associated with human subcapsular cataract. [Objective determination of optical density of xanthophyll after supplementation of lutein]. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. 1993. Antioxidative Mikronährstoffe und Katarakt: Ein Überblick und ein Vergleich der Kataraktstudien. 1986. Arch Ophthalmol. Drews-Botsch C. Schreier P. 1866-1870. 38. Remsch H. Snellen EL.65 66 67 68 69 70 Rathbun WB. Protection of retinal pigment epithelium from oxidative injury by glutathione and precursors. Taylor A. 1974. Nutrition and retina. Hagen TM. 70-88. Assia EI. Two nutrition intervention trials. Nadler D.. Davidson PC. 34. Holleschau AM. 64. 465-472. Jones DP. Fitzke FF. JAMA. Opinion on the Tolerable Upper Intake Level of Preformed Vitamin A (retinol and retinyl esters). Lang GE. Arch Ophthalmol. 3661-3668. 99. REACT: Kararaktprävention. Am J Clin Nutr. 82 83 84 85 229 . SCF (Scientific Committee on Food). Werness PG. 111. Hu TS. Guo WD. 321. 38. Haller J. Thamm E. 1246-1253. J Clin Epidemiol. Spraul CW. lens and plasma in relation to intake. 2003. Dev Ophthalmol. Vitamin C in human and guinea pig aqueous. Beuermann B. Jacques PF. and advanced age-related macular degeneration. 458. Jozwiak B. 193-202. Snodderly DM. 2002. 13. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin . Stahl W. Cutaneous and Ocular Toxicology. 52. Ophthalmologe. 2003. 1207-1211. 76 77 78 79 80 81 Semba RD and Dagnelie G. Invest Ophthalmol Vis Sci. Cohn W. Ascorbic acid levels in the aqueous humor of nocturnal and diurnal mammals. Dev Ophthalmol. Gragoudas ES. 272. Van Den Hoogen GW. 120-147. 368-371. Barker FM. Reiss GR. 181-189. Serum ascorbic acid and other correlates of self-reported cataract among older Americans. Measurement of carotenoids. Story L. 54. Berg A. Oeltgen P. 17.86 87 Taylor A and Hobbs M. Arrigoni E. Tietyen J. 55-62. Heinonen OP. Int J Vitam Nutr Res. 46-51. Teikari JM. 16. Teikari JM. and tocopherols in human lenses. lipoproteins. 76. Heinonen OP. 634-640. 1991. 1998. Hamilton CC. 2001. Tessier F. Changes in serum cholesterol and sterol metabolites after intake of products enriched with an oat bran concentrate within a controlled diet. Hallfrisch J. Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial. 2002. van Rees A. Behall KM. FASEB J. Laatikainen L. 16. Taylor A. 1990. 1997. Bartram P. Fat-soluble nutrient concentrations in different layers of human cataractous lens. Konig D. 19. Kasper H. Onning G. 40. Tang G. Amado R. 47. Haukka J. Baumstark MW. 1272-1281. 1997. 517-522. Hypocholesterolemic effects of oatbran or bean intake for hypercholesterolemic men. JPEN J Parenter Enteral Nutr. 59. Smith SF. Yeum KJ. 533-537. 1984. Scheppach W. Deibert P. 2004. Hallfrisch J. Taylor P. Dillon DW. Acta Ophthalmol Scand. Deakins DA. 502-505. 1998. 1146-1155. Acta Ophthalmol Scand. 71-81. 2 3 4 5 6 7 8 9 10 11 230 . ID 1465: “Beta-glucans” and “Blood lipid profile” 88 89 90 91 92 93 1 Amundsen H. Effect of a single oat bran cereal breakfast on serum cholesterol. 2000. Taylor A. Virtamo J. Palmgren J. Scholfield DJ. 17. retinoids. 75. 21. Food & Nutrition Research. Shang FM. 2756-2761. Effect of beta-glucan level in oat fiber extracts on blood lipids in men and women. Eur J Clin Nutr. and apolipoproteins in patients with hyperlipoproteinemia type IIa. 845-857. Mondon H. 224-229. 2005. Russell RM. Smith SF. Junes P. Russell RM. Rautalahti M. Oeltgen PR. 1992. 23. Oat-bran cereal lowers serum total and LDL cholesterol in hypercholesterolemic men. 309-315. Wooten BR and Hammond BR. Effects of oat gum on blood cholesterol levels in healthy young men. 49. Invest Ophthalmol Vis Sci. 2003. 6874. Birlouez-Aragon I. Virtamo J. 2001 assessment of nutritional influences on risk for cataract. Yeum KJ. 40. Anderson JW. Lipids significantly reduced by diets containing barley in moderately hypercholesterolemic men. 306-311. Scholfield DJ. Curr Eye Res. J Am Coll Nutr. Chen WJ. Moreaux V. Int Ophthalmol Clin. Anderson JW. Effect of an oat bran enriched diet on the atherogenic lipid profile in patients with an increased coronary heart disease risk. Gerlach S. 52. 1995. Eur J Clin Nutr. Nutrition. Macular pigment: influences on visual acuity and visibility. 1995. Bryant CA. Am J Clin Nutr. Behall KM. Albanes D. Decrease in vitamin C concentration in human lenses during cataract progression. Biorklund M. Antioxidants and cataract formation: a summary review. Beer MU. Andersson. 495-499. Rautalahti M. Schalch WM. Lipid responses of hypercholesterolemic men to oat-bran and wheat-bran intake. 36. Liesto K. J Am Coll Nutr. Sieling B. Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract. Petro MS. 1999. A1-A2. 678-683. Gilinsky NH. Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy. Barley consumption lowers cholesterol in men and overweight women. Liesto K. Behall KM. Spencer DB. Grathwohl D. Mensink RP. 68. 2003. O'Neal DS. Anderson JW. Am J Clin Nutr. Keller F. Ann Nutr Metab. Am J Clin Nutr. 2003. A controlled randomized lifestyle intervention study. Wu SY and Leske MC. 225-240. Story J. 47. Prog Retin Eye Res. Franz IW. Nutrition Research. 23.gov/~dms/2lg-toc. Guidance for Industry: A Food Labeling Guide. Increasing whole grain foods (barley or wheat & rice) in a step 1 diet lowers blood pressure in moderately hypercholesterolemic men. Lairon D. The apolipoprotein E gene and the serum low-density lipoprotein cholesterol response to dietary fiber. Scholfield DJ. 1993. Nutrition Research. Ann NY Acad Sci. Portugal H. Windhauser MM. 13. Tong A. Blood pressure reduced by whole grain diet containing barley or whole wheat and brown rice in moderately hypercholesterolemic men. Rosner B. 56. 1994. Diets containing soluble oat extracts improve glucose and insulin responses of moderately hypercholesterolemic men and women. Bruce R. 265. 1992. 455-459. Sundberg B. Deakins DA. Stern H. Aman P. Senft M. Sacks FM. Davy BM. 325-333. Am J Clin Nutr. Khoury A. Scholfield DJ. 623. Lester SB. Genetic variation associated with differences in the response of plasma apolipoprotein B levels to dietary fibre. Behall KM. Hallfrisch J. 223-229. Bruce R. 55. Guild M. 1998. 379-384. Davy KP. Bracci P. Dillon DW. JAMA. Hallak K. 299-302. Armand M. Jenkins DJ. 61. Behall KM.12 Braaten JT. 1993. Serum apolipoprotein and lipid profile effects of an oat-bran-supplemented. Connelly PW. healthy population. Drennan KB. 148. Stern H. Cara L. Davrath LR. Lafont H. Dubois C. Senft M. Am J Clin Nutr. 585-593. Bradley-White P. 387-398. 1991. Hegele RA. Jenkins AL. 61. Bernard PM. Morris SK. Gold K. Oat bran increases serum acetate of hypercholesterolemic men. Vessby B. Hegsted M. CFSAN (FDA's Center for Food Safety and Applied Nutrition). 1988. Am J Clin Nutr. Demark-Wahnefried W. 128. Oat bran as a cholesterol-reducing dietary adjunct in a young. Davidson MH. Dubois C. Wood PJ. Kamal-Eldin A. Jenkins DJ. 90. J Am Diet Assoc. Pauli AM. Beske SD. Zahariadis G. Dugan LD. Yeast-leavened oat breads with high or low molecular weight beta-glucan do not differ in their effects on blood concentrations of lipids. Effects of oat bran. Behall KM. Pintilia M. 1993. Nguyen T. Bassin S. Story K. 1995. Ho RC. Borel P. Clin Sci (Lond). Scott FW. 30-42. J Am Diet Assoc. Anderson JW. J Nutr. Wong N. 269-275. 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 231 . 1833-1839. A dose-controlled study. Wood CL. Hallfrisch J. 1990. 42. Knehans AW. Lairon D. Willett WW. 134. Bova J. 94. Connelly PW. West J Med. Van Treeck D. Am J Clin Nutr. Armand M. 1994. A655-A655. Lowe MK.cfsan. FASEB J. 465474. insulin. low-fat diet in children with elevated serum cholesterol. Full-fat rice bran and oat bran similarly reduce hypercholesterolemia in humans. 69. Iftner C. 1999. 1384-1388. Eur J Clin Nutr. rice bran. Bridges SR. Portugal H. Reduced serum cholesterol with dietary change using fat-modified and oat bran supplemented diets. J Nutr. 425-436. 2004. Melby CL. or glucose in humans. 1631-1642. Wolynetz MS. 2002. 351-358. 865-869. Soluble fiber and serum lipids: a literature review. wheat fiber. 85. Pauli AM. Kashtan H. 2003. Gold KV and Davidson DM. Stabilized rice bran and oat bran lower cholesterol in humans. 16. Gerhardt AL and Gallo NB. Am J Clin Nutr. Metabolism. http://vm. 48. Corey P. Am J Clin Nutr. 429-431. Cholesterol-lowering effects of dietary fiber: a metaanalysis. Scholfield DJ. Bernard PM. Baker S. Hallfrisch J. Frank J. and wheat germ on postprandial lipemia in healthy adults. 1995.html. Kashtan H. 2002.fda. Burns JH. 76. Collins MW. Oat betaglucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Jenkins AL. High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middleaged and older men. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. Chronic oat bran intake alters postprandial lipemia and lipoproteins in healthy adults. 1991. Brown L. Glore SR. Bowering J. Cohen PS. Hegele RA. 1992. 81-88. Lovegrove JA. 369. Haffner SM. Williams CM. Randomized. Malik KC. 157. Hay K. 1992. J Fam Pract. Moran A. Myers S. Leadbetter J. 967-970. 2002. Am J Clin Nutr.32 Jenkins DJ. J Fam Pract. J Nutr. 1999. Emam A. Marcon N. soy protein and isoflavones. Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. 84. Effects on the human serum lipoprotein profile of beta-glucan. 2005. Montez MG. 2003. Kendall CW. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. Effect of oatbran on mild hyperlipidaemia. 819-826. 2002. Kahn RF. Noakes M. Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men. J Am Diet Assoc. Monro JA. 1992. 2494-2505. Ginsberg HN. Davidson MH. Palmas W. Keenan JM. Ramakrishnan R. Hepatology. 132. Ball MJ. Wheat-bran and oat-bran supplements' effects on blood lipids and lipoproteins. Do beans and oat bran add to the effectiveness of a low-fat diet? Eur J Clin Nutr. 967-974. Nestel PJ. 49-55. 72. Story JA. Vollendorf NW. Wenz JB. Parker TL. Milon H. Am J Clin Nutr. Fiquet C. Am J Clin Nutr. and glucose metabolism in mildly hypercholesterolemic men. 34. Kestin M. 2000. Oat bran supplementation for elevated serum cholesterol. McCaffrey DJ. 661-666. Wong JM. 34. 841-845. Minkin S. 81. Leiter LA. Bruce WR. Brouns F. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. 46. Sieling B. 1991. Effects of increasing quantities of oat bran in hypercholesterolemic people. 313-319. controlled. Wursch P. 1981. Wenz JB. 77. Mensink RP. Modest doses of beta-glucan do not reduce concentrations of potentially atherogenic lipoproteins. de Souza R. 1991. Kirby RW. Clohessy A. 54. 305-308. 2005. Garner J. Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. McCord RS. Anderson JW. Jenkins AL. Royle PJ. 33. Davidson KW. 1994. Cooper GJ. Poppitt SD. Jenkins DJ. Ripsin C. 2002. Singer W. McArdle BH. 641-648. Marlett JA. Stern HS. 1450-1457. Comparative effects of three cereal brans on plasma lipids. garlic and tocotrienols. 51. plant sterols and stanols. Lepre F and Crane S. 2003. MetabolismClinical and Experimental. J Fam Pract. Moss R. 824-829. Kerckhoffs DA. Daggy BP. Rizkalla SW. 78. Am J Cardiol. Kerckhoffs DA. 1990. Slama G. Vidgen E. Kay RM. 2003. Keenan JM. 1990. Ripsin CM. Coles GD. blood pressure. Mensink RP. Kashtan H. Haack VS. Hosig KB. Faulkner DA. Mulvey TB. Chen WJ. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Hornstra G. Trautwein EA. Mann JI. Am J Clin Nutr. Vidal H. 711-718. Med J Aust. O'Mullane J. 51. Clifton PM. Albrecht HH. Karmally W. Bruzzo F. Am J Clin Nutr. 55. Maki KC. 10. 78. McIntosh GH. Frazel C. Josse RG. Whole-grain rye and wheat foods and markers of bowel health in overweight middle-aged men. 380-387. Connelly PW. Keogh GF. Oppert JM. Oat ingestion reduces systolic and diastolic blood pressure in patients with mild or borderline hypertension: a pilot trial. crossover trial of oat bran in hypercholesterolemic subjects. Keenan JM. 1198-1203. Am J Clin Nutr. Holleran SF. Turnquist L. Branstetter A. 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 232 . Am J Clin Nutr. Am J Clin Nutr. Pins JJ. Huang ZQ. Shinnick FL. Am J Clin Nutr. Cholesterol-lowering effect of beta-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when beta-glucan is incorporated into bread and cookies. Hornstra G. Kabir M. 52. Foster PR. 600-608. A clinical trial of oat bran and niacin in the treatment of hyperlipidemia. Mechanism of serum cholesterol reduction by oat bran. Marchie A. 1992. Miller RE. Rees ED. Martinez W. Mackay S and Ball MJ. 221-227. 37-46. 1992. 976-980. Fam Pract Res J. Huang Z. 105. 20. Lapsley KG. Newsome-White R. J Nutr. Outpatient management of diabetes mellitus with patient education to increase dietary carbohydrate and fiber. 147-152. Neutze JM. 3317-3325. Wydra M. 601-605. soya milk. Thye FW. Consumption of oat milk for 5 weeks lowers serum cholesterol and LDL cholesterol in free-living men with moderate hypercholesterolemia. 42. 398-400. Greenberg AS. Onning G. 211-220. Fulcher RG. Ripsin CM. Clifton PM. Gates JE. Lichtenstein AH. Le Leu R. 157. Am J Clin Nutr. Romero JE. Mil Med. 43. Smith KN. The addition of oatbran to a low fat diet has no effect on lipid values in hypercholesterolaemic subjects. 1992. Oste R. Fontaine-Bisson B. Do whole-grain oat cereals reduce the need for antihypertensive medications and improve blood pressure control? Journal of Family Practice. Thom S. 6. lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Gee MI.Davidson MH. 567-568. 1985. Welch RR. Lack of effect of dietary oats on serum cholesterol. Dallal GE. Burgess MB. Keenan JM. Oste R. 1204-1208. Dugan LD. Keenan JM. Geleva D. Slavin JL. 322. 52. Guar gum and plasma cholesterol. Sever P. Am J Clin Nutr. Pins JJ. 583-588. Hardin RT. Curley CB. 601-608. 96. 85. 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 233 . O'Connor PJ. Lundquist I. Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure. Effect of high-amylose starch and oat bran on metabolic variables and bowel function in subjects with hypertriglyceridemia. Arterioscler Thromb. Effect of oat bran consumption on total serum cholesterol levels in healthy adults. J Nutr. 83. Schneeman BO. 353-359. Lipid profiles after the daily consumption of an oat-based cereal: a controlled crossover trial. Farquhar JW. Ann Nutr Metab. A meta-analysis. 11. 1991. Garg ML. N Engl J Med. Davis PA. Robitaille J. Cherney LM. 359-366. 301-309. Effect of an oat bran-rich supplement on the metabolic profile of overweight premenopausal women. 2002. Onning G. Pick ME. Effect of guar gum and an oat fiber source on plasma lipoproteins and cholesterol in hypercholesterolemic adults. 2006. Oste R. Hawrysh ZJ. Elmstahl S. Wallmark A.52 53 Naumann E. 267. Poulter N. Kestin M. Redard CL. Swain JF. Ann Nutr Metab. Galaviz S. Noakes M. 137. Spiller GA. Toth E. J Am Diet Assoc. Cookies enriched with psyllium or oat bran lower plasma LDL cholesterol in normal and hypercholesterolemic men from Northern Mexico. 1254-1261. 17. 6. 726728. Concentrated oat betaglucan. 1465-1470. Ann Nutr Metab. Mo Med. 2005. McIntosh G. Thomas W. Elmer PJ. 131. 1996. 1992. Stewart ML. Romero AL. 1998. Tchernof A. 1998. Jacobs DR. Akesson B.. JAMA. Jr. Onning G. 66-69. Das SK. Rouse IL. Sheppa CM. 2001. 59. Liu K. Persson M. Beling S. Dietary fiber and gender: effect on postprandial lipemia. Poulter C. Chang CL. 1990. Mensink RP. Turnbull WH. 944951. 1988. NZ Med J. Beta-glucan incorporated into a fruit drink effectively lowers serum LDL-cholesterol concentrations. 1996. 1992. Effects of consumption of oat milk. Cuff A. Diabetes Care. Hegsted M. Saudia TL. 837-845. Oat products and lipid lowering. Nichols SF. Vohl MC. 1990. Barfield BR. Couture P. Nutr J. 1999. 2007. O'Kell RT and Duston AA. Demark-Wahnefried W. Queenan KM. 141-148. 1994. 8. Stewart FM. Kaiser DL. Davidson DM. Sacks FM. 64. 49. Theuwissen E and Mensink RP. van Rees AB. Frazel C. a fermentable fiber. Corrales A. or cow's milk on plasma lipids and antioxidative capacity in healthy subjects. Am J Clin Nutr. Am J Clin Nutr. 105. 51. Van Horn L. 2007. Nestel PJ. Saltzman E. Schaefer EJ. Stevens J. Simultaneous intake of beta-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. Roberts SB. J Am Coll Nutr. Fernandez ML. Barger J. Akesson B. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. 3. 1564-1569. 51. 1-37. Subpart e 101. 1992. 46. Liao Y. Toskala E. 759-764. Kesaniemi YA. Jones PJH. Liu K. Uusitupa MI. Jones PJ. Andersson H. Van Horn L. Lathosterol and other non-cholesterol sterols during treatment of hypercholesterolaemia with beta-glucan-rich oat bran. Bourque C. Liu KA. ID 1466: “Beta sitosterol” and “Cholesterol” 73 74 75 76 77 78 79 80 81 82 83 84 85 1 Title 21. Mazza G (ed.) CRC press. St-Onge MP. Oat bran lowers plasma cholesterol levels in mildly hypercholesterolemic men. Dahlgren S. Prev Med. Nestel P. 1992.72 Torronen R. 177-181. Metabolism. 234 2 3 4 . and N-3 fatty acids improves cardiovascular risk profile in overweight women. Lundin E. Lee MS. Lotter AP. 1986. 1992. Uusitupa MI. Liu KA. Eur J Clin Nutr. Lipids in Health and Disease. 2003. Effects on serum lipids of adding instant oats to usual American diets. Hallmans G. 1987. Stenling R. Journal of the American Dietetic Association. 1998. Tidehag P. Masa DB. 13. 1986. Stamler J. In: Functional Foods: Biochemical and Processing Aspects. Reduction of total and LDL-Cholesterol in plasma by Rolled Oats. Askali FC. 1995. 2003. Ballew C. 621-627. Topping D. Joensuu T. Stamler J. Chapter I Food and Drug Administration Departement of Health and Human Services. Scand J Prim Health Care. J Am Diet Assoc. Effects of a stanolenriched diet on plasma cholesterol and triglycerides in patients treated with statins. Papamandjaris AA. 99-105. oatmeal-enhanced diet. Makinen E. 2. 183-188. Emidy L. Effect of oat bran on plasma cholesterol and bile acid excretion in nine subjects with ileostomies. 49. phytosterols. Giumetti D. Moon YK. Am J Public Health. 651-659. 435-438. Ruuskanen E. Effects of an oat bran concentrate on serum lipids in free-living men with mild to moderate hypercholesterolaemia. J Am Coll Nutr. Winblad I. Harkonen H. King J. 86. Code of Federal Regulations. J Clin Nutr Gastroenterol. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Kansanen L. 92. 1991. J Med Food. Lee HS. Consumption of an oil composed of medium chain triacyglycerols. Kesaniemi YA. Kervinen K. Serumlipid response to oat product intake with a fat-modified diet. Eur J Clin Nutr. 607-611. 136-140. Myllymaki O. Hughes R. 2004. S Afr Med J. Abumweis SS. Ruth K. Ruuskanen E. Cohn JS. 2006. Whyte JL. Castillo JC. Ballew C. Van Horn L. 446-449. Mallillin AC. 69. Stamler J. Trinidad TP. 81. Kervinen K. J Nutr Sci Vitaminol (Tokyo). Am J Clin Nutr. Boca Raton. 377-386. Kim YH. Castro Cabezas M. 771-777. A controlled study on the effect of beta-glucan-rich oat bran on serum lipids in hypercholesterolemic subjects: relation to apolipoprotein E phenotype. 1997. Subchapter B Food for Human Consumption Part 101 Food labeling. 56. de Vries JH. Functional Oat Products. Zhang JX. 381-387. Wood PJ and Beer MU. 118-121. 1988. Effects of an oats fibre tablet and wheat bran in healthy volunteers. 2004. Iestra J. 11. Loyola AS. Aman P. Yang JL. Liao YL. Pan WH. 17. Malkki Y.83 Health claims: plant sterol/stanol esters and risk of coronary heart disease (CHD). Moag-Stahlberg A. Effect of oat bran supplemented diet on hypercholesterolaemia. Barley beta-glucan lowers serum cholesterol based on the up-regulation of cholesterol 7alpha-hydroxylase activity and mRNA abundance in cholesterol-fed rats. 106. 7. Miettinen TA. Valdez DH. Hewitt J. van Staveren WA. Serum lipid response to a fat-modified. Resaba RL. Parker D. J Am Diet Assoc. Bosaeus I. Uusitupa M. Emidy LA. McArthur R. Turnbull WH and Leeds AR. Vorster HH. Vanhorn LV. Korpela H. Berger A. Odendaal I. Laitinen J. The cholesterol-lowering effect of coconut flakes in humans with moderately raised serum cholesterol. Food and Drugs. Van Oostrom AJ. 1992. Hanninen O. Sarkkinen ES. 52. Raeini-Sarjaz M. Howard B. 2004. 2007. Kris-Etherton P. Jones PJ. Lithell H. 132. Parsons W. 98. Feng JY. Kerckhoffs DA. Curr Opin Clin Nutr Metab Care. 2001. Normen AL. Lichtenstein AH. Rudel L. Werner I. 2006. 751-756. Pelled D. 1392-1398. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Kastelein JJ. 320. Nutr Rev. Lourbakos A. Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. 2005. Andersson HA. IAS (International Atherosclerosis Society). Carnethon M. Effects of an increased content of cereal fibre in the diet of Type 2 (non-insulin-dependent) diabetic patients. Jonker C. Andersson SW. Hornstra G. Short-term administration of tall oil phytosterols improves plasma lipid profiles in subjects with different cholesterol levels. 342. De Graaf J. 69. e25-28. garlic and tocotrienols. Bremmer M. 636-640. Am J Clin Nutr. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005. 479-488. Law M. Journoud M. 2000. 563-570. Plant sterol and stanol margarines and health. Garg A. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. 47.5 Chan YM. Brands M. Howell T. Jones PJ. Van Dam M. soy protein and isoflavones. Konig J. Franch HA. Olive oil containing olive oil fatty acid esters of plant sterols and dietary diacylglycerol reduces low-density lipoprotein cholesterol and decreases the tendency for peroxidation in hypercholesterolaemic subjects. Arterioscler Thromb Vasc Biol. Harris WS. Br J Nutr. Jialal I. 272-277. JAMA. plant sterols and stanols. Gustafsson IB. Cholesterol-lowering efficacy of a sitostanolcontaining phytosterol mixture with a prudent diet in hyperlipidemic men. MacDougall DE. 235 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 . De Sauvage Nolting PR. Grundy SM. 26. 42. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. 1144-1150. Karanja N. 1984. Belsey EM. Tareilus EW. Van Horn L. 2494-2505. Dik MG. Chandalia M. Hovenkamp E. Atherosclerosis. von Bergmann K. Lefevre M. Nutr Rev. 81. 88. Lutjohann D. And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). N Engl J Med. 2002. Appel LJ. Letiembre M. 196. 24. 2003. Wylie-Rosett J. 65. Vanstone CA. 39-45. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk-the LASA study. 64. Daniels S. Haydn Pritchard P. Fassbender K. Walter S. Duchateau GS. 1998. 285. 1125-1132. Liu Y. A place for dietary fibre in the management of the metabolic syndrome. Effects on the human serum lipoprotein profile of beta-glucan. Asp NG. 348-354. Delzenne NM and Cani PD. 2003. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Diabetologia. 2486-2497. Lutjohann D. 2186-2191. Ellegard LH. Jones PJ. Boberg M. Jones PJ. Demonty I. 2000. Stalenhoef AF. Metabolism. Evaluation. 26. 2007. FDA (Food and Drug Administration). Devaraj S and Jialal I. 13511358. Dietary plant sterols and cholesterol metabolism. 2008. Am J Clin Nutr. Br J Nutr. FDA letter regarding enforcement discretion with respect to expanded use of an interim health claim rule about plant sterol/stanol esters and reduced risk of coronary heart disease. J Nutr. Vessby B. von Bergmann K. 861-864. Mensink RP. 2006. Lau VW. 283-288. Winston M. 8. Brinkley LJ. Devaraj S. Karlstrom B. Preferential efflux of phytosterols over cholesterol from macrophages. Harmonized clinical guidlines on prevention of atherosclerotic vascular disease. 2007. Lipids. Franklin B. Sacks F. 2002. Vega-Lopez S. 1999. Ntanios FY. Brouns F. Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels. Plant sterols are efficacious in lowering plasma LDL and non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons. BMJ. Trautwein EA. 2006. 2001. 282-283. Marangoni F. Regulation of cholesterol absorption by phytosterols. Sellers TA. Phytosterols. Manzato E. Hicks KB. Kushi LH. Rozner S and Garti N. 29. Stella R. Vanotti A. Role of plant sterols in cholesterol lowering. Moreau RA. Zambon A.8 to 2.2 g phytosterols per day. O'Dea K. Jacobs DR. and their conjugates in foods: structural diversity. Mascara T. Eur J Lipid Sci Technol. Hu FB. Tavani A. 41-48. La Vecchia C. J Am Coll Nutr. Moruisi KG. 207-211. Liu S. and cereal fiber intakes and markers of systemic inflammation in diabetic women. Jr. Carbohydrates. Meyer KA. Prog Lipid Res. Cicero A. Pinto A.) CRC Press. 2002. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. 11. Porrini M. McIntosh GH. Ostlund RE. 2004. Meijer GW. Am J Clin Nutr. Walker KZ. and Lin X. Muir JG. Colloids and Surfaces A: Physicochemical and Engineering Aspects. Cricelli C. Arabinoxylan fiber. Volpe M. Volpe R. Mensink RP. Dutta PC (ed. Folsom AR. Mannarino E. Stalenhoef AFH. Trautwein EA. 42. Mantzoros C. CRC Press. Muir JG. 103. Miettinen TA. S1-16. 457-500.). Qi L. Non-pharmacological control of plasma cholesterol levels. Am J Clin Nutr. 154-164. providing 1. 2007. cholesterol absorption and healthy diets. 102-106. 71. 77. phytostanols. Foster PR. Normen AL. Annu Rev Nutr. To determine the effect of increasing doses of tall oil derived phytosterols (Phytrol TM) on the plasma lipid levels of hypercholesterolemic patients. Cannella C. Walker KZ. Nutr Metab Cardiovasc Dis. Arabinoxylan fibre improves metabolic control in people with Type II diabetes. 2006. 80. Lupattelli G. Del Toma E. 41. 2000. doses and forms. 8. reduces the postprandial glucose response in normoglycemic subjects. 2005. Jr. Akoh CC and Lai O-M (eds. The activity and absorption relationship of cholesterol and phytosterols. Berger A. Boca Raton. Phytosterols and phytosterol esters. 2006. Blood cholesterol-lowering plant sterols: types. Groux MJ. 939966. Noakes M. Franz M. 129-132. Lipid Technology. 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 236 . 335-360. 967-974.. Eur J Clin Nutr. Piironen V. Catapano A. Opperman AM. Phytosterols. Piguet-Welsch C. 2006. Plant sterol-ester-enriched spreads as an example of a new functional food.24 Lu ZX. Verschuren WMM. Jr. Marrocco W. Journal of the Science of Food and Agriculture. Boca Raton. 1999. van Dam RM. Notarbartolo A. induces up to 10% reduction of the serum concentration of low density lipoprotein (LDL) cholesterol. Gaddi A. Riccardi G. 2003. Slavin J. Whole-grain. 2003. 435-456. Whitaker BD. 71. Sirtori C.. 18. 1123-1128. 533-549. 921-930. O'Dea K. Oosthuizen W. Ostlund RE. Plant sterols: biosynthesis. In: Phytosterol as functional food components and nutraceuticals. 2002. 42. 621-628. 2004. Lampi AM. 487-491. quantitative analysis. Eur J Nutr. Royle PJ. Toivo J. Diabetes Care. 2008. Novartis Consumer Health Study and Forbes Meditech Inc.. 41-45. 2007. bran. 22. 58. Curr Atheroscler Rep. Poli A. Sagalowicz L. biological function and their importance to human nutrition. Ntanios F. and incident type 2 diabetes in older women. Jr. Non-esterified plant sterols solubilized in low fat milks inhibit cholesterol absorption--a stable isotope double-blind crossover study. Bernini F. and health-promoting uses. Monnard IE. 25. Three types of products with added Reducol (a mixture of non-esterified plant sterols and stanols): bread spread. Protocol CLF 9904. Gattone M. 2000. 2000. Kuipers F. In: Healthful Lipids. Am J Clin Nutr. Whole-grain rye and wheat foods and markers of bowel health in overweight middle-aged men. 2000. Frohlich J. Lu ZX. Pouteau EB. Moreau RA. Paoletti R. Aureli P. Phytosterols in human nutrition. Ostlund RE. a byproduct of wheat flour processing. dietary fiber. yoghurt and yoghurt drink and three portions per day of either spread or yoghurt or one portion of yoghurt drink with added Reducol. Lindsay DG. Lipids. 12721278. 108. Jantschko W.44 Tikkanen MJ. 91-103. 233-239. Sridhar R. Allegra M. Volpe R. Champagne CM. Monique Verschuren WM. Bongiorno A. Molhuizen HOF. Kapadia GJ. Tsuruta A. 50.] Alef. 2005. 2003. VRN (Valtion ravitsemusneuvottelukunta). Van Horn L.) extracts. Ocke MC. Nutr Cancer. 2003. J Agric Food Chem. 76. Netzel M. Nishino H. 2003. Mel‘nikov SM. Parsons WE. Betalains. Cai Y. Niittynen L. J Agric Food Chem. Livrea MA. Biochem Biophys Res Commun. Effectiveness of customary use of phytosterol/-stanol enriched margarines on blood cholesterol lowering. Verhagen H. Characterization of the activity of tyrosinase on betanidin. Plants: Diet and Health – The Report of the British Nutrition Foundation Task Force. McCoin M. ID 1468: “Betalains” and “Antioxidant properties” 45 46 47 48 49 50 1 Allegra M. Wolfs M. J Agric Food Chem. Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia. Furtmuller PG. 47. Duchateau GSMJE. Zederbauer M. 2001. Ji LL. Urinary pharmacokinetics of betalains following consumption of red beet juice in healthy humans. 2005. Technol. Tesoriere L. Bolling BW. Karppanen H. 2001. 1682-1688. Tesoriere L. Stintzing FC. de Jong N. 290-297. Garcia-Carmona F. 2006. Pharmacol Res. Kugler F. Frank T. Tuomilehto J. 2004. Ichiishi E. and DEN-induced phenobarbital promoted liver tumors in mice by extract of beetroot. Granit R. 837-844. NOR1-induced TPA promoted skin carcinogenesis. 88. Korpela R. Antioxidant activities of sicilian prickly pear (Opuntia ficus indica) fruit extracts and reducing properties of its betalains: betanin and indicaxanthin. Sun M. Escribano J. 44. Kohen R. Carle R. Strass G. Lin Y. Lee CH. Burke F. J Am Diet Assoc. 52. 53. BNF (British Nutrition Foundation). Trautwein EA. Sirtori C. 2005. Am J Clin Nutr. Corke H. Ntanios FY. 2008. Sikand G. Bucci A. Mukainake T. Takasaki M. cicla [L. 51. Parkin KL. Butera D. Harel S. Karmally W. Am J Cardiol. 1546-1551. Kris-Etherton PM. Wettasinghe M. 2975-2981. Cv. Hogstrom P. 2002. J Agric Food Chem. Quaas D. 49. 2002. Livrea MA. Mechanism of interaction of betanin and indicaxanthin with human myeloperoxidase and hypochlorous acid. Obinger C. 55. 171-185. Pintaudi AM. Bright Lights) by high-performance liquid chromatography-electrospray ionization mass spectrometry. 5178-5185. Edita Publishing Oy Helsinki. Suomalaiset ravitsemussuositukset – ravinto ja liikunta tasapainoon. 141-148. 287-331. Sundvall J. 2003. Vanstone CA. ssp. 332. Tokuda H. Pharmacol Res. phase II enzyme-inducing components from red beetroot (Beta vulgaris L. Chemoprevention of DMBA-induced UV-B promoted. Keinanen-Kiukaanniemi S. Effect of a diet based on low-fat foods enriched with nonesterified plant sterols and mineral nutrients on serum cholesterol. Antioxidant activity of betalains from plants of the amaranthaceae. Azuine MA. Carson JA. Food Chem Toxicol. 52. Carle R. Proposed mechanisms of cholesterol-lowering action of plant sterols. Di Gaudio F. 2 3 4 5 6 7 8 9 10 237 . Bitsch I. 2007. Fraone N. 105. Jones PJ. 2288-2294. J Agric Food Chem. Raeini-Sarjaz M. 6895-6901. Konoshima T. Identification of betalains from petioles of differently colored Swiss chard (Beta vulgaris L. Gandia-Herrero F. 2001. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. 1157-1162. Okuda Y. Stintzing FC. 2005. Pazzucconi F. Betalains--a new class of dietary cationized antioxidants. The evidence for dietary prevention and treatment of cardiovascular disease. Kanner J. Br J Nutr. 86. Eur J Lipid Sci. Bitsch R. 10269-10280. In situ and Ex situ adsorption and recovery of betalains from hairy root cultures of Beta vulgaris. 47-64. 2002. Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemia red blood cells. 16. Herbach KM. Brinkworth GD. Sanders MS. Sembries S. Rutherfurd-Markwick KJ. Bunch R. Felker P. Ilieva M. J Agric Food Chem. Free Radic Res. Di Gaudio F. Whyte PB. The effect of bovine colostrum supplementation on salivary IgA in distance runners. Relative inhibition of lipid peroxidation. 42. Tesoriere L. Increased resistance to oxidation of betalain-enriched human low density lipoproteins. Nutrition. J Agric Food Chem. Brinkworth GD. Coombes JS. Livrea MA. and antioxidant properties of cactus pear (Opuntia spp. 2002. 2005. Abbott MJ. Concentrated bovine colostrum protein supplementation reduces the incidence of self-reported symptoms of upper respiratory tract infection in adult males. Dongowski G. Dietrich H. 57. Nair MG. 228-232. 54. Free Radic Res. Gentile C. 1266-1270. Biosynthesis and radical scavenging activity of betalains during the cultivation of red beet (Beta vulgaris) hairy root cultures. Will F. 247269. Reddy MK. Tesoriere L. Int J Sport Nutr Exerc Metab. Buckley JD. 43-47. 2003. Eur J Nutr. Schliemann W. Livrea MA. Vogt T. Buckley JD. Allegra M. Oral bovine colostrum supplementation enhances buffer capacity but not rowing performance in elite female rowers. 2003. 2004. but not performance. 2004. and red beet pomaces in rats. Sellappan S. Butera D. Absorption. excretion. Ilieva M. Austen SK. Rudrappa T. Tesoriere L. 3 4 5 6 7 238 . Distribution of betalain pigments in red blood cells after consumption of cactus pear fruits and increased resistance of the cells to ex vivo induced oxidative hemolysis in humans. 2005. Strack D. Wall CR.11 Pavlov A. Conacher M. 2005. 577-588. 2006. Aswathanarayana RG. grape. Yi W. Buckley JD. Tuneva D. Am J Clin Nutr. and distribution of dietary antioxidant betalains in LDLs: potential health effects of betalains in humans. 640-644. Cross ML. 2003. Koleva I. 243-247. 2003. 53. 2001. Allegra M. Van Gammeren D. 1184-1188. Pavlov A. 12 13 14 15 16 17 18 19 20 21 ID 1475: “Bovine colostrum” and “Supports an increase in lean body mass when combined with resistance exercise” 1 2 Antonio J. Alexander-Lindo RL. Biotechnol Prog. Kovatcheva P. Stintzing FC. Dose effects of oral bovine colostrum on physical work capacity in cyclists. Physiological effects of extraction juices from apple. 53. Radical scavenging activity and stability of betalains from Beta vulgaris hairy root culture in simulated conditions of human gastrointestinal tract. 777-785. Livrea MA. Tesoriere L. 34. Med Sci Sports Exerc. The effects of bovine colostrum supplementation on body composition and exercise performance in active men and women. Mehrlander K. 349-365. and human tumor cell proliferation by natural food colors. 2002. Bourdon PC. Fazzari M. Neelwarne B. David A. Int J Sport Nutr Exerc Metab. 5. 9268-9273. 17. J Agric Food Chem. Mosshammer MR. 2005. 689-696. 65-79.) clones. Kovatcheva P. Bley T. 2002. Color. Phytochemistry. Crooks CV. 442-451. 60. 941-945. Allegra M. 20. Brinkworth GD and Buckley JD. Effect of bovine colostrum on anaerobic exercise performance and plasma insulin-like growth factor I. J Sci Med Sport. Brinkworth GD. 2006. 2006. Z Naturforsch [C]. J Agric Food Chem. 40. betalain pattern. Livrea MA. Allegra M. D'Arpa D. Butera D. 37. 80. 53. 21. Georgiev V. Carle R. J Sports Sci. 753-761. Gulbin JP. Abbott MJ. Butera D. Recent advances in betalain research. Butera D. Bovine colostrum supplementation during endurance running training improves recovery. 62. Akoh CC. Plant Foods Hum Nutr. Marshall PA. cyclooxygenase enzymes. 12. Gentile C. Zhuo XG. Hackler L. 10446-10451. Huang CN. J Appl Physiol. 1117-1124. Brown NJ and Vaughan DE. Aalto J. Phase 1 study of multiple biomarkers for metabolism and oxidative stress after one-week intake of broccoli sprouts. Chang CY. hormone. Moore TJ. and IgG responses to bovine colostrum supplementation during training. Effects of bovine colostrum supplementation on immune variables in highly trained cyclists. 2007. Circulation. Antioxidant and antiproliferative activities of common vegetables. 1411-1420. Karanja N. Leppaluoto J. Boca Raton. endogenous mu-opioid agonists. Obarzanek E. Jost R. Caballero B. ID 1481: “Broccoli Sprout Powder” and “Antioxidant properties” 9 10 1 2 3 4 Benzie IFF and Strain JJ. 2005. Murashima M. 7421-7431. Pavillard B. Wang CK. Kadowitz PJ. Stevenson L. 56. Eberhardt MV. 56-67.). Peake J. Jeffery EH. Cadee JA. Chanton S. Pakkanen R. Scherz JC. 2006. and cellular measures of antioxidant activity of broccoli (Brassica oleracea L. Mero A. Lin PH. Var. Suzuki K. Proc Natl Acad Sci USA. PL175179. Diets and Antioxidant Defence. 2006. Effect of skim milk supplementation on blood cholesterol concentration. 2004. Elsevier. Kahkonen J. Juillerat MA. 2002. 1989. Bostick RM. Bovine casein hydrolysate (c12 Peptide) reduces blood pressure in prehypertensive subjects. J Agric Food Chem. 50. Effects of bovine colostrum supplementation on serum IGF-I. Jenkins DG. Takala T. Review of antioxidant function of Broccoli. 2 3 4 5 6 239 . Cho EJ. 437-444. Kobira K. Yoo HH. A clinical trial of the effects of dietary patterns on blood pressure. Kilara A. J Nutr Sci Vitaminol (Tokyo). Yokozawa T. IgA. Allen L.). Biofactors. Motley S. and triglycerides in a free-living human population. 2004. Liu RH. 336. Czapla MA. 2096-2102. Zadina JE. and saliva IgA during training. Brassica vegetable consumption reduces urinary F2-isoprostane levels independent of micronutrient intake. Wu X. CRC Press. J Am Coll Nutr. Vollmer WM. Kastin AJ. 1992. Buonopane GJ. 20. Tryptic phosphopeptides from whole casein. II. Okutsu M. N Engl J Med. 271-275. Rasi S. 83. 6910-6916. Carcinogenesis. IGF-I. Endomorphin 1 and 2. Fowke JH. 63-65. 93. 1998.8 Mero A. In: Dictionary of Nutraceuticals and Functional Foods. Physicochemical properties related to the solubilization of calcium. Sacks FM. IgG. Prentice A (eds. J Agric Food Chem. Berrocal R. decrease systemic arterial pressure in the rat. 97. 102. Correlation analyses of phytochemical composition. 11. Watanabe S. Eskin NAM and Tamir S. J Dairy Res. 62. In: Encyclopedia of Human Nutrition. Ness RM. Lee YA. J Appl Physiol. Keck AS. Uehara M. McCarthy RD. Cutler JA. Gao X and Talalay P. 2005. Pereira R. Parviainen T. Takala T. ID 1483: “C12-peption” and “Vascular health” 5 6 7 8 1 Appel LJ. Nykanen T. Antioxidants. Miikkulainen H. Windhauser MM. Svetkey LP. Bray GA. 1113-1122. 732-739. Juvik JA. 1-5. blood pressure. Am J Hypertens. 101. 2006. Smith JS. Morrow JD. 27. Vogt TM. J Appl Physiol. 117-131. Chen SL. Ge LJ. Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. 1997. Life Sci. 22. 2007. 52. chemical. 2002. Eskin NAM and Tamir S (eds. italica). Coombes JS. Kurashige A. 53. Chu YF. 11441151. Chen CW. Sun J. Angiotensin-converting enzyme inhibitors. Champion HC. Riski J. 335341. Shing CM. 1998. DASH Collaborative Research Group. Protective effects of broccoli (Brassica oleracea) against oxidative damage in vitro and in vivo. Oxford. Jokinen I. Nikula T. 1997. 124-127.7 8 FitzGerald RJ and Meisel H. Kerojoki O. 379-382. 1992. 6. Hypertension.go. 1995a. Nakamura Y. Yamamoto N. Nakamura Y. 2002. CRC Crit Rev Biochem. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Takano T. 1996. 1996. 1984. 381-411. 66. Nakamura Y. Tossavainen O. Overview on milk protein-derived peptides. Piilola K. 1253-1257. in human intestinal Caco-2 cell monolayers. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 240 . Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions. Kobayashi Y. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Gagnaire V. 1986. 78. Nakamura Y. 57. Alpha-lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Synthetic peptides corresponding to alpha-lactalbumin and beta-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. 1984. Sakai K. 2003. Kita E. 322-328. Karaki H. Masuda O. Yamamoto N. 367-371. Transepithelial transport of the bioactive tripeptide. 1996. Uchiwa H. 63. 1995b. McCarron DA.jp/english/topics/foodsafety/fhc/index. Costas R. 259-260. Analogy between fibrinogen and casein. Takemoto S. calcium intake. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. 158. J Dairy Res. 66. 45. Gillessen D. Dunn FW. Puerto Rico Heart Health Program study. Arai S. 513-517. Takano T. 2000. J Dairy Sci. FitzGerald RJ. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. 1996. Seppo L.a pilot study on humans. 767-771. and decreased hypertension in Puerto Rico. 378-384. Yamamoto M. 2002. Food for Special Dietary Uses. Toyama S. 1984. S33-37. Soria C. Korpela R. 96. 8.. 1535-1543. Sorlie PD. J Jpn Soc Nutr Food Sci. Korpela R. Fiat AM. Suomalainen T. Am J Clin Nutr. 64. Japan: Food with Health Claims. Life Sci. J Dairy Sci. Maeno M. Yamazaki S. Caen JP. Sipola M. Sugai R. Havlik RJ. 84 Suppl 1. Ondetti MA and Cushman DW. Korhonen H.mhlw. Pierre A. 79. Cruz-Vidal M. Ministry of Health. Antihypertensive effect of tryptic hydrolysate of milk casein in spontaneously hypertensive rats. 1996. Stanton JL. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. and Nutrition Labeling http://www. Poussa T. Blood pressure and nutrient intake in the United States. Milchwissenschaft. Tillotson J. The effect of a Lactobacillus helveticus LBK-16 H fermented milk on hypertension. Biosci Biotechnol Biochem. 326-330. Jolles P. Doi K. Sekiya S. Br J Nutr. Takano T. Imamura Y. 78. Biol Chem Hoppe Seyler. 377. Yamamoto N. 1990. 405-422.html. 16. Int Dairy Journal. Takano T. Jauhiainen T. 777-783. Labour. Identification of an antihypertensive peptide from casein hydrolysate produced by a proteinase from Lactobacillus helveticus CP790. Molle D. Satake M. Meisel H. 1998. Nakajima K. Takano T. 77. Meisel H. Sugano S. Kawamura Y. Seppo L. FNFC/FOSHU (Food with Nutrient Functional Claims/Foods for Specified Health Use). Sakai K. Kaarto H. Val-Pro-Pro. Vapaatalo H. Morris CD. Thomaidis A. Takano T. Garcia-Palmieri MR. Nurminen ML. Effect of an undecapeptide isolated from kappa-casein on platelet function. J Dairy Sci. Phosphopeptides interacting with colloidal calcium phosphate isolated by tryptic hydrolysis of bovine casein micelles. Murakami U. and Welfare. Hata Y. Henry HJ. 1316-1321. 1392-1398. Levy-Toledano S. Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers. 126. Am J Clin Nutr. 2000. 30633068. Shimizu M. Okubo A. Korpela R. Pihlanto-Leppala A. 363-373. 224. Mullally MM. Comp Biochem Physiol C. Ohni M. Leonil J. J Nutr. Eur J Biochem. Milk consumption. Jr. Nakamura Y. Science. Enjoh M. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Presence of the mu3 opiate receptor in endothelial cells. Finckenberg P. 1995. Milk protein-derived opioid receptor ligands. Nurminen ML. Goligorsky MS. Am J Clin Nutr. Walsh DJ and FitzGerald RJ. Vermeirssen V. Boston. 82. Korpela R. Zahorska-Markiewicz B. Astrup A. Montigon F. Van Beresteijn EC. 95-100. J Pept Sci. Bulletin-FIL-IDF. Teschemacher H. Caffeine: a double-blind. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Physiol Pharmacol. Sugai R. 17. Takano T. Poehlman ET. Arciero PJ. 99-117. Nissinen A. Verstraete W. Intestinal transport of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg through a Caco-2 Bbe monolayer. and cardiovascular effects in healthy volunteers. Graham HN. Spiller GA (ed. In: The American Heritage Dictionary of the English Language. Effect of long-term intake of milk products on blood pressure in hypertensive rats. A randomized. In: Proteins in Food Processing. 69.) Woodhead Publishing Limited. Anantharaman K. Vapaatalo H. Jauhiainen T. Am J Physiol. van Schaik M. 8. Houghton Mifflin Harcourt. Bougopoulos CL. 43. Lindstrom J. Boca Raton. Benowitz NL. McFadden CB. 759-767. J Hum Hypertens. Takano T. Townsend RR. placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Van Camp J. 2002. Calles-Escandon J. Effects of caffeine ingestion on NE kinetics. Milk derived peptides and hypertension reduction. Gardner AW.) CRC Press. Liu Y. Pittet P. 1056-1058. Arciero PJ. 49. J Dairy Sci. Coupling to nitric oxide production and vasodilation. Tappy L. Fay LB. Int Dairy Journal. 35-72. Am J Clin Nutr. In: Caffeine. Chemistry and Consumption of the Beverage. Santisteban J. 795-802. J Biol Chem. 101-107. Cannon S. Harbowy ME. 1388-1393. Korpela R. UK. 52. Mikkola L. 2001. fat oxidation. Vapaatalo H. Seppo L. Metabolism. Nindl BC. E1192-1198. Tea: The plant and its manufacture. Influence of age on the thermic response to caffeine in women. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Schindler C. Hyyrynen J. Nurminen ML. Gay LJ. 745-754. Finckenberg P. Krebs Y. 8. Jequier E. Koch G. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. 1990. Biopolymers. 2004. J Dairy Res. 228. 51. 40-46. 2002. ACE inhibitors and functional foods. Casares F. Gremaud G. The functional value of dairy proteins. Karhunen ML. Maeno M. 477-482. and energy expenditure in younger and older men. 268. Stefano GB. 2004. Balentine DA. 375-381. 30290-30293. Yamamoto N. Acheson KJ. 17-20. Yada RY (ed. ID 1484: “Caffeine” and “Fat metabolism/Energy expenditure” 28 29 30 31 32 33 34 35 36 37 38 1 2 Caffeine. Bilfinger TV. double-blind. Purification and characterization of an antihypertensive peptide from a yogurt-like product fermented by Lactobacillus helveticus CPN4. 2004. 33. Milk: does it affect blood pressure? A controlled intervention study. 989-997. Madsen J. J Intern Med. 270. Meirim I. 1999. Ford V. 1998. 2004.27 Sipola M. Gaskins HR. Sipola M. Korpela R. placebocontrolled study of its thermogenic. Schneiter P. 3 4 5 6 7 241 . 2000. Schaafsma G. Tuomilehto J. 79. Cadee JA. 1980. Hartman A. Deplancke B. Hein P. Magazine HI. 1998. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr. 103-111. Toubro S. Acheson KJ. Brantl V. Am J Hypertens. 18. Benowitz NL. 1998. Breum L. Tappenden KA. 1990. metabolic. 1997. 1995. 2000. Cambridge. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 242 . 39-41. Takeda Y. Schutz Y. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. Katsuragi Y. Shimasaki H. Cell Mol Life Sci. 50. and stress on cognitive performance and mood during U. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. 294-304. 1999. Jequier E. Nippon Rinsho Eiyo Gakkai Zasshi. Hadjicharalambous M. Dulloo AG. Effects of eight weeks of caffeine supplementation and endurance training on aerobic fitness and body composition. 1936. Kunii D. heart rate. Br J Sports Med. sleep loss. Geissler CA. Malek MH. Miller DS. Speckman KL. 20. Komine Y. placebo-controlled. Komatsu T. J Psychopharmacol. 2004. Caffeine as a psychomotor stimulant: mechanism of action. 1040-1045. 1981. Milne AL. Hase T. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Graham TE and Spriet LL. Haskell CF. Journal of Oleo Science. 250-261. A double-blind. J Med Invest. The effect of coffee and decaffeinated coffee on oxygen consumption. Matsui Y. Willson RJ. 2292-2298. Am J Clin Nutr. J Strength Cond Res. Yamamoto S. 6570. 2002. Holmen J. Chen WY.S. Housh DJ. Wesnes KA. Kimura J. 42. 269. 857-872. 875-887. 2006. Influence of caffeine on perception of effort. J Appl Physiol. 34. James WP. Shukitt-Hale B. Okamura M. Johnson GO. Sea-Air-Land. 2291-2294. 2005. Horton T. Yang ZB. 71. McNaughton LR. Hosoda K. Chen L. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Tokimitsu I. 2003. Inaoka S. Lovett R. Turner AP. Matsui K. 2518. Smith RG. Borgkvist A. Fathi M. Journal of Pharmacology and Experimental Therapeutics. Kennedy DO and Scholey AB. Coburn JW. Am J Clin Nutr. 3-8. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. The influence of caffeine ingestion on incremental treadmill running. Ishikura Y. 2004. Komatsu K. 1999. 51. Clinical efficacy of oolong tea on anti-simple obesity. Horst K. 1991. Arch JR. 1986. 2001. Lin BH. Kennedy DO. Georgiades E. 58. 2002. Chantre P and Lairon D. metabolism and exercise performance following a high-fat meal. Callingham BA. 60. 527-535. A glucose-caffeine 'energy drink' ameliorates subjective and performance deficits during prolonged cognitive demand. Cawthorne MA. Sakai T. Fisone G. 83-133. 70. Mensi N. 49. Hollands MA. 1989. 9. Shetty PS. Zvartau EE. Vandermander J. Performance and metabolic responses to a high caffeine dose during prolonged exercise. 24. Psychopharmacology (Berl). Effects of caffeine. Nehlig A. Pitsiladis YP. Jung RT. 164. 50. J Sports Sci. Anti-obesity effects of tea catechins in humans. Battig K. 1981. 109-112. Tulley R. 751-755. 21. Barrand MA. E671-678. Arnaud MJ. Navy SEAL training. Rohrer D. Chantre P. Scholey AB. Girardier L. Nakamori M. Collins A. Fredholm BB. 20. Oolong tea increases energy metabolism in Japanese females. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Clin Sci (Lond). 61. Am J Physiol. Phytomedicine. 2007. 599-605. 170175. Tharion WJ. Dulloo AG. Hosoda K. 44-50. Coffee: The demon drink? New Scientist. Kilduff LP. Ferrarra JM. Beck TW. Meguro S. 1995. Duret C. 331-333. Lieberman HR. Am J Clin Nutr. multi-dose evaluation of the acute behavioural effects of guarana in humans. Tsofliou F. Pharmacol Rev. Usiello A. pulse rate and blood pressure. Toyama K. 83-90. 20. Housh TJ. and methylxanthine metabolism in lean and obese women. Effects of caffeine on energy metabolism. Schmidt RJ. Appetite. 1998.8 9 10 11 Bracco D. Takahashi H. Matsui Y. 2006. Zahorska-Markiewicz B. Ishikura Y. 131. Coffee induced thermogenesis and skin temperature. 16. The effect of caffein on the heat production. 34. Anderson ME. Wiley E. 13. 1984. Lambert J. 51. Turconi G. 119-129. 2002. Pittet P. 2001. 3 4 5 6 7 8 9 10 11 243 . 40-46. Roberfroid M. Berlin. Itakura H. Psychopharmacology (Berl). Arnaud MJ. Nehlig A. 1998. Fay LB. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. Heidelberg. Fern E. Acheson KJ. 139-150. Functional food science and behaviour and psychological functions. 1990. Westerterp-Plantenga MS. Caffeine and the central nervous system: mechanisms of action. Anantharaman K. Oolong tea increases metabolic rate and fat oxidation in men. Battig K and Buzzi R. Yamamoto S. 1980. Cox H. Madsen J. Alford C. Aub JC. 18. Br J Nutr. 80 Suppl 1. Cena H. Rumpler W. Oxford. Am J Clin Nutr. 2004. 176. 2001. biochemical. 19. Hawley JA. Barone JJ and Roberts HR. Klein R. Westerterp-Plantenga MS. 1999. Caballero B. Blundell JE. 247-253. Daval JL. Cha YS. Tsuchida T. Meirim I. Caffeine and related methylxanthines: possible naturally occurring pesticides. 1986. Jequier E. Arch Intern Med. Caffeine consumption. Schindler C. Lanzola E. Elsevier. Dye L. Blood glucose and human memory. J Nutr. Schneiter P. 2001. Twentieth paper. Nathanson JA.). Improved 2000meter rowing performance in competitive oarswomen after caffeine ingestion. and cardiovascular effects in healthy volunteers. Rogers PJ.28 29 30 31 32 33 34 35 36 Means JH. Choi SK. Suh H. Seale J. 1994. Wescott R. Methylxanthines are the psycho-pharmacologically active constituents of chocolate. Gaffan EA. Du Bois EF. 17. 759-767. Ryu S. 989-997. Hopkins WG. 184-187. Prentice A (eds. Allen L. metabolic. Kovacs EM. Prog Med. placebocontrolled study of its thermogenic. Int J Obes Relat Metab Disord. 33. Judd J. Astrup A. Joung SS. Int J Sport Nutr Exerc Metab. Lejeune MP. 10. Cannon S. 1996. The effects of red bull energy drink on human performance and mood. Food Chem Toxicol. 22. Montomoli C. Stepto NK. Tappy L. Am J Clin Nutr. Clinical calorimetry. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. ID 1485: “Caffeine (from tea/coffee/chocolate or added in pure form)” and “Cognitive and mental performance” 1 2 Lexikon der Biochemie. 126-130. Caffeine: a double-blind. 2004. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. 2000. Reduction of body fat in humans by long-term ingestion of catechins. 2005. 464-475. 2848-2852. Obes Res. Fraser SF. Science. Gremaud G. 537-541. 226. Krebs Y. 47. Toubro S. Lee S. 8388. 1195-1204. Hosoda K. Hein P. Debry G. Nakamura H. Neuropsychobiology. 2005. Specter S. 139-170. Psychopharmacology (Berl). In: Encyclopedia of Human Nutrition. Bruce CR. Breum L. Komatsu T. Gay LJ. Acheson KJ. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr. Smit HJ. 113. Montigon F. Spektrum. Clevidence B. Effect of coffee on the speed of subject-paced information processing. 412-419. Lim K. 21. metabolic and psychostimulant effects. 2189-2203. Brain Res Brain Res Rev. J Nutr Sci Vitaminol (Tokyo). S173-193. 1917. Terracina D. 1993. Tagliabue A. Bellisle F. 79. Westenhofer J. Fantino M. 1992. 832-839. Sawaki T. Benton D and Owens DS. Fletcher RJ. 139-146. Caffeine. Amino Acids. Knuttgen H. Blood glucose influences memory and attention in young adults. Wirth O. 44-50. 188-192. 140. Brice CF and Smith AP. Berglund B and Hemmingsson P. Hopkins WG. Prentice A. J Sports Med Phys Fitness. Encyclopedia of Human Nutrition Elsevier. 93. 1997. 258-266. Neurosci Biobehav Rev. 233-238. 155-158. 378-385. Davies P. 15. 1998. Dorea JG and da Costa TH. Food sources and intakes of caffeine in the diets of persons in the United States. 110-113. Sunram SI. 1982. 3. 11. 2005. Int J Sports Med. Sports Med. Am J Clin Nutr. 1997. Herb RA. Marlowe B. 2002. 116-119. Hawley JA. Is coffee a functional food? Br J Nutr. Energiajuomien piristävät yhdisteet. McNaughton LR. 1995. The use of caffeine versus prophylactic naps in sustained performance. 2002. Med Sci Sports. Tristram S. Meyer AH. Glucose and memory: fractionation of enhancement effects? Psychopharmacology (Berl). 1978. J Biosoc Sci. Poortmans J (eds. Fine BJ. Dalsky GP. 31. Fink WJ. Costill DL. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 244 . Riley RH. www.12 13 14 15 16 17 18 19 20 Benton D. 2000. EVIRA (Finnish Food Safety Authority). Donohoe RT and Benton D. Carbohydrate ingestion. 10. Tharion WJ. 2005. Cadarette BS. Sleep. Revision. Parker PY. Durlach PJ. Dulloo AG. Caffeine ingestion prior to incremental cycling to exhaustion in recreational cyclists. Effects of caffeine on mood and performance: a study of realistic consumption. 18. 1990.). Gregory J. 425-432. 105. Bruce CR. 1983. Miller DS. Ferrauti A and Weber K. Psychopharmacology (Berl). 1993. Geissler CA. Int J Sports Med. 871-877. Davies P. Flinn S. McNaughton L. Psychopharmacology (Berl). Horton T. J Am Diet Assoc. Evans WJ. Oxford. Leeds. 137. 293-308. Kofeiini. Neuropsychologia. blood glucose and mood. Collins A. Bonnet MH. Human Kinetics Europe. Psychopharmacology (Berl). 1994. Lidder PG. 145. Eisenbrand G. 114.evira. 97-104. Cognitive functioning is susceptible to the level of blood glucose. Berube CL. 1996. Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. Lieberman HR. Johnson RK. Med Sci Sports Exerc. Effects of caffeine or diphenhydramine on visual vigilance. 595-607. 1999. Allen L. 259-270. 234-236. 164. 2005. The supply of glucose to the brain and cognitive functioning. 1994. 1991. Wang MQ. Benton D. 28. Vogel JA. 49. Caballero B. Gomez S. Stuttgart. Metabolic and ergogenic effects of carbohydrate and caffeine beverages in tennis. 1998. 26. 32. 32. Levine L. French C. Caffeine and exercise performance. An update. Effects of varied dosages of caffeine on endurance exercise to fatigue. 188-193. 773-782. Posner BM. Tristram S. Zur Auswirkung von Koffein im Tennis. Klein R. 1423. Kobrick JL. Struder HK. J Sports Med Phys Fitness. Anderson ME. 2006. Donohoe RT. Benton D. RÖMPP Lexikon Lebensmittelchemie. Frary CD. Enhancement of 2000-m rowing performance after caffeine ingestion. Schreier P. In: Biochemistry of Exercise Conference Proceedings. 1958-1963. 37. Parker PY. 1989. Ferrauti A. Powers SK. The effects of a low dose of caffeine on cognitive performance.fi/portal/fi/elintarvikkeet/elintarviketietoa/energiajuomat/energiajuomien_piristavat_yhdisteet/. Foster JK. Weber K. Psychopharmacology (Berl). Caffeine ingestion during exercise to exhaustion in elite distance runners. Thieme. Fraser SF. Arand DL. Dodd SL. Effects of caffeine ingestion on metabolism and exercise performance. Leistungssport 49-53. Owens DS. 463-479. Stepto NK. Psychopharmacology (Berl). Lane J. Graham TE and Spriet LL. 1995. Dye L. Acute dose-effect relationships of caffeine and mental performance. 26 Suppl. Psychopharmacology (Berl). Woodson PP. Jr. Hindmarch I. headache. 2000. 149. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. 1-11. 1046-1050. Neuropsychobiology. 252. Rigney U. Hoyland A. Tikuisis P. Human Psychopharmacolgy: Clinical and Experimental. 110. Graham TE and Spriet LL. Arch JR. J Appl Physiol. Aviat Space Environ Med. 2292-2298. Riedel WJ. Ernährungsmedizin und Diätetik. Lawton CL. coffee and water on alertness. Moore KL. 2291-2294. 539-545. Heishman SJ. Psychopharmacology (Berl). Hollands MA. 1988. Parkin C. 970-978. 354-361. 1993. Preston KL. 38. 76. 9. Griffiths RR. Metabolic. 1996. 2004. Quinlan P. sleep onset and sleep quality. Keefe AA. Acute effects of macronutrient manipulations on cognitive test performance in healthy young adults: a systematic research review. 32-41. Caffeine improves cognitive performance after strenuous physical exercise. 339-350. Wolf B. Multiple caffeine doses maintain vigilance during early morning operations. Brouns F. 20. Caffeine for the sustainment of mental task performance: formulations for military operations. Stuttgart. Thorne D. 45-52. Acute caffeine intake before and after fatiguing exercise improves target shooting engagement time. Rose MS. Johnson D. Low-dose caffeine discrimination in humans. J Appl Physiol. 1991. 179. 139. Belenky G. and sleep. 75. 1998. Am J Clin Nutr. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. 72-85. Psychopharmacology (Berl). Hogervorst E. 119-128. Kamimori GH. Cawthorne MA. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. 813-825. Jarvis MJ. Fulco CS. 1981. Performance and metabolic responses to a high caffeine dose during prolonged exercise. Urban & Fischer. Hindmarch I. 6. Quinlan PT. Gillingham RL. Acute and chronic effects of caffeine on performance. 1994. Aviat Space Environ Med. Stanley N. 2005. 71. Kennedy DO. J Pharmacol Exp Ther. and exercise performance responses to various doses of caffeine.36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 Frewer LJ and Lader M. Trad LA. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology (Berl). Caffeine and exercise performance. 230-238. 2001. Kovacs E. The effects of caffeine on two computerized tests of attention and vigilance. Hasenfratz M and Battig K. mood. Wissenschaftliche Verlagsgesellschaft mbH. Hahn A. 51 52 53 54 55 56 57 58 245 . Neurosci Biobehav Rev. Sannerud CA. Can J Appl Physiol. Wesnes KA. Kasper H and Wild M. National Academy Press. Haskell CF. Hewlett P and Smith A. Cymerman A. 865-871. Scholey AB. 281-287. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. 2006. 94. Evans SM. Forte VA. Psychopharmacology (Berl). 32. 203-216. 2001. 2007. cardiovascular and subjective parameters. Aviat Space Environ Med. Hum Psychopharmacol.. 2005. 78. 1991. Effect of caffeine on submaximal exercise performance at altitude. 867-874. A naturalistic investigation of the effects of day-long consumption of tea. Rock PB. München. 2008. 65. Graham TE and Spriet LL. 1994. 1990. Young PM. Caffeine. Jolles J. Griffiths RR and Woodson PP. S103-119. The effects of black tea and other beverages on aspects of cognition and psychomotor performance. James JE. 2000. 1998. Caffeine physical dependence: a review of human and laboratory animal studies. coffee and ephedrine: impact on exercise performance and metabolism. Graham TE. IoM (Institute of Medicine). Rycroft J. Int J Sports Med. 1999. EEG. catecholamine. 34. 114. 22. Sports Science Exchange (Gatorade Sports Science Institute). 437-451. Thesis. Caffeine. 38.). Magkos F and Kavouras SA. and cognition.. Shukitt-Hale B. Glucose administration. Human Psychopharmacology: Clinical and Experimental 5. 1995. Snel J. 2001. 1982. Aging. Navy SEAL training. 2001. 2003. 168-177. 2001. Mahmud A and Feely J. 147-154. 275-324. 92. In: Nutritional Ergogenic Aids. Nutr Rev. 1994. 401-413. 373-380. 2003. and stress on cognitive performance and mood during U. Karies. Effects of repeated caffeine administration on cognition and mood. Effects of caffeine. 33. Bertelsen B. Influence of caffeine on selective attention in well-rested and fatigued subjects. Roberts C. 1998. 1995. heart rate and cognitive performance: effects of increasing mental effort. Smith AP and Jones DM (eds. Lorist MM. In: Handbook of Human Performance: Health and Performance. 69 70 71 72 73 74 75 76 77 78 79 80 81 82 246 . 171-175. New York. Wiley-VCH. 1996. Loke WH. Brain Cogn. 91-102. 227-231. 63-71. Effects of caffeine. Caffeine and selective visual processing. Leathwood PD and Pollet P. Kennedy DO and Scholey AB. 490. Psychophysiology. Coviella IL. Kok A. and caffeinerelated information on physiological and psychological arousal. Kok A. Kok A. Acute effects of caffeine on selective attention and visual search processes. mood and energy.59 60 61 62 63 64 65 66 67 68 Kenemans JL and Lorist MM. Kennedy DO and Scholey AB. 411-421. 31. Lieberman HR. 2002. 1998. Snel J. 40. Lieberman HR. Caffeine and human information processing. 1994. 339-348. Kaffe. Electroencephalogr Clin Neurophysiol. Caffeine deprivation affects vigilance performance and mood. 1997. Röhm K-H. Can J Appl Physiol. Moeller H. Snel J. 453-467. Lorist MM and Tops M. Lorist MM. and information processing: an event-related potential analysis. Flaten MA. Caffeine effects on perceptual and motor processes. Wolinsky I and Driskell JA (eds. 52. 308-312. Lorist MM.500-metre swim. 149. 164. Psychopharmacology (Berl). Speckman KL. Psychopharmacology (Berl). 17. Lieberman HR. Boca Raton. A glucose-caffeine 'energy drink' ameliorates subjective and performance deficits during prolonged cognitive demand. 1987. Nutrition. 2000. Lorist MM. Tulley R. Sea-Air-Land. 250-261. 20. 1995. Eur J Pharmacol. Glucose improvement of memory: a review. 2004. Academic Press. Kase. Messier C. Acute effect of caffeine on arterial stiffness and aortic pressure waveform. Mulder G. Tharion WJ. sleep loss. 245-254. caffeine-associated stimuli. J Psychiatr Res. Lorist MM and Snel J. Weinheim. CRC-Press. Pharmacol Biochem Behav. Diet-induced mood changes in normal populations. 1995. The effects of low doses of caffeine on human performance and mood. Wurtman RJ. Lorist MM. Lane JD and Phillips-Bute BG. Appetite. 59. Emde GG. caffeine. Psychopharmacology (Berl). 354-361. Koolman J. Appetite. Caffeine. Caffeine. Psychopharmacology (Berl). Caffeine ingestion and performance of a 1.). 461-471. Mulder G. 102. Mulder G. brain function and cognitive performance. Hypertension. and caffeine on cognitive performance. 525-534. The effects of ginseng. Snel J. Psychophysiology. 2004. Lieberman HR. MacIntosh BR and Wright BM. Psychopharmacology (Berl). Physiol Behav. 1990. 65. Mikalsen A. Kok A. 33-57. 96. 1992. 42. University of Amsterdam. ephedrine. 113. Lieberman HR.S. Electroencephalogr Clin Neurophysiol. 157. 331-333. 2004. 82-94. fatigue. Influence of caffeine on information processing stages in well rested and fatigued subjects.Biochemie im Alltag. 53. 213-219.83 84 85 86 Miller LS. De Ruiter MB. The influence of different doses of caffeine on visual task performance. 2007. 1991. Ho C-T. 103-108. Psychopharmacology (Berl). Owens DS and Benton D. and chemistry. mood. Efficacy of a 'functional energy drink' in counteracting driver sleepiness. Journal of Psychophysiology. coffee and water ingestion on physiological responses and mood: the role of caffeine. 2001. Thomas M. 2005. Pharmacol Biochem Behav. Jeukendrup AE. Mood and psychomotor performance effects of the first. Lombardo TW. 1989. 30. and task performance in deprived and nondeprived coffee drinkers. Barberger-Gateau P. Parker PY. 2002. Sing H. Snel J. 471-478. 2000. 247 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 . de Haan A. 16. 66. Paluska SA. 57. Quinlan PT. 15. Rao A. O'Brien DC. O'Keeffe MK. Quinlan P. Caffeine and sports activity: a review. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). 2001. Int J Sports Med. Aspinall L. 145-165. 1998. 9. Owens DS. Curr Sports Med Rep. Am Chem Society. Galinski C. 106-113. 1995. 59. 134. Lorist M. Carriere I. Roth T. 1994. Physiol Behav. Plath D. Caffeine effects on the brain and behaviour: A metabolic approach. Drinking glucose improves listening span in students who miss breakfast. Aspen J. Aachen. 536-545. Psychophysiology. Physiol Behav. 2000. The effects of combined caffeine and glucose drinks on attention in the human brain. Schieberle P (eds. Riby LM. 201-207. Benton D. Thorne D. Reyner LA and Horne JA. Bosman MJ. 1993. Hu H. Rycroft JA. Rosenthal L. Ratliff-Crain J. 1999. 37-48. Parliment TH. physiological effects. Nutr Neurosci. Nehlig A and Debry G. The acute physiological and mood effects of tea and coffee: the role of caffeine level. Rogers PJ and Dernoncourt C. 1995. Snel J. 225-230. 2000. Educational Research. but not of subsequent. 359-365. Nehlig A. Caffeine and time of day effects on a force discrimination task in humans. McCann U. 215-223. 69. Physiol Behav. Belenky G. 4. 85.). Int J Sports Med. Effects of hot tea. 112. Psychopharmacology (Berl). The impact of raising blood glucose on reaction times. 164173. 1039-1045. Lane J. Ancelin ML. Nobre AC. Alerting effects of caffeine after normal and restricted sleep. Dartigues JF. Portet F. Neuropsychopharmacology. Tarnopolsky MA. The effects of caffeine on visual selective attention to color: an ERP study. 37. Roy BD. 13. Caffeine reversal of sleep deprivation effects on alertness and mood. 2. Behav Pharmacol. Moore KL. Pasman WJ. 8. Meyer & Meyer Sport. Morris N and Peter Saril. 280-286. 62. 1994. 427-447. Lane J. Rouaud O. 1997. The impact of age and task domain on cognitive performance: a meta-analytic review of the glucose facilitation effect. The effect of different dosages of caffeine on endurance performance time. Ritchie K. 19-28. de Mendonca A. 43. Zwyghuizen-Doorenbos A. Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. 75. 8. An acute oral dose of caffeine does not alter glucose kinetics during prolonged dynamic exercise in trained endurance athletes. 46-53. 141-153. Penetar D. Baum A. Ernährung im Sport. water and beverage type. Cardiovascular reactivity. Eur J Appl Physiol. 1998. In: Caffeineated beverages: Health benefits. Health Psychol. Neumann G. Ruijter J. 2004. Brain Impairment. 427-439. Fowler SC. cup-of-coffee equivalent doses of caffeine consumed after overnight caffeine abstinence. Robelin M and Rogers PJ. Roehrs T. Blood glucose and subjective energy following cognitive demand. Neuropsychobiology. Caffeine and exercise. Washington DC. 2007. 331-335. 1117-1125. 2003. 611-618. Pharmacol Biochem Behav. 1997. Kamimori G. Ruijter J. van Baak MA. 5. Neurology. Spiller GA. Dyck DJ. 217-223. Effects of ‗energy‘drinks on mood and mental performance: critical methodology. 473-482. 47. 2004. Coffee and health. CRC press. Neuropsychobiology. Lorist MM. Urban & Fischer Scholey AB and Kennedy DO. Effects of caffeine on human behavior. Human Psychopharmacology: Clinical and Experimental. Wilson ME. Graham TE. Schmiedel V. 635-642. 255-290. 1999. Smith AP. 40. Hultman E. Physiol Behav. 2000. 315-321. J Nutr Sci Vitaminol (Tokyo). 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 248 . especially for sportsmen. 157. SCF (Scientific Committee on Food). Amino Acids. Hauser E. Hughes SC. Sturgess W. 1992. Choi SK. Flynn R. 26. 7. 2000. Lim K. Smit HJ. 1993. Heine H. 1999. Neuropsychobiology. Effects of low doses of caffeine on cognitive performance. Joung SS. Smith AP. Breakfast cereal and caffeinated coffee: effects on working memory. 29-37. New York. Effects of caffeine given before and after lunch on sustained attention. 319-324. Gallagher J. 1997. Effects of low dose caffeine given in different drinks on mood and performance. Smith A. Snel J. Brockman P. Food quality and preference. 111. Investigation of the effects of coffee on alertness and performance during the day and night. 152. 19. Smith AP. The influence of caffeine on sustained attention: an ERP study. Lützner H. 14. Thomas M. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. The influence of caffeine on spatial-selective attention: an event-related potential study. 2001. 176. 2004. 160-163. Perez C. Food Chem Toxicol. Evans CD. Spriet LL. 2000. Lorist MM. Kendrick AM. 167-173. Psychopharmacology (Berl). 139-146. 317-326. Glucose facilitation of cognitive performance in healthy young adults: examination of the influence of fast-duration. 1992.106 107 108 109 110 111 112 Ruijter J. Nutr Neurosci. Maben AL. 1992. Clark R. 67. Effects of breakfast and caffeine on performance and mood in the late morning and after lunch. In: Caffeine. Sunram-Lea SI. 473-477. 2223-2233. 320-330. Leathwood P. Ludwig DA. Mood and cognitive performance effects of "energy" drink constituents: caffeine. Smit HJ and Rogers PJ. 2001. Arch Pediatr Adolesc Med. Snel J. 2004. 11. Leitzmann C.) Raven Press. Nicham R. de Ruiter MB. Ruijter J. Ryu S. time of day and pre-consumption plasma glucose levels. Savoca MR. 2001. Peyrl A. Savory M. Smith A. Eaton-Williams P. attention. E891-898. Rogers PJ. Smit HJ and Rogers PJ. Smith AP. 2002. 9-17. Cha YS. Harshfield GA. Suh H. 1999. Foster JK. Thomas M. 198-204. Psychopharmacology (Berl). Caffeine ingestion and muscle metabolism during prolonged exercise in humans. 1998. Durlach P. Lee S. De Ruiter MB. mood and thirst in low and higher caffeine consumers. 23. The association of caffeinated beverages with blood pressure in adolescents. Rusted JM. and cardiovascular function. Garattiini S (ed. Boca Raton. Neuropsychobiology. Gallagher J. coffee and tea. Cederblad G. caffeine and herbal flavouring fractions. Cognitive and physiological effects of an "energy drink": an evaluation of the whole drink and of glucose. 13. MacLean DA. 158. Maben A. 1990. A taurine and caffeine-containing drink stimulates cognitive performance and well-being. Psychopharmacology (Berl). Whitney H. mood. Handbuch für die Therapie. J Psychopharmacol. Clin Neurophysiol. Caffeine and the common cold. Ernährungsmedizin in der Naturheilkunde. Snel J. 262. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. Steptoe A and Wardle J. 2002. 127-139. 1243-1255. Mood and drinking: a naturalistic diary study of alcohol. Am J Physiol. 2001. glucose and carbonation. Caffeine. 27. Seidl R. Perry K. 141. Cotton JR. 2000. Smith A. Pharmacol Biochem Behav. 66. Psychopharmacology (Berl). Coffee and caffeine: sleep and wakefulness. 46-54. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. In: Beverages in Nutrition and Health. Oxford. 2001. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. 234-236. 2005. Klein R. Pittet P. 1995. Caffeine and Health. Bell DG and McLellan TM. Kalmijn S. 226-232. Encyclopedia of Human Nutrition Elsevier. Wilson T and Temple NJ (eds. Sleep. Cannon S. Bishop NC. Int J Sport Nutr Exerc Metab. Psychopharmacology (Berl). 1982. Breum L. 27. metabolic. Wemple RD. Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. Teedrogen und Phytopharmaka. 1990. Buijsse B. 51. 539-547. 2006. Tunger L. Caffeine: a double-blind. 80. Tijhuis M. 180. Klein R. 16. Hawley JA. 433-439. 61. 33. Int J Sport Nutr Exerc Metab. Van Dongen HP. Anderson ME.129 130 131 132 Ternes W. Bridge CA and Jones MA. Prentice A. Kjaer M. Psychopharmacology (Berl). Stepto NK. Improved 2000meter rowing performance in competitive oarswomen after caffeine ingestion. Caudwell P. 2002. Zijdewind I. Effect of repeated caffeine ingestion on repeated exhaustive exercise endurance. 119. Lebensmittel-Lexikon. Price NJ. 171-186. Stuttgart. Nissinen A. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. 40-46. Toubro S. Enhancement of 2000-m rowing performance after caffeine ingestion. J Appl Physiol. 2003. 2005. Hopkins WG. Behr's Verlag. Weinberg BA and K BB. Acute effects of caffeine ingestion at rest in humans with impaired epinephrine responses. Bruce CR. Jequier E. Szuba MP. van Gelder BM. 3. 2005. 24. 1958-1963. Humana Press. 2000. Anantharaman K. Int J Sports Med. McKeever KH. 989-997. J Appl Physiol. Distribution of caffeine levels in urine in different sports in relation to doping control before and after the removal of caffeine from the WADA doping list. Int J Sports Med. 35. Wichtl M. The effect of caffeine on cognitive task performance and motor fatigue. Astrup A. Täufel A. 24-35. Exercise endurance 1. Effects of caffeine on cognition and mood without caffeine abstinence. The effect of caffeine ingestion on neutrophil oxidative burst responses following prolonged cycling. Graham TE. Lorist MM. Giampaoli S. Van Soeren M. The effect of caffeine ingestion on 8 km run performance in a field setting. placebocontrolled study of its thermogenic. Hawley JA. Dinges DF. Mohr T. Lamb DR. 2002. Hamburg. 2006. Caballero B. 3. 1996. Madsen J. Allen L. Zahorska-Markiewicz B. 1348-1354. Zobel M. Stepto NK. 2006. 1227-1234. Bruce CR. van Duinen H. 2 3 4 5 6 7 8 9 249 . 2007. Fraser SF. Med Sci Sports Exerc. Fraser SF. and 6 h after caffeine ingestion in caffeine users and nonusers. Van Thuyne W and Delbeke FT. Berglund B and Hemmingsson P. 18. 10. 1980. Hopkins WG. Eur J Clin Nutr. and cardiovascular effects in healthy volunteers. 24. 813-819. Anderson ME. Kapoor SC. 2004. 759-767. Am J Clin Nutr. 93. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. Hein P. 133 134 135 136 137 138 139 ID 1486: “Caffeine (from tea/coffee/chocolate or added in pure form)” and “Physical Performance (short term and endurance activities)” 1 Acheson KJ. 745-750. 999-1005. Walker GJ. 32. Med Sci Sports Exerc. 66-70. 464-475. Wissenschaftliche Verlagsgesellschaft. Bell DG and McLellan TM.). Kromhout D. Warburton DM. Am J Clin Nutr. 2000. Int J Sports Med. Mullington JM. Dixon N. 1997. J Sports Sci. Effect of a divided caffeine dose on endurance cycling performance. 2002. 69-78. French C. Sports Med. 867-874. 2004. Costill DL. postexercise urinary caffeine concentration. Caffeine ingestion during exercise to exhaustion in elite distance runners. 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 250 . Effects of caffeine ingestion on utilization of muscle glycogen and lipid during leg ergometer cycling. Ahmaidi S. Fulco CS. McNaughton LR. Doherty M and Smith PM. Young PM. Struder HK. 1991. 785807. 1980. van Soeren MH. Metabolic and ergogenic effects of carbohydrate and caffeine beverages in tennis. 188-193. Effects of caffeine ingestion on exercise testing: a meta-analysis. 1994.. Berube CL. 49. Eur J Appl Physiol Occup Physiol. Levine L. Collomp K. 37. Davies P. Montgomery PG. Effects of caffeine ingestion on rating of perceived exertion during and after exercise: a meta-analysis. 2003. Dodd SL. 111-138. Roberts A. Gregory J. Leeds. J Sports Med Phys Fitness. Trappe SW. 1993. Graham TE and Spriet LL. Powers SK. 1423.10 Cadarette BS.). Goodpaster BH. 93. Audran M. Trad LA. and plasma paraxanthine. Chatard JC. Caffeine and exercise performance (Gatorade Sports Science Institute). Desbrow B. In: Biochemistry of Exercise Conference Proceedings. 1978. The effects of a low dose of caffeine on cognitive performance. Int J Sports Med. 626-646. 155-158. Stannard SR. Fink WJ. Effects of caffeine ingestion on metabolism and exercise performance. Fink WJ. Rock PB. 1996. Metabolic. 78. Cymerman A. 31. Essig D. Int J Sport Nutr Exerc Metab. Horton T. 44-50. Hawley JA. Costill DL. Graham TE. Int J Sport Nutr. 425-432. 6. J Sports Med Phys Fitness. 2292-2298. 1989. 1995. and exercise performance responses to various doses of caffeine. Effect of caffeine ingestion on perception of effort and subsequent work production. 258-266. Bruce CR. Caffeine and exercise: metabolism. Van Handel PJ. Martin DT. Tristram S. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. 871-877. Med Sci Sports. 377-380. Effect of caffeine on submaximal exercise performance at altitude. Revision. Burke LM. Dulloo AG. 1994. Dalsky GP. Prefaut C. J Appl Physiol. Benefits of caffeine ingestion on sprint performance in trained and untrained swimmers. Vogel JA. 140. 2005. Caffeine ingestion prior to incremental cycling to exhaustion in recreational cyclists. 1991. Jr. 10. Collins A. Sports Med. Herb RA. Cox GR. Forte VA. Graham TE and Spriet LL. 1-11. 1997. Sports Science Exchange. J Appl Physiol. Tristram S. Caffeine and exercise performance. Knuttgen H. Flinn S. Evans WJ. Geissler CA. 11. Graham TE. Human Kinetics Europe. 9. Costill DL. J Appl Physiol. Durlach PJ. 31. endurance and performance. 1983. 1996. 1992. McNaughton L. 71. Weber K. Rose MS. catecholamine. 1998. Poortmans J (eds. Performance and metabolic responses to a high caffeine dose during prolonged exercise. 1557-1562. 65. 15. Anderson ME. Scand J Med Sci Sports. 2001. 14. Can J Appl Physiol. Moquin A. 94. Macrides TA. 990-999. 19. Graham TE and Spriet LL. 86-90. Conway KJ. Posner BM. 539-545. Aviat Space Environ Med. Davies P. Cole KJ. Am J Clin Nutr. Effects of varied dosages of caffeine on endurance exercise to fatigue. 1. 64. Int J Sports Med. 14-23. Rush JW. Caffeine and exercise: metabolism and performance. 15. Doherty M and Smith PM. 1990. Ferrauti A. 116-119. Miller DS. Orr R. Starling RD. J Appl Physiol. Effect of different protocols of caffeine intake on metabolism and endurance performance. Psychopharmacology (Berl). An update. 1981. Thomas M. Low-dose caffeine discrimination in humans. headache. Ivy JL. Physiol Behav. Neuropsychobiology. 15. Aviat Space Environ Med. Thorne D. Caffeine improves cognitive performance after strenuous physical exercise. 1995. 171-175. 16. Can J Appl Physiol. 11. 666-672. physiological effects. Curr Sports Med Rep. Fink WJ. McLellan TM. 2003. Kamimori GH. 110. J Appl Physiol. 1998. and performance. Graham TE. Psychopharmacology (Berl). Penetar D. Pharmacol Biochem Behav. 2nd. Riedel WJ. Keisler BD and Armsey TD. Caffeine and exercise. 168-177. 75. Voss DM. Sing H. Int J Sports Med. 1837-1844. de Haan A. 1995. 1993. Leathwood PD and Pollet P. Vollebregt L. Caffeine reversal of sleep deprivation effects on alertness and mood. 6-11. Parliment TH. 1996. Galinski C. 2001. 81. 709-715. 17. 5. 20. Effect of caffeinated drinks on substrate metabolism. Lane JD and Phillips-Bute BG. 34. Caffeine ingestion and performance of a 1. 2000. Caffeine improves physical performance during 24 h of active wakefulness. Preston KL. 33. Stegen J. Jeukendrup AE. Wolf B. Friars D. Cole KG. Belenky G. 46-53. 1999. and endurance responses to caffeine during intense exercise. 1998. Little effect of caffeine ingestion on repeated sprints in teamsport athletes. Aviat Space Environ Med. Kamimori GH. 822-825. Int J Sports Med. Kovacs EM. Metabolic catecholamine. 32-41. Griffiths RR. Am J Clin Nutr. McCann U. McLellan TM. Arch JR. 1990. Paton CD. 2001. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. James JE. 20. Kamimori G. 45-52. Caffeine for the sustainment of mental task performance: formulations for military operations. Jackman M. Woodson PP. 970-978. Rogers PJ and Dernoncourt C. Bell DG. Johnson D. MacIntosh BR and Wright BM. Caffeine and sports activity: a review.500-metre swim. 89. Am Chem Society. Bell DG. 354-361. Med Sci Sports Exerc. In: Caffeineated beverages: Health benefits. 1998. Schieberle P (eds. J Psychiatr Res. Influence of caffeine and carbohydrate feedings on endurance performance. 215-219. Med Sci Sports. 1039-1045. Nehlig A and Debry G. 59. Curr Sports Med Rep. caffeine excretion. Jarvis MJ. and sleep. Kovacs E. 1998. Friars D. J Appl Physiol. Graham TE. 47 48 49 50 51 52 53 251 . 1979. The effect of different dosages of caffeine on endurance performance time. 225-230. Acute and chronic effects of caffeine on performance. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology (Berl). Lower RW. Costill DL. Paluska SA. Diet-induced mood changes in normal populations. 76. Caffeine maintains vigilance and improves run times during night operations for Special Forces. Int J Sports Med. Wendling P. National Academy Press. 213-219. 252. 647-654. 2291-2294. 65. Hollands MA. Caffeine effects on the brain and behaviour: A metabolic approach. J Pharmacol Exp Ther. mood. 2. Heishman SJ. Cawthorne MA. Brouns F. 2005. Hogervorst E. IoM (Institute of Medicine). van Baak MA. Jolles J. Pasman WJ. 1993. 85.31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Greer F. 112. Ho C-T. Washington DC.). 2004. 147-154. Comparison of caffeine and theophylline ingestion: exercise metabolism and endurance. Evans SM. 1982. Caffeine as an ergogenic aid. J Appl Physiol. Hopkins WG. and chemistry. Nehlig A. Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. 1994. 2000. Sannerud CA. 2006. 215-223. Caffeine deprivation affects vigilance performance and mood. 1658-1663. 38. Brouns F. 359-365. Effects of low doses of caffeine on cognitive performance. Hein P. Calles-Escandon J. Geissler CA. 551-556. Cha YS. Cairns SP. Arch Pediatr Adolesc Med. Med Sci Sports Exerc. Coleman D. 2006. MacLean DA. Am J Clin Nutr. 813-819. Maben A. Joung SS. Benowitz NL. Boca Raton. 2001. Harbowy ME. and cardiovascular effects in healthy volunteers. Chemistry and Consumption of the Beverage. Lamb DR. Kapoor SC. 1998. Effects of caffeine on prolonged intermittent-sprint ability in team-sport athletes. 37. Flynn R. 2001. Neuropsychopharmacology. Influence of age on the thermic response to caffeine in women. metabolic. Neuropsychobiology. SCF (Scientific Committee on Food). Suh H. Wiles JD. Hackett LP. 1990. 2000. Am J Physiol. Sleep. Hopkins WG. Int J Obes Relat Metab Disord. Graham TE. 268. 2001. Cannon S. Spriet LL. 2004. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Dinges DF. Harshfield GA. 167-173. Price NJ. Cornelius MF. Tegerdine M. 66-70. Collins A. 139-146. J Nutr Sci Vitaminol (Tokyo). Effects of caffeine on cognition and mood without caffeine abstinence. Warburton DM. 27. Caffeine ingestion and muscle metabolism during prolonged exercise in humans. Arciero PJ. 23. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. Rusted JM. Leathwood P. Spiller GA (ed. 44-50. 1995. 1994. 38. 18. Szuba MP. 2006. 49. 119. fat oxidation. 158. 1992. 101-107. Evans CD. 1165-1171. Graham HN. Walker JF. Am J Physiol. Horton T. Zwyghuizen-Doorenbos A. Plath D. 49. 47. Ludwig DA. Benowitz NL. 1995. Stuart GR. Savory M. Wemple RD. Metabolism. Effect of caffeine and/or cigarette smoking on resting energy expenditure. placebocontrolled study of its thermogenic. 262. Savoca MR.) CRC Press. Dawson B. Cederblad G. especially for sportsmen. Roth T. Dyck DJ. 152. and energy expenditure in younger and older men. McKeever KH. 40-46. Smith AP. Am J Clin Nutr. Multiple effects of caffeine on simulated high-intensity team-sport performance. 160-163. Psychopharmacology (Berl). Brockman P. Psychopharmacology (Berl). Breum L. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. The effects of caffeine ingestion on performance time. 2000. Ryu S. Bishop D. 103-108. E891-898. 473-477. 1993. Med Sci Sports Exerc. Int J Sports Med. Effects of caffeine ingestion on NE kinetics. E1192-1198. 24. 1998-2005. 18. Stamford BA. 2005. Balentine DA. Gardner AW. In: Caffeine. Smith AP. Caffeine: a double-blind. Swaine IL. 1997. Van Dongen HP. 4. Schneiker KT. Miller DS. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. 217-223. Smit HJ and Rogers PJ. Dulloo AG. Vogel RL. The association of caffeinated beverages with blood pressure in adolescents. Madsen J. speed and power during a laboratory-based 1 km cycling time-trial. 1989. ID 1487: “Caffeine” and “Supports resting metabolic rate and thermogenesis” 1 Arciero PJ. Tea: the Plant and its Manufacture. 35-72. Hultman E. Thomas M. Investigation of the effects of coffee on alertness and performance during the day and night. Effects of caffeine given before and after lunch on sustained attention. 24. Nindl BC. 1990. Alerting effects of caffeine after normal and restricted sleep. Roehrs T. Wilson ME. 1991. Mullington JM. 759-767. J Sports Sci. 2 3 4 5 6 252 . 578-585. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. Eaton-Williams P. Cook C.54 55 56 57 58 59 60 61 62 63 64 65 66 67 Rosenthal L. Choi SK. Neuropsychobiology. Astrup A. mood and thirst in low and higher caffeine consumers. Toubro S. Lim K. Poehlman ET. Collins LC. Bougopoulos CL. Lee S. 51. Bruce CR. Improved 2000meter rowing performance in competitive oarswomen after caffeine ingestion. Med Sci Sports Exerc. Nadeau A. Enhancement of 2000-m rowing performance after caffeine ingestion. Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. Celik S. Am J Clin Nutr. Engels HJ. Lanzola E. Human Kinetics Europe. Levine L. 8 9 10 11 12 13 ID 1488: “Caffeine” and “Supports exercise performance (reduction in perceived exertion. Tagliabue A. Terracina D. Denadai BS and Denadai ML. 2002. Plantes thérapeutiques: tradition. 2 3 4 5 6 7 8 9 10 11 12 253 . Poortmans J (eds. Hein P. Dussault J. 1990. Anderson ME. Am J Clin Nutr. Influence of caffeine on metabolic and cardiovascular functions during sustained light intensity cycling and at rest. 1990. 1958-1963. Evans WJ. Int J Sports Med. Can J Physiol Pharmacol. 989-997. Dorsey JL. Powers SK. Astrup A. Encyclopedia of Human Nutrition Elsevier. 581-585. Klein R. 1040-1045. Klein R. Med Sci Sports.7 Dulloo AG. 1423. 1998. 2000. and 6 h after caffeine ingestion in caffeine users and nonusers. Duret C. Herb RA. Tech & Doc. 155-158. 2005. Stepto NK. Toubro S. J Appl Physiol. Cannon S. 39. 1983. Dalsky GP. Graham TE. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Costill DL. Am J Clin Nutr. 871-877. Montomoli C. Ann Nutr Metab. Bouchard C. Koot P and Deurenberg P. Fraser SF. 10-16. Breum L. Effects of varied dosages of caffeine on endurance exercise to fatigue. 464-475. 68. 3. Effects of caffeine on time to exhaustion in exercise performed below and above the anaerobic threshold. and cardiovascular effects in healthy volunteers. Knuttgen H. Anantharaman K. Paris. 1999. Mensi N. Astrup A. Vandermander J. Hopkins WG. 1994. 1999. Int J Sport Nutr Exerc Metab. Comparison of changes in energy expenditure and body temperatures after caffeine consumption. Poehlman ET. Exercise endurance 1. Fraser SF. Leeds. 361-370. 18. Wirth JC. Anderson ME. Bell DG and McLellan TM. 1999. Cena H. Madsen J. Eur J Clin Nutr. Bruce CR. An update. J Appl Physiol. 67. science et thérapeutique. 63. 93. Caffeine and exercise performance. 70. 2000. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Sports Med. 31. Wichtl M and Anton R. Chantre P. 15. 32. Sathasivam P. Hopkins WG. Tremblay A. Theriault G. Vogel JA. Rohrer D. 135-142. Caffeine: a double-blind. Zahorska-Markiewicz B. Allen L. 1227-1234. The effect of prior exercise and caffeine ingestion on metabolic rate and hormones in young adult males. Cadarette BS. Dodd SL. In: Biochemistry of Exercise Conference Proceedings. The effect of caffeine. 1980. Fink WJ. 57-64. 1993. 1978. 2009. Hawley JA. metabolic. Posner BM. LaChance P. Int J Sport Nutr. 1889-1895. Coffee induced thermogenesis and skin temperature.). Caballero B. pratique officinale. Despres JP. 759-767. 51. improve time to exhaustion and exercise capacity)” 1 Acheson KJ. Belza A. 1989. Prentice A. Berglund B and Hemmingsson P. 1982. Influence of caffeine on metabolic responses of men at rest in 28 and 5 degrees C. Int J Obes Relat Metab Disord. 537-541. Girardier L. 10. Jequier E. Effects of caffeine ingestion on metabolism and exercise performance. green tea and tyrosine on thermogenesis and energy intake. Vallerand AL. Turconi G. MacNaughton KW. Fathi M. Toubro S. Hawley JA. Braz J Med Biol Res. 9. 234-236. Berube CL. 33. 10. 1995. Pittet P. 3. Stepto NK. placebocontrolled study of its thermogenic. Oxford. McNaughton LR. J Appl Physiol. J Appl Physiol. Flinn S. J Appl Physiol. Trad LA. Jr.. Caffeine ingestion during exercise to exhaustion in elite distance runners. 65. Krzeminski K. 425-432. J Sports Med Phys Fitness. Evans SM. 32-41. Kovacs E. 1998. Rock PB. Nazar K. Graham TE and Spriet LL. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology (Berl). Durlach PJ. Leathwood PD and Pollet P. Pekkarinen H. 140. 1999. 539-545. Geissler CA. 1990. 258-266. Neuropsychobiology. Graham TE and Spriet LL. Greer F. 171-175. 110. Int J Sports Med. Revision. 1991. Metabolic catecholamine. Physiol Behav. Caffeine for the sustainment of mental task performance: formulations for military operations. Gregory J. 81. Chmura J. Hollands MA. Wolf B. mood. Arch JR. Rose MS. 157. Influence of caffeine. 1998. 1995. Performance and metabolic responses to a high caffeine dose during prolonged exercise. Friars D. Hibbert E. Caffeine improves cognitive performance after strenuous physical exercise. Riedel WJ. Friars D. 354-361. Petersen KF. 85. French C. Brouns F. J Appl Physiol. McNaughton L. Low-dose caffeine discrimination in humans. Woodson PP. Sathasivam P. Vogel SM. Tristram S. Graham TE. Forte VA. Sports Science Exchange (Gatorade Sports Science Institute). 1993. J Clin Endocrinol Metab. 1-11. 188-193. 1837-1844. Psychopharmacology (Berl). Caffeine deprivation affects vigilance performance and mood. 1989. Psychopharmacology (Berl). Wendling P. Cawthorne MA. 1997. 89. 17. Collins A. 78. 2000. Ziemba AW. 2001. Sannerud CA. 970-978. Aviat Space Environ Med. 2292-2298. Shulman GI. Horton T. J Psychiatr Res. Davies P. 2170-2175. and endurance responses to caffeine during intense exercise. catecholamine. 1996. 1658-1663. Tristram S. Goforth HW. 20. 9. Comparison of caffeine and theophylline ingestion: exercise metabolism and endurance. 49. Jackman M. Effect of caffeine on submaximal exercise performance at altitude. 31. Davies P. 1990. James JE. Lane JD and Phillips-Bute BG. 71. J Sports Med Phys Fitness. 147-154. 85. Miller DS. The effects of a low dose of caffeine on cognitive performance. Graham TE. Jarvis MJ. Metabolic. Young PM. Prusaczyk WK. headache. 2001. Am J Clin Nutr. 2000. J Pharmacol Exp Ther. 197-201. Kruk B. Schneider KE. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 254 . 116-119. 11. 2291-2294. Preston KL. Kaciuba-Uscilko H. 883-889. 1994. 1982. Metabolic and exercise endurance effects of coffee and caffeine ingestion. Hogervorst E. Graham TE and Spriet LL. Krssak M. Cymerman A. Caffeine ingestion prior to incremental cycling to exhaustion in recreational cyclists. J Appl Physiol. 65. 1998. Franklin C. National Academy Press. Griffiths RR. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. 1991. 44-50. Am J Clin Nutr. Metabolic and ergogenic effects of carbohydrate and caffeine beverages in tennis. 37. 1998. Diet-induced mood changes in normal populations. Caffeine and exercise performance. 45-52. Int J Sports Med. 867-874. and exercise performance responses to various doses of caffeine. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. Heishman SJ. 38. 252. 34. Acute and chronic effects of caffeine on performance. Weber K. and sleep. Fulco CS. Graham TE. Effects of caffeine on muscle glycogen utilization and the neuroendocrine axis during exercise. Ferrauti A.13 Dulloo AG. Struder HK. IoM (Institute of Medicine). 1981. cold and exercise on multiple choice reaction time. 1996. Laurent D. Jolles J. Mullington JM. SCF (Scientific Committee on Food). Choi SK. Investigation of the effects of coffee on alertness and performance during the day and night. 152. 112. 2003. Dinges DF. and chemistry. Pasman WJ. Flynn R. intermittent exercise. Br J Sports Med. Caffeine as a lipolytic food component increases endurance performance in rats and athletes. Jpn J Physiol. Cha YS. Sing H. Ryu S. Thomas M.35 36 37 38 McLellan TM. Psychopharmacology (Berl). 813-819. Kapoor SC. Penetar D. Caffeine eliminates psychomotor vigilance deficits from sleep inertia. E891-898. 78. Jeukendrup AE. Schieberle P (eds. 24. Aviat Space Environ Med. Tate C. Eaton-Williams P. 2000. 1995. The effect of different dosages of caffeine on endurance performance time. van Baak MA. Ishiko T. Arch Pediatr Adolesc Med. Am Chem Society. Maeda J. Neuropsychobiology. 109-112. Regular caffeine consumption: a balance of adverse and beneficial effects for mood and psychomotor performance. 1986. Harshfield GA. In: Caffeineated beverages: Health benefits. Plath D. Smith AP. Neuropsychopharmacology. 1493-1501. 47. 1994. Kamimori GH. Roehrs T. 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 255 . Roth T. Thomas M. Sleep. 2001. Caffeine has a small effect on 5-km running performance of well-trained and recreational runners. MacLean DA. Ludwig DA. Rogers PJ and Dernoncourt C. 167-173. 262. exercise endurance. Lim K. Effects of caffeine given before and after lunch on sustained attention. Psychopharmacology (Berl). Lee S. Paluska SA. Belenky G. 1998. 8. Caffeine and sports activity: a review. Price NJ. Ishiko T. Int J Sports Med. Cederblad G. Am J Physiol. Nehlig A and Debry G. Graham TE. Pharmacol Biochem Behav. Rusted JM. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. Perez M. 203-207. Kamimori G. Alerting effects of caffeine after normal and restricted sleep. Ho C-T. 103-108. McCann U. Zwyghuizen-Doorenbos A. 37-44. physiological effects. Szuba MP. 1998. Evans CD. Suh H. Caffeine effects on the brain and behaviour: A metabolic approach. 85. Hultman E. Caffeine and exercise. Paton CD. 2007. Int J Sports Med. J Nutr Sci Vitaminol (Tokyo). O'Brien BJ. 1993. O'Rourke MP. 473-477. 5. Trice I and Haymes EM. 1993. Effect of sucrose and caffeine ingestion on performance of prolonged strenuous running. 231-233. Effects of sucrose or caffeine ingestion on running performance and biochemical responses to endurance running. Wilson ME. Voss DM. Joung SS. 225-230. 15. Int J Sports Med. Caffeine reversal of sleep deprivation effects on alertness and mood. 871-877. Neuropsychobiology. 1987. Thorne D. 51. Caffeine ingestion and muscle metabolism during prolonged exercise in humans. 8. 2. especially for sportsmen. 46-53. 2001. Smith AP. 139-146. Caffeine ingestion attenuates the VO(2) slow component during intense exercise. Washington DC. 2001. Lucia A. McNaughton LR. J Sci Med Sport. Galinski C. Caffeine effects on physical and cognitive performance during sustained operations. 20. 217-223. 761-764. Int J Sport Nutr. Savoca MR. 2000. Brockman P. Sasaki H. Nehlig A. Effects of low doses of caffeine on cognitive performance. 213-219. 359-365. Smit HJ and Rogers PJ. 23. Sasaki H. 1991. Dyck DJ. 215-223. 2004. Smith SJ. 59. The association of caffeinated beverages with blood pressure in adolescents. Maben A. 160-163. Parliment TH. Effect of caffeine on metabolism. 2008. Van Soeren MH and Graham TE. mood and thirst in low and higher caffeine consumers. Savory M. J Appl Physiol. Int J Sports Med. Effects of caffeine ingestion on exercise-induced changes during highintensity. 2001. 27. 1039-1045. 261-265. 1992. 16. Knez WL. The influence of caffeine ingestion on incremental treadmill running. Leathwood P. Usui S.). 4. Curr Sports Med Rep. Van Dongen HP. and catecholamine responses after withdrawal. Takaoka I. 11. Spriet LL. 1990. Rosenthal L. 1995. 158. Santalla A. 1987. de Haan A. The effect of caffeine ingestion on 8 km run performance in a field setting. Graham TE. Coleman D. Int J Sport Nutr Exerc Metab.58 59 60 Warburton DM. 867-874. McKeever KH. Cox GR. 1995. 93. Effects of caffeine ingestion on utilization of muscle glycogen and lipid during leg ergometer cycling. 1227-1234. 2001. 111-138. Bell DG and McLellan TM. Berglund B and Hemmingsson P. 78. 10. 1993. 1423. 990-999. 1995. 10. speed and power during a laboratory-based 1 km cycling time-trial. Int J Sport Nutr Exerc Metab. 24. 18. Benefits of caffeine ingestion on sprint performance in trained and untrained swimmers. Costill DL. Prefaut C. Caffeine and exercise: metabolism and performance. Moquin A. Effect of different protocols of caffeine intake on metabolism and endurance performance. Bruce CR. 3. 3. 64. 2006. Klein R. 24. Effect of a divided caffeine dose on endurance cycling performance. 89. Metabolic. Montgomery PG. Sports Med. postexercise urinary caffeine concentration. Exercise endurance 1. 2002. 2003. Hopkins WG. Dalsky GP. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 256 . Martin DT. Bruce CR. Int J Sports Med. Med Sci Sports Exerc. Audran M. Van Handel PJ. Effects of caffeine ingestion on exercise performance at low and high altitudes in cross-country skiers. 31. 377-380. Fraser SF. Improved 2000meter rowing performance in competitive oarswomen after caffeine ingestion. 35. 86-90. Swaine IL. van Soeren MH. J Sports Sci. Burke LM. Fink WJ. Can J Appl Physiol. Chatard JC. 2000. Orr R. J Appl Physiol. J Sports Sci. Int J Sports Med. 1557-1562. Tegerdine M. Rush JW. Lamb DR. Caffeine and exercise: metabolism. Stepto NK. Desbrow B. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. Graham TE. Effect of repeated caffeine ingestion on repeated exhaustive exercise endurance. 464-475. J Appl Physiol. 1. Effects of caffeine on cognition and mood without caffeine abstinence. Anderson ME. Sports Med. Graham TE. 785807. Comparison of caffeine and theophylline ingestion: exercise metabolism and endurance. Anderson ME. Dodd SL. Stepto NK. Hawley JA. Eur J Appl Physiol Occup Physiol. 1980. Conway KJ. Fraser SF. Doherty M and Smith PM. 1165-1171. Friars D. 2003. Ahmaidi S. Int J Sports Med. and 6 h after caffeine ingestion in caffeine users and nonusers. J Appl Physiol. 2006. 119. Enhancement of 2000-m rowing performance after caffeine ingestion. Wemple RD. Herb RA. endurance and performance. The effects of caffeine ingestion on performance time. J Appl Physiol. Effects of caffeine ingestion on exercise testing: a meta-analysis. 1992. 1997. Greer F. Stannard SR. and plasma paraxanthine. Hopkins WG. ID 1489: “Caffeine” and “Endurance during short term high intensity exercise” 1 Anderson ME. 66-70. Klein R. Graham TE and Spriet LL. 1837-1844. Powers SK. Macrides TA. Effects of caffeine ingestion on metabolism and exercise performance. 155-158. 32. 234-236. 1348-1354. and exercise performance responses to various doses of caffeine. Bell DG and McLellan TM. 1958-1963. Essig D. 433-439. Hawley JA. Med Sci Sports. 2002. 14. catecholamine. Hawley JA. 2004. Roberts A. Wiles JD. Collomp K. An update. 1982. 2000. Costill DL. Caffeine and exercise performance. 1978. 15. 93. Bridge CA and Jones MA. 2000. Med Sci Sports Exerc. J Appl Physiol. Bruce CR. 40-46. 94. Psychopharmacology (Berl). 626-646. 19. 1994. Pasman WJ. 2005. Med Sci Sports Exerc. Hultman E. A rapid effect of caffeinated beverages on two choice reaction time tasks. 2002. McLellan TM. Aviat Space Environ Med. 20. Effects of caffeine or diphenhydramine on visual vigilance. 822-825. 709-715. 164. Psychopharmacology (Berl). Keisler BD and Armsey TD. Graham TE. 5. Little effect of caffeine ingestion on repeated sprints in teamsport athletes. 75. Kovacs EM. 2005. ID 1491: “Caffeine (with or without carbohydrate)” and “Enhances mental alertness during intense muscular activity. 2004. 2006. Spriet LL. Friars D. 140. McLellan TM. Nutr Neurosci. Cederblad G. Bell DG. 1992. Kamimori GH. Costill DL. 20. Curr Sports Med Rep. Graham TE. 2001. 1994. 75. 1999.18 19 20 21 22 23 24 25 Hogervorst E. van Baak MA. Wendling P. 1658-1663. 2006. 1998. Jeukendrup AE. 433-442. 188-192. 22. 865-871. Kennedy DO. Psychopharmacology (Berl). Schneiker KT. 813-825. Med Sci Sports Exerc. 2nd. Bell DG. 1165-1171. E891-898. Effect of caffeinated drinks on substrate metabolism. 1998-2005. speed and power during a laboratory-based 1 km cycling time-trial. 647-654. MacLean DA. Voss DM. Brouns F. Caffeine improves physical performance during 24 h of active wakefulness. Lower RW. Med Sci Sports Exerc. Ivy JL. 262. Dyck DJ. Effects of repeated doses of caffeine on performance and alertness: new data and secondary analyses. Durlach PJ. 339-350. 11. Caffeine ingestion and muscle metabolism during prolonged exercise in humans. 24. Tharion WJ. Durlac PJ. Multiple effects of caffeine on simulated high-intensity team-sport performance. caffeine excretion. Haskell CF. J Appl Physiol. J Appl Physiol. 114. 85. The effects of caffeine ingestion on performance time. Effects of caffeine on mood and performance: a study of realistic consumption. Tipper SP. 2004.500-metre swim. Wesnes KA. Lieberman HR. Hum Psychopharmacol. 33. Riley RH. 1979. Hopkins WG. 1996. Hopkins WG. Influence of caffeine and carbohydrate feedings on endurance performance. 116-119. Vollebregt L. Kobrick JL. Metabolic catecholamine. 1995. Gillingham RL. Wiles JD. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. 215-219. MacIntosh BR and Wright BM. Int J Sports Med. Effects of caffeine on prolonged intermittent-sprint ability in team-sport athletes. Caffeine as an ergogenic aid. Int J Sports Med. 5. de Haan A. J Sports Sci. Stegen J. 6-11. 354-361. 233-238. Tikuisis P. Tegerdine M.” 26 27 28 29 30 31 1 2 3 4 5 6 7 Brice CF and Smith AP. Scholey AB. Dawson B. 2005. Caffeine improves cognitive performance after strenuous physical exercise. Psychopharmacology (Berl). 666-672. 37. 2002. Med Sci Sports. Cole KG. Bishop D. Kamimori GH. Acute caffeine intake before and after fatiguing exercise improves target shooting engagement time. Johnson D. and endurance responses to caffeine during intense exercise. Howard L. 38. Hackett LP. Fine BJ. 76. Can J Appl Physiol. Caffeine maintains vigilance and improves run times during night operations for Special Forces. Jolles J. Caffeine ingestion and performance of a 1. Cook C. 81. and performance. 2006. Am J Physiol. Keefe AA. Paton CD. 1998. Aviat Space Environ Med. 179. Edmunds R. Psychopharmacology (Berl). Swaine IL. Hewlett P and Smith A. Stuart GR. 168-177. 16. 257 . Coleman D. Kovacs E. 2007. Riedel WJ. Cairns SP. 1995. The effect of different dosages of caffeine on endurance performance time. 225-230. Brouns F. Jackman M. Aviat Space Environ Med. 578-585. Fink WJ. Marlowe B. The effects of a low dose of caffeine on cognitive performance. Effects of low doses of caffeine on cognitive performance. Elmadfa I. Loew D. Stuttgart. Efficacy of Lpropionylcarnitine treatment in patients with left ventricular dysfunction. März W. Ernährungslehre. The effect of caffeine on cognitive task performance and motor fatigue. Bässler KH. Philadelphia. 1994. Food Chem Toxicol. Bell DG. 1267-1273. 14. Aviat Space Environ Med. Speckman KL. SCF (Scientific Committee on Food). 1993. Zeviani M. 2004. 3. Eur Heart J. 539-547. Canale C. Belenky G. Caffeine improves cognitive performance after strenuous physical exercise. 15. Brunelli C.). 2005. 40. 2004. Loew D. 245-254. Johnson D. Eugen Ulmer. L-Carnitin. Jolles J.). Bartlett K and Eaton S. Schonfeld DH. 39-45. 2003. 1987.Shils ME. 1994. 14. Carnitine. Pillay M. 2005. Böhles HJ. Caffeine: implications for alertness in athletes. Pietrzik K. Bässler KH. 354-361. Nutrition. Broquist HP. Aviat Space Environ Med. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Tulley R. 404-407. 233-259. Multiple caffeine doses maintain vigilance during early morning operations. 2005. 459-465. Corsi M. 40. McLellan TM. 473-482. 24. Smith A. and stress on cognitive performance and mood during U. Urban & Fischer. 2000. Zijdewind I. ID 1492: “Carnitine” and “Fat metabolism” 12 13 14 15 16 17 18 19 1 Arenas J. sleep loss. Riedel WJ. 1991. Coviella IL. Carnitine. 1046-1050. Lieberman HR. Smith A. Terracchini V. e113. Pola P. 1983. 2002. Effects of caffeine. Mitochondrial beta-oxidation. Rogers NL and Dinges DF. Brouns F. Siekmeier R. D'Iddio S. Deutsche Zeitschrift für Sportmedizin 44. Thorne D. 1997. 2005. Psychopharmacology (Berl). 308-312. Pietrzik K (eds. Johnson D. especially for sportsmen. Sea-Air-Land. Sturgess W. training. Belenky G. 180. 167-173. Valentini G. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. Lorist MM. Roberts C. 349-356. 152. Effects of low dose caffeine given in different drinks on mood and performance. Borum PR. 20. Effects of caffeine on human behavior. Emde GG. Muscle Nerve. Encinas AR. Kamimori GH. Kamimori GH. In: Vitamin-Lexikon für Ärzte. Kruijssen DA. Eur J Biochem. Shukitt-Hale B.S. Clin Sports Med. serum. Didonato S. Annu Rev Nutr. 1999. Smit HJ and Rogers PJ. Wurtman RJ. Smith IF. Appetite. 462-469. Psychopharmacology (Berl). Golly I. Golly I. 1999. Apotheker und Ernährungswissenschaftler. van Duinen H. The effects of low doses of caffeine on human performance and mood. 2 3 4 5 6 7 8 9 258 . Evangeliou A. München. Lea & Febiger. 1243-1255. Lieberman HR. Kovacs E. 125-130. Der einfluss von LCarnitin auf den lipidstoffwechsel von hochleistungssportlern. 76. Lohrer H. Lieberman HR. 164. Shike M (eds. Navy SEAL training. 1994. and urine of nonprofessional athletes: effects of physical exercise. and L-carnitine administration. Int J Sports Med. Tharion WJ. Carnitine in muscle. Caffeine maintains vigilance and marksmanship in simulated urban operations with sleep deprivation. Remme WJ. In: Modern Nutrition in Health and Disease. mood and thirst in low and higher caffeine consumers. Gallagher J. Caponnetto S. Ricoy JR. Psychopharmacology (Berl). brain function and cognitive performance. 92. Bartels GL. 2001. 250-261. 76. 598-604. Psychopharmacology (Berl). Am J Cardiol. Human Psychopharmacology: Clinical and Experimental.8 9 10 11 Hogervorst E. 2002. 74. Olson JA. Masperone MA. 271. Föhrenbach R. 35-40. 1979. Newton RU. Orthomolekulare Medizin: ein Leitfaden fur Apotheker und Arzte. Fatty acid import into mitochondria. 110. Mit Pathobiochemie Springer. Stuttgart. 335-343. J Strength Cond Res. 136. 152-157. Swan PD. Ciociaro D. The carnitine system and body composition. In: Modern Nutrition in Health and Disease. Johnston CS. Rubin MR. Kitani T. Hakkinen K. The role of carnitine in normal and altered fatty acid metabolism. Buzzigoli G. Richter T. Misaki H. Stuttgart. 41. 2000. Brandi LS. French DN. 51. Murray RK. 35. Norwalk. Kerner J and Hoppel CL. Wolters M. Philadephia. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Nicolai R. J Nutr. carnitine and choline supplementation of rats decreases body fat and serum leptin concentration as does exercise. 17. Appleton & Lange. Int J Sports Med. 2002. 1990. Baltimore. 375-388. Gomez AL. Hongu N and Sachan DS. 2004. Ernährung. Jemiolo B. 41. Opie LH. S62-67. 1389-1391. 97. 2003. 1994. Caballero B. Metabolism. Marginal vitamin C status is associated with reduced fat oxidation during submaximal exercise in young adults. Shike M. Am J Kidney Dis. Int J Sports Med. Acylcarnitine deficiency in chronic fatigue syndrome. and endurance in exercising rats. Reda E. Tagawa S. Santoro D. Ratamess NA. 537-544. Stuttgart. Wissenschaftliche Verlagsgesellschaft. 2000. 1993. 2003. Am Heart J. 2003. Ströhle A. S3543.10 Giamberardino MA. Effects of prolonged Lcarnitine administration on delayed muscle pain and CK release after eccentric effort. Muller DM. Caffeine. Vecchiet L. Basiswissen Biochemie. 2006. Plioplys AV and Plioplys S. Craig BW. Volek JS. Benatti P. 455-462. 10. 1311-1323. Loster H. Biochim Biophys Acta. Valente R. Takahashi M. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Kerner J and Hoppel C. 40 Suppl 1. 50. Harper's biochemistry. 1989. Di Lisa F. Pauly DF and Pepine CJ. Kraemer WJ. Fatty acid oxidation in human skeletal muscle. 2006. Acta Diabetol. Cousins R (eds. Heidelberg. Granner DK. Seim H. Decrease in respiratory quotient during exercise following L-carnitine supplementation. Ross C. 1486. 169-174. 594600. Saggini R. Natali A. Löffler G. Berlin. Faraggiana D. 2004. 2005. 320-324. Effects of acute hypercarnitinemia during increased fatty substrate oxidation in man. 16-23. 42. Metabolism. 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 259 . 1997. S106-113. Eclache JP. Neuropsychobiology. Lippincott Williams & Wilkins. Sharman MJ. Kim E. S4-12. Shils ME. Mayes PA. Gröber U. Hahn A. Carnitine palmitoyltransferase-I and regulation of mitochondrial fatty acid oxidation Monatshefte für Chemie. 2006. Ferrannini E. Cha YS. 1996. 130. 1-17. J Clin Invest. 2002. Hoppel C. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Hahn A. 18 Suppl 1. Rebouche CJ. Yamaguti K. 17. Kuratsune H.). D'Iddio S. Calvani M. 3. 1607-1609. Am J Kidney Dis. Carnitine. Wissenschaftliche Verlagsgesellschaft mbH. 2003. Clin Infect Dis. Corte C. Rodwell VW. Exercise training and supplementation with carnitine and antioxidants increases carnitine stores. Journal of Nutritional Science and Vitaminology. Dragani L. The role of carnitine in myocardial dysfunction. Park H. triglyceride utilization. Maurer CA. Pecori N. 2006. Jensen MD. Kiess W. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Wissenschaftliche Verlagsges. 2000. Nutr Metab (Lond). The effects of L-carnitine L-tartrate supplementation on hormonal responses to resistance exercise and recovery. Gorostiaga EM. E474-482. Tunger L. Giamberardino MA. The effect of l-carnitine on fat oxidation. Expert Rev Anti Infect Ther. 175. Policchio D. 102. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. D'Alessandro A. Cerio R. S37-43. 131-132. Ross C. Vecchiet L. Baltimore. An analysis of 3 multicenter studies and a bibliographic review]. 1992. Broquist HP. Ruff LJ. 211214. Deutsches Ärzteblatt. 709-715. Volek JS. 282. 1998. Lebensmittel-Lexikon. 7 8 9 10 11 12 13 260 . 2002. Van Wouwe JP. Int J Vitam Nutr Res. Fernandez C and Proto C. Supplementation of L-carnitine in athletes: does it make sense? Nutrition. Oliveiro U. A752-A759. 1361. Doron S and Gorbach SL. 53. Lingetti M. Maurer CA. In: Modern Nutrition in Health and Disease. [L-carnitine in the treatment of chronic myocardial ischemia. Scarrow AM. 65. 2006. 2006. Pallone F. Ratamess NA. ID 1493: “Carnitine” and “Muscle metabolism / Recovery after exercise” 35 36 37 38 39 40 1 2 3 4 5 6 Biancone L. Van Lunteren E. Ripari P. Drugs Exp Clin Res. Maccari F. Probiotika. 2006. 2002. J Appl Physiol. Shike M. Gomez AL. 2002. D'Souza AL. 2005. Gorostiaga EM. 4. Zobel M. Giamberardino MA. 417-429. 169-174. 45. Mancini M. Dig Liver Dis. Biochem J. Stryer L. Täufel A. Siliprandi N. 17-21. Bischoff SC and Manns MP. BMJ. 53-60. Masterson KA. NADH and FADH2 are generated in each round of fatty acid oxidation. 1991. Vohra S. 1996. Johnston BC. D'Alessandro L. Vecchiet L. Gaynor P. New York. 1034. 377-383. 10. Hamburg. Carnitine delays rat skeletal muscle fatigue in vitro. Kraemer WJ. Eclache JP. Int J Sports Med. 140. 20. Rubin MR. Monteleone I. Dragani L. 2003. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria? Curr Issues Intest Microbiol. Pieralisi G. 1981.). Effects of prolonged Lcarnitine administration on delayed muscle pain and CK release after eccentric effort. In: Biochemistry. Biochim Biophys Acta. and body composition in slightly overweight subjects. 4. Cacciatore L.) Freeman. Saggini R. Metabolism. 1595-1600. Metabolic changes induced by maximal exercise in human subjects following L-carnitine administration. Ternes W. 17. 324. CMAJ. Vavassori P. 353-377. 1995. Carnitine. 2004. Cocozza M.33 34 Schek A. Carnitine deficiency during valproic acid treatment. Shils ME. Caballero B. 1993. 34 Suppl 2. 459-465. Grattarola G. 1002-1006. Carnitine biosynthesis in mammals. Probiotics for pediatric antibiotic-associated diarrhea: a metaanalysis of randomized placebo-controlled trials. 2004. Lippincott Williams & Wilkins. Bulpitt CJ. Karlic H and Lohninger A. Int J Sports Med. 17. 225-235. Clin Ter. Präbiotika und Synbiotika: Stellenwert in Klinik und Praxis. 261-275. Philadephia. Supina AL. Decrease in respiratory quotient during exercise following L-carnitine supplementation. Ciarimboli M. Del Vecchio Blanco G. Menabo R. Sorrentino FP. Rajkumar C. Cooke J. Coto V. Blum S and Schiffrin EJ. Acetyl CoA. Di Lisa F. Resident bacterial flora and immune system. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. 361. 1989. Brass EP. Wutzke KD and Lorenz H. 75. Am J Physiol Endocrinol Metab. Imparato L. L-carnitin: ein schlankheitsmittel? Ernährungs-Umschau. Stryer L (ed. protein turnover. Cousins R (eds. Vaz FM and Wanders RJ. L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress. Rengo F. Porfido FA. 320-324. Valente R. Behr's Verlag. 1990. Probiotics: their role in the treatment and prevention of disease. 2002. 2005. Di Lisa F. Muller DM. 2003. Seim H. Tagawa S. 132-138. 2007. Murray RK. 1993. Maggini S. 1990. 2005. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. 455-462. L(-)-Carnitine and its precursor. 136. 40. French DN. Ther Umsch. 2007. 13. 44.). 1389-1391. 2006. 1034. 259-264. Volek JS. Spiering BA. 17. Loster H. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe. 1996. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Craig BW. 261 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 . Ernährungs-Umschau. Metabolism. 537-546. Am J Clin Nutr. Spiering BA. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. de Vrese M. 2002. Misaki H. Richter T. Seim H. Monatshefte für Chemie/Chemical Monthly. Sanders ME. Kraemer WJ. Neuropsychobiology. Rodwell VW. Ciociaro D. Hakkinen K. Rubin MR. Meta-analysis of probiotics for the prevention of traveler's diarrhea. MMW Fortschr Med. Schrezenmeir J. Norwalk. 87 Suppl 2. Anderson JM. Kitani T. Newton RU. Banziger KR. Kraemer WJ. Brandi LS. 64. Pankau H. L-Carnitine supplementation results in improved recovery after strenuous exercise: a preliminary study. 1996. J Clin Gastroenterol. Giamberardino MA. Ann Nutr Metab. 97-105. Basel. Kleber HP. J Strength Cond Res. 2006. Marteau P and Boutron-Ruault MC. Effects of acute hypercarnitinemia during increased fatty substrate oxidation in man. Buzzigoli G. 40-45. 17-21. Summary of probiotic activities of Bifidobacterium lactis HN019. Meier R and Lochs H. Travel Med Infect Dis. 42. Ferrannini E. Takahashi M. Marteau PR. Siliprandi N. 73. 1383-1390. Granner DK. Protection from gastrointestinal diseases with the use of probiotics. Volek JS. New York. Neuropsychobiology. Metabolism. Metabolic changes induced by maximal exercise in human subjects following L-carnitine administration. Kiess W. 1995. 161-169. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Packer L (eds. 2001. Santoro D. Vingren JL. Harper's biochemistry. 1994. Fragala MS. Krämer K. Ratamess NA. 2006. 217-241. Kuratsune H. Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate. 5. Maccari F. Ripari P. 776-783. Clin Infect Dis. Am J Gastroenterol. Volek JS. 101.and probiotics]. Faraggiana D. Maresh CM. Pecori N. Lebendkeime in fermentierten Milchprodukten–ihre Bedeutung für die Prophylaxe und Therapie. McFarland LV. 2002. Vecchiet L. Antibiotikaassoziierte Diarrhoen. Di Lisa F. Eichler K. 51. 21. Plioplys AV and Plioplys S. [Pre. 35. 812-822. Hoppe PP. 430S-436S. Natali A. L-Carnitine supplementation: A new paradigm for its role in exercise. S62-67. 32. Acylcarnitine deficiency in chronic fatigue syndrome. Schauer J. Loster H. The effects of L-carnitine L-tartrate supplementation on hormonal responses to resistance exercise and recovery. Cardiovasc Drugs Ther. 2007. J Strength Cond Res. S153-157. Vingren JL. Jemiolo B. Probiotika halten die Darmflora in der Balance. 16-23. Ho JY. ischemically induced cardiac insufficiency. Miehe K. Walter P. 18 Suppl 1. 28-30.14 15 Kasper H. 148. 1997. McFarland LV. Sharman MJ. Gomez AL. 2001. 1999. Appleton & Lange. Pieralisi G.[Therapeutic possibilities of probiotics in antibiotic-related diarrhea]. Hatfield DL. Biochim Biophys Acta. Punzel M. Cellier CJ. Marcel Dekker. 2000. Yamaguti K. Plioplys AV and Plioplys S. Kramer S and Bischoff SC. Stiller O. 43. Menabo R. Nutritional advantages of probiotics and prebiotics. In: Nutraceuticals in Health and Disease Prevention. Mayes PA. Kraemer WJ. Br J Nutr. 594600. gamma-butyrobetaine. 86-88. Pagnin E. Ciarimboli M. Porfido FA. 2006. 23. 405-414. Davini P. Kraemer WJ. 149. Antoine JM. Curr Opin Gastroenterol. Lamanna F. 1-18. 2 3 4 5 6 7 8 9 10 262 . Guarino G. Castellano A. 45. oxidative stress and cardiac dysfunction in children with chronic renal failure: effects of L-carnitine supplementation. 367-372. Vallebona A. Gomez AL. Calvani M. Mugellini A. 1994. Policchio D. New York. 627-632. Digiesi V. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter. Lai C. Lopez F. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: semiautomatic computerized analysis of M-mode tracing. Rubin MR. Stuttgart. Watzl B and Leitzmann C. Sorgente L. Brodbeck B. Walker WA. Cicero AF. Mancini M. Nutrition Research. Nicolai R. Hamed EA. Metabolism. Fogari R. 2003. randomized. Trucco G. 1997. The effect of l-carnitine on fat oxidation. 17. Rengo F. Mereto PE. Cerio R. Radzikowski A. 391-395. Rossouw J. Hernandez F. Oliveiro U. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials.35 36 Stryer L. 17. The effect of L-carnitine supplementation on plasma carnitine levels and various performance parameters of male marathon athletes. Int J Clin Pharmacol Ther Toxicol. Hippokrates. Wutzke KD and Lorenz H. 1429-1439. Mohamed NA. 1988. 18. El-Metwally TH. L-Carnitine effects on chemical composition of plasma lipoproteins of rabbits fed with normal and high cholesterol diets. Bisi G. Clin Ther. Lipids. Diaz M. 107. Imparato L. Freeman. Derosa G. Schiavoni G. Vanderhoof JA and Young RJ. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Ahmad AR. Drugs Exp Clin Res. Calo LA. Cherchi A. Szajewska H. Clin Ter. Novo S. Cantini F. and body composition in slightly overweight subjects. Bioaktive Substanzen in Lebensmitteln. Am J Physiol Endocrinol Metab. Angelino F. 270-277. 26. Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. 221-224. Pessina AC. Sorrentino FP. protein turnover. 225-235. 355-365. Ruszczynski M. Ciccarelli L. ID 1494: “Carnitine” and “Heart health” 37 38 39 40 41 42 1 Cacciatore L. L-carnitine adjuvant therapy in essential hypertension. Arrigoni-Martelli E. 1002-1006. J Pediatr. 2000. Goulet O. Basic Res Cardiol. Boem A. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Lingetti M. 17. Cocozza M. Int J Cardiol. Gaddi A. Drugs Exp Clin Res. Ratamess NA. 2004. 54-60. D'Alessandro L. Gaynor P. E474-482. Reale A. 75-83. 144. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Canale C. 95. Caponnetto S. Ann Saudi Med. Immordino R. 25. double-blind. 58-62. Grattarola G. D'Alessandro A. Terrachini V. Bigalli A. 1985. 1981. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. 2001. placebo controlled crossover study. Dyslipidemia. Calvani M. 53. Morelli L. 282. Strano A. Romeo F. Volek JS. Davis PA. Biagini A. Reda E. 2006. 2002. Rizzon P. Rosolen G. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. 1995. 2006. Int J Clin Pharmacol Ther Toxicol. Loots JM. 569-572. 1992. The role of probiotics in the treatment of intestinal infections and inflammation. 1991. Biochemistry. European Journal of Nutrition. 35. Semplicini A. 2003. Manzoli U. Kruger MC. Coto V. Urbina JA. Swart I. Masperone MA. 2000. Valice S. 23. L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress. Moghaddas S. Flores VB. Nishihara K. 136. Kumaran S. Int J Sports Med. Murray RK. Harper's biochemistry. Yamazaki N. Appleton & Lange. 25. Jpn Heart J. He D. Walter P. Narkiewicz M. Carnitin zur unterstutzung der gewichtsabnahme bei adipositas (Carnitine as supporting agent in weight loss in adiposity).11 12 Fernandez C and Proto C. 1543-1545. 1996. L-Carnitine supplementation: A new paradigm for its role in exercise. 21. 140. 2006. Vingren JL. Patel A. 90-96. The role of carnitine in myocardial dysfunction. Mondola P. Maggini S. 2001. J Assoc Physicians India. Aliwalas D. 353-377. The effect of L-carnitine on the apolipoprotein pattern of rats fed a cholesterol-rich diet. L-carnitine moderately improves the exercise tolerance in chronic stable angina. Loster H. ischemically induced cardiac insufficiency. 507-512. Peduzzi P. Cardiovasc Drugs Ther. Panneerselvam C. Suchorzewska J. Jpn Circ J. [L-carnitine in the treatment of chronic myocardial ischemia. Am J Kidney Dis. 1998. Dragani L. 320-324. Supplementation of L-carnitine in athletes: does it make sense? Nutrition. Suzuki Y. Jacoba KGC. 125. Norwalk. Kobayashi A. Santillo M. Schauer J. Defensor V. Valente R. Kosolcharoen P. Abarquez RFJ. 20. Giamberardino MA. Comp Biochem Physiol B. 2004. 2005. 13. FASEB J. S3543. Stiller O. Karlic H and Lohninger A. Gupta A. Saggini R. Sison JM. Panneerselvam C. Current Therapeutic Research. Smolenski RT. L-Carnitine supplementation results in improved recovery after strenuous exercise: A preliminary study. Arztezeitschrift fur Naturheilverfahren [Medical Journal for natural Therapy]. Filipek T. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe. Bochum Lurz R and Fischer R. 2006. 11. 1999. Kamikawa T. Supplemental conditionally essential nutrients in cardiovascular disease therapy. Thomsen JH. 263 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 . Yamazaki N. Clinical Drug Investigation. Cardiovasc Res. 2005. 709-715. Topacio GO. 89. 51. Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. 20. 1981. Abe M. 2003. 2004. Punzel M. 1383-1390. Iyer RN. Belfiore A. Reversal of mitochondrial defects before ischemia protects the aged heart. Löster H. 1992. Anusuya Devi M. 39. Pauly DF and Pepine CJ. 753-764. parallel. Kendler BS. Ponte Press. 587597. Volek JS. 41. Carnitine and cardiovascular diseases. Exp Aging Res. 1984. Masumura Y. Subathra M. Hoppel CL. 48. 21-29. 1996. Effects of prolonged Lcarnitine administration on delayed muscle pain and CK release after eccentric effort. 86-94. Lango R. Rodwell VW. Di Lisa F. Influence of Lcarnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. 56. Lysiak-Szydlowska W. Monatshefte für Chemie/Chemical Monthly. Mech Ageing Dev. Kobayashi A. randomised. Savitha S. Santangelo F. Clin Ter. 55-67. 1050-1052. 1988. 2000. 31. 2003. Lesnefsky EJ. 2000. 1996. Improved exercise tolerance after administration of carnitine. Nappi J. J Cardiovasc Nurs. Ann Nutr Metab. Vajifdar BU. An analysis of 3 multicenter studies and a bibliographic review]. 44. Hayashi H. Masumura Y. Shug A. 69-73. L-carnitine treatment for congestive heart failure-experimental and clinical study. Supplementation of L-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats. 12-15. Effect of L-Carnitine on the limitation of infarct size in one-month postmyocardial infarction cases: a multicentre. Balu M. Abola MT. placebo-controlled trial. Spiering BA. Miehe K. Pankau H. Kraemer WJ. 86. Khan AA. Kumaran S. Banziger KR. 537-546. 9-16. 1992. Vecchiet L. 30. L-carnitine and DL-alpha-lipoic acid reverse the age-related deficit in glutathione redox state in skeletal muscle and heart tissues. Lokhandwala YY. Granner DK. Mayes PA. 17. Malaguarnera M. Lucani E. Rastogi SS. Leotta C. L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress. 45-50. Kraemer WJ. 21. Cardiology. 108-113. Wang L. Fragala MS. 21–59. 650-659. Finocchiaro G. New York. Metabolism. 115-119. Kraemer WJ. Cederblad G. Racek J. 101-109. Plasma carnitine in pregnancy. Sirtori CR. Pojer M. L-carnitine and alpha-lipoic acid improve age-associated decline in mitochondrial respiratory chain activity of rat heart muscle. Spiering BA. Biogerontology. 88. Olegard R. Beegum R. placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Mostafa N. Gaynor P. Anderson JM. 761-767. Birreci A. Ratamess NA. L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Volek JS. Di Giacomo S. Pharmacol Res. Vingren JL. Dell'Arte S. 26. Niklasson A. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition. 1998. J Strength Cond Res. Schattauer. 1981. Stuttgart. Niaz MA. Kruger MC. Biochemistry. Carnitine in maternal and neonatal plasma. double-blind. 235-242. E474-482. Postgrad Med J. lipid profile and fatigue. Carnitine and its role in cardiovascular disease. 7. Sachan DS. Vesela E. 2002. 1997. 1999. A randomized controlled trial. Pazzucconi F. 2006. 10. Nutrition Research. Rizzon P. 17. Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia. discussion 21. Zeng Q. 106. Clin Ter. Ho JY. Carnitine and lipoic acid alleviates protein oxidation in heart mitochondria during aging process. The therapeutic potential of carnitine in cardiovascular disorders. Gomez AL. 259-264. Singh RB. The effect of L-carnitine supplementation on plasma carnitine levels and various performance parameters of male marathon athletes. Acta Paediatr Scand. Drugs Aging. Lucani G. Sayed-Ahmed MM. Ferrara S. Gitzelmann R. 1987. 2003. Xie J. Swart I. Hahn P. 74. Hatfield DL. Koverech A. 1996. J Huazhong Univ Sci Technolog Med Sci. Tarantini G. Iliceto S. Clin Ther.32 33 Pepine CJ. Loots JM. Marino A. Stefanutti C. Calabresi L. 2001. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. Bruzzi P. Sethumadhavan S and Chinnakannu P. 61. 2000. 500-504. 1991. Albertsson-Wikland K. Heart Dis. Maresh CM. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Steinmann B (eds. Vivenzio A. Agarwal P. 1981. Scrutinio D. Baerlocher K. Gad MZ. A randomised. 140. Khattab MM. 13. 44. Freeman. Rubin MR. Trefil L. Rydgren B. Retter AS. Scholte HR and de Jonge PC. Am J Physiol Endocrinol Metab. New York. 2-21. Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate. Stryer L. Am J Obstet Gynecol. 2001. Baldassarre D.). 405-414. Nutr Metab Cardiovasc Dis. 282. 2006. 2007. Jankovy'ch V. Rossouw J. Pistone G. Wittmann B. 2006. 20. 218-223. Effect of L-carnitine supplementation in hemodialysis patients. 72. ID 1495: “Carnitine” and “Pregnancy” 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 1 2 Bargen-Lockner C. Volek JS. function and transport of carnitine in health and disease. 188-191. Nephron. 1. 247-251. 412-414. 149. J Gerontol A Biol Sci Med Sci. 1985. Boni L. In: Carnitin in der Medizin. 215-223. 2006. 264 . Bondioli A. The protective effect of L-carnitine on ischemia-reperfusion heart. Sethumadhavan S and Chinnakannu P. Lipids. 83-90. 299. Lohinger A. Park JS. Corbelletta C. Antioxid Redox Signal. Pregnancy-associated carnitine deficiency causes downregulation of carnitine acyltransferase genes: reversal by carnitine supplementation is dose dependent. 2001. 2002. 1988. 2005. Lohninger S. Grignaffini A. Penn D. 5. Carotenoid action on the immune response. Yasuhara M. Auer B. A comparison of lycopene and astaxanthin absorption from corn oil and olive oil emulsions. 2001. Legenstein E. Bertone ER. Winter SC. 134. Editions Tec&Doc. 136. Hofbauer R. Methods Enzymol. ID 1496: “Carotenoids from fruits and vegetables juices” and “Antioxidant properties” 7 8 9 10 11 1 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Salzer H. Marz R. Sevelda P. Karlic H. and neonates and children. Naito Y. A comparison of the anticancer activities of dietary betacarotene. Am J Clin Nutr. 8. Carotenoid Science. Vytiska-Binstorfer E. Wang X. Chew BP. Jinniate S. Wolf H. 1995. Sevelda P. 233-242.3 4 5 6 Cederblad G. 12. 134-136. 1995. Lohninger A. 192. Fahraeus L. 1740. canthaxanthin and astaxanthin in mice in vivo. bacterial load and modulates cytokine release by splenocytes. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. urinary excretion and renal clearance of L-carnitine during pregnancy: a reversible secondary L-carnitine deficiency. 115-120. Superior skin protection via Astaxanthin. Biochim Biophys Acta. 1999. 87-93. 1999. Plasma carnitine and renal-carnitine clearance during pregnancy. Bertram JS and Vine AL. Anticancer Res. Oka S. Carnitinspiegel während der Schwangerschaft. 1981. Toyokuni S. Clin Chim Acta. 89-91. 1999. 1523-1533. 3 4 5 6 7 8 9 10 265 . pylori infected mice with antioxidant astaxanthin reduces gastric inflammation. Pace S. Hankinson SE. Legenstein E. Mascher D. Plasma carnitine concentrations in pregnancy. 2001. Salzer H. Genger H. Schmidt-Sommerfeld E. Benzie IF and Strain JJ. J Nutr. 1849-1853. Bennedsen M. 15/5/II LB 285. 185-189. Wong MW. 35. 21-24. 2005. Linn LS. 70. Willen R. 1986. Furr HC. Gynecol Endocrinol. 44. Kuchide M. Andersen LP. Treatment of H. Salzer H. Lohninger A. Schoderbeck M. 35. 379-383. Salzer H. Yao L. Z Geburtsh u Perinat. Ann Nutr Metab. Cancer Causes Control. Tokuda H. 257S-261S. Wong TS. Rosner B. J Perinat Med. Verrotti C. A population-based case-control study of carotenoid and vitamin A intake and ovarian cancer (United States). Lohninger A. 139-144. The influence of maternal fat metabolism on fetal carnitine levels. 803-806. Aoi W. Cardace G. 2003. Maoka T. D'Iddio S. Clark RM. Willet WC. 5. Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes. 243. Monatshefte für Chemie [Chemical Monthly]. Carnitine in pregnancy. Apports nutritionnels conseillés pour la population française. 477-485. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Early Hum Dev. Mascher H. Marzo A. Yoshikawa T. She L. Immunol Lett. FASEB J. Wadstrom T. Newcomb PA. 170-178. Chew BP and Park JS. Plasma concentration. Paris. Stampfer MJ. Cancer prevention by retinoids and carotenoids: independent action on a common target. 5. 2000. Tammaa A. Egan KM. Lohninger A. Arakane K. Karlic H. Genger H. Helton E. 19. cord blood. Cavatorta E. The role of L-carnitine in pregnancy and disorders of lipid metabolism. Sakuma K. 1994. 15-27. 2004. 44. Lindgren K. 2000. 23. 2002. 1802-1811. Nutr Metab Cardiovasc Dis 7. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Les antioxidants et les autres éléments protecteurs dans les jus de fruits et légumes. Aromaa A. 1997. Rissanen A. Lignell A. Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver. Kistler A. enhances in vitro immunoglobulin production in response to a T-dependent stimulant and antigen. Wolz E. Jyonouchi H. El Garem Y. lung. 1995. Liechti H. Metabolism and CYPinducer properties of astaxanthin in man and primary human hepatocytes. Sun S. Suschetet M. Gross MD. 38. 1392-1394. Guerin M. Olaizola M. BMJ. 272. Pichard L. J Pharmacol Exp Ther. Russell RM. Le Bon AM. Pettersson A. Yeum KJ. 459-516. 81. Trends Biotechnol. 114. Nutr Cancer. Jewell C and O'Brien NM. Astaxanthin. randomized trial. 257-262. Mercke Odeberg J. Gross MD. Gross GJ and Lockwood SF. 2005. Carotenoid actions and their relation to health and disease. Pasteur Institute-Lille. Berges R. 314. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Mahmoud A. Krinsky NI. Hammond BR. Garland DL. Snodderly DM. Sun S. Schoonjans F. 1997. 26. Mol Aspects Med. Gradelet S. Arch Toxicol. a carotenoid without vitamin A activity. Nutr Cancer. 2005. 1997. J Nutr. Eur J Pharm Sci. Hayes A. Asian J Androl. 210-216. 2003. 299304. Serum antioxidant vitamins and risk of cataract. laboratoires Chauvin. Sies H. 1795-1801. 23. 171-183. In: Micronutrition et oeil en pratique: les bases. 433443.. Jyonouchi H. 34-39. 2003. Modulation of aflatoxin B1 carcinogenicity. 215-224. 1995. Eertmans F. Haematococcus astaxanthin: applications for human health and nutrition. 2005. 2004.11 Comhaire FH. Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. Lecerf JM. Astorg P. 7. 59-65. Gross GJ and Lockwood SF. Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Aaran RK. Iijima K. 221-227. Tomita Y. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 266 . augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. Hoglund P. Daubrawa F. Huntley ME. Combined conventional/antioxidant "Astaxanthin" treatment for male infertility: a double blind. Cancer Lett. Khachik F. 235-242. 125. Effect of carotenoids on in vitro immunoglobulin production by human peripheral blood mononuclear cells: astaxanthin. kidney and small intestine of the rat. Lecerf JM. Attias J. Br J Nutr. Lauver DA. 21. 36. Heliovaara M.) Baush & Lomb. 2507-2511. Lockwood SF. 305. 686-692. 38. 75. 2000. Bernstein PS. Johnson EJ. Yaish LB. 2005. Fuhrman B. Jyonouchi H. 2005. Invest Ophthalmol Vis Sci. Knekt P. a carotenoid without vitamin A activity. 2483-2492. Maurel P. Jr. 75. Dietary modification of human macular pigment density. J Nutr. Stahl W. Gross M. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Sun S. 221-223. Antitumor activity of astaxanthin and its mode of action. 135. 1999. Mol Cell Biochem. Astaxanthin diminishes gap junctional intercellular communication in primary human fibroblasts. 2005. Edwards RB. Krinsky NI and Johnson EJ. 1999. 19. Les pigments xanthophylles. Life Sci. Oesterhelt G. 1997. Invest Ophthalmol Vis Sci. Tomato lycopene and beta-carotene inhibit low density lipoprotein oxidation and this effect depends on the lipoprotein vitamin E content. Lucchesi BR. genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Groupe d‘Experts en Micronutrition Oculaire (ed. 665-675. 1992. Effects of astaxanthin on accommodation. Effects of astaxanthin and vitamin C on the prevention of gastric ulcerations in stressed rats. Gragoudas ES. Urabe K. Uonomi T. 57. Kotake S. 2004. 482-490. 297306. Woods JA. Maoka T. Yoshida N. J Agric Food Chem. Liaaen-Jensen S. Dietary carotenoids protect human cells from damage. Hautvast JG. Antiatherosclerotic efficacy of policosanol. Rice-Evans CA. 1996. Changes in visual function following peroral astaxanthin. 48 49 267 . Sommerburg O. Blair N. O'Sullivan SM. 2000. Tinkler JH. Honma C. Nutr Sci Vitaminol ( Tokyo ). Davison AJ. J Photochem Photobiol B. Oxidative stress-related molecules and liver fibrosis. Dietary factors that affect the bioavailability of carotenoids. and E. Nakata D. Tatsumi K. Antioxidants properties of phenolic compounds. Carotenoid interactions. 1997. critical flicker fusion. Haller J. 35. Eye Disease Case-Control Study Group. Naguib YM. Serum beta-carotene response to supplementation with raw carrots. 757-764. carrot juice or purified beta-carotene in healthy non-smocking women. 2000. J Nutr. 2003. Carcinogenesis. 2005. Hannineni O. Japanese Journal of Clinical Ophthalmology. 1999. 503-506. van den Berg H. Bohm F. Br J Nutr. Naito Y. 2004. 1150-1154. Isobe R. 14131420. Pool-Zobel BL. Minenaka Y. Bub A. Antioxidant activities of astaxanthin and related carotenoids. 48. Bjerkeng B. Bird AC. Hiller R. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Yannuzzi LA. 2. Rechkemmer G. 55. Sakurai S. Torronen R. Use of Tween 40 and Tween 80 to deliver a mixture of phytochemicals to human colonic adenocarcinoma cell (CaCo-2) monolayers. 565-575. 2001. Invest Ophthalmol Vis Sci. Yoshikawa T. Willett W. Hasegawa G. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. 283-285. J Hepatol. Yazawa K. 2004. JAMA. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. 135-141. 26942701. 20. Rovati LC. Keunen JEE. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Arzneimittelforschung. Yamada T. Aoi W. Burton TC. Dunn B. Uchiyama K. Truscott TG. Nadamoto T. Journal of Traditional Medicines. 2002. 44. Mizuki N. Takahashi J. J Nutr Biochem. Nutr Rev. and advanced age-related macular degeneration. vitamins A. Otaka Y. Br J Ophthalmol 82. Sanada M. Ajani UA. 1997. 272. 2005. 1994. and pattern visual evoked potential in visual display terminal workers. Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. Schalch W. Biofactors. 51. Wollowski I. Nakamura N. Ohgami K. 44 45 46 47 Setnikar I. 407-433. red yeast rice extract and astaxanthin in the rabbit. Nutr Res 16. 1051-1054. C. 32 33 34 35 36 37 38 39 40 41 42 43 Seddon JM. Shimada Y. Paganga G. Nishida T. Nishikawa YWA. 18. Mykklnen H. 49-59. Osterlie M. Hayasaka S. Horiguchi M. 26. Muller H. Dietary carotenoids. 19. 130. Shiratori K. Trends Plant Sci. 91. 907–910. Hayasaka Y. 1847-1850. Hakkinen S. Abematsu Y. 1994. Senin P. Sperduto RD. Ohno S. 152-159 Rousseau EJ. 312-317. Lehmusaho M. 1998. Weststrate JA. 11. Miller NJ. Parola M and Robino G. Protection by beta-carotene and related compounds against oxygen-mediated cytotoxicity and genotoxicity: implications for carcinogenesis and anticarcinogenesis. 170-173. van Het Hof KH. 1992.31 Nagaki Y. West CE. 58. Ichimura M. O'Brien NM. Free Radic Biol Med. Miller DT. 1-10. Kuijk FJGMv. Farber MD. 13. Nakamura A. 2000. Van Loon LJ. Kocak D. 13. Luden ND. Early postexercise muscle glycogen recovery is enhanced with a carbohydrate-protein supplement. Ivy JL. S119. [Submitted for publication]. 2001. Int J Sport Nutr Exerc Metab. Molecular and integrative physiology of intestinal peptide transport. Daniel H. van de Schoor PA. Katch VL. 486-494. 2000. Saris WH. Effect of a carbohydrate-protein supplement on endurance performance during exercise of varying intensity. Murase N. Flechsenhar K and Alf D. Manders RJ. S125. Alf D and Broja. 1999. 2004. Mizuno M. Saris WH and van Loon LJ. Esmarck B. Kjaer M. ID 1497: “Casein protein hydrolysate” and “Physical performance” 1 2 3 4 Alf D. Orthopadische Praxis. 2006. Improved time to exhaustion with carbohydrate-protein hydrolysate beverage. Katsumura T. Med Sci Sports Exerc. Jeukendrup AE. Carbohydrate and protein hydrolysate beverage improves late-race cycling performance and prevents post-exercise muscle damage. Hammer MC. Anjo M. Osada T. 2005. 148. Olsen S. 31. The effect of free glutamine and peptide ingestion on the rate of muscle glycogen resynthesis in man. SCF (Scientific Committee on Food). Cosmetic benefit of dietary supplements including astaxanthin and tocotrienol on human skin. 93. Flohr JA. Pratt CA. 2006. Lehman KL. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. Jr. [Submitted for publication]. Kime R. Pratt CA. Ichimura S. Timing of postexercise protein intake is important for muscle hypertrophy with resistance training in elderly humans. Shiroishi K. Widzer MO. 38. Todd MK. 2002. 2006. 361-384. J Appl Physiol. 112-117. Effects of increasing insulin secretion on acute postexercise blood glucose disposal. Sprague RC. Damon BM. van Hall G. Philadelphia. Todd MK. Van Breda E. Keizer HA. Shimomura K. Romano-Ely BC. Williams & Wilkins. Med Sci Sports Exerc. [Nutrition and health--nutrition and performance in sports]. Saunders MJ. 2004. Seifert JG. 2006. 535. McCauley TR. Ready SL. Effects of a carbohydrate-protein beverage on cycling endurance and muscle damage. Kies A. Saunders MJ. Lippincott. Laurent TS. Todd K. McArdle WD. Saunders MJ. 268-275. Price TB. J Physiol. Andersen JL. Kuipers H. 2001. 1608-1616. 5 6 7 8 9 10 11 12 13 14 15 16 17 18 268 . Int J Sports Med. Katch FI. Goforth HW. especially for sportsmen. 66. [Submitted for publication]. 21. Ivy JL. 2001. 38.50 Yamashita E. Kane MD. Results of a postmarketing surveillance study of collagen hydrolysate CHAlpha™. 21. Saunders MJ. Burke E. Med Sci Sports Exerc. FOOD Style. Exercise Physiology:Energy. 41. 301311. Broja J. Nutrition and Human Performance. 25-30. S20. J Int Soc Sports Nutr. Moore RW. 2004. 38. Wagenmakers AJ. 382-395. J. Milk peptide PeptoPro® intake enhances bicycle exercise performance after exhaustive exercise. Moore RW. 3.. Effect of an isocaloric carbohydrate-proteinantioxidant drink on cycling performance. Med Sci Sports Exerc. 1233-1238. Annu Rev Physiol. A peptide recovery drink (PeptoPro®) improves subsequent performance in top athletes. Baltimore. Med Sci Sports Exerc. Kurasowa Y. Butt A. 36. Ned Tijdschr Geneeskd. Comparison of a commercial intact whey protein sports drink with a peptide sports drink (PeptoPro®) in well trained athletes. 2003. 708-712. 13371344. Res PT. Parsons EC. Kies AK. 2002. Mori-Matsumura M. Kaastra B. Richter EA. The effect of two sports drink formulations on muscle stress and performance. Nutr Rep Int. Ikeda I. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Nutritional Rep Int. ID 1499: “Chitosan” and “Weight Management” 20 21 22 1 Abelin J and Lassus A. 2004. 72. Int J Obes Relat Metab Disord. Wagenmakers AJ. Grottammare. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. Fogt DL. Falk JD. 20. Kobayashi E. Atec. Helsinki: August October. 327-334. 96-105. Dietary supplements for body-weight reduction: a systematic review. Pittler MH and Ernst E. 105– 122. Deuchi K. 2508-2513. Grottammare. Furda I (ed. Effects of recovery beverages on glycogen restoration and endurance exercise performance. Muzzarelli RAA. 1995. Raven PB. Chitosan Per Os: From Dietary Supplement to Drug Carrier. 1983. Hill ML. 2003. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 269 . Effects of Chitosan hydrolysates on lipid absorption and on serum and liver lipid concentrations in rats. 72. 130. 2000. Giustina A and Ventura P. 1993. Otsuka SI. 79. A meta-analysis. Kruijshoop M. Verhagen H. Sugano M. Macchi G. Fat binder. Furda I. 16. 23. Weight-reducing regimens in obese subjects: effects of a new dietary fiber integrator. Muzzarelli RAA (ed. Sweden Colombo P and Sciutto AM. J Strength Cond Res. 1979. 714-719. 59. The hypolipidemic activity of chitosan and other polysaccharides in rats. Kruijshoop M. 12-19. Nagyvary JJ. Schmidt ML. Ingestion of protein hydrolysate and amino acid-carbohydrate mixtures increases postexercise plasma insulin responses in men. 18. In: Chitosan Per Os: From Dietary Supplement to Drug Carrier. Acta Toxicol Ther.) American Chemical Society. Aminopolysaccharides-their potential as dietary fiber. Nonabsorbable lipid binder. van Loon LJ. Saris WH. 2000. 1996. 1980. Williams MB. Shizukuishi M. 1999. J Nutr. Nagyvary J. The binding of micellar lipids to chitosan. Maximizing postexercise muscle glycogen synthesis: carbohydrate supplementation and the application of amino acid or protein hydrolysate mixtures. MATS Medical AB. Study MMA#001 performed at ARS Medicina. 2000. Wilkins AK. Stockholm. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. Wagenmakers AJ. 2000. 1983. In: Chitosan Per Os: From Dietary Supplement to Drug Carrier.) Atec. Reduction of absorption of dietary lipids and cholesterol by Chitosan and its derivatives and special formulations. Am J Clin Nutr. 106-111. Kanauchi O. 17. 19. Yugari Y. Thompson JL. 16. Biosci Biotechnol Biochem. Sasaki E.) Atec. Am J Clin Nutr. Saris WH. 677-684. 2000. Washington DC. Okuda H. 1996.19 van Loon LJ. 17. Imasato Y. Acta Toxicol Ther. 529-536. 199-214. Nauss JL. Bradbury EL. Ivy JL. Chitosan as a treatment for body weight reduction. Effect of chitosan on serum and liver cholesterol levels in cholesterol-fed rats. Furda I. 287-302. 41. Muzzarelli RAA (ed. van Loon LJ. Abelin J and Rossner S. Kimura Y. 1995. a study of safety in obese patients. Grottammare. Kobayashi T. Medical Research Report. 1994. Am J Clin Nutr. Iwamoto Y. 2000. 1995. Furda I. Yoshida K. Han LK. Hatano K. A new approach to the treatment of obesity: chitosan's effects on body weight reduction and plasma cholesterol's levels. 174-179. Lipids. In: ACS Symposium Series: Unconventional Sources of Dietary Fiber. 431-435. 1979. Verhagen H. Saris WH. J Agric Food Chem. Acta Toxicol Ther. Wagenmakers AJ. L112 biopolymer–fat blocker as a weight reducer in patients with moderate obesity. Ernst E and Pittler MH. 786-790. Nutritional aspects of chitosan employment in hypocaloric diet. 303-322. ID 1501: “Acerola” and “Antioxidant activity” 19 20 21 22 23 24 25 26 1 Bohm U. 1992. 42-49. 25. Veneroni G. Dubin M. 215-230. Dubin M. Rice K. Marietta M. 2001. Gastroenterology. Hiratsuji Y. Optimale Therapie durch individuelle Diagnostik. J Am Nutraceut Assoc. 1399-1403. Kozyreva OG. Clinical nutrition (Edinburgh). Roch M.18 Schiller RN. 18. Sanford PA. 1995. Canty DJ. Buchman AL. Nakashima K. Pfisterer M. 1993. Moukarzel AA. Fukuda N. Low plasma free choline is prevalent in patients receiving long term parenteral nutrition and is associated with hepatic aminotransferase abnormalities. Muzzarelli RAA (ed. Wildman REC (ed. Hypocholesterolemic effects of chitosan in cholesterol-fed rats. Veneroni F. Rice K. Jenden D. Zikakis JP (eds. Hypocholesterolemic action of chitosans with different viscosity in rats. 1983. An in vivo proton magnetic resonance spectroscopy study. Sugano M. Awal M. 1992. FASEB J. London. Sugano M. Lecithin and choline: new roles for old nutrients. Jenden DJ. a new dietary integrator. 2006. 327-339. Guarino C. 12. 20. Ohtakara A. 1980. Rice KM. 187-191. Buchman AL. Wurtman RJ. Contos S. Jenden DJ. Rationelle Diagnostik in der Orthomolekularen Medizin. Hashimoto M. 23. 1363-1370. JAMA.). Vahouny GV. Enomoto K. Grottammare. MVS Medizinverlage Stuttgart. Hiratsuji Y. Decreased brain choline uptake in older adults. Am J Clin Nutr. 472-478. 33. Izume M. Gornbein J. Roch MH. Canty DJ and Zeisel SH. double-blind. Jenden DJ. Cohen BM. Ament ME. 102. Dubin MD. Yoshida K. Muzzarelli RAA (ed. Fujikawa T. placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. Lecithin and choline in human health and disease. Hepatology. Zeisel SH. Sugano M. Grottammare. Muss C. Brine CJ. Yurgelun-Todd D. 2 3 4 5 6 7 8 9 270 . 38. 16. Watanabe S. In: Handbook of Nutraceuticals and Functional Foods. 1996. Fischer LM. 2001. Elsevier. Moukarzel A. 22. Nutr Rep Int. 33-37. Boca Raton. Tripodi S. Common genetic polymorphisms affect the human requirement for the nutrient choline. Song J. 55-62. Kishi A. 1996. 1995. 52.) CRC Press. Ventura P. Am J Clin Nutr. A randomized. Gornbein J. Ament ME. Barrager E. Acta Toxicol Ther. 278-284. 2001. Roch M. 1995. 531-537. In: Chitin enzymology. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. 4. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Sugano M. Fujikawa T. Moukarzel A. Lipid lowering activity of chitosan. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Schauss AG. Lipid-lowering effect of chitosan dietary integrator and hypocaloric diet in obese subjects. 1994. 902907. Ament ME. Pownall H. Ahn C. Nichols EJ. Galanko JA. In: Chitin enzymology. Comparative effects of chitosan and cholestyramine on lymphatic absorption of lipids in the rat. Nutr Rev. Roch M. Ament ME. 63–67. 274. Sciutto AM and Colombo P. Babb SM. Hasegawa Y. 2004. 1988.) Atec. JPEN J Parenter Enteral Nutr. In: Advances in chitin and chitosan. Cassidy MM. 1336-1344. 423-443. Lightfoot FB. Satchithanandam S. Inklusive Prävention und Good Aging. Sohel M. Hypocholesterolemic activity of partially hydrolyzed chitosans in rats. 260268. Hirano S. Effect of a new chitosan on hyperlipidemia and overweight in obese patients. 1978. Buchman AL. 787-793. Buchman AL. Farley W. Furda I. A novel use of chitosan as a hypocholesterolemic agent in rats. da Costa KA. Stoll AL. Eckhert CD.) Atec. De Bernardi M. Hasegawa Y. Renshaw PF. Lipids. 639-646. 649. 271 . 9.pdrhealth. Niacin. ZLR. Shronts EP. 1991. Abgrenzung Lebensmittel/Arzneimittel. Choline http://www. CRC Press. Hahn A. 5. J Am Coll Nutr. Philadephia. 229-250. Zeisel SH. Spallholz JE. Dietary Reference Intakes for Thiamin. Löffler G and Petrides PE. Zeisel SH. 1990. Handbuch für die Therapie. Schmiedel V. Ernährung–Physiologische Grundlagen. 1993. Ernährung des Menschen. Munchen. an essential nutrient for humans. da Costa KA. Lamont JT. Zeisel SH.OLG Koln. and Disease.com/drug_info/nmdrugprofiles/nutsupdrugs/cho_0283. lipotrope deficiency and the development of liver disease including liver cancer: a new perspective. Ross AC. 6062. Heine H. Pantothenic Acid. Folate. Biochemie der Ernährun Steinkopff. Fischer LM. 1998. Biotin. 2005. 1974. Caballero B. 1997. Darmstadt. Zeisel SH. para 2. 85. 2006. Sheard NF. and Choline. Natural Standard Inc: The Authority on Integrative Medicine.naturalstandard. Zeisel SH and Niculescu MD Shils ME. 2093-2098. Stuttgart. 26. Prävention. Blackburn GL. Abnormal liver function in malnourished patients receiving total parenteral nutrition: a prospective randomized study.com/index-abstract. 1275-1285. Berlin. Allen RH. Choline deficiency and TPN associated liver dysfunction: a case report. Stuttgart. Nutrition: chemistry and biology. Eugen Ulmer Verlag. Lu TS. FASEB J. Choline Phospholipids Health.shtml. National Academy Press (NAP). Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans. Annu Rev Nutr. 1.para 1 LMBG. Bistrian B. 255-260. Fischer LM. Springer Verlag. Wolters M. Tayek JA. 2001. 1997.05. Cousins RJ. Modern Nutrition in Health and Disease. Choline: critical role during fetal development and dietary requirements in adults. Stabler SP. 76-83. 1998. J Am Diet Assoc. Da Costa KA. AOACS Press. Franklin PD. Burgerstein's Handbook of Nutrition: Micronutrients in the Prevention and Therapy of Disease. Beiser A. Wissenschaftliche Verlagsgesellschaft. Ernährungsmedizin in der Naturheilkunde. Lützner H. Ströhle A. Proc Natl Acad Sci USA. Sex and menopausal status influence human dietary requirements for the nutrient choline. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft. 16025-16030. 1998.asp?createabstract=/monographs/herbssupplements/patient-choline. Driskell JA. 2006. Nutrition. 1998. Choline: Natural Standard Bottom Line Monograph. 1999. Baltimore. Vitamin B(12). quiz 647-638. 14. Kwock L. Boylan LM. Lab Invest. 26. Ghoshal AK and Farber E. Zimmermann M. Choline deficiency. daCosta KA. Thieme. Urban & Fisher. 2001. 2005. Kohlmeier M. ID 1504: “Chondroitin” and “Joint Health” 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 Rechtsprechung . 102. http://www.asp. Shike M. Lang K.10 11 Elmadfa I and Leitzmann C. Stuttgart.2004 . Choline. 2007. Leitzmann C. Vitamin B(6). Washington DC. Physicians' Desk Reference (PDR). Biochemie und Pathobiochemie. Riboflavin. 97. Am J Clin Nutr. Stewart PW. Zeisel SH. 68. Alexander EA. Essential nature of choline with implications for total parenteral nutrition. Boca Raton. 109-120.6 U 136/02 "Glucosaminsulfat II" . Zeisel SH and Szuhaj BF. Sheard NF. Hahn A. 21 AMG. Hager L. 2006. IoM (Institute of Medicine). 2006. Lippincott Williams & Wilkins. Stuttgart. Philippi AF. 62. Leeb BF. on normal and interleukin-1 conditioned equine articular cartilage explant metabolism. O'Dell JR. Lane NE. 31-36. placebo controlled trial of a topical cream containing glucosamine sulfate. Smolen JS. and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized. Baxter GM. Shi H. Molitor JA. Grynfeltt M. Regulatory Toxicology and Pharmacology. Drugs & Aging. 227-231. Annals of the Rheumatic Diseases. Van AP. Kaklamanis P. 54. 18. The role of chondroitin sulfate in the management of osteoarthritis. 2512-2512. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slowacting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Cohen M. Mai T. Zimmerman-Gorska I. Martin-Mola E. Bannwarth B. A randomized. double-blind. Hungerford DS and Jones LC. 68. Equine Veterinary Journal. 146. Verbruggen G. 1145-1155. Bingham CO. Glucosamine. chondroitin sulfate. Klein MA. 2004. Oddis CV. Trotter GW. Moreland LW. 2006. Davenport G. Journal of Rheumatology. 457-464. 30. chondroitin. Fraser-Reid BO. 354. Pavelka K. 709-715. Schnitzer TJ. Hooper MM. Lohmander S. [Results of a multicenter study of chondroitin sulfate (Condrosulf) use in arthroses of the finger. N Engl J Med. British Journal of General Practice. Frisbie DD. Montag K. McIlwraith CW. 85-91. Reda DJ. Mazieres B. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. 2003. Chondroitin sulfate in osteoarthritis of the knee: A prospective. Glycoscience: Chemistry and Chimical Biology I-III. 272 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 . Combe B. 27. Leffler SG. Hathcock JN and Shao A. Tondut J. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). double blind. 1998. Wolfe F.pdf.2 3 Bruyere O and Reginster JY. 2006. Wiener medizinische Wochenschrift (1946). 795-808. Weisman MH. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. and camphor for osteoarthritis of the knee. Heidelberg. Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis. 2003. Thiem J. 2005. Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses. Yocum DE. 164. 2006. Journal of Arthroplasty. Schumacher HR. Jackson D. Leeb BF. Forsyth RK. Pendleton A. Cush JJ. 37. placebocontrolled pilot study. Bijlsma JWJ. Jordan KM. Lequesne M. STOPP (STudy on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4&6 sulfate (CS). Osteoarthritis and Cartilage. 6. 609. www. 47. Schweitzer H. 2007. Swoboda B. Bradley JD. 2001. Dougados M. Chan PS. 2003. Petera P. Moskowitz RW. 2007.ibsa-ch. Brigden CV. Herrero-Beaumont G. Northrop AJ. chondroitin sulfate. 205-211. and the two in combination for painful knee osteoarthritis. 622.com/eular_2006_amsterdam_vignon-2. Sawitzke AD. Effects of glucosamine hydrochloride and chondroitin sulphate. 1999. 2003. Rheumatology and musculoskeletal medicine. Jun. Kahan A. American Journal of Veterinary Research. 28. Leffler CT. Furst DE. Clegg DO. double blind. Supplement. Orthopedics Today Monographs. Arden NK. 78-83. Neumann K. Punzi L. 2001. Tatsuta K. alone and in combination. Journal of Rheumatology. placebo controlled multicenter clinical study. Lewis D. 2000. Risk assessment for glucosamine and chondroitin sulfate. Orth MW. knee and hip joints]. Kim PD. Glucosamine. Dieppe P. Leeb B. Mazieres B. 573. Gunther K. 1-18. 5-9. Serni U. Brandt KD. Equine veterinary journal. Bucsi L and Poor G. 173-181. Williams HJ. 2007. Jackson CG. Hauselmann H. Glucosamine and chondroitin sulfate are effective in the management of osteoarthritis. Caron JP. Springer Verlag. Harris CL. Military Medicine. Journal of Rheumatology. 24. Wolfe R. Dechant JE. Mosure JC. 1996. Doherty M. 2003. 52. Dieppe PA. 51-56. Simanek V. 59. S24. Felson DT. 17. 2002. Rovetta G. 149. Sanchez J. randomised. 779-786. Verbruggen AA. 2008. 66. Stucki G. Galactosaminoglycuronoglycan Sulfate (Matrix) in Therapy of Tibiofibular Osteoarthritis of the Knee. 7. Martel-Pelletier J. Parcell S. American Family Physician. 163. Drugs under Experimental and Clinical Research. 936-944. Sterchi R. Juni P. Alternative medicine review: a journal of clinical therapeutic. Henrotin Y. Drugs under Experimental and Clinical Research. Dieppe PA. 2000. Bruyere O. Rovetta G. Zaim M. Regitz M. Ulrichova J. Mola EM. 2005. Annals of the Rheumatic Diseases. Sulfur in human nutrition and applications in medicine. 2007. Bilinskaya MA. 65-67. Annals of Internal Medicine. pain and hand dysfunction. Arden N. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre. Morelli V. Reginster JY. 2007. 580-U551. Vergés J. Evaluation of chondroitin sulfate (CS) efficacy and safety in patients with symptomatic hand osteoarthritis (HOA) and osteopenia. Arthritis Rheum. Amelingmeier E. Archives of Internal Medicine. 735-740. Moragues-Pastor C. 339-344. The Journal of rheumatology. Bryehlmann P. 12. Annals of the Rheumatic Diseases. Serni U. 1996. Michel BA. Bannwarth B. A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions. Gallo J. 2005. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Prospective study of high frequency sonography in patients with symptomatic knee osteoarthritis treated with chondroitin sulfat: 74A. Molfetta G. Heraud F. Zimmermann-Gorska I. Boccanera L.20 Mazieres B.A systematic quality assessment and meta-analysis. 283. Weseloh G. LaValley MP. De Agustín J. Trelle S. Naquin C. De Vathaire F. Dougados M. Meta-analysis: Chondroitin for osteoarthritis of the knee or hip. placebo-controlled study. Shmitd EI. Symptom and structure modifying properties of chondroitin sulfate in Osteoarthritis. Pelletier JP. Dmitrieva ME. 1996. Kren V. Mazieres B. France) in patients with coxarthrosis. Gunther KP. RÖMPP-lexikon Chemie. Pavelka K. Richy F. 67. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. 62. 2007. Mini-Reviews in Medicinal Chemistry. Balestra V. Burgi U. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. Doherty M. Sabata R. Falbe J. Vignon E. Kaklamanis PM. 30. Lohmander S. Lequesne M. Zegels B. Reginster JY. 67. Soldatov DG. Möller I. Saponati G. Morreale P. 2004. Cooper C. Gulin JP. Frey D. double-blind. Hauselmann HJ. 1385. Glucosamine and chondroitin for treatment of osteoarthritis . Monfort J. Herrero-Beaumont G. Pendleton A. 1514-1522. 23. The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals. 2007. Alternative therapies for traditional disease states: Osteoarthritis. Ethgen O. Annals of the Rheumatic Diseases. Garnero P. Jama-Journal of the American Medical Association. Bijlsma JWJ. Galati M. Medizinische Medien Informations GmbH. Reichenbach S. 7. Annals of the Rheumatic Diseases. Garcia-Giralt N.A comprehensive meta-analysis. 22. Bocchi L. 11-16. Georg Thieme Verlag. 146. Manopulo R. Leeb B. Belozerova IV. Möller I. Swoboda B. 1469-1475. osteophytes. Marti N. 1051-1061. Pharmindex. 487-487. Scherer M. 53-57. Cluzeau F. 2006. Weaver V. Römpp H. Martinez M. Bruyere O. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. Terapevticheskii Arkhiv. 2000. 79. Hucher M. McAlindon TE. Journal of Clinical Rheumatology. 639-645. 273 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 . 2003. Burgi E. Monteforte P. 1991. Condrosulf 800mg. Cucherat M. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Montell E. Long-term efficacy and safety of chondroitin sulphate (Structum. 2003. Moragues C. 2007. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis . Tunger L. 269-276. Täufel A. Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses. Clinical efficiency and pharmacoeconomical evaluation of treatment by chondroitinsulphate (Structumc) in patients with primary osteoarthritis (POA). 2003. 68. 6-13. 2512-2512. Harris CL. Vignon E. Orth MW. double-blind. Marcolongo R. 385-392. N Engl J Med. OARSI Satellite Symposium. 9. 39-46. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis and Cartilage. DeVathaire F. 2000. Fahmi H. Uebelhart D. Lewis D. Shi H. Delmas PD. Wolfe R. Osteoarthritis and Cartilage. Caron JP. Gorham J. 2007. chondroitin sulfate. 6. 2007. Cush JJ. Forsyth RK. Sawitzke AD. Wang DA. Arthritis Research & Therapy. Clegg DO. Williams JM. Drugs & Aging. Multifunctional chondroitin sulphate for cartilage tissue-biomaterial integration. Thonar EJMA. Glucosamine and Chondroitin Sulfate as Therapeutic Agents for Knee and Hip Osteoarthritis. Weisman MH. Barcelona. May. Schumacher HR. Bourgeois P. 6. and the two in combination for painful knee osteoarthritis. 12. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. 24. Matoso L. 2007. Cohen M. Bingham CO. 1998. Osteoarthritis and Cartilage. 2001. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Nature Materials. Lane NE. Wuisman PI. Hooper MM. Delcambre B. 622. double blind.6 Suppl A. multicenter study versus placebo. R117. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slowacting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Malaise M. Zhang JW. ID 1505: “Chondroitin Sulphate” and “Joint Health and Mobility” 41 42 43 44 45 46 47 48 1 2 Chondroitin Sulfate: Mechanism of Action and Clinical Response in Osteartritis. Strehin I. Sharma B. 2007. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Bradley JD. Goemaere S. Chantraine A. Vignon E. 31-36. Osteoarthritis Cartilage. Northrop AJ. TopMedizin. Wolfe F. Mai T. 6. Ternes W. Veys EM. Elisseeff JH. van Blitterswijk WJ. Moskowitz RW. 6. 24. Reda DJ. randomized. 709-715. Yocum DE. 30. Molitor JA. Kuntz JL. Lajeunesse D. 3. 2004. Vergés J. Furst DE. Brigden CV. Chales G. Zobel M.39 40 Soroka NF and Chyzh KA. chondroitin sulfate. A randomized. 573. BMC Complement Altern Med. Rozenberg S.6-sulfate in the acute degradation of articular cartilage in the rabbit. Lebensmittel-lexikon. Fioravanti A. 1998. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report. Moreland LW. Thonar EJMA. Osteoarthritis and Cartilage. Jackson CG. van de Nes JC. Klein MA. Fairbrother DH. 795-808. American Journal of Veterinary Research. Dehais J. 2006. 61. Martel-Pelletier J. 1998. Equine veterinary journal. Tat S. Piperno M. O'Dell JR. 25-30. Mailleux E. and camphor for osteoarthritis of the knee Journal of Rheumatology. 2. 354. Uebelhart D. Schnitzer TJ. 3 4 5 6 7 8 274 . Montell E. Williams HJ. Glucosamine. Cascio B. Oddis CV. Osteoarthritis and Cartilage. Varghese S. Bruyere O and Reginster JY. 6. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year. 1998. 2005. Pelletier JP. 1998. Chan PS. Lavigne M. 2003. Fermanian S. Uebelhart D. placebo controlled trial of a topical cream containing glucosamine sulfate. Behr's Verlag DE. Bucsi L and Poor G. 2006. 39-46. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Verbruggen G. Protective effect of exogenous chondroitin 4. 2002. Ann Rheum Dis. Brandt KD. Supplement. 173-181. 23. Kahan A. Vignon E. Journal of Rheumatology. De Vathaire F. 1051-1061. 2006. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Kren V. 5-9. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis . Bruyere O.6-sulfate in the acute degradation of articular cartilage in the rabbit. 17. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 275 . Rovetta G. The Journal of Rheumatology. 149.pdf Leeb BF. 28. 51-56. 85-91. double-blind. Martel-Pelletier J. Combe B. 70. Trelle S. chondroitin. Juni P. Dieppe PA. 1514-1522. Chondroitin 4 and 6 sulfate: A symptomatic slow-acting drug for osteoarthritis does also have structural modifying properties. Journal of Rheumatology. 67. 1999. Military Medicine. 6. 52. 2007. Kim PD. 1385. 2000. Van AP. STOPP (STudy on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4&6 sulfate (CS). Glucosamine. 2003. 47. Meta-analysis: Chondroitin for osteoarthritis of the knee or hip. 9. Uebelhart D. 2008. Montag K. 1997. Williams JM. Stucki G. Vignon E. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. 146. Mazieres B. Frey D. Regulatory Toxicology and Pharmacology. Drugs under Experimental and Clinical Research. Morreale P. Alternative medicine review: a journal of clinical therapeutic. Richy F. Hungerford DS and Jones LC. Tondut J. Annals of the Rheumatic Diseases. Garcia-Giralt N. 7. 580-U551. Osteoarthritis & Cartilage. 7. Montell E. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. 2002. Glucosamine and chondroitin for treatment of osteoarthritis . Galati M. 2007. 2007. Martel-Pelletier J. placebocontrolled pilot study. Delmas PD. Bruyere O. JAMA. Chantraine A.ibsa-ch. Monfort J. Glucosamine and chondroitin sulfate are effective in the management of osteoarthritis.com/eular_2006_amsterdam_vignon-2. Journal of Arthroplasty.9 10 11 12 13 Hathcock JN and Shao A. 6-13. Uebelhart D. 78-83. Uebelhart D. Scherer M. Sterchi R. The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. Risk assessment for glucosamine and chondroitin sulfate. Tat S. Osteoarthritis and Cartilage. 6. double blind. Thonar EJMA. Ulrichova J. Protective effect of exogenous chondroitin 4. 1998. placebo controlled multicenter clinical study. Heraud F. Mosure JC. 2005. Fahmi H. Mini-Reviews in Medicinal Chemistry. 1998. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. Condrosulf 800mg. 27. Bryehlmann P. Ethgen O. Delmas PD. 2005. Felson DT. 164. Cucherat M. Parcell S. 735-740. 779-786. 18. Sulfur in human nutrition and applications in medicine. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. 163. R117. Reichenbach S. Burgi U. Chondroitin sulfate in osteoarthritis of the knee: A prospective. 5. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007. Grynfeltt M. 2007. Michel BA.A comprehensive meta-analysis. Reginster JY. Schweitzer H. Zegels B. Pelletier JP. Bocchi L. LaValley MP. Lajeunesse D. Simanek V. 1469-1475. Gulin JP. Henrotin Y. Annals of Internal Medicine. Symptom and structure modifying properties of chondroitin sulfate in Osteoarthritis. 22. Reginster JY. 283. Arthritis Research & Therapy. Burgi E. Lavigne M. 2003. Osteoarthritis and Cartilage. Manopulo R. Zhang JW. Galactosaminoglycuronoglycan Sulfate (Matrix) in Therapy of Tibiofibular Osteoarthritis of the Knee.A systematic quality assessment and meta-analysis. McAlindon TE. Thonar EJMA. Leffler CT. 39-46. Archives of Internal Medicine. www. Pelletier JP. and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized. Thonar E. Saponati G. Smolen JS. 1996. Gallo J. Vergés J. Boccanera L. Arthritis Rheum. Philippi AF. Pharmindex. 2000. 205-211. 2001. 1991. 53-57. Leffler SG. 2. Kondo K. Grassi D. Necozione S. Ferri C. Am J Clin Nutr. Br J Nutr. Valeri L. 1436-1441. 2007. J Nutr. Ding X. Pasqualetti P. Am J Clin Nutr. Vignon E. Miyatake H. 137. Engler MB and Engler MM. Arch Intern Med. 59. 12. Chocolate and prevention of cardiovascular disease: a systematic review. Polyphenols: chemistry. Rafter J. Clin Dev Immunol. Lippi C. Nutrition Research. 166. 749-758. Piperno M. Circulation. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Yoshida T. Phytochemistry. Waterhouse AL. Corti R. Luscher TF. Kromhout D. 709-717. and nutritional significance. Polyphenols and disease risk in epidemiologic studies. Nakamura Y. and cardiovascular mortality: the Zutphen Elderly Study. 2005. 2376-2382. Nutr Metab (Lond). The vasculoprotective effects of flavonoid-rich cocoa and chocolate. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Wuisman PI. Girotra S. 81. Hypertension. Kondo K. Necozione S. Fioravanti A. 611-614. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo. dietary sources. BMC Complement Altern Med. 2005. Baba S. 2006. Osakabe N. Serafini M. Fraga CG. and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr. 12. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Yasuda A. Ferri C. Hermann F. IUBMB Life. 99. 24. Osakabe N. 317S-325S. Stewart AJ. Ito H. Lotito SB. Yasuda A. Proanthocyanidin glycosides and related polyphenols from cacao liquor and their antioxidant effects. multicenter study versus placebo. Plant polyphenols: how to translate their in vitro antioxidant actions to in vivo conditions. Hatano T. Nutr Rev. 3. 2007. Regular consumption of a flavanol-rich chocolate can improve oxidant stress in young soccer players. 2005. 268S-276S. 316-328. Osteoarthritis and Cartilage. Feskens EJ. 116. 2003. Carrasquedo F. Pellegrini N. Tamura T. 59. Cocoa intake. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year. Ruschitzka F. 317-333. Sudano I. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report. 2007. Natsume M. Buijsse B. 695-706. Del Rio D. Hutfless SM. Halliwell B. Desideri G. Schmitz HH. Matoso L. 2007.30 Uebelhart D. Fukuda K.and hypercholesterolemic humans after intake of different levels of cocoa powder. Ding EL. 2007. 269-276. Kido T. Keen CL. 11-17. Nutr Metab Cardiovasc Dis. Fraga CG. Cooper KA. 2005. Lazarus S. van de Nes JC. Kanegae M. double-blind. 398-405. van Blitterswijk WJ. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Baba S. 2006. 2. 411-417. Williamson G. Spieker L. Grassi D. 15. 1-11. Hermann M. Bravo L. Muto Y. Mailleux E. 3. 56. Cooper KA. 46. 308-315. Flammer AJ. Health promotion by flavonoids. 81. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans. Noll G. Natsume M. tocopherols. Desideri G. 2005. ID 1506: “Cocoa flavanols” and “Antioxidative properties” 31 1 2 Arts IC and Hollman PC. 276 3 4 5 6 7 8 9 10 11 12 13 14 15 16 . 2004. Marcolongo R. tocotrienols. Actis-Goretta L. randomized. Malaise M. metabolism. Jenner A. Donovan JL. Kok FJ. 2005. Blumberg JB. 85. 2004. 2002. Am J Clin Nutr. Cocoa and health: a decade of research. DeVathaire F. Takizawa T. Kato Y. Lippi C. Croce G. 1998. Osakabe N. 81. blood pressure. Ottaviani JI. Natsume M. Keen CL. Record IR. 3663-3667. J Nutr. Matsumoto A. Holt RR. Grundy SM. Jialal I. Holt RR. 11. Itakura H. and hydroxyl radical production. J Atheroscler Thromb. 2006. Iwamoto T. Noll G. Virtanen JK. Macdonald I. 2004. 2003. Keen CL. Natsume M. Luscher TF. Dose-Response Study of Daily Cocoa Intake on the Oxidative Susceptibility of Low-Density Lipoprotein in Healthy Human Volunteers. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Kondo K. Fraga CG. Hypertension. 49. Dietary flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function. Poulter N. 20. Mehrinfar R and Frishman WH. Moriarty H. Yasuda A. 2005. Chocolate consumption. 2109S-2114S. Schmitz H. fecal water antioxidant activity. Flavanol-rich cocoa: a cardioprotective nutraceutical. Nyyssonen K. Kondo K. Mutanen M. I6-27. Binggeli C. 131. Hermann F. McInerney JK. Heart. Preston M. S103-109. 116. 42 Suppl 1. 41-49. 2001. 109-115. Spieker LE. Devaraj S. 132. Takizawa T. 46. Chocolate: food as medicine/medicine as food. Lotito S. 50. Chevaux K. Sies H. discussion 440S-442S. Kaikkonen J. Kondo K. 77. Tokunaga T. Cocoa. 2002. Kondo K. flavanols and cardiovascular risk. Mann NJ. Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. 81. Sudano I. Den Hond E. 2000. Osakabe N. 2004. Takizawa T. Corti R. J Cardiovasc Pharmacol. Curr Opin Lipidol. Sinclair AJ. 16. Am J Clin Nutr. 298S-303S. Voutilainen S. Iwamoto A. Francis MA. Rein D. Journal of Health Science. 2006. Igarashi O. Daily cocoa intake reduces the susceptibility of low-density lipoprotein to oxidation as demonstrated in healthy human volunteers. PASSCLAIM . Riesen W. 130. Cocoa antioxidants and cardiovascular health. 679-684. Itakura H. Singh I. 2001. 13. Nutrition and Cancer. J Am Coll Nutr. 2007. Yamagishi M. Natsume M. Schmitz HH. Noakes M. Aro A. German JB. Finis D. Adachi T. Hoffmann A. Coletti C. 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 277 . the Kuna. Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. 2002. 2008. 379-387. 2004. Dark chocolate improves endothelial and platelet function. 1727-1746. Hirano R. J Nutr Sci Vitaminol (Tokyo). Is it the dark in dark chocolate? Circulation. 2360-2362. consequence. 2003. ten Meer HU. Griffin BA. Salonen JT. Rassaf T. Mursu J. Campos H. 1466-1473. Murphy KJ. Osakabe N. 47. Hermann M. Kamiyama M. Kleinbongard P. Eur J Nutr. 2007. Iwamoto T. Antioxidant effects of polyphenols in chocolate on low-density lipoprotein both in vitro and ex vivo. Oteiza PI. Mathur S. 2000. Lotito SB and Frei B. 2000. 1351-1359. Free Radic Res. British journal of cardiology. Am J Clin Nutr. Stahl W. Jackson L. Kelm M. Kamiyama M. Martinez G. Free Radic Biol Med. Pike MJ. 7. Hollenberg NK. discussion 119-121. Hollenberg NK and Fisher ND. Baba S. J Nutr. 199-204. Schmitz HH. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Kris-Etherton PM and Keen CL. 74-80. Ruschitzka F. 164-168. McCullough ML. Rissanen TH. Yasuda A. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause. 37. 119-120. Mensink RP. Baba S. Cardiol Rev. 41. or epiphenomenon? Free Radic Biol Med.Diet-related cardiovascular disease. 34. Osakabe N. Hollenberg NK. Effects of cacao liquor polyphenols on the susceptibility of low-density lipoprotein to oxidation in hypercholesterolemic rabbits. Pannemans D. 47 Suppl 2. Osakabe N. 2003. Bird AR. Takizawa T. 93-99. 92. Itakura H. and the epidemiology of flavanols. 436S-439S.17 Heiss C. J Cardiovasc Pharmacol. Schmitz HH. Chronopoulos AK. Epicatechin in human plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status. 2006. Nurmi T. Turner AH. Fraga CG. Hirano R. Keen CL. 13. Jung N.37 Robbins RJ. J Nutr. Keen CL. 47 Suppl 2. Vlachopoulos C. Vascular protection by dietary polyphenols. Taubert D. 2000. Agricultural Research Service: Phytonutrients PL FAQs. Johnson IT. which have antioxidant activity. 2000. Almajano MP. Wiswedel I. Klaus W.usda. Holt RR. WHO Technical Report Series 916. Taffera P. Human urine: epicatechin metabolites and antioxidant activity after cocoa beverage intake.gov. ID 1507: “Cocoa flavanols” and “Vascular health” 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 1 Allen RR. Estruch R. 2002. Schomig E. Cocoa procyanidin chain length does not determine ability to protect LDL from oxidation when monomer units are controlled. Ndiaye M. 54. Carson L. Chataigneau T. Wang JF. 2006. 2004. Effect of dark chocolate on arterial function in healthy individuals: cocoa instead of ambrosia? Curr Hypertens Rep. Am J Clin Nutr. Jr. Valtuena S. Taubert D. Bose P. Schini-Kerth VB. Vinson JA. 2003. JAMA. Samman N. Kwik-Uribe C. Polyphenols in chocolate. 2008. Sakane T. Dietary intake and bioavailability of polyphenols. 53.ars. Bugianesi R. Ensunsa JL. Proch J. Roesen R. J Agric Food Chem. 1029-1030. Effects of cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in humans. 2007. J Agric Food Chem. Schmitz HH. Shuta D. JAMA. Stefanadis C. 2115S2119S. 2006. Sies H. 5041-5048. Report of a Joint WHO/FAO Expert Consultation. 645-652. 596-602. Stoclet JC. Oak MH. Free Radic Res. 424. 2073S2085S. http://www. 49-60. 8. J Nutr. J Nutr Biochem. J Nutr. Saltmarsh M. Suzuki N. Lazarus SA. 2001. Kris-Etherton PM. and a significant contributor to antioxidants in the European and American Diets. Serafini M. 725-731. Eur J Pharmacol. nutrition and prevention of chronic diseases. 37. Am J Clin Nutr. Schmitz HH. Expert Report: Diet. 278 . Daily consumption of a dark chocolate containing flavanols and added sterol esters affects cardiovascular risk factors in a normotensive population with elevated cholesterol. Gruening M. Hirsch D. 138. De Santis S. 2004. Fraga CG. Free Radic Biol Med. Agbor GA. 299-313. modulate immune functions in humans in vitro. 2007. Keen CL. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. Berkels R. 2003. 74. Muchler S. Fraga CG. 290. Crozier A. Chocolate is a powerful ex vivo and in vivo antioxidant. Lehmann C. Holt RR. 81. 2005. Steinberg FM. Schramm DD. 943-949. Proch J. Nature. Schewe T. Vinson JA. Evans EM. an antiatherosclerotic agent in an animal model. Alexopoulos N. Scalbert A. 177. USDA. Erdman JW. 41. Wan Y. 1997. Flavanol-rich cocoa drink lowers plasma F(2)-isoprostane concentrations in humans. 1013. 130. Sanbongi C. Plasma antioxidants from chocolate. Antioxidant and membrane effects of procyanidin dimers and trimers isolated from peanut and cocoa. 411-421. 130. Oteiza PI. Cell Immunol. Bilbao ML. 298. 129-136. Kropf S. El Bedoui J.. 215S-217S. 205-211. Keen CL. Schmitz HH. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. 2003. Pfister E. WHO/FAO. discussion S119-121. 2005. Maiani G. Scalbert A and Williamson G. 8071-8076. Kwik-Uribe C. Hammerstone JF. Andres-Lacueva C. Lamuela-Raventos RM. Chataigneau M. Verstraeten SV. Polyphenols: antioxidants and beyond. Hammerstone JF. 500. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. Etherton TD. Analysis of flavanols in foods: what methods are required to enable meaningful health recommendations? J Cardiovasc Pharmacol. S110-118. 2006. Roura E. Roesen R. blood pressure. Lauer T. S122-127. 317S-325S. Chiu EY. 32. Hughes M. Blumberg J. diabetes mellitus. Kelm M. Engler MB and Engler MM. 88. Buijsse B. Serafini M. Malloy MJ. Nutr Metab Cardiovasc Dis. Lotito SB. Baba S. Kleinbongard P. Heiss C. 2003. Engler MB. Osakabe N. and nutritional significance. Fisher ND. discussion S172-126. J Am Coll Nutr. and cardiovascular mortality: the Zutphen Elderly Study. 2008. Paul SM. 74. 3. Spieker L. Katz DL. 2007. Hollenberg NK. 2004. Kelm M. Arch Intern Med. 58-63. 317-333.2 Arts I. Folts JD. Cooper KA. 51. Girotra S. Nakamura Y. metabolism. Gerhard-Herman M. Carrasquedo F. 2007. Stewart AJ. Lauer T. 284-287. 227-232. 1998. Ding X. Howe PR. Ding EL. Coates AM. Ottaviani JI. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. 103. Cocoa intake. J Nutr. Faridi Z. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 279 . Corti R. Merx M. Hollman P. Parker C. Flavanol-rich cocoa induces nitricoxide-dependent vasodilation in healthy humans. Int J Obes (Lond). Natsume M. 81. 2008. Int J Med Sci. Ali A. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. Bayard V. Rassaf T. 2792-2798. Circulation. Acute dark chocolate and cocoa ingestion and endothelial function: a randomized controlled crossover trial. The vasculoprotective effects of flavonoid-rich cocoa and chocolate. 15. Feskens EJ. Matern S. Polyphenols: chemistry. J Am Coll Cardiol.. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Rassaf T. Del Rio D. Chamorro F. Does flavanol intake influence mortality from nitric oxide-dependent processes? Ischemic heart disease. Schmitz HH. Flammer AJ. Perlman JA. Engler MM. Dutta S. Nutr Rev. Iafrati MD. Noll G. Kwak HK. Nutrition Research. 47 Suppl 2. Kondo K. Browne A. Bravo L. Keen CL. Allen RR. Kleinbongard P. Lazarus S. 316-328. 2005. Nutr Metab (Lond). Schroeter H. Njike VY. 53-58. Arts IC and Hollman PC. 2008. 2006. 23. Sudano I. J Cardiovasc Pharmacol. dietary sources. Am J Clin Nutr. 2005. Kanegae M. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Balzer J. Luscher TF. Ivanov V. 137. 2141-2149. Heussen N. Buckley JD. Clin Dev Immunol. Mietus-Snyder ML. Erdman JW. 17 Suppl 1. Deak LR. 24 695-706. Jr. controlled trial. randomized. 2376-2382. 11-17. Hermann M. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo. 21. Frei B. 2004. 1436-1441. Hollenberg N. Chocolate and prevention of cardiovascular disease: a systematic review. Circulation. 197-204. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. and cancer in panama. Schroeter H. Gross HB. 56. Carson L. Pellegrini N. Yasuda A.and hypercholesterolemic humans after intake of different levels of cocoa powder. Keen CL. Asia Pac J Clin Nutr. Heiss C. Polyphenols and disease risk in epidemiologic studies. Feskens E. 2005. Kromhout D. Tamura T. Flavanols and cardiovascular health: effects on the circulating NO pool in humans. Brouzos P. 2008. Motta J. Fraga CG. Bueno de Mesquita H. 411-417. J Hypertens. Regular consumption of a flavanol-rich chocolate can improve oxidant stress in young soccer players. Evans EM. 4. Actis-Goretta L. 2006. Hutfless SM. Freedman JE. 166. Kok FJ. Kwik-Uribe C. Kromhout D. 2001 Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. Davison K. Ruschitzka F. 2006. stroke. Am J Clin Nutr. Effects of cocoa flavanols on risk factors for cardiovascular disease. Balzer J. Li L. 1289-1296. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked. Hermann F. Milbury P. 2281-2286. Am J Clin Nutr. 116. 12. 2001. Chen CY. 2. 2007. 119-120. J Cardiovasc Pharmacol. Hermann F. Rivera J. and cocoa flavanols. Schewe T. 2006. JAMA. Blumberg JB. Cocoa. J Nutr. Matsumoto A. 2006. Rivera A. Hollman PC. Osakabe N. 130. Am J Clin Nutr. 47 Suppl 2. JAMA. J Nutr Sci Vitaminol (Tokyo). 2006. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Meinking T. Cassidy A. 49. Kleinbongard P. Dark chocolate inhibits platelet aggregation in healthy volunteers. J Cardiovasc Pharmacol. Journal of Cardiovascular Pharmacology. 46. 287. Schmitz HH. Taplin D. 88. discussion S206-189. Rimm EB. 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 280 .21 Grassi D. Vicaria-Clement M. flavanols and cardiovascular risk. Cohn JS. Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. 171-176. Actis-Goretta L. Lozano ML. Holt RR. Antioxidant effects of polyphenols in chocolate on low-density lipoprotein both in vitro and ex vivo. Kelm M. 2005. Schroeter H. Keen CL. Lippi C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. 1007-1011. 379-386. 1997. Flavonoids. Zhu QY. Lazarus SA. Hammerstone JF. Sies H. 342. Preston M. Hermann M. 2000. 11. S128-135. J Nutr. 2003. Keen CL. Ferri C. Dietary flavanols and platelet reactivity. Zhao L. Innes AJ. Effects of cocoa extracts on endothelium-dependent relaxation. Igarashi O. Procyanidin content and variation in some commonly consumed foods. McCullough M. 2005. Bancroft AJ. Heiss C. 74-80. 14. MacDonald I. Iwamoto A. Kondo K. J Thromb Haemost. J Cardiovasc Pharmacol. May J. Natsume M. Benavente-Garcia O. Kennedy G. Hooper L. 47. Desideri G. Heiss C. Feskens EJ. Keen CL. Lazarus SA. Grassi D. J Cardiovasc Pharmacol. 369-376. Dark chocolate improves endothelial and platelet function. Dejam A. Lancet. flavonoid-rich foods. McLaren M. Poulter N. Hollenberg NK. S99-S102. Sies H. Itakura H. Hertog MG. 199-204. Kelm M. Hollenberg N. Le Cornu KA. Aging. Croce G. 2002. Hollenberg NK. Valeri L. 2212-2213. Heptinstall S. Lippi C. Rassaf T. Ryder JJ. Kromhout D. Kroon PA. Schmitz HH. 2004. Sudano I. 2003. discussion S206-199. Katan MB. Spieker LE. 2005. 2002. S197205. 130. 3. Momma TY. Sies H. Platelets. Vicente V. Necozione S. Castillo J. Finis D. Fraga CG. 611-614. 46. discussion S172-126. Kleinbongard P. Am J Clin Nutr. and cardiovascular risk: a meta-analysis of randomized controlled trials. 1993. Schmitz HH. 47 Suppl 2. 2000. Luscher TF. Vascular effects of cocoa rich in flavan-3-ols. Br J Cardiol. Fox S. Vascular action of cocoa flavanols in humans: The roots of the story. 2000. Belch JJ. Schmitz H. 2006. Noll G. and hypertension in the Kuna of Panama. acculturation. Endothelial function. Binggeli C. 38-50. Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. Am J Clin Nutr. S187-196. 290. Guerrero JA. 92. Heart. 2086S-2092S. Necozione S. 398-405. Hirano R. Hypertension. Lazarus SA. 81. Martinez G. Hall WL. 47 Suppl 2. McCormick K. 76. Schramm DD. 2008. Hypertension. Holt RR. 1030-1031. Corti R. 325-327. Kwik-Uribe C. Takizawa T. Passan D. Balzer J. Ferri C. Desideri G. Karim M. Riesen W. 2006. Heiss C. Matern S. Kleinbongard P. Sullards MC. Ruschitzka F. nitric oxide. 798-804. Holt RR. Kappagoda CT. Schramm DD. 29. Pasqualetti P. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. Harvey I. 2105S-2108S. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Hoffmann A. Chocolate consumption and platelet function. Kelm M. Hammerstone JF. salt intake. 2007. Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Review of 97 bioavailability studies.Diet-related cardiovascular disease. Offord EA. Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo. Ensunsa JL. Keevil JG. Keen CL. Pike MJ. Morand C. Scalbert A and Williamson G. 79. 36-40. 230S-242S. Itakura H. PASSCLAIM . Jimenez L. Life Sci. 73. 2003. Am J Clin Nutr. Sies H. Keen CL. Takizawa T. Am J Clin Nutr. 53. 2000. 211-215. 47 Suppl 2. Dietary flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function. Cocoa inhibits platelet activation and function. Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin. but not orange juice or grapefruit juice. Holt RR. McCullough ML. Reed JD. Jackson L. 22-26. Schmitz HH. Polyphenols: food sources and bioavailability. Enslen M. 2000. Epicatechin in human plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status. 2008. 109-115. 2002. Keen CL. I. Morand C. Hypertension. 53-56. Gosselin R. Free Radic Res. Stahl W. 476. Schrader HR. 53-56. Mehrinfar R and Frishman WH. 280-283. 1999. 106. Wun T. Schnorr O. 2002. Stahl W. discussion 119-121. 191-197. Yasuda A. Eur J Nutr. Tavazzi I. Arch Biochem Biophys. 17 Suppl 1. Am J Clin Nutr. 30-35. Rein D. Francis MA. J Nutr. Preston M. 857869. Eur J Clin Nutr. Sinclair AJ. Kondo K. Scalbert A. Moriarty H. Campos H. Wang JF. Bioavailability and bioefficacy of polyphenols in humans. Lotito S. Schmitz HH. Schramm DD. Keen CL. 2008. Neukam K. Rein D. Schramm DD. Mathur S. 2001. Aro A. Rein D. Den Hond E. Gosselin R. Williamson G. Chocolate procyanidins decrease the leukotriene-prostacyclin ratio in humans and human aortic endothelial cells. Mann NJ. Schmitz HH. Martinez G. 2006. Folts JD. German JB. 48 49 50 51 52 53 54 55 56 57 58 59 60 281 . 2008. Thromb Res. Keen CL. Kleinbongard P. Am J Clin Nutr. Remesy C. J Cardiovasc Pharmacol. 2006. 2073S2085S. Pannemans D. Baba S. Schramm DD. Jialal I. Plasma kinetics in man of epicatechin from black chocolate. Cocoa antioxidants and cardiovascular health. Grundy SM. 2005. Schmitz HH. 72. 2000. 298S-303S. bioavailability and bioactivity. Schmitz HH. Fraga CG. Osman HE. Food effects on the absorption and pharmacokinetics of cocoa flavanols. J Nutr. 77. Coletti C.41 42 43 44 45 46 47 Keen CL. 130. Grape juice. 73. Karim M. ten Meer HU. Pearson DA. Asia Pac J Clin Nutr. 2003. Sies H. Paglieroni TG. 130. Holt RR. Oteiza PI. 81. Schroeter H. Heinrich U. 2004. Cardiol Rev. Dietary intake and bioavailability of polyphenols. Wang JF. Polagruto JA. 2003. Griffin BA. Flavanol-rich cocoa: a cardioprotective nutraceutical. 2005. 130. Hollenberg NK. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Chronopoulos AK. Scalbert A. Paglieroni TG. Ensunsa JL. Lazarus SA. Eur J Nutr. 132. German JB. Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. the Kuna. 2000. Am J Clin Nutr. 16. Tronnier H. Remesy C. 81. Wun T. Cocoa flavanols . Keen CL. 727-747. 3663-3667.measurement. Schmitz HH. Pearson DA. 42 Suppl 1. Manach C. 1466-1473. Brossette T. Am J Clin Nutr. Devaraj S. Manach C. Kwik-Uribe C and Bektash RM. inhibits human platelet aggregation. J Nutr. Schmitz HH. Momma TY. Iwamoto T. I6-27. Holt RR. Richelle M. Singh I. 2109S-2114S. 2001. Murphy KJ. Chevaux K. 34. Mutanen M. 46. Daily cocoa intake reduces the susceptibility of low-density lipoprotein to oxidation as demonstrated in healthy human volunteers. Turner AH. Kirkpatrick NJ. Kamiyama M. Mensink RP. Holt RR. Gonsalves JL. Fraga CG. 93-99. Osakabe N. S103-109. J Nutr. and the epidemiology of flavanols. Holt RR. Vlachopoulos C. 645-652.ars. 500. Luscher TF. 299-313. Orozco TJ. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. USDA Agricultural Research Service. J Nutr. S136-150. Schramm DD. Report of a Joint WHO/FAO Expert Consultation. 1024-1029. 2002. J Cardiovasc Pharmacol. Schmitz HH. 1013. Gruening M. as compared with nonflavonoid white chocolate. J Nutr Biochem. Hirsch D. 785-791. 2001. Acute effect of oral flavonoid-rich dark chocolate intake on coronary circulation. 2004. Chronic consumption of flavanol-rich cocoa improves endothelial function and decreases vascular cell adhesion molecule in hypercholesterolemic postmenopausal women. Schmitz HH. 424-429. Human Nutrition Research Center. Flammer A. El Bedoui J.usda. Holt RR. 2005. 304S-312S. 411-421. Schewe T. Int J Cardiol. 2003. Flavanol-rich cocoa drink lowers plasma F(2)-isoprostane concentrations in humans. Kris-Etherton PM. Cocoa polyphenols and inflammatory mediators. 2007. USDA. Kelm M. Ensunsa JL. Schmitz HH. Wan Y. Watzl B and Rechkemmer G. USDA Database for the Flavonoid Content of Selected Foods. Stefanadis C. Heiss C. discussion 788. Proc Natl Acad Sci USA. Corti R. Serafini M. Maiani G. Arch Intern Med. Wiswedel I. Wang-Polagruto JF. 2004. Kleinbongard P. Valtuena S. Agricultural Research Service: Phytonutrients PL FAQs. 498–502. 167. Lazarus SA. Vascular protection by dietary polyphenols. 131. 2001. Hollenberg NK. 282 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 . nutrition and prevention of chronic diseases. Roesen R. Taubert D. Schroeter H. Lee K. Murayama T. 37. Schmitz HH. 2005. Holt RR. Am J Hypertens. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Keen CL. 2003. Effects of cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in humans. 13. Sies H. Nakamura K. 47 Suppl 2. Holt RR. Keen CL. S177-186. Etherton TD. Sies H. Berkels R. Stoclet JC. Lee L. USDA Agricultural Research Service. discussion S172-136. Heiss C. 2003. 2003. 2003. Nutrient Data Laboratory Beltsville. Ndiaye M. Sudano I. WHO Technical Report Series 916. Nature. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. J Nutr. dietary and postprandial oxidative stress. Keen CL. 596-602. Sevanian A. 626-634. Protection of endothelial function: targets for nutritional and pharmacological interventions. Am J Clin Nutr. 47 Suppl 2. Proch J. 2006. Daimon M. Nature. Komuro I. Expert Report: Diet. by transthoracic Doppler echocardiography in healthy adults. Effect of dark chocolate on arterial function in healthy individuals. Roesen R. Steinberg FM. Ernährungs-Umschau. Nutritional. Stahl W. 1029-1030. 787-788. Kwik-Uribe C. Kropf S. Keen CL.gov. Oak MH. Keen CL. Polagruto JA. 74. Alexopoulos N. 290. Sies H. USDA Database for the Flavonoid Content of Selected Foods. Schini-Kerth VB. Hermann F. Pfister E. 18. Free Radic Biol Med. Wakatsuki Y. Chataigneau M. Klaus W. Plasma antioxidants from chocolate. Sies H. 969972. Balzer J. 2115S2119S. JAMA. Steinberg FM. 103. 2000. Schmitz HH. Crozier A. 2005. Spieker LE. 135. Kelm M. Flavonoide. Villablanca AC. discussion S206-179. Eur J Pharmacol. Taubert D. J Cardiovasc Pharmacol. 424. Ensunsa JL. Nutrition: milk and absorption of dietary flavanols. Cocoa procyanidin chain length does not determine ability to protect LDL from oxidation when monomer units are controlled. Noll G. Chataigneau T. http://www. Schewe T. 48. Wang JF. De Santis S. 81. Funabashi N. Aznaouridis K. Schomig E. Fraga CG. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. 426. Shiina Y. Nutrient Data Laboratory Beltsville. Economou E. Bugianesi R. 2007. Andreadou I. Am J Clin Nutr. Schrader HR. 2006. 2009. WHO/FAO. 2006. Human Nutrition Research Center. Holt RR. 130.61 62 Schroeter H. Vinson JA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. 2003. Totowa. 27. Ceballos G. double-blind. Randomized.82 Yamazaki KG. Ernährung des Menschen. metabolism and pharmacokinetics. Mancini M. Gouni-Berthold I. s257-263. Land JM. Vadhanavikit S. Stuttgart. 2006. 1994. Bellandi F. Short. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 283 . Hodgson JM. Effect of coenzyme Q10 on essential arterial hypertension. ID 1509: “Coenzyme Q10 (Ubiquinone)” and “Heart health” 1 2 Berdanier CD. Georgi C. 659-676. Cantini F. Burke V. Berthold HK. 47. Di Mauro S. Cruz M. Croft KD. 2005. Clin Cardiol. Crane FL. Collins C and Kemper KJ. 2002. Proc Natl Acad Sci USA. South Med J. Vidne BA. 82. Folkers K. Mortensen SA. Bhagavan HN and Chopra RK. Littarru GP. Elmadfa I and Leitzmann C. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Expert Group on Vitamins and Minerals. Watts GF. 1999. Feldman EB. Eugen Ulmer Verlag. Coenzyme Q10 in: Orthomolekulare Medizin. Bisi G. Brodbeck B. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. In: Dietary Supplements Toxicology and Clinical Pharmacology. Integr Cancer Ther. 295-299. Villarreal F. Gröber U. 2005. 2005. Gildemeister R. 2002. 15 Suppl. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Gibney M. Stuttgart. 2003. Playford DA. Guarino GC. Kok F. Dvir D. Humana press. Hallikainen M. Digiesi V. Cupp M and Tracy T. 94. J Am Coll Nutr. 53-85. Mol Aspects Med. Handbook of Nutrition and Food. 1990. H761-767. 591-598. 30113016.and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Free Radic Res. 2002. tissue uptake. 1112-1117. 1137-1142. Vered Y. Naini A. Damian MS. Am J Physiol Heart Circ Physiol. 4. Drug Saf. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Boca Raton. 110-130. Cantini F. Stamler A. Georghiou GP. Heales SJ. Brocchi A. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized. Ellenberg D. Hahn A. 2006. 20. Co-Enzyme Q10 (CoQ10 or Ubiquinone). Vorster H. 29. Biochemical functions of coenzyme Q10. 2001. placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Neuenschwander R. Lauermann J. Gylling H. Burke BE. Barraza-Hidalgo M. Taylor and Francis Book. Aravot D. Simonis G. Erman A. Coenzyme Q10 in essential hypertension.). 110. 2004. placebo-controlled study. 2008. 1985. Duncan AJ. 40. Hargreaves IP. Stuttgart. 445-453. Conklin KA. Circulation. Introduction to Human Nutrition (The Nutrition Society Textbook) Wiley Blackwell Oxford. 28. The Longwood Herbal Task Force and The Center for Holistic Pediatric Education and Research. 703712. Eur J Clin Nutr. 2006. Oradei A. Coenzyme Q10. Digiesi V. Berman M. 56. Coenzyme Q10: absorption. Romero-Perez D. Sauter W. Rivas M. 2004. New Jersey. Curr Ther Res. Dwyer JT. Safe Upper Levels for Vitamins and Minerals. Drug Saf. Cortez-Gomez B. 901-904. Ben-Gal T. 2001. Wissenschaftliche Verlagsgesellschaft. CRC Press. 2004. Olson RD. Krone W. 295. Cupp M and Tracy T (eds. 841-845. Wissenschaftliche Verlagsgesellschaft. Coates K. Mortensen SA. Monograph. Kwong L. 284 37 38 39 40 41 42 43 . J Vit Nutr Res. 1998. Sacher ML. Littarru GP and Tiano L. 2004. 7. Pannemans D. 25. Hughes K. Sheeran F. 58-61. Dietary reference intakes for vitamines and minerals. Leong JY. Rosenfeldt FL. Sacco R. Clinical aspects of coenzyme Q10: an update. 3. 61. Lass A. 2005. Rosenfeldt FL. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Rabinov M. 10. Landau SW. German JB.21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 IoM (Institute of Medicine). 79-89. 2006. 154-167. 14–17 April 2005. Marasco S. J Thorac Cardiovasc Surg. Linnane A. Coenzyme Q10.com/health/coenzyme-q10/NS_patient-coenzymeq10. Rationale. Langsjoen JO. Nagley P. Am J Ther. 2005. Griffin BA. 2005. 42 Suppl 1. Krum H. Lyon W. 2003.mayoclinic. 2002. 42. Haas SJ. Rohde M. 22-30. Sohal RS. Biofactors. Deficiency of coenzyme Q10 in human heart disease. Arch Neurol. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Lippa S. 18. 91-100. Naini A. Krum H. PASSCLAIM . Rosenfeldt F. Washington DC. Systematic review of effect of coenzyme Q10 in physical exercise. 57-58. Pick A. Rosenfeldt FL. discussion 463-355. Kersten R. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. human tissues. 199-205. Dietary Supplements. Mischley L. Langsjoen AM. 2005. Rundek T. Aro A. DiMauro S. 167-178. Ann NY Acad Sci. Ann Pharmacother. Mitochondrion. Dietrick K. Pharmaceutical Press. 1999. 9. Biofactors. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Fiorini RM. InternationalCoQ10 Association. Hadj A. Lucas LA. Pepe S. Biofactors. 1999. Marasco S. 18. Altern Med Rev. 1972. 2003. Mol Aspects Med. Davis B. Presented at the 4th conference of the International CoQ10 Association Los Angeles. 4. Biofactors. Coenzyme Q10 http://www. Mortensen SA. Sacher HL. Symptomatic effects of coenzyme Q10 in heart failure: Q-SYMBIO study status. Pepe S. Ng K. Ichkhan K. Watts GF. 2004. Lyon W. Langsjoen PH and Langsjoen AM. 2007. 1997. 355-359. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. National Academies Press. Littarru GP. 889-892. 66-72. 147-152. Nagley P. London. Folkers K. Sacher A. Levy HB and Kohlhaas HK. Part II. 641-646. Mitochondrial coenzyme Q content and aging. 129. J Hum Hypertens. Biofactors. I6-27. 290-294. 18 Suppl. and patients. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Stahl W. Biomedical and Clinical Aspects of Coenzyme Q. Mazzanti L. Rowland M. 297-306. 273-284. Mutanen M. 21. Coenzyme Q-10 and cardiovascular health. Haas SJ. Considerations for supplementing with coenzyme Q10 during statin therapy. 6. California. Sheeran FL. Littarru GP. Mason P. Rosenfeldt F. S137-144. Ho L. Curr Opin Clin Nutr Metab Care. Agner E. Pepe S. 2003. Eur J Nutr. Esmore D. 291-305. Esmore D. Mayoclinic. Bailey M. Hilton D. Altern Ther Health Med. 8. Overview of the use of CoQ10 in cardiovascular disease. 9. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Jones K. McKenna DJ. 959. 1997. Sacher M. Langsjoen PH. 2007. Wowk M. Metabolic and diagnostic implication of human blood CoQ10 levels. quiz 31. Marasco SF. Oradei A. 2532. Coenzyme Q10 in cardiovascular disease. Mensink RP. Smith J. 1991. Internat. Mortensen SA. 2001. ten Meer HU. 2005. Ou R. Coenzyme Q10 protects the aging heart against stress: studies in rats. Krum H. 40. Dooley F. Den Hond E. Pepe S.Diet-related cardiovascular disease. hypertension and heart failure. Leth A. design and end-points of "Q-symbio"--a multinational trial. Dallner G. 36. 2002. 21. Normal antioxidant activity” 51 52 53 54 1 Alleva R. 1997. Sarter B. Am Fam Physician. Okamoto T. Biochim Biophys Acta. 381-386. 2005. Villalba JM. Philadephia. 2. Littarru GP. Mortensen SA. San Diego. Mol Aspects Med. Curatola G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Holmer G. Turunen M. 16. Baltimore. Biochemical and clinical consequences of inhibiting Coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical overview. Am J Clin Nutr. 201-206. Role of coenzyme Q10 in chronic heart failure. Toyama S. 218-228. Stuttgart. Sejersgard Jakobsen T. Deutsche Apotheker Zeitung. 92. 70. 72. Thieme Verlag. Coenzyme Q10 supplementation and heart failure. Shils M. 2002. 2007. J Cardiovasc Nurs. 64. S159-168. Arsenio L. 7. 183-191. 2 3 4 5 6 7 8 9 10 285 . Yamagami T. angina. Paulsen G. 171-199. de Cabo R. SCF. 18 Suppl. Ubichinon/Coenzym Q. Köhrle J. Kennedy DT. Arroyo A. 1065-1070. Briviba K and Zilliken F. The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions. 1997. 65. 15. Nutr Rev. Academic Press. Metabolism and function of coenzyme Q. 2004. 179. Navas P. 2001. Tyurin VA. 1998. 1660. Olsson J. Bässler KH. Int J Vitam Nutr Res. Vilaseca MA. Strain JJ. Encyclopedia of Human Nutrition. Artuch R. Antioxid Redox Signal. Ross C. 411. 311-315. Florkowski CM. 1999. Molyneux SL. Kubo H. Scott RS. 1986. Folkers K. Giles JT. George PM. Pietrzik K. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Effect of coenzyme Q10 on essential hypertension: a double-blind controlled study. 1994. 286-287. NADH and NADPH-dependent reduction of coenzyme Q at the plasma membrane.44 45 46 47 48 49 50 Sadler MJ. Young JM. Strey CH. Littarru GP. 1995. Moreno J. Tran MT. Weber C. 2005. Campistol J. Beal MF. 9-20. Coenzyme Q10 and cardiovascular disease: a review. Advances in Therapy. Coenzyme Q10. Vitamine. Folkers K. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Loew D. Caballero B. 337-343. 2006. Pharmacotherapy. and hypertension. Stuttgart. Takagi M. Proc Natl Acad Sci USA. Decreased serum ubiquinone-10 concentrations in phenylketonuria. Devaraj S. ID 1510: “Coenzyme Q10 (Ubiquinone)” and “Antioxidant properties. Mitchell TM. Cambra FJ. Shike M. Lambruschini N. 251-262. 286293. Singh U. Biomedical and Clinical Aspects of Coenzyme Q. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. Cousins R. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Caballero B. Battino M. Lippincott Williams & Wilkins. J Bioenerg Biomembr. Report of the Scientific Committee on Nutrient and energy intakes for the European Community. Frega N. 1994. 892-895. Atherosclerosis. 797-806. Burgess JR. 2004. Tomasetti M. Livelli sierici di CoQ10 dopo l'assunzione di alimenti integrati con gli antiossidanti CoQ10 e vitamina E. Golly I. Bliznakov E and Wilkins D. Modern Nutrition in Health and Disease. 2000. Kishi T. 1999. Akagami H. Progress in Nutrition. Jialal I. 9388-9391. Kagan VE. Bonakdar RA and Guarneri E. In: Vitamin-Lexikon Gustav Fischer. Frampton CM. 2005. Schümann K. Soja AM and Mortensen SA. Biesalski H-K. 1992. 1271. 341. Curr Neurovasc Res. Coenzym Q 10. Stuttgart. Sinatra ST. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. J Am Coll Nutr. neurodegeneration. 389-397. 22-30. PDR for nutritional supplements. Elmadfa I and Leitzmann C. Schreier P. 1988. Levine M. Thomson Healthcare. 2001. Feng X. Römpp-Lexikon Lebensmittelchemie. 2005. 447-459. Boca Raton. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins. CRC Press. Chew GT and Watts GF. 2004. Bhagavan HN. Wolters M. Ströhle A. Bayne AC. Kontush A. Nyyssonen K. 1995. cancer and diabetes mellitus. Hubner C. Coenzyme Q oxidation reduction reactions in mitochondrial electron transport. The emerging role of coenzyme Q-10 in aging. Collins C and Kemper KJ. Karlsson J.11 Chapidze G. Ernster L and Dallner G. and oxidative stress in the rat. and plasma levels. Sharp RE. Cragg G. 2002. Ann NY Acad Sci. Dutton PL. 851-857. Coates P. QJMed. Relative bioavailability of coenzyme Q10 formulations in human subjects. Hughes K. FEBS Lett. Serbinova E. Antioxidants and exercise. Ong CN. Kagan V. 109-113. Mischley L.). Dhanasekaran M and Ren J. physiological and medical aspects of ubiquinone function. Lee BL. Effects of coenzyme Q(10) administration on its tissue concentrations. 20-25. 6973. 2006. Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese. White J (eds. 36. In: Orthomolekulare Medizin: Ein Leitfaden für Apotheker und Ärzte. Jones K. Eisenbrand G. Ernährung–Physiologische Grundlagen. Ubichinon. Biochemical functions of coenzyme Q10. Stuttgart. 68. 97. 195-204. 132-138. Packer L. Hoetzel D. 537-548. 32. Gröber U (ed. 2004. Tuomainen TP. Prävention. Int J Vitam Nutr Res. Hendler S and Rorvik D. mitochondrial oxidant generation. Ernährung des Menschen. 627-638. Champaign. Morris P. 2006. Kapanadze S. 2002. Lee J. Stuttgart. Jana CK. Hahn A. Georgian Med News. Kagan VE and Quinn PJ (eds. Reichmann H. Blackman MR. Daldal F. 1995. Biochem Biophys Res Commun. Coenzyme Q10: absorption. Ohnishi T. antioxidative properties. Moser C. 533-540. Coenzyme Q-10 and cardiovascular health. determinants. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 286 . Chopra RK.). 1018. Forster MJ. 2001. cardiovascular disease. Finckh B. Gröber U. Salonen JT. Dallner G and Stocker R. Free Radic Biol Med. 591-598. Low density lipoprotein oxidizability by copper correlates to its initial ubiquinol-10 and polyunsaturated fatty acid content. Human Kinetics. Wissenschaftliche Verlagsgesellschaft. 1994. Stuttgart. Eugen Ulmer Verlag. 1997. Biochemical. 2005. Leonard M. 1990. 33. 2005. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH. Kaikkonen J. In: Coenzyme Q: molecular mechanisms in health and disease. 2001. Gibney BR. Crane FL. Gille G. 2004. Co-Enzyme Q10 (CoQ10 or Ubiquinone). Kohlschutter A. 2. 1999. McKenna DJ. 169. Meyer AH. Bachutashvili Z. Beisiegel U. Coenzyme Q10. Biochim Biophys Acta. Altern Ther Health Med. 10. Hahn A. Thieme. Stuttgard. New York. 1998. Rausch WD. Sohal RS. Hughes K. The Longwood Herbal Task Force and The Center for Holistic Pediatric Education and Research. 20. quiz 31. 2002. 2004. Moss J. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'.) Wissenschaftliche Verlagsgesellschaft mbH. Kwong LK. Latsabidze N. Free Radic Biol Med. Stuttgart. Hung ST. Kamzalov S. Goldman R. Free Radic Res. Rebrin I. Dolidze N. Darrouzet E. 2002. Marcel Dekker. In: Encyclopedia of Dietary Supplements. 2001. Coenzyme Q10. 39. Stocker R. Temple NJ. Oxon.com/health/coenzyme-q10. Biochemie und Pathobiochemie Springer Medizin Verlag. 1974. pharmafoods. Ochoa JJ. Munchen. Kagan VE. 223. Niaz MA. In: Functional foods: designer foods. Rowland M. Gujrati S. 1998. Heine H. 9. Bhagvan HN. Heidelberg. Ubichinones. 25. Ou R. Mason P. Singh UP. 223-228. Niaz MA. Yamamoto Y. In: Antioxidants in human health and disease. 2002. 247-254. nutraceuticals Goldberg I (ed. 959. Munchen. Langsjoen PH and Langsjoen AM. 149-154. 43 44 45 46 47 48 49 50 51 52 53 54 55 56 287 . Kumar A. Sarter B. Huertas JR. 8. Nepomuceno EA. Clinical aspects of coenzyme Q10: an update. Quinn PJ. Littarru GP. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. 73-86. Mataix J. Md. Dietary Supplements. Coenzyme Q supplementation protects from age-related DNA double-strand breaks and increases lifespan in rats fed on a PUFA-rich diet. Ann NY Acad Sci. Overview of the use of CoQ10 in cardiovascular disease. Battino M. 2003.35 36 37 38 39 40 41 42 Lang K.) Aspen Publishers. Biofactors. Biofactors. 161-166. 1999. Altern Med Rev. J Cardiovasc Nurs. Gutierrez-Rios P. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. 3. 1999. human tissues. Singh M. Yanagisawa M. 1999. 2005. 2006. Singh RG. UK. 9-20. 2004. Singh RB. Tak NW. Fabisiak JP. Schmidt E and Schmidt N. Pharmaceutical Press. 273-284. Okamoto K. 641-646. Schmiedel V. Kumar A. Effects of Coenzyme Q10 in New Indications with Antioxidant Vitamin Deficiency. J Neurol Sci. Linnane A. Singh RB. Modern Nutrition in Health and Disease. Journal of Nutritional and Environmental Medicine. Leitzmann C. 1999.). Leitfaden Mikronährstoffe. 1997. Biochemie der Ernährung. Elsevier Urban & Fischer. Coenzyme Q10 protects the aging heart against stress: studies in rats. 2002. Shike M. Suzuki Y. Mohr D. Gaithersburg. and patients. Biofactors. CABI Publ. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Quiles JL. 9. 2004. 2005. Ochoa JJ. Monograph. Bowry VW. Tanaka M. Löffler G and Petrides PE. Garg ML (eds. Ernährungsmedizin in der Naturheilkunde. 189194. www. Mataix J. Lützner H. 355-359. Nagley P. 1994. Sindberg CD. Urban & Fischer. Randomized. Exp Gerontol. Rastogi SS. Lin RIS. Life-long supplementation with a low dosage of coenzyme Q10 in the rat: effects on antioxidant status and DNA damage. Huertas JR. Curr Opin Clin Nutr Metab Care. 2008. Cousins R. Singh RB and Singh MM. 13. Littarru GP and Tiano L. Coenzyme Q10 and cardiovascular disease: a review. discussion 463-355. Frias ML. 9. Baltimore. Basu TK. Biofactors. double-blind. Singh RB. Wallingford. 2005. 58-61. 2001. Orthomolekulare Prävention und Therapie (Gebundene Ausgabe). Esmore D. Lyon W. Pepe S. London. Shils M. 1992. Mayoclinic. 219-224. Sohmiya M. 25. Moesgaard S. Lippincott Williams & Wilkins. Steinkopff-Verlag. Darmstadt. Biochim Biophys Acta. placebo-controlled trial of coenzyme Q10 in patients with end-stage renal failure. Moshiri M. Taneja C. Ross C. Singh VP. Tanino Y. Expansion of antioxidant function of vitamin E by coenzyme Q. Rastogi SS. Marasco S. Quiles JL. 16. Rosenfeldt FL. Journal of Nutritional and Environmental Medicine. 2004. Antioxidant vitamins and coenzyme Q10 in the prevention and treatment of coronary artery disease and diabetes. Caballero B. 1126. Philadephia. 13-22.mayoclinic. 9. Zobel M. 1646-1650. Thomas SR. Witting PK. Puhl W. 1998. Stocker R. 29. Paulsen G. 290-297. Špaček P. Beeinflussung des Gelenkknorpels durch Kollagenhydrolysat – ein wissenschaftliches Kompendium. Weber C. Hamburg. Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. XVII. Mahaney MC. Science. Am J Clin Nutr. Biocell Technology. Tomasetti M. 18 . 2006. Winkler-Stuck K. Adam M. Helejová H. Int J Vitam Nutr Res. Alkayali A. Yamamoto Y. 1993. Sejersgard Jakobsen T. Frei B. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. Kagan VE and Quinn PJ (eds. Rainwater DL. Pettersson K. 1997. Clark K. Morales A. Ternes W. Wang XL. An estimate of collagen consumption among Spain‘s population. Pandey S. US. 1999. Ubiquinol/ubiquinone ratio as a marker of oxidative stress. Pförringer W. Letters J. 67. Role of mitochondria in neuronal cell death induced by oxidative stress. Le CH. Moskowitz R. May collagen hydrolysate rich diet (CHRD) extend the effect of calcitonin in postmenopausal osteoporosis? Connective Tissue Diseases. Fletcher MJ. 2005. Thomas SR and Stocker R. Kasper H. 5 6 7 8 288 . 241-246. 9. 2002. US Patent 6.319. Klaus W. Treatment of rheumatoid arthritis with oral type II collagen. 1027-1032. Oesser S. ID 1513: “Collagen hydrolysate” and “Joint health” 58 59 60 61 62 63 64 65 66 67 68 69 70 1 2 3 4 Adam M. Sikorska M. 2005. 207-224. Mechanisms of antioxidant action of ubiquinol-10 for low density lipoprotein. 2004. GELITA Health Initiative. 29. Galianová A.323. Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Barinaga M. Jürgen S. 27. 261. 2004.36. Weber C.). Apothekerjournal. Kremer JM. 2004. Williams M. In: Coenzyme Q: molecular mechanisms in health and disease. 36. 618-627. 1669-1670. 41. Methods Mol Biol. Finger E. Shils M. 1994. 25 . 220. 41-48. Treating arthritis with tolerance. Ross C. Künzel D. Holmer G. Alleva R. Stocker R. 1995. J Neurol Sci. Blahoš J. Witting PK. Stocker R. LLC. Shike M.57 Somayajulu M. Journal of Clinical Biochemistry and Nutrition. Adam M. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Lippincott Williams & Wilkins. Adam M. placebo-controlled trial. 1999. neuroprotection by Coenzyme Q10. 1998. Rippe J. Hung M. double-blind. 2001. Stocker R. 649-655. Method of making hydrolyzed collagen type II. A role for reduced coenzyme Q in atherosclerosis? Biofactors. 2000. Clegg DO. Baltimore. Bowry VW.2461. 80. Sports Nutrition (eds). 2000. Mortensen SA. 1991. 123-129.22. Cousins R (eds. Stocker R. CRC Press. Philadephia. Proc Natl Acad Sci USA. Arthritis Rheum. St Clair EW. Kunz WS. Trentham DE. 18. Int J Vitam Nutr Res. Coenzyme Q10 as a front-line antioxidant against oxidative stress. 1991. Caballero B. 295-305. Behr's Verlag. McCarthy S. Wiedemann FR. The coenzyme Q10 content of the average Danish diet. Lebensmittel-Lexikon. Tunger L. Welche Wirkung haben Gelatinepräparate? Therapiewoche. Chasan-Taber S. 1998. Results of a multicenter. No authors listed.). Wallesch CW. Littarru GP. 41. Free Radic Biol Med. 2456 . Neurobiol Dis. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Weisman M. In: Modern Nutrition in Health and Disease. 64. 88. Free Radic Biol Med. Barnett ML. Bysted A. Gelatine – möglicher medizinischer Einsatz. Yamamoto Y and Yamashita S. Taufel A. Borowy-Borowski H. Boca Raton. Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Hllmer G. Furst D. 186. 311-315. Rheumatic Disease Clinics of North America. Benito P. Iwai K. Carpenter MR. Carpenter RL. 486 . Hesse K. Kleintiermedizin. Eid K. Cell Immunol. Ärztliche Praxis. J Biol Chem. Natural Pharmacy. Kang AH. 9. 6531-6536. Fujita K. Sato K. 2002. Flechsenhar K and Alf D. Int J Sports Med. Hernandez AD. Angelopoulos TJ. Danone. 2005(a). a seis meses. 36. Covance Laboratories. 13 . Kerwar SS. Rippe JM. Ohtsuki K. 2005. Taguchi Y. 101-118. 2995-3000. Nacher M. S67-S70. Niemeyer A. 87. Morimatsu F. 1984. Stuart JM.395. Beuker F. Benito-Ruiz P. 64. Collagen-induced arthritis in rats: antigen-specific suppression of arthritis and immunity by intravenously injected native type II collagen. Oronsky AL. Lowndes J. Suppression of type II collagen-induced arthritis by the intravenous administration of type II collagen or its constituent peptide alpha 1 (II) CB10. Hydrolyzed collagen effect on cellular proliferation and protein synthesis in human chondrocyte cultures. 37. Synergistic effects of D-glucosamine and collagen peptides on healing experimental cartilage injury. 16. 379 . Rippe JM.3134. Effectiveness of a collagen hydrolysate-based supplement on joint pain.Endlich schmerzfrei durch Biostoffe. 1982 Gut genährter Knorpel knirscht nicht mehr. 2. range of motion and muscle function in individuals with mild osteoarthritis of the knee: a randomized clinical trial. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Εstudio clínico. J Agric Food Chem. Appelt K. 2221-2232.22. SIBR. Collagen hydrolysate in joint health. 3. Ann Rheum Dis. Higashi A. 17.16. 2006. multicéntrico. 53. Acute oral toxicity study of BioCell Collagen II® in rats. 606-610. 41. 2003. Kline G. Cremer MA. Deal LD and Moskowitz RW. Bello AE and Oesser S. (Submitted for publication). 17 . Med Sci Sports Exerc. (unpublished). 2003. McCarthy SM. Sakamoto K. Okamoto Y. Matumoto T. 1996. Eck T. Purification and characterization of a collagen-degrading protease from Porphyromonas gingivalis. Peel JB. Hasegawa T. 131. Clark K. Clin Sports Med. Angelopoulos TJ. 1983. Collagen hydrolysate supplementation improve symptoms in patients with severe osteoarthritis. Clinical study shows hyaluronic acid in Bio-Cell Collagen II® found to have significant absorption and bioavailability. Full scientific dossier on the Health Benefits of 10gr Hydrolyzed Collagen in a fermented milk. Miyatake K. Curr Med Res Opin. 26. Hashida M. J Immunol. 2006. Biochemical and clinical examinations on the effects of regular applications of gelatine on degenerative damages of the motoric system. Ergebnisse einer Anwendungsbeobachtung zu Kollagen-Hydrolysat CHAlpha. Orthopädische Praxis. Nakamura Y. 357-365. Vervuert I. Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. Anwendungsbeobachtung über die Supplementierung von Gelatinehydrolysat bei arthrotischen Hunden. 2001. Landes MJ. Götz B. Döll M. Macromol Biosci. aleatorizado prospectivo. 269. Townes AS. Neutraceuticals as therapeutic agents in osteoarthritis. 289 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 . 2006. Morimatsu F. Minami S. Study of gelatin supplemented diet on amino acid homeostasis in the horse. 2006.494.9 10 11 12 Bedi GS and Williams T. 1544. 2007. Equine Vet J. Glaza SM. 2005. Arthrose . Kido Y. 2005(b). Suppl. Englert ME. Carpenter MR. y en condiciones naturalísticas. Rosenfeld J. 3130 . S91-S92. 1994. sobre la influencia de la administración diaria de 10 gramos de hidrolizado de colágeno en el tratamiento de la artrosis de rodilla. 25. Judy W. 2005. Clark KL. (unpublished). Carpenter RL. 22. 599-606. 1/2. 1999. Disparate effects of gelatine hydrolysates on human chondrocytes. Thornhill TS. 596-603. Nutritional considerations in joint health. Nakabo Y. doble ciego. Glowacki J. Herbig. Monfort J. Coenen M. 2004. 565 . 51st Annual Meeting of the Orthopaedic Research Society. Oesser S and Seifert J. 2004. Savage S. Biochemical characterization of human collagenase-3. 3153-3157. Saliman JD. Dorner B. 2001.32 33 34 35 36 37 Kasper H. Adv Skin Wound Care.568. A randomized double blind clinical pilot trial evaluating the safety and efficacy of hydrolyzed collagen type II (BioCell Collagen II®) in adults with osteoarthritis. 1970. Semin Arthritis Rheum. Moskowitz RW. Lopez-Otin C. Nomura Y. 1999. Kelly T-AN. 1996. Kasugai S. 2003. 129. Knight G. Kann eine Gelatine/L-Cystin-Mischung die Kollagen. Maroudas A. 87-99. 1120-1126. Oesser S and Seifert J. 52. 135-141. 1544-1550. 30. Nutrition. Die Medizinische Welt.und Proteoglykansynthese stimulieren? Therapiewoche. 1532-1535. Oesser S. München. Bullough P.5097. Knauper V. Urban & Schwarzenberg. Zur unterstützenden Therapie bei Osteo-und Chondropathien [On supportive therapy for osteo-and chondropathy]. Biocell Collagen II: Subchronic Toxicity Study (90 Day Repeated Dose Oral Gavage Study in Rats). 44. Cranio. 92-96. 2004. Cell Tissue Res. Archivos de Medicina del Deporte. Murphy G. 2000. J Bone Joint Surg Br. 5094 . Therapiewoche. 11. Ernährungsmedizin und Diätetik. Therapiewoche. Rippe JM. The distribution of collagen in human articular cartilage with some of its physiological implications. Maloney MJ. New York. 2007. Ito K. Smith B. 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 290 . Hung CT. Oohashi K. Martin-Mola E and Blanco F. Statman LY. Kasper H. 2003. Watanabe M. XV 277-282. fortified. Babel W. 2007. Role of collagen hydrolysate in bone and joint disease. Product Safety Laboratories. 1996. Increase in bone mineral density through oral administration of shark gelatin to ovariectomized rats. Sato K. Report of the scientific evidence supporting the effectiveness of collagen hydrolysate for joint disorders. 393-399. Sheldon E. Urban & Fischer Bei Elsevier. 2005. 2005. Merkel DJ. Pressure ulcer healing with a concentrated. 1993. The effects of collagen hydrolysat on symptoms of chronic fibromyalgia and temporomandibular joint pain. Collagen hydrolysate increases the mechanical properties and type II collagen synthesis of tissue engeneered articular cartilage. J Agric Food Chem. Muir H. 19. 1891-1895. Ohara H. 43. 55. Einfluss von Kollagenfragmenten auf Neusynthese und Degra-dation der extrazellulären Knorpelmatrix. Matsumoto H. Oral administration of (14)C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). 2006. Comparison of quantity and structures of hydroxyproline-containing peptides in human blood after oral ingestion of gelatin hydrolysates from different sources. 930-938. Washington DC. 271. collagen protein hydrolysate supplement: a randomized controlled trial. 1989. 2000. Wild M. 554-563. 54. Oberschelp U. 1979. 311. 1985. Kasper H. Redovian V. Ng KW. Olson GB. Posthauer ME. Paper no 0259. Iwai K. 39. Seeligmüller K and Happel KH. 1998. Miami Research Associates. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Dem Knorpel auf die Sprünge helfen. Ateshian GA. Olson J. 47-49. J Biol Chem. Orthopädische Praxis. Seeligmüller K and Happel KH. Z Erfahrungsheikunde. Ernährungsmedizin und Diätetik. 2005. Individuelle Arthrosetherapie ist möglich. Krug E. Effecto de los hidrolizados de gelatina en la prevención de las lesiones en deportistas (Effects of gelatine hydrolysates in the prevention of sportsmen and women injuries). Lee SK. Die chondroprotektive Wirkung von Gelatine. Burghardt W. J Nutr. Seifert J. 21. 18101813. 18. The Ballantine Publishing Group. 41. 2003. The Joint Health Prescription. Ribas Fernández JLl and Molinero Pérez O. Adam M. 1987. 75. 5. Weh L and Petau C. 15-17. 2008. J Nutr. 102. Combitchi D. Schmiegelow PG. Gehring W and Gloor M. Gaullier JM. Walrand S. Collomb M. 130. Conjugated linoleic acids in milk fat: Variation and physiological effects. Blankson H. Änderungen des Gewebeeigenschaften durch Gelatineeinnahme – eine biomecahnische in-vivo. Wadstein J. Dippel FW. Hafler DA. Bye A. 35 S-Methionin und 3 H-Thymidin im Tierexperiment. Eur J Lipid Sci Technol. zur wirkung einer vitamin-aminosaure-kombination auf das haarwachstum. 25. 567-557. 1977. Gubzova Z. 114-115. Quantitative autoradiographische Untersuchungen an Haaren. 2943-2948. Gudmundsen O. Cutaneous and Ocular Toxicology. Schmid A. Obrigkeit DH. Weiner HL.55 Stancikova M. Stancik R. Puschmann M. 12-16. TNO Nutrition and Food Research. 1019-1025. Oepen T. 56 57 58 59 60 ID 1514: “Combination of millet extract + L-cystine + vitamin B5 (calcium panthothenate)” and “Support of hair growth” 1 2 3 4 5 Babey-Dölle 1993. 2002. Rovensky J. 684-688. Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers. Arztliche Praxis. Blankson H. Noirt F. 1999. J N Soc Cosmet Chem. Effects of oral administration of type II collagen on rheumatoid arthritis. Jugert FK. Bruno C. 2006. Collagen in the treatment of rheumatic diseases oral tolerance. 16. Kastner HG. Zeitschrift fur haut-krankheiten. 53-67. Haut und Nägeln mit den Vorläufern 36 S-Cystin bzw. Was ist dran an der Gelatine? Extracta Orthopaedica. 2001. Lipids. Trentham DE. 8453-8460. 1347-1361. Wadstein J. Lindner J. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. Berndt G. Ryhänen EL. Kubicki J. 24. 1981. 13-22. Bio-kapseln lassen die haare spriessen. Thom E. 1982. 39. Chiotelli E. Wechsler D. Digestibility of collagen hydrolysate during passage through a dynamic gastric and small intestinal model (TIM-1). Lorenzo C. Expert report to justify the meaningfulness of the combination Priorin (R). Dynesius-Trentham RA. Morganti P. Orav EJ. Mucke C. Clinical trial results support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies. and Miliacin on Metabolic and Proliferative Capacity of Keratinocytes.orálna tolerancia). 2000. 2002. Gudmundsen O. Zeitschrift fur Allgemeinmedizin. International Dairy Journal. Stakkestad JA. or placebo. Fagertun H. Fagertun H. Berven G. ID 1516: “Conjugated linoleic acid (CLA)” and “Weight management” 1 Berven G. 56. Merk HF. Sewell KL. 17271730. Gudmunsen O. Lassel T. (Kolagén V liečbe reumatických chorôb . Science. Xenobiotics in Vitro: The Influence of LCystine. Int J Vitam Nutr Res Suppl. 37. Sieber R. Zeijdner EE. 455-462. L-cystine. Randazzo S. 1999. Thom E. 4. J Agric Food Chem. Therapeutic action of pantothenic acid. Bratislavské lekárske listy 100. and calcium pantothenate. 2000. Fidanza A. Fliegner L. Extracta Orthopaedica. Mwewa S. Consumption of a functional fermented milk containing collagen hydrolysate improves the concentration of collagen-specific amino acids in plasma. Letter to the editor. 2006. 33. Phototrichogram evaluation of hair growth products: Results of a doubleblind randomized study in women with androgenetic alopecia using an oral combination products of Millet seed extract.Pilotstudie. 31. 6 7 8 2 3 4 291 . 1993. 261. Pantothenat. 7790-7795. Blankson H. Dethlefs J and Schneider W. 2000. 1983. Therapiewoche. Weh L. Hals O. 95-96. Lejeune MP. Facci M. Int J Obes Relat Metab Disord. 2001. Roche HM. Serafini M. Ferreira MP. Gaullier JM. Hoivik HO. 773-781. Hoye K. Pinkoski C. 25. Noone E. Conjugated linoleic acid supplementation in humans--metabolic effects. Ewaschuk JB. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects. Melissopoulou A. Toubro S. Ros E. 137. Halse J. O'Shea M. Br J Nutr. 12. 2007. Arnaiz JA. Conway J. Tsigilis N. 352-361. 292 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 . 1129-1135. Hoye K. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Miller P. 525-536. and resting metabolic rate in overweight subjects. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. Conjugated linoleic acid: a novel therapeutic nutrient? Nutr Res Rev. 44. Letter to the editor for "Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans" Am J Clin Nutr 2004 79:1118-25. Thuillier P. Gudmundsen O. 135. Conjugated linoleic acid reduces body fat in healthy exercising humans. Six months supplementation with conjugated linoleic acid induces regionalspecific fat mass decreases in overweight and obese. Gaullier JM. Almada AL. 27. 2003. Nurminiemi M. 2007. 79. Laso N. Halse J. 79. J Strength Cond Res. Larsen TM. 1118-1125. 1268-1274. Chilibeck PD. 531-538. J Lipid Res. Steck SE. Am J Clin Nutr. 38. Am J Clin Nutr. Smedman A and Vessby B. 606-612. Riserus U. 2003. 325-334. 860-867. 2006. 339-348. Deulofeu R. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy. 2007. Eur J Clin Nutr. 392-396. 2005. 2234-2241. Westerterp-Plantenga MS. Brugue E. 2004. Conjugated linoleic acids: all the same or to everyone its own function? Reprod Nutr Dev. Terpstra AH. Farthing JP. 2002. Int J Obes Relat Metab Disord. Thom E. 2001. and selected hematological markers. strength. J Nutr. 2004. 57. Einerhand A. Candow DG. Vik H. 585-594. cis-12) on body composition and metabolic syndrome components. Kreider RB. 2003.5 Gaullier JM. 2006. Ring S. Chalecki AM. Astrup A. Wadstein J. Gibney AN. Saris WH. The effects of conjugated linoleic acid supplementation during resistance training. Martin JC and Valeille K. Berglund L. Vessby B. Mougios V. Vidal S. Gudmundsen O. Br J Nutr. J Nutr. Kamphuis MM. Lafuente A. 173-188. J Int Med Res. Petridou A. Lejeune MP. Toubro S. 2005. Fagertun H. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. Kamphuis MM. Effects of milk supplementation with conjugated linoleic acid (isomers cis-9. Zello GA. Am J Clin Nutr. Vidal J. 81. Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies. overweight humans. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. 778-784. Larsen TM. Kristiansen K. Esliger D. Hardin JW. Hassfeld C. 2001. Wilson M. 98. 14. 1188-1193. 2001. Albright CD. Halse J. trans-11 and trans-10. Gudmundsen O. 16. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. Gudmundsen O. 2002. Carne X. The effect of conjugated linoleic acid supplementation after weight loss on body weight regain. 550-560. Syvertsen C. 2001. Westerterp-Plantenga MS. Gudmundsen O. Hoye K. Effects of conjugated linoleic acid supplementation during resistance training on body composition. 42. Lipids. Matsakas A. Effect of conjugated linoleic acid on body composition and plasma lipids in humans: an overview of the literature. body composition. bone density. 840-847. Nikolaidis M. 97. Sagredos A. 29. Greenwood M. 36. Fagertun H. Astrup A. Med Sci Sports Exerc. 83. J Nutr Biochem. Vik H. Mas S. Kristiansen K. Am J Clin Nutr. Saris WH. Austin GL. 35. 778-784. 1315-1328. Close RN. Wechsler D. Blankson H. Gudmundsen O. 767-772. 79. 1701-1709. Conjugated linoleic acid improves insulin sensitivity in young. 42. 1153S-1158S. Hoye K. 2006. Thom E. Khanal RC. Conjugated linoleic acid and obesity control: efficacy and mechanisms. 2001. 455-462. Wang YW and Jones PJ. 2000. Atkinson RL. Ryhänen EL. Vik H. Schmid A. overweight humans. Whigham LD. Gaullier JM. Hals O. Potential health benefits of conjugated linoleic acid (CLA): a review. Wechsler D. 130. Diabetes. Lipids. Gudmunsen O. Fagertun H. Am J Clin Nutr. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain. Toomey S. Fagertun H. Gudmundsen O. Gaullier JM. 2006. Kristiansen K. International Dairy Journal. Gaullier JM. Halse J. Gudmundsen O. 79. Moloney F. Halse J. Nelson GJ. Wadstein J. 2007. Dietary conjugated linoleic acid and body composition. Keim NL. Ryhänen EL. Roche HM. Food and Chemical Toxicology. Horn WF. Conjugated linoleic acids in milk fat: Variation and physiological effects. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy. Blankson H. 2004. Stakkestad JA. 1347-1361. Int J Obes (Lond). Mohede ICM. Conjugated linoleic acids in milk fat: Variation and physiological effects. Blankson H. J Nutr. Antidiabetic effects of cis-9. Keim NL. Denmark Berven G. Nugent A. Int J Obes Relat Metab Disord. 574-582. Wadstein J. Dyck DJ. Buchholz AC. Fagertun H. Conjugated linoleic acid supplementation in humans: effects on fatty acid and glycerol kinetics. Abstract: Clinical implications for conjugated linoleic acid (CLA) in the treatment of obesity. 2007. 36. Benito P. 2005. Sieber R. Watras AC. ID 1517: “Conjugated linoleic acid (CLA)” and “Insulin sensitivity” 1 2 3 4 Collomb M. Gale B. Med Sci Sports Exerc. Loscher CE. Whigham LD. 85.24 25 26 27 28 29 30 Wang Y and Jones PJ. O'Shea M. 2004. 102. sedentary humans. Am J Clin Nutr. 16. Eyjolfson V. 2004. Kelley DS. Clinical trial results support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies. 2004. Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers. 135. Allan B. Asian-Australasian Journal of Animal Sciences. Zhang Z. Schoeller DA. Schoeller DA. ID 1518: “Conjugated linoleic acid (CLA)” and “Body Weight management” 1 2 Atkinson R. 777-782. 1203-1211. trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Bye A. 2000. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Noone E. 28. Fagertun H. 2004. 2004. 16. Eur J Lipid Sci Technol. 37. Am J Clin Nutr. Watras AC. Sieber R. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. Gudmundsen O. Lipids. Kristiansen K. 2007. Thom E. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. Spriet LL. Vik H. J Nutr. 56. Van Loan MD. Collomb M. Berven G. 36. Lipids. 2002. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. 17. 941-955. 1999. Zambell KL. 2943-2948. 1019-1025. 481-487. 1118-1125. 31. Hoye K. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. 3 4 5 6 7 293 . 814-820. International meeting: LIPID FORUM. Schmid A. International Dairy Journal. Walaski HP. 2000. Zambell KL. 1347-1361. Greenwood M. 79. Currie DL. Gudmundsen O. strength. 1934-1939. Nicolosi RJ. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 294 . 2005. 57. J Nutr Biochem. 36. Smedman A and Vessby B. Czarnecki SK. Horne CA. Mullen A. Moloney F. Wilson TA. O'Shea M. Tsigilis N. Nurminiemi M. 16. Nunes EA. lymphocyte proliferation and polymorphonuclear cells function in Beagle dogs. 1129-1135. 83. Ferreira MP. 773-781. 2001. Tanhoffer RA. 80. Hoivik HO. Thom E. Kritchevsky D. Am J Clin Nutr. LeBlanc AM. Kamphuis MM. Bonatto SJ. Conjugated linoleic acid reduces body fat in healthy exercising humans. Gudmundsen O. 611-616. Syvertsen C. Ring S. 550-560. Taylor JS. Effects of conjugated linoleic acid supplementation during resistance training on body composition. Mougios V. Fernandes LC. Gudmundsen O. Serafini M. Westerterp-Plantenga MS. J Int Med Res. 472S-477S. 135. 81. 531-538. Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. Sagredos A. 2002. McLeod RS. Saris WH. Int J Obes Relat Metab Disord. Pinkoski C. and resting metabolic rate in overweight subjects. 2001. Conjugated linoleic acid supplementation in humans--metabolic effects. Lipids. Conjugated linoleic acid supplementation. Almada AL. Int J Obes Relat Metab Disord. 307-312. Mitchell PL. Am J Clin Nutr. bone density. Eur J Clin Nutr. Krabbe EL. 887-895. 2003. Esliger D. Astrup A. Kamphuis MM. Riserus U. Candow DG. Lipids. Berglund L. 62-67. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. 2000. Roche HM. Yeow TP. The effects of conjugated linoleic acid supplementation during resistance training. 2007. Langille MA. 97. Br J Nutr. Rivera NL. 1268-1274. 606-612. Lejeune MP. Chilibeck PD. 2008. Czarnecki SK. Farthing JP.8 Gaullier JM. 25. body composition. and lipoprotein metabolism in patients with type 2 diabetes mellitus. 2005. Wright S. 585-594. 84. Letter to the editor for "Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans Am J Clin Nutr2004 79:1118-25". Hoye K. 29. Melissopoulou A. 2004. Ewaschuk JB. Wright S. Westerterp-Plantenga MS. 1169S-1174S. Saris WH. Six months supplementation with conjugated linoleic acid induces regionalspecific fat mass decreases in overweight and obese. Conjugated linoleic acid isomer effects in atherosclerosis: growth and regression of lesions. Larsen TM. 2003. Tepper SA. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Lock AL. 2001. Petridou A. Butter naturally enriched in conjugated linoleic acid and vaccenic acid alters tissue fatty acids and improves the plasma lipoprotein profile in cholesterol-fed hamsters. 840-847. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. Tso P. James P. Maiorka A. Kritchevsky D. Kreider RB. Wilson M. J Nutr. Williams SR. J Am Coll Nutr. atherosclerosis. 19. 27. 392-396. Halse J. 2006. Am J Clin Nutr. Conjugated linoleic acids. J Strength Cond Res. Toubro S. The effect of dietary supplementation with 9-cis:12-trans and 10-trans:12-cis conjugated linoleic acid (CLA) for nine months on serum cholesterol. Matsakas A. Einerhand A. Frenneaux MP. and hepatic very-low-density lipoprotein metabolism. 2004. insulin sensitivity. Am J Clin Nutr. Facci M. de Oliveira HH. 38. 2004. Nolan JJ. 2006. Hassfeld C. 2006. Bauman DE. 39. Med Sci Sports Exerc. Res Vet Sci. Wadstein J. Tepper SA. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects. Vessby B. Conjugated linoleic acid impairs endothelial function. 325-334. Zello GA. 12. Nikolaidis M. 2001. Rhys R. and selected hematological markers. Arterioscler Thromb Vasc Biol. 339-348. Salter AM. Lejeune MP. 26. The effect of conjugated linoleic acid supplementation after weight loss on body weight regain. Food and Chemical Toxicology. Biesalski HK. Burke DG. Saati A. Culligan CJ. 2004. Am J Physiol. 170. 107-125. 2004. Wilson TA. Holt LE. 614-620. Kotyla T. Int J Sport Nutr Exerc Metab. Noakes TD. 2003. 2006. Low dose creatine supplementation enhances sprint phase of 400 meters swimming performance. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. 1996. Watras AC. Creatine in humans with special reference to creatine supplementation. J Med Assoc Thai. Chad KE. 235244. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans.26 Tricon S. Balsom PD. 2003.trans-11 and trans-10. 1203-1211. power. Jones EL. 481-487. Banerjee T. 1995. 2007. Howell S. 80. 13. Casey A. Thieme. Sasaki H. Hiruma E. Saichandee P. Ekblom B. Wilson GR. 42. Branch J and Williams M. Effects of creatine loading on muscular strength and endurance of female softball players. J Appl Physiol. 41-48. 2000. Conjugated linoleic acid isomers reduce blood cholesterol levels but not aortic cholesterol accumulation in hypercholesterolemic hamsters. 78. 2005. Burdge GC.cis-12 conjugated linoleic acid on blood lipids in healthy humans. Int J Obes (Lond). Ernährungsmedizin. Van Loan MD. Davison KS. 85. Kew S. Williams CM. Silver S. Oral creatine supplementation decreases plasma markers of adenine nucleotide degradation during a 1-h cycle test. Effect of creatine supplementation on body composition and performance: a metaanalysis. Walaski HP. 2111-2117. Barnes WS. 217-224. Schoeller DA. Constantin-Teodosiu D. 2004. Atkinson RL. Myburgh KH. 35. Nelson GJ. 268-280. Zhang Z. 2002. Burke DG. Chilibeck PD. Is the use of oral creatine supplementation safe? Journal of sports medicine and physical fitness. Creatine as an ergogenic supplement. Buchholz AC. Lipids. Am J Clin Nutr. Bemben MG and Lamont HS. Sanguanrungsirikul S. 481-487. Grimble RF. Cooke WH. Sports Med. and total work. 2004. 5 6 7 8 9 10 11 12 13 14 295 . Nicolosi RJ. S228-232. Branch JD. Gale B. Yaqoob P. Int J Sport Nutr Exerc Metab. Smith Palmer T. 2000. Effect of creatine supplementation on aerobic performance and anaerobic capacity in elite rowers in the course of endurance training. Close RN. J Sports Med Phys Fitness. Whigham LD. 2004. 2003. Ayoama R. Chilibeck PD. Whigham LD. O'Shea M. Conjugated linoleic acid supplementation in humans: effects on body composition and energy expenditure. Chwalbinska-Moneta J. Mohede ICM. 777-782. 2000. 13. Soderlund K. Russell JJ. 2007. Watras AC. Zambell KL. Creatine supplementation and exercise performance: recent findings. Grandjean PW. Keim NL. Kelley DS. 18. The effect of continuous low dose creatine supplementation on force. Bold A. 411-416. Creatine supplementation combined with resistance training in older men. 1994. Bizzarini E and De Angelis L. Effect of oral creatine supplementation on power output and fatigue during bicycle ergometry. Hultman E. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain. 2001. 35. ID 1520: “Creatine” and “Energy metabolism” 27 28 29 30 31 1 2 3 4 Anomasiri W. Am J Clin Nutr. Kritchevsky D. 198-226. 10. 43. 44. Sports Med. 33. Schoeller DA. 670-673. Opposing effects of cis-9. E3137. 1701-1709. Calder PC. Med Sci Sports Exerc. 41. Benito P. Bellinger BM. 271. 87 Suppl 2. Stuttgart. Performance enhancing substances in sport and exercise. Greenhaff PL. 31. Chrusch MJ. Int J Sport Nutr Exerc Metab. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. 173-183. Lipids. Acta Physiol Scand. Am J Physiol. 81-104 Maughan RJ. Champaign. Sports Med. Ruiz JR. Attwood J. Greenhaff PL. Nowitz A. In: Nutritional Ergogenic Aids. Influence of ingesting a carbohydrate-electrolyte solution on endurance capacity during intermittent. Dietary creatine supplementation and fatigue during high-intensity exercise in humans. 232-237.). Op't Eijnde B. Greenhaff PL. Gibney MJ. 504-520. Spiering BA. 2003. 1422. Constantin-Teodosiu D. Creatine. Strength and power in sport. 51-60. Morton J. Question number EFSA-Q-2003-125. 21. 2008. Gröber U. Processing Aids and Materials in Contact with Food on a request from the Commission related to Creatine monohydrate for use in foods for particular nutritional uses. Phillips G. Mendonca MA. New York. Van Leemputte M. Gotshalk LA. Casey A. Snow RJ. Dailly A. Nissen SL and Sharp RL. Hultman E. McKenna MJ. Green A. Orthomolekulare Medizin: Ein Leitfaden für Apotheker und Ärzte. Georg Thieme Verlag. European Specialist Sports Nutrition Alliance and Child R. E725-730. 2007. 651-659. Scientific justification for creatine maintenance and creatine loading doses proposed by the European Specialist Sports Nutrition Alliance (ESSNA). Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Kraemer WJ. 2002. Timmons J. Kreider RB. Creatine supplementation improves muscular performance in older women. Med Sci Sports Exerc. Vingren JL. Hultman E. 625-633. Urso B. Kreatin – der Muskelenergator. 1994. 1999. 43. 5. Wissenschaftliche Verlagsgesellschaft. 2003. Demeure R. 2002. Grober U. Kocak S and Karli U. J Physiol. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Hatfield DL. Human Kinetics. Castillo Garzon MJ. Lakomy HK. Bodin K. Effect of exogenous creatine supplementation on muscle PCr metabolism. 2003. Komi PV. 13. Effects of creatine on body composition and strength gains after 4 weeks of resistance training in previously nonresistance-trained humans. MacDonald IA. 2004. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Pitsiladis YP. Greenhaff PL. Greenwood M. Boca Raton. high-intensity shuttle running. Roche HM. Poortmans JR. Leutholtz BC. Maughan RJ and Shirrefs SM (eds. 2000. 94. Muscle creatine loading in men. Mesa JL. J Appl Physiol. Effects of creatine supplementation on performance and training adaptations.). J Appl Physiol. Goudemant JF. Francaux M. 32. Van Hecke P. Falbe J and Regizt M. 1996. In: Biochemistry of Exercise. Creatine supplementation and exercise performance. Nutrition and metabolism. 26. 244. 81. Dymarkowski S. Dickson I. 1996. Soderlund K. Cederblad G. J Sports Med Phys Fitness. Soderlund K. Greenhaff PL. Fragala MS. Selig SE. 2001. 89-94. 2004. Labarque V. Effects of high dose oral creatine supplementation on anaerobic capacity of elite wrestlers. 102. 223-231. 13. Richter EA. Tasker L. Grant S. CRC Press. Williams C. Blackwell Publishing Oxford. Timmons JA. UK.15 EFSA. Kilduff LP. 283-290. Int J Sport Nutr Exerc Metab. Int J Sport Nutr. 488-492. Kenny AM. 94-101. J Sports Sci. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 296 . 536. Stuttgart. J Appl Physiol. 1995. 139-145. Volek JS. Wolinsky I and Driskell J (eds. 266. 2001. Deutsche Apotheker Zeitung. Eur J Appl Physiol. 141. Opinion of the Scientific Panel on Food Additives. Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. Mol Cell Biochem. 903-944. 87. Nicholas CW. Creatine supplementation increases muscle total creatine but not maximal intermittent exercise performance. 2003. 1996. Römp Lexikon Chemie. Hespel P. Int J Sports Med. 2003. Gonzalez-Gross MM. Hyslop P. 1994. 1995. 2244-2252. Gutierrez Sainz A. 219. Kreider RB. Bodin K. Soderlund K. Stuttgart. Hultman E. Cooke CB. Report of the Scientific Committee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. Hamburg. especially for sports men SCF/CS/NUT/SPORT/5 Final (corrected) SCF (Scientific Committee on Food). Havenetidis K. Paradisis G. 2003. Clarkson P. Tunger L. Ternes W. 2001. Med Sci Sports Exerc. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Ching S. Diabetes. Kemp J. 2005. Zobel M. Täufel A. Parise G. 1999. Israel RG. Effect of creatine supplementation on sprint exercise performance and muscle metabolism. Ostojic SM. 1667-1673. J Appl Physiol. 19. 84. 297 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 . Matott RP. 2000. Greenhaff PL. Kraemer WJ. Balsom PD. Urso B. Mihic S. Duncan ND. Ekblom B. 2002. 82. 609-614. Kern M. Yarasheski KE. Selig SE. J Appl Physiol. Med Sci Sports Exerc. SCF (Scientific Committee on Food). 17. Hespel P. O'Hara JP. Putukian M. 1999. 2001. Lawrence S. Preen D. 1998. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. Effects of acute creatine loading with or without carbohydrate on repeated bouts of maximal swimming in high-performance swimmers. 1349-1356. 935-950. 2001. Katz A. Fink WJ. Hespel PJ. 95103. 85. Smith SA. 32. Creatine supplementation and high intensity exercise: influence on performance and muscle metabolism. J Strength Cond Res. Tarnopolsky M. 14. Zhao S. Effect of creatine loading on longterm sprint exercise performance and metabolism. Mazzetti SA. 2003. Hood C. Role of submaximal exercise in promoting creatine and glycogen accumulation in human skeletal muscle. Staron RS. Adopted by the SCF on 22/6/2000. Spriet LL. 1998. 1994. Stathis CG. 31. Kraemer WJ. Shomrat A. King RF. Theodorou AS. 2001. 1147-1156. Med Sci Sports Exerc. 91. Behr's Verlag DE. 87. 822-831. 321-325. J Strength Cond Res. 174. Eur J Appl Physiol. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Devor ST. Eichner ER. The physiological and health effects of oral creatine supplementation. 265-269. Jolesz FA. Brose A. Pearson DR. 2004. SCF/CS/NUT/SPORT/9 Final 12/9/2000. Scientific basis and practical aspects of creatine supplementation for athletes. 1041-1047. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. American College of Sports Medicine roundtable. 814. McCartney N. 17. Lebensmittel-lexikon. Creatine supplementation and age influence muscle metabolism during exercise. Int J Sport Nutr Exerc Metab. Hultman E. 87. Greenhaff PL. Williams MH. 2004. Gomez AL. Soderlund K.37 38 39 40 Op 't Eijnde B. Fielding RA. Clin Sci. 2000. Weinstein Y. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. Creatine supplementation in young soccer players. Opinion of the Scientific Committee on Food on safety aspects of creatine supplementation. Wagenmakers AJ. 421-424. Abstracts of 6th International Conference on Guanidino Compounds in Biology & Medicine. Dawson B. Montain SJ. Cell Biology International. 2001. Nutrition. McKenna MJ. Acta Physiol Scand. 33. Greenhaff PL. J Appl Physiol. J Strength Cond Res. especially for sportsmen. Price TB. Tarnopolsky MA. Effect of creatine feeding on maximal exercise performance in vegetarians. J Appl Physiol. Zientara GP. 598-604. Swim performance following creatine supplementation in Division III athletes. Rawson ES. Tarnopolsky MA. Robinson TM. Report on Scientific Commitee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. Parise G. 20. SCF (Scientific Committee on Food). Volek JS and Rawson ES. Volek JS. Rawson ES and Volek JS. Beilby J. 706-717. Terjung RL. Snow RJ. Selsby JT. Sewell DA. 2001. 2000. Zanker CL. Miles MP. Clarkson PM. MacLennan D. Richter EA. 57-65. 25. Meyer RA. 2005. Goodman C. Beckett KD. 50. 18-23. Leutholtz BC. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. 219. 216-234. Health implications of creatine: Can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience. structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Bird SP. Kreider RB. Journal of Sports Science and Medicine. Creatine supplementation and exercise performance: an update. Chilibeck PD. 2002. 2005. Intracellular compartmentation. Human Kinetics. Branch JD. Wyss M. Maughan RJ and Shirrefs SM (eds. 35. Hultman E. J Am Coll Nutr. ID 1522: “Creatine” and “Muscular effort / Recovery” 4 5 6 7 8 9 10 11 12 13 1 Bemben MG and Lamont HS. 17. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Culligan CJ. Blackwell Publishing. Burke DG. Oxford. ID 1521: “Creatine” and “Muscular effort” 59 60 61 1 2 3 Bemben MG and Lamont HS. Boca Raton. 2. Williams MH and Branch JD. Creatine Supplementation and Exercise Performance: A Brief Review. Nicolay K. 2003. In: Biochemistry of Exercise. International journal of sport nutrition and exercise metabolism. 2005. 822-831. Nutrition and metabolism. Champaign. Constantin-Teodosiu D. 235. 1992. Rawson ES and Volek JS. 2003. Williams MH and Branch JD. 35. 2004. 10. Creatine supplementation and exercise performance: an update. Int J Sport Nutr Exerc Metab. 2001. 244. 2000. 21-40. 1998. and total work. Biochem J. The effect of continuous low dose creatine supplementation on force. 17. Eppenberger HM. 175195. In: Performance-Enhancing Substances in Sport and Exercise. Greenwood M Wolinsky I and Driskell JA. 2003. 2006. Mol Cell Biochem. SCF (Scientific Committee on Food). Timmons J. Casey A. Human Kinetics. Wittmann E. Soderlund K. Dietary creatine supplementation and fatigue during high-intensity exercise in humans. J Am Coll Nutr. Kreider RB. Effects of creatine supplementation on performance and training adaptations. 651-659. Greenhaff PL. 89-94. 2003. Bahrke MS and Yesalis CE (eds. 281 ( Pt 1). Creatine supplementation and exercise performance: recent findings. Nissen SL and Sharp RL. 216-234. 17. 123-132. Sports Med. 13. 107-125. 2002. UK. 94.). Nutritional ergogenic aids. Bodin K. J Appl Physiol. Report of the Scientific Committee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. Bewirkt die Supplementation mit Kreatinmonohydrat eine Verbesserung der Kraftausdauer bei untrainierten Frauen? Wyss M and Schulze A. Sports Med. Smith Palmer T.). Effect of creatine supplementation on body composition and performance: a metaanalysis. Branch JD and Williams MH. Green A. Creatine as an ergogenic supplement.58 Wallimann T. 2003. Creatine supplementation and exercise performance: recent findings. 243-260. Champaign. 107-125. 198-226. 298 . 112. Roche HM. Brdiczka D. power. CRC Press. Gibney MJ. Holt LE. Silver S. 1998. 2003. J Strength Cond Res. especially for sportsmen. MacDonald IA. 1996. Rawson ES and Volek JS. Greenhaff PL. In: Biochemistry of Exercise. Smith Palmer T. 2003. 2003. Holt LE. Timmons J. Green A. Effects of creatine supplementation on performance and training adaptations. The effect of continuous low dose creatine supplementation on force. 175195. Hultman E. CRC Press. Culligan CJ. 216-234. 2002. In: Performance-Enhancing Substances in Sport and Exercise.). Burke DG. ID 1523: “Creatine” and “Bodily Constitution” 4 5 6 7 8 9 10 11 12 13 1 2 Bemben MG and Lamont HS. 10. 2000. Creatine as an ergogenic supplement.2 3 Bird SP. Soderlund K. MacDonald IA. Human Kinetics. 2005. 219. Hultman E. Soderlund K. 13. Champaign. Human Kinetics. Human Kinetics. Sports Med. Creatine supplementation and exercise performance: an update. Dietary creatine supplementation and fatigue during high-intensity exercise in humans. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Branch JD. 651-659. Chilibeck PD. 13. Roche HM. Greenwood M Wolinsky I and Driskell JA. Maughan RJ and Shirrefs SM (eds. Constantin-Teodosiu D. International journal of sport nutrition and exercise metabolism. 244. 244. Mol Cell Biochem. UK. 2003. Nutrition and metabolism. Green A. Casey A. 2003. Bodin K. 2004. Nutrition and metabolism. Creatine supplementation and exercise performance: recent findings. Burke DG. Blackwell Publishing Oxford. Bodin K. Silver S. Creatine Supplementation and Exercise Performance: A Brief Review. Silver S. Nissen SL and Sharp RL. 2000. 2003. In: Performance-Enhancing Substances in Sport and Exercise. Casey A. Creatine as an ergogenic supplement. Human Kinetics. 3 4 5 6 7 299 . 123-132. Mol Cell Biochem. Bahrke MS and Yesalis CE (eds. Bahrke MS and Yesalis CE (eds. The effect of continuous low dose creatine supplementation on force. Champaign. Report of the Scientific Committee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. UK. Constantin-Teodosiu D. 107-125. Branch JD and Williams MH. J Appl Physiol. Kreider RB. 2001.). and total work. Smith Palmer T.). Gibney MJ. MacDonald IA. Branch JD. 1998. 235. Timmons J. Holt LE. especially for sportsmen. Int J Sport Nutr Exerc Metab. Kreider RB. 822-831. Oxford. Branch JD and Williams MH. 94. Blackwell Publishing. Dietary creatine supplementation and fatigue during high-intensity exercise in humans. and total work. 198-226. 89-94. SCF (Scientific Committee on Food). 2003. Leutholtz BC. Roche HM. power. power. Maughan RJ and Shirrefs SM (eds. Greenhaff PL. 198-226. 2002. 2. Champaign. 235. Chilibeck PD. 2003. 2003. Boca Raton. 35. 1996. Champaign. J Strength Cond Res. Effects of creatine supplementation on performance and training adaptations. 17. Int J Sport Nutr Exerc Metab. 17.). Effect of creatine supplementation on body composition and performance: a metaanalysis. Culligan CJ. Kreider RB. Gibney MJ. 2003. Journal of Sports Science and Medicine. Williams MH and Branch JD. 219. 89-94. Effect of creatine supplementation on body composition and performance: a metaanalysis. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. In: Biochemistry of Exercise. International Journal of Sport Nutrition and Exercise Metabolism. 175195. 10. J Am Coll Nutr. 1996. Nutritional ergogenic aids. 123-132. 2007. 2000. Sports Med. 11. J Trauma. Neurosci Res. 268-280. Frahm J. 234-238. Wilson GR. 481-487. Med Sci Sports Exerc. 1997. 170. Becque MD. Effects of creatine supplementation on isometric force-time curve characteristics. placebo-controlled. 2147-2150. Noakes TD. Draper N. 2003. Wilken B. Dyson RJ. 61. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Journal of Strength & Conditioning Research. Proc Biol Sci. Leutholtz BC. 35. Swain J. 279-285. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Bemben MG. An assessment of the risks of creatine on the consumer and of the veracity of the claims relating to sports performance and the increase of muscle mass. Am J Physiol. 1999. 6 7 8 300 . 270. Sasaki H. 107-125. Digney AL. Effects of creatine loading on muscular strength and endurance of female softball players. McMorris T. 18. Ayoama R. Sports Med. mood state. 1994. Creatine Supplementation and Exercise Performance: A Brief Review. Lochmann JD. Bold A. 277. Hanefeld F. 322-329. on cognitive and psychomotor performance. Charissis G. Oral creatine monohydrate supplementation improves brain performance: a double-blind. 217-224. Rae C. 2000. 2006. McMorris T. 17. Creatine supplementation and exercise performance: recent findings. Med Sci Sports Exerc. Bird SP. Evangeliou A. Earnest CP. Pouwels PJ. SCF (Scientific Committee on Food). Nutritional ergogenic aids. Boca Raton. Swain JP. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2003. Tuttle TD. Acta Physiol Scand. Journal of Sports Science and Medicine. Harris RC. 517-528. Howard A. Tsapaki E. Spanaki M. 2001. cross-over trial. Ekblom B. 185. ID 1525: “Creatine” and “Increasing Strength” 3 4 5 6 7 1 2 3 4 5 AFSSA. Effects of Creatine Monohydrate Ingestion on Intermediate Duration Anaerobic Treadmill Running to Exhaustion. Soderlund K. R698-704. Creatine in humans with special reference to creatine supplementation.8 9 10 Kreider RB. and plasma concentrations of catecholamines and cortisol. Knehans AW. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study. 2005. with mild exercise. 2000. 654-658. Bemben MG and Lamont HS. Bemben DA. Watanabe A. Hodgson C. Greenwood M Wolinsky I and Driskell JA. 43. Mitchell TL. 42. Balsom PD. Effects of oral creatine supplementation on muscular strength and body composition. Report of the Scientific Committee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. Kotsiou M. 2001. 33. 2002. Bates TC. 2003. Kalostos G. 1876. Mielcarz G. 2006. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Dye L. especially for sportsmen. 14. Almada AL. J Sports Med Phys Fitness. Sakellaris G. 32. Creatine supplementation and cognitive performance in elderly individuals. Kato T. CRC Press. J Strength Cond Res. Rawson ES and Volek JS. Bellinger BM. Psychopharmacology (Berl). Oral creatine supplementation decreases plasma markers of adenine nucleotide degradation during a 1-h cycle test. Hiruma E. Effect of creatine supplementation and sleep deprivation. McEwan SR. Corbett J. Melrose DR. 822-831. 2003. Kato N. Harris RC. Spilioti M. Myburgh KH. Tamiolaki M. ID 1524: “Creatine” and “Cognitive performance” 1 2 Dechent P. Collard K. 2004. 93-103. 2. Hespel P.and lower-body Wingate performance. Human Kinetics. Greenhaff PL. Timmons J. Howell S. Hultman E. 2004. Casey A. Med Sci Sports Exerc. Mendonca MA. 271. Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am J Clin Nutr. Green JM. Cottrell GT. Int J Sport Nutr Exerc Metab. 72. 35. J Strength Cond Res. 1996. Urso B. Chilibeck PD. Cooke WH. Human Kinetics. Champaign. Branch JD and Williams MH. 22. Mansfield ER. 32. 301 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 . 1997. Demeure R. Effect of creatine and weight training on muscle creatine and performance in vegetarians. The effect of continuous low dose creatine supplementation on force. Goudemant JF. 10. Engelhardt M. 607S-617S. 2003. In: Biochemistry of Exercise. Med Sci Sports Exerc. 2002. power. 13. Hultman E. Int J Sport Nutr Exerc Metab. Candow DG. 2002. 349-364. 2001. Scientific justification for creatine maintenance and creatine loading doses proposed by the European Specialist Sports Nutrition Alliance (ESSNA). Effect of creatine supplementation on body composition and performance: a metaanalysis. 18-23. The influence of recovery duration on high-intensity exercise performance after oral creatine supplementation. Greenhaff PL. Constantin-Teodosiu D. 670-673. Chilibeck PD. Burke DG. 1998. Vingren JL. Int J Sport Nutr Exerc Metab. Int J Sport Nutr Exerc Metab. Soderlund K. Int J Sports Med. 2008. Fragala MS. 2003. 2007. 44. Is the use of oral creatine supplementation safe? Journal of sports medicine and physical fitness. Hamilton KL. 10. 277-289. Culligan CJ. 454-467. Creatine as an ergogenic supplement. Smith JE. Smith Palmer T. Chilibeck PD. and total work. Kenny AM. 2000. Creatine supplementation improves muscular performance in older women.). Int J Sport Nutr Exerc Metab. Effect of oral creatine supplementation on power output and fatigue during bicycle ergometry. 2000. Smith-Palmer T. Bahrke M and Yesalis C (eds. Reuter I. 173-183. J Appl Physiol. Eijnde BO. 16. Burke DG. 223-231. Effect of creatine supplementation on aerobic performance and anaerobic capacity in elite rowers in the course of endurance training. Volek JS. Parise G. Casey A and Greenhaff PL. Green A. Marley RJ. Effect of exogenous creatine supplementation on muscle PCr metabolism. Barnes WS. E3137. Casey A. Coast JR. 993-996. European Specialist Sports Nutrition Alliance and Child R. Meyers MC. Branch JD.9 10 11 12 Bizzarini E and De Angelis L. 36-41. Can J Appl Physiol. Chwalbinska-Moneta J. 78. 15. 1996. The effect of whey protein supplementation with and without creatine monohydrate combined with resistance training on lean tissue mass and muscle strength. Effect of recovery interval on multiple-bout sprint cycling performance after acute creatine supplementation. Martin D. Cooke WH and Barnes WS. 411-416. Bodin K. 102. Berbalk A. Am J Physiol. 219. Champaign. 2003. Candow DG. Holt LE. Francaux M. Tarnopolsky M. 2001. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. 2000. Mahoney D. Burke DG. Hohzorn C. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Silver S. Skelly WA. Spiering BA. McLester JR. 235244. Hatfield DL. Trimble MH. Gotshalk LA. Constantin-Teodosiu D. Eur J Appl Physiol. Oral creatine supplementation and upper extremity anaerobic response in females. Richter EA. Kraemer WJ. 1123-1129. 2001. Davidson KS. Poortmans JR. Maughan RJ and Shirrefs SM (eds. Farthing J. Gilliam JD. Greenhaff PL. 21. 11. Herb RA. 2000. 198-226. 1995. The effects of creatine supplementation on repeated upper. J Strength Cond Res. Med Sci Sports Exerc. 2000. 1946-1955. 13. In: Performance enhancing substances in sport and exercise. Effect of oral creatine supplementation on isokinetic torque production.). Dietary creatine supplementation and fatigue during high-intensity exercise in humans. 139-145. Creatine supplementation in endurance sports. Diabetes 50. Grandjean PW. Neumann G. 109-116. 30. 33. Preen D. Cederblad G. 1994. Boca Raton. J Sports Sci. J Appl Physiol. McNaughton LR. 32. Creatine. Selig SE. Kreider RB. Effects of creatine supplementation on performance and training adaptations. J Nutr. 2001. 2002. Dickson I. Soderlund K. J Appl Physiol. Nissen SL and Sharp RL. 81-104 McKenna MJ. Creatine supplementation: a comparison of loading and maintenance protocols on creatine uptake by human skeletal muscle. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. 18-23. 1422. Komi PV. Hyslop P. J Appl Physiol. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Mol Cell Biochem. Mesa JL. 488-492. Nicholas CW. 91. 95103. Nissen S. Int J Sport Nutr Exerc Metab. 43. Kreider RB. Morton J. Creatine supplementation in young soccer players. high-intensity shuttle running.30 31 32 33 Hultman E. Mihic S. Preen D. 13. and sprint performance. Ostaszewski P. 17. Ruiz JR. Richter EA. 236-240. Diabetes. Greenhaff PL. 2003. 1041-1047. 903-944. The effects of creatine supplementation on high-intensity exercise performance in elite performers. 2001. Dawson B. 97-111. 1995. Muscle creatine loading in men. Grant S. 558-566. discussion 2895S. 2004. 2003. Parise G.). Sacharuk J. 244. 2001. Castillo Garzon MJ. Wolinsky I and Driskell J (eds. Gonzalez-Gross MM. Int J Sport Nutr Exerc Metab. 2888S-2894S. Tasker L. 2000. Gutierrez Sainz A. Timmons JA. 78. Oral creatine supplementation improves multiple sprint performance in elite ice-hockey players. 1999. 134. 232-237. J Appl Physiol. 2001. Nowitz A. 2004. Ibanez J. Creatine supplementation increases muscle total creatine but not maximal intermittent exercise performance. Dawson B. Gorostiaga EM. 2003. Greenhaff PL. J Sports Med Phys Fitness. Ostojic SM. Potential ergogenic effects of arginine and creatine supplementation. Med Sci Sports Exerc. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. Dalton B. MacLennan D. Lawrence S. 504-520. Attwood J. Sports Med. 39. Rawson ES and Clarkson PM. Beilby J. 2002. Ching S. Jowko E. 2003. Lakomy HK. Izquierdo M. Williams C. Effect of creatine loading on longterm sprint exercise performance and metabolism. Georg KP. 71-75. Acute creatine supplementation in older men. 332-343. 1998. 189-196. Strength and power in sport. Atter T. Kilduff LP. Wolfe RR. 814. Greenwood M. Int J Sports Med. 1999. 89-94. Tarnopolsky MA. 34. Pitsiladis YP. 94. Effects of creatine supplementation on muscle power. Int J Sport Nutr Exerc Metab. 26. Med Sci Sports Exerc. Yarasheski KE. Leutholtz BC. Hespel P. Nutrition. Eur J Appl Physiol Occup Physiol. CRC Press. 2244-2252. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 302 . Borsheim E. endurance. 81. 651-659. Effects of high dose oral creatine supplementation on anaerobic capacity of elite wrestlers. Jones AM. Zieniewicz A. Jank M. Snow RJ. Influence of ingesting a carbohydrate-electrolyte solution on endurance capacity during intermittent. Dailly A. Phillips G. 13. Urso B. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. 21. Op 't Eijnde B. Goodman C. In: Nutritional Ergogenic Aids. Effects of creatine on body composition and strength gains after 4 weeks of resistance training in previously nonresistance-trained humans. 283-290. 50. Med Sci Sports Exerc. Kocak S and Karli U. Wilczak J. 13. 2003. 2004. Gonzalez-Badillo JJ. 1996. Tarr J. 14. Ching S. Goodman C. Beilby J. J Sports Med Phys Fitness. 87. Paddon-Jones D. Utter AC. 29. J Strength Cond Res. Int J Sport Nutr. Spriet LL. 452-463. 2002. J Strength Cond Res. 34. Selig SE. 2004. 174. Clarkson P. J Appl Physiol. 1998. Aust J Sci Med Sport. 136145. 1999. Eichner ER. 1999. 2003. 10. Kemp J. Effects of creatine monohydrate supplementation during combined strength and high intensity rowing training on performance. or indices of muscle damage and hepatic and renal function. Gomez AL. Staron RS. 26. Report on Scientific Commitee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. E974-979.51 52 53 54 55 Rawson ES. 413-419. Hue O. Applied Physiology. Hespel PJ. Med Sci Sports Exerc. 20. Rawson ES and Volek JS. Kern M. Volek JS and Rawson ES. Sewell DA. Gillies EM. Volek JS. 17. McDonough PJ. Rishaug P. Hultman E. McKenna MJ. 2000. Selsby JT. Creatine monohydrate supplementation enhances highintensity exercise performance in males and females. Vincent WJ. Snow RJ. Berwick JP. Casey A. 421-424. Mazzetti SA. 2000. Kraemer WJ. Meyer RA. 1304-1310. 598-604. J Appl Physiol. Am J Physiol. Role of submaximal exercise in promoting creatine and glycogen accumulation in human skeletal muscle. and muscle mechanics. Swim performance following creatine supplementation in Division III athletes. 9. resistance exercise performance. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Steenge GR. Yaspelkis BB. Br J Sports Med. Greenhaff PL. 2000. 706-717. 2000. Williams MH. Creatine enhances oxygen uptake and performance during alternating intensity exercise. 9. Hruby J. Effect of creatine supplementation on sprint exercise performance and muscle metabolism. Greenhaff PL. 1998. Casey A. Int J Sport Nutr. Robinson TM. Duncan ND. Fadel PJ. Zhao S. 32. Garner B. 609-614. Galy O. 275. Boros R. 2001. Norris SR. Hoke T. 84. Stevenson SW and Dudley GA. 32. Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. O'Bryant HS. Dietary creatine supplementation does not affect some haematological indices. Sanborn K. Sewell DA. especially for sports men SCF/CS/NUT/SPORT/5 Final (corrected) Schneider DA. Stevenson SW and Dudley GA. Creatine loading. 379-385. Price TB. 822-831. Scientific basis and practical aspects of creatine supplementation for athletes. Syrotuik DG. 284-288. 2001. Kraemer WJ. Lambourne J. 3rd. Rico-Sanz J and Mendez Marco MT. Greenhaff PL. SCF (Scientific Commitee on Food). Macdonald IA. Med Sci Sports Exerc. Tarnopolsky MA and MacLennan DP. MacIntosh BR. 57-65. 31. Smith LL. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc. Int J Sport Nutr Exerc Metab. Acta Physiol Scand. Pierce KC. and Metabolism. 146-165. 65-68. 33. 56 57 58 59 60 61 62 63 64 65 66 67 68 69 303 . Johnson RL. Robinson TM. American College of Sports Medicine roundtable. Urbanski RL. Devor ST. Miles MP. Greenhaff PL. 17. 2001. J Strength Cond Res. Steenge G. Tarnopolsky MA. Med Sci Sports Exerc. Dietary creatine supplementation and muscular adaptation to resistive overload. Effects of in-season (5 weeks) creatine and pyruvate supplementation on anaerobic performance and body composition in American football players. Stone ME. 1667-1673. Pearson DR. Putukian M. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. Nutrition. 87. Bryan SN. Stone MH. Wagenmakers AJ. Israel RG. 1997. 2003. Bell GJ. Game AB. 1999. 2001. 15. Creatine supplementation and the total work performed during 15-s and 1-min bouts of maximal cycling. 1147-1156. Beckett KD. Terjung RL. Clarkson PM. Nutrition. Fink WJ. Creatine supplementation differentially affects maximal isometric strength and time to fatigue in large and small muscle groups. 1999. Stathis CG. Champaign. Med Sci Sports Exerc. 123-132. Wiroth JB. ID 1528: “Creatine” and “Brain / Memory / Older people / Parents” 1 2 Dechent P. J Sports Sci Med. J Appl Physiol. Effect of creatine supplementation on body composition and performance: a metaanalysis. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Eppenberger HM. 109-112. Boca Raton. 235244. 21-40. Batheja A.). Earnest CP. Nissen SL and Sharp RL. Journal of Strength & Conditioning Research. 1996. Holt LE. 1998. Bull A. Housh T. Hanefeld F. J Am Coll Nutr. Effects of Creatine Monohydrate Ingestion on Intermediate Duration Anaerobic Treadmill Running to Exhaustion. Eur J Appl Physiol. Greenhaff PL. 107-125. Eckerson J. 2000. CRC Press. 94. Creatine. 2. 11. Moore G. 281 ( Pt 1). ID 1526: “Creatine” and “Increasing Mass” 71 72 73 1 2 3 4 5 Bemben MG and Lamont HS. Branch JD. J Appl Physiol. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Effects of oral creatine and resistance training on myosin heavy chain expression. Creatine supplementation and exercise performance: recent findings. 304 . Human Kinetics. Rawson ES and Volek JS. 244. 234-238. 216-234. Kreider RB. Chilibeck PD. Effects of creatine supplementation on performance and training adaptations. Bahrke M and Yesalis C (eds. 2005. Almada AL. Biochem J. 2003. J Am Coll Nutr. 216-234. 2002. Williams MH and Branch JD. Cramer J. Bermon S. Int J Sport Nutr Exerc Metab. Dolisi C. Effect of creatine loading on neuromuscular fatigue threshold. ID 1527: “Creatine” and “Increasing Workout Capacity” 6 7 8 9 10 11 1 Stout J. 2003. In: Performance-enhancing substances in sport and exercise. Dietary creatine supplementation and fatigue during high intensity exercise in humans. Smith Palmer T. 17. 2003. 2003. Champaign. Effects of oral creatine supplementation on maximal pedalling performance in older adults. Branch JD. 2001. 2001. 17. Pouwels PJ. Brdiczka D. Int J Sport Nutr Exerc Metab. In: Nutritional Ergogenic Aids. 2004. 1998. Silver S. Creatine as an ergogenic supplement. Perry S. Frahm J.). 2003. Mitchell TL. Am J Physiol. power. Sports Med. Intracellular compartmentation. 1997. 822-831. J Strength Cond Res. 17. 13. Bird SP. 1999. 10. Nicolay K.70 Wallimann T. 651-659. and total work. Dalloz E. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Kreider RB. 33. 533-539. structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. R698-704. 1674-1681. 1992. 2000. 89-94. 84. Creatine supplementation and exercise performance: a brief review. Creatine supplementation and exercise performance: an update. The effect of continuous low dose creatine supplementation on force. Wilken B. Mol Cell Biochem. In: Biochemistry of exercise. Burke DG. Creatine supplementation and exercise performance: an update.). Wyss M. Andrei S. Williams MH and Branch JD. Ebersole K. Greenwood M. Human Kinetics. 198-226. 35. Leutholtz B. Hebuterne X. 88. Culligan CJ. Wolinsky I and Driskell J (eds. Maughan RJ and Shirrefs SM (eds. Willoughby DS and Rosene J. 277. 42. Kato N. Paz HL. 270. Ball RO. Jahoor F. fatty acids. 37. McMorris T. Hoor TT. 2147-2150. Lohrke S. Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology. Brown LA. 26. 14. Evangeliou A. Dyson RJ. De Rosa SC. Pencharz PB. 94. Rae C. Arons MM. Total sulfur amino acid requirement in young men as determined by indicator amino acid oxidation with L-[1-13C]phenylalanine. 2007. Lauterburg BH. National Academies Press. Thitoff A. Code of Federal Regulations (Revised 2008). 2006. Varriale A. Bausman T. 1840-1845. 1333-1345. J Trauma. Harris RC. 2002. 52. Am J Clin Nutr. Food and Drugs. carbohydrate. placebo-controlled. Jung A. protein. Hodgson C. Tamiolaki M. 2 3 4 5 6 7 8 9 10 11 12 13 305 . Proc Natl Acad Sci USA. Draper N. Howard A. Creatine supplementation and cognitive performance in elderly individuals. Kalostos G. Harris RC. IoM (Institute of Medicine). Johnson E. Washington DC. 2004. Chest. 2003. 127-131. cross-over trial. Charissis G. 517-528. with mild exercise. fat. Dietary sulphur amino acid adequacy influences glutathione synthesis and glutathione-dependent enzymes during the inflammatory response to endotoxin and tumour necrosis factor-alpha in rats. 164-172. Jackson AA. 1967-1972. cholesterol. 101-107. Am J Clin Nutr. 239-247. Chapter I Food and Drug Administration Departement of Health and Human Services. Foreman MG. Kato T. 80. Alcohol Clin Exp Res. Dickinson DA and Forman HJ. Exp Gerontol. Aging-related changes in the thiol/disulfide redox state: implications for the use of thiol antioxidants. 112. 74. Ela SW. Effect of creatine supplementation and sleep deprivation. Oral creatine monohydrate supplementation improves brain performance: a double-blind. Eur J Clin Pharmacol. The Antioxidant in ARDS Study Group. Dietary reference intakes for energy. 36. Swain JP. 2006. 287-305. Spilioti M. 92. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2002. Neurosci Res. Roederer M. Subchapter B Food for Human Consumption Part 101 Food labeling. 2001. Synthesis of erythrocyte glutathione in healthy adults consuming the safe amount of dietary protein. Wheeler AP. Tsapaki E. Eggers J. Watanabe A. ID 1529: “Cystein rich protein hydrolysates” and “Glutathione metabolism” 4 5 6 7 1 Title 21. 1991. Bernard GR. Spanaki M. 2004. Hunter EA and Grimble RF. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. 61. 2002. McEwan SR. 1989. Burgunder JM. Morris PE. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study. 2005. 297-305. Bobb A. 1997. Russell JA. 488-504. Mielcarz G. 185. Deresinski SC. Glutathione in defense and signaling: lessons from a small thiol. mood state. Wright PE. Moss M. 1997. Wykes LJ. Dye L. 93-103. 973. Psychopharmacology (Berl). 2002. Droge W. Herzenberg LA. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Anderson MT. Swain J. 279-285. Kotsiou M. Effects of chronic hepatic dysfunction on pulmonary glutathione homeostasis. Clin Sci (Lond). Collard K. and plasma concentrations of catecholamines and cortisol. Di Buono M. Bates TC. Pharmacol Ther. Proc Biol Sci. and amino acids. on cognitive and psychomotor performance. Ann NY Acad Sci. Int J Toxicol. 23. 756760. Gibson NR. 1997. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Corbett J. Wilfong E. fiber. Arfsten D. Glutathione metabolism and its role in hepatotoxicity. Dubs JG. DeLeve LD and Kaplowitz N. Glutathione deficiency is associated with impaired survival in HIV disease. Digney AL. Sakellaris G. 322-329.3 McMorris T. Lu Y. Earnest CP. Blood glutathione synthesis rates in healthy adults receiving a sulfur amino acid-free diet. Hannibal NS. Almada AL. muscular strength and body composition. Almada AL. [Glutathione and N-acetylcysteine in the prevention of free-radical damage in the initial phase of septic shock]. Watanabe A. Saez GT. 134. 55. 153. Beeh KM. Ajami AM. Vukovich MD. 2002. 1990. Moss M. Buhl R. Comparison of creatine ingestion and resistance training on energy expenditure and limb blood flow. J Lab Clin Med. Proc Natl Acad Sci USA. Guidot DM. muscular strength and body composition. 31. 414-419. Metabolism. Beeh KM. 165–188. 1995. 2000. Sternberg P. 153. 2000. The effect of creatine monohydrate ingestion on anaerobic power indices. Jr. 72. Effects of long-term supplementation with whey proteins on plasma glutathione levels of HIV-infected patients. Acta Physiol Scand. Wakabayashi H. 207-209. 105. 97. Mills BJ. Kohri H. Int J Food Sci Nutr. The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. Brown LA. Schlaak JF. 2000. 207-209. Viña J. 2001. Earnest CP. Gentile CL. Tompkins RG. 131141. Bell G. Thiol homeostasis and supplements in physical exercise. Lang CA. Moraldi E. 161. Hamed J. 93. Gentile CL. 1995. The effect of creatine monohydrate ingestion on anaerobic power indices. Higuchi K. Even PC. 2001. Marcel Dekker. Hannibal NS. 2000. 171-178. Niiya K. Toxicology. 140. Snell PG.. Mitchell TL. 2004. 41. Wong-Lambertina M. J Med. Liu MC. Micke P. 283-302. High blood glutathione levels accompany excellent physical and mental health in women ages 60 to 103 years. Zurakowski D. In: Biothiols in Health and Disease. 267-274. Metabolism. De Gaudio AR. Nindl BC. Micke P. New York. Sen CK and Packer L. Comparison of creatine ingestion and resistance training on energy expenditure and limb blood flow. Simbelie KL. 2004. Acta Physiologica Scandinavica. Am J Clin Nutr. Shimizu Y. Makarios-Lahham L. Mariotti F. 1429-1434. Boca Raton. Am J Respir Crit Care Med. Acute ingestion of dietary proteins improves post-exercise liver glutathione in rats in a dose-dependent relationship with their cysteine content. 413-417. 5071-5076. Emi N. Okada K. Variability in glutathione-dependent detoxication in vivo and its relevance to detoxication of chemical mixtures. 1995. 306 . Nindl BC. Novelli GP. Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. Kuwabara Y. Lu XM. Lyons J. 31. Meister A. Tome D. Yasuyama T. Middleton N. Hamed J. Kondoh Y. 2002.). Ortolani O. ID 1531: “EAS Creatine (EAS Phosphagen)” and “Increasing Strength” 16 17 18 19 20 21 22 23 24 25 26 1 2 Arciero PJ. Vina JR. Richie J. Perez RL. Brown LA. Glutathione: metabolism and physiological functions. 2001. Murrell SA. Jelen P. Usui WM. ID 1532: “EAS Creatine (EAS Phosphagen)” and “Increasing Mass” 1 2 Arciero PJ. 50. Rodriguez R. Conti A. 128-131. Rodriguez R. Mitchell TL. Snell PG. Yu YM. 50. Whole blood and mononuclear cell glutathione response to dietary whey protein supplementation in sedentary and trained male human subjects. 2002. Ten Hoor T. CRC press. Vukovich MD. 1995. Nutritional therapy of chronic hepatitis by whey protein (non-heated). Strategies for increasing cellular glutathione. Buhl R. Rauh-Pfeiffer A. Tsukishiro T. Eur J Clin Invest. Eur J Nutr. Huneau JF. Recenti Prog Med. Lang HL. Ito H. 125-129.14 15 Jones DP. J Nutr. Mastropaolo W. Packer L and Cadenas E (eds. 1429-1434. 653S-669S. Castillo L. Laplaize B. Young VR. 12-18. Sako T. 2006. Mol Cell Biochem. 153. Gentile CL. Kuwamori M. 126. Grindstaff PD.3 Grindstaff PD. The effects of creatine supplementation on anaerobic working capacity. Hoffman J. 1995. Effect of creatine and betaalanine supplementation on performance and endocrine responses in strength/power athletes. 3rd. Kuwamori M. Effect of creatine and beta alanine supplementation on performance and endocrine responses in strength/power athletes. Almada A. 2006. 16. The effect of creatine monohydrate ingestion on anaerobic power indices. 330-346. Alexander C. 135-138. Stout JR. Effects of 28 days of beta-alanine and creatine monohydrate supplementation on aerobic power. and time to exhaustion. Mol Cell Biochem. Zoeller RF. Ferreira M. Comparison of creatine ingestion and resistance training on energy expenditure and limb blood flow. Faigenbaum AD. Faigenbaum A. Chance B. Stout J. Zoeller RF. 2007. Hoffman J. Ratamess NA. Reinardy J. Chance B. Almada AL. 430-446. 2003. Cantler E. Plisk S. 430-446. O'Kroy J A. Stout J. Stout JR. Eckerson JM. Wilson M. Plisk S. Mangine G. Wilson M. Wood L. Mitchell TL. ventilatory and lactate thresholds. Alexander C. 73-82. Effects of creatine supplementation on body composition. Bishop R. Hamaoka T. strength. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. Wilson M. Ebersole KT. 73-82. Ratamess N. Amino Acids. Hoffman J. Kreider RB. Kreider RB. 30. Stout J. Int J Sport Nutr. Nindl BC. Faigenbaum A. Mangine G. 7. 20. 33. and sprint performance. Grindstaff P. Katsumura T. 30. 13. 505-510. 1998. Rodriguez R. 330-346. Kreider R. Med Sci Sports Exerc. Stout JR. O'Kroy J. Kang J. Kreider R. Int J Sport Nutr. 38. muscular strength and body composition. Med Sci Sports Exerc. Wood L. 50. Hamaoka T. 38. Kimura N. Earnest CP. Mangine G. Torok DJ. 126. 1999. Kimura N. Cantler E. 1997. Almada AL. 244. 7. 1997. Hannibal NS. Bishop R. Kang J. Almada AL. 207-209. Int J Sport Nutr Exerc Metab. 105-112. Mangine G. Hamed J. Effect of creatine and beta alanine supplementation on performance and endocrine responses in strength/power athletes. Kurosawa Y. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. 2001. Stout J. 2003. The effects of creatine supplementation on anaerobic working capacity. Effects of creatine supplementation on body composition. Effect of creatine and betaalanine supplementation on performance and endocrine responses in strength/power athletes. Int J Sport Nutr Exerc Metab. Wilson M. 1429-1434. Cramer JT. Ratamess N. Torok DJ. Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise. Mielke M. Faigenbaum AD. Sako T. and sprint performance. Ratamess NA. J Strength Cond Res. Hoffman J. Housh TJ.ACSM Annual Conference presentation. Med Sci Sports Exerc. strength. Snell PG. 135-138. 105-112. The Journal of Strength and Conditioning Research. Housh TJ. The Journal of Strength and Conditioning Research. Grindstaff P. Vukovich MD. Eckerson JM. Ebersole KT. 16. 1998. Reinardy J. 2006. 2 3 4 5 6 7 8 307 . Almada A. Stout JR. Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise. ID 1533: “EAS Creatine (EAS Phosphagen)” and “Increasing Lifting Volume and Performance” 4 5 6 7 8 9 10 1 Arciero PJ. 2006. 13. Metabolism. 928-931.ACSM Annual Conference presentation. Mielke M. Katsumura T. Acta Physiol Scand. 1999. 2006. 244. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Med Sci Sports Exerc. Ferreira M. Kurosawa Y. 3rd. 1429-1434. 153. Kimura N. Mielke M. Earnest CP. 505-510. Ebersole KT. 126. Earnest CP. Katsumura T. Hoffman J. Wood L. Zoeller RF. Kreider RB. 33. O'Kroy J A. 50. Housh TJ. Acta Physiologica Scandinavica. 928-931. 20. 1995. Almada AL. Metabolism. Metabolism. Effect of creatine and betaalanine supplementation on performance and endocrine responses in strength/power athletes. ID 1535: “EAS Creatine (EAS Phosphagen) and “Increasing Work Capacity” 2 3 4 1 Stout JR. The effect of creatine monohydrate ingestion on anaerobic power indices. Int J Sport Nutr. 153. Hannibal NS. 2007. Int J Sport Nutr Exerc Metab. O'Kroy J. 244. Kurosawa Y. and time to exhaustion. 1997. Alexander C. ID 1534: “EAS Creatine (EAS Phosphagen)” and “Increasing Power” 10 1 Arciero PJ. Kang J. 2006. Mol Cell Biochem. 105-112. Torok DJ. 135-138. Wilson M. 16. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. J Strength Cond Res. Grindstaff P. Mielke M. Acta Physiol Scand. Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise. Gentile CL. Katsumura T. Hannibal NS. The effect of creatine monohydrate ingestion on anaerobic power indices. Vukovich MD. Zoeller RF. Mol Cell Biochem. Bishop R. Comparison of creatine ingestion and resistance training on energy expenditure and limb blood flow. Hamed J. 1429-1434. 430-446. Effects of 28 days of beta-alanine and creatine monohydrate supplementation on aerobic power. Med Sci Sports Exerc. Faigenbaum AD. Almada AL. Faigenbaum A. Effects of creatine supplementation on body composition. Hoffman J. Ferreira M. Torok DJ. 330-346. Wilson M. Hamed J. Cramer JT. Stout J. Vukovich MD. Stout J. 2006. Mitchell TL. Hamaoka T. 2001. Ratamess NA. 1995. 330-346. Nindl BC. Comparison of creatine ingestion and resistance training on energy expenditure and limb blood flow. Stout JR. Snell PG. Amino Acids. muscular strength and body composition. Alexander C. Almada AL. 7. Kimura N. 50. 244. Plisk S. and sprint performance. The effects of creatine supplementation on anaerobic working capacity. Effect of creatine and beta alanine supplementation on performance and endocrine responses in strength/power athletes. Mangine G. Rodriguez R. Nindl BC. Mitchell TL. Eckerson JM. Sako T.ACSM Annual Conference presentation. Grindstaff PD. 207-209. ventilatory and lactate thresholds. Mangine G. Bishop R. 2006. 105-112.9 Stout JR. 73-82. Kreider R. 13. Grindstaff PD. Reinardy J. 38. Chance B. 1997. Wood L. The Journal of Strength and Conditioning Research. Ratamess N. 207-209. muscular strength and body composition. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise. Kuwamori M. 1998. ID 1536: “EAS Phosphagen Elite and “Increasing Strength” 1 2 Arciero PJ. Kuwamori M. 2003. 2003. Med Sci Sports Exerc. 30. 3 4 5 6 7 308 . Hamaoka T. Gentile CL. Wilson M. Int J Sport Nutr. Chance B. Snell PG. Kreider R. Rodriguez R. 7. Almada A. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Kurosawa Y. Sako T. strength. 1999. 2001. Cantler E. Almada A. 430-446. Stout J. Stout JR. Zoeller RF. Torok DJ. Reinardy J. ID 1537: “EAS Phosphagen Elite” and “Increasing Work Capacity” 10 1 Stout JR. 30. 2007. The Journal of Strength and Conditioning Research. Comparison of creatine ingestion and resistance training on energy expenditure and limb blood flow. O'Kroy J A. ID 1542: “EAS Phosphagen HP” and “Increasing Lifting Volume and Performance” 1 Kreider RB. and sprint performance. Effect of creatine and betaalanine supplementation on performance and endocrine responses in strength/power athletes. ID 1538: “EAS Phosphagen Elite” and “Enhancing Training Volume & Intensity” 1 Hoffman J. and time to exhaustion. Effects of 28 days of beta-alanine and creatine monohydrate supplementation on aerobic power. 2001. Cramer JT. Amino Acids. 33. 50. Grindstaff P. 13. Housh TJ. Kang J. J Strength Cond Res. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. 2006. Hamed J. Ratamess N. Faigenbaum A. 20. Effect of creatine and betaalanine supplementation on performance and endocrine responses in strength/power athletes. Mielke M. Mielke M. Effects of 28 days of beta-alanine and creatine monohydrate supplementation on aerobic power. 73-82. ventilatory and lactate thresholds. Mielke M. Ferreira M. 2006. Effects of creatine supplementation on body composition. Reinardy J. Torok DJ. Ferreira M. 2006. Grindstaff P. Vukovich MD. ventilatory and lactate thresholds. Almada AL. J Strength Cond Res. Stout JR. O'Kroy J.8 9 Stout JR. Amino Acids. O'Kroy JA. Ratamess N. strength. strength. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. Int J Sport Nutr Exerc Metab. 33. 1998. Mangine G. 16. Ebersole KT. Plisk S. Effects of creatine supplementation on body composition. Wilson M. Hannibal NS. 2007. Stout JR. and sprint performance. Cantler E. 309 . 505-510. Almada AL. 505-510. 1998. Stout J. O'Kroy J. 135-138. 30. ID 1539: “EAS Phosphagen Elite” and “Increasing Exercise Thresholds” 1 Zoeller RF. ID 1543: “EAS Phosphagen HP” and “Enhancing Anaerobic Working Capacity” 1 Arciero PJ. 1999. 430-446. Faigenbaum A. Torok DJ. Zoeller RF. Med Sci Sports Exerc. 20. Zoeller RF. 16. Plisk S. Wilson M. Mangine G. Cramer JT. 73-82. The effects of creatine supplementation on anaerobic working capacity. Kang J. Torok DJ. Nindl BC. and time to exhaustion. Mielke M. 928-931. Int J Sport Nutr Exerc Metab. Med Sci Sports Exerc. ID 1541: “EAS Phosphagen HP” and “Increasing Mass” 1 Kreider RB. ID 1540: “EAS Phosphagen HP” and “Increasing Strength” 1 Hoffman J. 2006. Metabolism. Gentile CL. Eckerson JM. 928-931. Cantler E. 1429-1434. Wood L. 244. Torok DJ. Cramer JT. Mielke M. Zoeller RF. 2006. 13. Koo MW. Faigenbaum AD. Mangine G. Stout JR.ACSM Annual Conference presentation. Kang J. 31. Zoeller RF. Almada AL. Chance B. Wilson M. Creatine supplementation enhances anaerobic ATP synthesis during a single 10 sec maximal handgrip exercise. Frandsen E. 430-446. Beneficial effects of green tea--a review. Ng EH. 33. 432-436. J Soc Gynecol Investig. 38. 2006. Wilson M. strength. Ratamess N. Sako T. Med Sci Sports Exerc. Stout J. 30. Amino Acids. 1997. Zuckerbraun HL. muscular strength and body composition. Kurosawa Y. Ferreira M. double-blind 8-week intervention in obese subjects. 2003. 2002. Kimura N. 25. 505-510. Alexander C. 135-138. Crespy V and Williamson G. Katsumura T. Mielke M. Snell PG. 153. Faigenbaum A. Hoffman J. Int J Obes (Lond). 928-931. 105-112. Tremblay A. 2005. Hoffman J. Kuwamori M. 2007. Effects of 28 days of beta-alanine and creatine monohydrate supplementation on aerobic power. Chan CC. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. Artacho R. Plisk S. 20. 121-130. Med Sci Sports Exerc. 73-82. In vitro cytotoxicity of (-)-catechin gallate. 330-346. a minor polyphenol in green tea. Cabrera C. 1995. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled. Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men. Dore J. Hamaoka T. Int J Sport Nutr. Mitchell TL. The effect of creatine monohydrate ingestion on anaerobic power indices. Phytomedicine. 2006.2 Earnest CP. 134. Acta Physiologica Scandinavica. Int J Sport Nutr Exerc Metab. 171-180. 1999. Ebersole KT. Mol Cell Biochem. Br J Nutr. Effects of Chinese green tea on weight. 2006. 2007. The effects of creatine supplementation on anaerobic working capacity. Berube-Parent S. Weinerman SM. Almada AL. Ratamess NA. 13. Kreider R. O'Kroy J A. Mangine G. ventilatory and lactate thresholds. Kondrup J. Tang OS. J Strength Cond Res. Stout JR. O'Kroy J. 2004. 171. 63-68. 2007. Stout J. A review of the health effects of green tea catechins in in vivo animal models. Stout JR. 7999. 16. 207-209. Effect of creatine and beta alanine supplementation on performance and endocrine responses in strength/power athletes. Eckerson JM. and time to exhaustion. Gimenez R. Reinardy J. and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome--a randomized placebo-controlled trial. rich in EGCG” and “Weight management” 3 4 5 6 7 8 9 10 1 2 Babich H. Chantre P and Lairon D. Rodriguez R. 3431S-3440S. 2006. Yeung WS. Pelletier C. J Am Coll Nutr. 9. ID 1544: “Epigallo-catechin-3-gallate (EGCG) / Green tea extract. Effect of creatine and betaalanine supplementation on performance and endocrine responses in strength/power athletes. Housh TJ. Belza A. 94. Effects of creatine supplementation on body composition. and sprint performance. J Nutr. 126. Grindstaff P. Grindstaff PD. 3 4 5 6 7 310 . 1998. Almada A. Ho PC. Effects of twenty-eight days of beta-alanine and creatine monohydrate supplementation on the physical working capacity at neuromuscular fatigue threshold. The Journal of Strength and Conditioning Research. Toxicol Lett. 7. Cantler E. Bishop R. Kreider RB. Torok DJ. 3-8. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Biochim Biophys Acta. 2001. 15. Yamamoto S. Meguro S. Nutritional intervention study to investigate the effects of the green tea extract TEAVIGO™. 50. Yamamoto S. Charité Berlin. Inaoka S. 2000. 24. Dietary fats. Valcic S. Ishikura Y. Lejeune MP. (submitted for publication). Nijs I. 2005. 2002. 2004-2005. Br J Nutr. Journal of Oleo Science. 51. Tea. Acheson KJ. Moulin J. Kovacs EM and Mela DJ. Komatsu T. Komatsu T. 2006. Fathi M. 2848-2852. 1088-1095. Hase T. Hase T. 2003. Anti-obesity effects of green tea: from bedside to bench. Reduction of body fat in humans by long-term ingestion of catechins. 233-236. Thielecke F and et al. 70. Chantre P. Komine Y. Hiipakka RA. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 311 . Shimotoyodome A. Prog Med. 7-15. Tokimitsu I. Effect of a thermogenic beverage on 24-hour energy metabolism in humans. Chen CL. Takahashi H. Hou J. Effects of combination of regular exercise and tea catechins intake on energy expenditure in humans. Komine Y. 2006. high in EGCG. Effects of green tea on weight maintenance after body-weight loss.8 Dulloo AG. Nakamori M. 1427. 1195-1204. 22. Liebler DC. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Girardier L. Metabolically active functional food ingredients for weight control. 122-129. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Relationship among habitual tea consumption. caffeine and sympathetic activity. Obes Res. Mensi N. Rudelle S. Liao S. 59-78. Cristiani I. 131. Wu CH. Green tea and thermogenesis: interactions between catechin-polyphenols. Nagao T. Lejeune MP. Obesity (Silver Spring). 141. Matsui Y. Obes Rev. Soga S. 91. Takeda Y. Ishikura Y. Westerterp-Plantenga MS. 2189-2203. and diabetes. Rohrer D. 431-437. 50. Antioxidant chemistry of green tea catechins. Zhao B. Mol Nutr Food Res. Int J Obes Relat Metab Disord. Wang Y. Tokimitsu I. Girardier L. Hosoda K. 81. 2001. Meguro S. Dulloo AG. 81. 2005. Mol Nutr Food Res. Shimasaki H. 7. 50. obesity. St-Onge MP. Inaba M. 2007. dairy. 2007. Murase T. 2004. Sakai T. Chem Res Toxicol. and body fat distribution. 349-355. 599-605. Rumpler W. Oolong tea increases energy metabolism in Japanese females. Vandermander J. 13-23. Tanaka Y. Kao YH. Lee MJ. Obes Res. Chang HH. ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers. Chang CJ. Thielecke F. J Nutr.. Am J Clin Nutr. Kovacs EM. New oxidation products of (-)-epigallocatechin gallate and (-)-epigallocatechin from their reactions with peroxyl radicals. Seale J. 1999. 50. Hosoda K. 188-210. 1999. Itakura H. Chang TC. 13. Tsuchida T. 252-258. Oolong tea increases metabolic rate and fat oxidation in men. 2000. Vandermander J. 2000. 176-187. Mace K. Burr JA. Tappy L. Kao YH. 170175. Wang RH. Am J Clin Nutr. Anti-obesity effects of tea catechins in humans. Toyama K. Timmermann BN. 2005. Journal of health science. Hu J. Kunii D. Seydoux J. Westerterp-Plantenga MS. 13. Soga S. 11. Okamura M. Clevidence B. Endocrinology. and nuts: potential functional foods for weight control? Am J Clin Nutr. Sawaki T. 2006. 980-987. on the fat oxidation in overweight/obese volunteers. Xin W. 2003. Kovacs EM. Komatsu K. Chantre P. Tokimitsu I. J Med Invest. Guo Q. 801-810. 1040-1045. Haramizu S. Duret C. Katsuragi Y. percent body fat. Lu FH. Shen S. Wolfram S. Judd J. Wiley E. teas. Nakamura H. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. 2005. Chang CS. Ferruzzi MG. Ota N. 1998. 4. Lee MJ. 32. Iha M. Okabe S. Pietta P. 1995. Gardana C. Okubo T. 12. 2005. Chang HH. Suganuma M. 599-605. J Nutr Sci Vitaminol (Tokyo). 307-310. Antihyperglycemic effect of oolong tea in type 2 diabetes. mice. Chen L. Wang MF. Chen L. Meng X. 1998. J Nutr Biochem. 3431S-3440S. Suga K. Bombardelli E. Inaoka S. 1995. Journal of Oleo Science. 2001. Polyphenols: chemistry. 43. 693-696. Clin Exp Pharmacol Physiol. Cancer Epidemiol Biomarkers Prev. Katsuragi Y. 2003. (-)-epigallocatechin-3gallate. Imai K and Nakachi K. 26. 73. 310. Li H. Chen L. 15. Sang S. Rizvi SI. Anis R. 1998. 2002. Shimbo M. Yang CS. Clevidence B. Absorption. 1045-1050. Morazzoni P. Fukino Y. Crit Rev Food Sci Nutr. A review of the health effects of green tea catechins in in vivo animal models. 70-75. Sheng S. Sueoka N. A review of latest research findings on the health promotion properties of tea. Nutr Rev. Aoki N. Bronner WE and Beecher GR. Ho CT. Mutat Res. Protective role of tea catechins against oxidation-induced damage of type 2 diabetic erythrocytes. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Lee MJ. J Chromatogr A. Yamamoto S. 481-486. Ann Intern Med. Absorption and distribution of tea catechin. Iso H. Imai K. Prabhu S. 2005. 11. 89-143. Liao ML. 2003. Zaid MA. Bondoc FY. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Cancer inhibition by green tea. rich in EGCG” and “Blood glucose levels” 1 2 3 4 5 6 7 8 9 10 11 12 Bravo L. Dufresne CJ and Farnworth ER. Tokimitsu I. Yang CS. Food Chemistry. Kao YH. 144. 56. 805. Yang CS. 679-684. 10251032. 335-342. Tada Y. and nutritional significance. 1714-1718. J Nutr. Record IR and Lane JM. 393-399. Crespy V and Williamson G. 1042-1050. in the rat. Sun Y. 1997. Diabetes Care. 2001. 50. 404-421. 2001. Simonetti P. Hosoda K. Tea. Lambert G. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Balentine DA. Tamakoshi A. Sueoka E. Higdon JV and Frei B. elimination of tea polyphenols in rats. Meguro S. Takahashi H. and rats. 46. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans. Method for determining the content of catechins in tea infusions by high-performance liquid chromatography. 402. Biochem Mol Biol Int. 13 14 15 16 17 18 19 20 312 . metabolism. Kozu T. Li H. 137-142. Cancer Epidemiol Biomarkers Prev. Lee MJ. Relationship between rate and extent of catechin absorption and plasma antioxidant status. 2002. Mol Nutr Food Res. Fujiki H. distribution. 50. 1997. J Nutr Sci Vitaminol (Tokyo). Drug Metab Dispos. and antioxidant functions. Gobbo S. 134. Brusamolino A. metabolism. 554562. obesity. Tea catechins and polyphenols: health effects. Komine Y. Meng X. Nakachi K. BMJ.ID 1545: “Epigallo-catechin-3-gallate (EGCG) / Green tea extract. Chem Res Toxicol. Hase T. dietary sources. Fukui M. Mishra N. Simulated intestinal digestion of green and black teas. Lee MJ. 2006. Yang CS. Iso H. Anti-obesity effects of tea catechins in humans. Komori A. 1998. Shimasaki H. Maliakal P. and diabetes. 317-333. Mohr S. 25. 895-903. Takeda Y. Wang ZY. Chuang CK. 2004. Matsui Y. 43. Nakagawa K and Miyazawa T. 51. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. Analysis of plasma and urinary tea polyphenols in human subjects. Chen CL. Lu H. 188-210. Lee MJ. 2006. Date C. Wakai K. Zhu N. 213-217.) O. 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ID 1546: “Epigallo-catechin-3-gallate (EGCG) / Green tea extract. Prev Med. Tokunaga S. 2004. Beneficial effects of green tea--a review. Biofactors. Coffee consumption and glucose tolerance status in middle-aged Japanese men. Tanaka K. Yang GY. 356-358. 84. Iwase Y. 2145-2151. Weber P. Ann Epidemiol. Van Amelsvoort JM. 1995. 4. Richard-Caudron AS. Effects of green tea consumption on inflammation. 2001. Pineau B. Kim NH. 13. Method for determining the content of catechins in tea infusions by high-performance liquid chromatography. Kono S. Gießen. Decourt JP. Van Hof KH. Wissenschaftlicher Kongreß der Deutschen Gesellschaft für Ernährung. Mathot JN. 1998. Girault N. 130. Takahashi T. 31. Haller J. Wu JB. 4. Plasma concentrations of individual tea catechins after a single oral dose in humans. 50. Mol Nutr Food Res. J Chromatogr A. 176-187. Int J Vitam Nutr Res. Seo JA. insulin resistance and pulse wave velocity in type 2 diabetes patients. Klassiker als Trendgetränk: Teekonsum auf hohem Niveau stabil Deutsche Teewirtschaft mit Geschäftsjahr zufrieden. Ogawa S. Yang CS. Girault J. Press Release. Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. J Am Coll Nutr. Shirai K. 24092412. Yang CS and Landau JM.21 Ryu OH. Sasazuki S. Thielecke F. Doi Y. Kodama H. 313 . 2006. and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. Kuntze Zeitschrift für Phytotherapie. 704-710. Tsubono Y. Koyanagi S. Spitzer V. Xenobiotica. 2004. Kawano T. 18. Tsuneki H. XXXVIII. Yamaji T. Takada K. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Lee KW. Wiersma A. Iitoi Y. Kimura I. Kim SG. Hiyamuta K. rich in EGCG” and “Cardio-vascular health” 1 2 Bronner WE and Beecher GR. Mulder TP. Levitt MD. 73-79. 551-555. Mizoue T. Baik SH. Takeshita A. Am J Clin Nutr. 7999. Yoshimasu K. Schlesier K. Teeverband. 2006. Lee J. 401-408. Washio M. Chung JY. Shimizu E. 137-142. Mineshita M. Arakawa K. Terasawa M. 269-278. 2000. An extract of black. 2004. 231-246. Lee MJ. Anti-obesity effects of green tea: from bedside to bench. Choi KM. Scholz E and Betram B. Zhong L. 88-101. A single ascending dose study of epigallocatechin gallate in healthy volunteers. 2003. Meng X. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. Ho CT. 26. 22. Ishizuka M. Yang GY. Choi DS. Unterschiede im protektiven Potential von Grün-und Schwarztee aus gleichen Teeblättern. 805. Wolfram S. Yamaguchi K. Proc Soc Exp Biol Med. Weber P. Chung JY. Liu Y. Effects of tea consumption on nutrition and health. Tabata S. 891-901. 10. 71. 2000. Nakagaki O. Diabetes Res Clin Pract. 25. Liao J. Kono S. J Nutr. 1999. Li C. Ullmann U. Lee MJ. 2006. Der Teestrauch . Artacho R. Diabetologia. 220. Wang Y. Böhm V. Kim S. Furne JK. 1997. Ullmann U. Decourt JD. Gimenez R. Tijburg LB. Dietary differences with green tea intake among middle-aged Japanese men and women. Nii T. Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. 2003. 47. Akabane M. Yang CS. Mechanisms of inhibition of carcinogenesis by tea. Sasaoka T. Ideishi M. Cabrera C. 31. Bitsch R. Girault J. 2000. 2006. Arai H.Camellia sinensis (L. green. Haller J. Kim HY. 74. Tsugane S. 2001. J Int Med Res. Mohri M. BMC Pharmacol. Murakami T and Ohsato K. 434. 13. 693-696. Higdon JV and Frei B. Baik SH. All teas are not created equal: the Chinese green tea and cardiovascular health. Kim SG. 1995. Ahn YK. Lee J. 38-42. BR40-45. Effects of green tea intake on the development of coronary artery disease. Lee MJ. 665-670. Buytenhek R. Sun Y. Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein. Tarquinio M. Nakagawa K. 68. Locher R. 2000. Federici A. JACC. 2007. 2003. 21. Puddey IB. J Agric Food Chem. Langius JAE. Effects of green tea consumption on inflammation. JAMA. 1485-1486.3 Chen ZY. 2006. Marasciulo FL. Crit Rev Food Sci Nutr. Barton M. Tomita T. Chen L. 292. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. Ho WK. 2007. Murohara T. cancer. 2006. Yamamoto H. E1378-E1387. 108. Jeong MH. Nara Y. Chae HJ. 1052-1057. Yun JH. Yao XQ. Ohmori K. Devine A. Preventive effects of green tea catechins on spontaneous stroke in rats. Int J Cardiol. Am J Physiol Endocrinol Metab. van Duyvenvoorde W. German JB. 2006. Suter PM. 43. and antioxidant functions. Suganuma M. Tsuji I. 271A. Kuriyama S. Frankel EN. Cho SH. 46. Tea intake is inversely related to blood pressure in older women. Tabuchi M. Cheng X. Aeschbach R. 835840. Cheng TO. 296. 4. Princen HMG. Tsubono Y. improves endothelial function and insulin sensitivity. Choi DS. 1995. BMJ. Hodgson JM. 2004. Biofactors. Miyatake K. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Inhibition of endothelial cell mediated lowdensity lipoprotein oxidation by green tea extracts. 1-7. 1255-1265. Imai K. 393-399. Kim J. Nakaya N. J Nutr. Wang ZY. insulin resistance and pulse wave velocity in type 2 diabetes patients. Ikeda K. Huang Y. Kim HY. Analysis of plasma and urinary tea polyphenols in human subjects. Kangawa K. Kim NH. Yamori Y. Mizuno K. Med Sci Monit. 41. 356-358. Lee KW. 90. Seo JA. reduces blood pressure. Miyazawa T. Li H. 301-308. Nishino Y. 833-841. Tijburg LBM. Xu JW. Vetter W. Epigallocatechin gallate. Emmanuele L. 133. a green tea polyphenol. 18. 49-54. 1998. 2004. Nakachi K. Blonk C. Colantuono G. Pearson DA. Meinders AE. Kim W. Gobbo S. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. 2883-2886. Tiravanti E. 2003. 70. Saito K. Arterioscler Thromb Vasc Biol. Law WI. Imai K and Nakachi K. Uematsu M. Shimazu T. 1998. Sakai S. Suzuki C. Eur J Pharmacol. Lee MC. Prince RL. 2000. Inami S. Potenza MA. J Nutr. 2006. 134. Green tea consumption and mortality due to cardiovascular disease. 71. Njelekela M. Itoh T. Ikeda M. Takano T. Nagaya N. Pijl H. No Effect of Consumption of Green and Black Tea on Plasma Lipid and Antioxidant Levels and on LDL Oxidation in Smokers. 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 314 . Balentine DA. Tea catechins and polyphenols: health effects. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. 2004. Cancer Epidemiol Biomarkers Prev. Umegaki K. Montagnani M. 89-143. Circ J. 2002. 13. 310. Ryu OH. Beilin LJ. Acta Pharmacol Sin. and protects against myocardial ischemia/reperfusion injury in spontaneously hypertensive rats (SHR). Ohba T. 1445-1449. Seimiya K. Quon MJ. Diabetes Res Clin Pract. and all causes in Japan: the Ohsaki study. Sano J. Circ J. Matsuyama S. Lau CW. Yang CS. Choi KM. Inhibitory effects of purified green tea epicatechins on contraction and proliferation of arterial smooth muscle cells. Miyake S. Green tea reverses endothelial dysfunction in healthy smokers. Heart. 2003. metabolism. Chan SY. Kikuchi N. Kang JC. Dietary green tea intake preserves and improves arterial compliance and endothelial function. Negishi H. Kondo T. Razak F. 1534-1540. Nii T. Foss OP. 57. 128. 585-590. Yang F. Koyanagi S. 1997. 401-408. 26. 315 . 137-140. 2334-2340. Ichinowatari Y. 4. Mol Nutr Food Res. Kensington Books. Tea consumption and cardiovascular disease: effects on endothelial function. 1987. Onen CL. Tverdal A. Hiyamuta K. Gitomer A. Chapter Five: Individual nutrients and herbs. 157. The effects of green tea ingestion over four weeks on atherosclerotic markers. Hunt H and Rice T. Rumboldt Z. 1998. J Am Coll Nutr. Der Teestrauch . 164. Obesity and the risk of myocardial infarction in 27. Solvoll K. 366. Tanomsup S. Sung H. blood pressure. Res Commun Chem Pathol Pharmacol. Iwase Y. and coronary and total mortality. 2003. Shimizu H. Washio M. Yang YC. Tanaka K. 37. Chun S. 2005. 50. 1989. Dietary differences with green tea intake among middle-aged Japanese men and women. Ann Clin Biochem. Akabane M. Abel R. Mohri M. Jena/Thüringen. Shirai K. Weisgerber UM. Comparative efficacy of inter-cal "Ester-C" calcium ascorbate. 218-228. Fujisaku S. Arai H.. The role of tea and tea flavonoids in cardiovascular health. J Nutr. 1995. 2006. Ideishi M. Ida Y. Kawano T. Safety and tolerance of ester-C compared with regular ascorbic acid. Kuntze Zeitschrift für Phytotherapie. 337-343. Arch Intern Med. 16401649. Possible contribution of green tea drinking habits to the prevention of stroke. The Best Supplements for Your Health. Vita JA. Symposium. The protective effect of habitual tea consumption on hypertension. J Nutr. Alexopoulos N.000 participants from 52 countries: a case-control study. Jr. Dima I. Vlachopoulos C.22 Sasazuki S. 2002. Arakawa K. Germany. Suda S. McClain CJ. Vitamine und Zusatzstoffe in der Ernährung von Mensch und Tier: 7. Takeshita A. Lisheng L. Sharma AM. Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans. 2004. 23. Anand SS. Stefanadis C. Yoshimasu K. relationship to cholesterol. 231-246. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. 216-223. 171-178. Kono S. Hawken S. Ounpuu S. 2000. Varilek GW. Almeida LM. Kato K. 1995. de Villiers WJ. Tsugane S. Lee DH. Lang CC. Wangai P. Watanabe T. Wu CH. Iitoi Y. La Jolla. 11. Inc. Lee YW. Lu FH. Part two: A supplement encyclopedia. Katan MB. 2000. Andreadou I. Bautista L. Schlesier K and Bitsch R. Takada K. Goldberg D.Camellia sinensis (L. Mattern T. Gruenwald J. Assessment of the protective potential of green tea. Tea flavonoids and cardiovascular disease: a review. Crit Rev Food Sci Nutr. Aznaouridis K. Results of a study prepared for Inter-Cal Corporation by the Life Management Group. Commerford P. 3293S-3297S. Lee W.. Ikeda M.) O. 292-297. 2006. Takahashi T. 42. Laranjinha JA. Stangl K. Folts JD. 2005. Adv Ther. Nakagaki O. Tea consumption. 546-553. Liu Y. Kodama H. Maiani G. Acute effect of black and green tea on aortic stiffness and wave reflections. 1997. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. Busch R. Wu JS. Yusuf S. 133. Stangl V. Graubaum HJ. Park H. CA 92037. Hisamichi S. Tijburg LB. 771-785. An acute study on the relative gastro-intestinal absorption of a novel form of calcium ascorbate. Prev Med. Sato Y. 1999. Tohoku J Exp Med. Chang CJ. Min WK. Franzosi MG. Bentley C. Lorenz M. Lancet. 21. Ann Epidemiol. 25. 10. Tsubono Y. 1992. 704-710. Jang S. Tokunaga S. New York. Doi Y. Serafini M. Preventive Medicine. ID 1547: “Ester-C” and “Antioxidant properties/Immune health” 23 24 25 26 27 28 29 30 31 32 33 34 35 36 1 2 3 4 Bush MJ and Verlangieri AJ. Scholz E and Bertram B. Nakatsuka H. 2006. J Nutr Biochem. Stensvold I. Kruger MC. Sun D. Coetzer H. total urinary hydroxyproline. 81-84. Morita I. The Gale Group. O'Dowd A. Part I. 1994. Biochemical profile of osteoporotic patients on essential fatty acid supplementation. Kruger MC. 13-19. Coetzer H. van Papendorp DH. Bhattacharya A. Lingan K. Clinical study shows Zila's Ester-C(R) superior to vitamin C. Urolithiasis. Fay MJ. Kirk FR. The treatment of idiopathic recurrent urolithiasis with fish oil and evening primrose oil—a double blind study. 1995. Read NW. Calcium. Bogentoft C. 12061216. Horrobin D. Steinmann CM. van Papendorp DH. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Ansell D. Vermaak WJ. Aging (Milano). 2003. Kruger MC. Wright JV. Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks. 575–580. 47. 18. Claassen N. Sakaguchi K. 1994. 10. Buck AC. Buck AC. de Winter R. Suen RM. Seppa M. Rothwell MC. 48. Murota S. Coetzer H. Chemist & Druggist. Richardson A. International Clinical Nutrition Review. Claassen N. Annu Rev Nutr. Ester-C is a plus for cold sufferers. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. 1990. van Papendorp DH. 325-334. 267-270. Zaman K. Horrobin D. Lawrence R. Kruger MC. 2002. Life Sci. Comparison of the anti-scorbutic activity of L-ascorbic acid and Ester C in the non-ascorbate synthesizing Osteogenic Disorder Shionogi (ODS) rat. Bone. Gut. 1995. double-blind study proves Ester-C tolerant than regular vitamin C. Prostaglandins Leukot Essent Fatty Acids. 385-394. 53. Pye DW. Coetzer H. Br J Nutr. 629-635. Kruger MC. Claassen N. 22752281. 1996. Rumsey RD. 16. 83. 1994. Van Papendorp DH. Calcium transport by isolated brush border and basolateral membrane vesicles: role of essential fatty acid supplementation. 385S-392S. Bannon AW. Littlewood JJ. gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. 1991. Prostaglandins Leukot Essent Fatty Acids. 3. Fernandes G. Sturrock RD. Madhok R.5 6 7 Moyad MA and Combs MA. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. 15. J Urology.and postmenopausal women: two randomized controlled trials of Efacal v. Macdiarmid JI. and bone calcium content. 96-104. 50. Comparative studies of ―Ester C‖ versus L-ascorbic acid. 285-319. Potgieter HC. Nutrition Research. Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre. ID 1552: “Evening primrose oil and fish oil” and “Bone health” 8 9 1 Bassey EJ. Coetzer H. Meddings R. Gericke G. 1995. James A. ID 1553: “Formulated palm and oat oil emulsion” and “Weight management” 2 3 4 5 6 7 8 9 10 11 1 2 Blundell JE. Krishnan A. Verlangieri AJ. Characteristics of lipid substances activating the ileal brake in the rat. calcium alone. The prevention of experimental nephrocalcinosis with eicosapentaenoic acid and evening primrose oil. Brown NJ. 1998. 10. 50. Control of human appetite: implications for the intake of dietary fat. Zila Nutraceuticals Inc. Belch JJ. 257-266. 2006. 2000. 25-35. 2007. 1988. The effect of different n-6/n-3 essential fatty acid ratios on calcium balance and bone in rats. 1993. Ann Rheum Dis. 16. Jenkins R. Cotton JR. 1990. 316 . Vitamin C Dietary Supplements: An Objective Review of the Clinical Evidence. Lawton CL. Jackson R. 1126-1129. 2. Smellie WS. Semin Prev Altern Med. Prostaglandins Leukot Essent Fatty Acids. J Bone Miner Res. 149. 31. Effect of Fabuless on body composition. 1999. Viberg A. Bates TE. 69. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Livingstone MB. A review. 2007. E447-453. Physiol Rev. Ileal brake: a sensible food target for appetite control. McCaffrey TA. Trotman IF. Int J Obes Relat Metab Disord. 274280. Zhao XT. a 12 week study on overweight 2 women during gradual weight loss. Gastroenterology. Holst JJ. Am J Clin Nutr. Skogar S. Soenen S. Sundberg B. Intestinal transit is more potently inhibited by fat in the distal (ileal brake) than in the proximal (jejunal brake) gut. Welch RW. Van Citters GW and Lin HC. 24. Dunne A. Westerterp-Plantenga MS. Gutniak M. The ileal brake: a fifteen-year progress report. Welch RW. Grimble GK. Gastrointestinal hormones and food intake. 2002. 2005. Morris AP. Maljaars PW. Rowland IR. 25. 1409-1439. Naslund E. 95. Reid CA. Spiller RC. Hänni A. Misiewicz JJ. Short-term effects of yoghurt containing a novel fat emulsion on energy and macronutrient intakes in non-obese subjects. Mela DJ. 8. Arnold M. Diepvens K. Hall JC. Burns AA. Eur J Clin Nutr. 2008. Int J Obes Relat Metab Disord. Read NW. 31. Bloom SR. Burns AA. 2000. Dunne A. Reid CA. 2006. Am J Physiol Endocrinol Metab. 288. Wallace JM. Horowitz M. Vahl TP. Rowland IR. Lee YC. 367-373. Livingstone MB. overweight and obese subjects. Gastroenterology. Curr Gastroenterol Rep. Van Citters GW and Lin HC. Wang L. Olsson J. Physiol Behav. 56. Seeley RJ. Lin HC. Farrar GB. Moss G. 68. 1997. 2001. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. 117. Rowland IR. 86. 317 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 . Effect o droplet of a fat emulsion delivered in the small intestine on satiety and food intake in healthy volunteers. 114-117. 60. Higgins BE. 525-530.MANUSCRIPT. Dig Dis Sci. Rossner S. 365-374. Wittert GA. 1419-1425. 942949. Ileal brake: neuropeptidergic control of intestinal transit. Logan CM. D'Alessio DA. 1984. Woods SC. The physiology of glucagon-like peptide 1. Hellstrom PM. 95. The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man. Lee Y. Dunne A. Zuurendonk P. Steijns J. Kinsman RI. Diepvens K. Welch RW. 1487-1496. 179S-181S. Dose-response effects of a novel fat emulsion (Olibra) on energy and macronutrient intakes up to 36 h post-consumption. 6-12. Westerterp-Plantenga M. 368-377. Strader AD and Woods SC. Mullaney U. Ghatei MA. Gut. Effects of small-intestinal fat and carbohydrate infusions on appetite and food intake in obese and nonobese men. 1. 2006. Investigation of the medium-term effects of Olibratrade mark fat emulsion on food intake in non-obese subjects. 42. Short-term effects of a novel fat emulsion on appetite and food intake. Gastrointestinal regulation of food intake. Chapman IM. Robson PJ. Novel food technologies: enhancing appetite control in liquid meal replacers. Goble EA. 2007. 1999. Silk DB. Steijns J. 19-25. 2007. Welch I. Olsson R. McFarlane A. Mela DJ. 175191. 128. O'Neill B. Obesity (Silver Spring). Livingstone MB. Physiol Behav. Strader AD. 271-281. Peters HP. NTR1515 human study. 1984. Long-term effects of consumption of a novel fat emulsion in relation to body-weight management. 404-409. 2007. Jandacek RJ. Blackhall NW. Welch RW. Masclee AA. 87. 2005. Int J Obes (Lond). 2006. 14 Suppl 4. 1081-1091. 2008. Livingstone MB. 13-23. Lindmark L.3 Burns AA. 2008. Eur J Clin Nutr. Maljaars PW. Am J Clin Nutr. J Clin Invest. Curr Gastroenterol Rep. 1998. Dunne A. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Robson PJ. Bloom SR. The effects of yoghurt containing a novel fat emulsion on energy and macronutrient intakes in non-overweight. Cummings DE and Overduin J. 25. Br J Dermatol. 2006. viral infections in atopic eczema. Woods SC. 2. Patrizi A. 14 Suppl 4. 1981. Abate G. Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy. Clin Investig. Horrobin DF. 139-150. 615-628. 1991. 211-217. 1989. 70. 1997. 128. 15. Bordoni A. 728-740. 1411-1414. Meigel W. Di Lorio A. Burton J. 25. Kerscher MJ and Korting HC. Importance of dietary gamma-linolenic acid in human health and nutrition. Gastroenterology. Manku MS. Burton JL. 2004. Mattila L. Miller CC. Prostaglandins Leukot Med. Burton JL. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. 174176. 503-524. Potential of evening primrose. Elles K. Oral evening-primrose-seed oil improves atopic eczema. 75-90. Burton JL. 30. 9. Am J Clin Nutr. Relationship between plasma essential fatty acid changes and clinical response. 2000. Fan YY and Chapkin RS. Ziboh VA. J Int Med Res. Zeegers MP. 1. Horrobin DF. 171S-178S. Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. 1998. Uotila P. 71. 2006. Burton JL. ID 1554: “Gamma Linolenic acid (GLA) from Evening primrose Oil” and “Skin health” 1 2 3 4 5 Andreassi M. Oliwiecki S. Treatment of atopic eczema with evening primrose oil. 150. discussion 736S-737S. 1993. Horrobin DF. black currant. Littlewood S. 121. 278. 6 7 8 9 10 11 12 13 14 15 16 17 318 . 117. Manku MS. Evening primrose oil in the treatment of atopic eczema: effect on clinical status. Schalin-Karrila M.24 25 Welch I. Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Dettke T. Levels of essential and other fatty acids in plasma and red cell phospholipids from normal controls and patients with atopic eczema. 7. 89. Ann Nutr Metab. 47-57. Where do we go from here in light of more recent discoveries? Curr Pharm Biotechnol. 2000. Horrobin DF. 732S-736S. 266-274. Arch Gerontol Geriatr. Lancet. Thijs C. 1982. Kyte V. Lancet. Clin Exp Dermatol. Jansen CT. 11201122. 57. 1985. plasma phospholipid fatty acids and circulating blood prostaglandins. Amerio P. Wexler D. Jenkins K. Saunders K. Obesity (Silver Spring). Br J Dermatol. Lovell CR. Read NW. Med Hypotheses. Morse NL and Clough PM. 32. Post-viral fatigue syndrome. 1982. Br J Dermatol. Am J Clin Nutr. acne vulgaris and psoriasis. A meta-analysis of randomized. Stewart JC. Manku M. borage. 1992. Wright S and Burton JL. Wright S. Holt PJ. Horrobin DF. Morse N. Forleo P. 2001. 11-19. Essential-fatty-acid metabolites in plasma phospholipids in patients with ichthyosis vulgaris. 45. J Nutr. Oral essential fatty acid supplementation in atopic dermatitis-a meta-analysis of placebo-controlled trials. Fatty acid metabolism in health and disease: the role of delta-6-desaturase. van Gool CJ. Gould DJ. Guenther L. Grattan C. 1990. Mattila L. 167-171. Dietary synergies in appetite control: distal gastrointestinal tract. 1990. Morse PF. Treatment of atopic eczema with evening primrose oil: rationale and clinical results. 224-228. and fungal oils in human health. Masci S. Cho Y. 71. Horrobin DF. Acta Derm Venereol. Brosche T and Platt D. Horrobin DF. Allen R. Barre DE. 361S-366S. placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Jansen CT. and essential fatty acids. Stewart C. Wright S. Effect of borage oil consumption on fatty acid metabolism. 1293-1297. transepidermal water loss and skin parameters in elderly people. Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites. 1987. Anguera A. 53. Sahagun AM. Sierra Vega M. Bast A. Basora J. Forattini C. 2001. Dietary fiber and weight regulation. Metabolism. Hong S. Luque X. Rozwodowska M. ID 1556: “Glucomanan” and “Weight management” 1 2 3 4 5 Bénéfices santé des fibres hydrosolubles. Williams PA. Experiences with three different fiber supplements in weight reduction. 37. Current therapeutic research. Med Sci Sports Exerc. DiFabio D. Prévention et Santé. 1995. Med Sci Monit. 1988. 2007. Saltzman E. 49 Suppl 3. 1995. Diez Liebana MJ. Mondelo A. 44. Calle Pardo AP. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation. Eur J Clin Nutr. Roberts SB. Chesy G. Br J Nutr. Sweetman SC (ed. 2005. Nutr Hosp. Nutrition. Bullo M. Narejos S. Volek JS. Keithley J and Swanson B. 1993. 33. Pansarasa O. 1995. 5 6 7 8 9 10 11 12 13 14 15 319 . Torres F. Bertorelli L. Reffo GC. Farres X. Shimshi M. 19. Reffo GC. Ho JY. 2004. 269-274. Ghirardi PE. 2001. Nutr Rev. G E N. Meadows J. Glucomannan and obesity: a critical review. Altern Ther Health Med. Chang YH. Balanza R. 45-50. Erling T. Forattani C. 11. Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. 753-758. Della Valle G. 47. 2005. Hong Y. 59. Glucomannan in hypertensive outpatients: pilot clinical trial. Hatfield DL. Nutritional supplementation in male college soccer players: effects on performance and oxidative stress. Olszewska D. Fernandez Martinez N. Doi K. Borrell M. Howarth NC. 2006. J Agric Food Chem. 49. London. 2008. Influence of an orally effective superoxide dismutase (glisodin) on strenuous exercise induced changes of blood antioxidant enzymes and plasma lactate. 11. 53. Berrizbeitia ML. Blood free radical antioxidant enzymes and lipid peroxides following long-distance and lactacidemic performances in highly trained aerobic and sprint athletes. Effect of altitude training on the peroxidation and antioxidant enzymes in sportsmen. Wang Y. Biomacromolecules. Clin Ter. NUTRANEWS: Sciences. 2005. Xia J. PI5-8. Williams CA. Maresh CM. [Glucomannan: properties and therapeutic applications]. Li B. 1109-1113. 1149-1158. [Use of glucomannan dietary fiber in changes in intestinal habit]. Fragala MS. 22-27. Gonzalez Canga A. Silvestre R. Sweetman SC. Somenzini L. 2002. allowing sports people to improve performance” 1 2 3 4 Arent SM. Salas-Salvado J. [Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients]. Greenwood J. Garcia Vieitez JJ. Grain-size effect on the structure and antiobesity activity of konjac flour. Castro Robles LJ. 2004. Viebke C. Drewa G. Dijkstra H. 129-139. 1616. Control of physical exercise of rats in a swimming basin. Cho SH. Effect of adding exercise to a diet containing glucomannan. Marzatico F. Wozniak A. In: Martindale: The Complete Drug Reference. Current therapeutic research. 6. Physiol Behav. Rakowski A. 1380-1387. Florholmen J. S190-197. Mai 2006. Marsicano LJ. 2005. Physicochemical characterization of konjac glucomannan. Effect of konjac fibre (glucomannan) on glucose and lipids. Cairella M and Marchini G. Birketvedt GS.) Pharmaceutical Press. 271-276. 1990. Xie B.ID 1555: “Glisodin” and “Prevents lactic acid build up. Ghirardi PE. Pellegrino J. 7-14. 30-34. 235-239. 7404-7407. 146. Spiering BA. 56. Ratcliffe I. 1-5. 99. J Sports Med Phys Fitness. Rutgers University. Glucomannan. 1997. Kramer K. Kraemer WJ. 2005. 1977-1986. Vingren JL. Muzutani T. Franzoni M. 29. 11. Rigon F. Brighenti F. Antonello I. Journal of the Science of Food and Agriculture. Sievenpiper JL. Simeone D. 2004. Jenkins DJ. Behforooz A. 1984. 84. 1112-1119. nonabsorbable and low glycaemic index carbohydrates. Shils M. Vuksan V. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. Vidgen E. Piggott J. 133-136. Hirota T. Ferrara A. Wu WT. Mitsuoka T. Walsh DE. Martindale: The Extra Pharmacopoeia. Encyclopedia of Human Nutrition. Klinger R. Donzelli R. Williams & Wilkins. Del Giudice E. 601-606. J Pediatr. Spadafora P. 87. Toraldo C. carbohydrate. Strain JJ. 421-425. Fujiwara S. Minerva Med. Gobber D. Staiano A. Facchin P. Shike M. 22. Axelsen M. Augustin LS. Rocca F. Curzio M. 1989. 1999. 1992. Prada A. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Del Bianco R. fiber. James WPT Garrow JS. and amino acids. 1991. Ital J Gastroenterol.16 17 18 Vido L. Vuksan V. James WPT. 320 . Tozzi A. Khanna S. London. Modern Nutrition in Health and Disease. National Academies Press. Vita PM. Yaghoubian V. Wu WT. Caspani P. fatty acids. The potential use of hydrolysed konjac glucomannan as a prebiotic. 1999. Josse R. London. Passaretti S. protein. Donne MD. Reynolds JE. Ralph A. Dietary reference intakes for energy. Pharmaceutical Press. Leiter LA. Ross A. Liu SY. Churchill Livingstone. Am J Gastroenterol. fat. cholesterol. Food Chem Toxicol. Liu YJ. 2006. Jenkins DJ. Effect of Konjac mannan on intestinal microbial metabolism in mice bearing human flora and in conventional F344 rats. Cuccurullo F. 1991. Sadler MJ. 49-56. Effect of glucomannan on obese patients: a clinical study. 135-139. 1993. 487-490. Washington DC. 2005. Marzio L. 2002. Viscous and nonviscous fibres. Padiatr Padol. 913-919. Int J Obes. Miele E. 1112-1119. Ernährung des Menschen. 289-293. 2000. IoM (Institute of Medicine). Elmadfa I and Leitzmann C. 2006. Liu YJ. Colombo E. ID 1557: “Glucomannan (Konjac)” and “Bowel / colonic function” 19 1 2 3 4 Chen HL. Edinburgh. Konjac acts as a natural laxative by increasing stool bulk and improving colonic ecology in healthy adults. 888-891. Bruce-Thompson C. Tester RF. Academic Press. 1999. 58. Caballero B. Curr Opin Lipidol. 1758-1766. Chen HL. 136. blood lipids and coronary heart disease. Pieramico O. Cheng HC. 23. A randomized controlled metabolic trial. 41-45. Dinelli M. Restelli A. 28. Owen R. Nakazato H. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. Comin U. 2007. 8. 22. 2000. 1996. Human Nutrition and Dietetics. Cheng HC. 2000. San Diego. Konjac acts as a natural laxative by increasing stool bulk and improving colonic ecology in healthy adults. Kendall CW. Nutrition. Med Hypotheses. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. McCarty MF. Mouth-to-cecum transit time in patients affected by chronic constipation: effect of glucomannan. Diabetes Care. 22. 83. Liu SY. Stuttgart. [Chronic use of glucomannan in the dietary treatment of severe obesity]. ID 1558: “Glucomannan (Konjac)” and “Prebiotic action / Bifidogenic action” 5 6 7 8 9 10 11 1 2 3 4 Al-Ghazzewi FH. Baltimore. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Nutrition. Eugen Ulmer Verlag. Olson J. Toraldo C. 1989. Encyclopedia of Human Nutrition. Uso de la fibra dietética de glucomannan en la modificación del hábito intestinal. Passaretti S. fatty acids. Med Hypotheses. 987-988. 1999. 2005. Reynolds JE. Human Nutrition and Dietetics. Dietary properties of glucomannan in intestinal function disturbances . Scarpignato C. Miele E. 2004. Calle Pardo ÁP. J Pediatr. James WPT Garrow JS. 2004. Baba S. Ernährungsmedizin und Diätetik. Baltimore. Dietary reference intakes for energy. Axelsen M. Edinburgh. Martindale: The Extra Pharmacopoeia. and amino acids. Vuksan V. 45-50. Glucomanano: propiedades y aplicaciones terapéuticas. 2006. Wissenschaftliche Verlagsgesellschaft. Stuttgart. Treatment of diabetes with glucomannan (konjac mannan). Mondelo A. fatty acids. Prada A. Bioaktive Substanzen in Lebensmitteln. 2005. Chen H. Modern Nutrition in Health and Disease. 23. 11. 2002. Castro Robles LJ. 2002. Effect of Konjac mannan on spontaneous liver tumorigenesis and fecal flora in C3H/He male mice. carbohydrate. Simeone D. 2000. Human Nutrition and Dietetics Churchill Livingstone. ID 1559: “Glucomannan (Konjac)” and “Reduction of glycemic response” 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 Doi K. Marzio L. Pieramico O. 2000. Academic Press. Urban & Fischer Bei Elsevier. Shils M. protein. Viscous and nonviscous fibres. National Academies Press.5 6 Garrow JS. Wang J. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Del Giudice E. Comin U.Expert Opinion. London. Del Bianco R. Williams & Wilkins. Cuccurullo F. 116. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. 49. Matsuura M. Berrizbeitia ML. Jenkins DJ. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. London. Augustin LS. Edinburgh. Mizutani T and Mitsuoka T. 2005. Cheng H. Washington DC. fat. Nutritional Sciences Journal. Ital J Gastroenterol. 888-891. Curzio M. Shike M. 2000. Pharmaceutical Press. 1999. 1982. Lancet. Dietary reference intakes for energy. García Vieitez JJ. Fernández Martínez N. Gröber U. Wild M. Donzelli R. 49-56. Ralph A. GEN. Hosp. Ross A. fat. Ralph A. James WPT. Hippokrates. 421-425. 30. Sierra Vega M. 2000. Watzl B and Leitzmann C. 1999.Expert Opinion. Kawara A. Díez Liébana MJ. nonabsorbable and low glycaemic index carbohydrates. 17. carbohydrate. cholesterol. Stuttgart. Ferrara A. Rocca F. 84. Effects of Konjac Glucomannan on the Defecation Characteristics and Nutritional Status in Healthy Adults. Kendall CW. 2002. Tozzi A. fiber. Marsicano LJ. Curr Opin Lipidol. Washington DC. Churchill Livingstone. 487-490. 1. Orthomolekulare Medizin. IoM (Institute of Medicine). 1991. Olson J. cholesterol. Colombo E. protein. and amino acids. 7-14. fiber. McCarty MF. 19. James WPT. Nutr. IoM (Institute of Medicine). Burghardt W. Franzoni M. San Diego. Caballero B. 41-45. Sadler MJ. Donne MD. blood lipids and coronary heart disease. National Academies Press. Cancer Lett. Evaluation of the pharmacological properties of glucomannan an its therapeutic activity in chronic constipation . Staiano A. Dinelli M. Pasaretti S. London. Strain JJ. González Canga A. Am J Gastroenterol. Mouth-to-cecum transit time in patients affected by chronic constipation: effect of glucomannan. 1995. Sahagún AM. 321 . 58. 136. 1979. 1996. Kasper H. Liu Y. James WPT. 27-32. Kendall CW. Vuksan V. Bruce-Thompson C. Food Chem Toxicol. Sievenpiper JL. 11. IoM (Institute of Medicine). London. 11. fat. 2000. Jenkins DJ. 1999. 2002. Shils M. 2000. Spadafora P. Reynolds JE. Leiter LA. 1999. Glucosamine and Arthritis update. Reynolds JE. Ross A. Caballero B. Garrow JS.4 Jenkins DJ. blood lipids and coronary heart disease. Modern Nutrition in Health and Disease. 2000. San Diego. 58. James WPT. Jenkins DJ. Leiter LA. 22. Vuksan V. 4. 1999. 585-589. Josse R. Spadafora P. Academic Press. Ralph A. Sievenpiper JL. protein. 23. London. A randomized controlled metabolic trial. 487-490. Pharmaceutical Press. Owen R. Diabetes Care. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. nonabsorbable and low glycaemic index carbohydrates. 58. Yaghoubian V. nonabsorbable and low glycaemic index carbohydrates. Jenkins DJ. Sadler MJ. Dietary reference intakes for energy. Leiter LA. Diabetes Care. Baltimore. Josse R. Williams & Wilkins. McCarty MF. Vuksan V. Olson J. blood lipids and coronary heart disease. Augustin LS. Axelsen M. 193-195. Vidgen E. Bandolier. http://www. Augustin LS. 1984. 1996. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. London. Olson J. Encyclopedia of Human Nutrition. McCarty MF. Altern Med Rev. 187-201.ac. Curr Opin Lipidol. and amino acids. Martindale: The Extra Pharmacopoeia. Brighenti F. Curr Opin Lipidol. safety considerations and efficacy. Human Nutrition and Dietetics.uk/bandolier/band85/b85-2. 1999. side effects. Diabetes Care.ox. National Academies Press. Med Hypotheses. Martindale: The Extra Pharmacopoeia. Edinburgh. 487-490. Viscous and nonviscous fibres. Effect of glucomannan on obese patients: a clinical study. Brighenti F. 1995. Int J Obes. fatty acids. Bruce-Thompson C. 1996. Novokmet R. Shike M. Walsh DE. Williams & Wilkins. Xu Z. Behforooz A. Vuksan V. 49-56. Med Hypotheses. 8. 2005. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. Axelsen M. Anderson JW. 289-293. 913-919. Glucosamine sulphate. A randomized controlled metabolic trial. ID 1560: “Glucomannan (Konjac)” and “Cholesterol level” 5 6 7 8 9 1 2 3 4 Arvill A and Bodin L. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. 61. 43. Brighenti F. Borzelleca JF. Churchill Livingstone. 2000. 913-919. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Vuksan V. Baltimore.medicine. 2005. Shike M. Swilley JA. Josse RG. Vidgen E. Washington DC. cholesterol. Modern Nutrition in Health and Disease. Glucosamine effects in humans: a review of effects on glucose metabolism. Am J Clin Nutr. 1999. Pharmaceutical Press. Kendall CW. fiber. 9-14. 1999. carbohydrate. Shils M. Sievenpiper JL. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Nicolosi RJ. Viscous and nonviscous fibres. Vidgen E. 2002. Strain JJ. Owen R. 49-56. 322 . ID 1561: “Glucosamine” and “Joint health” 5 6 7 8 9 10 1 2 3 4 Dona Summary of Product Characteristic. Spadafora P. 22. Owen R. Jenkins DJ.html. Drugs Aging. Crit Rev Food Sci Nutr. Bruyere O and Reginster JY. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Schwab W. Weisman MH. 1960. 11. Braham R. EMEA/405628/2006. 37. Glucosamine. 1998. placebo-controlled study evaluating the effect of glucosamine sulfate. Wiley-VCH Fajardo M and Di Cesare PE. Schnitzer TJ. 2004. Innes JF. Dawson B. Rheumatic Disease Clinics of North America. Roseman S. Goggs R. Nutrition in Clinical Practice. Olejarova M. RÖMPP Lexikon Lebensmittelchemie. Northrop AJ. Deroisy R. Moreland LW. Reginster JY. Brigden CV. Nutraceuticals as therapeutic agents in osteoarthritis. Glucosamine sulfate for osteoarthritis. Journal of manipulative and physiological therapeutics. Henrotin Y. Cush JJ. Harris CL. Results from a 3-year prospective. 22. Deal CL and Moskowitz RW. Bingham CO. 8. 2003. 1999. Furst DE. Efficacy of a combination of FCHG49 glucosamine hydrochloride. Tanko LB.. Goodman C. Jr. 1-5. Equine Vet J Suppl. Journal of Biological Chemistry. Vaughan-Thomas A. 1998. Reginster JY. 36-42. 5 – 19. 68. Forsyth RK. Carter SD. 235. Clegg PD. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Reginster JY. Menopause. The effect of glucosamine supplementation on people experiencing regular knee pain. Giacovelli G. 795-808. Nutraceutical therapies for degenerative joint diseases: a critical review. chondroitin sulfate. 709-715. Bruyere O. 2004. Carbohydrates in chemistry and biology. Bruyere O. 2000. TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage. Ghosh S. Disease-modifying therapies for osteoarthritis: current status. Opinion of the Committee for Medcinal Products for Human Use (CHMP) following an Article 29(4)1 referral for Glucomed and associated names International NonProprietary Name (INN): glucosamine hydrochloride. Bruyere O. Rovati LC. Bradley JD. 3rd. Br J Sports Med. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Brandt KD. 1997. 138-143. Caron JP. Gottlieb MS. 379-395. EMEA (European Medicins Agency). 2005. 11. 45. Drugs Aging. Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses. Bondy CA. Das A. Meyer AH. Molitor JA. 354. Schumacher HR. Herbal and Related Remedies. 622-625. 145-164.5 6 7 Bartels CL and Miller SJ. and Hammad TA. Jackson CG. Hart GW. Chondroitin Sulfate. 580587. and Collagen Hydrolysate. Blumenthal HJ. Yocum DE. Ethgen O. 2006. 20. Ernst B. Am J Vet Res. O'Dell JR. 573-580. Williams HJ. 2000. Stuttgart. Osteoarthritis Cartilage. 343-350. 2005. and the two in combination for painful knee osteoarthritis. Shi H. Honore A. 141-161. Wolfe F. Reda DJ. Shakibaei M. The Role of Glucosamine. Henrotin YE. Davidson E. Schreier P. Collette J. Sawitzke AD. 45-49. Lane NE. Rovati LC. Da Camara CC. Klein MA. Enzymatic synthesis of glucosamine 6-phosphate. Seidel L. Clin Exp Rheumatol. Sinaÿ P. discussion 49. 2003. 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 323 . Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Mobasheri A. Eisenbrand G. 400. Glucosamine metabolism V. Thieme. N Engl J Med. 25. Clegg DO. 2006. 2007. 13. Giacovelli G. The Annals of pharmacotherapy. 32. Rovati LC. Chan PS. Christgau S. Oddis CV. Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment. 2006. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Deroisy R. 2006. Jr. Pavelka K. Gatterova J. 22. 1265-1273. Orth MW. Hooper MM. 2007. 24. Moskowitz RW. 44. 78-83. 2005. Herrero-Beaumont G. Felson DT. Magdalou J. Rovarti LC.24 Gouze JN. 20. N Engl J Med. Osteoarthritis Cartilage. Kelly GS. J Rheumatol. Hahn A. What a difference a year makes: reflections on the ACR recommendations for the medical management of osteoarthritis. The neglect of glucosamine as a treatment for osteoarthritis: a personal perspective. Glucosamine and chondroitin sulfate. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Ouzzine M. Blanco FJ. Laffon A. McColl GJ. Prävention. Jha AK. Stuttgart. Wissenschaftliche Verlagsgesellschaft. 1994. 9. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized. Setnikar I. Med J Aust. Li Z. 26. 2007. 324 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 . Araujo D. Unum in Die Efficacy (GUIDE) trial. Benito P. McAlindon TE. Muller-Fassbender H. Hahn A. 1999. Chu Q. Martin-Mola E. Marenco JL. Risk assessment for glucosamine and chondroitin sulfate. placebo-controlled study using acetaminophen as a side comparator. Hart RC.nih. double-blind. Bach GI. J Arthroplasty. 44. glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. 42. Current Rheumatology Reports. Wein C. 18. Trabado MC. 14-21. McMillan R. 1998. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. Altern Med Rev. LaValley MP. 2000. 1-3. 1469-1475. Branco J. 47. Kochevar D. 52. Paulino J. McAlindon TE. 3. Netter P. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms vs placebo and acetaminophen: results from the Glucosamine. 555-567. 265-274. 2423-2430. Hulse DA. 2006. JAMA. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. Hathcock JN and Shao A. 2006. 4. McQuay HJ and Moore RA. Houpt JB. Interleukin-1β down-regulates the expression of glucuronosyltransferase I. http://vsearch. Porto A. Paget-Dellio SD. Medical hypotheses. Stuttgart. Orav EJ. 99-115. Ströhle A. 1041-1060. 353. Jackson CGR. Hochberg MC. 2005. 20. Glucosamine: a review of its use in the management of osteoarthritis. Blanco FJ. 2003. 2007. Wolters M. Bordji K.gov/vivisimo/cgi-bin/query-meta?inputform=simple&v%3Asources=medlineplusbundle&v%3Aproject=medlineplus&query=glucosamine+2006+joints. Glucosamine. 5-9. 1997. Nutraceuticals: do they work and when should we use them? Best Pract Res Clin Rheumatol. Benito P. 2003. Arthritis Rheum. Gulberti S. Martin-Mola E.nlm. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH. S108-111. Bandolier. Nutritional ergogenic aids. 2001. Arthritis Rheum. Ernährung-Physiologische Grundlagen. McCarty MF. Del Carmen Trabado M. Fournel-Gigleux S. Epstein AM. Glucosamine and chondroitin sulfate are effective in the management of osteoarthritis. Figueroa M. 2001. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Medline Plus. Arthritis & Rheumatism.the Hospital Quality Alliance program. 2001. a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effects in rat chondrocytes. 283. 2001. Care in US hospitals . Regulatory Toxicology and Pharmacology. Matheson AJ and Perry CM. Pharmacological therapies for the treatment of osteoarthritis. Hungerford DS and Jones LC. 75-80. 27-39. 115-127. Osteoarthritis cartilage. 2004. 1994. Herrero-Beaumont G. Drugs Aging. 323-327. 2006. Roman JA. 3. 460. Glucosamine and arthritis. Johnson KA. Ivorra JA. Haase W. 56. Effects of an orally administered mixture of chondroitin sulfate. Gulin JP. 175 Suppl. 473-478. Terlain B. 2005.securesites. Lejeune E. 9. 64. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Wells G. Am Med Assoc. Setnikar I. 1998. Usha PR and Naidu MU. Glucosamine for Osteoarthritis. Recent advances in glucosamine and chondroitin supplementation. Albright A. Clin Drug Investig. 39. 43. Roseman S.cgi. CD002946. placebo-controlled clinical trial. 48. Pharmindex alkamazási előirat. Osteoarthritis: an overview of the disease and its treatment strategies. Parazzini F. 1109-1113. The effect of nutritional supplements on osteoarthritis. Cicuttini FM. Gossett C. Pavelka K. Giacovelli G. 2113-2123. http://medletbest. Pharmaceutical Press Electronic version Qiu G. 1993. 163. München. [Evidence-based evaluation of study results of symptomatic glucosamine therapy]. Rovati L. 2001. Double-Blind. Caporali R. Potters Ltd. doubleblinded. Hochberg MC. Z Rheumatol. 275-296. 1-10. Arch Intern Med. Placebo-Controlled. Olejarova M. 41527-41542. 1632-1634. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised. Houpt J.45 46 47 Nowlan C and Wetmore S. Randomized. 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 325 . 2005. Arch Intern Med. Towheed TE. Arzneimittelforschung. Cimmino MA. Giacovelli G. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Prentice LF. 17. Owens S. Richy F. 2007. Sarzi-Puttini P. 2005. Wagner P. Channark P. Atzeni F. Kittikulsuth W. 2002. Robinson V. The Lancet. Reginster JY. Suthisisang C. J Knee Surg. Treating osteoarthritis pain. Reiter S. 51. Arzneimittel-Forschung. Randomised. Wluka AE. Zaninelli A. Milch und Milchprodukte in der Ernährung des Menschen. Zanolo G. Vangsness CT. 2003. 49. Setnikar I. Placebo-Controlled Study of Oral Glucosamine. Parallel. 251-256. Henrotin Y. Rovati LC. 3. Machacek S. 2003. 2003. Ann Pharmacother. BMC Complement Altern Med. Anastassiades TP. Wang Y. Glucosamine in osteoarthritis and gastrointestinal disorders: an exemplar of the need for a paradigm shift. Altern Med Rev. Shea B. Dacre JE. Pharmacokinetics of glucosamine in man. 1080-1087. Jr. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Reflections on glycobiology. 2004. 2007. 2. 2004..com/scripts/search. Palumbo R. Reginster JY. Ethgen O. Methylsulfonylmethane and their Combination in Osteoarthritis. Bruyere O. 1982. Harris MD. 1998. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report. Maxwell L. Vitetta L. Scarpa R. Gatterova J. Deroisy R. Scroggie DA. Doubleblind Study. 1587-1590. Canali S. 1514-1522. Semin Arthritis Rheum. Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis A 3-Year. 469-474. Wuisman PI. 35. Can Fam Physician. van Blitterswijk WJ. Medical hypotheses. Glucosamine therapy for treating osteoarthritis. Gao S. 456-466. Short report: ibuprofen versus glucosamine sulfate. Volkswirtschaftlicher Verlag. van de Nes JC. Cucherat M. Poolsup N. Rovati LC. randomized clinical trial. J Biol Chem. 276. 162. 24. 163. Lee RL. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled. 353363. 2005. 2004. 185-193. Russell AL. Bruyere O. 2003. The Medical Letter on Drugs and Therapeutics. Cochrane Database Syst Rev. Henrotin Y. 357. Renner E. 2001. Giacovelli G. Canesi B. 347-349. Dietary Supplements: Glucosamine.. Lopez ST. Weisman MH. Nederlands tijdschrift voor geneeskunde. Cush JJ. Arthritis Rheum. Pavelka K. Ethgen O. Hagers Handbuch der Drogen und Arzneistoffe: Mehrplatzversion/Windows/Update Springer Medizin Verlag. 105. confirmatory trial. nonmineral dietary supplements and concurrent use of medications. Bingham CO. Olejarova M. 2006. 1999. Paget-Dellio SD. 43. Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis A 3-Year. 2006. J Rheumatol. Richy F. Henrotin Y.. Clegg DO. Wein C. 162. Reichling J. Wein C. 187-201. randomized. Cibere J. Klein MA. Moreland LW. 146. Lee RL. Giacovelli G. Reginster JY. 2423-2430. 11. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. 2004. Arthritis Rheum. 2001. S400. N Engl J Med. Paul I. 3rd. Schumacher HR. 1819. Henrotin Y. S384. HagerROM 2006. independent. 1999. Journal of the American Dietetic Association. Gatterova J. Sawitzke AD. Brandt KD. Glucosamine. Arch Intern Med. Keller K. 2005. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH. Ebel S. and the two in combination for painful knee osteoarthritis. placebo-controlled clinical trial. 795-808. Deroisy R. Olejarova M. Heidelberg. Reda DJ. 357. Williams HJ. Paget-Dellio SD. Hahn A. Hong P. Giacovelli G. prospective trial. safety considerations and efficacy. doubleblind. Honore A. Singer J. Doubleblind Study. Wolfe F. Molitor JA. Borzelleca JF. Schulz V. Nicolosi RJ. Esdaile JM. Reginster JY. Houpt JB. Cucherat M. Glucosamine effects in humans: a review of effects on glucose metabolism. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. Bruyere O. Lane NE. Blaschek W. J Rheumatol. Lejeune E. O'Dell JR. Rovati LC. placebo-controlled. 42. Jr. [Glucosamine and chondroitin sulfate as a possible treatment for osteoarthritis]. Henrotin YE. Hötje H. Schnitzer TJ. 43. Harris CL. Randomized. Deroisy R. placebo-controlled study evaluating the effect of glucosamine sulfate. Rovati LC. 1999. Pareo-Tubbeh SL. placebo-controlled. 2003. chondroitin sulfate. Garry PJ. 2113-2123. Ethgen O. 354. Arthritis Rheum. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Bartlott W. 51. Am Med Assoc. Reginster JY. Reginster JY. Furst DE. Rovati LC. Stuttgart. 163. Waters DL. 2005. Oddis CV. 251-256. 2006. ID 1563: “Glucosamine (Glucosamine HCl or Glucosamine sulphate)” and “Joint health” 2 3 4 5 6 7 8 9 1 2 Anderson JW. Rovati LC. Canvin J. Giacovelli G. Bruyere O. Gatterova J. Jackson CG. 26. Dacre JE. Henrotin Y. 738-745. Pope J. Moskowitz RW. Seidel L. 54-63. side effects. 1514-1522. Hackenthal E. Giacovelli G. Kopec JA. Grant E. 2003. Pavelka K. double-blind. The Lancet. 26. 1-5. Holzgrabe U. especially knees” 1 Bruyere O. Results from a 3-year prospective. Osteoarthritis Cartilage. 3 4 5 326 . McMillan R. randomized. placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Glucosamine sulfate significantly reduces progression of knee osteoarthritis over 3 years: a large. 2423-2430. 2002. Correlation between radiographic severity of knee osteoarthritis and future disease progression. 2002. Gossett C. Giacoveli G. Placebo-Controlled. Machacek S.66 Wold RS. Houpt JB. Bijlsma JW. Randomized. Yocum DE. Glucosamine sulfate decreases progression of knee osteoarthritis in a long-term. 2000. Yau CL. Food Chem Toxicol. Robinson DB. Lee RL. Hooper MM. Bradley JD. Thorne A. Baumgartner RN. Machacek S. McMillan R. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised. ID 1562: “Glucosamine” and “Joint health. Butler LM. Increasing trends in elderly persons' use of nonvitamin. Shi H. Bingham CO. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Jr. 2001. 2007. 327 2 3 4 5 . Correlation between radiographic severity of knee osteoarthritis and future disease progression. 11. Seidel L. placebo-controlled clinical trial. Osteoarthritis Cartilage. Olejarova M. Chan PS. The Lancet. Dacre JE. Giacovelli G. 162. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Hooper MM. Menopause. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Abadie E. 2005. Glucosamine. 1-5. Devogelaer JP. chondroitin sulfate. 25. Reginster JY. N Engl J Med. TopMedizin. 13. Moreland LW. Robinson V. Kreutz G. 709-715. Laslop A. Hulse DA. Drugs Aging. Bouvenot G. Bradley JD. Harris CL. placebo-controlled study evaluating the effect of glucosamine sulfate. Doubleblind Study. CD002946. 11. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Giacovelli G. 68. 343-350. 2002. Sawitzke AD. 2002. Lemmel EM. Hart RC. Kahan A. 1999. 357. Olejarova M. Osteoarthritis Cartilage. Osteoarthritis Cartilage. Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis A 3-Year. Reginster JY. Henrotin YE. Giacovelli G. 251-256. Lane NE. Reginster JY. Lee RL.6 7 Parcell S. 24. Efficacy of a combination of FCHG49 glucosamine hydrochloride. and Collagen Hydrolysate. The Role of Glucosamine. 379-395. Randomized. Pavelka K. Bruyere O. Machacek S. 9. 573-580. Effects of an orally administered mixture of chondroitin sulfate. Chu Q. ID 1565: “Glucosamine hydrochloride” and “Joint Health” 2 3 4 5 1 Altman RD. Lejeune E. Am Med Assoc. Houpt J. 13-19. Cochrane Database Syst Rev. Gatterova J. Giacovelli G. 2006. 8. Rovati LC. Branco J. 795-808. Reginster JY. Honore A. Placebo-Controlled. Van De Putte L. 22-44. Henrotin Y. Anastassiades TP. Nutraceuticals as Therapeutic Agents in Osteoarthritis. Pavelka K. Moskowitz RW. 2001. 138-143. Sulfur in human nutrition and applications in medicine. Weisman MH. 2000. Schnitzer TJ. Reda DJ. TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. 2003. Vanhaelst L. Rovati LC. 2004. Am J Vet Res. 26. Oddis CV. Shea B. Gatterova J. 2005. Deroisy R. Rovati LC. Klein MA. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised. Schumacher HR. Bruyere O. Osteoarthritis Cartilage. 11. Furst DE. 7. Kochevar D. 2001. Rovati LC. Reginster JY. Bruyere O. 2004. Chondroitin Sulfate. and the two in combination for painful knee osteoarthritis. Avouac B. Gatterova J. Maxwell L. and Hammad TA. Pavelka K. Brandt KD. Herrero-Beaumont G. Wolfe F. Deal CL and Moskowitz RW. Rovati LC. Molitor JA. Gossett C. Deroisy R. Shi H. 2113-2123. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Deroisy R. Calvo G. Clegg DO. O'Dell JR. Ethgen O. Glucosamine therapy for treating osteoarthritis. Wells G. 14-21. Towheed TE. Bruyere O and Reginster JY. Altern Med Rev. Pavelka K. 354. Rheumatic Disease Clinics of North America. Cush JJ. Jackson CG. Olejarova M. Williams HJ. Das A. ID 1564: “Glucosamine (Glucosamine HCl or Glucosamine sulphate) and Chondroitin sulphate” and “Joint health” 8 9 10 1 Bruyere O. Hochberg MC. 138-143. Giacovelli G. glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Orth MW. Menkes CJ. Results from a 3-year prospective. Bruyere O. Dreiser RL. 2007. Caron JP. Menopause. Yocum DE. Johnson KA. placebo-controlled study using acetaminophen as a side comparator. Branco J. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Kaklamanis PM. Tanko LB. Hawker G. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. 56. 36-42. Mazieres B. Gatterova J. 39. Serni U. Mazieres B. Gunther KP. Paulino J. O'Dell JR. 22. Ann Rheum Dis. 2002. 2007. Pendleton A. Giacovelli G. Cooper C. Suthisisang C. Weseloh G. 47. du Berger R. Alvarez-Soria MA. Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis A 3-Year. Bijlsma JW. Mola EM. Herrero-Beaumont G. Collette J. Brigden CV. Clin Exp Rheumatol. Wagner P. 2000. Forsyth RK. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 328 . Felson DT. Vangsness CT. 11. Williams HJ. Jackson CG. 2007. Lequesne M. Placebo-Controlled. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. 555-567. 1080-1087. The reverse glucosamine sulfate pathway: application in knee osteoarthritis. Blanco FJ. Marenco JL. Kaklamanis P. Pendleton A. Pavelka K. Doubleblind Study. Lequesne M. Dieppe P. Badley ES. 49. Martin-Mola E. Am Med Assoc. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Swoboda B. Olejarova M. Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses. Pavelka K. Gulin JP. Glucosamine. Rheumatology and musculoskeletal medicine. Zimmerman-Gorska I. 8. Giacovelli G. JAMA. Cluzeau F. 354. Wolfe F. Giacovelli G.. Herrero-Beaumont G. Equine Vet J Suppl. Brandt KD. Shi H. Benito P. McAlindon TE. Wilkins A. Dougados M. 2007. Pavelka K. 622-625. Gunther K. Ann Pharmacother. 2006. Arden NK. Jr. Bannwarth B. Del Carmen Trabado M. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Leeb B. 215-225. Doherty M. Gatterova J. Bijlsma JW. Olejarova M. Hathcock JN and Shao A. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized. Olejarova M. Figueroa M. Doherty M. Regulatory Toxicology and Pharmacology. Schumacher HR. Arthritis Rheum. Molitor JA.6 Christgau S. Randomized. double-blind. Rovati LC. 59. Laffon A. Rovati LC. 2006. Cush JJ. Relief in mild-tomoderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. J Knee Surg. 1145-1155. Punzi L. 2004. Poolsup N. 78-83. Glucosamine sulfate prevents total joint replacement in the long-term follow-up of knee osteoarthritis patients. Hauselmann H. chondroitin sulfate. Expert Opin Pharmacother. Kittikulsuth W. 795-808. Schnitzer TJ. Lane NE. 2004. Castaneda S. Ivorra JA. Machacek S. Largo R. 3rd. Oddis CV. 730-737. Furst DE. Bradley JD. Harris CL. 2000. Northrop AJ. Risk assessment for glucosamine and chondroitin sulfate. Davenport G. Swoboda B. Bruyere O. 54. and the two in combination for painful knee osteoarthritis. 2004. 2004. Lohmander S. 17. Arden N. Klein MA. Reginster JY. 2004 Glucosamine is associated with improved osteoarthritis outcomes. Arthritis Rheum. 2003. Pavelka K. Sawitzke AD. 457-464. Bingham CO.. Yocum DE. Arth Rheum 50. Weisman MH. Channark P. 1469-1475. Osteoarthritis and Cartilage. 2113-2123. Verbruggen AA. Hooper MM. 2005. Rovati LC. Abrahamowicz M. Deroisy R. Moskowitz RW. Recent advances in glucosamine and chondroitin supplementation. Verbruggen G. Herrero-Beaumont G. 2003. Rovati LC. Porto A. Leeb B. Jordan KM. 185-193. Jr. Lohmander S. Martin-Mola E. 62. Pavelka K. Moreland LW. Serni U. Henrotin Y. Owens S. Bruyere O. Ann Rheum Dis. Reda DJ. LaValley MP. 162. 936-944. Hauselmann HJ. N Engl J Med. Clegg DO. 283. Herrero-Beaumont G. Zimmermann-Gorska I. Br J Gen Pract. Dougados M. Bannwarth B. Rovati LC. Araujo D. Reginster JY. Dieppe PA. BMC Complement Altern Med. Puchstein C. Satellite Meeting on the Metabolic Relationship Between Glutamine Glutamate. glutamine and niacin on memory. Reginster JY. L-Glutamin. 2003. Wissenschaftliche Verlagsgesellschaft. Drent ML. 1994. 2001. Stuttgart. 2004. Boca Raton. Thomson Healthcare. 38-44. Assessment of joint space narrowing with conventional standing antero-posterior radiographs: relief in mild-to-moderate pain is not a confounder in recent osteoarthritis structure-modifying drug trials. Ethgen O. Glutamine and arginine: immunonutrients for improved health. Gossett C. 2003. Anastassiades TP. Georg Thieme Verlag. Möller R. 2004. A14-18. Gröber U. van de Nes JC. New York. Lee RL. Stählin HB. Double-Blind. 157-168. Schulz V. Pölert W. 2002. 63. Wildman REC. Groß E. Hendler S and Rorvik D. 31-36. 287-292. Rovati LC. 2000. Blonde-Cynober F. 3. 32. Falcao de Arruda IS and de Aguilar-Nascimento JE. Stuttgart. 3 4 5 6 7 8 9 10 11 329 . Robinson V. Pratt VC. 106. Ebel S. 353363. Deroisy R. Keller K. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised. Höltje HD. Hertz L. Multizentrische klinische Doppelblindstudie zum Nachweis der cerebralen Leisungssteigerung durch ein oral aufgenommenes Glutaminsäure-Präparat. Fraikin G. Richy F. Bruyere O. Alan Liss. glutamate. Reichling J. Placebo-Controlled Study of Oral Glucosamine. Henrotin Y. Stuttgart. Wells G. 2006. CD002946. Kluthe R. Holzgrabe U. placebo-controlled clinical trial. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report. Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients. Henrotin Y. 14 Suppl A. In: Handbook of nutraceuticals and functional foods. Reginster JY. Lejeune E. Towheed TE. 2. 357. Elmadfa I and Leitzmann C. 269-275. 19. Hackenthal E. 2005. Glucosamine therapy for treating osteoarthritis. Glutamine. 2003. Hoffmann J. Shea B. Rotblatt M and Ziment I. In: Evidence-based herbal medicine. Current concepts in the therapeutic management of osteoarthritis with glucosamine. Hagers Handbuch der Drogen und Arzneistoffe.22 Reginster JY. 6. and GABA in the central nervous system. Med Sci Sports Exerc. 2001. Osteoarthritis Cartilage.: Einzelplatzversion/Windows/Up-Date Biesalski HK. Arch Intern Med. GH and IGF-I secretion in middle-aged and elderly subjects. Bruyere O. Blaschek W. Kasper H. CRC Press. Nutr Neurosci. PDR for Nutritional Supplements. 9. Parallel. Clin Drug Investig. ID 1570: “Glutamine” and “Mental health” 23 24 25 26 27 28 29 30 1 2 Arwert LI. Eugen Ulmer Verlag. Hanley & Belfus. Randomised. 2005. 2003. Maxwell L. van Blitterswijk WJ. Aussel C. 1993. In: Hager ROM 2004. The Lancet. Methylsulfonylmethane and their Combination in Osteoarthritis. Field CJ. Pavelka K. 163. Jatros Neurologie. 24. 2004. Use of ornithine alpha-ketoglutarate in clinical nutrition of elderly patients. Johnson I. Hochberg MC. Osteoarthritis Cartilage 2. 251-256. Giacovelli G. Houpt J. 73-75. Cynober L. Wuisman PI. Giacovelli G. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Heil BM. Ernährung des Menschen. Cucherat M. S377-388. 2004. Barthlott W. Bruyere O. Usha PR and Naidu MU. Nutrition. Orthomolekulare Medizin. 1514-1522. Bull Hosp Jt Dis. Henrotin Y. Fürst P. Effects of an oral mixture containing glycine. Reginster JY. Clin Sci (Lond). 1983. Ernährungsmedizin. Cochrane Database Syst Rev. Rovati LC. Dacre JE. 2004. 2001. Deijen JB. ). Glutamine supplementation in serious illness: a systematic review of the evidence. McEntee WJ and Crook TH. Dörrzapf A. Chappell D. Lee DC. Crit Care Med. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs.de/arthrose-arthritis/arthrose/arthrose. 2003. 30. Double-blind. 2006. Song EK. 32. Park HB. Complementary Therapies in Medicine. Gay PE. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). La Gazette Médicale.). 37. Dev Med Child Neurol. Couch RA. Vet Ther. Perna canaliculus in the treatment of arthritis. Psychopharmacology (Berl). 92. easy fatigue and maladroitness: preliminary trial of monosodium glutamate in adults. Clinical efficacy and safety of Lyprinol. Gibson SLM and Gibson RG. Dissertation Ludwig-Maximilians-Universität. Reichling J. Stuttgart. Wissenschaftliche Verlagsgesellschaft mbH. Hackenthal E. 1998. 1992. Stuttgart. Hahn A. memory. HagerROM 2006. Su X. Hötje H. ID 1571: “Green Lipped Mussel Extract. Billard H. Schulz V. Lexikon der Lebensmittel und der Lebensmittelchemie. 2005.A freeze dried powder extract of New Zealand Green Lipped Mussel Perna canaliculus” and “Joint health” 1 2 http://arthrose-und-arthritis. The treatment of arthritis with a lipid extract of Perna canaliculus: a randomized trial. 1980. 391-401. Miller TE. 93. Lynn R. Madsen JA. 6. Physiol Bohemoslov. Glutamine. L'extrait de Perna canaliculus. 2006. Vrba R.12 13 14 15 16 17 18 Kripke B. In: Martindale: The Extra Pharmacopoeia. 1993. Conway V. Holzgrabe U. Novak F. Keller K. 1956. München. Bui LM and Bierer TL. Seong SC. Ebel S. 2007. 24. 212-216. Familial learning disability. 1785-1786. 111. 745-751. 803-806.12. Jung YB. Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. and the aging brain. 467-478 3 4 5 6 7 8 9 10 11 12 13 330 . Glutamine. Pharmaceutical Press. Audeval B and Bouchacourt P. pp. Heidelberg. Kleintierpraxis. 35. 1986. Behandlung deformierter Arthropathien beim Diensthund mit einem neuen Glykosaminoglykanpräparat. 397-407. 2000. 1982. London. Role of glutamin in restorative processes of the brain. [Studies on metabolic function of the brain and on its relation to physical stress. 224. Nahrungsergänzungsmittel. 2001 Die Wirksamkeit des Extraktes der ―Grünlippigen Muschel‖ (Perna canaliculus) bei Pferden mit degenerativen Gelenkerkrankungen. Heyland DK. Ormrod DJ. 2003. Täufel A. placebo-controlled study of the mussel Perna canaliculus (New Zealand Green-Lipped Mussel) in gonarthritis (arthritis of the knee). Hagers Handbuch der Drogen und Arzneistoffe: Mehrplatzversion/Windows/Update Springer Medizin Verlag.]. Drover JW. Son JH. Practitioner. Gazette médicale de France(1969). 2022-2029. 1982. Byun KY. a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. In: Martindale: The Extra Pharmacopoeia. 95. 1985. Tunger L. Ternes W. Wissenschaftliche Verlagsgesellschaft. Watkins WB. 955-960. 4. Korthäuer W and de la Torre J. 2007. 122-126. Blaschek W. 272-278. 257-268. Bartlott W. Reynolds JE. Pharmaceutical Press.gelenkverschleiss. 97-101. Sweetman SC (eds. Gibson SL. Halpern GM. Glutamate: its role in learning. Cho SH. 2002. Martindale W. Eur Ann Allergy Clin Immunol. V. la moule aux orles verts de Nouvelle-Zélande en rhumatologie. 111-115.html. NZ Med J. London. Avenell A. Gibson RG. Sweetman SC (eds. 5. Allerg Immunol (Paris). Weisser PA. Dacre JE. 277. Clin Exp Rheumatol. 2000. 357. placebo-controlled clinical trial. Pollard B. 39. 117-128. 2001. 30. 2001. Scott JE. ID 1575: “5-HTP” and “Mood enhancement” 1 Nardini M. 54. 2004. The anti-inflammatory activity of Perna canaliculus (NZ green lipped mussel). Effects of hyaluronic acid on cartilage degradation. 2004. Wang CT. TopMedizin. 6. 6. Hyaluronan fragments: an information-carrying system? Horm Metab Res. a double-blind study. Henrotin Y. Knudson CB and Knudson W. Moskowitz RW. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. 2. 75-82. 2397-2404. 466-471. 2000. Lee RL. Reginster JY. NZ Med J. Gossett C. 67-68. 4589-4592. Rovati LC. 2007. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect. 2004. Guilford WG. Semin Arthritis Rheum. Curr Opin Rheumatol. Ann Rheum Dis. Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. Treatment of depression with L-5hydroxytryptophan combined with chlorimipramine. 427-435. 19-24. 3. Current Pharmaceutical Analysis. 11. 35. Clin Orthop Relat Res. Lyprinol: anti-inflammatory and uterine-relaxant activities in rats. Int J Clin Pharmacol Res. Role of hyaluronic acid in joint lubrication. Curran N. 1999. Malavaki CJ. Hyaluronic acid supplementation. 2003. Bourguignon LY. Giacovelli G. 2006. 318-326. Turley EA. 187-193. 86-A. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells. Noble PW. Swann DA. Borghesi R. 251-256. FASEB J. Deroisy R. Uebelhart D and Williams JM. Chang CJ. Hyaluronan. 1983. Lin YT. 538-545. 32. 33. Lejeune E. A meta-analysis of randomized controlled trials. Iannuccelli M. 19-25. Dougados M. Allerg Immunol (Paris). Karamanos NK. Ankenbauer-Perkins KL. Shiels IA and Whitehouse MW. 1974. 2639-2645. 1980. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised. Hou SM. ID 1572: “Hyaluronic Acid” and “Joint Health” 16 17 18 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Bucci LR and Turpin AA. Curr Rheumatol Rep. J Rheumatol Suppl. The Lancet. 12. Hedderley D. 1992. Radin EL. 239-250. Rossler A and Hinghofer-Szalkay H. 2000. with special reference to a model for dysmenorrhoea. 1992. 92. Theocharis AD. FASEB J. Pelletier JP and Martel-Pelletier J. 10. 54. 2002. Laurent TC and Fraser JR. cartilage and components of synovial fluid. Signaling properties of hyaluronan receptors.14 15 Miller TE and Ormrod D. 1994. Bruyere O. Hyaluronan Determination: Biological Significance Analytical Tools. Battistini N. in vitro and in the tissues. 3. De Stefano R. Ghosh P. Will the Real Hyaluronan Please Stand Up? Journal of Applied Nutrition. 331 . Lin J. New Zealand Veterinary Journal. 279-283. Nazimiec M. Hyaluronan and CD44: modulators of chondrocyte metabolism. J Biol Chem. 1993. Supramolecular organization of extracellular matrix glycosaminoglycans. Lamari FN. Kanakis I. Lewinnek G. 114-118. J Bone Joint Surg Am. S152-162. body composition and strength. 1981. Lamboley CR. Effects of beta-hydroxy-betamethylbutyrate on muscle damage after a prolonged run. 23. Knuttgen HG and Komi PV. Ltd. Med Sci Sports Exerc. Godard MP. 89. Ostaszewski P. Kreider RB. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. Injury to skeletal muscle fibers during contractions: conditions of occurrence and prevention. 1993. 17. Calanchini B. J Plant Physiol. Rathmacher J. Panton L. 2000. Effects of calcium beta-hydroxy-betamethylbutyrate (HMB) supplementation during resistance-training on markers of catabolism. Effects of beta-hydroxy-beta-methylbutyrate on aerobicperformance components and body composition in college students. Trappe SW. 1990. Åstrand PO and Rodahl K. 1994. 558-566. 53-81. In: Strength and power in sport: Olympic Encyclopedia of sports medicine. Vopr Pitan. Faidley TD. Almada AL. Komi PV (ed. 16. 20. 1991. Tryptophan and 5-hydroxytryptophan for depression. New York. The role of protein and amino acids in sustaining and enhancing performance. Schulze KE. 24. Washington DC. Chichester. Jowko E. Effect of feeding ß-hydroxy-ßmethylbutyrate (HMB) on leucine and fat metabolism in mammary gland. 19-22. 2116-2119. 472-479. 739-743. 17.) Wiley-Blackwell. Carrithers JA. Hamilton JG. Lodge JK. IoM (Institute of Medicine). 503-509. 32. CD003198. McGraw-Hill Inc. Rathmacher JA. Psychopathology. part II: effects on hematology. 790-796. Vitamin E bioavailability in humans. Lodish H. Biochim Biophys Acta.). Gallagher PM. 1999.. New York. Zieniewicz A. 911-921. Wilson M. 1993. Efremov VV and Sakaeva EA. 1957. 1340-1344. hepatic and renal function. Faulkner JA. Chater 7: Running and tissue damage. Knitter AE. Turner J. 2002. The plasma membrane. 122-139. Royer D. Shaw K. Darnell J. Inherent difficulties in defining amino acid requirements. KogaKusha. Basic definitions for exercise. In: Molecular cell biology. Sharp R. National Academies Press. Moschini M. Sacharuk J. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. 3-6. FASEB J. 1999. Sullivan AC. Jank M. John Wiley & Sons. 7:A70 4 5 6 7 8 9 10 11 12 13 14 15 16 332 . Lipids. 73. In: Improving Sports Performance in Middle and Long-Distance Running: A Scientific Approach to Race Preparation. Textbook of Work Physiology. Child RB. Petersen A. Nutrition. Int J Sports Med. Mathias MM. Baltimore D. 3 ID 1577: “HMB (B-hydroxy B-methylbutyrate monohydrate)” and “Minimize muscle protein breakdown” 1 2 3 Adamson LF and Greenberg DM. Schwarz W. 1974.2 Poldinger W. Beta-hydroxy-betamethylbutyrate ingestion. 2005. 1999. Nissen S. Nissen S. 5669. Fatty acid and cholesterol synthesis from specifically labeled leucine by isolated rat hepatocytes. Opiteck JA. Wilczak J. 2007. [The relationship between urinary creatine and creatinine excretion in experimental animals and physical exertion and different concentrations of vitamin E in their rations]. Ltd. J Appl Physiol. 1970. 2001. Int J Sport Nutr Exerc Metab. Brooks SV. Cochrane Database Syst Rev. 162. Freeman. Del Mar C. Fallowfield JL and Wilkinson DM (eds. Ferreira M. 6. Sultan J. Dionne IJ. The significance of certain carboxylic acids as intermediates in the biosynthesis of cholesterol. 2000. Phys Ther. Jenkins D. Jr. Beta-hydroxy-betamethylbutyrate (HMB) supplementation does not affect changes in strength or body composition during resistance training in trained men. Rathmacher JA. 2005. Fuller JC. 2000. 2001. DeLany JP. Metabolic changes limiting muscle performance. 17. In: Biochemistry of Exercise. Effect of beta-hydroxy beta-methylbutyrate on the onset of blood lactate accumulation and V(O)(2) peak in endurance-trained cyclists. 1981. Sabourin PJ and Bieber LL. Wagenmakers AJ. Chromiak J. The significance of certain carboxylic acids as intermediates in the biosynthesis of cholesterol. 1998. J Nutr. Baier S. 245-267. 11. Int J Sport Nutr Exerc Metab. 786-790.) Human Kinetics. Muscle amino acid metabolism at rest and during exercise: role in human physiology and metabolism. Occurrence of beta-hydroxy-beta-methylbutyrate in foods and feeds. Rathmacher J. Snook JT. Champaign. 384-396. Nutrition. The Journal of Nutritional Biochemistry. Nissen S. Eur J Appl Physiol Occup Physiol. Howatson G. van Someren KA. 2001. Paul GL. 300-311. Sports Med. 15. Int J Sport Nutr Exerc Metab. Arch Biochem Biophys. Panton LB. Noakes TD. Edwards AJ. 132-144. 1957. 734-739. 130. Rathmacher JA. 1986. Rice D. Stubbs NB. 2003. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Sharp R. 287-314. Ransone J. 333 . 1994. Logan P. Saltin B (ed. J Nutr. Hahn AG. Nissen SL and Abumrad NN. Biochimica et biophysica acta. 472-479. FASEB J. 1997. Slater G.. 2095-2104. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. 1996. 81. 206. J Strength Cond Res. 323-343. Jr. Vukovich MD and Dreifort GD. 26.17 Nissen S. 16. Formation of beta-hydroxyisovalerate by an alpha-ketoisocaproate oxygenase in human liver. Keech A. Lefavi R. Sharp RL. beta-hydroxy-betamethylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. 131. Abumrad N. 23. O'Connor DM and Crowe MJ. Seifert JG. Lee H.hydroxy B. 43. Vukovich M. 32. Subcellular distribution and partial characterization of an alphaketoisocaproate oxidase of rat liver: formation of beta-hydroxyisovaleric acid. 64-68. Ray M. 491-497. Exerc Sport Sci Rev. Panton L. Metabolism. Effect of exercise on serum enzyme activities in humans. Bohlken RM. 442-450. Nissen S. Nissen S. 58. 1937-1945. 2049-2052. 11. Jenkins D. 8. Int J Sport Nutr Exerc Metab. Connelly AS. 1983. 8:A464. 2000. 4. The effect of beta-hydroxy beta-methylbutyrate on muscular strength and body composition in collegiate football players. Fuller JC. ID 1578: “HMB (B. Short-term beta-hydroxy-beta-methylbutyrate supplementation does not reduce symptoms of eccentric muscle damage. Vukovich MD. Coates C. 1987. 2001. 2001. Sahlin K. 160-164.. J Appl Physiol. Paddon-Jones D. Effects of beta-hydroxy-beta-methylbutyrate and creatine monohydrate supplementation on the aerobic and anaerobic capacity of highly trained athletes. J Strength Cond Res. 413-424.methylbutyrate monohydrate)” and “Increasing strength” 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 1 Adamson L and Greenberg D. Zhang Z. Serum and urinary markers of skeletal muscle tissue damage after weight lifting exercise. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. 34-39. Kirby TE. Neighbors K. Nutritional role of the leucine metabolite [beta]-hydroxy [beta]methylbutyrate (HMB). Trappe S. Vukovich M. J Sports Med Phys Fitness. Sabourin PJ and Bieber LL. 15. 2003. Rathmacher JA. 1989. Knuttgen HG and Komi PV. Child RB. Sultan J. Inherent difficulties in defining amino acid requirements. Nissen SL and Sharp RL. Darnell J. In: Molecular cell biology. Kirby TE. 3-6. 81. 2116-2119. Chichister. Ferreira M. Vopr Pitan. 2003. Nutrition. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. Sacharuk J. 1970. Chromiak J. 11. Paddon-Jones D. 94. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. 2095-2104. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Faulkner JA. 1987. Jank M. Short-term beta-hydroxy-beta-methylbutyrate supplementation does not reduce symptoms of eccentric muscle damage. J Nutr Biochem. 73. J Plant Physiol. McGraw-Hill Inc. Fatty acid and cholesterol synthesis from specifically labeled leucine by isolated rat hepatocytes. Int J Sport Nutr Exerc Metab. In: Strenght and power in sport. Mathias MM. 334 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 . Eur J Appl Physiol Occup Physiol. Effect of feeding ß-hydroxy-ßmethylbutyrate (HMB) on leucine and fat metabolism in mammary gland. 734-739. 17. Sullivan AC. FASEB J. Nissen S. 442-450. 651-659. Godard MP. Kreider RB. 1997. J Strength Cond Res. 739-743. John Wiley&Sons. 1989. Lefavi R. 2001. 2005. Baltimore D. Paul GL. Wilczak J. 58. 300-311. Fuller JC. 32. Noakes TD. Int J Sports Med. Rathmacher J. Lipids. 558-566. 16. Nissen S. 1993. 17. Baier S. 19-22. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Lodish H. Vitamin E bioavailability in humans. [The relationship between urinary creatine and creatinine excretion in experimental animals and physical exertion and different concentrations of vitamin E in their rations]. In: Improving sports performance in middle and longdistance running. Almada AL. 162. Ltd. 790-796. Seifert JG. In: The role of protein and amino acids in sustaining and enhancing performances. Brooks SV. Nissen S. 20. Abumrad N. 2003. 786-790. Komi PV (ed. KogaKusha. 1999. Effects of calcium beta-hydroxy-betamethylbutyrate (HMB) supplementation during resistance-training on markers of catabolism. Ostaszewski P. Serum and urinary markers of skeletal muscle tissue damage after weight lifting exercise. Zieniewicz A. Lodge JK. 6.Volume III of the Enciclopedia of Sports Medicine. 1993. 169216. Running and tissue damage. 2001. 16. Fallowfield JL and Wilkinson DM (eds. Connelly AS. England. Moschini M. 245-267. 1974. Trappe SW. Faidley TD. Panton LB. Ransone J. Ray M. Effect of exercise on serum enzyme activities in humans. 1999. Energy liberation and transfer. Opiteck JA. Basic definitions for exercise. 1999. 8. Phys Ther. Beta-hydroxy-betamethylbutyrate ingestion. 1990. Ltd. Schulze KE. 7:A70 Nissen S. Millward DJ. part II: effects on hematology. Buffin Lane. Sports Med. Med Sci Sports Exerc. Neighbors K. 1996. Sharp R. Wilson M. New York. Nissen SL and Abumrad NN. Jowko E. 2000. Snook JT.). Efremov VV and Sakaeva EA.. DeLany JP. Nutritional role of the leucine metabolite beta-hydroxy betamethylbutyrate (HMB). Carrithers JA. Rathmacher JA. The plasma membrane. Gallagher PM. National Academy Press. Scientific American Books Inc. Injury to skeletal muscle fibers during contractions: conditions of occurrence and prevention. 2000. 4. Jr. J Appl Physiol. 1992. 911-921. Rathmacher JA. 1981..2 3 Åstrand PO and Rodahl K. Washington DC. The effect of beta-hydroxy beta-methylbutyrate on muscular strength and body composition in collegiate football players. Jenkins D. 34-39. Nutrition. Keech A. 492-530. body composition and strength. In: Textbook of Work Physiology. J Appl Physiol. 503-509. Hamilton JG. Rice D. hepatic and renal function.) Blackwell Science Ltd. Panton L. Beta-hydroxy-betamethylbutyrate (HMB) supplementation does not affect changes in strength or body composition during resistance training in trained men. Metabolism. 132-144. Nutrition. Nissen S.. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. 1981. 1998. Coates C. Vukovich M. 2000. Metabolic changes limiting muscle performance. beta-hydroxy-betamethylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. Nissen S. J Nutr. 8. Jr. 2 3 4 5 6 7 8 9 10 11 12 335 . Zhang Z. 384-396. Slater G. Effect of beta-hydroxy beta-methylbutyrate on the onset of blood lactate accumulation and V(O)(2) peak in endurance-trained cyclists. 11. J Nutr. Vukovich MD and Dreifort GD. Wilczak J. Exerc Sport Sci Rev. Dionne IJ. 651-659. Jenkins D. 1996. 160-164.. Effects of beta-hydroxy-betamethylbutyrate on muscle damage after a prolonged run. Int J Sport Nutr Exerc Metab. Panton L. Abumrad N. 2049-2052. Muscle amino acid metabolism at rest and during exercise: role in human physiology and metabolism. 130. Arch Biochem Biophys. Int J Sport Nutr Exerc Metab. J Appl Physiol. Edwards AJ. 1983. Nissen S. 1994. Royer D. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. 300-311. 734-739. 2000. Sharp RL. J Appl Physiol. In: Biochemistry of Exercise. Howatson G. 206. 26. Int J Sport Nutr Exerc Metab. 131. 15. 287-314. J Strength Cond Res. 323-343. 2000. Baier S. Vukovich MD. Subcellular distribution and partial characterization of an alphaketoisocaproate oxidase of rat liver: formation of beta-hydroxyisovaleric acid. Panton LB. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. FASEB J. Nissen SL and Sharp RL. Nutrition. J Nutr Biochem. 558-566. Effects of beta-hydroxy-beta-methylbutyrate on aerobicperformance components and body composition in college students. Wagenmakers AJ. Champaign. Bohlken RM. Vukovich M. Jr. 8:A464. 17. Occurrence of beta-hydroxy-beta-methylbutyrate in foods and feeds. van Someren KA. 2005. 1340-1344. Nissen S. Stubbs NB. Fuller JC. Petersen A. Logan P. Rathmacher JA. ID 1579: “HMB (B-hydroxy B-methylbutyrate monohydrate)” and “Increasing Mass” 24 25 26 27 1 Jowko E. 81. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. 2001. 15. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. 491-497. 2003. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. Sabourin PJ and Bieber LL. 17. 2095-2104. Sharp R. Lamboley CR. Nissen S. Saltin B (ed. 89. Connelly AS. Ostaszewski P. Ray M. Fuller JC. Rice D. Formation of beta-hydroxyisovalerate by an alpha-ketoisocaproate oxygenase in human liver. Rathmacher JA. Rathmacher JA. Rathmacher J. Lee H. Sacharuk J. Trappe S. J Appl Physiol. 2001. 2001. Jank M. Rathmacher JA. 1937-1945.) Human Kinetics. 16. 1997. Zieniewicz A. Sharp R. Knitter AE. 1986. 413-424. 5669. 94. Sahlin K. 32. Nissen SL and Abumrad NN. Hahn AG.23 Sabourin PJ and Bieber LL. 2007. 2001. Nutritional role of the leucine metabolite beta-hydroxy betamethylbutyrate (HMB). Chichister. 6. Nutrition. Fatty acid and cholesterol synthesis from specifically labeled leucine by isolated rat hepatocytes. 911-921. 503-509. Lodish H and Baltimore D Freeman WH. New York.Volume III of the Encyclopedia of Sports Medicine. 1993. 2003. 1992. Lipids. Lamboley CR. Int J Sport Nutr Exerc Metab. 1994. The plasma membrane. 1974. Kreider RB. Fallowfield JL and Wilkinson DM (eds. Sharp R. Lodish H. 8. Vopr Pitan. 739-743. Hamilton JG. hepatic and renal function. 2095-2104. Inherent difficulties in defining amino acid requirements. Royer D. Ltd. Darnell J. 23. Petersen A. [The relationship between urinary creatine and creatinine excretion in experimental animals and physical exertion and different concentrations of vitamin E in their rations]. 94. Rice D. Dionne IJ. 16. J Appl Physiol. Effects of calcium beta-hydroxy-betamethylbutyrate (HMB) supplementation during resistance-training on markers of catabolism. 19-22. Zieniewicz A.) Blackwell Science Ltd. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. 651-659. Energy liberation and transfer. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Int J Sports Med. Scientific American Books Inc. Nissen SL and Abumrad NN. Efremov VV and Sakaeva EA. 1990. 169216. 1996.). Basic definitions for exercise. Panton L. New York. Med Sci Sports Exerc.methylbutyrate monohydrate)” and “Increasing exercise lactate threshold and VO2 peak” 1 2 3 Adamson L and Greenberg D. Nissen S. Nutritional role of the leucine metabolite beta-hydroxy betamethylbutyrate (HMB). Jowko E. 1981.ID 1580: “HMB (B-hydroxy B. Injury to skeletal muscle fibers during contractions: conditions of occurrence and prevention. 2007. 5669. 1422. John Wiley&Sons. Buffin Lane. 1340-1344. New York. 1970. 162. 2000. Sharp R. Child RB. 790-796. 336 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 . Chichister. 2116-2119. 17. Faulkner JA. 1999. 26. 558-566. Wilczak J. 1997. Baltimore D. Trappe SW. 1990. Wilson M. Ostaszewski P. Almada AL. Ferreira M. Phys Ther. body composition and strength. 1999. Komi PV (ed. Carrithers JA. Schulze KE. Molecular Cell Biology. Nissen S. Sullivan AC. 73. 2000. Jr. Nissen SL and Sharp RL. Rathmacher JA. Åstrand PO and Rodahl K. In: The role of protein and amino acids in sustaining and enhancing performances. 20. J Appl Physiol. Knuttgen HG and Komi PV. 32. Beta-hydroxy-betamethylbutyrate ingestion. Rathmacher JA. Jank M. Med Sci Sports Exerc. part II: effects on hematology. 1957. In: Improving sports performance in middle and longdistance running. Mathias MM. Lodge JK. 81. Vitamin E bioavailability in humans. 2005. Opiteck JA. Running and tissue damage. 17. Brooks SV.. Komi PV. Knitter AE. 472-479. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. In: Molecular cell biology. Freeman. 1999. In: Strenght and power in sport. 300-311. J Nutr Biochem. 89. Effects of beta-hydroxy-betamethylbutyrate on muscle damage after a prolonged run. 492-530. Millward DJ. Sacharuk J. In: Textbook of Work Physiology. Effects of beta-hydroxy-beta-methylbutyrate on aerobicperformance components and body composition in college students. J Appl Physiol. Ltd. Fuller JC. 3-6. Godard MP. Biochimica et biophysica acta. KogaKusha. National Academy Press.. Washington DC. Ray M. The significance of certain carboxylic acids as intermediates in the biosynthesis of cholesterol. Strength and power in sport.. J Plant Physiol. McGraw-Hill Inc. Abumrad N. Connelly AS. Gallagher PM. 2001. J Strength Cond Res. Exerc Sport Sci Rev. 131. Stubbs NB. Slater G. 4. Vukovich MD. Metabolism. 413-424. J Appl Physiol. Rathmacher JA. 2 3 4 337 . 26. Jenkins D. Jr. Occurrence of beta-hydroxy-beta-methylbutyrate in foods and feeds. Connelly AS. Baier S. Fuller JC. 132-144. Ostaszewski P. Int J Sport Nutr Exerc Metab. Subcellular distribution and partial characterization of an alphaketoisocaproate oxidase of rat liver: formation of beta-hydroxyisovaleric acid. 558-566. Sahlin K. Keech A. Serum and urinary markers of skeletal muscle tissue damage after weight lifting exercise. Bohlken RM. 11. Nissen S. ID 1582: “HMB” and “lean body mass” 23 24 25 26 27 28 29 30 31 32 33 34 1 Jowko E. Rathmacher J. 34-39. The effect of beta-hydroxy beta-methylbutyrate on muscular strength and body composition in collegiate football players. 2001. 17. Nissen S. Howatson G. 786-790. Sacharuk J. Nutrition. 15. 1983. FASEB J. 2000. Bohlken RM. 160-164. 58. Vukovich MD and Dreifort GD. Paddon-Jones D. Metabolic changes limiting muscle performance. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. Effect of beta-hydroxy beta-methylbutyrate on the onset of blood lactate accumulation and V(O)(2) peak in endurance-trained cyclists. 16. Ray M. 206. Effect of exercise on serum enzyme activities in humans. Stubbs NB. 1981. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. Paul GL. Rathmacher JA. Coates C. Abumrad N. Edwards AJ. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. 1987. Sharp R. Neighbors K. Wagenmakers AJ. In: Biochemistry of Exercise. Sabourin PJ and Bieber LL. 491-497. Nissen S. Beta-hydroxy-betamethylbutyrate (HMB) supplementation does not affect changes in strength or body composition during resistance training in trained men. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Jank M. Nutrition.21 22 Noakes TD. 323-343. Muscle amino acid metabolism at rest and during exercise: role in human physiology and metabolism. Vukovich MD. 81. Rathmacher JA. 8. Hahn AG. Seifert JG. Nissen S. 2001. J Nutr. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. 2001. Eur J Appl Physiol Occup Physiol. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. 734-739. Sabourin PJ and Bieber LL. 2000. Nissen S. 16. Baier S. Vukovich M. Chromiak J. J Nutr. Snook JT. 1994. 1986. Nutrition. 384-396.) Human Kinetics. 1996. Rathmacher JA. Jenkins D. 2005. 1998. Panton LB. DeLany JP. 2001. 11. Formation of beta-hydroxyisovalerate by an alpha-ketoisocaproate oxygenase in human liver. 2049-2052. 2001. 2001. 734-739. 131. Short-term beta-hydroxy-beta-methylbutyrate supplementation does not reduce symptoms of eccentric muscle damage. 245-267. Rice D. Ransone J. 287-314. J Strength Cond Res. Arch Biochem Biophys. 1989. Wilczak J. Zieniewicz A. 17. Zhang Z. Logan P. Champaign. 2095-2104. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. 15. Panton LB. 2003. Sports Med. 2049-2052. Int J Sport Nutr Exerc Metab.. 32. Lefavi R. 442-450. Lee H. Kirby TE. Int J Sport Nutr Exerc Metab. Saltin B (ed. van Someren KA. Ray M. Jank M. Int J Sport Nutr Exerc Metab. Effects of beta-hydroxy-betamethylbutyrate on muscle damage after a prolonged run. Sharp R. 2000. Knitter AE. Zieniewicz A. 15. 17. 413-424. Wilczak J. 81. Jr. 17. 1996. 1996. Petersen A. Sacharuk J. 2095-2104. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. Abumrad N. Rice D. 15. J Appl Physiol. Int J Sport Nutr Exerc Metab. Connelly AS. Edwards AJ.. van Someren KA. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. Fuller JC. Rathmacher JA. Nutrition. Jr. J Appl Physiol. Rice D. Zieniewicz A. 2001. Rathmacher JA. 2 3 4 2 3 4 2 3 4 338 . Nissen S. Sacharuk J. J Appl Physiol. 413-424. Howatson G. Zieniewicz A. Ray M. Rice D. Ostaszewski P. Jank M. 89. Knitter AE. Nissen S. 1340-1344. Sharp R. Wilczak J. Int J Sport Nutr Exerc Metab. 2001. 1996. Sharp R. 2005. 89. 558-566.. ID 1587: “HMB and HMB/KIC combinations” and “changes in muscle strength during training” 1 Jowko E. Nissen S. Abumrad N. Nissen S. 15. Nutrition. 558-566. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. Fuller JC. 413-424. 1340-1344. Edwards AJ. 2000. Ostaszewski P. 558-566. J Appl Physiol. J Appl Physiol. 2000. 558-566. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. Sharp R. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. 2095-2104. 2095-2104. Howatson G. Nissen S. Effects of beta-hydroxy-betamethylbutyrate on muscle damage after a prolonged run. Rathmacher JA. van Someren KA. Ray M. 81. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. 2005. Edwards AJ. Wilczak J.ID 1584: “HMB and HMB/KIC combinations” and “exercise induced muscle breakdown” 1 Jowko E. ID 1585: “HMB and HMB/KIC combinations” and “muscle recovery after training” 1 Jowko E. Wilczak J. Nissen S. Abumrad N. 1340-1344. Sharp R. Sharp R. 2001. Ostaszewski P. Effects of beta-hydroxy-betamethylbutyrate on muscle damage after a prolonged run. van Someren KA. Petersen A. Howatson G. Jr. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. Nutrition. Ostaszewski P. 89. Nutrition. 17. Zieniewicz A. 2001. ID 1586: “HMB and HMB/KIC combinations” and “normal muscle repair” 1 Jowko E. Rathmacher JA. 2005. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. 81. 17. Panton L. Rathmacher JA. Knitter AE. Connelly AS.. J Appl Physiol. Sacharuk J. Nissen S. Panton L. Panton L. Petersen A. Sacharuk J. Fuller JC. Rathmacher JA. Jank M. Connelly AS. Jank M. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. Rathmacher JA. Robbins KK. 1987. Gill DL. Aviv A. 1996. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 339 . Luther J. 1990. 2005. Benjamin J. Benjamin J. Viljoen SL. Agam G. 79-86. 1995. Glasman A. Brink CB. Int J Eat Disord. A natural antioxidant. Metab Brain Dis. 19. Calcium signalling mechanisms in endoplasmic reticulum activated by inositol 1. Inositol as an add-on treatment for bipolar depression. Prog Neuropsychopharmacol Biol Psychiatry. 153. Kofman O. 60-66. 2001. 67-84. Inositol prevents folate-resistant neural tube defects in the mouse. Cai F. Liao X. Jr. Gelber D. 729735. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. 47-55. Harvey BH. Hardan A. ID 1588: “Inositol (Common Names: Inositol. Nutrition. Edwards AJ.. Mallinger AG. 37. May WL. Baier S. Levine J. 2. Bipolar Disord. 1084-1086. Cell Calcium. Stein DJ. Verfaille S. Rathmacher JA. Colodny L and Hoffman RL. Nissen S. Levine J. Panton LB. 152. 1219-1221. cross-over placebo controlled trial. 1995. 363-374. Am J Psychiatry. Aviv A. Miller CJ. 81. Ray M. Agam G. 432-447. 49. Inositol treatment in psychiatry. Nat Med. 167-175. Am J Psychiatry. 3. Fux M. Metab Brain Dis. Sharp R. Abumrad N. J Pediatr Ophthalmol Strabismus. Connelly AS. [Preliminary report of efficacy of diabetic polyneuropathy treated with large dose inositol]. Manipulation of inositollinked second messenger systems as a therapeutic strategy in psychiatry. Gershon S. 51-70. Elizur A. Belmaker RH. Psychopharmacol Bull. Double-blind. Seedat S. 1996. Fuller JC. Mullaney JM. Chengappa KN. 2000. Stein DJ. 262. Levine J. 29. 1996. Levine J. 125-134. Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells. 1995. Belmaker RH. Altern Med Rev. 2004. 19. Warwick J. Ghosh TK. Bersudsky Y. Howatson G. 10. 15.2 Nissen S. 2004. J Biol Chem. Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. Levine J. 20. Borne MJ. de Kock SE. Fux M. crossover trial of inositol treatment for panic disorder. Suppression of colonic cancer by dietary phytic acid. 1989. Belmaker RH. 31. 1997. van Someren KA. Rawson JE. Supplementation with beta-hydroxy-betamethylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exerciseinduced muscle damage in man. 2000. Vagnucci A. 2095-2104. 19. Belmaker RH. Levine J. Empson KL. Hua Xi Yi Ke Da Xue Xue Bao. Buttenfield J. 734-739. Inositol treatment of Alzheimer's disease: a double blind. 413-424. Bersudsky Y. Kupfer DJ.4. Rice D. placebo-controlled. Nutr Cancer. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training. 201-203. McVey J. 11-19. Friedman CA. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. Belmaker RH. Kofman O. Pollock B. Levy D. Graf E. Adv Biochem Psychopharmacol. 11647-11650. Graf E and Eaton JW. 1998. Int J Sport Nutr Exerc Metab. Phytic acid. Eaton JW. Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Liang J.5-trisphosphate and GTP. 21. Inositol--clinical applications for exogenous use. 3. Effect of inositol on bulimia nervosa and binge eating. James M. Benjamin J. 16. 345-348. J Appl Physiol. Greene ND and Copp AJ. Harvey BH. myo-inositol)” and “Cognitive and mental performance” 3 4 1 Barak Y. 2000. 1993. Carey PD. Temple DM. Levine J. Wu YK. Iron absorption and bioavailability in rats of micronized dispersible ferric pyrophosphate. J Neural Transm. Efficacy of ironfortified Ultra Rice in improving the iron status of women in Mexico. 44. Borenstein M. Kofman O. 1998. A micronised. 147-155. Low dose 'Sprinkles'-. 140-149. Inositol as a treatment for psychiatric disorders: a scientific evaluation of its clinical effectiveness. Rao TP. Borenstein M. Hefez A. 2004. Hirve S. 1995. A meta-analysis. 29. Glycosyl-phosphatidylinositol anchored membrane enzymes. 344-347. Juneja LR. Sakaguchi N. Naik S. Juneja LR. Food Nutr Bull. Op den Kamp D. 3-9. 91-100. 1995. Long-term effects of extreme situational stress on sleep and dreaming. Double-blind. Gonzalves M. Manila: Food and Nutrition Research Institute. 107-112. Hyder Z. Indian Pediatr. Juneja LR. 1993. Benjamin J. Belmaker RH. Christofides A. 270-273. Rahman S and Neuman RS. 2004. 2008. Nutrition delivery system: a novel concept of nutrient fortification. Sakaguchi N. Levine J. Barak Y. 57. Walczyk T. Garcia-Guerra A. 144. 495-508. Martin M. Yamaguchi R. 1999. 45. Elliott T. Townsend Letter for Doctors and Patients. 74. 2004. J Agric Food Chem. Am J Psychiatry. Sakaguchi N. 79-84. Am J Psychiatry. dispersible ferric pyrophosphate with high relative bioavailability in man. 2004. Controlled trials of inositol in psychiatry. 1999. Serlin RC. 53-60. Porcayo M.17 18 19 20 21 22 23 24 25 26 27 28 29 Greist JH. Rao TP. 52. Pandit A. 199-215. 266. Biol Psychiatry. Susnosky M. Phytic acid in health and disease. Szor H. Handbook of industrial biocatalysis. Crit Rev Food Sci Nutr. Consumption of rice fortified with selected iron fortificants reduces anemia prevalence among schoolchildren. 795-798. Double-blind. 1997. Juneja LR. 349-351. Eur Neuropsychopharmacol.. Jefferson JW. Zlotkin S. 152. Metz L. Zeder C. Nakata K. Bhave S. Nanbu H. Teratology. controlled trial of inositol treatment of depression. Inositol addition does not improve depression in SSRI treatment failures. Frolov K. Khandelwal M. Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. 8132-8136. ID 1589: “Iron-Micronised microencapsulated ferric pyrophosphate” and “Blood. 1995. Fidler MC. Am J Obstet Gynecol. 2007. haemoglobin and energy production” 1 2 3 Angeles-Agdeppa I. Reece EA. 91. Levine J. Elizur A. Onofre G. 312. 4 5 6 7 8 340 . Arch Gen Psychiatry. crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Levine J. Katzelnick DJ. 106. 2005. 2001. Sakaguchi N. Abrahamse L. Mishory A. Hotz C. 536-539. Hooper NM. 21. 792-794. Int J Vitam Nutr Res. 1997. Belmaker RH. 52. 7. Nick G. Palatnik A. 1997. Reece EA. Bavdekar A. Handbook of functional dairy products. 35. Davidsson L. Greiner T. Belmaker RH. Nemets B. 631. 2004. J Clin Psychopharmacol. Khandelwal M. Fux M.an innovative approach to treat iron deficiency anemia in infants and young children. Iron fortification of dairy products: a novel approach. Lavie P. Wu YK. controlled. 335-339. Schauer C. Myo-inositol reduces serotonin (5-HT2) receptor induced homologous and heterologous desensitization. In vitro iron availability from iron-fortified whole-grain wheat flour. Zhou JR and Erdman JW. Br J Nutr. Kobak KA. Brain Res. Dietary myo-inositol therapy in hyperglycemiainduced embryopathy. Jankowski S. Mishori A. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Jr. Clin Chim Acta. 1987. 1-13. Levine J. Nanbu H. 2004. Hurrell RF. 176. Kloots W. Nagorski K. serum insulin. 94. 1984. Metabolism. Kozianowski G. Br J Nutr. C-Peptid und freie Fettsäuren im Vergleich mit Glucose. Unpublished. 2002. Wortley GM. 93. 1984. Comparative study of isomalt and sucrose by means of continuous indirect calorimetry. Spengler M. Wirkung des Zuckeraustauschstoffes Isomalt auf Stoffwechsel-und Risikoparameter bei Patienten mit Diabetes mellitus Typ 2. Result published in Sydney University's GI Database at www. 16. [Palatinit® in type II diabetics: effect in blood glucose. Schaffer V. Scheppach W. Melcher R.9 Wortley G. Untersuchungen zur Stoffwechselbeeinflussung durch akute Palatinitgaben: Vergleich zu Fructose und Saccharose bei Typ-IIDiabetes. 1991. 1984. Thiebaud D. Nutr Res Rev. Gorick S. 45. 62. 65-70. 808-813. 44. 2006. Seruminsulin. 1910-1913. Ciardi J. Hessdörfer S. 174-177. SUGiRS. acid production and glucan synthesis. Eur J Clin Nutr. 2005. Kaspar L and Spengler M. 1980. Kozianowski G. 163-191. Wirkung oraler Gaben von Palatinit auf den Insulinverbrauch bei Typ-I Diabetikern. Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers. Willinger B. 105-113. University of Würzburg (unpublished). Jahnke K. Karle EJ. Dusel G. Schmitz H. 1985. Theis S. Bramstedt F. Palatinit® bei Typ-II Diabetikern:Wirkung auf Blutglucose. 9. 1976.com. Haslbeck M. Dorbath D. Bowen WH. 978-998. 60-64. 107. 2005. Schmitz H. fructose-based and isomalt-based chocolates on postprandial metabolism in non-insulin-dependent diabetics. Effects of conventional sucrose-based. Verhandlungen der Deutschen Gesellschaft für Innere Medizin. Comparative Study of the Cariogenic Effects of Palatinit. Aktuelle Ernährungsmedizin. 64. Spengler M. Dorbath D. Jacot E.Isomalt. Pometta D. Journal of Dental Research. Blutglucose und Seruminsulin nach oraler Applikation von Palatinit im Vergleich zu Glucose bei Diabetikern vom Erwachsenentyp. Livesey G. Effects of sugar substitutes on bacterial growth. 2003. Menzel T. 1983. 9. Leusner S. C peptide and free fatty acids in comparison with glucose]. Deutsche Medizinische Wochenschrift. Gostner A. ID 1591: “Isomalt” and “Dental health – General” 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 Lebensmittelverordnung (LMV) des Schweizerischen Bundesrates vom 1. 341 . Holub I.glycemicindex. Theis S. Br J Nutr. European Parliament and Council Directive 94/35/EC of 30 June 1994 on sweeteners for use in foodstuffs. Z Gastroenterol. Aktuelle Ernährungsmedizin. Bender G. 1997. Schöffling K. Trabichet C. 2005. Greenwood RH. Gierlich P. Petzoldt R. with emphasis on low glycaemic properties. Drost H. ID 1590: “Isomalt” and “Low glycemic properties” 1 2 European Parliament and Council Directive 94/35/EC of 30 June 1994 on sweeteners for use in foodstuffs. Glycaemic Index Report . Cooke D. Johnson IT. Mehnert H. Iron availability of a fortified processed wheat cereal: a comparison of fourteen iron forms using an in vitro digestion/human colonic adenocarcinoma (CaCo-2) cell model. Spengler M. 1994. Glahn R. 65-71. Schauber J. Kudlich T. Effects of a 12-week administration of isomalt on metabolic control in type-II-diabetics. Xylitol and Saccharose in Animals. Felber JP. Rolla G. Aktuelle Ernährungsmedizin. 182. 1982. 575-581. Health potential of polyols as sugar replacers. 68. Good C. Bachmann W. Low-glycaemic diets and health: implications for obesity. Dusel G. Allolio B. Marz 1995. Spengler M. Zumbe A. 561-566. Gostner A. Livesey G. Gee JM. Gugger E. Luhrs H. Proc Nutr Soc. 33. Spengler M. Gehring F. Lauer P. 10. 131. Dorbath D. Eidgenössische Departement des Innern (EDI). 1999. J Dent Res. 2. Kudlich T. The science and practice of caries prevention. Laboratory studies of sweets re-formulated to improve their dental properties. Imfeld TN. Schaffer V. 26. 2004. 1983. Dusel G. Verordnung des EDI über Speziallebensmittel vom 23. 5. 1987.und Saccharoseaustauschstoff-Lösungen. Physiological factors affecting salivary flow rate. FDA (Food and Drug Administration). 34. 551-554. [Palatinite--a new sugar substitute and its caries prophylactic evaluation]. Theis S. Kariesprophylaxe. 5. Health claims: dietary noncariogenic carbohydrate sweeteners and dental caries. Monographs in Oral Science. Karle EJ and Gehring F. 2005. Scheppach W. 673-678. Status of ISOMALT in Japan. 1996. Grenby TH and Mistry M. 2004. Melcher R. 1992. 77-96. 555-558. Dtsch Zahnarztl Z. 53-68. April 2007). 1994. 1981. US FDA 21CFR§101. Featherstone JDB. 1979. Z Ernahrungswiss. Karle EJ and Gehring F. 32-40. 21. Kozianowski G. 575-581. unter besonderer Beriicksichtigung mikrobiologischer Aspekte. 1. 887-899. Cariogenic properties of sugar substitutes examined in gnotobiotic rat experiments. 13-19. 1987. Br J Nutr. Gehring F. Lutz F. Journal of Clinical Dentistry. Schiffer S. Menzel T. 1978. Oral Dis. 104. J Am Dent Assoc. 2000. Clinical caries studies with polyalcohols. Featherstone JD. oral sugar clearance. 82-82. Dtsch Zahnarztl Z. Intra. Caries Res. Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers. Saccharose-Austauschstoffe und ihre Bedeutung fur die Kariesprophylaxe. Gehring F and Karle EJ. European Commission. 1994. Effects of Isomalt Sweetener on the Caries Process. 1983.5 6 7 8 9 CSPI (Center for Science in the Public Interest). Imfeld T and Muhlemann HR. Schweiz Monatsschr Zahnmed. 176-182.80. Imfeld T. Pharmacol Ther Dent.und extraorale pH Messungen an Zahnplaques des Menschen nach Spülungen mit einigen Zucker. 1978. 1981. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 342 . Gehring F. Identification of low caries risk dietary components. Gehring F and Hufnagel HD. Dawes C. 33. Schauber J. Functional Foods: Public Health Boon 21st Century Quackery? CSPI Reports. Dawes C and Macpherson LM. Measurement of interdental plaque pH in humans with an indwelling glass pH electrode following a sucrose rinse: a long-term retrospective study. Revision of the scientific opinion on the effects of xylitol and other polyols on caries development adopted by the Scientific Committee on Medicinal Products and Medical Devices on 2 June 1999. Cariogenicity and acidogenicity of food. 1978. [Sweetening agent. Effects of nine different chewing-gums and lozenges on salivary flow rate and pH. Luhrs H. November 2005 (Stand am 1. ERGOB Conf. 2002. 94. Dtsch Zahnarztl Z. Palatinit under specific consideration as to microbiological and caries-prophylactic aspects]. 1198. Imfeld TN. 20. 1979. Karle EJ and Gehring F. Firestone AR. and the sensation of dry mouth in man. 11. 648-653. Oralprophylaxe. FOSHU. A literature review. Caries Res. 2007. 96-106. confectionery and beverages. Gostner A. 66 Spec No. Proc. 941-945. 189-191. 3. [Palatinit and xylitol in a gnotobiotic rat experiment]. 36. [Studies on cariogenicity of sugar substitutes in xerostomized rats]. 27. Influence of Palatinit (isomalt) and xylitol on demineralization / remineralization on bovine enamel. 2006. J Dent Res. 1. 37-40. 4. Enamel remineralisation by isomalt-toothpaste in situ. 174-183. Rodriguez AB. 14. Sugar-free sweets and their role in caries prevention. Van Loveren C. 335-340. Fennig S. Hirotani M. Nomura H. 11-17. Kunz C. 568-573. The circadian rhythm of tryptophan in breast milk affects the rhythms of 6-sulfatoxymelatonin and sleep in newborn. Adv Exp Med Biol. Correlation between breakfast tryptophan content and morning-evening in Japanese infants and students aged 0-15 yrs. Sialic acid in human milk: composition and functions. van der Hoeven JS. Heine WE. 81. 699-722. Sugawara M. 2006. 46. Barriga C. Leach SA. Cubero J. 657-661. Grauer E. Rial R. Greece. Improved circadian sleep-wake cycle in infants fed a day/night dissociated formula milk. Baier W. Tietze W. Sentko A and Livesey G. Aparicio S. J Nerv Ment Dis. 2004. Behav Brain Res. 2004. Nakano T. Prophylaxe Impuls. Klein N. Sugar substitutes and remineralization. Treves I. 2006. 10. Takatsuka T. functional. 13.27 Leach SA. Remineralization of the teeth by dietary means. Tome D. Dtsch Zahnarztl Z. 10. 2571-2575. Prophylaxe Impuls. 301306. 38. Takeuchi H. Maeda M. Zuckerfreie Süßwaren in der Kariesprophylaxe. Barriga C. 11-15 Oct 1982. 174-183. Proceedings of a workshop. In: Demineralization and Remineralization of Teeth. Cariogenicity of disaccharide alcohols in rats. 20. Neuro Endocrinol Lett. 2001. The significance of tryptophan in infant nutrition. 705-710. Sugar alcohols: what is the evidence for caries-preventive and caries-therapeutic effects? Caries Res. Even PC. Oxford. IRL Press. Leach SA and Edgar WM (eds. Narciso D. 26. (unpublished). 79. 28 29 30 31 32 33 34 35 36 ID 1594: “Lacprodan CGMP-10 (active ingredient: Sialic acid)” and “Plays a role in development of the brain” 1 Cubero J. 286-293. Caries Res. Levkovitz Y. Stößer L. Invest Ophthalmol Vis Sci. Kawakami H. S135-138. Clandinin MT. Esteban S. Rudloff S. Deutz NEP. Takatsuka T. 2002. 1999. Sanchez J. Samos. 26. Agalmanyi EA. Green RM. Acta Paediatr Taiwan. Valero V. 61-66. Rivero M. Markus CR. 2001. 1980.). 2000. Bloch Y. Effect of L-tryptophan on memory in patients with schizophrenia. 467. Tietze W. Garau C. van der Hoeven JS. Dietary ganglioside and long-chain polyunsaturated fatty acids increase ganglioside GD3 content and alter the phospholipid profile in neonatal rat retina. 2005. Oligosaccharides in human milk: structural. Park EJ. Stößer L. Lammers J. Strobel S. and metabolic aspects. A Scientific Documentation. 1979. Minet-Ringuet J. Le Ruyet PM. Evening Dietary Tryptophan Improves PostSleep Behavioral and Brain Measures of Memory Function iIn Healthy Subjects. Palatinit internal report. 373-380. Harada T. 2 3 4 5 6 7 8 9 10 343 . J Physiol Anthropol. 2006. 42. Rivero M. 152. Sentko A. A tryptophan-rich protein diet efficiently restores sleep after food deprivation in the rat. Annu Rev Nutr. 1987. 2005. Influence of disaccharide alcohols on the oral microflora. Suh M. 2007. 2000. Parvez H. 1983. Valero V. 191. Neuro Endocrinol Lett. Jonkman LM. England. 42. Sentko A. Isomalt – Dental Aspects. 2003. Caries Res. 201207. Cariology Today. Rodriguez AB. Current Topics in Nutraceutical Research. Ophir-Shaham O. Influence of tryptophan supplementation of soy-based infant formulas on protein quality and on blood and brain tryptophan and brain serotonin in the rat model. Frigerio G. 2002. Guidoni G. Yu B. O'Connell NC. Bellomo G. 2003. Sarwar G. Efficacy of SF 68 in the Treatment of Acute Diarrhea a PlaceboControlled Trial. 561-569. 28. Martinez E. 1033-1035. Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly. ID 1595: “Lactic acid bacteria/ Entero coccus faecium” and “Intestinal health” 12 13 14 15 16 17 18 19 20 21 1 2 3 Allen SJ. D'Souza AL. Clandinin MT. 27. Brand-Miller J. Held S. Clin Rev Allergy Immunol. Diet-induced changes in membrane gangliosides in rat intestinal mucosa. Petocz P. Am J Clin Nutr. Probiotics for treating infectious diarrhoea. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Bulpitt CJ. Petocz P. Cooke J. 324. Dans LF. 40. plasma and brain. D'Apuzzo V and Salzberg R. Suh M. Lewenstein A. 78. Biological properties of SF 68. and tryptophan supplementation of formulas increases brain tryptophan and serotonin in rats. Lunn BS. Karim M. Psychol Med. Brand-Miller J. 265–271. Brancato V. 2001. 466-470. 1024-1029. 74. Am J Clin Nutr. Hu H. Wang B. Scandinavian Journal of Gastroenterology. Eur J Clin Nutr. Nutr Neurosci. 1996. 9. 275284. 129. Wang B and Brand-Miller J. Plant Foods Hum Nutr. Wang B. 39. 927-936. 581-589. Liquid concentrates are lower in bioavailable tryptophan than powdered infant formulas. Curr Ther Res. a new approach for the treatment of diarrheal diseases. Steiner K. 1692-1697. The role and potential of sialic acid in human nutrition. Therapeutische Umscau. BMJ. J Nutr. Sepe N. Probiotics in clinical conditions. 2003. Rajkumar C. 41-49. and cognitive function. Gregorio G. J Nutr. 56. Costa G. Steinberg LA. Buydens P and Debeuckelaere S. 2002. 85. Tryptophan intake influences infants' sleep latency. Frigerio G. Borgia M. Petocz P. Klaassen T. 2005. 1982. Wang B. Brain Behav Immun. Curr Ther Res. 1999. 967-981. Birch LL. Mangiagle A. 31. 4 5 6 7 8 9 344 . Am J Clin Nutr. A controlled clinical study on streptococcus faecium preparation for the prevention of side reactions during long term antibiotic treatment. Begg D. 16. Sun Y. Curr Ther Res. 22. Tryptophan. 887 . Dietary sialic acid supplementation improves learning and memory in piglets. Die Behandlung der akuten diarrho in der padiatrie mit streptococcus faecium: resultate einer doppelblindstudie. Okoko B. Concentration and distribution of sialic acid in human milk and infant formulas. A controlled double blind study of SF68 strain as a new biological preparation for the treatment of diarrhea in pediatrics. 2007. Picciano MF. 2002. Nicastro L. Hatch TF. Moroni M. O'Brien JT. Wang B. Simone P. 33. 1979. 31. Ramanujam K. 1992. 57. 487495. 1781-1791. 1361. Brand-Miller J. McVeagh P.11 Park EJ. 510-515. J Pediatr Gastroenterol Nutr. 2007. 26. 1981. Belvisi A. McVeagh P. 1982. Sarwar G and Botting HG. A double-blind comparison of two different treatments for acute enteritis in adults. Hu H. 122. Camarri E.891. Brain ganglioside and glycoprotein sialic acid in breastfed compared with formula-fed infants. Porter RJ. 147-154. 2001. Chemotherapy. McGreevy P. 1351-1369. 1980. Schmitt JA. 2003. Borgia R. Riedel WJ. Yu B. Frigerio G. 2006. Molecular characterization of pig ST8Sia IV--a critical gene for the formation of neural cell adhesion molecule and its response to sialic acid supplement in piglets. Marteau PR. Marini G. Cochrane Database Syst Rev. 255-273. mood. Monograph. 48. Westwick JK. Brenner DA. Biesalski H-K. Pietrzik K. Golly I. Influence of lutein supplementation on macular pigment. Lecithin for dementia and cognitive impairment. ID 1597: “Lecithin” and “For fat metabolism” 1 Higgins JP and Flicker L. Thieme Verlag. 2002. Stahlgren LH. Altern Med Rev. 17. Cox AD. Li J. Terashima K. 1994. Goldbohm RA. Ling YB. 303-307. Munchen. 1997. Tang ZF. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. 543-549. Langkamp-Henken B. Urban & Fischer. Fumagalli I. ID 1602: “L-glutamine” and “Intestinal Health” 1 2 3 L-glutamine. 29-32. van Norren D. Appetite. assessed with two objective techniques. 1999. Leader LM. Heim F. 150. 2001. Glutamine and the gastrointestinal tract. Stuttgart. Schümann K. ID 1603: “Lutein (Marigold Extract)” and “Required for Macular Pigmentation in the eyes which helps maintenance of healthy eye functions” 4 5 6 1 2 3 4 Lutein and zeaxanthin. Glutamine prevents parenteral nutrition-induced increases in intestinal permeability. 41. JPEN J Parenter Enteral Nutr. 2004. 2005. Vitamin-Lexikon für Ärzte. Rippe RA.theanine” and “Cognitive function” 1 2 Parnell H. Argenzio RA. 10. Klopping WA. Bhosale P. Bässler KH. Loew D. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. Combined effects of L-theanine and caffeine on cognition and mood. Hao Z. Liu F. 333-338. Karly M. Ziegler TR. Li J. Vonbank F. World J Gastroenterol. 22232228. 18. Zhao da Y. 6. Yokogoshi H. 47. HPLC measurement of ocular carotenoid levels in human donor eyes in the lutein supplementation era. 2000. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Toxicol Lett. Chen W. CD001015. D'Apuzzo V. Lodi R. Alves-Rodrigues A and Shao A. 272. Köhrle J. Bazargan N. Bernstein PS. Suzuki K. G943-953. Glutamine and recombinant human growth hormone protect intestinal barrier function following portal hypertension surgery. 13. 3. van de Kraats J. Braun L. Rycroft JA. 128-135. 355-362. 2000. 2002. 396-401. J Int Med Res. Tan L. 406-410. The science behind lutein. Vitamine. van Norel J. 2000. 2007. 5 6 345 . Xu RY.10 Wunderlich PF. Zeltner L. Wu B. 14th Lecture meeting for Scientific Research on Tea. 2006. Martindale RG. Berschneider HM. Apotheker und Ernährungswissenschaftler. Seto J. 57-83. The effects of L-theanine for learning ability on Rats. Rhoads JM. L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Li Y. Invest Ophthalmol Vis Sci. Curr Opin Clin Nutr Metab Care. Berendschot TT. 273. Altern Med Rev. Yu Z. 2007. 92. 2006. 3322-3326. Am J Physiol. ID 1600: “L. Lin N. Politta G. Cochrane Database Syst Rev. 1989. Tumori. Owen GN. Invest Ophthalmol Vis Sci. Mares-Perlman JA. 2001. Duncan JL. 132. Michel P. Relation between dietary intake. 2003. Bone RA. Wissenschaftliche Verlagsgesellschaft. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. Johnson EJ. Ciulla TA. 371-381. Fisher AI. Hammond BR. 1795-1801. serum concentrations. Krinsky NI. Exp Eye Res. Skin Pharmacol Physiol. Russell RM. Millen AE. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Yeum KJ. Maurette JM. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Cideciyan AV. Elmadfa I and Leitzmann C. J Nutr. Bejot M. Annu Rev Nutr. Bone RA. Moore LL. 19. 71. Johnson EJ. Brehme U. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Landrum JT. Maguire MG. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. 2006. 153. MacDonald IM. Laube H. 2002. De Castro E. Emmons JM. 518S-524S. Klein R. Stuttgart. 60. Ophthalmology. 147-164. Marks DA. Landrum JT. Jr. Aleman TS. Overview. Sprague KE. Mares-Perlman JA. Snodderly DM. Greger JL. Hahn A. Dietary modification of human macular pigment density. Dagnelie G. 51-60. 992-998. 38. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. 2003. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 346 . Leitzmann C. Lyle BJ. Bone RA. 2000. Cooper DA. 1997. Piccardi M. 2004. Heinrich U. Gröber U. Optometry. Mares-Perlman JA. Am J Epidemiol. 796-802. Steinberg JD. 110. Landrum JT. Serum and macular pigment response to 2. Guerra LH. Pratt LM. Stuttgart. Curran-Celentano J. Larossi G. J Nutr. and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Falsini B. Lutein and zeaxanthin in the eyes. Joa H. 2000. 74. Jr. Bieber ML. Danis RB. FAO/WHO Expert Committee on Food Additives (JECFA). 2001. Stone EM. Valentini P. Hippokrates. 149. Br J Nutr. Jacobson SG. Castaneda C. Exp Eye Res. 1555-1562. Block G. 487-502. 224-231. 1999. Hammond BR. Macular pigment and lutein supplementation in choroideremia. 2001. Landrum JT.. Hankinson SE. Qin J. Klein R. Krinsky NI. Stuttgart. 2002. Eugen Ulmer Verlag. Zorge IS. Tronnier H. 801-809. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Landrum JT. Bennett J. Ernährung des Menschen. Report 63rd Meeting in Geneva Switzerland 8th -17th June Granado F. 71. Hammond BR. Wissenschaftliche Verlagsgesellschaft mbH. 171-201. Olmedilla B. 2003. Stuttgart. Antioxidant supplements improve parameters related to skin structure in humans.. Palta M. Am J Clin Nutr. Klein BE. Gardner LM. 2002. 23. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Merendino E. Wang XD. Ficek TL. 71. Nutritional and clinical relevance of lutein in human health. 1997. 2000. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. 41. 57-62. 65. Wright JD. Orthomolekulare Medizin. 1988. discussion 61.7 8 9 Bone RA. 2006. Stahl W. Am J Epidemiol. 2000. Llerena CM. Ernährung in Prävention und Therapie. 424-432. serum and diet of human subjects. Invest Ophthalmol Vis Sci. 2003. Kilburn MD. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. Ruiz CA. Russell RM. Dixon Z. Müller C. 74. Hahn A. 90. Fadda A. Edwards RB. McDonald TM. Exp Eye Res. Snodderly DM. Yeum KJ. Assoc Res Vision Ophthalmol. Chen Y. Millen AE. Am J Clin Nutr. Blanco I. 133. 239-245.4 mg dosage of lutein. Relative stability of carotenoid radical cations and homologue tocopheroxyl radicals. Adackapara CA. Monograph. 1997. 22. Ribaya-Mercado JD and Blumberg JB. Delori FC. Richer S. Clemons TE. The first 200 years. SanGiovanni JP. E. Historic perspectives. Chew EY. Shao A and Hathcock JN. Sperduto RD. 2005. Altern Med Rev. Dev Ophthalmol. 1981. 56. A real time kinetic study of antioxidant hierarchy. 257-265. 3rd. Staurenghi G. Blanco I. Corridan B. Southon S. Watzl B and Leitzmann C. Retina. 38. 103-110. Assoc Res Vision Ophthalmol. Macular carotenoids: lutein and zeaxanthin. 904-909. Ophthalmologe. Bird AC. 261-266. Gerosa F. Blanco I. Ternes W. Journal of the Science of Food and Agriculture. Cajigal C. Olmedilla B. Macular yellow pigment. Vaquero M. Stuttgart. Lutein. 296-310. 70-88. 75. Granado F. supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind. 417. Nutrition. Vaquero M. ID 1604: “Lutein” and “Eye health” 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 1 2 Lutein and zeaxanthin. placebo-controlled pilot study. Tunger L. Gil-Martinez E. 2005. 2001. 2007. Sunness JS. 23. 78. Stahl W. Double-masked. 102. Milton RC. 28. Melia BM. 216-230. Pulido J. 213-219. FEBS letters. Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. J Am Coll Nutr. Nutr Rev. Stiles W. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. 2007. Mortensen A and Skibsted LH. Nutr Rev. 42. placebo-controlled. 1998. A European multicentre. 511-519. 2005. 347 . Lang JC. 10. 1225-1232. 2003. 21-24. Wright AJ. Seddon JM. 2004. Retina. Pei K. Dagnelie G. Arch Ophthalmol. Bioaktive Substanzen in Lebensmitteln. Jr. van den Berg H. 2004. Täufel A. 1. Lebensmittel-Lexikon Behr. Granado F. Optometry. Rudy D. Lutein in patients with cataracts and agerelated macular degeneration: a long-term supplementation study. Hippokrates. Regul Toxicol Pharmacol. Stuttgart. Risk assessment for the carotenoids lutein and lycopene. Prooxidant actions of carotenoids in biologic systems. 2005. 567S-587S. Palozza P. 125. carotene-rich palm oil. and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 2008. 128-135. 2006. Dietary lutein and zeaxanthin: possible effects on visual function. Thurnham D. Watzl B and Leitzmann C. Hininger I. Statkute L.28 Massacesi AL. 1999. 59-64. Granado F. 289-298. Pruett RC. Optometry. [Macular pigment and age-related macular degeneration]. 2001. 2005. 2001. The relationship of dietary carotenoid and vitamin A. Dibernardo CW. 81. Frankowski J. Devenport J. Blanco I. Olmedilla B. Faletra R. van Kuijk FJ. Clin Sci (Lond). 98. Hippokrates. Gensler G. lutein or lycopene: analysis of serum responses. but not alpha-tocopherol. 19. The effect of oral supplementation of macular carotenoids (lutein and zeaxanthin) on the prevention of age-related macular degeneration: A 18 months of follow up study. Olmedilla B. Lutein and zeaxanthin and their potential roles in disease prevention. Ferris FL. randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Stringham JM and Hammond BR. 2002. placebo-controlled supplementation study with alpha-tocopherol. Nyland J. Pauleikhoff D. Lindblad AS. Nussbaum JJ. 63. Orzalesi N. S234. Bioaktive Substanzen in Lebensmitteln. Tsipursky M. 45. Chopra M. 447-456. Richer S.. Koh HH. The macular xanthophylls. Neuringer M. 2000. 2004. Nurtrition and eyes. «la lutéine. Berendschot TTJM. assessed with two objective techniques. 2005. Beatty S. Marks DA. van Norren D. 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 348 . 2001. Br J Ophthalmol. Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials. Steinberg JD. 41. Astley SB and Lindsay DG. Golly I. van de Kraats J.3 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 287-291. 2008. Lott MN. 3322-3326. 41. Emmons JM. Boulton M. 1873-1881. van de Kraats J. Sumaroka A. Apotheker und Ernährungswissenschaftler. Jacobson SG. Loew D. Steinberg JD. Gardner LM. Boulton ME. Goldbohm RA. van Norren D. van Norel J. Schierle J. Henson D. 2002. Schalch W. 439-446. 23. Beatty S. 48. 2008. 83. Invest Ophthalmol Vis Sci. Surv Ophthalmol. 2002. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. European Research on the Functional Effects of Dietary Antioxidants (EUROFEDA). 867-877. Ahmed SS. Pantelyat AY. Swider M. Clin Nutr. Photoprotective carotenoids lutein and zeaxanthin: their role in AMD. Maguire MG. Henson D. Jacobson SG.6'R). Dagnelie G. 42. Invest Ophthalmol Vis Sci. contribue à protéger la rétine et le cristallin de l'oxydation» relatives à un complément alimentaire contenant de la lutéine sous forme libre. 4. 2003-SA2005. Carden D. Phil M. 2000. 2001. Comp Biochem Physiol B Biochem Mol Biol. The role of oxidative stress in the pathogenesis of age-related macular degeneration. 383-399. Bahrami H. Bieber ML. constituant majeur de la rétine et du cristallin. Bartlett HE and Eperjesi F. 27. Beatty S. 1999. Klopping WAA. Berendschot TT. Conclusions. 3322-3326.70-88. 42. Augustin AJ. Klopping WA. Deutsche Apotheker Zeitung. 70-78. Invest Ophthalmol Vis Sci. Chico JD. Aleman TS. 151. Murray IJ. Toxicol Lett. Henson DB. 218-227. 150. 29-31. Johnson EJ. 45. Vitamin-Lexikon für Ärzte. A randomised controlled trial investigating the effect of lutein and antioxidant dietary supplementation on visual function in healthy eyes. «la Lutéine renforce la protection de la rétine et du cristallin contre l'oxydation». Duncan JL. Windsor EA. München. Murray IJ. Alves-Rodrigues A and Shao A. Pietrzik K. 2003. Marcus DM. 2008. Macular pigment and risk for agerelated macular degeneration in subjects from a Northern European population.6'S)-3'-dehydro-lutein as common metabolites and comparison to humans. Investigative Ophthalmology & Visual Science. van Norel J. Stone EM. AVIS de l‘Agence française de sécurité sanitaire des aliments relatif à l'évaluation des justifications scientifiques des allégations «la lutéine Contribue à protéger la rétine et le cristallin de l'oxydation». Aleman TS. Koh H. Ophthalmic Physiol Opt. 2002. Albert GI. 2004. Schwartz SB. Current Nutrition & Food Science. 23. Macular pigment and age related macular degeneration. 2005. 2007. Invest Ophthalmol Vis Sci. Duncan KG. Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations. Afzal A and Afzal M. Goldbohm RA. 2000. 50. The science behind lutein. 115-134. Bartlett H and Eperjesi F. Gardner LM. de Castro E. 23. 6. 57-83. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. 183-193. Surv Ophthalmol. Boulton M. 2006. 1319-1329. Development in Ophthalmology. Cideciyan AV. Influence of lutein supplementation on macular pigment. Mol Aspects Med. «la lutéine est l'un des constituants majeurs de la rétine et du cristallin». Koh H. assessed with two objective tecniques. Augustin AJ(ed). Urban & Fischer. 23. 38. 127-134.129-131. Hoeller U. Metabolism of lutein and zeaxanthin in rhesus monkeys: identification of (3R. Bässler KH. BMC Ophthalmol. Cideciyan AV.and (3R. Influence of lutein supplementation on macular pigment. Melia M. 71-73. Weiss H. 270-277. Chasan-Taber L. Exp Gerontol. Rochette Y. Tyssandier V. 109. Bhosale P and Bernstein PS. 573-582. Seddon JM. Gellermann W. Van Poppel G. Köhrle J. Borel P. Pathophysiologie. 517-524. 2002. Cangemi FE. Klopping-Ketelaars IA. de Vries AJ. Brown L. Goldbohm RA. 1998. FASEB J. Am J Clin Nutr. Vision Res. Thieme. 76. Tarsis SL. Plasma carotenoids and diabetic retinopathy. Lairon D. Weber P.22 Berendschot TT. Kilburn MD. Gomez CM. 71. 2003-2011. O'Dea K. 211-218. 132. Berendschot TT. 2004. BMC Ophthalmol. Brazionis L. Schrezenmeir J. Rock E. 61-66. 2003. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. 48. Ruiz CA. 2007. Macular pigment in donor eyes with and without AMD: a case-control study. 1740. 1998. Br J Nutr. 38-50. Yoshida MD. Schümann K. Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. 49. Gomez CM. 1995. McClane RW. 120. 2002. Physiologie. 42. Macular pigment density in relation to serum and adipose tissue concentrations of lutein and serum concentrations of zeaxanthin. 2007. Bernstein PS. Willett WC. Invest Ophthalmol Vis Sci. Bone RA. Klopping-Ketelaars IA. 1985. Ophthalmology. 2001. Surv Ophthalmol. Structure and properties of carotenoids in relation to function. 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 349 . Invest Ophthalmol Vis Sci. J Nutr. Dixon Z. 3. Landrum JT. 70. Bone RA. Invest Ophthalmol Vis Sci. 133. Zhao DY. Hankinson SE. Springer. 2005. Menendez E. Gorrand JM. Bhosale P. Boirie Y. Raman detection of macular carotenoid pigments in intact human retina. 64. Landrum JT. Bone RA. 39. 9. A prospective study of carotenoid intake and risk of cataract extraction in US men. Van Norren D. 1531-1535. 1732-1737. Verdier E. 2008. 2002. Broekmans WM. Bernstein PS. TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. Landrum JT. Biesalski H-K. Stuttgart. Broekmans WM. 1997. Liaaen-Jensen. Kardinaal AF. McClane RW. Friedes LM. 595-603. Kardinaal AF. 38. serum and diet of human subjects. Biosynthesis and Metabolism. Alexandre-Gouabau MC. Therapie. Llerena CM. Twaroska EE. Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. Canter PH and Ernst E. Short-term supplementation with lutein affects biomarkers of lutein status similarly in young and elderly subjects. J Lab Clin Med. van Poppel G. Landrum JT. Pfander H. Giovannucci EL. 2003. Tibor SE. Ermakov IV. Wang W. Bernstein PS. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Landrum JT. Arch Ophthalmol. 235-240. 992-998. Lens aging in relation to nutritional determinants and possible risk factors for age-related cataract. Britton G. Lutein and zeaxanthin in the eyes. Zhao da Y. 1997. Grolier P. 239-245. 2002. 543-549. Simonet L. 2000. Vitamine. Rowley K. 116-121. Gellermann W. Vitamine. Beaufrere B. Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision--a systematic review of placebo-controlled trials. Grolier P. Mayne ST. Katz NB. 1999. Azais-Braesco V. Borel P. Biochim Biophys Acta. 1780-1787. 1551-1558. Britton G. Exp Eye Res. 25. Exp Eye Res. Guerra LH. In: Carotenoids. Itsiopoulos C. Stuttgart. Preliminary identification of the human macular pigment. 7. Spiegelman D. Biesalski HK. Vidal I. 101. Thieme Verlag. Am J Clin Nutr. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. Bone RA. Wintch SW. Bone RA. Tijburg LB. HPLC measurement of ocular carotenoid levels in human donor eyes in the lutein supplementation era. Rimm EB. Cardinault N. Chen Y. 1998. Oxidative stress status and antioxidant status are apparently not related to carotenoid status in healthy subjects. Arch Ophthalmol. 2007. Exp Eye Res. Deineka VI. vitamins. Anal Chem. Application of nutrigenomics in eye health. 2007. 357. Hankinson SE. Forum Nutr. Schalch W. Speizer FE. J Chromatogr B Biomed Sci Appl. 220-223. Nutritional antioxidants and age-related cataract and maculopathy. 87. Coudray C. Donaldson MJ and Pulido JS. Kohler K. and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. 535S-539S. Hankinson SE. 2001. and carotenoids and risk of age-related maculopathy. Sairafi B. Am J Clin Nutr. Sorokopudov VN. 2006. Voragen AG. Clin Chim Acta. 49. Seddon JM. 129. Chakravarthy U. serum concentrations. Albert K. 74. Glaser T. Abalain JH. Young IS. vegetables. 1999. TyM.. 796-802. Willett WC. Liu S. Carriere I. 2007. Dagnelie G. Curran-Celentano J. 1993. 132. 349-355. Christen WG. 47. EDCC Study Group. Barberger-Gateau P. van het Hof KH. Carre JL. carotenoids and retinol are inversely associated with cataract in a North Indian population. 41. Jr. 1999. Gaziano JM. Hammond BR. 84. Nutritional supplementation in age-related macular degeneration. Burke JD. Rosner B. Dachtler M. Albert K. Curran Celentano J. 2002. Optometry. 73. Danis RB. 720. Flowers of Marigold (Tagetes) Species as a source of xanthophylls. 2001. 104-109. Deineka LA. 667-674. Linssen JP. 70. Am J Clin Nutr. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Cho E. Camparini M. Dherani M. Maraini G. Invest Ophthalmol Vis Sci. Kohler K. Arch Ophthalmol. 509-516. Yu. 2008. Glynn RJ. Rosner B. 1837-1843. Cooper DA. 126. 71. Am J Clin Nutr. Eye Disease Case-Control Study Group. Buring JE. 2008. Delcourt C. Price GM. Delcourt C. 2005. Ciulla TA. Treatment of nonexudative (dry) age-related macular degeneration. Dachtler M. John N. J Nutr. 2329-2335. Hankinson SE. 18. Blood levels of vitamin C. 211-216. Rosner B. Prospective study of intake of fruits. 2007. Lycopene but not lutein nor zeaxanthin decreases in serum and lipoproteins in age-related macular degeneration patients. Stampfer MJ. Hammond BR. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. 2004. 3328-3335. Cho E. Combined HPLC-MS and HPLC-NMR on-line coupling for the separation and determination of lutein and zeaxanthin stereoisomers in spinach and in retina. Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. and risk of cataract in women: a prospective study. 2006. vitamins C and E. 17. Jr. 1998. 122. Zorge IS. Chasan-Taber L. Delage M. Antioxidant status and neovascular age-related macular degeneration. Curr Opin Ophthalmol. Reversed-phase high-performance liquid chromatographic identification of lutein and zeaxanthin stereoisomers in bovine retina using a C30 bonded phase. Gupta SK. 111. Colditz GA. Curr Opin Ophthalmol. 102-109. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. 267-274. Castenmiller JJ. 883892. Rock E. Coleman H and Chew E. Willett WC. Mazur A. Relation between dietary intake. Colditz GA. Pratt LM. Grolier P. In vivo assessment of retinal carotenoids: macular pigment detection techniques and their impact on monitoring pigment status. The food matrix of spinach is a limiting factor in determining the bioavailability of beta-carotene and to a lesser extent of lutein in humans. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 350 . Invest Ophthalmol Vis Sci. Chiu CJ and Taylor A. 34-42. 147-164. Dietary carotenoids. Fletcher AE. Pharmaceutical Chemistry Journal. McDonald TM. 168-175. Seddon JM. J Nutr. Arch Ophthalmol. 2008. Murthy GV.43 Cardinault N. West CE.. 229-245. Rambeau M. 2000. 60. Willett WC. Hall NF. Fernandez MM and Afshari NA. Wang JJ. discussion 61. 2002. Bieber ML. Wooten BR. Ernährung des Menschen. Fadda A. Snodderly DM. Krinsky NI. Gardner LM. Jacobson SG. Br J Nutr. 1997. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Ophthalmology. Montvale (NJ). Jr. Snodderly DM.. 1998. Piccardi M. Iarossi G. PDR for Herbal Medicines. Macular pigment and lutein supplementation in choroideremia. 385. Stuttgart.. Olmedilla B. Wolters M. 1998. [The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD)].. Ophthalmology. Mitchell P. 1983. 2006. Edwards RB.. Bennett J. Exp Eye Res. Stuttgart. Safranow K. 101103. Stuttgart. 371-381. Russell RM. Lutein: sight for sore eyes. vitamin E and specific carotenoids in Spain. Granado F. Elmadfa I and Leitzmann C. Hammond BR. Ham WT. 2461-2465. Nutritional and clinical relevance of lutein in human health. Brendler T. Ströhle A. Gale CR. 109. Berenguer A. 2272-2278. Hammond BR. Jr. 2140-2144. Short-wavelength-sensitive-cone sensitivity loss with aging: a protective role for macular pigment? J Opt Soc Am A. 1998. De Castro E. 4. Wissenschaftliche Verlagsgesellschaft. Curr Opin Ophthalmol. Postepy Hig Med Dosw (Online). 44. Invest Ophthalmol Vis Sci. Hahn A. Valentini P. 51-60. Flood V. Gröber U. 1996. 61. Dorronsoro M. Lang JC. Ocular hazards of light sources: review of current knowledge. 2005. Phillips DI. Prävention. Barricarte A. Riverhead Books New York. Wooten BR. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Emmons JM. 38.62 Drobek-Slowik M. Martinez C. Jr. 10051011. 74. Marks DA. 2002. Dietary modification of human macular pigment density. Orthomolekulare Medizin. Eugen Ulmer Verlag. Karczewicz D. Falsini B. Johnson EJ. 2003. 19. Vision Res. 2008. 90. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. 2004. Gruenwald J. 91. 110. Arch Biochem Biophys. 487-502. Martyn CN. Blanco I. Wissenschaftliche Verlagsgesellschaft. 2003. 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 351 . 2008. Arnaud R. Hammond BR. Duncan JL. 39. Agudo A. 1988. Franciose JL. Carotenoids in the retina and lens: possible acute and chronic effects on human visual performance. Current Topics in Nutraceutical Research. Merendino E. Maguire MG. Jose Tormo M. Preservation of visual sensitivity of older subjects: association with macular pigment density. 2003. 397-406. Stone EM. Webb K. Gonzalez CA. 25. 1795-1801. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH. Amiano P. Wooten BR. Quiros JR. CD000253. 36. In: The nutraceutical revolution:20 cutting edge nutrients to help you design your own perfect whole life program. Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Aleman TS. Dietary sources of vitamin C. Garcia-Closas R. Jose Sanchez M. Stuttgart. Navarro C. MacDonald IM. 41-46. Curran-Celentano J. Dolores Chirlaque M. Nutrition and the prevention of cataracts.. Steinberg JD. 2837. Ernährung–Physiologische Grundlagen. Haegerstrom-Portnoy G. 3003-3009. 2002. Serum and macular responses to antioxidant supplementation versus a carotenoid-rich dietary intervention in the elderly. Thompson PDR. J Occup Med. Lutein and zeaxanthin status and risk of age-related macular degeneration. Manzi F. Invest Ophthalmol Vis Sci. Snodderly DM. Evans JR and Henshaw K. 2007. Invest Ophthalmol Vis Sci. Jr. 2002. Cochrane Database Syst Rev. 66-70. Cideciyan AV. 69. Ardanaz E. 2006. 550-556. 5. Askew EW. Smith W. Hahn A. Br J Nutr. Bernstein PS. Hammond BR. Jaenicke C. Jr. Firshein R. 2001. Yeum KJ. 2006. Izumi-Nagai K. 70. Stahl W. Springer Verlag. Lutein from Tagetes erecta (Clinical and technical assessment-CTA) 63rd meeting JFCA. 3. In: Hager's Handbuch der pharmazeutischen Praxis. 2002. 71. The color code: a revolutionary eating plan for optimum health. Hyperion. New York. Dratz EA. 2006. Nagai N. 585-588. Johnson EJ. 93 94 95 96 97 98 99 100 101 102 103 104 352 . Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Harris TL. Springer Verlag. Coleman HR. Cancer mortality and serum levels of carotenoids. Jin XH. Underwood A. Invest Ophthalmol Vis Sci. van Kuijk JG. Keller K. 1992. Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg yolk. JECFA (Joint FAO/WHO Expert Committee on Food Additives). 247-251. Invest Ophthalmol Vis Sci. Ageing health. 49. Yagi A. Johnson KC. and Wooten BR. Tronnier H. Iannaccone A. 333-336. Yoshida K. Invest Ophthalmol Vis Sci. 850-855. 2007. Wang XD.84 85 86 87 88 89 90 91 92 Hammond BR. Hirano T. Ohgami K. 2562-2568. Invest Ophthalmol Vis Sci. Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Oike Y. Chew EY. 160-164. Inibition of lipid peroxidation and superoxide generation by deterpenoids from Rosmarinus officinalis. 2555-2562. Rimpler H. Asian Pac J Cancer Prev. and tocopherol: a population-based follow-up study of inhabitants of a rural area of Japan. Yeum KJ. 2002. Hioki R. Handelman GJ. Ohgami K. Vaccinium myrtillus L. Ferris FL. Arterioscler Thromb Vasc Biol. 27. Suzuki K. Hansel R. 224-231. and macular pigmentation. Iseki K. Am J Clin Nutr. Caldarella SM. 2005. Joseph JA. 2005. JECFA (Joint FAO/WHO Expert Committee on Food Additives). 2004. Planta medica. Satofuka S. Carotenoids in the human macula and whole retina. 10–15. The role of carotenoids in human health. 48. Castaneda C. Hansel R. Russell RM. Inhibitory effects of lutein on endotoxin-induced uveitis in Lewis rats. Hammond BR. Best sources of lutein and its relation to eye health. 1051. 2000. Reay CC. Handelman GJ. 2001. 2007. Ilieva I. Harris T. Haraguchi H. Nadeau D. 2003. Ishida S. Junghans A. In: Hager's Handbuch der pharmazeutischen Praxis. Maurette JM. Schneider G. Antioxidant supplements improve parameters related to skin structure in humans. 2000. Kim J. Schaefer EJ. Rosmarinus. Chung HY. Bejot M. Aoki K. Heinrich U. Ohno S. 6. Schneider G. Umezawa K. Hammond BR. Gallaher KT. 3864-3869. 1988. Todd WA. Ohno S. Snodderly DM. Zeaxanthin (Clinical and technical assessment-CTA) 63rd meeting JFCA. Kurata M. 56-65. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older. 2008. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. 1458-1465. de Monasterio F. Saito T. Keller K. Mura M. Am J Clin Nutr. Huang LL. Am J Clin Nutr. 5. Okamura N. Kritchevsky SB. The influence of supplemental lutein and docosahexaenoic acid on serum. 391. Skin Pharmacol Physiol. In: The colour code: a revolutionary eating plan for optimum health. Joseph JA. Snodderly DM. Blumberg JB. 1521-1529. 3rd. Nadeau D. Schleicher RL. Macular pigment optical density in the elderly: findings in a large biracial Midsouth population sample. Wong WT. 1999. Berlin. 87. Johnson EJ. The retina as nutritionally responsive tissue. Stahl W. Qin J. Arch Biochem Biophys. Sies H. Kenyon E. Koyama Y. Lichtenstein AH. 1555-1562. lipoproteins. with or without AMD. 25. Jr. 315-319. 61. Rimpler H. New York. Ozawa Y. CFF thresholds: relation to macular pigment optical density. retinol. 2004. 29. Johnson EJ. Shiratori K. Ochiai J. Underwood A. 2007. Satterfield S. Ophthalmic Physiol Opt. Nutr Clin Care. 1995. Berlin. Suzuki Y. Nightingale ZD. 19. Ito Y. 47. Johnson EJ. 2008. Tsubota K. Hyperion. Bone RA. New York. 2001. 540S542S. Kim J. 5476-5486. Steidl S. 47. Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rats. Kilburn MD. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Ferris FL. de Moura FF. Bone RA. Detolla L. J Sci Food Agric 81. Hegelund E. Discusses chemistry of lutein and zeaxanthin. Exp Eye Res. Annu Rev Nutr. A one year study of the macular pigment: the effect of 140 days of a lutein supplement. 171-201. Arch Biochem Biophys. 2006. Khachik F. lutein and zeaxanthin in the human plasma. Itagaki Y. 65. relation to AMD. 2002. 2008. Barbur JL. 57-62. Oxford Press. 1135-1140. Khachik F. Kvansakul J. Exp Eye Res. Chronic ingestion of (3R. Krinsky NI. Divakar S. cataracts. In: Carotenoids in health and disease. Sies H. Landrum JT. The macular pigment: a possible role in protection from agerelated macular degeneration. McLeod S. and the macular pigment. 82. Kopsell DA. Invest Ophthalmol Vis Sci. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. 47. Zhao Z. 49. 23. Baskaran V.3'R. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. Lakshminarayana R. Landrum JT. Aruna G. Sangeetha RK. Free Radic Biol Med. 3rd. Barker FM. Feather J. 1997. de Moura FF. Rodriguez-Carmona M. 828-839. Bone RA. Kidmose U. 28-40. Gierhart DL. Bhaskar N. 1997. Knuthsen P. 5234-5242. Invest Ophthalmol Vis Sci. Curran-Celentano J. 918-923.105 106 Khachik F. Kim SR. Koh HH. Lutein. 2008. 79. noninvasive assessment of carotenoids in the human eye. Nakanishi K. Ophthalmic Physiol Opt. Lefsrud MG. Landrum JT and Bone RA. 1802-1811. Chew EY. 2006. 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 353 . 21-27. Kopcke W. Khachik F. Chen XQ. 385. Mayne ST. 1997. 1645-1651. Kiokias S and Gordon MH. Sprague KE.6'R)-lutein and (3R. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Shipley S. Krinsky NI. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress. 2001.3'R)zeaxanthin in the female rhesus macaque. Spinach cultigen variation for tissue carotenoid concentrations influences human serum carotenoid levels and macular pigment optical density following a 12-week dietary intervention. 38. Kopsell DE. 2003. J Agric Food Chem. Metabolism of Dietary Carotenoids and Their Potential Role in Prevention of Cancer and Age-Related Macular Degeneration In: Functional Foods for Disease Prevention. Schalch W. Marcel Dekker. 362-371. The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older. Moore LL.) genotypes after deep frozen storage. Justesen U. Nolan D. Fowler B. bioavailability. London E. Thompson DJ. Photooxidation of A2-PE. Sparrow JR. Sanchez R. 537-556. 38. Edelenbos M. Carotenoids and flavonoids in organically grown spinach (Spinacia oleracea L. 2006. 132. Adv Pharmacol. 2003. Gerweck C. Bernstein PS. 26. 79988005. Murray IJ. 2006. 45. 2004. 2004. Possible degradation/biotransformation of lutein in vitro and in vivo: isolation and structural elucidation of lutein metabolites by HPLC and LC-MS (atmospheric pressure chemical ionization). Invest Ophthalmol Vis Sci. and protection by lutein and zeaxanthin. Invest Ophthalmol Vis Sci. 1998. Landrum JT. Possible biologic mechanisms for a protective role of xanthophylls. Exp Eye Res. Joa H. J Nutr. Johnson M. Garland DL. 54. Carden D. dietary sources. Krinsky NI. 57. Flaws J. Lutty G. Kilburn MD. Cohen LA. Douglass LW. 2006. Beatty S. Kowluru RA. Menon B. carotenoids in the skin. Edgar DF. 982-993. Wenzel AJ. a photoreceptor outer segment fluorophore. zeaxanthin. Eur J Clin Nutr. Snodderly DM. Bowen P. Shoff SM. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Klein R. Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and serum in the Carotenoids in the Age-Related Eye Disease Study. 2001. Greger JL. Beatty S. Lyle BJ. 1999. Snodderly DM. Stacewicz-Sapuntzakis M. The potential role of dietary xanthophylls in cataract and age-related macular degeneration. Mares JA. Bilberry fruit. 1518-1523. an Ancillary Study of the Women's Health Initiative. Blodi BA. Bhosale P. Am J Epidemiol. Klein BE. Palta M. 2005. 1999. 2008. Mares JA. Blumberg JB. Arch Ophthalmol. 141. Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. Loane E. J Am Coll Nutr. Klein ML. Ernährung in Prävention und Therapie. 149. 1995. Kelliher C. Millen AE. Klein ML. Arch Ophthalmol. Mares-Perlman JA and Kelin R. Brady WE. 124. Marshall J. Tinker L. In: Nutritional and environmental influences on the eye. Beatty S. Leitzmann C. O'Donovan O. Wallace RB. Surv Ophthalmol. Parekh N. Palta M. 2008. Bowen PE. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. 266-272. Am J Clin Nutr. 2008. Dietary lutein reduces ultraviolet radiation-induced inflammation and immunosuppression. Br J Ophthalmol. Optometry. Mares-Perlman JA. Voland R. Mills S and K. LaRowe TL. 322-334. Mares-Perlman JA. Klein R. 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 354 . 92. 1151-1162. Klein ML. 801-809.) CRC Press. Bilberry fruit. Am J Epidemiol. 272-277. 1999. Arch Ophthalmol. Johnson EJ. Predictors of optical density of lutein and zeaxanthin in retinas of older women in the Carotenoids in Age-Related Eye Disease Study. 84. Tinker L. Boulton M. Haus GJ. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Stuttgard. Brady WE. Bernstein PS. 19. Faulhaber D. Ding W. Johnson EJ. B. Boca Raton.123 LaRowe TL. Klein R. Michel P. 2000. Hanson KM. 523-531. Klein R. 2006. Wooten BR. Klein R. Müller C. Gruber MJ. Jacques PF. 122. Greger JL. Macular pigment density and age-related maculopathy in the Carotenoids in Age-Related Eye Disease Study. Chappell RJ. Laube H. Chappell RJ. 115. Snodderly DM. 2004. Blodi B. Margrain TH. Macular pigment: new clinical methods of detection and the role of carotenoids in agerelated macular degeneration. Taylor A (ed. Am J Clin Nutr. Ophthalmology. Klein BE. 510517. 2000. Mares-Perlman JA. Moeller SM. Sliney DH. London. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. 68-81. Palta M. Hippokrates. 79. 2006. Parekh N. Edinburgh. Mares JA. Granstein RD. Edinburgh. Lyle BJ. Kodali S. 354-364. An ancillary study of the women's health initiative. Klein BE. Wooten BR. Ritenbaugh C. 69. Nolan JM. 522S-527S. 1995. 2008. Block G. Nolan JM. Moeller SM. 153. Brehme U. Moeller SM. Hahn A. 53. Mares JA. 876-883 e871. 2008. In: The Essential Guide to Herbal Safety. 23. Ritenbaugh C. Leung IY. Diet and nuclear lens opacities. Serum carotenoids and tocopherols and incidence of age-related nuclear cataract. J Invest Dermatol. 297-302. Do blue light filters confer protection against agerelated macular degeneration? Prog Retin Eye Res. Gehrs KM. Peters S. 126. In: Principles and Practices of Phytotherapie (Modern Herbal Medecine). Mares-Perlman JA. 1107-1122. Vaccinium myrtillus L. 424-432. London. Chappell R. Wright JD. Am J Epidemiol. 262-264. Mares-Perlman JA. Loane E. Klein BE. 2001. 1163-1168. Diet and age-related macular pigmentation. an ancillary study of the Women's Health Initiative. Ritter LL. Palta M. Moeller SM. Fisher AI.) Churchill Livingstone. 113. The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. Wallace RB. Lee EH. Churchill Livingstone. Mills S and Bone K. 2004. Elsevier (ed. Retina. Jacques PF. Nussbaum JJ. 2001. 61-74. Hiramitsu T. Olmedilla B. Rechkemmer G. Palozza P. placebo-controlled pilot study. O OD. 1. Blanco I. 84. 310-316. Hubbard LD. in separate or combined oral doses. 81. Sandstrom MM. Granado F. Bruno C. Jasper P. O'Connell E. 114. Bub A. 257-265. supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind. Greenberg D. Au Eong KG. Macular carotenoid levels of normal subjects and age-related maculopathy patients in a Japanese population. Verdiev B. Altern Med Rev. Beatty S. Historic perspectives. Pruett RC. 8491-8496. 5. 115. 821-830. I: effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll-free rhesus monkeys. A European multicentre. Beatty S. O'Connell ED. Loane E. 164-173. Beatty S. Ann Acad Med Singapore. Invest Ophthalmol Vis Sci. In vivo and in vitro proliferative and differentiation activity of human embryonic retinal cells. Eur J Nutr. Granado F. Hininger I. Cajigal C. Vaquero M. Granado F. 87. Plasma concentrations of carotenoids in healthy volunteers after intervention with carotenoid-rich foods. 2007. Skinmed. FEBS Lett. Gil-Martinez E. 261-266. Olmedilla B. Cancer Lett. Laurent JM. Corridan B. Exp Eye Res. Murray MT. Lutein in patients with cataracts and agerelated macular degeneration: a long-term supplementation study. Neelam K. 1997. 35-44. 19. 2007. 2002. 45. Aleksandrova MA. Taylor A. Southon S. Am J Clin Nutr. Thurnham D. American journal of natural medicine. The relationships between macular pigment optical density and its constituent carotenoids in diet and serum. carotene-rich palm oil. Delori FC. The first 200 years. Fabrizi G. Beatty S. Macular carotenoids and age-related maculopathy. 2006. Stack J. 571-582. 56. Relative stability of carotenoid radical cations and homologue tocopheroxyl radicals. Fujii H. Nolan JM. 102. Willett WC. 48. Granado F. Nolan JM. Olmedilla B. Iseki K. Bull Exp Biol Med. Watzl B. 447-456. Obana A. Proc Natl Acad Sci USA. Bilberry (Vaccinium myrtillus). 2008. Blanco I. Tanito M. 2004. Marcheselli VL. Stack J. Mortensen A and Skibsted LH. Zinov'eva RD. Stack J. Chopra M. 3234-3243. Hankinson SE. Prooxidant actions of carotenoids in biologic systems. Intake of zinc and antioxidant micronutrients and early age-related maculopathy lesions. Grigoryan EN. Ophthalmology. Nutritional manipulation of primate retinas. 179181. Chylack LT. 1997. 296-310. Supplementation with lutein (4 months) and alpha-tocopherol (2 months). Bernstein PS. 2007. 2004. Podgornyi OV. 2001. Lutein. Ophthalmic Epidemiol. 1998. Nolan JM. 21-24. 147-157. but not alpha-tocopherol. 904-909. A real time kinetic study of antioxidant hierarchy. Morris MS. 2004. in control men. 2008. 288-298.142 143 Morganti P. 14. 517-522. The Effect of Bilberry Nutritional Supplementation on Night Visual Acuity and Contrast Sensitivity. Nutrition. Maddock L. Mitashov VI. van den Berg H. 139. 1997. Muller H. Nolan J. Mukherjee PK. Vaquero M. 101. Sukhikh GT. 2003. Bazan NG. Johnson EJ. 417. Blanco I. 1981. Neuroprotectin D1: a docosahexaenoic acidderived docosatriene protects human retinal pigment epithelial cells from oxidative stress. 4. Smirnova YA. 712-722. Panova IG. Hotta Y. Journal of the Science of Food and Agriculture. Diet and risk factors for age-related maculopathy. 38. placebo-controlled supplementation study with alpha-tocopherol. Kyle J. Neuringer M. Poltavtseva RA. Invest Ophthalmol Vis Sci. O'Connell E. 2005. Clin Sci (Lond). Gil-Martinez E. 35. Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Wright AJ. 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 355 . 1999. Muth ER. 3. Nutr Rev. Hirano T. Gohto Y. Serhan CN. 17-21. Snodderly DM. Ohira A. Macular yellow pigment. Blanco I. Mizuno S. lutein or lycopene: analysis of serum responses. Olmedilla B. Protective effects of oral antioxidants on skin and eye function. vitamin A. Wiedemann P. 2007. [Macular pigment and age-related macular degeneration]. Milton RC. 2252-2259. Stiles W. Prog Retin Eye Res. Pauleikhoff D. 154-161. 511-519. Richer SP. Nutr Rev. 1997. Ruffin MTt. 2004. Die Bedeutung von Antioxidantien und Spurenelementen bei der Entstehung und Prävention der altersabhängigen Makuladegeneration. 359-366. 2003. Chew EY. J Am Optom Assoc. 2005. Renzi LM and Johnson EJ. Devenport J. 216-230. Ortega RM. Schleicher RL. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Nyland J. McKee RW. J Nutr Elder. 2000. Rock CL. Optometry. 66. Nutr Cancer. placebo-controlled. While Emerging Science Suggests Benefits of Spinach and Lutein Supplementation. Rice-Evans CA. Chen H. 40-35. 122. 2006. Statkute L. 2008. Landrum JT. 2002. 2003. Ferris FL. Rudy D. Lutein and Age-Related Ocular Disorders in the Older Adult: a review. Richer S. Stiles W. 26. 24. Pulido J. The lutein antioxidant supplementation trial. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. 381-398. 213-219. Lindblad AS. and estrogen receptor status in breast cancer. 2001. 44. 144. Invest Ophthalmol Vis Sci. Saxe GA. Politi LE. 98. Invest Ophthalmol Vis Sci. Rapp LM. 76. 96-100. 26. Ernährung & Medizin. Richer SP. Plasma carotenoid levels in human subjects fed a low carotenoid diet. 2003. Maple SS. 18. van Kuijk FJ. ARMD--pilot (case series) environmental intervention data. Optometry. Rock CL. Ferris FL. Piermarocchi S. 75. 3rd. Saviano S. 37-38. López-Sobaler AM. Parisi V. Phytochemicals and age-related eye diseases. Bull Exp Biol Med. Rodriguez-Rodriguez E. Holloway DE. Girotti R. Rotstein NP. 115. Tatikolov AS. J Nutr. 41. Nyland J. Sampson J.162 163 Panova IG. Fric E. de Moura FF. Seddon JM. Pauleikhoff D. randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Pulido J. SanGiovanni JP. Pei KY. Ophthalmology. 465-472. Invest Ophthalmol Vis Sci. Chew EY. Ophthalmologe. Clemons TE. SanGiovanni JP and Chew EY. 125. Aparicio A. 2007. Invest Ophthalmol Vis Sci. Gensler G. Clinical and Refractive Optometry. 1996. Thompson DJ. Arch Ophthalmol. 139-157. Int J Vitam Nutr Res. 1999. The Age-Related Eye Disease Study Found an Antioxidant/Mineral Supplement Decreases the Progression of Age-Related Macular Degeneration. 105. Sperduto RD. Correlation between the content of albumin and carotenoids in human vitreous body during prenatal development. Rehak M. Dose-ranging study of lutein supplementation in persons aged 60 years or older. 105-110. Sukhikh GT. 5227-5233. Choi JH. Rudy D. Richer S. 2007. 70. Rosenthal JM. 281-296. 47. Richer S. Schottenfeld D. Bermejo LM. 2008. [Lutein and antioxidants in the prevention of age-related macular degeneration]. Bone RA. Frankowski J. 24-36. 2007. Bramley PM. 1992. 78. 2006. Swendseid ME. Tedeschi M. Lang JC. Ophthalmologe. 356 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 . Pei K. 25. Why do we expect carotenoids to be antioxidants in vivo? Free Radic Res. E. Khachik F. Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. 1225-1232. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. 3rd. Bird AC. Gallinaro G. German OL. 43. de Monasterio F. The relationship between antioxidant nutrient intake and cataracts in older people. Jacob RA. 324-333 e322. Tsipursky M. and C intake with age-related macular degeneration in a case-control study: AREDS Report No. Carotenoids. Kim J. Statkute L. August DA. 22. 681-683. The relationship of dietary carotenoid and vitamin A. 2542-2542. 2008. 1. Marín-Arias LI. Double-masked. Rhone M and Basu A. 1200-1209. Varano M. 87-138. Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. Frankowski J. Bingham SA. In: Nutritional and environmental influences on the eye. Am J Clin Nutr. Cruysberg JR. Thamm E. Invest Ophthalmol Vis Sci. 85. Dayhaw-Barker P. de Boer B. Sperduto RD. Johnson E. Sies H. 99. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Lang GE. macular pigmentation and lipoproteins.) CRC Press. Fitzke FF. 53-57. Bird AC. Caldarella M. Miller DT. The carotenoids of the human retina. 25. A2E and blue light in the retina: the paradigm of age-related macular degeneration. Taylor A (ed. Biol Chem. Barker FM. 383. 368-371. Schalch W. van Kuijk FJ. Sandstrom MM. vitamins A. [Objective determination of optical density of xanthophyll after supplementation of lutein]. 1999. van Kuijk FJ. 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 357 . Schweitzer D. 1999. Lewis JW. The influence of lutein and docosahexaenoic acid on their serum concentrations. J Opt Soc Am A Opt Image Sci Vis. 270-275. Kopcke W. Keunen JE. Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. Brown PK. Robson AG. Scott KJ. 61. 2002. Chung H. Neuringer M. 2002. Hiller R. 1996. Semba RD and Dagnelie G. In: Nutritional and environmental influences on the eye. and E. Are lutein and zeaxanthin conditionally essential nutrients for eye health? Med Hypotheses. Florida. Snodderly DM. 491-495. 23. Hart DJ. Retinal pigment epithelial cell distribution in central retina of rhesus monkeys. Mellerio J. Snodderly DM. Sommerburg OG. Schalch W. Snodderly DM. Nutrition. lycopene and beta-carotene from vegetables and fruits. Siems WG. Yannuzzi LA. Arch Biochem Biophys. Zhao DY. 907-910. Ophthalmologe. 465-472. Blair N. Delori FC. 128-135. Verbeek AL. Sommerburg O. I. 2007. and discrimination from other yellow pigments in primate retinas. Snellen EL. 1992. Ajani UA. Auran JD. 1999. 1999. The correlation between the intake of lutein. Leung IY. Acta Ophthalmol Scand.) CRC Press. Carotenoids in the retina--a review of their possible role in preventing or limiting damage caused by light and oxygen. Seddon JM. Gellermann W. Invest Ophthalmol Vis Sci. 62. die Carotenoide des gelben Flecks in der Netzhaut des menschlichen Auges Ernährung. FEBS Lett. 305-308. 2815-2818. Seddon JM. van Kuijk FJ. 2008. Farber MD. Briviba K. 2002. The macular pigment. 1984. Thurnham DI. 62. Curr Eye Res. 1448S-1461S. Driomina ES. 82. EXS. Van Den Hoogen GW. 304S-307S. Beuermann B. Willett W. 19. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Cohn W. Boca Raton. Lutein und Zeaxanthin.the LUXEA (LUtein Xanthophyll Eye Accumulation) study. Bird AC. Burton TC. Hoyng CB. 409-418. Hammer M. Shaban H and Richter C. Br J Ophthalmol. Br J Nutr. 1998. Sharifzadeh M. 2007. 537-545. Remsch H.183 184 185 186 Schalch W. 75. Kliger DS. Lang GK. 43. 660-673. Am J Clin Nutr. Resonance Raman imaging of macular pigment distributions in the human retina. Day K. Multivitamin-multimineral supplements and eye disease: age-related macular degeneration and cataract. Boca Raton. 947-957. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin . Spraul CW. Gragoudas ES. 458. Hurst JS. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Zucker CL. Schalch W. Eye Disease Case-Control Study Group. 2002. and blood plasma concentrations in a group of women aged 50-65 years in the UK. 1413-1420. Barker FM. Snodderly DM and Hammond BR. 427. Taylor A (ed. 1994. Stahl W. JAMA. Lutein and zeaxanthin are associated with photoreceptors in the human retina. 80. Poster. Junghans A. 272. 25. Absorbance spectra. 2003. Haller J. C. localization. 280-298. and advanced agerelated macular degeneration. Snodderly D. 1998. Dietary carotenoids. In vivo phsycophysical assessment of nutritional and environmental influences on human ocular tissue:lens and macular pigment. Bernstein PS. 1995. Lutein Supplementation Study Evaluating Two Macular Carotenoid Measurement Methods: Resonance Raman Spectroscopy and Heterochromatic Flicker Photometry. Bouteloup C. Trieschmann M. 2005. Thurmann PA. 59-64. 85. Toyoda Y. Austermann U. Wintch SW. 2007. Klein ML. Wenzel AJ. 82-88. Macular pigment: influences on visual acuity and visibility. Garnett KM. Pauleikhoff D. Craft N. Subczynski WK. Hippokrates. Rochtchina E. Long term dietary supplementation with zeaxanthin reduces photoreceptor death in lightdamaged Japanese quail. Johnson EJ. Kanis MJ. 132-137. 44. 2008. In: Herbal Drugs and Phytopharmaceuticals. and beta-carotene compete for incorporation into chylomicrons. Wong ZY. Ophthalmology. Dorey CK. and 3-dehydro-lutein after multiple oral doses of a lutein supplement. Grolier P. Invest Ophthalmol Vis Sci. Wang JJ. Wisniewska A. Connor SL. 2002. Langner A. Heimes B. 2008. Nolan JM. 88-97. Effect of dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in age-related macular degeneration. Craft NE. Smith W. Lutein and zeaxanthin measured separately in the living human retina with fundus reflectometry. 762-769. Wichtl M. Am J Clin Nutr. Aebischer JC. A Double Blind. Caris-Veyrat C. 2006. Sundelin SP and Nilsson SE. 21. 475-484. 2002. Placebo Controlled. van Kuijk FJ. Dorey CK. 31. 5568-5573. 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 358 . Cheng KM. Delori FC. Trieschmann M. Ophthalmic Physiol Opt. 85. van de Kraats J. 2002b. 75. 75. Cheng KM. Stringham JM and Hammond BR. Arch Ophthalmol. Connor WE. Thomson LR.203 204 205 206 Stringham JM and Hammond BR. Mares JA. Fobker M. Thomson LR. 2005. lycopene. 2007. 2003. Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. van Norren D. Prog Retin Eye Res. Vegetable-borne lutein. Macular pigment: a review of current knowledge. zeaxanthin. 2001. Fuld K. Free Radic Biol Med. 225-240. Toyoda Y. Bernstein PS. Widomska J. Garnett KM. Alexander R. 84. Watzl B and Leitzmann C. Tan JS. Exp Eye Res. Nichols CR. Jr. Optom Vis Sci. Am J Clin Nutr. 124. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. with no adverse effect on the medium-term (3-wk) plasma status of carotenoids in humans. 329-335. 3538-3549. Stringham JM. Luthert P. Beatty S. Cohn W. 2008. 2006. Gellermann W. Myrtilli fructus siccus. Zhao D. Acta Biochim Pol. 217-225.. Mitchell P. 2008. Macular pigment optical density at four retinal loci during 120 days of lutein supplementation. Dietary antioxidants and the longterm incidence of age-related macular degeneration: the Blue Mountains Eye Study. Gerweck C. Macular pigment and visual performance under glare conditions. Plasma kinetics of lutein. Hense HW. Dietary lutein and zeaxanthin: possible effects on visual function. 63. 49. 1999. McClane RW. Tenter U. Hermans P. 526-534. Danis RP. Tyssandier V. Borel P. Ermakov IV. 53. 22. 2007. 82. Nichols CR. 718-728. Schalch W. Wooten BR and Hammond BR. Flood V. Bioaktive Substanzen in Lebensmitteln. monopolar. Am J Clin Nutr. Carotenoid-membrane interactions in liposomes: effect of dipolar. Stuttgart. Whitehead AJ. Pauleikhoff D. 529-542. Stuttgart. Amiot MJ. 2002a. Exp Eye Res. Invest Ophthalmol Vis Sci. Bird AC. Macular pigment in the human retina: histological evaluation of localization and distribution. Genders SW. Eye. Cardinault N. Medpharm Scientific Publishers. 43. Delori FC. Hughes S. Curran-Celentano J. Sheehan JP. 115. Lipofuscin-formation in retinal pigment epithelial cells is reduced by antioxidants. 2002. 1744-1744. and nonpolar carotenoids. Wang W. 334-341. Nutr Rev. 27. 1038-1045. Azais-Braesco V. Invest Ophthalmol Vis Sci. Ophthalmologe. The LUNA Study. Cogdell R (eds. Carotenoids and ocular health. Lipids. 36. Zhao DY. Young A. Agudo A. retinoids. and tocopherols in human lenses. Austermann U. An W. 2003. 223-234. Effect of supplemented and topically applied antioxidant substances on human tissue. 81. Wolff K. 121. 363-379. Freedberg I. 1232-1238. Tang G. The macular pigment: short. Pathak MA. 1995. Young A. Katz S (eds. Dietary sources of vitamin C. Navarro C. 13-34. 1999. The science behind lutein. 2005. 592-598. Hu DN. Cogdell R (eds. 339-348. Philips N. 1999. Marcel Dekker. 19. 2004. Roberts JE.). Dorronsoro M. 53-68. Darvin M. 2000. 1999. New York. Measurement of carotenoids. Chen J. Freedberg I. Kluwer Academic. 1562-1573. Astner S. McGraw-Hill. New York. Trahanovsky WS. Skin Pharmacol Physiol. In: Fitzpatrick's Dermatology in General Medicine. Gonzalez CA. Skin Pharmacol Physiol. Allergic contact dermatitis. Frank HA YA. Wolff K. Skin as an organ of protection.) Kluwer Academic. Elias PM and Feingold KR. Hense HW. but not lutein. The electronic states of carotenoids.). 2756-2761. Use of a 13C tracer to quantify the plasma appearance of a physiological dose of lutein in humans. Barricarte A. Serfass RE. Zastrow L. Britton G. Carotenoids in membranes. 2009. Quiros JR. Carotenoid radicals and the interaction of carotenoids with active oxygen species. Austen KF. Frank H. Bailey AL. 2008. vitamin E and specific carotenoids in Spain. Austen KF. Martinez C. 4. New York. Britton G.). 57-83. Belsito DV. 106. Eisen A. Fobker M. 29-36. In: The photochemistry of carotenoids. 137-159. Yao L. Dietary lutein/zeaxanthin decreases ultraviolet B-induced epidermal hyperproliferation and acute inflammation in hairless mice. Arnaud R. Phototoxicity of indocyanine green on human retinal pigment epithelium in vitro and its reduction by lutein. 2004. Southon S. Britton G. The Netherlands. Invest Ophthalmol Vis Sci. Goukassian D. 399-405. Kluwer Academic. Dietary lutein/zeaxanthin partially reduces photoaging and photocarcinogenesis in chronically UVB-irradiated Skh-1 hairless mice. Zhao L and Sweet BV. The Netherlands. Parrado C. 65. 238-247. Granstein RD. Dolores Chirlaque M. 537-540. Eisen A. Christensen RL. Pauleikhoff D. Astner S. Yeum KJ. In: Cosmoceuticals science and technology-Cosmeceuticals: drugs vs.). Jose Tormo M. J Invest Dermatol. In: Fitzpatrick's dermatology in general medicine. J Lab Clin Med. Berenguer A. McGraw-Hill. Liang Y.). 1999. Frank H. In: Fitzpatrick's Dermatology in General Medicine. Ardanaz E. Beta-carotene and lycopene. Rius-Diaz F. Wu A. Lademann J. Goldsmith LA. Heimes B. Gonzalez S. 1999. Goldsmith LA. Wolff K. Gruszecki WI. Garcia-Closas R. In: The photochemistry of carotenoids. Mihm MC. Gonzalez S. McGraw-Hill. 35. 164-174. Wu WC. Russell RM. Jose Sanchez M. Eisen A. Zeimer M. Bhosale P. Hughes DA. Freedberg I. 2006. White WS.222 Wright AJ. 2007. Cogdell RJ (ed. Photoaging. Goukassian DA. 10051011. Pathak MA. ID 1605: “Lutein” and “Skin health” 223 224 225 226 227 228 1 2 Alves-Rodrigues A and Shao A. 1999. In: The photochemistry of carotenoids. Bernstein PS.and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. 2000. Cunningham WJ. 3 4 5 6 7 8 9 10 11 12 359 . Edge R and Truscott TG.). Current Topics in Nutraceutical Research. The Netherlands. 134. 91. cosmetics. Br J Nutr. supplementation changes the plasma fatty acid profile of healthy male non-smokers. Goldsmith LA. 1999. Amiano P. Katz S (eds. Austen KF. 2006. 283-291. Taylor A. 20. New York. Sterry W. Elsner P and Maibach HI (eds. Am J Health Syst Pharm. Photochemistry and Photobiology. Lutein and zeaxanthin for macular degeneration. 150. 1447-1461. Toxicol Lett. Photoimmunology. Katz S (eds. Regulation of the extracellular matrix remodeling by lutein in dermal fibroblasts. Sagebiel RW. A nonsaponification method for the determination of carotenoids. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Gellermann W. Aust LB (ed. Skin conditioning benefits of moisturizing products. Tronnier H. Williams G. 2004. retinoids. 2008. Mason RP. 2007. McGraw-Hill. 16. 373-379. Protective effects of oral antioxidants on skin and eye function. Al-Amin M. Palombo P. Scholz TA. Wolff K. Hanson KM. 331-339. Maurette JM. Katz S (eds. Pathak MA. 233-246. Dietary lutein reduces ultraviolet radiation-induced inflammation and immunosuppression. J Invest Dermatol. McNulty HP. 310-316. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev. Granstein RD. McGraw-Hill. Cardillo A. Goldsmith LA. 199-210. 1998. Kochevar IE. New York. Arena R.). melanoma cells. 510517. 2742-2763. McNaughton SA. Bruno C. Photophysics. 139-144. Fabrizi G. Green AC. and ultraviolet radiation exposed fibroblasts. Lin Y. 2. Cancer Epidemiol Biomarkers Prev. 29. 465-472. 46. 23. Beneficial long-term effects of combined oral/topical antioxidant treatment with the carotenoids lutein and zeaxanthin on human skin: a double-blind. effects. Marenus KD. Ding W. 13. Goldsmith LA. 16. 2006. Potischman N. 2001. Kodali S. Wolff K. Peng YM. Gonzalez S. Momin A. Antioxidant supplements improve parameters related to skin structure in humans. J Dermatol Sci. lutein and astaxanthin in cultured fibroblasts. Skin Pharmacol Physiol. O'Connor I and O'Brien N. Lin Y. Peng YS. 224-231. Nutr Cancer.13 14 15 16 Hata TR. Freedberg I. Guarneri F. JECFA (Joint FAO/WHO Expert Committee on Food Additives). 2002. Bejot M. Nghiem P. Moon T. Melville. Lee EH. Austen KF. 1998. In: Fitzpatrick's Dermatology in General Medicine. Valenzano F. Keller T. Pathak MA. Hendrix C. 1768. 19. 609-618. 441-448. Katz S (eds. Arch Dermatol Res. Kripke ML. 122. New York. Morganti P. Gaffney P. Tucker MA. Curr Probl Dermatol. 1995. Ruocco V. Biochim Biophys Acta. Halpern A. Ermakov IV. retinoids. Lange BA and Buettner GR. Concentrations and plasma-tissue-diet relationships of carotenoids. Philips N. Del Ciotto P. 1999. Morganti P. Peng YM. New York. 2004. 2007. 220-229. Ruocco E. Katz S (eds. Austen KF.) Estee Lauder Research Laboratories. Faulhaber D. Clin Toxicol (Phila). Bruno C. 176-180. 3. 1042-1051. Eisen A. Elder DE. Antioxidants and basal cell carcinoma of the skin: a nested case-control study. and tocopherols in humans.). Skin Pharmacol Physiol. 115. Austen KF. Peters S. Jacob RF.). Roe DJ. Noninvasive raman spectroscopic detection of carotenoids in human skin. McClane RW. 2005. Skinmed. Roberts R. Eisen A. Byun J. New York. Freedberg I. Carcinogenesis: Ultraviolet Radiation. Int J Cosmet Sci. J Invest Dermatol. Pershing LK. Sun-protetcive agents: formulations. Modulation of UVA light-induced oxidative stress by beta-carotene. 18-25. 167-174. 226-230. In: Fitzpatrick's Dermatology in General Medicine. Photochemistry and Photobiology. 2004. Fitzpatrick TB. and side effects. 1999. and tocopherols in solid human tissues. 1999. Cancer Causes Control. Wolff K. Hamilton S. Marks GC. McGraw-Hill. Fluhr J. Freedberg I. 2007. Fabrizi G. Millen AE. Role of topical and nutritional supplement to modify the oxidative stress. Aghassi DS. Tuason M. 2004. 2000. Lockwood SF. 20. 24. Heinrich U. In: Fitzpatrick's Dermatology in General Medicine. Guerry Dt. In: Cosmetic science and technology-Cosmetic Claim substantiation. Ritenbaugh C. Morganti P. Misbahuddin M. Lutein from Tagetes erecta (Clinical and technical assessment-CTA) 63rd meeting JFCA. Khachik F. placebo-controlled study. Peng YS. 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 360 . Electron paramagnetic resonance detection of free radicals in UVirradiated human and mouse skin. Eisen A. Holly EA. 299. Goldsmith LA. All-E lutein and 3'-epilutein in the epidermis of chronic arsenic poisoning. Stahl W. Parrish JA. 1993. Hartge P. Taylor EJ and Evans FJ. 2004. Arch Biochem Biophys. Chen L. Bub A. 1989. Subar A. Sies H. ID 1608: “Lycopene” and “Antioxidant properties” 37 38 39 1 2 Lycopene. 15. Thiele JJ. Krutmann J. 135. Ojha SK. Nandave M. Block G. Duncan C. Packer L. 50. 2373-2378.php. Stacewicz-Sapuntzakis M. Carcinogenesis. 15345-15349. AID Infodienst Verbraucherschutz-Ernährung-Landwirtschaft. Future Oncol. 1-29. Arch Biochem Biophys. M. cosmetics. Stahl W. 2006. 78-78. van Breemen R. 532-538. McGraw-Hill. Ghosh L. 2005. Grether-Beck S. Singlet oxygen mediates the UVA-induced generation of the photoaging-associated mitochondrial common deletion. Freedberg I. 1998. Ruzicka T. Di Mascio P. Astley SB and Elliott RM. In: Cosmoceuticals science and technology-Cosmeceuticals: drugs vs. Yaar M and Gilchrest BA. 18. Lycopene and prostate cancer.). 19. Sharifi R. 3 4 5 6 7 8 9 10 11 12 361 . 1999. Kumari S. 2003. Elsner P and Maibach HI (eds. Fruit. 2004. http://www. Gupta SK. Willoughby M and H. 274. Bradley S and Shinton R. Segger D and Schonlau F. Anti-psoriatic action of lutein demonstrated by inhibition of rat photodermatitis. Effect of fruit and vegetable intake on skin carotenoid detected by non-invasive Raman spectroscopy. Marcel Dekker. Antioxidant defense systems in skin. Patterson B. Christov-Tzelkov K. Goldsmith LA. 16971706. 227. Cooper DA. Austen KF. heart disease. Bowen P. J Dermatolog Treat. 355. Dreher F. New York. Melville. 1. 69-86.was-wiressen. Cardioprotective effect of lycopene in the experimental model of myocardial ischemia-reperfusion injury. 1999. Ansari MS and Ansari S. Nutr Cancer. Watzl B. How strong is the evidence that lycopene supplementation can modify biomarkers of oxidative damage and DNA repair in human lymphocytes? J Nutr. 1998. 289. 886-893. 1998. Cutaneous biometrics and claim support. Eisen A. Berneburg M. Why is there an association between eating fruit and vegetables and a lower risk of stroke? Journal of Human Nutrition and Dietetics 11. In: Fitzpatrick's Dermatology in General Medicine. 145-187. Wolff K. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Mol Cell Biochem.). 25. Kim HS. Aust LB (ed. and agerelated macular degeneration: a review of recent research. Arya DS. Briviba K. Dietary carotenoids and certain cancers. New York. 2000. 2002. Effects of supplementing a low-carotenoid diet with a tomato extract for 2 weeks on endogenous levels of DNA single strand breaks and immune functions in healthy non-smokers and smokers. 89. 1999. 222-226. 1992. Mittal R. Bansal P. 1206-1212. Exp Biol Med (Maywood). 201-214. 2005. New York. and cancer prevention: a review of the epidemiological evidence. J Biol Chem.) Estee Lauder Research Laboratories. 274. Wingerath T. Kulling SE. 57. 363-372. Supplementation with Evelle improves skin smoothness and elasticity in a double-blind. 8. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Ageing of skin. 1998. Katz S (eds. Monograph. 2071S-2073S. Eldridge AL. Altern Med Rev. J Med Assoc Thai. Peters JC.I. Briviba K. Nutr Rev. Sies H. Kurten V. Kaiser S.33 34 35 36 Rerksuppaphol S and Rerksuppaphol L. vegetables. In: Cosmetic science and technology-Cosmetic Claim substantiation. Tomaten haben antioxidative und antikanzerogene Eigenschaften. Journal of Pharmacy and Pharmacology.de/abisz/tomaten_gesunde_ernaehrung_2937. Sies H. 425-430. Xanthophyll esters in human skin. 336-342. 2006. Rechkemmer G. placebo-controlled study with 62 women. Moseneder J. 271274. Martin BC. Huttunen JK. 2003. 41. Flynn M. JAMA. Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. 388-415. Negri E. Dietary antioxidants and beneficial effect on oxidatively damaged DNA. Med Clin North Am. Epidemiology. Free Radic Biol Med. Kritchevsky SB. 26. Effect of lycopene on DNA oxidative damage of cells in rats. 39. 2006. Clinton SK. Article in Chinese. 1998. 9. J Obstet Gynaecol Res. Joshi S. lycopene. Stuttgart. Lykopin und Lutein -starke Antioxidantien aus der Carotinoid-Familie. Rechkemmer G. http://www. 1992. 152. Am J Epidemiol. 189-191. 1999. Wollowski I. Wolters M. Silva AA. Stampfer MJ. lipofuscin formation and blue light damage. Gomez-Gracia E. Singal PK. Morris DL. 79. 299-304. Carcinogenesis. Medeiros MH. 391-398. Arch Biochem Biophys. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. Misra R. Gong MC. Braz J Med Biol Res. Hahn A. Pohar KS. Doc Ophthalmol. Tomatoes. Pandey RM. Li X. Gomes OF. World J Urol. Atherosclerosis. Krinsky NI. 951-971. Brunk UT. Berti C. blood pressure. LycoRed as an alternative to hormone replacement therapy in lowering serum lipids and oxidative stress markers: a randomized controlled clinical trial. 32. 1997. Nat Clin Pract Urol. Gomes OF. 272. Multiple Risk Factor Intervention Trial Research Group. Gaziano JM. Porrini M. Di Mascio P. 1439-1441. Matos HR. Moller P and Loft S. Hennekens CH. Frei B. Role of different types of vegetables and fruit in the prevention of cancer of the colon. An update on coronary risk factors. Lycopene and myocardial infarction risk in the EURAMIC Study. Kannel WB and Wilson PW. Di Mascio P. cigarette smoking. Willett WC. Miller EC. 746-761. and prostate cancer risk. 187-195. 2005. 38-43. Drug Insight: lycopene in the prevention and treatment of prostate cancer. Heimann JC. Brusamolino A. Shi G. 383. and breast. 93-99. rectum. 2. Neaton JD and Wentworth D. Kark JD. 203-210. Protective effect of lycopene on lipid peroxidation and oxidative DNA damage in cell culture. Kok FJ. Lycopene and beta-carotene protect in vivo iron-induced oxidative stress damage in rat prostate. 9-14. Davis CE. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Na L. 21. Masaev V.13 14 Franceschi S. Overall findings and differences by age for 316. A prospective study of tomato products. Qin Q. Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Pan H. Nilsson SE. Ringstad J. lycopene and prostate cancer: a clinician's guide for counseling those at risk for prostate cancer. 1995. Br J Nutr. Mangi S. Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate. 618-626. Giovannucci E. Rimm EB. 1847-1850. 2003. Arch Biochem Biophys. 396. La Vecchia C. Kohlmeier L. Favero A. Hatta A. Matos HR. 112. Mascio PD. Aging of cultured retinal pigment epithelial cells: oxidative reactions. Arch Intern Med. 2006. 2005. Guarnieri S. 2006. Johnson EJ. Matos HR. Mittal S. Medeiros MH. Marques SA. Martin-Moreno JM. Visioli F. Serum cholesterol. Muller H. and death from coronary heart disease. Kardinaal AF. 1997. Bahnson R. 362 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 . 13-16. Riso P. Hulsmann O. 18. Ridker PM. 146. 338-341. Capelozzi VL. 2002. Das Novamex-Lexikon der Nährstoffe von A bis Z. Gupta SK. Thamm M.de/Lexikon/Phytamine/Phytamine_Lykopin_Lutein.novamex. Riemersma R. Wei Sheng Yan Jiu 33. Sundelin SP. Steck SE. Serum carotenoids and coronary heart disease. 56-64. 106. Talamini R. 2006. Medeiros MH. Wihlmark U. 56-59. Guns ES and Cowell SP. 2004. 93. Khaper N. 1995. Pool-Zobel BL. Free Radic Biol Med. Bub A. 171-177.html Palace VP. Parpinel M. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. J Natl Cancer Inst.099 white men. 1994. Liu Y. 2000. 94. 2001. Organosan. Levy J. other carotenoids. Yilmaz S. Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. Sapp SK. Vivekananthan DP. Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. Karas M. Zhao X. Woolf H. Penn MS. Di Stefano A. Lycopene and 1. Epidemiology and the role of antioxidants in preventing coronary heart disease: a brief overview. Recovery of human lymphocytes from oxidative DNA damage. 101-107. Hippokrates. Yeum KJ. Stahl W. 908-913. Catignani GL. Torbergsen AC and Collins AR. Hsu A.34 35 36 37 38 Rao AV. Junghans A. Briviba K. 218. 127-134. de Boer B. 39. 33. Driomina ES. Danilenko M. 1994. Norkus EP. 2002. 2006. and the prevention of coronary heart disease. Proc Nutr Soc. Aldini G. Karahan I. 1997. Am J Clin Nutr. Role of lycopene and tomato products in prostate health. and phytoene levels in human serum and protects against UV-lightinduced erythema. Lancet. Tronnier H. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Nutr Cancer. 227. Musaeus N. Am J Clin Nutr. Atessahin A. Stahl W. Sesso HD. Stanghellini E. Stahl W and Sies H. Supplementation with tomato-based products increases lycopene. Ettorre A. Siler U. Topol EJ. 43. Andreassi L. Toxicology. Woodall AA. phytofluene. Kraemer K. Sies H. Arch Biochem Biophys. 22. 54-60. 425-430. Sies H. Aust O. Photochem Photobiol Sci. 2 3 4 5 363 . Urol Oncol. 2017-2023. 2005. Goralczyk R. 1. 1740. Krinsky NI. 2004. Eur J Nutr. 2003. 361. Biochim Biophys Acta. Lazarus S. Aust O. 164-171. 1-18. 59-65. 47-53. Jackson MJ. Exp Biol Med (Maywood). Tronnier H. Lycopene. Biochim Biophys Acta. J Eur Acad Dermatol Venereol. Willcox JK. 83. 1740. Rasmussen H. Plasma lycopene. 18. Russell RM. Sharoni Y. 2004. FEBS Lett. tomatoes. Ansari MS and Gupta NP. 105-112. Lycopene and prostate cancer. 415-420. 75. ID 1609: “Lycopene” and “Prostate health” 39 40 41 42 43 44 45 46 47 48 1 Amir H. Carotenoids and protection of phospholipids in solution or in liposomes against oxidation by peroxyl radicals: relationship between carotenoid structure and protective ability. 430. Ansari MS and Ansari S. Yermiahu T. 1998. 2000. 79. Ozer S. Biochim Biophys Acta. Lycopene-rich products and dietary photoprotection. 2005. Sahna E. Stacewicz-Sapuntzakis M and Bowen PE. Lycopene: modes of action to promote prostate health. Future Oncol. 2006. 575-586. Stuttgart. Giat J. Int J Vitam Nutr Res. 2005. 53. Tomatoes and cardiovascular health. 202-205. 80-85. 1336. 2004. Heinrich U. Stahl W. Watzl B and Leitzmann C. 2005. Riemersma RA. Bioaktive Substanzen in Lebensmitteln. 52-55. 2006. Britton G. and retinol and the risk of cardiovascular disease in women. 1999. 427. Sies H. Levy R. Crit Rev Food Sci Nutr. Wertz K. Protective effect of lycopene on adriamycininduced cardiotoxicity and nephrotoxicity. the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect.25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Bioactivity and protective effects of natural carotenoids. 163-169. Andreassi M. 2003. 238-242. 2004. 2005. Gaziano JM. Johnson EJ. 305-308. Antioxidant activity of topically applied lycopene. 5. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Heinrich U. Buring JE. Kristal AR. Lauridsen ST. biology. 19. Cancer Res. van Breemen R. J Natl Cancer Inst. 22nd Annual Meeting of the American Society of Preventive Oncology. Lycopene attenuates oxidative stress induced experimental cataract development: an in vitro and in vivo study. Gröber U. Hsing AW. 532-538. Ashton D. Chemopreventive efficacy of lycopene on 7. Dietary factors and risks for prostate cancer among blacks and whites in the United States. 274. the lipid status. 1999. Guns ES and Cowell SP. and tocopherol and risk of prostate cancer. 317-331. Kaiser S. 87. Greenberg RS. J Natl Cancer Inst. 38-43. J Natl Cancer Inst. Willett WC. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Ziegler RG. and cancer: review of the epidemiologic literature. 93. Jakobsen J. Schoenberg JB. Van den Brandt PA. 56. 38. Hoover RN. 2002. Torner J. Di Mascio P. Ascherio A. Nagini S. Breinholt V. Drug Insight: lycopene in the prevention and treatment of prostate cancer. tomato-based products. Trivedi D. van Breemen R. Bowen PE. anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. Jr. 865-874. Stacewicz-Sapuntzakis M. Fraumeni JF. Sharifi R. Bethesda. 2000. 82. Ma J. lycopene. Duncan C. and implications for human health and disease. Putnam S. Lynch C. 227. Parker A. 201-210. Tomatoes. 2. Fitoterapia. 25-34. Sacks FM. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Colditz GA. 1999. Cerhan J. Caamano-Isorna F. Willett WC. 2003. 59. 92. 1990. Cantor K. Cancer Lett. 391-398. Intake of carotenoids and retinol in relation to risk of prostate cancer. lycopene. Giovannucci E. Retinol. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Chen L. Serologic precursors of cancer.6 Bhuvaneswari V. Swanson GM. Verma SD. 91. Robbies M. Polk BF. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. Intestinal absorption of lycopene from different matrices and interactions to other carotenoids. Liu Y. Rimm EB. Schwartz AG. Chen L. Nutr Rev. 72. Fruit and vegetable intakes and prostate cancer risk. 13. Ghosh L. Nat Clin Pract Urol. and the antioxidant capacity of human plasma. Hayes RB. Srivastava S. Swanson C. Wissenschaftliche Verlagsgesellschaft. Goldbohm RA. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. 1139-1150. Bohm V and Bitsch R. 1767-1776. Giovannucci E. 941-946. Chiu B. 1998. and prostate cancer risk. 2001. Maryland. 2002. 1995. Liff J. Velmurugan B. Gupta SK. 2008. Takkouche B. Halder N. Balasenthil S. 61-68. Pottern LM. Dagnelie PC. Cancer Epidemiol Biomarkers Prev. Ramachandran CR. carotenoids. 794-799. Daneshvar B. Hennekens CH. Lycopene: chemistry. Joshi S. Stampfer MJ. Wallace R. Stampfer MJ. 94. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 364 . 886-893. Bowen P. Gann PH. 2001. 154. Cancer Epidemiol Biomarkers Prev. Silverman DT. Cohen JH. Gridley G. 2005. 1225-1230. 1998. Brown LM. Stampfer MJ. Clinton SK. 2004. BJU Int. Giovannucci E. Stacewicz-Sapuntzakis M. Exp Biol Med (Maywood). 35-51. 2000. J Natl Cancer Inst. Sies H. 2004. Rimm EB. 93. 1999. Orthomolekulare Medizin: Ein Leitfaden für Apotheker und Ärzte. J Natl Cancer Inst. Eur J Nutr.. 1999. Comstock GW. 1989. 340-345. Abbey H. Kim HS. Diet. Nutrition. Stuttgart. 1872-1879. Christov-Tzelkov K. Arch Biochem Biophys. Willett W. A cohort study of diet and prostate cancer risk. Sharifi R. Ghosh L. Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. J Natl Cancer Inst. 8. Duncan C. Giovannucci E.12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. 118-125. Etminan M. Stanford JL. A prospective study of tomato products. Schuurman AG. Kirsh VA. Bishop DT. Urol Oncol. Crawford ED. 3754-3759. Christov K. Klein R. Goyal NK. Hislop GT. Saxena S. 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 365 . 119-123. Jr. 861-868. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Am J Clin Nutr. Bolder CA. Stemmermann GN. Fishman D. Prall OW. Nahum A. 10. Norrish AE. 678-687. Li YW. Nutr Cancer. de Ridder CM. Wu AH. fruits. J Nutr. 15. Rao D. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Cancer. Howe GR. Palta M. Sharoni Y. antioxidants. Amir H. 2000. Urban DA. Ghosh L. 173-184. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. 3428-3436.26 27 Jain MG. Madar Z. 1997. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. 1989. Arch Ophthalmol. Am J Epidemiol. 113. Davey GK. and prostate cancer risk: findings from case-control studies in Canada. Prostate cancer and dietary carotenoids. Sharifi R. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. 2003. Levy J. Lee J. Nutr Cancer. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. 70. 1997. 76. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Danilenko M. 2001. Schroder FH. West DW. Pontes EJ. 2001. 92-98. Hankin JH. Bowen P. Scher HI. Cancer Epidemiol Biomarkers Prev. Ghadirian P. J Nutr. Brady WE. Sarkar FH. Cancer Epidemiol Biomarkers Prev. Watts CK. Key TJ. 598-604. 2001. Whittemore AS. 136. Chatterjee N. Obermuller-Jevic UC. Wildhagen MF. Mills PK. Wiley ER. Peters U. 40-47. Duncan C. Arora RP. Polak-Charcon S. Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. Protective effect of lycopene on lipid peroxidation and oxidative DNA damage in cell culture. 133. Giat Y. 1995. Le Marchand L. Nahum A. Arch Biochem Biophys.. Hirsch K. Plant foods. Limpens J. Kucuk O. Hayes RB. Chen L.. Crissman JD. 383-385. Reuter VE. and prostate cancer in Adventist men. Kaplan I. Fraser GE. Kolonel LN. Cordon-Cardo C. Jr. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Lu QY. Gallagher RP. Vegetables. Dixon LB. Medeiros MH. Carotenoids in human buccal mucosa cells after 4 wk of supplementation with tomato juice or lycopene supplements. Mares-Perlman JA. A case-control study of diet and prostate cancer. Livny O. Heber D. Reifen R. Koifmann A. 20. Kolonel LN. Di Mascio P. Marshall JR. Cancer Epidemiol Biomarkers Prev. Stacewicz-Sapuntzakis M. Sharpe SJ. 6. 151. 1518-1523. 2002. Oncogene. legumes and prostate cancer: a multiethnic case-control study. Wood DP. 2005. Phillips RL. 47. Br J Cancer. Howe GR. Silcocks PB. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Levy J. 2006. 64. 2006. Appleby PN. Kramer K. 132. Pollak MN. 487-491. Wilkens LR. Nutr Cancer. Danilenko M. Cohort study of diet. Beeson WL. 795-804. 56-59. Go VL. Mohanty NK. Nomura AM. Hankin JH. Dreon DM. 2000. Paffenbarger RS. Karas M. Zhang ZF. Bowen P. Jackson RT. 9. Matos HR. lifestyle. van Weerden WM. 34. Khachik F. Banerjee M. Am J Epidemiol. Sharoni Y. Djuric Z. 1991. Leitzmann MF. 23. 490-494. Clevidence BA. Singh UP. Segal S. 383. 215-219. Klein BE. Sakr W. John EM. 1999. 1287-1293. Paetau I. 2000. Schwartz B. Mayne ST. 101-111. Wilkens LR. Cancer Epidemiol Biomarkers Prev. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. 749-756. Hung JC. Cancer Epidemiol Biomarkers Prev. Grignon D. Craft NE. Skeaff CM. 10. Bertram JS. 36. Kim HS. 2000. 1999. Brown ED. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. Bahnson R. 19. Carcinogenesis. Tronnier H. Aust O. 1847-1850. 2006. Clinton SK. 31. Goralczyk R. and the risk of prostate cancer: a nested case-control study. Tomatoes. Trichopoulos D. Photochem Photobiol Sci. 2003. Sowell AL. Vegetable and fruit composition and prostate cancer risk: a cohort study in The Netherlands. van Breemen RB. 189-192. lycopene and prostate cancer: a clinician's guide for counseling those at risk for prostate cancer. 1998.. 2005. Signorello LB. 366 . Hunziker PB. the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. Schoenberg JB. Monograph. Stahl W. Goldbohm R. Platz EA. 80. Yeum KJ. J Nutr. 2000. 1023-1032. Biochim Biophys Acta. Wertz K. Arch Biochem Biophys. 115. Sies H. Rechkemmer G. Graubard BI. Boscoboinik D. Curr Eye Res. Lycopene: modes of action to promote prostate health. Mayne ST. 202-205. Mitchell P. Schwartz SJ. Rochtchina E. Hoover RN. Muller H. Denelavas A. and risk of prostate cancer in US Blacks and Whites. Azzi A. 271-274. 373. 199-203. 2008. Wuu J. How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia? J Nutr. Dietary antioxidants and the longterm incidence of age-related macular degeneration: the Blue Mountains Eye Study. Russell RM. Lycopene-rich products and dietary photoprotection. Bub A. Lymphocyte lycopene concentration and DNA protection from oxidative damage is increased in women after a short period of tomato consumption. Torbergsen AC and Collins AR. Tzonou A. 1997. 334-341. 704-708. Cancer Epidemiol Biomarkers Prev. World J Urol. Taylor A. 250. Tan JS. other serum carotenoids. 135. 336-342. 5. Ophthalmology. 127-134. van den Brandt P.45 Pastori M. J Nutr. 9-14. 2005. Herzog A. Plasma and dietary carotenoids. Biochem Biophys Res Commun. 502-505. Arch Biochem Biophys. Wollowski I. Stimulation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. Schuurman A. 135. Diet and cancer of the prostate: a case-control study in Greece. Pfander H. Swanson CA. Greenberg RS. Jr. Altern Med Rev. 2050S-2052S. Swanson GM. Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer. Miller EC. 1999. Siler U. Emmerich T. Serum lycopene. Clinton SK. Nutr Cancer. 2002. 673-680. DeGroff V. Ziegler RG. 13. Hunziker W. Flood V. Goralczyk R. Pohar KS. 18. 2004. Hayes RB. Barella L. Fat-soluble nutrient concentrations in different layers of human cataractous lens. 7. Cancer Epidemiol Biomarkers Prev. 238-242. Gong MC. Heinrich U. Spitzer V. Am J Epidemiol. 2003. 80-85. Leitzmann M. Porrini M and Riso P. Erdman JW. Lagiou P. Lycopene effects on rat normal prostate and prostate tumor tissue. 2004. Sies H. Martin HD. Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. 1998. 2005. Stahl W. Siler U. Wertz K. Stacewicz-Sapuntzakis M and Bowen PE. Giovannucci E. Seifert N. 582-585. 1998. 430. 21. ID 1611: “Lycopenes from tomato juices” and “Antioxidant properties” 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 1 Lycopene. Pool-Zobel BL. 39. 1740. Shang FM. Lein M. Wu K. 260-269. Trichopoulou A. Int J Cancer. 130. 2062S-2064S. Recovery of human lymphocytes from oxidative DNA damage. von Laar J. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. 8. Schalch WM. Role of lycopene and tomato products in prostate health. Dorant E. 2000. Smith W. Wang JJ. 155. Rao AV and Agarwal S. Vogt TM. Willett WC. Eur J Nutr. 1999. 2000. CMAJ. 135. Agarwal S and Rao AV. Intestinal absorption of lycopene from different matrices and interactions to other carotenoids. Chirlaque M. 52-55. and zeaxanthin. Borden LS. beta-carotene. 2005. The role of antioxidants in nutritional support. Pera G. A European Commission Concerted Action Funded within the FAIR-RTD programme. 981-984. Thieme Verlag. Lipids. Biesalski H-K.. Moseneder J. Pietrzik K. Exp Biol Med (Maywood). 16. Monir M. Rao AV. Tomato lycopene and its role in human health and chronic diseases. Tomatoes versus lycopene in oxidative stress and carcinogenesis: conclusions from clinical trials. Lycopene and the lung. Köhrle J. 2002. Urology. Hu JJ. Dorronsoro M. Quiros JR. Duncan C. Basu A and Imrhan V. Kesse E. Stuttgart. Sharifi R. 67. Antioxidant activity of topically applied lycopene. Key TJ. Lund E. 2000. Stanghellini E. 118-125. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Arab L. Welch AA. 739-744. Christov-Tzelkov K. Torti FM. 4. Pala V. Kim HS. 2002. 2006. Mattisson I. Shen H. Andreassi L. Steck-Scott S. Vineis P. Effects of supplementing a low-carotenoid diet with a tomato extract for 2 weeks on endogenous levels of DNA single strand breaks and immune functions in healthy non-smokers and smokers. 227. Gerber M. Gustav Fischer. Tjonneland A. Bilton R. 2005. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 367 . Bueno-de-Mesquita HB. Sanchez-Perez MJ. 146. 1387-1396. Role and control of the antioxydants in the tomato processing industry. the lipid status. 1998. Galasso R. Eur J Intern Med. van Breemen R. Schümann K. Al-Delaimy WK. 2005. 38. Grolier P. Biesalski HK. Bohm V. Ettorre A. 2002. van Kappel AL. Ferruzzi MG. Naska A. Puspitasari-Nienaber NL. 9-15. Barricarte A. 33. 2002. Trolox equivalent antioxidant capacity of different geometrical isomers of alpha-carotene. The antioxidants in tomatoes and tomato products and their health benefits. Kulling SE. Di Stefano A. Stuttgart. 1257-1261. Schwartz SJ. 894899. Ghosh L. Lycopene Content of Tomato Products: Its Stability. Peeters PH. Wirsansky I. 593-596. Palli D. Bub A. Watzl B. Blum A. Orv Hetil. J Eur Acad Dermatol Venereol. Eur J Clin Nutr.2 3 4 5 Agarwal S and Rao AV. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. 2373-2378. 2071S-2073S. Johansson I. and the antioxidant capacity of human plasma. Agarwal A. Clavel-Chapelon F. Spencer E. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. The beneficial effects of tomatoes. Bowen P. Stacewicz-Sapuntzakis M. Wirfalt E. Stindt D. Bässler KH. Riboli E. How strong is the evidence that lycopene supplementation can modify biomarkers of oxidative damage and DNA repair in human lymphocytes? J Nutr. Apotheker und Ernährungswissenschaftler. Fleishauer AT. 16. Carcinogenesis. 18. Miller AA. Vitamin-Lexikon für Ärzte. Trichopoulou A. 886-893. 2004. Bohm V and Bitsch R. van Gils CH. 2007. [Lycopene--a natural antioxidant]. Nagel G. 2004. Jr. Nutrition. Bioavailability and In Vivo Antioxidant Properties. 25. 2001. Slimani N. Banhegyi G. Jr. 59. 402-404.. Bingham S. 50. Clark PE. Agarwal S. Lee WR. Loew D. Harmon M. 2000. Briviba K. Ben-Arzi S. Eur J Clin Nutr. 61. Astley SB and Elliott RM. lycopene. Alsaker EH. Andreassi M. 227. Lovato J. 163. Tumino R. Steghens JP. 2000. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Linseisen J. Rechkemmer G. Golly I. Chen L. Boeing H. Vitamine. Boutron-Ruault MC. 295-303. 1621-1624. Ocke MC. Jena. Ferrari P. 2002. 221-226. 1999. Eur J Nutr. J Agric Food Chem. Nilsson S. Hall MC. Leoni C. Olsen A. Exp Biol Med (Maywood). Overvad K. 2005. D'Agostino R. J Med Food. Plasma carotenoids as biomarkers of intake of fruits and vegetables: individual-level correlations in the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. Gross MD. and cancer: review of the epidemiologic literature. Narayan KM. Wolters M. 112. The American journal of clinical nutrition. 153. Schuurman AG. Eugen Ulmer. Hatta A. 168-176. 317-331. 2002. Giovannucci E. Jacobs DR. Hennekens CH. 340-345. Gärtner C. Ernährung des Menschen. A case-control study. 1767-1776. Colditz GA. Elmadfa I and Leitzmann C. Cooper DA. Di Mascio P. 57. Kaiser S. 87. lycopene. Lebwohl M. 2006. Oberhollenzer F. Van den Brandt PA. Caamano-Isorna F. and autoantibodies against MDA-LDL with carotid atherosclerosis. 13. Diet. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. 2004. 2000. and agerelated macular degeneration: a review of recent research. Martines D. Liu Y. Sturniolo GC. Belcher JD. 135. The ARIC Study Investigators. Intake of carotenoids and retinol in relation to risk of prostate cancer. Stuttgart. Jr. 376382. Etminan M. Ridker PM. 2005. Sies H. Krinsky NI. 1997. 1995. anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. High plasma levels of alpha. Willett WC. Dagnelie PC. Folsom AR. Nutr Rev. Dietary carotenoids and certain cancers. LDL susceptibility to oxidation.. Sterry W. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Meinke M. Stampfer MJ. Iribarren C. tomato-based products. 47. 2003. 94. Lycopene: chemistry. Giovannucci E. 532-538. Arch Biochem Biophys. Stampfer MJ. Tomatoes or lycopene: a role in prostate carcinogenesis? J Nutr. Nutr Metab Cardiovasc Disease. Bonvicini P. 149. Cancer Epidemiol Biomarkers Prev. 3. J Natl Cancer Inst. 181-187. Tomatoes. Willett WC. 2005. Prävention Therapie. Atherosclerosis Risk in Communities. Ernährung–Physiologische Grundlagen. Rimm EB. 2006. Kiechl S. Rimm EB. Sloot S. Arterioscler Thromb Vasc Biol. Darvin ME. Goldbohm RA. Atherosclerosis. 35-51. 1998. Giovannucci E. 1999.and beta-carotene are associated with a lower risk of atherosclerosis: results from the Bruneck study. Protective effects of lycopene against ultraviolet B-induced photodamage. and prostate cancer risk.21 22 23 24 25 Clinton SK. J Natl Cancer Inst. Wei H. Eldridge AL. 17. Naccarato R. 1139-1150. biology. Ascherio A. 187-195. Atherosclerosis. 116-122. D'Odorico A. 1995. Flynn M. 391-398. Gersonde I. 2004. Gao D. Antioxidants in adipose tissue and myocardial infarction in a Mediterranean area. 1171-1177. Das DK. 1998. 39. Lu Y. 449-455. Gomez-Aracena J. tomatoes. Takkouche B. Maulik N. Bowman BA. 7. Willeit J. Otani H. Stahl W. lycopene. Ströhle A. Sies H. 93. Will JC. Johnson EJ. Non-invasive in vivo detection of the carotenoid antioxidant substance lycopene in the human skin using the resonance Raman spectroscopy. 56. Wissenschaftliche Verlagsgesellschaft mbH. and coronary heart disease. Eckfeldt JH. 1989. J Natl Cancer Inst. Albrecht H. 1999. 2006. Fazekas Z. Nutr Cancer. 201-214. Frei B. Gaziano JM. 231-239. and implications for human health and disease. Hahn A. Garcia-Rodriguez A. 1999. Das S. Egger G. Ford ES. 91. Saladi RN. 274. Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey. Peters JC. 1997. A prospective study of tomato products. Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. 66. Clinton SK. 2057S-2059S. 1997. Stuttgart. Lademann J. Laser Physics Letters. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. heart disease. Free Radic Res. Lycopene is more bioavailable from tomato paste than from fresh tomatoes. Hahn A. Association of serum vitamin levels. Lycopene. 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 368 . Nutr Rev. The Euramic study in Malaga. BJU Int. Graham S. Mannisto S. 2006. Watanabe Y. Pietinen P. Levy J and Sharoni Y. McCullough ML. Cartmel B. Fuchs CS. Ozasa K. Tsugane S. Serum carotenoids and mortality from lung cancer: a case-control study nested in the Japan Collaborative Cohort (JACC) study. Cancer Sci. Intakes of fruits and vegetables. van den Brandt PA. Umar SL. Young C. Wakai K. Olsson AG. Rowland K. The Rotterdam Study. Ando M. Mannisto S. 960-965. Seki N. 4. BMJ. 23. 148. Tan W. Virtamo J. Rohan TE. Virtamo J. 629-633. Hahn A. 2007. Lecerf JM. Suzuki K. 2005. Anderson K. Goodwin WJ. Ando M. Seki N. Martin-Moreno JM. 57-63. Arch Biochem Biophys. 309-333. Capelozzi VL. Elwing B. Pasteur Institute-Lille. Suzuki K. Buring JE. Nikcevich D. Spiegelman D. Zheng T. Kucinskiene Z. Abaravicius A. Jatoi A. Lung cancer mortality and serum levels of carotenoids. Freudenheim JL. 40-48. Medeiros MH. Tomate. Thamm M. Mascio PD. Willett WC. Kondo T. S82-91. Phytothérapie. Ozasa K. Colditz G. E. Am J Epidemiol. Low plasma lycopene concentration is associated with increased mortality in a cohort of patients with prior oral. Free Radic Biol Med. 2002. Kristenson M. and folic acid in men and women: a case-control study nested in the JACC Study. 49-58. 210. lycopène et prévention cardiovasculaire. retinol. Huttunen JK. Spiegelman D. 246-255. Martin BC. 2004. Foods & Food Ingred J Jpn. Riemersma R. Leitzmann C. Minorsky PV. Tamakoshi A. Lycopene and human health. Albanes D. 2007. Feskanich D. Lin H. Functional claims of art 13: Lycopene in tomato juices. Gomez-Gracia E. 396. Urology. The functions of tomato lycopene and its role in human health. Hunter DJ. Colditz GA. Kobayashi M. Nishino Y. 13. Burch P. Food Reviews International. Willett WC. Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50. Rohan TE. J Epidemiol. Elinder LS. S140149. Leitzmann M. Ding X-L. 2003. Geleijnse JM. Hillman D. Serum carotenoids and atherosclerosis. 2003. Freudenheim JL. 22. 130. Albanes D. 165. Giovannucci E. Masaev V. Vanyo JM. Müller C. Miller AB. Gomes OF. 1077-1078. Flynn PJ. 13. Adami HO.. 2004. Launer LJ. Ernährung in Prävention und Therapie: Ein Lehrbuch. 69. Giovannucci E. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. 2001. Virtanen M. Watanabe Y. Miller AB. Wolk A. Ohno Y. Virtamo J. 2006. Zieden B. 1997. Razinkoviene L. Smith-Warner SA. Taylor PR. Morton R. Stuttgart. Dietary antioxidants and beneficial effect on oxidatively damaged DNA. Klipstein-Grobusch K. Kondo T. Nishino Y. tocopherols. Br J Cancer. Brehme U. Yaun SS. pharynx or larynx cancers. 49-56. 314. 2000. 618-626. 2006. Sasaki S. Zhang SM. Hofman A. J Epidemiol. Kok FJ. Goldbohm RA. Kark JD. 289-294. Cancer Epidemiol Biomarkers Prev.42 Ito Y. Schatzkin A. 1997. A tomato-based. Lycopene: Its Properties and Relationship to Human Health. Wakai K. Witteman JC. C in relation to the risk of bladder cancer in the ATBC cohort study. Michel P. Dakhil S. 87. Ohno Y. 2001. lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. 369 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 . 2006. Lecerf JM. 41. Mayne ST. 2002. 34-42. J Am Coll Nutr. Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate. 2004. Albanes D. Lycopene and myocardial infarction risk in the EURAMIC Study. Smith-Warner SA. Harnack L. 146. 388-415. Matos HR. Ito Y. Plant Physiol. Cerhan JR. van den Brandt PA. Goldbohm RA. Atherosclerosis. 15 Suppl 2. Ringstad J. carotenoids and vitamins A. Kardinaal AF. Jr. Tamakoshi A. Cerhan JR. Boeing H. Calkauskas H. Hunter DJ. Am J Epidemiol. Hippokrates .Georg Thieme. Kun Y. Dietary carotenoids and risk of colorectal cancer in a pooled analysis of 11 cohort studies. 94. Steck SE. Bergdahl B. Laube H. Moller P and Loft S. Kohlmeier L. Michaud DS. 171-177. Validity of a self-administered food frequency questionnaire used in the 5-year follow-up survey of the JPHC Study Cohort I to assess carotenoids and vitamin C intake: comparison with dietary records and blood level. Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans. Salonen R. 202-205. Sesso HD. Role of lycopene and tomato products in prostate health. Lycopene and Human Health. Kramer TR. Risk assessment for the carotenoids lutein and lycopene. Tomatoes. Postaire E. 152. 2006. Regul Toxicol Pharmacol. double-blind. discussion 930-921. Kapeller P. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. Gaziano JM. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Comstock GW. 56. Espana. 85. 2003. Salonen JT. Prooxidant actions of carotenoids in biologic systems. Roobol MJ. Eur Urol. Salonen JT. Rao LG. Rao AV. Offenbacher H. 11. Bejot M. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. 1997. Jungmann H. 1187-1195. 257-265. Barcelona. Luther V. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. Nyyssonen K. Nutr Rev. Singal PK. 2004. Sies H and Stahl W. Helzlsouer KJ. Am J Clin Nutr. 2000. 18. Br J Nutr. Prospective study of carotenoids. Plasma lycopene. Arterioscler Thromb Vasc Biol. 99-164. 48. 95-100. 561-569. Stacewicz-Sapuntzakis M and Bowen PE. Paetau I. 1998. Brown ED. 2005. Muller H. Br J Nutr. Esterbauer H. 1997. Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. Riemersma RA. 79. Nyyssonen K. Am J Clin Nutr. Lakka TA. Rao V. 68. Visioli F. 2003. Porrini M. Kostner GM. 922-930. 289-298. Wollowski I. and retinol and the risk of cardiovascular disease in women. Schroder FH. Schumacher M. Randomized. Evidence for antioxidant nutrientsinduced pigmentation in skin: results of a clinical trial. 2677-2681. 1023-1033. Clevidence BA. Wildhagen MF. 1997. 53. Khachik F. Tronnier H. Adv Food Nutr Res. 2005. 45. Carcinogenesis. Broom JI. Schmidt R. 746-761. J Neurol Sci. Salonen R. Palace VP. Int J Vitam Nutr Res. Schmidt H. Salonen R. Non-nutritive bioactive constituents of plants: lycopene. and retinoid concentrations and the risk of breast cancer. Boeve ER. Biochim Biophys Acta. 47-53. Sivenius J. Bub A. 749-754. Fazekas F. Rissanen TH. Kaplan GA. 77. van Helvoort A. 2006. 1999. 93-99. Duttaroy AK. Ray MR. Salonen JT. Roob G. Rechkemmer G. Beecher GR. Proc Nutr Soc. Palozza P. 59-65. 2001. tocopherols. Am J Clin Nutr. Biochem Mol Biol Int. Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. 2006. Epidemiology and the role of antioxidants in preventing coronary heart disease: a brief overview. Riso P. 2005. other carotenoids. Pool-Zobel BL. Hoffman SC. Webb DJ. Lycopene. Zuijdgeest-van Leeuwen SD. 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 370 . 84. Weinrauch V. Khaper N. de Mutsert R. 2006. Caledonian. 1994. Horgan G. Hayn M. Whelan S. Voutilainen S. Free Radic Biol Med. 20. Buring JE. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Voutilainen S. Chittams J.61 O'Kennedy N. Rissanen T. Voutilainen S. 42. 1998. lutein and zeaxanthin. 93. Norkus EP. Rissanen TH. 26. Cancer Epidemiol Biomarkers Prev. Berti C. 133-138. Norkus EP. Kersten I. Kaplan GA. Guarnieri S. 1847-1850. 451-457. Shao A and Hathcock JN. Qin Q. 15-21. 1740. Heinrich U. Sato R. 51. Crosbie L. 73. Brusamolino A. Alberg AJ. 2002. Consumption of vegetables reduces genetic damage in humans: first results of a human intervention trial with carotenoid-rich foods. Eber B. Nyyssonen K. Am J Clin Nutr. Nutr Rev. Nosaka N. 2003. 2006. Mae T. 507-513. Borel P. 361. 1982. Enhanced thermogenesis and diminished deposition of fat in response to overfeeding with diet containing medium chain triglyceride. Herzberg GR. Hematological and biochemical effects of parenteral nutrition with medium-chain triglycerides: comparison with long-chain triglycerides. 2001. Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. 1992. Can J Physiol Pharmacol. 37. Tyssandier V. 2161-2166. Aoyama T. van den Berg H. Crit Rev Food Sci Nutr. 1996. Tanaka H. Torbergsen AC and Collins AR. Effect of tomato product consumption on the plasma status of antioxidant microconstituents and on the plasma total antioxidant capacity in healthy subjects. 23. 148-156. Stahl W. 53. 163-169. Carotenoid interactions. 85. 678-682. Nakagawa K. Burgerstein's handbook of nutrition: micronutrients in the prevention and therapy of disease. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy? J Lipid Res. 83. 35. Caris-Veyrat C. 101-107. 1265-1271. Thieme Publishing Group. Arai N. Biochim Biophys Acta. Voutilainen S. Watzl B and Leitzmann C.81 82 83 Stahl W and Sies H. Guilland JC. 2005. 39. de Boer B. Stahl W and Sies H. 83. Nakai Y. Rasmussen H. Russell RM. Ball MJ. 2003. 1999. 1154-1161. Woolf H. Honda S. Boirie Y. Krinsky NI. 2007. 57. Georg Thieme. 80-85. 1994. Driomina ES. 1-10. Hashim SA. Baba N. Serum antioxidants and myocardial infarction. 2017-2023. 71. Zhao X. 54. 1-9. Bioactivity and protective effects of natural carotenoids. 2007. Yeum KJ. High-level medium-chain triglyceride feeding and energy expenditure in normal-weight women. White MD. Briviba K. Biosci Biotechnol Biochem. Tomatoes and cardiovascular health. The Lancet. Comstock GW. J Med Invest. 708-726. Musaeus N. Stuttgart. Kraemer K. 2000. Klag MJ. Yokota S. Lazarus S. 427. Rissanen TH. 916-922. Am J Clin Nutr. 2006. Aoki F. 43. Topol EJ. Am J Clin Nutr. Carotenoids and cardiovascular health. Salkeld RM. 1991. 122. J Am Coll Nutr. Asakura T. Carotenoid mixtures protect multilamellar liposomes against oxidative damage: synergistic effects of lycopene and lutein. Frey A. Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Aldini G. 1999. Feillet-Coudray C. Recovery of human lymphocytes from oxidative DNA damage. Vivekananthan DP. ID 1614: “Medium Chain Triglycerides (MCT)” and “Weight management” 84 85 86 87 88 89 90 91 92 93 94 1 2 Alexandrou E. Bioaktive Substanzen in Lebensmitteln. 2004. Eur J Nutr. Am J Clin Nutr. Bach AC. 206-214. Zimmermann M and Burgerstein L. Ingenbleek Y. Bureau S. Reich M. Willcox JK. 385-388. Sies H. 2007. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Research on the nutritional characteristics of medium-chain fatty acids. Nurmi T. Stuttgart. Kishida H. Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. Stahl W and Sies H. Sapp SK. 305-308. 336. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation. Catignani GL. Bracco EF. 1-18. Kasai M. 1998. 90. Lycopene: a biologically important carotenoid for humans? Arch Biochem Biophys. 1996. AmiotCarlin MJ. Hsu A. Bouteloup-Demange C. Junghans A. Schuep W. FEBS Lett. the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. Kitano M. Mursu J. Street DA. Am J Clin Nutr. 371 3 4 5 6 . J Nutr. 1740. Penn MS. Johnson EJ. Coudray C. 1989. Fink WJ. New York. Arteaga A. Girardier L. Cesana B. Torbay N. Peret J. 1987. Sensations induced by medium and long chain triglycerides: role of gastric tone and hormones. Doenecke D. Binnert C. Gut. Hahn A. Abumrad NN. Effect of a saturated medium-chain triglyceride on serumlipids in man. Deng B. 536-540. 1. Sharp T. Ravussin E. Peters JC. J Clin Invest. Heller HJ. 36. 1994. 76. Ma J. Girard J. Hauenschild A. Geelen MJ. Koolman J. 48. Greene HL. J Nutr Sci Vitaminol (Tokyo). Choi YH. 1997. Dietary medium-chain fatty acids raise and (n-3) polyunsaturated fatty acids lower hepatic triacylglycerol synthesis in rats. Mabayo RT. 1992. Chanez M. 2007. Okumura J. Feldheim W. 407-416. Greene HL. 1019-1024. 985-991. Metabolic effects induced by long-term feeding of medium-chain triglycerides in the rat. Peracchi M. 1. Metabolism. Int J Sports Med. 1985. Sharp T. Geliebter A. Overfeeding with medium-chain triglyceride diet results in diminished deposition of fat. 1998. and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans. 4-8. Nosaka N. 1984. Flatt JP. Kurzes Lehrbuch der Biochemie für Mediziner und Naturwissenschaftler. Jelinek J. 1960. Am J Clin Nutr. Vandermander J. Effects of dietary fat on postprandial substrate oxidation and on carbohydrate and fat balances. Stuttgart. Eugen Ulmer Verlag. 1996. Kirkland JL. Maki H. Abumrad N. Mensi N. 1980. 1990. Chantre P. 2003. 32-36.7 8 Barbera R. Dulloo AG. Ohra A. Am J Clin Nutr. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. 50. Takeuchi H. 2449-2456. Bracco EF. 2006. Yang D. Comparison of the effects of medium-chain triacylglycerols. 595-601. Beynen AC. Beylot M. Jequier E. Sun J. Metabolism. 1105-1108. Short term effects of dietary medium-chain fatty acids and n-3 long-chain polyunsaturated fatty acids on the fat metabolism of healthy volunteers. 41-45. J Lipid Res. Acheson KJ. 46. Stuttgart. Laville M. 38. 50. Riou JP. Hill JO. Twenty-four-hour energy expenditure and urinary catecholamines of humans consuming low-to-moderate amounts of medium-chain triglycerides: a doseresponse study in a human respiratory chamber. palm oil. Swift LL. Kurzes Lehrbuch der Biochemie für Mediziner und Naturwissenschaftler. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 372 .versus long-chain triacylglycerols. Furuse M. Hans D. 641-648. Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. Klor HU. Ivy JL. Corkey BE. 15-20. Metabolism. 67. Guo W. 10. Ernährung des Menschen. 2003. Eur J Clin Nutr. Boehm G. Bois-Joyeux B. Hashim SA. 31. Kasai M. Mittelkettige Triglyceride (MCT): Geeignet zur Kontrolle des Körpergewichts? Ernährungs-Umschau. Fathi M. Thermogenesis in humans during overfeeding with medium-chain triglycerides. Okazaki M. Stuttgart. 2000. 1995. Wissenschaftliche Verlagsgesellschaft mbH. Denke MA. Elmadfa I and Leitzmann C. Pachiaudi C. 1-4. 37. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight freeliving type 2 diabetic Chinese subjects. Contribution of medium and long chain triglyceride intake to energy metabolism during prolonged exercise. 2002. Basilisco G. Karlson P. 1983. Beermann C. 1998. Brighenti F. Bijleveld C. Reinecker T. 152-158. Aoyama T. J Nutr. Comparison of diet-induced thermogenesis of foods containing medium. Van Itallie TB. Costill DL. Han JR. 125. Yang D. Chen CG. Feeding behavior in rats fed diets containing medium chain triglyceride. Am J Clin Nutr. Peters JC. Hill JO. Suzuki Y. Maglischo E. Lancet. Van Itallie TB. Georg Thieme Verlag. 56. Crozier G. 807-814. Harada Y.and medium-chain triacylglycerols. Karlson P. Stuttgart. Kondo K. 2. Georg Thieme. 52. Cater NB. Influence of human obesity on the metabolic fate of dietary long. 65. Physiol Behav. Bianchi PA. Kaler M. Schoots WJ. 815-817. Lipids Health Dis. Hashim SA. Rolls BJ. Value of VLCD supplementation with medium chain triglycerides. Nakamura M. Asia Pac J Clin Nutr.or longchain triglyceride emulsions. Br J Nutr. 1992. Kasai M. Aoyama T. 7. 10. Biosci Biotechnol Biochem. 2002. Uto H. White MD. 2003. Tsuji H. Effect of dietary medium. Jones PJ. 1393-1400. Nosaka N. Igarashi O. 67. Tsuji H. 48. White MD. Ohara A. 1374-1382. Effects of highly purified structured lipids containing medium-chain fatty acids and linoleic acid on lipid profiles in rats. 46-50. Am J Clin Nutr. 1999. Itakura M. Int J Obes Relat Metab Disord. Jones PJ. 2002. 2006. Ogawa A. Okazaki M. 24. Kondo K. Aoyama T. Kasai M. 1987. Effect of medium chain triglyceride on lipogenesis and body fat in the rat. Papamandjaris AA. 48. Krotkiewski M. 91. 55. Uto H. Watanabe S. 2006. Negishi S. Metabolically active functional food ingredients for weight control. Tsuji H. Haruna H. Kasai M. Larger diet-induced thermogenesis and less body fat accumulation in rats fed medium-chain triacylglycerols than in those fed long-chain triacylglycerols. Components of total energy expenditure in healthy young women are not affected after 14 days of feeding with medium-versus long-chain triglycerides. 524-529. 1483-1492. Okazaki M. Ney DM. 1988. 2006. Phytosterols mixed with medium-chain triglycerides and high-oleic canola oil decrease plasma lipids in overweight men. 2003. Matsuo T and Takeuchi H. Effects of margarine containing medium-chain triacylglycerols on body fat reduction in humans. 2001. Biosci Biotechnol Biochem. Nosaka N. Nakamura M. Effects of structured medium. 66-71. J Nutr Sci Vitaminol (Tokyo). Nosaka N. 391-395. Takeuchi H. Effects of dietary medium-chain triacylglycerols on serum lipoproteins and biochemical parameters in healthy men. Energy expenditure in rats maintained with intravenous or intragastric infusion of total parenteral nutrition solutions containing medium. Metabolism. Kasai M. 108. Okazaki M. Papamandjaris AA. 122. 12. Suzuki Y. Okazaki M. Takeuchi H. Gnizak N. 613-620. Jones PJ. Kondo K. Int J Obes Relat Metab Disord. Saito M. Roynette CE. 2003. Effect of medium-chain triglycerides on the postprandial triglyceride concentration in healthy men. J Nutr. Medium-chain triglycerides. 2000. Biosci Biotechnol Biochem. 219-225. Kasai M. 1937-1943. 2003. 67. Nosaka N. 66. 16. Marten B. 1978.and long-chain triacylglycerols in diets with various levels of fat on body fat accumulation in rats. Kovacs EM and Mela DJ. 46-53. Suzuki Y. 2007. Igarashi O. Kondo K. Kubota F.and long-chain triacylglycerols on bodyfat accumulation in healthy young subjects. 128-130. 10. 290-298. Aoyama T. 56. Tsuji H. Takeuchi H. J Oleo Sci. Kasai M. Obes Rev. Noguchi O. Matsuo T. 11581166. Kondo K. Maki H. Ooyama K. 283-287. 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 373 . 1713-1718. 151-160. Schrezenmeir J. Keesey RE. Rothwell NJ and Stock MJ. Takahashi I. Okazaki M. Metabolism. 2004. Food intake in dieters and nondieters after a liquid meal containing medium-chain triglycerides. Nakhasi DK. 36. Endogenous fat oxidation during medium chain versus long chain triglyceride feeding in healthy women. Asia Pac J Clin Nutr. Rudkowska I. Aoyama T. Dietary medium. Aoyama T. Nagata J. Rivera J. Maki H. Effects of a liquid diet supplement containing structured medium. Maki H. 25. Lavau MM and Hashim SA. Obes Res. Laster LJ. International Dairy Journal. Ikeda I. J Atheroscler Thromb. Igarashi O. Lasekan JB. Summerfelt A. 7. J Nutr. Kondo K. Stimulation of thermogenesis and brown fat activity in rats fed medium chain triglyceride. Raeini-Sarjaz M.28 Kasai M. 273-280. Pfeuffer M. Aoyama T.and long-chain triacylglycerols accelerate diet-induced thermogenesis in humans. Nosaka N.and long-chain triacylglycerols (MLCT) on accumulation of body fat in healthy humans. Matsuo M. 59-78. Hirvonen MD. 2001. 2003.and long-chain fatty acids on body fat accumulation in rats. Ogawa A. Aoyama T. 2002. 69. 48. Am J Clin Nutr. Tsuji H. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind. Caballero B. St-Onge MP and Jones PJ. 27. Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. Petersen M. Baltimore. 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 374 . Int J Obes Relat Metab Disord. 1996. 564-569. Jones PJ. Hornstra G. Jones PJ. Am J Clin Nutr. Ehnholm C. Tholstrup T. medium-chain. Parsons WD. Stubbs RJ and Harbron CG.and long-chain fatty acids stimulates fatty acid metabolism in white adipose tissue of rats. Takeuchi H.47 48 49 50 Scalfi L. Dietary fats. Fantino M. Influence of medium-chain and longchain triacylglycerols on the control of food intake in men. Takeuchi H. Effects of medium-chain fatty acids and oleic acid on blood lipids. Campbell RG. Greater rise in fat oxidation with medium-chain triglyceride consumption relative to long-chain triglyceride is associated with lower initial body weight and greater loss of subcutaneous adipose tissue. 630-634. Biosci Biotechnol Biochem. 1997. Peters JC. Modern Nutrition in Health and Disease. Postprandial thermogenesis in lean and obese subjects after meals supplemented with medium-chain and long-chain triglycerides. Tsuji H. St-Onge MP. Am J Clin Nutr. Am J Clin Nutr. glucose. 20. 56. 70. dairy. Suzuki M. Kubota F. 53. Ross R. Obes Res. 1998. 1982. 44. Nakamura M. Takeuchi H. 1746-1754. 1986. and mixed-chain triglycerides. Shinohara H. Taguchi N.to long-chain triglycerides in isoenergetically dense diets: effect on food intake in ad libitum feeding men. 1565-1571. 1992. J Nutr. and nuts: potential functional foods for weight control? Am J Clin Nutr. 131. Aoyama T. 47. St-Onge MP. Welle SL. Shike M. 226-234. 27. Kasai M. Maggio CA. Lund P. Kasai M. 95-102. Effect of triacylglycerols containing medium. Bourque C. 2006. lipoproteins. 1254-1263. J Nutr. J Lipid Res. 112. 2001. 1811-1818. St-Onge MP. Thermic effect of medium-chain and long-chain triglycerides in man. Shinohara H. 395-402. 11. 881-886. Randomly interesterified triacylglycerol containing medium. Greenwood MR. 2002. Contaldo F. Int J Obes Relat Metab Disord. Effect of triacylglycerols containing mediumand long-chain fatty acids on serum triacylglycerol levels and body fat in college athletes. 2005. Jauhiainen M. Sandstrom B. Biosci Biotechnol Biochem. Van Wymelbeke V. Parsons WE. Kasai M.versus long-chain triglycerides for 27 days increases fat oxidation and energy expenditure without resulting in changes in body composition in overweight women. controlled trial in healthy men and women. 435-444. Warenko MK. Wu J. Kondo K. Taguchi N. 2003. Himaya A. and oleic acid on serum lipoproteins in healthy subjects. 2004. Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. Cousins R. Okazaki M. Ross C. Swift LL. 2005. Am J Clin Nutr. Temme EH. 267-269. Effects of medium chain fatty acids (MCFA). 1130-1133. 2001. Kasai M. 2919-2926. Covert manipulation of the ratio of medium. Greene HL. 2003. 68. Turkenkopf IJ. J Nutr. Int J Obes Relat Metab Disord. J Nutr Sci Vitaminol (Tokyo). 132. 7-15. Louis-Sylvestre J. Shils M. Itakura M. myristic acid. Coltorti A. and lipid transfer protein activities. 1991. Lippincott Williams & Wilkins. 2006. 2853-2859.and long-chain fatty acids on energy expenditure and hepatic fatty acid metabolism in rats. Effect of randomly interesterified triacylglycerols containing medium. St-Onge MP and Jones PJ. 79. Ross R. 329-332. 38. J Nutr Sci Vitaminol (Tokyo). Plasma lipids and lipoproteins during 6 d of maintenance feeding with long-chain. Philadephia. Hill JO. teas. Seaton TB. 81. Hoy CE. Medium. 109-114. Mensink RP. Effect of high fat weanling diets containing either medium-chain triglycerides or long-chain triglycerides on the development of obesity in the Zucker rat. insulin. J Nutr. Edwards BB. [Preliminary study of L-methionine in the treatment of rheumatoid polyarthritis]. Regulation of sulfur amino acid metabolism in men in response to changes in sulfur amino acid intakes. 1979. Garlick PJ. 1999. FASEB J. Osteoarthritis and nutrition.1. Report. 2003. 967613647.. 2001. J Nutr. Delrieu F. Molecular Genetics and Metabolism. 883-889. Amor B. Kumamoto S. 2460-2471. 2003. Pencharz PB. Infantile hypermethioninemia and hyperhomocysteinemia due to high methionine intake: a diagnostic trap. Rev Rhum Mal Osteoartic. 55. Batz F. Regan MM. 375 6 7 8 . Filer LJ. Braverman N. 995-997. A848. Jayakar P. 2006. Alternative Medicine Review. 2003. Functions of sulfur-containing amino acids in lipid metabolism. Jr. 2004. 12. Sparing of methionine requirements: evaluation of human data takes sulfur amino acids beyond protein. 2005. Cole DE. Soeters PB. Hitchens K. Garganta C. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Fomon SJ. 2000. Hasegawa T. 8. CA: Therapeutic Research Faculty 1521p. Substrate oxidation and control of food intake in men after a fat-substitute meal compared with meals supplemented with an isoenergetic load of carbohydrate. Wykes LJ. Japanese Pharmacology and Therapeutics. J Nutr. The anti-inflammatory effect of MSM. Oda H. Cysteine kinetics and oxidation at different intakes of methionine and cystine in young adults. 33. 32. Di Buono M. Jones PJ. Pomper M. 2006.66 Van Wymelbeke V. 136. Fukagawa NK. Cysteine (Cys) and methionine (Met) intakes associated with normal growth of healthy. Cardinal Nutrition Rat Carrageenan Air Pouch Model No. Hasegawa T. 491-499. J Nutr. White MD. Harvey Mudd S. Tezcan K. 133. Howard P. 136. Raguso CA. Enhanced postprandial energy expenditure with mediumchain fatty acid feeding is attenuated after 14 d in premenopausal women. 69. 8. Papamandjaris AA. Young VR. Adequate range for sulfur-containing amino acids and biomarkers for their excess: lessons from enteral and parenteral nutrition. 1998. Am J Clin Nutr. Am J Clin Nutr. 2006. 136. 32. Jellin JM. 2006. Appleton J. 733-739. 1694S-1700S. or medium-chain triacylglycerols. 1676S-1681S. 136. 2006. 49. Osteoarthritis Cartilage. 620-630. Nelson SE. Stockton. Am J Clin Nutr. White Eagle Toxicology Laboratories Vancouver. long-chain triacylglycerols. Ziegler EE. term infants fed casein hydrolysate formula (CHF). 286-294. Ampola MG. 79. 1217. 326-330. Japanese Pharmacology and Therapeutics. Ferrand B. van de Poll MC. Hypocaloric feeding in obese women: metabolic effects of medium-chain triglyceride substitution. Louis-Sylvestre J. Fantino M. 2006. Ueno S. 2001. From nutraceuticals to functional foods: a systematic review of the scientific evidence. 1722S-1725S. Toxicity of methionine in humans. Kumamoto S. Anti-inflammatory effect of methylsulfonylmethane (MSM) in mice. Natural medicines comprehensive database. 74. Gregory P. Buratovich N. Waters RF. 2000. 1988. Yoshikai Y. Methionine fortification of a soy protein formula fed to infants. Yost TJ and Eckel RH. Ameye LG and Chee WS. 6-16. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Am J Clin Nutr. 71. Levy HL. J Nutr. ID 1616: “Methylsulfonylmethane (MSM)” and “Joint support” 8 9 10 1 2 3 4 5 Methylsulfonylmethane (MSM) Monograph. McCandless SE. Axelrod LJ. Dejong CH. Am J Clin Nutr. R127. ID 1615: “Methionine” and “Lipid metabolism” 67 68 1 2 3 4 5 6 7 Borschel MW and Baggs GE. Kronick J. ISBN. Carlson P. Kim LS. 2006. 421-428. 14. Ueno S. 1666S-1669S. Arthritis Res Ther. 1989. Ball RO. (A Preliminary Correspondence). 2002. 212-224. Abstract 692. Adiga S. Mukhyaprana P. International Journal of Industrial Ergonomics. Open-label. 2007. Leitfaden Mikronährstoffe: Orthomolekulare Prävention und Therapie. 2000. Florida. 2000. Sachidananda A. Appelboom T. 2004. 2004. [Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis]. 213. World Congress on Osteoarthritis. Alternative medicine review: a journal of clinical therapeutic. 22. Elsevier GmbH Deutschland. ID 1618: “Moderated sodium carbohydrate-electrolyte drinks” and “Hydration” 1 2 Baker LB. 2005. Riazantseva TA. Smith JF. Usha PR and Naidu MU. Sex differences in voluntary fluid intake by older adults during exercise. 3 4 5 376 . Arthrosetherapie und Knorpelprophylaxe. Bishop PA. ID 1617: “Methylsulfonylmethane (MSM) in combination with glucosamine HCl” and “Joint support synergistic effect” 11 12 13 14 15 16 1 2 3 4 5 Kim LS. Clin Drug Investig. Parallel. Osteoarthritis Cartilage. Methylsulfonylmethane and their Combination in Osteoarthritis. Lauderdale. Fluid and fuel intake during exercise. Jayaprakash B. Buratovich N. randomized. 692-699. 22. Reiff RV. Med Sci Sports Exerc. 24. 37. AIHAJ. Gillard B. Mansfield ER. Current Therapeutic Research. Amiel D. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. 14. Howard P. 61. Patol Fiziol Eksp Ter. Munce TA. 57-66. Moore RD and Morton J. Rich BS. 1991. 511-521. controlled pilot study of the effects of a glucosamine complex on Low back pain. Bishop PA. Bauman TR. 50. 7. Palatability ratings of different beverages of heat exposed workers in a simulated hot industrial environment.M. Randomised. Riedl T. 22-44. Casa DJ. Oshima Y. Clapp AJ. Diminishing inflammatory joint disease in MRL/1pr mice ingesting dimethyl sulfoxide (DMSO) or methylsulfonylmethane (MSM). Sigidin Ia A. Effects of carbohydrate-electrolyte content of beverages on voluntary hydration in a simulated industrial environment. Vidyasagar S. Roberts WO. 286-294. 2005. Parcell S. Waters RF. 61-65. 1998. 3. 24. Iranian Journal of Pharmacology and Therapeutics. 37-39. The Effect Of Distilled Methylsulfonylmethane (MSM) on Human Chondrocytes in vitro. 66. Armstrong LE. Kenney WL. 2002. 1985. 2004. Clin Drug Investig. Alternative medicine review: a journal of clinical therapeutic. Stone JA. Placebo-Controlled Study of Oral Glucosamine. Usha PR and Naidu MU. 23. Int J Anti-Aging Med 1. Tant L. Parallel. 2002. 7. Smith JF. Clapp AJ. J Athl Train. Pleskovskaia GN. Federation of American Societies for Experimental Biology 69th Annual Meeting. California. Double-Blind. Theodosakis J. Sulfur in human nutrition and applications in medicine. Shashikiran U. 2000. J Sports Sci. Placebo-Controlled Study of Oral Glucosamine. National Athletic Trainers' Association Position Statement: Fluid Replacement for Athletes. 2004. 26. 2004. Double-Blind. Bairy LK. Randomised. 39-55. Munchen. Schmidt E and Schmidt N.9 10 Lawrence RM. Anaheim.S. 353363. Efficacy and Tolerability of Glucosamine-Chondroitin Sulphate-Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. Sulfur in human nutrition and applications in medicine. Methylsulfonylmethane and their Combination in Osteoarthritis. Montain SJ. Venikova MS. Parcell S. Österreichischen Apothekerzeitung. 789-796. Murav'ev Iu V. Methylsulfonylmethane (M. 35. Hillman SK. 2006.) A double-blind study of its use in degenerative arthritis. Rao S. 353363. Axelrod LJ. Coyle EF. Homma Y. 1999. Ruden TM. Impact of beverage acceptability on fluid intake during exercise. 1329-1336. Murray R. Rehrer NJ. Tada N. 2004. Bar-Or O. Consistency in preventing voluntary dehydration in boys who drink a flavored carbohydrate-NaCl beverage during exercise in the heat. J Appl Physiol. Nakajuma K. 384-391. Wagenmakers AJ. The effect of mycoprotein intake (12 and 24g per day) over 4 weeks on serum cholesterol levels. Montain SJ. 68. Saris WH. Bar-Or O. 1996. 2005. J Appl Physiol. Rivera-Brown AM. 2002. J Appl Physiol. Nishio E. Wheeler K. Nishiwaki M. Brouns F. 1992. Hosoai K. 1995. Int J Sports Med. Int J Sport Nutr Exerc Metab. Int J Sport Nutr. Riley MD. 1998. Progress in Medicine. 57-63. Dodd S. Tomiyasu K. and carbohydrate oxidation during prolonged exercise. Kagami A. 2142-2150. Noakes TD. Yamashita T. Sharp RL. Fluid replacement drinks during high intensity exercise: effects on minimizing exercise-induced disturbances in homeostasis. 2 3 377 . Horn M. Baier SM. Shirreffs SM. Bleiler TL. Sodium replacement and fluid shifts during prolonged exercise in humans. Effect of sodium in a rehydration beverage when consumed as a fluid or meal. 468-475. Ishikawa T. 1994. 54-60. Shippee RL. 2004. Yoshida H. Wilk B. 85. Nakamura H. Gonzalez-Alonso J. 15. 266-278. Westerterp K. Heaps CL. 60. Drink composition. Summers RW. 12. voluntary drinking. Yamagami H. Ishikawa T. Effects of 8 week ingestion of mycoprotein on plasma levels of lipids and Apo (Lipo) proteins. Powers SK. J Sports Sci. Eur J Appl Physiol Occup Physiol. Ito T. 1847-1851. 35. Armstrong LE. Eur J Appl Physiol. trained. Cheuvront SN. 1998. 81-92. Frontera WR. 15. 183-195. Sanders B. Ayaori M. 80. Yamashita T. Kaji D. 419-425. 1972-1976. 15. 84. Effect of drink flavor and NaCL on voluntary drinking and hydration in boys exercising in the heat. Leiper JB. Beckers EJ. Murray R. 1992. Effect of Myco-proteins intake on serum lipids of healthy subjects. Burke LM. Int J Sport Nutr Exerc Metab. ID 1619: “Mycoprotein” and “Cholesterol maintenance” 13 14 15 16 17 18 19 20 21 1 Homma Y. King DS. 72. 399-406. Intestinal water absorption from select carbohydrate solutions in humans. 73. Nakamura H. 14. 1995. Stofan J. Kumagai Y. J Appl Physiol. 22. Takahashi Y. Akanuma M. Aviat Space Environ Med. Keller H. Progress in Medicine. Horn M. Appetite. 1-9. Rogers J. Gastric emptying. and fluid balance in exercising. 86. Kriemler S. Halliday D. Kikuchi H. Takada K. Passe D. Vrijens DM and Rehrer NJ. Higashi K. Impact of beverage acceptability on fluid intake during exercise Int J Sport Nutr Exerc Metabol 14. Tulley R. Sodium-free fluid ingestion decreases plasma sodium during exercise in the heat. Nakamura H. Saito Y. J Appl Physiol. 1992. 1997. Yoshida H. 219-229. 13. Bryan MW. 86. J Appl Physiol. Gutierrez R. 61-74. Carbohydrate-electrolyte solution effects on physical performance of military tasks. Ryuzo A. Shiga H. Schedl HP. Coyle EF. Hayashi K. absorption. Effect of flavor and awareness of kilojoule content of drinks on preference and fluid balance in team sports. 1999. Prog Med. heat-acclimatized boys. Gastric emptying and intestinal absorption of a lowcarbohydrate sport drink during exercise.6 7 8 9 10 11 12 Gisolfi CV. 7884. 1990. Kumagai Y. 1112-1117. Miyajima E. 8. Passe DH. Landry G. Rehydration after exercise with common beverages and water. Ohsuzu F. Minehan MR. Summers RW. Maughan RJ. Lambert GP. Dennis SC. Inadera H. Fluid and electrolyte needs for preparation and recovery from training and competition. Lawler J. Tharion WJ. 220-235. 2000. Wilk B and Bar-Or O. Miyajima E. Ray ML. Ishikawa T. Gutierrez JC. 2001. 63-72. Suzuki J. Turnbull WH. 1992. Volaufova J. Kondo CR. The effect of natural carotenoid (palm fruit carotene) intake on skin lipid peroxidation in hairless mice. Eur J Med Res. ID 1621: “Natural Palm Oil Carotenes” and “Antioxidant properties/protection of DNA” 2 3 4 1 Astley SB. Esashi T. Paul AW. ID 1620: “Mycoprotein” and “Reduction in calorie content due to increased satiety” 1 Burley VJ. satiety and subsequent food consumption. Totsuka Y. Choo M.4 5 6 Turnbull WH. Someya K. 303-314. 1992. Arnett C. 1994. 2003. 646-650. Edwards DG. Feeding mice palm carotene prevents DNA damage in bone marrow and reduction of peripheral leukocyte counts. Evidence that dietary supplementation with carotenoids and carotenoid-rich foods modulates the DNA damage: repair balance in human lymphocytes. 210-223. 2004. Am J Clin Nutr. Elliott RM. 2005. Turnbull WH. European Journal of Clinical Nutrition. 315-324. 2003. Berbert AA. Leeds AR. 1135-1140. 165-172. Bessey D. tofu or chicken upon subsequent eating behaviour. Packer L. Ortego L. 2006. Am J Clin Nutr. 378 . Southon S. The tolerance and nutritional value of two microfungal foods in human subjects. 67-70. 881-886. Martin CK. The Effect of myco-protein on hunger. and enhances survival following X-ray irradiation. 1997. J Nutr Sci Vitaminol (Tokyo). 55. 1943-1947. 21. 46. The antioxidant effect of palm fruit carotene on skin lipid peroxidation in guinea pigs as estimated by chemiluminescence-HPLC method. 9. 41-48. Curtis CL. Effects of consuming mycoprotein. 18. Dietary fatty acids and immune reactions in synovial tissue. 1984. 8. Almendra CL. 28. Leeds AR. Influence of a High-Fiber Food (Myco-Protein-Asterisk) on Appetite . 1991. 415-419. 1990. 1993. Carcinogenesis. Distribution and antioxidant activity of a palm oil carotene fraction in rats. Geiselman PJ. Blundell JE. Br J Nutr. 91. Williamson DA. Miyazawa T. Obesity in Europe. Lo CW. Kiokias S and Gordon MH. Archer DB. 381-387. Miyazawa T. Kitano H. Lovejoy J. 285-292. 2004. Drug Discov Today. Nutrition. Udall JN. ID 1627: “Omega-3 fatty acids (Hi-EPA) with Glucosamine” and “Joint health” 2 3 4 5 6 1 2 3 4 Adam O. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress. 40. Pain. Umegaki K. Eur J Clin Nutr. Goldberg RJ and Katz J. Biological basis for the benefit of nutraceutical supplementation in arthritis. 40.Effects on Satiation (within Meals) and Satiety (Following Meals). Walton J. Edwards GD. The American Journal of Clinical Nutrition (USA). Serbinova E. Harwood JL. 91. J Nutr Sci Vitaminol (Tokyo). Am J Clin Nutr. 40. Young VR. 507-512. Leeds AR. 47. Leeds AR. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Matsuo T. 409-418. Murakoshi M. Someya K. 57. 131-136. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. 1993. Murakoshi M. Scrimshaw NS. 1994. hunger and safety. Appetite. 129. Biochem Int. Caterson B. Kitano H. Turnbull WH. Totsuka Y. Effect of mycoprotein on blood lipids. Greenway F. Uramoto H. 52. Acute effects of mycoprotein on subsequent energy intake and appetite variables. Mycoprotein reduces blood lipids in free-living subjects. 58. 2007. Dent CM. Dichi I. Walton J. 208-211. Goldberg DP. Seifert MF. 1984. 2005. 41. Psychosom Med. discussion 417S-420S. Patol Fiziol Eksp Ter. J Neural Transm. Gelenberg AJ. Stuttgart. 410S-416S. 1977. Knoll J. The Healing Nutrients Within: Facts. Dietary supplements and natural products as psychotherapeutic agents. Preliminary note. 33. Gröber U. 226. Goldberg IK. 1283-1284. Exp Biol Med (Maywood). 123-134. Ludolph E. DLPA: To end chronic pain and depression. Open study (author's transl)]. Li Y. Rennie KL. 59. 2002. J Rheumatol. 81-87. 712-728. J Hum Nutr Diet. Therapy of depression by phenylalanine. [Possible molecular mechanisms of brain dysfunction in phenylketonuria]. [DL-phenylalanine as an antidepressant. J Am Board Fam Pract. 1992. Tyrosine for the treatment of depression. Lippman HE. ID 1629: “Phenylalanine” and “Mental health” 1 2 3 4 5 6 7 8 9 10 Beckmann H.html. 364-365. Basic Health Publications. Brainfood . Growdon JH. 1979. Kostiuk PG and Martyniuk AE. Spatz H. Am J Psychiatry. Neuropsychopharmacology. 20. 132. Tyrosine for the treatment of depression. In: The Best Supplements For Your Health. 1985. Gelenberg AJ and Gibson CJ. Orthomolekulare Medizin: Ein Leitfaden für Apotheker und Ärzte. Phenylalanine. 49-58. 2006. Fugh-Berman A and Cott JM. 97-109. Birkmayer W. Health and Age. Kneipp-Verlag. Collateral benefits of fish oil therapy for rheumatoid arthritis. 92. Nachon M.com/html/res/com/ConsSupplements/Phenylalaninecs. J Am Coll Nutr. Omega-3 polyunsaturated fatty acids and skeletal health. Arzneimittelforschung. 485-497. 18. Beckmann H. The role of ascorbic acid in the oxidation of tryptophan to 5-hydroxytryptophan. 61. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia. 3. Sved AF. Watkins BA. Cooper JR. 1980. 1978. Athen D. 34-36. Laguna Beach. L-tyrosine in depression. 163-173. Giromer A. 1961. Fischer E. 28. Hughes J.healthandage. Kiefer I and Zifko U. Nierenberg AA. Olteanu M. Cole JO. CA. Ann NY Acad Sci. Gardos G. Seifert MF. Practical applications of fish oil (Omega-3 fatty acids) in primary care. Dl-phenylalanine in depressed patients: an open study. L-deprenyl plus L-phenylalanine in the treatment of depression. 2003.. 2001. 1980. Kensington Publishing Corp. Individual Nutrients and Herbs. Li Y. Oh R. 25. Wojcik JD. 2002. 227. Braverman ER. Nutr Health. Fox A and Fox B. 1975. 137.Fit im Kopf durch richtige Ernährung. New York. J Neural Transm. 622-623. 206. and New Research on Amino Acids. 1984. 2006. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. Beckmann H and Ludolph E. Jebb SA. 1931-1933. Riederer P. 16. Lancet. 6. Matthews JD.5 6 7 8 9 Lau CS. Linauer W. New York. 241-247. Findings. Arzneimittelforschung. 1992. Nutritional management of rheumatoid arthritis: a review of the evidence. 28-36. Wurtman RJ. Leoben. 11 12 13 14 15 16 17 18 379 . 2001. Wissenschaftliche Verlagsgesellschaft. Heller B. Strauss MA. DL-phenylalanine versus imipramine: a double-blind controlled study. http://www. Abel R. 2003. 1999. Zimmer R. Watkins BA. 2. Dugan SJ. Lang R. Arch Psychiatr Nervenkr. Long Shadow Books. Rogers K. Amino Acid and Protein Requirements: Cognitive Performance. 55. Neuropsychopharmacology. FDA (Food and Drug Administration). Kobayashi M. Guidance for Industry: Guidance on the Labeling of Certain Uses of Lecithin Derived from Soy Under Section 403(w) of the Federal Food. La Droitte P. Galli C. Medicine) IIo (ed.com/articles/articles-andnewletters/research-articles-index/alternative-complementary-medicine-topics/dlpa-natural-relief-forchronic-pain/. 69. O'Brien JT. TX. Wynn P. 1988. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Morris R. Low-density lipoprotein cholesterol responsiveness to diet in normolipidemic subjects. Phenylalanine in affective disorders. Goldberg A. 66-70. 1996. Matsuoka R. 1983.an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. Porter RJ. Schmidt E and Schmidt N. Maderna P. Edwards J. and Cosmetic Act. 1985. Lipids.pdrhealth. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. 283288. The American Botanical Council.aspx?contentFileName=ame0338. In: The Role of Protein and Amino Acids in Sustaining and Enhancing Performance. Cahiers de nutrition et de diététique. The significance of phosphatidylcholine for the lipid metabolism. 561566. ID 1630: “Phosphatidyl choline / lecithin” and “Cholesterol / Heart health” 20 21 22 23 24 25 26 27 28 29 1 2 3 4 5 6 7 8 Barter PJ. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. Metabolism. Tunger L. 1999. TX. Inoue T. 2000. Baruah S. Washington DC. Biosci Biotechnol Biochem. Blumenthal M. Lucas Meyer Publikation Nr. Ternes W. 7-13. 2005. 1983. 2005. 1986. Munich.afpafitness. 380 9 . Mosnik DM. 1998. Cobb MM and Risch N. and Brain Function. 42. Drug. Elsevier Urban & Fischer. Kravitz H. Herbal Medicine: Expanded Commission E Monographs American Botanical Council. J Clin Psychiatry. 1993. Stress. Wissenschaftliche Verlagsgesellschaft. Jeffriess H. Altern Med Rev. Med Hypotheses. 16. Hamada T. 751. Polichetti E. Lexikon der Lebensmittel und der Lebensmittelchemie. Austin. Gallagher P. Takashima K. 607-615. Luna A. 47. 20.) National Academy Press. Adv Biol Psychiatry. Chanussot F. Biochim Biophys Acta. Ikeda I. Täufel A.com/drugs/altmed/altmedmono. PDR health. Blumenthal M. 2000. Am J Geriatr Psychiatry. Phenylalanine. Giani E. Kodama Y. 1997.19 Lieberman HR. Austin. http://www. Effects of acute tryptophan depletion on mood and cognitive functioning in older recovered depressed subjects. Russell AL and McCarty MF. http://www. DL-phenylalanine markedly potentiates opiate analgesia . Yaryura-Tobias JA. Bonacker U. Fawcett J. Scott A.6. Stuttgart. Stevenson PS. Leitfaden Mikronährstoffe: Orthomolekulare Prävention und Therapie. 2000. Imaizumi K. Oral polyunsaturated phosphatidylcholine reduces platelet lipid and cholesterol contents in healthy volunteers. 2006. Hydrolysis of micellar phosphatidylcholine accelerates cholesterol absorption in rats and Caco-2 cells. Phipps AJ. Gusovsky F. 1726-1732. DLPA: Natural Relief for Chronic Pain. Sabelli HC. Use of neurotransmitter precursors for treatment of depression.xml&contentName=Phenylalanine&contentId=494#Print. Meyers S. 2004. 305-311. Evidence that lecithin:cholesterol acyltransferase acts on both high-density and lowdensity lipoproteins. 137-147. La lécithine de soja en alimentation humaine. Sirtori CR. Javaid JI. Tremoli E. Spring B. 10. 2005. 13. 5. 64-71. 261-270. Brinckmann J. Gianfranceschi G. 136-146. 31. Evidence that polyunsaturated lecithin induces a reduction in plasma cholesterol level and favorable changes in lipoprotein composition in hypercholesterolemic rats. Malli L. 67-73. 1999. 98-107. 67. 2. 1529. 11. Katan MB. Mastellone I. Nemeth N. Iovanna C. 129-134. Life Sci. Hesse K. N Engl J Med. 1976. Int J Clin Pharmacol Ther Toxicol. Heintz B. Leonardi J. 1998. Beynen AC. Am J Clin Nutr. 2005. D'Arecca MA. Nagao K and Yamagita T. Kupke D. 32. Oremek G. Lecithin intake and serum cholesterol. Physiological Functions of Phospholipids. Olthof MR. Ridker PM. Dietary polyenylphosphatidylcholine decreases cholesterolemia in hypercholesterolemic rabbits: role of the hepato-biliary axis. Hoccom M. Schmidt U. Portugal H. The Merck Index-an Encyclopedia of Chemicals. Knuiman JT. Katan MB. Polichetti E. Gres S. Polichetti E. Lairon D. 659-664. The hypocholesterolemic and antiatherogenic effects of topically applied phosphatidylcholine in rabbits with heritable hypercholesterolemia. 471-478. Nie Y.) Springer. Chanussot F. 54-63. 1994. Obenchain JR. Reduction of hyperlipidemia with 3-sn-polyenylphosphatidylcholine in dialysis patients. 1406-1416. 461466. Oremek G. Cholesterol-lowering effect of soyabean lecithin in normolipidaemic rats by stimulation of biliary lipid secretion. 187-200. 1989. O'Connor GT. 1990. Manson JE. Am J Clin Nutr. The primary prevention of myocardial infarction. 1986. 1-23. Artery. Jonas A. de la Maisonneuve C. Schneider E. 266-268. Pauli AM.10 11 Hawthorne JN. Kommission E. Brink EJ. Peeters H (ed. In: Phospholipide in Biochemie. 38. Verhoef P. Effect of EPL on the Lipid Metabolism of the Arterial Wall and Other Tissues. Farnarier C. Stimulation of the apo AI–high density lipoprotein system by dietary soyabean lecithin in humans. Kirsten R. In: Phosphatidylcholine: Biochemical and Clinical Aspects of Essential Phospholipids. Vignolini F. 82. Heckelman PE. Biochim Biophys Acta. Kesaniemi YA and Grundy SM. 43. Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients. endothelial cell. Soya lecithin and lipid metabolism. Portugal H. Am J Clin Nutr. Trockenextrakt (35-67: 1) aus Ginkgo-biloba-Blättern. De La Porte PL. 659-667. Schettler G (ed. Merck Research Laboratories. Hennekens CH. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 381 . 2000. Kaplanski G. 9. 326. Dietary soybean phosphatidylcholines lower lipidemia: mechanisms at the levels of intestine. 2001. Lorec AM. Diaconescu N. Int J Clin Pharmacol Ther. Howard AN and Patelski J. Plaskett. The influence of lecithin on hyperlipemia-a report on prevention and treatment of hyperlipoproteinemia. Jimenez MA. 111-117. Luna A. Fong K. Kiese M. Lucas Meyer brochure. 1994. 1981. Portugal H. 1996. Pauli AM. Budavari S. Br J Nutr. Pharmakologische Wirkungen von Phospholipiden. 49. Gallipeau JAR. 22. 1996. Scarino ML. 1989. Nelson K. 120. 245-256. La Droitte P. Buring JE. Janisson A. Nelson K. and hepato-biliary axis. 2000. The Journal of Nutritional Biochemistry. Marin V. Polichetti E. Yousef I. Smith A. 2563-2576. Tosteson H. Luna A. Polichetti E. J Oleo Sci. Janisson A. Chanussot F. J Nutr. Effects of dietary polyenylphosphatidylcholine on metabolism of cholesterol and triglycerides in hypertriglyceridemic patients. Phospholipids and blood cholesterol. 53-56. Portugal H. 75. Domingo N. de la Porte PL. Stuttgart. Mengheri E. 1992. Drugs and Biologicals. Mekki N. Lafont H. He JL. 1244-1247. Satterfield S.) Thieme. Reimann HJ. 1972. Lecithin cholesterol acyltransferase. Heintz B. Tuchweber B. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. Hebert P. O'Mullane JE. Kirsten R. La Droitte P. Neil MJ. Chanussot F. Experiment und Praxis. 2002. 27. Lorec AM. 2000. 1987. Hsia SL. Milikowski C. extrahiert mit Aceton-Wasser. Med Welt. J Nutr Biochem. Colombo L. Treatment of hypercholesterolaemia with oral lecithin. 1993. Psychopharmacol Bull. 201210. Kornman KS. N Engl J Med. Kaldonska M. Bartus RT. 399-403. Perea JE. Atherosclerosis. The value of cytidine-5-diphosphate-choline in the prevention of impairment of memory function after electric convulsive therapy. Wilson TA.31 32 Simons LA. 2005. Beiser A. Mysliwiec Z. Sheard NF. Nutr Rev. Cholesterol-lowering and HDL-raising properties of lecithinated soy proteins in type II hyperlipidemic patients. Witztum JL. Dean RL. Brain Res Dev Brain Res. Wurtman RJ. 360-364. 9. Noseda G. Crepaldi G. 301-303. Fragiacomo C. 781-786. Fernandez-Novoa L. Maternal dietary choline availability alters mitosis. Bertoldin T. Gaddi A. Gordon JR. Pawlik A. Nicolosi RJ. Brain Res Dev Brain Res. Senin U. Choline. 4-9. "Autocannibalism" of membrane choline-phospholipids: physiology and pathology. Ayuso-Gutierrez JL and Saiz-Ruiz J. 140. 1977. Alexander EA. Daniele D. McConnell JP. 52. 1982. Liscovitch M. J Gerontol. Ruys J. United Soybean Board. Mar MH. Lakher M. 1985. 140. Canty DJ and Zeisel SH. Tacconi M. 113. brain mapping. Albright CD. Cenacchi T. Soy lecithin fact sheet. FASEB J. Blusztajn JK. Lenzi S. Ann NY Acad Sci. Goas JA. Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: beyond linoleate. Avellone G. and coronary artery disease. Friedrich CB. Allen RH. Tompkins RK and Parkin LG. 123-129. Descovich GC. Hickie JB. Lecithin and choline in human health and disease. Zeisel SH. 262-266. Mouzo R. Gomez MJ. Effects of long-term ingestion of soya phospholipids on serum lipids in humans. 29. 1991. Lp(a) lipoprotein. Shaw T. 1980. Zeisel SH. Brilakis ES. Lecithin and memory training in suspected Alzheimer's disease. Clinical evaluation of lecithin as a lipid-lowering agent. Cacabelos R. 1997. Mannarino E. Holbrook PG. Brown EC. 1994. Smith RC. Phytotherapy Research. Aging (Milano). 2 3 4 5 6 7 8 9 10 11 382 . 5. Franco-Maside A. Choline availability alters embryonic development of the hippocampus and septum in the rat. 777. 1999. Meyer JS. ID 1631: “Phosphatidyl choline / lecithin” and “Cognitive function” 33 34 35 36 37 38 1 Albright CD. Da Col PG. A double-blind study. Farina C. 614-620. Meservey CM. Blusztajn JK and Wurtman RJ. Science. Sirtori M. Sirtori CR. 243-248. Lennon RJ. 115. Mar MH. 46-57. Cognition. an essential nutrient for humans. Fiori MG. Caamano J. Maire JC. Ann Nutr Metab. 37. Tsimikas S. Wojcicki J. placebo-controlled multicenter study on efficacy of phosphatidylserine administration. 7. Science. 1998. Zeisel SH. 1986. 353. 348-357. 22. Choline and cholinergic neurons. 2093-2098. Franklin PD. Laredo M. Richardson UI. Cattin L. 1999. 13-20. Gatti E. 327-339. 5. Corzo D. Citicoline improves memory performance in elderly subjects. Alvarez XA. Tsai AY. and immune factors. Berger PB. 19. 1996. 123-133. Lamont JT. Alvarez XA. Samochowiec L. Lippa AS. cerebrovascular hemodynamics. 209. Aust NZ J Med. Cacabelos R. Therapeutic effects of CDP-choline in Alzheimer's disease. Oxidized phospholipids. Brinkman SD. 221. Age-related changes in passive avoidance retention: modulation with dietary choline. 1983. Cognitive decline in the elderly: a doubleblind. 6. Miller ER. Fernandez-Novoa L. 147-153. Prog Neuropsychopharmacol Biol Psychiatry. 1995. 1982. Mauron C. Friedrich CB. Am J Surg. Zucchi-Dentone C. apoptosis and the localization of TOAD-64 protein in the developing fetal rat septum. Vroulis G. Methods Find Exp Clin Pharmacol. Da Costa KA. 1980. Brain acetylcholine: increase after systemic choline administration. Drachman DA. 2001. 1990. 261-270. 300. Groupe Francais d'Etude de la Tetrahydroaminoacridine. Zerbi F. 1997. Bergman H. Cornford EM. Effects of phosphatidylserine in age-associated memory impairment. Journal of Biological Chemistry. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia. 1010-1012. Carrier L. Arch Neurol. Wang PF. 1980. Carrier mediated blood-brain barrier transport of choline and certain choline analogs. Nutrient Content Claims Notification for Choline Containing Foods. 7. Crook TH. 1991. 944-950. FDA-CFSAN (U. Fine H. Tinklenberg J. 1975. An in vivo proton magnetic resonance spectroscopy study. 269-276. BMJ. Growdon JH. Treatment of Alzheimer's disease with short. Wedeking PW. Babb SM. 1982. 141-145. Petrie W. 1990. 4. Blusztajn JK. Elsevier. Bailey P. Dysken MW.). 1990. Fovall P. Corona GL. Oldendorf WH. 1986. Gross PL. 21. In: Present knowledge in Nutrition. 1995. Hori A. Bouchard R. Rosene DL. Amsterdarn. 30. Duffy FH. 239. 1989.. Eur Arch Psychiatry Neurol Sci. Tacrine (tetrahydroaminoacridine. 975-980. Gerstman LJ. Weintraub S. Goldberg E. Fovall P. Glosser G. 1980. 439449. Neurology. Dani S. Life Sci. 49-52. 17. Cholinomimetics and memory. Kahn RL. Rattan P. 1948. Sirio CA. 1095-1102. Fleming P. Pola A. Nunzi MG. S. Choline bitartrate treatment of Alzheimer-type dementias. Results of a Canadian double-blind. 239242. Fitzgerald CM. 174. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Meck WH. Tesfaye Y. Dysken MW. Savoldi F. THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. 37. Bacher Y. Dev Neurosci. Stoll AL. Rosen TJ. Mattis S. Prenatal availability of choline alters the development of acetylcholinesterase in the rat hippocampus. 1999. Corkin S. J Neurochem. Principals of neural aging. Hollister LE. 1975. Massari DC. 274. The chemical structure of Phosphatidylserine. 322. Decreased brain choline uptake in older adults. 383 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 . 32. multicenter study. Schinelli S. 147. Marshall C. Food and Drug Administration-Center for Food Safety and Applied Nutrition). 1987. Gauthier S. 41. Am J Psychiatry. Garrow T. Lecithin: absence of neurophysiologic effect in Alzheimer's disease by EEG topography. Williams CL. crossover. Hughes JE. 94-104. Chatellier G and Lacomblez L. ILSI Press. JAMA. Cohen EL and Wurtman RJ. Washington DC. The effect of choline chloride. Longenecker G. Davis KL.and long-term oral THA and lecithin: a double-blind study. Walter G. Pfefferbaum A. 219-234. N Engl J Med. Jope R. Jr. et al. Am J Psychiatry. Forch J. Lazarus LW. 1978. 1272-1276. Increase in rat brain acetylcholine induced by choline or deanol. Perryman KM. Braun LD. 495-499. Albert M. Fitten LJ. 644-649. Neurology. Ratner J. Bilder RM. 140. 4. Neurobiol Aging. Mohs RC. 1982. Selective effects of cholinergic treatment on verbal memory in posttraumatic amnesia. Cummins J. Harris CM. Finkel S. Memory decline in the aged: treatment with lecithin and physostigmine. 299-308. Cohen BM. 37. Bowman B and Russel R (eds. 1015-1019. Kopell BS.12 Cermak JM. Yesavage J. 16. Huff FJ.. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Frattini P. Clody DE. Wurtman RJ. McAnulty G. Lamontagne A. Davis JM. Davis JM. Cucchi ML. 1983. Neurology. Loy R. Haubrich DR. Effect of lecithin on memory in normal adults. 79-86. Yurgelun-Todd D. Romani A. Life Sci. Commun Psychopharmacol. Santagostino G. J Clin Neuropsychol. 2001. Durwen H. 902907. Saint-Martin M. Choline and carnitine. Renshaw PF. Tinklenberg JR. Albert MS. Perinatal choline supplementation increases the threshold for chunking in spatial memory. Haynes C. Davis KL. GG (eds. Adult-generated neurons in the dentate gyrus send axonal projections to field CA3 and are surrounded by synaptic vesicles. 671-672. 3045-3051. Wilson WA. Eur J Clin Pharmacol. Choline availability to the developing rat fetus alters adult hippocampal long-term potentiation. Pre. Clin Neuropharmacol. 17. 1980. Kopell BS. 1999. Kaye WH. Hardman JG. Hollister LE. The effect of tacrine and lecithin in Alzheimer's disease. A double-blind. Markakis EA and Gage FH. Tinklenberg JR. Choline-induced spatial memory facilitation correlates with altered distribution and morphology of septal neurons. Ladd SL. 51-59. Jones JP. 159167. Effect of phosphatidylcholine on explicit memory. J Clin Psychiatry.). 1982. Psychiatry Res. Swartzwelder HS. Peoples R. J Comp Neurol. National Academy Press. Levy R. 1998. Gunther J. Schmechel D. Williams CL. Schultz K. Water-soluble vitamins. Rogers H. CD001015. Smith RA. Ebert MH. 41. thiamine. Choline supplementation during prenatal development reduces proactive interference in spatial memory. Mohs RC. Cermak JM. 249-251. 47. panthothenic acid. Williams CL. 2. J Neurol Neurosurg Psychiatry. Dietarv reference intakes for folate. 10. niacin. Sommer SA. Meck WH and Williams CL. Dev Psychobiol.and postnatal choline supplementation produces long-term facilitation of spatial memory. 2. 47. 295. 1997. Meck WH and Williams CL. Am J Psychiatry. Utley C. 406. 24. Loy R. Chronic dietary choline represses age-related loss of dendritic spines in mouse neocortical pyramidal cells. Holloway D. 16. Little A. J Neurol Sci. and choline. A. Mohs RC and Davis KL. Neuroreport. Brain Res Dev Brain Res. Neuroreport.33 Heyman A. 1991. Dietary choline supplementation in pregnant rats increases hippocampal phospholipase D activity of the offspring. Choline chloride treatment of memory deficits in the elderly. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. Biol Psychiatry. Meck WH. Meck WH. 279-286. J Neural Transm Suppl. Lecithin for dementia and cognitive impairment. Higgins JP and Flicker L. McGraw-Hill Inc. 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 384 . 1653-1659. 48. Krishnan R. 8. 339-353. Jenike MA. 1986. S39-42. 8. In: Goodman and Gilman‘s: The pharmacological basis of therapeutics. Simultaneous temporal processing is sensitive to prenatal choline availability in mature and aged rats. 449-460. Chuaqui-Kidd P. Lancet. Marcus R and Coulston AM. 1979. A population pharmacodynamic analysis of five clinical trials. Treatment of postconcussional symptoms with CDP-choline. 1996. 1999. LaBerge S. Levin HS. Institute of Medicine and National Academy of Sciences USA. LoCastro S. 1994. 118. 17-23. 1999. 1991. biotin. 1996. 736-742. Limbird LE. 1987. Holler T. Heller H. 1988. 1982. placebo controlled trial of high-dose lecithin in Alzheimer's disease. 540-549. Choline chloride effects on memory: correlation with the effects of physostigmine. 373-382. 3053-3059. Meck WH. 21. 275-280. 1993. Hand D. Mervis RF. Weingartner H. Brain Res Dev Brain Res. 149-156. Yesavage JA. Gwyther L. 1997. Williams CL. Lecithin in Alzheimer's disease. Ruddon RW. Gillin JC. 118. 1555-1572. Washington DC. riboflavin. Heyer D. 1982. Wilkinson W. Cochrane Database Syst Rev. Failure of long term high-dose lecithin to retard progression of earlyonset Alzheimer's disease. FASEB J. Meck WH and Williams CL. J Neuropathol Exp Neurol. 1985. 1275-1277. Smallberg S. 103 Suppl. Sitaram N. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. 2003. Holford NH and Peace K. vitamin B12. Adv Exp Med Biol. Levy R. Blusztajn JK. Toscano W. 136. Molinoff PB. 293295. Peters BH and Levin HS. Brain Res. 1999.shtml. PDR Health. Schenk F and Brandner C. 106. 173-188. Sitaram N. Life Sci. 484. 441-448. Panijel M. Psychobiology. Gillin JC. Plazebokontrollierte Doppelblindstudie bei gesunden Probanden.pdrhealth. Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. The influences of rearing environment and neonatal choline dietary supplementation on spatial learning and memory in adult rats. 1704-1709. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. 104. 1982. Wurtman RJ. 106-112. Sorgatz H. Gillin JC. lntroduction. Wurtman RJ. Trommer BA. Prenatal dietary choline supplementation decreases the threshold for induction of long-term potentiation in young adult rats. Hollister LE. 1989. Sitaram N. 1999. 53. 1985. Gershon S. Davis KL. Placebocontrolled double-blind study in healthy probands]. 1994. Fortschritte der Medizin. Exogenous choline enhances the synthesis of acetylcholine only under conditions of increased cholinergic neuronal activity. Tinklenberg JR. 79. 36. Meck WH. 193-197. Wirkung von Lecithin auf Befindlichkeit und Konzentration. and neonatal choline dietary supplementation on spatial and nonspatial learning and memory in adult rats. 266-270. 23. Schmidt DE. Spiers PA. Pardridge WM. 1983. Sorgatz H. Interaction of choline and scopolamine in human memory. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus.55 56 57 58 59 60 61 62 Mohs RC. 1978. Brinkman S. 45. Ann Neurol. Fortschr Med. 105. 1. 35. [Review]. Neurobiol Aging. Weingartner H. Ulus IH. J Neurochem. Mauron C. Science. 328-342. 1988. Sorgatz H. [Effect of lecithin on memory performance. 39. 1790-1796. 2. Life Sci. J Clin Psychiatry. 63 64 65 66 67 68 69 70 71 72 73 74 75 385 . van Praag H. Lieberman HR. Phosphatidylcholine. Human serial learning: enhancement with arecholine and choline impairment with scopolamine.und Ganzheitsmedizin Schattauer. 217-227. 21-25.com/drug_info/nmdrugprofiles/nutsupdrugs/pho_0288. Behav Brain Res. Williams CL. 1980. Yoon H. 1993. 643-646. 1986. Blood-brain transport of nutrients. Domino EF. 22. Tees RC. Hochanadel GS. 37. 1986. Wecker L. 6. Caine ED. 1998. Trends Neurosci. Poirier J. 201. Citicoline improves verbal memory in aging. Mohs RC and Davis KL. 5029-5034. 1996. [Effect of lecithin on health status and concentration. Federation Proceedings. Evaluating the validity of a learning and memory test (LGT-3) in 45 to 55-year-old patients]. Dev Psychobiol. Therapiewoche. 302-313. The influences of sex. 1999. 1555-1560. 1979. Choline: Selective enhancement of serial learning and encoding of low imagery words in man. Weingartner H. rearing environment. Choline chloride effects on memory in the elderly. Tamminga CA. http://www. 274-276. 1995.and postnatal choline treatment on place-learning abilities in rat. Gage FH. Pomara N. 525-530. Swartzwelder HS. Therapeutische Wirksamkeit von Lecithin bei Gedächtnis. 233-236. Kempermann G. 17. 1986. 2047-2049. 1978. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. 44. Myers D.und Konzentrationsstörungen. 219-221. Effects of physostigmine and lecithin on memory in Alzheimer disease. J Neurophysiol. Arch Neurol. Pyapali GK. Blusztajn JK. Zum Wirkspektrum supplemetären Lecithins auf das Verhalten. Nat Neurosci. Turner DA. lndirect effects of peri. Tees RC. Natur. Amaducci L. Amaducci L. 1986. Aporti F. al Se (ed. Benton D. Electroencephalography and Clinical Neurophysiology. Meck WH. Dopamine (DA) and serotonin metabolic levels in the cerebrospinal fluid (CSF) in Alzheimer's presenile dementia under basic conditions and after stimulation with cerebral cortex phospholipids (BC-PL). Ziliotto G. Zeisel SH and Holmes-McNary M. van Gool WA. Loew D. 1977. Effect on cognition. 13. 513-523. Golly I. 225-238. behavioural disturbances and burden experienced by the carers. Munchen. Marcel Dekker. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Bässler KH. Aporti F. 1988. Bracco L. Choline: an essential nutrient for humans. Rubini R. 2000. Austrian Federal Ministry of Social Safety and Generations. 669-671. 1485-1494. Williams CL. Psychopharmacol Bull. Brain Res. 224. an open study. Kasper H. New York. 2000. Human apolipoprotein E: the Alzheimer's disease connection. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Teunisse S. Wurtman RJ. Growdon JH. 19. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Heyer DD. Zanotti A. J Neurol. Handbook of vitamins. 1990. Toffano G. Hypertrophy of basal forebrain neurons and enhanced visuospatial memory in perinatally choline-supplemented rats. Calderini G. FASEB J. Ann NY Acad Sci. S156-S156. Borsato R. Valzelli L. Tesco G. Toffano G. Kluthe R. 2004. 2.) Williams and Wilkins Baltimore. Use of phosphatidylserine in Alzheimer's disease. 528S-531S.76 Weinstein HC. 16. In: Modern Nutrition in Health and Disease. 2001. 68-69. Loy R. Zanotti A. Physiol Behav. Pölert W. Nutrition. Zeisel SH. Stuttgart. Vitamin-Lexikon für Ärzte.902/3-IX/b/12a/01: Zulassung einer gesundheitsbezogenen Angabe. 24. Zeisel SH. functioning in daily life. J Neurol. Choline: needed for normal development of memory. 47. 2001. 169-178. Piersanti P. 7. 24. Goldstein L. Populin R. Ammassari-Teule M. Rubini R. Clin Trials J. 755-760. 1998. 104-108. Urban & Fischer. Fürst P. Wood JL and Allison RG. Oral phosphatidylserine in elderly patients with cognitive deterioration. Lippi A. Pietrzik K. Latorraca S. 1980. Choline and phosphatidylcholine. Chronic administration of phosphatidylserine during ontogeny enhances subject-environment interactions and radial maze performance in C57BL/6 mice. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Agedependent spontaneous EEG bursts in rats: effects of brain phosphatidylserine. Argentiero V and Tavolato B. GZ 333. Sorbi S. Stählin HB. J Am Coll Nutr. 1987. 210-212. 10. 1999. 1985. Ann Neurol. 1997. Lecithin consumption raises serum-free-choline levels. Hirsch MJ. Zeisel SH. 794. 61. Puchstein C. Crook TH. Weisgraber KH and Mahley RW. EEG and behavioural patterns in aging rats: Effect of brain phosphatidylserine. 5 6 7 8 9 10 11 386 . 1982. Baldereschi M. ID 1632: “Phosphatidyl serine” and “Mental health / Cognitive function” 77 78 79 80 81 82 83 84 85 1 2 3 4 Allegro L. 53-58. Maritati M. 3015-3021. Nutr Neurosci. Wettstein A. 1991. 1991. 1983. Georg Thieme Verlag. 34-38. 115120. Nabb S. Donohoe RT. Fed Proc. 245-249. 41. Effects of consumption of choline and lecithin on neurological and cardiovascular systems. Lancet. Fagioli S. Apotheker und Ernährungswissenschaftler. 130-134. Bescheid des Österreichischen Bundesministerium für soziale Sicherheit und Generationen. 640. Pavone F. Neurobiol Aging. Favaretto V. 238. 1996. 4. Sillance B. Ernährungsmedizin. Biesalski HK. Phosphatidylserine supplementation supports cognitive function: an evaluation of the evidence to support an article 13 health claim in the European Union. 3. 28. Health Request Publications. Acta Neurol Scand. Gyselynck-Mambourg AM. Lysophosphatidylserine. 45. Hippius H. Petrie W. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. 229-233. Castellano C. 1987. Kathmann N. Gerke S. Prog Clin Biol Res. Cocito L. 298-299. Neurosci Lett 101. Cenacchi T. Bove D. 1989. 1982. Yesavage J. placebo-controlled multicenter study on efficacy of phosphatidylserine administration. 1992. Age-related alterations of NMDA-receptor properties in the mouse forebrain: partial restoration by chronic phosphatidylserine treatment.. Phosphatidylserine and Cognitive Dysfunction and Dementia (Qualified Health Claim: Final Decision Letter). Aging (Milano). Pharmacol Res Commun. Ylieff M. Pantothensäure. B12. Populin R. Doubleblind cross-over study of phosphatidylserine vs. JANA. 189-198. Katz RM. A practical method for grading the cognitive state of patients for the clinician. Crook TH. Effects of phosphatidylserine in Alzheimer's disease. 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 387 . Clin. Epilepsy Research 17. Fagioli S. 5. Crook T. Cholin. Biotin. 2003. Pavone F. 1992. Frankhänel S and Gaßmann B. Fiori MG. 1983.). 2000. 1991. An open trial. 1989. Bruni A and Toffano G. 591:602. 1994. 24. 174-180. 49-53. Baggen M. 1998. Eugen Ulmer Verlag. Clin Trials J . Tinklenberg J. CABA and phosphatidylserine in human photosensitivity: a pilot study. 45-55. B2. 24. Crepaldi G. Funfgeld EW. 99-103. 469-484. Farina C. Ernährungsumschau. Phosphatidylserine in elderly patients. Drago F. Massari DC. Cognitive decline in the elderly: a doubleblind. Dietary Reference Intakes Report 2: Vitamine B1. Treatment of age-related cognitive decline: effects of phosphatidylserine. McHugh PR. FDA (Food and Drug Administration). 136-140. Trials j. Crook TH. Baggio C. 1998. Cranata Q and DiMichele J. 24. Phosphatidylserine administration during postnatal development improves memory in adult mice. Yesavage J (eds. Effects of phosphatidylserine in age-associated memory impairment. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Satzger W. 2. Dietary supplementation with phospholipids and docohexaenoic acid for age-related cognitive impairment. 20-28. Toffano G. In: Anti-aging medical therapeutics.12 13 14 15 16 17 Bracco L. Munch U. Petrie W. 1998. Hurlet A. Brain Res. a short-lived intermediate with plasma membrane regulatory properties. Elmadfa I and Leitzmann C. Filburn C. 73. Toffano G. Psychopharmacol Bull. Clinical studies on the activity of phosphatidylserine (PS). Richstein B. Folstein MF. Caffarra P and Santamaria V. Nunzi MG. Palm E. Wells C. Ernährung des Menschen. 12. Bertoldin T. 2007. Mistlberger G. 1993. Cargill Food Ingredients GmbH. Tinklenberg J. 1975. Phosphatidylserine facilitates learning and memory processes in aged rats. Delwaide PJ. 317. 1987. 123-133. 1990. Massari DC. 109-114. 61-66. Oliverio A. Folsäure. Engel RR. Cenacchi B. The effects of phosphatidylserine in patients with mild cognitive decline: an open trial. Gunther W. Folstein SE. Stuttgart. Human tolerability of oral phosphatidylserine assessed through laboratory examinations. Aging Brain and Dementia: New Trends in Diagnosis and Therapy. 125-130. 1235-1246. 14. Catalano Rossi Danielli L. 644-649. 1992. 149-155. 1987. J Psychiatr Res. 1986. 41. Eur Neuropsychopharmacol. Nedwidek P. Clin Trials J. 584. placebo in patients with early dementia of the Alzheimer type. "Mini-mental state". California. Crook TH. Niacin. Cohen SA and Muller WE. Neurology. 4. Ann NY Acad Sci. Hellhammer J. Fit im Kopf durch richtige Ernährung. Sakai M. Hashimoto S. Riedel WJ. Fries E. Goldman RE. 1997. Springer-Verlag. Mielke R. Phosphatidylserine in elderly patients. Jpn J Pharmacol. Nutr Neurosci. Nutritional News. 327-331. 121134. LaBerge S. 24. 1993. 24. Cozens DD. 5.com/books_online/ps/phosphatidylserine. Effect of phosphatidylserine on free radical susceptibility in human diploid fibroblasts. Brouns F. Granata Q and Di Michele J. Phosphatidylserine: The remarkable brain cell nutrient. 1993. Van Boxtel MP. An open trial. Yamatoya H. Herholz K. 1993. Szelies B. Kessler J. Clin Trials J. Kneipp-Verlag. Suzuki S. 24. A neuropsychological. Berlin. Marina del Rey. and cognitive training in Alzheimer's disease. 1992. Buss C. Latorraca S.34 35 Fünfgeld EW and Nedwidek P. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. brainfood. The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly. 25-32. 1987. Kudo S. J Neural Transm Park Dis Dement Sect. Rehovot. EEG. 7. 2002. 337-343. 45-50. Jolles J. The effect of soy lecithin phosphatidylserine treatment on daily functioning and self-reported general condition in patients with Alzheimer‘s disease. 197-201. Stress. 1990. Amaducci L. Mielke R. Nutr Neurosci. Jorissen BL. 447-450. Riedel WJ.html. Altern Med Rev. 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 388 . Piersanti P. Clin Trials J .springboard4health. Engert V. California. Furushiro M. 1999. 144-161. Yokokura T. 119-126. Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Toffano G (eds. Heiss WD. Hebrew University of Jerusalem. Rehovot. Anti-Aging Medical Therapeutics. Effect of Phosphatidylserine on Cerebral Glucose Metabolism in Alzheimer's Disease (With 1 color plate). Szelies B. 1997. Neurobiol Aging. 1996. Sommer SA. 540-549. Kaplan Hospital. Van Boxtel MP. Ladd SL. Brouns F. and Hadassah Medical School. Golly F. http://www. Hellhammer D. 16. Long-term effects of phosphatidylserine. Chronic treatment with phosphatidylserine restores muscarinic cholinergic receptor deficits in the aged mouse brain. Clin Neuropharmacol. Hershkowitz D. Kidd PM. Szelies B. Tuch A. Tesco G. Gindin J. Sorbi S. 2006. Slansky I. Verhey FR. Richold M. Ledeen RW. Kessler J. 4. Gelbmann CM and Muller WE. 73-77. 88-98. Phosphatidylserine (PS) A. In: Phospholipids in the Nervous System: Biochemical and Molecular Pathology. pyritinol. 2004. Neurohomologous phosphatidylserine in Parkinsonian subjects with associated disorders of cerebral metabolism. 13. Dementia. Safety of soy-derived phosphatidylserine in elderly people. Gindin J Geriatric Institute for Education and Research KMC. Israel.). and PET investigation. 75. 42-61. Dementia. 11. 1987. Effects of oral administration of soybean lecithin transphosphatidylated phosphatidylserine on impaired learning of passive avoidance in mice. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Piacentini S. Kidd PM. 5. Toscano W. 1. 695. 1987. Ponds RW. Kiefer I and Zifko U. Heiss WD. 2001. Heywood R. Horrocks LA. Clinical Trials Journal. 1993. Larocca JN. Rutenberg D. 1989. 6. Long-Term Traetment of Dementia Alzheimer Type with Phosphatidylserine: Effect on Receptors and Microviscosity of Lymphocyte and Trombocyte Membrane. Makman MH. Jorissen BL. 1994. Health Quest Publications. Klinkhammer P. remarkable brain cell nutrient. Kidd PM. 99-103. Bazan NG. Heiss WD. Leoben. Shishido Y. Herholz K. 1995. Effect of phosphatidylcholine on explicit memory. Toxicology of a phosphatidylserine preparation from bovine brain. Poste and G. Effect of brain phosphatidylserine administration. In: Phospholipids: Biochemical. Beinat L. Massarotti M. Lombardi G. London. Nishizuka Y. Polleri A. 349-357. Fosfatidilserina e disturbi della memoria nell'anziano. Brain cortex phospholipids liposomes effects on CSF HVA. Cahiers de Nutrition et de Dietetique. Paton C. Phosphatidylserine and memory problems in aged subjects. Nerozzi D. Zanotti A. Masturzo P. Panerai A. Calcium-induced phase changes and fusion in natural and model membranes. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Maj M. Clin Trials J. Amsterdam. 393-398. 265270. Dietary Supplements. The Pharmaceutical Journal. 1365-1370. Lombardi CF. Maj M. Pepeu IM. 36. Filippi U. Cocito L. Natale M. 1992. 957-975. 1989. Nizzo MC. Gallamini A. Milan F. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Balbi D. Bonura ML. Dendritic spine loss in hippocampus of aged rats. Scotto P. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res. Terapia farmacologica con fosfatidil serina in 40 pazienti ambulatoriali con sindrome demenziale senile. 399404. 259. 1986.). 1978. Beinat L. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Petrelli L. Pharmaceutical. 267-274. Nunzi MC. Monteleone P. Therapiewoche. in eta climaterica e senile. Science. 5-HIAA and on prolactin and somatotropin secretion in man. Plenum Press. Papahadjopoulos D. La Cbnica Terapeutica 120. 209-212. TSH circadian secretions in aged men and effect of phosphatidylserine treatment. Brambilla F. McDaniel MA. 1978. Hanin I and Pepeu C (eds. 1987. 1987. Giometto B. In: Membrane Fusion. Maggioni M. Kemali D. Risultati clinici della fosfatidil-serina in 40 donne affete da turbe psico-organiche. New York. Tegos S. Palmieri R.L. Amaducci L. 1984. 33. 2007. 93-102. 73-83. Malli GL. Pepeu G. 2001. New York. Murialdo G. Plenum Press. 501-510. Polato P. Behavioral and morpho-functional correlates of brain aging: a preclinical study with phosphatidylserine. Tanzillo C. Palmieri G. Panijel M. Maffini M. Nunzi MG. 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 389 . Adv Exp Med Biol. Nunzi MG. Nicholson (eds. 1996. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men.55 56 57 58 Loeb C. Neuroendocrinology. 243-248. 1990. 81. Einstein GO. Louis-Sylvestre J. 2003. 1987. Toffano G. Chronobiologia. 1. Benassi E. 1987. Therapeutic properties of phosphatidylserine in the aging brain. Nobile P. Minen'a Medica 80. Advances in Experimental Medicine & Biology #318: Relativistic and Electron Correlation Effects in Molecules and Solids. Bo GP. de Palma D. Manfredi M. 8. Pharmaceutical Press. Bondiolotti GP. A review of phosphatidylserine pharmacological and clinical effects. 1990. Polleri A. 1990. J Neural Transm. Toffano G. Guidolin D. 1997. 52. Acta Psychiatr Scand. Maier SF. Kemali D. 1990. Advances in the treatment of Alzheimer's disease. 34. Eur J Clin Pharmacol. Cenacchi T.). 5029-5034. 318. Sottini C. Inzoli MR. 693697. Epilepsy Res. La Clmica Terapeutica. 1999. 19. 43. 120. Turnover of inositol phospholipids and signal transduction. Picotti GB. 1987. 42. Neurobiol Aging. and Analytical Considerations. Monteleone P. Toffano G. Tavolato B. "Brain-specific" nutrients: a memory cure? Nutrition.und Konzentrationsstörungen. 24. Mason P. C. 385-388. 17. Guidolin D. Elsevier/North-Holland. 1992. 73-80. 225. Therapeutische Wirksamkeit von Lecithin bei Gedächtnis. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Sakai M. Cenacchi T. Sorgatz H. Fortschr Med. 2004. Leon A. Neuroendocrine and behavioural effects of phosphatidylserine in elderly patients with abiotrophic or ascular dementia or mild depression. Kampf-Sherf O. 1990. Clinical Trials Journal. 8. Mauri M. Bescheid des Schweizerischen Bundesamt für Gesundheit Az. Urban & Fischer. Effects of consumption of choline and lecithin on neurological and cardiovascular systems. 1987. Wood JL and Allison RG. Villardita C. Vannucchi MG and Pepeu G. Clin Trials J. Kudo S. Puca FM. Chicago. Zobel M. 2005. Evaluating the validity of a learning and memory test (LGT-3) in 45 to 55-year-old patients].302. 104. Oppenheim Y. 23. Furushiro M. 1986. [Effect of lecithin on health status and concentration. Lexikon der Lebensmittel und der Lebensmittelchemie. Giannelli A. biological. Sakai M. Elsevier. Pennisi G. Nicoletti F. Beinat L. Mancuso A. 233-236. 106. 6. 24. 41. Illinois.12. Wissenschaftliche Verlagsgesellschaft. 1987. 42-48. 1986. Tunger L. 37. J Nutr Sci Vitaminol (Tokyo). Rosadini G. Clin Trials J. Multicentre clinical trial of brain PS in elderly patients with intellectual deterioration. 62-72. Clin Trials J. Phosphatidylserine: quantitative EEG effects in healthy volunteers. Grossman J. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. 302-307. [Effect of lecithin on memory performance. 94-98.und Ganzheitsmedizin. 84-93. 18. Fortschritte der Medizin. 1987. 1987. Sorgatz H. Stuttgart. Gorfine M. 24. 1987. Yamatoya H. Battistella A. Clin. 42. Merlo P. 1996. Sorgatz H. Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. 230-240. 27. Fourth International Colloquium on Lecithin: technological. Gualteri S. Zum Wirkspektrum supplemetären Lecithins auf das Verhalten. 1987. Sannita WG. Lehrman N. Rabboni M. 2001. Suzuki S. 1978. Exploratory trial of phosphatidylserine efficacy in mildly demented patients. Orlando P. Placebocontrolled double-blind study in healthy probands]. Schweizerisches Bundesamt für Gesundheit. Kudo S. Toffano C. Schreiber S. 643-646. 47-54. Wirkung von Lecithin auf Befindlichkeit und Konzentration. Natur. Bakur M.-819//ERN-BAT: Bewilligung für den Einsatz von Phosphatdylserin angereichertem Sojalecithin-Extrakt. 1093-1101. 8. Lerner B. Ternes W.77 78 79 Plutchik R. Nobili F.. Kataoka A. Lieberman M. 115-124. Modification of noradrenergic hypothalamic system in rat injected with phosphatidylserine liposomes. 137-146. 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 390 .13. Reliability and validity of a scale for assessing the functioning of geriatric patients. Grioli S. Life Sci. Clin Trials J. Pharmacokinetics of radiolabelled brain phosphatidylserine. Fed Proc. Cognitive decline in ageing brain:Therapeutic approach with phosphatidylserine. 1988. 491-500. The therapeutic value of phosphatidylserine effect in the aging brain. Leitfaden Mikronährstoffe. 24. 1987. Conte H. 24. Munchen. Agostinis C. 131. Minervini MG. 1970. 1982. 403-407. Plazebokontrollierte Doppelblindstudie bei gesunden Probanden. Yamatoya H. Salmeri G. 1990. Mazzari S. J Nutr. and therapeutic aspects held September 15-17. 3015-3021. An open trial of plantsource derived phosphatidylserine for treatment of age-related cogntive decline. 1993. Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats. Double-blind placebo-controlled trial of phosphatidylserine in elderly subjects with arteriosclerotic encephalopathy. J Am Geriatr Soc. Toffano G. Sinforiani E. Isr J Psychiatry Relat Sci. 106-112. Savarese MA. Täufel A. Maggioni FS. 2951-2956. Neuropsychobiology. Teolato S. Neurobiol Aging. Ransmayr C. 18-24. 24. Kelly D. Savoini G. 24.Trials. Toffano G. Orlando P. Schmidt E and Bieger W. 2000. Bell D. 65. J Nutr Biochem. 47. 29. Choline: an essential nutrient for humans. 2000. 1987. 669-671. benefits and side effects. Phytosterols and phytostanols: functional food cholesterol busters. 217-227. 767776. MacDougall DE. Ntanios F. Rubini R. Jones P. Gallo LL. 2007. 16. 6. 751-756. 195-206. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Phytosterols: applications and recovery methods. 1988. Life Sci. Moghadasian MH and Frohlich JJ. 8. Hendricks H. Sarkkinen ES. Sang Thrombose Vaisseaux. Paoletti R. Les phytostérols: une nouvelle approche diététique de l'hypercholestérolemie. 9 10 11 12 13 14 15 16 17 18 19 391 . Calderini G. Jones PJ. Zeisel SH. Brassicasterol. Nguyen TT. Stigmastanol. 107. 319-327. Essman WB (ed. 2335-2350. Neveu C. 2003. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. 14. de Jong A. Tanaka K. Plat J. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. 588-594. MacDougall DE. Fernandes P and Cabral JM. Can J Physiol Pharmacol. PlantSterol/Stanol Esters and Coronary Heart Disease. Normen AL. 2006. J Lipid Res. Curr Opin Lipidol. 63-67. Serfaty-Lacrosniere C. Law M. 2109-2112. Sugano M.) Karger. 35-40. Food technology. Nutr Rev. Inhibition of cholesterol absorption in rats by plant sterols. Ellegard LH. Devaraj S and Jialal I. 1999. Feng JY. Mayo Clin Proc. Jones PJ. Vahouny GV. Stigmasterol. Chapman J. van Vliet T. Am J Med. 483-490. Campesterol. J Nutr. 2007. Short-term administration of tall oil phytosterols improves plasma lipid profiles in subjects with different cholesterol levels. Weststrate J. Nutr Rev. 1999. 2001. 95102. 18. Dietary phytosterols: a review of metabolism. Dong ZP. Bruckert E. 1995. 2003. Sorokin AV. 1999. Hicks KB and Moreau RA. 1997. 11. Katan MB. Interim Final Rule. Campestanol)” and “Cholesterol metabolism” 99 1 2 3 4 5 6 7 8 Acuff RV. 362-369. 1998. Dietary phytosterols as cholesterol-lowering agents in humans.98 Zanotti A. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hupercholesterolaemic subjects. 348-354. Dietary plant sterols and cholesterol metabolism. Vanstone CA. In: Nutrients and Brain Function. John S. Grundy SM. 130. New York. Thompson PD. Bruckert E. 64. Nutrition. J Nutr. Ikeda I. 78. Food Labeling: Health Claims. 98. 53. 2001. Bioresour Technol. Metabolic effects of plant sterols and stanols (Review). 129. 55. Nigon F. Andersson SW. Metabolism. 312-316. The cholesterol-lowering action of plant stanol esters. Miettinen T. Pharmacological properties of phosphatidylserine: effects on memory function. Meijer G. 2007. 39-45. 75. Toffano G. place dans la prise en chargedu patient hyperlipidémique. The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects. Hallikainen MA. FDA (Food and Drug Administration). Chauvois D. 2000. Parsons W. Ling WH and Jones PJ. Cai DJ. 2000. ID 1634: “Phytosterols (mixture of Beta-sitosterol. Eur J Clin Nutr. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. 1573-1582. 8. Howell T. 2007. Uusitupa MI. OCL Oleagineux Corps gras Lipides. 965-978. Phytosterols and vascular disease. Andersson HA. 2000. Mensink RP. Lipids Health Dis. 57. Ergostanol. Les phytostérols. Effect of plant sterols and exercise training on cholesterol absorption and synthesis in previously sedentary hypercholesterolemic subjects. Patch CS. Clinical Science. 2002. Vanhanen H. [The mechanisms of blood LDL-cholesterol lowering by phytosterols--a review]. AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 41-45. Apports nutritionnels conseillés pour la population française. 1997. Murali G. 39. le 3 décembre 2004.04. 68. Vollmer WM.aprifel. 1995. 321. 2007. Meijer GW. Vissers MN. 291-295. des compléments alimentaires et un cocktail/nectar de jus. Moore TJ. Paris. 1117-1124. 1994. Balu M. Improving the nutritional quality of microwave-vacuum dried strawberries: A preliminary study. Modulatory role of grape seed extract on agerelated oxidative DNA damage in central nervous system of rats. Rohm K. 15. Jones PJ. Health and Nutrition. High protection by grape seed proanthocyanidins (GSPC) of polyunsaturated fatty acids against UV-C induced peroxidation. Panneerselvam C. Mordret F. Bray GA. Sangeetha P. 157-162.coli sur les parois des voies urinaires» et sur l‘emploi de la «cranberry/canneberge» ou «Vaccinium macrocarpon» dans des jus concentrés. 469-473. Food Science and Technology International.. AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 2001. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. Bohm V. Lin PH.. Phytosterols and health implications-efficacy and nutritional aspects. Rocz Panstw Zakl Hig. 58. 149. Jr. Perrin JL. A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. Belbraouet S. Varady KA. 2004.. Vasc Health Risk Manag. Svetkey LP. Lehtovirta H. 2000. Phytosterols in human nutrition. Yankah VV and Jones PJH. 2007. Scholze G. 72. N Engl J Med. Tapsell LC. 47-51. 336. Williams PG. French agency for the promotion of fresh fruits and vegetables. Saisine n° 2004-SA-214. 2004. 2004. ID 1636: “Polyphenols from processed fruits and vegetables and juices” and “Antioxidant properties” 25 26 27 28 29 1 2 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). absorption efficiency. Miettinen T. 2006. 3 4 5 6 7 8 392 .liste. 2007. 899-907. faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. 533-549. Gordon M.php?m=2&rub=54. http://www. Zock PL. A clinical trial of the effects of dietary patterns on blood pressure. 37-41. Serum levels. 42.com/articlessante. Katan MB. 31-38.20 21 22 23 24 Ostlund RE. Bouhamidi R. 2006. 12. 87. Am J Clin Nutr. cholesterol absorption and healthy diets. coli sur les parois urinaires» pour un nectar/cocktail de jus de cranberry/canneberge Maisons-Alfort. Jr. 22. 67-75. Comptes Rendus De L Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences. Aprifel. 2001. Debry G. Kuhnert S. Annu Rev Nutr. Mirabel D. Brain Research Bulletin. Lipids. Kajander J. Pages X. Pelletier X. 61-67. 1510-1515. 2. de l‘Agence française de sécurité sanitaire des aliments d‘évaluation des justificatifs concernant l‘allégation «contribue à diminuer la fixation de certaines bactéries E. Appel LJ.04. Curr Opin Lipidol. 2006. Phytosterols and cholesterol metabolism. Jr. Vogt TM. Avis relatif à l‘évaluation des justificatifs concernant l‘allégation «contribue à diminuer la fixation de certaines bactéries E. Nouvelot A. Ostlund RE. Afssa-Saisine n°2003SA-0352. 1998. Phytosterols. Editions Tec&Doc. Sacks FM. Ostlund RE. Ann Nutr Metab. Prevost V. 12. Windhauser MM. 22-30. Effect of plant sterols from rice bran oil and triterpene alcohols from sheanut oil on serum lipoprotein concentrations in humans. Transl Res. Karanja N. Wlodarek D. Saisine liée n°2003-SA-0056 et 2003-SA-0352. Cutler JA. Obarzanek E. 06. Houweling AH. 9 10 Bravo L, 1998. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutrition Reviews, 56, 317-333. Caccetta RAA, Burke V, Mori TA, Beilin LJ, Puddey IB, Croft KD, 2001. Red wine polyphenols, in the absence of alcohol, reduce lipid peroxidative stress in smoking subjects. Free Radical Biology and Medicine, 30, 636-642. Carando S and Teissedre PL, 1999. Catechin and procyanidin levels in French wines: contribution to dietary intake. Basic life sciences, 66, 725. Carini M, Aldini G, Bombardelli E, Morazzoni P, Facino RM, 2000. UVB-induced hemolysis of rat erythrocytes: Protective effect of procyanidins from grape seeds. Life Sciences, 67, 1799-1814. Caruso D, Visioli F, Patelli R, Galli C, Galli G, 2001. Urinary excretion of olive oil phenols and their metabolites in humans. Metabolism-Clinical and Experimental, 50, 1426-1428. Castillo J, Benavente-Garcia O, Lorente J, Alcaraz MJ, Redondo A, Ortuno A, Del Rio JA, 2000. Antioxidant activity and radioprotective effects against chromosomal damage induced in vivo by X-rays of flavan-3-ols (Procyanidins) from grape seeds (Vitis vinifera): Comparative study versus other phenolic and organic compounds. Journal of Agricultural and Food Chemistry, 48, 1738-1745. Chaovanalikit A and Wrolstad RE, 2004. Total anthocyanins and total phenolics of fresh and processed cherries and their antioxidant properties. Journal of Food Science, 69, C67-C72. Covas MI, Nyyssonen K, Poulsen HE, Kaikkonen J, Zunft HJF, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Baumler H, Nascetti S, Salonen JT, Fito M, Virtanen J, Marrugat J, Grp ES, 2006. The effect of polyphenols in olive oil on heart disease risk factors - A randomized trial. Annals of Internal Medicine, 145, 333-341. Covas MI, Ruiz-Gutierrez V, de la Torre R, Kafatos A, Lamuela-Raventos RM, Osada J, Owen RW, Visioli F, 2006. Minor components of olive oil: Evidence to date of health benefits in humans. Nutrition Reviews, 64, S20-S30. Covas MI, 2007. Olive oil and the cardiovascular system. Pharmacological Research, 55, 175-186. Dai Q, Borenstein AR, Wu YG, Jackson JC, Larson EB, 2006. Fruit and vegetable juices and Alzheimer's disease: The Kame Project. American Journal of Medicine, 119, 751-759. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AAE, Bertelli A, 1999. Cardioprotection of red wine: Role of polyphenolic antioxidants. Drugs under Experimental and Clinical Research, 25, 115120. Day AP, Kemp HJ, Bolton C, Hartog M, Stansbie D, 1997. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. Annals of Nutrition and Metabolism, 41, 353-357. Dewettinck K, Goddyn K, Anthierens K, Verbeken D, Van Camp J, 2006. Bibliographical study on the nutritional benefits of processed fruit and vegetables. OEITFL study. Durak I, Cimen MYB, Buyukkocat S, Kacmaz M, Ozturk HS, 1999. The effect of red wine on blood antioxidant potential. Current Medical Research and Opinion, 15, 208-213. FIAC (Federation des Industries d' Aliments Conserves), 2007. Polyphènols dans les fruits et lègumes transformès. Fito M, Covas MI, Lamuela-Raventos RM, Vila J, Torrents J, de la Torre C, Marrugat J, 2000. Protective effect of olive oil and its phenolic compounds against low density lipoprotein oxidation. Lipids, 35, 633638. Fito M, Cladellasc M, de la Torre R, Marti J, Alcantara M, Pujadas-Bastardes M, Marrugat J, Bruguera J, Lopez-Sabater MC, Vila J, Covas MI, 2005. Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial. Atherosclerosis, 181, 149-158. Gorinstein S, Caspi A, Libman I, Lerner HT, Huang DJ, Leontowicz H, Leontowicz M, Tashma Z, Katrich E, Feng SB, Trakhtenberg S, 2006. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: Studies in vitro and in humans. Journal of Agricultural and Food Chemistry, 54, 1887-1892. 393 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Jamroz A and Beltowski J, 2001. Antioxidant capacity of selected wines. Medical Science Monitor, 7, 1198-1202. Katan MB and Hollman PCH, 1998. Dietary flavonoids and cardiovascular disease. Nutrition Metabolism and Cardiovascular Diseases, 8, 1-4. Lairon D and Amiot MJ, 1999. Flavonoids in food and natural antioxidants in wine. Current Opinion in Lipidology, 10, 23-28. Lecerf JM, 1999. Les antioxidants et les autres elements protecteurs dans les jus de fruits et legumes. Pasteur Institute-Lille. Lecerf JM, 2006. Polyphenols in juices and processed fruits and vegetables. Pasteur Institute-Lille. Leighton F, Cuevas A, Guasch V, Perez DD, Strobel P, San Martin A, Urzua U, Diez MS, Foncea R, Castillo O, Mizon C, Espinoza MA, Urquiaga I, Rozowski J, Maiz A, Germain A, 1999. Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. Drugs under Experimental and Clinical Research, 25, 133-141. Llopiz N, Puiggros F, Cespedes E, Arola L, Ardevol A, Blade C, Salvado MJ, 2004. Antigenotoxic effect of grape seed procyanidin extract in Fao cells submitted to oxidative stress. Journal of Agricultural and Food Chemistry, 52, 1083-1087. Machowetz A, Poulsen HE, Gruendel S, Weimann A, Fito M, Marrugat J, de la Torre R, Salonen JT, Nyyssonen K, Mursu J, Nascetti S, Gaddi A, Kiesewetter H, Baumler H, Selmi H, Kaikkonen J, Zunft HJF, Covas MI, Koebnick C, 2007. Effect of olive oils on biomarkers of oxidative DNA stress in Northern and Southern Europeans. FASEB J, 21, 45-52. Manach C, Scalbert A, Remesey C, Morand C, 2006. Consommation et biodisponibilitè des polyphènols. In: Les polyphénols en agroalimentaire. Sarni-Machado P and Cheynier V (eds.). Tech & Doc, Lavoisier, Paris, 361-390. Marrugat J, Covas MI, Fito M, Schroder H, Miro-Casas E, Gimeno E, Lopez-Sabater MC, de la Torre R, Farre M, Investigators S, 2004. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation - A randomized controlled trial. European Journal of Nutrition, 43, 140-147. AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris. Miro-Casas E, Covas MI, Farre M, Fito M, Ortuno J, Weinbrenner T, Roset P, de la Torre R, 2003. Hydroxytyrosol disposition in humans. Clinical Chemistry, 49, 945-952. Natella F, Belelli F, Gentili V, Ursini F, Scaccini C, 2002. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. Journal of Agricultural and Food Chemistry, 50, 7720-7725. Ninfali P and Bacchiocca M, 2003. Polyphenols and antioxidant capacity of vegetables under fresh and frozen conditions. Journal of Agricultural and Food Chemistry, 51, 2222-2226. Noroozi M, Angerson WJ, Lean MEJ, 1998. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. American Journal of Clinical Nutrition, 67, 1210-1218. PaceAsciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM, 1996. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clinica Chimica Acta, 246, 163-182. Ramirez-Tortosa MC, Urbano G, Lopez-Jurado M, Nestares T, Gomez MC, Mir A, Ros E, Mataix J, Gil A, 1999. Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in freeliving men with peripheral vascular disease. Journal of Nutrition, 129, 2177-2183. Ruano J, Lopez-Miranda J, Fuentes F, Moreno JA, Bellido C, Perez-Martinez P, Lozano A, Gomez P, Jimenez Y, Jimenez FP, 2005. Phenolic content of virgin olive oil improves ischemic reactive hyperemia in hypercholesterolemic patients. Journal of the American College of Cardiology, 46, 1864-1868. Sarni-Manchado P and Cheynier V, 2006. Les polyphenols en IAA. Tech & Doc, Lavoisier, Paris. Sato M, Maulik N, Das DK, 2002. Cardioprotection with alcohol - Role of both alcohol and polyphenolic antioxidants. Alcohol and Wine in Health and Disease, 957, 122-135. 34 35 36 37 38 39 40 41 42 43 44 45 46 47 394 48 49 Serafini M, Maiani G, Ferro-Luzzi A, 1998. Alcohol-free red wine enhances plasma antioxidant capacity in humans. Journal of Nutrition, 128, 1003-1007. Serafini M, Laranjinha JAN, Almeida LM, Maiani G, 2000. Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans. Journal of Nutritional Biochemistry, 11, 585-590. Simonetti P, Ciappellano S, Gardana C, Bramati L, Pietta P, 2002. Procyanidins from Vitis vinifera seeds: In vivo effects on oxidative stress. Journal of Agricultural and Food Chemistry, 50, 6217-6221. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD, 1999. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation, 100, 1050-1055. Tedesco I, Russo M, Russo P, Iacomino G, Russo GL, Carraturo A, Faruolo C, Moio L, Palumbo R, 2000. Antioxidant effect of red wine polyphenols on red blood cells. Journal of Nutritional Biochemistry, 11, 114-119. Valdez LB, Actis-Goretta L, Boveris A, 2002. Polyphenols in red wines prevent NADH oxidation induced by peroxynitrite. Alcohol and Wine in Health and Disease, 957, 274-278. Visioli F, Caruso D, Galli C, Viappiani S, Galli G, Sala A, 2000. Olive oils rich in natural catecholic phenols decrease isoprostane excretion in humans. Biochemical and Biophysical Research Communications, 278, 797-799. Visioli F, Galli C, Bornet F, Mattei A, Patelli R, Galli G, Caruso D, 2000. Olive oil phenolics are dosedependently absorbed in humans. FEBS Letters, 468, 159-160. Visioli F, Galli C, Plasmati E, Viappiani S, Hernandez A, Colombo C, Sala A, 2000. Olive phenol hydroxytyrosol prevents passive smoking-induced oxidative stress. Circulation, 102, 2169-2171. Visioli F, Poli A, Galli C, 2002. Antioxidant and other biological activities of phenols from olives and olive oil. Medicinal Research Reviews, 22, 65-75. Visioli F, Caruso D, Grande S, Bosisio R, Villa M, Galli G, Sirtori C, Galli C, 2005. Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. European Journal of Nutrition, 44, 121-127. Vissers MN, Zock PL, Wiseman SA, Meyboom S, Katan MB, 2001. Effect of phenol-rich extra virgin olive oil on markers of oxidation in healthy volunteers. European Journal of Clinical Nutrition, 55, 334341. Yamaguchi F, Yoshimura Y, Nakazawa H, Ariga T, 1999. Free radical scavenging activity of grape seed extract and antioxidants by electron spin resonance spectrometry in an H2O2/NaOH/DMSO system. Journal of Agricultural and Food Chemistry, 47, 2544-2548. Zhao J, Wang JN, Chen YJ, Agarwal R, 1999. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3 '-gallate as the most effective antioxidant constituent. Carcinogenesis, 20, 1737-1745. ID 1637: “Polyphenols (general and from grape, olive and cacao in particular)” and “Antioxidant properties” 50 51 52 53 54 55 56 57 58 59 60 61 1 AbuAmsha R, Croft KD, Puddey IB, Proudfoot JM, Beilin LJ, 1996. Phenolic content of various beverages determines the extent of inhibition of human serum and low-density lipoprotein oxidation in vitro: Identification and mechanism of action of some cinnamic acid derivatives from red wine. Clinical Science, 91, 449-458. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D, 2006. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. Journal of Agricultural and Food Chemistry, 54, 980-985. Adrian J, Portus J, Frangne R, 1995. La science alimentaire de A à Z. Tech & Doc, Lavoisier, Paris. 2 3 395 4 5 6 7 8 AFSSA (Agence Française de Sécurité Sanitaire des Aliments), 2001. Apports nutritionnels conseillés pour la population française. Editions Tec&Doc, Paris. Aherne SA and O'Brien NM, 2002. Dietary flavonols: Chemistry, food content, and metabolism. Nutrition, 18, 75-81. Ariga T, 2004. The antioxidative function, preventive action on disease and utilization of proanthocyanidins. Biofactors, 21, 197-201. Aviram M and Fuhrman B, 1998. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis, 137, S45-S50. Bagchi D, Krohn RL, Balmoori J, Bagchi M, Garg A, Stohs SJ, Kumpulainen JT, Salonen JT, 1999. Comparative in vitro and in viva free radical scavenging abilities of a novel grape seed proanthocyanidin extract and selected antioxidants. Special Publication-Royal Society Of Chemistry, 240, 178-187. Bentivegna SS and Whitney KM, 2002. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food Chem Toxicol, 40, 1731-1743. Benzie IF, Szeto YT, Strain JJ, Tomlinson B, 1999. Consumption of green tea causes rapid increase in plasma antioxidant power in humans. Nutr Cancer, 34, 83-87. Berset C Sarni-Manchado P and Cheynier V, 2006. Antioxydants phénoliques. Structure, propriétés, sources végétales.Les Polyphénols en Agroalimentaire. Tec&Doc, Lavoisier, Paris. Bors W and Saran M, 1987. Radical scavenging by flavonoid antioxidants. Free Radic Res Commun, 2, 289-294. Bors W, Heller W, Michel C, Saran M, 1990. Flavonoids as Antioxidants - Determination of RadicalScavenging Efficiencies. Methods in Enzymology, 186, 343-355. Bors W, Heller W, Michel C, Saran M, 1990. Radical chemistry of flavonoid antioxidants. Advances in experimental medicine and biology, 264, 165. Bors W, 1997. Antioxidant effects of flavonoids. Biofactors, 6, 399-402. Bors W and Michel C, 1999. Antioxidant capacity of flavanols and gallate esters: pulse radiolysis studies. Free Radical Biology and Medicine, 27, 1413-1426. Bors W and Michel C, 2002. Chemistry of the antioxidant effect of polyphenols. Alcohol and Wine in Health and Disease, 957, 57-69. Boyle SP, Dobson VL, Duthie SJ, Hinselwood DC, Kyle JA, Collins AR, 2000. Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. Eur J Clin Nutr, 54, 774-782. Bravo L, 1998. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutrition Reviews, 56, 317-333. Brehme U, Hahn A, Laube H, Leitzmann C, Michel P, Müller C, 2001. Ernährung IN Prävention UND Therapie. Hippokrates Verlag, Stuttgart. Buettner G, 1993. The pecking order of free radicals and antioxidants: lipid peroxidation, a-tocopherol, and ascorbate. Archives of Biochemistry and Physics 300, 535-543. Carratu B and Sanzini E, 2005. Biologically-active phytochemicals in vegetable food. Annali dell'Istituto Superiore di Sanita, 41, 7-16. Cartron E, Carbonneau M-A, Fouret G, Leger CL, Descomps B, 1998. Effects of phenolic compounds of various origins on the antioxidant status of LDL. COST 916, Polyphenols in Food, Series: European Commission – Science Research Development. Cassidy A, Hanley B, Lamuela-Raventos RM, 2000. Isoflavones, lignans and stilbenes - origins, metabolism and potential importance to human health. Journal of the Science of Food and Agriculture, 80, 1044-1062. Cherubini A, Beal MF, Frei B, 1999. Black tea increases the resistance of human plasma to lipid peroxidation in vitro, but not ex vivo. Free Radical Biology and Medicine, 27, 381-387. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 396 26 27 28 29 30 31 32 Chun OK, Kim DO, Lee CY, 2003. Superoxide radical scavenging activity of the major polyphenols in fresh plums. J Agric Food Chem, 51, 8067-8072. Clifford M, 2005. Functional Food Science and defence against reactive oxidative species. "Phytochemicals: Medicine or Nutrient?‖, London, p. 87 -93. Cook NC and Samman S, 1996. Flavonoids - Chemistry, metabolism, cardioprotective effects, and dietary sources. Journal of Nutritional Biochemistry, 7, 66-76. Curin Y and Andriantsitohaina R, 2005. Polyphenols as potential therapeutical agents against cardiovascular diseases. Pharmacological Reports, 57, 97-107. da Luz PL and Coimbra SR, 2004. Wine, alcohol and atherosclerosis: clinical evidences and mechanisms. Brazilian Journal of Medical and Biological Research, 37, 1275-1295. Davalos A, Gomez-Cordoves C, Bartolome B, 2003. Commercial dietary antioxidant supplements assayed for their antioxidant activity by different methodologies. J Agric Food Chem, 51, 2512-2519. Day AP, Kemp HJ, Bolton C, Hartog M, Stansbie D, 1997. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. Ann Nutr Metab, 41, 353-357. Decker EA, 1997. Phenolics: prooxidants or antioxidants? Nutr Rev, 55, 396-398. Demrow HS, Slane PR, Folts JD, 1995. Administration of Wine and Grape Juice Inhibits in-Vivo Platelet Activity and Thrombosis in Stenosed Canine Coronary-Arteries. Circulation, 91, 1182-1188. Dragsted LO, 2003. Antioxidant actions of polyphenols in humans. International Journal for Vitamin and Nutrition Research, 73, 112-119. Durak I, Avci A, Kacmaz M, Buyukkocak S, Cimen MYB, Elgun S, Ozturk HS, 1999. Comparison of antioxidant potentials of red wine, white wine, grape juice and alcohol. Current Medical Research and Opinion, 15, 316-320. El SN and Karakaya S, 2004. Radical scavenging and iron-chelating activities of some greens used as traditional dishes in Mediterranean diet. International Journal of Food Sciences and Nutrition, 55, 67-74. Engelhardt U, 2001. Flavonoide/ Polyphenole. In: Praxishandbuch Functional Food. Erbersdobler HF and Meyer AH (eds.). Behr´s Verlag, Hamburg. Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, Kwak HK, Milbury P, Paul SM, Blumberg J, Mietus-Snyder ML, 2004. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr, 23, 197-204. Erba D, Riso P, Bordoni A, Foti P, Biagi PL, Testolin G, 2005. Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. J Nutr Biochem, 16, 144-149. Farag RS, El-Baroty GS, Basuny AM, 2003. Safety evaluation of olive phenolic compounds as natural antioxidants. Int J Food Sci Nutr, 54, 159-174. FAV Health, Symposium International sur les effets santé des fruits et des légumes, http://www.isfae.org/viewmeeting.php?meeting=52. Fisher ND, Hughes M, Gerhard-Herman M, Hollenberg NK, 2003. Flavanol-rich cocoa induces nitricoxide-dependent vasodilation in healthy humans. J Hypertens, 21, 2281-2286. Fitzpatrick DF, Hirschfield SL, Coffey RG, 1993. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol, 265, H774-778. Franke AA, Cooney RV, Henning SM, Custer LJ, 2005. Bioavallability and antioxidant effects of orange juice components in humans. Journal of Agricultural and Food Chemistry, 53, 5170-5178. Frede W, 2006. Taschenbuch für Lebensmittelchemiker. Springer, Hamburg. Fuhrman B, Buch S, Vaya J, Belinky PA, Coleman R, Hayek T, Aviram M, 1997. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr, 66, 267-275. 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 397 48 49 50 51 Fuhrman B and Aviram M, 2001. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Current Opinion in Lipidology, 12, 41. Galli C and Visioli F, 2001. Antioxidant properties of Mediterranean diet. Int J Vitam Nutr Res, 71, 185188. Geleijnse JM, Launer LJ, Van der Kuip DA, Hofman A, Witteman JC, 2002. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr, 75, 880-886. Gimeno E, Fito M, Lamuela-Raventos RM, Castellote AI, Covas M, Farre M, de La Torre-Boronat MC, Lopez-Sabater MC, 2002. Effect of ingestion of virgin olive oil on human low-density lipoprotein composition. Eur J Clin Nutr, 56, 114-120. Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, Haytowitz D, Gebhardt S, Prior RL, 2004. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. J Nutr, 134, 613-617. Hahn A, 2006. Der Markt für Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. In: Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Hahn A (ed.) Wissenschaftliche Verlagsges. Hahn A, Ströhle A, Wolters M, 2006. Ernährung. Wissenschaftliche Verlagsges, Stuttgart. Halliwell B, 1999. Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev, 57, 104-113. Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, Wold AB, Haffner K, Baugerod H, Andersen LF, Moskaug O, Jacobs DR, Jr., Blomhoff R, 2002. A systematic screening of total antioxidants in dietary plants. J Nutr, 132, 461-471. Halvorsen BL, Carlsen MH, Phillips KM, Bohn SK, Holte K, Jacobs DR, Jr., Blomhoff R, 2006. Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States. Am J Clin Nutr, 84, 95-135. Hammerstone JF, Lazarus SA, Schmitz HH, 2000. Procyanidin content and variation in some commonly consumed foods. J Nutr, 130, 2086S-2092S. Harada M, Kan Y, Naoki H, Fukui Y, Kageyama N, Nakai M, Miki W, Kiso Y, 1999. Identification of the major antioxidative metabolites in biological fluids of the rat with ingested (+)-catechin and (-)-epicatechin. Biosci Biotechnol Biochem, 63, 973-977. Harborne JB and Williams CA, 1998. Anthocyanins and other flavonoids. Natural Product Reports, 15, 631-652. Heim KE, Tagliaferro AR, Bobilya DJ, 2002. Flavonoid antioxidants: chemistry, metabolism and structureactivity relationships. J Nutr Biochem, 13, 572-584. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D, 1993. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet, 342, 1007-1011. Hertog MG and Hollman PC, 1996. Potential health effects of the dietary flavonol quercetin. Eur J Clin Nutr, 50, 63-71. Higdon JV and Frei B, 2003. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr, 43, 89-143. Hirano R, Sasamoto W, Matsumoto A, Itakura H, Igarashi O, Kondo K, 2001. Antioxidant ability of various flavonoids against DPPH radicals and LDL oxidation. J Nutr Sci Vitaminol (Tokyo), 47, 357-362. Hollman PC, 1997. Bioavailability of flavonoids. Eur J Clin Nutr, 51 Suppl 1, S66-69. Hollman PCH, van Trijp JMP, Buysman M, vd Gaag MS, Mengelers MJB, de Vries JHM, Katan MB, 1997. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS letters, 418, 152-156. Hollman PC, Feskens EJ, Katan MB, 1999. Tea flavonols in cardiovascular disease and cancer epidemiology. Proc Soc Exp Biol Med, 220, 198-202. 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 398 69 70 71 Hollman PC and Katan MB, 1999. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol, 37, 937-942. Hollman PC and Katan MB, 1999. Health effects and bioavailability of dietary flavonols. Free Radic Res, 31 Suppl, S75-80. Janisch K, Hippeli S, Dornisch K, Kern S, Elstner EF, 2002. Determination of the antioxidative potential of human plasma after supplementation with pycnogenol and whey. Food Research International, 35, 257266. Janssen K, Mensink RP, Cox FJ, Harryvan JL, Hovenier R, Hollman PC, Katan MB, 1998. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr, 67, 255-262. Karakaya S, El SN, Tas AA, 2001. Antioxidant activity of some foods containing phenolic compounds. Int J Food Sci Nutr, 52, 501-508. Kaur C and Kapoor HC, 2001. Antioxidants in fruits and vegetables-the millennium's health. International Journal of Food Science & Technology, 36, 703-725. Keen CL, Holt RR, Oteiza PI, Fraga CG, Schmitz HH, 2005. Cocoa antioxidants and cardiovascular health. Am J Clin Nutr, 81, 298S-303S. Kelawala NS and Ananthanarayan L, 2004. Antioxidant activity of selected foodstuffs. Int J Food Sci Nutr, 55, 511-516. King A and Young G, 1999. Characteristics and occurrence of phenolic phytochemicals. J Am Diet Assoc, 99, 213-218. Knekt P, Jarvinen R, Reunanen A, Maatela J, 1996. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ, 312, 478-481. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A, 2002. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr, 76, 560-568. Kromhout D, 1999. Are antioxidants effective in primary prevention of coronary heart disease? In: Natural Antioxidants and Anticarcinogens in Nutrition, Health and Disease. Kumpulainen JT and Salonen JT (eds.). Royal Society of Chemistry, 20-26. Kuhnau J, 1976. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet, 24, 117-191. Lairon D and Amiot MJ, 1999. Flavonoids in food and natural antioxidants in wine. Curr Opin Lipidol, 10, 23-28. Langley-Evans SC, 2000. Consumption of black tea elicits an increase in plasma antioxidant potential in humans. Int J Food Sci Nutr, 51, 309-315. Lanningham-Foster L, Chen C, Chance DS, Loo G, 1995. Grape extract inhibits lipid peroxidation of human low density lipoprotein. Biol Pharm Bull, 18, 1347-1351. Lecerf JM, 1999. Les antioxydants et les autres éléments protecteurs dans les jus de fruits et légumes. Pasteur Institute-Lille. Leenen R, Roodenburg AJ, Tijburg LB, Wiseman SA, 2000. A single dose of tea with or without milk increases plasma antioxidant activity in humans. Eur J Clin Nutr, 54, 87-92. Leenen R, Roodenburg AJ, Vissers MN, Schuurbiers JA, van Putte KP, Wiseman SA, van de Put FH, 2002. Supplementation of plasma with olive oil phenols and extracts: influence on LDL oxidation. J Agric Food Chem, 50, 1290-1297. Leitzmann C and Watzl B, 1999. Bioaktive Substanzen in Lebensmitteln. Hippokrates, Stuttgart. Limasset B, le Doucen C, Dore JC, Ojasoo T, Damon M, Crastes de Paulet A, 1993. Effects of flavonoids on the release of reactive oxygen species by stimulated human neutrophils. Multivariate analysis of structure-activity relationships (SAR). Biochem Pharmacol, 46, 1257-1271. 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 399 90 91 92 Linseisen J, Radtke J, Wolfram G, 1997. [Flavonoid intake of adults in a Bavarian subgroup of the national food consumption survey]. Z Ernahrungswiss, 36, 403-412. Lopez S, Pacheco YM, Bermudez B, Abia R, Muriana FJG, 2004. Olive oil and cancer. Grasas y Aceites (España), 55, 33-41. Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R, 1994. Free radicals scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44, 592-601. Manach C, 1998. Flavonoids bioavailability. Thèse, Centre de Recherche en Nutrition Humaine - INRA Clermont-Ferrand. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L, 2004. Polyphenols: food sources and bioavailability. Am J Clin Nutr, 79, 727-747. Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr, 81, 230S-242S. Marrugat J, Covas MI, Fito M, Schroder H, Miro-Casas E, Gimeno E, Lopez-Sabater MC, de la Torre R, Farre M, 2004. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. Eur J Nutr, 43, 140-147. Masella R, Giovannini C, Vari R, Di Benedetto R, Coni E, Volpe R, Fraone N, Bucci A, 2001. Effects of dietary virgin olive oil phenols on low density lipoprotein oxidation in hyperlipidemic patients. Lipids, 36, 1195-1202. Masella R, Di Benedetto R, Vari R, Filesi C, Giovannini C, 2005. Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes. J Nutr Biochem, 16, 577-586. Masquelier J, Michaud J, Laparra J, Dumon MC, 1979. [Flavonoids and pycnogenols]. Int J Vitam Nutr Res, 49, 307-311. Milbury PE, Cao G, Prior RL, Blumberg J, 2002. Bioavailablility of elderberry anthocyanins. Mechanisms of ageing and development, 123, 997-1006. Minoggio M, Bramati L, Simonetti P, Gardana C, Iemoli L, Santangelo E, Mauri PL, Spigno P, Soressi GP, Pietta PG, 2003. Polyphenol pattern and antioxidant activity of different tomato lines and cultivars. Ann Nutr Metab, 47, 64-69. Miura Y, Chiba T, Tomita I, Koizumi H, Miura S, Umegaki K, Hara Y, Ikeda M, Tomita T, 2001. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr, 131, 27-32. Miyagi Y, Miwa K, Inoue H, 1997. Inhibition of human low-density lipoprotein oxidation by flavonoids in red wine and grape juice. Am J Cardiol, 80, 1627-1631. Morel I, Lescoat G, Cillard P, Cillard J, 1994. Role of flavonoids and iron chelation in antioxidant action. Methods Enzymol, 234, 437-443. Mukai K, Nagai S, Ohara K, 2005. Kinetic study of the quenching reaction of singlet oxygen by tea catechins in ethanol solution. Free Radic Biol Med, 39, 752-761. Nakagawa K, Ninomiya M, Okubo T, Aoi N, Juneja LR, Kim M, Yamanaka K, Miyazawa T, 1999. Tea catechin supplementation increases antioxidant capacity and prevents phospholipid hydroperoxidation in plasma of humans. J Agric Food Chem, 47, 3967-3973. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA, 2001. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr, 74, 418-425. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM, 1996. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta, 246, 163-182. Pataki T, Bak I, Kovacs P, Bagchi D, Das DK, Tosaki A, 2002. Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am J Clin Nutr, 75, 894-899. Pietta PG, 2000. Flavonoids as antioxidants. J Nat Prod, 63, 1035-1042. 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 400 111 Princen HM, van Duyvenvoorde W, Buytenhek R, Blonk C, Tijburg LB, Langius JA, Meinders AE, Pijl H, 1998. No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers. Arterioscler Thromb Vasc Biol, 18, 833-841. Proteggente AR, Pannala AS, Paganga G, Van Buren L, Wagner E, Wiseman S, Van De Put F, Dacombe C, Rice-Evans CA, 2002. The antioxidant activity of regularly consumed fruit and vegetables reflects their phenolic and vitamin C composition. Free Radic Res, 36, 217-233. Rasmussen SE, Frederiksen H, Struntze Krogholm K, Poulsen L, 2005. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol Nutr Food Res, 49, 159-174. Reed J, 2002. Cranberry flavonoids, atherosclerosis and cardiovascular health. Crit Rev Food Sci Nutr, 42, 301-316. Remesy C, Manach C, Demigne C, Texier O, Regerat F, 1996. Nutritional interest of flavonoids. Medecine et Nutrition, 32, 17-27. Ricci D, Giamperi L, Bucchini A, Fraternale D, 2006. Antioxidant activity of Punica granatum fruits. Fitoterapia, 77, 310-312. Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB, 1995. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res, 22, 375-383. Rice-Evans CA, Miller NJ, Paganga G, 1996. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med, 20, 933-956. Rice-Evans C, 1999. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Proc Soc Exp Biol Med, 220, 262-266. Rice-Evans CA, Paganga G, Miller N, 1999. The polyphenolic content of fruit and vegetables and their antioxidant activities. What does a serving constitute? Free Radic Res, 30, 153-162. Rice-Evans C, 2001. Flavonoid antioxidants. Current medicinal chemistry, 8, 797-807. Rijken PJ, Balentine DA, van Mierlo CAJ, Paetau-Robinson I, van de Put F, Quinlan PT, Weisgerber UM, Wiseman SA, 2002. Antioxidant and other properties of green and black tea. Oxidative Stress and Disease, 8, 371-400. Robak J and Gryglewski RJ, 1996. Bioactivity of flavonoids. Pol J Pharmacol, 48, 555-564. Rohdewald P Rice-Evans CA and Packer L, 1998. Flavonoids in Health and Disease. Marcel Dekker, New York. Santos-Buelga C and Scalbert A, 2000. Proanthocyanidins and tannin-like compounds-nature, occurrence, dietary intake and effects on nutrition and health. Journal of the Science of Food and Agriculture, 80, 10941117. Schmandke H, 2006. Prenylflavonoide in Hopfen und Bier – ihre biochemischen und biologischen Effekte. Ernährungsumschau 6, 225-229. Schmiedel V, Leitzmann C, Lützner H, Heine H, 2001. Ernährungsmedizin in der Naturheilkunde. Urban & Fischer, Munchen. Schramm DD, Wang JF, Holt RR, Ensunsa JL, Gonsalves JL, Lazarus SA, Schmitz HH, German JB, Keen CL, 2001. Chocolate procyanidins decrease the leukotriene-prostacyclin ratio in humans and human aortic endothelial cells. Am J Clin Nutr, 73, 36-40. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M, 2006. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA, 103, 1024-1029. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D, 2005. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem, 16, 360367. 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 401 131 132 Serafini M, Ghiselli A, Ferro-Luzzi A, 1996. In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr, 50, 28-32. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD, 1999. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation, 100, 1050-1055. Sudheesh S and Vijayalakshmi NR, 2005. Flavonoids from Punica granatum--potential antiperoxidative agents. Fitoterapia, 76, 181-186. Sung H, Nah J, Chun S, Park H, Yang SE, Min WK, 2000. In vivo antioxidant effect of green tea. Eur J Clin Nutr, 54, 527-529. Takahama U, 1985. Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: mechanism of antioxidative function. Phytochemistry, 24, 1443-1446. Talbott SM, 2003. A guide to understanding dietary supplements. The Haworth Press, Binghamton. Tapiero H, Tew KD, Ba GN, Mathe G, 2002. Polyphenols: do they play a role in the prevention of human pathologies? Biomed Pharmacother, 56, 200-207. Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg. Tourino S, Selga A, Jimenez A, Julia L, Lozano C, Lizarraga D, Cascante M, Torres JL, 2005. Procyanidin fractions from pine (Pinus pinaster) bark: radical scavenging power in solution, antioxidant activity in emulsion, and antiproliferative effect in melanoma cells. J Agric Food Chem, 53, 4728-4735. Tournaire C, Croux S, Maurette MT, Beck I, Hocquaux M, Braun AM, Oliveros E, 1993. Antioxidant activity of flavonoids: efficiency of singlet oxygen (1 delta g) quenching. J Photochem Photobiol B, 19, 205-215. Van Amelsvoort JMM, Hof KHV, Mathot JNJJ, Mulder TPJ, Wiersma A, Tijburg LBM, 2001. Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica, 31, 891-901. Vercauteren J, Arnaudinaud V, Mas T, Verge S, Soulet S, Castagnino C, Cheze C, 1998. Y-a-t‘il encore une place demain pour des aliments sans polyphenols ? Lettre scientifique de l'institut français pour la nutrition, 68, 1-8. Vitalis B, Vitalija P, Saulius K, Rimantas VP, 2003. Polyphenols and anthocyanins in fruits, grape juices and wines, and evaluation of their antioxidant activity. Lithuania Medicina, 39, 104-112. Vlachopoulos C, Aznaouridis K, Alexopoulos N, Economou E, Andreadou I, Stefanadis C, 2005. Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens, 18, 785-791. Walle T, 2004. Absorption and metabolism of flavonoids. Free Radic Biol Med, 36, 829-837. Weinbrenner T, Fito M, de la Torre R, Saez GT, Rijken P, Tormos C, Coolen S, Albaladejo MF, Abanades S, Schroder H, Marrugat J, Covas MI, 2004. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. J Nutr, 134, 2314-2321. Wildman REC, 2001. Handbook of nutraceuticals and functional foods. CRC press, Boca Raton. Williams RJ, Spencer JP, Rice-Evans C, 2004. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med, 36, 838-849. Wiseman SA, Balentine DA, Frei B, Malvy D, Remesy C, 2000. Les antioxydants du thé. Cah Nutr Diet 35, 23-33. Wiseman SA, Tijburg LB, van de Put FH, 2002. Olive oil phenolics protect LDL and spare vitamin E in the hamster. Lipids, 37, 1053-1057. Wood JE, Senthilmohana ST, Peskin AV, 2002. Antioxidant activity of procyanidin-containing plant extracts at different pHs. Food Chemistry 77, 155-161. Yamakoshi J, Saito M, Kataoka S, Kikuchi M, 2002. Safety evaluation of proanthocyanidin-rich extract from grape seeds. Food Chem Toxicol, 40, 599-607. Yehuda S and Mostofsky DI, 2005. Nutrients, Stress and Medical Disorders. Humana Press. 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 402 154 155 156 Zenebe W and Pechanova O, 2002. Effects of red wine polyphenolic compounds on the cardiovascular system. Bratisl Lek Listy, 103, 159-165. Zern TL and Fernandez ML, 2005. Cardioprotective effects of dietary polyphenols. J Nutr, 135, 2291-2294. Zhao CY, Shi YM, Yao SD, Jia ZJ, Fan BT, Wang WF, Lin WZ, Lin NY, Zheng RL, 2003. Scavenging effects of natural phenols on oxidizing intermediates of peroxynitrite. Pharmazie, 58, 742-749. ID 1638: “Polyphenols from olive (olive fruit, olive mild waste waters or olive oil)” and “Antioxidant properties” 1 2 3 Hagers Handbuch der pharmazeutischen Praxis. 1995. Springer Verlag, Berlin. Aguilera CM, Ramirez-Tortosa MC, Mesa MD, Gil A, 2001. [Protective effect of monounsaturated and polyunsaturated fatty acids on the development of cardiovascular disease]. Nutr Hosp, 16, 78-91. Aguilera CM, Mesa MD, Ramirez-Tortosa MC, Nestares MT, Ros E, Gil A, 2004. Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease. Clinical Nutrition, 23, 673-681. Bonanome A, Pagnan A, Caruso D, Toia A, Xamin A, Fedeli E, Berra B, Zamburlini A, Ursini F, Galli G, 2000. Evidence of postprandial absorption of olive oil phenols in humans. Nutr Metab Cardiovasc Dis, 10, 111-120. Bondia-Pons I, Schroder H, Covas MI, Castellote AI, Kaikkonen J, Poulsen HE, Gaddi AV, Machowetz A, Kiesewetter H, Lopez-Sabater MC, 2007. Moderate consumption of olive oil by healthy European men reduces systolic blood pressure in non-Mediterranean participants. J Nutr, 137, 84-87. Covas MI, Fito M, Lamuela-Raventos RM, Sebastia N, de la Torre-Boronat C, Marrugat J, 2000. Virgin olive oil phenolic compounds: binding to human low density lipoprotein (LDL) and effect on LDL oxidation. Int J Clin Pharmacol Res, 20, 49-54. Covas MI, de la Torre K, Farre-Albaladejo M, Kaikkonen J, Fito M, Lopez-Sabater C, Pujadas-Bastardes MA, Joglar J, Weinbrenner T, Lamuela-Raventos RM, de la Torre R, 2006. Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds in humans. Free Radic Biol Med, 40, 608-616. Covas MI, Nyyssonen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Baumler H, Nascetti S, Salonen JT, Fito M, Virtanen J, Marrugat J, Group ES, 2006. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med, 145, 333-341. Cuevas AM and Germain AM, 2004. Diet and endothelial function. Biol Res, 37, 225-230. Demonty I, Chan YM, Pelled D, Jones PJ, 2006. Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. Am J Clin Nutr, 84, 1534-1542. Edgecombe SC, Stretch GL, Hayball PJ, 2000. Oleuropein, an antioxidant polyphenol from olive oil, is poorly absorbed from isolated perfused rat intestine. J Nutr, 130, 2996-3002. Esti M, Cinquanta L, Panfili G, Manzi P, Marconi S, Pizzoferrato L, 2004. Effects of variety and olive ripeness on nutritional quality and oxidative stability of extra virgin olive oils. Journal of Food Agriculture and Environment, 2, 129-134. Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C, Lapetra J, Saez G, Ros E, 2006. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med, 145, 1-11. Fito M, Cladellas M, de la Torre R, Marti J, Alcantara M, Pujadas-Bastardes M, Marrugat J, Bruguera J, Lopez-Sabater MC, Vila J, Covas MI, 2005. Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial. Atherosclerosis, 181, 149-158. Hashim YZ, Eng M, Gill CI, McGlynn H, Rowland IR, 2005. Components of olive oil and chemoprevention of colorectal cancer. Nutr Rev, 63, 374-386. 403 4 5 6 7 8 9 10 11 12 13 14 15 Ruiz-Gutierrez V. de la Torre-Fornell R. Kaikkonen J. 319-326. 785-791.16 17 Lapointe A. Perez Jimenez F. Malorni W. Roset P. Urbano G. 42-51. Würtele G. Fuentes F. Solfrizzi V. Moschandreas J. Matarrese P. Wurtele G. Fraone N. Miro-Casas E. Nascetti S. Coni E. 140-147. 17. Farre M. Lopez-Segura F. Mataix J. Vari R. Ros E. Lamuela-Raventos R. Ramirez-Tortosa MC. 1864-1868. Schroder H. J Am Coll Cardiol. Weimann A. Owen RW. Sera F. Moreno JA. Fito M. Spiegelhalder B. Mata P. Marrugat J. Giovannini C. The SUN cohort study (Seguimiento University of Navarra). 46. SoriguerEscofet F. Romani A. Lozano A. 21. Weinbrenner T. Fito M. Villar-Ortiz JR. 12. Mier W. Ceroti M. Lemieux S. Nyyssonen K. Gomez P. Bellido C. Perez-Martinez P. Alvarez de Cienfuegos G. Bonanome A. Giacosa A. Mir A. Perez-Jimenez F. Lopez-Jurado M. Farre M. Eur J Clin Nutr. Haubner R. Ordovas J. D'Archivio M. Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. 2007. Lopez-Miranda J. Poulsen HE. Lairon D. 129. 945-952. Dolara P. Koebnick C. 2003. Escrich E. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. Bartsch H. Daily consumption of a high-phenol extra-virgin olive oil reduces oxidative DNA damage in postmenopausal women. Wiseman S. Phenolic content of virgin olive oil improves ischemic reactive hyperemia in hypercholesterolemic patients. Baumler H. Owen RW. Covas MI. 404 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 . 10241029. 2005. Cabello-Moruno R. Hull WE. Di Benedetto R. Kafatos A. 95. Colomer R. Barja G. Vasculoprotective effects of oleic acid: epidemiological background and direct vascular antiatherogenic properties. Trichopoulos A. International conference on the healthy effect of virgin olive oil. Palli D. J Nutr. 2004. Visioli F. 2006. Osada J. Salonen JT. 45-52. Chamorro-Quiros J. Ruano J. 2001. van Putte KP. Ramirez-Tortosa MC. Kris-Etherton PM. 43. Mulinacci N. Vissers MN. Lopez-Sabater MC. Galli C. Blanco A. 1195-1202. Giovannelli L. 36. Jimenez Y. Br J Nutr. Masella R. Villalba-Montoro JM. Volpe R. The role of virgin olive oil components in the modulation of endothelial function. Hydroxytyrosol disposition in humans. Covas MI. Garcia Luna PP. Effects of dietary virgin olive oil phenols on low density lipoprotein oxidation in hyperlipidemic patients. Effect of olive oils on biomarkers of oxidative DNA stress in Northern and Southern Europeans. Gruendel S. J Nutr Biochem. Scazzocchio B. Hidalgo L. 38. 127-131. 2005. 2004. Public Health Nutr. 9. J Nutr. Zunft HJ. Saieva C. Eur J Cancer Prev. Pitozzi V. Covas I. Giovannini C. Nestares T. Di Benedetto R. Bartsch H. 2004. Gomez MC. Owen RW. Perona JS. Masella R. 13. Bucci A. Corella-Piquer D. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols. 107. Hull WE. Haubner R. Couillard C. Martinez-Gonzalez MA. Fito M. Ortuno J. Eur J Nutr. 49. Marrugat J. Hull E. FASEB J. Giovacchini V. PinedaPriego M. 2006. Olives and olive oil in cancer prevention. Selmi H. Bartsch H. 2000. Martinez-Gonzalez MA. Pacheco-Reyes R. 2000. Quiles JL. Nutr Metab Cardiovasc Dis. Machowetz A. 2002. Olive-oil consumption and health: the possible role of antioxidants. 645-658. 35. Massaro M and De Caterina R. Kafatos A. 17. 1999. 742-751. Caruso D. Giacosa A. The lancet oncology. Visioli F. Spiegelhalder B. Gaforio JJ. Lopez-Miranda J. J Nutr Biochem. Miro-Casas E. Food Chem Toxicol. 134. Sanchez-Rovira P. Salvini S. Mataix J. Ruiz-Gutierrez V. Clin Chem. Badimon L. 1. Effects of dietary factors on oxidation of low-density lipoprotein particles. Mursu J. 2177-2183. Extra virgin olive oil phenols and markers of oxidation in Greek smokers: a randomized cross-over study. 56. de la Torre R. Gil A. Gaddi A. de la Torre R. Covas MI. 429-445. Gimeno E. lignansand squalene. 647-659. Spiegelhalder B. simple phenols. Extra-virgin olive oil increases the resistance of LDL to oxidation more than refined olive oil in freeliving men with peripheral vascular disease. Masala G. 2006. Perucho M. secoiridoids. 2002. Battino M. 2006. Vari R. Bortolomeazzi R. Eur J Clin Invest. Kiesewetter H. de la Torre R. Lipids. 421-424. 19. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. Modesti D. 2000. Tormos C. Ann Intern Med. 409-417. 39 40 41 42 43 ID 1639: “Polyphenols from olive (olive fruit. Roodenburg AJ. 217. on low density lipoprotein oxidizability in rabbits. J Urol. Farre-Albaladejo M. Marrugat J. 333-341. alcohol and atherosclerosis: clinical evidences and mechanisms. Plasmati E. Di Benedetto R. 2001. Masella R. J Agric Food Chem. Hydroxytyrosol. J Nutr. Catala A. Covas MI. Schroder H. Lopez-Sabater C. 2001. 65-75. Schulman RN. Fito M. 2169-2171. 386-393. Visioli F. Poli A. Willett WC. Group ES. Pujadas-Bastardes MA. Zock PL. Lipids. Pharmacol Rep. Katan MB. Zunft HJ. Rijken P. Abanades S. Int J Impot Res. Marrugat J. 145. Lamuela-Raventos RM. 2006.dependently absorbed and increases the antioxidant capacity of rat plasma. Patelli R. as a component of olive mill waste water. Free Radic Biol Med. Gall C. Vissers MN. Olive phenol hydroxytyrosol prevents passive smoking-induced oxidative stress. de la Torre K. Di Pasquale M. Leenen R. Nyyssonen K. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Kaikkonen J. 2001. 42. Nascetti S. Med Res Rev. 131. Mulinacci N. Carlini EA. 1998. 490-492. 608-616. 37. 2005. Visioli F and Galli C. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. 2000. is dose. Fito M. Weinbrenner T. crossover study. Padma-Nathan H. ErnährungsUmschau. 2006. 1999. Biological properties of olive oil phytochemicals. Gutierrez VR. 301-305. Mursu J. Zarini S. 2002. Free Radic Res. Kiesewetter H. Vincieri FF. Poulsen HE. Mattei R. 45-54. Plasmati E. Forest CP. Mol Cell Biochem. 2001. Coni E. 102. Romani A. hydroxytyrosol and oleuropein on the non-enzymatic lipid peroxidation of rat liver microsomes. Galli C. Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds in humans. 2007. Hernandez A. 97-107. 3065S-3073S. 209-221. 105-110. 48. Siroky MB. Nutr Rev. 2005. 47. Fito M. placebocontrolled. Saez GT. da Luz PL and Coimbra SR. 40. Galli C. Weinbrenner T. de la Torre R. 35-41. „Phenolische Inhaltstoffe der Olive mit antioxidativen Eigenschaften ―. Braz J Med Biol Res. Visioli F. J Nutr. Conte D. Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized. Covas MI. Coolen S. 2002. Visioli F. de la Puerta R. Liker HR. 564-567. 9. 1275-1295. 3 4 5 6 7 8 405 . Visioli F. Sala A. Caruso D. Kaikkonen J. Visioli F and Galli C. Wine. Aviram M. J Nutr. Galli C. 2004. Circulation. Salonen JT. 2004. Curin Y and Andriantsitohaina R. Olive oil phenols are absorbed in humans. Galli G. an olive oil biophenol. 57 Suppl. 134. Public Health Nutr. Mulinacci N. 34. Crit Rev Food Sci Nutr. Covas MI.33 34 35 36 37 38 Schmandke H. Antioxidant and other biological activities of olive mill waste waters. 35. 142-147. Joglar J. 56. olive mild waste waters or olive oil)” and “Lipid metabolism” 1 2 Azadzoi KM. 2002. The effect of tyrosol. de la Torre R. The Mediterranean diets: What is so special about the diet of Greece? The scientific evidence. de la Torre R. Viappiani S. Protective effect of oleuropein. 174. 2006. Baumler H. 2314-2321. Albaladejo MF. Virtanen J. 132. 22. Romani A. The Mediterranean diet: science and practice. Colombo C. double-blind. Polyphenols as potential therapeutical agents against cardiovascular diseases. 3397-3401. Gaddi A. The effect of minor constituents of olive oil on cardiovascular disease: new findings. Simopoulos AP. Antioxidant and other biological activities of phenols from olives and olive oil. Kremastinos DT. Lekakis J. Clin Exp Pharmacol Physiol. Zock PL. Galli C. Ellinger S. 159-165. Eur J Cardiovasc Prev Rehabil. Hashimoto M.9 Iijima K. J Agric Food Chem. Supplementation of plasma with olive oil phenols and extracts: influence on LDL oxidation. Biofactors. 2005. Mulinacci N. van Putte KP. 102. The antioxidative function. 50. 140-147. Single and repeated moderate consumption of native or dealcoholized red wine show different effects on antioxidant parameters in blood and DNA strand breaks in peripheral leukocytes in healthy volunteers: a randomized controlled trial (ISRCTN68505294). 159-174. Magiatis P. 2002. Yoshizumi M. Fito M. 605-615. dietary intake. 2001. Hosoda K. Med Res Rev. Major phenolic compounds in olive oil: metabolism and health effects. Galli C. Schuurbiers JA. Ernahrung & Medizin. 2000. Nitric oxide. 58. and protection against cardiovascular disease. 33. Covas MI. 2004. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene. 2002. Toba K. Red wine polyphenols. 22. ID 1640: “Polyphenols from red wine” and “Antioxidant properties” 10 11 12 13 14 15 16 17 18 19 20 21 1 Abu-Amsha Caccetta R. Romani A. 406 2 3 4 5 . Editions Tec&Doc. 43. Conte D. Circulation. Geus L. 101. Eto M. 103. Sudoh N. Hydroxytyrosol. Hernandez A. Lopez-Sabater MC. 4. Arendt BM. 2004. Visioli F. Olive phenol hydroxytyrosol prevents passive smoking-induced oxidative stress. Plasmati E. 2002. Katan MB. 2000. Rallidis LS. Beilin LJ. Andreadou I. Ako J. Free Radic Biol Med. 1999. Nutr J. Apports nutritionnels conseillés pour la population française. Eur J Nutr. Vissers MN. Poli A. Rasmussen SE. de la Torre R. Mulinacci N. 2169-2171. Effects of red wine polyphenolic compounds on the cardiovascular system. 20. Tuck KL and Hayball PJ. Gall C. 2005. 49. 197-201. Romani A. 20-26. 636-642. Nakahara K. 21. Kim S. 2001. Viappiani S. Spengler U. Visioli F. Mori TA.dependently absorbed and increases the antioxidant capacity of rat plasma. 2001. Kohler S. is dose. Medical nutrition therapy of patients with atherosclerotic vascular diseases and hypertension by means of perilla oil and black grape extract as dietary food for special medical purposes. Vissers MN. Mol Nutr Food Res. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. bioavailability. 12. preventive action on disease and utilization of proanthocyanidins. Eur J Clin Nutr. Skaltsounis AL. 301-305. Bioavailability and antioxidant effects of olive oil phenols in humans: a review. 636-644. Patelli R. Ouchi Y. Niestroj M. J Nutr Biochem. Farre M. as a component of olive mill waste water. Sala A. Ariga T. Wiseman SA. J Agric Food Chem. Antioxidant and other biological activities of olive mill waste waters. 47. Visioli F. Vincieri FF. Frederiksen H. 2003. Visioli F. Circulation. Paris. Galli G. Colombo C. Kazantzoglou G. Bratisl Lek Listy. Malek FA. 596-600. Caruso D. Schroder H. Gimeno E. Free Radic Res. 13. Zenebe W and Pechanova O. Marrugat J. 805-811. 2004. 2002. Leenen R. in the absence of alcohol. Vamvakou G. 34. Antioxidant and other biological activities of phenols from olives and olive oil. 65-75. Burke V. Piper J. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. 2005. Achike FI and Kwan CY. Galli C. AFSSA (Agence Française de Sécurité Sanitaire des Aliments). van de Put FH. Poulsen L. Plasmati E. Muller WU. reduce lipid peroxidative stress in smoking subjects. Struntze Krogholm K. Roodenburg AJ. 2005. Croft KD. 3397-3401. Zarini S. Kekic K. Goerlich R. human diseases and the herbal products that affect the nitric oxide signalling pathway. 30. Fimmers R. Miro-Casas E. Dietary proanthocyanidins: occurrence. 30. Puddey IB. 955-965. Liang YQ. 1290-1297. Soulet S. de Gaetano G. Wine. Murali G. Bouhamidi R. Alcohol consumption and mortality: is wine different from other alcoholic beverages? Nutr Metab Cardiovasc Dis. Carini M. 113-120. Alvarez-Sala LA. 169-188. 2007. dietary sources. 1996. 335-341. Bustamante A. (+)Catechin in human plasma after ingestion of a single serving of reconstituted red wine. 2001. 242-247. Am J Clin Nutr. 1997. Bagchi D.6 7 8 Aviram M. Balu M. 225-230. Fernandez-Sola J. Fernandez-Cruz A. dealcoholized red wine and red grape juice. 34. Stohs SJ. 1998. Dumas M. Antunez E. Am J Clin Nutr. Castilla M. 2007. Wong R. Puddey IB. 321. Panneerselvam C. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. 71. Crozier A. 2000. Polyphenols: Chemistry. 469-473. Basic life sciences. J Nutr Health Aging. Facino RM. Vercauteren J. metabolism. Krohn RL. 317-333. 66. Burns J. Ingestion of red wine significantly increases plasma phenolic acid concentrations but does not acutely affect ex vivo lipoprotein oxidizability. Carando S and Teissedre PL. High protection by grape seed proanthocyanidins (GSPC) of polyunsaturated fatty acids against UV-C induced peroxidation. Garg A. 71. Munoz-Garcia B. Brouillard R. 2001. Concomitant consumption of red wine and polyunsaturated fatty acids in edible oil does not influence the peroxidation status of chylomicron lipids despite increasing plasma catechin concentration. Atherosclerosis. 2006. German JB. Blackhurst DM and Marais AD. Estruch R. Egido J. Rotilio D. Ethanol beverages containing polyphenols decrease nuclear factor kappa-B activation in mononuclear cells and circulating MCP-1 concentrations in healthy volunteers during a fat-enriched diet. Lean ME. Bertelli AA. Morazzoni P. 6. 2006. 103-108. Comptes Rendus De L Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences. Sacanella E. Bub A. 2002. Decreased tumor necrosis factor-induced adhesion of human monocytes to endothelial cells after moderate alcohol consumption. Rechkemmer G. 249-258. Atherosclerosis. research and cardiovascular disease: instructions for use. Heeb D. Villa A. 2004. 403-410. Eur J Clin Chem Clin Biochem. Dietary antioxidants. 11. Modulatory role of grape seed extract on agerelated oxidative DNA damage in central nervous system of rats. 2000. 67-74. Biofactors. Cardiovascular protective effects of resveratrol. 1998. Malvidin-3-glucoside bioavailability in humans after ingestion of red wine. 80. Life Sciences. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 407 . 209-223. Kasim-Karakas SE. 40. UrbanoMarquez A. Bagchi M. Nutrition Reviews. Castagnino C. Am J Clin Nutr. Delaunay JC. 1998. peroxidation and cardiovascular risks. Brain Research Bulletin. 195. 1799-1814. Watzl B. Beilin LJ. 725. Aviram M and Fuhrman B. Nicolas JM. Walzem RL. 67. 2004. Bell JR. and the antiatherogenicity of antioxidants. Atherosclerosis. Polyphenols produced during red wine ageing. 16. Res Commun Mol Pathol Pharmacol. Donovan JL. Berke B. Eur J Nutr. 1999. Caccetta RA. 179-189. Cheze C. Badia E. and a grape seed proanthocyanidin extract in vitro. Bravo L. Tran MX. Bradamante S. 137 Suppl. and nutritional significance. S45-50. Barenghi L. Briviba K. Lamuela-Raventos RM. 31-38. 192. UVB-induced hemolysis of rat erythrocytes: Protective effect of procyanidins from grape seeds. 550-558. Millan J. 22. Arnaudinaud V. Gomez-Gerique J. Croft KD. Nouvelot A. Aldini G. 2000. 56. Barbaste M. Fougerousse A. Sangeetha P. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis. 599-608. 95. Bombardelli E. George F. Catechin and procyanidin levels in French wines: contribution to dietary intake. 6. Cardiovasc Drug Rev. Prevost V. Blanco-Colio LM. 1997. Martin-Ventura JL. 68. Nutr Metab Cardiovasc Dis. Waterhouse AL. Oxygen free radical scavenging abilities of vitamins C and E. Sato M. Journal of Agricultural and Food Chemistry. Howard AN. Das DK. Waterhouse AL. 1275-1295. 96. 428-439. 1162-1170. Free Radic Res. Bitsch R. Filesi C. 2003. 54. 37. The French paradox: lessons for other countries. 2004. 128-135. Donati MB. Ann NY Acad Sci. 2000. Del Rio JA. Fitzsimons PE. 1998. Mediterranean diet and the French paradox: two distinct biogeographic concepts for one consolidated scientific theory on the role of nutrition in coronary heart disease. Cimen MY. alcohol and atherosclerosis: clinical evidences and mechanisms. Morrice PC. 48. Redondo A. Erdmann E. Cordova AC. 423-435. Kanner J. Fouret G. 33. 2000. Castillo J. 408 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 . J Nutr. 208-213. dietary sources and bioavailability. Walzem RL. 2005. Steele GM. 2007. Cardioprotection of red wine: role of polyphenolic antioxidants. Braz J Med Biol Res. 20. 1999. Ozturk HS. Adv Exp Med Biol. Hansen RJ. Mysytaki E. 1993. Clin Cardiol. Drink to prevent: review on the cardioprotective mechanisms of alcohol and red wine polyphenols. Bertelli A. Kacmaz M. Antioxidant activity and radioprotective effects against chromosomal damage induced in vivo by X-rays of flavan-3-ols (Procyanidins) from grape seeds (Vitis vinifera): Comparative study versus other phenolic and organic compounds. J Am Coll Surg. Clin Chem. Boucher F. Laporte F. 1999. Lancet-London. Bohm M. de Lange DW and van de Wiel A. 1998. Croft KD. 217-223. 52. Jackson LS. Bell JR. Lorente J. 420-424. 173-186. 200. Potential health benefits from the flavonoids in grape products on vascular disease. Donovan JL. Netzel M. Drugs Exp Clin Res. da Luz PL and Coimbra SR. Gargiulo R. 341. Weinbrenner T. Constant J. Inhibition of oxidation of human lowdensity lipoprotein by phenolic substances in red wine. 1999. Fito M. De La Torre R. Ferrieres J. 2003. Flesch M. 2002. Bertelli AA. Ortuno A. The mediterranean lecture: wine and thrombosis--from epidemiology to physiology and back. German JB. Catechin is present as metabolites in human plasma after consumption of red wine. Iacoviello L. de Gaetano G. Strain JJ. Jenkinson AM. Basic Res Cardiol. 2003. and the French paradox. 854. Parks E. 15. 466-471. 1662-1668. D'Archivio M. Can J Physiol Pharmacol. Eur J Clin Nutr. 25. 505. Wine. Folts JD. Lamuela-Raventos R. 4. 435-442. Chopra M. 348-361. Bitsch I. McPhail DB. 37. Gardner PT. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. Di Benedetto R. Cardiovasc Res. Alcohol and the risk of myocardial infarction. Rosenkranz S. Di Castelnuovo A. Curr Med Res Opin. Covas MI. 81. Heart. Benavente-Garcia O. Frankel EN. 107-111. Masella R. Duthie GG. Monnier L. The chemistry and biological effects of flavonoids and phenolic acids.25 Cartron E. Postprandial effects of wine consumption on lipids and oxidative stress biomarkers. Pathophysiol Haemost Thromb. ischemic heart disease. Descomps B. The cardiovascular protective effect of red wine. 2004. Thurnham DI. Buyukkocak S. Carbonneau MA. Alcohol. Lauret C. Drugs Exp Clin Res. 46. Farre-Albadalejo M. Engelman RM. Konstantinidou V. Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Alcaraz MJ. Maulik G. Leger CL. 2002. de Lorgeril M. 95-111. Polyphenols. Kinsella JE. Redwine beneficial long-term effect on lipids but not on antioxidant characteristics in plasma in a study comparing three types of wine--description of two O-methylated derivatives of gallic acid in humans. Strass G. 503-515. Michel F. Ray PS. de Leiris J. Bioavailability of anthocyanidin-3-glucosides following consumption of red wine and red grape juice. 90. The effect of red wine on blood antioxidant potential. Sumpio BE. German JB. 129. Giovannini C. Pedersen MW. 733-736. 1021-1035. Salen P. 2001. 29. 1997. 454-454. Frank T. Durak I. 2003. Semin Vasc Med. Ann Ist Super Sanita. 43. 115-120. Berke-Schlessel DW. Paillard F. 1738-1745. 2004. Kasim-Karakas S. 904-908. Del Rosso A. 2008. Pleiotropic effects of resveratrol. Martinez-Martinez F. Cerinic MM. Cuevas A. Kerboull M. 645-658. Morand C. Atherosclerosis. 133-141. Stef G. Archives of Internal Medicine. 549-554. 17-20. 2002. Aviram M. In: Les polyphénols en agroalimentaire (Collection STAA). Jamroz A and Beltowski J. Parkes JG. Hartiala JJ. Effects of dietary factors on oxidation of low-density lipoprotein particles. Kalin R. 16. Urzua U. Goldberg DM. 989. 22. 7. 43. Eur J Clin Nutr. Maiz A. Greenrod W. A novel function of red wine polyphenols in humans: prevention of absorption of cytotoxic lipid peroxidation products. Ungvari Z. Castillo O. Menopause Int. Wu J. Aravanis C. Parkka JP. 155-187. Puiggros F. Pacher P. Granados-Soto V. Salvado MJ. 35-38. 2004. J Bone Joint Surg Br. e176-181. 21. Scalbert A. 2007. Giugliano D. Fidanza F. Gorelik S. Csiszar A. 2003. Hahn SE. Moderate acute intake of dealcoholized red wine. Nedeljkovic S. 2003. Menotti A. 2003. Kiviniemi TO. Espinoza MA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Toikka JO. Paris. Cardiol Clin. Red wine reduces oxidative stress in patients with acute coronary syndrome. an anti-inflammatory phytoestrogen. a grape seedderived proanthocyanidin extract. J Nutr Biochem. Leighton F. Remesey C. Labinskyy N. Righi A. 591. but not de-alcoholized red wine increases coronary flow reserve. 449-457. Saraste A. Crit Rev Food Sci Nutr. Manach C. Antioxidant capacity of selected wines. Free Radic Res. Kanner J. A moderate dose of red wine. Bagchi D. Generini S. 1083-1087. 1995. FASEB J. Plasma polyphenols and antioxidants. Fenech M. Lavoisier. Viikari J. Current medicinal chemistry. San Martin A. Jansen A. Rozowski J. Foncea R. Ardevol A. 2003. VCAM-1 and E-selectin) in systemic sclerosis. 819-825. Das DK. 233-244. Godoy I.46 47 48 49 50 51 52 Fuhrman B. Am J Clin Nutr. Activin. 3844. Beyond alcohol: beverage consumption and cardiovascular mortality. oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. Drugs Exp Clin Res. Lopez-Velez M. Saraste M. 381-386. Guasch V. Lavy A. Sarni-Manchado P and Cheynier V (eds. Stockley CS. 2005. 17. Consommation et biodisponibilitè des polyphènols. Grape flavonoids and menopausal health. 2005. Goldfinger TM. Leighton F. 2006. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. 13. 2000. Nutr Metab Cardiovasc Dis. 41-46. 195. Burcham P. 2007. Kohen R. Raitakari OT. Strobel P. Blade C. 237. is protective against radiation-induced DNA damage ex vivo -results of a comparative in vivo intervention study in younger men. 2003. Foncea R. 290-301. Mizon C. Lehtimaki T. Perez DD. Kromhout D. Ling RS. Veress G. 13. Antigenotoxic effect of grape seed procyanidin extract in Fao cells submitted to oxidative stress. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study.). Mutat Res. Huntley AL. Journal of Agricultural and Food Chemistry. 165-169. 2006. Perez DD. 155. Lapointe A. 104. Vascular dysfunction in aging: potential effects of resveratrol. Llopiz N. Diez MS. 52. Ligumsky M. Guarda E. Drug News Perspect. Sedel L. Urquiaga I. Oroszi G. Germain A. 61. Giampaoli S. 1198-1202. Clin Chim Acta. Blackburn H. Cespedes E. Hertog MG. Int J Cardiol. 299-307. 2006. 36. reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1. Buzina R. Couillard C. Huxley RR and Neil HA. 10. Langlais F. Beyond the French paradox: the impact of moderate beverage alcohol and wine consumption in the prevention of cardiovascular disease. but not alcohol. Dietary antioxidants for cardiovascular prevention. The 'French paradox'. Del Valle-Ribes C. Arola L. Medical Science Monitor. Abbey M. 85. 409 53 54 55 56 57 58 59 60 61 62 63 64 65 66 . 1995. Lemieux S. 25. 1995. 57. 1999. 2001. Romero C. The study of phenolic compounds as natural antioxidants in wine. Koskenvuo JW. Venegas R. 2000. 227-246. J Clin Pharm Ther. 50. 33. Kendall MJ. Morazzoni P. Wine. Rasmussen SE. Preuss HG. 2002. Comp Biochem Physiol C Toxicol Pharmacol. Parks DA and Booyse FM. Gentili V.67 Mann GE. Mol Nutr Food Res. Pignatelli P. 25. Siow RC. Mojzisova G and Kuchta M. Rahman I. Lancet. 2007. 6. 2001. Di Santo S. Perez DD. Leighton F. 2002. Bagchi D. Struntze Krogholm K. Jayaprakasha GK. 2006. 957. 7720-7725. Dietary proanthocyanidins: occurrence. 250-256. 31. Cardiovascular Protection by Alcohol and Polyphenols Role of Nitric Oxide. bioavailability. Poulsen L. 74. Micallef M. Lewandowski P. Renaud S and De Lorgeril M. 2001. 385-389. Fimognari F. Boelens PG. Cardiovasc Res. 410 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 . 188. 72. Maron DJ. Ghiselli A. Palada I. Violi F. J Agric Food Chem. Red wine consumption increases antioxidant status and decreases oxidative stress in the circulation of both young and old humans. Regulation of inflammation and redox signaling by dietary polyphenols. Clin Exp Pharmacol Physiol. 409-422. Music I. Echard B. Rodrigo R and Bosco C. Am J Clin Nutr. Dietary flavonoids and risk of coronary heart disease. 1043-1058. Oxidative stress and protective effects of polyphenols: comparative studies in human and rodent kidney. 49. and oxidative damage. Annals of the New York Academy of Sciences. Buchetti B. Cardiovascular protection from alcoholic drinks: scientific basis of the French Paradox. The increase in human plasma antioxidant capacity after red wine consumption is due to both plasma urate and wine polyphenols. 2006. A review. Biochem Pharmacol. Castillo O. Journal of Agricultural and Food Chemistry. Natella F. Nood EV. Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. San Martin A. Antioxidant activities of grape (Vitis vinifera) pomace extracts. Curr Atheroscler Rep. 529-535. Rowlands DJ. 52. An evaluation of the antioxidant activity of a standardized grape seed extract. Hoorn DEV. Free Radic Biol Med. Ursini F. Scaccini C. 136145. 159-174. Strobel P. 261-274. Kandaswami C. Physiol Res. Nijveldt RJ. Nutr J. Ann NY Acad Sci. 2002. antioxidant defenses. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. 957. and protection against cardiovascular disease. 1439-1452. 27. Nuttall SL. heart disease. 115-121. Foncea R. 1992. Obad A. Carnevale R. Atherosclerosis. Myers A. diet. Leucoselect. 418-425. 2002. 6. 50. Li FY. 2000. 2007. and cancer. Murthy KNC. Tutuncuoglu SO. 23. de Winter P. 2004. 73-78. Biswas SK. Boban M. Brizic I. 2006. Cuevas A. Theoharides TC. 317-327. Jr. 2008. 50. alcohol. Germano G. Bui M. 1998. Wallerstedt D. Middleton E. Talpur N. Bombardelli E. Puddey IB. 27. 77-83. 142. Morton LW. and the French paradox for coronary heart disease. Wine. 2000. Lexis L. Kirkham PA. Dujic Z. 2005. Croft KD. Natella F. Katalinic V. Lenti L. 5909-5914. 673-751. Abu-Amsha Caccetta R. Norren KV. Rodrigo R and Rivera G. 2002. Renal damage mediated by oxidative stress: a hypothesis of protective effects of red wine. Flavonoids for reduction of atherosclerotic risk. Diez MS. Frederiksen H. 197. platelets. Chemistry and biological effects of dietary phenolic compounds: relevance to cardiovascular disease. Van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications1–3. Modun D. The effects of plant flavonoids on mammalian cells: implications for inflammation. 2006. 152159. 75. Rev Port Cardiol.. Atherosclerosis. Vukovic J. Pharmacol Rev. dietary intake. Urquiaga I. 1523. Providencia R. Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. Singh RP. Vasquez L. Belelli F. J Med. 339. Urquiaga I and Leighton F. Bramati L. 2002. 314-318. de Jong SA. J Clin Lab Anal. Galaverna G. 957. 495-504. Ferro-Luzzi A. European Journal of Clinical Nutrition. 114-119. Am J Clin Nutr. Procyanidins from Vitis vinifera seeds: In vivo effects on oxidative stress. 2005. 2005. Van der Gaag MS. Italian heart journal: official journal of the Italian Federation of Cardiology. Sforza S. Das DK. Van den Berg R. II. Vigna GB. 50. Williamson G and Manach C. Williams MJ. red wine and spirits has counteracting effects on plasma antioxidants in middle-aged men. 2. Sun GY. Ghidini C. German JB. Palumbo R. Journal of Nutritional Biochemistry. Faruolo C. Serafini M. Proceedings of the National Academy of Sciences. Whelan AP. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Tsang C. Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans. Ndiaye M. Maiani G. 55-64. Diamandis EP. 2003. 299-313. 1994. Russo M. Maffei Facino R. Soleas GJ. De Gaetano G. 15. Role of chemopreventers in human diet. Metabolism. 81. Simonyi A. Howie M. and antioxidants. 27. Laranjinha JA. Carini M. 11. 53. Sato M. 33. 128. 2000. 2002. Tedesco I. Stoclet JC. Review of 93 intervention studies. Frankel EN. 1003-1007. 11. Carraturo A. Vescovi PP. Polyphenols in red wines prevent NADH oxidation induced by peroxynitrite. 233-240. Alcohol and Wine in Health and Disease. 957. Hendriks HF. Serafini M. Costantini F. The ―French Paradox‖ and beyond: neuroprotective effects of polyphenols. Mol Nutr Food Res. J Nutr Biochem. Oak MH. The influence of moderate red wine consumption on antioxidant status and indices of oxidative stress associated with CHD in healthy volunteers. Pietta P. Mezzetti A. Moderate consumption of beer. 1997. Duthie GG. Older plasma lipoproteins are more susceptible to oxidation: a linking mechanism for the lipid and oxidation theories of atherosclerotic cardiovascular disease. Lancet. 11. Maulik N. Mullen W. Free Radical Biology and Medicine. Alcohol-free red wine enhances plasma antioxidant capacity in humans. Bombardelli E. 500. Marchelli R. Catapano A. Vitaglione P. 2000. tea. Sun AY. 2005. Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. 265277. The cardiovascular implications of alcohol and red wine. 32. Vascular protection by dietary polyphenols. Schena F. Chataigneau T. and role in disease prevention. Watkins S. Simonetti P. Metabolism. 2004. Schaafsma G. 344. Bioavailability of trans-resveratrol from red wine in humans. Walzem RL. Gardana C. Crozier A. Duthie SJ. 1250-1257. Maiani G. Russo GL. Journal of Nutrition. Ciappellano S. Di Castelnuovo A. 54. Fellin R. Higgins S. The relationship between wine consumption and cardiovascular risk: from epidemiological evidence to biological plausibility. Eur J Pharmacol. 122-135. 2000. Red wine. Antioxidant effect of red wine polyphenols on red blood cells. 7460-7464. Plant polyphenol antioxidants and oxidative stress. Wine as a biological fluid: history. Am J Ther. Boveris A. Fogliano V. Stavric B. 92. 319-332. Valdez LB.88 Rotondo S. Ghiselli A. El Bedoui J. production. 2004. 2002. Hansen RJ. Aldini G. 1. 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 411 . Journal of Agricultural and Food Chemistry. 2008. 287-313. Iacomino G. 1995. Br J Nutr. Almeida LM. Van den Berg H. 6217-6221. Moio L. Chataigneau M. Biol Res. Ann NY Acad Sci. 586-591. 2002. McCormick MP. 626. 318-323. Schini-Kerth VB. Sutherland WH. Acute effect of drinking red and white wines on circulating levels of inflammation-sensitive molecules in men with coronary artery disease. Tangerini A. Zanca R. 49. 585-590. Goldberg DM. Ferro-Luzzi A. 93. Morazzoni P. 243S-255S. Clin Biochem. 1994. Russo P. Bioavailability and bioefficacy of polyphenols in humans. 274-278. Serafini M. 2000. 1998. 52. 2001. Actis-Goretta L. Saremi A and Arora R. Lean ME. Caporaso N. De Simone R. 103. and the antiatherogenicity of antioxidants. Alcohol. de Gaetano G and Cerletti C. 2001. Red wine polyphenols. J Nutr. Zhao J. Mori TA. Agarwal R. Clin Cardiol. Berke-Schlessel DW. 159-165. 20. Cascon E. Dedieu F. Wine. Villa A. Monnier L. 2 3 4 5 6 7 8 9 10 11 12 13 14 412 . 2544-2548. Huang YZ. Mechanism of cardioprotection by resveratrol. Sumpio BE. S45-50. 1275-1295. Chen YJ. 636-642. 1996. ID 1641: “Polyphenols derived from red wine” and “Lipid metabolism” 111 112 113 1 Abu-Amsha Caccetta R. 2291-2294. 1998. Carbonneau MA. 47. 428-439. Int J Mol Med. 1999. 51. Free Radic Biol Med. 2004. J Am Coll Surg. 2002. Ariga T. 2004. 34. Cardiovasc Drug Rev. Clin Chem. Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis. Nutr Metab Cardiovasc Dis. Puddey IB. 169-188. 242-247. 11. Wine. 135. Carcinogenesis. Blade C. Yoshimura Y. Fouret G. Monnier L. Salvado MJ. 75. Zenebe W and Pechanova O. Zou JG. 200. Strain JJ. 1997. Zern TL and Fernandez ML. 46. Wine and cardiovascular disease. Bertelli AA. Avellone G. Descomps B. Aviram M. Descomps B. Bonnet C. Bradamante S. Beilin LJ. in the absence of alcohol. Léger CL. Licata G. Nonalcoholic components in wine reduce low density lipoprotein cholesterol in normocholesterolemic rats. 60. Improvement in the antioxidant status of plasma and low-density lipoprotein in subjects receiving a red wine phenolics mixture. Fitzsimons PE. 3-17. a phenolic antioxidant present in red wine (Review). Campisi D. 420-424. 2001. 41-47. Braz J Med Biol Res. The cardiovascular protective effect of red wine. Di Garbo V. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3 '-gallate as the most effective antioxidant constituent. Jackson LS. Carbonneau MA.109 110 Wu JM. 1998. Lipids. 2006. Nakazawa H. Scaglione R. 36. 235-240. Constant J. Effects of red wine polyphenolic compounds on the cardiovascular system. Bruder JL. reduce lipid peroxidative stress in smoking subjects. Michel F. Barenghi L. Journal of the American Oil Chemists' Society. Eur J Clin Chem Clin Biochem. Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. 1997. Cardioprotective effects of dietary polyphenols. Howard AN. Michel F. 1999. and the French paradox. Bratisl Lek Listy. Burke V. Arola L. 20. 2000. alcohol and atherosclerosis: clinical evidences and mechanisms. 30. 2005. da Luz PL and Coimbra SR. Cordova AC. Supplementation with wine phenolic compounds increases the antioxidant capacity of plasma and vitamin E of low-density lipoprotein without changing the lipoprotein Cu(2+)-oxidizability: possible explanation by phenolic location. Raneli G. 599-608. 137 Suppl. Atherosclerosis. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. 682-690. Ardevol A. 383-388. Leger CL. 37. Wang ZR. Eur J Clin Nutr. Hsieh TC. Eur J Clin Nutr. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis. Chopra M. Roig R. 2005. Croft KD. Aviram M and Fuhrman B. Journal of Agricultural and Food Chemistry. Atherosclerosis. 195. 1162-1170. 1737-1745. Free radical scavenging activity of grape seed extract and antioxidants by electron spin resonance spectrometry in an H2O2/NaOH/DMSO system. 2007. Cardiovascular protective effects of resveratrol. Wang JN. 2001. 4750. 8. 2001. research and cardiovascular disease: instructions for use. Yamaguchi F. ischemic heart disease. 22. Thurnham DI. Buzina R. Giampaoli S. 22. Granados-Soto V. 63. Am J Clin Nutr. van de Wiel A. 287-294. Assen NA. Mamo JC. 90. Kromhout D. 59. Inoue H. Diamandis EP. Atherosclerosis. Couillard C. Kohen R. 904-908. 2002. 1995. 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 413 . 4. Effect of red wine and red grape extract on blood lipids. 57. J Nutr Biochem. Singh RP. Pal S. 454-454. Naissides M. Parks E. Dankner G. 107-111. Lavy A. The role of alcohol in the anti low density lipoprotein oxidation activity of red wine. 155-187. 237. Kanner J. Ferrieres J. James AP. Garovic-Kocic V. Nielsen ILF. 329-334. Fuhrman B. Ch. Naissides M. Red wine antioxidants bind to human lipoproteins and protect them from metal ion-dependent and -independent oxidation. Blackburn H. 2003. hematology and coagulation: favorable effect of red wine on plasma high-density lipoprotein. 449-455. Markel A. Clin Chim Acta. 365-370. Drug News Perspect. Fuhrman B. Lancet-London. Am J Cardiol. 401-408. 2004. 128-135. 101-104. Pleiotropic effects of resveratrol. Fidanza F. Hm van Golde P. Pal S. 246. Rosenkranz S. Hansen AS. Basic Res Cardiol. Sloots LM. The French paradox: lessons for other countries. Goldberg DM. Parkes JG. Ivanov V. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. 438-445. 2004. Jansen A. 16. 147. James AP. Menotti A. 2008. Inhibition of human low-density lipoprotein oxidation by flavonoids in red wine and grape juice. Ann Nutr Metab. Am J Clin Nutr. 173-186. Frei B. and other risk factors for cardiovascular disease. Gorelik S. 183-193. Archives of Internal Medicine. Alcohol and the risk of myocardial infarction. Semin Vasc Med. Nedeljkovic S. Hertog MG. Pm Wielders J. 2001. Hart H. Lapointe A. 1995. 38. Dragsted LO. Pace-Asciak CR. Beyond alcohol: beverage consumption and cardiovascular mortality. 1995. 1993. M. 381-386. J Agric Food Chem. Murthy KNC. 2001. 645-658. Inhibition of oxidation of human lowdensity lipoprotein by phenolic substances in red wine. Thurnham D. N. 1999. 1994. Stalenhoef AF. 2003. Mamo JC. Atherosclerosis. 49. 1627-1631. 1996. Howard A. Atherosclerosis. Lavy A. de Rijke YB. Goldberg DM. Sloots L. 155. 549-554. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Effect of dietary supplementation of red or white wine on human blood chemistry. Flesch M. Katan MB. 1996. Marckmann P. 41-46. 61. 1997. Antioxidant activities of grape (Vitis vinifera) pomace extracts. German JB. 2006. The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. 341. Ligumsky M. Aviram M. 2002. 299-307. Strain J. Miyagi Y. 50. haemostatic factors. Kanner J. 2005. Frankel EN. Eur J Clin Nutr. P.15 16 de Lange DW and van de Wiel A. 59. Drink to prevent: review on the cardioprotective mechanisms of alcohol and red wine polyphenols. 177. Red wine consumption and inhibition of LDL oxidation: what are the important components? Med Hypotheses. Aviram M. J Agric Food Chem. Aravanis C. Ben-Amotz A. Hahn SE. 80. Effects of dietary factors on oxidation of low-density lipoprotein particles. 96. Kinsella JE. Miwa K. 185. Bohm M. Lemieux S. Huxley RR and Neil HA. A novel function of red wine polyphenols in humans: prevention of absorption of cytotoxic lipid peroxidation products. Nielsen SE. Wine: does the colour count? Clinica Chimica Acta. Bouma B. FASEB J. 17. 5909-5914. 4442-4449. Aviram M. Grønbæk M. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. 2004. Erdmann E. Chopra M. Carr AC. European journal of clinical nutrition. Jayaprakasha GK. Fuhrman B. The effect of acute red wine polyphenol consumption on postprandial lipaemia in postmenopausal women. Heart. Vermeulen W. Red wine consumption does not affect oxidizability of low-density lipoproteins in volunteers. Demacker PN. 2006. Presser D. J Agric Food Chem. Ruf JC. 37. Beneficial effects of a moderate consumption of red wine on cellular cholesterol efflux in young men.37 38 Nigdikar SV. 1401-1404. 287-313. 1998. Mechanism of cardioprotection by resveratrol. Red Wine and Cardiovascular Disease 1. 339. Parks DA and Booyse FM. Senault C. Effects of red wine polyphenolic compounds on the cardiovascular system. Effect of red wine consumption on low-density lipoprotein oxidation and atherosclerosis in aorta and coronary artery in Watanabe heritable hyperlipidemic rabbits. 49. National Drinks Survey. metabolism. 93. Wollin SD and Jones PJH. Martin PT. Rotondo S. De Gaetano G. ID 1643: “Polyphenols from tea” and “Antioxidant properties / Heart health” 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 1 2 3 4 Personal communication from UK Tea Trade Technical Committee. Nutrition. 243S-255S. Pal S. 101. Williamson G and Manach C. 2004. Dacombe C. 2005. The cardiovascular implications of alcohol and red wine. McClean E. 2001. 63. 4724-4730. Tsang C. Zenebe W and Pechanova O. wine and platelet function. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. and the French paradox for coronary heart disease. Di Castelnuovo A. Am J Ther. Ho N. 1. alcohol. Bratisl Lek Listy. Howard AN. http://nccam. 1997. and role in disease prevention. McGrath LT. Wang ZR. Duthie SJ. Wine. Fumeron F. Allister E. 700-706. platelets. a phenolic antioxidant present in red wine (Review). Huang YZ. 414 . Duthie GG. 131. Hsieh TC. 2005. 159-165. 8. Rigaud D. 1523. Zern TL and Fernandez ML. International Journal of Obesity. 103. 1995. Dubois P. 2000. 1999. J Nutr. J Agric Food Chem. Lean ME. Bruder JL. 1992. 2003. Wu JM. 265277. Am J Clin Nutr. Italian heart journal: official journal of the Italian Federation of Cardiology. Alcohol. 2005. Mamo J. Sharpe PC. 135. 133. Hauw P. Diamandis EP. Goldberg DM. Biol Res. 88. 233-240. Croft K. Pal S. Effect of red wine consumption on lipoprotein (a) and other risk factors for atherosclerosis. 2008. Crozier A. 2291-2294. Archbold PR. The influence of moderate red wine consumption on antioxidant status and indices of oxidative stress associated with CHD in healthy volunteers. 28. Br J Nutr. 2001. 115-121. Astill C. 957. Howie M. Griffin BA. Mamo J. Renaud S and De Lorgeril M. Cardiovascular Protection by Alcohol and Polyphenols Role of Nitric Oxide. 10. Int J Mol Med. 258-265. 15. Qjm. 2002. Naissides M.gov/. production. and cardiovascular diseases: NMCD. Saremi A and Arora R. The relationship between wine consumption and cardiovascular risk: from epidemiological evidence to biological plausibility. 3-17. Luc G. 209-215. J Clin Lab Anal. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. Journal of Nutrition. Alcohol. Betoulle D. 2001. Humphrey PG. J Nutr. Wakabayashi Y. 68. Williams NR. 47. Wine as a biological fluid: history. Soleas GJ. Lancet. 11. 5340-5347. Higgins S. Santos C. Mullen W. 2002. Review of 93 intervention studies. Young IS. 2. II. 324-326. 81. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. Am J Clin Nutr. 2001. Bioavailability and bioefficacy of polyphenols in humans.nih. Cardioprotective effects of dietary polyphenols. 2001. Polyphenolics and fat absorption. 2004. National Center for Complementary and Alternative Medicine (NCCAM). Annals of the New York Academy of Sciences. Zou JG. Birch MR. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. 1999. Ernährungs-Umschau. 2170-2174. Nedeljkovic S. 1743-1750. 1990. Inc. Hertog MG. 1999. Buzina R. Cao J. Giampaoli S. 2001. Nutr Cancer. Duffy SJ. Apostolides Z. Dietary antioxidants in disease prevention. Medical Economics Company. Fractionation of green tea extracts. Lancet. Pols HA. Ioannides C. 2001. J Sci Agric. Aravanis C. Huang M. 13. 1999. Engelhardt UH. 244-250. 39. Volsteedt Y. 45. Comparison of the antioxidant content of fruits. Feskens EJ. 125. 1999. Consumption of green tea causes rapid increase in plasma antioxidant power in humans. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Anaheim. correlation antimutagenic effect with flavonol content. 1991. Menotti A. The bactericidal activity of tea against Helicobacter pylori. Lu Y. Pekkarinen M. Blackburn H. 1993. 19. Katan MB. Gesamtphenolgehalte und antioxidative Kapazität handelsüblicher Getränke. Toshima H. 1985. Hofman A. Copeland E. 31. Engelhardt UH. Letters in Applied Microbiology. Bertram B. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 415 . Deutsches Tee-Institut. Jaenicke C. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. 219th American Chemical Society Meeting. Letters in Applied Microbiology. Strain JJ. Hodgson JM. Bu-Abbas A. Henn T and Stehle P. Biochem Pharmacol. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Katan MB. Xu Y. Holbrook M.5 6 7 8 9 10 11 Benzie IF. Vita JA. Launer LJ. 63-69. Jr. 2004. Bushman JL. Arch Intern Med. Frei B. Kromhout D. vegetables and teas measured as vitamin C equivalents. Physician‘s Desk Reference for Herbal Medicines. Tomlinson B. Polyphenole in Tee. Leake DS. Geleijnse JM. 229-233. Proc Soc Exp Biol Med. Biochim Biophys Acta. 835. 34-35. 315-321. Gordon M. Hollman PC. Brendler T. Diker KS. 1007-1011. 1995. 308-313. 155. Hertog MG. 881-886. Conney AH. 2001. Gokce N. 1998. Hamburg. 2004. Akan M. Clifford MN. Circulation. Feskens EJM. Nat Prod Rep. Nutr Cancer. 83-87. Hollman PCH. Puddey IB. Jessup W. Walker R. Arch Intern Med. Witteman JC. Inhibitory effect of green and black tea on tumor growth. Hamburg. Corvazier E and Maclouf J. Klaunig JE. Caffeinated Beverages Symposium. Yurdakok M. 159. 1996. Chemopreventive effects of green and black tea on pulmonary and hepatic carcinogenesis. 589-597. Short. 12. Gruenwald J. Eur J Clin Nutr. Diker KS and Hascelik G. 75. Beilin LJ. 220. 29. de Whalley CV. 1996. In: Wissenschaftlicher Informationsdienst Tee. Chen J. USA. Simic BS. 151-159. 1999. Kromhout D. 55. Fujiki H. Burke V. Green tea and cancer in humans: a review of the literature. Baker RI. du Toit R. Interference of some flavonoids and non-steroidal anti-inflammatory drugs with oxidative metabolism of arachidonic acid by human platelets and neutrophils. Swerdloff PL. 34. 1997. The bactericidal activity of tea against Campylobacter jejuni and Campylobacter coli.and longterm black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Deutsches TeeInstitut. Szeto YT. 381-386. Hoult JR. Keaney JF. Xie J. 1998. 1998. Mori TA. 342. Lou Y. 453-462. 104. Toxicology. Krebsvorbeugende und krebshemmende Wirkung von Tee. Rankin SM. Two stages of cancer prevention with green tea. Fidanza F. Fundam Appl Toxicol. 166. Jansen A. 1994. 151-156. In: Wissenschaftlicher Informationsdienst Tee. J Cancer Res Clin Oncol.. Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans. 299-300. Hascelik G. 265-273. Inhibition of endothelial cell mediated lowdensity lipoprotein oxidation by green tea extracts. and glutathione S-transferase in rats. Chu IS. 637-642. 1996. 1998. 501-508. Jr. Mutat Res. 19. National Institute of Health (NIH). Landau JM. Hertog MG. Crosbie L. Frankel EN. Gmeiner B. 1998. 1999. 2000. Lin JK. Leenen R. Gao YT. 1981-1985. Arch Intern Med. Ganguly DK. 54. Lin YP. Hour TC. Nakagawa K. Wiseman SA. Maatela J. 438-443. Su Y. Caries Res. Vedasiromoni JR. 569-579. Antimutagenic and anticarcinogenic activity of tea polyphenols. Hollman PC. 37. 153-162. 24. 478-481. into human plasma. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. A single dose of tea with or without milk increases plasma antioxidant activity in humans. Okuda S. The polyphenolic content of fruit and vegetables and their antioxidant activities. Hypolipidemic effect of green tea leaves through induction of antioxidant and phase II enzymes including superoxide dismutase. J Agric Food Chem. 1996. Hsing AW. Hunter K. 501-507. Stender G. Rice-Evans CA. 46. Miyazawa T. Chen ZY. 5768-5772. 8. 70. Tijburg LB. 2248-2251.gov/medlineplus/druginfo/natural/patient-green_tea. 1997. 312. 1445-1449. Yang CS. 111. 2000. Modulation of human platelet function by food flavonoids.. 87-92. Tijburg LB. 2001. Reunanen A. Otake S. Kuroki T. 25. Keli SO. 1999. Cheng CY. Kelly C. Lin JK.html. catalase. Fraumeni JF. El SN. 2000. Kapiotis S. 1893-1899. Wien Klin Wochenschr. Dai Q. 48. Miller N. (-) epigallocatechin-3-gallate. 1991. BMJ. Aeschbach R. Leung LK. Antioxidant activity of some foods containing phenolic compounds. Role of glutathione in the antiulcer effect of hot water extract of black tea (Camellia sinensis). 48. Dutta-Roy AK. Frass M. Katiyar SK and Mukhtar H. 297-300. and incidence of stroke: the Zutphen study. Feskens EJ. Lapczynski S. 197S. Engelhardt UH. International Journal of Oncology. Biosci Biotechnol Biochem. Handler S. Paganga G. Huang Y. 1998. Karakaya S. Flavonoids and other polyphenols in consumer brews of tea and other caffeinated beverages. McLaughlin JK. Tas AA. Juan IM. Protection against nitric oxide toxicity by tea. http://www. Kromhout D. antioxidant vitamins. Liang YC. Chen R.27 Hofbauer R. Kuroda Y and Hara Y. Int J Cancer. J Agric Food Chem. Roodenburg AJ. 2001. 1998. Green tea (Camellia sinensis). Green tea consumption and the risk of pancreatic and colorectal cancers. Knekt P. J Nutr. 34. Gordon MJ. 69-97. Chow WH. What does a serving constitute? Free Radic Res. 278-282. Carcinogenesis. Inhibition of eleven mutagens by various tea extracts. Anticaries effects of polyphenolic compounds from Japanese green tea. Yang GY. 255-258. 2848-2852. 30. Paquay JB. Wang ZY. Wiseman SA. Haenen GR. Ding W. Int J Food Sci Nutr. Tijburg LB. Makimura M. Van Het Hof KH. 131. Katan MB. Lau YW. Ji BT. Inhibition of spontaneous formation of lung tumors and rhabdomyosarcomas in A/J mice by black and green tea. 52. 156. 2001. 46. Maity S. 78. 221-238. Biochem Soc Trans. J Agric Food Chem. Zhang Z. Lin YL. Maiwald B. Hirasawa M. Free Radic Res. 1996. Speiser W. Blot WJ. 1999. 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 416 . Pearson DA. Bast A. Dose-dependent incorporation of tea catechins. 436.nih.nlm. gallic acid and caffeine. Food Chem Toxicol. Dietary flavonoids. Lakenbrink C. 285-292. Flavonoid intake and coronary mortality in Finland: a cohort study. German JB. Nishihara Y. 1999. Jpn J Pharmacol. 1997. The green tea extract epigallocatechin gallate is able to reduce neutrophil transmigration through monolayers of endothelial cells. J Agric Food Chem. 61. Eur J Clin Nutr. Tea in chemoprevention of cancer: epidemiologic and experimental studies. Addition of milk does not affect the absorption of flavonols from tea in man. Jarvinen R. 1996. (-)epigallocatechin-3-gallate and (-)-epigallocatechin. Thromb Haemost. Steele VE. Tea flavonoids and cardiovascular disease: a review. Ikigai H. 1991. Foss OP. lipid oxidation and fibrinogen in the hamster: mechanisms for the epidemiological benefits of tea drinking. http://www. Free Radic Res. Biochem Biophys Res Commun. especially tea flavonols. Winter A. 75. Buring JE. 433. Balentine DA. J Agric Food Chem. Tverdal A. 1995.49 50 51 52 Pietta PG. Aoyagi K. black tea and selected polyphenol extracts measured by in vitro bioassays. 52. Katan MB. 70. Steele VE. Crit Rev Food Sci Nutr. Boone CW. Preclinical efficacy studies of green and black tea extracts. Am J Epidemiol. Sarkar A and Bhaduri A. Suzuki T. 149. Balentine D. 1995. 2001. 771-785. 1995. J Appl Bacteriol. Sigman CC. Sigman CC. Inhibitory effects of green tea polyphenols on glucan synthesis and cellular adherence of cariogenic streptococci. van het Hof KH. 2001. 1996. Simonetti P. 21. Effect of green and black tea supplementation on lipids. Koyama A. Bombardelli E. and coronary and total mortality. Plant flavonoids. 1997. Thromb Res. Sharma S. Bitsch I. Smith DM and Dou QP. Teng CM. The protective activity of tea against infection by Vibrio cholerae O1. Vinson JA and Dabbagh YA. Stensvold I. Tzeng SH. 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 417 . Kelloff GJ. Proc Soc Exp Biol Med. Ko WC. FEBS Lett. 1999. 28-32. Ferro-Luzzi A. Shahrzad S. Wargovich MJ. Int J Food Microbiol. Bramley PM. Sato T. Toda M. 17.naturaldatabase. 2925-2929. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Miller NJ. Weststrate JA. Yamamoto T. Comparative chemopreventive mechanisms of green tea. 945-949. 43. Bagheri D. Kim M. Mehta R. Serry MM. Brusamolino A. Agricultural and biological chemistry. 162-167. Surono IS and Hosono A. Coffee and tea intake and the risk of myocardial infarction. Okubo S. Sakanaka S. Solvoll K. Mehta R. Scholz E and Bertram B. relationship to cholesterol. Natural Medicines: Comprehensive Database. are powerful antioxidants using an in vitro oxidation model for heart disease. Zhu S. 7. J Nutr. Vinson JA. 1996. Ko FN. Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. Catechin metabolites after intake of green tea infusions.com. 546-553. Serafini M. Inhibition of platelet aggregation by some flavonoids. 111-118. 284. Stoner GD. 44-46. Int J Mol Med. 1990. 2001. Eur J Clin Nutr. Lagarde M. 63-67. Pridham JB. Kelloff GJ. blood pressure. 91-100. In vivo antioxidant effect of green and black tea in man. Jang J. Kuntze. Tea consumption. Prev Med. Carcinogenesis. 1996. 54. N-3 fatty acid-induced lipid peroxidation in human platelets is prevented by catechins. Hennekens CH. Black tea is a powerful chemopreventor of reactive oxygen and nitrogen species: comparison with its individual catechin constituents and green tea. Shimamura T. Suzuki Y. Tijburg LB. 1999. Zeitschrift für Phytotherapie. Therapeutic Research Faculty. Eur J Clin Nutr. Camellia sinensis (L. Bioavailability of catechins from tea: the effect of milk. 2000. Gardana C. 1998. Sesso HD. Mattern T. 1992. Bolwell PG. Green tea induces polyphenols epigallocatechin inhibts DNA replication and consequently induces leukaemia cell apoptosis. 50. 1998.) O. Gaziano JM. Polette A. Zhu S. 235-250. Lemaitre D. Weisgerber UM. 1998. 220. 375-383. 356-359. 21. 22. Folts JD. Morse MA. 210-212. 645-652. 2800-2802. Bacterial mutagenicity of terasi and antimutagenicity of Indonesian jasmine tea against terasi. 37. Der Teestrauch. Tijburg LB. Boone CW. 8. Kivits GA. 64. Vericel E. Rice-Evans CA. Dabbagh YA. Biofactors. Sharma S. 49-58. Ghiselli A. Bagheri D. 109-112. Weisburger JH. 1991. Morazzoni P. 1207-1210. 32. 131. 173-178. 70 Wang ZY, Huang MT, Ferraro T, Wong CQ, Lou YR, Reuhl K, Iatropoulos M, Yang CS, Conney AH, 1992. Inhibitory effect of green tea in the drinking water on tumorigenesis by ultraviolet light and 12-Otetradecanoylphorbol-13-acetate in the skin of SKH-1 mice. Cancer Res, 52, 1162-1170. Wang ZY, Huang MT, Ho CT, Chang R, Ma W, Ferraro T, Reuhl KR, Yang CS, Conney AH, 1992. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res, 52, 66576665. Warden BA, Smith LS, Beecher GR, Balentine DA, Clevidence BA, 2001. Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr, 131, 1731-1737. Wichtl M, 2004. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. Medpharm GmbH Scientific Publishers, Stuttgart, Germany. Xu Y, Ho CT, Amin SG, Han C, Chung FL, 1992. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res, 52, 38753879. Yamada J and Tomita Y, 1994. Antimutagenic activity of water extracts of black tea and oolong tea. Bioscience, Biotechnology, and Biochemistry (Japan), 58, 2197-2200. Yang TT and Koo MW, 1997. Hypocholesterolemic effects of Chinese tea. Pharmacol Res, 35, 505-512. Yang GY, Liao J, Kim K, Yurkow EJ, Yang CS, 1998. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis, 19, 611-616. Yang CS, Kim S, Yang GY, Lee MJ, Liao J, Chung JY, Ho CT, 1999. Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Proc Soc Exp Biol Med, 220, 213-217. Yen GC and Chen HY, 1995. Antioxidant activity of various tea extracts in relation to their antimutagenicity. J Agric Food Chem, 43, 27-32. Yochum L, Kushi LH, Meyer K, Folsom AR, 1999. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol, 149, 943-949. Yoshida H, Ishikawa T, Hosoai H, Suzukawa M, Ayaori M, Hisada T, Sawada S, Yonemura A, Higashi K, Ito T, Nakajima K, Yamashita T, Tomiyasu K, Nishiwaki M, Ohsuzu F, Nakamura H, 1999. Inhibitory effect of tea flavonoids on the ability of cells to oxidize low density lipoprotein. Biochem Pharmacol, 58, 1695-1703. Zhu QY, Huang Y, Chen ZY, 2000. Interaction between flavonoids and alpha-tocopherol in human low density lipoprotein. J Nutr Biochem, 11, 14-21. 71 72 73 74 75 76 77 78 79 80 81 82 ID 1644: “Propolis” and “Immune Support Propolis helps to protect cells from free radical damage and helps maintain a healthy immune system through action of high levels of antioxidant bioflavonoids.” 1 Abdel-Latif MM, Windle HJ, Homasany BS, Sabra K, Kelleher D, 2005. Caffeic acid phenethyl ester modulates Helicobacter pylori-induced nuclear factor-kappa B and activator protein-1 expression in gastric epithelial cells. Br J Pharmacol, 146, 1139-1147. Ansorge S, Reinhold D, Lendeckel U, 2003. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch C, 58, 580-589. Ayres DC, Marcucci MC, Giorgio S, 2007. Effects of Brazilian propolis on Leishmania amazonensis. Mem Inst Oswaldo Cruz, 102, 215-220. Bankova V, 2005. Recent trends and important developments in propolis research. Evid Based Complement Alternat Med, 2, 29-32. Banskota AH, Tezuka Y, Kadota S, 2001. Recent progress in pharmacological research of propolis. Phytother Res, 15, 561-571. Bone K, 1994. Propolis: a natural antibiotic. Australian Journal of Medical Herbalism, 6, 61-65. 2 3 4 5 6 418 7 Boyanova L, Gergova G, Nikolov R, Derejian S, Lazarova E, Katsarov N, Mitov I, Krastev Z, 2005. Activity of Bulgarian propolis against 94 Helicobacter pylori strains in vitro by agar-well diffusion, agar dilution and disc diffusion methods. J Med Microbiol, 54, 481-483. Boyanova L, Kolarov R, Gergova G, Mitov I, 2006. In vitro activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria. Anaerobe, 12, 173-177. Bratter C, Tregel M, Liebenthal C, Volk HD, 1999. [Prophylactic effectiveness of propolis for immunostimulation: a clinical pilot study]. Forsch Komplementarmed, 6, 256-260. Burdock GA, 1998. Review of the biological properties and toxicity of bee propolis (propolis). Food Chem Toxicol, 36, 347-363. Cardile V, Panico A, Gentile B, Borrelli F, Russo A, 2003. Effect of propolis on human cartilage and chondrocytes. Life Sci, 73, 1027-1035. Castaldo S and Capasso F, 2002. Propolis, an old remedy used in modern medicine. Fitoterapia, 73 Suppl 1, S1-6. Celik S, Gorur S, Aslantas O, Erdogan S, Ocak S, Hakverdi S, 2007. Caffeic acid phenethyl ester suppresses oxidative stress in Escherichia coli-induced pyelonephritis in rats. Mol Cell Biochem, 297, 131138. Chen CN, Weng MS, Wu CL, Lin JK, 2004. Comparison of Radical Scavenging Activity, Cytotoxic Effects and Apoptosis Induction in Human Melanoma Cells by Taiwanese Propolis from Different Sources. Evid Based Complement Alternat Med, 1, 175-185. Claus R, Kinscherf R, Gehrke C, Bonaterra G, Basnet P, Metz J, Deigner HP, 2000. Antiapoptotic effects of propolis extract and propol on human macrophages exposed to minimally modified low density lipoprotein. Arzneimittelforschung, 50, 373-379. Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y, 2004. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. Arch Pediatr Adolesc Med, 158, 217-221. Crisan I, Zaharia CN, Popovici F, Jucu V, Belu O, Dascalu C, Mutiu A, Petrescu A, 1995. Natural propolis extract NIVCRISOL in the treatment of acute and chronic rhinopharyngitis in children. Rom J Virol, 46, 115-133. Cuesta A, Rodriguez A, Esteban MA, Meseguer J, 2005. In vivo effects of propolis, a honeybee product, on gilthead seabream innate immune responses. Fish Shellfish Immunol, 18, 71-80. de Rezende R, da Silva GP, Pimenta FC, da Costa S, de Rezende LR, 2006. Antimicrobial activity of two Brazilian commercial propolis extracts. Brazilian Journal of Oral Sciences, 5. Dimov V, Ivanovska N, Manolova N, Bankova V, Nikolov N, Popov S, 1991. Immunomodulatory action of propolis. Influence on anti-infectious protection and macrophage function. Apidologie, 22, 155-162. Dimov V, Ivanovska N, Bankova V, Popov S, 1992. Immunomodulatory action of propolis: IV. Prophylactic activity against gram-negative infections and adjuvant effect of the water-soluble derivative. Vaccine, 10, 817-823. Dobrowolski JW, Vohora SB, Sharma K, Shah SA, Naqvi SA, Dandiya PC, 1991. Antibacterial, antifungal, antiamoebic, antiinflammatory and antipyretic studies on propolis bee products. J Ethnopharmacol, 35, 77-82. Drago L, Mombelli B, De Vecchi E, Fassina MC, Tocalli L, Gismondo MR, 2000. In vitro antimicrobial activity of propolis dry extract. J Chemother, 12, 390-395. Fischer G, Cleff MB, Dummer LA, Paulino N, Paulino AS, de Oliveira Vilela C, Campos FS, Storch T, D'Avila Vargas G, de Oliveira Hubner S, Vidor T, 2007. Adjuvant effect of green propolis on humoral immune response of bovines immunized with bovine herpesvirus type 5. Vet Immunol Immunopathol, 116, 79-84. Fischer G, Conceicao FR, Leite FP, Dummer LA, Vargas GD, Hubner Sde O, Dellagostin OA, Paulino N, Paulino AS, Vidor T, 2007. Immunomodulation produced by a green propolis extract on humoral and cellular responses of mice immunized with SuHV-1. Vaccine, 25, 1250-1256. 419 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Focht J, Hansen SH, Nielsen JV, van den Berg-Segers A, Riezler R, 1993. Bactericidal effect of propolis in vitro against agents causing upper respiratory tract infections. Arzneimittelforschung, 43, 921-923. Frenkel K, Wei H, Bhimani R, Ye J, Zadunaisky JA, Huang MT, Ferraro T, Conney AH, Grunberger D, 1993. Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester. Cancer Res, 53, 1255-1261. Gekker G, Hu S, Spivak M, Lokensgard JR, Peterson PK, 2005. Anti-HIV-1 activity of propolis in CD4(+) lymphocyte and microglial cell cultures. J Ethnopharmacol, 102, 158-163. Grange JM and Davey RW, 1990. Antibacterial properties of propolis (bee glue). J R Soc Med, 83, 159160. Guang HM and Du GH, 2006. Protections of pinocembrin on brain mitochondria contribute to cognitive improvement in chronic cerebral hypoperfused rats. Eur J Pharmacol, 542, 77-83. Harish Z, Rubinstein A, Golodner M, Elmaliah M, Mizrachi Y, 1997. Suppression of HIV-1 replication by propolis and its immunoregulatory effect. Drugs Exp Clin Res, 23, 89-96. Hartwich A, Legutko J, Wszolek J, 2000. [Propolis: its properties and administration to patients treated for some surgical diseases]. Przegl Lek, 57, 191-194. Ichikawa H, Satoh K, Tobe T, Yasuda I, Ushio F, Matsumoto K, Endo K, Ookubo C, 2002. Free radical scavenging activity of propolis. Redox Rep, 7, 347-350. Inokuchi Y, Shimazawa M, Nakajima Y, Suemori S, Mishima S, Hara H, 2006. Brazilian green propolis protects against retinal damage in vitro and in vivo. Evid Based Complement Alternat Med, 3, 71-77. Irmak MK, Koltuksuz U, Kutlu NO, Yagmurca M, Ozyurt H, Karaman A, Akyol O, 2001. The effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in comparison with alpha-tocopherol in rat kidneys. Urol Res, 29, 190-193. Irmak MK, Fadillioglu E, Sogut S, Erdogan H, Gulec M, Ozer M, Yagmurca M, Gozukara ME, 2003. Effects of caffeic acid phenethyl ester and alpha-tocopherol on reperfusion injury in rat brain. Cell Biochem Funct, 21, 283-289. Ivanovska N, Stefanova Z, Valeva V, Neychev H, 1993. Immunomodulatory action of propolis: VII. A comparative study on cinnamic and caffeic acid lysine derivatives. Comptes Rendus-Academie Bulgare des Sciences, 46, 115-117. Ivanovska ND, Dimov VB, Pavlova S, Bankova VS, Popov SS, 1995. Immunomodulatory action of propolis. V. Anticomplementary activity of a water-soluble derivative. J Ethnopharmacol, 47, 135-143. Jaiswal AK, Venugopal R, Mucha J, Carothers AM, Grunberger D, 1997. Caffeic acid phenethyl ester stimulates human antioxidant response element-mediated expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene. Cancer Res, 57, 440-446. Jasprica I, Mornar A, Debeljak Z, Smolcic-Bubalo A, Medic-Saric M, Mayer L, Romic Z, Bucan K, Balog T, Sobocanec S, Sverko V, 2007. In vivo study of propolis supplementation effects on antioxidative status and red blood cells. J Ethnopharmacol, 110, 548-554. Kartal M, Yildiz S, Kaya S, Kurucu S, Topcu G, 2003. Antimicrobial activity of propolis samples from two different regions of Anatolia. J Ethnopharmacol, 86, 69-73. Khalil ML, 2006. Biological activity of bee propolis in health and disease. Asian Pac J Cancer Prev, 7, 2231. Khayyal MT, el-Ghazaly MA, el-Khatib AS, 1993. Mechanisms involved in the antiinflammatory effect of propolis extract. Drugs Exp Clin Res, 19, 197-203. Khayyal MT, el-Ghazaly MA, el-Khatib AS, Hatem AM, de Vries PJ, el-Shafei S, Khattab MM, 2003. A clinical pharmacological study of the potential beneficial effects of a propolis food product as an adjuvant in asthmatic patients. Fundam Clin Pharmacol, 17, 93-102. Kimoto T, Arai S, Kohguchi M, Aga M, Nomura Y, Micallef MJ, Kurimoto M, Mito K, 1998. Apoptosis and suppression of tumor growth by artepillin C extracted from Brazilian propolis. Cancer Detect Prev, 22, 506-515. 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 420 46 47 Koo H, Gomes BP, Rosalen PL, Ambrosano GM, Park YK, Cury JA, 2000. In vitro antimicrobial activity of propolis and Arnica montana against oral pathogens. Arch Oral Biol, 45, 141-148. Koo H, Rosalen PL, Cury JA, Ambrosano GM, Murata RM, Yatsuda R, Ikegaki M, Alencar SM, Park YK, 2000. Effect of a new variety of Apis mellifera propolis on mutans Streptococci. Curr Microbiol, 41, 192196. Koru O, Toksoy F, Acikel CH, Tunca YM, Baysallar M, Uskudar Guclu A, Akca E, Ozkok Tuylu A, Sorkun K, Tanyuksel M, Salih B, 2007. In vitro antimicrobial activity of propolis samples from different geographical origins against certain oral pathogens. Anaerobe, 13, 140-145. Kosenko SV and Kosovich T, 1990. [The treatment of periodontitis with prolonged-action propolis preparations (clinical x-ray research)]. Stomatologiia (Mosk), 69, 27-29. Kujumgiev A, Tsvetkova I, Serkedjieva Y, Bankova V, Christov R, Popov S, 1999. Antibacterial, antifungal and antiviral activity of propolis of different geographic origin. J Ethnopharmacol, 64, 235-240. Kumazawa S, Hamasaka T, Nakayama T, 2004. Antioxidant activity of propolis of various geographic origins. Food Chemistry, 84, 329-339. Liu CF, Lin CH, Lin CC, Lin YH, Chen CF, Lin SC, 2005. Protective effect of propolis ethanol extract on ethanol-induced renal toxicity: an in-vivo study. Am J Chin Med, 33, 779-786. Lofty M, 2006. Biological activity of bee propolis in health & disease. Asian Pacific Journal of Cancer Prevention, 7. Marcucci MC, 1995. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie, 26, 83-99. Marquele FD, Stracieri KM, Fonseca MJ, Freitas LA, 2006. Spray-dried propolis extract. I: physicochemical and antioxidant properties. Pharmazie, 61, 325-330. Marquez N, Sancho R, Macho A, Calzado MA, Fiebich BL, Munoz E, 2004. Caffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factors. J Pharmacol Exp Ther, 308, 993-1001. Martinez Silveira G, Gou Godoy A, OnaTorriente R, Palmer Ortiz MC, Falcon Cuellar MA, 1988. Preliminary study of the effects of propolis in the treatment of chronic gingivitis and oral ulceration. Rev Cubana Estomatol, 25, 36-44. Miorin PL, Levy Junior NC, Custodio AR, Bretz WA, Marcucci MC, 2003. Antibacterial activity of honey and propolis from Apis mellifera and Tetragonisca angustula against Staphylococcus aureus. J Appl Microbiol, 95, 913-920. Mishima S, Ono Y, Araki Y, Akao Y, Nozawa Y, 2005. Two related cinnamic Acid derivatives from Brazilian honey bee propolis, baccharin and drupanin, induce growth inhibition in allografted sarcoma S180 in mice. Biol Pharm Bull, 28, 1025-1030. Miyares C, Hollands I, Castaneda C, Gonzalez T, Fragoso T, Curras R, Soria C, 1988. [Clinical trial with a preparation based on propolis "propolisina" in human giardiasis]. Acta Gastroenterol Latinoam, 18, 195201. Moonis M, Ahmad I, Bachhawat BK, 1992. Macrophages in host defence--an overview. Indian J Biochem Biophys, 29, 115-122. Morelle J and Lauzanne E, 1990. Que peuvent nous apporter les extraits végétaux? Première partie: l‘ail, la propolis. Parfums, cosmétiques, arômes, 95, 77-95. Nagai T, Inoue R, Inoue H, Suzuki N, 2003. Preparation and antioxidant properties of water extract of propolis. Food Chemistry, 80, 29-33. Nagaoka T, Banskota AH, Tezuka Y, Midorikawa K, Matsushige K, Kadota S, 2003. Caffeic acid phenethyl ester (CAPE) analogues: potent nitric oxide inhibitors from the Netherlands propolis. Biol Pharm Bull, 26, 487-491. Nakajima Y, Shimazawa M, Mishima S, Hara H, 2007. Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. Life Sci, 80, 370-377. 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 421 66 Natarajan K, Singh S, Burke TR, Jr., Grunberger D, Aggarwal BB, 1996. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA, 93, 9090-9095. Nostro A, Cellini L, Di Bartolomeo S, Cannatelli MA, Di Campli E, Procopio F, Grande R, Marzio L, Alonzo V, 2006. Effects of combining extracts (from propolis or Zingiber officinale) with clarithromycin on Helicobacter pylori. Phytother Res, 20, 187-190. Oliveira AC, Shinobu CS, Longhini R, Franco SL, Svidzinski TI, 2006. Antifungal activity of propolis extract against yeasts isolated from onychomycosis lesions. Mem Inst Oswaldo Cruz, 101, 493-497. Orsi RO, Funari SRC, Soares A, Calvi SA, Oliveira SL, Sforcin JM, Bankova V, 2000. Immunomodulatory action of propolis on macrophage activation. Journal of Venomous Animals and Toxins, 6, 205-219. Orsolic N and Basic I, 2003. Immunomodulation by water-soluble derivative of propolis: a factor of antitumor reactivity. J Ethnopharmacol, 84, 265-273. Orsolic N, Knezevic AH, Sver L, Terzic S, Basic I, 2004. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J Ethnopharmacol, 94, 307-315. Orsolic N and Basic I, 2005. Water-soluble derivative of propolis and its polyphenolic compounds enhance tumoricidal activity of macrophages. J Ethnopharmacol, 102, 37-45. Orsolic N, Kosalec I, Basic I, 2005. Synergistic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour. Biol Pharm Bull, 28, 694-700. Orsolic N, Terzic S, Mihaljevic Z, Sver L, Basic I, 2005. Effects of local administration of propolis and its polyphenolic compounds on tumor formation and growth. Biol Pharm Bull, 28, 1928-1933. Oršolic N, Terzic S, Šver L, Bašic I, 2005. Polyphenolic compounds from propolis modulate immune responses and increase host resistance to tumour cells. Food and agricultural immunology, 16, 165-179. Park YK, Koo MH, Abreu JA, Ikegaki M, Cury JA, Rosalen PL, 1998. Antimicrobial activity of propolis on oral microorganisms. Curr Microbiol, 36, 24-28. Park JH, Lee JK, Kim HS, Chung ST, Eom JH, Kim KA, Chung SJ, Paik SY, Oh HY, 2004. Immunomodulatory effect of caffeic acid phenethyl ester in Balb/c mice. Int Immunopharmacol, 4, 429436. Pascual C, Gonzalez R, Torricella RG, 1994. Scavenging action of propolis extract against oxygen radicals. J Ethnopharmacol, 41, 9-13. Paulino N, Teixeira C, Martins R, Scremin A, Dirsch VM, Vollmar AM, Abreu SR, de Castro SL, Marcucci MC, 2006. Evaluation of the analgesic and anti-inflammatory effects of a Brazilian green propolis. Planta Med, 72, 899-906. Popova M, Silici S, Kaftanoglu O, Bankova V, 2005. Antibacterial activity of Turkish propolis and its qualitative and quantitative chemical composition. Phytomedicine, 12, 221-228. Radhakrishnan P, Palaniyandi S, Dhanapal S, 2006. Therapeutic effect of propolis and paclitaxel on hepatic phase I and II enzymes and marker enzymes in dimethylbenz(a)anthracene induced breast cancer in female rats. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 143, 349-354. Russo A, Troncoso N, Sanchez F, Garbarino JA, Vanella A, 2006. Propolis protects human spermatozoa from DNA damage caused by benzo[a]pyrene and exogenous reactive oxygen species. Life Sci, 78, 14011406. Samet N, Laurent C, Susarla SM, Samet-Rubinsteen N, 2007. The effect of bee propolis on recurrent aphthous stomatitis: a pilot study. Clin Oral Investig, 11, 143-147. Sa-Nunes A, Faccioli LH, Sforcin JM, 2003. Propolis: lymphocyte proliferation and IFN-gamma production. J Ethnopharmacol, 87, 93-97. Scazzocchio F, D'Auria FD, Alessandrini D, Pantanella F, 2006. Multifactorial aspects of antimicrobial activity of propolis. Microbiol Res, 161, 327-333. 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 422 86 Scheller S, Gazda G, Pietsz G, Gabrys J, Szumlas J, Eckert L, Shani J, 1988. The ability of ethanol extract of propolis to stimulate plaque formation in immunized mouse spleen cells. Pharmacol Res Commun, 20, 323-328. Scheller S, Gazda G, Krol W, Czuba Z, Zajusz A, Gabrys J, Shani J, 1989. The ability of ethanolic extract of propolis (EEP) to protect mice against gamma irradiation. Z Naturforsch C, 44, 1049-1052. Scheller S, Wilczok T, Imielski S, Krol W, Gabrys J, Shani J, 1990. Free radical scavenging by ethanol extract of propolis. Int J Radiat Biol, 57, 461-465. Schilcher H, Kammerer S, Wegener T, 2007. Pflanzenprofil Propolis. In: Leitfaden Phytotherapie. Elsevier GmbH, München, 209-210. Schwan WR, Huang XZ, Hu L, Kopecko DJ, 2000. Differential bacterial survival, replication, and apoptosis-inducing ability of Salmonella serovars within human and murine macrophages. Infect Immun, 68, 1005-1013. Serkedjieva J, Manolova N, Bankova V, 1992. Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids). J Nat Prod, 55, 294-302. Sforcin JM, Orsi RO, Bankova V, 2005. Effect of propolis, some isolated compounds and its source plant on antibody production. J Ethnopharmacol, 98, 301-305. Sforcin JM, 2007. Propolis and the immune system: a review. J Ethnopharmacol, 113, 1-14. Silici S and Koc AN, 2006. Comparative study of in vitro methods to analyse the antifungal activity of propolis against yeasts isolated from patients with superficial mycoses. Lett Appl Microbiol, 43, 318-324. Sonmez S, Kirilmaz L, Yucesoy M, Yucel B, Yilmaz B, 2005. The effect of bee propolis on oral pathogens and human gingival fibroblasts. J Ethnopharmacol, 102, 371-376. Speciale A, Costanzo R, Puglisi S, Musumeci R, Catania MR, Caccamo F, Iauk L, 2006. Antibacterial activity of propolis and its active principles alone and in combination with macrolides, beta-lactams and fluoroquinolones against microorganisms responsible for respiratory infections. J Chemother, 18, 164-171. Sun F, Hayami S, Haruna S, Ogiri Y, Tanaka K, Yamada Y, Ikeda K, Yamada H, Sugimoto H, Kawai N, Kojo S, 2000. In vivo antioxidative activity of propolis evaluated by the interaction with vitamins C and E and the level of lipid hydroperoxides in rats. J Agric Food Chem, 48, 1462-1465. Sy LB, Wu YL, Chiang BL, Wang YH, Wu WM, 2006. Propolis extracts exhibit an immunoregulatory activity in an OVA-sensitized airway inflammatory animal model. Int Immunopharmacol, 6, 1053-1060. Szmeja Z, Kulczynski B, Sosnowski Z, Konopacki K, 1989. [Therapeutic value of flavonoids in Rhinovirus infections]. Otolaryngol Pol, 43, 180-184. Taheri H, Rahmani H, Pourreza J, 2005. Humoral Immunity of Broilers is Affected by Oil Extracted Propolis (OEP) in the Diet. International Journal of Poultry Science, 4, 414-417. Takagi Y, Choi IS, Yamashita T, Nakamura T, Suzuki I, Hasegawa T, Oshima M, Gu YH, 2005. Immune activation and radioprotection by propolis. Am J Chin Med, 33, 231-240. Tan-No K, Nakajima T, Shoji T, Nakagawasai O, Niijima F, Ishikawa M, Endo Y, Sato T, Satoh S, Tadano T, 2006. Anti-inflammatory effect of propolis through inhibition of nitric oxide production on carrageenininduced mouse paw edema. Biol Pharm Bull, 29, 96-99. Tatefuji T, Izumi N, Ohta T, Arai S, Ikeda M, Kurimoto M, 1996. Isolation and identification of compounds from Brazilian propolis which enhance macrophage spreading and mobility. Biol Pharm Bull, 19, 966-970. Tosi B, Donini A, Romagnoli C, Bruni A, 1996. Antimicrobial activity of some commercial extracts of propolis prepared with different solvents. Phytotherapy Research, 10. Ugur A and Arslan T, 2004. An in vitro study on antimicrobial activity of propolis from Mugla province of Turkey. J Med Food, 7, 90-94. Von der Ohe W, 2006. Steckbrief Propolis. LAVES - Institut für Bienenkunde Celle. 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 423 107 108 Vynograd N, Vynograd I, Sosnowski Z, 2000. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the treatment of genital herpes (HSV). Phytomedicine, 7, 1-6. Weng MS, Liao CH, Chen CN, Wu CL, Lin JK, 2007. Propolin H from Taiwanese propolis induces G1 arrest in human lung carcinoma cells. J Agric Food Chem, 55, 5289-5298. ID 1645: “Propolis” and “Maintain oral healththrough the presence of high levels of antioxidant bioflavonoids” 1 2 3 Al-Shaher A, Wallace J, Agarwal S, Bretz W, Baugh D, 2004. Effect of propolis on human fibroblasts from the pulp and periodontal ligament. J Endod, 30, 359-361. Botushanov PI, Grigorov GI, Aleksandrov GA, 2001. A clinical study of a silicate toothpaste with extract from propolis. Folia Med (Plovdiv), 43, 28-30. Bruschi ML, Lara EH, Martins CH, Vinholis AH, Casemiro LA, Panzeri H, Gremiao MP, 2006. Preparation and antimicrobial activity of gelatin microparticles containing propolis against oral pathogens. Drug Dev Ind Pharm, 32, 229-238. Duarte S, Koo H, Bowen WH, Hayacibara MF, Cury JA, Ikegaki M, Rosalen PL, 2003. Effect of a novel type of propolis and its chemical fractions on glucosyltransferases and on growth and adherence of mutans streptococci. Biol Pharm Bull, 26, 527-531. Duarte S, Rosalen PL, Hayacibara MF, Cury JA, Bowen WH, Marquis RE, Rehder VL, Sartoratto A, Ikegaki M, Koo H, 2006. The influence of a novel propolis on mutans streptococci biofilms and caries development in rats. Arch Oral Biol, 51, 15-22. Gebaraa EC, Pustiglioni AN, de Lima LA, Mayer MP, 2003. Propolis extract as an adjuvant to periodontal treatment. Oral Health Prev Dent, 1, 29-35. Giamalia I, Steinberg D, Grobler S, Gedalia I, 1999. The effect of propolis exposure on microhardness of human enamel in vitro. J Oral Rehabil, 26, 941-943. Hayacibara MF, Koo H, Rosalen PL, Duarte S, Franco EM, Bowen WH, Ikegaki M, Cury JA, 2005. In vitro and in vivo effects of isolated fractions of Brazilian propolis on caries development. J Ethnopharmacol, 101, 110-115. Koo H, Vacca Smith AM, Bowen WH, Rosalen PL, Cury JA, Park YK, 2000. Effects of Apis mellifera propolis on the activities of streptococcal glucosyltransferases in solution and adsorbed onto saliva-coated hydroxyapatite. Caries Res, 34, 418-426. Koo H, Cury JA, Rosalen PL, Ambrosano GM, Ikegaki M, Park YK, 2002. Effect of a mouthrinse containing selected propolis on 3-day dental plaque accumulation and polysaccharide formation. Caries Res, 36, 445-448. Koo H, Rosalen PL, Cury JA, Park YK, Bowen WH, 2002. Effects of compounds found in propolis on Streptococcus mutans growth and on glucosyltransferase activity. Antimicrob Agents Chemother, 46, 1302-1309. Koru O, Toksoy F, Acikel CH, Tunca YM, Baysallar M, Uskudar Guclu A, Akca E, Ozkok Tuylu A, Sorkun K, Tanyuksel M, Salih B, 2007. In vitro antimicrobial activity of propolis samples from different geographical origins against certain oral pathogens. Anaerobe, 13, 140-145. Leitao DP, Filho AA, Polizello AC, Bastos JK, Spadaro AC, 2004. Comparative evaluation of in-vitro effects of Brazilian green propolis and Baccharis dracunculifolia extracts on cariogenic factors of Streptococcus mutans. Biol Pharm Bull, 27, 1834-1839. Magro-Filho O and de Carvalho AC, 1994. Topical effect of propolis in the repair of sulcoplasties by the modified Kazanjian technique. Cytological and clinical evaluation. J Nihon Univ Sch Dent, 36, 102-111. Oncag O, Cogulu D, Uzel A, Sorkun K, 2006. Efficacy of propolis as an intracanal medicament against Enterococcus faecalis. Gen Dent, 54, 319-322. Sabir A, Tabbu CR, Agustiono P, Sosroseno W, 2005. Histological analysis of rat dental pulp tissue capped with propolis. J Oral Sci, 47, 135-138. 424 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Shieh DB, Yang SR, Shi XY, Wu YN, Wu SN, 2005. Properties of BK(Ca) channels in oral keratinocytes. J Dent Res, 84, 468-473. Silva FB, Almeida JM, Sousa SM, 2004. Natural medicaments in endodontics -- a comparative study of the anti-inflammatory action. Braz Oral Res, 18, 174-179. Sonmez S, Kirilmaz L, Yucesoy M, Yucel B, Yilmaz B, 2005. The effect of bee propolis on oral pathogens and human gingival fibroblasts. J Ethnopharmacol, 102, 371-376. Steinberg D, Kaine G, Gedalia I, 1996. Antibacterial effect of propolis and honey on oral bacteria. Am J Dent, 9, 236-239. Uzel A, Sorkun K, Oncag O, Cogulu D, Gencay O, Salih B, 2005. Chemical compositions and antimicrobial activities of four different Anatolian propolis samples. Microbiol Res, 160, 189-195. ID 1646: “Protein hydrolysate” and “Insulin secretion and blood sugar levels” 1 Avis de la commission interministérielle d‘étude des produits destinés à une alimentation particulière (CEDAP) en date du 18 décembre 1996 sur les recommandations relatives au caractère non trompeur des seuils des allégations nutritionnelles fonctionnelles. BOCCRF (Bulletin Officiel de la Concurrence, de la Consommation et de la Répression des fraudes) du 7 octobre 1997. Berger S, Joondeph HC, Rachmeler B, 1964. The effect of protein ingestion on plasma insulin concentration. 37th Annual Meeting, Evanston, IL, 841. Berger S and Vongaraya N, 1966. Insulin response to ingested protein in diabetes. Diabetes, 15, 303-306. Burggraaf J, Geerts BF, M de Kam, 2008. A study on the effects on plasma insulin and glucose after a single meal replacement (InsuVital) with or without added Leucine in patients with T2DM. CHDR (Centre for Human Drug Research) Report. Calbet JA and MacLean DA, 2002. Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. J Nutr, 132, 2174-2182. Claessens M, Calame W, Siemensma AD, Saris WH, van Baak MA, 2007. The thermogenic and metabolic effects of protein hydrolysate with or without a carbohydrate load in healthy male subjects. Metabolism, 56, 1051-1059. Claessens M, Calame W, Siemensma AD, van Baak MA, Saris WH, 2007. The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects. Eur J Clin Nutr, 63, 48-56. Claessens M, Saris WH, van Baak MA, 2007. Glucagon and insulin responses after ingestion of different amounts of intact and hydrolysed proteins. Br J Nutr, 100, 61-69. Conn JW and Newburgh LH, 1936. The Glycemic Response to Isoglucogenic Quantities of Protein and Carbohydrate. J Clin Invest, 15, 665-671. Floyd JC, Jr., Fajans SS, Conn JW, Knopf RF, Rull J, 1966. Stimulation of insulin secretion by amino acids. J Clin Invest, 45, 1487-1502. Floyd JC, Jr., Fajans SS, Conn JW, Knopf RF, Rull J, 1966. Insulin secretion in response to protein ingestion. J Clin Invest, 45, 1479-1486. Floyd JC, Jr., Fajans SS, Pek S, Thiffault CA, Knopf RF, Conn JW, 1970. Synergistic effect of essential amino acids and glucose upon insulin secretion in man. Diabetes, 19, 109-115. Frid AH, Nilsson M, Holst JJ, Bjorck IM, 2005. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr, 82, 69-75. Hubbard R, Kosch CL, Sanchez A, Sabate J, Berk L, Shavlik G, 1989. Effect of dietary protein on serum insulin and glucagon levels in hyper- and normocholesterolemic men. Atherosclerosis, 76, 55-61. Kaastra B, Manders RJ, Van Breda E, Kies A, Jeukendrup AE, Keizer HA, Kuipers H, Van Loon LJ, 2006. Effects of increasing insulin secretion on acute postexercise blood glucose disposal. Med Sci Sports Exerc, 38, 268-275. 425 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Kloek J, Pasupuleti VK, van Loon LJC, 2008. Proteins, Protein Hydrolysates, and Bioactive Peptides in the Management of Type 2 Diabetes. In: Nutraceuticals, Glycemic Health and Type 2 Diabetes. Pasupuleti VK and Anderson JW (eds.). Wiley-Blackwell, Chichester. Krezowski PA, Nuttall FQ, Gannon MC, Bartosh NH, 1986. The effect of protein ingestion on the metabolic response to oral glucose in normal individuals. Am J Clin Nutr, 44, 847-856. Lang V, Bellisle F, Alamowitch C, Craplet C, Bornet FR, Slama G, Guy-Grand B, 1999. Varying the protein source in mixed meal modifies glucose, insulin and glucagon kinetics in healthy men, has weak effects on subjective satiety and fails to affect food intake. Eur J Clin Nutr, 53, 959-965. Lavigne C, Tremblay F, Asselin G, Jacques H, Marette A, 2001. Prevention of skeletal muscle insulin resistance by dietary cod protein in high fat-fed rats. Am J Physiol Endocrinol Metab, 281, E62-71. Lecerf JM, Lamotte C, Boukandoura B, Cayzeele A, Libersa C, Delannoy C, Borgiès B, 2008. Effects of two marine dietary supplements with high calcium content on calcium metabolism and biochemical marker of bone resorption. Eur J Clin Nutr. Epub 2007 May 23, 62, 879-884. Manders RJ, Wagenmakers AJ, Koopman R, Zorenc AH, Menheere PP, Schaper NC, Saris WH, van Loon LJ, 2005. Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr, 82, 76-83. Manders RJ, Koopman R, Sluijsmans WE, van den Berg R, Verbeek K, Saris WH, Wagenmakers AJ, van Loon LJ, 2006. Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces postprandial blood glucose excursions in Type 2 diabetic men. J Nutr, 136, 1294-1299. Manders RJ, Praet SF, Meex RC, Koopman R, de Roos AL, Wagenmakers AJ, Saris WH, van Loon LJ, 2006. Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Diabetes Care, 29, 2721-2722. Newsholme P, Brennan L, Bender K, 2006. Amino Acid Metabolism, β-Cell Function, and Diabetes. Diabetes, 55(Suppl. 2). Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM, 2004. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr, 80, 1246-1253. Nilsson M, Holst JJ, Bjorck IM, 2007. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr, 85, 996-1004. Nuttall FQ, Mooradian AD, Gannon MC, Billington C, Krezowski P, 1984. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. Diabetes Care, 7, 465-470. Nuttall FQ, 1985. Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content. Am Coll Nutrition, 4, 437-450. Nuttall FQ and Gannon MC, 1990. Metabolic response to egg white and cottage cheese protein in normal subjects. Metabolism, 39, 749-755. Pallotta JA and Kennedy PJ, 1968. Response of plasma insulin and growth hormone to carbohydrate and protein feeding. Metabolism, 17, 901-908. Pisters PW, Restifo NP, Cersosimo E, Brennan MF, 1991. The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. Metabolism, 40, 59-65. Prentice A, 2003. Passclaim-Bone health and osteoporosis. Rabinowitz D, Merimee TJ, Maffezzoli R, Burgess JA, 1966. Patterns of hormonal release after glucose, protein, and glucose plus protein. Lancet, 2, 454-456. Riccardi G, Aggett P, Brighenti F, Delzenne N, Frayn K, Nieuwenhuizen A, Pannemans D, Theis S, Tuijtelaars S, Vessby B, 2004. PASSCLAIM--body weight regulation, insulin sensitivity and diabetes risk. Eur J Nutr, 43 Suppl 2, II7-II46. SCF, 2003. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Calcium. Standards Australia Ltd, 2007. New yardstick for GI claims 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 426 37 Tessari P, Kiwanuka E, Cristini M, Zaramella M, Enslen M, Zurlo C, Garcia-Rodenas C, 2007. Slow versus fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2 diabetes. Diabetes Metab Res Rev, 23, 378-385. Tremblay F, Lavigne C, Jacques H, Marette A, 2003. Dietary cod protein restores insulin-induced activation of phosphatidylinositol 3-kinase/Akt and GLUT4 translocation to the T-tubules in skeletal muscle of high-fat-fed obese rats. Diabetes, 52, 29-37. van Loon LJ, Saris WH, Verhagen H, Wagenmakers AJ, 2000. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. Am J Clin Nutr, 72, 96-105. van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, Keizer HA, 2003. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care, 26, 625-630. van Loon C and Luc J, 2007. Amino acids as pharmaco-nutrients for the treatment of type 2 diabetes. Immunology, Endocrine & Metabolic Agents-Medicinal Chemistry 7, 39-48. von Post-Skagegard M, Vessby B, Karlstrom B, 2006. Glucose and insulin responses in healthy women after intake of composite meals containing cod-, milk-, and soy protein. Eur J Clin Nutr, 60, 949-954. ID 1647: “Quercetin” and “Antioxidant properties” 38 39 40 41 42 1 2 Quercetin Monograph. 1998. Alt Med Rev, 3, 14-143. Beatty ER, O'Reilly JD, England TG, McAnlis GT, Young IS, Geissler CA, Sanders TA, Wiseman H, 2000. Effect of dietary quercetin on oxidative DNA damage in healthy human subjects. Br J Nutr, 84, 919925. Caballero B, Allen L, Prentice A, 2005. Phytochemicals - Classification and occurrence, Potential Health Effects, Epidemiological Factors. In: Encyclopedia of Human Nutrition. Elsevier, Oxford. Choi JS, Choi BC, Choi KE, 2004. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm, 61, 2406-2409. Cotelle N, 2001. Role of flavonoids in oxidative stress. Curr Top Med Chem, 1, 569-590. Cushnie TP and Lamb AJ, 2005. Antimicrobial activity of flavonoids. Int J Antimicrob Agents, 26, 343356. Day AJ and Williamson G, 1999. Human metabolism of dietary quercetin glycosides. Basic Life Sci, 66, 415-434. Day AJ and Williamson G, 2001. Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma. Br J Nutr, 86 Suppl 1, S105-110. DiCenzo R, Frerichs V, Larppanichpoonphol P, Predko L, Chen A, Reichman R, Morris M, 2006. Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults. Pharmacotherapy, 26, 1255-1261. Dubick MA, 2002. Wine polyphenols and protection from atherosclerosis and ischemic heart disease: Drink to your health? In: Phytochemicals in Nutrition and Health. Meskin M, Bidlack WR, Davies AJ, Omaye ST (eds.). CRC, Boca Raton, 41-60 Dupuy J, Larrieu G, Sutra JF, Lespine A, Alvinerie M, 2003. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet Parasitol, 112, 337-347. Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, Parantainen J, Aro A, 2000. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol, 56, 545-553. Erlund I, Marniemi J, Hakala P, Alfthan G, Meririnne E, Aro A, 2003. Consumption of black currants, lingonberries and bilberries increases serum quercetin concentrations. Eur J Clin Nutr, 57, 37-42. Erlund I, Freese R, Marniemi J, Hakala P, Alfthan G, 2006. Bioavailability of quercetin from berries and the diet. Nutr Cancer, 54, 13-17. 427 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Goldberg G, 2003. Plants diet and health the report of a British Nutrition Foundation task force. Blackwell Science. Graefe EU, Derendorf H, Veit M, 1999. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther, 37, 219-233. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M, 2001. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol, 41, 492-499. Griffiths G, Trueman L, Crowther T, Thomas B, Smith B, 2002. Onions--a global benefit to health. Phytother Res, 16, 603-615. Hempel J, Pforte H, Raab B, Engst W, Bohm H, Jacobasch G, 1999. Flavonols and flavones of parsley cell suspension culture change the antioxidative capacity of plasma in rats. Nahrung, 43, 201-204. Hertog M, Van Peppel G, Verhoeven D, 1997. Potentially anticarcinogenic secondary metabolites from fruits and vegetables. In: Phytochemistry of Fruit and Vegetables. Tomas- Barberan F and Robins R (eds.). Oxford University Press, New York, 313-329. Hollman PC and Katan MB, 1999. Health effects and bioavailability of dietary flavonols. Free Radic Res, 31 Suppl, S75-80. Hubbard GP, Wolffram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA, 2006. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr, 96, 482-488. Jovanovic SV and Simic MG, 2000. Antioxidants in nutrition. Ann NY Acad Sci, 899, 326-334. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT, 2005. The antitumor activities of flavonoids. In Vivo, 19, 895-909. Kawanishi S, Oikawa S, Murata M, 2005. Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal, 7, 1728-1739. Kim KA, Park PW, Kim HK, Ha JM, Park JY, 2005. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol, 45, 941-946. Kitamura M and Ishikawa Y, 1999. Oxidant-induced apoptosis of glomerular cells: intracellular signaling and its intervention by bioflavinoid. Kidney Int, 56, 1223-1229. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A, 2002. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr, 76, 560-568. Kuo SM, 2002. Flavonoids and gene expression in mammalian cells. Adv Exp Med Biol, 505, 191-200. Lambert JD, Hong J, Yang GY, Liao J, Yang CS, 2005. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr, 81, 284S-291S. Lamson DW and Brignall MS, 2000. Antioxidants and cancer, part 3: quercetin. Altern Med Rev, 5, 196208. Leake D, 1997. The possible role of antioxidants in fruit and vegetables in protecting against coronary artery disease. In: Phytochemistry of Fruit and Vegetables. Tomas- Barberan F and Robins R (eds.). Oxford University Press, New York, 287-311. Lee KW and Lee HJ, 2006. The roles of polyphenols in cancer chemoprevention. Biofactors, 26, 105-121. Lopez-Lazaro M, 2002. Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anticancer Agents, 2, 691-714. MacRae HS and Mefferd KM, 2006. Dietary antioxidant supplementation combined with quercetin improves cycling time trial performance. Int J Sport Nutr Exerc Metab, 16, 405-419. Manach C, Williamson G, Morand C, Scalbert A, Remesy C, 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr, 81, 230S-242S. 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 428 37 Mertens-Talcott SU, Talcott ST, Percival SS, 2003. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J Nutr, 133, 2669-2674. Moon YJ, Wang X, Morris ME, 2006. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro, 20, 187-210. Morrow DM, Fitzsimmons PE, Chopra M, McGlynn H, 2001. Dietary supplementation with the antitumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res, 480-481, 269-276. Murota K and Terao J, 2003. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys, 417, 12-17. Neuhouser ML, 2004. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer, 50, 1-7. Okamoto T, 2005. Safety of quercetin for clinical application (Review). Int J Mol Med, 16, 275-278. O'Reilly JD, Sanders TA, Wiseman H, 2000. Flavonoids protect against oxidative damage to LDL in vitro: use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radic Res, 33, 419-426. Pacifici GM, 2004. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int J Clin Pharmacol Ther, 42, 488-495. Perez-Vizcaino F, Duarte J, Andriantsitohaina R, 2006. Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic Res, 40, 1054-1065. Plotņikov M and Tjukavkina N, 2005. Ārstniecības preparāti uz dikventina bāzes. Tomskas universitātes izdevums. Prior RL, 2003. Fruits and vegetables in the prevention of cellular oxidative damage. Am J Clin Nutr, 78, 570S-578S. Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM, 2005. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res, 574, 124-138. Ross JA and Kasum CM, 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr, 22, 19-34. Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB, 2002. Flavonol and flavone intakes in US health professionals. J Am Diet Assoc, 102, 1414-1420. Schilcher H, Kammerer S, Volkmann D, 2003. Leitfaden Phytotherapie. Urban & Fischer, Stuttgart. Sengupta A, Ghosh S, Bhattacharjee S, 2004. Allium vegetables in cancer prevention: an overview. Asian Pac J Cancer Prev, 5, 237-245. Serafini M, Bugianesi R, Salucci M, Azzini E, Raguzzini A, Maiani G, 2002. Effect of acute ingestion of fresh and stored lettuce (Lactuca sativa) on plasma total antioxidant capacity and antioxidant levels in human subjects. Br J Nutr, 88, 615-623. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J, 1999. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology, 54, 960-963. Terao J and Piskula MK, 1999. Flavonoids and membrane lipid peroxidation inhibition. Nutrition, 15, 790791. Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg. Valenzuela A, Sanhueza J, Nieto S, 2003. Cholesterol oxidation: health hazard and the role of antioxidants in prevention. Biol Res, 36, 291-302. van der Woude H, Gliszczynska-Swiglo A, Struijs K, Smeets A, Alink GM, Rietjens I, 2003. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer letters, 200, 41-47. 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 429 59 60 61 62 63 64 65 Vitaglione P, Morisco F, Caporaso N, Fogliano V, 2004. Dietary antioxidant compounds and liver health. Crit Rev Food Sci Nutr, 44, 575-586. Walle T, Walle UK, Halushka PV, 2001. Carbon dioxide is the major metabolite of quercetin in humans. J Nutr, 131, 2648-2652. Weisburger JH, 1999. Mechanisms of action of antioxidants as exemplified in vegetables, tomatoes and tea. Food Chem Toxicol, 37, 943-948. Williams RJ, Spencer JP, Rice-Evans C, 2004. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med, 36, 838-849. Williamson G and Manach C, 2005. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr, 81, 243S-255S. Wiseman H, 1999. The bioavailability of non-nutrient plant factors: dietary flavonoids and phytooestrogens. Proc Nutr Soc, 58, 139-146. Woodman OL and Chan E, 2004. Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol, 31, 786-790. ID 1648: “Red yeast rice (Monascus Purpureus / Ang-Khak)” and “Cholesterol” 1 2 3 Monascus purpureus (Red Yeast Rice) Monograph 2004. Alternative Medicine Review, 9, 209. Bliznakov EG, 2000. More on the Chinese red-yeast-rice supplement and its cholesterol-lowering effect. Am J Clin Nutr, 71, 152-154. Cicero AF, Brancaleoni M, Laghi L, Donati F, Mino M, 2005. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med, 13, 273-278. Havel RJ, 1999. Dietary supplement or drug? The case of cholestin. Am J Clin Nutr, 69, 175-176. Heber D, 1999. Dietary supplement or drug? The case for cholestin. Am J Clin Nutr, 70, 106-108. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL, 1999. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr, 69, 231-236. Jia Q, 2005. Traditional Chinese Medicine (TCM) Could Make‖ Health for One ‗True. Journoud M and Jones PJ, 2004. Red yeast rice: a new hypolipidemic drug. Life Sci, 74, 2675-2683. Leistner L, 1994. Die ernährungsphysiologische Bedeutung von Angkak. Fleischwirtschaft (Frankfurt), 74, 772-778. Li Z, Seeram NP, Lee R, Thames G, Minutti C, Wang HJ, Heber D, 2005. Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers. Journal of Alternative & Complementary Medicine: Research on Paradigm, Practice, and Policy, 11, 1031-1038. Lin CC, Li TC, Lai MM, 2005. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol, 153, 679-686. Liu L, Zhao SP, Cheng YC, Li YL, 2003. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem, 49, 1347-1352. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V, 2006. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine, 1, 4. Man RYK, Lynn EG, Cheung F, Tsang PSY, Karmin O, 2002. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Molecular and cellular biochemistry, 233, 153-158. O'Mathuna D, 1999. Cholestin used to treat hypercholesterolemia. Drug Utilization Review, 15, 71-75. 4 5 6 7 8 9 10 11 12 13 14 15 430 16 Patrick L and Uzick M, 2001. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev, 6, 248-271. Swanson B, Keithley JK, Zeller JM, Sha BE, 2002. A pilot study of the safety and efficacy of supplemental arginine to enhance immune function in persons with HIV/AIDS. Nutrition, 18, 688-690. Ternes W, Täufel A, Tunger L, Zobel M, 2005. Lebensmittel-Lexikon. Behr's Verlag, Hamburg. Thompson Coon JS and Ernst E, 2003. Herbs for serum cholesterol reduction: a systematic view. J Fam Pract, 52, 468-478. Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, Yu P, Yu L, Chen L, Zhu JS, 1997. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Current Therapeutic Research, 58, 964-978. Wei W, Li C, Wang Y, Su H, Zhu J, Kritchevsky D, 2003. Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits. J Nutr Biochem, 14, 314-318. ID 1650: “Rye Grass Pollen” and “Maintenance of normal urinary function” 17 18 19 20 21 1 2 3 4 Barry MJ and Roehrborn CG, 2001. Benign prostatic hyperplasia. BMJ, 323, 1042-1046. Braun L and Peyer P, 1993. A multicentre placebo-controlled study on the efficacy and tolerability of adenoprostal in patients with benign prostatic hyperplasia (BPH). Tribuna Medica Ticinese, 58. Buck AC, Rees RW, Ebeling L, 1989. Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol, 64, 496-499. Buck AC, Cox R, Rees RW, Ebeling L, John A, 1990. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol, 66, 398-404. Dutkiewicz S, 1996. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol, 28, 49-53. Hayashi J, Mitsui H, Yamakawa G, Suga A, Kai A, Shimabukuro T, Yanagi K, Fujisawa S, Takihara H, Kaneda Y, et al., 1986. [Clinical evaluation of Cernilton in benign prostatic hypertrophy]. Hinyokika Kiyo, 32, 135-141. Horii A, Iwai S, Maekawa M, Tsujita M, 1985. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy]. Hinyokika Kiyo, 31, 739-746. Jodai A, Maruta N, Shimomae E, Sakuragi T, Shindo K, Saito Y, 1988. [A long-term therapeutic experience with Cernilton in chronic prostatitis]. Hinyokika Kiyo, 34, 561-568. MacDonald R, Ishani A, Rutks I, Wilt TJ, 2000. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int, 85, 836-841. Rugendorff EW, Weidner W, Ebeling L, Buck AC, 1993. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol, 71, 433-438. Ueda K, Jinno H, Tsujimura S, 1985. [Clinical evaluation of Cernilton on benign prostatic hyperplasia]. Hinyokika Kiyo, 31, 187-191. Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G, 2000. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev, CD001042. Yasumoto R, Kawanishi H, Tsujino T, Tsujita M, Nishisaka N, Horii A, Kishimoto T, 1995. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther, 17, 82-87. 5 6 7 8 9 10 11 12 13 431 ID 1652: “Silica / Silicious earth” and “Essential part of the connective tissues, skin and hair” 1 2 3 4 5 6 7 8 9 10 Bellia JP, Birchall JD, Roberts NB, 1994. Beer: a dietary source of silicon. Lancet, 343, 235. Carlisle EM, 1976. In vivo Requirement for Silicon in Articular Cartilage and Connective Tissue Formation in the Chick. Journal of Nutrition, 106, 478. Carlisle EM, 1980. Biochemical and Morphological Changes Associated with Long Bone Abnormalities in Silicon Deficiency. Journal of Nutrition, 110, 1046. Carlisle EM, 1982. The nutritional essentiality of silicon. Nutr Rev, 40, 193-198. Carlisle E, 1984. Silicon. In: Biochemistry of the Essential Ultratrace Elements. Frieden E (ed.) Plenum Press, New York, 257-291. Carlisle EM and Alpenfels WF, 1984. The role of silicon in proline synthesis. Federation Proceedings, 43, 680. EFSA-NDA Panel, 2004. Opionion on tolerable upper intake level of silicon EFSA-Q-2003-018. The EFSA Journal The EFSA Journal 60, 1-11. Expert Group on Vitamins and Minerals, 2003. Safe Upper Levels for Vitamins and Minerals. Hahn A, 2006. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart. IoM (Institute of Medicine), 2000. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC. Jugdaohsingh R, Tucker KL, Qiao N, Cupples LA, Kiel DP, Powell JJ, 2004. Dietary Silicon Intake Is Positively Associated With Bone Mineral Density in Men and Premenopausal Women of the Framingham Offspring Cohort. Journal of Bone and Mineral Research, 19, 297-307. Kelsay JL, Behall KM, Prather ES, 1979. Effect of fiber from fruits and vegetables on metabolic responses of human subjects, II. Calcium, magnesium, iron, and silicon balances. American Journal of Clinical Nutrition, 32, 1876. Lassus A, 1993. Colloidal silicic acid for oral and topical treatment of aged skin, fragile hair and brittle nails in females. J Int Med Res, 21, 209-215. Lassus A, 1996. The effect of silicol gel compared with placebo on papulopustular acne and sebum production. A double-blind study. Journal of international medical research, 24, 340-344. Lassus A, 1997. Colloidal silicic acid for the treatment of psoriatic skin lesions, arthropathy and onychopathy. A pilot study. J Int Med Res, 25, 206-209 Loeper J, Goy J, Fragny M, Troniou R, Bedu O, 1988. Study of fatty acids in atheroma induced in rabbits by an atherogenic diet with or without silicon i.v. treatment. Life Sci, 42, 2105-2112. Nielsen FH, 1991. Nutritional requirements for boron, silicon, vanadium, nickel, and arsenic: current knowledge and speculation. FASEB J, 5, 2661-2667. Pennington JAT, 1991. Silicon in foods and diets. Food Addit Contam, 8, 97-118. Popplewell JF, King SJ, Day JP, Ackrill P, Fifield LK, Cresswell RG, di Tada ML, Liu K, 1998. Kinetics of uptake and elimination of silicic acid by a human subject: A novel application of 32Si and accelerator mass spectrometry. Journal of Inorganic Biochemistry, 69, 177-180. Reffitt DM, Jugdaohsingh R, Thompson RPH, Powell JJ, 1999. Silicic acid: its gastrointestinal uptake and urinary excretion in man and effects on aluminium excretion. Journal of Inorganic Biochemistry, 76, 141147. Ruislip S, 2001. The effects of Silicol Skin on moderate to severe acne: UK field survey. Advances in Therapy, 18, 93-99. Schwarz K, 1973. A Bound Form of Silicon in Glycosaminoglycans and Polyuronides. Proceedings of the National Academy of Sciences, 70, 1608-1612. 432 11 12 13 14 15 16 17 18 19 20 21 22 Altabre C. 2006. 2005. 42. Afaq F and Mukhtar H. Holum JR. John Wiley & Sons Inc. 113-118. 2005. 28. Villota R and Hawkes JG. Cancelo MJ. 23. 222-230. prospective and non-randomized trial. 1991. Imbert P. Dietary silicon and bone health. ID 1653: “Sodium bicarbonate” and “Supports an optimal pH environment in the stomach” 1 2 3 4 5 Brady JE. 2005. 1999. Seaborn CD and Nielsen FH. 85-92. 1999. Exp Dermatol. Haya J. and ornithine transaminase enzyme activity in liver. Natural medicines comprehensive database.) Merr in climacteric symptomatology: a multicentric. Lancet. 1986. Italy. Albert A. Llaneza P. 289-321. The American Heritage® Science Dictionary. 1977. Olson J. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L. Michaelsen KF. Shamir R. 83. 2002. Ribes C. Adlercreutz H. Goldin B. Sripanyakorn S. Goulet O. Lancet. 1992. Turck D. Antacids and Anti-Reflux Agents. CRC critical reviews in food science and nutrition.com. Rieu D. Chantre P. 13-13. http://www. Dietary phyto-oestrogens and the menopause in Japan. Puntis J. open. Russell JW. CRC Press. Julia D. Duran M. 538-539. Lauritzen C and Studd J (eds. 247-258. Shike M. 30. 2002. Punsar S. Merck. Buendia E. 15. 44. Seaborn CD and Nielsen FH. Koletzko B. Adlercreutz H. Houghton Mifflin Harcourt. Adlercreutz H. Quereda F. 1233. J Pediatr Gastroenterol Nutr. Cabero A. Manubens M. Brains and Blood Vessels? Nutrition Today. Milan. Silicon: A Nutritional Beneficience for Bones. 2009. 483-525. 339. Washington N. 352-361.23 24 25 26 27 28 29 30 Schwarz K. Ross A. Baltimore. Therapeutic Research Faculty. Phytoestrogens and breast cancer. Silicon deprivation decreases collagen formation in wounds and bone. Taylor & Francis. Phyto-oestrogens and cancer. 9. Ricci BA. 1974. Symposium on Efficacy and Safety of Isoflavones for Climacteric Women. Adlercreutz H. Minano A. Modern Nutrition in Health and Disease. 2006. Botanical antioxidants in the prevention of photocarcinogenesis and photoaging. Lancet Oncol. Lignans and human health. Soy protein infant formulae and follow-on formulae: a commentary by the ESPGHAN Committee on Nutrition. Food applications and the toxicological and nutritional implications of amorphous silicon dioxide. 1.). Vazquez F. 89. In: Current Management of Menopause. 2003. J Steroid Biochem Mol Biol. Rigo J. Lanchares JL. 678-684. Elsevier Health Sciences. Biological Trace Element Research. Phytoestrogens. Thompson RPH. 1993. Williams & Wilkins. Hamalainen E. Boca Raton.naturaldatabase. 3. London and New York. Axelsson I. Crit Rev Clin Lab Sci. ID 1654: “Soy Isoflavones” and “Menopause” 1 2 3 4 5 6 7 8 Program of symposium 13-14 may. 271-283. Chemistry: Matter and Its Changes. Porter RS and Kaplan JL. 2000. Powell JJ. Silicon Dioxide And Certain Silicates. Phytomedicine. Drugs and Pharmacology for Nurses. Adlercreutz H. The Merck Manual of Medical Information. 2002. Szajewska H. 364-373. Hopkins SJ. Gorbach S. WHO (World Health Organisation). Shils M. Karvonen MJ. Kleinedler S and Spitz S. Seventeenth Report of the Joint FAO/WHO Expert Committee on Food Additives. Inverse relation of silicon in drinking water and atherosclerosis in Finland. 2007. Nutrition Bulletin. 9 433 . Agostoni C. Castelo-Branco C. Jugdaohsingh R. Baro F. 2002. Am J Clin Nutr. Climacteric. The nature and utility of the phytoestrogens: a review of the evidence. 134. Goodwin L. 1998. Bonaiuto M. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic. 15. discussion 417S-420S. Washnock CS. J Nutr. Bonaccorsi G. Is there a difference between soy foods and soy supplements? Johns-HopkinsMed-Lett-Health-After-50. 8. Alekel DL. Soy isoflavones and saponins: A natural soy solution to age-old problem. J Nutr. 2000. 2001. Forini E. 13. Pansini F. Indole-3-carbinol is a negative regulator of estrogen. 94. Allen JK. Estrogens and lipids. 12. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. 2000. 11-33. 3068-3075. Arjmandi BH. 70. Cancellieri F. Bonaccorsi G. 8. 1999. Stewart JW. Polito F. 30 31 434 . quiz 23. 2004. 101-113. Auborn KJ. Toda T. Gaudio A. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol. 20. 5. Chen D. Haarbo J. Dietary phytoestrogens and estrogen inhibit experimental atherosclerosis. Christiansen C. Albertazzi P. Altavilla D. 2006. 173-185. Albertazzi P. 1998. Curtis C. A review of non-hormonal options for the relief of menopausal symptoms. 1999. 12-15. 42. Atkinson C. De Aloysio D. Frisina A. Oosthuizen W. Harvard women's health watch. Arjmandi BH and Smith BJ. placebo-controlled study. Rosen EM. Scollen S. Fan S. Chandraskaren A. Bitto A. Breinholt V. Cannata ML.10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Albertazzi P. Minutoli L. 91. 464S-474S. 92. Smith BM. Anderson JW. Squadrito F. What we still don't know about soy. Day NE. Soy isoflavones' osteoprotective role in postmenopausal women: mechanism of action. 2007. 229-231. Lubrano C. Pansini F. Agro food industry hi tech 10. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Albertazzi P and Purdie D. 2002. 2002. 14. Williams DE. Alexandersen P. Cardiovascular and renal benefits of dry bean and soybean intake. Mazzaferro S. Prescrire Int. 133. and phytoestrogens reduce cardiovascular risk markers after menopause? Postgrad Med. Can HRT designer estrogens. Harv Health Lett. 3. No authors listed. Adamo EB. 662S663S. 23-30. Kwiterovich PO. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Morton MS. 2006. Marini H. Zanotti L. 130. Obstet Gynecol. 2470S-2475S. J Nutr. J Am Coll Nutr. postmenopausal women: a two-year randomized. Menopause. The role of phytoestrogens in the prevention and treatment of osteoporosis in ovarian hormone deficiency. No authors listed. Loktionov A. Soy and cardiovascular disease: cholesterol lowering and beyond. 111. Altern Med Rev. 2007. 4. Bingham SA. D'Anna R. De Aloysio D. Ariyo AA and Villablanca AC. 2007. Frisina N. Am J Clin Nutr. Anthony MS. 1999. 2003. 130-137. Becker DM. No authors listed. 62-63. 6-11. Modest protective effects of isoflavones from a red clover-derived dietary supplement on cardiovascular disease risk factors in perimenopausal women. but there's still a place for soy in our diets. 106-114. J Clin Endocrinol Metab. double-blind. Bottazzi M. 2002. 72. Carter TH. 1759-1764. Lindenstruth KA. No authors listed. Arditi T and Meredith T. Treat Endocrinol. Menopause. Corrado F. 1-3. 151-159. Soy protein and isoflavones haven't held up well in clinical trials. 844-852. Phytoestrogens and endometrial hyperplasia. 2000. 6. The effect of dietary soy supplementation on hot flushes. The not-soy-good results. Atteritano M. Germain AS. 2004. Peterson CT. Soy isoflavones. 11. 398S-402S. J Nutr Biochem. 32. 2001. Maturitas. and evidence of an interaction with ApoE genotype in 49-65 year-old women. 2001. 376-378. Hanson KB. No authors listed. S18-27.and postmenopausal women: the Soy Estrogen Alternative Study. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Fleshner N. 50. Willett WC. Kimiagar M. Brand RM and Jendrzejewski JL. 2002. Keyler DE. J Med Food. Red clover isoflavones and menopausal health. Lopaczynski W. Forum Nutr. Ojumu A. 1191-1201. 76. 1191-1200. 22. Pharmacol Ther. Breslau NA. Composition. Nutritional aspects of prostate cancer: a review. Naughton MJ. red blood cell uptake. 927-935. Soya and Health. Can J Urol. Morgan TM. Burke GL. 2002. Drugs. 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 435 . Pak CY. Padyab M. Esmaillzadeh A. Coward L. 2003. Baker JI. Busby MG. Briefing Paper. Clinical Reviews in Bone and Mineral Metabolism. Am J Clin Nutr. 2002. 157-177. Zeisel SH. 10 Suppl 1. Hendrich S. 2002. 69-72. Soy protein and isoflavone effects on vasomotor symptoms in peri. Buttyan R. Bland DR. Brinkley L. 2005. Journal of Cellular Biochemistry. Effect of high-dose isoflavones on cognition. 2003. 109-123. British Nutrition Foundation. Effect of genistein on in vitro and in vivo models of cancer. 2000. 2004. Blackwell Publishing. androgens. Short-term Effects of Phytoestrogen-rich Diet on Postmenopausal Women. Schell MJ. Barnes S. Rosier A. Wisniewski A. Blumenfeld AJ. 85. Tanos V. Plants: Diet and Health. 317327. J Clin Endocrinol Metab. J Endocrinol Invest. Black TM. Bhandari A. Bosland MC. Chemoprevention strategies for prostate cancer. Am J Clin Nutr. Bloedon LT. Bruno T. 10. Leggett K. Altern Med Rev. Effects of oral genistein in mice. Melamed J. Investig. Hypercholesterolemia and endothelium dysfunction: role of dietary supplementation as vascular protective agents. 32. J Dermatol Sci. Bemis DL. Singh AK. Walden PD. Shmueli A. 1995. Pediatr Pathol Mol Med. McCormick DL. Hu FB. 131-141. Am J Clin Nutr. Soy and its isoflavones: a review of their effects on bone density. Dobs AS. Zeleniuch-Jacquotte A. 7. 150-155. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. Yao F. and serum protein binding of phytoestrogens extracted from commercial kudzu-root and soy preparations. Albright C. Washburn SA. Vitolins MZ. 147-153. 59. 2. quality of life. Lumey LH. Anthony M. Casselman B. 11 Suppl 2. Menopause. 2001. J Nutr. 735-741. Schenker JG. Brynin R. Menopause.32 Azadbakht L. Branca F and Lorenzetti S. Song MY. 66. Beneficial role of dietary phytoestrogens in obesity and diabetes. 15. Katz AE. Crawford SE. Huang L. 2009. 100-111. Curr Vasc Pharmacol. Birt DF. Oxford. 125. 1997. Clinical trials of natural products as chemopreventive agents for prostate cancer. Dix KJ. 341-356. discussion 936. Health effects of phytoestrogens. Benlhabib E. Shaoul R. Expert Opin. BNF (British Nutrition Foundation). Eur J Cancer Prev. 7. 4-7. Barnes S. Wang W. 2006. Jeffcoat AR. 1126-1137. 140-146. 777S-783S. Brzezinski A. Hill KD. Button BJ and Patel N. 2002. John M. 45-52. 2007. 2003. and lipoprotein in post-menopausal women. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. 2002. Basaria S. 76. Dietary agents in cancer prevention: flavonoids and isoflavonoids. 1988. Reenstra WW. 4. Adlercreutz H. 2004. Bhathena SJ and Velasquez MT. Mehrabi Y. 90. 1995. Crowell JA. Boak L and Chin-Dusting JP. 5. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Br Menopause Soc. Dupree K. Topical treatment with (-)-epigallocatechin-3-gallate and genistein after a single UV exposure can reduce skin damage. Thomas BF. Phytoestrogens for osteoporosis. Trachtenberg J. 2008. 2004. 2. Legault C. 89-94. Barentsen R. Peterson TG. Chen CY. Boca Raton. Cassidy A. CRC press. De Lucia D. 2004. 58. Cassidy A and De Pascual-Teresa S. Cassidy A and Faughnan M. Landgren BM. Pauli GF. Menopause. 2005. 2006. Matos MP. 73. Chiechi LM. 17-21. Wilczek B. Lise Nielsen I. Panariello S. In: Nutritional Aspects of Bone Health. Ho SC.55 56 Cai DJ. 13. 2003. New SA and Bonjour J-P (eds. Marelli G. 246-254. Carroll DG. Role of diet in prostate cancer development and progression. Spence LA. 2003. controlled trial. Minerva Ginecol. Weaver CM. Nappo C. 42. Gustafsson JA. Cross H. 2003. Nonhormonal therapies for hot flashes in menopause. (hops) with an emphasis on estrogenic properties. D'Amore M. The hypoglycemic effects of soy isoflavones on postmenopausal women. 2004. Laselva G. Giovannucci EL. and calcium intake: a double-blind. 85-92. Rimbach G. 2006. Dai Q. 2007. Phytother Res. Critical review of health effects of soyabean phyto-oestrogens in postmenopausal women. 301-326. Dietary Isoflavones and Coronary Artery Disease-Proposed Molecular Mechanisms of Action. 457-464. Unfer V. Steiner C. Woo JL. 9. Chen Z. Câmara MT. 1096-1099. 13. 8152-8160. 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 436 . Chadwick LR. In: Nutrigenomics. Ferrari A. 663. 82-87. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. Ho SS. Shaw NS. Cambridge. 71-81. Loizzi P. Phytomedicine. Nutrition Bulletin. Urol Clin North Am. 972-978.). Farnsworth NR. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized. 2006. Schiavelli MP. Wolk A. Valerio T. 421-438. 666. Packer L (eds. Cheng G. Atkins S. 23. 20. Chester EA. Cheng SY. Proc Nutr Soc. Casini ML. D'Ambrosio F. Chiechi LM. Soy for cardiovascular indications. 57. Shu XO. Menopause. Manios Y. 119-131. 2002. 489-496. Occhiuto F. J Br Menopause Soc. Committee on Toxicity draft report on phyto-oestrogens and health – review of proposed health effects of phyto-oestrogen exposure and recommendations for future research. Secreto G. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. J Clin Oncol. 28. Nutr Cancer. Franke AA. 2007. Campos MG. Samperi S. Industrial Crops & Products. Fuchs J. [The effects of phytoestrogen therapy on the endometrium in postmenopausal women]. 2005. Branca F. J Womens Health (Larchmt). 2006. Cunha MM. Guerra V.). Lam SS. Venturelli E. 29. 2001. 1080-1086. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. The pharmacognosy of Humulus lupulus L. 33. 65. Torella M. Putignano G. The role of soy phytoestrogens in prostate cancer. The variability of isoflavones in soy seeds and the possibility of obtaining extracts for over the counter tablet preparations that can be standardized. Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause. Tsai KS. crossover. Caserta R. Zheng W. Maturitas. 2002. 14. 241246. Gann PH. randomized. 551-555. Am Fam Physician. Hall W. Chen YM. Caserta L. Cisternino AM. 2003. Castle EP and Thrasher JB. Fanelli M. De Pasquale R. 1999. 2005. Royal Society of Chemistry. placebo-controlled study. Williamson G. Circosta C. Soy isoflavones and bone health. 2000. 85. double-blind. 205-213. Warner M. Chan JM. Cassidy A. Jin F. Custer LJ. Proc Nut Soc. Cassidy A. 468-473. 295-300. Palumbo DR. body weight. Albertazzi P. Fertil Steril. Dietary phytoestrogens and bone health. 59. 76-92. Carriero C. Tetens I. 11. Maturitas. Isoflavone treatment for acute menopausal symptoms. viii-ix. 45. Papaleo E. Cantatore F. 2006. Am J Health Syst Pharm. Phyto-oestrogens through the life cycle. 26. Effects of isoflavones from red clover (Trifolium pratense) on skin changes induced by ovariectomy in rats. 61. Urology. Ayton R. Recent Results Cancer Res. Bitto A. 1998. 13. Pienta KJ. Urology. Altavilla D.. Bhuiyan M. Fortunato N. Meliala A. Clarkson TB and Anthony MS. Dalais FS.76 77 78 CKF (Commissie Keuring Fytoproducten). 12. Polito F. Demonty I. Kallay E. Phytoestrogens and coronary heart disease. Phytoestrogens and Health. Tebbe A. 132. Wahlqvist ML. Squadrito F. Devareddy L. 648-655. 51. Squadrito G. 2007. Marini R. Suter DA. Minutoli L. Adams MR. 164. Paden SL. Khalil DA. Korlagunta K. Sarkar FH. 65. Kim YC. 2004. endometrium. Baviera G. Altavilla D. 94. Farhan H. Archives de pédiatrie. 235-237. Int J Oncol. Cline JM. 2003. Bartolone S. 259-263. Muqim N. Minerva Ginecol.and placebo-controlled study. 1091-1097. Adamo EB.S. 107-134. Davis JN. 2007. 2006. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U. 1076-1078. double-blind. 64. Fertil Steril. Park MK. 148-155. Nutr Rev. 1998. Atteritano M. 2002. Romeo A. Murkies AL. 124-129. Manhardt T. De Franciscis P. Zarcone R. Corrado F. Effects of the phytoestrogen genistein on hot flushes. Adler S. 189-203. Corrado F. Obasanjo IO. Clinical inquiries: What is the dietary treatment for low HDL cholesterol? J Fam Pract. D'Anna R. Jacques PF. Antico F. 55. Hooshmand S. Jones PJ. Phytochemicals for the prevention of breast and endometrial cancer. Medley G. Peterson R.women: the Framingham study. Shay N. Soares SE. Effects of genistein on hot flushes in early postmenopausal women: a randomized. Moustaid-Moussa N. 2004. 2004. 413-425. Colacurci N. Menopause. 1998. Cirillo M. Higginbotham A. 1996. Strauss BJ. 276-282. Role of isoflavones in the hypocholesterolemic effect of soy. Cho KW. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Beckett LA. 2006. 2005. 13. 42-52. Menopause. 16. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Jr. double-blind EPT. 2002. Grobbee DE. Regulation of extrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention. 2003. Crawford P. Wahlqvist ML. Cross HS. Li Y. Paschold JC. Hackman RM. 1031-1035. Climacteric. deVere White RW. Thomson WK. Effects of soy isoflavones on menopausal neurovegetative symptoms. 11. 56. D'Anna R. Cancer Treat Res. Arjmandi BH. Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Marini H. Lamarche B. 2007. 692-699. Cline JM and Hughes CL. Sun B. 589-604. van der Schouw YT. Bitto A. Squadrito F. de Kleijn MJ. 2003. 2000. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 437 . Wattanapenpaiboon N. Crisafulli A. Baillieres Clin Endocrinol Metab. 407-412. Anthony MS. Master file Soy Isoflavones (Glycine max). Cancellieri F. (Phyto-estrogènes et aliments à base de soja chez le nourrisson et l‘enfant: la prudence est de mise) Phytoestrogens and soy foods in infants and children: caution is needed. Gaudio A. Comité de nutrition de la Société française de pédiatrie. 400-404. and vaginal epithelium in postmenopausal women: a 1-year randomized. 14. Bellmer DD. Kucuk O. 510-515. Effects of dietary phytoestrogens in postmenopausal women. 2004. Ann NY Acad Sci. Weiland T. J Nutr. Borrelli A. Triolo O. Davis J. Menopause. placebo-controlled study. Marini H. COT (Committee on Toxicity of Chemicals in Food Consumer Products and the Environment). Ann Nutr Metab. O'Connor T. Rice GE. Dalais FS. Banz W. Wilson PW. Cannata ML. Grehan M. Frisina N. Fornaro F. 1. 963. Cohen LA. Frydenberg M. The effects of fructo-oligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats. Frisina N. Nutrition and prostate cancer: a review. 63. Kaluba-Skotarczak A. what does not. Cleve Clin J Med. K(+)ATPase reduction in streptozotocin diabetic rats. Kazikowska A. J Clin Endocrinol Metab. Phipps WR. 160-170. Branca F. S39-43. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. Ill. 767772. [The safety and tolerance of isoflavones (Soyfem) administration in postmenopausal women]. 634-649. 2007. Finking G. Br J Nutr. 17. J Womens Health (Larchmt). Hess B. Soy isoflavone phytopharmaceuticals in interleukin-6 affections. Fischer L. 91. 2003. Boan J. 153-165. 2005. Kurzer MS. Jeffcoat AR. J Nutr. Champaign. Vanden Berghe W. 2006. 2003. Boca Raton. anti-cancer and anti-inflammatory therapy. In: Phytoestrogens and Health. De Naeyer A. Yeh LM. 11. The effect of soy protein isolate on bone metabolism. Geller SE and Studee L. Not all soy products are created equal: caution needed in interpretation of research results. 2000. 253-271. Human Nutrition. randomized. Crowell JA. Seremak-Mrozikiewicz A. Phyto-oestrogens. Seremak-Mrozikiewicz A. Food sources of phyto-oestrogens and their precursors in Europe. Xu X. Mendes RH. 78. 2004. Hanke H. Dunn AV. Menopause. the principal soy isoflavone. Bello-Klein A. J Obstet Gynaecol. Franzon R. Dietary soy prevents brain Na+. 88-94. 9. Scalfi L. low-cholesterol diet. 1171-1185. 2002. Lavalleur J. Kaluba-Skotarczak A. 69. Chantre P. AOCS Press. 78. 2004. Phytoestrogens: potential benefits and implications for breast cancer survivors. 307-311. J Clin Endocrinol Metab. 1999. Franke AA. Erdman JW. 107-112. Lampe JW. 1229S-1233S. Duncan AM. 2005.. Fletcher RJ. Underhill KE. 361-365. Kazikowska A. Doerge DR. Thomas BE. 2006.). 89 Suppl 1. [Efficacy of standardized isoflavones extract (Soyfem) (52-104 mg/24h) in moderate and medium-severe climacteric syndrome]. Puk E. 290-298. Incorporating soy protein into a low-fat. 2005. 67. 19. 617-631. Multi-purpose nutraceuticals at the crossroad of hormone replacement. Effects of a standardized soy extract on hot flushes: a multicenter. Zeisel SH. Hollenbeck CB. Elsevier. placebo-controlled study. 1999. 2004. Drews K. Setchell KD. Messina M. 48. Phipps WR. Geissler C and Powers H. Kurzer MS. The value of phytoestrogens as a possible therapeutic option in postmenopausal women with coronary heart disease. Mares P. Ginekol Pol. 772-780. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Valentine JL. 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 438 . Koch MA. 2004. 2002. 14. 2003. Best Pract Res Clin Endocrinol Metab. Young JF. Metabolism and disposition of genistein. Maskarinec G. Haegeman G. Malec M. Di Mattei V. Phytoestrogens and body composition. Gilani GS and Anderson JJB (eds. 2007. Haynatzka V. Stinchcombe T. Botanical and dietary supplements for menopausal symptoms: what works. Wyse AT. 329-334. 2003. 2006. Ginekol Pol. Morimoto Y. 68. Modest hormonal effects of soy isoflavones in postmenopausal women. Gallagher JC. Satpathy R. Phytoestrogens and Health. Malec M. J Womens Health (Larchmt). Duffy C and Cyr M. Drews K. Duncan AM. 84. Dijsselbloem N. 15. Faure ED. Jr. Puk E. Luecke RH. CRC Press. Hollenbeck PL. Nutr Cancer. 12. Diabetes Res Clin Pract. double-blind. 3479-3484. Journal of Clinical Nutrition. 455-459. In: Phytoestrogens in Functional Foods. Biochem Pharmacol. 134. FSA (Food Standards Agency UK). Menopause. Urinary isoflavonoids as a dietary compliance measure among premenopausal women. Chiarani F. Rafferty K.96 Dewell A. Mahoney C. Badger TM. 89. In: PDR for Herbal Medicines (Physician's Desk Reference for Herbal Medicines) Medical economics. 16. 31. J Cardiovasc Nurs. 50-63. Kilpatrick ES. Griffith AP and Collison MW. Soybean. Gonzalez S. 15. Loeser RF. 1998. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. 2004. Ksycinska H. 2002. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. 30. 6. Guha N. J Nutr. 99. McMichael Phillip D. Ham KD. J Chromatogr A. Brown M. Kwan ML. The cardiovascular effects of soy products. Lazinsky A. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. 1871-1873. Howell A. questions about other components. 3507S-3512S. Osteoarthritis Cartilage. benefit and safety concerns. Jpn J Cancer Res. Berlin. 13. 2004. Sehgal AR. 2002. Chromatographic quantification of isoflavones (why and how). Clinical trials in cancer prevention: current results and perspectives for the future. 2000. Effects of long-term estrogen replacement therapy on articular cartilage IGFBP-2. 84. Wei H. Obstet Gynecol. 1000-1007. CRC Press. Drug Metabol Drug Interact. 68. Improved methods for the extraction and analysis of isoflavones from soy-containing foods and nutritional supplements by reversed-phase high-performance liquid chromatography and liquid chromatography-mass spectrometry. 2005. 2005. de Lima GR. 389-394. collagen and proteoglycan levels in ovariectomized cynomolgus monkeys. Jayagopal V. 2009. Soares JM. Baracat EC. 397-413. BMC Neurosci. Hillman GG. Breast Cancer Res Treat. Haimov-Kochman R and Hochner-Celnikier D. Harkness LS. Haidar MA. Lerner E. Kataoka T. Hansel B. 10-22. Grynkiewicz G. 2001. Bundred NJ.117 118 119 Goldwyn S. Gruenwald J. 13-15. Boca Raton. 2006. Gutierrez-Zepeda A. 134. 18-20. IGFBP-3. Am J Clin Nutr. Hot flashes revisited: pharmacological and herbal options for hot flashes management. Fiedler K. Yudelev M. J Womens Health (Larchmt). 2007. 4. 2005. Springer Verlag. 913. Ito A. Harding C. Luo Y. 1998. Health claims for soy protein. Sarkar FH. Caan BJ. Dohi K. Han KK. Carlson CS. 12. Che M. 7. Wu Y.). 707-708. Jr. Yin H. Grynkiewicz G and Opolski A. 329-350. Lecithinum ex soja (soja lecithin). 160-168. Henkel J. Phytoestrogens and their effects on cancer. Promotion of health by soy isoflavones: efficacy. Dietary soy supplementation is estrogenic in menopausal women. Greenwald P. Quesenberry CP. Wang Y. Santell R. 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 439 . Oravec D. 137142. Ipriflavone: an important bone-building isoflavone. In: Hager's Handbuch der pharmazeutischen Praxis Teil. Gotoh T. Morton M. Wu Z. Chapman T. Raffoul JJ. Yamada K. Ramza J. 2004. 1956-1964. Lindgren BR. Altern Med Rev. BMC Cancer. Link CD. 1999. 17. What does the evidence tell us? Acta Obstet Gynecol Scand. Ham KD. Zagrodzka J. Jr. Head KA. Gould V. 46. Castillo AL. Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. 54. 1992. 261-289. 972979. FDA Consum. Weltzien EK. 2000. quiz 75-56. Atkin SL. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. Bartoszek A. Khan I. In: Carcinogenic and Anticarcinogenic Food Components Baer-Dubowska W.. Zhao B. Acta Chromatographica. 2000. Kucuk O. 2007. 4.. 34. Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. Diabetes Care. 2002. Hasler CM. Chemoprevention of N-nitroso-Nmethylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. Carlson CS. Loeser RF. Oegema TR. Arthritis Rheum. Malejka-Giganti D (eds. Soy. Woodman OL.com. Wu SC. Hulem R and Blair RM. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. Duell EA. Oral intake of soy isoflavone aglycone improves the aged skin of adult women. Holzbeierlein JM. 2001. Soy protein consumption and bone mass in early postmenopausal Chinese women. Jou HJ. Lee JH. 195-207. Risks and benefits of soy isoflavones for breast cancer survivors. 2003. Junior JM. Oncol Nurs Forum. Kemp C. Yang HP. Schmidt M. Natural medicines comprehensive database: Soy. Chung JH. Huang SY. Howes JB. 2008. Leung PC. 14. Lee SK. 2008. Hu SA. 2006. Use of alternative and complementary medicine in menopause. 53. 17. 74. Allred CD. Baik HW. Sobey CG.naturaldatabase. J Am Diet Assoc. Fisher GJ. Shin JI. Huntley AL and Ernst E. 79. Knight DC. Stavale JN. Curr Opin Urol. Ho SC. Yamaguchi H. Humfrey CD. 338. 99-107. 509-517. Ansbacher R. Maturitas. 2005. 102. 1141. 2007. 2003. 6. Osteoporos Int. Soy isoflavones for postmenopausal symptoms. Arii M. 14. Chrissobolis S. Sham A. quiz 39. Huang HY. 249-263. 1363-1369. 2006. Adv Nurse Pract. Int J Gynaecol Obstet. 31. EGCG. 694-699. 53.138 139 140 141 142 143 144 Ho SC. Matsuyama A. Nunes MG. J Nutr Biochem. Allred KF. Izumi T. Genistein. 49-58. 2001. Park OJ. Thrasher JB. 145 146 147 148 149 150 151 152 153 154 155 156 157 158 440 . Baracat EC. 1-9. 2007. Chan SG. Jackman KA. Ling PY. 835-841. 203-211. Phytoestrogens and human health effects: weighing up the current evidence. Planta Med. Doerge DR. Haidar MA. Voorhees JJ. 2000. 2004. J Invest Dermatol. 32-38. 16. An examination of evidence. 90. Kang S. Wu WH. http://www. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. 51-59. Hwang JT. Ha J. Lee YK. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. 2005. Chu KS. 15. Jellin JM. 2006. Obata A. Chen Y. Biochem Biophys Res Commun. J Bone Miner Res. Helferich WG. 2004. Brain Res. 835-842. Comparison of 70 mg and 35 mg isoflavone soya supplement for menopause symptoms. Int J Gynaecol Obstet. 57-62. Lau J. Yi Q. McIntosh J. Saito M. Hammoud MM. Lam S. 2006. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Quadros LG. Kaari C. Vasorelaxant and antioxidant activity of the isoflavone metabolite equol in carotid and cerebral arteries. Karko KL. 100. 2005. 2957-2962. Maturitas. Chang FW. 47. Ling PY. and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. 17-22. Nat Toxins. Wong E. 1998. Park IJ. Gregory P. Imhof M. Horner NK and Lampe JW. Howes LG. Hitchens K. 55. Improvement of menopausal symptoms by soy isoflavones: a randomized double-blind study. Jou HJ. Kang HJ. Ju YH. Soy for the treatment of perimenopausal symptoms--a systematic review. 131. Woo J. 2002. Wu SC. Gocan A. 159-160. 120. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. Int J Gynaecol Obstet. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF7) tumors implanted in athymic nude mice. The role of soy phytoestrogens in prostate cancer. Yang HT. 1368-1380. J Nutr. Batz F. J Nutr Sci Vitaminol (Tokyo). Wan YS. Shieh MJ. 44-49. Maturitas. Yang TC. 67. Br J Nutr. Kim SY. Howes JB. Protective effects of dietary soy isoflavones against UV-induced skin-aging in hairless mouse model. Hahne JC. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Kotsopoulos D. Kelloff GJ. 93. A randomized. 2005. Obstet Gynecol. van der Schouw YT. Malone WA. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Mallett A. Krebs EE. Lubet RA. Gynecol Oncol. 69-78. 137. 161-167. Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay. Cancer Metastasis Rev. Obstet Gynecol. 13-18. 2005. Kennedy AR. Schickel M. 174-186. Park WS. Seiden MV. Lampe JW. Climacteric. Belgium. Su NW. Roche M. Wan XS. J Am Coll Nutr. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Boone CW. Pan W. Barrett-Connor E. 805-813. Ann Intern Med. 824-836. 441 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 . Li L. 11. Billings PC. Ensrud KE. 111-124. Kritz-Silverstein D and Goodman-Gruen DL. Knight DC and Eden JA. 1995. Pepper M. Oct. 4. Lee JY. 43. 2001. and bone metabolism in postmenopausal women. 2007. Kok L. Agents. placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women. 62. J Nutr. Dalais FS. Grobbee DE. Brussels. 897904. Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study. 46-51. biomarkers.). MacDonald R. Ricciotti HA. Zhou J. 2003. King RA and Bursill DB. 2002. 2000. Klein A. Aleman A. 2004. 57. Soy isoflavones: impact on health and disease. Kronenberg F and Fugh-Berman A. 8. Kim WG. Sim YC. Lee MH. Kritz-Silverstein D. Kim SJ. Urology. 867-872. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. 196-202. 813821. 556-562. Perry AK. Am J Clin Nutr. Lieberman R. 317-323. 2008. 2006. 13-14. Steele VE. 10. de Haan EH. Duska L. 1996. 3. Von Muhlen D. Knight DC. Teede HJ. Garant Publishers. Eden JA. 100. 2002. and cohorts for chemopreventive agent development in prostate cancer. Menopause. Phytoestrogens for treatment of menopausal symptoms: a systematic review. 125. 15. McGrath BP. Complementary and alternative medicine for menopausal symptoms: a review of randomized. Blackburn GL. Belg Katz AE. 1998. 2001. A review of the clinical effects of phytoestrogens. Liang YL. 666S-674S. 52. Kardinaal AFM. 125-132. Descheemaeker K and Debruyne I (eds. Adair N. bone mineral density. He X. In: Soy and Health 2000: Clinical Evidence. J Womens Health Gend Based Med. Wilt TJ. 2002. 2000. 2004. 87.159 160 Kao FJ. 2002. Menopause. 12. Starcke S. Kucuk O. Bressel MA. Kreijkamp-Kaspers S. Howes LG. 2277-2281. Kreijkamp-Kaspers S. Newberne PM. Sigman CC. Lee SJ. Effect of water-to-bean ratio on the contents and compositions of isoflavones in tofu. Dietetic Applications [International Conference]. Incorporating soy proteins into baked products for use in clinical studies. Louvain. Kopelovich L. 56-62. Supko JG. 157-162. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr Cancer. Hogemeier O. Flavonoid and botanical approaches to prostate health. 21. J Gerontol A Biol Sci Med Sci. Dietary phytoestrogen intake and cognitive function in older women. 2002. Dombrowski F. Kok L. Higley HR. 2004. Climacteric. Crowell JA. Grobbee DE. Kiriakidis S. 104. Chemoprevention of prostate cancer. J Altern Complement Med. 205-209. Wernert N. J Agric Food Chem. Jha HC. Klein BP. Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. 2000. van der Schouw YT. controlled trials. Menopause. 23. Khaodhiar L. Usual dietary isoflavone intake. Eur J Nutr. 2005. 2005. Oka R. Nicolosi R. 2001. Induction of apoptosis in breast cancer cells MDA-MB231 by genistein. Biochem Pharmacol. Tournas JA. 7. 16. Takimoto C. van der Burg B. Brown J. 275-285. Ockene IS. 16. Kurzer MS. J Mammary Gland Biol Neoplasia. 2004. The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Liao CH. Messina M. 26-30. Kucuk O. 1998. Kumar N. Mol Pharmacol. Gustafsson JA. 98108. 193-200. 9. 18. 691-794. Carlsson B. Chiriboga D. Bergan R. Li Y. Soy isoflavones reduce postmenopausal hot flush frequency and severity:results of a sistematic review and meta-analysis of randomized controlled trials. A pilot study of phytoestrogen content of soy foods and traditional Chinese medicines for women's health in Hong Kong. Lissin LW. Sarkar FH. 1983S-1986S. Woo J. 201-205. a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. A Journey of Discovery in Functional Dietary Components and Epidemiology. Phytoestrogen supplement use by women. 2008. 3166-3172. Lin JY. Lee YB. Melby MK. Safe SH. 2003. Monteiro-Riviere NA. Lyu LC. Am J Med. van der Saag PT. 442 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 . Kyle E. J Nutr. Cooke JP. Unpublished. Endocrinology. Setchell KD. Cochrane Database Syst Rev. Guh JH. Allen K. El-Rayes BF. Zielinski J. Nedeljkovic-Kurepa A. Sarkar FH. Lethaby AE. Toxicology. 24. Burch JA. Kronenberg F. Inflammopharmacology. 87-95. 2002. 51. Soy isoflavones and cognitive function. 2002. 641-649. Kim YJ. Flavonoids as anticancer agents: structure-activity relationship study. Isoflavones in breast cancer chemoprevention: where do we go from here? Front Biosci. 1999. 2. 2004. Li M. CD001395. 9. 67-76. Li Y. Poon P. 1999. 246-257. 15. Int J Food Sci Nutr. 227-229. Marjoribanks J. Lakshmi S. Timing of exposure and mammary cancer risk. 118 Suppl 12B. e90-95. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. 2008. J Nutr. 43. 195. Philip PA. 2004. Isoflavones improve vascular reactivity in postmenopausal women with hypercholesterolemia. Oncogene. Merriam PA. 2927-2934. Ali S. placebo-controlled trial. 2031-2038. Li Y. 2007. Photodermatol Photoimmunol Photomed. Kurzer MS. Anti-cancer agents. Roberts H. Taku K. 2004. Menopause: a review of botanical dietary supplements. 139. Int J Oncol. Effect of soy protein containing isoflavones on blood lipids in moderately hypercholesterolemic adults: a randomized controlled trial. Teng CM. 61-66. 69-76. Phytoestrogens for vasomotor menopausal symptoms. Bhuiyan M. Low Dog T. Kurzer MS. Curt G. Current medicinal chemistry. 4252-4263. Lemmen JG. Lopez-Lazaro M. Genistein inversely affects tubulin-binding agent-induced apoptosis in human breast cancer cells. 1997. J Am Coll Nutr. 24. Chung HW. Olendzki BC. Corton JC. Kurzer MS. Holm-Jensen T. 525-533. Soy consumption for reduction of menopausal symptoms. Heine J. Vasc Med. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Topical isoflavones provide effective photoprotection to skin. Sohn HS. Soymilk or progesterone for prevention of bone loss--a 2 year randomized. 2004. Ellis KL. 26. 2002. Hormonal effects of soy in premenopausal women and men. Upadhyay S. Riccardi D. Journal of Nutrition Society of Taiwan. 570S-573S. Ma Y. 132. Lee R. Kazi A. Neckers L. Lydeking-Olsen E. J Nutr Biochem. Lee YJ. Pan SL. Lamartiniere CA. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein.180 Kuiper GG. 2005. Eden J. 67. Bhuiyan M. Kronenberg F. 2004. 2004. 55. 28. Lee HJ. Beck-Jensen JE. 133. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Sarkar FH. 1462-1469. 117-131. Marini H. Wang PY. 272-282. Merz-Demlow BE.and postmenopausal breast cancer. phytoestrogens and cereal extracts. 288-292. 574-575. Minutoli L. 1032-1041. Lee J. Maskarinec G. 2007. 62. Cell Cycle. 74. Duncan AM. 165-169. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. 1597-1605. Toxicology. Gaudio A. Cardiovasc Res. McDonald R. Int J Cancer. 2004. 61. 2005. Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. Eur J Cancer Prev. Rowlands DJ. Schneider S. McCarty MF. Mackey R and Eden J. Polito F. 2004. 1. Mahady GB. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Natl Med Assoc. Siow RC. Gurpide E. Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion. 93. Isoflavones made simple . Atteritano M. Nutr Clin Care. 2006. Nutr Rev. Wangen KE. Messina MJ. Metabolic syndrome: soybean foods and serum lipids. Messina MJ. Therapeutic options: hormone replacement therapy-soy therapy. 96. McCarthy B. Soy. Emerging evidence on the role of soy in reducing prostate cancer risk. 1992. 2008. 2008. Med Hypotheses. 12. 2005. Butsch A. Duncan AM. MacGregor CA. 302-308. 2006. Markiewicz L. Paul J. Ma DF. Phipps WR. 839-847. 45. 440-443. 83. Adamo EB. Raveche E. J Med Food. Chang V. Soy foods for breast cancer survivors and women at high risk for breast cancer? J Am Diet Assoc. Vito D.203 Ma DF. 2002. 443 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 . Li FY. 2005. 3. de Winter P. 1524-1528. Soy isoflavones improve plasma lipids in normocholesterolemic. Qin LQ. Dillingham BL. Mayr U. Mazzaferro S. Merritt JC. Katoh R.genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. 244-251. Muti P. 392-397. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. 75. and breast cancer. Corrado F. Dietary lignan intakes and risk of pre. 2001. 111. 5. 708-714. 146. 105. 71. D'Anna R. Validation of two in vitro test systems for estrogenic activities with zearalenone. Wang PY. 66. Schwander SK. Mammographic densities in a one-year isoflavone intervention. 63. 1998. J Steroid Biochem Mol Biol. McVeigh BL. J Natl Med Assoc. Canney PA. 2007. Mansour A. Soyfoods. Garey J. 707-728. 2003. Merritt JC. Patterson G. Trevisan M. 2003. premenopausal women. Adlercreutz H. 6. Katoh R. Messina M and Bennink M. Frisina A. Messina M. Donepudi S. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials. Phytoestrogens and the menopause. Eur J Clin Nutr. 135-149. isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Do soy isoflavones cause endometrial hyperplasia? Nutr Rev. Wilson S. Altavilla D. 1-11. 1093-1114. Lubrano C. 2004. Bitto A. Messina M and Hughes C. 57-64. 2003. Am J Clin Nutr. soy phytoestrogens (isoflavones). Carlin L. Kotenko S. Lampe JW. 27. Carr TP. Climacteric. Williams AE. Baillieres Clin Endocrinol Metab. Squadrito F. Edge SB. Maskarinec G. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Freudenheim JL. 41. Mann GE. Ann Intern Med. Frisina N. Cannata ML. McCann SE. 399-405. Am J Clin Nutr. 1993. 2000. Am J Clin Nutr. Bonaiuto M. Kurzer MS. 1999. 155-161. Soy foods and soybean isoflavones and menopausal health. 12. 1998. In vitro bioassays of non-steroidal phytoestrogens. Qin LQ. Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. Eur J Cancer. Xu X. Clin Nutr. 70. 261-274. Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis. 1999. 2002. Moyad MA. 21. Moore JO. J Nutr. FEBS Lett. 13. 7. Wang Y.4'. Munro IC. Morabito N. Soy isoflavones. 97-102. D'Anna R. Alekel DL. Drug Deliv. Nagata C. Altavilla D. Zee OP. 27. Cilurzo F. Carcinogenesis. Corrado F. Strauss BJ.7-trihydroxyisoflavone on the expression of matrix metalloproteinase-1. Volpini G. 89. Kucuk O. 2007. Warm A. prednisone) chemotherapy. Monti M. 2006. 2002. Gao D. Stephen AM. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. Soy. 769-774. Frisina N. Zhou X. Semin Urol Oncol. 156-171. 17. Pizzoleo MA. Moon HI. Morton MS.7-trihydroxyisoflavone on ultraviolet-induced matrix metalloproteinases-1 expression in human skin fibroblasts. 13.4'. Ho S. Casiraghi A. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. 2. J Natl Cancer Inst. Messina M. 17. Evaluation of ex vivo human skin permeation of genistein and daidzein. Watanabe S. 58. 2006. Biol Pharm Bull. Cincotta M. Regulation effect of 2'. Mucci M. Messina M. Flamm WG. Wei H. Aboukameel A. Arslanoglu S. Nagata C. Isoflavones and skeletal health: are these molecules ready for clinical application? Osteoporosis International. Moon HI and Chung JH. Al-Katib A. 89. 139. Report on the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment. 2005. Monteiro SC. 2006. Metab Brain Dis. 323-334. 22. 91-96. 2003. Gaudio A. 2003.226 227 228 229 230 231 232 233 Messina M. J Bone Miner Res. 1627-1635. Harwood M. 30-32. Wyse AT. Lombard C. McCaskill-Stevens W. 361-368. Kucuk O. Agro Food Industry HiTech. 14. doxorubicin. Curr Opin Clin Nutr Metab Care. Adlercreutz H. Minghetti P. Magnolia bark extract. Moro GE. 2005. Management of bovine protein allergy: new perspectives and nutritional aspects. The effect of 2'. Maturitas. 1275-1284. Phelps R. 209-213. 29. Nutr Rev. 2004. 1904-1912. 1361-1368. Burger HG. 1998. Doerge DR. Lebwohl M. 2006. Lasco A. Migliaccio S and Anderson JJB. Murkies AL. vincristine. Ann Allergy Asthma Immunol. Shimizu H. Setchell KD. Mol Cancer Ther. Kurisu Y. Mattos CB. J AOAC Int. Stebbins WG. Messina M. lactobacilli. 28. 2000. K (+)-ATPase and cholinesterases. 580. 2003. Mancino P. and prostate cancer. 649-658. Montanari L. 411-415. Lampe JW. Scherer EB. Benvenuti C. 2006. 1121-1134. 2173-2175. Sarkar F. Chung JH. J Nutr. Vergara C. Papadia LS. 2006. 61. Lampe JW. 1-33. 234 235 236 237 238 239 240 241 242 243 244 245 444 . Supplementation with vitamins E plus C or soy isoflavones in ovariectomized rats: effect on the activities of Na(+). Soy isoflavones: a safety review. Takatsuka N. Miniello V. Doull J. 796S-802S. Ientile R. Soyfoods and soybean isoflavones for promoting bone health. and workshop proceedings. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Wilcox G. Int J Epidemiol. Hlywka JJ. 832-836. Kwak JH. 2009. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. vitamin D3 and calcium. 1995. Messina M. Squadrito F. 189-195. Carraro C. 98. commentary. Crisafulli A. disease prevention. Mohammad RM. 128. Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Controlled clinical study in menopause. Addressing the soy and breast cancer relationship: review. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide. 2 in ultraviolet-B irradiated primary cultured old aged human skin fibroblasts. Minerva Ginecol. Janfaza M. 1743-1744. Nedrow A. Curr Opin Urol. 48. 2001. 93. 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 445 . Haney E. Cardiovascular actions of selective estrogen receptor modulators and phytoestrogens. Soybean foods and their benefits: potential mechanisms of action. NTP-CERHR (National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction). A comparison of oral micronized estradiol with soy phytoestrogen effects on tail skin temperatures of ovariectomized rats. 215-229. Anthony MS. 2004. 2006. 63. Pontes A. De Luca L. van der Schouw YT. An update on chemoprevention strategies in prostate cancer for 2006. 73-79. 2003. Kim YA. Review of the epidemiological evidence. NTP-CERHR (National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction). The Role of Isoflavones in Menopausal Health: Consensus Opinion of The North American Menopause Society.] Merr). Nutrition reviews. Miller J. Dias R. Menopause. Am J Epidemiol. 2005. Lampe JW. 56. Keinan-Boker L. Levy L. Crawford S. Phytoestrogens and breast cancer risk. 171-183. Nahas Neto J. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Pan Y. Soy protein and bone mineral density in older men and women: a randomized trial. J Clin Endocrinol Metab. 2006. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches. Kumar K. Kim CW. 295. 2006. 58. 1230-1239. Nobert GS.epnet. Jeon YK. Walker M. Villablanca AC. 2000. Orsatti FL. Omoni AO and Aluko RE. Menopause 215-229. Dalben I. Qu P. Maturitas. 2006. LaCroix AZ. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. Traiman P. 2006. Kim JE. Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. Humphrey L. Holub BJ. 2005. 2003. Maturitas. Nahas EA. Neill MG and Fleshner NE. and placebo-controlled study. Nelson HD. Potter JD. 16. Soy (Glycine max [L. 2007. Park SS. 2001. Bull Cancer. 4077-4079. 132-137. Nestel P. 2000. 249-258. 171-174. Kidney Int.246 247 Nagata C. 372-380. NIH (National Institute of Health). Maturitas. 2004. Soy product intake and hot flashes in Japanese women: results from a community-based prospective study. Kawakami N. Isoflavones-Herbs and Supplements. double-blind. Wong JA. NAT main index (Natural and Alternative Treatments web page). Newton KM. 270-277. 153. Collins FW. NAMS (The North American Menopause Society). The role of isoflavones in menopausal health: Consensus opinion of the North American Menopause Society. Fu R. 77. Oerter Klein K. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized. 272-283. Role of soy protein in cholesterol-lowering: how good is it? Arterioscler Thromb Vasc Biol. Carvalho EP. 55.com/GetContent. 63. E59-66. 2002. Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma. NTP-CERHR expert panel report on the reproductive and developmental toxicity of genistein. Grobbee DE. 271-278. Kim YN. 7. Chang RJ. Kraak MM. Shimizu H. Philbrick DJ. Bureau DP. Prev Cardiol. Vesco KK. North American Menopause Society. The Journal of The North American Menopause Society. Binns M. http://healthlibrary. Nahas-Neto J. Takatsuka N. Clarkson TB. 7. Oliveira ML. 88. Nicolaidis C. Petri Nahas E. JAMA. Cancer Chemother Pharmacol. 22. Li SS. NTP-CERHR expert panel report on the reproductive and developmental toxicity of soy formula. Evidence that soyasaponin Bb retards disease progression in a murine model of polycystic kidney disease. Nandur R. 2006. 2057-2071. Breast Cancer Res Treat. Peeters PH. 790-793. 8. Kim H. 2003.aspx?token=e0498803-7f62-4563-8d47-5fe33da65dd4. Potter JD and Steinmetz K. Pop EA. Biological properties of genistein. 2007. Eur J Clin Nutr. Nutr Rev. 2001. Wang Y. 2007. Ramsey LA. J Clin Oncol. J Am Acad Dermatol. Polkowski K and Mazurek AP. health products and infant formulas. 2006. Rehman A. Potter SM. Stillman RJ. Che M. Rasool AH. 2006. J Ren Nutr. 352-357. 39. Menopause. 2003. Soy protein and cardiovascular disease: the impact of bioactive components in soy. 1998. Cutaneous photodamage. Barton DL. 41. Muthugounder S. 587-592. 606S-611S. 11. 1999. quiz 20-12. Smerud KT. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. 414-420. 6. Int J Clin Pharmacol Ther. Int J Cancer. 730-738. Ross BS. Raffoul JJ. Soy in hypercholesterolaemia: a double-blind. Knoll ZE. Vitamin E and its effect on arterial stiffness in postmenopausal women--a randomized controlled trial.267 268 269 270 271 272 Phillips M. Skovlund E. Doerge DR. Jr. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. 1375S1379S. fruit and phytoestrogens as preventive agents. Wan Yusuf WN. 684-692. Can the combination of flaxseed and its lignans with soy and its isoflavones reduce the growth stimulatory effect of soy and its isoflavones on established breast cancer? Molecular Nutrition & Food Research. Makela S. 61-90. 7. Prostate. Baum JA. Pinnell SR. 51. Krupp KR. Velasquez MT. Hindin P. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. Quella SK. Hui LS. Potter SM. Santti R. apoptosis. Power KA and Thompson LU. LaVasseur BI. 2004. Evaluation of the composition and concentration of isoflavones in soy based supplements. 30. Adv Exp Med Biol. Protective effects of dietary phytoestrogens in chronic renal disease. Acta Pol Pharm. Animal models for the preneoplastic lesions of the prostate. J Nutr. 48. 546. 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 446 . Hot flashes--a review of the literature on alternative and complementary treatment approaches. Raffoul JJ. Food research international. and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial. 1996. Herbal & dietary supplements for hot flashes: here's what works--and what doesn't. Anticancer therapeutic potential of soy isoflavone. Teng H.. 26-30. Genistein inhibits radiationinduced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. Rahman AR. 2003. Kucuk O. Loprinzi CL. Ravindranath MH. Philp HA. 56. 1-19. Lahti T. Am J Clin Nutr. Puska P. 2002. 1999. Erdman JW. 8. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. 2000. 284-302. Phytoestrogens and the management of menopause. Hillman GG. Perera CO. 68. Adv Nurse Pract. 2003. Prevention of prostate-related cancers in Lobund-Wistar rats. Shay NF. IARC Sci Publ. Eur Urol. 2008. 121-165. Keithley JK. placebo-controlled trial. Miller KD. 183-193. 2000. oxidative stress. 107. Coan AD. Sloan JA. Swan D. Potter SM. 231-235. 125. Altern Med Rev. 18. A review of in vitro and in vivo data. Pollard M. Abrams J. Kucuk O. Fischer RG. 243-248. Swanson B. Korpelainen V. 56. 2003. Effects of a high daily dose of soy isoflavones on DNA damage. BMC Cancer. Forman JD. Hoie LH. Hillman GG. Fischer LM. Nakamura J. Bhathena SJ. and topical antioxidant protection. Gitzinger M. Vegetables. Novotny PJ. Zeller JM. 2491-2498. Pylkkanen L. 135-155. Presser N. 1995. Sarkar FH. Lee YM. 305-309. Banerjee S. 15. AWHONN Lifelines. Ranich T. Prabhakaran MP. 1068-1074. Zeisel SH. 1998. Viswanathan S. 7. 39. Knost JA. 1996. genistein. 120. 57. Sarkar FH. 45. Khaodhiar L. 49. 2006. 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 447 . International Journal of Cancer Prevention. Baker H. 2001. Photochem Photobiol. Lees KA. 99-104. Domanski D. 2007. Makela S. Goodison S. isoflavones. 11-33. Fugh-Berman AJ. Henning S. Saarinen NM. Elashoff R. Register TC. Isoflavone-mediated inhibition of tyrosine kinase: a novel antiinflammatory approach. 832-837. Nappi C. Hossein-Nezhad A. Smith E. Szabo C. Nguyen A. He J. 1999. Genistein and gut inflammation: role of nitric oxide. Mandato VD. Bifulco G. Sunderland R. 2004. Sacks FM. 1543-1544. 98. Tahbaz F. Handayani R. Blackburn GL. Shimazu K. 37. Lebwohl MG. Santoro NF. Kimiagar SM. Food Chem Toxicol. Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. Circulation. 11. 2002. Soy protein. Saladi RN. Arjmandi B. 89. Barnes K. Rubio R. Van Horn L. Cholesterol lowering benefits of soy and linseed enriched foods. 2007. 59-65. Sandoval M. Heber D. Berhow MA. Cui Y. Clark DA. Soja und Rotklee: Phytoestrogene in der Prävention. Nutr J. Assessment of soy phytoestrogens' effects on bone turnover indicators in menopausal women with osteopenia in Iran: a before and after clinical trial. Freedman RR. Proc Soc Exp Biol Med. 1. Sammartino A. 1767-1774. 857-866. Asia Pac J Clin Nutr. Bujnowski D. Mannick EE. 1034-1044. Warri A. Smeds A. J Nutr. Nutr Cancer. Zhang XJ. 45-49. Rosser CJ. Menopause. 17. Lichtenstein A. 633-640. Ikeda Y. 20-30. 2005. Ridges L. Samedi V. Shiverick KT. Winston M. 2003. Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys. 1548-1553. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Airio M. Larijani B. Di Stefano M. 2005. 964-972. Chemoprevention of skin cancer by isoflavone genistein. 2001. Chin A. 113. 2006. 10. 65-66. Rohr U and Mitglieder des Konsensustreffens-Wien. Protection against photoaging in the hairless mouse by the isoflavone equol. Badger TM. Rice L. 81. Meyer B. Uesugi T. 137. Moerman K. 179-181. 2. Rhodes M and Price KR. 2003. J Med Food. Academic Press/Harcourt Brace & Company Publishers. Role of dietary lignans in the reduction of breast cancer risk. 88. Am J Kidney Dis. 2004. Loprinzi CL. Howe P. Gynecol Endocrinol. Roudsari AH. 450-459. Prentice A (eds. and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Astheimer L. Sakemi T.). Reinwald S and Weaver CM. Kris-Etherton P. 51. Pharmazeutische-Zeitung. Jayo MJ. Setchell KD. Reynolds K. Preiser JC. A meta-analysis of the effect of soy protein supplementation on serum lipids. Miller MJ. 204-211. Salzman AL. 351357. Sadowska-Krowicka H. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. 217. 2004. Di Carlo C. Wu D. 1999. Anthony MS. Wei H. Rao JY. Daidzein-rich isoflavone-aglycones for menopausal symptoms.288 289 290 291 292 Reeve VE. Chew E. Sartippour MR. Allen L. 2005. In: Encyclopedia of Human Nutrition. Rowlands JC. Widyarini S. 40. Effects of genistein on the endometrium: ultrasonographic evaluation. J Clin Endocrinol Metab. Caballero B. 4362-4370. 2004. Harris W. Ricciotti HA. Reame NK. Mol Nutr Food Res. 2006. Brooks MN. Clarkson TB. 1998. Attenuating effect of a semipurified alcohol extract of soy protein on glomerular injury in spontaneous hypercholesterolemic male Imai rats. Soy isoflavones and bone health: a double-edged sword? J Nat Prod. 4. Eloby-Childess S. Wang H. Szabo NJ. Int J Gynaecol Obstet. Medrano T. Oliver PD. 30. Phytochemicals: classification and occurrence. 69. Am J Cardiol. Estrogenic and antiproliferative properties of soy sapogenols in human breast cancer cells in vitro. Apple S. New York. Sirtori CR. Setchell KD and Lydeking-Olsen E. 47-53. Ishibashi T. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Can Fam Physician. 3. human observational. Deutsche Apotheker Zeitung. 593S-609S. 2004. J Steroid Biochem Mol Biol. 1299-1308. 43. Sirtori CR and Lovati MR. Risks and benefits of soy phytoestrogens in cardiovascular diseases. 2004. 389-393. 1474S-1479S. 68. Somekawa Y. 67. Austin LM. Seidl MM and Stewart DE. Siow RC. Soy isoflavone analysis: quality control and a new internal standard. Takahashi A. Chiguchi M. Stark A and Madar Z. 6. Coffey DS. The rising incidence of breast cancer in women and prostate cancer in men. climacteric symptoms and osteoporosis. 23. Zirkin BR. Song T. Brown NM. Palena C. 37. Mango D. Aso T. 2007. J Asthma. Urology. Barua K. J Pediatr Endocrinol Metab. Effects of the isoflavone 4'. 8. Phytoestrogens: a review of recent findings. disposition. Dietary intake of soy genistein is associated with lung function in patients with asthma. de Winter P. 7. Ewing LL. Johnson SK. Riva A. Lazinsky A. Strandberg JD. 1992.) CRC Press. Subbiah MT. Soy proteins and cardiovascular disease. Soy proteins. 865-870.the phytoestrogens (review). Mastronarde J. Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes. and atherosclerosis. Sirtori CR and Johnson SK. Blumenthal M. Mancuso S. Oncol Rep. cholesterolemia. Murphy PA. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo. Miyao N. Tsukamoto T. Buseman G. 384-392. Phytoestrogens: end of a tale? Ann Med. 41. Creutzinger V. Adlercreutz H. 2002. 665-682.7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)induced photodamage. Heubi JE. 233-241. Am J Clin Nutr. Schmidt M. 44. Gynakologie-Soja-Isoflavone bei Wechseljahresbeschwerden-Effekte. Lebwohl M. 317-321. Mann GE. 833-843. 2001. Wise R. In: Soy in Health and Disease Prevention. 78. 1999. 1027-1035. 6. 423-438. J Nutr. Soy intake related to menopausal symptoms. Morazzoni P. Yuan J. Stephens FO. Dozor AJ. Michihiro S (ed. Bombardelli E. Wolfe B. Menopause. Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy? Menopause. 97. Setchell KD. 2002. Free Radic Biol Med. Liu JH. Scheiber MD and Rebar RW. 561-572. 1998. Rebar RW. Systematic review of scientific and lay literature. Bioavailability. Obstet Gynecol. and dietary intervention studies. 15. 2001. and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. Curr Atheroscler Rep. Boca Raton. cancer. Menopause. Drug Saf. 148. Breast cancer: aetiological factors and associations (a possible protective role of phytoestrogens). 755-760. 133. Sirtori CR. and bone mineral density in postmenopausal Japanese women. Lu Y. 2000. Holbrook JT. Signorile PG. Kitamura H. Stephens FO. 1999. 2005. 1997. Sharma OP. Shyong EQ.308 Sasamura H. Am J Clin Nutr. 1998. Zimmer-Nechimias L. Anselmi Angeli RA. Setchell KD. Scheiber MD. Aust NZ J Surg. Arnoldi A. Mechanismen und Anwendungssicherheit. 64. Jakate AS. 448 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 . Williams L. 2001. Phelps RG. Wei H. Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Scambia G. Rowlands DJ. Saladi RN. Masumori N. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. 2003. 105-111. Dietary influences: a possible preventive role for nature's sex hormone modifiers . Gallo D. 24. 2003. 909-925. serum lipids. Desai PB. 17-41. Alternative treatments for menopausal symptoms. 2008. Smith LJ. 45-51. 557564.5. Carcinogenesis. 2006. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. Li FY. 2001. 42. 109-115. Itoh N. Hanson SA. Biyani MK. soy protein isolate and bifidobacteria. Clough K. 48. 2007. Uesugi T. Biyani MK. 207-214. 2001. Wang RH. 83. Brown SS. 2001. 191205. This P. 8. Twaddle NC. Indian J Exp Biol. 24. J Chromatogr B Biomed Sci Appl. Nelson SE. Hormone-related dietary factors and estrogen/progesterone-receptor defined postmenopausal breast cancer Reproprint AB. 2001. High-throughput quantification of soy isoflavones in human and rodent blood using liquid chromatography with electrospray mass spectrometry and tandem mass spectrometry detection. daidzein and glycitein. effects on osteoporosis & menopausal symptoms. Tice JA. Toda T. 2003. Doerge DR. Banavalikar MM. 11-33. J Natl Cancer Inst. 475-486. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones. Tham DM. 2003. Fertil Steril. Biol Pharm Bull. Schinnar R. Int J Fertil Womens Med. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. Wang A. Taku K. Thiebaut AC. Strom BL. epidemiological. 39. Thomas BF. 760. 14. 7. Banavalikar MM.329 330 Stoll BA. 2007. 368-372. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. Taylor M. Alternatives to HRT: an evidence-based review. Jeffcoat AR. Taki Y. Development of an isoflavone aglycone-enriched soymilk using soy germ. Reuss F. Huber JC. Ettinger B. Haskell WL. Magdelenat H. genistin. Gardner CD. 472-479. Touillaud MS. and glycitin. Suthar AC. The North American Menopause Society. Ashton JF. 2001. JAMA. Wang X. Stockholm. 129-134. Clavel-Chapelon F. 8. 301-312. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. 1998. Cell Death Differ. Food research international. De La Rochefordiere A. an isoflavone from soy (Glycine max): part II--anti-cholesterol activity. 2007. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical. Shah NP. Indian J Exp Biol. Endocr Relat Cancer. 2001. Menopause. Bloeden LT. Leodolter S. Quantitative analysis of the principle soy isoflavones genistein. Karolinska Institute. Sammel MD. 2006. 777. Menopause. Phytoestrogens after breast cancer. The North American Menopause Society. 2004. 2000. Fournier A. 807-814. 1243-1249. 37. 2004. 290. Tsangalis D. 286. Wallace R. Deng CX. Ensrud K. Eating to beat breast cancer: potential role for soy supplements. Cao L. cell cycle arrest. 2002. 85. Am J Clin Nutr. an isoflavone from soy (Glycine max): part I--anti-cancer activity. Macones GA. J Chromatogr B Analyt Technol Biomed Life Sci. Churchwell MI. Suthar AC. and mitotic catastrophe. Stojanovska L. Dix KJ. 87. Cummings SR. Barnhart KT. and their primary conjugated metabolites in human plasma and urine using reversed-phase highperformance liquid chromatography with ultraviolet detection. Endoh K. 11. Busby MG. Phytoestrogens in clinical practice: a review of the literature. 511-519. 64-68. Stallings VA. 139-145. Suzuki R. Scheffler NM. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Mitchell RA. Fourquet A. Tsuji K. Sato Y. Ishida H. JAMA. 520-525. 2007. 1997. Zeisel SH. Drulis JM. Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints. Pharmacological activities of Genistein. 2223-2235. 215-229. Pharmacological activities of Genistein. Tscherne G. Watanabe S. 39. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. Boutron-Ruault MC. Blackwell T. 99. 11481156. Wilcox G. J Clin Endocrinol Metab. and mechanistic evidence. 2001. Hill JM. Ziegler EE. daidzin. Niravong M. Tominaga Y. Cross HS. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Tempfer CB. 449 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 . 223-225. Bentz EK. Ann Oncol. Umegaki K. 2002. Morgan T. Am J Clin Nutr. J Manag Care Pharm. Cohn W. Miura T. 1996. Wahala K. 2005. Barnes S. Ausman LM. Yamaguchi M. 1056-1068. 14-19. Radiation research. Vega-Lopez S. Anthony MS. Antioxidant and antipromotional effects of the soybean isoflavone genistein. 1509-1514. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. Wagner JD. Epidemiology of soy isoflavones and cardiovascular disease. 214-221. 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 450 . Verdegem PJ. 124-130. Burke GL. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. J Nutr. Kenemans P. 2004. 2001. placebocontrolled study. Washburn S. AOCS Press. Devaraj S. Chambers GK. Frank T. Vitolins MZ.). Johnson EJ. Sarkar FH. Menopause. Varani J. double-blind study. Retinoid-induced epidermal hyperplasia in human skin organ culture: inhibition with soy extract and soy isoflavones. 1449-1455. Joiner MC. 43-49. Kucuk O. 12. 1710-1715. 843-852. 221-228. 1998. Yeum KJ. 2002. and menopausal symptoms in perimenopausal women. J Clin Oncol. Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. 2377-2383. Riegger C. 269275. 1174-1184. randomized. Burke GL. Lobo R. Wattie A. Wang Y. Arai Y. controlled clinical trial. Upmalis DH. Lamia CA. Che M. Anthony MS. Ill. Van Patten CL. Atherosclerosis. Vincent A and Fitzpatrick LA. 2005. 260-267. Wuttke W. Gelmon KA. Zhang X. 19. Wang HJ and Murphy PA. Velasquez MT and Bhathena SJ. Watanabe S. 20. urine and feces of men after ingestion of 60 g baked soybean powder (kinako). van der Mooren MJ. Biofactors. Lateef H. 2005. 1995. Adv Ther. 412-420. Wang Y. Black cohosh: just another phytoestrogen? Trends Endocrinol Metab. Exp Mol Pathol. 2008. tolerability. Bradley L. J Agric Food Chem. 128. Safety. Proc Soc Exp Biol Med. 2000. 44. Kelley EA. Olivotto IA. Emons G. Jones PJ. 14. 1998. Metzner J. 176-183. Viereck V. Jialal I. Dietary phytoestrogens: a possible role in renal disease protection. Lebwohl M. 1999. Lecker JL. Ouchi K. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized. 236-242. Templeton E. Mass balance study of isoflavones during soybean processing. Bowen R. In: Phytoestrogens and Health Gilani GS and Anderson JJB (eds. Clin Obstet Gynecol. Wei H. van de Weijer PH. Prior JC. Ausman LM. Hillman GG. Effect of soy protein supplementation on serum lipoproteins. Wang Y. 44. 2004. 2000. Pharmacokinetics of soybean isoflavones in plasma. Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model.348 349 350 351 Uesugi S. Verhoeven MO. 73-80. van der Burgt LM. 2001. Ishiwata N. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized. 81. 22. 77. 7. 37. Cone FL. 75. blood pressure. Bowen R. Takahashi T. Sobue T. and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. Warren M. Wei H. Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Watanabe S. 22. Lichtenstein AH. Hislop TG. Carcinogenesis. Uehara M. Anthony M. 2004. Champaign. Ullmann U. Menopause. Soy phytoestrogens: research on benefits and risks. 16. Umland EM. Soy isoflavones: are they useful in menopause? Mayo Clin Proc. Cai Q. Adlercreutz H. double-blind. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter. 208. 173. Am J Kidney Dis. Mazur W. 2006. Doerge DR. 166. Menopause. Lichtenstein AH. Raffoul JJ. Soy protein reduces triglyceride levels and triglyceride fatty acid fractional synthesis rate in hypercholesterolemic subjects. 2005. 65-78. placebo-controlled. Perone P. 6. 7-13. Cline JM. prehypertensive. 126. Barnes S. Tseng CC. Husband AJ. 83. 2005. 2002. Grynkiewicz G. Widyarini S. 361-369. 81. Williams JP. J Womens Health (Larchmt). Husband AJ. Tyrosine kinase inhibitor effects on avian osteoclastic acid transport. Kris-Etherton PM. Widyarini S. Isoflavone genistein: photoprotection and clinical implications in dermatology. Parsons PG. Reeve VE. 167. Opolski A. 23. 253-262. Phytoestrogens in cancer prevention and therapy-mechanisms of their biological activity. 2001. Protective effect of the isoflavone equol against DNA damage induced by ultraviolet radiation to hairless mouse skin. Williamson G and Manach C. Isoflavonoid compounds from red clover (Trifolium pratense) protect from inflammation and immune suppression induced by UV radiation. Zhang X. 1491-1496. Photochem Photobiol. Phelps R. Walker C. Mousa SA. Anticancer Res. Reeve VE. 89. Wan P. 381-406. 2006. 831-839. Churchwell MI. Whiteman DC. Widyarini S. 667-690. 1995. 125. 21-29. 7. Gallagher NL. 16. Welty FK. 2357-2366. Wang Y. 2006. 3811S-3819S. 32-37. Lee KS. Reeve VE. 2002. Lebwohl M. 2003. Bordi PL. J Womens Health (Larchmt). Lu Y. J Nutr. 1998. 2007. Review of 93 intervention studies. Carcinogenesis. 2000. 21. Wu AH. Baillieres Clin Endocrinol Metab. Lebwohl MG. Newmark HL. 2005. Landau JM. Inhibition of carcinogenesis by dietary polyphenolic compounds. Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. Protective effect of the isoflavonoid equol against hairless mouse skin carcinogenesis induced by UV radiation alone or with a chemical cocarcinogen. Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein. 2005. 25. 2006. Isoflavonoid photoprotection in mouse and human skin is dependent on metallothionein. Menopause. Reeve VE. 631S-638S. 12. Zhou JR. 217-223. Wietrzyk J. Lew NS. Cancer Lett. II. Effect of soy nuts on blood pressure and lipid levels in hypertensive. 2005.368 369 370 371 Wei H. 10601067. 81. 243S-255S. Am J Clin Nutr. 1168-1173. 1998. 2006. J Invest Dermatol. 1369S-1374S. Wilcox JN and Blumenthal BF. Jarry H. Hilpert KF. Christoffel V. Palep SR. 198-204. Jordan SE. Phytoestrogens for hormone replacement therapy? J Steroid Biochem Mol Biol. J Nutr. Twaddle NC. Lew NS. Seidlova-Wuttke D. Flickinger BD. Welty FK. Saladi R. Arch Intern Med. J Vet Sci. 14. Lee KS. Hankin J. Reproductive actions of phytoestrogens. Messina MJ. and normotensive postmenopausal women. Empie MW. Doerge DR. Bioavailability and bioefficacy of polyphenols in humans. Williamson-Hughes PS. Am J Clin Nutr. Annu Rev Nutr. 74. Spinks N. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Yang CS. Zhou JR. Whitten PL and Naftolin F. 133. Pedley J. West SG. J AOAC Int. Allanson M. Yu MC. Quantification of tamoxifen and metabolites and soy isoflavones in human plasma using liquid chromatography with electrospray ionization tandem mass spectrometry. Blair HC. The association between soy nut consumption and decreased menopausal symptoms. Pike MC. Redox Rep. Williams LD. Huang MT. 68. Wuttke W. Lampe JW. Wang Y. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Moore J. 2007. Wei H. Juturu V. Widyarini S. 2001. Westphalen S. Boyle GM. Protective effect of isoflavone derivative against photocarcinogenesis in a mouse model. Shyong E. 133-147. 2002. Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy. Widyarini S. Photochem Photobiol. Nasca M. 185. 465-470. 5. 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 451 . Spinks N. 13. 156-158. S23-27. Bufalino L. Agnusdei D and Bufalino L. 2005. 1890-1895. Gugger ET. Albertazzi P. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. 1999. 13. Efficacy of ipriflavone in established osteoporosis and long-term safety. Wolk A. Arch Intern Med. 1995. 72. 2002. 457-464. Osteoporos Int. Chemoprevention of breast cancer: current status and future prospects. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Clinton SK. Cross H. 2006. Arjmandi BH and Smith BJ. 1988. 462-466. Li Q. Wilcox AJ. 62. 2004. Manios Y. 397-408. Williamson G. Committee on Toxicity draft report on phyto-oestrogens and health – review of proposed health effects of phyto-oestrogen exposure and recommendations for future research Nutrition Bulletin. Steiner C. Li L. 80. Branca F.388 Ye YB. placebo-controlled trial. J Nutr Biochem. 11. Germain AS. J Clin Endocrinol Metab. 42. 467. 2000. Critical review of health effects of soyabean phyto-oestrogens in postmenopausal women. Lise Nielsen I. Toda T. Carroll DG. 65. The nature and utility of the phytoestrogens: a review of the evidence. 2000. Haney AF. Watanabe S. Diamandis EP. Altern Med Rev. 1685-1690. 73. 317327. Am J Clin Nutr. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Cassidy A. 45. 844-852. Cassidy A. Su YX. Front Biosci. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. Baird DD. 241-243. 35-49. 16281635. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women: a single-blind randomized. Calcif Tissue Int. Soy isoflavone intake lowers serum LDL cholesterol: a metaanalysis of 8 randomized controlled trials in humans. 2005. Proc Nutr Soc. 165. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. 2006. Alekel DL. 140-146. Shu XO. Maturitas. Albertazzi P and Purdie D. Melby MK. Tanaka T. McLachlan JA. Soy and its isoflavones: a review of their effects on bone density. 7 8 9 10 11 452 . 76-92. Zheng W. Umbach DM. 2006. Zhuo XG. 2395-2400. Li H. Brinkley L. 134. 66. Hughes CL. Brynin R. Pak CY. Setchell KD. 5. Atkins S. Gao YT. Nonhormonal Therapies for Hot Flashes in Menopause. 1995. 2005. Wang Z. 130-137. 2006. Zhang X and Liu Y. 2249-2256. Gennari C. Tetens I. J Nutr. Blackburn GL. J Nutr. 61 Suppl 1. 2003. Tang XY. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. 327334. Zhan S and Ho SC. 129. Steroid hormone activity of flavonoids and related compounds. Eur J Nutr. 1997. Jenkins DJ. 9. Weinberg CR. Hall W. Zhongguo Linchuang Kangfu. American Family Physician. Zand RS. 7. Breast Cancer Res Treat. 28. Hanson KB. Yang G. 205-213. J Clin Endocrinol Metab. Am J Clin Nutr. Breslau NA. Guo Y. 2002. Zhou JR. Stewart JW. Zhao X. Peterson CT. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal. 173-185. Verbruggen MA. 2002. Soy isoflavones' osteoprotective role in postmenopausal women: mechanism of action. ID 1655: “Soy Isoflavones” and “Bone health and soy foods” 389 390 391 392 393 394 395 1 2 3 4 5 6 Agnusdei D. 81. bone-active drug ipriflavone. Cardiovascular protective effects of soy isoflavone. Lansdell L. Zhang X. Hill KD. Curr Opin Clin Nutr Metab Care. controlled trial. 253-271. Cincotta M. Phytoöstogene. Sadler MJ (ed. 2000. Crisafulli A. 234-239. 2004. Haney E. Geller SE and Studee L. Squadrito F. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. 11. Medical Economics Company. 589-599. Miller J. Vlietinck AJ. Huang HY. Osteoporos Int. Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause. Wahlqvist ML. Climacteric. Alekel DL. 9. Huber J. Ho SC. 2007. randomized. Pizzoleo MA. 2004. Lau J. 509-517. Murkies AL. 2003. Ho SC. Woo J. Phytoestrogens: recent developments. Wong E. Springer Verlag. 295. Katoh R. Sham A. 2004. 2006. 1904-1912. Soy protein consumption and bone mass in early postmenopausal Chinese women. Lydeking-Olsen E. Nedrow A. Hansel I. Ernährungs-Umschau. 2001. Vanden Berghe D. 7. Jaenicke C. Shieh MJ. 1363-1369. Messina M. Frisina N. 17. Phytotherapie als Alternative . Effects of long term soy dietary supplementation on bone mineral density. 69. Isoflavones and skeletal health: are these molecules ready for clinical application? Osteoporos Int. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Rice GE. J Nutr Biochem. In: 6th international symposium on the role of soy in preventing and treating chronic disease. Lam SS. JAMA. Lerner E. 1992. and calcium intake: a double-blind. Huang SY. 2006. Effects of dietary phytoestrogens in postmenopausal women. Morabito N. Yang HP. 1-7. Yang HT. Eur J Nutr. Soymilk or progesterone for prevention of bone loss--a 2 year randomized. Gruenwald J. Kulling S and Watzl B. Ma DF. D'Anna R. Kurzer MS. Climacteric. Lasco A. Harkness LS. body weight. Beck-Jensen JE. 1. 2006. Walker M. Vesco KK. Strauss BJ. 649-658. Planta Med. In: PDR for herbal medicines. New Jersey. Grehan M. De Bruyne T.12 Chen YM. 2057-2071. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. Leung PC. 246-257. Medley G. Yang TC. Yi Q. Ientile R. 43. DFG (Senatskommission zur Beurteilung der gesundheitlichen Unbedenklichkeit von Lebensmitteln). J Bone Miner Res. 2004. Altavilla D. Nelson HD. placebo-controlled trial. 2003. 1000-1007. Ho S. 2003. Best Pract Res Clin Endocrinol Metab. 2003. Berlin. 246-254.) Nutrition Bulletin. Isoflavone als Phytoestrogene in Nahrungsergänzungsmitteln und diätetischen Lebensmitteln für besondere medizinische Zwecke. Sehgal AR. Wang PY. Fiedler K. 16. 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 453 . J Bone Miner Res. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. Humphrey L. 2002. Soy and Red Clover for Midlife and Aging. 14. 245-263. Lam S. 14. Cos P. Oravec D. Phyto-oestrogens. Soya. J Womens Health (Larchmt). Eur J Clin Nutr. 2006. Louvrien F. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. 50. Chan SG. Fu R. 2006. 1998. Qin LQ. Ho SC. Dalais FS. 13. Phipps WR. 17. Nicolaidis C. 361-368. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. Ärzte Krone Sonderheft Frauengesundheit. Ho SS. 835-842. 30. Vergara C. Holm-Jensen T. Migliaccio S and Anderson JJ. Ayton R. Woo JL. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. Hager's Handbuch der pharmazeutischen Praxis. Chen Y. Menopause. 2003. Brendler T. Apers S. 124-129. Setchell KD. Pieters L. 2006.Klimakterium: Domäne der Phytoöstrogene sind leichte bis mittelschwere klimakterische Beschwerden. Duncan AM. Corrado F. Gaudio A. 17. An open label clinical trial to evaluate a satiety aid for weight loss in overweight to obese. Ishiwata N. 454 . Am J Clin Nutr. Watanabe S. Gumbmann MR. Chiguchi M. rice. Messina MJ. Lippl F. Obstet Gynecol. Dugan GM. 45. 2006. Peptides. Creutzinger V. 97. Kemin Consumer Care White Paper 2005. Williamson-Hughes PS. 1027-1035. Soy intake related to menopausal symptoms. and bone mineral density in postmenopausal Japanese women. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Cholecystokinin-Decreased Food-Intake in Rhesus-Monkeys. 221-228. 46. 109-115. 133. 2001. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. 7-20. 2006. 2005. 15. J Nutr.. Sadler MJ (ed. 2003. Jr. Ouchi K. 55. Wagenpfeil S. Somekawa Y. 165. Effects of the phytoestrogen genistein on bone loss. Baker EC. Heubi JE. Mchugh PR. Flickinger BD. Dana S. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. 2005. and dietary intervention studies. serum lipids. Dana S. placebo-controlled trial. 119. Biological Actions of Cholecystokinin. 135. healthy adults. 1994. Ye YB. 230. Kemin Industries. Empie MW. Levy L. Jakate AS. European Journal of Nutrition. Kemin Industries. Li H. and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. Gibbs J. 1243-1247. 2005. disposition. Tang XY. Hebeisen Y. Verbruggen MA. Li Q. Ishibashi T. Rackis JJ. LaCroix AZ. 1598-1609. Kemin Consumer Care White Paper 2005. Zimmer-Nechimias L. Wolfe B. Inc. Brown NM. Uehara M. J Nutr.) Nutrition Bulletin. 1890-1895. Zhang X. Li SS. Kemin Consumer Care White Paper 2005. Stillman RJ. Usui T. Schusdziarra V. Biofactors. 731-755. Pancreatic Response in Rats and Mice to Trypsin-Inhibitors from Soy and Potato after Short-Term and Long-Term Dietary Exposure. Kemin Industries. Potter SM. 270-277. 53. Erdmann J. 35 36 37 38 39 40 41 42 43 44 ID 1656: “Standardised Potato Extract” and 2Satiety/Weight management/Promotion of CCK release and soy foods” 1 2 3 4 5 6 7 Crawley JN and Corwin RL. Setchell KD. Setchell KD and Lydeking-Olsen E. Falasco JD. Aso T.33 34 Newton KM. Soy protein and bone mineral density in older men and women: a randomized trial. 15-18. Weaver CM and Cheong JM. Arch Intern Med. Qu P. 2005. 2006. 1976. Yang G. Pharmaceutical prospects of phytoestrogens. Teng H. 2006. Shay NF. 831-839. Inc.and pasta-rich test meals. In: 6th international symposium on the role of soy in preventing and treating chronic disease. Interim evaluation at one year. Potter JD. 1375S1379S. Soy isoflavones and bone health: the relationship is still unclear. Spangler WL. An open label phase II study of Satise® for appetite control and weight loss. Su YX. Bioavailability. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo. 2006. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women: a single-blind randomized. Shu XO. Endocr J. 22. Journal of Nutrition. Am J Clin Nutr. 2004. Gao YT. 2005. Desai PB. Squadrito F. 1998. Food intake and plasma ghrelin response during potato-. Zheng W. Maturitas. 13. 78. An open label phase II study of Satise® for appetite control and weight loss. Lampe JW. Dana S. 196-203. Baum JA. human observational. Uesugi S.cardiovascular risk prevention and climacteric symptoms: a two year double blind placebo controlled study. 593S-609S. Eur J Nutr. 2007. American Journal of Physiology. 68. Erdman JW. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. Inc. 2003. Menopause. 1989. 327334. 333-350. Rushakoff RJ. Pharmacology & toxicology. monitor peptide. diabetes. Peikin SR. 48. 2414-2423. Tatemoto K. Shao AE. Bjock I. L. 51-58. Folsch UR. Ritter RC. Reid DF. Covasa M. 2001. 1990. Diabetes Care. 279. Ostman E. White Paper 2005. 353-370. 16. Moore M. Green GM. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 455 . 32. Jensen RT. Dana S. Inc. Schwartz JG. 1996.C. Digestive Diseases and Sciences. 278. Owyang C. Oral-Administration of Proteinase Inhibitor-Ii from Potatoes Reduces Energy-Intake in Man. Herzig KH. Melton PM. Li Y. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Halford JCG. R676-R685. Beglinger C. Kemin Industries. Liddle RA. Blundell JE. Hill AJ. Ketterer S. 1993. American Journal of Physiology. 1988. Kemin Industries. 2002. Pancreas. 2002. Phillips WT. Current Drug Targets. Matson CA. 2. Regulation of Cholecystokinin Secretion by Intraluminal Releasing Factors. Schwartz JG. Jama-Journal of the American Medical Association. 1994. 181187. European Journal of Clinical Nutrition. and cardiovascular disease. 1999. Liddle RA. 241-246. Hu J. Leeman M. Reduced Postprandial Blood-Glucose Levels in Recently Diagnosed Non-Insulin-Dependent Diabetics Secondary to Pharmacologically Induced Delayed GastricEmptying. Discovery of a cholecystokinin-releasing peptide: Biochemical characterization and physiological implications. Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans. 91.Physiological mechanisms relating to obesity. 2000. 2005. Cannon TA. 263. Glycaemic and satiating properties of potato products. Kemin Consumer Care. 42. Hildebrand P. Neuropeptides. Dana S. Kissileff HR. 255-262. Pisunyer FX. 1999. Radosvich J. 81. 1675-1681. Beccaria L. 2008. 17. 1992. Cholecystokinin (Cck-8) Affects Gastric Pressure and Ratings of Hunger and Fullness in Women. Carter JD. 1998. Mclaughlin CL. R189-R195. Kemin Consumer Care White Paper. 1983. American Journal of Physiology-Regulatory Integrative and Comparative Physiology. Physiological-Role for Cholecystokinin in Reducing Postprandial Hyperglycemia in Humans. Mcmahan CA. Pharmacology of appetite suppression: Implication for the treatment of obesity. Guan D. 1995. and CCK receptors. The efficacy of potato proteinase inhibitor II in promoting weight loss in adults: a meta-analysis of clinical studies. American Journal of Physiology-Gastrointestinal and Liver Physiology. 1996). G319-G327. Miyasaka K and Funakoshi A. 2000. 287. 35. Edmonson B. Ludwig DDS. Proceedings of the National Academy of Sciences of the United States of America. 87-95. Inc. 33. Krautheim A. R452-R456. The effectiveness of potato proteinase inhibitor II in promoting satiety in healthy human subjects: cholecystokinin data. 244. Diazepam binding inhibitor is a potent cholecystokinin releasing peptide in the intestine (vol 93. Chinese Journal of Physiology. 38. 2005. 277-283. R882-R890. 2005. Journal of Clinical Investigation. Treatment with an Oral Proteinase-Inhibitor Slows Gastric-Emptying and Acutely Reduces Glucose and Insulin Levels after a Liquid Meal in Type-Ii Diabetic-Patients. CCK-releasing peptide. Matson CA. Regulation of cholecystokinin secretion in humans. 113-120. Drewe J. American Journal of Physiology.C. Baile CA. Cholecystokinin and leptin act synergistically to reduce body weight. Food-Intake Response to Modulation of Secretion of Cholecystokinin in Zucker Rats. Ryan CA. Goldfine ID. L. Peikin SR. American Journal of Physiology-Regulatory Integrative and Comparative Physiology. Liddle RA. Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Hu J. Phillips WT. Edmondson B. pg 7927. 387-399. Louie M. 2000. Ritter RC. Physiology & Behavior. Journal of Gastroenterology. 93. Luminal feedback regulation. Ohe Y. 14214-14214. Morita ET. Radosevich J. The glycemic index . Owyang C. 62. Schon I.8 Gutzwiller JP. sources. Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids. 15. Awata N. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. 1983b. Derr J. 40. oleic acid. 1991. Yamamura Y. Hasegawa H. A proteinase inhibitor extract from potatoes reduces postprandial blood glucose in human subjects. Am J Clin Nutr. Kris-Etherton PM. 12011205. WHO/FAO (World Health Organization). 1036-1040. In: Dietary Reference Intakes for Energy. 45. Food intake and the regulation of body weight. Schwartz MW. 371-377. Am J Clin Nutr. 65. Am J Clin Nutr. 2003. 2005. Awata N. and absorption. JANA. Keys A. 510-516. Diabetes Care. Kris-Etherton PM and Mustad VA. and Amino Acids. and linoleic acid on the serum lipoprotein profile of humans. Total and LDL cholesterol levels. Annual Review of Psychology. Fatty Acids. 1244-1248. digestion. Thijssen MA and Mensink RP. 2005. Woods SC. Atmaca G. 543-557. Double-blind randomized crossover trial of taurine in congestive heart failure. 255-277. 1988. 82. Sawamura A. 2001. 1970. Handbuch Protein und Aminosäuren. Ohta H. WHO Technical Report Series 916. Kris-Etherton PM. Gebauer SK. Mensink RP. ID 1658: “Taurine” and “Antioxidant properties” 5 6 7 8 9 10 11 12 1 2 3 4 Arndt K and Albers T. Plasma cholesterol-predictive equations demonstrate that stearic acid is neutral and monounsaturated fatty acids are hypocholesterolemic. Hasegawa H. Therapy of congestive heart failure with orally administered taurine. Seeley RJ. 5. Jespersen J. Jenkins AL. 1184-1193. 2005. Kris-Etherton PM and Yu S. 61. Etherton TD. Zhang J. Cholesterol. Curr Ther Res Clin Exp. 1994. Harada H. Sawamura A. 54. 456 . Antioxidant effects of sulfur-containing amino acids. Fiber. Nutrition and the Prevention of Chronic Diseases. Wolever TMS. 23. Etherton TD. 1029S-1036S. Griel AE. Yonsei Med J. N Engl J Med. Yu S. Tholstrup T. Chocolate feeding studies: a novel approach for evaluating the plasma lipid effects of stearic acid. Kishimoto S. 2004. Am J Clin Nutr. Josse RG. 51. Shao AE. Marckmann P. Sandstrom B. Washington DC. 34. Yamauchi K. 318. 562-564. 2005. Arnsberg. Ogura K. Essmann MK. Carbohydrate. Expert Report: Diet. 398-408. 59. 1997. Small differences in the effects of stearic acid. Am J Clin Nutr. Protein. 1628S-1644S. 6. 1129-1139. 29-38. Harada H. Comparison of effects of palmitic and stearic acids in the diet on serum cholesterol in man. Effects of stearic acid on plasma lipid and lipoproteins in humans. Psota TL. 1983. Baskin DG. 1193-1200. Wong GS. 2003. 483. National Academies Press. Clin Ther. Fat. Grande F. Effects of fats high in stearic acid on lipid and lipoprotein concentrations in men. Azuma J. Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. Lipids. IoM (Institute of Medicine). ID 1657: “Stearic acid” and “Lipid metabolism” 1 2 3 4 Bonanome A and Grundy SM. 776-788. Am J Clin Nutr. Vuksan V. Denke MA and Grundy SM. Anderson JT. Ogura K. Jenkins DJA. 1995. 60. Lipids.28 29 30 Spreadbury D. Beneficial Effect of LowGlycemic Index Diet in Overweight Niddm Subjects. 40. 2000. Azuma J. Novagenics Verlag. 1994. Am J Clin Nutr. Dietary stearic acid and risk of cardiovascular disease: intake. 1992. Kishimoto S. Lehrstuhl für Lebensmittelchemie. 214-215. Chesney RW. Han X. Seghieri G. Sarandol E.. High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism. Dawson R. Adv Exp Med Biol.). Budreau AM. Expert Consultation: Energy and protein requirements. 708-711. Amino Acids. Therapeutic applications of taurine. Prentice A. Reusens B. Ehrinpreis MN. Ohta H. Sturman J. 34. Helms RA. Huxtable RJ (eds. and nutrition. Mian M. 385-391. Taurin. Yang S. Ghirlanda G. Chronic taurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats. Rev Med Chil. Mattana A. Seminararbeit von Michael Bretz. Altern Med Rev. Bretz M. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. 1636S1640S. 23. Di Leo MA. 2003. 276-282. Free radicals. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. 3.Dr. 2007. [Biologic and physiologic role of taurine and its derivates]. Iwata H. Jpn Circ J. 117. Azuma J. The Role of Taurine in Infant Nutrition. Wu G. 22. Chesney RW. OKG. Biochemie. Maliakkal J. I S. Lepore D. 2004. 61. Nutrition. Awata N.P.05. Eugen Ulmer Verlag. Kishimoto S. 1994. Bidri M and Choay P. Messina S. 1115-1119. Remacle C. Lombardini JB. Canas P and Valenzuela A. Santini SA. 136. Am J Clin Nutr. 1989. 95-99. Anwendung. glutamine. Bouckenooghe T. 2002. 61. Heart Failure Research with Taurine Group. Long-term effect of taurine in congestive heart failure: preliminary report. 8. 833-837. 1-42. Ann Pharm Fr. Kinzie JL. 2006. author reply 215. The sulfur-containing amino acids: an overview. FAO/WHO/UNU (World Health Organization). Sawamura A. 1992. Franconi F. 9. Dirican M. Sawamura A. 55. J Nutr. 32. 2002. The cytoprotective role of taurine in exerciseinduced muscle injury. Biasetti M. Encyclopedia of Human Nutrition.2006 BGBl. 1998. Fang YZ. Schaffer S. Christensen M. Taurine: its biological role and clinical implications. Hamaguchi T. 1992. In: Taurine 3. Technical Report Series 724.Schreiner. Aromenverordnung (AromV). v.5 Azuma J. Kluwer Academic Publishers New York. Takihara K. Elsevier. Yamagami T. Elmadfa I and Leitzmann C. 128-136. Ernährung des Menschen. 1996. Cercone S. 18. Hasegawa H. 454-459. 15. Bundesrepublik Deutschland. Caputo S. Prof. Oxford. Franconi F. 1127. Tas S. Institut für Pharmazie und Lebensmittelchemie. Giardina B. Eugen Ulmer Verlag. 2002. 02. antioxidants. Stuttgart. 2006. Birdsall TC. Ishiyama T. [Taurine: a particular aminoacid with multiple functions]. Harada H. Is taurine a functional nutrient? Curr Opin Clin Nutr Metab Care. Bayerische Julius Maximiliams Universität Würzburg. Brosnan JT and Brosnan ME. 1985. Am J Clin Nutr. Stuttgart. 1985. 2002. Gentiloni Silveri N. 425-433. Jr. Caballero B. 2006. 56. Cynober L. 872-879. Clin Cardiol. 1998. Gironi A. Allen L. Ernährung des Menschen. Dominy J. Clin Exp Pharmacol Physiol. Luk GD. 1998. Awata N. arginine and so on: nutrients or drugs? Clin Nutr. neugefasst durch B. 728-733. 1985. 359. 463-476. Bennardini F. Cejka J. 309-324. Greco AV. Adv Pediatr. 1995. Elmadfa I and Leitzmann C. Miceli M. Azuma J. Desai TK. 2005. Amino Acids. Anichini R. 401-406. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 457 . Usefulness of taurine in chronic congestive heart failure and its prospective application. Chemie. Taurine deficiency after intensive chemotherapy and/or radiation. Ciuti M. Tang CS. Huxtable RJ. Huxtable RJ Huxtable RJ. 17. 75. 2401-2410. 32-36. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. 10. 1978. Sato Y. Ito T. Falke W. 1998. Clin Tech Small Anim Pract. Beijing Da Xue Xue Bao. Geiss K-R.). Noda H. 30. Taurine in health and disease. Kasper H. Circulation. Liss. Seghieri G. 2002. 2006. Liss. Raven. 232-237.). 123. a mechanism for the calcium modulatory actions of taurine. Physiological actions of taurine. Hahn A. Huxtable RJ. Kendler BS. Taurine is a possible anti-atherosclerotic agent. Curr Pharm Des. 1994. Ernährungsmedizin und Diätetik. 2004. Iwata H. Hum Reprod Update. 79-100. Hua HM. 262-270. Protection against cell damage due to hypoxia and reoxygenation: the role of taurine and the involved mechanisms. Cardiovascular actions of taurine. Lourenco R and Camilo ME. Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and its surroundings.28 29 30 31 32 33 34 35 36 37 38 Franconi F. Amino Acids. Nutr Hosp. New York. Taurine supplementation and diabetes mellitus. 39 40 41 42 43 44 45 46 47 48 49 50 51 458 . 207-215. Duchene S. Qiu ZG. Cynober L. Barbeau A and Huxtable RJ (eds. New Horiz. 337-346. München -Wien Baltimore. 1983. 2008. Thuillier F. New York. Geng B. 1996. 37. Metayer S. Michalk DV. Wissenschaftliche Verlagsgesellschaft mbH. Collin A. New York. 1987. Licht C. 72. From heart to hypothesis. Taurin. Kuriyama K. El Mouatassim S. Physiol Rev. Grimble RF. Tesseraud S. Nutritional antioxidants and the modulation of inflammation: theory and practice. Huxtable R and Michalk D. Seiliez I. In: The Role of Peptides and Amino Acids as Neurotransmitters. Kingston R. Geraert PA. Crenn P. 9. 2005. 4. Wang K-L. 1992. Gerhardt MC. Huxtable RJ. Ghirlanda G. Iwata H (eds. 5-17. Deutschland. 1994. 1. 2001. Huxtable RJ. Verlag Urban und Schwarzenberg. Jpn. In: Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Huxtable RJ. Ito T. Clinical Nutrition. 1994. Chang L. Menezo Y. 7. 19. Amino Acids. Guerin P. Franconi F. Zhongguo Zhong Yao Za Zhi. Elsevier GmbH. Myara A. Ito Y. Coudray-Lucas C. 53-97. Loizzo A. 2005. Hamm M. Plasma tauroconjugated bile acid levels in shortbowel (SB) patients undergoing home parenteral nutrition (HPN). 18. The therapeutic role of taurine in ischaemia-reperfusion injury. 2004. Giotti A. [Progress in research on function and mechanism of cardiac vascular system of taurine]. 2004. Ando K. 175-189. Freeman LM. Insights on function.). 1997. Huxtable RJ and Sebring LA Kuriyama K. Mechanisms through which sulfur amino acids control protein metabolism and oxidative status. 525-532. New York. J Nutr Biochem. New York. 13. Iglicki F.. 4. 13. Jester I. 653-658. 45-56. Mercier Y. Murray P. Messing B. Prev Med. Kasper H. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Curr Opin Clin Nutr Metab Care. 15 Suppl. 7. Stuttgart. Plenum Press. Du JB. Plenum. 1985. Fujita T. 2. Regulation of taurine in the heart In: Taurine and Neurological Disorders. Taurine: an overview of its role in preventive medicine. Azuma J. The effect of a taurine containing drink on performance in 10 endurance-athletes. 311-317. Ernährungsmedizin und Diätetik. Folia Pharmacol. 175-185. Kelly CJ. 2006. 1981. 215-219. Wingenfeld P. Lombardini JB and Kenny A (eds. 101-163. 1987. In: Advance in Experimental Medicine and Biology. metabolism and pharmacology of taurine in the brain. Interventional nutrition for cardiac disease. 1989. [A new strategy to treat hyperhomocysteinemia]. Associations between nutrition and cataract. 369-377. Natural Medicines Comprehensive Database. 151-160. 1997. Taurine in mammalian tissue. 1997. Clin Nutr. Thomson Healthcare PDRHealth. Mechanisms of myocardial protection by amino acids: facts and hypotheses. 226. Amino Acids. 1984. 103-108. Miwa S. Shike M. 19-25.asp?mono_id=1024&brand_id=. Timbrell JA. Saransaari P and Oja SS. Neurochem Res. Schneider SM. Nittynen L. Role of taurine in osmoregulation in brain cells: Mechanisms and functional implications. 13. 1-13. 2004. 278-285. Charles RP. Taurine prevents myocardial ischemia/reperfusion-induced oxidative stress and apoptosis in prolonged hypothermic rat heart preservation. 417-424. Role of feline maternal taurine nutrition in fetal cerebellar development: an immunohistochemical study. Lippincott Williams & Wilkins. 2003. Redmond HP.).com/drug_info/nmdrugprofiles/nutsupdrugs/tau_0246. 2005. Philadephia. Trivin F. Taurine and human nutrition. Taurine. 23. 1988. Stapleton PP. 1998. Plenum Press. 509-526. Sardesai VM. New York. Oriyanhan W. 42-48. Age-related retinal degeneration in animal models of aging: possible involvement of taurine deficiency and oxidative stress. Immunonutrition . Messing B. 216-222. Pasantes-Morales H. 22. Myara A. 19. Sturman JA and Lu P. Waterfield CJ. 365370. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. 47. 1989. Ernährungsumschau 47. Stapleton PP. Cousins R (eds. Nutr Rev. Coudray-Lucas C. Stehle P. Sole MJ and Jeejeebhoy KN. 31. 3. 318-326. Schuller-Levis GB and Park E. 16. Trachtman H and Sturman JA. Nutr Clin Pract. 303-311. In: Modern Nutrition in Health and Disease. Gen Pharmacol. 209217 Pasantes-Morales H and Schousboe A. Teil 1: Aminosauren. taurine and homocysteine in cardiovascular diseases. Quesada O. Taylor A. 2000. Br J Nutr. 2006. Gehrardt MF. 10. http://www. 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 459 . 1997. 453-462. 225-234.Nährstoffe mit immunmodulierender Wirkung. Joly F. Taurine: A therapeutic agent in experimental kidney disease. 20. Heart Vessels. Vapaatalo H. 11.). 1995. The in vivo and in vitro protective properties of taurine. Amino-acids. Komeda M. Taurine and neural cell damage. Amino Acids 12. 29. Seabra V. 1995. Schaffer SW. 11.com/monograph. Ikeda T. 627-633. Bouchier-Hayes DJ. Ann Med. Ros AC. FEMS Microbiol Lett. Cysteine and Taurine. Taurine status and response to intravenous taurine supplementation in adults with short-bowel syndrome undergoing long-term parenteral nutrition: a pilot study. 2000.naturaldatabase. Host defense--a role for the amino acid taurine? JPEN J Parenter Enteral Nutr. Yamazaki K. Clin Exp Pharmacol Physiol. Baltimore. Taurine. Role of arginine. Takaba K. Korpela R. Lombardini JB. In: Taurine 3. 2005. Huxtable RJ (eds. 96. O'Flaherty L. Pasantes-Morales H and Cruz C. Thuillier F. Stipanuk MH.shtml. Homocysteine. Bouchier-Hayes DJ. Protective effect of taurine and zinc on peroxidation-induced damage in photoreceptor outer segments. Taurine: new implications for an old amino acid. 2000. J Neurosci Res. 1996. 26. Redmond HP. Nurminen ML. 1996. Cynober L. Badran AM. Curr Opin Clin Nutr Metab Care. 1999. Cellular and Regulatory Mechanisms. Moran J. Amino Acids.52 53 54 55 Militante J and Lombardini JB.com online database. 281-292 Pisarenko OI. http://pdrhealth. 195-202. Caballero B. Shils ME. Role of antioxidants in health maintenance. Qi B. Datta SP. Amino Acids. 26. Amino Acids. 1. Hwang D-F. 2001. 735-740. Psychopharmacology (Berl). Yamori Y. 295-300. Wei M. L-tryptophan: a rational anti-depressant and a natural hypnotic? Aust NZ J Psychiatry. Baum M and Weiss M. Yamagami T. Miyazaki T. Sokejima S. 1694S-1700S. Burgerstein's Handbook of Nutrition: Micronutrients in the Prevention and Therapy of Disease.74 75 76 77 van de Poll MC. 1985. Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men. Non-nutritional uses of vitamin B6. 294. Amino Acids. 20. 42. 1976. 260-268. Mizushima S. 81. 899-904. Boman B. Adams PW. Malone DG. 2001. 1999. Ghubash R. Evidence for hypochlorous acid generation. 832-833. 203207. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Adv Exp Med Biol. Wynn V. Slivka A. 11. Dejong CH. Walter de Gruyter verlag. Effect of taurine on toxicity of vitamin A in rats. Eur Neuropsychopharmacol. 22. Matsuzaki Y. Strong R. Wescott R. 2003. 9. Biochemie der Ernährung. Bender DA. Zhonghua Yan Ke Za Zhi [Chinese J Opthalmol]. 6. Serum tryptophan in Crohn's disease. 1970. Klein R. Folkard J. 1973. ID 1671: “Tryptophan” and “Mental and nerve function” 4 5 1 2 3 4 5 6 7 8 9 L-Tryptophan. The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. Effect of pyridoxine hydrochloride (vitamin B 6 ) upon depression associated with oral contraception. 106. 403. memory and information processing in healthy volunteers without caffeine abstinence. Mol Aspects Med. 139-150. Baumblatt MJ and Winston F. Krymski M. Adequate range for sulfur-containing amino acids and biomarkers for their excess: lessons from enteral and parenteral nutrition. 136. 460 . 158. Br J Nutr. An evaluation of a caffeinated taurine drink on mood. The role of pterins and related factors in the biology of early postpartum depression. 101-197. Abou-Saleh MT. 1988. 415-419. 70. 1. 2006. Pu W. Ochiai N. Implications of interferoninduced tryptophan catabolism in cancer. [UV-induced DNA damage and protective effects of antioxidants on DNA damage in human lens epithelial cells studied with comet assay]. 83-97. 75-82. ID 1660: “Taurine” and “Ergogenic role in sports and exercise” 78 79 80 1 2 3 Alford C. Wu Z. 1983. Zhang J. Chlorination of taurine by human neutrophils. 1999. Anderson DN. Adv Exp Med Biol. Nara Y. 2006. Borden EC. Monograph. Ozaki Y. Sondel PM. The effects of red bull energy drink on human performance and mood. Hsieh H-S. Wang M. 52-56. Lancet. Rose DP. Stuttgart. Seed M. Yatabe Y. Soeters PB. Yan Q. 2008. Cox H. Scand J Gastroenterol. 11. 21. 322-328. Karim L. 2001. 623-629. Thieme. Bersellini E. J Clin Invest. Sweeney E. 425435. 2004. Biochemistry of tryptophan in health and disease. Altern Med Rev. Welzel E. Brown RR. 2001. 7-20. 1982. Berlin. J Nutr. Warburton DM. Yeh Y-H. Ikeda K. Kagamimori S. auto-immune diseases and AIDS. J Orthop Sci. Bender DA. 598-607. Izumi I. Lancet. 2006. Pyridoxine and the pill. 1991. Zimmermann M. Liu Z. Beeken WL. 1996. 8. Food Chemistry. Zhang M. Weiss SJ. Miyakawa S. Effects of taurine administration in rat skeletal muscles on exercise. Arch Gen Psychiatry. 39. Clin Chem. 3. Broyer M. Fuchs D. Wissenschaftliche Verlagsgesellschaft. 219-222. Improvement in central monoamine metabolism in adult coeliac patients starting a gluten-free diet. Etienne P. Dierich MP.10 Cangiano C. Price LH. 47. Goddard AW. Effects on the diet on brain neurotransmitters. 1998. Serotonin syndrome--a potentially fatal complication of antidepressant therapy. Eynard N. 1965. J Clin Psychiatry. 1996. 566-567. Contraception. 5. Fassbender K. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind. Bancroft J. Carcinoid syndrome associated with psychosis. Gröber U. Charney DS. 1990. two-centre study of combined and progestogen-only methods. Wachter H. 1983. Delgado PL. 36. 52. Delgado PL and Moreno FA. 2000. Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. Goodman WK. 144-145. Angelico F. Claustrat B. Walan A. Charney DS. Hallert C and Sedvall G. 51. Del Ben M. Laviano A. 299-304. Heninger GR. Inhibition by albumin of tryptophan uptake by rat brain. Reibnegger G. 26. 1983. Sourkes TL. 775-777. 267-271. Hallert C. 22. Cascino A. 41. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Reversal of psychopathology in adult coeliac disease with the aid of pyridoxine (vitamin B6). 23372340. Reibnegger G. 1988. Astrom J. 1998. Werner ER. 1994. Aghajanian GK. 262. 1976. 1990. Graham CA. 873-876. Effects of tryptophan depletion in panic disorder. Arch Gen Psychiatry. Werner-Felmayer G. 207-211. 411-418. 865-874. 1993. Salomon RM. Effects of tryptophan depletion in drug-free depressed patients. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Augeri FM. Kuhnen J. J Clin Psychiatry. Fuchs D. 4-11. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. 1991. Serotonin and its place in the pathogenesis of depression. Brain Res Brain Res Protoc. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Orthomolekulare Medizin: Ein Leitfaden für Apotheker und Ärzte. 1995. Moller AA. Delgado PL and Moreno FA. Preziosa I. 1977. Masiello P. Sholomskas DE. Hennerici M. Role of norepinephrine in depression. 13. 18. 2002. Psychol Med. 2000. Int J Obes Relat Metab Disord. Arch Neurol. Diabetes Metab. Aghajanian GK. 61 Suppl 1. Benzi L. 49 Suppl. Lestra C. 207-223. 1998. 163. Quincy C. Flachaire E. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Postgrad Med J. Price LH. Immunol Lett. 512. Charney DS. Walton KE. Nature. Effects of tryptophan load on amino acid metabolism in type 1 diabetic patients. Heninger GR. Heninger GR. Schwartz A. J Acquir Immune Defic Syndr. 21-25. 481-482. Schmidt R. Young SM. Fadda F. Bergamini E. 1994. A physiological method to selectively decrease brain serotonin release. placebo-controlled. 22. Br J Psychiatry Suppl. 461 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 . Serotonin function and the mechanism of antidepressant action. Stockle E. Stuttgart. Fernstrom JD. Delgado PL. Serotonin and the neurobiology of depression. Kischka U. 55. Metabolism. 51-56. 363-369. Miller HL. 648-654. Price LH. Werner ER. Maglaya C. Biol Psychiatry. 28. Scand J Gastroenterol. Navalesi R. Cocco S. Platelet serotonin content and free and total plasma tryptophan in healthy volunteers during 24 hours. Fierabracci V. Med J Aust. Coppen AJ and Doogan DP. Hanna SM. Novelli M. Mossner R. Ciccarone AM. Landis H. Rossi-Fanelli F. Ramos R. Corkeron MA. Moller AA. Stancampiano R. Farley TM. 1995. 66-72. Zaidan R. 1996. Menkes DB and MacDonald JA. Minner B. Biol Psychiatry. Blier P. Martinez J. Lipsey JR. Brown GL. Hernanz A and Polanco I. Lepkifker E. serotonin and neurotoxicity. Pihl RO. Aguerre S. 1990. Lehmann J. 116 ( Pt 6). 50. Jacobs MP. Karmally W. 21. The significance of tryptophan in human nutrition. 83-90. 136. Saito S. Rush AJ. Heeringa M. 70-73. Psychol Med. 266-273. Jacquemyn Y. The relationship between the psychological and immunological state in patients with atopic dermatitis. Mood change following bilateral hemisphere brain injury. Delbeke L. Suy E. 191-197. Gut. 53. 233-236. Wutzke KD. tryptophan and depression. 1996. 16. Manier G. Cancer cachexia and depressive states: a neuro-endocrine-immunological disease? Acta Med Okayama. 1980. Sverdlik A. Chaouloff F. Gorman JM. Heine W. Effect of L-tryptophan and other amino acids on sleep. Lauze C. 1997. 1992. Heninger GR. Janssen HL. Corticotropic and serotonergic responses to acute stress with/without prior exercise training in different rat strains. 231-235. Interferons. 1998. 1998. Iancu I. Brain. 1993. 30. Dannon PN. J Psychosom Res. Maes M. 1998. Effects of tryptophan depletion in drug-free adults with autistic disorder. Suppressant effects of dexamethasone on the availability of plasma L-tryptophan and tyrosine in healthy controls and in depressed patients. 2000. 1983. Bender DA. 1994. Heyes MP. Feenstra J. 1478-1481. Leyton M. Cohen DJ. Scharpe S. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. 787-790. 259-268. 31. Wilson WP. Saito K. Jenkins C. 847-858. Plasma precursor amino acids of central nervous system monoamines in children with coeliac disease. Tryptophan deficiency stupor--a new psychiatric syndrome. 9. Christiaens F. Bosmans E. Psychiatry Res. 66. Benkelfat C. Verkerk R. 32. Br J Psychiatry. Kelly WF. Price LH. Ombelet W. Naylor ST. Disturbances in dexamethasone suppression test and lower availability of L-tryptophan and tyrosine in early puerperium and in women under contraceptive therapy. 52-63. 151-162. J Dermatol Sci. Vickers JH. Acta Psychiatr Scand Suppl. Coplan JD. Raus J. 64. de Man RA. South Med J. Checkley SA. Arch Gen Psychiatry. Uomoto M. 168. 993-1000. 17-21. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Acta Physiol Scand. Martin CL. 19-23. Amino acids. Brouwer JT. 51. Lucki I. 22. 91-205. 1425-1450. 834-835. 125-132. Cushing's syndrome. De Meester I. Milstien S. Effects of pregnancy and delivery on the availability of plasma tryptophan to the brain: relationships to delivery-induced immune activation and early post-partum anxiety and depression. Rao K. 2000. Major LF. 2001. Aghajanian GK. 2000. Schotte C. Nutr Rev. 1973. Hashiro M and Okumura M. Maes M. 1998. Attenuation of synthesis from L-tryptophan by 6chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Papp LA. Claes M. 142. Radke M. Smits CM. Psychol Med. Duclos M. Postgrad Med J. 81. J Affect Disord. Baker GB. 143. 1-57. 73. Verkerk R. J Hepatol.31 32 33 34 35 36 Hartmann EL. Price TR. Hizuta A. McDougle CJ. Robinson RG. 241-243. Neuropsychopharmacology. Honkoop P. Etezadi S. Bipolar disorder associated with interferon-alpha treatment. 36. Young SN. [Major psychiatric side effects of interferon alpha-2b]. 44 Suppl. 1986. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Iwagaki H. Depression in radiation oncology patients: a preliminary evaluation. 462 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 . Schalm SW. Mormede P. van der Mast RC. Maes M. 1982. Kent JM. 1997. 421-430. Tanaka N. Br J Psychiatry. 300. 1995. 1991. Major EO. Takeuchi Y. Pearlson GD. The spectrum of behaviors influenced by serotonin. Acta Psychiatr Scand. Markey SP. 1618-1621. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. Carmody TJ. 44. Ned Tijdschr Geneeskd. Carcinoid and psychiatric symptoms. Leclercq C. Scharpe S. 45. J Psychopharmacol. 1999. den Boer JA. 375. Neurology. [Depression during interferon therapy in chronic hepatitis C patients--a prospective study]. Cantell K. Pardridge WM and Fierer G. Sandyk R. 1972. 1997.54 55 56 57 Meyer KC. J Lab Clin Med. Cytokineassociated emotional and cognitive disturbances in humans. 101-127. Brain Res. Acta Psychiatr Scand. Haack M. Oncol Rep. Takaoka K. Harding PE. 11. 40-42. 611-619. [Treatment of depression and sleep disorders. Otsubo T. Onuki M. Rustgi V. Valentine AD. Mullen KD. Niemi ML. 116. 51. Stocker R. 67. Takata T. McTavish SF. Scheibel RS. 1998. 1997. Harrold JA. Boon JC. Kraus T. Yirmiya R. albumin-bound pool in rats and in rabbits. Jones EA. Gutman H. 5-HT(1B). Niiranen A. 152. Byrne GI. Strong R. Renault PF. Nemeroff CB. 1389-1393. Tryptophan as a link between psychopathology and somatic states. Miller AH. 381-392. 1987. Moroni F. Kema IP. Moore DE. L-tryptophan in neuropsychiatric disorders: a review. Musselman DL. Reversible cognitive decline during high-dose alpha-interferon treatment. 99. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Paroxetine for the prevention of depression induced by high-dose interferon alfa. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Poutiainen E. Reichenberg A. Clin Sci. Hunt NH. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence. 961-966. Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. Marshak G. Schmidt E. Pollmacher T. 901-905. Psychosom Med. Korf J. 1999. 1998. 54. 126. Forman AD. Significance of serotonin and L-tryptophan in pathophysiology and therapy]. and 5HT(2A) receptors and 5-HT transporters in diet-induced obese rats. Adams PW. Gumnick JF. Mattson K. 1994. 127-144. 971-976. Russo S. Mitamura K. 90-97. Manatunga AK. 1999. 175-180. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. 78. 2001. 58. Elsevier GmbH Deutschland. Thomas SR. 2001. 47. Fokkema MR. Leitfaden Mikronährstoffe: Orthomolekulare Prävention und Therapie. Widdowson PS. N Engl J Med. Hoofnagle JH. Transport of tryptophan into brain from the circulating. Penna S. Takagi C. Talpaz M. Schachter J. Seishin Shinkeigaku Zasshi. Morag A. Yoshida M. Psychiatric complications of long-term interferon alfa therapy. Experimental vitamin B 6 deficiency and the effect of oestrogen-containing oral contraceptives on tryptophan metabolism and vitamin B 6 requirements. 1991. Hokkanen L. 530-540. 2004. 1992. Park S. 1995. Yahav J. Behavioral assessment of patients treated with alpha-interferon. Peters M. Kalayoglu MV. de Vries EG. 465-477. Meyers CA. Arch Intern Med. Fenig E. Chaudhri G. Jones DB. 445-452. Neurology. 2003. Pavol MA. 344. Park Y. 622-626. Tattam BN. Miyaoka H. 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 463 . Mattis PJ. 665-671. Willemse PH. Goodkin RS. Eur J Pharmacol. Iivanainen M. 41. 87-100. Rose DP. Increased binding at 5-HT(1A). 1995. 1997. Arch Gen Psychiatry. 1988. Riemann D and Vorderholzer U. Meyers CA. Rosenthal NS. Psychiatry Clin Neurosci. Lawson DH. 147. 6. 1577-1580. 1990. 672-676. Persistent neurotoxicity of systemically administered interferon-alpha. Rexer JL. Young AH. Nozaki O. Farkkila M. 65. 847. Laaksonen R. Reilly JG. Am J Pathol. Pharmacol Biochem Behav. Williams G. J Neurochem. Sulkes A. Brenner B. Arend RA. Sanni LA. Greiner K. Kamijima K. Farkkila M. 947-950. Ishii M. 42. Tryptophan metabolism in chronic inflammatory lung disease. Schuld A. Int J Neurosci. Fortschr Med. Brown RR. J Indian Med Assoc. 1993.3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Tryptophan depletion causes a rapid lowering of mood in normal males. Redox reactions related to indoleamine 2. The use of diet and dietary components in the study of factors controlling affect in humans: a review. J Neuropsychiatry Clin Neurosci. Asnis GM. 613-616. Arch Gen Psychiatry. Kaye WH. 2. 1985. 1969. Young SN. J Affect Disord. Brown SL. Degradation of tryptophan in patients with systemic lupus erythematosus. 1989. 1984. Psychopharmacology (Berl). Sonino N. Lancet. Psychopathology. 302-306. 2000. 9. Panneerselvam C. 260-270. Täufel A. Stohs S. 13. ID 1679: “VitaGrape® Grape Seed Extract 95% OPC” and “Excellent source of oligoremic proanthocyanidins that have been associated with the reduction of oxidative stress. Bleich A. Geller E. Nieminen P. Am J Psychiatry. Finn P. 67. Korn ML. Kerr IM. 508-511. 1987. Anxiety and depression in a community-based rheumatoid arthritis population. Manic episodes in two patients treated with interferon alpha. 35. Trivedi S. Effect of albumin binding and amino acid competition on tryptophan uptake into brain. 1984. Stark GR. Balu M. Inhibitors of the kynurenine pathway. 179-186. 2005. Cellular protection with proanthocyanidins derived from grape seeds. Hamburg. Smith SE. 469-473. 177-183. Effects of seven low-dose combined contraceptives on vitamin B6 status. 1977. Fallo F. 98. Sen CK. 89. 68. Biochemical aspects of tryptophan depletion in primates. Fairburn CG. Kahn RS. 19. Neuberger SK. Ann NY Acad Sci. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. Fernstrom MH. Stewart JW. Evaluation of L-tryptophan for treatment of insomnia: a review. Oldendorf WH. 2006. Low B6 levels in depressed outpatients. Kloosterboer HJ. 227-264. 1-8. Cowen PJ. Zobel M. Baker H. Serotonin and sleep. Meyers CA. 957. Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa. Strite D. How cells respond to interferons. 1998. Schmuth M. Braun L. 571-577. Ursin R. 377. 152. Ervin FR. 171-176. 4. Young SN. Harrison W. Sepp N. 6. Tunger L. 56. 2002. Raffi AR. 1986. Thomas SR and Stocker R. 18. J Neurochem. Quitkin F. Psychopharmacology (Berl). 1999. 82. van Praag HM. Fava GA. Sleep Med Rev. 1989. 1999. 292-294. Psychopharmacology (Berl). Widner B. Scand J Rheumatol. J Psychiatry Neurosci. Annu Rev Biochem. Redox Rep. 273-276. Kind S. Young SN. Symptomatic relapse in bulimia nervosa following acute tryptophan depletion. 87. 1999. 1015-1023. Clinical correlates of major depression in Cushing's disease. Silverman RH. Boscaro M. 1998.” 89 90 91 92 93 94 95 1 2 Bagchi D. 31. Haspels AA. Winston F. Ervin FR. Eur J Med Chem. 1-7. 1997. 40. Yuwiler A. Lebensmittel-Lexikon. Hakala M. Fuchs D. Ternes W. Stone TW. 173-177.75 76 77 78 79 80 81 82 83 84 85 86 87 88 Schneider-Helmert D and Spinweber CL. 1995. Soderlin MK. Pihl RO. Brain Res Bull. 467. 199-220. Behr's Verlag. Sangeetha P. Smith KA. Valentine AD. Biol Psychiatry. 55-69. Preuss HG. 235-244. 2000. Contraception. Bagchi M. Adv Exp Med Biol. 2002. Murali G. Oral contraceptives and depression. Williams BR. van der Vange N. Psychiatric symptoms in carcinoid syndrome. Weltzin TE. Kowald E. 377-384. 29. Wetzler S. 28. Modulatory role of grape seed extract on agerelated oxidative DNA damage in central nervous system of rats. 464 . Fernstrom JD. Pihl RO. 1668-1671. Schreiber RD. van der Berg H. Ray SD. 3D10 cells. Procyanidins as antioxidants and tumor cell growth modulators. 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 465 . 39-46. Ishii N. 295-300. Erlejman AG. Feng Y. Dulundu E. characterization. Harvey JS. Kern M. Hahn A. Grenier D. Hu H and Qin YM. Ashton AR. Procyanidins protect Caco-2 cells from bile acid. 77. Fujii H. Grape seed extract given three hours after injury suppresses lipid peroxidation and reduces hypoxic-ischemic brain injury in neonatal rats. 326-333. Yokozawa T. Fleschhut J. 2007. Gu L. 833-838. Nishioka H. Bogs J. Int J Cardiol. Free Radic Biol Med. J Cardiovasc Pharmacol. Nakagawa T. Li XH. Ozel Y. 2006. 134. Universität Karlsruhe. Ueno Y. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. J Nutr. Toklu H. 47. Downey MO. Mateus N. Eugen Ulmer Verlag. 22. Chandler HL. Med Sci Monit. Protective effect of red grape seeds proanthocyanidins against induction of diabetes by alloxan in rats. Rhodes PG. 2006.3 4 Barden CA. Stuttgart. Proanthocyanidin synthesis and expression of genes encoding leucoanthocyanidin reductase and anthocyanidin reductase in developing grape berries and grapevine leaves. 2004. Devi A. 2007. Houde V. Gebhardt S. 2005. 119. Wolters M. Prior RL. Ernährung des Menschen. 52. Prävention. Pediatr Res. 54. 1525-1531. Plant Physiol. Ercan F. Med Hypotheses. 139. Untersuchungen zum Metabolismus. Robinson SP. Calhau C. El-Alfy AT. Haytowitz D. 2007. Grape seed proanthocyanidin extract (GSPE) and antioxidant defense in the brain of adult rats. Kelm MA. Bomser JA. and antioxidative effects of oligomeric proanthocyanidin-L-cysteine complexes. Chandad F. Grape seed proanthocyanidin extract induced mitochondria-associated apoptosis in human acute myeloid leukaemia 14. Holden J. Sun B. 2007. 94-100. Lu P. Oteiza PI. Protective effects of grape seed proanthocyanidins against oxidative stress induced by lipopolysaccharides of periodontopathogens. Jolitha AB. Bhatt AJ. Leblanc MH. Am J Vet Res. Wissenschaftliche Verlagsgesellschaft. 503-509. Fridrich D. 2005. Fatani AJ. 2006. Wissenschaftliche Verlagsgesellschaft mbH. 2007. 50. Karthikeyan K. [Clinical and capillaroscopic evaluation of chronic uncomplicated venous insufficiency with procyanidins extracted from vitis vinifera]. Fraga CG. Tanner GJ. Devaraj SN. Pharmacol Res. BR124-129. Nonaka G. Ahmed AA. 61. 2004. Stuttgart. Mol Nutr Food Res. 115. J Gastroenterol Hepatol. Therapie.and oxidantinduced damage. Costantini A. Sato E. Cheng M. Gao HQ. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. 51. 12. 2392-2397. Preparation. 1999. zur Bioverfügbarkeit und zur antioxidativen Wirkung von Anthocyanen. Minerva cardioangiologica. Faria A. 1247-1256. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. Gedik N. Kohler N. 41. 885-892. Ströhle A. Hammerstone JF. Xu L. Cardioprotective effects of grape seed proanthocyanidins extracts in streptozocin induced diabetic rats. J Agric Food Chem. Ernährung–Physiologische Grundlagen. Hahn A. 417-421. 192-200. 2006. 69. Winterhalter P. The epidermal growth factor receptor and human topoisomerases represent potential cellular targets of oligomeric procyanidins. Grape seed extract reduces oxidative stress and fibrosis in experimental biliary obstruction. 2008. 2006. 55. de Freitas V. 2006. Li BY. Liu YM. 67. Iriti M and Faoro F. Pahlke G. 1371-1379. Beecher G. 613-617. 2006. Stuttgart. Sener G. J Agric Food Chem. J Periodontol. 2007. Chin Med J (Engl). 2005. 652-663. Grape phytochemicals: a bouquet of old and new nutraceuticals for human health. Effect of grape polyphenols on oxidative stress in canine lens epithelial cells. Bai BR. Topaloglu U. Hirose A. De Bernardi T. Colitz CM. Elmadfa I and Leitzmann C. 264-270. Marko D. Zhang H. Gotti A. Fritz J. 2004. Ma YB. Mantena SK and Katiyar SK. 2005. Grubbs C. Prior RL and Gu L. 53. 6194-6202. Lila MA. Smith M. Robert L. 579. 1603-1614. Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. SNU-C4. 2006. Baliga MS. Schmidt BM. 787-796. Renard G. 2008. 703-705. Nomoto H. J Nutr. 2004. Cheng M. 49. 4674-4678. 2008. World J Gastroenterol. 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 466 . 293-298. Zhang FL. Grape seed proanthocyanidins inhibit UV-radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling in human epidermal keratinocytes. Kim YJ. Kaur M. Salvado MJ. 1-11. Mutat Res. Gao HQ. Wei Sheng Yan Jiu. 16. Li XH. 2004. Morin B. 2006. 104. Chemoprevention of colorectal cancer by grape seed proanthocyanidin is accompanied by a decrease in proliferation and increase in apoptosis. 1682-1691. J Cardiovasc Pharmacol. Parikh H. Barnes S. Kim H. 12. 81-88. 2007. 81-106. 668-679. Haripriya D. Yao GY. Ray SD. 35. 2006. 66. Hamada H. Panneerselvam C. 231. Yoon SH. Arola L. 2005. Liu YN. You BA. Kim MJ. 40. Phytochemistry. Chung JH. Ma L. Clin Cancer Res. and caspase-3 activation via loss of mitochondrial membrane potential. 820-828. Proanthocyanidin exposure to B6C3F1 mice significantly attenuates dimethylnitrosamine-induced liver tumor induction and mortality by differentially modulating programmed and unprogrammed cell deaths. 49. Pechanek U. Carcinogenesis. Occurrence and biological significance of proanthocyanidins in the American diet. Puiggros F. Cancer Lett. Erdman JW. Leem KH. Back-regulation of six oxidative stress proteins with grape seed proanthocyanidin extracts in rat diabetic nephropathy. 27. 2007. 405-415. Bagchi D. Grape seed proanthocyanidins induce apoptosis and inhibit metastasis of highly metastatic breast carcinoma cells. Xu L. Hall P. Robert AM. Food Chem Toxicol. Iigo M. 11. Balu M. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma. Agarwal C. 411-415. Shen XN. Exp Gerontol. You BA. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents. 2006. Grape seed proanthocyanidins promote apoptosis in human epidermoid carcinoma A431 cells through alterations in Cdki-Cdk-cyclin cascade. 2005. 2264-2280. Anticancer effects of oligomeric proanthocyanidins on human colorectal cancer cell line. 2006. Llopiz N. 46. Ma YB. Kojima S. Age associated changes in erythrocyte membrane surface charge: Modulatory role of grape seed proanthocyanidins. Ravanat JL. J Agric Food Chem.. 53. Free Radic Biol Med. ÖAZ (Österreichischen Apothekerzeitung). Meeran SM and Katiyar SK. Jr. Narbonne JF. Singh RP. 2005. Li XL. Ribera D. Blade C. Kim HK. Katiyar SK. 3445S3452S. J Cell Biochem. 2003. Gao HQ. Park HJ. Badouard C. Agarwal R. Grape seed procyanidins prevent oxidative injury by modulating the expression of antioxidant enzyme systems. 2007. Ardevol A. 134. Exp Dermatol. Cancer Lett. 2005. Physiologische Bedeutung der phenolischen Inhaltsstoffe. 255. [Effects of grape seed proanthocyanidins extracts on experimental diabetic nephropathy in rats]. Effect of procyanidolic oligomers of Vitis vinifera on the biosynthesis and excretion of corneal glycosaminoglycans. Pathol Biol (Paris). Li BY.24 25 26 Katiyar SK. 12. Nutr Cancer. Tsuda H. Kirk M. Mantena SK. 40. 6080-6086. Effect of dietary fat-soluble vitamins A and E and proanthocyanidin-rich extract from grape seeds on oxidative DNA damage in rats. Li BY. Prasain JK. Gu M. Differential effects of blueberry proanthocyanidins on androgen sensitive and insensitive human prostate cancer cell lines. Sangeetha P. 240-246. 2005. Merrillon JM. 58. Wu YJ. Hippokrates. May 19-24. 533-538. Saniez MH.7 macrophages by inhibiting NFkB signaling pathway. Kardinaal AF. 291-299. J Pharm Pharmacol. Lebensmittel-Lexikon. 2007. 1247-1257. Chakrabarti S. van den Heuvel EG. Comparison of proanthocyanidins in commercial antioxidants: grape seed and pine bark extracts. 22. Pujadas G. Wils D. A1-894. 2002. 7 467 . Dietary fiber and Irritable Bowel Syndrome (submitted). Ardevol A. Sharma SD.43 Shao ZH. Stuttgart. Gao MT. Arola L. Watzl B and Leitzmann C. The immune-enhancing effects of dietary fibres and prebiotics. Zhang XY. Folts JD. 6. Tunger L. 57. Journal of Cardiovascular Pharmacology. 55. Liu NF. Cell Biol Toxicol. 995-1005. 6. Eur J Clin Nutr. 2005. Bioaktive Substanzen in Lebensmitteln. Varghese S. Katiyar SK. Abstracts of Digestive Disease Week and the 108th Annual Meeting of the American Gastroenterological Association Institute. Helsinki. Wu YJ. Harris RK. Yu J. Hsu CW. Bai DC. Wu YJ. Smith CS. Neut C. O'Brien BM. 2005. Matsuoka A. Pasman W. 2005. 2006. Wils D. Fujiwara K. 1993. Li J. Zobel M. 1999. Wu YJ. Zhang XY. Qin Y. Li W. Zheng TZ. Hodges AE. Slavin JL. J Agric Food Chem. Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-kappaB signaling in in vivo SKH-1 hairless mice. ID 1680: “Wheat dextrin” and “Bowel health/digestive health/bowel movement” 44 45 46 47 48 49 50 51 52 53 54 1 2 3 4 5 6 Lefranc-Millot C. 31-37. Eur J Clin Nutr. in adult men. with excellent tolerance. Bakker M. Liu NF. Blay M. S221-230. Proanthocyanidin from grape seeds enhances antitumor effect of doxorubicin both in vitro and in vivo. Meeran SM. Saniez-Degrave MH. 148-156. Cytotoxicity induced by grape seed proanthocyanidins: role of nitric oxide. Li WG. Salvado J. Behr's Verlag. Wakabayashi S. 55. Ternes W. Pasman WJ. Hamburg. 149-158. Li WG. NUTRIOSE® 06. Li WG. J Med Food. 1024-1034. Jpn J Nutr. Pharmazie. Kardinaal A. Pohorly JE. Li CQ. Wils D. a food dextrin. Waypa GB. Saniez MH. 2006. Polyphenolics in grape seeds-biochemistry and functionality. Shi J. Weber HA. Effects of indigestible dextrin on bowel movements. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. Stewart MLet al. J Agric Food Chem. Zhang XY. Amelioration of doxorubicin-induced myocardial oxidative stress and immunosuppression by grape seed proanthocyanidins in tumour-bearing mice. Gastroenterology. Vitrac X. Becker LB. 2004. 4357-4365. 132. Proanthocyanidin from grape seeds potentiates anti-tumor activity of doxorubicin via immunomodulatory mechanism. 51. Schley PD and Field CJ. Qu SY. Guthrie JR. The Dietary Fibre Conference. Mol Cancer Ther. Schumacker PT. 2007. Li WG. 445. 2007. Vitseva O. Robaugh D. 2007. Li D. Chang WT. Zhang XY. Ohkuma K. 2007. 60. Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264. Täufel A. 1043-1052. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells. 2005. Freedman JE. 2006. Short-term digestive tolerance of different doses of NUTRIOSE FB. Kakuda Y. on the gut ecosystem: a review. Algaier JW. Clark AP. Long-term gastrointestinal tolerance of NUTRIOSE FB in healthy men. 60. 46. Washington DC. Fernandez-Larrea J. 2005. Liu NF. 10461055. 5. Satouchi M. Int Immunopharmacol. Valls J. Terra X. 2003. Bai DC. 2005. Can J Physiol Pharmacol. Effects of a soluble fiber. Blade C. Hoek TL. 309-318. Anderson T. 83. Br J Nutr. 87 Suppl 2. 51. van den Heuvel EG. ID 1682: “Wheat dextrin” and “Heart Health” 7 8 9 1 2 Anderson JW. Willett WW. short. 1992. 43. Brandolini M. Lipid responses of hypercholesterolemic men to oat-bran and wheat-bran intake. Matsuoka A. Rosner B. Bazzano LA. 1065-1072. 1991. Fermentation of non-starch polysaccharides in mixed diets and single fibre sources: comparative studies in human subjects and in vitro. Slavin JL. Brown L. 472-479. calcium and zinc apparent absorption and retention in healthy young men. Sacks FM. Vermorel M. Ohkuma K. BouteloupDemange C. Am J Clin Nutr. Am J Clin Nutr. 88 Suppl 3. Eur J Clin Nutr. Prospective study of nutritional factors. 163. The immune-enhancing effects of dietary fibres and prebiotics. Stampfer MJ. 2004. in adult men. 58. 87 Suppl 2. 1475-1484. Tressol JC. Wils D. Rimm EB. Anderson JW. Wils D. calcium and zinc apparent absorption and retention in healthy young men. Morel JG. Wils D. 2000. Dillon DW. Slavin JL. Daniel M. Coudray C. 2002. Eur J Clin Nutr. Dietary fiber intake and reduced risk of coronary heart disease in US men and women: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Hengehold DA. Eur J Nutr. Br J Nutr. O'Neal DS. Helsinki. Sacks F. Sacks F. Gilinsky NH. Cholesterol-lowering effects of dietary fiber: a metaanalysis. Brandolini M. Schley PD and Field CJ. Montaurier C. blood pressure. Wisker E.8 Vermorel M. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Arch Intern Med. Fujiwara K. and its impact on magnesium. Am J Clin Nutr. Sinaud S. Sinaud S. Eur J Nutr. Saniez MH. Savarino V. A prospective study of nutritional factors and hypertension among US men. Energy value of a low-digestible carbohydrate. Loria CM. Neut C. 2003. Jpn J Nutr. NUTRIOSE FB. Willett WC. He J. Pulses and lipaemia. Kardinaal AF. 2004. NUTRIOSE FB. Pasman W. Stampfer MJ. BouteloupDemange C. 80. Rosner B. 1999. Long-term gastrointestinal tolerance of NUTRIOSE FB in healthy men. Short-term digestive tolerance of different doses of NUTRIOSE FB. Dietary fibre and irritable bowel syndrome. Wils D. Rayssiguier Y. and its impact on magnesium. 2006. Deakins DA. Ascherio A. Wheat dextrin (WD). Br J Nutr.and long-term effect: potential in the prevention of cardiovascular disease. 71. Giovannucci EL. 253-261. Saniez MH. 86. 1996. Hypertension. Circulation. Kardinaal A. 2004. 344-352. inulin. S221-230. and hypertension among US women. Oeltgen PR. Energy value of a low-digestible carbohydrate. Smith SF. and partially hydrolyzed guar gum (PHGG) produce unique short-chain fatty acid concentrations in model colonic fermentation. Vernet J. Witteman J. Wils D. Whelton PK. Feldheim W. 60. Digestive Disease Week. Lawrence A. Manson J. 30-42. Saviez-Degrave SH. The Dietary Fibre Conference. 1897-1904. 27. 54. Allgood LD. 1024-1034. Bakker M. 678-683. ID 1681: “Wheat dextrin” and “Bowel health/SCFA production” 1 2 3 4 5 6 Lefranc-Millot C. 10461055. Altringer LA. Washington DC. Paredes-Diaz A. 69. S263-271. Colditz GA. Jerdack GR. Rushton HA. 43. Tressol JC. 2002. Effects of indigestible dextrin on bowel movements. Willett WC. Montaurier C. Rosner B. Stewart ML. 344-352. 3 4 5 6 7 468 . Rave G. Vernet J. Anderson JW and Major AW. Ascherio A. Hennekens C. 2007. Wakabayashi S. 31-37. a food dextrin. Satouchi M. Ogden LG. 1993. Rayssiguier Y. 1998. Effects of Indigestible Dextrine on Bowel Movements. Pasman WJ. Br J Nutr. Coudray C. 2006. A possible protective effect of nut consumption on risk of coronary heart disease. 3317-3325. Pietinen P. Rimm EB. 51. 73. 370-376. Hankinson SE. 2003. 164. Final rule. Pins JJ. Stampfer MJ. Minekus M. Yang SI. Liu S and Willett WC. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results from the Scottish Heart Health Study. Vegetable. JAMA. 649-657. Whelton PK. 2003. Ford ES and Liu S. Hallmans G. Folsom AR. Elmer PJ. Woodward M. Korhonen P. JAMA. 1993. Kokubo S. 22. Iwatsuki K. Davidson DM. Fraser GE. Knekt P. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Hegsted M. 150. Goldbourt U. 2720-2727. 1996. J Hypertens. The Adventist Health Study. Dietary fiber and coronary disease: does the evidence support an association? Curr Atheroscler Rep. Hartman AM. 369. Albanes D. 932-938. Fed Regist. Jacobs DR.. Dietary fiber and coronary heart disease in middle-aged hypercholesterolemic men. Khaw KT and Barrett-Connor E. Miyaji K. 126. 2001. Demark-Wahnefried W. 1135-1138. 2003. 161. Augustsson K. 2004. Iwatsuki K. Takahashi N. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 469 . Liu K. Keenan JM. Takahashi H. 248-257. 289. 1996. Humble CG. J Fam Pract. 94. 454-461. Food labeling: health claims. 560-566. Effect of partially hydrolyzed guar gum on fecal output in human volunteers Nutrition Research. Am J Epidemiol. 2002. 2001. 572-576. Strahan TM. 500-505. Beeson WL. Malarcher AM. Arch Intern Med. 1993. vol. Turnbull WH. Willett WC. Havenaar R. 2004. Ascherio A. Oat ingestion reduces systolic and diastolic blood pressure in patients with mild or borderline hypertension: a pilot trial. Dunnewind B. 69. 1992. Kokubo S. Liu S. Kushi LH. Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. Bolton-Smith C. Welch RR. Beling S. Am J Epidemiol. Xiao JZ.. Circulation. Willett WC. 2002. 1093-1102. Dugan LD. Mozaffarian D. Curr Atheroscler Rep. Oat products and lipid lowering. Virtamo J. Turnquist L. Am J Clin Nutr. Willett WC. Biosci Biotechnol Biochem. and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. 4. 275. 5. The Alpha-Tocopherol. Virtamo J. Siscovick DS. Thye FW. Biosci Biotechnol Biochem. Ripsin CM. Kumanyika SK. Liu S. Ascherio A. Kim M. 73-80. A meta-analysis. Glycemic index and serum high-density lipoprotein cholesterol concentration among us adults. Sabate J. Effect of dietary fiber intake on blood pressure: a randomized. 68. O'Reilly E. 1999. Tyroler HA. Jelier M. Heitmann BL. Fraser GE. Holmes MD. Hayashi C. Moran A. Yamamoto T. Lemaitre RN. Pereira MA. 1073-1080. JAMA. He J. Spiegelman D. Cereal. Hu FB. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. 267. Jacobs DR. 13. Stampfer MJ. Lupton JR and Turner ND. Manson JE. Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. Spiegelman D. Bos M. 68. 1998. Kondo S. Krousel-Wood MA. 2005.Davidson MH. Giovannucci E. Kestin M. Tunstall-Pedoe H. fruit. 1416-1424. Kondo S. Dietary fiber and reduced ischemic heart disease mortality rates in men and women: a 12-year prospective study. 1992. Van Horn L. soluble dietary fiber from certain foods and coronary heart disease. Todd S. Suppressive effects of dietary fiber in yogurt on the postprandial serum lipid levels in healthy adult male volunteers. Dietary glycemic load and atherothrombotic risk. 1659-1666.8 9 10 11 12 13 FDA (Food and Drug Administration). Frazel C. double-blind. 68. Arch Intern Med. Yamanaka J. 2004. BetaCarotene Cancer Prevention Study. Streiffer RH. Effect of partially hydrolyzed guar gum (PHGG) on the bioaccessibility of fat and cholesterol. Rimm EB. Xiao JZ. fruit. 447-451. Burke GL. Willett WC. 152. Pietinen P. 9. Jr. Olson JL. 1987. Meyer KA. Keenan JM. and cereal fiber intake and risk of coronary heart disease among men. 197-202. Am J Clin Nutr. Jr. Arch Intern Med. Stevens J. Am J Prev Med. Muntner P. placebo-controlled trial. ) Woodhead Publishing Limited. 281. Thompson W. Manson JE. Desantadina MV. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Willett WC. Morris K. Dietary effect of guar gum and its partially hydrolyzed product on the lipid metabolism and immune function of Sprague-Dawley rats. 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 470 . JAMA. Trenerry C. Clifton PM. Frid AH. Mamiya S. Ikeda A. Tachibana H. Pencharz PB. 12. Campbell WW. 32. Arlington. USA. 91. Obes Res. 2004. Role of dairy products in modulating weight and fat loss: A multi-center trial. 239-248. Bjorck IM. Bioscience. Thomas SG. Schoeller DA. 2007. Layman DK. Sugano M. Christou DD. 137. A reduced ratio of dietary carbohydrate to protein improves body composition and blood lipid profiles during weight loss in adult women. 1999. 2005. Holst JJ. Calcium intake and adiposity. Higher protein intake preserves lean mass and satiety with weight loss in pre-obese and obese women. 411-417. Speizer FE. Colditz GA. Hu FB. Erickson DJ. Obesity (Silver Spring). Stampfer MJ. 5205-5211. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. Keogh JB. 362-371. UK. 133. Compositions and methods for treatment of body weight conditions. Zemel MB. Long SJ. Energy intake. Moran LJ. Br J Nutr. Apolzan JW. 133. Am J Clin Nutr. 1477-1483. 2163-2167. 2006. FASEB J. J Nutr. Am J Clin Nutr. Matkovic V. Noakes M. The satiating effect of dietary protein is unrelated to postprandial ghrelin secretion. 421-429. 582-590. 85. Holst JJ. Bastian E. 63. Campbell P. In: Functional Dairy Products. gastrointestinal hormone secretion and appetite. 2008. biotechnology. Saarela M (ed. Berall GB. Millward DJ. Carnell NS. 69-75. Mattes RD. Study Finds Whey Protein Improves Body Composition and Reduces Waist Circumference. Bellissimo N. 1998-2004.128. 996-1004. Dairy components in weight management. Noakes M. 2003. 2007. Nilsson M. 261S267S. 15. Kaku S. Inadequate dietary protein increases hunger and desire to eat in younger and older men. Hennekens CH. 2005. 2004. Carnell NS. 2003. J Nutr. Sather C. Van Loan M. Hall WL. Shiue H. 281-287. J Nutr. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Tokunaga Y. 0. 2003. The role of leucine in weight loss diets and glucose homeostasis. Campbell WW. Painter JE. Teegarden D. Luscombe-Marsh ND. Craig BA. Nilsson M. Clifton PM. Mechanisms of dairy modulation of adiposity. Casein and whey exert different effects on plasma amino acid profiles. US Patent Application. Lyle RM. Parikh SJ and Yanovski JA. 2006.252 A1. 2007. Am J Clin Nutr. Layman DK. A comparison of short-term appetite and energy intakes in normal weight and obese boys following glucose and wheyprotein drinks. Zemel MB. Anderson GH. 974S-979S. ghrelin. 89. and biochemistry. Int J Obes (Lond). 1478-1482. J Clin Endocrinol Metab. 2003. 2007. 2004. and cholecystokinin after different carbohydrate and protein preloads in overweight men. Yamada K. A845. Leidy HJ. O‘Donnell J and Baer D. 133. J Clin Endocrinol Metab. Zemel MB. 2003. Dunne C. Bowen J. 90. 1999. 134. 2007. Ward L and Bastian E. Mattes RD. Milstead A. 77. Ward L. Morgan LM. 252S-256S. ID 1683: “Whey Protein Milk Mineral Complex” and “Weight management” 29 1 2 3 Anderson GH and Moore SE. Dietary proteins in the regulation of food intake and body weight in humans. 82. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. J Nutr. J Nutr. Paulsen S. 18. US Whey Protein Research Consortium. Bjorck IM. Cambridge. Ohkura K.28 Wolk A. Wittert GA. Boileau RA. Expert Opin Emerg Drugs. Katz NB. Jr. 119-135. 2004. Bone RA. Zhao DY. Ophthalmic Epidemiol. Muir GJ. Preliminary identification of the human macular pigment. Kilburn MD. Hurst M. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Barker FM. 150.. Boulton ME. Jacobson SG. Twaroska EE. 183-193.nei. Carvalho LS. 42. Beatty S. Vision Res. Bernstein PS. Invest Ophthalmol Vis Sci. Marcus DM. Invest Ophthalmol Vis Sci. 843-849. Gomez CM. 439-446. Marks DA. 3322-3326. Kopcke W. 471 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 . 10. Mayne ST. Ciulla TA. Tibor SE. 57-83. Johnson EJ. Surv Ophthalmol. Cardinault N. Chylack LT. Alves-Rodrigues A and Shao A. Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. de Castro E. Murray IJ. Heier JS. Vitamine. Exp Eye Res. Monograph. 2004. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. 128-135. 64. Landrum JT. Khachik F. J Nutr. Invest Ophthalmol Vis Sci. Ophthalmology. Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. Bone RA. 42. Exp Eye Res. 42. Bone RA. Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Zhao DY. Taylor HR. The science behind lutein. 1873-1881. Macular pigment in donor eyes with and without AMD: a case-control study.ID 1684: “Zeaxanthin” and “Eye health and vision” 1 2 3 4 Lutein and zeaxanthin. assessed with two objective techniques. 2005.nih. Wu SY. Wang W. 46. Landrum JT. Rock E. Borel P. 235-240. van de Kraats J. The macular xanthophylls. Cideciyan AV. 9. 50. Neuringer M. 215-223. (NEI) National Eye Institute. Ahmed SS. 2002. Menendez E. 2005. 211-218. Gomez CM. 29. Klein BE. Macular pigment and risk for agerelated macular degeneration in subjects from a Northern European population. 122. O'Colmain B. Bieber ML. 573-582. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. Tarsis SL. Snodderly DM. Arch Ophthalmol. 41. Goldbohm RA. 2001. 109. 1780-1787. Landrum JT. 2005. 49-80. 992-998. Kempen J. Invest Ophthalmol Vis Sci. Aleman TS. 2000. Schümann K. Vingerling JR. 133. Klopping WA. 2001. Landrum JT. Gardner LM. Gorrand JM. 1988. 72. Friedman DS.aspx?id=120. Duncan JL. Biesalski H-K. Henson DB. Berendschot TT. 2001. 1997. Influence of lutein supplementation on macular pigment. Lott MN. Toxicol Lett. Koh H. Dietary Zeaxanthin or Lutein Improves Foveal Photo–protection From Blue Light in Xanthopyhll–free Monkeys. Thieme Verlag. 2003. The Age-Related Eye Disease Study 2 (AREDS2). Altern Med Rev. Spurenelemente und Mineralstoffe: Prävention und Therapie mit Mikronährstoffen. Ruiz CA. 1531-1535. Kopcke W. van Norel J. Bron A. 2002. Wintch SW. Maguire MG. Landrum JT. 487-494. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Bone RA. Brown NP. 2005. Tyssandier V. Bone RA. Schalch W. Guerra LH. Tarsis SL. Invest Ophthalmol Vis Sci. Ermakov IV. Fernandez L. Analysis of the macular pigment by HPLC: retinal distribution and age study. Friedes LM. Gellermann W. 2002. Congdon N. Steinberg JD. 2001. Stuttgart. 2003. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Köhrle J. McClane RW. Grolier P. Thien U. van Norren D. Carden D. Criswell MH. Bernstein PS. 25.gov/neitrials/viewstudyweb. Schalch W. Comer GM. http://www. 10. 1985. Vidal I. Invest Ophthalmol Vis Sci. Exp Gerontol. West S. Short-term supplementation with lutein affects biomarkers of lutein status similarly in young and elderly subjects. 38. 2000. Jr. Iarossi G. Delcourt C. Dietary modification of human macular pigment density. Granado F. Ströhle A. Stuttgart. Eter N. 147-164. Merendino E. Yeum KJ. Exp Eye Res. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Antioxidants and AMD in a European Population: the EUREYE Study. Hall NF. Hahn A. 1993. Valentini P. 2006. Wooten BR. 2005. 821-823. Macular pigment and lutein supplementation in choroideremia. Wolters M. Carotenoids as modulators of lipid membrane physical properties. Mitchell P. Hammond BR. Eye Disease Case-Control Study Group.21 22 23 Dagnelie G. Invest Ophthalmol Vis Sci. Schierle J. 23. Blanco I. Prog Retin Eye Res.. Arch Ophthalmol. Granata L. Invest Ophthalmol Vis Sci. Pfannkuch F. Schalch W. Bieber ML. Jacobson SG. Fite KV. Falsini B. Exp Eye Res. Prävention. 1740. Stuttgart. J Opt Soc Am A Opt Image Sci Vis. 111. Fadda A. Dietary modulation of lens zeaxanthin in quail. Br J Nutr. 167-179. Lutein and zeaxanthin status and risk of age-related macular degeneration. Munoz B. Piccardi M. Barker F. 110. 117. McCarty C. 417-424. Snodderly DM. Krohne TU. Antioxidant status and neovascular age-related macular degeneration. Emmons JM. 1795-1801. 90. Froescheis O. MacDonald IM. 564-572. Delage M.. 44. 20. Ophthalmology. Gale CR. Cousins F. Olmedilla B. Fort Meyers. Phillips DI. Marks DA. 2003. 108-115. Dorey CK. Aebischer JC. Bennett J. Nichols CR. 2002. 43. Stone EM. 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 472 . Friedman DS. Korte U. discussion 61. 2006. de Jong PT. Bausch J. 1187-1196. Snodderly DM. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Edwards RB. 487-502. an overlooked part of the anatomy of the fovea centralis: hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr retinoschisis. 51-60. Gruszecki WI and Strzalka K. Hammond BR. Holz FG. Johnson EJ. Wissenschaftliche Verlagsgesellschaft mbH. Gass JD. O'Colmain BJ. EDCC Study Group. 2329-2335. Florida. Prevalence of age-related macular degeneration in the United States. 59. 1997. 464-477. 533-559. Arch Ophthalmol. 122. Bengston CL. Duncan JL. 2002. Toward the Prevention of Age Related Macular Degeneration. Macular pigments: their characteristics and putative role. Muller cell cone. 2003. 2004. 1994. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Kempen J. 104-109. ARVO Summer Eye Research Conference. 2005. 2006. 371-381. Goralczyk R. Niggemann B. Craft NE. BioDrugs. Ocular safety of lutein and zeaxanthin in a long-term study in cynomolgous monkeys. Cheng KM. 38. Fletcher AE and EUREYE Study Group. New pharmacologic approaches to therapy for age-related macular degeneration. Davies NP and Morland AB. Optometry. 2003. 2004. 2006. Individual variations in the spatial profile of human macular pigment. Nutritional and clinical relevance of lutein in human health. De Castro E. Wissenschaftliche Verlagsgesellschaft. Drusen-like deposits in the outer retina of Japanese quail. Invest Ophthalmol Vis Sci. Nemesure B. Gardner LM. 71. 2005. Steinberg JD. 2461-2465. Biochim Biophys Acta. Carriere I. 1999. Arch Ophthalmol. Therapie. Invest Ophthalmol Vis Sci. McDonald TM. 1997. 47. Cideciyan AV. 81. 74. Russell RM. Exp Eye Res. Hahn A. Tomany SC. Sunlight Exposure. Martyn CN. Zorge IS. Aleman TS. Ernährung–Physiologische Grundlagen. Nahrungsergänzungsmittel und ergänzende bilanzierte Diäten. Krinsky NI. Barberger-Gateau P. 14. Maguire MG. Jr. 2546. Le Marchand L. Herrero C. Carotenoids in the human retina. Kessler MJ. Jr. Marshall J. Leung IY. Dawson WW. 224-231. Twarowska E. The Pharmacology of Chinese Herbs. 63. Measured by Two Methods. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Krinsky NI and Johnson EJ. Adler's Physiology of the Eye. Gilbert CE. Kopcke W. 385. Reay CC. Zucker CL. van Kuijk JG. Laudon F. 2005. 1999. Snodderly DM. 26. 2004. Hartmann D. Exp Eye Res. 173-176. 76. 1988. 82. LUXEA–Study Group. Liew SM. Kvansakul J. 2006. Spector TD. Carotenoids in the retina and lens: possible acute and chronic effects on human visual performance. II: effects of age. Graefes Arch Clin Exp Ophthalmol. Hammond CJ. 540S542S. 459-516. Invest Ophthalmol Vis Sci. Lam KW and But P. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. Henderson BE. Zeaxanthin. Thurmann PA. 243. Edgar DF. 19. Trautmann S. An ecological study of diet and lung cancer in the South Pacific. Seruvatu L. 2004. Handelman GJ. Murray IJ. or Their Combination in Healthy Volunteers – Results of the LUXEA–Study. Beatty S. Hankin JH. 2004. Int J Cancer. A primate model for age related macular drusen. 1999. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Sandstrom MM. Boca Raton. 410-417. 1995. Schalch W. 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 473 . 71. Bach F. Krinsky NI. 3244-3256. 79. Bone RA. 2006. Manner B. 828-839. 82. Mosby. Beatty S. Fitzke F. J Nutr. 41-46. Pure and Applied Chemistry. Louis. 67. Landrum JT. 11-16. Hope GM. Cohn W. Possible biologic mechanisms for a protective role of xanthophylls. Wilkens LR. 171-201. Carotenoid actions and their relation to health and disease. Huang KC. Llerena CM. Nutritional manipulation of primate retinas. and zeaxanthin on retinal pigment epithelium. Carotenoids in the human macula and whole retina. Mol Aspects Med. 1992. Mellerio J. Spector TD. Stahl W. Brinkmann C. Barker FM. Tronnier H. 45. Food Chemistry. 18-23. Barbur JL. 2237-2244. Gilbert CE. 2005. Effect of 6 Month Lutein Supplementation on Macular Pigment Levels. Carden D. 23. Ophthalmic Physiol Opt. Arch Biochem Biophys. Schalch W. Kim SR. Kolonel LN. Nolan D. 2001. Hart WM. Wustemeyer H. Beatty S. Central retinal thickness is positively correlated with macular pigment optical density. 21-27. Daniel R. Curran-Celentano J. 2006. 29. Marshall J. Fundus Autofluorescence & Heterochromatic Flicker Photometry. Sherwood MB. Van Kuijk FJG. CRC Press. 132. 2005. 850-855. Krinsky NI. Feather J. Mellerio J. Landrum JT. Van Kuijk FJ. 2006. 2006. lutein. Invest Ophthalmol Vis Sci. Antioxidant supplements improve parameters related to skin structure in humans. Wooten BR. Spitzer V. Engel HM. Ulshafer RJ. Macular pigment density in age-related maculopathy. Dratz EA. Hammond CJ. Schalch W. Jahn C. Baque P. 362-371. a potential health benefit to improve visual acuity. St. a photoreceptor outer segment fluorophore.. 26. 1992. Exp Eye Res. 47. Invest Ophthalmol Vis Sci. Invest Ophthalmol Vis Sci. Bejot M. Exp Eye Res. Am J Clin Nutr. Maurette JM. Annu Rev Nutr. n-3 fatty acids. 79. Sparrow JR. Liew SH. Stacewicz-Sapuntzakis M. Chen Y. Neuringer M. and protection by lutein and zeaxanthin. 915-920. Beecher GR. Photooxidation of A2-PE. 1999. 46. Mossner A. 2002. 2003. Kopcke W. Koh HH. Changes in Macular Pigment Optical Density Following Repeated Dosing With Lutein. Itagaki Y.41 42 43 44 Hammond BR. 222-227. Wolf S. Br J Ophthalmol. Bowen PE. Nakanishi K. Bone RA. Rodriguez-Carmona M. The content of zeaxanthin in Gou Qi Zi. Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. Heinrich U. Skin Pharmacol Physiol. Monaco WA and Wormington CM. Lutein in patients with cataracts and agerelated macular degeneration: a long-term supplementation study. Simon JD. Delori FC. 81. J Am Optom Assoc. 261-266. 1518-1523. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Wallace RB. Massachussetts. Schmidt M. ARMD--pilot (case series) environmental intervention data. Am J Epidemiol. Blanco I. Bowen P. Palta M. Arch Ophthalmol. Frankowski J. Southon S. 657-666. Nutrition. Thurnham D. Clin Sci (Lond). Sunderland. Olmedilla B. 1. Mares-Perlman JA.. Klein BE. Double-masked. Parekh N. Chopra M. Klein R. 24-36. 71. Gil-Martinez E. Wrona M. Pei K. placebo-controlled pilot study. 19. Zareba M. 2000. 1997. Klein ML. Oyster CW and Haver N. A real time kinetic study of antioxidant hierarchy.62 63 Malinow MR. 114. 2002. Invest Ophthalmol Vis Sci. 102. Richer S. placebo-controlled supplementation study with alpha-tocopherol. Blanco I. Fisher AI. Blodi B. 153. Neuringer M. 1974. Invest Ophthalmol Vis Sci. Ritter LL. 1999. 75. Vaquero M. Diet-related macular anomalies in monkeys. 417. Klein BE. 77. 1995. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Beutner S. supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind. Rapp LM. Moeller SM. Feeney-Burns L. Hininger I. Sarna T. Maple SS. Nyland J. Mares JA. 21-24. 41. 67. Pruett RC. 1998. 1999. Klein R. Nussbaum JJ. Granado F. Tinker L. 991-997. Pure and Applied Chemistry. Optometry. Wright AJ. A European multicentre. 1981. Lutein. 216-230. Rudy D. 447-456. Optometry. Brady WE. Journal of the Science of Food and Agriculture. The first 200 years. Nutritional influences on eye health. Granado F. Roberts JE. Lamb LE. Chemistry of carotenoid oxidation and free radical reactions. Vaquero M. Choi JH. Historic perspectives. Klein R. Richer S. Block G. Mares-Perlman JA. 1151-1162. Pawlak A. Walsh R. Blanco I. Wright JD. 1990. 2253-2262. Martin HD. Ruck C. 904-909. 1980. 2003. Sinauer Associates Inc. Mortensen A and Skibsted LH. 1200-1209. 2001. Olmedilla B. J Opt Soc Am. 70. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Arch Ophthalmol. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. 2006. Sinauer Associates Inc. Statkute L. 113. randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Richer S. 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 474 . 296-310. 19. Corridan B. Olmedilla B. Mares-Perlman JA. 1996. Stacewicz-Sapuntzakis M. The First Steps in Seeing. Retina. Granado F. van den Berg H. 2004. 2003. but not alpha-tocopherol. 857-863. 124. 2000. Macular pigment and chromatic aberration. carotene-rich palm oil. Optom Vis Sci. Ritenbaugh C.. Reading VM and Weale RA. The rhesus monkey as an animal model for age-related maculopathy. Peterson LH. Massachusetts. Sunderland. 253258. Cajigal C. 532-537. 1999. The Human Eye: Structure and Function. 231-234. lutein or lycopene: analysis of serum responses. Rozanowska M. 64. FEBS Lett. Rodieck RW. Macular yellow pigment. Palta M. Relative stability of carotenoid radical cations and homologue tocopheroxyl radicals. Sell S. Stiles W. Millen AE. Palta M. Photochem Photobiol. Brady WE. Tsipursky M. 424-432. Association of zinc and antioxidant nutrients with age-related maculopathy. 71. Arch Ophthalmol. Comparison of the aerobic photoreactivity of A2E with its precursor retinal. Pulido J. Greger JL. 2001. Mayer B. placebo-controlled. and advanced age-related macular degeneration. 1993. 301-307. 368-371. Schalch W. 112. Dietary lutein and zeaxanthin: possible effects on visual function. Ophthalmologe.a review of their possible role in preventing or limiting damage caused by light and oxygen. their children and healthy controls]. Schweitzer D. van Kuijk FJ. Acta Ophthalmol Scand. Absorbance spectra. San Diego. Spraul CW. 215. Farber MD. Friberg TR. 660-673. 2005. Hiller R. Curr Eye Res. Sies H. Chance B (ed. Lang GK. Sperduto RD. 1999. Lang GE. Schalch W and Barker FM.) Birkhäuser. 1992. In: Nutritional and environmental influences on the eye. Kurinij N. 97. 2005. Saari JC. 19. Sommerburg OG. C. Willett W. 2002. 176-179. 31. Sperduto RD. Ferris FL. 2005. Thamm E. 2002. Barker FM. Gragoudas ES. Arch Biochem Biophys. Biochim Biophys Acta. I. Yannuzzi LA. Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. Hu TS. Lutein and zeaxanthin are associated with photoreceptors in the human retina. 1999. Cheng QF. Li JY. Thamm E. Gruszecki WI. 81. Arch Ophthalmol. 101-107. Ocular and General Safety of Supplementation With Zeaxanthin and Lutein. Lindblad AS. Eye Disease Case-Control Study Group. Remsch H. Photochem Photobiol. Hurst JS. Snellen EL. Stone WL. In: Free Radicals and Aging. 25. Remsch H. A reinvestigation of the fatty acid content of bovine. 217-225. Dietary Carotenoids and Risk for Age-related Macular Degeneration in the Age-Related Eye Disease Study (AREDS). Promising but unproven hypotheses.82 83 Rozanowska M and Sarna T. 1305-1330. Auran JD. Stringham JM and Hammond BR. Academic Press. 270-275. Seddon JM. 475 95 96 97 98 99 100 101 . [Objective determination of optical density of xanthophyll after supplementation of lutein]. Vitamins. Dayhaw-Barker P. 99. Jr. Invest Ophthalmol Vis Sci. Dawsey S. Sperduto RD. 63.) CRC Press. Neovascular age-related macular degeneration and its relationship to antioxidant intake. 1740. Boca Raton. 2000. Ajani UA. Taylor PR. Bing L. Milton RC. minerals. Plasma Exposure Levels of Carotenoids and 3'–Dehydro–Lutein – Results of the LUXEA–Study. Grudzinski W. Beuermann B. Siems WG. The carotenoids of the human retina. Klein BEK. Brown PK. Gabrielska J. Invest Ophthalmol Vis Sci. Ophthalmologe. localization. Stahl W and Sies H. The Linxian cataract studies. and discrimination from other yellow pigments in primate retinas. Snodderly DM. Sujak A. Lewis JW. 1999. 1979. Farnsworth CC. Beuermann B. Schalch W. Blot WJ. Spraul CW. Hammer M. van Kuijk FJ. 272. The color difference in orbital fat. 1984. Borc R. 491-495. Delori FC. Verbeek AL. 80. Comparative studies of patients. and E. Arch Ophthalmol. 28. Dratz EA. 1994. Hoyng CB. SanGiovanni JP. Taylor A (ed. 46. Sundelin SP and Nilsson SE. Ca. 868-871. Kliger DS. vitamins A. Van Den Hoogen GW. 90 91 92 93 94 Seddon JM and Hennekens CH. Lang GE. Guo WD. 2005. 84-90. Everett DF. Arch Ophthalmol. Basel. Antioxidants in disease mechanisms and therapy. Zhao JL. 59-64. Sires BS. Light-induced damage to the retina: role of rhodopsin chromophore revisited. 1996.. 45. and macular degeneration. 14131420. Dietary carotenoids. Miller DT. 1246-1253. 119. Two nutrition intervention trials. Blair N. Nutr Rev. Cruysberg JR. 84 85 86 87 88 89 Seddon JM. Schweitzer D. Burton TC. Carotenoids in the retina . 111. rat and frog retinal rod outer segments. AREDS Research Group. Hammer M. Bioactivity and protective effects of natural carotenoids. Free Radic Biol Med. Lang GK. Hurst JS. 1994. Haller J. 387-397. JAMA. 371. Invest Ophthalmol Vis Sci. 2001. The macular pigment. Garwin GG. 2001. [Age-related maculopathy. 2004. Chew EY. Lipofuscin-formation in retinal pigment epithelial cells is reduced by antioxidants. Exp Eye Res. Mazurek P. 2006. Ophthalmology. Nichols CR. Craft N. Am J Clin Nutr. Trieschmann M. Failure of Oral Supplement Containing Lutein to Change Macular Pigment Density. 1038-1045. 136. Optometry and Vision Science. Newmark HL. they protect body cells and LDL from oxidative damages” No references provided ID 1697: “Lattasi (beta-galattosidasi)” and “Digestion” No references provided ID 1706: “squalene idrocarburo” and “Antioxidant activity. 25682573. Miller B. Täufel A. Craft NE. Sarna T. Ternes W. 502. Cheng KM. Yeger H. Mares JA. Young AJ and Lowe GM. Handelman GJ. 2001. Hense HW. 124. Nichols CR. Delori FC. Aebischer JC. Thomson LR. oleuropein complex polyphenol belonging to ai secoiridoids” and “Antioxidant activity. Invest Ophthalmol Vis Sci. Invest Ophthalmol Vis Sci. Macular Pigment: A Prospective Supplementation Study. Tenter U. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. Curran-Celentano J. 2 476 . 2002. 1094-1101. 2005. Whitehead AJ. 20-27. Rozanowska M. zeaxanthin. Schalch W. Antioxidant and prooxidant properties of carotenoids. Johnson MA. Dorey CK. 2004. Bressler NM. Cohn W. Arch Ophthalmol. Toyoda Y. 36. Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. Dorey CK. 2000. Wenzel AJ. Cheng KM. Macular pigment: a review of current knowledge. Garnett KM. 2002. Koren G. Garnett KM. Arch Biochem Biophys. 375-381. Zobel M. Lexikon der Lebensmittel und der Lebensmittelchemie. Bressler SB. Thomson LR. 43. Fine SL. Yolton D. 39. Invest Ophthalmol Vis Sci. Pauleikhoff D. Tunger L. Eur J Cancer. 43. Massof RW. Baruchel S. Stuttgart. Langner A. 2556-2565. 2006. 88-97. 2003. Wrona M. implications in cancer chemotherapy. 104. Zeaxanthin in combination with ascorbic acid or alphatocopherol protects ARPE-19 cells against photosensitized peroxidation of lipids. Thurmann PA. Heimes B. protection of body tessue and skin from oxidant agents (UV rays)” 1 Das B. Effect of dietary zeaxanthin on tissue distribution of zeaxanthin and lutein in quail. Nicolosi RJ. 2007. Langner A.102 Sunness JS. Barbato D. 2002. Danis RP. Plasma kinetics of lutein. 96. J Nutr. A 12-wk egg intervention increases serum zeaxanthin and macular pigment optical density in women. 385. ID 1690: “Alfa-galattosidasi” and “Digestion” 103 104 105 106 107 108 109 110 111 112 No references provided ID 1696: “hydroxytyrosol simple phenol. 72. Toyoda Y. Free Radic Biol Med. 1989. 47. DeRuyter B. 3538-3549. Wissenschaftliche Verlagsgesellschaft. 2006. 79. 1210-1221. Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. and 3-dehydro-lutein after multiple oral doses of a lutein supplement. Freedman MH. Is oleic acid or squalene the important preventive agent? Am J Clin Nutr. Gerweck C. 82. Baruchel H. 1990. Anleitung zum Einreichen von Zulassungsgesuchen für Husten. Scrimgeour CM. Arginine nutrition and cardiovascular function. 283. Tipton KD. 130. 52-77. 1999. secoiridoids. E122-129. 1989... ID 1714: “Ascorbic acid” and “Respiratory health” 1 Schweizerisches Heilmittelinstitut. 537-542. Bartsch H. Ferrando AA. Mier W. Lancet Oncol. Jr. Klein S. Wolfe RR. Commission on Life Sciences. Jr. Protein and amino acids. Bartsch H. 2000. rich in EGCG” and “Protection of body tissues and cells from oxidative damage” No references provided ID 1711: “Amino acids” and “Stimulate protein synthesis” 1 Bennet WM. Minerva Pediatr. Giacosa A. 273. 2626-2629. Giacosa A. Circulation. 2000. Tipton KD. Effects of amino acid intake on anabolic processes. Giovannini G. Food Chem Toxicol. ID 1715: “Ascorbic acid. Wolfe RR. McKinley LJ. 21232128. 647-659. 2007. Spiegelhalder B. 1. Eur J Clin Invest. 20. Rennie MJ. 1997. Connacher AA. Can J Appl Physiol. sodium salt” and “Respiratory health” 1 Swissmedic (Schweizerisches Heilmittelinstitut). Hull WE. Wolfe RR. Burnett JC. Lerman A. An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein. Wu G and Meininger CJ. Baligan M. Ambrosioni G. The effect of amino acid infusion on leg protein turnover assessed by L-[15N]phenylalanine and L-[1-13C]leucine exchange. Arginine: Clinical potential of a semi-essential amino. Tipton KD. Anleitung zum Einreichen von Zulassungsgesuchen für Hustenund Hals-bonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren. Postexercise net protein synthesis in human muscle from orally administered amino acids. Owen RW. Am J Physiol. 276. E648-657. Jr. 97. Am J Physiol. [L-arginine and immunity. Phillips SM. 41-50. ID 1708: “Epigallo-catechin-3-gallate (EGCG) / Green tea extract. 38. Wolfe RR. 2002. 7. ID 1712: “Arginine” and “For muscle integrity and haematopoiesis (red blood cells building)” 1 2 3 4 Appleton J. Borsheim E. In: Recommended Dietary Allowances. Washington DC. Giardina A. J Nutr.und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren. 2007. 107-112. National Academy Press. Study of pediatric subjects]. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols. 2000. Wurtele G. S220227. 2002. Spiegelhalder B. simple phenols. 26 Suppl. 1998. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Doyle D. Higano ST.3 4 Owen RW. Haubner R. 2001. 49. Olive-oil consumption and health: the possible role of antioxidants. Wolf SE. 512-522. Altern Med Rev. Am J Physiol Endocrinol Metab. 1997. Essential amino acids and muscle protein recovery from resistance exercise. 2 3 4 5 5 477 . lignansand squalene. Biolo G. E628-634. Holmes DR. Hull WE. Laghi MG.. Ebeler SE. Natural Medicines Comprehensive Database. Yoshikawa M. Collery P. Kensler TW. http://www. 228-232. 1997. John Libbey Eurotext. 2000.com/monograph.naturaldatabase. Egner PA. Fujita H. Burns SA. Yasumoto R. 523-524. Steinberg FM. Bailey GS. Nowell S.ID 1716: “Bonito protein peptide” and “Natural Blood Pressure Support” 1 2 Fujita H. 304-305. Chlorophyll. Van Hoorebeke C. Qian GS. Ohshima K. Fujita H. 1995. Mutat Res. Jacobson LP. Paris. 2003. Human volunteers study on antihypertensive effect of ―katsuobushi oligopeptide‖ (I). Calomme MR. 1999. Negretti de Bratter V. Absorption of silicon in healthy subjects. 123-127. http://www. Chlorophyllin intervention reduces aflatoxinDNA adducts in individuals at high risk for liver cancer. Clin Exp Pharmacol Physiol 22. Vingerhoets R. Wu Y. Proc Natl Acad Sci USA. 11491158. Mitchell AE. Peptide inhibitors for angiotensin I-converting enzyme from thermolysin digest of dried bonito. Supplementation of calves with stabilized orthosilicic acid. Nutr Cancer. ch-OSA is a stabilized and concentrated source of orthosilicic acid)” and “Maintenance and promotion of healthy connective tissue in bone by stimulating bone collagen synthesis. Cos P.asp?mono_id=626&brand_id=. Yoshikawa M.). Hasegawa M. 2001. 1997. Effect of dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and IQ and phase II hepatic enzymes. Van den Berghe DA. Hasegawa M. Chlorophyllin. Nutr Res 21. 564-569. Yoshikawa M. 1997. Jpn Pharmacol Ther. 1998. 212-221. Yokoyama K. 1541-1545. In: Metal Ions in Biology and Medicine. in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects. Zhu YR. Lamberts LV. Yamagami T. De Broe ME. Biosci Biotech Biochem 56. Munoz A. 3 4 5 6 7 2 3 4 5 6 ID 1718: “choline-stabilized orthosilicic acid (ch-OSA) (The mineral silicon is present in water as orthosilicic acid. 153-165. Human volunteers study on antihypertensive effect of ―katsuobushi oligopeptide (II). 98. Kuang SY.com/monograph. Etienne J-C (eds. Fujita H. Fujita H and Yoshikawa M. Fujita H. Chlorophyllin. Egner PA. 153157.com/drug_info/nmdrugprofiles/nutsupdrugs/chl_0069. Yokoyama K. Chiba H. Ohshima K. Natural Medicines Comprehensive Database.pdrhealth. Antihypertensive effect of thermolysin digest of dried bonito in spontaneously hypertensive rat. http://www. 46. Yamagami T. 478 . Jpn Pharmacol Ther 25. Abel S. Ohshima K.shtml. Groopman JD.naturaldatabase.asp?mono_id=626&brand_id= . Biological Trace Element Research. katsuobushi oligopeptide. 2001. Yasumoto R. LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein Immunopharmacol 44. Classification and antihypertensive activity of angiotensin Iconverting enzyme inhibitory peptides from food proteins. Chemoprevention with chlorophyllin in individuals exposed to dietary aflatoxin. ID 1717: “Chlorophyllin [Sodium copper chlorophyllin] and “Relief for Gastric Discomfort” 1 Dingley KH. 209-216. A placebo-controlled study on the effect of ―peptide soup‖ on blood pressure in borderline and hypertensive subjects. 25. J Food Sci 54. Helzlsouer KJ. Clifford AJ. Wang JB. PDR Health online database. Ubick EA. Effects of an ace-inhibitory agent. D'Haese PC.” 1 2 Calomme MR and Vanden Berghe DA. 147-151. Khassanova L. Healty women and men. 14601-14606. Yokoyama K. 1992. Bratter P. 2003. Ohshima K. 56. Chiarappa-Zucca ML. Yasumoto R. Zhang BC. Zhang QN. Gange SJ. Kensler TW. 1111-1114. 541-544. Calomme MR. 2006. 32. Journal of Bone and Mineral Research. Vanden Berghe A. Jugdaohsingh R. Bone. Khassanova L. 4 5 6 7 8 9 10 11 12 13 ID 1719: “choline-stabilized orthosilicic acid (ch-OSA) (The mineral silicon is present in water as orthosilicic acid. Kiel DP. Geusens P. Timchenko A. 147-153.). Jugdaohsingh R. Van Hoof V. Fresenius'Journal of Analytical Chemistry. 32. Lamberts L. Silicone intake is a major dietary determinant of bone mineral density in men and premenopausal women of the Framingham offspring cohort. Powell JJ. Jugdaohsingh R. John Libbey Eurotext. De Broe M. 2000. Bone. Silicon absorption from stabilized orthosilicic acid and other supplements in healthy subjects. D‘Haese P. 19. In: Metal Ions in Biology and Medicine. 2008. Calomme M. Favrier AE (eds. 297-307. Calomme MR and Vanden Berghe DA. Powell JJ. Anderson RA. 363. New York. Jonathan P. Tucker KL. Arch Dermatol Res. Powell JJ. Opionion on tolerable upper intake level of silicon EFSA-Q-2003-018. 11. Vingerhoets R. Evans BAJ. 20.3 Calomme M. Calomme M. Deelstra H. Mg. Calcif Tissue Int. Vanden Berghe D. 9. 227-232. Ogston N. Healthy women and men. Vanden Berghe DA. D‘Haese P. Supplementation of calves with stabilized orthosilicic acid. BMC Musculoskeletal Disorders. Behets GJ. Hampson GN. Negretti de Bratter V. Thompson RPH. Qiao N. 99-110. Partial Prevention of Long-Term Femoral Bone Loss in Aged Ovariectomized Rats Supplemented with Choline-Stabilized Orthosilicic Acid. Vanden Berghe D. Demeester N. Dietary Silicon Intake Is Positively Associated With Bone Mineral Density in Men and Premenopausal Women of the Framingham Offspring Cohort. Ravin J.). D‘HAese PC. Tucker KL. 292. Wijnen P. Qiao N. Powell JJ. Cos P. Sindambiwe JB. 2 3 4 479 . Calcified Tissue International. nails and hair in women with photodamaged skin. Mertens J. Calomme M. The EFSA Journal 60. Paris. Berghe DV. Cheung HFJ. 2003. Choline-stabilized orthosilicic acid supplementation as an adjunct to Calcium/Vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized. Silicon and bone health. De Broe ME. 70. 10.” 1 Barel A. Sindambiwe JB. Cos P. D'Haese PC. 2004. Spector TD. Effect on the Si. 297. Clarys P. Reffitt DM. 78. Van den Berghe DA. Spector TD. Effect of oral intake of choline-stabilized orthosilicic acid on skin. Van Hoorebeke C. Simon A. Cos P. Van Dyck K. Jugdaohsingh R. 1-11. 1111–1114. 1999. 127-135. Nathalie D. Liisa B. Collery P. Effect of bone turnover and BMD of low dose oral silicon as an adjunct to calcium/vitamin D3 in a randomized placebocontrolled trial. Van Hoorebeke C. Vingerhoets R. Jugdaohsingh R. 2003. Van Cauwenbergh R. Van Hoorebeke C. Bratter P. EFSA-NDA Panel. 2002. Calomme MR. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Lamberts LV. Robberecht H. Effect of choline stabilized orthosilicic acid on bone density in chicks. 153-165. ch-OSA is a stabilized and concentrated source of orthosilicic acid)” and “Helps support hair quality by helping to maintain healthy connective tissue in the dermis. 2005. Rogiers V. Bioavailability of silicon from food and food supplements. Kiel DP. Biol Trace Elem Res. Trace elements in man and animals. 228-232. 1997. In: Trace Elements in Man and Animals Roussel AM. 1998. Journal of Bone and Mineral Research. S192. and P concentrations in serum and the collagen concentration in skin and cartilage. Geusens P. Cos P. Ca. Cupples LA. Silicon absorption from stabilized orthosilicic acid and other supplements in healthy subjects. Calomme M. Vingerhoets R. Etienne J-C (eds. Anderson S. 2007. 56. Demeester N. Dirk B. Calomme MR. De Paepe K. 2004. Swaminathan R. Rami S. placebo-controlled trial. 2000. Gail C. 2005. Kluwer Academic Plenum Publishers. Vanden Berghe DA. J Nutr Health Aging. Lamberts LV. De Broe ME. Absorption of silicon in healthy subjects. Arsenic. Iodine. Copper. 2007. 363. Vanadium. and Zinc.5 EFSA. Chromium. Iodine. Iron. Nutr Rev. Manganese. ID 1720: “Co-Enzyme Q 10” and “For physiological energy” 6 7 8 9 1 Crane FL. Nickel. 2000. J Am Coll Nutr. Kossmann E. and ornithine transaminase enzyme activity in liver. 2000. Effect of oral intake of choline-stabilized orthosilicic acid on hair tensile strength and morphology in women with fine hair. Robberecht H. Deelstra H. Powell JJ. Van Dyck K. Boron. Jialal I. Analytical and Bioanalytical Chemistry. Van Cauwenbergh R. 1-11. Boron. 32. Iodine. Manganese. Copper. Vitamin K. Calomme M. 1999. 286293. 89. Iron. 251-261. 2003. Biochemical functions of coenzyme Q10. ID 1722: “Copper enriched Saccharomyces cerevisiae ATY-SC-108” and “Connective tissues” 1 IoM (Institute of Medicine). Vanadium. National Academies Press. Thompson RP. Coenzyme Q10 supplementation and heart failure. Molybdenum. Washington DC. 2002. The EFSA Journal. National Academies Press. Clarys P. Biol Trace Elem Res. Washington DC. Devaraj S. Barel A. Opinion of the scientific panel on dietetic products. Cheung HF. JHCI (Joint Health Claims Initiative). 2001. Silicon. 2003. Chromium. Silicon deprivation decreases collagen formation in wounds and bone. and Zinc. Hampson GN. Arsenic. Molybdenum. Wickett RR. 127-135. Dietary Reference Intakes for Vitamin A. 60. 2000. Final Technical Report A List of Well Established Nutrient Function Statements. JHCI (Joint Health Claims Initiative). Final Technical Report A List of Well Established Nutrient Function Statements. 2003. ID 1726: “Copper enriched Saccharomyces cerevisiae ATY-SC-108” and “Protection of body tissues and cells from oxidative damage” 2 1 IoM (Institute of Medicine). Arsenic. 499-505. Final Technical Report A List of Well Established Nutrient Function Statements. Washington DC. 2 480 . Ogston N. ID 1721: “Co-Enzyme Q 10” and “For maintenance and promotion of heart health” 1 Singh U. Bioavailability of silicon from food and food supplements. Nickel. 2004. Manganese. Chromium. Silicon. Seaborn CD and Nielsen FH. Arch Dermatol Res. and Zinc. Demeester N. Vitamin K. Bone. JHCI (Joint Health Claims Initiative). 541-544. National Academies Press. Nickel. Copper. Silicon. Dietary Reference Intakes for Vitamin A. Jugdaohsingh R. Dietary Reference Intakes for Vitamin A. nutrition and allergies on a request from the Commission related to the tolerable upper intake level of silicon: Request n° EFSA-Q-2003-018. Reffitt DM. Vanden Berghe D. Iron. 20. 2007. ID 1724: “Copper enriched Saccharomyces cerevisiae ATY-SC-108” and “Skin and hair pigment” 2 1 IoM (Institute of Medicine). Vanadium. Boron. Vitamin K. 299. 65. 591-598. Molybdenum. 2003. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Evans BA. Washington DC. 1998. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Hyaluronic acid Monograph. A 14-month pilot study. Molina V. Nickel. JAMA. 2000. Final Technical Report A List of Well Established Nutrient Function Statements. Saez F. Bulitta M. Illnait J. ID 1731: “Hyaluronic acid / Sodium Hyaluronate” and “Joint Health” 1 Therapeutic Research Faculty.aspx?cs=&s=ND&pt=100&i d=1062&ds=. Silicon. Gouni-Berthold I.com/(S(xlamzw45bahpju45aejhch55))/nd/Search. Iodine. Boron. Stuttgart. National Academies Press. 1-Triacontanol. Berthold HK. Int J Clin Pharmacol Res. Mas R. Fernandez JC. Gouni-Berthold I. Dietary Reference Intakes for Vitamin A. Menendez A. platelet aggregation and endothelemia in older hypercholesterolemic patients. Copper. Stusser R. 134-137. 33. Mas R. JHCI (Joint Health Claims Initiative). Castano G. 1996. ID 1748: “Policosanol [from sugarcane wax (Saccarum officinarum)]” and “Support for Healthy Blood Lipid Levels” 1 Arruzazabala ML. Valdes S. 61-64. Holzgrabe U. Keller K. Unverdorben S.from sugar cane (Saccharum officinarum). 295. Anleitung zum Einreichen von Zulassungsgesuchen für Husten. Manganese. Molina V. http://www. Prostaglandins Leukot Essent Fatty Acids. Unverdorben S. Molybdenum. Ebel S.und Halsbonbons sowie Pastillen der Abgabekategorie E im Meldeverfahren. 2007. Iron. 2 ID 1747: “Policosanol / Blend of aliphatic alcohols . Swissmedic. Mendoza S. Batista J. Valdes S. 2007. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. Carbajal D. 2262-2269. 58. Valdes S.” And “Cholesterol” 1 Berthold HK. Carbajal D. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. 2006. Degenhardt R. 2000. 2 3 4 5 6 481 . 20. Carbajal D.ID 1727: “Copper enriched Saccharomyces cerevisiae ATY-SC-108” and “Transport and metabolism of iron” 1 IoM (Institute of Medicine). Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Arruzazabala ML. Natural Medicines: Comprehensive Database. and Zinc. Arsenic. Wissenschaftliche Verlagsgesellschaft. Perez B. 119124. 105-116. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. Int J Tissue React. 1998. 2006. Noa M. Noa M. 835-840. Vanadium. Braz J Med Biol Res. Int J Clin Pharmacol Ther. Chromium. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. Hagers Enzyklopädie der Arzneistoffe und Drogen. Arruzazabala ML. Reichling J. Molina V. Degenhardt R. Mas R. 19. 1-Tetracosanol and 1-Hexacosanol . 1999. Fernandez L. Effects of policosanol and pravastatin on lipid profile. Arruzazabala ML. Schulz V. 34.consisting primarily of 1-Octacosanol. Vitamin K. 295.naturaldatabase. Menendez R. ID 1730: “Glycerol” and “Respiratory health” 1 2 Blaschek W. Hackenthal E. Bulitta M. Mas R. 2003. 2262-2269. Whanger PD. 14. Crespo N. and Gray WP. Zielke JC. 61. Gunay M. Maiani G. 13. 1045-1051. Stewart-Knox B. Lance P.com. A long-term study of policosanol in the treatment of intermittent claudication. Angiology. Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic Women. 2006. 1-10. Mas R. 59.7 8 9 Castano G. S1-4. Amor AM. Jr. 20.naturaldatabase. 7 482 . Castaño G. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Vlckova V. Therapeutic Research Faculty. Fernandez L. 52. ID 1756: “Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109” and “Bone formation” 1 2 3 4 5 6 Ilich JZ and Kerstetter JE. Simpson EE. J Am Coll Nutr. 752-760. Gouni-Berthold I and Berthold HK. Am Heart J. 79.pdrhealth. 2004. O'Connor JM. 2000. 10 11 12 13 14 ID 1751: “Selenomethionine enriched Saccharomyces cerevisiae ATY-SC-107” and “Protection of body tissues and cells from oxidative damage” 1 2 3 4 5 Combs GF. 143. 2001. Maylor EA. Toxicology. Castano G. Jacobs ET. Bardet L. Policosanol. Ann NY Acad Sci. 2000. Biol Trace Elem Res. O'Connor JM. Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise. Physicians' Desk Reference (PDR). Comparison of the Efficacy. Khaled S. 100. 91. Pharmacol Ther. Ferry M. Surai PF. 96. 187-195. 11-28. Selenium and its relationship to cancer: an update. 31-38. 2005. Fernandez J. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. 227. 2004. Effects of zinc supplementation on cognitive function in healthy middle-aged and older adults: the ZENITH study. Fernandez C. 19. 173-175. Policosanol. Baltaci AK. Cashman KD. 2006. Jackson MJ. Effects of zinc supplementation on blood rheology during exercise. Castano G. Más R. Kilic M. Illnait J. Cassanas G. 1998. Policosanol. Fernandez L. 103. Coudray C. Int J Clin Pharmacol Res. Selenium: from cancer prevention to DNA damage. 2004. 2006. Mas R. Fraser WD. Meunier N. Lukaski HC. Nottingham. 1999. Goulet AC. 2005.com. 2001. 356-365. 117-127. Studies into the anticancer effects of selenomethionine against human colon cancer. McConville C. Andriollo-Sanchez M. 1999. Fernandez JC. 2002. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gamez R. Importance of zinc in the elderly: the ZENITH study. Chemopreventive agents: selenium. 19. 179-192. Letavayova L. 2002. Polito A. http://www. Br J Nutr. Coudray C. Roussel AM. González RM. 1059. Nutrition in bone health revisited: a story beyond calcium. Clinical Drug Investigation. Secker DL. Orsetti A. International Journal of Angiology. Gynecol Endocrinol. Illnait J. Fernandez L. 2005. Meunier N. Lowe NM. 181-185. Is there a potential therapeutic value of copper and zinc for osteoporosis? Proc Nutr Soc. 26-32. Br J Nutr. 81. Lopez LE. an aliphatic alcohol sugarcane derivative: use in patients intolerant of or inadequately responsive to statin therapy. 715-737. 1-14. Wright CM. Illnait J. Eur J Clin Nutr. Alvarez E. Menendez R. Fernández JC. Nottingham University Press. Whayne TF. Effect of zinc supplementation on hematological parameters in athletes. Alvarez E. Nelson MA. Clin Hemorheol Microcirc. http://www. Selenium in nutrition and health. Natural Medicines: Comprehensive Database. Secker DL. 21. Mas Ferreiro R. Am J Clin Nutr. 115-125. Brozmanova J. Brun JF. J Am Coll Nutr. Johnson LK.8 9 Micheletti A. Kroncke KD. 1989. Canfield WK. Nilsson A. Hambidge KM. Hyperzincuria in individuals with insulin-dependent diabetes mellitus: concurrent zinc status and the effect of high-dose zinc supplementation. Gaoli Z. 66. Michiels N. insulinlike growth factor I concentrations. zinc. Zinc deficiency and normal contents of magnesium and calcium in metabolic X syndrome patients as assessed by the analysis of hair element concentrations. 316-321. Frid D. 27. Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India. JHCI (Joint Health Claims Initiative). Bajaj S. Papadopoulos T. Hotimsky A. Lukasiak J. Sies H. J Nutr. Zinc nutriture in type I diabetes mellitus: relationship to growth measures and metabolic control. Falkiewicz B. Biofactors. 2000. Am J Clin Nutr. Shike M. Ross AC. Saudi Med J. selenium and tellurium in the cellular defense against oxidative and nitrosative stress. Brown RG. 1994. Srisurapanon S. Effect of zinc supplementation on zinc status. 31. 1558-1562. 1998. Singh RB. J Med Assoc Thai. 639-642. 2003. Blostein-Fujii A. Rufini S. 2003. Modern Nutrition in Health and Disease. 175-178. 11. Neve J. Sjogren A. The influence of zinc supplementation on glucose homeostasis in NIDDM. 11. J Pediatr Gastroenterol Nutr. 2006. Vitamin K. 2001. Copper. DiSilvestro RA. Zouari N. Powell SR. National Academies Press. Supanit I. 461-466. Rastogi SS. Shoumin Z. Cunningham JJ. 577-582. Klotz LO. Mearkle PL. Final Technical Report A List of Well Established Nutrient Function Statements. Chromium. 22. The antioxidant properties of zinc. 78. ID 1757: “Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109” and “Immune System” 10 1 IoM (Institute of Medicine). Role of copper. Mahjoub S. 2003. Diabetes Res. 3 4 5 6 7 8 9 10 11 12 483 . J Am Coll Nutr. ID 1758: “Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109” and “Protection of body tissues and cells from oxidative damage” 2 1 2 Al-Maroof RA and Al-Sharbatti SS. 344-349. 15. 73-79. Lippincott Williams & Wilkins. Cajzer D. Apibal S. Manganese. 1448S-1451S. Willems D. Roongpisuthipong C. Iodine. and lipoprotein oxidation rates in vitro. Silicon. Katz C. Cousins R. 2000. Boron. Rossi R. 17. 344-350. 2001. Niaz MA. 3. Anderson RA. Arsenic. Kerkeni A. Washington DC. 1447S-1454S. 1984. Kajanachumpol S. Raz I. Siderova V. Shils ME. 564-570. and Zinc. 2006. Fu A. Zinc status in athletes: relation to diet and exercise. Molybdenum. Short-term zinc supplementation in women with non-insulin-dependent diabetes mellitus: effects on plasma 5'-nucleotidase activities. 577-584. Roussel AM. J Trace Elem Med Biol. 224. Nickel. Vanadium. Bergmann P. Matheau JM. 1995. Zinc supplementation increases bone alkaline phosphatase in healthy men. Katz M. Iron. J Nutr. Jablonska-Kaszewska I. 1997. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. Caballero B. Buchczyk DP. potassium and zinc deficiency in subjects with type II diabetes mellitus. Dabrowska E. Floren CH. 1988. Sports Med. Philadelphia. Magnesium. Malarkey W. Acta Med Scand. 2000. Peretz A. 130. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. 133. 139-141. Baltimore. Karsai D. 43. Dietary Reference Intakes for Vitamin A. copper status and cellular immunity in elderly patients with diabetes mellitus. Metabolism. Yun YP. J Nutr. a citrus flavonoid. 1257-1262. is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Son KH. Chung JH. Kang SG. A study to measure the glycaemic index and insulin index value of tagatose sugar. Effect of hesperidin and naringin on the plasma lipid profile and plasma antioxidant activity in rats fed a cholesterol-containing diet. Reunanen A. Do KM. Final Technical Report A List of Well Established Nutrient Function Statements. 3 2 3 4 5 6 7 8 9 484 . ID 1763: “Hesperidin (a component of citrus peel extract and precursor of hesperitin) (ingredient not found in the spanish food laws)” and “Cardiovascular health” 1 Bok SH. Int J Biochem Cell Biol. Iino H. Rissanen H. Forestieri AM. Lee JJ.Tagatose (ingredient not found in the spanish food laws)” and “Postprandial blood glucose” 1 2 Lu Y. 2003. 3644. Choi MS. Suzuki K. 2007. Choi MS. J Jap Soc Clin Nutr. (unpublished). Kumpulainen J. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Lee MK. Ishimi Y. Lipid-lowering efficacy of hesperetin metabolites in high-cholesterol fed rats. J Nutr. 50. Donner TW. Wu J. Glycaemic Index Research Report for Arla Foods (March 2004). Aromaa A. Leontowicz H. Atherosclerosis. 38. 133. 1995. Trakhtenberg S. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. 21-28. Choi MS. 194. Lo Curto RB. 327. Hayakawa J. Han XH. de la Consommation et de la Répression des fraudes) du 7 octobre 1997. Jastrzebski Z. Journal of the Science of Food and Agriculture. Lee MK. 2003. 2003. Wang X. Shimizu T. Park YB. 129-137. Hesperidin. 595-599. 1182-1185. Lee MK. Am J Clin Nutr. Park YB. BOCCRF (Bulletin Officiel de la Concurrence. SUGiRS (Sydney University's Glycaemic Index Research Service). Kim HK. Clin Chim Acta. Jeong TS. 2002. Zhang YH. Trovato A. 10. 1892-1897. 2003. Blunting effect of D-tagatose on blood glucose when administered orally with glucose in volunteer donors of boundary glycemic level. 1999. 71. Sakashita M. Jung ST. 109-134. Tagatose. Leontowicz M. Knekt P. Park YB. 87. Farmaco. 76. a Citrus flavonoid. Park YS. Hakulinen T. Kanazawa K. Monforte MT.ID 1759: “Zinc and copper enriched Saccharomyces cerevisiae ATY-SC-109” and “DNA synthesis / cell division” 1 Avis de la commission interministérielle d‘étude des produits destinés à une alimentation particulière (CEDAP) en date du 18 décembre 1996 sur les recommandations relatives au caractère non trompeur des seuils des allégations nutritionnelles fonctionnelles. 129. Masuyama R. Gralak M. Uehara M. Park YB. Jarvinen R. Jeong TS. Int J Vitam Nutr Res. 2008. 1134-1145. Diabetes Obes Metab. a new antidiabetic and obesity control drug. 144-152. Bok SH. Gorinstein S. 2001. Jin YR. Flavonoid intake and risk of chronic diseases. Levin GV. Chiba H. Biological effects of hesperidin. Madenokoji N. Jeong TS. inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. JHCI (Joint Health Claims Initiative). Lim Y. Heliovaara M. 560-568. 2007. Bae KH. a bioflavonoid. 2 ID 1762: “D. Kang MA. Krzeminski R. Galati EM. Choi MS. Interactive effect of hesperidin and vitamin E supplements on cholesterol metabolism in high cholesterol-fed rats. Jung UJ. Lee SH. 25. 2006. Kirjavainen S. Antiplatelet activity of hesperetin. 66. 2003. inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice.). Barrett M.5-13. Masuyama R. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. 26. 2006. Mantegazza P. 2 3 4 5 6 7 8 9 10 485 . Blache D. 2004. Herbal Remedies: Heilpflanzen. Ishimi Y. 14. and modulate lipid homeostasis in adipose tissue and liver. 2006. Wilcox LJ. Osbeck) peel. Das DK. 1892-1897. 2004. Suzuki K. Berti F. J Agric Food Chem. 103-120. Clin Calcium. Toxicology. Manfredi B. 42. Gruenwald J. Fitoterapia. Boston University. Lesgards JF. 2000. The Handbook of Clinically Tested Herbal Remedies. Academic Press. 280-286. Heaney RP (eds. Huff MW. naringenin and hesperetin. In: Nutritional Aspects of Osteoporosis.0% proanthocyanidins]” and “Antioxidant protection system” 3 4 5 1 Bagchi D. Journal of Food Hygiene and Safety. Yesilada E. 207216. Rossoni G. Lebensmittelchemie. leaves and grape skins: antioxidant and chemical characterization. 725-734. solvent of extraction acetone/water 8. Jaenicke C. 133. and Hesperidin on Experimental Alveolar Bone Loss. Acta Nutrimenta Sinica. a Citrus Flavanone. ID 1765: “Standardized grape seed extract [dry extract from grape seeds of vitis viniferaL. Orhan DD. Effects of Naringenin. Rustan I. 2006. 1997. (Vitaceae). J Lipid Res. Improves Bone Acquisition and Prevents Skeletal Impairment in Rats. 2004. DuMont. Timber Press. J Ethnopharmacol. Ray SD. Bagchi M. Uehara M. inhibit phosphodiesterase. DuMont's große Kräuterenzyklopädie. Bartolome B. 291-317. ID 1764: “Hesperidin (a component of citrus peel extract and precursor of hesperitin) (ingredient not found in the spanish food laws)” and “Bone health” 12 1 2 Abitbol TE. Wang X. Bombardelli E and Morazzoni P. HaiDe Z. 1669-1676. Vitis vinifera L. Kanazawa K. Hesperidin. DawsonHughes B. Song WS. 1995. Baek KS. Experimental Biology and Medicine. J Nutr. Hernandez-Ledesma B. Pruess HG. Brendler T. Joshi SS. Kim KY. 2004. 3. Choi YH. Ergun F. 378-381. Orhan N. revealed in vitro et es vivo a biological test. Monagas M. 29. In-vivo assessment of antidiabetic and antioxidant activities of grapevine leaves (Vitis vinifera) in diabetic rats. a citrus flavonoid. Procyanidins from Vitis vinifera seeds display cardioprotection in an experimental model of ischemia-reperfusion damage. Horcajada MN and Coxam V. Kuszynski CA. Secretion of hepatocyte apoB is inhibited by the flavonoids. van Wyk BE and Wink M. Burckardt P. Portland. 54.10 11 Peluso MR. 2001. Medicinal plants of the world. de Dreu LE. 51. Köln. Gomez-Cordoves C. 16. 2003. 2006. 1997. Stohs SJ. Hesperidin. Bown D and Koziol C. Ling L. Borradaile NM. 231. 319-327. a wine product. Goldman School of Graduate Dentistry. 1287-1299. 1988. Deutscher Apotheker Verlag. Wu J. 148. XiaoQuan Y. Commercial dietary ingredients from Vitis vinifera L. Rutin. Chiba H. Haworth Herbal Press. via reduced activity and expression of ACAT2 and MTP. Flavonoids attenuate cardiovascular disease. Antimicrobial Effect of Hesperidin on Dental Enamel Decalcification and Alveolar Bone Loss. Hesperidin and bone metabolism. 108. Antioxidant properties of plant extracts and transresveratrol. Uehara M. Aslan M. The antioxidants and antilipemic effects of flavonoids extracted from pomelo (Citrus grandis L. Prevention of osteoporosis by foods and dietary supplements. 22-26. Stuttgart. Hernry M. 187-197. 2001. New York. Drugs Exp Clin Res. 1999. Natural Pharmacy. 572. Tsipursky M. In: The Review of Natural Products. 1994. blocks amplification of IL-1 beta production by human monocytes. 1411-1414. BMJ. ID 1772: “Gamma-linolenic acid” and “Immune health” 1 2 3 No authors listed. DerMarderosian A and Beutler JA. Chebib M. EduFacts. Agriculture and Agri-Food Canada. Molecular biology of the GABA(A) receptor: functional domains implicated by mutational analysis. 1994. J Immunol. J Physiol. Drug Development Research. Gammalinolenic acid. 20. d214-233. 1-3. In: The Review of Natural Products. AAFC No. Gamma Linolenic Acid: A Natural Anti-inflammatory Agent . ID 1771: “Gamma-linolenic acid” and “Vascular health” 1 2 3 4 Berth-Jones J and Graham-Brown RA. Facts and Comparisons. 128. 46. Oil of evening primrose. Rudy D. randomized trial of lutein and antioxidant supplementation in the 486 . Martin IL and Dunn SMJ. Zurier RB. Pei K.260 Lema GM and Auerbach A.complementary structure . an unsaturated fatty acid with antiinflammatory properties. Gamma-Linolenic Acid. 1999. Importance of dietary gamma-linolenic acid in human health and nutrition. Does not show promise in atopic dermatitis. 1998. 1997. 1411-1414. Front Biosci. Vandenberg RJ. Fan YY and Chapkin RS.activity relationships. 7. Stiles W. Healthy Canadian Ingredient. Mason P. 4 5 DerMarderosian A and Beutler JA. 183200. placebo-controlled. Modes and models of GABA(A) receptor gating. 1996. Healthy Canadian Ingredient. 2004. Research Overview. Medicinal chemistry and molecular pharmacology of GABA receptors and glutamate transporters . Gamma-Linolenic Acid. 2004. 273. St. 309. 10057E. Oil of evening primrose. 10057E. Johnston GAR. Duke RK. 2001. 167. GABA(C) receptors: a molecular view. Agriculture and Agri-Food Canada. Rossetti RG. 2006. 2002. St. Statkute L. Pulido J. Fatty acids: which ones do we need? Pharmaceutical Journal. 1. 2001. Does not show promise in atopic dermatitis. Dunn SM. 490-496. 309. 128.ID 1768: “Gamma-amino butyric acid (GABA)” and “Mental health” 1 2 3 Davies M. GLA: a safe and effective anti-inflammatory omega-6 fatty acid. Patterson CA. Tocris Reviews. 2005. GABA receptors. Louis. Kapoor R. Facts and Comparisons. Nyland J. 382. Furse RK. J Nutr. Louis. Biol Chem. 750-752. Evening primrose oil. 255. 1998. Frankowski J. Enz R. Fan YY and Chapkin RS. 1997. BMJ. Mitrovic AD. 1111-1122. AAFC No. Mewett KN. 2006. ID 1774: “Gamma-linolenic acid” and “Bone health” 4 1 2 3 4 Berth-Jones J and Graham-Brown RA. 1437. 8. ID 1779: “Lutein” and “Antioxidant activity” 1 Richer S. Patterson CA. 1437. Evening primrose oil. J Nutr. 2006. Bateson AN. Importance of dietary gamma-linolenic acid in human health and nutrition. Double-masked.Part I. 739-746. Biofactors.C. Yunoki M. Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. Ono Y. 12. 2006. 243-248. Jayaprakasam B. Corry RJ. Kawauchi M. The inhibitory effects of berry polyphenols on digestive enzymes. 80. Biochim Biophys Acta.pdf. e17. Olson LK. Van Den Hoogen GW.com/pdf/products/Rutin_&_Melilotus. Hinselwood DC. ID 1785: “Superoxide dismutase” and “Antioxidant activity” 1 2 3 4 Baker GL. 53. Eur J Clin Nutr. Kemin Health. J Agric Food Chem. Collins AR. Rutin & Melilotus. 2002. Schutzki RE. Oxygen free radical induced damage in kidneys subjected to warm ischemia and reperfusion. Gene expression profile of isolated rat adipocytes treated with anthocyanins. Duthie SJ. Leverve X. Autor AP. Dobson VL. Yoshikawa T. Ogawa N. Trevithick-Sutton CC. 3 4 487 . 368-371. ID 1783: “Rutin” and “Vascular health” 1 Fusi F. 14. Forty Years of Superoxide Dismutase Research: the Work of Irwin Fridovich. 2006. Hill RL. Asari S.prollenium. 2006. 1127-1135. 202. 2004. 2004. Ann Surg. Kojo H. 23. 2005. Trevithick JR. Klaus M. Tai MH. 1997. Radermacher P. L. 2000. Speit G. http://www. 1017. J Neurotrauma. 216-230. Eur J Nutr. Prollenium Medical Technologies Inc. Mol Vis. 1985. 75. 774-782. Nishio S. Asanuma M. Influence of an orally effective SOD on hyperbaric oxygen-related cell damage. Ukita N. Kyle JA. Cruysberg JR. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). Tsuda T. Journal of Biological Chemistry. http://www. Sgaragli G. Sousa-Martins D. 281. Ohmoto T. Hoyng CB. Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. Optometry. Effects of quercetin and rutin on vascular preparations: a comparison between mechanical and electrophysiological phenomena.com/pdf/products/Rutin_&_Melilotus. 2005. Simoni RD. 28-31. Verbeek AL. Saponara S. McDougall GJ and Stewart D. 42. Muth CM. Technical Literature. Nair MG.prollenium. Report: KHBB-017-013. Rutin & Melilotus. Free Radic Res. Vareed SK. 1733. Pessina F. J Agric Food Chem. 2003. 38. Olson LK.intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). 2 ID 1789: “Anthocyanidines + proanthocyanidines” and “Carbohydrate metabolism and insulin sensitivity” 1 2 Jayaprakasam B. Collins M. Noguchi Y. The Lutein Antioxidant Supplementation Trial. Prollenium Medical Technologies Inc. Protective effect of superoxide dismutase. 137-147. Glenz Y. 2 3 4 Snellen EL. Foote CS. 189-195. 2005.pdf. Ueno Y. Nair MG. Gorelli B. The retinal carotenoids zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence and ESR study. 54. Effects of lecithinized superoxide dismutase on traumatic brain injury in rats. 628-641. Osawa T. Kresge N. 927-932. ID 1784: “Rutin” and “Antioxidant properties” 1 2 Boyle SP. 54. Acta Ophthalmol Scand. Neovascular age-related macular degeneration and its relationship to antioxidant intake. herbmed. Ammon HP. Weisman MH. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Smolen JS. 23. 205-211. ID 1794: “Boswellia + shark cartilage extract” and “Joints” 1 2 Boswellia serrata. 391-395. Effects of an acetone extract of Boswellia carterii Birdw. Cush JJ.intelihealth.5 Tsuda T. Kimmatkar N. Volpi N. 67. Malhotra P.org/. Leeb BF. Molitor JA. 31-36. Harris CL. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Ministry of Health and Family Welfare. Galati M. Osteoarthritis Cartilage. Wang LB. Sawitzke AD. Gupta I. 2000. Churchill Livingstone. 2006. Yocum DE. 1998. Osteoarthritis Cartilage. Berman BM. 2004. J Rheumatol. Bingham CO. (Burseraceae) gum resin on adjuvantinduced arthritis in lewis rats. 6-week clinical study. Database on Medical Plants used in Ayurveda. Kojo H. Reichling J. Saller R. Saponati G. 1184-1197. N Engl J Med. Bhavaprakasa of Bhavamisra: Original Text Along With Commentary and Translation: Including Nighantu Portion. 146. Furst DE. 27. Dennis TJ. Chaukhambha Orientalia. 2001. Sitaram B. 104-109. Gupta I. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Safayhi H. 354. 433-441. http://www. Gupta S. Boswellia serrata. Biochem Pharmacol. The Ayurvedic Pharmacopoeia of India.com/IH/ihtIH/EMI/8513/31402/348745. Yoshikawa T. Glucosamine. 2006. 71-79. Bucsi L and Poor G. Thawani V. Microarray profiling of gene expression in human adipocytes in response to anthocyanins. Parihar A. Complementary & Alternative Medicine: Boswellia (Boswellia serrata). 3rd. 1998. Moreland LW. Williams HJ. Parihar A. chondroitin sulfate. 1998. Yelne MB.. Zhang WY. Ma ZZ. Government of India. Central Council for Research in Ayurveda & Siddha. 3. 306-307. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 488 . Clegg DO. Ayurvedic Medicine: The Principles of Traditional Practice. Schmokel H. Reda DJ. Montag K. Boccanera L. Schumacher HR. London. Klein MA. Ueno Y. Khiyani R. Lao L. Pole S. 795-808. Manopulo R. Fitzi J. Churchill Livingstone. Altern Med Rev. Gupta V. 2005.html?d=dmtContent. New Dehli. J Ethnopharmacol. 10. O'Dell JR. Lane NE. Wolfe F. 1996. Bocchi L. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. InteliHealth. Dietary support with Boswellia resin in canine inflammatory joint and spinal disease. Morreale P. Mills S and Bone K Elsevier. Ammon HP. Moudgil KD. 6 Suppl A. Bucher S. 2000. Moskowitz RW. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind. Osawa T. Schnitzer TJ. Ludtke R. Gupta S. 2001. Planta Med. placebo-controlled. Safayhi H. 2006. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slowacting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Phytomedicine. J Rheumatol. Zhang RX. Edinburgh. Fan AY. Sharma PC. 511-514. Mohanasundaram J. 2003. Schweiz Arch Tierheilkd. Oddis CV. Bradley JD. Lee DY. Jr. 2003. 2005. The Essential Guide to Herbal Safety. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. Hingorani L. 2006. 1385-1391. 3. Hooper MM. New Dehli. Department of Indian Systems of Medicine and Homeopathy. 3-7. New Delhi. Brandt KD. Zhou AN. London. Ludtke R. Indian Ministry of Health and Family Welfare. Eur J Med Res. Jackson CG. 101. http://www. Edinburgh. 11. Shi H. and the two in combination for painful knee osteoarthritis. 71. India. Schweitzer H. 51. Maruyama H. Bejot M. Kumazawa Y. 795-798. Shay J. Tronnier H. Adv Food Nutr Res. 7. 2004. Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized. Nishihara T. Sansawa H. 1989. Lycopene. 2005. ElSohly HN.a natural antioxidant. Miyamoto E. 48. 737-742. CMAJ. 2002. 325-331. Planta Med. London. Kay RA. Major Herbs of Ayurveda. 79-91. J Nutr Sci Vitaminol (Tokyo). Fatty acid composition of Chlorella and Spirulina microalgae species. aphanizomenon flos-aquae and Chlorella pyrenoidosa. Takenaka S. Isolation of three high molecular weight polysaccharide preparations with potent immunostimulatory activity from Spirulina platensis. 29. Maurette JM. Rao LG. 146. ID 1796: “Carotenoids (alpha. Heinrich U. 30. 489 . Bartonichkova A. Gartner C. double-blind. 67. 2005. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind. Eichler O. 652-654. Smith B. 71. 98-101. Curr Med Chem Anticancer Agents. Ray MR. Am Heart J. Rotkovska D. Lycopene: a review of its potential as an anticancer agent. Skin Pharmacol Physiol. Ebara S. Crit Rev Food Sci Nutr. 2002. Merchant RE and Andre CA. 555-573. Heinrich U. 205-210. Increase in the radiation resistance of mice using Ivastimul. Watanabe F. Bhuvaneswari V and Nagini S. Paran E. Wiebusch M. lycopene)” and “Skin” 1 2 3 4 Banhegyi G. Sanny C. Pugh N. 3rd. placebo-controlled pilot study. 2000. 2006. Inhibition of mast cells by algae. 169. 2006. 2001. Shibata S. Characterization and bioavailability of vitamin B12-compounds from edible algae. ElSohly MA. Otles S and Pire R. Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans. Matsumoto K. Lycopene . hypertension. Stahl W. Annu Rev Nutr. Sies H. 224-231. Rao AV. Stahl W. 133.19 Williamson EM. Microalgae as food and supplement. and ulcerative colitis. 49. Radiobiologiia. 1991. 2006. Antioxidant supplements improve parameters related to skin structure in humans. Heinrich U. Sies H. 72. Churchill Livingstone. 111-117. Tronnier H. Sies H and Stahl W. 334-339. 2002. Kralovec J. 5. ID 1797: “Chlorella algae (Chorella pyrenoidosa)” and “Antioxidativity” 5 6 7 8 1 Halperin SA. 477-479. Planta Medica. placebo-controlled trial. Antioxidant and anti-cataract effects of Chlorella on rats with streptozotocin-induced diabetes. Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. Altern Ther Health Med. 151. 99-164. Jungmann H. J Med Food. 100. Kittaka-Katsura H. Price JA. Nguyen VC. J AOAC Int. Tomisaka K. Ross SA. Am J Clin Nutr. J Nutr Sci Vitaminol (Tokyo). Shevlin D. Nolan C. Edinburgh. Gazer B. Engelhard YN. Kometani T. 5. 24. Tronnier H. 2001. Stahl W. 19. 2003. 2003. beta and gamma carotene. 173-200. 1708-1714. Suppression of collagen-induced arthritis by oral administration of the citrus flavonoid hesperidin. A review of recent clinical trials of the nutritional supplement Chlorella pyrenoidosa in the treatment of fibromyalgia. Vatsek A. 2006. 2003. Natori Y. 1621-1624. ID 1799: “Citrus bioflavonoids” and “Joints” 2 3 4 5 6 7 8 9 1 Kawaguchi K. 627-635. J Nutr. Orv Hetil. Nutritional protection against skin damage from sunlight. 84. Pasco DS. 2001. Phytomedicine. 79. Arch Intern Med. J Med Invest. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Dulloo AG. James WP. pulse rate and blood pressure. Shetty PS. Fay LB. 34. Inaoka S. 50. Gremaud G. 599-605. Arnaud MJ. 131. Takahashi H. Meirim I. 1917. 759-767. Kimura J. Cawthorne MA. 1995. Am J Clin Nutr. Hein P. Am J Physiol. Horst K. Chen WY. 60. Seale J. Meguro S. 83-90. Tsuchida T. 989-997. 18. Montigon F. Tappy L. Schutz Y. Montomoli C. Acheson KJ. Journal of Oleo Science. Clin Sci (Lond). Hosoda K. 2189-2203. 1936. Katsuragi Y. Cena H. Clinical calorimetry. Hollands MA. Anti-obesity effects of tea catechins in humans. Matsui K. 9. 40-46. Matsui Y. Rohrer D. Girardier L. 537-541. 1999. 1990. Miller DS. Madsen J. Okamura M. Gay LJ. 2848-2852. Oolong tea increases energy metabolism in Japanese females. Anantharaman K. Takeda Y. 22. 1998. and methylxanthine metabolism in lean and obese women. Yang ZB. Effects of caffeine on energy metabolism. Dulloo AG. Prog Med. Oolong tea increases metabolic rate and fat oxidation in men. Judd J. 3-8. Clevidence B. Nakamori M. DuBois EF. A simple apparatus for comparative measurements of energy expenditure in human subjects: the thermic effect of caffeine. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Hase T. Komatsu T. Schneiter P. E671-678. Mensi N. 2004. Ishikura Y. Caffeine: a double-blind. Toyama K. The effect of caffeine on the heat production. 2001. Rumpler W. 2002. 1989. Nakamura H. The effect of coffee and decaffeinated coffee on oxygen consumption. 19. Fathi M. Yamamoto S. Lanzola E. Ishikura Y. 294-304. Astrup A. Twentieth paper. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. 20. 1981. Komine Y. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. Kunii D. heart rate. Arch JR. J Nutr. 49. Smith RG. Callingham BA. Reduction of body fat in humans by long-term ingestion of catechins. Collins A. 1994. Jung RT. Tokimitsu I. 1981. 50. Barrand MA. Yamamoto S. Am J Clin Nutr. 1040-1045. Jequier E. Itakura H. Chantre P and Lairon D. Lin BH. Zahorska-Markiewicz B. Geissler CA. Int J Obes Relat Metab Disord. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Vandermander J. Breum L. Coffee induced thermogenesis and skin temperature. 2002. 2291-2294. Schindler C. 70. Ferrarra JM. Tagliabue A. 527-535. 58. Am J Clin Nutr. Hosoda K. Sawaki T. Journal of Pharmacology and Experimental Therapeutics. Wiley E. Duret C. Willson RJ.ID 1800: “Epigallocatechin gallate (ECGC) + caffeine” and “Weight control” 1 Acheson KJ. Means JH. Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am J Clin Nutr. Komatsu K. Am J Clin Nutr. Terracina D. 269. 2001. 1980. Bracco D. Horton T. Hosoda K. Toubro S. Chantre P. metabolic. Jequier E. 33. Cannon S. Krebs Y. Sakai T. Matsui Y. Am J Clin Nutr. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 490 . Shimasaki H. Aub JC. Nippon Rinsho Eiyo Gakkai Zasshi. Komatsu T. Turconi G. 44-50. and cardiovascular effects in healthy volunteers. 2003. 170175. Chen L. 832-839. placebocontrolled study of its thermogenic. Clinical efficacy of oolong tea on anti-simple obesity. Pittet P. 51. Ali L. 55. 422-426. Ametov A. 2006. Kraemer K. 56. 49. Effect of ginger (Zingiber officinale Rosc. alpha-Lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet. Pattar GR. Dyck PJ. Gupta R. Yakhno N. 56. 2006. ID 1802: “Fenugreek + alpha-lipoic acid + chrome” and “Blood lipid levels” 1 Bordia A. alpha-Lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet. Effect of Trigonella foenum-graecum (fenugreek) extract on blood glucose. Abdel-Wahab YH. Zhang RJ. Diabetes Technol Ther. Ozercan IH. 1997. Rokeya B. Liu YH. Maus J. Ustundag B. 2 3 4 5 6 7 8 9 10 2 3 4 5 491 . Tackett L.ID 1801: “Fenugreek + alpha-lipoic acid + chrome” and “Carbohydrate metabolism and insulin sensitivity” 1 Bordia A. Br J Nutr. blood lipid and hemorheological properties in streptozotocin-induced diabetic rats. Chen G. Asia Pac J Clin Nutr. 2365-2370. 2007. Diabetes Educ. 2238-2244. Bhonagiri P. 2006. Xue WL. and enhancing insulin action. Nutrition. Sahin K. J Assoc Physicians India. Barinov A. Elmendorf JS. Flatt PR. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption. 1233-1240. Asia Pac J Clin Nutr. 56. Broadhurst CL and Domenico P. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. 33. 2007. Hannan JM. Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review. 2007. Khaleque J. Srivastava KC. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Molecular aspects of lipoic acid in the prevention of diabetes complications. Effect of Trigonella foenum-graecum (fenugreek) extract on blood glucose. Zhang J. Sriramoju V. 17. Liu YH. 1997.) on blood lipids. Gupta A. blood lipid and hemorheological properties in streptozotocin-induced diabetic rats. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Lal B. 1057-1061. 888-895. Gupta R. 16 Suppl 1. Komorowski JR. Prostaglandins Leukot Essent Fatty Acids. Raz I. blood sugar and platelet aggregation in patients with coronary artery disease. Li XS. Srivastava KC. 49. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. Gurieva I. 8. Wang ZL. 2007. 379-384. Novosadova M. Rimbach G. Cikim G. blood sugar and platelet aggregation in patients with coronary artery disease. Verma SK. Zhang RJ. Zhang J. Akhter M. Verma SK. 111-117. Ziegler D.) and fenugreek (Trigonella foenumgraecum L. Diabetes. Foster TS. Diabetes Care. 29. Onderci M. Munzel U. Li XS. Mol Endocrinol. 97. Lal B. 2238-2244. 2006. Liu P. 2007. Diabetes. Xue WL. Yi X and Maeda N. Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed. Metabolism. 2006. 2001.) on blood lipids. 857-870. 1057-1061. Gupta A.) and fenugreek (Trigonella foenumgraecum L. Yi X and Maeda N. Strawbridge AB. streptozotocin-treated rat. Prostaglandins Leukot Essent Fatty Acids. Effect of ginger (Zingiber officinale Rosc. 16 Suppl 1. Juturu V. 514-521. 379-384. 20. 2001. Samigullin R. Tuzcu M. Wang ZL. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. 55. 422-426. Packer L. Low PA. 2001. 677-687. J Assoc Physicians India. Caballero B. 2005. 24-26. Reed J. 2007. Feb. J Nat Prod. Lamarche B. 2004. 582-594. 1208-1215. 80-81. Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. 2005. Cardiovasc Hematol Disord Drug Targets. Couture P. Atherosclerosis. Fernandez S. Baltimore. Chonan O. 2007. Watanuki M. Ross AC. 2004. Fung ML. Holzlwimmer G. Leung TM. In: Modern Nutrition in Health and Disease. 210-213.? Innovations in Food Technology. Kurppa L. Vuorela HJ. Yasui H. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. Pietta PG. 473-481. Wounds UK 2003 Conference Abstracts. in vitro and in vivo. Flavomare spices for salt reduction and …. Flavomare. Kurppa L. Natural Treatments for Fungal Infection of Wounds. The effect on the oxidation and the free radical scavenging potential of Flavomare extract. Kurppa L. Phytochemicals. 7. 80-84. 2004. Crit Rev Food Sci Nutr. Changes in plasma antioxidant capacity and oxidized low-density lipoprotein levels in men after short-term cranberry juice consumption. Nikishchenko MN. Cassella JP. The effect of Flavomare extract on serum lipids and cholesterol. 2002. ID 1805: “Flavonoids from green tea. 91-95. atherosclerosis and cardiovascular health. 2003. Innovations in Food Technology. in frying. Martirosian AO. 137. Kiivet RA. selected flavonoids. 26. 2004. Cassella S. MCA laboratorio. Lippincott Williams & Wilkins. Cousins R. Antimicrobial activity of lactic acid bacteria from sour milk products "Narine". Philadelphia. Turku. "Karine". May. Charian LM. Ruel G and Couillard C. 42. Mol Nutr Food Res. S45-50. Shils ME. 135-144. Ruiz PA. Quintanilla-Fend L. Kurppa L. 2004. Basic component for all kinds of functional food . Mndzhoian Sh L.ID 1803: “Fermented whey” and “Gut health” 1 2 3 Ashford R. Feb. Flavomare. 1998. 44. May. 2006. 2003.Companies. J Nutr Sci Vitaminol (Tokyo). Shike M. 2000. SLK. Innovations in Food Technology. Hung MW. Ruel G.presentation of multifunctional spice. 54. Content of acrylamide decreased in potato chips with addition of a proprietary flavonoid spice mix. Innovations in Food Technology. Takahashi R. Green tea polyphenols as an anti-oxidant and antiinflammatory agent for cardiovascular protection. 301-316. 40. 1998. Evidences of the cardioprotective potential of fruits: the case of cranberries. Plant sterols-alone or in combination with synergistic acting. Akopian LG. Mursu J. 24-25. Prikl Biokhim Mikrobiol. 137 Suppl. Pomerleau S. Synergistic flavonoids. Tipoe GL. May. Hyvönen L. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. 856-861. Haller D. 692-701. 1035-1042. Helsinki. Innovations in Food Technology. Couillard C. Innovations in Food Technology. Flavonoids as antioxidants. Innovations in Food Technology. apple and onion” and “Antioxidativity” 1 2 3 4 5 6 7 Ahotupa DM. 2003. May. Feb. J Nutr. 63. Gallagher J. 2007. Kurppa LJ. and "Matsun". Background information for evaluating the use and possibilities of flavonoids in food technology. 71-73. Braune A. 5 6 7 8 492 . Cranberry flavonoids. ID 1804: “Flavonoids in cranberry juice” and “Antioxidativity” 1 2 3 4 Aviram M and Fuhrman B. Metabolism. 51. and lipid profile in streptozotocin-induced diabetic rats. 1578-1584. Lee JS. 79. Life Sci. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. 79. Innovations in Food Technology. Feb. Chen YH. 24-26. Feb. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. May. 2005. Albertazzi P. 2007. Chen S. Diabetes. 1369-1373. Ikeda A. 288. Flavomare. Am J Physiol Cell Physiol. 511. 2007. The botanical extracts of Achyrocline satureoides and Ilex paraguariensis prevent methylglyoxal-induced inhibition of plasminogen and antithrombin III. 2005. 80-81. Hepburn DA. Flavomare® spices for salt reduction and. Chen CL. Iso H. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Li J. Tea. Innovations in Food Technology. Life Sci. Aoki N. Wu BT. antioxidant enzyme activities. Jung UJ. 162. Hyvönen L. 2002. Suzuki Y. Chen CL. obesity. Sabitha KE. Wolfram S. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. in vitro and in vivo. Eck P. Mol Nutr Food Res. Ahotupa DM. Choi MS. 1709-1714. Howarth EM.. 2005. Crescenzi A. Kurppa L. Fernandez S. 2007. 18. May. Liu HC. Int J Obes (Lond). Nagao K. Kurppa L.. 56. 767-776. Lee MJ. 1245. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Ikeda I. Shyamaladevi CS. Hung PF. Yanagita T. Cho SY. 2006. Lee JH. 179-183. Kilpatrick ES. 114-120. Chen HC. 72. 2004. Chem Biol Interact. hepatic triacylglycerol.? Innovations in Food Technology. Pultz S. 21. 2003. Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways. Maruyama K. and activities of hepatic enzymes related to fatty acid synthesis in rats. Kurppa L. and diabetes. Kao YH. 10491053. Jennings PE. Kao YH. Kim BW. Kwon O. Klaus S. Koo SI and Noh SK. 493 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 . Levine M. apple and onion” and “Weight control” 1 Ae Park S. 2007. Dietary gallate esters of tea catechins reduce deposition of visceral fat. 2002. Bianco AC. 1207-1213. 69. MCA laboratorio. International Congress Series. Basic component for all kinds of functional food . Background information for evaluating the use and possibilities of flavonoids in food technology. Biosci Biotechnol Biochem. Biol Pharm Bull.presentation of multifunctional spice. Uzu K. 2006. Feb. Babu PV. Lee MJ. 279-292. 29. Innovations in Food Technology. Sung MK. Flavomare. Kim MJ. J Nutr Biochem. Christoffolete MA. Lee MK. FASEB J. Wu MH. 2002. Eur J Clin Nutr. 2006. The effect on the oxidation and the free radical scavenging potential of Flavomare. 953-960. Effect of flavonoids on formation of advanced glycation endproducts in vitro. Lee SJ and Lee KW. Effects of soy protein and genistein on blood glucose. Jayagopal V. Corpe CP. 62. 24-25. Kruhlak M. in frying. Kakuda T. Kurppa L. Chang HH. 30. Content of acrylamide decreased in potato chips with addition of a proprietary flavonoid spice mix. 2003. Harney JW. 91-95. Okubo T. 2008. Innovations in Food Technology. 2004. Hamamoto R. Kim HY and Kim K. Thone-Reineke C. Fukino Y. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. 25.ID 1806: “Flavonoids from green tea. 2005. Synergistic flavonoids. 2006. C1094-1108. Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells. Kobayashi M. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. 615623. 50. Bianco SD. Imaizumi K. 188-210. Seo JS. Turku. Park YB. Life Sci. 80-84. Diabetes Care. Huang SA. da-Silva WS. Atkin SL. Gugliucci A and Menini T. 366-377. Urology. 50. J Agric Food Chem. Price DT. Flaxseed lignan–bioactive ingredient for functional food. TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Nagao T. Nelson-Dooley C. Robertson CN. 2003. according to their structure. Ho CT. Mursu J. 437-441. Moritani T. Paulson DF. 3 494 . Lunceford N and Gugliucci A. Proposed mechanisms of (-)-epigallocatechin-3gallate for anti-obesity. Komine Y. Elste V. Flaxseed and cardiovascular risk. 2004. Choi YJ. 2005. Strobel P. Lo CY. Medical Sciences 409. Pan MH. 2007. and histopathologic features. 2006. Eur J Nutr. Anderson EE. 54-63. 386. Ryhanen EL. 2418-2422. Walther PJ. Trapping reactions of reactive carbonyl species with tea polyphenols in simulated physiological conditions. 13. Raederstorff D. Nakagawa T. Pihlava JM. 2006. Cho CS. 26. 3167-3173. Beneficial effects of tea catechins on dietinduced obesity: stimulation of lipid catabolism in the liver. 2002. Sang S. 2215-2225. Terasawa K. J Agric Food Chem. Gannon M. Tanaka Y. Vuorela HJ. 122-129. 139-146. May. Innovations in Food Technology. 2005. Murase T. Kim TG. Kiivet RA. Korhonen H. Mol Nutr Food Res. 50. Hamrick M. Curr Med Chem. Ann Nutr Metab. Wolfram S. 18-27. Leighton F. 967-977. 2005. Li S. Della-Fera MA. Tsi D. Shu S. 2007. Mol Nutr Food Res. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. Soga S. Baile CA. Perez-Acle T. Hase T. Calderon R. green tea extract and essence of chicken on body fat content in human subjects. Tian WX. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Int J Obes Relat Metab Disord. 49. Ono H. Tan D. Curr Med Chem. Juneja LR. 71-73. 2005. 2004. Lee HG. 2005. Moon HS. Allard C. 46. Nah AK. 58. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: Exploring the effects on hormonal levels. Yokozawa T. Demark-Wahnefried W. 81. The effect of Flavomare extract on serum lipids and cholesterol. 167. 1459-1464. Protective activity of green tea against free radical. Vollmer RT. 50. quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Sternberg M. 2007. 49. Urios P. Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose. Wu CH and Yen GC. Teixeira SR. Mursu J. Nutrition Reviews. 26. 28. 2001. Tokimitsu I. Aldunate R. Fitoterapia. Polascik TJ. May. D. 419-427. 85-98. Clinical study on the combined effect of capsaicin. 2005. prostate-specific antigen. 2002. 211-217. 2005. Kurppa LJ. 53. Myricetin. Nagasawa A. Plant sterols-alone or in combination with synergistic acting. The role of polyphenols in cardiovascular diseases. 2004. 2006. Am J Clin Nutr. Grigorova-Borsos AM. 471-478. J Nutr Sci Vitaminol (Tokyo). Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. Innovations in Food Technology. 1118-1128. Chem Biol Interact. Suzuki J. selected flavonoids. Hase T. ID 1808: “Flaxseed husk extract/lignans” and “Antioxidativity” 29 30 31 32 33 34 35 36 37 1 2 Bloedon LT and Szapary PO. 12. Tokimitsu I. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea.21 22 23 24 25 26 27 28 Lin JK and Lin-Shiau SY. Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes. University of Kuopio. Biochem J. Wang Y. 54-56. 62. Meguro S. Kiso Y. Doctoral dissertation: Kuopio University Publications.and glucose-mediated protein damage. 47-52. Inhibition of fatty acid synthase by polyphenols. Innovations in Food Technology. Weber P. 76. 269-275. Vet Ther. 32. Bergemann C. Waldschlager J. Swiss Pharma. Dietary Supplements. Allerg Immunol (Paris). 1996. 2005. Conway V. 3828-3835. 2003. Piechulla B. 2000. Cho SH. How does the bone denity change when melbrosia pld is administered additionally to a specific HRT during the perimenopause and menopause? A five years observation study. Dörling E. 51. Li T. ID 1813: “Green-lipped mussel (Perna canaliculus)” and “Musculoskeletal system” 1 2 Bui LM and Bierer TL. 2003. 11. 4. Pelka RB and Leuchtgens H. Perna canaliculus in the treatment of arthritis. 1. 2002. Webb AL and McCullough ML. Jeschke U. Schweizerische Zeitschrift für Heilpädagogik. 955-960. Thompson LU. 245-250. 495 . 1994. Chen JM. Bio-Strath and increased performance: a double blind trial of a herbal yeast preparation (Bio-Strath) on 60 subjects. Pelka RB. 2005. 272-278. Notabene Medici. Kragl U. Briese V. 3-4. Richter DU. 1991-1996. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). 212-216. 11. Eur Ann Allergy Clin Immunol. Dietary lignans: potential role in cancer prevention. 495504. 2005. ID 1816: “Herbal yeast plasmolycate (saccharomyces cerevisiae)” and “Mental state and performance” 3 4 1 2 3 4 5 6 7 Becker S. Selle G. ID 1810: “Floral pollen + fermented pollen + royal jelly” and “Bone” 5 6 7 8 9 1 Adam KH. Son JH. 8. 35. 2001. Physical Performance. Pre-geriatric study on Bio-Strath. Atherosclerosis. Mason P. Jacques H. Prasad K. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. 2005. Goss PE. Clinical Cancer Research. Seong SC. Lee DC. (unpublished). Neukomm M. Pre-Alzheimer study. 100. Anticancer Research. Byun KY. Obstetrics and Gynecology. Increasing powers of concentration. Gibson SL. Hamburg-Vienna. Park HB. Salomon W. 397-407. 25. 1981. A school trial with Bio-Strath Elixir. Effects on herbal yeast preparation in convalescent patients. Flax-seed extracts with phytoestrogenic effects on a hormone receptor-positive tumour cell line. Pharmaceutical Press. Forest JC. Jung YB. 11. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Nutrition and Cancer. 224. The influence of food supplement on the behaviour and the health of schoolchildren in a school for children with special needs. Halpern GM. GanzheitsMedizin. Schweiz Zschr GanzheitsMedizin 9. Ruth W. 179. 38-43. Server P.4 Lemay A. 1990. 2005. 117. 1997. London. Strasser-Weippl K. Dodin S. Joller PW. Gibson RG. Song EK. a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Effmert U. Practitioner. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Schwarzenbach FH and Brunner KW. Clinical efficacy and safety of Lyprinol. Ars Medici. 1980. Ziekle R. 1967. Chappell D. Kadri N. 1817-1822. 99. Inan M. 704-714. randomized. A double-blind controlled crossover study. 183. Manna R. Chernichovsky T. Monserrat F. Tamir A. Isidori A. Segal E. Savaiano DA and Kotz C. Tatali M. Gavaler J. Lactose intolerance. Jensen BH. 766-772. Pozza C. Curtis C. randomized. He M. Guidetti C. 65. 7 8 9 10 11 12 13 14 2 3 4 5 6 496 . Lactose malabsorption and tolerance of lactose-hydrolyzed milk. J Am Coll Nutr. Pediatrics. Lee K. 2006. Ruzafa C. 269-273. Montalto M. 188-192. 1987. Ito TY. Whipple B. Isidori AM. Rosenthal A. Recent advances in the management of lactose intolerance. Manna R. 79. 2002. 343-351. Walling AD. Grand RJ. 632-635. Gasbarrini A. Graziano L. Raz B. 2005. Medical treatment to improve sperm quality. Eur J Clin Nutr.naturalnurse. Cammarota G. Gianfrilli D. Miglioli M. 861-864. http://www. hormone activity” 1 Chen J. Graham DY. 81. 28. Callegari C. J Clin Gastroenterol. Scand J Gastroenterol. Cui H. 82. World J Gastroenterol. Jensen HJ. Gasbarrini A. 2004. Natural Pharmacy: Natural Aphrodisiacs. Barbara L. Management and treatment of lactose malabsorption. 1987. Ramirez FC. Klein RM. 1999. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind.htm. placebo-controlled study. 12. Basaran UN. Lavy A. Turan FN. Bian L. Trant AS. Efficacy of lactase-treated milk for lactose-intolerant pediatric patients. 11. Protective effect of Lcarnitine on testicular ischaemia-reperfusion injury in rats. 22. 369-378. Bone density in axial and appendicular skeleton in patients with lactose intolerance: influence of calcium intake and vitamin D status. 2006. 83. Uz YH. Iaina A. 1989. 1989. Curigliano V. Duodecim. The enhancement of female sexual function with ArginMax. 1145-1149. Influence of dietary arginine on the anabolic effects of androgens. Rozen GS. King S. Santoro L. Yang Y. Laktaasimalabsorptio epämääräisten vatsavaivojen syynä. a nutritional supplement. Dokmeci D. 1999. Dvorkin L. Montalto M. All lactase preparations are not the same: results of a prospective. Rask Pedersen E. Gasbarrini G. Aydogdu N. Gasbarrini G. Wollman Y. J Pediatr. 89. J Endocrinol. Santoro L. Enzyme replacement for lactose malabsorption using a beta-Dgalactosidase. 489-493. Bol Asoc Med P R. Does oral enzyme replacement therapy reverse intestinal lactose malabsorption? Am J Gastroenterol. Curigliano V. Hylander Moller E. Am J Gastroenterol. ID 1822: “L-carnitine” and “Sexual organs. Vastola M. Effect of exogenous beta-galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study. 83. 111. 691-698. 566-570. Sahi T. Covino M. Moskovitz M. 1988. Journal of Hygiene Research. 309-311.ID 1818: “Lactase enzyme” and “Digestion” 1 2 3 4 5 6 Barillas C and Solomons NW.com/naturalaphro. Lami F. 12. Polan ML. Nucera G. Am Fam Physician. 91-94. Am J Gastroenterol. 2007. 1983. 187-191. 25. Effective reduction of lactose maldigestion in preschool children by direct addition of beta-galactosidases to milk at mealtime. 201-207. 2006. 1987. Norby Rasmussen S. Effect of exogenous lactase on the absorption of lactose and its intolerance symptoms. Penafiel R. Ish-Shalom S. Efficacy of addition of exogenous lactase to milk in adult lactase deficiency. Vastola M. BJU Int. Yalcin O. DiPalma JA and Collins MS. Matzkin H. placebo-controlled trial. Reprod Biomed Online. Biller JA. Sofer M. Cuoco L. 2003. J Sex Marital Ther. 32. 17. 1994. 611-618. 1845-1850. Kamhi E. Keldsbo IL. Cell Biochem Funct. 290-293. Lopez-Contreras AJ. among women differing in menopausal status. 59. Cremades A. Swagerty DL. 1982. Yaniv I. 2002. Int J Obes Relat Metab Disord. Sci Aging Knowledge Environ. Ferri R. Richter T. Verrillo E. 70. Gorny P. McIntyre M. 85-93. Lebret T. Prog Med. Calderan A. 2293-2315. 29. Journal of Oleo Science. 65. 41. placebo-controlled.gov/medlineplus/druginfo/natural/patient-arginine. Itakura H. Anti-obesity effects of tea catechins in humans. 497 . 2005. Cardiovascular effects of carnosine. Rohdewald P. pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Metabolism. Botto H. Stanislavov R. 220-223. 1999. Urol Int. Garrett MR. 1389-1391. Worcel M. Girardier L. Curr Med Chem. Efficacy and safety of a novel combination of Larginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. 51. 2002.7 Kernohan AF. Stanislavov R and Nikolova V. Biochemistry (Mosc). Loster H. and body composition in slightly overweight subjects. 252-258. 2000. discussion 613. L-arginine. Komine Y. Borin G. ID 1824: “L-carnosine” and “Physical performance and condition” 2 3 4 5 6 1 2 3 Guiotto A. Am J Clin Nutr. 599-605. 53. 608-613. Improvement of erectile function with Prelox: a randomized. ID 1823: “L-carnitine + green tea extract” and “Weight control” 8 9 10 11 12 13 1 Dulloo AG. 207-213. An oral yohimbine/Larginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic. 402-407. J Sex Marital Ther. Worcel M. caffeine and sympathetic activity.html. Mathers MJ. 2004. Mensi N. Seim H. Nikolova V. 1999. 2001. Katsuragi Y. Wutzke KD and Lorenz H. 856-861. Bloch W.aspx?cs=&s=ND&pt=100&sh =10134&id=875. Takeda Y. 2002. Dulloo AG. 2005. Smith MA. NIH (National Institutes of Health). ID 1828: “L-5 hydroxytyptophan” and “Mental state and performance” 1 Bruni O. 1002-1006. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Fathi M. Seydoux J.nih. double-blind. Carnosine and carnosine-related antioxidants: a review. 2008. Perry G. L -5-Hydroxytryptophan treatment of sleep terrors in children. 22. Int J Impot Res. Chantre P. Vandermander J. 2003. Ruzza P. 2189-2203. 50. 2005. Reid JL. Matsui Y. Natural Medicines Comprehensive Database. Roberts PR and Zaloga GP. Tokimitsu I. Engelmann U. 2000. pe12. Reddy VP. 163. Eur Urol. Green tea and thermogenesis: interactions between catechin-polyphenols. protein turnover.nlm. Kiess W. Reduction of body fat in humans by long-term ingestion of catechins. Girardier L. Meguro S. Tsuchida T. Miano S. Klotz T. Treatment of erectile dysfunction with pycnogenol and L-arginine. Eur J Pediatr. crossover trial. 173-180. Tam SW.com/(S(fupplh45jl1g34550e2cp455))/nd/Search. Rohrer D. The effect of l-carnitine on fat oxidation. http://www. 63.naturaldatabase. Braun M. Inaoka S. Arginine (L-arginine). 2004. Br J Clin Pharmacol. Metabolism. Vandermander J. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Hughes DM. 1040-1045. Herve JM. 24. Muller DM. 2005. Chantre P. Nakamura H. Hase T. Takahashi H. Shimasaki H. http://www. Duret C. 20. 12. 59. Carnosine: a versatile antioxidant and antiglycating agent. Green LA. Takano T.2 Kahn RS. 84 Suppl 1. 2005. 237-243. J Nutr. S33-37. helveticus lactic acid bacteria)” and “Cardiovascular system” 1 Aihara K. Guyatt GH. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Hypertens. Vapaatalo H. Maron E. Mennear JH. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. Chobanian AV. 1495-1504. Int Clin Psychopharmacol. 194-199. 2000. 358-363. Wuolle K. 2005. 1600-1605. Kloek J. Cushman WC. Kupari M. 1996. Kawase M. 2005. 5-11. Bucher HC. 17. 1216-1223. J Psychopharmacol. Vasar V. a double-blind comparison of 5hydroxytryptophan. Cook DJ. 2006. Bakris GL. Nakajima K. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. 2007. Korpela R. 60. 1987. Koning TM. Poussa T. Poussa T. JAMA. Griffith LE. Hypertens Res. Am J Hypertens. clomipramine and placebo. Psychiatry Res. 953-958. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. Nakamura Y. Kamerbeek WD. J Dairy Sci. Rasmussen M. Kajimoto O. 2. Roccella EJ. Am J Clin Nutr. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hashimoto H. 18. 3 4 ID 1831: “Peptides (milk products fermented with L. Westenberg HG. Collin M. Korpela R. Lappalainen J. van Diest R. 289. Jones DW. Introduction. Ohni M. Meynen EE. Effect of longterm intake of milk peptides and minerals on blood pressure and arterial function in spontaneously hypertensive rats. Nakamura Y. Nakamura Y. Overbeek T. Hata Y.. Hosono A. 255-263. 2007. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Jr. Vapaatalo H. Helske S. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders. 2003. Schruers K. 24. FitzGerald RJ and Meisel H. Eur Heart J. Foltz M. Narva M. 489-496. 257-265. 767-771. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Milchwissenschaft. Vapaatalo H. Black HR. Turto H. 30. Bando I. and Treatment of High Blood Pressure: the JNC 7 report. Gispen-de Wied CC. The Seventh Report of the Joint National Committee on Prevention. Takahashi R. 137. Morita H. J Am Coll Nutr. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. 12. Bernard BK. Kawagishi R. tissue distribution and excretion of a radiolabelled analog of a milk-derived antihypertensive peptide. 1999. Jauhiainen T. Bianco V. Wright JT. Hirata H. Syvaranta S. ZhongJian C. 64. Kovanen PT. 18. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Materson BJ.. in rats. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. 2007. Detection. 84-92. 2002. 27. van Platerink C. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyI-L-proline): II. Mayranpaa M. Lowrie C. Nakamura Y. Korpela R. Kajimoto Y. Oparil S. Izzo JL. Cook RJ. 83. 2560-2572. Verhoeven WM. Laine M. Lindstedt KA. Ohki K. Evaluation. Int J Toxicol. Br J Nutr. Toru I. Hirota T. Oral absorption. International Dairy Journal. Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. Nurmela K. Jauhiainen T. 2004. Jr. Kerojoki O. Shlik J. Kitakaze M. Kyronpalo S. Mizuno S. Griez E. Werkkala K. 2005. 24 Suppl 4. Ile-Pro-Pro. 113. 33-45. Jauhiainen T. 498 2 3 4 5 6 7 8 9 10 11 12 13 . Yamamoto M. Hosoda M. Lommi J. 2000. 42 Suppl 1. 955-966. Am J Hypertens. 1982. J Biol Chem. Griffin BA. Korpela R. 2003. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. Korpela R. Manson JE. Nakamura Y. 1996. 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 499 . I6-27. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J AOAC Int. Eur J Nutr. Br J Nutr. Biosci Biotechnol Biochem. Rodgers A. 1253-1257. Den Hond E. J Biol Chem. The granulocyte-angiotensin system. Matsuura K. 2003. The primary prevention of myocardial infarction. Ueshima H. Bioactive peptides derived from food. 423-430. Robinson K. Masuda O. Masuda O. Milchwissenschaft. Mullis R. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. PASSCLAIM . 1406-1416. Yamamoto N. Nurminen ML. Mutanen M. Sipola M. Takano T. Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Wylie-Rosett J. Sakai K. 16. Lichtenstein AH. 488-489. 52. 2001. Rutherfurd-Markwick KJ and Moughan PJ. Ridker PM. J Dairy Sci. 745-754. Mitch WE. N Engl J Med. Aro A. Takano T.14 15 16 17 Klickstein LB. Kokkonen JO. Stahl W. International Dairy Journal. Tochikubo O. 77. Appel LJ. Takano T. Nakamura Y. 257. Daniels SR. Lawes CM. Nishimura S. 107. 945-960. 2006. Jr. Feigin VL. Goldberg IJ. 326-330. 124-127. O'Connor GT. Kajimoto Y. 2522-2524. 326. 8619-8622. on subjects with high-normal blood pressure or mild hypertension. J Med Food. Krauss RM. Bazzarre TL. 2005. Lindstedt KA. Gotou T. Nakamura Y.a pilot study on humans. 2001. Am J Clin Nutr. Kerojoki O. Seppo L. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. 57. Mizuno S. Kajimoto O. J Physiol Pharmacol. 1996. Vapaatalo H. 60. Seppo L. Aihara K. Yamamoto N. 777-783. 2003. Sakai K. Schechter NM. 94. 78. Kajimoto Y. Mizushima S. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. 701-706. St Jeor S. Ohshige K. Reilly CF. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. Stroke. 1995. Sano J. 8. Tribble DL. Bennett DA. 2004. J Nutr. 1982. Deckelbaum RJ. Howard B. Mensink RP. Kaempfer CE. Suomalainen T. Higuchi T. German JB.Diet-related cardiovascular disease. 2005. Meisel H. 2004. 30633068. Blood pressure and stroke: an overview of published reviews. Finckenberg P. 776-785. Travis J. Poussa T. Eckel RH. Effect of casein hydrolysate. 131. 84-91. Hebert P. Jauhiainen T. 257.. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. Tewksbury DA. J Dairy Sci. J Nutr. Nakamura Y. Korpela R. 2005. 35. Okubo A. 1996. Yabune M. prepared with protease derived from Aspergillus oryzae. Kovanen PT. 78. 17. Korhonen H and Pihlanto A. Bioactive peptides: production and functionality. ten Meer HU. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Synthetic peptides corresponding to alpha-lactalbumin and beta-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. The effect of a Lactobacillus helveticus LBK-16 H fermented milk on hypertension. Kotchen TA. Suttie J. Watanabe J. Nakamura Y. 2002. Mullally MM. Pannemans D. Wintroub BU. Kajimoto O. Nakagawa S. 377. 132-146. 1995. Angiotensin Iconverting activity of cathepsin G. Mizuno S. Hennekens CH. 1992. 126. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Role for chymase in heart failure: angiotensin IIdependent or -independent mechanisms? Circulation. 15042-15046. Kadowaki T. Buring JE. Santisteban J. Kris-Etherton P. FitzGerald RJ. 88. Yamazaki S. Tosteson H. Ohki K. Takano T. Biol Chem Hoppe Seyler. Satterfield S. Kimura M. Erdman JW. 259-260. Yamamoto N. Nakamura Y. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. 326-330. Academic Dissertation.34 35 36 Sipola M. 953-958. Sipola M.a pilot study on humans. 82. Nurminen ML. Nakamura Y. Academic Dissertation. Meynen EE. (unpublished). 795-802. The effect of a Lactobacillus helveticus LBK-16 H fermented milk on hypertension. Wuolle K. 137. Takano T. 355. 2 3 4 5 6 7 8 9 500 . Rönnback M. Verstraete W. 2002. 64. Yamamoto N. Yamamoto M. 37 38 39 40 41 42 43 ID 1832: “Peptides (isoleucine-proline-proline. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Bianco V. Antonie Van Leeuwenhoek. Sipola M. 2008. Takai S and Miyazaki M. Vermeirssen V. 767-771. 69. Jauhiainen T. Jauhiainen T. Mikkola L. 865-872. Jauhiainen T. 2000. 17. Rasmussen M. Am J Clin Nutr. 2007. Seppo L. Seppo L. Anti-hypertensive activity of fermented dairy products containing biogenic peptides. 1209-1211. Nutrition. Fagard RH. J Nutr. Van Camp J. Pocock S. Finckenberg P. Effect of long-term intake of milk products on blood pressure in hypertensive rats. Boissel JP. Effects of milk products and milk protein-derived peptides on blood pressure and arterial function in rats. Gueyffier F. 1600-1605. Groop PH. Korpela R. Qin LQ. 2003. Seppo L. 124-127. Kinetic and Clinical Studies. Xu JY. Tuomilehto J. Nissinen A. 2003. Nakajima K. 357-366. Am J Hypertens. J Hum Hypertens. 2005. Effects of milk products and milk protein-derived peptides on blood pressure and arterial function in rats. Korpela R. Effect of milk tripeptides on blood pressure: a metaanalysis of randomized controlled trials. 1. Hata Y. Lancet. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. van Platerink C. University of Helsinki. Suomen lääkärilehti. Ohni M. Vapaatalo H. 2007. Korpela R. Koning TM. Poussa T. Poussa T. 2002. Wuolle K. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. Thijs L. 1997. VPP)” and “Cardiovascular system” 1 Foltz M. Kalsiumin ja maidon peptidien verenpainevaikutukset. 18. 1996. Vapaatalo H. 2004. Am J Clin Nutr. Suomalainen T. Kerojoki O. 2002. A novel therapeutic strategy against vascular disorders with chymase inhibitor. Antihypertensive peptides derived from food proteins. IPP + valine-proline-proline. Jauhiainen T. Nissinen A. Curr Vasc Pharmacol. 57. Ekbom T. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Blood Pressure Lowering Effects of Lactobacillus helveticus Fermented Milk Containing Bioactive Peptides Ile-Pro-Pro and Val-Pro-Pro: Mechanistic. 933-940. Long-term intervention with Lactobacillus helveticus fermented milk improves arterial stiffness in hypertensive subjects. Korpela R. Wang JG. 77. 129-134. 2004. 333-340. Kautiainen H. University of Helsinki. Vapaatalo H. Korpela R. J Dairy Res. Lactobacillus helveticus fermented milk reduces arterial stiffness in hypertensive subjects. Gasowski J. Liu L. Li W. 217-224. Korpela R. Karhunen ML. 2007. 103-111. 92. Milchwissenschaft. Bioavailability of angiotensin I converting enzyme inhibitory peptides. Kloek J. Br J Nutr. Lindstrom J. Rönnback M. 59. Chang C. 43. Jauhiainen T. Biopolymers. International Dairy Journal. 2002. Hyyrynen J. Coope J. Vapaatalo H. 1265-1269. Tuomilehto J. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. 24. Jauhiainen T. Kyronpalo S. Staessen JA. 2007. Kerlikowske K. Takano T. Kautiainen H. University of Helsinki. Korpela R. 18. Jauhiainen T. 2002. PhD Thesis. Den Hond E. Wang PY. 68-69. Bazan NG. Tremblay-Mercier J. Carlson SE and Neuringer M. 3-11. Hirsch MJ. 318. Suomen lääkärilehti. Cunnane SC. Freemantle E. Etienne P. 1992. 25. De Jesus Moreno Moreno M. 1977. 1999. Gauthier S. 1992. Kuopion yliopisto. Hargreaves K. 200-201. 1265-1269. 87-138. 171-178. Nutr Rev. 99-106. energy substrates. The role of dietary fatty acids in biology: their place in the evolution of the human brain. Jauhiainen T. Lecithin in neurologic disorders. Lecithin consumption raises serum-free-choline levels. 2003. double-blind. Crawford MA. Ratner J. Impact of Dietary Fatty Acid Balance on Membrane Structure and Function of Neural Tissues. 213-220. Seppo L. Results of a placebocontrolled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions. Hauke W. Growdon JH. placebo-controlled trial. Improvement in quality of life in the elderly. 178-193. Tuomilehto J. lignans) + ascorbic acid” and “Antioxidativity” 11 1 Voutilainen S. Karhunen ML. 2007. 59. In: Neurobiology of Essential Fatty Acids (Advances in Experimental Medicine and Biology). 18. N Engl J Med. Polyunsaturated fatty acid status and neurodevelopment: a summary and critical analysis of the literature. Mikkola L. N Engl J Med. and brain function during aging. Lindstrom J. SanGiovanni JP and Chew EY. Murphy MG. 2. 34. Vandal M. Springer Verlag. The role of dietary fatty acids in biology: their place in the evolution of the human brain. Lecithin in neurologic disorders. Clandinin MT. randomized. 1978. 2005. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. 200-201. 50. 75. 24. 1999. Dastoor D. Lancet. Nissinen A. MMW Fortschr Med.). Heidelberg. Korpela R.10 Tuomilehto J. flavonoids. Hyyrynen J. 171-178. 197-210. 501 . Lecithin in Alzheimer's disease. 34. Toffano G (eds. Collier B. Suh M. 2003. Clin Ther. 50. Nutr Rev. Lancet. J Hum Hypertens. Prog Retin Eye Res. Prostaglandins Leukot Essent Fatty Acids. Crawford MA. 1992. Lipids. 2. 1978. ID 1834: “Phospolipids” and “Immunity” 1 2 3 Barbeau A. Volz HP. Kalsiumin ja maidon peptidien verenpainevaikutukset. Lipids. Windust A. Blachere JC. phenolic acids. Tremblay S. 299. 2004. Wurtman RJ. 299. Begin ME. 2004. Polyunsaturated fatty acid status and neurodevelopment: a summary and critical analysis of the literature. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter. anthocyanins. 1978. Impact of dietary fatty acid balance on membrane structure and function of neuronal tissues. Omega-3 fatty acids. Antioksidatiivisesti vaikuttavat elintarvikkeet (AVE). 1206. Nissinen A. 2006. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Jauhiainen T. Adv Exp Med Biol. Clandinin MT and Hargreaves KI. 3-11. ID 1833: “Phenol compounds of cranberry and lingonberry (catechins. Carlson SE and Neuringer M. 146. 197-210. Brenna JT. 795-802. ID 1835: “Phospolipids” and “Mental state and performance” 4 5 6 7 8 9 10 1 2 3 4 Barbeau A. Hehnke U. 1992. Clin Ther. 2003. 1035-1039. Krotkiewski M. Liu B. 85. Demonstration of superoxide dismutase enzymes in extracts of pollen and anther of Zea mays and in two related products. MacDonald R. 16. Einarsson R. Wang ZP. Begin ME. 4. 4 502 . Windust A. Clinical Hemorheology. Vandal M. Liu B. MMW Fortschr Med. 23. Blachere JC. Brzezinska Z. Lecithin consumption raises serum-free-choline levels. Palm S. Mac Donald R. Brenna JT. double-blind. Brzezinska Z. antioxidativity” 6 7 8 9 10 1 2 3 Chen HJ. Stark G. 2. 23. Volz HP. Lancet. 68-69. P5 on chronic prostatitis or infertility with chronic prostatitis. Belboul A. Improvement in quality of life in the elderly. Ishani A. 1. The effect of SOD-active plant substance (Polbax) on oxygen free radical (OFR) generation and blood cell rheology. Rutks I. Roberts D. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter.5 De Jesus Moreno Moreno M. Palm S. Baxtin and Polbax. 836-841. 1977. Prevention of muscle soreness by pretreatment with antioxidants. ID 1839: “Pollen pistil extract + SOD” and “Mental state and performance. Cunnane SC. ID 1840: “Pollen pistil extract + SOD” and “Physical performance and condition” 4 5 6 7 8 1 2 3 Chen HJ. 88-91. Prevention of muscle soreness by pretreatment with antioxidants. The effect of SOD-active plant substance (Polbax) on oxygen free radical (OFR) generation and blood cell rheology. Krotkiewski M. Krotkiewski M. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. 1978. Acta Pharmacol Sin. randomized. Brzezinska Z. Ma BL. Effects of pollen extract EA-10. Scandinavian Journal of Medicine and Science in Sports. Chen YR. 178-193. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. Cochrane Database Syst Rev. 24. Tremblay-Mercier J. and brain function during aging. Collier B. Belboul A. Brzezinska Z. Tremblay S. Wurtman RJ. Scandinavian Journal of Medicine and Science in Sports. Grimby G. 836-841. Prog Retin Eye Res. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Palm S. Ratner J. Ockerman PA. 191-199. Maughan RJ and Evans SP. Chen YR. 1995. 641-647. 213-220. 1992. Wang ZP. energy substrates. 1035-1039. Rutks I. Roberts D. 2000. 2. placebo-controlled trial. Antioxidant treatment of chronic fatigue syndrome. Wilt TJ. Freemantle E. Br J Sports Med. 76-80. Fu SJ. Clinical Hemorheology. BJU Int. Grana. CD001042. 1206. BJU Int. 87-138. Cernilton for benign prostatic hyperplasia. 15. 2004. Hauke W. Dastoor D. Wilt T. Growdon JH. 15. Etienne P. 75. 2000. Rutks I. 1994. Effects of pollen extract upon adolescent swimmers. MacDonald R. Clinical Practice of Alternative Medicine. Wilt TJ. Lecithin in Alzheimer's disease. Gauthier S. 85. Omega-3 fatty acids. 142-145. Ma BL. Krotkiewski M. 4. Results of a placebocontrolled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions. Acta Pharmacol Sin. 2002. 2002. Ishani A. Karlsson G. 2005. Palm S. 2000. Hirsch MJ. Fu SJ. 2000. Qin DS. 31. Qin DS. Lancet. 25. 99-106. 2006. Ishani A. SanGiovanni JP and Chew EY. 191-199. Hehnke U. Liu B. Effects of pollen extract EA-10. 641-647. 1995. 146. Grimby G. P5 on chronic prostatitis or infertility with chronic prostatitis. Liu B. Prostaglandins Leukot Essent Fatty Acids. 1994. Oden PC. 1982. 21-27. or ―Vaccinium macrocarpon‖. J Nat Prod. Cunningham DG. Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. and Pharmatoka S. Clinical Practice of Alternative Medicine. 2004. ID 1841: “Proanthocyanidins in cranberry juice” and “Urinary tract” 1 2 From tradition to 36 mg PAC per day measured byDMAC. Turk R. Grana. 2000. Bailey DT. Demonstration of superoxide dismutase enzymes in extracts of pollen and anther of Zea mays and in two related products. Vannozzi S. 173-181. 2000a. Foo LY. Glynn RJ. J Urol. AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé). 177. 751-754. A-Type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. Wobbe C. Effects of pollen extract upon adolescent swimmers.coli bacteria on the walls of urinary tracts and on the use of "cranberry" or "Vaccinium macrocarpon" in concentrated juices. Ockerman PA. 2000. Vorsa N. 2006. food additives and a juice cocktail/nectar. CD001042. 1982. 2000b. David K. 2005. Howell A. Einarsson R. cranberry sauce. Oxford University Press Canada.S. Phytochemistry. Letter to unknown recepient regarding proanthocyanidin value statement. Joseph Daugherty F. 1992. Ishani A. 3 4 5 6 7 8 9 10 11 12 13 14 503 . Denys P. Updated synthesis of the files submitted by GIKA / PHARMATOKA SAS to the French Government 2002. 2004. 16. Botto H. AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Cochrane Database Syst Rev. Templer C. 1994. 1. In: Quality Management of Nutraceuticals. 31. JAMA. The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated Escherichia coli in vitro. Chou MY. World Journal of Urology. Lu Y.1946/2002) is based. Baxtin and Polbax. O'Shea E. Dalton C. Monane M. 14. Afssa Petition N° 2006-SA-0256. 2002. 2007. Tempesta MS. Cernilton for benign prostatic hyperplasia. Formal opinion of the AFSSA (French Agency for Food Safety) relating to the evaluation of the evidence concerning the extension of the claim ―helps decrease the adherence of certain E. Grady R.).A. Br J Sports Med. Cunningham DG. 803. Lu Y. 1225-1228. 2357-2360. coli bacteria to the walls of the urinary tract" to the use of cranberry. Gika S. 142-145. sweetened dried cranberries and flavoured sweetened dried cranberries. 63. Lipsitz LA.A. Di Martino P. Howell AB.5 6 7 8 Maughan RJ and Evans SP. ACS Symposium Series No. Gupta K. Mac Donald R. 2007. Don Mills. Stapleton AE. Afssa Referral N°2003-SA0352. Gaillard JL. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. Analysis and standardization of cranberry products. Karlsson G. Antioxidant treatment of chronic fatigue syndrome. Stark G. 271. 237-241. Vorsa N. Ho C-T and Zheng QY (eds. Oden PC. Rutks I. 88-91. Avorn J. Howell AB. Cunningham DG. 2007. 24. Letter to Gunter Haesaerts. Opinion from the French national food safety agency relative to the evaluation of justifications concerning the claim "helps to reduce the fixation of certain E. 2006. GIKA France. Agniel R. Good practice recommendations. Wilt T.S. 76-80. Choodnovskiy I. Phytomedicine.. Can a concentrated cranberry extract prevent recurrent urinary tract infections in women? A pilot study. AFSSA (Agence Française de Sécurité Sanitaire des Aliments). in fresh and frozen cranberries. Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: a doubleblind randomized placebo-controlled cross-over trial. 151-166. Gurwitz JH. 54. 2008. Foo LY. 2008 on which the existing french health claim (dir. placebo-controlled trial. McMurdo ME. In: American Herbal Pharmacopoeia. Cranberry concentrate: UTI prophylaxis. Price RJ. 698-702. Howell AB. Nutrition. 2008. Appl Microbiol Biotechnol. Bissett LY. Oksman-Caldentey KM. Bourg G. Quality Control. Nuutinen M. 2005. 1085-1086. 1013-1016. 1997. Stothers L. Jepson RG. 2002. 1994. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind. Reduction of bacteriuria and pyuria using cranberry juice. 684-687. Can J Microbiol. Santa Cruz. Mol Nutr Food Res. 1999. In-vitro and in-vivo evidence of dosedependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. and cranberry derived supplementation on human urine and uropathogen adhesion to silicone rubber. Reed JD. Bourg G. 1998. J Urol. J Pediatr. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 504 . Van der Mei HC. Uhari M. Upton R. Clin Microbiol Infect. Foo LY.. 16. Mickelsen JN. Phillips G. Haverkorn MJ and Mandigers J. Koskela M. Crit Rev Food Sci Nutr. 1999. Winterbottom R. 1558-1562. Walton RJ. 2008. Age Ageing. 1571. Alakomi HL. 167-168. Kontiokari T. 8-18. 339. 272. 135. BMJ. 590. 9. Leahy M. Can J Urol. Sundqvist K. 34. Botto H. Crombie IK. Howell AB. Lavigne JP. Phytochemistry. Lavigne JP. Hendley JO. 273-278. Pathol Biol (Paris). Botto H. 2005. 2007. Puupponen-Pimia R. Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization. 51. 2005. CD001321. Trudell J. ascorbic acid.Standards of Analysis. Nohynek L. Anderson S. 2002. Busscher HJ. Cranberry (Vaccinium macrocarpon) and urinary tract infections: study model and review of literature. 14. Cranberry juice and urinary-tract health: science supports folklore. 322. 42. Howell AB. and Therapeutics. 2007. Krueger CG. 1984. Mickelsen RA. Pokka T. American Herbal Pharmacopoeia and Therapeutic Compendium. 67. 2000. 732-737. 55. 460-464. 691-694. CD001321. Cochrane Database of Systematic Reviews. Mihaljevic L. Vorsa N. Jr. J Fam Pract. 45. Reid G. Der Marderosian A. Cunningham DG. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Schlager TA. The effect of water. Bioactive berry compoundsnovel tools against human pathogens.15 Habash MB. Sobota AE. JAMA. 66. Howell AB. N Engl J Med. Cranberries for preventing urinary tract infections. 256-261. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. Cranberry proanthocyanidins and the maintenance of urinary tract health. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Walker EB. Cochrane Database Syst Rev. Henig YS and Leahy MM. 45. Jepson RG and Craig JC. 2004. Cranberry Fruit (Vaccinium macrocarpon Aiton) . 350-355. 3. 2281-2291. Barney DP. Sotto A. Sotto A. 2001. 2002. Cranberry for preventing urinary tract infections. 131. Craig J. Combescure C. J Nutr Biochem. Wang B. Effects of dietary supplementation with sea buckthorn (Hippophae rhamnoides) seed and pulp oils on atopic dermatitis. 2006. Vasankari T. 961-970. 1065-1069. J Agric Food Chem. Ahotupa M. EI-Khouri S. 2001. 5. Yang B. 1. 4 5 6 7 7 8 9 505 . Kusano S. 2001. Dietary Supplements. Katajisto JK. Stanley JC. New York. vascular. 1995. Stark JJ. Kallio HP. 2006. 14. 4. University of Turku. Thibodeau A. 108-113. J Nutr Biochem. Richardson D. 7364-7369. Oral bioavailability of a liquid cartilage extract: a human clinical trial. 13. J Surg Research. 2002. Dupont E. Pharmaceutical Press. Anti-inflammatory and analgesic activity of a water-soluble fraction from shark cartilage.ID 1850: “Sea buckthorn oil and flavonoids extracted from sea buckthorn berries” and “Antioxidativity” 1 2 3 Erkkola R and Yang B. ID 1852: “Shark cartilage” and “Joints. J Clin Oncol. Shahabi S. 1999. Effect of orally administered chondrosine on uptake of 35S sulfate into rat cartilage. Folkman J. 4. 2003. Kallio HP. Lane IW and Comac L. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Granick JL. de-Alencar JW. Liphophilic components of sea buckthorn (Hippophae rhamnoides) seeds and berries physiological effects of sea buckthorn oils. Kustannus Oy Duodecim. Mostafaie A. Avery Publishing Group. Fitoterapia. Miller DR. 2000. Sharks Don't Get Cancer: How Shark Cartilage Could Save Your Life. 11. Gaudreau P. Cho J and Kim Y. Wang J. Sharks: a potential source of antiangiogenic factors and tumor treatments. Shahrokhi S. Nat Med. 87. 551-584. Korte H. Trends in Food Science and Technology. 126. 643-646. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. 1992. Hassan ZM. 1999. Berbari P. Sea buckthorn oils: towards healthy mucous membranes. Turku. 21. 53-59. Helsinki. 160-167. Yang B and Kallio H. 491-495. Xavier-Filho J. Kallio H. Grebe SK. Sheikhian A. Mattila LM. Slim GC. ID 1853: “Shark cartilage” and “Joints” 1 2 3 4 5 6 Barber R. Kallio SE. Int Immunopharmacol.) and their effect on emerging risk factors for cardiovascular disease in humans. Viana GS. Kalimo KO. Delahunt B. Bargahi A. Anderson GT. Sakai S. Fontenele JB. 10. Feyzi R. Suomela JP. London. 1996. 2002. 54. Doctoral Thesis. Absorption of flavonols derived from sea buckthorn (Hippophae rhamnoides L. Composition and physiological effects of sea buckthorn (Hippophae) lipids. Yang B. Mar Biotechnol (NY). Thornton A. Sea buckthorn berry oil inhibits platelet aggregation. Johansson AK. 2002. Prudden JF. supportive tissue” 1 2 3 Enkovaara AL. 101 luontaistuotetta. 1985. 29. 644-650. Ghazanfari T. Saint-Cyr M. Effects of sea buckthorn (Hippophae rhamnoides L. 622-630. Garrel DR. Yakugaku Zasshi. Igarashi N. rheumatoid and other disease. Low molecular weight fraction of shark cartilage can modulate immune responses and abolish angiogenesis. 521-525. Yang B. 16. Toida T. 2005. Mansouri K. Peltola OJ. Anticancer Res. Yang B. 2005. Kallio HP. Dong Y. Mason P.) seed and pulp oils on experimental models of gastric ulcer in rats. 73. The treatment of human cancer with agents prepared from bovine cartilage. 3649-3655. Angiogenesis in cancer. AGROFood Industry Hi-Tech. 2001. Xing J. J Biol Response Mod. Germain L. 27-31. Davis PF. Yang B. 297-300. 1998. Braz J Med Biol Res. New York. 84. Karolinska Sjukhuset Stockholm. 1987. Kuprash LP. Wilson JD. 67. Clinical and experimental study of spirulina efficacy in chronic diffuse liver diseases. Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. Planta Med. Otles S and Pire R. 1991. Med. Harrison‘s Principles of Internal Medicine. Gilman A. Goodman LS. 2002. Pasco DS. 2001. Riechkina OO.10 11 Rauis J. 52. 4553. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. Derkach OV. 32-46. Update on the pharmacology of Spirulina (Arthrospira). dos Santos CP. Nutritional value of the alga Spirulina. McGraw-Hill. Gorobets OB. 232-240. Isselbacher KJ. 2004. Biological activity of Spirulina. Lik Sprava. Zh Mikrobiol Epidemiol Immunobiol. Chalmers Tekniska Högskola. Manchester. Dillon JC. Mao TK. Baturo AP. Araujo KG. Syraneutraliserande effekt av Samarin. London. Ross SA. ElSohly MA. J AOAC Int. 737-742. Microalgae Spirulina in human nutrition. 2003. Martin WR. Symonenkova NV. 8. Fauci AS. 11. Vopr Pitan. Dietary Supplements. Lik Sprava. Van de Water J. 1991. London. Fatty acid composition of Chlorella and Spirulina microalgae species. 1996. 8 9 10 11 12 506 . Sharabura LB. 1708-1714. Pugh N. Osteoarthritis Cartilage. an unconventional food. ID 1857: “Sodium bicarbonate + wine acid + anhydrous citric acid + sodium carbonate” and “Gut health” 1 2 3 4 5 Alminer L. Ceballos G. ID 1858: “Spirulina alga” and “Weight control” 1 2 3 4 5 6 7 Blinkova LP. Pharmaceutical Press. 27-30. 2002. 1965. 73. undersökt på TIM. 102-105. McGraw-Hill. Institut för Livsmedelteknik. Isolation of three high molecular weight polysaccharide preparations with potent immunostimulatory activity from Spirulina platensis. Phuc AP. Wisen O and Johansson C. aphanizomenon flos-aquae and Chlorella pyrenoidosa. Kostromina VP. 114-118. 2001. Arch Latinoam Nutr. Castillo LF. Evaluation of the efficacy of a plant adaptogen (spirulina) in the pathognic therapy of primary tuberculosis in children. Reynolds JE. Zilova IS. Bourges H. 2000. Martindale: The Extra Pharmacopoeia. 555-573. British Small Animal Veterinary Association (BSAVA) Congress. Virstiuk NG. 2001. 1984. World Rev Nutr Diet. Microalgae as food and supplement. Mazo VK. Use of shark cartilage in the treatment of secondary osteoarthritis in the dog. Kay RA. 77. Chamorro G. 2001. Rev Invest Clin. 48. 433-441. Pharmaceutical Press. Salazar M. Petersdorf RG. Chamorro G. Volpi N. Orynchak MA. Dubacq JP. Samarin – syraneutraliserande effect hos friska försökspersoner. 2003. Otroshchenko AO. ElSohly HN. Crit Rev Food Sci Nutr. Braunwald E. Favila L. Gmoshinskii IV. Salazar M. New York. Gastroenterologiska laboratoriet. Mason P. 1996. Panteleimonova TM. 89-93. Gorban EM. 2005. Jaffe JH. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Martin JB. Gershwin ME. 30. Klin. Pharmacology and toxicology of Spirulina alga. 389-399. J Med Food. 1995. J Nutr. Taguchi A. J Herb Pharmacother. Dagorn-Scaviner C. 621-626. 2007. Biol Psychol. 67. Mabeau S. L-theanine . Hoebler C. Tsuchihashi N. 5 6 2 3 4 5 6 7 8 507 . Nishide E. Reprod Nutr Dev. Am J Health Syst Pharm. 120. J Nutr. Antioxidative and Hepatoprotective Effects of Spirulina. Brownlee IA. Lognoné V. Ozeki M. Alpsten M. 40. J Control Release. In: Spirulina in Human Nutrition and Health. Hum Psychopharmacol. Lahaye M. Bioadhesive interaction and hypoglycemic effect of insulinloaded lectin-microparticle conjugates in oral insulin delivery system. Gray M. Lichen W and Ho JA. Boca Raton. Adachi T. 39-45. Okubo T. Guillon F. ID 1867: “Spirulina” and “Antioxidative” 1 2 Chopra K and Bishnoi M. 2000. L-Theanine reduces psychological and physiological stress responses. 21-30. 353360. 102. Piippo S. Harrison BJ. Holm G. Boca Raton. Juneja LR. Vaugelade P. Hashizume N. 28-30. 525-538. Jeong JH. 795-799.). 2002. Juneja LR. enzymatic inhibition and fermentative characteristics of dietary fibres from edible seaweeds. 1999. 1997. Garleb KA. Dettmar PW. Effect of viscous indigestible polysaccharides on pancreatic-biliary secretion and digestive organs in rats. 2006. 1997. 26. Hoebler C. 497-510. Ohta A. Chemical composition. Harada H. 55-61. 457-465. Non-starch polysaccharides extracted from seaweed can modulate intestinal absorption of glucose and insulin response in the pig. Oliver C. Kim JD. 619-639. Kim BY. Sandberg AS. 2003. Crit Rev Food Sci Nutr. Wolf BW. Takizawa T. The alginate reduce the postprandial glycaemic response by forming a gel with dietary calcium in the stomach of the rat. Barry JL. 1991. ID 1868: “Sodium alginate and ascophyllum nodosum” and “Alginate can reduce the activity of digestive enzymes and reduce glucose absorption. Nagato Y. 45. Allen A. Chu D-C. Bartholomeusz CF. Polyphenols found in ascophyllum nodosum inhibit enzyme activity and reduce the glycaemic load of meals” 1 Bobin-Dubigeon C. Antioxidant Profile of Spirulina: A Blue-Green Microalga. Luonnon lääkeyrtit 2. Bernard F. physico-chemical properties. 63. Ataya DG. 2006. Kimura S. Tsuchihashi F. Havler ME. Lai CS. In: Spirulina in Human Nutrition and Health. Gershwin ME and Belay A (eds. Wheeler KB. 2005. 2007. Tolli J. Liley DT. Kipnes MS. Nathan PJ. Park K. Int J Vitam Nutr Res. Alginate as a source of dietary fiber. Torsdottir I. Ikegami S. Innami S. 18. 199-204. Gershwin ME and Belay A (eds.). Gray MA. Lu K. 33-47. Zinker BA. Firkins JL. 121. Yokogoshi H. Darcy-Vrillon B. Glycemic and insulinemic responses of nondiabetic healthy adult subjects to an experimental acid-induced viscosity complex incorporated into a glucose beverage. CRC Press. Kimura K. 10. Nathan PJ. Sciences des Aliments. Onsoyen E. A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. Oliver C. 74. Nutrition. Pharmacology and therapeutic uses of theanine. 1990.a unique amino acid of green tea and its relaxation effect in humans. 6. 2005. Trends in Food Science and Technology. Phan KL. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. Kustannusosakeyhtiö Tammi.ID 1865: “Theanine + oat shoot extract” and “Mental state and performance” 1 2 3 4 Eschenauer G and Sweet BV. Lahaye M. CRC Press. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. 2007. Lu K. 2004. 19. Ohira H. Atherton MR. Pearson JP. Duee PH. 17. Nozawa S. Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. The reverse glucosamine sulfate pathway: application in knee osteoarthritis. Revel L. Pavlii AI. Bone Miner. Leone G. J Clin Endocrinol Metab. Gennari C. Cereda R. Effect of ipriflavone . Heisel J and Forster KK. 115-120. Herrero-Beaumont G. Larocca LM. Ipriflavone Prevents the Bone Mass Reduction in Premenopausal Women Treated with Gonadotropin Hormone-Releasing Hormone Agonists. Kaji M. Kim YB. 1994. 2005. 3 4 5 6 7 8 508 . 61. 183. 40. skin and nails” 1 2 Horvath K. 9-15. Schauss AG. 223-232. 1459-1462. 1997. 26. Somekawa Y. Efficacy of ipriflavone in established osteoporosis and long-term safety. Bufalino L. Therapy of osteoarthritis crystalline glucosamine sulphate/a review of the clinical effcacy. Manetti P. Masuzawa T. S23-S27. Chiguchi M. Toxicity of methylsulfonylmethane in rats. Ohta H. Wakana K. Spinetti A.On bone mass loss in the early years after menopause. 41. Castaneda S. Aso T. Weiss C. Bykova OV.Journal of the North American Menopause Society. Expert Opin Pharmacother. Shin DH. 8. Makita K. Drogovoz SM. Menopause . 2007. Pacini MA. Ishibashi T. Arzneimittelforschung. Taponeco F. Matulka RA. Pagano L. Saruwatari N. Oizumi K. 10. Shin YC. Ranelletti FO. Ryan B. 124-125. 51. Setnikar I. Ortolani S. 2002. Noker PE. 78. Sato Y. Agnusdei D. ID 1874: “Methylsulpony/methane (MSM)” and “To help strengthen hair. 457-463. Park SC. 1999. Kuno H. 1991. 3202-3206. Passeri M. 1998. Cappagli B. 45. Teofili L. Piaggesi L. 1048-1051. Largo R. 86. Glavits R. Alvarez-Soria MA. Ann Oncol. Zupanets IA. 2007. Bone and Mineral. 1999. 1999. Lacommare P. ID 1872: “Ipriflavone” and “Ipriflavone supresses bone resorption” 1 2 Agnusdei D and Bufalino L. Food Chem Toxicol. 2007. Crepaldi G. 19. Phytother Res. 23. Equitani F. Iakovleva LV. 2001. Efficacy of ipriflavone in preventing adverse effects of leuprolide. Shin JY. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Arzneimittelforschung. 215-225. Park RD. 1990. Fortschr Med Suppl. Park SH. Am J Phys Med Rehabil. 178-183. Horm Res. 1993. Kim JC. Physiologic importance of glucosamine. 5. 19-26. Antireactive properties of glucosamine sulfate. Mele L. Piantelli M. Somfai-Relle S. Appleton J. Gambacciani M. Oral developmental toxicity study of methylsulfonylmethane in rats. Isaia G. Calcified Tissue International. Financsek I. 1-12.a synthetic derivative of natural isoflavones . Mazzuoli G. Oral ipriflavone (7-isopropoxy-isoflavone) treatment for elderly patients with resistant acute leukemias. Komukai S. 157-161. Gonarthrosis--current aspects of therapy with glucosamine sulfate (dona200-S).ID 1869: “Glucosamine sulfate” and “Glucosamine sulfate possesses antiinflammatory activity” 1 2 3 4 5 6 No authors listed. Rovati LC. 36. 57. Magnuson BA. 1998. Kim SH. Reginster JY. 203-217. 977-984. Food Chem Toxicol. Facchini V. Teti GC. Fiziol Zh. Synergistic antiinflammatory effects of pinitol and glucosamine in rats. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Argus Research Laboratories. Soni MG. Seng JE. Covell D. Forbes PD. The toxicity profile of hydrolyzed aqueous olive pulp extract. 122. 1475-1479. Burdock GA. Food and Chemical Toxicology.ID 1875: “Olivenol livin' BEGIN” and “A potent source of antioxidant” 1 2 Bitler CM. Fellow ATS. Z Ernahrungswiss. GRAS Report. 2004. Crea R. No authors listed. Boll Soc Ital Biol Sper. Covell D. Diplomate ABT. 1977. Description of food in terms of food legislation categories: Food supplement. Viale TM. 27. Sambuco CP. Fu L. 54. Drug Chem Toxicol. 2004. 2004. Burdock Group Technology and Risk Assessment. Morganti P. 1971. Safety Assessment Report. Fellow ACT. Pollitt RJ and Stonier PD. Abdel-Razik SL. Biochem J. Sharper VA. ID 1877: “Olive Biophenols” and “A potent source of olive biophenols with strong anti-bacterial properties” 1 2 3 Ananth I. Christian MS. 27. Salem SI. GRAS Report. Sharper VA. Hoberman AM. Borzelleca JF. 54. Burdock GA. Hoberman AM. Christian MS. Safety Assessment Report. ID 1880: “Name of Food product: Triphala. 2004. Safety assessment of aqueous olive pulp extract as an antioxidant or antimicrobial agent in foods. Burdock GA. Christian MS. Bitler CM. Evaluation of Bacteriostatic/Bacteriocidal Effects of Freeze Dried Olive By Product Against Salmonella & Listeria Monocytogenes. Bruno C. 2005. Diener RM. Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Triphala has a strong antioxidant effect. 44. Borzelleca JF. 2005. Proteins of normal hair and of cystine-deficient hair from mentally retarded siblings. 309-330. Diplomate ABT. Hydrolyzed olive vegetation water in mice has antiinflammatory activity. Fu L. 59. Do benefits relate to a disease risk factor: No Target group: All adults aged 18 years and over” 3 4 1 2 3 Metwalli OM. Determination of GRAS Status of Hydrolyzed Aqueous Olive Pulp Extract (HIDROX) Used As An Antioxidant or Antimicrobial Agent. J Nutr. Bitler CM. Diener RM. A Study of Approximately 5 weeks to Evaluate Cutaneous and General Toxicity of Orally or Topically Administered OLIVENOL™ in CRL:SKH1-hrBR Hairless Mice. The toxicity profile of hydrolyzed aqueous olive pulp extract. Do benefits relate to a disease risk factor: No Target group: Adults aged 18 years and over with some exceptions. 20-25. Elsevier. Determination of GRAS Status of Hydrolyzed Aqueous Olive Pulp Extract (HIDROX) Used As An Antioxidant or Antimicrobial Agent. 1983. ID 1878: “Olive Biophenols” and “A potent source of olive biophenols that have anti-UV damage properties” 4 1 2 No authors listed. Christian MS. 2004. Damaj B. National Food Laboratory. 16. Description of food in terms of food legislation categories: Food supplement Was food on Irish market before 1st July 2007: No” and “Health benefits of food: healthy hair. Drug Chem Toxicol. Bitler CM. Colelli G. 241-247. 2006. 309-330. Seng JE. Elsevier. lactating women 509 . 135. Effect of low-protein diet and its duration on hair composition. Crea R. Burdock Group Technology and Risk Assessment. 903-915. skin and nails. If exceptions describe: Pregnant. Crea R. Fellow ATS. ID 1879: “Name of Food product: gelatin & cystine. Fellow ACT. 433-444. keratogenesis and structure of the hair. Gelatin-cystine. Fellow ATS. Crea R. Christian MS. Priyadarsini KI. 82. Lee HS. physico-chemical properties. 877-880. Studies on the aqueous extract of Terminalia chebula as a potent antioxidant and a probable radioprotector. Cheng HY. 1997. Protection against radiation oxidative damage in mice by Triphala. Lee KW. Naik GH. 2002. Barry JL. Won NH. Chaubey RC. Mishra KP. Lee HS. 7 8 9 10 11 12 13 14 ID 1881: “Name of Food product: Product-specific claim: Sodium alginate and ascophyllum nodosum. Rege NN. In vitro antioxidant studies and free radical reactions of triphala. Nunia V. 19. an ayurvedic formulation and its constituents. J Ethnopharmacol. 2004. Jeong EY. 28. Mishra B. Lahaye M. Reasons for excluding these groups: These groups of people should avoid taking Triphala just as they should avoid taking any unnecessary supplements due to being vulnerable populations. Pandey BN.and children. 21. 38. J Food Prot. Indian J Exp Biol. Phytother Res. 1639-1644. Kim HG. 95. Cytoprotective and immunomodulating properties of Amla (Emblica officinalis) on lymphocytes: an invitro study. Target group: Adults aged 18 years and over with some exceptions. 2007. Singh I. Yang CM. Lee H. People with brittle bones or calcium deficiency. 2005. 43. Sharma A. Yu KH. Lin CC. Lognoné V. 81. 2006. Sandhya T. 2000. Gangabhagirathi R. J Enthnopharmacol. Dagorn-Scaviner C. Naik DB. 2005. Priyadarsini KI. Mutat Res. Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Alginate can reduce the activity of digestive enzymes and reduce glucose absorption. Do benefits relate to a disease risk factor: Yes. 889-894. 582-586. 1997. Lim JH. Antioxidant and free radical scavenging activities of Terminalia chebula. Christina AJ. lactating women and children and those with brittle bones or calcium deficiency. Babu MD. Sairam K. 17. Kim KH. 28. RK KG. Antiulcerogenic effect of methanolic extract of Emblica officinalis: an experimental study. Kumar KV. J Postgrad Med. 619-639. Lin TC. 17-25. Thorat SP. 2002. 83-85. Sciences des aliments. 5-10. Antioxidant effects of aqueous extract of Terminalia chebula in vivo and in vitro. Triphala is not suitable during pregnancy as its "downward flowing" energy is believed to favour miscarriage” 1 2 3 4 5 6 Bhattacharya A. Antiinflammatory effect of the Indian Ayurvedic herbal formulation Triphala on adjuvant-induced arthritis in mice. Biol Pharm Bull. Jun W. Radioprotection of Swiss albino mice by Emblica officinalis. 69. Phytother Res. Evaluation of anti-pyretic and analgesic activity of Emblica officinalis Gaertn. 2005. 1398-1403. Goyal PK. Priyadarsini KI. Rasool M and Sabina EP. Bhilwade HN. Srikumar R. Perianayagam JB. Mohan H. 2006. Sheela Devi R. 11. Reasons for excluding these groups: Sodium alginate may decrease the absorption of calcium if taken concomitantly therefore it should be avoided by pregnant. Tamhane MD. Biol Pharm Bull. 530-538. 1-9. Ghosal S. 12-13. Mohan H. Biol Pharm Bull. Growth-inhibiting activity of active component isolated from Terminalia chebula fruits against intestinal bacteria. Banavalikar MM. Phytother Res. Agrawal VK. enzymatic inhibition and fermentative characteristics of dietary fibres from edible seaweeds. 2004. Hoebler C. Sai Ram M. Lee SH. Mabeau S. Immunomodulatory activity of triphala on neutrophil functions. Dahanukar SA. Sharma SK. Mishra KP. Bhagirathi RG. 1331-1335. Polyphenols found in ascophyllulm nodosum inhibit enzyme activity and reduce the glycemic load of meals. If exceptions describe: Pregnant. 26.” 1 Bobin-Dubigeon C. 609. Cho JH. Effect of oral administration of Terminalia chebula on gastric emptying: an experimental study. 2005. Bhattacharya SK. Jeya Parthasarathy N. Naik GH. Chemical composition. 2003. 19. Lathika KM. Joseph A. Rao Ch V. lactating women and children. 444-446. Description of food in terms of food legislation categories: food not covered by specific food legislation. Phytomedicine. Antioxidant activity of tannoid principles of Emblica officinalis (amla) in chronic stress induced changes in rat brain. 2205-2209. J Ethnopharmacol. 510 . 2002. Dettmar PW. 2001. Tsuchihashi N. 497-510. 67. 64. Norkus EP. Majeed M. Shen M. Leonhardt M. 45. Badmaev V. J Nutr. Thusu N. Piperine increases the bioavailability of the un-trapped HCA and enhances satiety. Lahaye M. Shigematsu N. Piperine. Onsoyen E. A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. Current Therapeutic Research. 9. 551-567. Park K. Physiol Behav. Summer. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity. 120. Kipnes MS. Reprod Nutr Dev. It may also trap a portion of HCA. 353360. 1991. Torsdottir I. 2005. Was food on Irish market before 1st July 2007: No” and “Health benefits of food: Alginate forms a gel in the stomach and promotes an immediate feeling of satiety. Nutrition. Tomi H. 7-13. Furuse M. 1997. Bioadhesive interaction and hypoglycemic effect of insulinloaded lectin-microparticle conjugates in oral insulin delivery system. Prakash L. 74. Shimasaki H. Bariatrician. 1999. randomized. Effect of viscous indigestible polysaccharides on pancreatic-biliary secretion and digestive organs in rats. 55-61. Also those with calcium deficiency or brittle bones. Effects of garcinia cambogia (Hydroxycitric Acid) on visceral fat accumulation: a double-blind. Okuhara Y. Conte A. Reasons for excluding these groups: HCA can influence the body’s own production of cholesterol and therefore it may influence indirectly the production of sterols. Ikegami S. Alginate as a source of dietary fiber. Hoebler C. Garleb KA. Ishii Y. 33-47. Lai CS. Pregnancy is a time of extreme sensitivity to steroid hormones so HCA should be avoided and also during lactation. Hrupka B. Ohta A. 1994. Harada H. 2 3 4 5 6 7 511 . Allen A. 795-799. Kimura S. 102. 525-538. Khajuria A. Tolli J. Tsuchihashi F. 121. Langhans W. placebo-controlled trial. 2002. Majeed M. How I do it in my bariatric practice: a nonprescription alternative in weight reduction therapy. an alkaloid derived from black pepper increases serum response of beta-carotene during 14-days of oral beta-carotene supplementation. Clouatre D and Rosenbaum M. New Canaan. Taguchi A. 2000. Jeong JH. 4 5 6 7 8 ID 1884: “Name of Food product: Product-specific claim: sodium alginate. Conn. Phytomedicine. Hashizume N. Description of food in terms of food legislation categories: food not covered by specific food legislation. Takizawa T. 11. Wheeler KB. J Control Release. lactating women. Firkins JL. Guillon F. 40. Sodium alginate may decrease the absorption of calcium if taken concomitantly therefore it should be avoided by pregnant. Do benefits relate to a disease risk factor: No Target group: Adults aged 18 years and over with some exceptions If exceptions describe: Pregnant. Pearson JP. J Nutr. children and those with brittle bones or calcium deficiencies. Vaugelade P. 191-196. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplementation. Yoshino G. Int J Vitam Nutr Res. 19. 621-626. 1990. Alpsten M. Holm G. Wolf BW. 109-113. Zinker BA. 2000.2 3 Brownlee IA. Effect of hydroxycitrate on food intake and body weight regain after a period of restrictive feeding in male rats. Hayamizu K. 2005. 2003. Kaneko I. Havler ME. Kim BY. 1993. ultrastructure and enzyme kinetics. 224-231. Sandberg AS. Nishide E. The alginate reduce the postprandial glycaemic response by forming a gel with dietary calcium in the stomach of the rat. Kim JD. J Nutr Biochem. Crit Rev Food Sci Nutr. Non-starch polysaccharides extracted from seaweed can modulate intestinal absorption of glucose and insulin response in the pig. 18. Nutrition Research. Duee PH. Adachi T. Bernard F. Ataya DG. Zutshi U. HCA and piperine. 381-388. Atherton MR. Darcy-Vrillon B. lactating women and children. Keats Publishing. The diet and health benefits of HCA (hydroxycitric acid). Innami S. Glycemic and insulinemic responses of nondiabetic healthy adult subjects to an experimental acid-induced viscosity complex incorporated into a glucose beverage. How this all-natural diet aid promotes weight loss and inhibits fat production.” 1 Badmaev V. Mol Cell Biochem. 8. 1621-1624. 1999-2001. Nutr Metab Cardiovasc Disease. DNA fragmentation and histopathological data over a period of 90 days. lycopene. and autoantibodies against MDA-LDL with carotid 9 10 11 12 13 512 . Bagchi M. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Eckfeldt JH. Lycopene: chemistry. 870-872. Frith WJ. High plasma levels of alpha. 1139-1150. Belcher JD. Kiechl S. Grolier P. Shigematsu N. 2005. 2002. Eur J Intern Med. BJU Int. 1998. 16. 1998. The Euramic study in Malaga. Bagchi M. Fluid gels. Gerber M. Monograph. 93. Suh H. J Natl Cancer Inst. 231-239. Preuss HG. Willett WC. Monir M. Gross MD. A prospective study of tomato products. 705-711. 7. Clinton SK. 20. 35-51. 89-103. 2004. Ohia SE. The effect of (-)-hydroxycitrate on energy intake and satiety in overweight humans. Effects of a combination fiber system on appetite and energy intake in overweight humans. Willeit J. 2005. Goldbohm RA. 56. 1767-1776. Lim K. 339-346. Van den Brandt PA. 135. Rimm EB. Bagchi D. Kincaid A. Bonvicini P. 2057S-2059S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. 94. Satyanarayana S. Oberhollenzer F. 376383. 67. Sloot S. 981-984. and implications for human health and disease. Giovannucci E. 2000. ID 1899: “Lycopenes from tomato pulp and sauces” and “Antioxidant Properties” 13 14 15 1 2 3 4 5 6 7 8 Agarwal S and Rao AV. [Lycopene--a natural antioxidant]. Bagchi D. Scheurink AJ. 238. Blum A. Orv Hetil. Gomez-Aracena J. Stohs SJ. Bagchi M. mixed fluid gels and satiety. Ablett S. Clinton SK. Colditz GA. Stampfer MJ. Okuhara Y. Ben-Arzi S. 90. 33.and time-dependent effects of a novel (-)-hydroxycitric acid extract on body weight. Sturniolo GC. Leoni C. Banhegyi G. Zardetto-Smith A. Nutr Metab (Lond). Rimm EB. hepatic and testicular lipid peroxidation. 2003. Bagchi D. Lipids. Giovannucci E. Nutr Rev. anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. Liu Y. Physiol Behav. 2006. Jacobs DR. 1997. 2. Diet.8 9 10 11 12 Louter-van de Haar J. Chatterjee A. 23. J Natl Cancer Inst. Lycopene. Martines D. 2002. Tomita K. Intake of carotenoids and retinol in relation to risk of prostate cancer. Jr. Egger G. biology. Atherosclerosis. Westerterp-Plantenga MS and Kovacs EM. Diabetes Obes Metab. 87. Dagnelie PC. Ohia SE. The beneficial effects of tomatoes. Food Hydrocolloids. Altern Med Rev. Antioxidants in adipose tissue and myocardial infarction in a Mediterranean area. 1995. Tomatoes or lycopene: a role in prostate carcinogenesis? J Nutr. Bilton R. Naccarato R. The white book of the European Commission Concerted Action: The antioxidants in tomatoes and tomato products and their health benefits. Association of serum vitamin levels. Folsom AR. Ascherio A. Dose. Yasmin T. Opere CA.and beta-carotene are associated with a lower risk of atherosclerosis: results from the Bruneck study. (-)-hydroxycitrate ingestion increases fat oxidation during moderate intensity exercise in untrained men. 26. Stampfer MJ. Wirsansky I. 146. Biosci Biotechnol Biochem. and prostate cancer risk. 254. Comparison of the effects of three different (-)-hydroxycitric acid preparations on food intake in rats. Mattes RD. 6. 2002. 171-180. Schuurman AG. 336-342. 2003. 2005. 2004. LeDay AM. Norton IT. Mol Cell Biochem. 2007. 391-398. 2003. 2005. Garcia-Rodriguez A. 2000. 153. 229239. D'Odorico A. Dey DK. Nieuwenhuizen AG. Willett WC. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. Rao CV. Wielinga PY. Iribarren C. Int J Obes Relat Metab Disord. LDL susceptibility to oxidation. 1997. Shara M. Stohs SJ.. 402-404. Olsson AG. 98. Roob G. In people with irritable bowel syndrom:” 1 Giaccari S. Clin Ter. Kok FJ. Yamamoto T. BMJ. Kapeller P. 133-138. 2003. Khachik F. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. 108. Boeing H. Tomate. Kohlmeier L. Candiani C. Bergdahl B. Schumacher M. 251-251. 90. Guarisco R. Yamamoto T. J Am Diet Assoc. Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans. 21-25. Marx SC. Arterioscler Thromb Vasc Biol. DeLegge MH. 629-633. Okubo T. 1997. Serum antioxidants and myocardial infarction. Salkeld RM. 17. Effect of partially hydrolyzed guar gum on fecal output in human volunteers. Nyyssonen K. 1282-1301. Brown ED. Am J Epidemiol. 40. Offenbacher H. Elinder LS. Kucinskiene Z. Hayn M. Patrick PG. Geleijnse JM. Salonen R. A case-control study. Eber B. 314. 1998. Allegretta L. Lycopene and myocardial infarction risk in the EURAMIC Study. Atherosclerosis. Lecerf JM. lycopène et prévention cardiovasculaire. Savarino V. The ARIC Study Investigators. Takahashi H. Beecher GR. ID 1903: “Sunfiber(enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity. 1154-1161. Martin-Moreno JM. Chittams J. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. 148. Montefusco A. Atherosclerosis Risk in Communities. Voutilainen S. 1171-1177. Schmidt R. Mansi C. Am J Clin Nutr. 1995. Serum carotenoids and atherosclerosis. Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50. 1994. 2000. Kramer TR. 15-21.atherosclerosis. Phytothérapie. J Neurol Sci. Kristenson M. Nutrition. Yamanaka J. Salonen JT. Arterioscler Thromb Vasc Biol. Siciliano IG. 1999. J Nutr Sci Vitaminol. 912-914. Abaravicius A. 49-56. Elwing B. Gomez-Gracia E. 2677-2681. Rissanen TH. 77. Weinrauch V. Launer LJ. Zieden B. Yang SIL. Klag MJ. Wako N. Ringstad J. Takahashi H. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. Thamm M. Comstock GW. 1993. Kim M. Paetau I. 146. Kostner GM. Martin BC. Salonen R. 4. Kark JD. Salonen JT. 2006. Schmidt H. 513 16 17 18 19 20 21 22 23 3 4 2 . 57. Delegge MH. Nutr res. 152. Masaev V. Kaplan GA. Nyyssonen K. Chiri S. Greenberg NA. Rissanen T. 13. 334-342. 649-657. Calkauskas H. In healthy people:” 1 2 Kirby DF. Clevidence BA. Effect of supplements of partially hydrolyzed guar gum on the occurrence of constipation and use of laxative agents. 1997. Schuep W. Razinkoviene L. Dulbecco P. Gastroenterology. 152. Riemersma R. van den Berg H. Giannini EG. Street DA. Witteman JC. 1-10. Ishihara N. ID 1902: “Sunfiber(enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity. 20. Kardinaal AF. 1994. Partially hydrolyzed guar gum: a fiber as coadjuvant in the irritable colon syndrome. 1187-1195. Influence of Partially Hydrolyzed Guar Gum on Constipation in Women. American Gastroenterological Association technical review on tube feeding for enteral nutrition. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation. Fazekas F. Tronci S. Hayashi C. Hofman A. 1997. Huttunen JK. Steck SE. 22. Gohman SM. Nutr Rev. Yamanaka J. 68. Esterbauer H. Voutilainen S. 1998. Sponziello G. 14 15 Klipstein-Grobusch K. 2000. 2006. Fleming CR. Grasso G. The Rotterdam Study. 2001. Carotenoid interactions. 618-626. Huyghens L. 1998. Carlsson B. Endocrinology. Andersen H. 50. 2000. Diamandis EP. van der Saag PT. Zand RS. 17. 301-305. 2001. Safe SH. Use of D-tagatose as a prebiotic food component. Buemann B. Arla FAS. randomized. and controlled trial. 18. Takagi K. 139. EP1056358. Shankardass K. D-tagatose--a novel low-calorie bulk sweetener with prebiotic properties. 139. 2004. Iguchi A. Tafner G. Microbial Ecology in Health and Disease. Usefulness of soluble dietary fiber for the treatment of diarrhea during enteral nutrition in elderly patients. Sarker SA. Marino M. 24. 8260. Suys E. Vigh ML and Andersen H. Spapen H. double-blind. Kemen M. 2045-2050. 1344-1352. 20. Control of diarrhea by fiber-enriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin Nutr. 13. van der Burg B. 4252-4263. Nabeshima T. Bertelsen H. 31. Van Malderen C. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Corton JC. 514 2 3 4 5 . Bottona E. ID 1905: “D-Tagatose” and “Intestinal health” 2 3 4 5 6 1 2 3 4 Bertelsen H. 35. Faedo A. 1999. A multicenter randomized open trial. Bowel function of long-term tube-fed patients consuming formulae with and without dietary fiber. Clinical Nutrition. Partially hydrolyzed guar gum-supplemented oral rehydration solution in the treatment of acute diarrhea in children. van der Saag PT. Safe SH. Carrara M. Goldin D. World Rev Nutr Diet. 35-39. 98-109. Microbial Ecology in Health and Disease. Fuchs GJ. 62. Tvede M. Carlsson B. 486490. 663-667. Yang Z. Brooks J. 1994. Ito I. Steroid hormone activity of flavonoids and related compounds. Ogura Y. Tsai M. 2007. 47-57. Reduction in diarrhea incidence by soluble fiber in patients receiving total or supplemental enteral nutrition. Venema K. 2006. J Parenter Enteral Nutr. Wei M. Chelswick K. Diltoer M. 2001. Homann HH. 508-512. 14. Opdenacker G. 1990. Li P. Vermunt SHF. Pichard C. Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. D-Tagatose increases butyrate production by the colonic microbiota in healthy men and women. Pantalena M. Satake S. 2005. Digestive Diseases and Sciences. Cohen LB. Nutrition. In people receiving total or supplemental enteral nutrition” 1 Alam NH. Verdianelli G. 2007. Saibil FG. DK) ID 1907: “Naringin (a component of citrus peel extract and precursor of naringenin)” and “Bone health” 1 Kuiper GG. Wong RW and Rabie AB. Kuiper GG. Mahalanabis D. 35-49. Meier R. 503. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective. Zhang Y. Corton JC. Spurr S. 2002. Cardin F. Endocrinology. Anti-osteoporosis activity of naringin in the retinoic acidinduced osteoporosis model. Khater YH. Lemmen JG. Sse WC. 18. 2000. Lemmen JG. 23. Fermentation of D-tagatose by human intestinal bacteria and dairy lactic acid bacteria. 2005. J Orthop Res. Viby J. Journal of Pediatric Gastroenterology and Nutrition. Nakao M. Effect of naringin on bone cells. Breast Cancer Res Treat. 1107-1112.3 Parisi G. 1998. Edington JD. Gustafsson JA. Schneider H. Senkal M. Am J Chin Med. Rushdi TA. 4252-4263. 85. Bardhan PK. Chuchmach S. ID 1904: “Sunfiber(enzymatically partially depolymerised guar gum)” and “Intestinal health and regularity. J Parenter Enteral Nutr. Gyr N. Gustafsson JA. Jenkins DJ. Stefanovich C. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Brink EJ. Jensen BB. Fuessenich C. 87-95. van der Burg B. Zumtobel V. 94. Ficek TL. function. Biomedical and Clinical Aspects of CoQ. 1991. Randomized. Yamabe H and Fukuzaki H. Bone. Fabrizi G. 857-862. 2001. Effect of CoQ10 on the metabolic response to work. Heizmann CW. Kleinert P. Watts GF. 2002. and clinical relevance. 28. Oradei A. The beneficial effect of coenzyme Q10 on the impaired aerobic function in middle aged women without organic disease. beta-carotene. Wright JD. 153. J Nutr. Tirelli F. Markers of bone turnover: biochemical and clinical perspectives. Littarru GP. 535-540. Morohashi M. Hankinson SE. Millen AE. 6. 59-79. s257-263. South Med J. 521-524. 541-545. de Lucca A. Mares-Perlman JA. 2005. 56. 6. Am J Epidemiol. 3. Burke V. Guarino GC. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. 1137-1142. Krinsky NI. Uitto J and Lichtenstein JR. ID 1916: “L-Methionine” and “Epidermic tissue” 1 Kizawa K. Moro L. 424-432. Neuenschwander R. Olson RD.Zeaxanthin” and “Antioxidant” 1 2 3 Higdon J. double-blind. Defects in biochemistry of collagen in diseases of connective-tissue. Coenzyme Q10 in essential hypertension. Journal of Investigative Dermatology. 299. Influence of CoQ10 on physical work capacity of athletes.(Ubiquinone)” and “Physical activity” 1 2 3 Cerioli G. 66. 23. Brocchi A. ID 1915: “L-Lysine” and “Bones” 1 2 3 Knott L and Bailey AJ. beta-cryptoxanthin.ubiquinone” and “Blood pressure” 1 2 3 Burke BE. 2002. ID 1913: “Coenzyme Q10. Pagani F. Overview. Millen AE. Mancini M. Biochem Biophys Res Commun. 1998. Inoue T. Cantini F. 2005. Merlino B. 1991. Mares-Perlman JA.alpha-carotene. Bellandi F. 1991. Morganti P. Francucci CM. 15 Suppl. Mol Aspects Med. Landrum JT. Croft KD. Bone RA. Bisi G. ID 1914: “Lutein/. 2004. Characterization of the cysteine-rich calcium-binding S100A3 protein from human hair cuticles. 1976. Fisher AI. 2001. 22. Biomedical and Clinical Aspects of CoQ. Annu Rev Nutr. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. 310-316. Mustani L. J Endocrinol Invest. Skinmed. Littaru GP. sedentary people and patients with mitochondrial disease.ID 1911: “Coenzyme Q10. 2003. 132. Block G. lycopene. Hodgson JM. Digiesi V. 171-201. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. 518S-524S. 2002. placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Playford DA. lutein and zeaxanthin. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. 181-187. Troxler H. 1112-1117. 1994. Zeppilli P. Bruno C. Protective effects of oral antioxidants on skin and eye function. Carotenoids. Klein R. Collagen cross-links in mineralizing tissues: A review of their chemistry. Toyoda M. Palta M. 8-13. Biomedical and Clinical Aspects of CoQ. Eur J Clin Nutr. 4 5 515 . Lochmann JD. 1994. Gillespie JM.uk/en/Publichealth/Healthimprovement/FiveADay/DH_134. 33. WHO/FAO/UNU (World Health Organization/Food Agriculture Organization/United Nations Univeristy). Knehans AW. Creatine Supplementation and Exercise Performance: A Brief Review. Soderlund K. J Sports Med Phys Fitness. Bemben MG. Effects of creatine loading on muscular strength and endurance of female softball players. 2589-2595. 516 2 3 4 5 6 7 8 9 . 2002. Br J Dermatol. Sports Med. Noakes TD. 44. An assessment of the risks of creatine on the consumer and of the veracity of the claims relating to sports performance and the increase of muscle mass.818. 2000. 268-280. Oral creatine supplementation decreases plasma markers of adenine nucleotide degradation during a 1-h cycle test. 123-132. Lorenz RT and Cysewski GR. Is the use of oral creatine supplementation safe? Journal of sports medicine and physical fitness. 18. Med Sci Sports Exerc. Bohm V. 481-487. Suppl 2:49-60. Bold A.2 3 4 Marshall RC. 2002. Ekblom B. Request for an opinion on substantial equivalence of Astaxanthinrich extract from Haematococcus Pluvialis algae 7-13 March. Myburgh KH. 2001. 2001. Tuttle TD. 2003. Electron Microsc Rev. Creatine in humans with special reference to creatine supplementation. 1876. Med Sci Sports Exerc. 43.dh. 81. 47-83. Sasaki H. WHO Press. Acta Physiol Scand. 5 A DAY Guidelines. Bird SP. US 6258855 ID 1921: “Chlorophyll in sprouted seed” and “Naturally occuring antioxidants directly neutralise free radicals” 1 2 DoH (Department of Health). Schwartz SJ. Bemben DA. 4. Report of a Joint WHO/FAO/UNU Expert Consultation. 654-658. Antioxidant and antimutagenic activity of dietary chlorophyll derivatives determined by radical scavenging and bacterial reverse mutagenesis assays. Geneva. Becque MD. 1969. 2000. Sulphur metabolism in relation to cutaneous disease. Effects of oral creatine supplementation on muscular strength and body composition. Hiruma E. Structure and biochemistry of mammalian hard keratin. ID 1918: “Astaxanthin from Haematococcus pluvialis” and “Beneficial for connective tissue and joints” 1 2 3 FSA (Food Standard Authority). WPO. Sports Med. Journal of Food Science. Orwin DF. Protein and Amino Acid Requirements in Human Nutrition. Method of retarding and ameliorating carpal tunnel syndrome. Wilson GR. 35.gov. Ayoama R. US Patent 6. Lignell A. 32. 2004. Melrose DR. 2003. 2007. Courtney PD. 217-224. Balsom PD. Effects of creatine supplementation on isometric force-time curve characteristics. ID 1922: “Creatine” and “Increasing Performance” 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). 2001. Bemben MG and Lamont HS. Bellinger BM. Journal of Sports Science and Medicine. 411-416. Ferruzzi MG. 2. Roe DA. 2000. 1991. 107-125.245. Creatine supplementation and exercise performance: recent findings. Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases. 2005. http://www. Bizzarini E and De Angelis L. 170. 67. Champaign. 16. The effect of whey protein supplementation with and without creatine monohydrate combined with resistance training on lean tissue mass and muscle strength. 1995.and lower-body Wingate performance. J Appl Physiol. Tarnopolsky M. Hespel P. Bahrke MS and Yesalis CE (eds. Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am J Clin Nutr. McLester JR. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Hultman E. Mahoney D. Berbalk A. Fragala MS. 277-289. Green JM. Am Diabetes Assoc. 271. power. Mansfield ER. Hamilton KL. 11. Demeure R. 102. 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 517 . 219. Martin D. Smith Palmer T. Eijnde BO. 36-41. 21. and total work. 2002. 2003. 13. Meyers MC. Int J Sport Nutr Exerc Metab. 173-183. Int J Sports Med. 993-996. 18-23. Herb RA. 2002. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. Casey A. Grandjean PW. Urso B. Constantin-Teodosiu D. Cooke WH. Med Sci Sports Exerc. Greenhaff PL. 72. Poortmans JR. 30. Greenhaff PL. J Appl Physiol. Kraemer WJ. 1998. Int J Sport Nutr Exerc Metab. Muscle creatine loading in men. Creatine supplementation in endurance sports. 2003. 454-467. Volek JS. Trimble MH. J Strength Cond Res. Med Sci Sports Exerc. 1997. 50. 2000. Chilibeck PD. Hultman E. J Strength Cond Res. 2000. 2000. 32. 2000. Effect of creatine supplementation on aerobic performance and anaerobic capacity in elite rowers in the course of endurance training. Creatine supplementation improves muscular performance in older women. Smith-Palmer T. 10. Soderlund K. Holt LE. 2001. Branch JD. Francaux M. Farthing J. Kenny AM. 35. Scientific justification for creatine maintenance and creatine loading doses proposed by European Specialist Sports Nutrition Alliance (ESSNA). Vingren JL. 78. Cederblad G. Barnes WS. Int J Sport Nutr Exerc Metab. Oral creatine supplementation and upper extremity anaerobic response in females. The influence of recovery duration on high-intensity exercise performance after oral creatine supplementation. 22. Int J Sport Nutr Exerc Metab. Howell S. Dietary creatine supplementation and fatigue during high-intensity exercise in humans. Effect of oral creatine supplementation on isokinetic torque production. Constantin-Teodosiu D. Chilibeck PD. Gotshalk LA. Eur J Appl Physiol. Chwalbinska-Moneta J. Greenhaff PL. Skelly WA. 1123-1129. 2001.10 11 12 Branch J and Williams M. 81. E3137. Cooke WH and Barnes WS. Bodin K. Hultman E. Burke DG. In: Performance enhancing substances in sport and exercise. Burke DG. 15. Chilibeck PD. Am J Physiol. Soderlund K. The effects of creatine supplementation on repeated upper. Mendonca MA. Timmons J. 235244. Green A. Candow DG. 2000. Casey A. Marley RJ. 13. Burke DG. Effect of exogenous creatine supplementation on muscle PCr metabolism. GreenhafT PL. Reuter I. 2001. Richter EA. 198-226. 139-145. Parise G. Casey A and Greenhaff PL. 607S-617S. Gilliam JD. 349-364.). Culligan CJ. Creatine as an ergogenic supplement. Davidson KS. Effect of recovery interval on multiple-bout sprint cycling performance after acute creatine supplementation. Effect of oral creatine supplementation on power output and fatigue during bicycle ergometry. Cottrell GT. 1994. Smith JE. The effect of continuous low dose creatine supplementation on force. Human Kinetics. Can J Appl Physiol. Effect of creatine and weight training on muscle creatine and performance in vegetarians. Med Sci Sports Exerc. Silver S. Goudemant JF. 670-673. Engelhardt M. Child R. Spiering BA. Candow DG. 2003. Coast JR. 2004. 109-116. 1996. 1946-1955. 10. Neumann G. Hohzorn C. Timmons JA. 1996. 223-231. 2008. Int J Sport Nutr Exerc Metab. 232-237. Hatfield DL. Effect of creatine supplementation on body composition and performance: a metaanalysis. 504-520. Komi PV. Gutierrez Sainz A. 2003. J Sports Med Phys Fitness. Kreider R. Goodman C. 18-23. Selig SE. Tasker L. 26. 2003. Effects of creatine supplementation on muscle power. 1422. Parise G. 32. Int J Sport Nutr Exerc Metab. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. 57-65. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. 1041-1047. Int J Sport Nutr Exerc Metab. 2004. Gonzalez-Gross MM. 651-659. Creatine supplementation: a comparison of loading and maintenance protocols on creatine uptake by human skeletal muscle. Lakomy HK. 34. Nowitz A. 2244-2252. McKenna MJ. McNaughton LR. Preen D. 2003. 89-94. Int J Sports Med. 17. Gonzalez-Badillo JJ. Mol Cell Biochem. Georg KP. Strength and power in sport. 91. 236-240. 1999. Dailly A. Gorostiaga EM. Diabetes. Sacharuk J. Dickson I. Tarnopolsky MA. B. Hespel P. Nissen SL and Sharp RL. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. Attwood J. MacLennan D. Ching S. Paddon-Jones D. Sports Med. Grant S. Oral creatine supplementation improves multiple sprint performance in elite ice-hockey players. Jank M. Hyslop P. Lawrence S. Rawson ES and Volek JS. Atter T. J Appl Physiol. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Snow RJ. 2001. 39. 488-492. J Appl Physiol. Williams C. J Nutr. 2002. Kocak S and Karli U. Ruiz JR. Med Sci Sports Exerc. Med Sci Sports Exerc. Rawson ES. Effects of creatine on body composition and strength gains after 4 weeks of resistance training in previously nonresistance-trained humans. Mihic S. Preen D. Potential ergogenic effects of arginine and creatine supplementation. J Sports Med Phys Fitness. 33. Urso B. 2888S-2894S. 2004. Tarr J. 2004. 87. 14. Effects of high dose oral creatine supplementation on anaerobic capacity of elite wrestlers. discussion 2895S. 50. Dawson B. 2003. J Strength Cond Res. Nissen S. 332-343. 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 518 . 2002. Influence of ingesting a carbohydrate-electrolyte solution on endurance capacity during intermittent. Castillo Garzon MJ. Kreider RB. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Goodman C. 244. 1994. Morton J. Beilby J. Creatine supplementation increases muscle total creatine but not maximal intermittent exercise performance. 43. 13. Ibanez J. 97-111. J Sports Sci. and et al. Ching S. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. and sprint performance. 78. Effects of creatine supplementation on performance and training adaptations. Creatine supplementation in young soccer players. 1998. 21. 2001. Phillips G. 94. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. 134. 2000. Mesa JL. 1995. Nutrition. Borsheim E. The effects of creatine supplementation on high-intensity exercise performance in elite performers. 283-290. 2001. 558-566. 95103. Clarkson PM. J Appl Physiol. Med Sci Sports Exerc. 174. Miles MP. 2003. Effect of creatine loading on longterm sprint exercise performance and metabolism. Nicholas CW. high-intensity shuttle running. 2001. Acute creatine supplementation in older men. 17. Acta Physiol Scand. Kilduff LP. 13. Creatine. Op 't Eijnde B. Jowko E. Jones AM. endurance. Yarasheski KE. Price TB.31 32 33 Izquierdo M. 2003. Wilczak J. 814. 2002. 822-831. 1999. Int J Sport Nutr Exerc Metab. Ostojic SM. 71-75. Greenhaff PL. Pitsiladis YP. Zieniewicz A. Dalton B. 903-944. Richter EA. Ostaszewski P. Rawson ES and Clarkson PM. 13. Eur J Appl Physiol Occup Physiol. Beilby J. Wolfe RR. Dawson B. 189-196. 20. Urbanski RL. 2001. Rishaug P. 1999. Med Sci Sports Exerc. Casey A. 2001. Bell GJ. Boros R. and Metabolism. Gillies EM. Role of submaximal exercise in promoting creatine and glycogen accumulation in human skeletal muscle. 706-717. Casey A. Israel RG. Nicolay K. Lambourne J. Sewell DA. 421-424. or indices of muscle damage and hepatic and renal function. Med Sci Sports Exerc. Zhao S. Tarnopolsky MA and MacLennan DP. 84. Kemp J. 216-234. 17. Mazzetti SA. Greenhaff PL. Spriet LL. Report on Scientific Commitee on Food on composition and specification of food intended to meet the expenditure of intense muscular effort. Sanborn K. 1992. Vincent WJ. 9. Hruby J. Smith LL. 1147-1156. Robinson TM. Greenhaff PL. Volek JS. Tarnopolsky MA. Snow RJ. Putukian M. 87. Selsby JT. 2000. Med Sci Sports Exerc. Syrotuik DG. 2000. Creatine supplementation and the total work performed during 15-s and 1-min bouts of maximal cycling. 275. E974-979. 609-614. J Am Coll Nutr. Swim performance following creatine supplementation in Division III athletes. J Appl Physiol. Aust J Sci Med Sport. 2003. 10. 136145. Kern M. Am J Physiol. Bryan SN. Stathis CG. resistance exercise performance. 1998. Creatine loading. Garner B. Meyer RA. 1997. 31. 284-288. Terjung RL. Greenhaff PL. Fink WJ. 1999. 1999. Br J Sports Med. Int J Sport Nutr Exerc Metab. Hue O. American College of Sports Medicine roundtable. 9. Nutrition. Creatine monohydrate supplementation enhances highintensity exercise performance in males and females. 281 ( Pt 1). Scientific basis and practical aspects of creatine supplementation for athletes. Int J Sport Nutr. Selig SE. McKenna MJ. Williams MH and Branch JD. Hultman E. 1304-1310. 1999. Macdonald IA. 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 519 . The physiological and health effects of oral creatine supplementation. McDonough PJ. Pearson DR. Steenge GR. 1998. 32. Steenge G. Wagenmakers AJ. Volek JS and Rawson ES. 2004. 379-385. Stone MH. Nutrition. Intracellular compartmentation. Williams MH. Fadel PJ. Med Sci Sports Exerc. SCF. Galy O. Kraemer WJ. J Strength Cond Res. J Appl Physiol. 1667-1673. Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. Stevenson SW and Dudley GA. Gomez AL. 29. 17. Eichner ER. structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis.53 54 55 Rico-Sanz J and Mendez Marco MT. Stevenson SW and Dudley GA. Effects of in-season (5 weeks) creatine and pyruvate supplementation on anaerobic performance and body composition in American football players. Devor ST. 146-165. 26. Wyss M. Clarkson P. MacIntosh BR. Hoke T. Staron RS. Pierce KC. 2001. 65-68. 413-419. Applied Physiology. Kraemer WJ. Brdiczka D. 34. Eppenberger HM. 15. and muscle mechanics. Berwick JP. Dietary creatine supplementation does not affect some haematological indices. Effects of creatine monohydrate supplementation during combined strength and high intensity rowing training on performance. 33. Yaspelkis BB. Norris SR. 1998. Creatine supplementation differentially affects maximal isometric strength and time to fatigue in large and small muscle groups. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Game AB. Biochem J. O'Bryant HS. Beckett KD. Effect of creatine supplementation on sprint exercise performance and muscle metabolism. Robinson TM. 21-40. Johnson RL. especially for sports men SCF/CS/NUT/SPORT/5 Final (corrected) Schneider DA. 2001. Stone ME. Hespel PJ. 598-604. 32. 452-463. 2000. Duncan ND. Dietary creatine supplementation and muscular adaptation to resistive overload. Wallimann T. 2000. Creatine supplementation and exercise performance: an update. Greenhaff PL. Utter AC. Creatine enhances oxygen uptake and performance during alternating intensity exercise. 3rd. Sewell DA. J Strength Cond Res. Int J Sport Nutr. Parise G. Candow DG. Myburgh KH. 6 7 8 9 10 11 12 13 14 15 16 17 18 520 . The effect of whey protein supplementation with and without creatine monohydrate combined with resistance training on lean tissue mass and muscle strength. Int J Sport Nutr Exerc Metab. Int J Sport Nutr Exerc Metab. Howell S.72 73 Willoughby DS and Rosene J. Journal of Sports Science and Medicine. Sports Med. 2003. Sports Med. ID 1923: “Creatine” and “Increasing Power” 1 2 3 4 5 AFSSA. Creatine as an ergogenic supplement. Effect of creatine supplementation on aerobic performance and anaerobic capacity in elite rowers in the course of endurance training. Chilibeck PD. Effects of oral creatine and resistance training on myosin heavy chain expression. 268-280. Effects of creatine loading on muscular strength and endurance of female softball players. 18. 44. 173-183. 2000. 2001. Effects of oral creatine supplementation on maximal pedalling performance in older adults. Sasaki H. Farthing J. 35. Ekblom B. 349-364. Dalloz E. 107-125. 2004. Dolisi C. 33. Creatine Supplementation and Exercise Performance: A Brief Review. 2001. power. Wiroth JB. 43.). Child R. 11. Am J Physiol. 123-132. Holt LE. 654-658. Creatine in humans with special reference to creatine supplementation. Bahrke MS and Yesalis CE (eds. Melrose DR. Med Sci Sports Exerc. Eur J Appl Physiol. Smith-Palmer T. Casey A and Greenhaff PL. 271. 84. Creatine supplementation and exercise performance: recent findings. An assessment of the risks of creatine on the consumer and of the veracity of the claims relating to sports performance and the increase of muscle mass. Tarnopolsky M. 481-487. 10. Andrei S. Bemben MG and Lamont HS. Chwalbinska-Moneta J. Int J Sport Nutr Exerc Metab. Silver S. Knehans AW. Bellinger BM. Branch JD. 1876. Culligan CJ. Becque MD. 1994. Bermon S. Lochmann JD. Greenhaff PL. Bizzarini E and De Angelis L. Wilson GR. Soderlund K. Smith Palmer T. 198-226. 2. In: Performance enhancing substances in sport and exercise. 32. Mahoney D. Oral creatine supplementation decreases plasma markers of adenine nucleotide degradation during a 1-h cycle test. E3137. Hebuterne X. Davidson KS. 2003. 35. 533-539. 2003. 13. Noakes TD. 235244. Effect of creatine and weight training on muscle creatine and performance in vegetarians. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Burke DG. Scientific justification for creatine maintenance and creatine loading doses proposed by European Specialist Sports Nutrition Alliance (ESSNA). Effect of creatine supplementation on body composition and performance: a metaanalysis. 1946-1955. J Sports Med Phys Fitness. Human Kinetics. Bemben DA. Bemben MG. Chilibeck PD. 2000. Casey A. 2005. 2000. 33. 2001. 2004. 2003. 411-416. Hultman E. Burke DG. 2001. Med Sci Sports Exerc. Champaign. Effects of creatine supplementation on isometric force-time curve characteristics. Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am J Clin Nutr. Acta Physiol Scand. Bird SP. 217-224. 2003. Hiruma E. Int J Sport Nutr Exerc Metab. Branch J and Williams M. 2002. Balsom PD. 13. Med Sci Sports Exerc. 2000. 607S-617S. 1674-1681. Is the use of oral creatine supplementation safe? Journal of sports medicine and physical fitness. Ayoama R. 170. Constantin-Teodosiu D. Burke DG. Med Sci Sports Exerc. Bold A. 72. The effect of continuous low dose creatine supplementation on force. 2004. Effects of oral creatine supplementation on muscular strength and body composition. and total work. Candow DG. Tuttle TD. Chilibeck PD. 1996. 2000. Bodin K. J Strength Cond Res. Mansfield ER. Dickson I. Vingren JL. Greenhaff PL. Barnes WS. Richter EA. Dietary creatine supplementation and fatigue during high-intensity exercise in humans. 2001. An introduction to energy production and performance. 504-520. 2002. Int J Sport Nutr Exerc Metab. Ibanez J. Green A. 993-996. Hultman E. Mol Cell Biochem. 26. Effects of creatine supplementation on performance and training adaptations. 1997. Med Sci Sports Exerc. Constantin-Teodosiu D. Neumann G. Oral creatine supplementation improves multiple sprint performance in elite ice-hockey players. Green JM. Gilliam JD. Hultman E. Georg KP. 1995. 558-566. Cederblad G. 39. Casey A.19 20 21 22 23 24 25 26 Cooke WH. 36-41. Komi PV. Med Sci Sports Exerc. Cottrell GT. 232-237. 78. Spiering BA. Hatfield DL. McLester JR. Sports nutrition. Kreider RB. Cooke WH and Barnes WS. 189-196. 199-228. 109-116. Med Sci Sports Exerc. Skelly WA. 1994. Muscle creatine loading in men. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization.Biochemistry of Exercise IX: Conference Proceedings. 454-467. J Sports Med Phys Fitness. 139-145. 17. Creatine. Mendonca MA. J Sports Med Phys Fitness. Kocak S and Karli U. 2003. endurance. Soderlund K. J Appl Physiol. Martin D.and lower-body Wingate performance. Sacharuk J. 34. Demeure R. Meyers MC. Driskell JA and Wolinski I (eds. 223-231. 1422. Wilczak J. In: Creatin supplementation and fatigue.). 277-289. Marley RJ. 2000. 1123-1129. Dailly A. 2001. Effects of creatine supplementation on muscle power. Effect of exogenous creatine supplementation on muscle PCr metabolism. Greenhaft PL. 1999. Jones AM. Eijnde BO. 1994. 488-492. 2004. 102. 1996. and sprint performance. 15. 2001. 2000. 89-94. 21. Creatine supplementation in endurance sports. 13. 244. Boca Raton. Gonzalez-Badillo JJ. Champaign. 219. Champaign. The influence of recovery duration on high-intensity exercise performance after oral creatine supplementation. 2003. 16. Izquierdo M. Trimble MH. Can J Appl Physiol. Am Diabetes Assoc. J Appl Physiol. 22. In: Human Kinetics. Effect of oral creatine supplementation on isokinetic torque production. Reuter I. Grandjean PW. Effects of creatine on body composition and strength gains after 4 weeks of resistance training in previously nonresistance-trained humans. Strength and power in sport. 2004. 18-23. 332-343. Effect of recovery interval on multiple-bout sprint cycling performance after acute creatine supplementation. In: Sports and Nutrition: fats and proteins. Grant S. Hyslop P. Volek JS. Hespel P. Herb RA. Jowko E. Soderlund K. Oral creatine supplementation and upper extremity anaerobic response in females. Pitsiladis YP. Atter T. Kenny AM. 2002. Gorostiaga EM. Jeukendrup A and Gleeson M. Tasker L. 32. Greenhaff PL. Smith JE. Attwood J. Eur J Appl Physiol. 81. 2008. Zieniewicz A. CRC Press. Berbalk A. 1998. Ostaszewski P. Int J Sport Nutr Exerc Metab. Hohzorn C. The effects of creatine supplementation on repeated upper. Timmons J. 50. 43. Human Kinetics. Nissen S. Hamilton KL. Kreider RB. J Strength Cond Res. Int J Sports Med. 10. Goudemant JF. Kilduff LP. Engelhardt M. Timmons JA. Francaux M. 27 28 29 30 31 32 33 34 35 36 37 38 39 521 . Poortmans JR. Effect of oral creatine supplementation on power output and fatigue during bicycle ergometry. Creatine supplementation improves muscular performance in older women. Coast JR. Kraemer WJ. Med Sci Sports Exerc. 30. Creatine and betahydroxy-beta-methylbutyrate (HMB) additively increase lean body mass and muscle strength during a weight-training program. Nutrition. Urso B. Effects of high dose oral creatine supplementation on anaerobic capacity of elite wrestlers. Jank M. Fragala MS. 670-673. Gotshalk LA. 2003. Hespel P. Op 't Eijnde B. Lawrence S. Int J Sport Nutr Exerc Metab. 2000. Snow RJ. Fadel PJ. Rawson ES and Volek JS. Beilby J. 2003. Beilby J. 2003. 2004. 2001. Nicholas CW. Mihic S. Greenhaff PL. Miles MP. Richter EA. Creatine enhances oxygen uptake and performance during alternating intensity exercise. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. 91. Int J Sport Nutr Exerc Metab. Williams C. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. 50. 2001. The effects of creatine supplementation on high-intensity exercise performance in elite performers. 379-385. Diabetes. 13. Selig SE. 1999. Stathis CG. Yarasheski KE. 822-831. Snow RJ. Mesa JL. 2002. 1997. 134. J Appl Physiol. Role of submaximal exercise in promoting creatine and glycogen accumulation in human skeletal muscle. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. Aust J Sci Med Sport. Berwick JP. 17. Eur J Appl Physiol Occup Physiol. Creatine supplementation in young soccer players. Paddon-Jones D. 95103. Br J Sports Med. J Strength Cond Res. Wolfe RR. 283-290. 94. Rico-Sanz J and Mendez Marco MT. McDonough PJ. 78. Lakomy HK. Nowitz A. 1667-1673. 84. Int J Sports Med. 2001. 87. McKenna MJ. Dawson B. Acute creatine supplementation in older men. 651-659. 18-23. Beckett KD.40 41 42 43 McKenna MJ. Dalton B. Influence of ingesting a carbohydrate-electrolyte solution on endurance capacity during intermittent. Greenhaff PL. 421-424. 814. Nissen SL and Sharp RL. Phillips G. Preen D. Robinson TM. Selig SE. discussion 2895S. Urso B. Steenge G. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Rawson ES. J Strength Cond Res. 21. Devor ST. Tarr J. or indices of muscle damage and hepatic and renal function. Effect of creatine loading on longterm sprint exercise performance and metabolism. 2244-2252. J Appl Physiol. 2000. 1998. 2004. Ostojic SM. Preen D. 2888S-2894S. 903-944. Goodman C. 17. McNaughton LR. especially for sports men SCF/CS/NUT/SPORT/5 Final (corrected) Schneider DA. 32. Tarnopolsky MA. 14. Kern M. Rawson ES and Clarkson PM. Report on composition and specification of food intended to meet the expenditure of intense muscular effort. Creatine supplementation and the total work performed during 15-s and 1-min bouts of maximal cycling. Sewell DA. Sewell DA. J Appl Physiol. J Nutr. 71-75. 65-68. Gutierrez Sainz A. Selsby JT. 284-288. Sports Med. Potential ergogenic effects of arginine and creatine supplementation. Acta Physiol Scand. 87. 34. 2000. 174. 97-111. J Appl Physiol. 2001. Borsheim E. 2003. 598-604. J Appl Physiol. 2002. 57-65. 1999. Morton J. J Sports Sci. Zhao S. Ruiz JR. SCF (Scientific Commitee on Food). Dawson B. Swim performance following creatine supplementation in Division III athletes. 29. Price TB. Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. MacLennan D. high-intensity shuttle running. 2003. Ching S. 1041-1047. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Creatine supplementation increases muscle total creatine but not maximal intermittent exercise performance. 1998. Clarkson PM. Goodman C. Ching S. 236-240. Robinson TM. Med Sci Sports Exerc. Med Sci Sports Exerc. Effect of creatine supplementation on sprint exercise performance and muscle metabolism. 1995. Dietary creatine supplementation does not affect some haematological indices. Gonzalez-Gross MM. 13. 32. Hultman E. 33. Casey A. Castillo Garzon MJ. 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 522 . Kemp J. Greenhaff PL. Creatine supplementation: a comparison of loading and maintenance protocols on creatine uptake by human skeletal muscle. Parise G. Lambourne J. Int J Sport Nutr. 21-40. Int J Sport Nutr Exerc Metab. Biochem J. Scientific basis and practical aspects of creatine supplementation for athletes. Favaretto V. Bryan SN. Ziliotto G. 2001. 2001. 1147-1156. 413-419. 33. Garner B. 216-234. Bermon S. Creatine supplementation differentially affects maximal isometric strength and time to fatigue in large and small muscle groups. 1999. Almada AL. Utter AC. Syrotuik DG. Eur J Appl Physiol.61 62 63 64 Steenge GR. 9. Boros R. Effects of oral creatine supplementation on maximal pedalling performance in older adults. Duncan ND. 2000. 10. 1998. 136145. Clin Trials J. Spriet LL. 533-539. Stone MH. 1992. Effects of creatine monohydrate supplementation during combined strength and high intensity rowing training on performance. Wagenmakers AJ. Smith LL. Pearson DR. Mitchell TL. 1999. E974-979. Nutrition. Nicolay K. Med Sci Sports Exerc. Williams MH. Gomez AL. and muscle mechanics. Dolisi C. Sanborn K. Galy O. Intracellular compartmentation. Stone ME. 146-165. Clarkson P. 11. Norris SR. Tarnopolsky MA and MacLennan DP. Dietary creatine supplementation and muscular adaptation to resistive overload. Fink WJ. Yaspelkis BB. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Game AB. 130-134. Effects of oral creatine and resistance training on myosin heavy chain expression. Andrei S. 234-238. 33. (Effective component: Phosphatidyl serine)” and “Stress reduction. Staron RS. J Am Coll Nutr. ID 1924: “EAS Creatine (EAS Phosphagen)” and “Increasing time to exhaustion” 65 66 67 68 69 70 71 72 73 74 1 Earnest CP. Creatine loading. 281 ( Pt 1). and Metabolism. Oral phosphatidylserine in elderly patients with cognitive deterioration. Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. 2001. ID 1927: “Lacprodan PL-20. Stevenson SW and Dudley GA. 2001. Amaducci L. J Strength Cond Res. Med Sci Sports Exerc. Hebuterne X. 452-463. 20. Eichner ER. Williams MH and Branch JD. Casey A. Enhanced memory function” 1 2 Allegro L. 1997. Kraemer WJ. Wallimann T. Creatine monohydrate supplementation enhances highintensity exercise performance in males and females. Israel RG. Volek JS and Rawson ES. 24. 32. Rishaug P. Greenhaff PL. Vincent WJ. 609-614. 2001. structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. MacIntosh BR. Effects of in-season (5 weeks) creatine and pyruvate supplementation on anaerobic performance and body composition in American football players. Applied Physiology. Bell GJ. Hespel PJ. resistance exercise performance. Macdonald IA. Eppenberger HM. Johnson RL. Milk protein concentrate with a high content of phospholipids. O'Bryant HS. 275. 9. Psychopharmacol Bull. Hue O. Gillies EM. Med Sci Sports Exerc. 2004. Volek JS. Effects of Creatine Monohydrate Ingestion on Intermediate Duration Anaerobic Treadmill Running to Exhaustion. Pierce KC. 15. 17. 1988. 31. Hoke T. Creatine supplementation and exercise performance: an update. The physiological and health effects of oral creatine supplementation. Putukian M. Wiroth JB. Brdiczka D. An open study. Greenhaff PL. 1998. 3rd. Terjung RL. Am J Physiol. Wyss M. 523 . Meyer RA. 706-717. 104-108. 26. Mazzetti SA. Hruby J. Nutrition. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Int J Sport Nutr. 24. Tarnopolsky MA. Journal of Strength & Conditioning Research. Dalloz E. 1674-1681. 84. American College of Sports Medicine roundtable. Urbanski RL. Willoughby DS and Rosene J. 1999. 1987. Kraemer WJ. Med Sci Sports Exerc. Stevenson SW and Dudley GA. 2000. 1304-1310. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). 24. 1995. 2001. 97. 81. Maj M. Bondiolotti GP. 36. Maggioni M. Aging (Milano). Mistlberger G. placebo-controlled multicenter study on efficacy of phosphatidylserine administration. 28. Cognitive decline in ageing brain. Gerke S. Kelly D. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients--effects of phosphatidylserine therapy. Maggioni M. Hellhammer D. McDaniel MA. 24. 1987. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Maier SF. Nicoletti F. 61-66. 1992. Sinforiani E. Pennisi G. Effects of phosphatidylserine in Alzheimer's disease. Funfgeld EW. Blood levels of cytokines in elderly patients with major depressive disorder. Eur Neuropsychopharmacol. 1993. Brambilla F. Satzger W. Granata Q and Di Michele J. Engel RR. 34. Therapeutic approach with phosphatidylserine. Sillance B. 24. 302-307. Prog Clin Biol Res. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. T-lymphocyte proliferative response to mitogen stimulation in elderly depressed patients. Crook T. Acta Psychiatr Scand. Brambilla F and Maggioni M. 1987. 309-313. Rutenberg D. Baggen M. Brambilla F. 109-114.3 4 5 Benton D. Schreiber S. Massari DC. Mauri M. Clinical Trials Journal. Hellhammer J. Monteleone P. 385-388. Panerai AR. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Clinical Trials Journal. 957-975. Doubleblind cross-over study of phosphatidylserine vs. 2004. 18-21. Kathmann N. Kampf-Sherf O. 7. 1998. 119-126. "Brain-specific" nutrients: a memory cure? Nutrition. 169-178. An open trial of plantsource derived phosphatydilserine for treatment of age-related cognitive decline. 2000. 37. An open trial. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 524 . Acta Psychiatr Scand. Salmeri G. Nutr Neurosci. Ransmayr G. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Hippius H. Phosphatidylserine in elderly patients. Cenacchi T. Munch U. 2. Cenacchi T. Petrie W. Farina C. Fiori MG. Villardita C. 2003. Einstein GO. 1996. Stress. 1987. Gorfine M. Panerai AE. Wells C. 1235-1246. 115-124. Psychopharmacol Bull. Panerai A. Natale M. 4. Isr J Psychiatry Relat Sci. 62-72. Engert V. Cognitive decline in the elderly: a doubleblind. placebo in patients with early dementia of the Alzheimer type. 1987. 1990. Tuch A. 24. Grioli S. The effects of phosphatidylserine in patients with mild cognitive decline. Agostinis C. 1989. Richstein B. Clin Trials J. Fries E. Caffarra P and Santamaria V. 123-133. Picotti GB. Donohoe RT. Sacerdote P. Beinat L. Merlo P. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Crepaldi G. Clin Trials J. 1987. 317. Clin Trials J. 149-155. 1992. 1992. Buss C. Bertoldin T. Nobile P. Brambilla F. 265270. 84-93. Maggioni M. 99-103. 42. J Affect Disord. Lerer B. Gunther W. Double-blind placebo-controlled trial of phosphatidylserine in elderly subjects with arteriosclerotic encephalopathy. Oppenheim Y. Eur J Clin Pharmacol. Kemali D. Nedwidek P. Neuropsychobiology. 5. Cenacchi T. Bove D. 24. 19. Gualtieri S. Mancuso A. Cenacchi T. 51-56. Sacerdote P. Nabb S. 1990. Mani RS. 2006. Landrum JT. Craig R. A2E and blue light in the retina: the paradigm of age-related macular degeneration. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. 2001. Junghans A. 631-643. 239. O'Donovan O. Macular carotenoids and age-related maculopathy. Ball RO. «la lutéine renforce la protection de la rétine et du cristallin contre l'oxydation». 2002. Toxicol Lett. CRC Press. 23. J Biol Chem. Davies NP and Morland AB. 43-47. 383. 2005. Stahl W. 309. Nagatsu T. Levitt M. 391. Sies H. oxidation. contribue à protéger la rétine et le cristallin de l'oxydation» relatives à un complément alimentaire contenant de la lutéine sous forme libre. zeaxanthin. Avis relatif à l'évaluation des justifications scientifiques des allégations «la lutéine contribue à protéger la rétine et le cristallin de l'oxydation». 219. San Diego. Neelam K. Annu Rev Nutr. 465-472. E835-843. 2002. 2910-2917. Mol Aspects Med. Offermann I. 2004. Udenfriend S. 533-559.. 2004. 2004.. Comptes rendus de l'Académie des sciences. 128-135. Beatty S. and conversion to tyrosine in humans studied with L-[1-13C]phenylalanine. Robelin N. Prog Retin Eye Res. Boca Raton. Quantitative measurement of 3'-oxolutein from human retina by normal-phase high-performance liquid chromatography coupled to atmospheric pressure chemical ionization mass spectrometry. Schmidt-Erfurth U. Kavanagh H. 171-201. 1996. Biol Chem. Are lutein and zeaxanthin conditionally essential nutrients for eye health? Med Hypotheses. European Research on the Functional Effects of Dietary Antioxidants (EUROFEDA). 2001. 287-291. constituant majeur de la rétine et du cristallin. Sciences de la vie. The significance of oxidative mechanisms in diseases of the retina. 430. 385. Landrum JT and Bone RA. O'Connell E. Bone RA.ID 1929: “L-Tyrosine” and “Essential for muscle function and for optimal muscle contraction” 1 2 3 4 5 Barany K. La L-tyrosine: traitement au long cours de la maladie de Parkinson. Newman LS. 23. Au Eong KG. 537-545. Krinsky NI. 70-76. 160-164. Semba RD and Dagnelie G. 1983. Nolan J. 57-83. Biochemistry of Smooth Muscle. 2 3 4 5 6 7 Lutein and zeaxanthin. 8 9 10 11 12 13 14 525 . Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Mouret J. «la lutéine est l'un des constituants majeurs de la rétine et du cristallin». Altern Med Rev. 10. Beatty S. 28-40. 296-301. Shaban H and Richter C. ID 1931: “Lutein” and “Macular pigment Blue light filter in eyes Antioxidant activity” 1 AFSSA (Agence Française de Sécurité Sanitaire des Aliments). Smillie LB. Smooth Muscle Biochemistry. 2005. Dick HB. Pencharz PB. Astley SB and Lindsay DG. The science behind lutein. Série 3. 150. 1964. Alves-Rodrigues A and Shao A. 35. Am J Physiol. Conclusions. Macular pigment optical density and its relationship with serum and dietary levels of lutein and zeaxanthin. Lemoine P. Kay CM. Tyrosine Hydroxylase. Arch Biochem Biophys. 23. Zello GA. Academic Press Inc. The Initial Step in Norepinephrine Biosynthesis. Augustin AJ. 61. 345. 259. Vibert P. Phenylalanine flux. 821-830. 2003. Klin Monatsbl Augenheilkd. 1989. and the macular pigment. Anal Biochem. Barany M. Arch Biochem Biophys. Ann Acad Med Singapore. Lehman W. Macular pigments: their characteristics and putative role. Sebert P. «la lutéine. 2003. Bhosale P and Bernstein PS. 2002. Afssa – Saisine n° 2003-SA-0205-Saisine liée 2002SA-0105. Nolan J. 2004. Monograph. Arch Biochem Biophys. Lutein. Mason RM. 17. 244-252. distribution and excretion of 99mtechnetium labeled hyaluronan after single oral doses in rats and beagle dogs. 526 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 . Coleman PJ. Bergin BJ. Sato M. 1997. Intestinal absorption of Hyal-Joint. 375-378. Matrix Biol. 1998. Size selectivity of hyaluronan molecular sieving by extracellular matrix in rabbit synovial joints. 76. Stromberg A. Presti D and Scott JE. 1996. A150-A151. 24. Hyaluronan: biological role and function in articular joints. 569-581. ID 1932: “Sodium Hyaluronate” and “Related to joint health” 1 2 3 Abatangelo G and O'Regan M.15 Whitehead AJ. 1996. Underhill CB. 4. Hyaluronan contributes to the enlargement of hypertrophic lacunae in the growth plate. Kikuchi T. 1038-1045. 38. Adachi N. Ogston AG and Stanier JE. Kiraly R. Hyaluronan. 2004.) radicals is dependent on hyaluronan molecular mass. 38. Am J Vet Res. Shimmei M. 1994. 1108-1112. 1999. Stick JA. 6. Balogh L. 645-656. 2003. 9-16. Bioibérica. Mason RM. Mathe D. elastic and lubricant properties. Miyachi Y. Pavasant P. Focal dermal hypoplasia (Goltz syndrome): a decreased accumulation of hyaluronic acid in three-dimensional culture. Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Levick JR. Kondo A. Mason RM.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. FASEB J. Nutritional Outlook. 281-288. 1995. Study of the effects of hyal-joint and hyaluronic acid on endogenous hyaluronic acid synthesis from synoviocytes. FASEB J. European Journal of Rheumatology and Inflammation. J Physiol. 2397-2404. Lynch TM. Yokoyama Y. Arch Ophthalmol. Levick JR. Pierce SW. Render JA. 510-519. 2005. Hyaluronan secretion by synoviocytes is mechanosensitive. Ray J. Uchio Y. 327-334. Bramlage LR. 119. Osteoarthritis Cartilage. 2004. Matsusaki M. Bioibérica SA. Acta Derm Venereol. Mares JA. 1992. Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH. Hyaluronan secretion into the synovial cavity of rabbit knees and comparison with albumin turnover. Arnoczky SP. Pitsillides AA. Roth SH. 129-132. Yamada H. Macular pigment: a review of current knowledge. J Physiol. 59. 365-367. 888892. Equine Vet J. 2006. Momberger TS. Danis RP. Levick JR. The physiological function of hyaluronic acid in synovial fluid. J Cell Physiol. 1995. Spain. Influence of exogenous hyaluronan on synthesis of hyaluronan and collagenase by equine synoviocytes. Absorption. 503 ( Pt 3). Hospital Juan Canalejo. Sabaratnam S. A controlled clinical investigation of 3% diclofenac/2. 124. Lloyd JW. Edwards JC. La Coruña. Caron JP. viscous. Ochi M. 18. J Cell Sci. Laurent TC and Fraser JR. 2005. 99-110. 2006. Janoki G. 1999. 15. 1996. Scott D. Coleman PJ. June. 109 ( Pt 2). Ishikawa O. Schauss AG. Rheumatology Service Research Unit. Skerry TM. Polyak A. Rheumatology (Oxford). Kawasaki K. Arunan V. Int J Tissue React. J Physiol. Cell Biochem Funct. 2005. Shizari T. Oral hyaluronan gel reduces post operative tarsocrural effusion in the yearling Thoroughbred. 567. 179. 1953. 142148. Joint immobilization reduces synovial fluid hyaluronan concentration and is accompanied by changes in the synovial intimal cell populations. 12. Harwood FL. Pachon J. Kesenheimer B. J Oral Pathol Med. Netzel M. Wada Y. Thompson JG. Journal of the American College of Nutrition. 755-762. Peinl S. Sheldon E. J Biomed Biotechnol. Habu M. 1998. Talalay P. Polyphenols commun. Maeda H. Urinary Excretion of Cyanidin Glucosides and Glucuronides in Healthy Humans After Elderberry Juice Ingestion. Effect of depletion of glycosaminoglycans and non-collagenous proteins on interstitial hydraulic permeability in rabbit synovium. 10367-10372. 343-345. Strass G. Scott D. 1997. Sonoda M. Sonntag S. Natl. Netzel M. Bitsch I. Wolf E. 629-643. Stojkovic P. Kolle S. Mason RM.gov. Ashhurst DE. multum in parvo. 49.uk/en/Publichealth/Healthimprovement/FiveADay/DH_134. ID 1940: “Anthocyans from elderberry juice” and “Antioxidant capability” 1 Bitsch R. Fahey JW. 10. Reichenbach HD. Takano H. Coleman PJ. Janssen M. Kalman D. Boehm V. 25. Zhang Y. Cancer Epidemiol Biomarkers Prev. A decrease in the molecular weight of hyaluronic acid in synovial fluid from patients with temporomandibular disorders.dh. Stephenson KK. Shapiro TA. J Agric Food Chem. ID 1937: “CLA (conjugated linoleic acid)” and “Antioxidant capability” 1 Yu L. 511 ( Pt 2). Bitsch I. 2004. Am J Sports Med. 2001. 7. 1997. 2001. Reproduction. Strasse G. 33. Hyaluronan. Rheumatol Int. Ariyoshi W. The effects of hyaluronan on the meniscus and on the articular cartilage after partial meniscectomy. Fukuda J. USA. Zakhartchenko V. European journal of rheumatology and inflammation. 38. Sci. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Talalay P. 94. Frank T. Valdeon A. Tominaga K. Levick JR. Effects of high concentrations of hyaluronan in culture medium on development and survival rates of fresh and frozen-thawed bovine embryos produced in vitro. 1995. A randomized double-blind placebo-controlled clinical trial evaluating the efficacy and safety of Hyal-joint™ compared to placebo for the improvement of quality of life in adults with osteoarthritis of the knee. Reduces the amount of oxidative stress or cell destruction caused by free radicals. Moriya H. Acad. 2004. 113-122. 25. Wenigerkind H. Bitsch R. Herbst M. 224-229. 15. 22 23 24 25 26 ID 1934: “Sulphoraphane Glucosinolate” and “Enhancing anti-oxidant activity. 2000. 5 A DAY Guidelines. 141-153. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. 2002. Abiona A. 501-508. J Physiol. Almada A. Heimer M. 2 527 . Takahashi T. 1987. http://www. Free radical scavenging properties of conjugated linoleic acids. 2006. 2004. Wade KL. Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens Proc. 124. 34523456. Smith MM and Ghosh P. Amiel D. Sinowatz F. Increased plasmatic antioxidant capacity in humans after ingestion of blackcurrant and elderberry juice.” 1 2 3 DoH (Department of Health). 367–368. Carle E. Stojkovic M. Fahey JW.20 21 Scott JE. Facial wrinkles & anti-wrinkle products. endocrine balance and mineral metabolism (calcium and magnesium). Li Z. In: Biochemistry of silicon and related problems. 33. J Nutr. Powell JJ.). 2006. 2105-2112. SEDIFA. hair. Dexsil Laboratories. Fragny M. Ellinger J. Zhang Y.5% de monométhyltrisilanol orthohydroxybenzoate de sodium. bone tissue and immunity]. Study on the ―anti-aging‖ effect of VitaSil. Ostéoporoses: technique d'exploration et thérapeutiques nouvelles. Bagchi M. Stohs SJ. 179-189. Sripanyakorn S. Garg A. etidronate and magnesium on bone mineral density: a retrospective study. 530-534. Res Commun Mol Pathol Pharmacol. 24812485. Bedu O. Loeper J. 1999. Krohn RL. L'action antiathéromateuse du silicium [Antiatheromatous action of silicon]. Hott M. Loeper J. Silicium. De Pollack C. conjonctyl. 2007. Thompson RPH. joints. 13. Bull Acad Natl Med. 136. Dietary silicon and bone health. Laponche AM. Short-term effects of organic silicon on trabecular bone in mature ovariectomized rats. treatment. Goy-Loeper J. ID 1942: “Lycopenes from tomato juice” and “Oxidative stress control” 1 Ellinger S. Chauvin M. 1979. Rozensztajn L. Lyon méditerranée médical. 2007. 28-29. Suchard M. 3 4 5 6 7 8 9 10 11 12 13 528 . discussion 534.v. 1979. Calcified tissue international. bone and blood vessels” 1 2 Alexander P. 1977. Henning SM. tomato products and lycopene in the prevention and treatment of prostate cancer: do we have the evidence from intervention studies? Curr Opin Clin Nutr Metab Care. Rozensztajn L. Heber D. 1349-1352. Silicon is an essential element for normal structure of connective tissues such as skin. 1993. Jugdaohsingh R. Troniou R. 1979. 30. Anti-inflammatory effect of VitaSil. Effects of silicon. Manufacturing Chemist. 2005. Stehle P. Goy-Loeper J. 397-408. Eisinger J. and a grape seed proanthocyanidin extract in vitro. 2006. 9. Oxygen free radical scavenging abilities of vitamins C and E. Detolle P. Goy J. Silicon. 1988. 1997. 269-280. Marie PJ.ID 1941: “Antioxidants from pomegranate juice” and “Oxidative stress control” 1 Bagchi D. Nutrition Bulletin. 222-230. Eisinger J and Clairet D. Corriol S. 46. Rev Rhum Mal Osteoartic. 6. sur la correction esthétique des rides du visage. Loeper J. Schiano A. Atherosclerosis. Brisou B. fluoride. Etude de l'effet des injections intradermiques répétée d'une solution aqueuse stérile à 0. Magnes Res. Eisinger F. 1977. Life Sci. 174-179. 163. Fragny M. Seeram NP. Eisinger J. Dexsil Laboratories. New York. Tomatoes. Bendz G and Lindqvist I (eds. Laponche AM. Study of fatty acids in atheroma induced in rabbits by an atherogenic diet with or without silicon i. Modrowski D. 247-249. tissu osseux et immunité [Silicon. 53. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. 2 ID 1945: “Monométhylsilanetriol: other substance with nutritionnal or physiological effects” and “Bioavailable Silicon form. 1987. Charnot Y and Peres G. The antiatheromatous action of silicon. 483-486. 95. 722-727. Plenum. 1993. Fragny M. Tran MX. 42. Sharov VG. Poland. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells. Kielty CM and Shuttleworth CA. Kim SS. Earnest CP. 413-427. Jacobson KA. 1993. Decollogne S. Effects of an oral treatment with ATP on skeletal muscle mitochondrial function in rats. 1997. Kichenin K and Seman M. Mann JK. Williams M. Valat JP. 1976. Kuznetsov AV. 211-232. Abraham EH. 88. 251-254. Gaba S. 10. Identification of two distinct vasodilator pathways activated by ATP in the mesenteric bed of the rat. Bidault F. 2001. Ventura-Clapier R. 38. Physiological and pathological roles of purines: an update. 25-34. Br J Pharmacol. 93. 1962-1968. Lucia A. Burnstock G. 294. 2005. Cho YH. Rôle du muscle dans les lombalgies. 133. J Pharmacol Exp Ther. 1992. Avouac B. 1993. 191-196. Valat JP. Cardiovascular and pulmonary response to oral administration of ATP in rabbits. 2002. 2000. Microsc Res Tech. 2005. Kichenin K. Kang I. Saussine M. 126-133. [Vascular effects of adenosinetriphosphate]. 62. 35. Angignard J. 205-214. Sequin J. 1978. A randomized. Dagnelie PC. Measuring the contribution of pharmacological treatment to advice to stay active in patients with subacute low-back pain: a randomised controlled trial. Chronic oral administration of ATP modulates nucleoside transport and purine metabolism in rats. Church TS. 32. ID 1950: “Collagen” and “Skin health” 1 2 Fallet C. 861-867. 1987. van Galen PJ. Poznan. Allaert FA. Salikhova A. structure-activity relationships.ID 1946: “Adenosine triphosphate (ATP)” and “Muscular and nervous system” 1 2 Agteresch HJ. 1114-1117. Synoviale. 2047. 2005. van den Berg JW. Avouac B. Saks VA. and therapeutic potential. Pellieux S. Arch Biochem Biophys. Baik HH. 14. Peggy P and Duquesnoy B. Biochim Biophys Acta. Morss GM. Leblond Y. 529 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 . Raven Press. Stanford SJ. Kim MS. Lee J. Gitlin JM. A basis for distinguishing two types of purinergic receptor Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Fatigabilité musculaire & muscles lombaires. Pharmacoepidemiol Drug Saf. 7th Congress of European Association for Clinical Pharmacology and Therapeutics. 2001. Rossignol M. 28. placebo controlled triphosphate in study of oral adenosine subacute low back pain. 491-503. 2000. Cahier cosmétopratique. Colson P. Burnstock G. Ha J. 1999. Réflexions Rhumatologiques. 825-832. Ann Fr Anesth Reanim. J Theor Biol. Microfibrillar elements of the dermal matrix. Roquefeuil B. Rossignol M. Drug Development Research. J Rheumatol. Jordan AN. Bannwarth B. 39. Allaert FA. Veksler V. Jurca R. Mitochondrial respiratory parameters in cardiac tissue: a novel method of assessment by using saponin-skinned fibers. Chaptal PA. 2000. Purinergic receptors. 983-990. Kapelko VI. Wilson JH. 36. Adenosine receptors: pharmacology. Burnstock G Straub R and Bolis L. 407-422. Rozenberg S. J Appl Physiol. Rozenberg S. Physiologie cutanée. Adenosine triphosphate: established and potential clinical applications. Métivier JC. Veksler VI. Angignard J. 1991. 58. 58. Peres G. Fouquet B. 401. Med Sci Sports Exerc. 892. 1-8. 2004. doubleblind. Mitchell JA. Le Moniteur des Pharmacies et des Laboratoires. Ellot M-T. Drugs. Kong Y. Seman M. J Med Chem. Effects of oral ATP supplementation on anaerobic power and muscular strength. Bannwarth B. Le Teuff G. 7. Singh DK. Pierard GE and Lapiere CM. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. 2003. Altern Med Rev. González M. 9. Monaco. Policosanol. Díaz E. 31 Suppl. Angelin B. Galman C. Collagen. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev. 129. Fernandez L. Gamez R.3 4 5 6 7 8 Matray-Bressand MD. Menendez R. Fernandez J. 1990. une alternative aux statines Nafas.naturaldatabase. 85-92. In: Peau programme jeunesse. 199. 2000. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. Int J Clin Pharmacol Res. 1997. 2002. Mesa M. Cordovi N. Actif‘s Guide AZ. Castaño G. Current Therapeutic Research. Robaina C. Fernandez L. Pons P. 2004. Illnait J. Ruszczak Z and Schwartz RA. Moreira M. 819-828. Sur une assise solide: le derme. Rudling M. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized.) Masson. 2005. www. 50. 56. Alpen. Natural Medicines Comprehensive Database. Current Therapeutic Research. 285289. Fernández L. Le secrets de jeunesse de la peau. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Fernandez L. 2001. Fernandez JC. 37-50. Mas R. 43-57. Structures et fonctions du derme et de l‘hypoderme. Mas R. 16. Alvarez E. 1994. Illnait J. 1999. 2005. Porter TD. Mas R. Illnait J. Br J Clin Pharmacol. Mas R. Mendoza S. 868875. Matray-Bressand MD. 1995. Jimenez S. In: Précis de Cosmétologie Dermatologique. Rodriguez M. In: Peau programme jeunesse. 2006. Más R. 2262-2269. Ed. Dermatology. ID 1951: “Policosanols” and “Cholesterol” 1 2 3 Policosanol. 568-575. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Monco. Alpen. Castano G. Illnait J. Gouni-Berthold I. Castano G. 2002. 1445-1453. Fernández JC. Am Heart J. Más R. Rodeiro I. J Pharmacol Exp Ther. Current Therapeutic Research. Berthold HK. Matrix Biol. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. 2002. 1992. Effects of policosanol on primary hypercholesterolemia: a 3-year open-extension follow-up. Illnait J. Policosanols. Más R. 318. Fernández L. Hernández F. 14. JAMA. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers. La peau: une couverture de survie. Gamez R. 2006. Monograph. Pourrias B. Castano G. Fernandez JC. Prunerias M (ed. 16. 255-262. Collagen uses in dermatology . 356-365. 12-13. 143. 2007. Fernández L. Amor AM. Unverdorben S. 4 5 6 7 8 9 10 11 12 13 14 15 530 . Degenhardt R. Gouni-Berthold I and Berthold HK. 51. Int J Clin Pharmacol Res. 1997. Li L. Canetti MM. Fernández JC. Millet P. Illnait J. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. 21. Tula L. 203-217. double-blinded study. Bulitta M. Drugs Exp Clin Res. 1. 295. Gastroenterology.com. 59-67. 2002. Piez KA. Ed. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Fernández JC. 87-89. History of extracellular matrix: a personal view. 31-44. Les secrets de jeunesse de la peau. Moreira M. Janikula M. Zayas M. 27-33. Gonzalez RM. 312-317. 58. 1020-1026. Canetti M.an update. Wang Y. 28. Lack LC and Wright HR.a chronobiotic and soporific hormone. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. 5. Sleep Med. 2007. Shapiro CM. 64. Smits MG. Lancet. Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. Management of chronic insomnia in elderly persons. 85. 1986. 1989. 2002. Chronobiology of sleep in humans. 2004. BMJ. discussion 317-321. Gruenwald J. Van Der Meer YG. 1991. 4. 376-383. Brown G. 144-150. Lack LC and Wright HR. placebocontrolled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Conaglen JV. Clinical management of delayed sleep phase disorder. 21. Hansen K. Dubocovich ML. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Kunz D. A randomized. Arch Gerontol Geriatr. Jet lag and melatonin. 63. 7. Lancet. Sack RL. Alvarez B. Lack LC and Wright HR. Lewy AJ. Enslen M. Role of policosanols in the prevention and treatment of cardiovascular disease. Delayed sleep phase syndrome response to melatonin. 303-317. 337. Thomas KH. Haimov I and Lavie P. 1205-1215. 1271-1278. 2007. Bain KT. Mundey K. 135-143. Dawson AG. 128-134. J Clin Endocrinol Metab. Jones PJ. 167-173. 1997. 1998. Tan DX. 2004. 1121-1124. Harsanyi K. Petrie K. CD001520. Kerkhof GA. Graubaum HJ. 31. 8. 1995. 89. Ann Pharmacother. Treating chronobiological components of chronic insomnia. Cell Mol Life Sci. 197-201. Melatonin: therapeutic use in sleep disorders. Grube B. Thompson L. 33. Eur J Appl Physiol. Adv Ther. Biol Psychiatry. Buttoo K. Haimov I and Lavie P. Chamberlain K. Sleep. Cutler NL. Chase JE and Gidal BE. Thompson L. 1997. Nagtegaal JE. Coste O. Sleep. 2001. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 531 . J Sleep Res. 526-530. Circadian characteristics of sleep propensity function in healthy elderly: a comparison with young adults. Dahlitz M. Am J Geriatr Pharmacother. 698-699. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slowrelease caffeine and melatonin. 705-707. Zee PC. Vignau J. 20. Pierard C. 294-300. Jindal R. 2005. 12181226. Benloucif S. Effect of melatonin on jet lag after long haul flights. 2007. 1997. Cochrane Database Syst Rev. Beaumont M. 2. 24. 183. Ciba Found Symp. Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. 168192. Bes F. Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Petrie K. Swart AC. French J. Herxheimer A and Petrie KJ. ID 1953: “Melatonin” and “Sleep-wake cycle regulation” 1 2 3 4 5 Arendt J and Marks V. 57-76. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. double-blind. Muller C. Melatonin . Blood ML. Brook R. 2006. Nutr Rev. 61. 298. Tilmann A. Reiter RJ. Bauer VK. Fontan A. Kayumov L. English J. 1993. Mahlberg R. 2001. Chauffard F. Lagarde D. 637-644. Psychosom Med. 40-48. 2003.16 Varady KA. Behav Sleep Med. Melatonin for the prevention and treatment of jet lag. Arendt J. Parkes JD. JAMA. 129. 2005. 1445-1453. Más R. Hernández F. ID 1954: “Policosanols” and “Cholesterol” 1 2 Policosanol. 1995. Rodriguez M. 34-42. 43-57. 27-33. 312-317. Moreira M. 255-262. double-blinded study. Gastroenterology. Berthold HK. Amor AM. and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed. 376-383. Fernández JC. Int J Clin Pharmacol Res. Policosanol. 31 Suppl. Rudling M. FSH. Role of policosanols in the prevention and treatment of cardiovascular disease. Jimenez S. Gonzalez RM. Current Therapeutic Research. Mas R. Drugs Exp Clin Res. Angelin B. Li L. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 532 . 2003. 31-44. Brusco LI. J Pharmacol Exp Ther. Illnait J. Fernandez J. 2002. Illnait J. Fernández L. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. 58. 203-217. Current Therapeutic Research. 30. Illnait J. Fernandez JC. Canetti M. 51. Fernandez L. Illnait J. Castano G. 2001. Effects of policosanol on primary hypercholesterolemia: a 3-year open-extension follow-up. 7. Fernández L. 1997. Fernandez L. 2262-2269. Porter TD. Rodeiro I. Fernández L. Díaz E. 2004. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Más R. Mas R. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. Más R. Alvarez E. Zayas M. 21. 56. Gamez R. Altern Med Rev. Wang Y. 61. 50. Lack of changes in serum prolactin. Benedetti C.com Pons P. 318. www. 59-67. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. une alternative aux statines? Nafas. Natural Medicines Comprehensive Database. Gouni-Berthold I and Berthold HK. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Canetti MM. 14. Robaina C. Illnait J. Pourrias B. Tula L. middle-aged. 1992. Orlando A. 2000. Nutr Rev. J Pineal Res. 2005. Fernandez L. Am Heart J. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers. Tuchscherr L. Noseda CM. Moreira M.naturaldatabase. TSH. 143. 2006. 356-365. 568-575. 868875. Bulitta M. Mas R. Singh DK. Castaño G. 2003. Unverdorben S. Mas R. Gamez R. Br J Clin Pharmacol. Fernández JC. 1994. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized. Castano G. Cardinali DP. 2002. Mendoza S. Janikula M. González M. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Menendez R. 819-828. 295. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Illnait J. Fernandez JC. and elderly patients. Degenhardt R. 1020-1026. Gouni-Berthold I. Mesa M. 2001. Cordovi N. 9. Policosanols. Monograph. Fernández JC. Galman C. Beltran JM. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev. Castano G.20 Siegrist C. Int J Clin Pharmacol Res. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. 1. Varady KA. 2006. Jones PJ. Current Therapeutic Research. Mol Nutr Food Res. Ann NY Acad Sci. 6. 301. 2495-2510. Borriello A. Delmas D. 2004. Gerhardsen G. 2005. Femal. Winther K.net. Role of chemopreventive agents in cancer therapy. Petersen F. Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation. Nature. Femal. 2003. parallel study. 1276-1279. 425. Ahmad N. Sirtuins: novel targets for metabolic disease. Photochem Photobiol Sci. Takada Y. Chen D and Guarente L. Ruby F. Aging research's family feud. 130-133. Finkel T. 2007. Aggarwal RS. 215. Baxter RA. 2005. Chemoprevention of photocarcinogenesis by selected dietary botanicals. Longevity research. Cancer Lett. Gruber D. Shishodia S. 6th Congress of European Society of Gynecology. 24. Cucciolla V. ID 1957: “Resveratrol” and “Antioxydant properties” 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Adhami VM. 13. Gruber J. Roos S. 46. Curr Opin Investig Drugs. Bhardwaj A. 7. Goudev AR. 8. 530-542. 2783-2840. Gerhardsen S. reduces hot flushes and improves quality of life in menopausal women: a randomized. Knogler W. Tang SY.passeportsante. Szanto E. Hall SS. 243-253. 15. Exp Dermatol. 2003. a natural remedy based on two pollen extracts reduces symptoms of PMS. Afaq F and Mukhtar H. Resveratrol: from basic science to the clinic. Halliwell B. Galletti P. 2005. 2003. Metka M. 2007. 2007. Journal of Cosmetic Dermatology. Fomitz G. 2-7. Int J Oncol. Jannin B. 17-28. Pollen. 2008. 2005. Resveratrol: preventing properties against vascular alterations and ageing. Cell Cycle. 162-170. www. Trends in Molecular Medicine. Drug discovery today. Couzin J. Rein E. 74-82. Wien Med Wochenschr. Sator M. 23. Della Ragione F. Huber JC. Latruffe N. 371-378. Oliva A. 2 3 4 5 533 . 144. 303. 129-140. placebo-controlled. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ageing: a toast to long life. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Climacteric. Anticancer Res. Zappia V. Aggarwal BB. 64-71. Botanical antioxidants in the prevention of photocarcinogenesis and photoaging. Dorai T and Aggarwal BB. Aziz MH. 2004. Suppression of ultraviolet B exposure-mediated activation of NFkappaB in normal human keratinocytes by resveratrol. 132-133. Science. In vino vitalis? Compounds activate life-extending genes. MedGenMed. 5. 2004. Elliott PJ and Jirousek M. 1165. [Placebo-controlled study of melbrosia in treatment of climacteric symptoms]. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Hedman C. 1100. SIR2: a potential target for calorie restriction mimetics. 2007. Ahmad N. Huber JC. 5.ID 1956: “Pollen” and “Menopause” 1 Georgiev DB. Baliga MS and Katiyar SK. 1994. 2006. Lefrancois P. Dionne J-Y. Neoplasia. Effects of an herbal medication containing bee products on menopausal symptoms and cardiovascular risk markers: results of a pilot openuncontrolled trial. Science. 2008. a herbal remedy made from pollen extracts. 377-395. Seeram NP. 6. 2004. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). 9. Afaq F. Manassiev N. Blagosklonny MV. Kumar R. 49. 218-224. 678-684. 12. 2003. Adli M. Baur JA. Schilder YD. 389. 221-231. Zipkin RE. Chung N. 2008. Leid M. 16. Chronic treatment with resveratrol induces redox stress. Le resvératrol: un phytonutriment extrait du raisin aux multiples propriétés. Pocar P. Guarente L. 2007. 191-196. Gutierrez-Cuesta J. Young HA. 2008. Basaga H. 2-7. Endocrinology. Helfand SL. Ward D. 2001. 771-776. 20. Mutat Res. Poli G. 23. Nature. Faraglia B. Zhang LL. inhibits cell proliferation and prevents oxidative DNA damage. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Miller C. 99-106. Lin JK and Tsai SH. Ignatowicz E and Baer-Dubowska W. Nature. Machado De Oliveira R. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Cohen HY. Pol J Pharmacol. Wood JG. Vitamin Research News. Does resveratrol activate yeast Sir2 in vivo? Aging Cell. Nutrition. Biochem Biophys Res Commun. Resveratrol protects against 4-HNE induced oxidative stress and apoptosis in Swiss 3T3 fibroblasts. Chen A. The effect of resveratrol on a cell model of human aging. 987-1002. Cattaneo A. 2007. Green JE. 341-344. Senawong T. Dirsch VM. Jiang WJ. Horseman RE. Valenzano DR. 2004. McBurney MW. 171180. 407-418. Cittadini A. Hudson TS. Terzibasi E. Howitz K. 2006. Lamming DW. Dawes IW. 2006. Topark-Ngarm A. Lavu S. 2001. 61-69. a natural chemopreventive agent against degenerative diseases. 26759-26766. 2005. Tatar M. Prévention et Santé. 67. Sirt1 protects the heart from aging and stress. 145. 1999. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Resveratrol. Lin RC. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Verdaguer E. Alcendor RR. Toward a unified theory of caloric restriction and longevity regulation. Modulation of sirtuins: new targets for antiageing. 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 534 . 429. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. 282. 496. Resveratrol: clinical and anti-aging benefits. 3. Sadoshima J. 1594-1601. Chung P. 1-10. 373. Zipkin RE. Howitz KT. 807-809. Pallas M. Nature. Mai. 2007. Cancer Res. 1114. 557-569. Kaeberlein M and Kennedy BK. Stefani M. 2007. 2004. Rogina B. 441. Adams JK. Sinclair DA. 2004. 1396-1398. Biol Chem. Howitz KT. Tajes M. Do we age on Sirt1 expression? Circ Res. 2007. Kisielewski A. Wang TT. 425. Bitterman KJ. 126. 53. Proc Natl Sci Counc Repub China B. 296-300. Morris BJ. 2004. 415-416. Sirtuins: novel targets for metabolic disease in drug development. 6. Nutranews. Resveratrol.17 Heiss EH. Ardito R. Curr Biol. Chemoprevention of cancer and cardiovascular disease by resveratrol. Arany P. a natural phenolic compound. Sinclair D. Mech Ageing Dev. Hsu CP. Sinclair DA. Design and synthesis of compounds that extend yeast replicative lifespan. Say yes to sirtuin. Fischer B. Aging Cell. Odewale I. Genade T. Ann NY Acad Sci. Spinney L. Wolf FI. Recent Patents on CNS Drug Discovery. Science. Cellerino A. Constitutive expression of CYP1A1 in bovine cumulus oocytecomplexes in vitro: mechanisms and biological implications. 6. Yang H. 18. 2007. Sgambato A. Scherer B. Gerontology: eat your cake and have it. Kutuk O. 100. Augustin R.and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. 430. 2004. Boninsegna A. 4-7. 2004. 2008. Biofactors. Nutranews. 2003. 35-43. Nunez NP. Markus MA. Sedding D and Haendeler J. Hursting SD. Wood JG. Picard F. Camins A. no to lamp shades. Nature. Sinclair DA. 8396-8405. Lavu S. Hartle DK. Domenici L. Pinese M. 686-689. Kurtev M. Kisielewski A. 2004. J Biol Chem. Hammar N. Oekonomopulos R. 256. Hendler SS and Rorvik D. 105-110. Liu Z. Rodriguez AI. Direct evidence for the involvement of two glucose 6-phosphate-binding sites in the glucose-6-phosphatase activity of intact liver microsomes. 1997. Ramos FC.ID 1959: “Taurine” and “Antioxidant/ detoxifying properties” 1 2 3 4 5 6 Aruoma OI. Schubert G. 2000. 2001. hypotaurine and their metabolic precursors. Vessby B.W. 118. Canfield WK. Burger HJ. Dictionnaire des plantes médicinales du monde . Canfield WK. Yamagami T. Arnlov J. 2004. 279-285. Int J Neurosci. Otto-Duessel M. 1016-1019. Herling AW. 1. 1998. Chlorogenic acid analogue S 3483: a potent competitive inhibitor of the hepatic and renal glucose6-phosphatase systems. High Alt Med Biol. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6phosphatase. Burger HJ. Ramos FC. Arion WJ. American Botanical Council. type 2 diabetes and impaired glucose tolerance in Swedish men and women. 916-922. Arch Biochem Biophys. and vitamin E on oxidative damage in hippocampus caused by the administration of 3-nitropropionic acid in rats. Herling AW. vitamin C. Carlsson S. Coffee consumption and risk of type 2 diabetes in Finnish twins. 26. Hoey BM. Su ML. Rodriguez-Martinez E. 291. 251-255. Swanson RJ. Antioxidant-mediated effects in a gerbil model of iron overload. Callaway ES. Hilding A. Carlsson S. Izumi I. Below P. ID 1961: “Lecithine de soja: soy lecithin” and “Rate cholesterol stabilization” 1 2 3 Blumenthal M. Burger HJ. Deutscher Apotheker Verlag. Schubert G. 2004. Schindler PW. Coffee consumption. Hemmerle H. Mechanisms of taurine antihypoxic and antioxidant action. 2007. Arion WJ. Herbal Remedies-Heilpflanzen. the microsomal glucose 6-phosphate transport protein by a direct binding assay. Arch Biochem Biophys. Bellet S. N. Kaprio J. Gruenwald J. Zhang M. Antioxidant effects of taurine. 40. Kharlamova ON. 114. Rivas-Arancibia S. PDR (Physician's Desk Reference) for nutritional supplements.S. J Intern Med. Hemmerle H. JAMA. 1199-1201. Qi B. Anuradha CV. Grill V. Response of liver antioxidant system to taurine in rats fed high fructose diet. Herbal Medicine: Expanded Commission E Monographs. Brinckmann J. 1997.réalités & croyances De Boeck. Moats R. 2002. Hammar N. Effects of coffee consumption on oral glucose tolerance curves in normal human subjects. 33. Austin. Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men. 273. Brendler T. Below P. Rozelle. Herling AW. Canfield WK. ID 1962: “Chlorogenic acids from Coffee” and “Glucose homeostasis” 1 Agardh EE. Rugerio-Vargas C. Borgonio-Perez G. The antioxidant action of taurine. Jaenicke C. 203207. Butler J. Sandberg H. Nandhini AT. 616-617. 1998b. Indian J Exp Biol. Stuttgart. Amino Acids. Feinberg L. Arion WJ. Aguilar M. Bruxelles. Biochem J. Vavilova GL. Schubert G. Riserus U. 2000. Int J Epidemiol. Ahlbom A. 645-652. Mankovskaya IN. 315-322. Kagamimori S. 6223-6227. Serebrovskaya TV. TX. 193-199. 17. Sokejima S. Grill V. 255. 1133-1145. Wood JC. 339. Coffee consumption and insulin sensitivity. Characterization of T1. J Biol Chem. Thomson Reuters. 1988. 1968. Hemmerle H. 2004. 2004. Acta Haematol. Boullard B. 7 2 3 4 5 6 7 535 . 351. Balakrishnan SD. Goldberg A. Metabolism. Efendic S. Halliwell B. 2004. Ostenson CG. 2004. De Castro O. Akinyanju PA. 442-450. Doutre MS. 11. France. 62-66. Light vision and chorioretinal circulation. Rosengren A. 107. plasma lipids and some factors involved in blood clotting. Manson JE. 255. Johansson S. 903-907. Dotevall A. Siou A. 1980. 56. 2003. 2003. Boissin JP. The effect. Coffee consumption and risk for type 2 diabetes mellitus. Baseline survey of JPHC study--design and participation rate. 1988. 1-8. A propos de 4 cas. McCarty MF. J Epidemiol. 88. 786. Evolution de la resistance capillaire. Coffee consumption and risk of type 2 diabetes mellitus. 1980. 119. Robert AM. 2004. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. 40. Herling AW. Gavignet-Jeannin C. 8. Lachance PA. Marache P. ID 1964: “Single and oligomeric flavan-3-ols” and “Vascular Activity” 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 Agache P. 1981. Schindler PW. 2002. Bord Méd. Prospects for glycerol-rescued hypoglycemia as a cancer therapy. Biard L. 137-145. 78. 2001. Choussat H. 1988. 1980. Yudkin J. 703-704. Aho K. 291. 1980. 2004. Mode d‘action des oligomères procyanidoliques sur la paroi vasculaire. Medicin Praticienne. 37-48. 453-460. 728-733. Inform. Nutr Metab. Beylot C. Willett WC. Below P. Dartenuc JY. Leitzmann MF. 302-305. Jousilahti P. 13. 360. Dietary phenolic compounds: inhibition of Na+dependent D-glucose uptake in rat intestinal brush border membrane vesicles. 2001. Wilhelmsen L. 1213-1219. Rippel R. 702-703. 8 536 . Alt Med Rev. Coffee consumption and risk of type 2 diabetes mellitus. Schubert G. Tuomilehto J. Lindstrom J. Welsch CA. Groult N. Tsugane S and Sobue T. Evaluation d‘une nouvelle therapeutique par la mesure de la resistance capillaire conjuctivale. 2003. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Coffee consumption and risk of type 2 diabetes mellitus. 2004. in volunteers. Hu FB. Hugonot H. Monograph. Durst G. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. Heliovaara M. Vie Méd. Johnston KL. Morgan LM. 144-151. Burger HJ. Stampfer MJ. JAMA. Med Hypotheses. J Nutr. J Med Chem. 2003. 1970. 1989. S24-29. Takahashi Y. 361. Therapeut. Paulus E. spontanement ou artificiellement diminuee par l‘action d‘une substance capillaro-toxique chez des personnes agees-action benefique d‘un agnet actif sur la micro-circulation. 1997. Naismith DJ. Kadowaki T. insulin. Isogawa A.8 Hemmerle H. Study of the effect of procyanidolic oligomers (Endotelon). Coffee and incidence of diabetes in Swedish women: a prospective 18-year follow-up study. of coffee and decaffeinated coffee on blood glucose. 2035-2038. Godeau G. van Dam RM and Feskens EJ. Résistance capillaire en gériatrie: étude d‘un microangioprotecteur–Endotélon. 1477-1478. 11. Clifford MN. Ann Intern Med. Robert L. J Intern Med. 286-289. 140. Toulouse. Bidel S. Hu G. Reunanen A. Am J Clin Nutr. 12. Ann Dermatol Venereol. 17-26. 361. author reply 703. J Fr Ophtalmol. Salazar-Martinez E. 89-95. Lancet. Corbe C. Lancet. l‘Endotelon. Noda M. Mise en évidence d‘un effet-dose dansl‘antagonismevis-à-visdelapapulehistaminique. Tsugane S. Lancet. Oligomeric Proanthocyanidins. Szanto S. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6phosphate translocase. International Congress on Angiology. Dubos C. Pustuloses exanthématiques aiguës généralisées. Bioulac P. Thelle D. Wasserman BP. 1698-1704. Ascherio A. Olivier-Martin F. 1951. 1976. Acta Ther. Etude d l‘Endotelon en opthalmologie. 1989. 223-237. Godeau G. (Unpublished). Action des Oligomeres Procyanidoliques sur le Cobaye Carence en Vitamin C. 14th Inflammation Research Association Meeting. Robert AM. Parienti JJ and Parienti-Amsellem J. 8. Vie Medicale 1981. Paitel D. 302-305. 101-105. [A study of the effects of procyanidol oligomers on capillary resistance in hypertension and in certain nephropathies]. 8. 90. Pfister A. Vilain P. 442-450. 31–39. 1399-1401. Masquelier J. Tixier JM. Sem Hop Paris. de Haan B. Acta Therapeutica. Williams R. Pourrat A. 3933-3939. Antioxidant activity of procyanidol oligomers and anthocyanins with regard to superoxide anion and lipid peroxidation. (Unpublished). Cambridge. Biol Pharm Bull. 1983. 1982. XVI Congress of the Oxygen Club of California on Oxidants and Antioxidants in Biology. Post JA. 19. 23. Chelmsford (USA). Masquelier J. 689. Masquelier J. Oligomeric Proanthocyanidin Complexes (OPCs) (Pycnogenols. Grape Seed Extract). Dumon MC. Anti-inflammatory and skin-hydrating properties of a dietary supplement and topical formulations containing oligomeric proanthocyanidins.9 10 11 12 Kemper KJ. Post traumatic edemas in sports: a controlled test of Endotelon W. Meunier MT. Oligomeric Proanthocyanidins Protect Vascular Endothelial Cells from Lipid Oxidation. Bos MA. 43-49. Bull Soc Chim Biol (Paris). 235-240. ESA Inc. Protection of Vascular Endothelial Cells From Oxidative Damage by Oligomeric Proanthocyanidins. Wunderlich O. Action comparée de divers facteurs vitaminiques P sur l'oxydation de l'acide ascorbique par les ions cuivriques. Unkovic J. 1981. 537 6 7 8 9 10 11 12 13 14 . Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti-elastase activity. 267-274. Hornebeck W. Effects physiologiques du vin: sa part dans l‘alcoolisme. 2003. Alt Med Rev.11:776-783. Sanofi Res Toul Cedex. 1981. 2006. Michaud J. Haworth Press. 1999. Hughes-Formella B. Stabilisation du collagène par les oligomères procyanidoliques. Rheographic and thermographic study of the effects on peripheral hemodynamics of an endotheoliotrophic. Inc. Bapat S. 33. Kemper KJ. Phytother. Acta physiologica Academiae Scientiarum Hungaricae. Laparra J. de Haan B. Independent Study. 1981. Activité angioprotectrice des oligomères procyanidoliques chez l‘animal-oedenme de la patte. Pine Bark Extract. Bull OIV. Vennat B. Bastide P. Gazave JM. Fialip J. Pine Bark Extract. Grape Seed Extract). Maryland. California. Biochem Pharmacol. 2006. Gaz Med France. Planta Med. USA. Barbier A. Masquelier J. Oligomeric Proanthocyanidin Complexes (OPCs) (Pycnogenols. 1980. Maffrand JP. In: The Handbook of Clinically Tested Herbal Remedies. Gaz Med de France. 1984. 557–578. Skin Pharmacol Physiol. New York. 1981. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Independent study. 56. 1999. 1988. Bapat S. Blazso G and Gabor M. double blind versus placebo study. Grillot A. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon de cobaye. Santa Barbara. ORAC Europe BV (The Netherlands). Dumas J. ID 1965: “Single and oligomeric flavan-3-ols” and “Dermal Activity” 13 14 15 16 1 2 3 4 5 Oligomeric Proanthocyanidins. Monograph. Oedema-inhibiting effect of procyanidin. 7. 88. Saracco JB and Estachy GM. Lagrue G. 57. Duroux E. Simon MT. Pouget MP. Meunier MT. Post JA. 20. 146-148. Savi P. 1996. 20352038. 33. 2007. 231-236. 1988. Barbier A. 2006. Planta Med Phytother. 1999. Pourrat A. California. Piriou Y. Wunderlich O. Action comparee de divers facteurs vitaminiques P sur l'oxydation de l'acide ascorbique par les ions cuivriques. Independent study. Meunier MT. Rayssiguier Y. ID 1970: “Superoxide dismutase (SOD)” and “Antioxidant properties” 1 Chaudiere J and Ferrari-Iliou R. 1345-1359. Hermans N. Bayle D. Unkovic J. Vlietinck AJ. Rock E. Masquelier J. 1996. Bapat S. Hughes-Formella B. Sanofi Res Toul Cedex. Berghe DV. Monograph. 43-49. Bull. de Haan B. Current medicinal chemistry. Pouget MP. Post JA. Atherosclerosis. Post JA. 1989. Williams R.ID 1966: “Single and oligomeric flavan-3-ols” and “Antioxidant Activity” 1 2 3 4 5 Oligomeric Proanthocyanidins.R. 2003. Oedema-inhibiting effect of procyanidin.I. Chelmsford (USA). 267-274. Anti-inflammatory and skin-hydrating properties of a dietary supplement and topical formulations containing oligomeric proanthocyanidins. Independent Study. de Haan B. Bos MA. Biol. De Bruyne T. 1998. 2003. Intracellular antioxidants: from chemical to biochemical mechanisms. Balasinska B. Proanthocyanidins in health care: current and new trends. 14th Inflammation Research Association Meeting. 302-305. Mazur A. 421-422. 31–39. 2007. Chim. 33. 949-962. Cos P. Activité angioprotectrice des oligomères procyanidoliques chez l‘animal-oedenme de la patte. Inhibitory effect of procyanidin-rich extracts on LDL oxidation in vitro. 10. Oligomeric Proanthocyanidins Protect Vascular Endothelial Cells from Lipid Oxidation. Laboratoire Etudes des effets génoprotecteurs et/ou génotoxiques de 2 échantillons. ORAC Europe BV(The Netherlands). 1988. XVI Congress of the Oxygen Club of California on Oxidants and Antioxidants in Biology. 1976. Skin Pharmacol Physiol. Maffrand JP. S. (Unpublished). 1999. In vivo antioxidant activity of procyanidin-rich extracts from grape seed and pine (Pinus maritima) bark in rats. 146-148. 28. 1973. 20. Michaud J. 442-450. Gueux E. Mazur A. Antioxidant activity of procyanidol oligomers and anthocyanins with regard to superoxide anion and lipid peroxidation. Blazso G and Gabor M. Dérivés Résiniques et Terpéniques SA rapport n°012511. Biol Pharm Bull. 76. Masquelier J. ID 1969: “Polyphenols from French maritime pine bark” and “antioxidant properties” 1 Busserolles J. (Unpublished). Vilain P. 145. Michaud J and Masquelier J.(Paris). Santa Barbara. 557–578. Pine Bark Extract. 1999. Vennat B. 2006. Produits et problèmes pharmaceutiques. 56. 1988. 23. 22-27. Effects physiologiques du vin: sa part dans l‘alcoolisme. 689. Laparra J. 1980. Apers S. Savi P. 1951. Duroux E. Action des Oligomeres Procyanidoliques sur le Cobaye Carence en Vitamin C. USA. Alt Med Rev. Lab C. Grape Seed Extract). 538 6 7 8 9 10 11 12 13 14 2 3 4 5 . Cambridge. Oligomeric Proanthocyanidin Complexes (OPCs) (Pycnogenols. Kemper KJ. 37. Acta physiologica Academiae Scientiarum Hungaricae. 8. Bastide P. Maryland. 235. Fialip J. Rock E. Int J Vitam Nutr Res. Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti-elastase activity. Protection of Vascular Endothelial Cells From Oxidative Damage by Oligomeric Proanthocyanidins. 2006. ESA Inc. 499-520.F. Bapat S. Soc. 19. Bull OIV. Masquelier J. Rayssiguier Y. Meunier MT. Food Chem Toxicol. Quelques aspects nouveaux de la connaissance des tanins catéchiques leurs relations avec la vitamine C2(P). Soursac M. Baltimore. 17. Mazier D. Testa B. 1980. Garrel C. Testa D. 2006. Leone G. Oter S. Speit G. Supplementation with gliadin-combined plant superoxide dismutase extract promotes antioxidant defences and protects against oxidative stress. 2007. Introna M. Ann Otol Rhinol Laryngol. 77-85. Muzykantov VR. Monaldi Arch Chest Dis. Ichikawa H. Paro Vidolin A. a vegetal sod with gliadin. 501-510. 321-326. Biofactors. 18. Akagiri S. Roch-Arveiller M. Ross C. Bracht H. Influence of an orally effective SOD on hyperbaric oxygen-related cell damage. Fridovich I. Oxidative stress. Speit G. Reduction of diabetes-induced renal oxidative stress by a cantaloupe melon extract/gliadin biopolymers. Caillard P. 2005. 52. The effect of oral supplementation with legume derived superoxide dismutase on erythrocyte superoxide dismutase in healthy volunteers. 2000. Yoshida N. Vouldoukis I. Curr Opin Clin Nutr Metab Care. Biopharm Drug Dispos. Effects of a cantaloupe melon extract/wheat gliadin biopolymer during aortic cross-clamping. 2004. 79. Iacovelli P. Giblin FJ. Mesolella M. Krauss P. Iaccarino F. Cousins R (eds. Zamaria N. Dietary antioxidants. Shike M. oxidant defence and dietary considerations. J Lab Clin Med. Radermacher P. Calenda A. Intensive Care Med. 2007. Coste P.). Kick J. Caballero B. Superoxide dismutases: defence against endogenous superoxide radical. Dugas B. Klaus M. Practicalities of glutathione supplementation in nutritional support. Bruckner UB. Glutathione in the upper respiratory tract. 957-962. Pharmacokinetics of superoxide dismutase in rats after oral administration. 1995. Antioxidant and anti-inflammatory properties of a Cucumis melo LC. 45-50. Mazier D. Kokura S. Kamate C. 1-21. MacNee W. 1997. Thomas J. Moss J. 927-932. ID 1971: “Glutathion” and “Antioxydant” 3 4 5 6 7 8 9 10 11 12 13 14 15 1 2 3 4 5 6 Gerard-Monnier D and Chaudiere J. 23. 165-174. Dever JM. Pacifico A. [Metabolism and antioxidant function of glutathione]. Tefit M. 2004. 2002. 67-75. extract rich in superoxide dismutase activity. Philadephia. Albicini M. Conti M. Maione F. oxykine. 539 . 380-381. Vouldoukis I. 1217. GliSODin. 16. Muth CM. 1996. Kamate C. Chronic obstructive pulmonary disease from science to the clinic: the role of glutathione in oxidant-antioxidant balance. Ronzio RA. 121-135. Hassan HM. Valencia E and Hardy G. Nakamura N. 94. in mice. Lacan D. Glutathione: a marker and antioxidant for aging. Targeting of superoxide dismutase and catalase to vascular endothelium. 49. Hauser B. 1978. Free Radic Res. Hasegawa G. Singh RJ. 117-119. Ciba Found Symp. Provost JC. Clinical evaluation of the protective effect of an antioxidant complex against polymorphic ligh eruption induced by a photoprovocation test. 104. Superoxide dismutases. Pathol Biol (Paris). Ciba Found Symp. 8. Phytother Res. 479-485. 1996. Glenz Y. 38. 33. Yoshikawa T. Eur Ann Allergy Clin Immunol. 2004. Blazquez S. Leverve X. Muth CM. as preventative agent vs. Naito Y. 1997. 85-95. Elbeze Y. 5. 71. In: Modern Nutrition in Health and Disease. J Ethnopharmacol. In: Vitamin and mineral requirements in human nutrition. 44. Dugas B. J Ocul Pharmacol Ther. 1994. Costa G. 2002. Hazebroucq G. Dermatological Experiences. as confirmed with carotid ultrasound-B imaging. J Control Release. Conti M. atherosclerosis. Radermacher P. 140. Leverve XM. 57-62. 77-93. 694-702. Uchiyama K. Ijichi T.2 Cloarec M. Simon F. 2001. Lippincott Williams & Wilkins. WHO/FAO (World Health Organization and Food and Agriculture Organization). Giuliano A. 2004. Postaire E. Journal of Applied Nutrition. 39. Schelzig H. Strater J. Ehrmann U. Shils M. Regnault C. Toyokuni S. Calenda A. Glutathione: a vital lens antioxidant. 125-142. Non-digestible oligosaccharides and polysaccharides: their physiological effects and health implications. 433-439. 83. Effects of fiber on plasma lipoprotein composition. 83. 12. 64A. McLean Ross AH. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. J Am Diet Assoc. Caruso I and Pietrogrande V. Sagasta CL. and placebo in the treatment of degenerative joint disease. ID 1976: “Acacia gum (gum arabic)” and “Acacia gum and cholesterol” 1 2 3 4 5 6 7 Eastwood MA. Ellis BK. S-adenosylmethionine in the treatment of osteoarthritis. 89-94. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Brydon WG. BMC Musculoskelet Disord. Anderson DM. Spiller GA. Mee KA and Gee DL. Apple fiber and gum arabic lowers total and low-density lipoprotein cholesterol levels in men with mild hypercholesterolemia. 81-83. 2002. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Summary-Evidence Report/Technology Assessment: Number 64. Gates JE. di Padova C. Anderson JR. Hoehler F. Jensen CD. Am J Med.). MA. 41. Am J Cardiol. 1987. 44. 1997. 5. 147-154. 6. Blackwell Science. Malden. Tobis JS. Sharma RD.ID 1973: “SAMe (S-adenosylmethionine)” and “Joint health. Osteoarthritis. 1987. 1987. Am J Clin Nutr. Sharma RD. Am J Med. 1983. Eastwood MA. Di Giorgio EE. Am J Med. 69. Nutrition Research. J Am Coll Nutr. Reinsch S. Haskell WL. Prosky L and McCleary BV (eds. 97. 1986. 2001. 1987. 1987. 368-375. S-Adenosyl-L-Methionine for Treatment of Depression. 83. 425-430. Lee WL. 60-65. Gum arabic metabolism in man. 51-55. 2 3 4 5 6 7 8 9 8 9 10 540 . Review of the clinical studies. Am J Med. and Liver Disease. Hypocholesterolemic activity of some Indian gums. Najm WI. Soeken KL. In: Advanced Dietary Fibre Technology. Double-blind controlled clinical trial of oral Sadenosylmethionine versus piroxicam in knee osteoarthritis. Harvey PW. Am J Med. 5. Maccagno A. Italian double-blind multicenter study comparing Sadenosylmethionine. 1982. Jensen CD. 83. 78-80. Vetter G. naproxen. 83. 1984. A study of the effects of dietary gum arabic in humans. 1985. Brydon WG. J Fam Pract. Am J Med. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Muller-Fassbender H. [ISRCTN36233495]. 1321-1326. Vahouny GV and Kritchevsky D (eds. 2003. Anderson DM. New York. 1987. Berman BM. Bausell RB. 381-389. 51. Caston OL. Nutrition Research. 1992. 1984. Role of water-soluble dietary fiber in the management of elevated plasma cholesterol in healthy subjects. Am J Clin Nutr. Konig B. mobility and joint comfort” 1 Agency for Healthcare Research and Quality (USA). Anderson DM. Agelli M. Gates JE. 72-77. Meyer D and Tungland B. Proc Nutr Soc. The effect of the polysaccharide composition and structure of dietary fibers on cecal fermentation and fecal excretion. Hypocholesterolemic effect of gum acacia in men. 83. 4. Whittam JH. Eastwood MA. Safety and efficacy of Sadenosylmethionine (SAMe) for osteoarthritis.). The effect of acacia gum and a watersoluble dietary fiber mixture on blood lipids in humans. In: Dietary Fiber: Basic and Clinical Aspects. Miller AF. 66-71. Plenum Pub Corp. Brydon WG. 2004. Anderson JR. Spiller GA. 1993. 37. Schneeman BO and Lefevre M. McKay LF. McLean Ross AH. 422-424. ID 1978: “Astaxanthin from Haematococcus pluvialis” and “Beneficial for connective tissue and joints” 1 Aoi W. Rakadzich Z. Astaxanthin: a review of its chemistry and applications. Pell JD. Sharma RD. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 541 . Antioxid Redox Signal. Nir Y and Spiller G. 1999. Spiller G. High-Power Antioxidant. 2003. 2001. Hypoglycemic effect of gum acacia in healthy human subjects. 1437-1441. Watanabe H. Meance S. US Patent 6. Méschériakova VA. Guerin M. Yoshikawa T.ID 1977: “Acacia gum (gum arabic)” and “Blood glucose control” 1 2 3 4 5 Castellani F. Goycoolea FM. 1998. Naguib Y. Bloomer RJ. Chaves S. Effect of daily use of natural astaxanthin on symptoms associated with Tennis Elbow (lateral humeral epicondylitis). 2006. 2004. Crit Rev Food Sci Nutr. Wortley GM. Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases. 44-49. Schilling B. 21. 2005. Haematococcus astaxanthin: applications for human health and nutrition. 2003. 2001. Felix-Valenzuela L. Cox-1 and Cox-2 Inhibition Celebrex and BioAstin. 16. Product focus-Fibregum™(Acacia gum) helps reduce the glycemic index of food products. Naito Y. Agro Food Industry Hi Tech. Maoka T. 5. J Nat Prod. Goto H. Dewell A. Hori N. Frémont G. Tokuda H. Plotnikova OA. Nutr Sci News. Dietary Supplements with Astaxanthin-rich Algal Meal Improves Muscle Endurance – A Double Blind Study on Male Students. Cronin JR. Pioneering Astaxanthin. Astaxanthin Clinical Trial for Delayed Onset Muscular Soreness. Weiss L. Huntley ME. 2001. Malmsten C. 139-144. Influence of non-starch polysaccharides on gastrointestinal endocrine mechanisms. 49 Suppl 3. 6. 46. BioAstin. US Patent 6. 2002. 1985. Glycemic index with a supplementation of acacia gum or a viscous acacia gum mix in type 2 diabetic women.855. Nutrition research. 58. S170-172. Chiu L. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. 69. Brunswick Laboratories. Fry A. Trends Biotechnol. a natural astaxanthin from microalge. 2006. 2007. The Potential of Astaxanthin: A New Multipurpose. 2006. 185-196. Haematococcus pluvialis algae pre-market notification. Food Standards Agency. 2001. Gee JM. 2002. Alternative & Complementary Therapies. 443-449. 2005. Toyokuni S. 5. a carotenoid with potential in human health and nutrition. Eur J Clin Nutr. Lignell A. FDA (Food and Drug Administration). Int J Sport Nutr Exerc Metab. Charaphétdinov CC. Astaxanthin. Nir Y and Spiller G. 1995. 8. BioAstin helps relieve pain and improves performance in patients with rheumatoid arthritis. Lorenz RT and Cysewski GR. Sankawa U. Hussein G. Journal of the American College of Nutrition. 2002.818. Astaxanthin supplementation does not attenuate muscle injury following eccentric exercise in resistance-trained men. Johnson IT. 2004. Method of retarding and ameliorating carpal tunnel syndrome. Yasuhara M. Glycaemic index and insulin index values of Fibregum enriched crispbreads.258. Sakuma K. Oka S. Matsumoto K. helps relieve pain and improves performance in patients with carpal tunnel syndrome (CTS). Higuera-Ciapara I. Request for an opinion on substantial equivalence of Astaxanthin-rich extract from Haematococcus Pluvialis algae. 21. 15. 2006.245. Kuchide M. 24-26. 210-216. Fry A. Olaizola M. Lee-Finglas WE. 401-412. New York. 16. Zeisel SH and Holmes-McNary M. 2006. National Academies Press. Tjokroprawiro A. Blumenthal M. Ross AC (eds. American Botanical Council. B. Marcel Dekker. Shike M. Pangemanan M. Gabler NK. Choline: needed for normal development of memory. Fitoterapia Aplicada. Gabler NK. Eagling DR. IoM (Institute of Medicine). Onions--a global benefit to health. 2006. Indian J Exp Biol. Hall T. Budhiarta AA. Dietary onion intake as part of a typical high fat diet improves indices of cardiovascular health using the mixed sex pig model. 2001. Antioxidant effect of onion oil (Allium cepa. riboflavin. 2000. Shils ME. 1555-1560. Crowther T. 1999. 22.). Washington DC Ladd SL. Marcus R and Coulston AM. 141 Suppl. Pikir BS. In: Goodman and Gilman‘s: The pharmacological basis of therapeutics.Vanaclocha. Allium cepa: dietary onion addition. Br J Nutr. Therapeutic values of onion (Allium cepa L. Osrowska E. 634-640. Augusti KT. 2000. Hypoglycaemic and antioxidant effects of onion. Int J Food Sci Nutr. Krishnakumar K. Rister R. 1998. Ross AC. Eagling DR. 603-615. ILSI Press. 179-185. Phytother Res. Caine ED. 91.. Water-soluble vitamins. Baltimore. Toxicol Lett. Goodman Gilman A (eds.). Faine LA. Clin Neuropharmacol. Diniz YS. 1995. Busse W. Olson JA. Bowman BA and Russel RM (eds. Metabolic effects of onion and green beans on diabetic patients. 540-549. Imsic M. 261-270. 34. 513-523. 1999.). Smith B. 1983. cavalier and var. 1978. J Chromatogr A. New York. Budhianto FX. The analysis of onion and garlic. haematological and haemostatic variables in healthy pigs. Dunshea FR. Philadelphia. 61-68. Washington DC. Zeisel SH. thiamine. Dietarv reference intakes for folate. 2003. vitamin B12. Tatham BG. Alves MJ. Dunshea FR. Gruenwald J. Soewondo H. ID 1986: “Allium cepa (Common Name: Onion)” and “Lipid metabolism” 1 2 Augusti KT. Choline and phosphatidylcholine. Consumption of brown onions (Allium cepa var. Jones RB. Modern Nutrition in Health and Disease. Handbook of vitamins. niacin. 1112. Vijayammal PL. 16. Ostrowska E. Stübing G. Sommer SA. destiny) moderately modulates blood lipids. Lanzotti V. Donosepoetro M. Austin. Cataneo AC. TX. Choline: Selective enhancement of serial learning and encoding of low imagery words in man. Helen A. Effect of phosphatidylcholine on explicit memory. Sitaram N. 54. Valencia. 116. panthothenic acid. Sterling SJ. LaBerge S. Griffiths G.). 2002. Novelli EL. Plant Foods Hum Nutr. Thomas B. 211-218. Gillin JC. antioxidant activity and hypoglycaemic effects on diabetic rats. Campos KE. 528S-531S. Olson JA. Trueman L. 241-246. 5 6 7 8 9 3 4 5 6 7 8 9 10 542 . Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol. Peris JB. Klein S. Choline and carnitine. et al. McGraw-Hill Inc.ID 1983: “Lecithin” and “Memory and concentration” 1 2 3 4 Garrow T. J Am Coll Nutr. Pranawa. Riggins C. Lippincott Williams & Wilkins. biotin. 2001. 1998. 1993.) and garlic (Allium sativum L. Tohoku J Exp Med. 61. In: Modern Nutrition in Health and Disease. Life Sci. Tatham BG. Wibowo JA. Tanuwidjaja SJ. Toscano W. In: Present knowledge in Nutrition. 1555-1572. 19. 1996. Zeisel SH. Shils ME. 3-22. Goldberg A. 2004. Colegio Oficial de Farmaceuticos de Valencia. Molinoff PB. Hardman JG. 1996. Shike M. Jois M. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. 671-676. Weingartner H. and choline. Ruddon RW. Williams and Wilkins Baltimore. Jois M. Limbird LE. Consumption of brown onions (Allium cepa var. 1112. Smith B. 2004. 211-218. Peris JB. Ostrowska E. Smith B. destiny) moderately modulates blood lipids. Guildford. Vijayammal PL. Gabler NK. Fitoterapia Aplicada. ID 1988: “Allium cepa (Common Name: Onion)” and “Antioxidative properties” 1 2 Augusti KT. Valencia. 116. Dietary onion intake as part of a typical high fat diet improves indices of cardiovascular health using the mixed sex pig model. Torrance. ID 1989: “Allium sativum (aged garlic) (Common Name: Aged garlic)” and “Antioxidant activity” 1 2 3 ESCOP (The European Scientific Cooperative on Phytotherapy). haematological and haemostatic variables in healthy pigs. Crowther T. 2006. Consumption of brown onions (Allium cepa var. Phytother Res. 603-615. Stuttgart. Thomas B. Dunshea FR. Ostrowska E. Helen A. Vijayammal PL. 603-615. Tatham BG. B. J Chromatogr A. Toxicol Lett. 1112. J Chromatogr A. Indian J Exp Biol. 61. Indian J Exp Biol. School of Physical Sciences. cavalier and var. Imsic M. Osrowska E. O‘Brien J and Gillies DG. 2006. Sickle cell anemia and anti-oxidant functions of garlic. Dunshea FR. Tatham BG. Toxicol Lett. 91. 179-185. Jois M. Augusti KT.) and garlic (Allium sativum L. 1996. Eagling DR. Jois M. 3-22. cavalier and var. Dietary onion intake as part of a typical high fat diet improves indices of cardiovascular health using the mixed sex pig model. 16. Thomas B. 61. Sterling SJ. Jones RB. Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol. 3-22. Dunshea FR. 2004. Trueman L. Sterling SJ. Eagling DR. Trueman L. 34. 16. Tatham BG. Fitoterapia Aplicada. 1995. 2006. 2002. Lanzotti V. Dunshea FR. 116. Gabler NK. 2000. GU2 5XH. 634-640. 1995. Niihara Y. Stübing G. Krishnakumar K.Vanaclocha. Valencia. Phytother Res. 61-68. Peris JB. Br J Nutr. 34. Antioxidant effect of onion oil (Allium cepa. destiny) moderately modulates blood lipids.ID 1987: “Allium cepa (Common Name: Onion)” and “Glucose metabolism” 1 2 Augusti KT. Colegio Oficial de Farmaceuticos de Valencia. 1996. Jois M. B. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Jois M. Imsic M. Colegio Oficial de Farmaceuticos de Valencia. 2002. Therapeutic values of onion (Allium cepa L. 1998. Tatham BG. The analysis of onion and garlic. Plant Foods Hum Nutr. Griffiths G. Eagling DR. 91.) and garlic (Allium sativum L. Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol. Jones RB. Helen A. 634-640. 2006.Vanaclocha.). Krishnakumar K. Harbor-UCLA Medical Center. Lanzotti V. 211-218. Stübing G. Onions--a global benefit to health. The analysis of onion and garlic. Crowther T. Gabler NK. Therapeutic values of onion (Allium cepa L. 2000. 179-185. Br J Nutr. Griffiths G. Eagling DR. 61-68. School of Biological Sciences. Plant Foods Hum Nutr. UK 3 4 5 6 7 3 4 5 6 7 543 . Products of the Maillard reaction in aged garlic extract are antioxidants. University of Surrey.). CA. 2003. Gabler NK. Antioxidant effect of onion oil (Allium cepa. haematological and haemostatic variables in healthy pigs. Augusti KT. Osrowska E. Thieme. Onions--a global benefit to health. Campbell JH. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. 782S-788S. Effect of garlic on cardiovascular disorders: a review. Flores FR. Efendy J. 136. 23. Krasnikov BF. Elkadi A. Lau BH. Kandil O. J Nutr. Nutrition Journal. Garlic revisited: therapeutic for the major diseases of our times? J Natl Med Assoc. European Directorate for the Quality of Medicines. Mauri P.129. Redox-sensitive proteins are potential targets of garlic-derived mercaptocysteine derivatives. 39. 2002. Med Res Rev. 80. Austin. 439-445. 1. 132. 33. Cooper AJ. J Nutr. Budoff MJ. Al-Mutawa'a S. Nutrition Research. The effect of (―Kyolic‖) on the development of atherosclerosis. 65. J Nutr. 1993. CA. Ali M. Bournemouth. Borek C. Garlic Reduces Dementia and Heart-Disease Risk. J Nutr. one-clip model of hypertension. Al-Hajeri D. Amagase H. Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. Nitric oxide mediates the blood-pressure lowering effect of garlic in the rat two-kidney. Bradley P. J Nutr. 2001. Garlic inhibits free radical generation and augments antioxidant enzyme activity in vascular endothelial cells. 1998. 445-450. Al-Qattan KK. 111-124. Carter J. 741S744S. Phytomedicine. Budoff M. 1988. 118. Campbell JH. 61-70. Kasuga S. 4487-4490. Rahman K. Campbell JH. J Vasc Res. Amagase H. Allison GL. 774S-776S. 1216.4 5 6 Pietta P. Newport Beach. Moriguchi T. 2006. 1006S-1009S. Aged garlic extract retards progression of coronary artery calcification. Pinto JT. 2000. Agarwal KC. 1998. Drobiova H. 2005. In: European Pharmacopoeia. J Nutr. Allison GL. Brinckmann J. Smith NJ. 16. Council of Europe. 835S-841S. 4. Molecular basis by which garlic suppresses atherosclerosis. Journal of agricultural and food chemistry 46. Lowe GM. 18. Comparison of oxidative damage of garlic preparation including enteric-coated garlic powder preparation and allicin-derived compounds on erythrocyte and duodenum. 136. 2006. 2006. Method and pharmaceutical composition for reducing serum homocysteine concentration. Niihara Y. 2006a. 1996. 2000. Banerjee S and Maulik S. Rosen RT. 7 8 9 10 11 12 13 14 15 16 17 18 544 . Takasu J. Adler AJ and Holub BJ. 2000. Simmons DL. Smith NJ. Campbell GR. Blumenthal M. Molecular Basis by Which Garlic Suppresses Atherosclerosis. 985-991. 131.918. Total antioxidant activity of selected medicinal plants. 2006. Wei Z and Lau BHS. 2004. Recent Advances on the Nutritional Benefits Accompanying the Use of Garlic as a Supplement. Campbell GR. British Herbal Compendium. 2006b. ID 1991: “Allium sativum (aged garlic) (Common Name: Aged garlic)” and “Heart Health” 1 2 3 4 5 6 Abdullah TH. Efendy JL. Garlic Powder. American Botanical Council. Strasbourg. 1998. 810S-812. Efendy JL. Prev Med. 789S-792S. 136. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. US Patent 6. Goldberg A. 1997. 1996 a. TX. Am J Clin Nutr. Thomson M. J Nutr. Amagase H. Herbal Medicine: Expanded Commission E Monographs. 136. Simonetti P. Aged garlic extract may inhibit aggregation in human platelets by suppressing calcium mobilization. Lu B. Therapeutic actions of garlic constituents. Rahman K. Campbell GR. British Herbal Medicine Association. 136. Lowe GM. 136. Shinryo To Shinyaku (New Drug Clin. Kikuchi N. 13. Lipids. Aged garlic extract improves blood pressure in spontaneously hypertensive rats more safely than raw garlic. Australia. 132. A261#1523. Brisbane. Wang-Cheng R. Nutrition Research. Liu L and Yeh Y. Hasegawa Y. Kohno M and Shirakura T. 2001. 12. 1662-1667. Clinical effect of Leopin-5(Le-5) on various complaints in the field of internal medicine. Lipids. Kikuchi N and Nishimura Y. A556#442. 37-42. 19. 139-149.com/Blue%20Book%20Reference%20(pdf). Inhibition of cholesterol biosynthesis by organosulfur compounds derived from garlic. Water-soluble organosulfur compounds of garlic inhibit fatty acid and triglyceride syntheses in cultured rat hepatocytes. Efendy JL. Regulation of HMG-CoA reductase by organosulfur compounds of garlic in primary cultures of rat hepatocytes.) 21.19 Efendy J. Harauma A and Moriguchi T. FASEB J. 1998. 136. 131. ESCOP (The European Scientific Cooperative on Phytotherapy). Shinyaku To Rinsho (Jpn J New Remedies Clin. 146-158. Gupta N and Porter TD. Lau BHS. 769S-773S. Shimizu K. Lau BHS. Clinical effects of LEOPIN-FIVE® (LP5) and garlic extract (GE)on peripheral microcirculation. Morihara N. 2001. 1976. Effect of an odor-modified garlic preparation on blood lipids. 197-203. Liu L and Yeh Y. Stuttgart. 73-77. Sumioka L. 43. Kawashima Y and Ochiai Y. Lau BH. 985S-988S. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Orlando (USA).kyolic. Campbell GR. 4. 755S-758S. Steiner M. 2000. 22. FASEB J. 1221.pdf. Lin R. Kyolic Aged Garlic Extract. Thioallyl compounds: potent inhibitors of cell proliferation. Uda S. 2003. 35. 136. 36. 1997. Suppression of LDL oxidation by garlic. Ochiai Y. 1984. More than 450 scientific publications on the extract contained in the product (Garlic). 2001. 395-400. Campbell GR. 'Kyolic'. 2006. Aged garlic extract inhibits homocysteine-induced CD36 expression and foam cell formation in human macrophages. Exhibit Hall A4. 1985. Munich (Germany) Ide N. The effect of aged extract. 349. Ide N. Organosulfur compounds of garlic inhibit fatty acid biosynthesis in cultured rat hepatocites. 2006. Nishiyama M. 3rd International Congress on Phytomedicine (3rd ICP). 131. Sumiyoshi H. J Nutr. Campbell J. Inhibition of cholesterol biosynthesis by organosulfur compounds derived from garlic. 26. Clinical experience of Kyoleopin® (KLE): clinical study on general fatigue associated with cold. Aged Garlic Extract and Vascular Homeostasis: Implication in Atherosclerosis. 700-708. Kawashima Y and Ochiai Y. Shinryou To Shin-yaku (Treatment and New Medicine). Kawashima Y. 1994. Garlic and garlic-derived compounds inhibit human squalene monooxygenase. Simmons DL. linical study of Kyoleopin for patients with hyperlipidemia. Simmons DL. Cardioprotection and garlic. Lam F. J Nutr. Yakuri To Chiryo. Weiss N. 377-388.). 1999. Liu L and Yeh Y. Campbell JH. 3012-3024. Sumi S. 7. 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 545 . ―Kyolic‖ on the development of atherosclerosis. 1989. Orange County Convention Center. Liu L and Yeh YY. Shibata H. The effect of the aged garlic extract. Lee ES. 1994. on the development of experimental atherosclerosis. 1997. J Nutr.557. Shinryou To Shin-yaku (Treatment and New Medicine). Keller C. Liu L and Yeh YY. Ishikawa S. Lancet. J Nutr. 1987. Ernst E. Atherosclerosis. Biochim Biophys Acta. 2021-2035. Clinical experience of Kyoleopin (Garlic Extract Preparation). 2000. http://www. Thieme. 1996 b. 2001. 131. Conference of the Anatomical society of Australia and New Zealand. Qureshi N. 17. Lin R. Qureshi A. 63-65. 143. Baltimore.com/(S(lugioiin2jvopk554jpnau3y))/nd/Search. 1994. J Nutr. thromboxane B2 and platelet aggregation in a hypercholesterolemic model. randomized. 136. 524. Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis. Lancaster T. 136.nih. Dietary Kyolic (aged garlic extract) and S-allyl cysteine reduces the level of plasma triglycerides. 16. 1994. 1990a. Neil HA. Abuirmeileh N. 39-45. placebo-controlled trial of garlic in patients stabilized on warfarin therapy. Miyoshi A and Hasegawa Y. 131. Rahman K and Lowe GM. 22. Eighteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors. J Nutr. 2006. Hodgeman J. 329-334.41 Liu L and Yeh Y. Orlando (USA).naturaldatabase. http://nccam. MD. 2002. J Nutr. 977S-979S. James KA. protects low density lipoprotein against in vitro oxidation. Callahan A. Moriguchi T. 39-56.aspx?cs=&s=ND&pt=100&id= 300&ds=&name=GARLIC&searchid=16597790. Silagy C and Neil A. 130. 2000. 2006. J R Coll Physicians Lond. Daily supplementation with aged garlic extract. 2001. Rahman K and Billington D. Sickle cell anemia: a potential nutritional approach for a molecular disease. Garlic as a lipid lowering agent--a meta-analysis. Pivovarova EM. 1016S-1019S. 2. 1984. J Nutr. Jones L. J Am Coll Nutr. Abuirmeileh N. First World Congress on the Health Significance of Garlic and garlic Constituents Washington DC. Garlic http://www. 1999. Tertov VV. Munday JS. 330-338. J R Coll Physicians Lond. Moore JW. Ohnishi T. Kirkwood SW. 2003. 131. Fowler GH. 27. 13. Nutrition. Takasugi N. 30. 399-404. Rahman K. Garlic and cardiovascular disease: a critical review. Qureshi N. Lin R. Rahman K. Garlic and aging: new insights into an old remedy. Ohnishi ST. Fray LM. 16. The effects of aged garlic extract on lipid peroxidation and the deformability of erythrocytes. Steiner M and Lin R. Washington DC. Double-blind. Jpn Pharmacol Therapeut.871. 736S740S. 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 546 . Qureshi A. US Patent 6. Exhibit Hall A4. Crain JL. 1996. Thompson KG. Cardiovascular and lipid changes in response to aged garlic extract ingestion. Historical perspective on garlic and cardiovascular disease. 2001. Sobenin IA. Ogunmola GB. 1999. Cahill J. Singh DK and Porter TD. 1995. Okuhara T. Atherosclerosis. Shinryou To Shinyaku. 2000. Therapeutic uses of specially processed garlic for sickle cell disease. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. SAlkyenyl Cysteines of Garlic Inhibit Cholesterol Synthesis by deactivating HMG-CoA reductase by organosulfur compounds of garlic in primary cultures of rats hepatocyte. Silagy CA. 28. Clinical study of garlic extract on peripheral circulation. Vos K. NIH (National Institute of Health). Rozenfeld V. 759S-764S. Orekhov AN. 1990b. Inhibition of sterol 4alpha-methyl oxidase is the principal mechanism by which garlic decreases cholesterol synthesis.254. Inhibition of cholesterol synthesis by Kyolic ( aged garlic extract) and S-allylcysteine in a hypercholesterolemic model. 2662-2665. Natural medicines Comprehensive Database. First World Congress on the Health Significance of Garlic and garlic Constituents. 21. Garlic (Allium sativum L. Orange Country Convention Center. Effect of Kyoleopin® on various unidentified complaints followed on internal disease. J Nutr. Ageing Res Rev. 2001.gov/health/garlic/. Direct anti-atherosclerosis-related effects of garlic. Sisca TS. 1994. Itakura Y. Annals of medicine. 1806-1820. but not raw garlic. Ohnishi T.). 3695-3701. WHO (World Health Organization). Takasu J. Yeh Y. CA. 1976. Nutrition Research. 803S-805S. J Nutr. J Nutr. 189-193. 1996. Uykimpang R. WHO Monographs on Selected Medicinal Plants. Springer-Verlag. Tokyo. Yeh Y. 1990. 93-102. 25. 866-870. Holbert D. Whitaker JR. 22. Yeh SH. Abahji T. CA.62 Steiner M. cholesterol. J Nutr. Amagase H. Am J Clin Nutr. 1997. Homocysteine-lowering action is another potential cardiovascular protective factor of aged garlic extract. 1998. Aged garlic extract therapy for sickle cell anemia patients. Aged garlic extract. Thomson M. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Development of Flavor. 456-466. Al-Qattan KK. 980S-984S. 131. 31. 1995. Yeh Y. Hoffmann U. Recent Advances on the Nutritional Benefits Accompanying the Use of Garlic as a Supplement. Allyl sulfur compounds of garlic inhibit cholesterol biosynthesis. 1998. 226-230. Ohigashi H. Adv Food Res. Washington DC. 2002. J Nutr. 989S-993S. Holbert D. Lin R. 45. 2005. Garlic reduced cholesterol in hypocholesterolemic men maintaining habitual diets. 131. 64. Aged garlic extract is a potential therapy for sickle-cell anemia. Toshikawa T (eds. 800S-802S. 29. Cholesterol lowering effects of aged garlic extract supplementation on free-living hypocholesterolemic men consuming habitual diets. BMC Blood Disord. Takasu J. Yeoman DJ. A double. Osawa T. Newport Beach. Niihara Y. 136. 1999. Steiner M and Li W. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. 1996. 13. Yeh SM. 904-908. Bordia T. 1998. Williams MJ. Yeh YY and Liu L. Odor. Terao J. WHO (World Health Organization). Sunga M. 37. United States Pharmacopoeial Convention. Nill L. Lim H-S. 136. Geneva. 2006. Yeh YY and Yeh SM. Lin RI. Yeh YY. 3. 2006. Phytother Res. 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 547 . Ali M. Garlic reduces plasma lipids by inhibiting hepatic cholesterol and triacylglycerol synthesis. Lin RIS. Bohn Stafleu Van Loghum Weiss N. 2005. 2006. a modulator of cardiovascular risk factors: a dose-finding study on the effects of AGE on platelet functions. Amagase H. First World Congress on the Health Significance of Garlic and Garlic constituents. Fytotherapeutisch compendium. Uykimpang R.and microcirculation.blind cross over study in moderately hypercholesterolemic men that compared the effect of Age Garlic Extract and placebo administration on blood lipids and platelet function. van Hellemont J. 136. 314-319. Aged garlic extract improves homocysteine-induced endothelial dysfunction in macro.). 2003. and triglycerides. Evans S. US Pharmacopoeia. 2001. Steiner M. Watanabe S. 2006. Including garlic in the diet may help lower blood glucose. 19. Newport Beach. Recent Advances on the Nutritional Benefits Accompanying the Use of Garlic as a Supplement. Sutherland WH. 745S-749S. 2. Picciano MF. 2001. Khan AH. J Cardiovasc Pharmacol. 2006. Niihara Y. Yeh SM. 136. J Am Coll Nutr. Sunga MA. Aged garlic extract improves endothelial function in men with coronary artery disease. 1994. Khan AH. and Pungency in Onion and Garlic. J Nutr. In: Food Factors for Cancer Prevention. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. de Jong SA. Keller C. McCormick MP. Yeh YY and Yeh SM. Steiner M and Lin RS. Shinyaku To Rinsho (Jpn J New Remedies Clin). 750S-754S. Yeh Y and Yeh SM. Steiner M. 545. Garlic extract attenuates hyperhomocysteinemia caused by folic acid deficiency in the rat. J Nutr. Lin RI. Ide N. Lipids. 73. United States Pharmacopoeial Convention. Alder R. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. European Pharmacopoeia. Mechanism of garlic (Allium sativum) induced reduction of hypertension in 2K-1C rats: a possible mediation of Na/H exchanger isoform-1. Aged garlic extract retards progression of coronary artery calcification. 2003. 2003. 161. Strasbourg. 217-222. Ele Visser (NPCF). ESCOP (The European Scientific Cooperative on Phytotherapy). CKF (Commissie Keuring Fytoproducten). 36. Washington DC. 1. 1988. J Nutr. Berry JA. Alnaqeeb MA. Thieme. Ramirez G. Austin. J Nutr. 2163-2175. Khan I. 239-249. A factorial trial including garlic supplements assesses effect in reducing precancerous gastric lesions. Budoff M. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. 131. Colquist S. Clarifying the real bioactive constituents of garlic. 2005. American Botanical Council. 136. 2006. 2004. 813-824. 2001. 716S-725S. Council of Europe. 16. Medicijnenkompas – Cholesterol. 15. Herbal interactions involving cytochrome p450 enzymes: a mini review. Garlic and cancer: a critical review of the epidemiologic literature. 2006. Delgoda R and Westlake AC. Ali M. 381-385. Suppression of LDL oxidation by garlic. Kreutzkamp T.84 Yokoyama K. Arch Intern Med. 301-308. ID 1992: “Alium sativum (Common Name: Garlic)” and “Heart Health/ Blood lipids” 85 1 2 3 Ackermann RT. Cardiovascular benefits of garlic (Allium sativum L). Brace LD. Brinckmann J. Effect of garlic on cardiovascular disorders: a review. Lawrence VA. Banerjee S and Maulik S. Arch Intern Med. Prostaglandins Leukot Essent Fatty Acids. Yu S and Qureshi N. Herbal Medicine: Expanded Commission E Monographs. Takasugi N. TX. Blumenthal M. What's cooking with garlic: is this complementary and alternative medicine for hypertension? J Am Acad Nurse Pract. National Conference on Cholesterol and high blood pressure. Toxicol Rev. 346-353. 136. 2005. Effect of garlic extract preparation containing vitamins (Kyoleopin®) and ginseng-garlic preparation containing vitamin B1 (leopin five®) on peripheral blood circulation of animals. J Nutr. 120-129. 2004. 2001. Drugs. Garlic shows promise for improving some cardiovascular risk factors. 985S-988S. Garlic. Wil Toenders (CVZ). Williams M.org/searchresult. European Directorate for the Quality of Medicines. 17. Allii Sativi Bulbus. 167. http://cms. 2007. Fuwa T. Lau BH. 2001. Kiazand A. J Nutr. 1032S-1040S. Wolschrijn H. 548 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 . Chatterjee LM.html?&searchfor=garlic&option=any&KY_WS_LOW=2636|2631|2 626|2627|2629|2633|2638|2641|. 4. sponsored by Cholesterol Education Program of the National Institutes of Health. Mulrow CD. 69. 1991.herbalgram. J Nutr. 2002. Edwards QT. Nutrition Journal. 136. 741S744S. Goldberg A. Izzo AA and Ernst E. ESCOP Monographs: The Scientific Foundation of Herbal Medicinal Products. Gail MH and You WC. Al-Qattan KK. American Botanical Council. Interactions between herbal medicines and prescribed drugs: a systematic review. Gardner CD. 23. J Am Acad Nurse Pract. 2000. Gardner CD. 33-49. Oyo Yakuri. Yoshi M. Block E. Morbidoni L. 2006. Fleischauer AT and Arab L. Stuttgart. 61. Buring D. Kraemer HC. Balise RR. Amagase H. Lookinland S. 2003. 813S-815S. 2006. 2001. Maradiegue A. 131. Lawson LD. 2002. J Cardiovasc Nurs. 1-4. Devane CL. Milner JA. Yoshihara M.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Aged garlic extract improves homocysteine-induced endothelial dysfunction in macro. J R Coll Physicians Lond. J Nutr. Garlic for treating hypercholesterolemia. Garlic.com/(S(php1ya453ptprinbaeemdyz3))/nd/Search. Yeh YY and Yeh SM. Fowler GH. Fytotherapeutisch compendium. WHO Monographs on Selected Medicinal Plants. 72. 745S-749S. protective effects against cancer. 1994. 49. 12. 57. 170-177. Rahman K and Lowe GM. Ruan Y.nlm. 131. Bergès R. 136. Ide N. 2002. 136. 103-106. J Nutr. Tanaka S. 67-81. NIH (National Institute of Health). Weiss N. Ackermann R. 957-958. J Nutr. 74. 2006. 39-45. Pargana E.html. Tattelman E.and microcirculation. United States Pharmacopoeial Convention. Loureiro V. Yeh YY and Liu L. Garlic and Cancer. Am Fam Physician. Arterburn J. Pires G. Weiss RF and Fintelmann V. Taylor RM. Neil HA. Watzl B and Leitzmann C. Bon AML.). 2006. Bioaktive Substanzen in Lebensmitteln. Mullins D. Abahji T.gov/medlineplus/druginfo/natural/patient-garlic. Ann Intern Med. Pittler MH. Ernährungs-Umschau. 3. 493-496. Utrecht. Bonn. Health effects of garlic. Chayama K. J Nutr. Aged garlic extract has potential suppressive effect on colorectal adenomas in humans. 133. Lawrence V. Clin Pharmacol Ther. 1994. 827S-831S. Lehrbuch der Phytotherapie. Teyssier C. Garlic and cardiovascular disease: a critical review. J Nutr. Evid Rep Technol Assess (Summ). Pinto JR. 2003. and clinical adverse effects. Heidenreich P. Russell N. 821S-826S. Richardson M. Stuttgart. Haruma K. Sulfide. 25-30. 989S-993S. Young V. Vickers A. Natural medicines Comprehensive Database. Thomson M and Ali M. Ernst E. Curr Cancer Drug Targets. Donovan JL. 28. United States Pharmacopoeial Convention. Kajiyama G. Harris M. Medicinal and Aromatic Plant Science and Biotechnology. Cahill J. Lancaster T. J R Coll Physicians Lond. Silagy CA.naturaldatabase. Keller C. 2006. Homocysteine-lowering action is another potential cardiovascular protective factor of aged garlic extract. Almeida MM. 1996. Amagase H. 2003. 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 549 . Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis. Scheltema & Holkema. A meta-analysis of the effect of garlic on blood pressure. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. 2003. 2007. Stevinson C. 2001. Siess MH. Kira K. Nill L. 2002. Hippokrates-Verlag. 1999. Silagy CA and Neil HA. J Nutr. Moore JW. Silagy C and Neil A. 20. Preclinical perspectives on garlic and cancer. 136. 463-468. Chiquette E. Allergy. 736S740S. 2005. Hodgeman J. 2006. 1999. Garlic: Effects on cardiovascular risks and disease.aspx?cs=&s=ND&pt=100&id =300&ds=&name=GARLIC&searchid=16599845. van Hellemont J. J Hypertens. US Pharmacopoeia. 420-429. 2000. 2000. Jones L. 750S-754S. 2006. http://www. Chavin KD. http://www. 30. 2006. Hippokrates. Block E. WHO (World Health Organization). Hoffmann U. Allergy to garlic. 136. Garlic (Allium sativum L. Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Aguilar C. Gardener C. 329-334. Gilbert Ramirez G. 1. WHO (World Health Organization).21 Markowitz JS. 136. Geneva.nih. 1999. Watzl B. Effects of garlic (Allium sativum L. A meta-analysis of randomized clinical trials. Vos K. Belloir C. Singh V. Garlic as a lipid lowering agent--a meta-analysis. Murlow C. Morbidoni L. and Aronia. 35. 399-407. Anthocyanins--an adjunct to cardiovascular therapy? Kardiol Pol. 1993. Kong JM. Hakulinen T. Paxton JW. Langner M. Kowalczyk E. Chia LS. 651. 361-367. Rutkowski M. 69. Phytochemistry. 923-933. On the ability of four flavonoids. and quercetin. Nardini M. Kopff M. Influence of anthocyanins from Aronia melanocarpa Elliot in experimental pancreatitis. 15. The influence of Aronia melanocarpa and acetylcysteine on selected after-effects in lead acetate poisoning. Bagchi M. Journal of Agricultural and Food Chemistry. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 550 . The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hypercholesterolemia. Roccazzello AM. Biometals. 2005. Diabetes Nutrition & Metabolism. Kopff M. 319-324. Interactions of herbs with cytochrome P450. 1999. 64. Kowalski J. ascorbic acid. 57. Cheng IF and Breen K. 1007-1011. 2002. 1999. Trombetta D. Kopff A. Kumpulainen J. Xu A. Feskens EJM. Polyphenols and disease risk in epidemiologic studies. Zeitschrift Fur Naturforschung C-a Journal of Biosciences. 221-223. and radical scavenging activity of Rubus. Polish Journal of Pharmacology. Stohs SJ. 1996. luteolin. 2005. 81. 76. Scaccini C. ID 1997: “Aronia melanocarpa (Common Name: Chokeberry)” and “Antioxidant properties/source of anthocyanins and polyphenols with antioxidant activity” 1 2 Arts ICW and Hollman PCH. Antioxidant activity of anthocyanin glycoside derivatives evaluated by the inhibition of liposome oxidation. Reunanen A. Katan MB. Archives of Internal Medicine. Ray SD. Bonina FP. Melegari M. Evaluation of oxidative stress in diabetic patients after supplementation with a standardised red orange extract. Polski Merkuriusz Lekarski. 395-398. Niedworok J. Blaszczyk J. 13. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. 2002. Diabetologia Polska. Influence of Anthocyanins From Aronia Melanocarpa Elliot on the Course of Experimental Diabetes. 54. Pruess HG. anthocyanins. Gabrielska J. and incidence of stroke . 2000. 1998. Pellati F. Zeitschrift Fur Naturforschung C-a Journal of Biosciences. Fijalkowski P. 560-568. Jankowski A. Rapisarda P. Knekt P. Polyphenols. naringenin. 2005. Ghiselli A. Jankowski A. American Journal of Clinical Nutrition. Bagchi D. Krzesinski P. Krzesinski P. 699-702. Aromaa A. 77-83. Benvenuti S. Huang M. Jiang W. Chia TF. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego. Niedworok J. Scalia G. 2003. 6.The zutphen study. Das DK. Kromhout D. 342. Saija A. 637-642. Blaszczyk J. Ribes. Kromhout D.45 Zhou S. 60. Antioxidant activity of different phenolic fractions separated from an Italian red wine. 87-95. Journal of Food Science. Kuszynski CA. Feskens EJM. 19. Kowalczyk E. Leotta C. 2002. Tringali G. Kowalczyk E. Szmigiel B. Bertelli D. 317s-325s. Dietary Antioxidant Flavonoids and Risk of Coronary Heart-Disease . Goh NK. Gabrielska J and Oszmianski J. Niedworok J. 14-19. Niedworok J. Jarvinen R. Brouillard R. 187-197. Jankowski A. Jankowska B. Joshi SS. 2003. 148. Hertog MGL. Gao Y. American Journal of Clinical Nutrition. 35-98. Analysis and biological activities of anthocyanins. 46.the Zutphen Elderly Study. Anthocyanins in medicine. Flavonoid intake and risk of chronic diseases. Baldi A. 332-336. Komorowska M. 55. Kura M. 2000. Jankowska B. C164-C169. Hollman PCH. baicilein. 2004. Rissanen H. 2000. Jankowska B. to suppress the fenton reaction of the iron-ATP complex. 2003. 2002. Polski Merkuriusz Lekarski. Smigielski J. 69. Keli SO. Lancet. Smigielski J. Anthocyanin extracts with antioxidant and radical scavenging effect. Heliovaara M. Puglia C. Jankowski A. Dietary flavonoids. Kowalczyk E. 8. Oszmianski J. Toxicology. Drug Metab Rev. antioxidant vitamins. Hertog MGL. 156. Kura M. Polski Merkuriusz Lekarski. Combination therapy of statin with flavonoids-rich extract from chokeberry fruits enhanced reduction in CAD risk markers in patients after MI. Wilczynski JAN. Wplyw na poziom fruktozy w nasieniu. 7720-7725. Stachowiak G. Bielak A. 61. Fijalkowski P. Wojsk. 2005. 72. Kubat Z. Ursini F. 2007. Belelli F. Effect of anthocyanins from Aronia melanocarpa elliot on skin angiogenesis reaction in mice. Deskur E. Wachowicz B. Therapeutical properties of anthocyanins from Aronia melanocarpa. 2005. Broncel M. Przemysl Spozywczy. Pawłowicz PS. 2002. Vegetable antioxidants – their properties and pharmacological effects. Application of anthocyanins in cardiovascular system disease therapy. 2006. 19. Juchnowicz P. Farmacja Polska. Journal of Agricultural and Food Chemistry. Krokera M. Wilczynski J. Archives of Perinatal Medicine. 19. 50. Tomczak A. Olas B. Pawlowicz P. Laniewska I. Koziorog-Kolacinska M. 36-39. Wlasciwosci przeciwutleniajace. 43. Problemy Terapii Monitorowanej. Stachowiak G. 983-988.19 20 Kowalczyk E. Milo B. Charyk K. 7378. Stachowiak GP. Horoszkiewicz-Hassan M. Scaccini C. Current Atherosclerosis Reports. 221. Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa. 28-30. 809-813. Kowalski J. 44. Ginekol Pol. Koter-Michalak M. Erler J. 6. 7. Przegl. 551 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 . Jankowska B. XXXVII. 2008. Aronia melanocarpa phenolics and their antioxidant activity. Stetkiewicz T. Mitek M and Gasik A. Szmigiel B. 70-77. Flavonoids for reduction of atherosclerotic risk. Stochmal A.-Med. Basta P. Pilaczynska-Szczesniak L. 2007. Kura M. Influence of natural anthocyanins derived from chokeberry (Aronia melanocarpa) extract in the generation of oxidized low density lipoproteins in pregnancies complicated by fetal intrauterine growth retardation (IUGR) of preeclamptic origin – the role of autoantibodies to oxidized low density lipoproteins. seeds of grape and bark of Yucca schidigera in vitro. 175-175. 2002. The influence of chokeberry juice supplementation on the reduction of oxidative stress resulting from an incremental rowing ergometer exercise. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. 2001. 1995. 570s-578s. 18. Naruszewicz M. 2002. International Journal of Sport Nutrition and Exercise Metabolism. Herba Polonica. Hincz P. Bobin O. Influence of natural anthocyanins derived from chokeberry (Aronia melanocarpa) extract on glycosylated hemoglobin level in pregnant women with insulin-dependent diabetes mellitus. Krzesinski P. 123-125. 9. 1997. Stefaniak W. 57. Wilczynski J. Pawłowicz P. Skarpanska-Steinborn A. Natella F. Application of natural anthocyanins extracted from chokeberry (Aronia melanocarpa) for treatment of oligospermia in men having increased levels of antibodies ANTI-O-LDL (OLAB). Oszmianski J and Wojdylo A. Zastosowanie naturalnych antocyjanów pochodzacych z ekstraktu aronii czarnoowocowej (aronia melanocarpa) w leczeniu oligospermii u mezczyzn z podwyzszonymi poziomami przeciwcial anty-O-LDL (OLAB). Prior RL. Influence on the fructose level in sperm. Krzesinski P. 15. Effect of Aronia melanocarpa anthocyanins on activity of antioxidant enzymes in patient with metabolic syndrome. Niedworok J. Maron DJ. 2004. ChojnowskaJezierska J. 2003. 2003. Kowalczyk E. Niedworok J. Fruits and vegetables in the prevention of cellular oxidative damage. Ginekol Pol. Bielak A. 48-58. Dluzniewski M. American Journal of Clinical Nutrition. 719-721. 222-227. 2001. Balneologia Polska. Pawlowicz P. 123-127. Blaszczyk J. Paliwczak AR. 72. 44. 108. Gentili V. European Food Research and Technology. Platelets. Antiulcer activity of anthocyanin from Aronia melanocarpa Elliot. 2001. 2005. Polish Journal of Gynaecological Investigations 3. 983988. Niedworok J and Jankowski A. 78. Oleszek W. Polifenole w zywnosci. 5-10. Atherosclerosis Supplements. Am J Clin Nutr. J Agric Food Chem. 76. antioxidant vitamins. 6. 6. 699-702. 2006. 2003. 2324-2333. 1465-1472. Kromhout D. 1996. Am J Clin Nutr. 2007. 54. Anton R. Anthocyanins in medicine. Katrich E. Szmigiel B. 560-568. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. 2006. Reunanen A. The Power of Nature: Aronia melanocarpa . 552 2 3 4 5 6 7 8 9 10 11 12 13 14 . Reunanen A. Komorowska M. Jankowski A. Influence of Aronia melanocarpa (Aronia melanocarpa Elliot) on the course of experimental diabetes. Knekt P. Wawer I. Frankel EN. 57. 1164-1170. BMJ. Katan MB. 57. SatueGracia MT. Journal of Agricultural and Food Chemistry. Diabetologia Polska. Gabrielska J and Oszmianski J. Jankowska B. Keli SO. 304-309. Human tumor cell growth inhibition by nontoxic anthocyanidins. Feskens EJ. 1997. Kowalczyk E. 18871892. the pigments in fruits and vegetables. 3362-3367. Heliovaara M. Cao GH. Haan-Archipoff G. Leontowicz M. 399-407. J Nutr. 76. Pol J Pharmacol. Polyphenols and disease risk in epidemiologic studies. Magnier C. Feskens EJ. Journal of Physiology and Pharmacology. Kumpulainen J. Naruszewicz M. 332-336. Nature‘s Print LTD. Czesnikiewicz-Guzik M. 637-642. Libman I. 611-626. Hertog MG. 478-481. Caspi A. Arts IC and Hollman PC. 2005. Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. 312. 319-324. Zhang YJ. Hakulinen T. 2006. Gabrielska J. Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts. 342. Journal of Agricultural and Food Chemistry. Blaszczyk J. 2002. Lobstein A. 100.. 2003. Kowalczyk E. Jankowski A. Lerner HT. Pryjma J. Life Sciences. 81. Bell DR and Gochenaur K. 2002. ID 1998: “Aronia melanocarpa (Common Name: Chokeberry)” and “Vein health/Vascular health” 38 39 40 41 42 1 Andriambeloson E. 1997. Flavonoid intake and risk of chronic diseases. 75-87. Anthocyanins as antioxidants on human low-density lipoprotein and lecithin-liposome systems. Dobrowolska-Zachwieja A. Z Naturforsch [C]. Kura M. Technol. Beretz A. 2006. Kopff A. Effects of Aronia melanocarpa Polyphenols on oxidative metabolism and apoptosis of neutrophils from obese and non-obese individuals. 1999. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Korbut R. Adamek-Guzik T. Guzik TJ. Knekt P. Stoclet JC. Vareed SK. Z Naturforsch [C]. Anthocyanin extracts with antioxidant and radical scavenging effect. 904-908. Zielinska-Przyjemska M. Jarvinen R. Kromhout D. Tashma Z. Antioxidant activity of anthocyanin glycoside derivatives evaluated by the inhibition of liposome oxidation. Niedworok J. Krzesinski P. Gorinstein S. Aromaa A. Dietary flavonoids. Rissanen H. Prior RL.37 Ryszawa N. Andriantsitohaina R. Pol. Niedworok J. Anthocyanins--an adjunct to cardiovascular therapy? Kardiol Pol. Huxley RR and Neil HA. Langner M.Nature Combined With Health. 2005. Jarvinen R. 87-95. Wang H. and incidence of stroke: the Zutphen study. 1996. Trakhtenberg S. 317S-325S. Eur J Clin Nutr. Oszmianski J. 156. Kopff M. Feng S. Oxygen radical absorbing capacity of anthocyanins. Lancet. Flavonoid intake and coronary mortality in Finland: a cohort study. Huang D. 60. 1993. Leontowicz H. 1999. Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans. 55. Maatela J. 1998. Heinonen M. 45. Hertog MG. Nair MG. Kawczynska-Drozdz A. Grajek W. 2005. 57. Aliment. 45. 1007-1011. Hollman PC. Olejnik A. 128. Acta Sci. Arch Intern Med. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. J Appl Physiol. 54. Przemysl Spozywczy. 1995. Niedworok J. Am J Clin Nutr. Kowalski J. 125. Balneologia Polska. Olas B. Wang H. 2005. 72.15 Kowalczyk E. Pol Merkur Lekarski. 2003. 70-77. Polish Journal of Gynaecological Investigations. 2008. 221. 384-389. 77. 809-813. 570S-578S. Oxygen Radical Absorbing Capacity of Anthocyanins. 57. Curr Atheroscler Rep. Wilczynski J. Polifenole w żywności Właściwości przeciwutleniające. Sesso HD. 9. Niedworok J and Jankowski A. Naruszewicz M. Stochmal A. Platelets. 2001. Tomczak A. Stachowiak G. Therapeutical properties of anthocyanins from Aronia melanocarpa. [The use of anthocyanins in the treatment of cardiovascular diseases]. Stetkiewicz T. 983-988. 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 553 . 9. Influence of natural anthocyanins derived from chokeberry (Aronia melanocarpa) extract in the generation of oxidized low density lipoproteins in pregnancies complicated by fetal intrauterine growth retardation (IUGR) of preeclamptic origin – the role of autoantibodies to oxidized low density lipoproteins. Naruszewicz M. Korbut R. 81. Guzik TJ. Archives of Perinatal Medicine. Krzesinski P. 1996. Willett WC. Adamek-Guzik T. Gaziano JM. Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI). 2003. 2001. Mitek M and Gasik A. J Physiol Pharmacol. Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. Pawlowicz P. Influence of natural anthocyanins derived from chokeberry (Aronia melanocarpa) extract on glycosylated hemoglobin level in pregnant women with insulin-dependent diabetes mellitus. Fijalkowski P. Prior RL. Erler J. 6. Vita JA. Millo B. Ascherio A. Aronia melanocarpa phenolics and their antioxidant activity European Food Research and Technology. Kura M. Buring JE. 2007. Stachowiak GP. Fruits and vegetables in the prevention of cellular oxidative damage. 2006. Oleszek W. Am J Clin Nutr. Prior RL. 123-125. 2003. Wawer I. 3. Flavonoids for reduction of atherosclerotic risk. The impact on fructose levels]. Rimm EB. Blaszczyk J. 2001. Oszmiański J and Wojdylo A. 611-626. 19. 2005. Rutkowski M. 719-721. 19. Kawczynska-Drozdz A. Pawłowicz PS. Smigielski J. 45. Fijalkowski P. Wilczyński J. Journal of Agricultural and Food Chemistry. Ann Intern Med. Stetkiewicz T. Krzesinski P. Atherosclerosis. The Power of Nature: Aronia melanocarpa . 2004. Maron DJ. 292S-297S. 5-10. Krokera M. Kowalski J. Nature‘s Print LTD. 57. Flavonoid intake and the risk of cardiovascular disease in women.Nature Combined With Health. 1997. Cao G. 304-309. Pryjma J. Pawłowicz P. Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa. 2006. Katan MB. Kowalczyk E. Kopff M. XXXVII. 78. seeds of grape and bark of Yucca schidigera in vitro. Wachowicz B. e179-184. Dluzniewski M. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. 36-44. Stampfer MJ. 2005. Ryszawa N. Wilczyński J. Blaszczyk J. [The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hypercholesterolemia]. Hincz P. Ginekol Pol. 19. 194. [Administration of natural anthocyanins derived from chokeberry (aronia melanocarpa) extract in the treatment of oligospermia in males with enhanced autoantibodies to oxidized low density lipoproteins (oLAB). 73-78. Bielak A. 108-110. Liu S. Vegetable antioxidants – their properties and pharmacological effects. Laniewska I. Farmacja Polsk. 28-30. Bobin O. Pol Merkur Lekarski. 651-653. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. 1400-1408. 2007. 2005. Am J Clin Nutr. Czesnikiewicz-Guzik M. Oosthuizen W. 1995. Britz TJ. Tai A. Neurosci Lett. 2005. 2000. Jerling JC. Bramati L. Alternative Medicine 70-71. Shimokawa S. 59. Sumbalova Z. 53. Lindsey KL. Minoggio M. 34-45. 157-166. J Agric Food Chem. Lin YC. 2001.UV/DAD. USA Ferreira D. Joubert E and Ferreira D. 1979. Klopper JF. Nakano M. Screening of South African food plants for antioxidant activity. Joubert E. Effects of rooibos tea extract on antigen-specific antibody production and cytokine generation in vitro and in vivo. Pietta P. Division of Nephrology. Regeneration of coenzyme Q9 redox state and inhibition of oxidative stress by Rooibos tea (Aspalathus linearis) administration in carbon tetrachloride liver damage. 2002. Nakano M. An investigation on the antimutagenic properties of South African herbal teas. Hesseling PB. Kasai N. Joubert E. Quantitative Characterization of Flavonoid Compounds in Rooibos Tea (Aspalathus linearis) by LC. S Afr Med J. Fajardo-Lira C. Kushi LH. Inukai N. 2129-2131. M Meyers. biotechnology. Sato F. 2004. [The effect of rooibos tea on iron absorption]. Product Dossier NESTEA® VitaoTM Rooibos tea. 73–88. 1999. Asanuma T. 983-994. 1026010267. Gelderblom WC. Physiol Res. Gvozdjakova A. Gelderblom WCA. Kunishiro K. 53. ID 1999: “Aspalathus linearis (Common Name: Rooibos/Red bush)” and “Antioxidant properties” 1 Letter and laboratory report from Professor A. Winterton P. Breet P. 85-88. 55. BPW (Beverage Partners Worldwide). 2137-2145. 24th May 1983. The suppression of age-related accumulation of lipid peroxides in rat brain by administration of Rooibos tea (Aspalathus linearis). Kuwabara M. 2005. Motsei ML. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 554 . Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Antioxidant and pro-oxidant activities of aqueous extracts and crude polyphenolic fractions of rooibos (Aspalathus linearis). 2005. 2003.Presentation to IFT Annual Meeting. Vancova O. California State University. 683-693. Rooibos tea as a likely health food supplement. 5513-5519. Sippa Cuppa Rooibos Tea. 1996. Antioxidants of Rooibos tea-a possible explanation for its health promoting properties? SA Journal of Food Science and Nutrition (South Africa). J Agric Food Chem. Chang YJ. 25. 1995. Jager AK. Gardana C. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. HerbalGram. 196. Chen CC. van Heerden PD. 2000. Mol Pharmacol. This marvelous tonic with a funny name relieves a myriad of symptoms (including mild depression). Am J Epidemiol. 2007. 943-949. Ulicna O. 2004. Erickson L. Flavonoids inhibit tumor necrosis factoralpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: structure-activity relationships. ―We have noticed a striking decrease in the frequency of recurrent stones in patients with hyperoxaluria when standard tea is substituted for rooibos tea". Meyer K.34 Yochum L. Jin T. and biochemistry. 67. Louisiana. Yamamoto I. Kucharska J. 471. 50. 66. Actions of black tea and Rooibos on iron status of primary school children. Huang WC. Mauri P. Inanami O. New Orleans. Rooibos Tea: Research into Antioxidant and Antimutagenic Properties. Seoul. Steenkamp JA. Kruger HS. Journal of Food Science. Bioscience. 149. 515-521. Nutrition Research. 631-632. Folsom AR. Chow MP. Bozek P. Kamen B. Joubert E. Greksak M. 2002. Effect of brewing method on antioxidant activity of rooibos tea Dept of Family Consumer Sciences. Marais C. Marnewick J. Proceedings of Recent Development of Technologies on Fundamental Foods for Health. 65. Simonetti P. 660-663. Itoh Y. 2000. Effects of anthocyanins and other phenolic compounds on the production of tumor necrosis factor alpha in LPS/IFN-gamma-activated RAW 264. Wang J and Mazza G. Rhodes University. 539-543. Presentation to the 28th Annual Conference of the South African Association of Botanists. 632-638. J Agric Food Chem. Nakano M. Swart P. BHT. von Gadow A. Anti-human immunodeficiency virus activity of oligosaccharides from rooibos tea (Aspalathus linearis) extracts in vitro. 21. Antioxidants in rooibos tea: dihydrochalcones and flavonoids. Germany. Fernandes AC. Comparison of the Antioxidant Activity of Aspalathin with That of Other Plant Phenols of Rooibos Tea (Aspalathus linearis). Snyckers FO and Salemi G. 216. Short communication Antioxidant scavenging potential of South African export herbal teas. Schulz H. Part 1. 70. Modulation of hepatic drug metabolizing enzymes and oxidative status by rooibos (Aspalathus linearis) and Honeybush (Cyclopia intermedia). Hansmann CF. 1974. Steenkamp V. Schmandke H. 1997. 50. Joubert E. Wichtl M. 2005. J Agric Food Chem. Ernahrungs-Umschau. J Agric Food Chem. green and black (Camellia sinensis) teas in rats. 2004. 128-130. Nakashima H. and BHA. 45.[alpha]-Tocopherol. Joubert E. 2004. 1-16. 2002. Phytother Res. South African Journal of Botany. Schütze W.7 macrophages. Rooibos Tea and Health. Joubert E. van Wyk. 4183-4189. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. 8113-8119. McKay DL and Blumberg JB. 18-20. Journal of the South African Chemical Institute 27. Medpharm GmbH Scientific Publishers Stuttgart. Van Rensburg CEJ. European Food Research and Technology. 19 20 21 22 23 24 25 26 27 28 555 . Quercetin as the major in vitro active component of rooibos tea. Gelderblom WC. 51. 5-7. Studies of South African Medicinal plants. 1997.18 Marnewick JL. 2007. Van Der Westhuizen F. 11. A review of the bioactivity of South African herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Quantification of quality parameters for reliable evaluation of green rooibos (Aspalathus linearis). Leukemia. 2003. 52. 2003.